{
  "ctfidf_model": {
    "bm25_weighting": false,
    "reduce_frequent_words": false
  },
  "vectorizer_model": {
    "params": {
      "analyzer": "word",
      "binary": false,
      "decode_error": "strict",
      "encoding": "utf-8",
      "input": "content",
      "lowercase": true,
      "max_df": 1.0,
      "max_features": null,
      "min_df": 2,
      "ngram_range": [
        1,
        4
      ],
      "stop_words": "english",
      "strip_accents": null,
      "token_pattern": "(?u)\\b\\w\\w+\\b",
      "vocabulary": null
    },
    "vocab": {
      "background": 12999,
      "oxycontin": 56107,
      "controlled": 20442,
      "release": 69800,
      "oxycodone": 54472,
      "hydrochloride": 36001,
      "purdue": 66498,
      "pharma": 61008,
      "stamford": 76881,
      "ct": 21360,
      "approved": 11531,
      "1995": 2233,
      "food": 32231,
      "drug": 26493,
      "administration": 8201,
      "fda": 31273,
      "moderate": 47135,
      "severe": 74899,
      "chronic": 16179,
      "pain": 56344,
      "crushing": 21349,
      "snorting": 76346,
      "delayed": 23189,
      "tablets": 80107,
      "results": 71536,
      "rapid": 67375,
      "increased": 37819,
      "absorption": 6607,
      "high": 35063,
      "peak": 60300,
      "serum": 74691,
      "concentrations": 18735,
      "propensity": 65691,
      "addiction": 7736,
      "trend": 82939,
      "prescription": 64146,
      "abuse": 6638,
      "imperative": 36913,
      "physicians": 61434,
      "health": 34667,
      "care": 14996,
      "providers": 66181,
      "recognize": 68571,
      "clinical": 16748,
      "presentation": 64676,
      "overdose": 54268,
      "know": 40877,
      "manage": 43113,
      "associated": 12207,
      "complications": 18555,
      "objectives": 50535,
      "review": 72251,
      "discuss": 25281,
      "current": 21423,
      "trends": 82958,
      "specific": 76578,
      "effects": 27789,
      "body": 14189,
      "systems": 80035,
      "recognition": 68569,
      "symptomatology": 79871,
      "differential": 24937,
      "diagnosis": 24329,
      "management": 43138,
      "discussion": 25300,
      "findings": 31766,
      "acute": 7606,
      "opioid": 51347,
      "overdoses": 54323,
      "nonspecific": 49851,
      "making": 43007,
      "difficult": 24959,
      "presents": 64711,
      "typical": 83379,
      "opiate": 51283,
      "including": 37584,
      "decreased": 22935,
      "miosis": 46667,
      "hypothermia": 36291,
      "bradycardia": 14311,
      "hypotension": 36286,
      "altered": 9693,
      "mental": 44811,
      "status": 77251,
      "presence": 64580,
      "picture": 61485,
      "suspected": 79763,
      "early": 27248,
      "ventilation": 86060,
      "oxygenation": 56211,
      "administered": 8093,
      "generally": 33008,
      "sufficient": 78969,
      "prevent": 64839,
      "death": 22690,
      "absence": 6587,
      "confirmation": 19496,
      "cautious": 15423,
      "naloxone": 48422,
      "receptor": 68452,
      "antagonist": 11056,
      "antidote": 11183,
      "diagnostic": 24341,
      "therapeutic": 80915,
      "summary": 79090,
      "increasing": 38089,
      "rates": 67541,
      "continue": 20120,
      "present": 64602,
      "challenges": 15701,
      "aware": 12981,
      "potential": 63119,
      "patients": 58817,
      "seeking": 74346,
      "recreational": 68772,
      "use": 84133,
      "1917": 2202,
      "parenteral": 58203,
      "used": 84818,
      "mainly": 42868,
      "treatment": 82412,
      "postoperative": 62691,
      "combinations": 17619,
      "example": 30428,
      "acetaminophen": 7109,
      "introduction": 39915,
      "cancer": 14760,
      "related": 69542,
      "non": 49560,
      "problems": 65254,
      "studies": 77633,
      "performed": 60564,
      "osteoarthritis": 53857,
      "neuropathic": 49222,
      "postherpetic": 62656,
      "neuralgia": 49170,
      "diabetic": 24312,
      "neuropathy": 49273,
      "pharmacodynamic": 61058,
      "mu": 48105,
      "agonist": 9276,
      "closely": 17072,
      "resembles": 71050,
      "morphine": 47526,
      "distinct": 25538,
      "differences": 24703,
      "particularly": 58406,
      "pharmacokinetic": 61105,
      "profile": 65471,
      "old": 50997,
      "basic": 13471,
      "pharmacology": 61241,
      "neglected": 49090,
      "field": 31683,
      "research": 70977,
      "estimated": 29617,
      "nearly": 48862,
      "people": 60395,
      "drugs": 26864,
      "started": 77006,
      "medicines": 44715,
      "approximately": 11555,
      "11": 1084,
      "million": 46483,
      "americans": 9810,
      "2016": 2726,
      "2018": 2807,
      "46": 4614,
      "802": 5872,
      "died": 24524,
      "result": 71469,
      "opioids": 52652,
      "heroin": 34978,
      "illicitly": 36658,
      "manufactured": 43336,
      "fentanyl": 31407,
      "national": 48664,
      "institutes": 39072,
      "2020": 2889,
      "crisis": 21167,
      "https": 35929,
      "www": 87388,
      "gov": 33341,
      "accessed": 7008,
      "06": 575,
      "june": 40537,
      "prescribe": 63794,
      "oral": 53479,
      "alternative": 9713,
      "therapeutics": 80972,
      "importance": 36976,
      "understanding": 83631,
      "choice": 16108,
      "influence": 38583,
      "detrimental": 24137,
      "outcomes": 54005,
      "medications": 44588,
      "led": 41332,
      "misuse": 46702,
      "rampant": 66985,
      "highly": 35386,
      "prescribed": 63802,
      "treating": 82383,
      "reflected": 69190,
      "increase": 37717,
      "retail": 72069,
      "sales": 73247,
      "866": 6016,
      "1997": 2236,
      "2007": 2484,
      "initially": 38874,
      "suggested": 79021,
      "addictive": 7780,
      "false": 31165,
      "claimed": 16614,
      "formulation": 32327,
      "contributed": 20231,
      "carried": 15134,
      "pills": 61497,
      "immediate": 36696,
      "burst": 14620,
      "typically": 83391,
      "nasal": 48650,
      "insufflation": 39136,
      "intravenous": 39808,
      "injection": 38932,
      "liability": 41636,
      "hypothesis": 36294,
      "exhibit": 30508,
      "unique": 83749,
      "contributes": 20235,
      "likability": 41769,
      "susceptibility": 79758,
      "various": 85957,
      "mechanisms": 44133,
      "likely": 41794,
      "contribute": 20221,
      "rate": 67422,
      "pharmacokinetics": 61156,
      "pharmacodynamics": 61082,
      "actions": 7455,
      "mesolimbic": 44860,
      "reward": 72432,
      "compared": 18062,
      "possibility": 62524,
      "molecular": 47278,
      "cellular": 15506,
      "interactions": 39384,
      "selective": 74423,
      "marketing": 43422,
      "strategies": 77408,
      "difference": 24564,
      "disorders": 25391,
      "united": 83774,
      "states": 77077,
      "abusers": 6929,
      "addicted": 7734,
      "initial": 38827,
      "course": 20987,
      "legal": 41362,
      "physician": 61422,
      "consequently": 19597,
      "pressure": 64737,
      "medical": 44333,
      "better": 13699,
      "orthopedic": 53822,
      "surgery": 79291,
      "total": 81702,
      "joint": 40486,
      "arthroplasty": 11736,
      "control": 20258,
      "critical": 21226,
      "restoring": 71453,
      "mobility": 47004,
      "maintaining": 42897,
      "patient": 58529,
      "satisfaction": 73382,
      "period": 60674,
      "epidemic": 29124,
      "surgeons": 79264,
      "frequently": 32541,
      "influenced": 38602,
      "treat": 82270,
      "long": 42283,
      "acting": 7371,
      "commonly": 17826,
      "past": 58445,
      "decade": 22802,
      "paradigm": 58121,
      "shift": 75137,
      "favor": 31255,
      "multimodal": 48197,
      "limited": 41912,
      "major": 42925,
      "topics": 81698,
      "pressures": 64751,
      "narcotic": 48580,
      "minor": 46623,
      "prescriptions": 64424,
      "second": 74178,
      "factors": 31066,
      "motivated": 48016,
      "development": 24207,
      "approach": 11453,
      "look": 42406,
      "perioperative": 60823,
      "interventions": 39654,
      "reduce": 68828,
      "consumption": 19863,
      "wound": 87353,
      "injections": 38974,
      "peripheral": 60857,
      "nerve": 49110,
      "blocks": 14089,
      "shown": 75326,
      "finally": 31752,
      "recommend": 68579,
      "evidence": 30140,
      "based": 13270,
      "program": 65531,
      "avoids": 12975,
      "narcotics": 48625,
      "facilitates": 31037,
      "discharge": 25089,
      "home": 35506,
      "readmissions": 67992,
      "complaints": 18430,
      "public": 66374,
      "concerns": 18840,
      "regarding": 69238,
      "canada": 14746,
      "charges": 15920,
      "medicine": 44702,
      "community": 17913,
      "media": 44164,
      "coverage": 21014,
      "biased": 13776,
      "objective": 50361,
      "analyze": 10811,
      "compare": 18004,
      "representations": 70755,
      "journals": 40496,
      "north": 49954,
      "american": 9786,
      "newspapers": 49424,
      "attempt": 12546,
      "shed": 75130,
      "light": 41767,
      "social": 76351,
      "problem": 65233,
      "methods": 45233,
      "using": 85282,
      "searches": 74164,
      "literature": 42111,
      "databases": 22194,
      "samples": 73323,
      "drawn": 26451,
      "924": 6164,
      "stories": 77401,
      "published": 66421,
      "2005": 2456,
      "27": 3471,
      "197": 2214,
      "articles": 11792,
      "33": 3974,
      "fields": 31684,
      "substance": 78794,
      "anesthesiology": 10962,
      "general": 32949,
      "internal": 39456,
      "themes": 80909,
      "perspectives": 60973,
      "represented": 70761,
      "evaluations": 29970,
      "presented": 64684,
      "analyzed": 10819,
      "statistically": 77190,
      "emphasized": 28730,
      "negative": 49060,
      "focusing": 31978,
      "crime": 21162,
      "legitimate": 41382,
      "conveyed": 20743,
      "law": 41247,
      "enforcement": 28925,
      "analysis": 10623,
      "revealed": 72212,
      "degree": 23170,
      "especially": 29549,
      "conclusion": 18856,
      "prevalence": 64767,
      "proliferation": 65602,
      "inconsistent": 37707,
      "messages": 44862,
      "plays": 62001,
      "role": 72729,
      "persistent": 60916,
      "diversion": 25585,
      "established": 29581,
      "requiring": 70897,
      "intervention": 39622,
      "article": 11759,
      "processes": 65344,
      "subsequent": 78775,
      "occurred": 50825,
      "impossible": 37047,
      "deserving": 23693,
      "war": 86706,
      "notion": 49996,
      "poison": 62145,
      "falling": 31162,
      "step": 77319,
      "theorized": 80913,
      "multiply": 48308,
      "aim": 9370,
      "moving": 48059,
      "theoretical": 80911,
      "registers": 69382,
      "exploring": 30736,
      "study": 77877,
      "broad": 14445,
      "range": 67242,
      "collected": 17443,
      "2009": 2513,
      "2013": 2616,
      "reports": 70709,
      "legislative": 41380,
      "assembly": 11900,
      "ontario": 51126,
      "internet": 39487,
      "policy": 62178,
      "documents": 25670,
      "position": 62440,
      "papers": 58086,
      "news": 49421,
      "releases": 70025,
      "produced": 65373,
      "government": 33348,
      "agencies": 9211,
      "advocacy": 8861,
      "organizations": 53777,
      "professional": 65464,
      "bodies": 14186,
      "think": 81091,
      "tribal": 83213,
      "pharmaceutical": 61014,
      "industry": 38484,
      "state": 77029,
      "attempted": 12549,
      "disparate": 25409,
      "intensified": 39213,
      "helped": 34914,
      "produce": 65354,
      "welfare": 86991,
      "dependence": 23458,
      "task": 80516,
      "stratifying": 77459,
      "proper": 65697,
      "secure": 74301,
      "integrity": 39202,
      "painkillers": 58015,
      "protect": 65916,
      "vehicles": 86048,
      "normal": 49897,
      "stable": 76836,
      "opposed": 53408,
      "excess": 30450,
      "contemporary": 20094,
      "attempts": 12551,
      "contain": 20061,
      "multiplicity": 48305,
      "individualized": 38317,
      "approaches": 11489,
      "serve": 74708,
      "safety": 73117,
      "widely": 87051,
      "regarded": 69237,
      "larger": 41171,
      "press": 64726,
      "overwhelmingly": 54370,
      "focused": 31973,
      "police": 62173,
      "concerned": 18837,
      "nuanced": 50115,
      "draw": 26447,
      "theory": 80914,
      "regulation": 69496,
      "qualitative": 66662,
      "24": 3138,
      "journal": 40493,
      "contrast": 20212,
      "agents": 9225,
      "responsible": 71398,
      "proposed": 65797,
      "solutions": 76447,
      "significant": 75416,
      "concerning": 18838,
      "nature": 48748,
      "authors": 12717,
      "responsibility": 71397,
      "ways": 86781,
      "mitigate": 46762,
      "issue": 40318,
      "regulatory": 69503,
      "conclusions": 19023,
      "responses": 71381,
      "represent": 70743,
      "strategic": 77407,
      "lost": 42441,
      "retain": 72073,
      "client": 16731,
      "populations": 62404,
      "tools": 81690,
      "necessary": 48877,
      "jobs": 40476,
      "claim": 16613,
      "table": 80073,
      "responding": 71326,
      "semi": 74509,
      "synthetic": 79946,
      "structurally": 77581,
      "similar": 75892,
      "codeine": 17194,
      "equipotent": 29271,
      "producing": 65421,
      "analgesic": 10135,
      "formulations": 32369,
      "percodan": 60540,
      "percocet": 60530,
      "tylox": 83317,
      "roxicodone": 72878,
      "form": 32267,
      "forms": 32306,
      "doses": 26114,
      "10": 651,
      "30": 3659,
      "mg": 45678,
      "recommended": 68615,
      "160": 1901,
      "12": 1198,
      "year": 87420,
      "los": 42425,
      "county": 20968,
      "department": 23420,
      "coroner": 20790,
      "toxicology": 81947,
      "laboratory": 41022,
      "detected": 23934,
      "67": 5469,
      "cases": 15214,
      "36": 4111,
      "determined": 24057,
      "paper": 58072,
      "provide": 66026,
      "information": 38631,
      "postmortem": 62671,
      "tissue": 81446,
      "distributions": 25572,
      "identified": 36414,
      "introduce": 39909,
      "concept": 18818,
      "pill": 61487,
      "seemingly": 74354,
      "intact": 39165,
      "free": 32485,
      "tablet": 80085,
      "isolation": 40306,
      "identification": 36410,
      "specimens": 76637,
      "achieved": 7309,
      "liquid": 42074,
      "extraction": 30964,
      "screening": 74038,
      "quantitation": 66792,
      "gas": 32836,
      "chromatography": 16152,
      "nitrogen": 49499,
      "phosphorus": 61370,
      "detection": 23953,
      "mass": 43446,
      "spectrometry": 76656,
      "respectively": 71142,
      "d3": 21681,
      "standard": 76884,
      "assays": 11893,
      "linear": 42008,
      "distribution": 25556,
      "ranges": 67352,
      "case": 15152,
      "examples": 30430,
      "heart": 34867,
      "blood": 14103,
      "femoral": 31401,
      "13": 1443,
      "35": 4054,
      "liver": 42171,
      "kg": 40681,
      "16": 1837,
      "urine": 84066,
      "122": 1420,
      "22": 3006,
      "bile": 13796,
      "19": 2154,
      "49": 4766,
      "15": 1666,
      "vitreous": 86350,
      "82": 5899,
      "gastric": 32850,
      "119": 1194,
      "21": 2932,
      "reformulated": 69197,
      "hcl": 34628,
      "orf": 53738,
      "developed": 24163,
      "tamper": 80328,
      "deterrent": 24103,
      "product": 65424,
      "risk": 72503,
      "consequences": 19588,
      "noninterventional": 49752,
      "single": 76040,
      "session": 74729,
      "asked": 11834,
      "participants": 58261,
      "medically": 44426,
      "healthy": 34811,
      "users": 85224,
      "aged": 9138,
      "18": 2022,
      "years": 87518,
      "older": 51026,
      "consider": 19601,
      "available": 12787,
      "supplies": 79175,
      "placebo": 61607,
      "original": 53782,
      "oc": 50795,
      "assess": 11901,
      "attractiveness": 12606,
      "tampering": 80346,
      "abusing": 6937,
      "provided": 66116,
      "assessed": 11973,
      "properties": 65704,
      "products": 65442,
      "hypothetical": 36315,
      "feedback": 31328,
      "preferences": 63632,
      "preferred": 63636,
      "overall": 54177,
      "males": 43068,
      "females": 31384,
      "mean": 43652,
      "age": 8964,
      "51": 4943,
      "complete": 18437,
      "interview": 39688,
      "sessions": 74737,
      "judged": 40498,
      "attractive": 12604,
      "valuable": 85811,
      "desirable": 23860,
      "tampered": 80344,
      "studied": 77605,
      "rated": 67526,
      "view": 86219,
      "doctor": 25655,
      "shopping": 75152,
      "obtaining": 50785,
      "multiple": 48258,
      "prescribers": 64014,
      "pharmacies": 61052,
      "analgesics": 10359,
      "produces": 65418,
      "supply": 79176,
      "represents": 70764,
      "open": 51145,
      "cohort": 17334,
      "changes": 15769,
      "brand": 14375,
      "extended": 30848,
      "er": 29383,
      "comparator": 17988,
      "july": 40507,
      "2010": 2534,
      "versus": 86094,
      "january": 40412,
      "2011": 2572,
      "ims": 37213,
      "longitudinal": 42396,
      "data": 21841,
      "covering": 21018,
      "150": 1805,
      "65": 5403,
      "reformulation": 69210,
      "50": 4795,
      "comparators": 18001,
      "largest": 41187,
      "decreases": 23056,
      "young": 87711,
      "adults": 8536,
      "73": 5641,
      "paying": 60249,
      "cash": 15273,
      "61": 5303,
      "receiving": 68313,
      "highest": 35339,
      "dose": 25773,
      "62": 5329,
      "90": 6069,
      "decrease": 22881,
      "characteristics": 15845,
      "magnitude": 42809,
      "reductions": 69108,
      "number": 50133,
      "75": 5689,
      "reduction": 69034,
      "substantially": 78860,
      "did": 24398,
      "occur": 50820,
      "higher": 35196,
      "youth": 87744,
      "payment": 60250,
      "thresholds": 81155,
      "prescriber": 64007,
      "pharmacy": 61256,
      "threshold": 81149,
      "suggesting": 79026,
      "captured": 14961,
      "effect": 27410,
      "actual": 7599,
      "shoppers": 75151,
      "semisynthetic": 74519,
      "practice": 63389,
      "equally": 29240,
      "effective": 27583,
      "times": 81413,
      "potent": 63088,
      "given": 33148,
      "epidurally": 29193,
      "provides": 66199,
      "updated": 83981,
      "special": 76556,
      "focus": 31968,
      "controversy": 20680,
      "mediated": 44304,
      "visceral": 86251,
      "agonism": 9269,
      "possible": 62527,
      "analgesia": 9890,
      "discussed": 25288,
      "investigation": 40068,
      "propose": 65796,
      "plausible": 61988,
      "explanation": 30702,
      "question": 66877,
      "discontinued": 25240,
      "delisted": 23202,
      "formulary": 32318,
      "replaced": 70427,
      "resistant": 71092,
      "2012": 2588,
      "impact": 36793,
      "discontinuing": 25253,
      "unreported": 83932,
      "45": 4561,
      "recruited": 68789,
      "primary": 64983,
      "specialty": 76573,
      "sites": 76163,
      "interviewed": 39689,
      "semistructured": 74518,
      "guide": 34401,
      "capture": 14960,
      "experiences": 30637,
      "efficacy": 28208,
      "alternate": 9707,
      "relationships": 69729,
      "additional": 7835,
      "interviews": 39693,
      "conducted": 19336,
      "obtain": 50751,
      "perceptions": 60529,
      "discontinuation": 25220,
      "expand": 30538,
      "aspects": 11860,
      "process": 65334,
      "emergent": 28698,
      "areas": 11642,
      "divergence": 25581,
      "include": 37349,
      "supported": 79220,
      "perceived": 60442,
      "majority": 42981,
      "experiencing": 30638,
      "describing": 23668,
      "insignificant": 39054,
      "coincided": 17416,
      "need": 48904,
      "optimize": 53440,
      "practices": 63421,
      "characterize": 15888,
      "reported": 70483,
      "pattern": 60189,
      "tracking": 81974,
      "database": 22160,
      "time": 81186,
      "periods": 60816,
      "august": 12659,
      "switch": 79817,
      "queried": 66872,
      "identify": 36485,
      "variables": 85884,
      "included": 37372,
      "incident": 37335,
      "counts": 20966,
      "involved": 40092,
      "security": 74302,
      "features": 31296,
      "defined": 23118,
      "post": 62553,
      "905": 6125,
      "incidents": 37341,
      "percent": 60444,
      "26": 3414,
      "peaked": 60324,
      "remained": 70259,
      "steady": 77302,
      "steadily": 77300,
      "296": 3628,
      "2015": 2685,
      "slightly": 76249,
      "2014": 2645,
      "weekdays": 86881,
      "entered": 29057,
      "dead": 22682,
      "following": 32092,
      "replacement": 70429,
      "new": 49304,
      "fully": 32613,
      "explained": 30700,
      "concurrent": 19263,
      "increasingly": 38131,
      "malignant": 43091,
      "synthesized": 79944,
      "pharmacological": 61204,
      "thoroughly": 81134,
      "recently": 68439,
      "fairly": 31158,
      "striking": 77502,
      "discrepancy": 25267,
      "relatively": 69773,
      "low": 42445,
      "binding": 13811,
      "protein": 65922,
      "activation": 7467,
      "active": 7483,
      "metabolites": 44963,
      "enhanced": 28964,
      "passage": 58439,
      "central": 15578,
      "nervous": 49133,
      "transport": 82239,
      "critically": 21230,
      "humans": 35981,
      "particular": 58398,
      "pharmacogenomics": 61103,
      "population": 62297,
      "makers": 43005,
      "implemented": 36944,
      "seldom": 74380,
      "regulating": 69495,
      "insurance": 39141,
      "reimbursement": 69513,
      "discourage": 25258,
      "prescribing": 64025,
      "specified": 76632,
      "dispensed": 25415,
      "provincial": 66277,
      "programs": 65553,
      "hospitalizations": 35661,
      "2006": 2470,
      "march": 43357,
      "2017": 2766,
      "prior": 65133,
      "authorization": 12715,
      "receive": 68036,
      "reduced": 68897,
      "fills": 31728,
      "naive": 48396,
      "substitution": 78877,
      "oxyneo": 56290,
      "variant": 85907,
      "allowing": 9642,
      "previous": 64893,
      "detectable": 23932,
      "points": 62117,
      "substantial": 78841,
      "suggest": 78979,
      "restrictions": 71462,
      "formularies": 32317,
      "targeted": 80493,
      "benefit": 13613,
      "altering": 9704,
      "differently": 24952,
      "canadian": 14754,
      "extend": 30845,
      "regulations": 69499,
      "private": 65191,
      "insurers": 39163,
      "follow": 32008,
      "headaches": 34662,
      "refractory": 69221,
      "treatments": 82894,
      "require": 70799,
      "setting": 74759,
      "monitored": 47310,
      "fatal": 31229,
      "access": 6988,
      "demand": 23247,
      "outside": 54168,
      "leads": 41316,
      "danger": 21826,
      "sell": 74505,
      "instead": 39064,
      "alleviate": 9591,
      "protection": 65918,
      "vital": 86338,
      "activity": 7554,
      "prevented": 64859,
      "encountered": 28773,
      "misusing": 46758,
      "order": 53702,
      "determine": 23985,
      "taking": 80297,
      "medication": 44445,
      "ordered": 53725,
      "immunoassay": 36771,
      "screen": 74025,
      "appeared": 11391,
      "dismissed": 25361,
      "request": 70781,
      "test": 80751,
      "indicated": 38231,
      "sufficiently": 78977,
      "levels": 41539,
      "minimum": 46608,
      "level": 41444,
      "detect": 23925,
      "like": 41771,
      "help": 34895,
      "future": 32759,
      "misunderstandings": 46701,
      "experienced": 30598,
      "followed": 32044,
      "taken": 80266,
      "overview": 54366,
      "monitoring": 47315,
      "woman": 87184,
      "broken": 14452,
      "syndrome": 79916,
      "cardiomyopathy": 14988,
      "abrupt": 6581,
      "postsurgical": 63048,
      "withdrawal": 87115,
      "history": 35448,
      "remarkable": 70316,
      "term": 80612,
      "multi": 48142,
      "degenerative": 23167,
      "emergency": 28668,
      "day": 22235,
      "hospital": 35555,
      "knee": 40855,
      "revision": 72426,
      "onset": 51107,
      "dyspnea": 27233,
      "mild": 46423,
      "chest": 15971,
      "st": 76821,
      "segment": 74369,
      "elevation": 28566,
      "characteristic": 15842,
      "myocardial": 48381,
      "infarction": 38510,
      "elevated": 28558,
      "cardiac": 14978,
      "biomarkers": 13859,
      "coronary": 20779,
      "angiography": 10980,
      "left": 41345,
      "ejection": 28464,
      "fraction": 32452,
      "severely": 75027,
      "regional": 69349,
      "wall": 86700,
      "motion": 48013,
      "abnormalities": 6577,
      "noted": 49985,
      "addition": 7793,
      "therapy": 80983,
      "treated": 82320,
      "positive": 62444,
      "airway": 9504,
      "aspirin": 11868,
      "metoprolol": 45668,
      "heparin": 34947,
      "infusion": 38694,
      "dopamine": 25717,
      "systolic": 80045,
      "function": 32621,
      "recovered": 68729,
      "completely": 18515,
      "fourth": 32435,
      "knowledge": 40881,
      "previously": 64932,
      "adult": 8483,
      "illustrates": 36668,
      "continuing": 20153,
      "adequate": 7957,
      "perioperatively": 60856,
      "dependent": 23496,
      "potentially": 63248,
      "life": 41681,
      "threatening": 81144,
      "crucial": 21320,
      "different": 24834,
      "oxn": 54410,
      "combination": 17539,
      "recent": 68387,
      "surgical": 79623,
      "specialties": 76571,
      "clarify": 16645,
      "advantages": 8612,
      "disadvantages": 25080,
      "method": 45163,
      "retrieved": 72093,
      "performing": 60651,
      "systematic": 79971,
      "search": 74104,
      "pubmed": 66442,
      "scopus": 73697,
      "randomized": 67041,
      "trials": 83098,
      "retrospective": 72106,
      "prospective": 65812,
      "eligible": 28579,
      "inclusion": 37684,
      "996": 6498,
      "procedures": 65292,
      "referred": 69155,
      "colorectal": 17522,
      "gynecologic": 34483,
      "thoracic": 81118,
      "evaluated": 29854,
      "showed": 75225,
      "superiority": 79150,
      "bowel": 14264,
      "seven": 74864,
      "groups": 34083,
      "adverse": 8618,
      "events": 30000,
      "recovery": 68733,
      "minimize": 46594,
      "induced": 38370,
      "constipation": 19743,
      "calculate": 14675,
      "conditional": 19288,
      "power": 63288,
      "comparative": 17977,
      "observed": 50643,
      "baseline": 13405,
      "isolate": 40303,
      "variability": 85863,
      "attributable": 12607,
      "modify": 47250,
      "formulae": 32316,
      "illustration": 36670,
      "examine": 30331,
      "null": 50131,
      "posited": 62439,
      "hypotheses": 36293,
      "impacts": 36862,
      "ancillary": 10886,
      "pre": 63457,
      "directly": 25059,
      "observable": 50592,
      "varied": 85929,
      "size": 76179,
      "assumed": 12506,
      "change": 15713,
      "designs": 23857,
      "initiated": 38877,
      "calculations": 14718,
      "conditioned": 19294,
      "account": 7071,
      "context": 20106,
      "emerged": 28662,
      "rural": 73042,
      "america": 9784,
      "purpose": 66514,
      "temporal": 80584,
      "geographic": 33106,
      "kentucky": 40602,
      "medicaid": 44324,
      "recipients": 68565,
      "cross": 21244,
      "sectional": 74277,
      "completed": 18458,
      "divided": 25617,
      "regions": 69363,
      "appalachia": 11372,
      "claims": 16615,
      "1998": 2241,
      "2002": 2436,
      "stratified": 77448,
      "disability": 25071,
      "assistance": 12191,
      "families": 31177,
      "file": 31697,
      "1999": 2243,
      "2001": 2427,
      "adjusting": 8060,
      "proportion": 65738,
      "region": 69341,
      "significantly": 75642,
      "05": 470,
      "appalachian": 11373,
      "disabled": 25076,
      "economic": 27307,
      "area": 11621,
      "contributing": 20239,
      "availability": 12777,
      "facilitate": 31030,
      "aims": 9471,
      "tapentadol": 80376,
      "250": 3393,
      "converted": 20721,
      "amenable": 9782,
      "intranasal": 39745,
      "design": 23694,
      "repeated": 70398,
      "measures": 44034,
      "employed": 28739,
      "40": 4304,
      "served": 74715,
      "took": 81667,
      "place": 61597,
      "york": 87707,
      "ny": 50348,
      "participated": 58387,
      "measurements": 44018,
      "outcome": 53901,
      "percentage": 60506,
      "yield": 87695,
      "solution": 76437,
      "descriptive": 23676,
      "spent": 76682,
      "manipulating": 43314,
      "examined": 30367,
      "behaviors": 13556,
      "clearly": 16724,
      "individuals": 38329,
      "willing": 87102,
      "particles": 58397,
      "100": 967,
      "001": 93,
      "extracted": 30946,
      "52": 4973,
      "37": 4167,
      "02": 348,
      "008": 276,
      "contained": 20062,
      "longer": 42365,
      "01": 286,
      "relief": 70091,
      "appear": 11382,
      "liked": 41786,
      "regularly": 69484,
      "employing": 28746,
      "technology": 80553,
      "promising": 65654,
      "reducing": 69010,
      "iv": 40360,
      "faster": 31212,
      "predictable": 63558,
      "does": 25671,
      "routes": 72852,
      "allows": 9644,
      "convenient": 20688,
      "dosing": 26303,
      "initiation": 38893,
      "phase": 61268,
      "able": 6561,
      "tolerate": 81613,
      "intake": 39176,
      "switched": 79822,
      "route": 72835,
      "partly": 58428,
      "kappa": 40583,
      "receptors": 68535,
      "offers": 50958,
      "comparing": 18345,
      "report": 70441,
      "safe": 73068,
      "greater": 33420,
      "fewer": 31624,
      "action": 7427,
      "consistent": 19689,
      "geriatric": 33127,
      "adjustments": 8075,
      "pharmacologic": 61192,
      "make": 43000,
      "important": 36990,
      "historically": 35446,
      "went": 86993,
      "variety": 85948,
      "subjective": 78644,
      "reasons": 68018,
      "difficulty": 24973,
      "objectively": 50534,
      "diagnose": 24321,
      "healthcare": 34793,
      "societal": 76363,
      "effort": 28429,
      "risen": 72495,
      "dramatically": 26438,
      "paralleling": 58149,
      "concomitant": 19246,
      "companies": 17941,
      "responded": 71298,
      "developing": 24200,
      "designed": 23824,
      "deter": 23970,
      "remoxy": 70338,
      "strong": 77508,
      "tolerability": 81515,
      "exists": 30530,
      "generic": 33042,
      "cr": 21048,
      "approval": 11523,
      "hydrocodone": 36042,
      "methadone": 45034,
      "utilizing": 85744,
      "centers": 15564,
      "pcc": 60274,
      "intentional": 39344,
      "exposure": 30749,
      "reason": 68013,
      "codes": 17305,
      "quarterly": 66854,
      "000": 15,
      "calculated": 14682,
      "2004": 2450,
      "regression": 69412,
      "slopes": 76259,
      "quarter": 66847,
      "poisson": 62166,
      "indicating": 38257,
      "lack": 41045,
      "interaction": 39368,
      "vary": 85986,
      "indicate": 38216,
      "unfavorable": 83725,
      "gathered": 32910,
      "oxy": 54437,
      "hydro": 36000,
      "women": 87190,
      "date": 22216,
      "conclusive": 19245,
      "evidences": 30296,
      "investigating": 40063,
      "gender": 32927,
      "analyzing": 10877,
      "dimension": 25014,
      "differ": 24539,
      "according": 7033,
      "confirming": 19511,
      "incidence": 37252,
      "demonstrated": 23329,
      "gastrointestinal": 32863,
      "reactions": 67951,
      "female": 31349,
      "subjects": 78672,
      "equal": 29227,
      "male": 43017,
      "main": 42821,
      "parameters": 58154,
      "relate": 69541,
      "specifically": 76623,
      "cyp3a4": 21633,
      "metabolism": 44920,
      "assessing": 12099,
      "useful": 85194,
      "relation": 69709,
      "cyp2d6": 21587,
      "genotype": 33096,
      "considering": 19663,
      "paucity": 60233,
      "european": 29736,
      "union": 83747,
      "work": 87267,
      "highlights": 35380,
      "oxytrex": 56293,
      "combines": 17678,
      "ultra": 83416,
      "naltrexone": 48534,
      "animal": 10990,
      "minimizes": 46603,
      "physical": 61378,
      "tolerance": 81567,
      "prolonging": 65645,
      "late": 41220,
      "stage": 76860,
      "evaluate": 29762,
      "volunteers": 86411,
      "putative": 66600,
      "mechanism": 44123,
      "alteration": 9689,
      "coupling": 20984,
      "agonists": 9318,
      "inhibitory": 38815,
      "excitatory": 30472,
      "constant": 19737,
      "conversion": 20706,
      "decreasing": 23067,
      "acts": 7597,
      "potency": 63067,
      "managing": 43280,
      "somatic": 76453,
      "origin": 53781,
      "wide": 87041,
      "settings": 74852,
      "scope": 73693,
      "comprehensive": 18620,
      "evaluation": 29951,
      "perspective": 60960,
      "clinic": 16740,
      "medline": 44726,
      "embase": 28635,
      "cochrane": 17165,
      "compile": 18416,
      "profiles": 65514,
      "emerging": 28709,
      "support": 79186,
      "prolonged": 65610,
      "fast": 31199,
      "controlling": 20654,
      "hours": 35725,
      "providing": 66245,
      "clinically": 16972,
      "meaningful": 43911,
      "improving": 37191,
      "quality": 66672,
      "spectrum": 76675,
      "types": 83362,
      "relevant": 70041,
      "suitable": 79052,
      "popular": 62290,
      "superior": 79122,
      "bioavailability": 13835,
      "terms": 80699,
      "influences": 38605,
      "elimination": 28609,
      "unlike": 83893,
      "metabolized": 44991,
      "cytochrome": 21650,
      "impaired": 36870,
      "dysfunction": 27221,
      "utilized": 85740,
      "sustained": 79774,
      "benefits": 13628,
      "deaths": 22731,
      "usually": 85694,
      "polysubstance": 62226,
      "combined": 17634,
      "psychostimulants": 66365,
      "benzodiazepines": 13651,
      "alcohol": 9523,
      "little": 42144,
      "cost": 20860,
      "hospices": 35554,
      "valued": 85827,
      "ineffective": 38488,
      "insufficient": 39120,
      "intense": 39208,
      "sedation": 74305,
      "hallucinations": 34537,
      "nausea": 48754,
      "vomiting": 86438,
      "beneficial": 13593,
      "unsuccessfully": 83950,
      "weak": 86782,
      "tramadol": 82019,
      "dihydrocodeine": 24988,
      "attributed": 12610,
      "affinity": 8944,
      "possibly": 62552,
      "penetration": 60387,
      "brain": 14314,
      "barrier": 13254,
      "plasma": 61894,
      "displays": 25478,
      "renal": 70350,
      "impairment": 36881,
      "production": 65436,
      "introduced": 39910,
      "launched": 41246,
      "outline": 54111,
      "rules": 73038,
      "equianalgesic": 29255,
      "ratio": 67710,
      "modern": 47218,
      "involves": 40118,
      "optimizing": 53445,
      "includes": 37582,
      "utilization": 85727,
      "modalities": 47012,
      "consideration": 19620,
      "matching": 43493,
      "physiology": 61474,
      "pd": 60288,
      "duration": 27145,
      "pk": 61573,
      "agent": 9215,
      "requirements": 70876,
      "steroidal": 77341,
      "anti": 11110,
      "inflammatory": 38550,
      "nsaids": 50098,
      "options": 53468,
      "specialized": 76569,
      "helpful": 34915,
      "pains": 58020,
      "migraine": 46417,
      "headache": 34654,
      "remain": 70244,
      "option": 53448,
      "limiting": 41968,
      "goal": 33270,
      "achieve": 7289,
      "maximum": 43579,
      "measured": 43950,
      "ir": 40190,
      "titration": 81475,
      "maximize": 43577,
      "considers": 19668,
      "dramatic": 26431,
      "costs": 20893,
      "large": 41117,
      "company": 17942,
      "offered": 50955,
      "justify": 40571,
      "undertaken": 83662,
      "preparations": 63779,
      "comparable": 17943,
      "advantage": 8606,
      "frequent": 32532,
      "dosed": 26112,
      "infrequently": 38689,
      "lower": 42566,
      "considered": 19624,
      "considerably": 19617,
      "appropriate": 11495,
      "children": 16018,
      "covariate": 21009,
      "fat": 31225,
      "human": 35936,
      "poorly": 62278,
      "quantified": 66778,
      "pooled": 62237,
      "concentration": 18666,
      "preterm": 64756,
      "neonates": 49104,
      "intramuscular": 39739,
      "buccal": 14468,
      "epidural": 29164,
      "nonlinear": 49756,
      "mixed": 46784,
      "models": 47104,
      "scale": 73480,
      "70": 5546,
      "individual": 38286,
      "described": 23648,
      "clearance": 16709,
      "infants": 38502,
      "237": 3133,
      "weeks": 86887,
      "44": 4521,
      "110": 1161,
      "compartment": 18391,
      "model": 47018,
      "best": 13681,
      "disposition": 25498,
      "parameter": 58152,
      "estimates": 29642,
      "cl": 16607,
      "48": 4680,
      "cv": 21542,
      "71": 5585,
      "clearances": 16722,
      "220": 3048,
      "64": 5377,
      "q3": 66617,
      "volume": 86390,
      "98": 6456,
      "76": 5734,
      "rapidly": 67399,
      "v2": 85750,
      "slow": 76261,
      "28": 3529,
      "weight": 86970,
      "volumes": 86404,
      "abs": 6584,
      "minutes": 46640,
      "nasogastric": 48660,
      "159": 1835,
      "relative": 69733,
      "673": 5486,
      "lag": 41079,
      "value": 85818,
      "neonate": 49103,
      "reached": 67932,
      "end": 28781,
      "scaling": 73593,
      "expenses": 30567,
      "japan": 40466,
      "quantity": 66822,
      "disposed": 25494,
      "known": 40896,
      "city": 16601,
      "cities": 16599,
      "official": 50975,
      "disposal": 25481,
      "association": 12468,
      "sheet": 75133,
      "worth": 87351,
      "2019": 2850,
      "20": 2263,
      "oxinorm": 54409,
      "institutions": 39102,
      "micrograms": 46368,
      "fen": 31406,
      "dispensing": 25437,
      "common": 17727,
      "huge": 35935,
      "small": 76271,
      "package": 56321,
      "simulation": 76029,
      "smaller": 76310,
      "units": 83830,
      "ms": 48076,
      "contin": 20118,
      "suppository": 79237,
      "sublingual": 78753,
      "hepatitis": 34962,
      "virus": 86247,
      "infectious": 38517,
      "disease": 25315,
      "infections": 38515,
      "rising": 72498,
      "alarming": 9514,
      "version": 86083,
      "exposed": 30738,
      "growth": 34377,
      "median": 44170,
      "222": 3054,
      "infection": 38512,
      "unintended": 83739,
      "declared": 22860,
      "largely": 41163,
      "excessive": 30458,
      "polydrug": 62192,
      "abused": 6915,
      "substances": 78823,
      "pose": 62431,
      "required": 70815,
      "warnings": 86721,
      "strongest": 77570,
      "warning": 86718,
      "risks": 72664,
      "point": 62075,
      "classes": 16666,
      "investigated": 40032,
      "diazepam": 24366,
      "adds": 7942,
      "depressant": 23559,
      "alter": 9679,
      "antinociceptive": 11235,
      "reversed": 72237,
      "fourfold": 32428,
      "reversal": 72231,
      "potentiate": 63271,
      "locomotor": 42240,
      "having": 34600,
      "potentiating": 63279,
      "reverses": 72245,
      "strategy": 77429,
      "32": 3900,
      "feasible": 31288,
      "circumvent": 16581,
      "street": 77463,
      "price": 64966,
      "durability": 27141,
      "center": 15514,
      "survey": 79691,
      "key": 40662,
      "informant": 38628,
      "streetrx": 77469,
      "researched": 71039,
      "surveillance": 79679,
      "radars": 66947,
      "average": 12854,
      "adjusted": 8014,
      "census": 15511,
      "declined": 22864,
      "persisted": 60912,
      "lesser": 41425,
      "extent": 30923,
      "self": 74451,
      "geometric": 33119,
      "despite": 23869,
      "crush": 21329,
      "solubility": 76435,
      "continued": 20129,
      "series": 74648,
      "fibromyalgia": 31681,
      "conditions": 19303,
      "affect": 8893,
      "probably": 65225,
      "aetiologies": 8887,
      "respond": 71297,
      "therapies": 80976,
      "standards": 76990,
      "assessment": 12105,
      "robust": 72711,
      "assesses": 12097,
      "bias": 13761,
      "november": 50027,
      "searched": 74133,
      "reviewed": 72371,
      "bibliographies": 13781,
      "reviews": 72401,
      "trial": 82993,
      "clinicaltrials": 17015,
      "world": 87303,
      "organisation": 53757,
      "international": 39468,
      "registry": 69403,
      "platform": 61982,
      "unpublished": 83922,
      "selection": 74403,
      "criteria": 21185,
      "randomised": 67008,
      "rcts": 67910,
      "double": 26335,
      "blind": 13915,
      "participant": 58253,
      "emphasis": 28728,
      "collection": 17494,
      "independently": 38171,
      "event": 29979,
      "issues": 40332,
      "tiers": 81178,
      "tier": 81177,
      "derived": 23629,
      "meeting": 44757,
      "subject": 78623,
      "minimal": 46568,
      "equivalent": 29278,
      "intensity": 39215,
      "intention": 39341,
      "imputation": 37212,
      "dropouts": 26479,
      "200": 2393,
      "comparison": 18364,
      "parallel": 58125,
      "failed": 31137,
      "meet": 44756,
      "numbers": 50277,
      "involving": 40120,
      "utility": 85719,
      "254": 3404,
      "204": 2922,
      "painful": 58000,
      "ranged": 67338,
      "group": 33524,
      "titrated": 81466,
      "60": 5217,
      "120": 1395,
      "daily": 21685,
      "benztropine": 13679,
      "sources": 76504,
      "improved": 37094,
      "moderately": 47214,
      "observation": 50593,
      "forward": 32419,
      "locf": 42230,
      "lasting": 41208,
      "86": 6003,
      "63": 5349,
      "needed": 48965,
      "harmful": 34586,
      "uncertain": 83464,
      "rr": 72881,
      "95": 6205,
      "confidence": 19434,
      "interval": 39548,
      "ci": 16362,
      "23": 3066,
      "withdrawals": 87169,
      "occurring": 50865,
      "69": 5513,
      "83": 5923,
      "43": 4493,
      "nnt": 49525,
      "03": 400,
      "unbiased": 83460,
      "suggests": 79036,
      "cause": 15342,
      "lethal": 41435,
      "respiratory": 71262,
      "depression": 23566,
      "breathing": 14416,
      "antinociception": 11215,
      "modeling": 47094,
      "constructed": 19808,
      "functions": 32727,
      "combine": 17633,
      "wanted": 86704,
      "unwanted": 83972,
      "hypothesized": 36307,
      "predominantly": 63602,
      "tested": 80795,
      "received": 68088,
      "ventilatory": 86062,
      "visit": 86259,
      "nociceptive": 49540,
      "electrical": 28504,
      "thermal": 81078,
      "tests": 80852,
      "regular": 69473,
      "intervals": 39603,
      "analyses": 10581,
      "carbon": 14968,
      "dioxide": 25027,
      "kinetics": 40841,
      "stood": 77388,
      "basis": 13476,
      "probability": 65217,
      "minus": 46632,
      "offset": 50977,
      "values": 85829,
      "site": 76155,
      "causing": 15404,
      "ranging": 67354,
      "ng": 49427,
      "ml": 46818,
      "obtained": 50755,
      "extrapolated": 30975,
      "tidal": 81173,
      "partial": 58235,
      "55": 5063,
      "mmhg": 46989,
      "creation": 21157,
      "contrary": 20210,
      "expectation": 30547,
      "close": 17066,
      "zero": 87757,
      "likelihood": 41787,
      "likeability": 41785,
      "alters": 9752,
      "modulation": 47261,
      "input": 39042,
      "differs": 24958,
      "errors": 29514,
      "manual": 43329,
      "verification": 86076,
      "resource": 71125,
      "intensive": 39331,
      "identifying": 36541,
      "manifestation": 43308,
      "driven": 26461,
      "procedure": 65266,
      "generalized": 32997,
      "additive": 7912,
      "gam": 32823,
      "enabled": 28759,
      "explicit": 30706,
      "incorporation": 37714,
      "demographic": 23267,
      "birth": 13877,
      "patterns": 60194,
      "contamination": 20092,
      "accuracy": 7098,
      "set": 74753,
      "58": 5150,
      "incorrect": 37715,
      "manually": 43334,
      "domain": 25703,
      "expert": 30684,
      "positives": 62512,
      "resulting": 71526,
      "predictive": 63571,
      "59": 5177,
      "outperformed": 54164,
      "systemic": 80019,
      "administrative": 8394,
      "investigate": 39996,
      "harms": 34593,
      "measure": 43933,
      "ed": 27321,
      "visits": 86274,
      "poisoning": 62156,
      "publicly": 66413,
      "insured": 39157,
      "february": 31302,
      "29": 3592,
      "select": 74381,
      "income": 37698,
      "score": 73701,
      "matched": 43482,
      "estimate": 29603,
      "months": 47425,
      "delisting": 23203,
      "milligrams": 46476,
      "equivalents": 29336,
      "mmes": 46983,
      "person": 60939,
      "week": 86823,
      "fell": 31340,
      "25": 3315,
      "decline": 22861,
      "corresponded": 20843,
      "hydromorphone": 36144,
      "disorder": 25367,
      "province": 66274,
      "quantities": 66817,
      "partially": 58249,
      "increases": 38051,
      "funded": 32732,
      "policies": 62174,
      "escalated": 29520,
      "extremely": 30981,
      "practitioner": 63447,
      "contact": 20046,
      "interpretation": 39497,
      "tapered": 80481,
      "causes": 15391,
      "plan": 61866,
      "norwegian": 49974,
      "eventually": 30138,
      "refused": 69227,
      "payments": 60252,
      "cooperation": 20748,
      "inpatient": 39007,
      "rehabilitation": 69508,
      "unit": 83763,
      "dexmedetomidine": 24292,
      "dex": 24275,
      "response": 71329,
      "tourniquet": 81921,
      "ischemia": 40286,
      "reperfusion": 70421,
      "injury": 38986,
      "c57": 14650,
      "mice": 46268,
      "construct": 19807,
      "mouse": 48031,
      "randomly": 67209,
      "sham": 75105,
      "morris": 47976,
      "water": 86754,
      "maze": 43619,
      "spatial": 76540,
      "learning": 41325,
      "memory": 44790,
      "expression": 30826,
      "nf": 49425,
      "\u03bab": 87782,
      "tlr4": 81492,
      "m1": 42782,
      "cd68": 15435,
      "tnf": 81499,
      "m2": 42784,
      "il": 36605,
      "markers": 43406,
      "hippocampus": 35430,
      "western": 86998,
      "blot": 14163,
      "staining": 76875,
      "spontaneous": 76750,
      "synaptic": 79911,
      "currents": 21511,
      "sepscs": 74601,
      "recorded": 68660,
      "electrophysiology": 28551,
      "alleviated": 9602,
      "declines": 22873,
      "regulated": 69492,
      "frequency": 32508,
      "amplitude": 9854,
      "impair": 36867,
      "inhibiting": 38774,
      "abnormal": 6576,
      "transmission": 82224,
      "hippocampal": 35427,
      "neurons": 49215,
      "microglia": 46365,
      "phenotype": 61347,
      "pathway": 58510,
      "exact": 30318,
      "endothelial": 28867,
      "aimed": 9433,
      "explore": 30717,
      "vivo": 86376,
      "vitro": 86353,
      "reveal": 72209,
      "sigma": 75377,
      "rat": 67416,
      "ischemic": 40288,
      "histopathological": 35440,
      "ldh": 41276,
      "expressions": 30841,
      "claudin": 16692,
      "afterward": 8961,
      "elisa": 28619,
      "rt": 73032,
      "qpcr": 66643,
      "immunofluorescence": 36780,
      "adopted": 8467,
      "inflammation": 38546,
      "genes": 33055,
      "tissues": 81454,
      "microvascular": 46385,
      "cells": 15492,
      "hypoxic": 36321,
      "blotting": 14165,
      "subsequently": 78783,
      "silencing": 75885,
      "cell": 15470,
      "apoptosis": 11369,
      "stimulated": 77362,
      "evidenced": 30294,
      "upregulated": 84011,
      "docking": 25654,
      "bind": 13809,
      "deletion": 23198,
      "attenuated": 12583,
      "collectively": 17504,
      "alleviates": 9604,
      "ciprofloxacin": 16565,
      "concomitantly": 19257,
      "auc": 12623,
      "failures": 31154,
      "label": 40967,
      "way": 86772,
      "crossover": 21284,
      "400": 4389,
      "po": 62052,
      "starting": 77011,
      "31": 3838,
      "vs": 86500,
      "cmax": 17094,
      "regimens": 69330,
      "tmax": 81495,
      "concluded": 18853,
      "orally": 53685,
      "bioavailable": 13843,
      "ethanol": 29677,
      "tail": 80240,
      "assay": 11874,
      "seen": 74355,
      "subcutaneous": 78598,
      "challenge": 15690,
      "twice": 83289,
      "reverse": 72235,
      "true": 83251,
      "neuronal": 49208,
      "expected": 30551,
      "relationship": 69711,
      "immersion": 36757,
      "existed": 30522,
      "metabolic": 44903,
      "component": 18576,
      "1996": 2234,
      "expenditures": 30565,
      "pa": 56315,
      "strict": 77499,
      "beneficiaries": 13607,
      "secondary": 74201,
      "aggregate": 9253,
      "records": 68716,
      "details": 23918,
      "systematically": 80007,
      "random": 66993,
      "meta": 44886,
      "opiates": 51318,
      "accounted": 7080,
      "expenditure": 30564,
      "109": 1076,
      "annually": 11033,
      "nonsignificant": 49847,
      "refined": 69183,
      "unfortunately": 83727,
      "precipitated": 63511,
      "mor": 47491,
      "ca": 14658,
      "transient": 82193,
      "medium": 44722,
      "sized": 76187,
      "spiny": 76731,
      "freely": 32496,
      "animals": 11001,
      "imaging": 36683,
      "d1": 21678,
      "cre": 21134,
      "expressing": 30824,
      "direct": 25036,
      "adenosine": 7951,
      "indirect": 38282,
      "aid": 9366,
      "miniaturized": 46567,
      "genetically": 33089,
      "indicator": 38276,
      "paradoxically": 58124,
      "transients": 82195,
      "purposes": 66596,
      "separate": 74585,
      "injected": 38913,
      "cerebral": 15641,
      "cortex": 20851,
      "cortical": 20853,
      "pyramidal": 66611,
      "electrophysiological": 28550,
      "slices": 76243,
      "confirmed": 19502,
      "membrane": 44785,
      "hyperpolarization": 36272,
      "excitability": 30471,
      "postsynaptic": 63053,
      "demonstrate": 23310,
      "dissociation": 25523,
      "locomotion": 42239,
      "striatal": 77496,
      "functional": 32687,
      "connectivity": 19545,
      "confounded": 19518,
      "comorbidity": 17938,
      "thalamus": 80896,
      "sensory": 74571,
      "processing": 65348,
      "representing": 70762,
      "pure": 66504,
      "dual": 27110,
      "opioidergic": 52651,
      "adrenergic": 8475,
      "armed": 11682,
      "14": 1543,
      "days": 22455,
      "resting": 71439,
      "magnetic": 42800,
      "resonance": 71119,
      "seed": 74343,
      "048": 468,
      "bilateral": 13791,
      "anterior": 11101,
      "cingulate": 16563,
      "005": 261,
      "supports": 79233,
      "exert": 30499,
      "sample": 73286,
      "sizes": 76188,
      "validate": 85780,
      "australia": 12679,
      "line": 41984,
      "internationally": 39486,
      "limits": 41978,
      "short": 75153,
      "hospitals": 35668,
      "electronic": 28529,
      "queensland": 66870,
      "evaluating": 29943,
      "written": 87373,
      "utilised": 85716,
      "uncontrolled": 83492,
      "interrupted": 39536,
      "december": 22818,
      "2021": 2910,
      "analysed": 10571,
      "sequential": 74632,
      "came": 14741,
      "september": 74605,
      "month": 47381,
      "implementation": 36926,
      "restrictive": 71464,
      "resulted": 71499,
      "efforts": 28436,
      "tailored": 80260,
      "ensure": 29041,
      "judicious": 40501,
      "extensively": 30920,
      "remains": 70285,
      "predict": 63546,
      "separated": 74591,
      "hour": 35691,
      "washout": 86744,
      "inhaled": 38763,
      "mixture": 46809,
      "oxygen": 56199,
      "72": 5609,
      "minute": 46634,
      "flow": 31932,
      "saturation": 73468,
      "continuously": 20196,
      "180": 2118,
      "endpoint": 28877,
      "slope": 76258,
      "035": 434,
      "statistical": 77169,
      "significance": 75402,
      "likewise": 41854,
      "testing": 80817,
      "poses": 62435,
      "concern": 18821,
      "house": 35878,
      "enacted": 28762,
      "address": 7922,
      "schedule": 73610,
      "ii": 36553,
      "outpatient": 54113,
      "149": 1660,
      "pcp": 60282,
      "attention": 12563,
      "wrote": 87379,
      "opana": 51140,
      "38": 4223,
      "47": 4645,
      "office": 50966,
      "scrutiny": 74058,
      "warranted": 86726,
      "provider": 66172,
      "habits": 34497,
      "institution": 39073,
      "compliance": 18533,
      "regulator": 69501,
      "signaling": 75388,
      "enriched": 28985,
      "signal": 75383,
      "transduction": 82174,
      "modulator": 47264,
      "controls": 20663,
      "coupled": 20970,
      "complexes": 18530,
      "negatively": 49084,
      "promote": 65661,
      "positively": 62509,
      "modulates": 47259,
      "lacking": 41064,
      "gene": 32941,
      "regulates": 69494,
      "rewarding": 72433,
      "furthermore": 32746,
      "modulate": 47252,
      "symptoms": 79872,
      "terminal": 80683,
      "na\u00efve": 48825,
      "continuous": 20156,
      "inpatients": 39037,
      "palliative": 58032,
      "team": 80537,
      "retrospectively": 72174,
      "improvement": 37140,
      "68": 5491,
      "performance": 60548,
      "survival": 79754,
      "377": 4219,
      "somnolence": 76461,
      "reasonable": 68015,
      "resistance": 71090,
      "property": 65722,
      "molecules": 47295,
      "commercial": 17700,
      "compressive": 18634,
      "strength": 77471,
      "heat": 34878,
      "extract": 30945,
      "maintained": 42885,
      "milling": 46482,
      "released": 70021,
      "immediately": 36743,
      "milled": 46446,
      "dumping": 27137,
      "cover": 21013,
      "abuser": 6928,
      "matrix": 43537,
      "accessible": 7010,
      "decision": 22843,
      "recognized": 68572,
      "sedative": 74335,
      "psychotropic": 66368,
      "substituted": 78872,
      "concurrently": 19273,
      "ability": 6548,
      "alternatives": 9750,
      "respiration": 71260,
      "conjunction": 19541,
      "nonclinical": 49720,
      "worsening": 87334,
      "benzodiazepine": 13648,
      "arterial": 11708,
      "pco": 60281,
      "representative": 70756,
      "clozapine": 17081,
      "quetiapine": 66913,
      "risperidone": 72686,
      "zolpidem": 87767,
      "trazodone": 82269,
      "carisoprodol": 15121,
      "cyclobenzaprine": 21552,
      "mirtazapine": 46690,
      "topiramate": 81699,
      "paroxetine": 58231,
      "duloxetine": 27122,
      "exposures": 30802,
      "exceeded": 30434,
      "considerable": 19608,
      "utilisation": 85710,
      "resources": 71128,
      "pilot": 61550,
      "projects": 65596,
      "optimise": 53438,
      "concepts": 18819,
      "stewardship": 77349,
      "suite": 79055,
      "principles": 65131,
      "science": 73677,
      "local": 42199,
      "audits": 12652,
      "guided": 34410,
      "sensitive": 74541,
      "educational": 27400,
      "repeat": 70391,
      "audit": 12649,
      "departments": 23452,
      "eds": 27369,
      "24h": 3311,
      "cumulative": 21388,
      "0001": 52,
      "91": 6128,
      "013": 337,
      "accompanied": 7023,
      "facilitated": 31036,
      "advance": 8589,
      "topic": 81694,
      "harm": 34575,
      "scheme": 73662,
      "default": 23096,
      "implement": 36922,
      "australian": 12695,
      "add": 7724,
      "implications": 36959,
      "practitioners": 63448,
      "practical": 63386,
      "pragmatic": 63453,
      "achievable": 7288,
      "adapt": 7717,
      "steps": 77329,
      "consistently": 19719,
      "demonstrable": 23309,
      "compelling": 18404,
      "prospect": 65811,
      "predicting": 63566,
      "surrogates": 79673,
      "improve": 37053,
      "efficiency": 28419,
      "reproducible": 70775,
      "analytically": 10807,
      "blinded": 13995,
      "validated": 85782,
      "chromatographic": 16145,
      "spectrometric": 76653,
      "oxymorphone": 56217,
      "17": 1924,
      "serial": 74642,
      "assessments": 12147,
      "signs": 75872,
      "vas": 85998,
      "questionnaires": 66900,
      "prompt": 65673,
      "pathological": 58501,
      "syndromes": 79924,
      "investigators": 40082,
      "earlier": 27240,
      "accurate": 7099,
      "predictions": 63570,
      "deterx": 24133,
      "xtampza": 87408,
      "chewed": 15977,
      "triple": 83233,
      "dummy": 27126,
      "nondependent": 49726,
      "crushed": 21331,
      "differentiate": 24947,
      "fasted": 31205,
      "fed": 31316,
      "ratings": 67687,
      "visual": 86301,
      "analog": 10520,
      "scales": 73588,
      "liking": 41855,
      "squares": 76802,
      "max": 43543,
      "ls": 42744,
      "error": 29509,
      "good": 33291,
      "feeling": 31334,
      "bioequivalent": 13847,
      "respective": 71140,
      "swallowed": 79805,
      "rationale": 67808,
      "pressing": 64730,
      "classical": 16673,
      "morphinan": 47522,
      "precipitating": 63516,
      "pharmacotherapies": 61245,
      "depressed": 23563,
      "methylxanthines": 45666,
      "class": 16650,
      "stimulant": 77353,
      "caffeine": 14669,
      "theophylline": 80910,
      "primarily": 64974,
      "antagonism": 11055,
      "stimulate": 77360,
      "enhancing": 28979,
      "neural": 49166,
      "nuclei": 50118,
      "medulla": 44755,
      "independent": 38156,
      "plethysmography": 62016,
      "swiss": 79814,
      "webster": 86820,
      "basal": 13264,
      "dependently": 23541,
      "min": 46503,
      "reversible": 72248,
      "reversing": 72249,
      "augment": 12654,
      "cyp2d": 21585,
      "contribution": 20245,
      "permeability": 60903,
      "efflux": 28427,
      "variation": 85913,
      "affecting": 8924,
      "exogenous": 30535,
      "nicotine": 49468,
      "induces": 38469,
      "smokers": 76335,
      "microdialysis": 46352,
      "flick": 31914,
      "selectively": 74446,
      "intracerebroventricular": 39730,
      "propranolol": 65808,
      "inhibitor": 38790,
      "inducing": 38471,
      "fold": 31980,
      "ratios": 67813,
      "affected": 8914,
      "inversely": 39993,
      "correlated": 20809,
      "ex": 30309,
      "003": 246,
      "hepatic": 34949,
      "substrate": 78883,
      "minimizing": 46604,
      "establish": 29579,
      "cerebrospinal": 15643,
      "fluid": 31940,
      "csf": 21358,
      "epi": 29121,
      "undergoing": 83508,
      "elective": 28484,
      "gynecological": 34492,
      "catheter": 15312,
      "placed": 61858,
      "t12": 80055,
      "l1": 40959,
      "spinal": 76698,
      "sampling": 73369,
      "l3": 40961,
      "built": 14478,
      "nonmem": 49795,
      "software": 76411,
      "compartments": 18401,
      "space": 76518,
      "depot": 23558,
      "transfer": 82178,
      "apparent": 11378,
      "fixed": 31870,
      "039": 438,
      "precisely": 63522,
      "accurately": 7103,
      "usa": 84106,
      "characterized": 15911,
      "develops": 24260,
      "pkc": 61591,
      "pregabalin": 63653,
      "experimental": 30655,
      "cd": 15432,
      "implanted": 36920,
      "mini": 46562,
      "pumps": 66481,
      "delivering": 23212,
      "challenged": 15695,
      "\u03bcg": 87784,
      "contributory": 20257,
      "factor": 31047,
      "medicate": 44442,
      "emotional": 28725,
      "thought": 81136,
      "consisting": 19725,
      "somatosensory": 76458,
      "affective": 8930,
      "dorsal": 25734,
      "acc": 6969,
      "fmri": 31965,
      "scan": 73594,
      "ingestion": 38742,
      "correlations": 20838,
      "putamen": 66599,
      "right": 72474,
      "correction": 20799,
      "comparisons": 18384,
      "preliminary": 63711,
      "idea": 36403,
      "disruption": 25507,
      "sought": 76478,
      "derivative": 23618,
      "hs": 35905,
      "attenuate": 12575,
      "retaining": 72075,
      "enrolled": 28993,
      "preference": 63620,
      "saline": 73253,
      "sets": 74758,
      "conditioning": 19302,
      "blocked": 14081,
      "hot": 35679,
      "plate": 61968,
      "abdominal": 6524,
      "writhing": 87370,
      "subanalgesic": 78593,
      "condition": 19274,
      "void": 86385,
      "aversive": 12954,
      "nociception": 49536,
      "subadditive": 78592,
      "compound": 18601,
      "loss": 42429,
      "occurs": 50866,
      "clear": 16698,
      "physically": 61419,
      "experience": 30569,
      "maintenance": 42906,
      "phases": 61324,
      "stabilization": 76829,
      "cold": 17420,
      "pressor": 64734,
      "scheduled": 73633,
      "physiologic": 61455,
      "expired": 30696,
      "breath": 14415,
      "signals": 75395,
      "understand": 83620,
      "sensitivity": 74553,
      "describes": 23663,
      "physiological": 61457,
      "euphoric": 29726,
      "cerebrovascular": 15647,
      "stroke": 77507,
      "worldwide": 87323,
      "glucose": 33245,
      "deprivation": 23612,
      "reliability": 70077,
      "experiments": 30679,
      "viability": 86185,
      "firstly": 31847,
      "application": 11423,
      "mrna": 48069,
      "tight": 81179,
      "junction": 40535,
      "proteins": 65943,
      "cytokines": 21670,
      "damage": 21819,
      "manner": 43321,
      "importantly": 37042,
      "exhibited": 30509,
      "relieved": 70220,
      "guidelines": 34425,
      "dyspnoea": 27234,
      "inferiority": 38529,
      "relieving": 70227,
      "multicentre": 48174,
      "assigned": 12164,
      "numeric": 50289,
      "rating": 67649,
      "terminated": 80692,
      "78": 5772,
      "41": 4409,
      "00": 0,
      "08": 621,
      "requirement": 70868,
      "drowsiness": 26488,
      "effectiveness": 27743,
      "registration": 69383,
      "umin": 83444,
      "ctr": 21368,
      "manufacturers": 43339,
      "incorporating": 37713,
      "technologies": 80552,
      "exhaustive": 30506,
      "incremental": 38142,
      "fashion": 31196,
      "iterative": 40355,
      "description": 23671,
      "pertinent": 60975,
      "chemical": 15946,
      "real": 67998,
      "scenarios": 73607,
      "applied": 11431,
      "interpreted": 39508,
      "ease": 27277,
      "manipulation": 43315,
      "materials": 43503,
      "purity": 66512,
      "deterrence": 24101,
      "breathlessness": 14418,
      "distress": 25547,
      "etiologies": 29711,
      "optimally": 53437,
      "multisite": 48310,
      "arm": 11662,
      "hourly": 35722,
      "anzctr": 11290,
      "org": 53743,
      "arms": 11683,
      "ethics": 29686,
      "committee": 17726,
      "recruitment": 68801,
      "services": 74724,
      "modified": 47234,
      "council": 20921,
      "mm": 46922,
      "analogue": 10548,
      "worst": 87336,
      "157": 1832,
      "155": 1828,
      "74": 5667,
      "81": 5879,
      "reach": 67928,
      "target": 80484,
      "prespecified": 64722,
      "existence": 30523,
      "controversial": 20676,
      "yr": 87745,
      "gynaecological": 34482,
      "operation": 51214,
      "rescue": 70924,
      "320": 3942,
      "unexpected": 83716,
      "eudract": 29722,
      "reference": 69127,
      "challenging": 15707,
      "anesthesiologists": 10953,
      "leading": 41299,
      "progress": 65568,
      "pcia": 60276,
      "register": 69367,
      "web": 86809,
      "chinese": 16090,
      "infrastructure": 38686,
      "wanfang": 86703,
      "vip": 86236,
      "sufentanil": 78937,
      "ramsay": 66986,
      "numerical": 50306,
      "scores": 73817,
      "md": 43635,
      "i2": 36330,
      "93": 6168,
      "85": 5973,
      "promoted": 65667,
      "deeper": 23093,
      "77": 5754,
      "97": 6434,
      "odds": 50894,
      "88": 6034,
      "improves": 37180,
      "surgeries": 79282,
      "prospero": 65905,
      "ac": 6941,
      "uk": 83409,
      "project": 65586,
      "overnight": 54347,
      "stay": 77271,
      "inappropriate": 37240,
      "wards": 86711,
      "sydney": 79844,
      "monthly": 47417,
      "admissions": 8413,
      "fifth": 31685,
      "comprising": 18638,
      "plus": 62023,
      "academic": 6942,
      "detailing": 23917,
      "39": 4258,
      "115": 1180,
      "postintervention": 62665,
      "coefficient": 17310,
      "dropped": 26480,
      "002": 234,
      "volunteer": 86410,
      "cirrhosis": 16583,
      "transplantation": 82236,
      "noroxycodone": 49924,
      "half": 34509,
      "strongly": 77575,
      "explored": 30730,
      "determining": 24097,
      "1000": 1030,
      "\u03bcm": 87800,
      "characterization": 15886,
      "powder": 63285,
      "analytical": 10800,
      "content": 20095,
      "uniformity": 83733,
      "particle": 58394,
      "500": 4914,
      "\u00b5m": 87777,
      "excipient": 30467,
      "impacted": 36857,
      "dissolution": 25525,
      "antidepressants": 11168,
      "inhibit": 38768,
      "serotonin": 74670,
      "norepinephrine": 49887,
      "reuptake": 72197,
      "mode": 47015,
      "venlafaxine": 86054,
      "supraspinal": 79253,
      "proxy": 66286,
      "reflex": 69195,
      "stimulation": 77368,
      "sole": 76423,
      "foot": 32241,
      "muscle": 48359,
      "channel": 15833,
      "electroencephalogram": 28520,
      "evoked": 30302,
      "stimulations": 77376,
      "simultaneously": 76037,
      "curve": 21517,
      "aucs": 12646,
      "emg": 28718,
      "latencies": 41224,
      "computed": 18652,
      "peaks": 60331,
      "source": 76492,
      "04": 440,
      "shifted": 75139,
      "mid": 46389,
      "network": 49156,
      "exerts": 30503,
      "reflect": 69185,
      "balance": 13227,
      "descending": 23645,
      "inhibition": 38775,
      "facilitation": 31039,
      "hand": 34547,
      "ongoing": 51081,
      "going": 33282,
      "undetected": 83711,
      "urinalysis": 84051,
      "437": 4518,
      "usual": 85687,
      "enzyme": 29097,
      "multiplied": 48306,
      "emit": 28722,
      "300": 3808,
      "supplemental": 79161,
      "shorter": 75207,
      "cocaine": 17132,
      "illustrate": 36666,
      "clinics": 17042,
      "rigorous": 72484,
      "stability": 76826,
      "decisions": 22852,
      "eligibility": 28574,
      "cesarean": 15673,
      "section": 74268,
      "link": 42043,
      "anesthetics": 10975,
      "behavioral": 13541,
      "cognitive": 17319,
      "stem": 77312,
      "biological": 13849,
      "differentiation": 24951,
      "weaker": 86798,
      "successfully": 78918,
      "allowed": 9635,
      "unnecessary": 83911,
      "proactively": 65210,
      "funding": 32734,
      "savings": 73472,
      "proven": 66024,
      "enhance": 28948,
      "governments": 33355,
      "discontinue": 25238,
      "framing": 32482,
      "framework": 32478,
      "frames": 32477,
      "explanatory": 30705,
      "selected": 74385,
      "fund": 32729,
      "strips": 77505,
      "diabetes": 24309,
      "political": 62187,
      "debate": 22796,
      "surrounding": 79674,
      "reflection": 69192,
      "complexity": 18532,
      "causal": 15332,
      "told": 81513,
      "frame": 32475,
      "applying": 11443,
      "shape": 75113,
      "timing": 81438,
      "withdraw": 87114,
      "mo": 46999,
      "025": 389,
      "intravenously": 39891,
      "additionally": 7905,
      "neurotoxicity": 49291,
      "requires": 70892,
      "intrathecal": 39790,
      "routine": 72859,
      "culture": 21379,
      "cytotoxicity": 21676,
      "underlying": 83601,
      "toxicity": 81930,
      "neuroblastoma": 49185,
      "0125": 336,
      "96": 6416,
      "cultures": 21383,
      "yl": 87704,
      "bromide": 14455,
      "apoptotic": 11370,
      "cytometry": 21673,
      "electron": 28525,
      "microscopy": 46377,
      "images": 36680,
      "appearance": 11390,
      "numerous": 50327,
      "probable": 65223,
      "vacuoles": 85756,
      "antagonists": 11076,
      "prepared": 63788,
      "thebaine": 80900,
      "nmr": 49522,
      "spectroscopy": 76674,
      "computational": 18649,
      "density": 23397,
      "311": 3885,
      "assignment": 12185,
      "spectra": 76650,
      "frequencies": 32507,
      "shifts": 75142,
      "experimentally": 30676,
      "theoretically": 80912,
      "agreements": 9352,
      "absorptions": 6617,
      "105": 1061,
      "cm": 17087,
      "87": 6017,
      "ppm": 63299,
      "continues": 20146,
      "arir": 11654,
      "composed": 18594,
      "overlapping": 54344,
      "barriers": 13259,
      "emax": 28634,
      "bipolar": 13874,
      "desire": 23863,
      "slower": 76267,
      "tolerated": 81617,
      "discrimination": 25274,
      "nineteen": 49479,
      "80": 5820,
      "endpoints": 28908,
      "questions": 66905,
      "questionnaire": 66887,
      "maximal": 43571,
      "determinations": 23984,
      "twofold": 83312,
      "delivery": 23214,
      "believed": 13582,
      "predictor": 63580,
      "reinforcing": 69521,
      "behavior": 13526,
      "experiment": 30653,
      "morning": 47517,
      "worked": 87289,
      "sampled": 73321,
      "money": 47304,
      "afternoon": 8960,
      "finger": 31841,
      "presses": 64729,
      "computer": 18659,
      "reinforcer": 69519,
      "delivered": 23206,
      "empirical": 28735,
      "convert": 20720,
      "subsidy": 78793,
      "expanded": 30539,
      "market": 43407,
      "repatriation": 70388,
      "linked": 42047,
      "nsw": 50109,
      "veterans": 86174,
      "affairs": 8890,
      "dva": 27200,
      "card": 14976,
      "holders": 35502,
      "residing": 71082,
      "clients": 16732,
      "dispensings": 25463,
      "initiations": 38902,
      "initiating": 38886,
      "uptake": 84017,
      "buprenorphine": 14514,
      "initiate": 38876,
      "preceding": 63499,
      "highlight": 35372,
      "potentiation": 63280,
      "endothelin": 28870,
      "et": 29668,
      "imidazoline": 36692,
      "adrenoceptor": 8479,
      "documented": 25664,
      "adrenoceptors": 8480,
      "involvement": 40115,
      "subtypes": 78896,
      "understood": 83655,
      "bu224": 14467,
      "similarly": 76009,
      "demonstrating": 23384,
      "enhancement": 28976,
      "conclude": 18850,
      "peripherally": 60887,
      "activating": 7466,
      "expressed": 30813,
      "afferent": 8940,
      "nerves": 49132,
      "gut": 34478,
      "novel": 49998,
      "cr665": 21116,
      "bag": 13222,
      "oesophageal": 50942,
      "probe": 65228,
      "generate": 33036,
      "fit": 31857,
      "vi": 86184,
      "fitted": 31863,
      "transit": 82196,
      "feeding": 31329,
      "delay": 23188,
      "089": 635,
      "steeper": 77310,
      "0035": 255,
      "selectivity": 74447,
      "effectively": 27724,
      "nonsurgical": 49861,
      "managed": 43129,
      "payer": 60245,
      "markov": 43439,
      "simulate": 76026,
      "simulated": 76027,
      "occurrence": 50852,
      "aes": 8866,
      "switching": 79829,
      "inputs": 39043,
      "surveys": 79745,
      "medicare": 44432,
      "fee": 31324,
      "schedules": 73659,
      "wholesale": 87037,
      "acquisition": 7362,
      "2008": 2496,
      "dollars": 25701,
      "57": 5123,
      "99": 6480,
      "139": 1541,
      "144": 1645,
      "79": 5794,
      "92": 6150,
      "dominant": 25708,
      "corresponding": 20845,
      "com": 17531,
      "admission": 8403,
      "persistence": 60914,
      "s8": 73056,
      "reviewing": 72399,
      "royal": 72879,
      "tasmania": 80521,
      "lists": 42103,
      "supplied": 79173,
      "determination": 23979,
      "reporting": 70682,
      "853": 5997,
      "thirty": 81101,
      "authorities": 12713,
      "progression": 65572,
      "indications": 38271,
      "cncp": 17105,
      "monte": 47378,
      "carlo": 15123,
      "scientific": 73684,
      "foundation": 32425,
      "teae": 80535,
      "supplemented": 79170,
      "sparingly": 76536,
      "opinion": 51343,
      "demonstrates": 23375,
      "achieving": 7331,
      "gi": 33142,
      "productive": 65437,
      "working": 87295,
      "modeled": 47092,
      "strengthened": 77476,
      "centric": 15639,
      "scleroderma": 73690,
      "skin": 76198,
      "ulcers": 83413,
      "consecutive": 19554,
      "rheumatology": 72460,
      "complicated": 18544,
      "standing": 76993,
      "classified": 16685,
      "organization": 53764,
      "mundipharma": 48355,
      "pharmaceuticals": 61046,
      "milan": 46422,
      "italy": 40340,
      "administrated": 8199,
      "dosage": 25740,
      "20mg": 2931,
      "deviation": 24261,
      "pittsburgh": 61566,
      "sleep": 76211,
      "index": 38185,
      "psqi": 66321,
      "night": 49472,
      "56": 5092,
      "markedly": 43396,
      "monitor": 47305,
      "pharmacotherapy": 61248,
      "adherence": 7992,
      "subtherapeutic": 78891,
      "quinine": 66921,
      "tracer": 81969,
      "examination": 30323,
      "urinary": 84052,
      "cyp3a": 21628,
      "displayed": 25470,
      "t1": 80050,
      "safely": 73108,
      "94": 6185,
      "postdose": 62644,
      "appears": 11397,
      "candidate": 14921,
      "missed": 46695,
      "insoluble": 39056,
      "viscous": 86256,
      "currently": 21487,
      "men": 44793,
      "subscale": 78773,
      "chewing": 15981,
      "prevalent": 64824,
      "distressing": 25551,
      "terminally": 80687,
      "ill": 36618,
      "accumulated": 7090,
      "injectable": 38910,
      "containing": 20066,
      "hydrocotarnine": 36139,
      "136": 1534,
      "varying": 85992,
      "degrees": 23179,
      "alo": 9652,
      "pellets": 60376,
      "sequestered": 74635,
      "intended": 39203,
      "sodium": 76402,
      "chloride": 16101,
      "aue": 12653,
      "2h": 3651,
      "validity": 85802,
      "104": 1059,
      "152": 1823,
      "133": 1525,
      "nonmedical": 49772,
      "inter": 39352,
      "underline": 83599,
      "static": 77165,
      "dynamic": 27214,
      "quantitative": 66795,
      "qst": 66648,
      "methodology": 45227,
      "latency": 41226,
      "cpt": 21047,
      "consisted": 19669,
      "measuring": 44105,
      "diffuse": 24976,
      "noxious": 50046,
      "summation": 79112,
      "ts": 83268,
      "predicted": 63561,
      "027": 395,
      "prediction": 63567,
      "quantify": 66783,
      "paracetamol": 58089,
      "pot": 63062,
      "sublingually": 78759,
      "occasions": 50815,
      "ppt": 63301,
      "156": 1831,
      "552": 5088,
      "potencies": 63066,
      "mathematical": 43532,
      "evolution": 30305,
      "quantification": 66770,
      "sparse": 76537,
      "percutaneous": 60541,
      "radiofrequency": 66964,
      "ablation": 6560,
      "technique": 80543,
      "anesthesia": 10898,
      "comfort": 17691,
      "immobilization": 36762,
      "society": 76367,
      "grade": 33364,
      "ultrasound": 83431,
      "remifentanil": 70321,
      "checked": 15941,
      "periprocedural": 60896,
      "later": 41233,
      "movements": 48057,
      "allergic": 9587,
      "reaction": 67942,
      "rigidity": 72482,
      "satisfactory": 73447,
      "relieves": 70226,
      "procedural": 65262,
      "develop": 24142,
      "metrics": 45670,
      "la": 40962,
      "mitigation": 46768,
      "rems": 70349,
      "cohorts": 17410,
      "ero": 29505,
      "tolerant": 81609,
      "ordering": 53729,
      "screens": 74055,
      "definitions": 23162,
      "usage": 84111,
      "episodes": 29205,
      "met": 44867,
      "definition": 23160,
      "deemed": 23081,
      "filled": 31699,
      "consumed": 19822,
      "traditional": 81981,
      "limit": 41883,
      "budget": 14473,
      "placing": 61864,
      "annual": 11009,
      "base": 13266,
      "share": 75117,
      "member": 44770,
      "members": 44772,
      "adding": 7790,
      "148": 1657,
      "945": 6203,
      "0248": 388,
      "062": 593,
      "0008": 91,
      "replacing": 70436,
      "levofloxacin": 41624,
      "laparoscopy": 41112,
      "modelling": 47102,
      "021": 384,
      "interquartile": 39513,
      "enters": 29068,
      "absorbed": 6606,
      "circulation": 16575,
      "laparoscopic": 41089,
      "permeation": 60904,
      "unusual": 83969,
      "fatality": 31247,
      "child": 16007,
      "exhibiting": 30518,
      "mouth": 48040,
      "staggering": 76874,
      "toxicological": 81939,
      "tricyclic": 83214,
      "discharged": 25186,
      "unresponsive": 83935,
      "cardiopulmonary": 14989,
      "arrest": 11696,
      "resuscitative": 72068,
      "pronounced": 65679,
      "arrival": 11702,
      "autopsy": 12769,
      "submitted": 78764,
      "screened": 74028,
      "techniques": 80547,
      "contents": 20104,
      "34": 4014,
      "230": 3123,
      "limitation": 41895,
      "forensic": 32261,
      "middle": 46400,
      "suffering": 78963,
      "seventy": 74885,
      "pupil": 66485,
      "indication": 38267,
      "simple": 76017,
      "verbal": 86069,
      "return": 72185,
      "indicates": 38251,
      "clinicians": 17025,
      "avoid": 12957,
      "belief": 13579,
      "younger": 87725,
      "intranasally": 39762,
      "api": 11362,
      "pupillometry": 66492,
      "irritation": 40283,
      "yielded": 87696,
      "epidemiological": 29159,
      "document": 25660,
      "problematic": 65248,
      "admitted": 8419,
      "2000": 2413,
      "lawrence": 41252,
      "detoxification": 24136,
      "534": 5031,
      "governmental": 33354,
      "household": 35879,
      "mentioned": 44835,
      "vicodin": 86195,
      "53": 5013,
      "predictors": 63585,
      "diagnoses": 24326,
      "enzymes": 29110,
      "genotypes": 33101,
      "poor": 62253,
      "metaboliser": 44916,
      "pm": 62038,
      "extensive": 30915,
      "em": 28630,
      "genotyped": 33099,
      "variants": 85909,
      "brief": 14426,
      "inventory": 39975,
      "bpi": 14297,
      "eortc": 29117,
      "qlq": 66629,
      "c30": 14644,
      "tiredness": 81442,
      "associations": 12492,
      "variance": 85903,
      "anova": 11044,
      "covariance": 21007,
      "ancova": 10888,
      "ordinal": 53732,
      "logistic": 42252,
      "regressions": 69471,
      "covariates": 21010,
      "413": 4439,
      "noroxymorphone": 49944,
      "caused": 15376,
      "consequence": 19587,
      "failure": 31145,
      "play": 61989,
      "changing": 15831,
      "chart": 15924,
      "mmt": 46994,
      "historical": 35443,
      "element": 28556,
      "charts": 15936,
      "transition": 82200,
      "exploratory": 30712,
      "dependency": 23493,
      "uds": 83402,
      "marked": 43391,
      "stepwise": 77333,
      "epoxy": 29217,
      "hydroxy": 36236,
      "methoxy": 45637,
      "methylmorphinan": 45661,
      "relevance": 70027,
      "discriminative": 25278,
      "stimulus": 77379,
      "rats": 67837,
      "suppressed": 79240,
      "rhesus": 72447,
      "monkeys": 47350,
      "capsules": 14957,
      "placebos": 61857,
      "summarized": 79087,
      "demonstration": 23385,
      "head": 34643,
      "neck": 48897,
      "oncologic": 51068,
      "resections": 71049,
      "observational": 50606,
      "oncological": 51069,
      "operations": 51236,
      "propofol": 65734,
      "sevoflurane": 75054,
      "postoperatively": 62989,
      "began": 13516,
      "dizziness": 25631,
      "pruritus": 66295,
      "insomnia": 39057,
      "retention": 72077,
      "requested": 70789,
      "suspension": 79767,
      "operative": 51241,
      "ood": 51134,
      "successful": 78909,
      "otd": 53882,
      "oxygesic": 56212,
      "multicenter": 48153,
      "identical": 36406,
      "recalled": 68031,
      "run": 73039,
      "09": 636,
      "consistency": 19685,
      "underestimated": 83498,
      "motor": 48023,
      "symptom": 79856,
      "parkinson": 58227,
      "dopaminergic": 25727,
      "correct": 20796,
      "accordingly": 7069,
      "troublesome": 83247,
      "pr": 63302,
      "nrs": 50053,
      "severity": 75030,
      "recording": 68712,
      "global": 33218,
      "impression": 37049,
      "cgi": 15682,
      "bfi": 13755,
      "statistics": 77240,
      "adjustment": 8067,
      "efficacious": 28197,
      "apap": 11345,
      "components": 18592,
      "bunionectomy": 14483,
      "q12h": 66616,
      "summed": 79114,
      "totpar": 81919,
      "perceptible": 60525,
      "329": 3973,
      "266": 3466,
      "135": 1532,
      "131": 1519,
      "se": 74100,
      "114": 1177,
      "66": 5444,
      "spid": 76686,
      "169": 1922,
      "hysterectomy": 36323,
      "remedication": 70319,
      "precise": 63521,
      "42": 4444,
      "converting": 20741,
      "circulating": 16572,
      "demethylated": 23256,
      "metabolite": 44942,
      "parent": 58190,
      "excretion": 30494,
      "demethylation": 23259,
      "keto": 40620,
      "complemented": 18436,
      "p450": 56301,
      "cyp": 21568,
      "3a": 4291,
      "alpha": 9661,
      "beta": 13697,
      "oxymorphol": 56216,
      "oxycodol": 54470,
      "lives": 42189,
      "constriction": 19805,
      "abundance": 6634,
      "principal": 65125,
      "negligible": 49091,
      "oxidative": 54394,
      "reductive": 69121,
      "burden": 14599,
      "musculoskeletal": 48367,
      "structured": 77590,
      "ge": 32923,
      "cns": 17112,
      "gave": 32914,
      "capacity": 14947,
      "favorable": 31258,
      "costly": 20892,
      "qaly": 66623,
      "gain": 32811,
      "excipients": 30468,
      "marketed": 43417,
      "pretreated": 64758,
      "calorie": 14739,
      "breakfast": 14392,
      "untoward": 83955,
      "bioequivalence": 13846,
      "cis": 16585,
      "125": 1425,
      "54": 5036,
      "white": 87012,
      "sd": 74059,
      "proportional": 65784,
      "normalized": 49917,
      "blockade": 14076,
      "compatible": 18403,
      "fasting": 31223,
      "coat": 17128,
      "experts": 30692,
      "opinions": 51345,
      "split": 76739,
      "difficulties": 24971,
      "routinely": 72867,
      "metabolize": 44990,
      "cro": 21235,
      "asa": 11814,
      "iii": 36578,
      "breast": 14405,
      "anaesthesia": 9864,
      "premedication": 63721,
      "midazolam": 46393,
      "pl": 61595,
      "pca": 60258,
      "device": 24266,
      "loading": 42195,
      "036": 435,
      "rest": 71411,
      "movement": 48042,
      "103": 1057,
      "hypertension": 36275,
      "tachycardia": 80236,
      "confusion": 19528,
      "agitation": 9266,
      "preventing": 64861,
      "respect": 71131,
      "hyperalgesia": 36257,
      "viscera": 86250,
      "electricity": 28511,
      "induction": 38474,
      "perfusion": 60653,
      "acid": 7339,
      "capsaicin": 14952,
      "oesophagus": 50944,
      "venous": 86056,
      "necessarily": 48875,
      "quadratic": 66655,
      "measurable": 43930,
      "coadministration": 17120,
      "ascending": 11822,
      "flexible": 31908,
      "unilateral": 83735,
      "likert": 41850,
      "sum": 79072,
      "responders": 71320,
      "ibuprofen": 36341,
      "263": 3462,
      "256": 3406,
      "withdrew": 87174,
      "completion": 18524,
      "greatest": 33500,
      "fewest": 31675,
      "euphoria": 29724,
      "optimal": 53418,
      "neuroinflammation": 49195,
      "pathogenic": 58500,
      "neurodegenerative": 49189,
      "diseases": 25354,
      "glial": 33213,
      "mediators": 44323,
      "neurodegeneration": 49188,
      "induce": 38365,
      "astrocyte": 12514,
      "proinflammatory": 65583,
      "lipopolysaccharide": 42068,
      "lps": 42743,
      "inhibited": 38770,
      "overexpression": 54339,
      "fibrillary": 31679,
      "acidic": 7345,
      "hallmarks": 34536,
      "reactive": 67976,
      "tumor": 83276,
      "necrosis": 48901,
      "interleukin": 39445,
      "1\u03b2": 2261,
      "nuclear": 50116,
      "endogenous": 28845,
      "translocation": 82222,
      "nucleus": 50124,
      "astrocytes": 12515,
      "pretreatment": 64762,
      "suppress": 79238,
      "targeting": 80501,
      "astrocytic": 12518,
      "tap": 80369,
      "clinformatics": 16736,
      "mart": 43442,
      "match": 43481,
      "demographics": 23294,
      "chi": 15984,
      "squared": 76800,
      "differed": 24558,
      "539": 5035,
      "821": 5915,
      "185": 2141,
      "07": 600,
      "2900": 3622,
      "550": 5085,
      "084": 632,
      "047": 467,
      "charge": 15919,
      "190": 2200,
      "respects": 71259,
      "sub": 78575,
      "examines": 30421,
      "illicit": 36628,
      "labor": 41015,
      "abusable": 6636,
      "markets": 43431,
      "observe": 50640,
      "employment": 28747,
      "applications": 11430,
      "physiologically": 61470,
      "pbpk": 60253,
      "modality": 47014,
      "pediatrics": 60366,
      "pediatric": 60344,
      "goodness": 33334,
      "visualize": 86336,
      "anatomy": 10885,
      "ages": 9246,
      "progressive": 65576,
      "opportunity": 53405,
      "university": 83852,
      "teaching": 80531,
      "china": 16086,
      "allocated": 9610,
      "89": 6054,
      "bolus": 14211,
      "lockout": 42236,
      "face": 31013,
      "legs": 41389,
      "consolability": 19729,
      "flacc": 31892,
      "pacu": 56328,
      "extubation": 30993,
      "boluses": 14226,
      "raw": 67905,
      "parents": 58217,
      "registered": 69375,
      "chictr": 15996,
      "cn": 17100,
      "2023": 2920,
      "kratom": 40956,
      "derives": 23637,
      "mitragyna": 46777,
      "speciosa": 76647,
      "korth": 40953,
      "tree": 82937,
      "coffee": 17317,
      "powders": 63287,
      "tea": 80530,
      "extracts": 30969,
      "millions": 46498,
      "globally": 33236,
      "eliminate": 28602,
      "alkaloid": 9578,
      "mitragynine": 46780,
      "arrestin": 11698,
      "al": 9513,
      "rep": 70377,
      "188": 2151,
      "gases": 32847,
      "240": 3294,
      "milder": 46438,
      "evident": 30297,
      "storage": 77396,
      "cds": 15438,
      "centres": 15638,
      "legislation": 41367,
      "kept": 40603,
      "discrepancies": 25266,
      "arise": 11656,
      "acceptable": 6979,
      "anecdotal": 10895,
      "stock": 77382,
      "check": 15940,
      "formulated": 32323,
      "triplicate": 83239,
      "enteral": 29054,
      "syringes": 79968,
      "checks": 15945,
      "recommendations": 68590,
      "bottles": 14259,
      "personnel": 60956,
      "chosen": 16141,
      "adaptor": 7723,
      "noradrenaline": 49872,
      "hypothesize": 36304,
      "modest": 47224,
      "translate": 82211,
      "carrier": 15142,
      "precursor": 63541,
      "si": 75366,
      "sol": 76414,
      "gel": 32924,
      "preparation": 63777,
      "temperatures": 80582,
      "pore": 62411,
      "easily": 27280,
      "fabricated": 31012,
      "constitute": 19799,
      "mechanical": 44109,
      "vehicle": 86044,
      "man": 43108,
      "presenting": 64701,
      "tma": 81494,
      "disclosed": 25216,
      "recurrent": 68817,
      "relapsing": 69540,
      "complement": 18432,
      "accounts": 7083,
      "detailed": 23912,
      "burn": 14611,
      "capabilities": 14943,
      "throughput": 81162,
      "ideal": 36404,
      "palatable": 58030,
      "transmucosal": 82229,
      "citrate": 16600,
      "microg": 46355,
      "pulse": 66468,
      "oximetry": 54407,
      "observer": 50733,
      "anxiety": 11267,
      "taste": 80522,
      "psychosis": 66361,
      "uncommon": 83482,
      "personal": 60946,
      "familiar": 31175,
      "psychiatric": 66322,
      "hospitalized": 35666,
      "psychotic": 66367,
      "olfactory": 51049,
      "aberrant": 6542,
      "manifested": 43310,
      "abruptly": 6583,
      "fluctuating": 31938,
      "alternating": 9712,
      "lucid": 42752,
      "ones": 51080,
      "subsided": 78792,
      "antipsychotic": 11258,
      "marijuana": 43380,
      "rational": 67807,
      "colleagues": 17440,
      "vaporized": 85862,
      "cannabis": 14932,
      "meaningfully": 43920,
      "commentary": 17699,
      "initiatives": 38905,
      "transdermal": 82141,
      "patch": 58481,
      "tocopheryl": 81505,
      "phosphate": 61364,
      "tpm": 81962,
      "patches": 58495,
      "reaching": 67940,
      "dermal": 23638,
      "preclinical": 63525,
      "activate": 7458,
      "glia": 33212,
      "suppression": 79244,
      "certain": 15649,
      "tetracycline": 80874,
      "antibiotic": 11143,
      "minocycline": 46622,
      "reduces": 68988,
      "enhances": 28977,
      "repeatedly": 70420,
      "institute": 39067,
      "type": 83318,
      "grouped": 34082,
      "836": 5946,
      "underwent": 83672,
      "orthopaedic": 53815,
      "832": 5943,
      "regardless": 69282,
      "subgroups": 78620,
      "4th": 4794,
      "helsinki": 34919,
      "015": 343,
      "hr": 35890,
      "standardized": 76950,
      "serving": 74727,
      "coughing": 20917,
      "hemodynamics": 34941,
      "infusions": 38734,
      "hemodynamic": 34936,
      "dosages": 25765,
      "hepatocellular": 34965,
      "map": 43345,
      "spo": 76742,
      "bispectral": 13887,
      "bis": 13885,
      "entering": 29063,
      "operating": 51208,
      "room": 72772,
      "t0": 80049,
      "beginning": 13519,
      "t2": 80057,
      "t3": 80062,
      "t4": 80064,
      "injecting": 38922,
      "shows": 75359,
      "functioning": 32722,
      "credible": 21159,
      "favored": 31263,
      "fatigue": 31251,
      "dry": 27100,
      "dyspepsia": 27228,
      "ae": 8864,
      "improvements": 37169,
      "correlation": 20824,
      "structure": 77585,
      "leukoencephalopathy": 41443,
      "axon": 12991,
      "demyelination": 23386,
      "matter": 43541,
      "lesions": 41421,
      "neurotoxic": 49290,
      "damgo": 21824,
      "adenocarcinoma": 7949,
      "express": 30812,
      "axonal": 12992,
      "tracks": 81975,
      "accumulation": 7094,
      "amyloid": 9863,
      "app": 11371,
      "damages": 21821,
      "pro": 65205,
      "machinery": 42794,
      "integrated": 39192,
      "stress": 77484,
      "isr": 40314,
      "structures": 77594,
      "suppresses": 79242,
      "bax": 13488,
      "altogether": 9754,
      "degeneration": 23166,
      "promoting": 65670,
      "rise": 72487,
      "contributor": 20252,
      "unclear": 83472,
      "service": 74720,
      "sr": 76810,
      "557": 5090,
      "presentations": 64683,
      "288": 3590,
      "242": 3301,
      "324": 3948,
      "administrations": 8393,
      "381": 4250,
      "generated": 33037,
      "recognised": 68568,
      "overuse": 54364,
      "noticed": 49994,
      "breakthrough": 14395,
      "chronically": 16358,
      "undergo": 83500,
      "compete": 18409,
      "enter": 29050,
      "ingested": 38737,
      "tailed": 80256,
      "paired": 58022,
      "benign": 13641,
      "minimally": 46581,
      "invasive": 39965,
      "preoperatively": 63764,
      "myomectomy": 48384,
      "5mg": 5207,
      "diaries": 24356,
      "106": 1064,
      "consented": 19581,
      "ome": 51052,
      "iqr": 40157,
      "102": 1052,
      "3d": 4295,
      "2d": 3646,
      "refill": 69159,
      "pelvic": 60380,
      "morbidities": 47506,
      "read": 67982,
      "felt": 31348,
      "awareness": 12984,
      "excellent": 30439,
      "education": 27378,
      "covered": 21015,
      "gestational": 33135,
      "postnatal": 62686,
      "650": 5430,
      "trihydrate": 83226,
      "infant": 38500,
      "unconjugated": 83487,
      "compounds": 18605,
      "noncompartmental": 49721,
      "changed": 15759,
      "careful": 15099,
      "175": 2011,
      "completers": 18520,
      "q6h": 66622,
      "spid24": 76690,
      "emesis": 28714,
      "009": 280,
      "037": 436,
      "011": 332,
      "pathways": 58522,
      "affects": 8934,
      "noradrenergic": 49879,
      "glutamate": 33256,
      "neurotransmitter": 49294,
      "prefrontal": 63651,
      "creatine": 21151,
      "glutamatergic": 33258,
      "herbal": 34969,
      "counter": 20933,
      "john": 40477,
      "wort": 87350,
      "makes": 43006,
      "prone": 65676,
      "behavioural": 13569,
      "shortened": 75205,
      "4h": 4793,
      "004": 257,
      "greatly": 33507,
      "serotonergic": 74668,
      "fluvoxamine": 31963,
      "fever": 31622,
      "shivering": 75146,
      "fulfilling": 32612,
      "resolution": 71110,
      "naranjo": 48575,
      "meperidine": 44839,
      "dextromethorphan": 24295,
      "inhibitors": 38801,
      "differentiating": 24950,
      "nonmalignant": 49763,
      "defining": 23157,
      "grown": 34376,
      "fundamental": 32730,
      "sustain": 79771,
      "kingdom": 40850,
      "tracked": 81973,
      "cohen": 17332,
      "427": 4491,
      "osmotic": 53849,
      "oros": 53801,
      "ensures": 29046,
      "anticipated": 11156,
      "discrete": 25269,
      "follows": 32225,
      "pairs": 58026,
      "created": 21146,
      "receives": 68312,
      "dissatisfied": 25510,
      "satisfied": 73456,
      "suffer": 78956,
      "recurrence": 68814,
      "translated": 82213,
      "utilities": 85718,
      "reaches": 67939,
      "compliant": 18539,
      "uncertainty": 83466,
      "euros": 29757,
      "017": 345,
      "qalys": 66626,
      "yielding": 87702,
      "icer": 36391,
      "gained": 32815,
      "net": 49149,
      "germany": 33132,
      "horizon": 35541,
      "2nd": 3654,
      "3rd": 4302,
      "failing": 31143,
      "final": 31739,
      "anonymized": 11038,
      "cheaper": 15939,
      "meaning": 43910,
      "dominated": 25709,
      "ranking": 67372,
      "unchanged": 83468,
      "limitations": 41898,
      "interpreting": 39510,
      "restricted": 71456,
      "generalizability": 32992,
      "extrapolation": 30978,
      "sourced": 76503,
      "aetiology": 8888,
      "charlson": 15921,
      "cox": 21025,
      "hazards": 34619,
      "contacts": 20060,
      "accident": 7012,
      "subset": 78789,
      "episode": 29204,
      "829": 5922,
      "ahr": 9358,
      "532": 5029,
      "402": 4399,
      "517": 4971,
      "363": 4158,
      "irr": 40275,
      "attendance": 12554,
      "739": 5666,
      "572": 5145,
      "917": 6148,
      "851": 5995,
      "989": 6479,
      "938": 6183,
      "figures": 31696,
      "768": 5752,
      "971": 6449,
      "699": 5534,
      "352": 4102,
      "877": 6033,
      "799": 5814,
      "962": 6429,
      "748": 5687,
      "601": 5292,
      "residual": 71083,
      "confounding": 19523,
      "gr\u00fcnenthal": 34386,
      "undertreated": 83666,
      "depending": 23548,
      "adequately": 7976,
      "absolute": 6592,
      "interindividual": 39439,
      "coefficients": 17314,
      "finding": 31758,
      "confirms": 19512,
      "isobolographic": 40295,
      "synergistic": 79928,
      "rodents": 72721,
      "coadministered": 17118,
      "sulphate": 79071,
      "intercepts": 39406,
      "hypoxaemic": 36317,
      "m10": 42783,
      "disproportionate": 25503,
      "impede": 36911,
      "widespread": 87079,
      "sponsored": 76748,
      "proactive": 65209,
      "named": 48554,
      "aspect": 11858,
      "informants": 38629,
      "zip": 87763,
      "surveyed": 79743,
      "rank": 67361,
      "persons": 60957,
      "digit": 24980,
      "code": 17191,
      "calendar": 14720,
      "quarters": 66857,
      "pervasive": 60979,
      "country": 20965,
      "needs": 49054,
      "evolved": 30307,
      "fact": 31045,
      "great": 33412,
      "compromised": 18640,
      "tetrahydrocannabinol": 80875,
      "thc": 80898,
      "unknown": 83876,
      "hypothesised": 36303,
      "netherlands": 49155,
      "hg": 35057,
      "inhalation": 38760,
      "eu": 29718,
      "bone": 14230,
      "cibp": 16542,
      "proteomic": 65949,
      "profiling": 65521,
      "cord": 20765,
      "briefly": 14435,
      "3530": 4104,
      "cut": 21535,
      "adp": 8471,
      "conduction": 19425,
      "material": 43499,
      "proteomics": 65950,
      "verified": 86077,
      "fluorescent": 31951,
      "localized": 42217,
      "horn": 35548,
      "believe": 13581,
      "alleviation": 9606,
      "clock": 17046,
      "atc": 12522,
      "issued": 40330,
      "note": 49984,
      "administering": 8193,
      "convenience": 20685,
      "flexibility": 31907,
      "easier": 27279,
      "comply": 18574,
      "regimen": 69296,
      "afforded": 8952,
      "cannabinoids": 14931,
      "act": 7367,
      "synergistically": 79935,
      "answer": 11049,
      "evening": 29975,
      "investigations": 40077,
      "curves": 21532,
      "augments": 12658,
      "allow": 9630,
      "surgeon": 79263,
      "prospectively": 65890,
      "nonopioid": 49801,
      "location": 42224,
      "penile": 60390,
      "mucosa": 48140,
      "graft": 33395,
      "october": 50872,
      "transitioned": 82206,
      "bupivacaine": 14486,
      "liposomal": 42070,
      "intraoperatively": 39784,
      "116": 1183,
      "unused": 83958,
      "preoperative": 63732,
      "percentages": 60519,
      "overprescribing": 54353,
      "counseling": 20923,
      "optimized": 53443,
      "intermittent": 39453,
      "diameter": 24350,
      "miotic": 46673,
      "equivalence": 29275,
      "limburg": 41882,
      "grunenthal": 34383,
      "aachen": 6508,
      "classification": 16675,
      "margin": 43376,
      "predefined": 63543,
      "itching": 40342,
      "perception": 60527,
      "casework": 15272,
      "involve": 40091,
      "gap": 32831,
      "conjugated": 19537,
      "\u00b5l": 87776,
      "diluted": 25009,
      "900": 6121,
      "acquity": 7363,
      "uplc": 83991,
      "waters": 86764,
      "xevo": 87404,
      "tqd": 81966,
      "phenotypes": 61348,
      "categorized": 15303,
      "metabolizers": 45002,
      "intermediate": 39448,
      "im": 36671,
      "ultrarapid": 83425,
      "um": 83437,
      "showing": 75323,
      "perturbations": 60977,
      "transporters": 82246,
      "metabolizing": 45013,
      "locus": 42244,
      "deleterious": 23197,
      "ddis": 22677,
      "xenobiotic": 87401,
      "pxr": 66610,
      "car": 14964,
      "aryl": 11813,
      "intraperitoneally": 39787,
      "microarray": 46344,
      "polymerase": 62199,
      "chain": 15686,
      "immunoblotting": 36776,
      "abcb1": 6520,
      "metacore": 45017,
      "assembled": 11898,
      "activated": 7460,
      "signature": 75396,
      "lead": 41277,
      "undesirable": 83706,
      "substrates": 78887,
      "dissolve": 25527,
      "tract": 81976,
      "releasing": 70026,
      "packaging": 56322,
      "surface": 79257,
      "attain": 12542,
      "dies": 24531,
      "obstruction": 50744,
      "toxic": 81923,
      "perforation": 60546,
      "om": 51050,
      "benzedrine": 13646,
      "bad": 13220,
      "006": 269,
      "mood": 47482,
      "lowest": 42728,
      "sparing": 76527,
      "smoked": 76334,
      "immersed": 36755,
      "elicit": 28568,
      "synergy": 79937,
      "cannabinoid": 14926,
      "oic": 50984,
      "analytic": 10799,
      "trade": 81978,
      "targin": 80506,
      "offsets": 50978,
      "laxative": 41254,
      "deterministic": 24100,
      "hospitalization": 35652,
      "interventional": 39653,
      "2003": 2444,
      "publication": 66409,
      "exceeding": 30435,
      "doubled": 26412,
      "communication": 17908,
      "tertiary": 80727,
      "referral": 69151,
      "peri": 60656,
      "staff": 76855,
      "email": 28633,
      "nurses": 50336,
      "pharmacists": 61057,
      "doctors": 25659,
      "656": 5440,
      "371": 4211,
      "602": 5293,
      "equated": 29247,
      "communications": 17911,
      "325": 3949,
      "lbp": 41264,
      "suboptimally": 78767,
      "responsive": 71404,
      "nonsteroidal": 49852,
      "relaxants": 69798,
      "cyclo": 21550,
      "oxygenase": 56209,
      "prn": 65199,
      "nonrandomized": 49837,
      "tid": 81171,
      "sharp": 75122,
      "dull": 27119,
      "deep": 23087,
      "spine": 76728,
      "lumbar": 42753,
      "neurologic": 49199,
      "examinations": 30330,
      "discontinuations": 25234,
      "0005": 87,
      "007": 273,
      "interference": 39420,
      "0004": 86,
      "tolerable": 81564,
      "hepatotoxicity": 34968,
      "corroborate": 20849,
      "australians": 12709,
      "commence": 17695,
      "linkage": 42045,
      "6000": 5291,
      "ward": 86708,
      "postdischarge": 62638,
      "hierarchical": 35061,
      "comorbidities": 17933,
      "dissemination": 25514,
      "monash": 47299,
      "peer": 60367,
      "accordance": 7031,
      "statement": 77073,
      "african": 8957,
      "italian": 40339,
      "ethnicity": 29699,
      "chief": 16000,
      "complaint": 18425,
      "sickle": 75367,
      "scc": 73604,
      "illness": 36661,
      "radiated": 66953,
      "uncontrollable": 83491,
      "crises": 21166,
      "childhood": 16014,
      "denied": 23391,
      "illegal": 36621,
      "family": 31178,
      "carry": 15144,
      "image": 36678,
      "nordic": 49885,
      "countries": 20951,
      "stricter": 77500,
      "developments": 24259,
      "ambulatory": 9762,
      "registries": 69399,
      "norway": 49972,
      "denmark": 23392,
      "sweden": 79809,
      "separately": 74593,
      "ddd": 22666,
      "user": 85221,
      "declining": 22874,
      "board": 14177,
      "wealth": 86804,
      "direction": 25056,
      "shortening": 75206,
      "stays": 77299,
      "gaining": 32817,
      "piritramide": 61563,
      "cholecystectomy": 16129,
      "regard": 69232,
      "impairments": 36907,
      "dying": 27210,
      "planned": 61877,
      "subgroup": 78614,
      "advanced": 8591,
      "eastern": 27283,
      "cooperative": 20749,
      "oncology": 51070,
      "164": 1915,
      "138": 1539,
      "lung": 42761,
      "metastases": 45023,
      "means": 43921,
      "confirm": 19490,
      "accepted": 6987,
      "doubts": 26415,
      "added": 7728,
      "entity": 29083,
      "monotherapy": 47373,
      "decades": 22809,
      "pos": 62427,
      "relievers": 70225,
      "turn": 83286,
      "fatalities": 31241,
      "motives": 48022,
      "painkiller": 58014,
      "europe": 29730,
      "rare": 67406,
      "discusses": 25297,
      "vigilance": 86230,
      "nonoral": 49818,
      "epidemiology": 29163,
      "far": 31189,
      "load": 42194,
      "manipulate": 43312,
      "vigilant": 86231,
      "exercise": 30497,
      "perform": 60547,
      "stratification": 77447,
      "maintain": 42881,
      "outweigh": 54169,
      "dexamethasone": 24280,
      "hallux": 34539,
      "valgus": 85772,
      "osteotomy": 53875,
      "metatarsal": 45030,
      "operatively": 51273,
      "ended": 28833,
      "pod": 62063,
      "165": 1917,
      "049": 469,
      "pods": 62074,
      "pregnant": 63694,
      "fetal": 31618,
      "disruptions": 25508,
      "maternal": 43518,
      "neurobehavioral": 49180,
      "hypothalamus": 36290,
      "offspring": 50979,
      "ctl": 21364,
      "breeding": 14422,
      "gestation": 33133,
      "battery": 13487,
      "cognition": 17318,
      "voluntary": 86409,
      "socio": 76386,
      "developmental": 24257,
      "weaning": 86807,
      "adulthood": 8535,
      "weighed": 86969,
      "counterparts": 20949,
      "prenatal": 63725,
      "sex": 75057,
      "encoding": 28768,
      "neuropeptide": 49282,
      "hormone": 35543,
      "epigenetic": 29195,
      "dnmt3a": 25653,
      "mothers": 48008,
      "permanent": 60898,
      "underpinning": 83611,
      "scarce": 73598,
      "district": 25573,
      "140": 1636,
      "225": 3057,
      "210": 2990,
      "477": 4677,
      "223": 3055,
      "137": 1536,
      "disciplines": 25215,
      "trauma": 82259,
      "specialist": 76565,
      "april": 11597,
      "231": 3124,
      "714": 5606,
      "rarely": 67408,
      "variable": 85879,
      "med": 44160,
      "182": 2136,
      "desaturation": 23643,
      "nephrolithotomy": 49108,
      "minimized": 46602,
      "kidney": 40821,
      "stone": 77387,
      "elderly": 28470,
      "tandem": 80357,
      "2d6": 3647,
      "glomerular": 33237,
      "filtration": 31735,
      "gfr": 33138,
      "creatinine": 21154,
      "oldest": 51046,
      "infinity": 38540,
      "youngest": 87743,
      "properly": 65703,
      "titrate": 81461,
      "individually": 38322,
      "aversion": 12952,
      "inactive": 37221,
      "pfizer": 60991,
      "diminish": 25020,
      "designated": 23823,
      "transformed": 82190,
      "aucinf": 12645,
      "flushing": 31962,
      "conventional": 20690,
      "traumatic": 82265,
      "injured": 38981,
      "sci": 73672,
      "np": 50048,
      "anticonvulsants": 11163,
      "spain": 76520,
      "collated": 17439,
      "persisting": 60933,
      "para": 58088,
      "anticonvulsant": 11162,
      "got": 33340,
      "worse": 87328,
      "eq": 29223,
      "5d": 5203,
      "relieve": 70211,
      "noncancer": 49701,
      "985": 6477,
      "338": 4012,
      "788": 5793,
      "carefully": 15108,
      "environment": 29091,
      "spe": 76544,
      "roughly": 72831,
      "diagnosed": 24322,
      "nsaid": 50088,
      "nonresponders": 49841,
      "tonic": 81657,
      "eeg": 27408,
      "unpleasantness": 83919,
      "spectral": 76651,
      "localization": 42216,
      "delta": 23232,
      "hz": 36329,
      "theta": 81089,
      "bands": 13244,
      "indices": 38281,
      "band": 13242,
      "inferior": 38523,
      "frontal": 32602,
      "gyrus": 34493,
      "qt": 66650,
      "sudden": 78935,
      "na": 48390,
      "channels": 15836,
      "clamp": 16638,
      "voltage": 86387,
      "protocols": 66001,
      "beating": 13505,
      "ic": 36379,
      "483": 4757,
      "inactivation": 37220,
      "arrhythmia": 11701,
      "inactivated": 37219,
      "addicts": 7789,
      "slowly": 76269,
      "fractures": 32462,
      "hip": 35415,
      "forearm": 32254,
      "td": 80526,
      "german": 33129,
      "generics": 33054,
      "801": 5871,
      "766": 5751,
      "496": 4791,
      "850": 5994,
      "probabilistic": 65211,
      "variations": 85923,
      "paravertebral": 58179,
      "block": 14032,
      "pvb": 66605,
      "ponv": 62233,
      "attending": 12557,
      "anesthesiologist": 10952,
      "postanesthesia": 62633,
      "sedated": 74303,
      "symbol": 79850,
      "ocular": 50892,
      "coordination": 20753,
      "750": 5725,
      "convulsions": 20744,
      "steeply": 77311,
      "economies": 27318,
      "700": 5576,
      "compuscript": 18645,
      "intra": 39713,
      "provinces": 66276,
      "coinciding": 17418,
      "drivers": 26466,
      "marker": 43404,
      "excreted": 30492,
      "noninvasively": 49755,
      "residential": 71068,
      "cessation": 15675,
      "sequestration": 74639,
      "247": 3309,
      "intersubject": 39546,
      "mornings": 47521,
      "quantifiable": 66767,
      "modestly": 47228,
      "estimation": 29659,
      "inexpensive": 38497,
      "medico": 44718,
      "rotate": 72818,
      "cpp": 21041,
      "taper": 80480,
      "witnesses": 87180,
      "rotation": 72820,
      "caution": 15408,
      "newly": 49414,
      "acetyl": 7269,
      "protocol": 65952,
      "institutional": 39091,
      "informed": 38677,
      "consent": 19578,
      "plastic": 61964,
      "reconstruction": 68642,
      "vertebrae": 86165,
      "fusion": 32756,
      "measurement": 44014,
      "glucuronide": 33248,
      "pump": 66477,
      "pharmacist": 61056,
      "assisted": 12194,
      "consultation": 19814,
      "341": 4044,
      "assist": 12188,
      "mechanistic": 44156,
      "recall": 68030,
      "unrelated": 83925,
      "word": 87263,
      "stimuli": 77378,
      "occasion": 50812,
      "pair": 58021,
      "circumstances": 16578,
      "strikingly": 77504,
      "depressive": 23607,
      "datasets": 22215,
      "oregon": 53737,
      "uncovered": 83496,
      "458": 4613,
      "480": 4754,
      "hazard": 34613,
      "fistulas": 31856,
      "complex": 18526,
      "furosemide": 32745,
      "pedal": 60343,
      "edema": 27363,
      "conversely": 20705,
      "aggressive": 9257,
      "inadequate": 37226,
      "lorazepam": 42415,
      "psychological": 66338,
      "elucidate": 28622,
      "rheumatic": 72451,
      "644": 5400,
      "computerized": 18662,
      "290": 3621,
      "153": 1824,
      "354": 4105,
      "complication": 18547,
      "withholding": 87177,
      "potently": 63282,
      "hypersensitivity": 36274,
      "accompanying": 7028,
      "carrageenan": 15132,
      "intraplantar": 39789,
      "cpa": 21038,
      "paw": 60240,
      "update": 83975,
      "professionals": 65465,
      "inception": 37249,
      "online": 51094,
      "dichotomous": 24374,
      "grading": 33384,
      "687": 5510,
      "mr": 48065,
      "gabapentin": 32786,
      "537": 5034,
      "downgraded": 26418,
      "heterogeneity": 35048,
      "considerations": 19623,
      "instructions": 39109,
      "tabs": 80233,
      "appointment": 11444,
      "increments": 38148,
      "pod1": 62069,
      "autologous": 12754,
      "rib": 72467,
      "grafting": 33397,
      "expectations": 30548,
      "laryngoscope": 41201,
      "prisma": 65186,
      "cinahl": 16556,
      "psycinfo": 66369,
      "library": 41661,
      "citations": 16591,
      "raters": 67540,
      "title": 81457,
      "abstract": 6622,
      "text": 80881,
      "fulfilled": 32611,
      "collaboration": 17433,
      "tool": 81680,
      "newcastle": 49400,
      "ottawa": 53890,
      "nos": 49977,
      "remaining": 70280,
      "lengths": 41416,
      "drawing": 26449,
      "inguinal": 38752,
      "anesthetic": 10966,
      "offer": 50946,
      "t10": 80054,
      "l2": 40960,
      "intraoperative": 39765,
      "ropivacaine": 72786,
      "162": 1911,
      "312": 3886,
      "446": 4558,
      "425": 4489,
      "384": 4252,
      "303": 3827,
      "469": 4644,
      "295": 3627,
      "antiemetic": 11184,
      "offering": 50957,
      "verify": 86078,
      "indexes": 38215,
      "177": 2016,
      "dangerous": 21827,
      "suppressing": 79243,
      "simultaneous": 76032,
      "combining": 17680,
      "west": 86994,
      "bend": 13592,
      "wisconsin": 87109,
      "sided": 75372,
      "identifier": 36482,
      "oxynorm": 56291,
      "east": 27282,
      "invited": 40087,
      "participate": 58383,
      "angiotensin": 10981,
      "blockers": 14086,
      "diuretics": 25580,
      "powered": 63292,
      "observations": 50637,
      "exacerbated": 30312,
      "escalating": 29521,
      "window": 87107,
      "digital": 24984,
      "dus": 27196,
      "feature": 31291,
      "activities": 7544,
      "du": 27109,
      "healing": 34664,
      "redressing": 68826,
      "wounds": 87366,
      "amplitudes": 9855,
      "p14": 56297,
      "subcortical": 78597,
      "networks": 49165,
      "p25": 56298,
      "brainstem": 14373,
      "strengths": 77478,
      "intubated": 39959,
      "microwave": 46388,
      "tumour": 83281,
      "capsule": 14953,
      "cancers": 14920,
      "start": 77001,
      "022": 385,
      "dezocine": 24304,
      "020": 381,
      "033": 431,
      "instability": 39060,
      "precipitate": 63508,
      "cardiovascular": 14992,
      "pharmacovigilance": 61253,
      "tilidine": 81183,
      "prr": 66287,
      "analogous": 10545,
      "organ": 53751,
      "mono": 47354,
      "quasi": 66862,
      "827": 5921,
      "374": 4214,
      "453": 4608,
      "179": 2021,
      "1500": 1820,
      "pupillary": 66490,
      "film": 31729,
      "600": 5284,
      "mcg": 43623,
      "predose": 63606,
      "pearson": 60332,
      "0011": 229,
      "oa": 50350,
      "modulating": 47260,
      "disproportionately": 25505,
      "temperature": 80581,
      "modulated": 47257,
      "psychophysical": 66360,
      "unaffected": 83454,
      "phenomenon": 61346,
      "beings": 13575,
      "outpatients": 54157,
      "medicinal": 44700,
      "gps": 33363,
      "316": 3889,
      "republic": 70779,
      "hungary": 35992,
      "imagine": 36682,
      "automated": 12755,
      "masked": 43445,
      "202": 2887,
      "058": 573,
      "proportions": 65791,
      "nonetheless": 49737,
      "warrant": 86723,
      "dihydrocodeinone": 24996,
      "spontaneously": 76762,
      "hypoventilation": 36316,
      "today": 81509,
      "kinase": 40835,
      "isolated": 40304,
      "root": 72782,
      "ganglia": 32828,
      "drg": 26454,
      "eliciting": 28572,
      "indicative": 38275,
      "mitigated": 46766,
      "knockout": 40874,
      "acutely": 7711,
      "neuron": 49207,
      "pks": 61594,
      "toronto": 81700,
      "qualification": 66659,
      "ground": 33523,
      "30mg": 3835,
      "3mg": 4299,
      "dental": 23398,
      "indicators": 38279,
      "dentists": 23417,
      "specialists": 76566,
      "84": 5951,
      "maxillofacial": 43568,
      "dutch": 27197,
      "behaviour": 13568,
      "favourable": 31267,
      "diclofenac": 24379,
      "intramuscularly": 39744,
      "apparatus": 11377,
      "opening": 51202,
      "commencing": 17698,
      "ns": 50087,
      "victims": 86205,
      "ethnographic": 29700,
      "victim": 86204,
      "medicated": 44443,
      "philadelphia": 61358,
      "ultimately": 83415,
      "conflicts": 19516,
      "funnel": 32741,
      "violence": 86235,
      "risky": 72685,
      "rehabilitative": 69510,
      "growing": 34357,
      "contaminated": 20091,
      "reddit": 68821,
      "posts": 63042,
      "subreddits": 78771,
      "subsample": 78772,
      "thematic": 80903,
      "226": 3061,
      "mention": 44834,
      "pressed": 64728,
      "suspicion": 79769,
      "composition": 18600,
      "communities": 17912,
      "motility": 48012,
      "microbiome": 46347,
      "longstanding": 42405,
      "microbiota": 46348,
      "host": 35677,
      "enduring": 28922,
      "pups": 66494,
      "weaned": 86806,
      "fecal": 31314,
      "bacterial": 13219,
      "alterations": 9690,
      "rodent": 72717,
      "utero": 85707,
      "similarities": 76006,
      "raises": 66980,
      "born": 14250,
      "origins": 53799,
      "hypoxia": 36319,
      "intoxication": 39709,
      "sensors": 74570,
      "fluctuations": 31939,
      "awake": 12977,
      "entry": 29086,
      "behaviorally": 13555,
      "addressing": 7939,
      "bid": 13785,
      "plantar": 61892,
      "evoke": 30301,
      "electromyography": 28524,
      "electroencephalography": 28521,
      "n1": 48387,
      "moved": 48041,
      "relating": 69708,
      "agonistic": 9317,
      "branded": 14383,
      "sold": 76416,
      "marketplace": 43429,
      "initiative": 38903,
      "hospitalisation": 35651,
      "metropolitan": 45671,
      "199": 2224,
      "111": 1163,
      "shoulder": 75221,
      "confounders": 19521,
      "termed": 80682,
      "evaluates": 29939,
      "inherent": 38765,
      "prototypical": 66017,
      "anxiolytic": 11286,
      "restoration": 71451,
      "conflict": 19513,
      "operant": 51203,
      "upward": 84023,
      "narrow": 48646,
      "abolished": 6579,
      "intriguing": 39904,
      "feel": 31330,
      "successive": 78929,
      "multivariable": 48315,
      "items": 40350,
      "consensus": 19573,
      "levorphanol": 41627,
      "incomplete": 37701,
      "kinetic": 40839,
      "manufacturer": 43338,
      "labels": 41014,
      "appearing": 11396,
      "guidance": 34399,
      "minority": 46629,
      "equianalgesia": 29254,
      "listed": 42100,
      "q1": 66614,
      "allergy": 9590,
      "record": 68652,
      "modelled": 47100,
      "race": 66933,
      "449": 4560,
      "upper": 83997,
      "infiltrating": 38535,
      "endometriosis": 28853,
      "resection": 71046,
      "prominent": 65649,
      "123": 1422,
      "142": 1642,
      "prompted": 65674,
      "url": 84096,
      "http": 35919,
      "aspx": 11871,
      "pid": 61486,
      "adolescence": 8434,
      "resolves": 71117,
      "coincident": 17417,
      "resolved": 71116,
      "extra": 30937,
      "ophthalmic": 51281,
      "corneal": 20773,
      "consenting": 19585,
      "drops": 26486,
      "exclusion": 30484,
      "pregnancy": 63688,
      "glaucoma": 33211,
      "eye": 31001,
      "topical": 81695,
      "diary": 24360,
      "isoflurane": 40300,
      "nitrous": 49503,
      "oxide": 54399,
      "cough": 20914,
      "pethidine": 60983,
      "israel": 40315,
      "ministry": 46619,
      "inhabitants": 38757,
      "aiming": 9469,
      "gaba": 32783,
      "relates": 69707,
      "mors": 47979,
      "synapses": 79910,
      "vesicular": 86170,
      "transporter": 82243,
      "transgenic": 82191,
      "lacks": 41068,
      "mediate": 44303,
      "acquire": 7356,
      "littermate": 42141,
      "dilated": 25002,
      "insufficiency": 39119,
      "reliable": 70080,
      "neuraxial": 49177,
      "contraindicated": 20207,
      "plexus": 62017,
      "blockades": 14079,
      "amounts": 9833,
      "immune": 36763,
      "flurbiprofen": 31959,
      "axetil": 12988,
      "radical": 66956,
      "crc": 21133,
      "sf": 75096,
      "cd4": 15434,
      "natural": 48736,
      "killer": 40830,
      "nk": 49507,
      "forth": 32415,
      "postsurgery": 63047,
      "count": 20928,
      "flatus": 31902,
      "immunosuppression": 36787,
      "consecutively": 19572,
      "participating": 58390,
      "algorithm": 9566,
      "108": 1071,
      "080": 628,
      "322": 3946,
      "weakly": 86801,
      "rheumatoid": 72454,
      "arthritis": 11731,
      "nonselective": 49842,
      "celecoxib": 15448,
      "200mg": 2532,
      "dysmenorrhoea": 27227,
      "tension": 80609,
      "800": 5864,
      "400mg": 4397,
      "ulcer": 83411,
      "naproxen": 48563,
      "mining": 46617,
      "bayesian": 13490,
      "bayes": 13489,
      "793": 5810,
      "366": 4163,
      "622": 5345,
      "740": 5680,
      "consumers": 19859,
      "predominant": 63601,
      "myoclonus": 48383,
      "delirium": 23201,
      "052": 566,
      "206": 2924,
      "tremor": 82938,
      "alert": 9554,
      "residents": 71069,
      "faculty": 31135,
      "driver": 26464,
      "transparency": 82234,
      "engagement": 28933,
      "communicate": 17906,
      "interestingly": 39415,
      "actually": 7603,
      "peers": 60373,
      "decomposition": 22875,
      "bodily": 14187,
      "fluids": 31945,
      "matrices": 43535,
      "pericardial": 60666,
      "pf": 60990,
      "humor": 35990,
      "skeletal": 76190,
      "wean": 86805,
      "college": 17508,
      "rheumatologists": 72459,
      "composite": 18595,
      "getting": 33137,
      "sleepiness": 76238,
      "2a": 3634,
      "2b": 3636,
      "trialsearch": 83209,
      "int": 39164,
      "carcinoma": 14975,
      "peking": 60374,
      "puncture": 66483,
      "administer": 8090,
      "068": 598,
      "024": 387,
      "waking": 86691,
      "981": 6476,
      "362": 4157,
      "041": 460,
      "012": 333,
      "018": 346,
      "discriminate": 25270,
      "neutral": 49300,
      "evaluable": 29759,
      "excluded": 30474,
      "sequence": 74628,
      "define": 23115,
      "nested": 49144,
      "refills": 69172,
      "univariate": 83836,
      "multivariate": 48338,
      "280": 3580,
      "length": 41397,
      "adjuncts": 8011,
      "varicose": 85927,
      "vein": 86049,
      "repair": 70378,
      "alfentanil": 9558,
      "consumer": 19855,
      "soon": 76471,
      "corrected": 20797,
      "qtc": 66652,
      "electrocardiograms": 28514,
      "prolongation": 65609,
      "augmented": 12657,
      "ether": 29682,
      "androgen": 10893,
      "formation": 32296,
      "reservations": 71053,
      "1994": 2231,
      "1320": 1523,
      "slight": 76244,
      "dealing": 22688,
      "training": 82008,
      "come": 17687,
      "prenatally": 63731,
      "resident": 71065,
      "circuits": 16570,
      "microglial": 46366,
      "phagocytosis": 61003,
      "accumbens": 7087,
      "nac": 48392,
      "pruning": 66293,
      "trajectory": 82018,
      "virtually": 86245,
      "adolescent": 8439,
      "deficits": 23113,
      "extinction": 30934,
      "translating": 82215,
      "histamine": 35435,
      "liberation": 41659,
      "catecholamine": 15286,
      "elicited": 28570,
      "bpm": 14303,
      "catecholamines": 15287,
      "plans": 61889,
      "payers": 60248,
      "migration": 46421,
      "restriction": 71461,
      "migrated": 46420,
      "irrespective": 40277,
      "117": 1186,
      "340": 4043,
      "124": 1423,
      "461": 4637,
      "directional": 25057,
      "enrollment": 29030,
      "disclosures": 25217,
      "chen": 15970,
      "employees": 28743,
      "profit": 65522,
      "undertake": 83661,
      "paid": 56342,
      "manuscript": 43341,
      "revised": 72424,
      "nationwide": 48730,
      "mail": 42818,
      "536": 5033,
      "japanese": 40468,
      "certified": 15669,
      "268": 3469,
      "192": 2203,
      "conduct": 19331,
      "feasibility": 31282,
      "telephone": 80566,
      "answered": 11054,
      "uniform": 83732,
      "categories": 15294,
      "language": 41083,
      "handling": 34561,
      "living": 42190,
      "anonymous": 11039,
      "documenting": 25669,
      "simplified": 76023,
      "q4": 66618,
      "earliest": 27247,
      "3515": 4101,
      "763": 5749,
      "236": 3132,
      "662": 5464,
      "533": 5030,
      "588": 5175,
      "747": 5686,
      "subsets": 78791,
      "goals": 33281,
      "pancreatitis": 58061,
      "hp": 35882,
      "endoscopic": 28859,
      "retrograde": 72099,
      "cholangiopancreatography": 16127,
      "ercp": 29495,
      "1990": 2225,
      "ercps": 29496,
      "212": 2993,
      "yearly": 87516,
      "urgent": 84042,
      "bleeding": 13908,
      "decompressive": 22878,
      "ketamine": 40607,
      "sternotomy": 77338,
      "adjunctive": 8005,
      "ninety": 49482,
      "artery": 11722,
      "bypass": 14629,
      "cabg": 14662,
      "tracheal": 81970,
      "023": 386,
      "032": 425,
      "panel": 58064,
      "unspecified": 83944,
      "727": 5640,
      "596": 5199,
      "shared": 75118,
      "mis": 46691,
      "directed": 25053,
      "unscheduled": 83942,
      "robotic": 72707,
      "vaginal": 85757,
      "entire": 29070,
      "assumptions": 12510,
      "derive": 23628,
      "saving": 73471,
      "203": 2921,
      "avoided": 12967,
      "regulators": 69502,
      "serves": 74719,
      "motivating": 48018,
      "combat": 17533,
      "trained": 81997,
      "ivsa": 40406,
      "preserved": 64720,
      "wistar": 87112,
      "491": 4785,
      "florence": 31926,
      "409": 4407,
      "134": 1529,
      "alleviating": 9605,
      "monotherapies": 47372,
      "existing": 30524,
      "warrants": 86735,
      "gather": 32906,
      "233": 3127,
      "geographical": 33116,
      "loci": 42232,
      "outliers": 54110,
      "percentile": 60523,
      "urban": 84025,
      "suburban": 78899,
      "filling": 31715,
      "uses": 85281,
      "ranked": 67370,
      "yields": 87703,
      "843": 5970,
      "practicable": 63385,
      "regime": 69295,
      "efficient": 28420,
      "parts": 58434,
      "segmented": 74372,
      "bootstrapped": 14247,
      "660": 5463,
      "564": 5118,
      "truven": 83256,
      "marketscan": 43432,
      "icd": 36385,
      "fisher": 31851,
      "commercially": 17714,
      "uninsured": 83737,
      "seek": 74345,
      "metastasis": 45024,
      "clinician": 17021,
      "tend": 80595,
      "appropriately": 11521,
      "escalate": 29519,
      "psychosocial": 66362,
      "nursing": 50338,
      "narcolepsy": 48579,
      "deficient": 23108,
      "hypocretin": 36282,
      "daytime": 22658,
      "respondents": 71305,
      "disturbed": 25578,
      "nocturnal": 49555,
      "paralysis": 58151,
      "fracture": 32454,
      "hospice": 35550,
      "femur": 31405,
      "humerus": 35989,
      "pelvis": 60382,
      "radius": 66975,
      "competing": 18410,
      "censoring": 15510,
      "inverse": 39986,
      "weighting": 86989,
      "862": 6014,
      "432": 4514,
      "373": 4213,
      "initiators": 38906,
      "incidences": 37329,
      "weighted": 86985,
      "albeit": 9519,
      "dwelling": 27201,
      "adolescents": 8451,
      "susceptible": 79760,
      "710": 5604,
      "dilute": 25008,
      "interpret": 39495,
      "negatives": 49089,
      "217": 3002,
      "confirmatory": 19498,
      "unless": 83892,
      "collecting": 17493,
      "pnd": 62049,
      "vessels": 86172,
      "principally": 65129,
      "intrinsic": 39905,
      "kor": 40941,
      "dor": 25731,
      "mapk": 43350,
      "caspase": 15274,
      "species": 76575,
      "ros": 72812,
      "prevention": 64869,
      "606": 5296,
      "405": 4402,
      "ketorolac": 40633,
      "tromethamine": 83240,
      "responder": 71316,
      "laparotomy": 41113,
      "dexketoprofen": 24291,
      "quartiles": 66861,
      "dxm": 27207,
      "student": 77596,
      "mann": 43316,
      "whitney": 87033,
      "emptive": 28751,
      "magnesium": 42797,
      "parenterally": 58216,
      "kinds": 40838,
      "salts": 73282,
      "lactate": 41070,
      "intestinal": 39697,
      "ions": 40150,
      "sac": 73061,
      "intestines": 39701,
      "organic": 53756,
      "synergetic": 79926,
      "innovative": 39006,
      "sinus": 76147,
      "ess": 29570,
      "nonblinded": 49700,
      "reserved": 71055,
      "logs": 42282,
      "118": 1189,
      "black": 13899,
      "asian": 11830,
      "exclusions": 30488,
      "noncompliance": 49724,
      "subanalysis": 78594,
      "nonusers": 49865,
      "cruciate": 21322,
      "ligament": 41755,
      "acl": 7353,
      "aclr": 7355,
      "adductor": 7944,
      "canal": 14757,
      "acb": 6968,
      "lb": 41262,
      "thrice": 81158,
      "omes": 51066,
      "126": 1432,
      "quadriceps": 66656,
      "autograft": 12752,
      "amounted": 9832,
      "ibudilast": 36340,
      "qid": 66628,
      "0mg": 650,
      "1st": 2255,
      "40mg": 4408,
      "remainder": 70258,
      "50mg": 4941,
      "70kg": 5583,
      "blunted": 14168,
      "files": 31698,
      "dataset": 22213,
      "nutrition": 50346,
      "noninstitutionalized": 49751,
      "criterion": 21224,
      "category": 15308,
      "stronger": 77566,
      "hoc": 35494,
      "prioritize": 65184,
      "preexisting": 63614,
      "reviewers": 72396,
      "integration": 39200,
      "milligram": 46450,
      "mme": 46945,
      "prolapse": 65601,
      "ra": 66928,
      "ga": 32781,
      "axillary": 12989,
      "brachial": 14307,
      "bypassing": 14638,
      "track": 81972,
      "readiness": 67986,
      "shot": 75219,
      "portion": 62419,
      "predispose": 63594,
      "lipophilic": 42067,
      "powerful": 63294,
      "coma": 17532,
      "speed": 76679,
      "recordings": 68714,
      "transiently": 82194,
      "hyperthermia": 36277,
      "monotonically": 47376,
      "biphasic": 13870,
      "vasodilation": 86038,
      "drop": 26474,
      "profound": 65523,
      "core": 20772,
      "sprinkling": 76789,
      "applesauce": 11418,
      "naltrexol": 48533,
      "irb": 40267,
      "950": 6412,
      "swallowing": 79806,
      "just": 40567,
      "107": 1068,
      "101": 1048,
      "entirely": 29077,
      "sporadic": 76764,
      "sprinkled": 76787,
      "fall": 31161,
      "injuries": 38984,
      "instance": 39062,
      "metabolizes": 45012,
      "explaining": 30701,
      "swedish": 79811,
      "167": 1919,
      "257": 3407,
      "tripled": 83237,
      "adherent": 7998,
      "ibm": 36335,
      "mortality": 47980,
      "213": 2994,
      "af": 8889,
      "355": 4106,
      "mated": 43496,
      "659": 5443,
      "voriconazole": 86492,
      "timed": 81405,
      "inhibits": 38826,
      "drastically": 26446,
      "inadequately": 37234,
      "success": 78902,
      "cosmetic": 20859,
      "facial": 31029,
      "stata": 77028,
      "spearman": 76551,
      "purely": 66508,
      "rs": 73026,
      "interested": 39413,
      "heritable": 34972,
      "traits": 82015,
      "adjunct": 8001,
      "polymorphic": 62206,
      "mutations": 48375,
      "alleles": 9586,
      "polymorphisms": 62214,
      "covariables": 21006,
      "examiner": 30418,
      "genotyping": 33103,
      "quantitated": 66791,
      "gc": 32916,
      "homozygous": 35536,
      "heterozygous": 35056,
      "definitive": 23163,
      "pharmacogenomic": 61102,
      "upregulation": 84014,
      "necessitating": 48895,
      "optimization": 53439,
      "reportedly": 70681,
      "rotigotine": 72827,
      "monoamine": 47360,
      "oxidase": 54390,
      "levodopa": 41623,
      "sensations": 74537,
      "nondopaminergic": 49734,
      "toxin": 81959,
      "dbs": 22663,
      "physiotherapy": 61475,
      "essential": 29573,
      "simply": 76025,
      "complainants": 18420,
      "nonpharmacological": 49827,
      "complicating": 18546,
      "oxazepam": 54383,
      "nitrazepam": 49495,
      "poly": 62188,
      "suicidal": 79045,
      "rectum": 68809,
      "insertion": 39049,
      "distinguish": 25543,
      "packing": 56324,
      "concealment": 18664,
      "hidden": 35060,
      "residence": 71060,
      "facilities": 31040,
      "create": 21137,
      "analyse": 10570,
      "compartmental": 18400,
      "ordinary": 53736,
      "equations": 29251,
      "roles": 72770,
      "misused": 46754,
      "counted": 20929,
      "probabilities": 65216,
      "smallest": 76316,
      "vrs": 86498,
      "cam": 14740,
      "icu": 36397,
      "correlates": 20821,
      "184": 2139,
      "lifetime": 41747,
      "idu": 36547,
      "hcv": 34641,
      "needle": 49050,
      "sharing": 75121,
      "paraphernalia": 58178,
      "educating": 27376,
      "injectors": 38980,
      "curb": 21415,
      "hiv": 35491,
      "stigma": 77351,
      "spending": 76681,
      "macrophages": 42796,
      "homeostatic": 35529,
      "intensification": 39212,
      "actively": 7543,
      "sensitized": 74567,
      "exerted": 30502,
      "opposite": 53409,
      "hapten": 34570,
      "transferred": 82181,
      "generation": 33040,
      "intermediates": 39452,
      "nitric": 49496,
      "antigen": 11202,
      "immunity": 36770,
      "weakest": 86800,
      "safer": 73111,
      "viewed": 86224,
      "homolog": 35535,
      "rho": 72462,
      "sprague": 76767,
      "dawley": 22222,
      "thoracotomy": 81131,
      "prepare": 63787,
      "lymphoma": 42778,
      "immunohistochemistry": 36781,
      "messenger": 44866,
      "transferase": 82180,
      "labeling": 41012,
      "troponin": 83245,
      "automatic": 12761,
      "biochemical": 13844,
      "analyzer": 10875,
      "remarkably": 70317,
      "evidently": 30300,
      "raised": 66979,
      "notably": 49982,
      "discovered": 25262,
      "qrt": 66646,
      "pcr": 60283,
      "lowered": 42726,
      "displaying": 25477,
      "devastating": 24141,
      "assault": 11873,
      "endo": 28836,
      "newark": 49397,
      "called": 14730,
      "consciousness": 19550,
      "anatomical": 10880,
      "inject": 38907,
      "foreign": 32259,
      "pulmonary": 66463,
      "counseled": 20922,
      "keywords": 40680,
      "names": 48558,
      "electrocardiogram": 28512,
      "ecg": 27299,
      "opium": 53400,
      "supra": 79248,
      "atrial": 12538,
      "fibrillation": 31680,
      "capability": 14944,
      "cautiously": 15424,
      "periodic": 60815,
      "undergone": 83594,
      "appendectomy": 11413,
      "eliminated": 28606,
      "contacted": 20050,
      "phone": 61360,
      "208": 2927,
      "270": 3513,
      "ensuring": 29047,
      "neutrophils": 49303,
      "influx": 38610,
      "toll": 81646,
      "hemorrhage": 34943,
      "neutrophil": 49302,
      "infiltration": 38536,
      "wet": 87009,
      "pg": 60996,
      "protective": 65919,
      "attribute": 12609,
      "explain": 30697,
      "neurotrophic": 49296,
      "bdnf": 13500,
      "nonparametric": 49824,
      "depends": 23551,
      "peptides": 60441,
      "bead": 13501,
      "array": 11695,
      "cytokine": 21668,
      "rna": 72693,
      "genomics": 33095,
      "downregulated": 26419,
      "incision": 37342,
      "immunosuppressive": 36789,
      "photorefractive": 61374,
      "keratectomy": 40604,
      "prk": 65196,
      "antibiotics": 11144,
      "steroids": 77348,
      "tetracaine": 80873,
      "laser": 41205,
      "vision": 86258,
      "chadds": 15683,
      "ford": 32252,
      "pennsylvania": 60392,
      "faces": 31022,
      "141": 1639,
      "undermanaged": 83610,
      "devices": 24272,
      "oxycodon": 54471,
      "ear": 27239,
      "nose": 49979,
      "throat": 81160,
      "ent": 29049,
      "275": 3522,
      "163": 1914,
      "complained": 18421,
      "exception": 30444,
      "obstipation": 50743,
      "deliver": 23205,
      "ivpca": 40405,
      "english": 28940,
      "abstracted": 6627,
      "revman": 72431,
      "abstracts": 6633,
      "ingredient": 38749,
      "rd": 67922,
      "substituting": 78875,
      "expansion": 30544,
      "psychoactive": 66331,
      "formally": 32294,
      "licit": 41667,
      "racial": 66944,
      "socioeconomic": 76397,
      "elements": 28557,
      "fueled": 32608,
      "killing": 40833,
      "chemistry": 15956,
      "standpoint": 76995,
      "foundational": 32427,
      "syntheses": 79940,
      "clandestine": 16640,
      "bladder": 13905,
      "discomfort": 25218,
      "crbd": 21132,
      "trans": 82121,
      "prostate": 65910,
      "034": 432,
      "6h": 5536,
      "coded": 17192,
      "extramedical": 30971,
      "victoria": 86206,
      "intent": 39336,
      "comorbid": 17932,
      "behaviours": 13574,
      "accidental": 7013,
      "glasgow": 33209,
      "decedents": 22815,
      "compiled": 18417,
      "intoxications": 39710,
      "incidental": 37337,
      "comprised": 18636,
      "overlap": 54340,
      "acquired": 7357,
      "seeds": 74344,
      "posterior": 62652,
      "limbic": 41880,
      "midbrain": 46399,
      "informational": 38676,
      "503": 4932,
      "respondent": 71302,
      "antibodies": 11145,
      "sociodemographic": 76390,
      "interviewer": 39691,
      "470": 4671,
      "returned": 72192,
      "leaving": 41329,
      "466": 4642,
      "binomial": 13828,
      "posttest": 63055,
      "drinking": 26459,
      "informing": 38682,
      "edition": 27365,
      "personality": 60950,
      "curtail": 21516,
      "moment": 47296,
      "nsduh": 50107,
      "147": 1653,
      "cb": 15428,
      "enkephalin": 28982,
      "tetrapeptide": 80878,
      "radioligand": 66969,
      "bivalent": 13895,
      "bound": 14260,
      "derivatives": 23620,
      "gtp\u03b3s": 34388,
      "antiallodynic": 11140,
      "provision": 66279,
      "junior": 40564,
      "guideline": 34416,
      "randomisation": 67006,
      "170": 1997,
      "complied": 18573,
      "appropriateness": 11522,
      "precipitation": 63518,
      "unlikely": 83896,
      "calls": 14733,
      "poisons": 62163,
      "centre": 15631,
      "advice": 8857,
      "pass": 58436,
      "ingesting": 38741,
      "diminished": 25022,
      "299": 3632,
      "simulations": 76030,
      "virtual": 86243,
      "ensured": 29045,
      "polypharmacy": 62222,
      "inform": 38614,
      "loq": 42414,
      "omeprazole": 51064,
      "citalopram": 16588,
      "oxybutynin": 54469,
      "analytes": 10797,
      "omeq": 51065,
      "672": 5485,
      "178": 2018,
      "692": 5531,
      "038": 437,
      "028": 397,
      "ranks": 67374,
      "anaesthetic": 9884,
      "balanced": 13234,
      "rectally": 68806,
      "lymphocyte": 42776,
      "cortisol": 20857,
      "phospholipase": 61369,
      "a2": 6506,
      "unimportant": 83736,
      "hypnotics": 36281,
      "flunitrazepam": 31947,
      "reinforce": 69514,
      "zones": 87770,
      "counties": 20950,
      "postulates": 63061,
      "relations": 69710,
      "consolidated": 19733,
      "distributed": 25553,
      "607": 5299,
      "log": 42246,
      "spline": 76738,
      "scaled": 73587,
      "disproportionally": 25502,
      "matches": 43492,
      "populated": 62296,
      "linearity": 42039,
      "premature": 63718,
      "obese": 50357,
      "immature": 36695,
      "accounting": 7082,
      "ceasing": 15444,
      "ceiling": 15445,
      "drive": 26460,
      "529": 5012,
      "010": 331,
      "cyp450": 21646,
      "polymorphism": 62211,
      "sertraline": 74690,
      "varies": 85943,
      "va": 85751,
      "copyright": 20758,
      "wiley": 87100,
      "sons": 76470,
      "boards": 14185,
      "joinpoint": 40483,
      "die": 24522,
      "northern": 49965,
      "southern": 76514,
      "rose": 72813,
      "598": 5201,
      "1990s": 2227,
      "slowed": 76266,
      "2000s": 2426,
      "finland": 31844,
      "france": 32483,
      "ireland": 40270,
      "switzerland": 79843,
      "sharply": 75125,
      "notwithstanding": 49997,
      "equates": 29248,
      "totaling": 81917,
      "bivariate": 13896,
      "wilcoxon": 87089,
      "cci": 15431,
      "square": 76792,
      "adjust": 8012,
      "gamma": 32824,
      "567": 5120,
      "796": 5812,
      "unadjusted": 83451,
      "essentially": 29578,
      "complicate": 18541,
      "absent": 6591,
      "streams": 77462,
      "denominators": 23395,
      "examining": 30426,
      "postmarketing": 62668,
      "builds": 14477,
      "adf": 7982,
      "san": 73373,
      "mateo": 43497,
      "king": 40846,
      "bristol": 14440,
      "tn": 81498,
      "agreement": 9350,
      "pseudo": 66315,
      "validation": 85797,
      "lp": 42740,
      "abbott": 6513,
      "laboratories": 41018,
      "park": 58225,
      "nj": 49506,
      "promise": 65652,
      "adfs": 7988,
      "paediatric": 56337,
      "eat": 27292,
      "attend": 12553,
      "school": 73667,
      "extremity": 30985,
      "missing": 46697,
      "withheld": 87176,
      "fear": 31280,
      "mask": 43444,
      "unsafe": 83938,
      "buccally": 14472,
      "provisional": 66280,
      "guarding": 34398,
      "operated": 51207,
      "adversely": 8853,
      "overcome": 54267,
      "vulnerability": 86686,
      "cautionary": 15421,
      "delays": 23196,
      "morbidity": 47507,
      "enables": 28760,
      "solid": 76428,
      "technical": 80541,
      "077": 618,
      "056": 569,
      "noninferior": 49741,
      "replace": 70426,
      "laced": 41042,
      "counterfeit": 20943,
      "wider": 87078,
      "unintentional": 83742,
      "seizures": 74379,
      "seized": 74376,
      "seizure": 74377,
      "trafficking": 81995,
      "424": 4488,
      "298": 3631,
      "186": 2143,
      "alprazolam": 9668,
      "metamizol": 45021,
      "retinal": 72089,
      "0023": 243,
      "205": 2923,
      "finishing": 31843,
      "expensive": 30568,
      "ramsey": 66992,
      "antagonistic": 11075,
      "guanosine": 34391,
      "thio": 81092,
      "triphosphate": 83230,
      "nm": 49514,
      "rightward": 72480,
      "competitive": 18412,
      "antagonized": 11095,
      "228": 3064,
      "356": 4107,
      "809": 5877,
      "approximation": 11594,
      "supporting": 79222,
      "incompletely": 37704,
      "colorado": 17521,
      "utah": 85702,
      "maryland": 43443,
      "oud": 53892,
      "clonidine": 17060,
      "360": 4153,
      "potentiated": 63276,
      "idazoxan": 36402,
      "yohimbine": 87706,
      "potentiates": 63278,
      "adjuvant": 8076,
      "selecting": 74401,
      "mailing": 42820,
      "list": 42099,
      "weekly": 86884,
      "situations": 76174,
      "choices": 16126,
      "exclusively": 30490,
      "barely": 13250,
      "erector": 29497,
      "spinae": 76694,
      "thoracolumbar": 81125,
      "decompression": 22876,
      "132": 1522,
      "sitting": 76169,
      "histories": 35447,
      "designer": 23854,
      "590": 5195,
      "260": 3459,
      "ruled": 73037,
      "330": 4003,
      "dl": 25647,
      "instruments": 39118,
      "comprise": 18635,
      "fps": 32444,
      "estimating": 29655,
      "equation": 29250,
      "avoiding": 12973,
      "exposing": 30748,
      "sh": 75102,
      "dna": 25652,
      "superoxide": 79152,
      "dismutase": 25365,
      "sod": 76401,
      "glutathione": 33259,
      "gst": 34387,
      "interact": 39362,
      "amino": 9820,
      "acids": 7346,
      "enzymatic": 29096,
      "cited": 16596,
      "escalation": 29528,
      "prefer": 63617,
      "modes": 47220,
      "dealers": 22686,
      "friends": 32598,
      "unpleasant": 83917,
      "creating": 21153,
      "addressed": 7936,
      "manipulated": 43313,
      "deviations": 24265,
      "refers": 69158,
      "subcutaneously": 78608,
      "meant": 43926,
      "filtered": 31731,
      "abscess": 6585,
      "granulomatous": 33405,
      "scarring": 73603,
      "starch": 76999,
      "microcrystalline": 46350,
      "cellulose": 15508,
      "silica": 75887,
      "pvp": 66608,
      "forthcoming": 32416,
      "fourier": 32429,
      "transform": 82184,
      "infrared": 38684,
      "cutaneous": 21536,
      "manifestations": 43309,
      "attenuates": 12593,
      "muscles": 48364,
      "mechanically": 44120,
      "attenuating": 12597,
      "boy": 14290,
      "cargo": 15118,
      "surplus": 79664,
      "timely": 81407,
      "ingestible": 38740,
      "biosensor": 13864,
      "ion": 40141,
      "gradient": 33382,
      "stomach": 77386,
      "reader": 67983,
      "deployed": 23555,
      "instructed": 39103,
      "approached": 11488,
      "completing": 18522,
      "ingest": 38735,
      "ceased": 15442,
      "9th": 6504,
      "reflecting": 69191,
      "tabulated": 80235,
      "277": 3525,
      "401": 4398,
      "524": 5009,
      "complementary": 18434,
      "validates": 85795,
      "566": 5119,
      "209": 2928,
      "notable": 49981,
      "eighteen": 28449,
      "ago": 9268,
      "newer": 49403,
      "rescheduling": 70923,
      "iqvia": 40185,
      "nalorphine": 48418,
      "bni": 14176,
      "devoid": 24274,
      "c6": 14656,
      "carbonyl": 14971,
      "bond": 14228,
      "allyl": 9651,
      "ring": 72486,
      "molecule": 47293,
      "modifications": 47233,
      "bup": 14485,
      "reluctance": 70240,
      "stored": 77398,
      "automation": 12763,
      "orders": 53731,
      "nationally": 48725,
      "grams": 33403,
      "mentions": 44837,
      "455": 4610,
      "430": 4512,
      "563": 5117,
      "806": 5874,
      "4526": 4607,
      "609": 5300,
      "838": 5948,
      "865": 6015,
      "propoxyphene": 65801,
      "plotted": 62022,
      "alerts": 9556,
      "flag": 31896,
      "near": 48856,
      "plots": 62020,
      "fivefold": 31864,
      "priority": 65185,
      "phenomena": 61345,
      "situation": 76172,
      "t5": 80065,
      "t6": 80066,
      "t7": 80068,
      "statistic": 77168,
      "stimulating": 77364,
      "municipal": 48357,
      "0024": 244,
      "paindetect": 57998,
      "nation": 48663,
      "french": 32504,
      "244": 3304,
      "1950": 2208,
      "1180": 1191,
      "146": 1651,
      "excluding": 30483,
      "dextropropoxyphene": 24299,
      "giving": 33207,
      "requests": 70796,
      "mir": 46675,
      "414": 4440,
      "193": 2204,
      "643": 5399,
      "473": 4673,
      "261": 3460,
      "mallinckrodt": 43104,
      "512": 4968,
      "cardiorespiratory": 14991,
      "tennessee": 80604,
      "cyclic": 21549,
      "certificates": 15667,
      "hrs": 35903,
      "176": 2015,
      "128": 1437,
      "154": 1825,
      "420": 4482,
      "facets": 31028,
      "supplementation": 79169,
      "thyroid": 81166,
      "balancing": 13237,
      "wake": 86690,
      "resist": 71089,
      "pipeline": 61559,
      "viscosity": 86255,
      "hard": 34573,
      "forming": 32305,
      "hold": 35501,
      "undetermined": 83712,
      "truly": 83254,
      "deterring": 24132,
      "compromise": 18639,
      "innovations": 39005,
      "651": 5436,
      "hundreds": 35991,
      "federal": 31321,
      "students": 77601,
      "plateaued": 61976,
      "denver": 23419,
      "authority": 12714,
      "feet": 31339,
      "cp": 21036,
      "etoricoxib": 29714,
      "soft": 76409,
      "swelling": 79813,
      "anesthesiological": 10951,
      "proved": 66020,
      "advancement": 8602,
      "website": 86817,
      "2x10": 3657,
      "eda": 27359,
      "mobilization": 47005,
      "retropubic": 72103,
      "prostatectomy": 65912,
      "rrp": 73020,
      "nights": 49477,
      "preferable": 63618,
      "dangers": 21828,
      "presently": 64710,
      "repository": 70742,
      "dates": 22221,
      "instrumental": 39115,
      "probit": 65231,
      "repetitive": 70422,
      "translational": 82218,
      "intracellular": 39727,
      "extracellular": 30940,
      "trigger": 83222,
      "defensive": 23105,
      "phosphorylation": 61373,
      "translation": 82216,
      "mrnas": 48075,
      "adaptation": 7718,
      "depend": 23456,
      "plasticity": 61967,
      "skip": 76210,
      "visually": 86337,
      "stabilized": 76832,
      "launch": 41245,
      "escitalopram": 29536,
      "spray": 76778,
      "puff": 66459,
      "diaphoresis": 24355,
      "sweating": 79807,
      "diarrhea": 24358,
      "blurred": 14171,
      "etiologic": 29709,
      "ssri": 76817,
      "antidepressant": 11166,
      "causality": 15338,
      "infrequent": 38687,
      "ht": 35906,
      "1a": 2247,
      "neuromuscular": 49205,
      "proof": 65684,
      "cb1": 15429,
      "psychomotor": 66350,
      "prototypic": 66015,
      "10mg": 1079,
      "feelings": 31337,
      "bronx": 14456,
      "nontraumatic": 49863,
      "item": 40345,
      "323": 3947,
      "participation": 58393,
      "contexts": 20115,
      "england": 28939,
      "durations": 27195,
      "ninth": 49491,
      "modification": 47230,
      "immunodeficiency": 36777,
      "aids": 9368,
      "veteran": 86173,
      "overwhelming": 54369,
      "delineate": 23199,
      "980": 6475,
      "337": 4011,
      "homicide": 35531,
      "suicide": 79047,
      "analogs": 10546,
      "cheap": 15938,
      "deadly": 22683,
      "threat": 81142,
      "compounded": 18604,
      "atypical": 12620,
      "narrative": 48641,
      "metabolizer": 45000,
      "preemptive": 63607,
      "transurethral": 82247,
      "\u00b5g": 87773,
      "intrathecally": 39805,
      "calculating": 14713,
      "prs": 66289,
      "supervision": 79159,
      "methamphetamine": 45137,
      "mexico": 45676,
      "2022": 2918,
      "unusually": 83971,
      "ostensibly": 53854,
      "authentic": 12711,
      "speaking": 76546,
      "oriented": 53780,
      "micro": 46336,
      "xanax": 87397,
      "adderall": 7733,
      "encounters": 28774,
      "fentanyls": 31614,
      "amphetamines": 9852,
      "methamphetamines": 45153,
      "uniformly": 83734,
      "located": 42220,
      "featured": 31295,
      "occasionally": 50814,
      "normalization": 49915,
      "unregulated": 83924,
      "wave": 86767,
      "geography": 33118,
      "versions": 86093,
      "proximity": 66285,
      "consume": 19819,
      "purchased": 66496,
      "procurement": 65351,
      "121": 1416,
      "rmb": 72692,
      "292": 3624,
      "establishment": 29601,
      "cream": 21136,
      "inf": 38498,
      "viable": 86187,
      "quite": 66924,
      "dementia": 23255,
      "undertreatment": 83667,
      "retest": 72083,
      "instrument": 39113,
      "checklist": 15944,
      "surprisingly": 79669,
      "responsiveness": 71408,
      "degradation": 23168,
      "pharmacoepidemiological": 61094,
      "confounder": 19519,
      "309": 3834,
      "936": 6182,
      "crude": 21328,
      "aor": 11292,
      "conflicting": 19514,
      "depth": 23614,
      "gastrectomy": 32849,
      "allocating": 9619,
      "pneumoperitoneum": 62051,
      "affiliated": 8941,
      "postanaesthesia": 62629,
      "compression": 18632,
      "noninferiority": 49746,
      "toxicities": 81929,
      "chemotherapy": 15964,
      "focuses": 31977,
      "citation": 16589,
      "wos": 87352,
      "1992": 2229,
      "directions": 25058,
      "funds": 32740,
      "publications": 66411,
      "charted": 15935,
      "vosviewer": 86494,
      "author": 12712,
      "655": 5439,
      "887": 6052,
      "bm": 14173,
      "california": 14728,
      "diego": 24529,
      "161": 1910,
      "nih": 49478,
      "occurrences": 50864,
      "784": 5790,
      "diltiazem": 25007,
      "3a4": 4292,
      "isoenzymes": 40299,
      "ketoconazole": 40623,
      "erythromycin": 29518,
      "ritonavir": 72688,
      "aprepitant": 11596,
      "separations": 74600,
      "analysing": 10622,
      "bureau": 14608,
      "coronial": 20792,
      "financial": 31757,
      "465": 4641,
      "ageing": 9209,
      "unable": 83446,
      "minimise": 46589,
      "south": 76509,
      "wales": 86693,
      "exist": 30520,
      "sent": 74580,
      "nurse": 50332,
      "eighty": 28452,
      "decided": 22841,
      "dedicated": 23079,
      "consulted": 19816,
      "resided": 71059,
      "reliably": 70088,
      "blunting": 14169,
      "blocking": 14087,
      "cdc": 15436,
      "cautioned": 15422,
      "optum": 53476,
      "ehr": 28447,
      "219": 3004,
      "216": 3000,
      "multilevel": 48189,
      "multinomial": 48253,
      "begin": 13518,
      "oas": 50355,
      "accelerated": 6971,
      "pc": 60257,
      "exponential": 30737,
      "deceased": 22812,
      "bed": 13511,
      "scene": 73608,
      "microscopic": 46376,
      "pneumonia": 62050,
      "lobe": 42198,
      "grew": 33517,
      "eddp": 27362,
      "doxylamine": 26425,
      "discovery": 25263,
      "facing": 31043,
      "pathologists": 58504,
      "solely": 76426,
      "worsened": 87332,
      "easy": 27289,
      "teenagers": 80557,
      "inability": 37216,
      "sepsis": 74602,
      "emboli": 28658,
      "endotracheal": 28875,
      "intubation": 39960,
      "echocardiogram": 27303,
      "catheterization": 15321,
      "obstructive": 50746,
      "aspiration": 11866,
      "danish": 21831,
      "characterise": 15840,
      "poisonings": 62160,
      "501": 4930,
      "348": 4052,
      "cyclooxygenase": 21557,
      "biosynthesis": 13866,
      "indomethacin": 38364,
      "antipyretic": 11260,
      "historic": 35441,
      "arkansas": 11661,
      "pdmp": 60295,
      "certificate": 15665,
      "windows": 87108,
      "816": 5897,
      "qualitatively": 66669,
      "detecting": 23952,
      "motivation": 48019,
      "dsm": 27104,
      "lived": 42169,
      "compares": 18344,
      "conservative": 19598,
      "liberal": 41657,
      "nonadherence": 49698,
      "discover": 25261,
      "bony": 14242,
      "encapsulated": 28766,
      "transmitting": 82228,
      "worn": 87327,
      "receiver": 68307,
      "hands": 34565,
      "orthopedics": 53840,
      "attitudes": 12602,
      "beliefs": 13580,
      "operate": 51206,
      "stopped": 77390,
      "interacting": 39365,
      "willingness": 87103,
      "instructional": 39108,
      "suspect": 79762,
      "ade": 7948,
      "sedatives": 74340,
      "slovakia": 76260,
      "portugal": 62426,
      "gains": 32819,
      "immersing": 36756,
      "alpha2": 9667,
      "haemodynamic": 34502,
      "anaesthesiologists": 9881,
      "painless": 58019,
      "standardised": 76940,
      "query": 66875,
      "retained": 72074,
      "propagation": 65690,
      "cluster": 17082,
      "clusters": 17086,
      "recycling": 68819,
      "promotes": 65669,
      "prolongs": 65646,
      "gives": 33205,
      "intolerant": 39707,
      "silico": 75888,
      "intravascular": 39807,
      "pool": 62236,
      "5h": 5206,
      "held": 34894,
      "unbound": 83461,
      "reflects": 69194,
      "endocytosis": 28844,
      "incorporated": 37710,
      "pay": 60243,
      "201": 2533,
      "014": 340,
      "favour": 31266,
      "unpredictable": 83921,
      "pharmacogenetic": 61096,
      "metric": 45669,
      "formal": 32290,
      "accomplished": 7030,
      "lessons": 41428,
      "learned": 41324,
      "eliminating": 28608,
      "ohio": 50983,
      "statewide": 77161,
      "postguideline": 62655,
      "preguideline": 63702,
      "assuming": 12508,
      "visiting": 86273,
      "214": 2998,
      "anaesthetics": 9888,
      "antiepileptics": 11198,
      "psycholeptics": 66337,
      "psychoanaleptics": 66336,
      "antihistamines": 11203,
      "relied": 70090,
      "detects": 23969,
      "aggregated": 9254,
      "5000": 4929,
      "clonazepam": 17056,
      "io": 40140,
      "observing": 50738,
      "ultraviolet": 83436,
      "uv": 85749,
      "antihyperalgesia": 11204,
      "prove": 66019,
      "des": 23642,
      "covers": 21019,
      "relies": 70209,
      "391": 4281,
      "compromising": 18641,
      "emergence": 28665,
      "halothane": 34542,
      "130": 1515,
      "traditionally": 81992,
      "walking": 86698,
      "neurological": 49200,
      "resolving": 71118,
      "neurosurgical": 49288,
      "platelet": 61977,
      "craniotomy": 21129,
      "encourage": 28777,
      "stakeholders": 76880,
      "hope": 35537,
      "binds": 13825,
      "prudent": 66292,
      "adhere": 7990,
      "explorative": 30711,
      "proton": 66008,
      "biomarker": 13857,
      "consuming": 19860,
      "statements": 77076,
      "surge": 79261,
      "characterizing": 15917,
      "texas": 80879,
      "encompassing": 28772,
      "austin": 12678,
      "fastest": 31220,
      "375": 4215,
      "30s": 3836,
      "norfentanyl": 49893,
      "positivity": 62513,
      "circadian": 16566,
      "rhythm": 72466,
      "disturbances": 25577,
      "melatonin": 44763,
      "secretion": 74265,
      "saliva": 73276,
      "delaying": 23195,
      "diverted": 25609,
      "termination": 80693,
      "advised": 8860,
      "extension": 30909,
      "ole": 51048,
      "sign": 75382,
      "129": 1441,
      "investigator": 40080,
      "postprocedure": 63041,
      "phenytoin": 61357,
      "descriptions": 23675,
      "surrogate": 79670,
      "sensor": 74568,
      "pleth": 62014,
      "beats": 13506,
      "diastolic": 24362,
      "distinguished": 25545,
      "pertaining": 60974,
      "equality": 29239,
      "malignancies": 43088,
      "brought": 14459,
      "ec": 27297,
      "floor": 31925,
      "exacerbation": 30315,
      "diphenhydramine": 25028,
      "glass": 33210,
      "sensation": 74536,
      "radial": 66952,
      "understudied": 83660,
      "designing": 23856,
      "preventable": 64857,
      "357": 4108,
      "organisational": 53761,
      "preserve": 64719,
      "cystectomy": 21649,
      "batches": 13484,
      "defecation": 23098,
      "ileus": 36612,
      "031": 424,
      "leftover": 41351,
      "mandated": 43300,
      "toilet": 81512,
      "sink": 76146,
      "unlocked": 83899,
      "disposing": 25497,
      "engage": 28931,
      "tailor": 80259,
      "usefulness": 85220,
      "intractable": 39736,
      "psycho": 66330,
      "logical": 42251,
      "habitual": 34498,
      "mmpi": 46991,
      "augmentation": 12655,
      "hypothermic": 36292,
      "pi3k": 61483,
      "akt": 9511,
      "preperitoneal": 63792,
      "hernia": 34973,
      "cavity": 15427,
      "mesh": 44857,
      "installed": 39061,
      "0038": 256,
      "0015": 231,
      "liabilities": 41632,
      "gaps": 32833,
      "demographically": 23293,
      "broadly": 14451,
      "contextual": 20116,
      "lh": 41631,
      "sexually": 75095,
      "uterine": 85703,
      "illnesses": 36663,
      "multidimensional": 48178,
      "caring": 15119,
      "myths": 48386,
      "obstacles": 50740,
      "pathophysiology": 58508,
      "nonpharmacologic": 49825,
      "antihyperalgesic": 11205,
      "irradiation": 40276,
      "occlusive": 50818,
      "characterised": 15841,
      "215": 2999,
      "noninvasive": 49754,
      "inductive": 38483,
      "cage": 14670,
      "compensatory": 18408,
      "inspiratory": 39058,
      "duty": 27198,
      "cycle": 21544,
      "rct": 67908,
      "wished": 87111,
      "thirteen": 81098,
      "nonopioids": 49817,
      "prophylactic": 65723,
      "efficiently": 28426,
      "113": 1173,
      "sleeve": 76240,
      "1200": 1414,
      "commencement": 17697,
      "centrally": 15620,
      "broader": 14449,
      "enantiomers": 28765,
      "desmethyl": 23866,
      "m3": 42785,
      "kilogram": 40834,
      "ed50": 27358,
      "quinidine": 66920,
      "enantiomer": 28764,
      "overcame": 54266,
      "crystal": 21356,
      "consists": 19728,
      "ingredients": 38750,
      "apis": 11363,
      "preferential": 63634,
      "allodynia": 9622,
      "ulceration": 83412,
      "multifactorial": 48186,
      "restraints": 71454,
      "korea": 40946,
      "analogues": 10569,
      "653": 5438,
      "317": 3895,
      "relaxant": 69797,
      "hyperkinetic": 36268,
      "shortly": 75216,
      "stigmatized": 77352,
      "attempting": 12550,
      "classify": 16690,
      "viewing": 86225,
      "video": 86210,
      "vignettes": 86232,
      "depicting": 23553,
      "courses": 21004,
      "posttraumatic": 63056,
      "amnesia": 9831,
      "tbi": 80525,
      "comprises": 18637,
      "aa": 6507,
      "disorientation": 25408,
      "orientation": 53779,
      "\u03c72": 87802,
      "preceded": 63498,
      "sooner": 76472,
      "imminent": 36760,
      "comprehensively": 18631,
      "ascertain": 11824,
      "prefectural": 63616,
      "tended": 80596,
      "pharmetrics": 61266,
      "studying": 78571,
      "accidents": 7020,
      "inflicted": 38582,
      "creates": 21150,
      "transitions": 82210,
      "monetary": 47303,
      "prices": 64971,
      "431": 4513,
      "pharmacoeconomic": 61092,
      "epigastric": 29194,
      "flap": 31898,
      "donor": 25710,
      "catheters": 15322,
      "dissolving": 25529,
      "resists": 71109,
      "liquids": 42096,
      "insufflated": 39135,
      "intolerable": 39702,
      "guard": 34397,
      "receipt": 68032,
      "deidentified": 23186,
      "279": 3528,
      "435": 4516,
      "814": 5894,
      "378": 4220,
      "436": 4517,
      "825": 5919,
      "tables": 80081,
      "704": 5579,
      "783": 5789,
      "771": 5770,
      "epithelial": 29215,
      "removal": 70329,
      "fellow": 31342,
      "defect": 23099,
      "eyes": 31006,
      "bandage": 13243,
      "lens": 41419,
      "removed": 70335,
      "0003": 84,
      "prophylaxis": 65731,
      "ondansetron": 51077,
      "tropisetron": 83242,
      "antiemetics": 11192,
      "metoclopramide": 45667,
      "audited": 12650,
      "emetic": 28715,
      "prince": 65124,
      "hyoscine": 36253,
      "spasm": 76538,
      "fourteen": 32433,
      "estrous": 29665,
      "hormonal": 35542,
      "estrus": 29667,
      "diestrus": 24532,
      "ovariectomized": 54173,
      "estradiol": 29662,
      "progesterone": 65525,
      "ovariectomy": 54175,
      "restored": 71452,
      "transversus": 82251,
      "abdominis": 6536,
      "plane": 61870,
      "regards": 69292,
      "meq": 44855,
      "confers": 19433,
      "stretching": 77495,
      "therapists": 80982,
      "flexion": 31912,
      "thumb": 81164,
      "advancing": 8605,
      "snorted": 76345,
      "cleaned": 16697,
      "output": 54165,
      "045": 465,
      "063": 594,
      "078": 619,
      "onwards": 51133,
      "083": 631,
      "059": 574,
      "1980": 2218,
      "026": 391,
      "046": 466,
      "prognostic": 65527,
      "corticosteroids": 20855,
      "corticosteroid": 20854,
      "suitability": 79051,
      "amikacin": 9817,
      "sigmoidal": 75380,
      "uridine": 84050,
      "bde": 13499,
      "282": 3583,
      "reasonably": 68017,
      "instances": 39063,
      "reconstructive": 68650,
      "oropharyngeal": 53800,
      "insulin": 39139,
      "crp": 21318,
      "leukocyte": 41442,
      "030": 423,
      "040": 459,
      "lessen": 41422,
      "chose": 16140,
      "sound": 76491,
      "ppar\u03b3": 63296,
      "ligands": 41762,
      "reproduce": 70773,
      "targets": 80505,
      "benzyl": 13680,
      "methyl": 45640,
      "phenyl": 61353,
      "benzamide": 13645,
      "replicated": 70439,
      "preferring": 63649,
      "constraints": 19804,
      "kansas": 40580,
      "pathology": 58505,
      "310": 3884,
      "207": 2925,
      "264": 3463,
      "318": 3897,
      "blue": 14166,
      "072": 611,
      "neonatal": 49095,
      "nows": 50045,
      "natal": 48662,
      "perinatal": 60668,
      "spanning": 76523,
      "lactation": 41073,
      "hyperactivity": 36255,
      "sequelae": 74627,
      "ox": 54379,
      "paod": 58070,
      "contraindication": 20208,
      "iatrogenic": 36332,
      "handwritten": 34566,
      "218": 3003,
      "regenerated": 69293,
      "weights": 86990,
      "averaged": 12950,
      "195": 2207,
      "1080": 1074,
      "incorrectly": 37716,
      "overdosing": 54337,
      "underscores": 83618,
      "schizophrenia": 73665,
      "interruption": 39542,
      "provoked": 66282,
      "remission": 70327,
      "deterioration": 23975,
      "encompasses": 28771,
      "integrating": 39199,
      "programmes": 65551,
      "961": 6428,
      "overprescription": 54357,
      "opportunities": 53402,
      "rounds": 72834,
      "tkr": 81491,
      "tau": 80523,
      "sulfate": 79062,
      "implements": 36956,
      "ethical": 29683,
      "commission": 17724,
      "pancreatic": 58058,
      "amylase": 9861,
      "digestion": 24978,
      "rule": 73036,
      "crest": 21161,
      "baby": 12995,
      "girl": 33147,
      "radiological": 66972,
      "topically": 81697,
      "hindpaw": 35414,
      "freund": 32589,
      "fca": 31272,
      "diffusion": 24977,
      "linearly": 42040,
      "advertising": 8856,
      "undiagnosed": 83713,
      "requesting": 70795,
      "attributes": 12616,
      "organizational": 53776,
      "drawbacks": 26448,
      "steroid": 77339,
      "meloxicam": 44768,
      "deficiency": 23106,
      "testosterone": 80850,
      "obesity": 50359,
      "hyperlipidemia": 36269,
      "234": 3129,
      "division": 25629,
      "permits": 60908,
      "ameliorate": 9778,
      "elicits": 28573,
      "alternatively": 9749,
      "allosteric": 9626,
      "modulators": 47265,
      "pams": 58056,
      "pam": 58054,
      "jumping": 40533,
      "shakes": 75103,
      "unreliable": 83928,
      "overt": 54362,
      "ameliorated": 9779,
      "giant": 33145,
      "hemangiomas": 34923,
      "aspartate": 11853,
      "malformations": 43087,
      "ice": 36389,
      "packs": 56325,
      "supplement": 79160,
      "abdomen": 6523,
      "said": 73242,
      "abstinence": 6618,
      "congenital": 19531,
      "defects": 23102,
      "tube": 83272,
      "placental": 61862,
      "trophoblast": 83241,
      "mixtures": 46816,
      "te": 80529,
      "quotient": 66926,
      "aq": 11615,
      "ad": 7715,
      "rely": 70241,
      "carpometacarpal": 15131,
      "anonymously": 11041,
      "823": 5917,
      "tendon": 80601,
      "utilize": 85739,
      "suture": 79801,
      "choose": 16134,
      "practicing": 63446,
      "totaled": 81916,
      "junctions": 40536,
      "mv": 48377,
      "recover": 68728,
      "establishing": 29600,
      "mirror": 46687,
      "histological": 35437,
      "progressively": 65582,
      "colostomy": 17527,
      "rectal": 68802,
      "stoma": 77385,
      "lidocaine": 41669,
      "tomography": 81651,
      "proximal": 66284,
      "347": 4051,
      "qrs": 66645,
      "530": 5027,
      "1600": 1909,
      "112": 1170,
      "940": 6200,
      "scoring": 74021,
      "adequacy": 7954,
      "2400": 3298,
      "mcmaster": 43629,
      "universities": 83848,
      "womac": 87182,
      "intensities": 39214,
      "burning": 14618,
      "paresthesia": 58223,
      "esmethadone": 29540,
      "rel": 69536,
      "1017": 1051,
      "isomer": 40307,
      "uncompetitive": 83485,
      "nmda": 49517,
      "infused": 38691,
      "fr": 32449,
      "reinforcement": 69516,
      "attenuation": 12598,
      "phenylpiperidine": 61354,
      "heterogeneous": 35054,
      "coanalgesic": 17125,
      "unsupervised": 83953,
      "misadventure": 46692,
      "pharmacotherapeutics": 61244,
      "substitutions": 78882,
      "1h": 2250,
      "lasted": 41207,
      "raising": 66981,
      "cervical": 15671,
      "irreversible": 40279,
      "autonomic": 12767,
      "subacute": 78583,
      "emphasize": 28729,
      "positioning": 62442,
      "hydrate": 35998,
      "inevitably": 38496,
      "hemorrhoidectomy": 34944,
      "embedded": 28656,
      "sponge": 76746,
      "anal": 9889,
      "condyloma": 19426,
      "symptomatic": 79868,
      "hemorrhoids": 34945,
      "cg": 15681,
      "immunoreactivity": 36783,
      "victorian": 86209,
      "jurisdictions": 40566,
      "273": 3519,
      "019": 347,
      "transported": 82242,
      "modifying": 47251,
      "glucocorticoids": 33244,
      "790": 5804,
      "army": 11688,
      "washington": 86741,
      "dc": 22664,
      "minimization": 46593,
      "distinctive": 25540,
      "manufacture": 43335,
      "crafting": 21124,
      "civil": 16603,
      "criminal": 21164,
      "investment": 40086,
      "adhd": 7989,
      "addictions": 7779,
      "quebec": 66869,
      "jan": 40410,
      "dec": 22800,
      "progressed": 65569,
      "241": 3300,
      "bp": 14292,
      "076": 617,
      "840": 5969,
      "4200": 4483,
      "sympathomimetic": 79854,
      "underreported": 83613,
      "limb": 41876,
      "gold": 33283,
      "ladder": 41076,
      "928": 6166,
      "processed": 65343,
      "locations": 42228,
      "centered": 15563,
      "port": 62412,
      "stains": 76878,
      "randomization": 67039,
      "statistician": 77239,
      "lesion": 41420,
      "422": 4485,
      "maine": 42867,
      "dap": 21832,
      "facilitating": 31038,
      "arrests": 11700,
      "064": 595,
      "crack": 21120,
      "stimulants": 77356,
      "miscellaneous": 46693,
      "tightly": 81182,
      "pads": 56336,
      "heightened": 34893,
      "189": 2152,
      "522": 5006,
      "443": 4555,
      "327": 3970,
      "666": 5466,
      "708": 5581,
      "temporally": 80591,
      "bitartrate": 13894,
      "rrs": 73022,
      "congress": 19533,
      "laws": 41253,
      "shall": 75104,
      "ascertained": 11825,
      "dea": 22679,
      "racemic": 66942,
      "zopiclone": 87771,
      "unconscious": 83489,
      "supportive": 79230,
      "escape": 29532,
      "145": 1650,
      "bundle": 14481,
      "branch": 14374,
      "morphology": 47975,
      "iliac": 36613,
      "smoking": 76336,
      "glycol": 33264,
      "cigarette": 16553,
      "radio": 66963,
      "telemetry": 80565,
      "chow": 16144,
      "burned": 14617,
      "hypnotic": 36280,
      "dressings": 26453,
      "competition": 18411,
      "gray": 33409,
      "diamorphine": 24353,
      "subpopulations": 78770,
      "polyclonal": 62191,
      "escherichia": 29534,
      "coli": 17432,
      "methodologies": 45226,
      "defence": 23104,
      "anticancer": 11151,
      "calibration": 14724,
      "181": 2129,
      "676": 5488,
      "680": 5507,
      "uncommonly": 83484,
      "scenario": 73606,
      "equipped": 29274,
      "dural": 27143,
      "umbilical": 83439,
      "arrestees": 11697,
      "1272": 1436,
      "2432": 3303,
      "thirds": 81095,
      "fifths": 31690,
      "acetylfentanyl": 7278,
      "furanylfentanyl": 32744,
      "crimes": 21163,
      "exceptions": 30449,
      "monoaminergic": 47363,
      "hepatically": 34960,
      "readily": 67984,
      "reinforcers": 69520,
      "poppy": 62289,
      "baker": 13223,
      "yeast": 87693,
      "microbial": 46346,
      "transformation": 82187,
      "strains": 77405,
      "engineered": 28937,
      "heterologous": 35055,
      "pseudomonas": 66318,
      "putida": 66601,
      "biosynthetic": 13867,
      "flux": 31964,
      "strain": 77403,
      "titer": 81455,
      "specificity": 76631,
      "titrating": 81474,
      "copy": 20756,
      "engineering": 28938,
      "fermentation": 31615,
      "titers": 81456,
      "sustainable": 79773,
      "rectus": 68810,
      "sheath": 75127,
      "rsb": 73027,
      "midline": 46407,
      "allocation": 9620,
      "transabdominal": 82122,
      "interferon": 39434,
      "shorten": 75204,
      "licensed": 41666,
      "7th": 5819,
      "urologic": 84099,
      "gabapentinoid": 32809,
      "975": 6452,
      "hemoglobin": 34942,
      "sa": 73058,
      "tas": 80515,
      "socially": 76362,
      "disadvantaged": 25079,
      "lacerations": 41044,
      "laceration": 41043,
      "repairs": 70387,
      "epinephrine": 29201,
      "let": 41430,
      "eyelid": 31005,
      "cornerstone": 20774,
      "lengthy": 41418,
      "urogynecology": 84098,
      "military": 46440,
      "perineorrhaphy": 60670,
      "exparel": 30545,
      "lateral": 41240,
      "perineal": 60669,
      "cumulatively": 21413,
      "color": 17520,
      "mark": 43390,
      "concordance": 19260,
      "endorsement": 28857,
      "dilaudid": 25004,
      "fair": 31155,
      "debilitating": 22799,
      "vaso": 86035,
      "pwid": 66609,
      "vancouver": 85860,
      "stop": 77389,
      "sciatic": 73673,
      "gradually": 33389,
      "withdrawn": 87172,
      "interesting": 39414,
      "qualities": 66671,
      "voluntarily": 86408,
      "discharges": 25212,
      "decremental": 23077,
      "advances": 8603,
      "prison": 65188,
      "google": 33338,
      "scholar": 73666,
      "theme": 80904,
      "highlighted": 35377,
      "supervised": 79155,
      "productivity": 65438,
      "justice": 40569,
      "billion": 13801,
      "vast": 86039,
      "asi": 11827,
      "connect": 19542,
      "maps": 43354,
      "452": 4606,
      "979": 6455,
      "507": 4938,
      "390": 4280,
      "clustering": 17085,
      "km": 40854,
      "las": 41204,
      "el": 28466,
      "bordering": 14249,
      "nktr": 49510,
      "draft": 26427,
      "approvals": 11530,
      "suboxone": 78768,
      "nucynta": 50130,
      "polymer": 62198,
      "conjugates": 19538,
      "book": 14244,
      "polarized": 62172,
      "longitudinally": 42404,
      "housing": 35881,
      "portenoy": 62418,
      "foley": 32005,
      "1986": 2222,
      "attendant": 12555,
      "influential": 38609,
      "seeks": 74353,
      "discussions": 25314,
      "interpretations": 39507,
      "exploration": 30710,
      "reassessment": 68024,
      "overlooked": 54346,
      "shifting": 75141,
      "researchers": 71044,
      "dynamics": 27217,
      "dilemma": 25006,
      "preventive": 64889,
      "potassium": 63063,
      "herg": 34971,
      "underlie": 83597,
      "171": 2002,
      "microm": 46371,
      "capable": 14945,
      "purported": 66513,
      "reintroduced": 69534,
      "ensued": 29039,
      "invalid": 39962,
      "korean": 40950,
      "teaes": 80536,
      "343": 4047,
      "506": 4937,
      "383": 4251,
      "168": 1920,
      "172": 2004,
      "spreading": 76781,
      "obvious": 50793,
      "unsystematic": 83954,
      "tackle": 80238,
      "fighting": 31694,
      "biomedical": 13860,
      "investigates": 40062,
      "linking": 42058,
      "narratives": 48645,
      "snc80": 76343,
      "u50": 83399,
      "488h": 4763,
      "phased": 61323,
      "307": 3833,
      "709": 5582,
      "nominal": 49559,
      "offs": 50976,
      "msic": 48100,
      "depressants": 23562,
      "alberta": 9520,
      "pretest": 64757,
      "handle": 34559,
      "tylenol": 83315,
      "janssen": 40411,
      "hepatectomy": 34948,
      "6th": 5541,
      "algometer": 9564,
      "thermode": 81088,
      "motivations": 48020,
      "forums": 32418,
      "archive": 11620,
      "tapering": 80482,
      "576": 5148,
      "922": 6162,
      "mentioning": 44836,
      "1020": 1055,
      "508": 4939,
      "captures": 14962,
      "amendment": 9783,
      "hci": 34627,
      "analyser": 10580,
      "mediplus": 44721,
      "229": 3065,
      "consultations": 19815,
      "udt": 83403,
      "apnea": 11364,
      "adaptive": 7722,
      "abandoned": 6511,
      "polysomnography": 62224,
      "hypopnea": 36284,
      "hi": 35059,
      "oxyhemoglobin": 56213,
      "nadir": 48394,
      "arousal": 11692,
      "seventeen": 74882,
      "1966": 2210,
      "en": 28755,
      "meetings": 44761,
      "synthesis": 79941,
      "2c9": 3645,
      "meal": 43650,
      "pyrexia": 66612,
      "poverty": 63284,
      "explanations": 30703,
      "genetic": 33070,
      "oct1": 50871,
      "europeans": 29753,
      "methylnaltrexone": 45662,
      "dextrorphan": 24303,
      "c4": 14648,
      "c5": 14649,
      "polyspecific": 62225,
      "possesses": 62521,
      "impedes": 36912,
      "388": 4256,
      "395": 4286,
      "tasks": 80520,
      "subtle": 78892,
      "whilst": 87011,
      "episodic": 29214,
      "attribution": 12618,
      "marginal": 43377,
      "confident": 19487,
      "impacting": 36860,
      "dawn": 22232,
      "249": 3310,
      "267": 3468,
      "151": 1821,
      "resultant": 71498,
      "spite": 76735,
      "nmu": 49523,
      "multimedia": 48193,
      "caucasian": 15330,
      "agency": 9212,
      "evolving": 30308,
      "implicated": 36957,
      "implementing": 36953,
      "368": 4165,
      "hallucinogens": 34538,
      "957": 6415,
      "bupropion": 14598,
      "correcting": 20798,
      "cumberland": 21384,
      "empirically": 28737,
      "inner": 39002,
      "satisfy": 73464,
      "unmet": 83903,
      "indwelling": 38485,
      "hematoma": 34928,
      "immunological": 36782,
      "refer": 69124,
      "lymphocytes": 42777,
      "drastic": 26445,
      "insight": 39051,
      "summarizes": 79089,
      "references": 69146,
      "uniquely": 83762,
      "suited": 79059,
      "adoption": 8469,
      "furanyl": 32742,
      "francisco": 32484,
      "000ng": 92,
      "anilino": 10986,
      "phenethyl": 61340,
      "piperidine": 61560,
      "anpp": 11048,
      "trace": 81968,
      "entities": 29078,
      "geographically": 33117,
      "olds": 51047,
      "349": 4053,
      "interfere": 39417,
      "constitutes": 19801,
      "british": 14442,
      "columbia": 17528,
      "bc": 13493,
      "coroners": 20791,
      "discectomy": 25087,
      "reoperations": 70375,
      "445": 4557,
      "reoperation": 70371,
      "enthusiasm": 29069,
      "421": 4484,
      "629": 5348,
      "agreed": 9346,
      "aside": 11833,
      "formations": 32299,
      "stocked": 77383,
      "rejected": 69535,
      "somewhat": 76459,
      "dispense": 25414,
      "stated": 77072,
      "restrict": 71455,
      "440": 4552,
      "589": 5176,
      "enrolment": 29038,
      "476": 4676,
      "pooling": 62251,
      "appetite": 11416,
      "thirst": 81097,
      "asthma": 12513,
      "incarceration": 37247,
      "triggered": 83223,
      "carrying": 15147,
      "heavy": 34888,
      "loads": 42197,
      "trash": 82258,
      "latino": 41244,
      "neighborhood": 49093,
      "spanish": 76522,
      "speak": 76545,
      "purchasing": 66497,
      "air": 9503,
      "illegally": 36627,
      "predisposing": 63595,
      "inconclusive": 37706,
      "nephrotoxicity": 49109,
      "magnified": 42808,
      "amlodipine": 9828,
      "571": 5144,
      "lieu": 41679,
      "cyclosporine": 21567,
      "transplant": 82235,
      "trough": 83249,
      "407": 4405,
      "569": 5122,
      "atorvastatin": 12528,
      "simvastatin": 76038,
      "digoxin": 24985,
      "acyclovir": 7713,
      "ionization": 40145,
      "submissions": 78762,
      "exhibits": 30519,
      "imprint": 37052,
      "precursors": 63542,
      "neighboring": 49094,
      "cutoff": 21538,
      "314": 3888,
      "346": 4050,
      "valid": 85773,
      "aging": 9263,
      "pugh": 66460,
      "newest": 49410,
      "crowded": 21313,
      "assets": 12159,
      "valdecoxib": 85760,
      "rofecoxib": 72723,
      "gastroduodenal": 32859,
      "flare": 31900,
      "positions": 62443,
      "scaffold": 73478,
      "versatile": 86081,
      "moieties": 47270,
      "tka": 81487,
      "periarticular": 60663,
      "closure": 17080,
      "milestones": 46439,
      "pdmps": 60298,
      "explicitly": 30707,
      "encouraged": 28778,
      "outlines": 54112,
      "postmarket": 62667,
      "clarifies": 16644,
      "massive": 43477,
      "hosted": 35678,
      "quadrupled": 66658,
      "574": 5146,
      "faced": 31021,
      "ais": 9508,
      "visited": 86270,
      "limbs": 41881,
      "tried": 83221,
      "reassessed": 68023,
      "paralleled": 58148,
      "liberate": 41658,
      "inherently": 38767,
      "structural": 77579,
      "acetic": 7266,
      "distinguishable": 25544,
      "break": 14388,
      "nma": 49516,
      "owing": 54377,
      "frail": 32472,
      "frailty": 32474,
      "empiric": 28734,
      "laos": 41088,
      "ddds": 22675,
      "domestic": 25707,
      "gdp": 32922,
      "599": 5202,
      "361": 4156,
      "asia": 11829,
      "florida": 31927,
      "oversight": 54361,
      "contributors": 20255,
      "regulate": 69490,
      "marginally": 43378,
      "disturbance": 25576,
      "modulatory": 47267,
      "db": 22660,
      "adr": 8472,
      "cyp3a5": 21643,
      "cachexia": 14667,
      "fluoroquinolone": 31954,
      "fq": 32445,
      "clarified": 16642,
      "082": 630,
      "achievement": 7329,
      "striatum": 77498,
      "begun": 13525,
      "loxp": 42739,
      "d2": 21679,
      "choline": 16132,
      "hyperlocomotion": 36270,
      "cues": 21374,
      "enrollees": 29028,
      "coding": 17309,
      "algorithms": 9567,
      "811": 5893,
      "187": 2146,
      "cachectic": 14664,
      "drd2": 26452,
      "prochlorperazine": 65350,
      "\u03bc1": 87783,
      "oprm1": 53412,
      "wild": 87097,
      "prolactin": 65598,
      "mutation": 48374,
      "atp": 12531,
      "cassette": 15275,
      "subfamily": 78611,
      "tacrolimus": 80239,
      "itraconazole": 40357,
      "prednisolone": 63597,
      "triazole": 83212,
      "antifungals": 11201,
      "breastfeeding": 14413,
      "milk": 46442,
      "weekends": 86883,
      "weekend": 86882,
      "southwestern": 76515,
      "virginia": 86239,
      "spot": 76766,
      "desired": 23865,
      "fail": 31136,
      "nonprescribed": 49832,
      "agree": 9345,
      "external": 30933,
      "biologic": 13848,
      "urgently": 84048,
      "disc": 25085,
      "accountability": 7079,
      "messaging": 44863,
      "quartile": 66858,
      "queries": 66874,
      "085": 633,
      "forces": 32251,
      "mat": 43480,
      "implants": 36921,
      "implant": 36915,
      "delivers": 23213,
      "protrusion": 66018,
      "introduces": 39912,
      "scd": 73605,
      "integrates": 39198,
      "extant": 30843,
      "etiology": 29712,
      "placenta": 61861,
      "pentazocine": 60393,
      "estrogen": 29664,
      "comparably": 17976,
      "belongs": 13586,
      "epoxymorphinans": 29222,
      "characterisation": 15839,
      "mediates": 44319,
      "inverted": 39995,
      "bell": 13583,
      "shaped": 75114,
      "stereoselectivity": 77335,
      "phantom": 61004,
      "contradictory": 20206,
      "squamous": 76790,
      "reveals": 72230,
      "leaves": 41328,
      "amputation": 9856,
      "fake": 31160,
      "ftp": 32607,
      "volatilization": 86386,
      "lethargy": 41438,
      "unsuccessful": 83949,
      "sentinel": 74581,
      "914": 6146,
      "navippro": 48823,
      "624": 5346,
      "misusers": 46757,
      "separating": 74595,
      "purifying": 66511,
      "chemically": 15953,
      "evolve": 30306,
      "recipes": 68563,
      "websites": 86818,
      "beads": 13502,
      "layers": 41261,
      "categorical": 15288,
      "imaginable": 36681,
      "265": 3464,
      "nalbuphine": 48410,
      "transformations": 82189,
      "morphinans": 47525,
      "diene": 24530,
      "backbone": 12998,
      "inspired": 39059,
      "rigid": 72481,
      "oxime": 54402,
      "alkaloids": 9579,
      "hypotensive": 36289,
      "oxo": 54436,
      "codeinone": 17304,
      "oh": 50982,
      "hplc": 35884,
      "isomers": 40308,
      "substituents": 78870,
      "saturated": 73467,
      "dihydro": 24987,
      "definitely": 23159,
      "unsaturated": 83941,
      "molar": 47272,
      "ellipticities": 28621,
      "127": 1435,
      "359": 4110,
      "872": 6029,
      "839": 5950,
      "743": 5683,
      "exceeds": 30437,
      "tdf": 80528,
      "works": 87300,
      "robustness": 72714,
      "explores": 30735,
      "damaging": 21822,
      "dentist": 23415,
      "arriving": 11705,
      "extractions": 30968,
      "teeth": 80560,
      "massachusetts": 43474,
      "ap": 11343,
      "autoimmune": 12753,
      "starts": 77027,
      "progresses": 65570,
      "malnutrition": 43105,
      "disparity": 25411,
      "display": 25469,
      "inefficiency": 38492,
      "gastroenterologist": 32860,
      "divergent": 25582,
      "formulate": 32321,
      "stakeholder": 76879,
      "curbing": 21418,
      "carolina": 15126,
      "166": 1918,
      "academy": 6963,
      "otolaryngology": 53884,
      "nice": 49467,
      "zealand": 87750,
      "biosis": 13865,
      "isi": 40290,
      "emphasizing": 28733,
      "arises": 11658,
      "unacceptable": 83448,
      "antiplatelet": 11256,
      "recommending": 68640,
      "art": 11707,
      "accelerate": 6970,
      "melbourne": 44764,
      "temazepam": 80578,
      "chevron": 15976,
      "akin": 9510,
      "radiographic": 66966,
      "fellowship": 31344,
      "ankle": 11005,
      "angle": 10982,
      "hva": 35994,
      "views": 86226,
      "274": 3520,
      "deformity": 23165,
      "polytrauma": 62230,
      "620": 5343,
      "questionable": 66884,
      "insights": 39053,
      "sert": 74689,
      "transfected": 82176,
      "ligand": 41760,
      "burdensome": 14607,
      "encouraging": 28780,
      "pending": 60384,
      "excision": 30469,
      "158": 1833,
      "ecstasy": 27319,
      "purposive": 66598,
      "methylphenidate": 45664,
      "apparently": 11381,
      "471": 4672,
      "residency": 71063,
      "yes": 87694,
      "lortab": 42424,
      "lorcet": 42423,
      "darvocet": 21838,
      "correctly": 20804,
      "unaware": 83459,
      "raise": 66977,
      "facility": 31042,
      "instruction": 39107,
      "cotton": 20913,
      "try": 83266,
      "kind": 40837,
      "workers": 87290,
      "van": 85859,
      "broaden": 14448,
      "approximate": 11553,
      "963": 6430,
      "unexplained": 83722,
      "alongside": 9660,
      "russia": 73053,
      "accessibility": 7009,
      "reserve": 71054,
      "287": 3589,
      "245": 3306,
      "0206": 383,
      "pairwise": 58027,
      "dimensional": 25015,
      "inefficient": 38493,
      "visualization": 86335,
      "ddi": 22676,
      "interactive": 39404,
      "concise": 18849,
      "scalable": 73479,
      "endorsed": 28856,
      "sexual": 75094,
      "hormones": 35545,
      "equilibrium": 29268,
      "dialysis": 24348,
      "tha": 80894,
      "diverse": 25583,
      "constituents": 19798,
      "oe": 50940,
      "487": 4761,
      "942": 6202,
      "saw": 73474,
      "inferred": 38534,
      "amphetamine": 9842,
      "crowdsourced": 21316,
      "retrieve": 72092,
      "exploited": 30708,
      "gram": 33402,
      "092": 646,
      "oin": 50993,
      "akathisia": 9509,
      "affinities": 8943,
      "2c": 3638,
      "desmethyltramadol": 23868,
      "monoacetylmorphine": 47355,
      "interacted": 39364,
      "micromolar": 46372,
      "driving": 26468,
      "road": 72698,
      "traffic": 81993,
      "bac": 12997,
      "bromazepam": 14453,
      "clobazam": 17045,
      "nordiazepam": 49883,
      "phenazepam": 61335,
      "parametric": 58176,
      "thousand": 81138,
      "assistants": 12193,
      "civilian": 16604,
      "endocarditis": 28841,
      "staphylococcus": 76997,
      "aureus": 12677,
      "contains": 20088,
      "equipment": 29270,
      "filters": 31733,
      "salt": 73281,
      "spiked": 76692,
      "heated": 34884,
      "bacteria": 13218,
      "methicillin": 45156,
      "sterile": 77336,
      "survived": 79756,
      "heating": 34885,
      "incorporate": 37709,
      "640": 5397,
      "perineural": 60671,
      "ilioinguinal": 36617,
      "iliohypogastric": 36616,
      "583": 5171,
      "unavailability": 83457,
      "timeframe": 81406,
      "phentermine": 61352,
      "strenuous": 77481,
      "esomeprazole": 29541,
      "hydrochlorothiazide": 36041,
      "745": 5684,
      "scr": 74024,
      "deltoid": 23246,
      "anuria": 11266,
      "hydration": 35999,
      "bicarbonate": 13784,
      "engaging": 28936,
      "prostaglandin": 65908,
      "e2": 27237,
      "vascular": 86031,
      "parecoxib": 58186,
      "preservative": 64716,
      "tonsillectomy": 81661,
      "exacerbating": 30314,
      "adapted": 7720,
      "apc": 11361,
      "unsatisfactory": 83940,
      "possibilities": 62523,
      "questioned": 66885,
      "functionality": 32718,
      "preincisional": 63705,
      "21st": 3005,
      "determinants": 23977,
      "segmentation": 74371,
      "peaking": 60329,
      "breakpoints": 14394,
      "era": 29484,
      "stark": 77000,
      "affording": 8953,
      "tizanidine": 81486,
      "yrs": 87749,
      "obstetric": 50741,
      "mortem": 48000,
      "822": 5916,
      "lc": 41265,
      "underreporting": 83614,
      "collect": 17441,
      "redistribution": 68825,
      "biopsy": 13863,
      "spleen": 76737,
      "ethylidene": 29703,
      "dimethyl": 25017,
      "diphenylpyrrolidine": 25031,
      "passive": 58442,
      "eluxadoline": 28629,
      "irritable": 40280,
      "presumed": 64753,
      "kruskal": 40957,
      "wallis": 86701,
      "597": 5200,
      "loperamide": 42412,
      "diphenoxylate": 25030,
      "multidisciplinary": 48179,
      "ailments": 9369,
      "scrutinized": 74057,
      "offices": 50974,
      "unexpectedly": 83721,
      "stand": 76883,
      "presumably": 64752,
      "rf": 72445,
      "cryoablation": 21353,
      "tumors": 83280,
      "locally": 42218,
      "conscious": 19548,
      "postulated": 63060,
      "carboxy": 14972,
      "cooh": 20745,
      "commenced": 17696,
      "complexities": 18531,
      "da": 21684,
      "nonprescription": 49835,
      "addresses": 7938,
      "engaged": 28932,
      "possession": 62522,
      "bath": 13485,
      "dipyrone": 25034,
      "coxibs": 21035,
      "coanalgesics": 17126,
      "gabapentinoids": 32810,
      "motivator": 48021,
      "941": 6201,
      "509": 4940,
      "403": 4400,
      "played": 61999,
      "ecological": 27305,
      "272": 3516,
      "916": 6147,
      "df": 24308,
      "influencing": 38607,
      "popularity": 62292,
      "btp": 14463,
      "accompany": 7027,
      "porto": 62423,
      "shunting": 75365,
      "alcoholic": 9548,
      "biotransformation": 13869,
      "encephalopathy": 28767,
      "196": 2209,
      "nonsmokers": 49850,
      "instituted": 39071,
      "strictly": 77501,
      "523": 5008,
      "congruent": 19534,
      "sensible": 74539,
      "msh": 48099,
      "anemia": 10897,
      "ss": 76816,
      "clipping": 17044,
      "aneurysm": 10977,
      "mins": 46631,
      "aneurysms": 10978,
      "pi": 61479,
      "calcium": 14672,
      "verapamil": 86068,
      "prolong": 65603,
      "neuroexcitatory": 49193,
      "unrelieved": 83929,
      "intracranial": 39734,
      "ketoprofen": 40625,
      "societies": 76366,
      "824": 5918,
      "apnoea": 11368,
      "disordered": 25389,
      "labeled": 41009,
      "clarity": 16649,
      "undesired": 83708,
      "occasional": 50813,
      "catastrophizing": 15284,
      "unsecure": 83943,
      "calculator": 14719,
      "individualizing": 38321,
      "1993": 2230,
      "seasonal": 74175,
      "884": 6051,
      "398": 4289,
      "447": 4559,
      "926": 6165,
      "858": 6001,
      "initiates": 38885,
      "183": 2138,
      "778": 5771,
      "opi": 51282,
      "581": 5169,
      "kaiser": 40576,
      "permanente": 60899,
      "kpnc": 40955,
      "hypogonadism": 36283,
      "283": 3585,
      "generating": 33039,
      "custom": 21533,
      "customize": 21534,
      "encourages": 28779,
      "adulterants": 8532,
      "substitutes": 78874,
      "eventual": 30136,
      "business": 14622,
      "quick": 66916,
      "listened": 42101,
      "write": 87368,
      "tendency": 80599,
      "reinforced": 69515,
      "places": 61863,
      "strive": 77506,
      "apart": 11360,
      "circulated": 16571,
      "forum": 32417,
      "entries": 29084,
      "caregivers": 15115,
      "c1": 14639,
      "720": 5636,
      "aripiprazole": 11653,
      "621": 5344,
      "bevacizumab": 13754,
      "bortezomib": 14252,
      "alfa": 9557,
      "acetate": 7265,
      "ferric": 31616,
      "carboxymaltose": 14974,
      "hpv": 35888,
      "vaccine": 85754,
      "lacosamide": 41069,
      "prilocaine": 64973,
      "vincristine": 86234,
      "diphtheria": 25033,
      "conjugate": 19535,
      "polyethylene": 62195,
      "epoetin": 29216,
      "recombinant": 68577,
      "sb": 73475,
      "sch": 73609,
      "solifenacin": 76434,
      "telmisartan": 80577,
      "th": 80893,
      "302": 3825,
      "recommendation": 68586,
      "lot": 42444,
      "levo": 41621,
      "mainstay": 42873,
      "swallow": 79804,
      "avoidance": 12966,
      "hydrophilic": 36233,
      "quaternary": 66867,
      "450": 4605,
      "phenotypic": 61349,
      "mandible": 43305,
      "prostheses": 65915,
      "covid": 21020,
      "pandemic": 58063,
      "plant": 61890,
      "accumulates": 7091,
      "antitussive": 11262,
      "papaverine": 58071,
      "noscapine": 49978,
      "transcripts": 82135,
      "adjacent": 8000,
      "elucidation": 28626,
      "gasoline": 32848,
      "solvents": 76452,
      "sniffing": 76344,
      "anderson": 10890,
      "874": 6031,
      "inhalant": 38759,
      "ef": 27409,
      "trending": 82956,
      "downward": 26422,
      "establishes": 29599,
      "subutex": 78901,
      "newborns": 49399,
      "accept": 6974,
      "acetaminophene": 7264,
      "vasculitis": 86034,
      "malignancy": 43090,
      "glioma": 33217,
      "submission": 78761,
      "neoplasm": 49106,
      "symposium": 79855,
      "proceedings": 65333,
      "cleft": 16727,
      "lip": 42063,
      "8954": 6066,
      "0006": 89,
      "struggled": 77595,
      "workgroup": 87294,
      "098": 649,
      "inappropriately": 37245,
      "rendering": 70369,
      "antagonize": 11093,
      "forskolin": 32414,
      "camp": 14743,
      "possess": 62519,
      "ip": 40153,
      "surpassed": 79662,
      "488": 4762,
      "metabolising": 44919,
      "cytochromes": 21665,
      "cyp2c19": 21577,
      "cyp2c9": 21582,
      "phenotyping": 61350,
      "antipsychotics": 11259,
      "tamoxifen": 80327,
      "inefficacy": 38491,
      "pms": 62046,
      "desipramine": 23858,
      "amitriptyline": 9823,
      "haloperidol": 34541,
      "prodrug": 65352,
      "ums": 83445,
      "propafenone": 65689,
      "postmenopausal": 62670,
      "clopidogrel": 17065,
      "ppis": 63298,
      "carriers": 15143,
      "ph": 61000,
      "imipramine": 36694,
      "vitamin": 86349,
      "supratherapeutic": 79254,
      "normalised": 49914,
      "quicker": 66918,
      "plants": 61893,
      "suppressant": 79239,
      "antimicrobial": 11213,
      "catalysts": 15280,
      "genomic": 33094,
      "summarize": 79086,
      "ends": 28921,
      "sale": 73244,
      "nasally": 48659,
      "principle": 65130,
      "modafinil": 47008,
      "borne": 14251,
      "mind": 46560,
      "arsenal": 11706,
      "specialities": 76568,
      "demands": 23254,
      "undergoes": 83505,
      "constituting": 19802,
      "adjuvants": 8088,
      "\u03b12": 87779,
      "reliance": 70089,
      "transcriptomics": 82134,
      "metabolomics": 45016,
      "unprecedented": 83920,
      "isolating": 40305,
      "sequencing": 74631,
      "cdna": 15437,
      "candidates": 14924,
      "transcriptome": 82133,
      "proteome": 65948,
      "functionally": 32720,
      "accreditation": 7084,
      "lungs": 42770,
      "abscesses": 6586,
      "inhalational": 38761,
      "focal": 31967,
      "segmental": 74370,
      "glomerulonephritis": 33241,
      "han": 34546,
      "methylenedioxymethamphetamine": 45656,
      "mdma": 43644,
      "hyperpyrexia": 36273,
      "histology": 35439,
      "alcoholism": 9552,
      "prescriptive": 64578,
      "lab": 40966,
      "lastly": 41217,
      "definite": 23158,
      "arisen": 11657,
      "treatable": 82319,
      "therapeutically": 80969,
      "naturally": 48746,
      "belonging": 13585,
      "chapter": 15837,
      "vice": 86193,
      "versa": 86080,
      "membranes": 44788,
      "appreciate": 11451,
      "transmitter": 82227,
      "cholinergic": 16133,
      "gabaergic": 32785,
      "lowering": 42727,
      "sm": 76270,
      "portal": 62416,
      "ester": 29602,
      "997": 6500,
      "darbepoetin": 21833,
      "eslicarbazepine": 29538,
      "eluting": 28627,
      "stent": 77318,
      "239": 3136,
      "albumin": 9521,
      "doxorubicin": 26424,
      "lopinavir": 42413,
      "maraviroc": 43355,
      "paclitaxel": 56326,
      "pan": 58057,
      "posaconazole": 62430,
      "prucalopride": 66291,
      "peptide": 60439,
      "sirolimus": 76153,
      "tartrate": 80514,
      "vp": 86497,
      "hyper": 36254,
      "maois": 43344,
      "moclobemide": 47007,
      "ah": 9353,
      "7921": 5807,
      "mt": 48101,
      "looking": 42408,
      "denial": 23390,
      "unrestricted": 83937,
      "auditory": 12651,
      "interrogation": 39535,
      "span": 76521,
      "enable": 28758,
      "searching": 74170,
      "atom": 12527,
      "heterocyclic": 35046,
      "indole": 38362,
      "organisms": 53763,
      "collections": 17502,
      "poats": 62060,
      "cows": 21023,
      "adopt": 8466,
      "conservatively": 19600,
      "tr": 81967,
      "axis": 12990,
      "541": 5059,
      "sera": 74641,
      "rewards": 72444,
      "vulnerable": 86687,
      "mmpr": 46992,
      "modal": 47009,
      "561": 5115,
      "787": 5792,
      "029": 399,
      "generalizable": 32994,
      "cnp": 17110,
      "brazil": 14386,
      "lamotrigine": 41082,
      "querying": 66876,
      "learn": 41323,
      "542": 5060,
      "mediation": 44322,
      "categorised": 15301,
      "taxonomy": 80524,
      "duplicate": 27140,
      "eb": 27295,
      "rigor": 72483,
      "multitude": 48314,
      "posed": 62434,
      "universally": 83847,
      "applicants": 11422,
      "herpetic": 35043,
      "phn": 61359,
      "shingles": 75143,
      "necessity": 48896,
      "sensitization": 74566,
      "chemicals": 15954,
      "pmps": 62045,
      "pmp": 62043,
      "fiscal": 31848,
      "953": 6413,
      "966": 6432,
      "enormous": 28984,
      "durable": 27142,
      "simplify": 76024,
      "breakdown": 14391,
      "originated": 53795,
      "ligation": 41766,
      "anorectal": 11042,
      "hematological": 34924,
      "myeloid": 48378,
      "leukemia": 41441,
      "febrile": 31301,
      "septic": 74624,
      "shock": 75150,
      "drainage": 26429,
      "drained": 26430,
      "spread": 76780,
      "hematopoietic": 34930,
      "marrow": 43441,
      "shrank": 75364,
      "transplants": 82238,
      "aggravated": 9250,
      "skills": 76197,
      "consulting": 19817,
      "consults": 19818,
      "quantitatively": 66814,
      "words": 87265,
      "conversation": 20704,
      "discussing": 25299,
      "consult": 19813,
      "communicating": 17907,
      "lacked": 41063,
      "necessitates": 48894,
      "expanding": 30541,
      "schools": 73671,
      "curriculum": 21515,
      "circumventing": 16582,
      "pharmacophore": 61243,
      "filter": 31730,
      "scored": 73814,
      "subjected": 78643,
      "revealing": 72229,
      "appreciable": 11450,
      "analytics": 10809,
      "contrasted": 20219,
      "epidemiologic": 29158,
      "neuroimaging": 49194,
      "homes": 35530,
      "benchmarking": 13590,
      "warfarin": 86712,
      "nitrofurantoin": 49498,
      "transcription": 82130,
      "enrolling": 29029,
      "coming": 17694,
      "comparatively": 17986,
      "dealer": 22685,
      "aggravating": 9251,
      "triggering": 83224,
      "force": 32245,
      "mounted": 48029,
      "stiffness": 77350,
      "snap": 76342,
      "identifies": 36484,
      "precipitants": 63507,
      "safest": 73116,
      "levobupivacaine": 41622,
      "mexiletine": 45677,
      "precautions": 63497,
      "carbamazepine": 14965,
      "valproate": 85807,
      "fulminant": 32619,
      "764": 5750,
      "exceptionally": 30446,
      "illuminated": 36665,
      "multitarget": 48313,
      "oih": 50991,
      "etiological": 29710,
      "integrative": 39201,
      "underutilized": 83670,
      "puts": 66603,
      "falls": 31164,
      "distance": 25535,
      "passed": 58440,
      "multifaceted": 48184,
      "counselling": 20927,
      "dispensations": 25413,
      "quintile": 66923,
      "apply": 11442,
      "disparities": 25410,
      "preparedness": 63790,
      "lines": 42041,
      "inequities": 38494,
      "readmission": 67989,
      "oversedation": 54360,
      "anxiolytics": 11288,
      "consumo": 19862,
      "medicamentos": 44431,
      "updates": 83988,
      "interfering": 39433,
      "synthase": 79939,
      "nowadays": 50044,
      "catalytic": 15281,
      "quantum": 66846,
      "mechanics": 44122,
      "rankings": 67373,
      "fluctuated": 31937,
      "369": 4166,
      "cyclodextrin": 21556,
      "soluble": 76436,
      "hydroxypropyl": 36250,
      "formed": 32300,
      "adulteration": 8534,
      "incumbent": 38155,
      "antibody": 11149,
      "thorough": 81132,
      "specimen": 76634,
      "inside": 39050,
      "screenings": 74054,
      "infancy": 38499,
      "predominated": 63605,
      "summarise": 79083,
      "format": 32295,
      "neuropsychiatric": 49284,
      "disabling": 25077,
      "upcoming": 83974,
      "cranial": 21126,
      "pallidum": 58053,
      "transcranial": 82126,
      "rtms": 73035,
      "underway": 83671,
      "novo": 50043,
      "bupivicaine": 14513,
      "triamcinolone": 83210,
      "nortriptyline": 49969,
      "continuation": 20119,
      "presumptive": 64754,
      "873": 6030,
      "barbiturates": 13247,
      "favoring": 31264,
      "maxillary": 43567,
      "nonnarcotic": 49797,
      "qol": 66633,
      "domains": 25704,
      "tx": 83314,
      "mirrored": 46688,
      "enjoyment": 28980,
      "directing": 25055,
      "butorphanol": 14625,
      "ketobemidone": 40622,
      "untreated": 83957,
      "quickly": 66919,
      "begins": 13524,
      "eras": 29487,
      "benchmark": 13589,
      "mma": 46944,
      "renewal": 70370,
      "cast": 15276,
      "iontophoretic": 40151,
      "acupuncture": 7605,
      "transcutaneous": 82137,
      "emerge": 28661,
      "portions": 62422,
      "seniors": 74535,
      "standardization": 76944,
      "posing": 62438,
      "compiling": 18418,
      "applicable": 11420,
      "inadvertent": 37239,
      "phenelzine": 61339,
      "restlessness": 71450,
      "extremities": 30984,
      "mastectomy": 43478,
      "bisoprolol": 13886,
      "restarted": 71438,
      "universal": 83845,
      "mapping": 43353,
      "sense": 74538,
      "adenoidectomy": 7950,
      "delphi": 23231,
      "221": 3053,
      "wellbeing": 86992,
      "generations": 33041,
      "boomers": 14245,
      "intergenerational": 39435,
      "binge": 13826,
      "doing": 25699,
      "disadvantage": 25078,
      "logit": 42281,
      "gen": 32926,
      "differentially": 24941,
      "policymakers": 62186,
      "ig": 36548,
      "ready": 67993,
      "compulsive": 18644,
      "subtype": 78894,
      "370": 4210,
      "binders": 13810,
      "interstitial": 39545,
      "identifiers": 36483,
      "641": 5398,
      "545": 5062,
      "358": 4109,
      "016": 344,
      "568": 5121,
      "temporarily": 80594,
      "304": 3828,
      "805": 5873,
      "619": 5327,
      "528": 5011,
      "impulsivity": 37210,
      "hits": 35490,
      "takes": 80296,
      "legislatures": 41381,
      "equaled": 29238,
      "lay": 41259,
      "adrs": 8481,
      "southeastern": 76513,
      "255": 3405,
      "cf": 15678,
      "stenosis": 77317,
      "hypertrophy": 36279,
      "iron": 40272,
      "colectomy": 17431,
      "albuterol": 9522,
      "refractoriness": 69220,
      "fluoroscopic": 31956,
      "oswestry": 53877,
      "cooled": 20746,
      "100mg": 1046,
      "pathophysiological": 58506,
      "glycoprotein": 33265,
      "gp": 33356,
      "sar": 73380,
      "normeperidine": 49921,
      "hodgkin": 35499,
      "lisinopril": 42097,
      "diet": 24533,
      "inr": 39045,
      "tobacco": 81502,
      "dysuria": 27236,
      "dietary": 24535,
      "supplements": 79172,
      "platelets": 61981,
      "caveats": 15426,
      "reproducibility": 70774,
      "applicability": 11419,
      "norpd": 49952,
      "365": 4161,
      "543": 5061,
      "224": 3056,
      "inducer": 38462,
      "isoform": 40301,
      "updating": 83990,
      "235": 3131,
      "174": 2008,
      "258": 3408,
      "333": 4007,
      "grey": 33518,
      "conference": 19429,
      "alike": 9571,
      "frontline": 32604,
      "fascial": 31195,
      "fascia": 31193,
      "bilaterally": 13795,
      "exacerbate": 30311,
      "live": 42168,
      "nephrectomy": 49107,
      "donors": 25714,
      "retroperitoneal": 72102,
      "bmi": 14174,
      "0000001": 50,
      "characterizes": 15916,
      "reservoir": 71058,
      "ft": 32606,
      "ot": 53880,
      "ethnic": 29697,
      "allele": 9583,
      "attacks": 12541,
      "heme": 34932,
      "protoporphyrin": 66013,
      "nifedipine": 49471,
      "enalapril": 28763,
      "interruptive": 39543,
      "hindering": 35411,
      "native": 48735,
      "visible": 86257,
      "silent": 75886,
      "143": 1643,
      "695": 5533,
      "345": 4049,
      "350": 4100,
      "seconds": 74263,
      "bariatric": 13251,
      "medd": 44163,
      "manuscripts": 43343,
      "psychometric": 66347,
      "weaknesses": 86803,
      "priori": 65179,
      "methodologic": 45223,
      "phenol": 61344,
      "ut": 85701,
      "predominance": 63600,
      "functionalization": 32719,
      "methylene": 45650,
      "amido": 9815,
      "bifunctional": 13790,
      "skeleton": 76193,
      "avenues": 12853,
      "isc": 40284,
      "accommodate": 7022,
      "hrqol": 35900,
      "finnish": 31845,
      "271": 3515,
      "ici": 36393,
      "994": 6497,
      "630": 5372,
      "457": 4612,
      "844": 5971,
      "deliveries": 23210,
      "restricting": 71460,
      "causation": 15339,
      "formalized": 32293,
      "confound": 19517,
      "uncomplicated": 83486,
      "integral": 39190,
      "identifiable": 36409,
      "alleged": 9582,
      "diminishing": 25025,
      "stabilizing": 76835,
      "admixture": 8433,
      "underestimation": 83499,
      "endoscopy": 28866,
      "septal": 74604,
      "pharyngitis": 61267,
      "antifungal": 11199,
      "recognizing": 68575,
      "paramount": 58177,
      "omission": 51067,
      "631": 5373,
      "idiopathic": 36546,
      "alliance": 9609,
      "solicited": 76427,
      "disagreed": 25081,
      "clearer": 16723,
      "antiinflammatory": 11210,
      "originally": 53793,
      "refecoxib": 69123,
      "marine": 43387,
      "frog": 32601,
      "cravings": 21131,
      "627": 5347,
      "rheumatism": 72453,
      "refilling": 69171,
      "selling": 74507,
      "reflective": 69193,
      "exceptional": 30445,
      "distinction": 25539,
      "accumulating": 7092,
      "hc": 34624,
      "fears": 31281,
      "realized": 68011,
      "introducing": 39914,
      "employer": 28744,
      "privately": 65194,
      "dissection": 25512,
      "0002": 83,
      "taa": 80072,
      "adopting": 8468,
      "thrombosis": 81161,
      "employ": 28738,
      "mitigating": 46767,
      "scarcity": 73602,
      "coingestion": 17419,
      "326": 3969,
      "334": 4008,
      "surg": 79260,
      "lasers": 41206,
      "retina": 72088,
      "238": 3134,
      "mechanistically": 44159,
      "fidelity": 31682,
      "crossed": 21282,
      "trap": 82255,
      "purification": 66509,
      "representation": 70754,
      "hydroxyzine": 36252,
      "underrepresented": 83615,
      "deserves": 23692,
      "appreciated": 11452,
      "hematology": 34926,
      "724": 5638,
      "973": 6450,
      "sixteen": 76177,
      "inserted": 39048,
      "heavily": 34887,
      "spoke": 76745,
      "hub": 35934,
      "imposes": 37046,
      "causative": 15340,
      "correspond": 20842,
      "738": 5665,
      "correspondence": 20844,
      "ki": 40820,
      "deal": 22684,
      "alcoholics": 9551,
      "antiarrhythmics": 11142,
      "prokinetics": 65597,
      "atropine": 12540,
      "opiod": 51346,
      "antineoplastic": 11214,
      "anthracyclines": 11109,
      "alkylating": 9580,
      "cisplatin": 16587,
      "electrocardiographic": 28516,
      "grades": 33381,
      "ht3": 35915,
      "granisetron": 33404,
      "dolasetron": 25700,
      "benzoylecognine": 13678,
      "284": 3586,
      "residences": 71062,
      "unexplored": 83723,
      "permitted": 60909,
      "cent": 15513,
      "powdered": 63286,
      "jersey": 40473,
      "alaska": 9518,
      "aror": 11691,
      "glycaemic": 33262,
      "ors": 53811,
      "043": 463,
      "implicit": 36971,
      "ups": 84015,
      "ultrasonic": 83429,
      "wong": 87259,
      "rash": 67415,
      "227": 3063,
      "cigarettes": 16554,
      "tranquilizers": 82120,
      "reliever": 70222,
      "implantation": 36919,
      "pnb": 62048,
      "1g": 2248,
      "60min": 5301,
      "15mg": 1836,
      "48h": 4764,
      "2mg": 3652,
      "325mg": 3968,
      "513": 4969,
      "penicillin": 60389,
      "unremarkable": 83931,
      "bilirubin": 13797,
      "ray": 67907,
      "complain": 18419,
      "prehospital": 63703,
      "hypoxemia": 36318,
      "exchange": 30466,
      "extracorporeal": 30942,
      "mediating": 44320,
      "oxygenated": 56210,
      "bi": 13760,
      "multifunctional": 48188,
      "addictovigilance": 7788,
      "lockdown": 42234,
      "continuity": 20155,
      "partners": 58433,
      "noteworthy": 49993,
      "highlighting": 35378,
      "suspicious": 79770,
      "ihr": 36552,
      "monocentric": 47364,
      "364": 4160,
      "mounting": 48030,
      "086": 634,
      "blunt": 14167,
      "ofa": 50945,
      "flank": 31897,
      "frequentist": 32537,
      "423": 4486,
      "imprecision": 37048,
      "ventilated": 86059,
      "5037": 4935,
      "iss": 40317,
      "trended": 82955,
      "stopwatch": 77394,
      "automatically": 12762,
      "programmed": 65549,
      "permit": 60907,
      "interface": 39416,
      "fobs": 31966,
      "mixing": 46808,
      "proficiency": 65470,
      "sp": 76517,
      "script": 74056,
      "pace": 56318,
      "746": 5685,
      "leg": 41359,
      "awakenings": 12980,
      "rem": 70242,
      "otolaryngologists": 53883,
      "transactions": 82125,
      "corresponds": 20848,
      "scheduling": 73661,
      "trading": 81980,
      "purchase": 66495,
      "multidrug": 48183,
      "terminology": 80694,
      "1258": 1431,
      "unknowingly": 83875,
      "accessing": 7011,
      "meth": 45033,
      "knowingly": 40880,
      "nh": 49462,
      "nhs": 49466,
      "transaction": 82124,
      "excruciating": 30495,
      "pomi": 62232,
      "underlines": 83600,
      "thr": 81141,
      "predicts": 63593,
      "milliequivalents": 46448,
      "exceed": 30433,
      "overprescribed": 54351,
      "584": 5172,
      "survivors": 79757,
      "outreach": 54166,
      "northeast": 49961,
      "darvon": 21839,
      "intercostal": 39407,
      "valium": 85806,
      "zofran": 87766,
      "pectoralis": 60340,
      "lipid": 42066,
      "hearing": 34865,
      "complaining": 18424,
      "cochlea": 17164,
      "inclusive": 37697,
      "goods": 33336,
      "2072": 2926,
      "salbutamol": 73243,
      "592": 5196,
      "919": 6149,
      "dispensation": 25412,
      "optional": 53467,
      "393": 4284,
      "submit": 78763,
      "612": 5323,
      "postdural": 62648,
      "spiritual": 76733,
      "massage": 43475,
      "relaxation": 69799,
      "954": 6414,
      "conducting": 19424,
      "illuminate": 36664,
      "constituted": 19800,
      "pulsed": 66475,
      "anatomic": 10878,
      "electromagnetic": 28522,
      "disposable": 25480,
      "corporation": 20794,
      "functioned": 32721,
      "305": 3829,
      "midst": 46409,
      "reimbursed": 69512,
      "00001": 51,
      "fas": 31192,
      "wv": 87381,
      "transportation": 82241,
      "859": 6002,
      "suppositories": 79236,
      "syrup": 79969,
      "calibrators": 14727,
      "separation": 74596,
      "agilent": 9262,
      "zorbax": 87772,
      "c18": 14642,
      "elution": 28628,
      "formic": 32302,
      "methanol": 45154,
      "mrm": 48067,
      "recoveries": 68731,
      "remove": 70334,
      "ignored": 36550,
      "legally": 41366,
      "gone": 33290,
      "belatedly": 13576,
      "hads": 34500,
      "convergent": 20702,
      "subscales": 78774,
      "biases": 13780,
      "programme": 65548,
      "colonic": 17517,
      "transcriptional": 82132,
      "reductase": 69033,
      "reticuline": 72087,
      "immense": 36754,
      "qor": 66637,
      "dimensions": 25016,
      "833": 5944,
      "unresponsiveness": 83936,
      "retrieval": 72091,
      "10th": 1081,
      "90th": 6126,
      "463": 4638,
      "binary": 13806,
      "1445": 1649,
      "doubling": 26414,
      "referrals": 69154,
      "syncope": 79915,
      "resumed": 72065,
      "nodules": 49558,
      "questioning": 66886,
      "distinguishes": 25546,
      "convey": 20742,
      "malformation": 43086,
      "lm": 42193,
      "eating": 27293,
      "boston": 14253,
      "sclerotherapy": 73691,
      "delineation": 23200,
      "neuroleptic": 49198,
      "mcl": 43628,
      "535": 5032,
      "substitute": 78871,
      "lessening": 41424,
      "478": 4678,
      "publically": 66408,
      "capita": 14950,
      "relapses": 69539,
      "immunoassays": 36775,
      "personalised": 60949,
      "sector": 74300,
      "875": 6032,
      "418": 4443,
      "steep": 77309,
      "acknowledging": 7352,
      "abusive": 6940,
      "urologists": 84104,
      "urology": 84105,
      "correlate": 20806,
      "message": 44861,
      "quantifying": 66789,
      "methodological": 45224,
      "arthroscopic": 11749,
      "meniscectomy": 44810,
      "absolutely": 6604,
      "cutting": 21541,
      "syringe": 79966,
      "collects": 17507,
      "trainees": 82007,
      "trainee": 82006,
      "645": 5401,
      "skilled": 76194,
      "856": 5999,
      "gauge": 32911,
      "198": 2217,
      "688": 5511,
      "putting": 66604,
      "midwest": 46415,
      "assistant": 12192,
      "manager": 43279,
      "standardize": 76946,
      "mmse": 46993,
      "barthel": 13261,
      "deficit": 23110,
      "breaths": 14420,
      "fusions": 32758,
      "ganey": 32827,
      "hcahps": 34625,
      "342": 4045,
      "426": 4490,
      "box": 14289,
      "planning": 61888,
      "timepoints": 81412,
      "personalized": 60952,
      "btds": 14460,
      "6566": 5441,
      "erythema": 29517,
      "ast": 12511,
      "alt": 9678,
      "fixation": 31865,
      "hernias": 34977,
      "asymptomatic": 12521,
      "recurrences": 68816,
      "groin": 33522,
      "testis": 80849,
      "op": 51138,
      "averaging": 12951,
      "metabolised": 44915,
      "inducers": 38467,
      "mellitus": 44767,
      "tubulointerstitial": 83275,
      "operational": 51233,
      "discouraged": 25260,
      "privacy": 65190,
      "286": 3588,
      "differing": 24954,
      "billing": 13800,
      "795": 5811,
      "esp": 29544,
      "medians": 44300,
      "attributing": 12617,
      "anticholinergic": 11154,
      "neuropsychological": 49285,
      "appraised": 11447,
      "595": 5198,
      "neurodevelopment": 49191,
      "mating": 43534,
      "mimic": 46500,
      "dams": 21825,
      "moud": 48028,
      "thickness": 81090,
      "ventral": 86064,
      "tegmental": 80561,
      "vta": 86683,
      "anomalies": 11037,
      "752": 5728,
      "3928": 4283,
      "orthosteric": 53844,
      "nam": 48553,
      "catalepsy": 15278,
      "shell": 75135,
      "mesocorticolimbic": 44858,
      "occluded": 50817,
      "bottle": 14257,
      "drove": 26487,
      "populous": 62409,
      "michigan": 46334,
      "construction": 19812,
      "internally": 39467,
      "904": 6124,
      "ambulate": 9758,
      "predisposition": 63596,
      "operationalized": 51235,
      "sem": 74508,
      "latent": 41230,
      "invariance": 39964,
      "regressed": 69411,
      "892": 6064,
      "phencyclidine": 61336,
      "craving": 21130,
      "categorise": 15300,
      "987": 6478,
      "oes": 50941,
      "geospatial": 33126,
      "389": 4257,
      "rhode": 72464,
      "island": 40293,
      "dakota": 21818,
      "484": 4759,
      "mucosal": 48141,
      "advantageous": 8611,
      "contraindications": 20209,
      "4000": 4396,
      "dysmenorrhea": 27226,
      "aggregation": 9256,
      "sulfa": 79060,
      "urological": 84101,
      "unconsumed": 83490,
      "boys": 14291,
      "align": 9568,
      "0026": 245,
      "bd": 13498,
      "propacetamol": 65688,
      "utilising": 85717,
      "c57bl": 14651,
      "grip": 33520,
      "rotarod": 72817,
      "gait": 32820,
      "zone": 87769,
      "nesting": 49148,
      "sexes": 75093,
      "pathogenesis": 58499,
      "sustainability": 79772,
      "peritoneal": 60897,
      "departmental": 23451,
      "videos": 86218,
      "646": 5402,
      "disseminated": 25513,
      "halved": 34543,
      "relapse": 69538,
      "232": 3126,
      "abstinent": 6621,
      "whites": 87032,
      "stages": 76872,
      "n2": 48388,
      "dilation": 25003,
      "curettage": 21422,
      "613": 5324,
      "substantiated": 78868,
      "hampered": 34544,
      "intraclass": 39731,
      "penetrating": 60386,
      "choosing": 16136,
      "precision": 63523,
      "underused": 83669,
      "ltot": 42751,
      "collective": 17503,
      "harnessing": 34598,
      "representatives": 70760,
      "convened": 20683,
      "60s": 5302,
      "50s": 4942,
      "balances": 13236,
      "shortcomings": 75203,
      "interprofessional": 39512,
      "extending": 30908,
      "classic": 16672,
      "5th": 5212,
      "campaign": 14744,
      "057": 572,
      "749": 5688,
      "notes": 49992,
      "1192": 1197,
      "warm": 86713,
      "074": 613,
      "efficacies": 28196,
      "cyclopropylmethyl": 21563,
      "14\u03b2": 1662,
      "dihyroxy": 24998,
      "5\u03b1": 5213,
      "6\u03b1": 5542,
      "isoquinolyl": 40309,
      "acetamindo": 7108,
      "mepivacaine": 44853,
      "assessors": 12157,
      "bothersome": 14256,
      "additives": 7921,
      "518": 4972,
      "044": 464,
      "051": 565,
      "lasts": 41218,
      "sternal": 77337,
      "hypothesise": 36302,
      "cumulated": 21386,
      "expiratory": 30693,
      "bold": 14209,
      "pet": 60982,
      "positron": 62515,
      "emission": 28719,
      "edge": 27364,
      "phasic": 61331,
      "ipsilateral": 40156,
      "sural": 79255,
      "wrist": 87367,
      "economical": 27315,
      "bq123": 14304,
      "object": 50360,
      "investigational": 40076,
      "radiculopathy": 66962,
      "762": 5748,
      "marital": 43388,
      "compensation": 18407,
      "litigation": 42140,
      "replicate": 70438,
      "pathologies": 58503,
      "adapting": 7721,
      "mapped": 43352,
      "border": 14248,
      "crossing": 21283,
      "oct": 50870,
      "sprain": 76777,
      "datamart": 22212,
      "waste": 86749,
      "robot": 72704,
      "ralp": 66984,
      "marcaine": 43356,
      "nacl": 48393,
      "tolterodine": 81650,
      "ambulation": 9760,
      "ambulated": 9759,
      "386": 4254,
      "976": 6454,
      "metastatic": 45026,
      "radiation": 66954,
      "specialised": 76564,
      "ovid": 54371,
      "1974": 2216,
      "1982": 2220,
      "and2": 10889,
      "favouring": 31271,
      "smd": 76317,
      "bear": 13503,
      "fees": 31338,
      "aud": 12647,
      "epilepsy": 29200,
      "freedom": 32495,
      "saes": 73067,
      "291": 3623,
      "306": 3831,
      "ensuing": 29040,
      "taiwan": 80265,
      "690": 5530,
      "871": 6028,
      "939": 6184,
      "ich": 36392,
      "468": 4643,
      "drain": 26428,
      "placement": 61859,
      "craniectomy": 21127,
      "intraventricular": 39903,
      "connected": 19543,
      "burdens": 14606,
      "6j": 5540,
      "feed": 31326,
      "arr": 11693,
      "chance": 15712,
      "246": 3308,
      "fourths": 32442,
      "underscore": 83616,
      "acknowledge": 7347,
      "antiepileptic": 11194,
      "classifications": 16684,
      "blinding": 14026,
      "refute": 69228,
      "pocket": 62061,
      "costing": 20891,
      "194": 2205,
      "eighth": 28451,
      "certainty": 15657,
      "379": 4222,
      "276": 3524,
      "252": 3402,
      "favoured": 31270,
      "756": 5729,
      "385": 4253,
      "394": 4285,
      "392": 4282,
      "559": 5091,
      "acceptability": 6976,
      "determinant": 23976,
      "vaccination": 85753,
      "coronavirus": 20786,
      "vaccines": 85755,
      "vaccinated": 85752,
      "wanting": 86705,
      "allay": 9581,
      "mix": 46783,
      "968": 6433,
      "742": 5682,
      "456": 4611,
      "deprived": 23613,
      "540": 5058,
      "governance": 33346,
      "framed": 32476,
      "justification": 40570,
      "multicomponent": 48177,
      "191": 2201,
      "promis": 65651,
      "shortness": 75217,
      "flushes": 31961,
      "itt": 40358,
      "contract": 20200,
      "kit": 40852,
      "flatulence": 31901,
      "longest": 42395,
      "hrec": 35897,
      "witness": 87178,
      "interim": 39438,
      "awaiting": 12976,
      "rises": 72497,
      "clustered": 17084,
      "concentrated": 18665,
      "sprays": 76779,
      "kits": 40853,
      "ma": 42787,
      "away": 12985,
      "warranting": 86734,
      "nsp": 50108,
      "ost": 53853,
      "classifying": 16691,
      "judgment": 40500,
      "1817": 2135,
      "homelessness": 35527,
      "background oxycontin": 13140,
      "oxycontin controlled": 56129,
      "controlled release": 20535,
      "release oxycodone": 69919,
      "oxycodone hydrochloride": 55172,
      "purdue pharma": 66499,
      "pharma stamford": 61012,
      "stamford ct": 76882,
      "food drug": 32232,
      "drug administration": 26520,
      "administration fda": 8263,
      "moderate severe": 47164,
      "severe chronic": 74927,
      "chronic pain": 16254,
      "delayed release": 23193,
      "release tablets": 70012,
      "tablets results": 80213,
      "results rapid": 71902,
      "release drug": 69830,
      "drug increased": 26649,
      "serum concentrations": 74694,
      "trend increased": 82946,
      "increased prescription": 37995,
      "prescription drug": 64203,
      "drug abuse": 26499,
      "health care": 34675,
      "care providers": 15068,
      "providers recognize": 66193,
      "clinical presentation": 16872,
      "associated complications": 12235,
      "objectives review": 50588,
      "discuss current": 25282,
      "current trends": 21484,
      "trends abuse": 82960,
      "review specific": 72359,
      "specific effects": 76589,
      "effects drug": 27906,
      "drug body": 26541,
      "differential diagnosis": 24938,
      "diagnosis management": 24335,
      "clinical findings": 16817,
      "acute opioid": 7653,
      "opioid overdoses": 52020,
      "making diagnosis": 43009,
      "oxycontin overdose": 56161,
      "bradycardia hypotension": 14313,
      "altered mental": 9700,
      "mental status": 44830,
      "clinical picture": 16857,
      "sufficient prevent": 78975,
      "administration naloxone": 8307,
      "receptor antagonist": 68473,
      "diagnostic therapeutic": 24346,
      "therapeutic effects": 80939,
      "increasing rates": 38123,
      "rates prescription": 67623,
      "abuse oxycontin": 6800,
      "continue present": 20125,
      "physicians aware": 61436,
      "patients seeking": 59949,
      "recreational use": 68783,
      "use oxycodone": 84580,
      "oxycodone clinical": 54783,
      "clinical use": 16965,
      "use 1917": 84146,
      "parenteral oxycodone": 58212,
      "oxycodone used": 56057,
      "used mainly": 84991,
      "treatment acute": 82424,
      "acute postoperative": 7685,
      "postoperative pain": 62842,
      "pain combinations": 56564,
      "example oxycodone": 30429,
      "oxycodone acetaminophen": 54625,
      "moderate pain": 47154,
      "pain introduction": 56973,
      "used manage": 84992,
      "manage cancer": 43117,
      "cancer related": 14905,
      "related pain": 69654,
      "pain chronic": 56536,
      "chronic non": 16220,
      "non cancer": 49572,
      "pain problems": 57434,
      "controlled studies": 20581,
      "studies performed": 77809,
      "performed postoperative": 60612,
      "pain cancer": 56506,
      "cancer pain": 14812,
      "pain osteoarthritis": 57301,
      "osteoarthritis related": 53867,
      "pain neuropathic": 57233,
      "neuropathic pain": 49231,
      "pain postherpetic": 57390,
      "postherpetic neuralgia": 62657,
      "neuralgia diabetic": 49171,
      "diabetic neuropathy": 24315,
      "pharmacodynamic effects": 61062,
      "effects oxycodone": 28056,
      "typical mu": 83384,
      "mu opioid": 48116,
      "opioid agonist": 51421,
      "agonist oxycodone": 9301,
      "closely resembles": 17077,
      "resembles morphine": 71051,
      "pharmacokinetic profile": 61144,
      "old drug": 51004,
      "pharmacology oxycodone": 61242,
      "abuse drugs": 6717,
      "prescription opioid": 64273,
      "opioid medicines": 51925,
      "approximately 11": 11558,
      "11 million": 1135,
      "million americans": 46485,
      "used prescription": 85084,
      "prescription drugs": 64217,
      "2016 2018": 2730,
      "result opioid": 71484,
      "opioid overdose": 52009,
      "overdose including": 54293,
      "including prescription": 37664,
      "prescription opioids": 64323,
      "opioids heroin": 52943,
      "heroin illicitly": 35005,
      "illicitly manufactured": 36659,
      "manufactured fentanyl": 43337,
      "2020 opioid": 2906,
      "overdose crisis": 54273,
      "https www": 35933,
      "drugs abuse": 26865,
      "abuse opioids": 6795,
      "opioids opioid": 53118,
      "june 2020": 40553,
      "physicians continue": 61438,
      "oral opioids": 53610,
      "opioids moderate": 53057,
      "severe pain": 74966,
      "importance understanding": 36989,
      "understanding drug": 83632,
      "drug choice": 26546,
      "outcomes opioid": 54064,
      "opioid prescription": 52130,
      "prescription medications": 64251,
      "oxycodone misuse": 55456,
      "highly prescribed": 35398,
      "prescribed opioid": 63905,
      "opioid medications": 51909,
      "medications treating": 44691,
      "treating moderate": 82394,
      "retail sales": 72072,
      "1997 2007": 2239,
      "non addictive": 49566,
      "formulation oxycodone": 32351,
      "oxycodone oxycontin": 55609,
      "contributed opioid": 20233,
      "opioid crisis": 51681,
      "burst release": 14621,
      "nasal insufflation": 48654,
      "intravenous injection": 39835,
      "review oxycodone": 72329,
      "oxycodone pharmacology": 55682,
      "abuse liability": 6746,
      "hypothesis oxycodone": 36297,
      "contributes high": 20236,
      "high likability": 35119,
      "likability abuse": 41770,
      "mechanisms likely": 44144,
      "likely contribute": 41802,
      "high abuse": 35065,
      "rate oxycodone": 67494,
      "oxycodone including": 55243,
      "clinical drug": 16792,
      "pharmacokinetics pharmacodynamics": 61181,
      "compared opioids": 18230,
      "receptor interactions": 68499,
      "strategies drug": 77413,
      "likely contributes": 41804,
      "oxycodone opioid": 55563,
      "opioid use": 52460,
      "use disorders": 84328,
      "use abuse": 84162,
      "national crisis": 48677,
      "crisis united": 21182,
      "united states": 83776,
      "states opioid": 77126,
      "opioid abusers": 51388,
      "physician prescribed": 61429,
      "prescribed medications": 63891,
      "medical care": 44335,
      "orthopedic surgery": 53836,
      "surgery total": 79606,
      "total joint": 81822,
      "joint arthroplasty": 40487,
      "arthroplasty pain": 11738,
      "pain control": 56599,
      "control surgery": 20430,
      "patient satisfaction": 58754,
      "early postoperative": 27266,
      "postoperative period": 62936,
      "period opioid": 60759,
      "opioid misuse": 51937,
      "misuse epidemic": 46720,
      "epidemic orthopedic": 29142,
      "orthopedic surgeons": 53833,
      "surgeons frequently": 79271,
      "treat pain": 82309,
      "pain pain": 57317,
      "pain medications": 57163,
      "medications long": 44641,
      "long acting": 42284,
      "acting opioids": 7408,
      "opioids oxycontin": 53143,
      "past decade": 58460,
      "multimodal pain": 48226,
      "limited opioid": 41948,
      "review discuss": 72285,
      "surgeons prescribe": 79278,
      "prescribe narcotic": 63799,
      "narcotic pain": 48600,
      "major minor": 42960,
      "minor complications": 46624,
      "effects associated": 27831,
      "associated prescriptions": 12392,
      "development alternative": 24212,
      "alternative pain": 9733,
      "pain management": 57053,
      "management strategies": 43266,
      "multimodal approach": 48214,
      "interventions reduce": 39680,
      "reduce postoperative": 68880,
      "postoperative opioid": 62811,
      "opioid consumption": 51599,
      "peripheral nerve": 60867,
      "nerve blocks": 49119,
      "clinical results": 16895,
      "recommend evidence": 68580,
      "evidence based": 30153,
      "based program": 13368,
      "parenteral narcotics": 58208,
      "rapid discharge": 67378,
      "discharge home": 25125,
      "pain related": 57509,
      "related complaints": 69573,
      "concerns regarding": 18845,
      "regarding oxycontin": 69264,
      "oxycontin purdue": 56174,
      "pain medicine": 57169,
      "media coverage": 44166,
      "biased objective": 13779,
      "objective analyze": 50375,
      "north american": 49957,
      "american newspapers": 9796,
      "shed light": 75131,
      "social problem": 76357,
      "problem associated": 65234,
      "associated oxycontin": 12371,
      "oxycontin methods": 56148,
      "methods using": 45621,
      "medical literature": 44367,
      "samples drawn": 73343,
      "27 north": 3502,
      "articles published": 11802,
      "substance abuse": 78795,
      "abuse pain": 6801,
      "pain anesthesiology": 56452,
      "internal medicine": 39461,
      "abuse addiction": 6641,
      "death use": 22729,
      "use oxycontin": 84590,
      "treatment pain": 82732,
      "law enforcement": 41249,
      "revealed high": 72213,
      "high degree": 35081,
      "addiction medicine": 7745,
      "conclusion prevalence": 18973,
      "regarding drug": 69247,
      "plays role": 62010,
      "role drug": 72743,
      "problem background": 65235,
      "background past": 13146,
      "oxycontin diversion": 56134,
      "pain patient": 57332,
      "consumption methods": 19952,
      "study based": 77980,
      "broad range": 14446,
      "2009 2013": 2516,
      "government agencies": 33349,
      "enforcement agencies": 28927,
      "results pharmaceutical": 71865,
      "pharmaceutical industry": 61027,
      "public health": 66376,
      "health crisis": 34702,
      "use drug": 84343,
      "opioid painkillers": 52041,
      "approaches pain": 11493,
      "health safety": 34770,
      "safety background": 73126,
      "larger opioid": 41177,
      "problems related": 65261,
      "addiction misuse": 7748,
      "oxycontin pain": 56168,
      "qualitative analysis": 66663,
      "analysis 24": 10627,
      "results significant": 71951,
      "significant differences": 75497,
      "nature problem": 48751,
      "oxycodone semi": 55881,
      "semi synthetic": 74511,
      "synthetic opioid": 79952,
      "structurally similar": 77584,
      "morphine producing": 47894,
      "analgesic effects": 10214,
      "oxycodone prescribed": 55740,
      "immediate release": 36707,
      "release formulations": 69864,
      "formulations including": 32382,
      "administration approved": 8218,
      "release form": 69858,
      "form oxycodone": 32289,
      "oxycodone immediate": 55229,
      "release forms": 69860,
      "forms oxycodone": 32311,
      "prescribed doses": 63854,
      "doses 10": 26117,
      "10 30": 702,
      "30 mg": 3749,
      "mg recommended": 46198,
      "160 mg": 1904,
      "mg 12": 45709,
      "12 year": 1389,
      "year period": 87481,
      "toxicology laboratory": 81953,
      "laboratory detected": 41027,
      "detected oxycodone": 23944,
      "oxycodone 67": 54592,
      "67 cases": 5474,
      "paper provide": 58082,
      "tissue distributions": 81451,
      "oxycodone cases": 54769,
      "cases controlled": 15229,
      "intact drug": 39169,
      "drug free": 26637,
      "identification oxycodone": 36413,
      "oxycodone postmortem": 55706,
      "postmortem specimens": 62683,
      "achieved using": 7328,
      "liquid liquid": 42094,
      "liquid extraction": 42090,
      "gas chromatography": 32840,
      "chromatography nitrogen": 16168,
      "nitrogen phosphorus": 49501,
      "phosphorus detection": 61371,
      "chromatography mass": 16161,
      "mass spectrometry": 43456,
      "respectively oxycodone": 71226,
      "oxycodone d3": 54920,
      "d3 used": 21682,
      "used internal": 84978,
      "internal standard": 39463,
      "linear 10": 42009,
      "10 mg": 786,
      "mg tissue": 46242,
      "tissue distribution": 81450,
      "ranges oxycodone": 67353,
      "oxycodone 36": 54566,
      "heart blood": 34868,
      "46 mg": 4627,
      "mg 36": 45747,
      "femoral blood": 31402,
      "10 13": 670,
      "13 mg": 1487,
      "mg 35": 45746,
      "11 mg": 1132,
      "mg kg": 45947,
      "19 49": 2176,
      "49 mg": 4776,
      "mg 15": 45714,
      "24 82": 3180,
      "82 mg": 5908,
      "119 mg": 1195,
      "mg total": 46244,
      "total 21": 81741,
      "reformulated oxycontin": 69201,
      "oxycontin oxycodone": 56162,
      "oxycodone hcl": 55147,
      "hcl controlled": 34630,
      "developed tamper": 24193,
      "abuse deterrent": 6681,
      "reduce risk": 68892,
      "product abuse": 65425,
      "abuse misuse": 6777,
      "single session": 76137,
      "session study": 74736,
      "asked participants": 11840,
      "healthy recreational": 34841,
      "recreational opioid": 68776,
      "opioid users": 52616,
      "aged 18": 9153,
      "18 years": 2109,
      "years older": 87625,
      "use commonly": 84250,
      "commonly available": 17840,
      "original oxycontin": 53788,
      "oxycontin oc": 56156,
      "oc tablets": 50811,
      "orf tablets": 53740,
      "tablets compared": 80129,
      "compared opioid": 18226,
      "opioid formulations": 51814,
      "participants provided": 58345,
      "provided information": 66139,
      "use assessed": 84206,
      "oxycodone products": 55772,
      "30 participants": 3784,
      "participants 27": 58271,
      "27 males": 3495,
      "males females": 43074,
      "females mean": 31394,
      "mean age": 43673,
      "age 35": 8994,
      "35 years": 4099,
      "years range": 87651,
      "range 18": 67263,
      "18 51": 2052,
      "sessions participants": 74747,
      "opioid products": 52223,
      "results suggested": 71997,
      "recreational drug": 68773,
      "drug abusers": 26512,
      "tamper deterrent": 80329,
      "deterrent products": 24127,
      "doctor shopping": 25658,
      "prescriptions multiple": 64519,
      "prescribers pharmacies": 64020,
      "opioid analgesics": 51475,
      "diversion abuse": 25586,
      "abuse represents": 6866,
      "major public": 42968,
      "health issue": 34723,
      "methods open": 45410,
      "open cohort": 51147,
      "cohort study": 17382,
      "study assessed": 77970,
      "brand extended": 14378,
      "extended release": 30854,
      "release er": 69834,
      "er oxycodone": 29452,
      "oxycodone product": 55771,
      "product oxycontin": 65435,
      "oxycontin comparator": 56124,
      "comparator opioids": 17996,
      "july 2009": 40512,
      "2009 june": 2526,
      "june 2010": 40542,
      "january 2011": 40437,
      "june 2013": 40545,
      "introduction reformulated": 39951,
      "brand er": 14376,
      "oxycodone abuse": 54617,
      "deterrent properties": 24128,
      "properties using": 65721,
      "longitudinal data": 42401,
      "data covering": 21931,
      "million patients": 46492,
      "patients 65": 58886,
      "prescriptions results": 64558,
      "results reformulation": 71911,
      "decreased 50": 22966,
      "oxycodone comparators": 54817,
      "decreases rates": 23066,
      "rates occurred": 67603,
      "young adults": 87714,
      "available dose": 12798,
      "increased increasing": 37933,
      "increasing number": 38111,
      "pharmacies conclusions": 61054,
      "conclusions rate": 19182,
      "oxycodone decreased": 54932,
      "decreased substantially": 23047,
      "did occur": 24467,
      "characteristics associated": 15847,
      "associated higher": 12279,
      "abuse risk": 6870,
      "high dose": 35084,
      "dose specific": 26080,
      "magnitude decrease": 42810,
      "effect reformulation": 27549,
      "doctor shoppers": 25657,
      "oxycodone semisynthetic": 55884,
      "semisynthetic opioid": 74521,
      "opioid analgesic": 51446,
      "widely used": 87060,
      "used clinical": 84878,
      "clinical practice": 16859,
      "oxycodone morphine": 55467,
      "equally effective": 29241,
      "morphine 10": 47531,
      "10 times": 942,
      "times potent": 81433,
      "potent oxycodone": 63115,
      "oxycodone given": 55114,
      "article provides": 11778,
      "provides updated": 66242,
      "updated review": 83984,
      "pharmacokinetic pharmacodynamics": 61139,
      "controversy regarding": 20681,
      "regarding oxycodone": 69263,
      "oxycodone mediated": 55381,
      "mediated effects": 44309,
      "visceral pain": 86253,
      "possible role": 62548,
      "role peripheral": 72759,
      "peripheral opioid": 60879,
      "opioid analgesia": 51440,
      "analgesia discussed": 9952,
      "discussed present": 25294,
      "question oxycodone": 66882,
      "oxycodone analgesia": 54711,
      "oxycontin commonly": 56122,
      "commonly prescribed": 17861,
      "medications chronic": 44599,
      "drug formulary": 26634,
      "tamper resistant": 80333,
      "resistant formulation": 71100,
      "oxycontin patients": 56169,
      "patients prescribed": 59669,
      "prescribed treat": 63993,
      "treat chronic": 82287,
      "patients chronic": 59065,
      "aged 45": 9187,
      "45 years": 4603,
      "years 13": 87522,
      "recruited primary": 68794,
      "primary care": 64990,
      "care specialty": 15082,
      "interviews conducted": 39695,
      "patients experiences": 59285,
      "patients pain": 59618,
      "pain medical": 57148,
      "physicians perceived": 61445,
      "majority patients": 42993,
      "patients experiencing": 59286,
      "experiencing negative": 30646,
      "negative impact": 49075,
      "need optimize": 48941,
      "optimize pain": 53442,
      "management practices": 43245,
      "practices objective": 63430,
      "objective characterize": 50384,
      "data reported": 22091,
      "time periods": 81324,
      "2007 2010": 2486,
      "2010 2011": 2539,
      "2016 august": 2736,
      "august 2010": 12662,
      "hydrochloride extended": 36016,
      "database queried": 22182,
      "queried identify": 66873,
      "identify characteristics": 36494,
      "drug products": 26751,
      "variables analyzed": 85887,
      "analyzed included": 10833,
      "drugs involved": 26985,
      "related information": 69625,
      "information data": 38638,
      "original formulation": 53786,
      "defined post": 23146,
      "post reformulation": 62616,
      "period results": 60788,
      "results total": 72018,
      "51 percent": 4960,
      "26 percent": 3452,
      "commonly reported": 17873,
      "number total": 50268,
      "peaked 2010": 60325,
      "remained steady": 70276,
      "initially increased": 38875,
      "increased 2007": 37835,
      "2010 13": 2536,
      "2016 total": 2763,
      "reports decreased": 70721,
      "2009 2015": 2518,
      "slightly increased": 76255,
      "increased 2015": 37839,
      "2015 2016": 2688,
      "involved oxycodone": 40106,
      "2009 2014": 2517,
      "decreased 2014": 22949,
      "2014 2015": 2649,
      "majority reported": 42997,
      "formulation oxycontin": 32356,
      "new formulation": 49329,
      "formulation abuse": 32328,
      "oxycontin reported": 56182,
      "fully explained": 32615,
      "trends total": 82989,
      "time period": 81322,
      "period oxycodone": 60763,
      "increasingly used": 38137,
      "used treatment": 85174,
      "acute cancer": 7610,
      "cancer chronic": 14770,
      "non malignant": 49623,
      "malignant pain": 43101,
      "pain oxycodone": 57310,
      "oxycodone synthesized": 55974,
      "pharmacological properties": 61229,
      "recently oxycodone": 68446,
      "oxycodone fairly": 55066,
      "selective opioid": 74437,
      "opioid receptor": 52232,
      "receptor agonist": 68461,
      "relatively low": 69780,
      "low binding": 42453,
      "protein activation": 65923,
      "activation oxycodone": 7477,
      "oxycodone analgesic": 54712,
      "analgesic efficacy": 10224,
      "active metabolites": 7520,
      "central nervous": 15592,
      "active transport": 7536,
      "review studies": 72360,
      "studies basic": 77654,
      "oxycodone pharmacokinetics": 55677,
      "role pharmacogenomics": 72761,
      "population pharmacokinetics": 62375,
      "properties oxycodone": 65718,
      "compare oxycodone": 18039,
      "standard opioid": 76922,
      "opioid clinical": 51582,
      "responding opioid": 71327,
      "crisis canada": 21168,
      "policy makers": 62184,
      "supply interventions": 79181,
      "opioids using": 53380,
      "using national": 85510,
      "national databases": 48680,
      "opioids dispensed": 52862,
      "programs opioid": 65558,
      "january 2006": 40423,
      "march 2017": 43368,
      "prior authorization": 65136,
      "patients receive": 59760,
      "reduced oxycontin": 68965,
      "particularly opioid": 58416,
      "opioid naive": 51967,
      "naive patients": 48401,
      "patients reduced": 59871,
      "reduced overall": 68957,
      "overall opioid": 54216,
      "opioid prescriptions": 52171,
      "suggesting limited": 79028,
      "abuse resistant": 6867,
      "effect total": 27572,
      "total opioid": 81860,
      "opioid substitution": 52383,
      "chronic users": 16354,
      "users prescription": 85263,
      "opioids effects": 52878,
      "changes opioid": 15802,
      "opioid related": 52297,
      "related hospitalizations": 69618,
      "results suggest": 71991,
      "targeted opioids": 80499,
      "additional benefit": 7848,
      "treatment opioid": 82697,
      "standard treatments": 76937,
      "chronic administration": 16183,
      "administration opioid": 8316,
      "analgesics use": 10513,
      "use opioids": 84553,
      "opioids clinical": 52785,
      "clinical setting": 16899,
      "closely monitored": 17075,
      "medications potential": 44662,
      "addiction abuse": 7737,
      "abuse fatal": 6726,
      "limited access": 41916,
      "access opioids": 6998,
      "providers prescribing": 66192,
      "prescribing opioids": 64094,
      "alleviate pain": 9600,
      "order determine": 53710,
      "determine patient": 24035,
      "patient taking": 58798,
      "taking medication": 80307,
      "medication prescribed": 44538,
      "drug screen": 26782,
      "screen results": 74027,
      "appeared oxycodone": 11394,
      "oxycodone based": 54745,
      "based results": 13376,
      "practice patient": 63408,
      "patient request": 58744,
      "test performed": 80778,
      "performed time": 60641,
      "time using": 81397,
      "using gas": 85401,
      "patient did": 58620,
      "high levels": 35117,
      "levels oxycodone": 41587,
      "oxycodone urine": 56046,
      "detect presence": 23931,
      "presence oxycodone": 64598,
      "oxycodone immunoassay": 55235,
      "help prevent": 34911,
      "present case": 64607,
      "case patient": 15182,
      "patient followed": 58644,
      "provide overview": 66085,
      "overview analgesic": 54367,
      "year old": 87454,
      "old woman": 51022,
      "heart syndrome": 34875,
      "medical history": 44365,
      "long term": 42321,
      "dependence associated": 23463,
      "associated treatment": 12457,
      "multi joint": 48147,
      "patient presented": 58719,
      "presented emergency": 64690,
      "emergency department": 28670,
      "day discharge": 22300,
      "discharge hospital": 25126,
      "hospital following": 35593,
      "following total": 32214,
      "total knee": 81825,
      "knee arthroplasty": 40857,
      "acute onset": 7652,
      "chest pain": 15972,
      "st segment": 76824,
      "acute myocardial": 7649,
      "myocardial infarction": 48382,
      "coronary angiography": 20780,
      "revealed major": 72218,
      "ejection fraction": 28465,
      "opioid therapy": 52405,
      "positive airway": 62446,
      "airway pressure": 9507,
      "therapy morphine": 81031,
      "hospital day": 35577,
      "syndrome opioid": 79920,
      "opioid withdrawal": 52641,
      "withdrawal reported": 87150,
      "reported previously": 70634,
      "case illustrates": 15175,
      "number opioid": 50188,
      "opioid dependent": 51704,
      "dependent patients": 23528,
      "life threatening": 41739,
      "background role": 13194,
      "role analgesia": 72733,
      "management postoperative": 43240,
      "pain different": 56716,
      "different combinations": 24853,
      "oral analgesics": 53494,
      "oxycodone naloxone": 55488,
      "naloxone oxn": 48476,
      "oxn combination": 54411,
      "used different": 84918,
      "different surgical": 24924,
      "surgical specialties": 79653,
      "specialties aim": 76572,
      "aim study": 9402,
      "study clarify": 77990,
      "advantages disadvantages": 8613,
      "oxn pain": 54418,
      "management surgical": 43271,
      "surgical patients": 79640,
      "patients method": 59496,
      "method authors": 45172,
      "included studies": 37557,
      "systematic search": 80004,
      "pubmed scopus": 66454,
      "results studies": 71970,
      "studies randomized": 77821,
      "randomized controlled": 67058,
      "controlled trials": 20621,
      "retrospective studies": 72167,
      "prospective study": 65884,
      "eligible inclusion": 28584,
      "inclusion review": 37694,
      "review total": 72366,
      "996 patients": 6499,
      "patients included": 59391,
      "studies reported": 77826,
      "orthopedic procedures": 53830,
      "procedures studies": 65327,
      "colorectal gynecologic": 17525,
      "thoracic surgery": 81124,
      "surgery procedures": 79538,
      "procedures respectively": 65323,
      "respectively analgesic": 71168,
      "analgesic effect": 10195,
      "effect oxn": 27513,
      "10 studies": 931,
      "studies oxn": 77800,
      "postoperative bowel": 62721,
      "bowel function": 14266,
      "function evaluated": 32646,
      "studies patients": 77805,
      "patients treated": 60058,
      "treated oxn": 82361,
      "did significant": 24501,
      "function compared": 32637,
      "compared control": 18116,
      "control groups": 20347,
      "regarding possible": 69271,
      "possible adverse": 62529,
      "adverse events": 8721,
      "events conclusion": 30028,
      "postoperative recovery": 62960,
      "control achieved": 20268,
      "achieved combination": 7317,
      "different analgesics": 24845,
      "analgesics including": 10436,
      "oxn oral": 54417,
      "oral analgesic": 53491,
      "analgesic combination": 10164,
      "combination potential": 17601,
      "minimize effects": 46597,
      "effects opioid": 28034,
      "opioid induced": 51847,
      "induced constipation": 38399,
      "recovery period": 68753,
      "period studies": 60795,
      "previously observed": 64948,
      "baseline data": 13423,
      "observed data": 50668,
      "rates opioid": 67605,
      "opioid product": 52222,
      "null hypothesis": 50132,
      "impact reformulation": 36851,
      "pre post": 63483,
      "conclusion pre": 18968,
      "data account": 21863,
      "baseline follow": 13434,
      "opioid abuse": 51363,
      "health problem": 34754,
      "particularly rural": 58421,
      "examine temporal": 30363,
      "temporal geographic": 80587,
      "methods cross": 45294,
      "cross sectional": 21254,
      "sectional analysis": 74278,
      "analysis completed": 10657,
      "data medicaid": 22006,
      "pharmacy claims": 61257,
      "1998 2002": 2242,
      "2002 analyzed": 2441,
      "analyzed claims": 10823,
      "claims 1999": 16617,
      "2001 2002": 2429,
      "significantly higher": 75718,
      "higher rates": 35315,
      "oxycodone prescription": 55744,
      "prescription claims": 64176,
      "similar findings": 75921,
      "findings observed": 31798,
      "economic health": 27311,
      "contributing increased": 20243,
      "increased use": 38041,
      "aims examine": 9484,
      "resistant formulations": 71101,
      "tapentadol hydrochloride": 80416,
      "er 50": 29394,
      "50 mg": 4849,
      "250 mg": 3395,
      "intranasal study": 39760,
      "intravenous abuse": 39809,
      "abuse study": 6882,
      "study design": 78064,
      "design randomized": 23771,
      "repeated measures": 70411,
      "measures study": 44099,
      "study designs": 78105,
      "oxycontin 40": 56109,
      "40 mg": 4342,
      "served positive": 74717,
      "positive control": 62457,
      "control drug": 20296,
      "drug taken": 26798,
      "taken study": 80293,
      "study setting": 78486,
      "setting studies": 74826,
      "took place": 81675,
      "patient setting": 58780,
      "setting new": 74790,
      "new york": 49390,
      "york ny": 87709,
      "participants experienced": 58303,
      "oxycodone abusers": 54623,
      "participated study": 58389,
      "study measurements": 78305,
      "measurements primary": 44031,
      "primary outcome": 65055,
      "outcome study": 53996,
      "percentage participants": 60509,
      "participants indicated": 58316,
      "tampered tablets": 80345,
      "tablets primary": 80208,
      "active drug": 7508,
      "descriptive variables": 23688,
      "time spent": 81380,
      "tablets examined": 80156,
      "behaviors clearly": 13558,
      "100 001": 979,
      "drug extracted": 26629,
      "versus 37": 86107,
      "37 02": 4169,
      "02 008": 350,
      "solutions drug": 76448,
      "01 study": 330,
      "05 conclusions": 503,
      "pain relief": 57515,
      "oxycodone tablets": 55977,
      "approach reducing": 11476,
      "reducing abuse": 69011,
      "abuse potential": 6810,
      "tapentadol extended": 80409,
      "release intravenous": 69872,
      "intravenous iv": 39840,
      "immediate postoperative": 36702,
      "iv administration": 40367,
      "administration results": 8361,
      "faster onset": 31214,
      "onset pain": 51121,
      "predictable pharmacokinetics": 63560,
      "administration routes": 8366,
      "allows convenient": 9647,
      "convenient dosing": 20689,
      "effective analgesia": 27589,
      "early phase": 27263,
      "phase postoperative": 61313,
      "addition patients": 7825,
      "patients able": 58915,
      "tolerate oral": 81614,
      "oral intake": 53553,
      "iv oral": 40391,
      "oral dosing": 53527,
      "dosing based": 26307,
      "iv morphine": 40382,
      "morphine widely": 47971,
      "used control": 84897,
      "control postoperative": 20394,
      "oxycodone oxycodone": 55604,
      "kappa mu": 40588,
      "opioid receptors": 52269,
      "offers potential": 50963,
      "potential advantages": 63129,
      "published studies": 66439,
      "studies comparing": 77669,
      "iv oxycodone": 40392,
      "oxycodone iv": 55318,
      "iv opioids": 40390,
      "postsurgical pain": 63051,
      "pain report": 57615,
      "report oxycodone": 70467,
      "oxycodone safe": 55860,
      "safe effective": 73075,
      "effective analgesic": 27594,
      "analgesic studies": 10339,
      "oxycodone associated": 54732,
      "associated greater": 12268,
      "greater pain": 33472,
      "control fewer": 20299,
      "fewer severe": 31667,
      "severe adverse": 74907,
      "onset action": 51108,
      "action results": 7449,
      "results consistent": 71645,
      "consistent studies": 19717,
      "studies oxycodone": 77802,
      "oxycodone reported": 55834,
      "special populations": 76563,
      "clinical reports": 16885,
      "reports oxycodone": 70735,
      "oxycodone pharmacologic": 55680,
      "intravenous oxycodone": 39867,
      "oxycodone potentially": 55720,
      "important new": 37018,
      "new old": 49341,
      "pain generally": 56805,
      "objective subjective": 50523,
      "period time": 60802,
      "potential adverse": 63130,
      "adverse effects": 8635,
      "effects commonly": 27857,
      "available medications": 12822,
      "medications recently": 44667,
      "pain number": 57249,
      "number prescriptions": 50240,
      "prescriptions opioid": 64526,
      "risen dramatically": 72496,
      "use concomitant": 84263,
      "increase opioid": 37765,
      "misuse diversion": 46718,
      "diversion pharmaceutical": 25601,
      "pharmaceutical companies": 61021,
      "developing variety": 24206,
      "variety opioid": 85954,
      "formulations designed": 32375,
      "designed deter": 23831,
      "deter abuse": 23971,
      "products difficult": 65446,
      "remoxy extended": 70339,
      "release formulation": 69861,
      "strong opioid": 77524,
      "opioid oxycodone": 52024,
      "oxycodone review": 55856,
      "review efficacy": 72287,
      "efficacy safety": 28354,
      "safety tolerability": 73231,
      "based available": 13285,
      "published literature": 66434,
      "abuse oxycodone": 6799,
      "oxycodone increase": 55244,
      "introduction generic": 39928,
      "generic controlled": 33044,
      "release cr": 69816,
      "cr oxycodone": 21074,
      "oxycodone evaluated": 55047,
      "evaluated effect": 29876,
      "misuse abuse": 46703,
      "oxycodone hydrocodone": 55198,
      "hydrocodone methadone": 36101,
      "methadone morphine": 45101,
      "utilizing data": 85745,
      "data poison": 22047,
      "poison control": 62153,
      "control centers": 20281,
      "intentional exposure": 39345,
      "codes used": 17308,
      "measures abuse": 44035,
      "abuse opioid": 6793,
      "opioid specific": 52373,
      "quarterly rates": 66856,
      "rates 100": 67542,
      "100 000": 968,
      "000 population": 43,
      "10 000": 652,
      "000 patients": 36,
      "patients calculated": 59038,
      "calculated year": 14712,
      "2004 changes": 2454,
      "year year": 87514,
      "analyzed using": 10863,
      "using poisson": 85564,
      "poisson regression": 62167,
      "regression regression": 69455,
      "oxycodone methadone": 55394,
      "morphine did": 47645,
      "did change": 24416,
      "decreased significantly": 23040,
      "hydrocodone prescription": 36128,
      "rates significantly": 67634,
      "significantly increased": 75753,
      "changes oxycodone": 15808,
      "rates compared": 67564,
      "opioids statistically": 53309,
      "statistically significant": 77198,
      "time opioid": 81303,
      "opioid interaction": 51874,
      "results did": 71660,
      "did vary": 24519,
      "population rates": 62379,
      "rates patient": 67619,
      "pcc data": 60275,
      "data indicate": 21990,
      "oxycodone followed": 55097,
      "followed immediate": 32060,
      "oxycodone data": 54924,
      "data gathered": 21976,
      "increase abuse": 37727,
      "abuse prescription": 6836,
      "opioid drugs": 51747,
      "drugs oxycodone": 27024,
      "oxycodone oxy": 55597,
      "liability prescription": 41646,
      "opioids study": 53317,
      "study aims": 77937,
      "specific focus": 76592,
      "summary literature": 79106,
      "differences pharmacokinetic": 24784,
      "pharmacokinetic pharmacodynamic": 61131,
      "findings study": 31822,
      "study suggest": 78519,
      "differ according": 24540,
      "according gender": 7044,
      "significant difference": 75467,
      "difference incidence": 24623,
      "incidence adverse": 37254,
      "demonstrated increased": 23346,
      "gastrointestinal adverse": 32864,
      "adverse reactions": 8838,
      "female subjects": 31379,
      "recent clinical": 68391,
      "clinical studies": 16907,
      "studies include": 77747,
      "equal number": 29233,
      "female male": 31361,
      "male subjects": 43059,
      "main outcome": 42836,
      "differences gender": 24744,
      "crucial role": 21321,
      "role metabolism": 72747,
      "effect higher": 27465,
      "higher cyp3a4": 35227,
      "cyp2d6 genotype": 21604,
      "paucity data": 60234,
      "data regarding": 22086,
      "regarding gender": 69252,
      "european union": 29751,
      "work highlights": 87276,
      "impact new": 36821,
      "new abuse": 49305,
      "deterrent formulations": 24113,
      "data concerning": 21923,
      "oxytrex pain": 56295,
      "pain therapeutics": 57909,
      "oral opioid": 53599,
      "oxycodone ultra": 56038,
      "ultra low": 83417,
      "low dose": 42466,
      "antagonist naltrexone": 11068,
      "development physical": 24246,
      "physical dependence": 61387,
      "dependence analgesic": 23461,
      "analgesic tolerance": 10345,
      "late stage": 41223,
      "clinical development": 16788,
      "development pain": 24244,
      "treatment moderate": 82664,
      "evaluate safety": 29843,
      "safety efficacy": 73145,
      "efficacy oxycodone": 28315,
      "oxycodone naltrexone": 55525,
      "studies conducted": 77673,
      "conducted healthy": 19364,
      "healthy volunteers": 34849,
      "volunteers patients": 86428,
      "dose naltrexone": 25966,
      "protein coupling": 65930,
      "coupling opioid": 20985,
      "associated opioid": 12352,
      "opioid tolerance": 52427,
      "tolerance dependence": 81580,
      "dependence opioid": 23481,
      "opioid agonists": 51429,
      "receptor activity": 68454,
      "agonist antagonist": 9278,
      "antagonist combination": 11061,
      "development tolerance": 24252,
      "tolerance physical": 81599,
      "dependence background": 23464,
      "background oxycodone": 13131,
      "oxycodone strong": 55939,
      "opioid acts": 51396,
      "mu kappa": 48111,
      "kappa opioid": 40590,
      "receptors pharmacological": 68553,
      "pharmacological actions": 61205,
      "actions similar": 7457,
      "strong opioids": 77542,
      "opioids specific": 53307,
      "greater analgesic": 33430,
      "analgesic potency": 10292,
      "potency morphine": 63078,
      "oxycodone managing": 55368,
      "managing neuropathic": 43289,
      "somatic pain": 76454,
      "pain malignant": 57051,
      "malignant non": 43095,
      "established wide": 29597,
      "wide range": 87044,
      "range settings": 67333,
      "review aims": 72253,
      "provide comprehensive": 66044,
      "comprehensive evaluation": 18623,
      "role clinical": 72736,
      "clinical settings": 16900,
      "order provide": 53720,
      "provide evidence": 66061,
      "use clinic": 84239,
      "using medline": 85487,
      "medline embase": 44733,
      "embase cochrane": 28641,
      "cochrane databases": 17174,
      "databases used": 22211,
      "review review": 72354,
      "review provides": 72344,
      "provides information": 66223,
      "pharmacodynamics oxycodone": 61086,
      "established clinical": 29584,
      "clinical data": 16779,
      "emerging data": 28710,
      "data support": 22137,
      "support use": 79218,
      "oxycodone visceral": 56079,
      "receptors oxycodone": 68552,
      "oxycodone available": 54739,
      "formulations oral": 32395,
      "parenteral administration": 58204,
      "administration findings": 8266,
      "prolonged release": 65621,
      "oxycodone offers": 55558,
      "fast onset": 31202,
      "onset analgesia": 51109,
      "analgesia controlling": 9940,
      "controlling pain": 20658,
      "pain 12": 56365,
      "12 hours": 1291,
      "clinically meaningful": 16983,
      "relief moderate": 70143,
      "pain improving": 56851,
      "improving quality": 37205,
      "quality life": 66717,
      "broad spectrum": 14447,
      "spectrum pain": 76677,
      "pain types": 57946,
      "conclusions oxycodone": 19144,
      "oxycodone provides": 55783,
      "provides significant": 66237,
      "significant pain": 75591,
      "points difference": 62129,
      "difference opioids": 24644,
      "alternative morphine": 9726,
      "morphine oxycodone": 47801,
      "oxycodone popular": 55702,
      "opioids united": 53365,
      "superior morphine": 79129,
      "morphine oral": 47796,
      "oral absorption": 53481,
      "absorption bioavailability": 6608,
      "bioavailability similar": 13842,
      "similar terms": 75997,
      "protein binding": 65925,
      "gender age": 32929,
      "unlike morphine": 83894,
      "oxycodone metabolized": 55393,
      "metabolized cytochrome": 44995,
      "severely impaired": 75028,
      "liver dysfunction": 42176,
      "oxycodone frequently": 55107,
      "sustained release": 79785,
      "release opioids": 69908,
      "analgesic benefits": 10158,
      "benefits effects": 13629,
      "effects similar": 28158,
      "cr morphine": 21069,
      "morphine cr": 47632,
      "oxycodone similar": 55918,
      "similar morphine": 75950,
      "morphine opioids": 47795,
      "opioids abuse": 52692,
      "oxycodone usually": 56069,
      "usually associated": 85695,
      "polysubstance abuse": 62227,
      "oxycodone combined": 54805,
      "psychostimulants opioids": 66366,
      "opioids benzodiazepines": 52750,
      "benzodiazepines alcohol": 13653,
      "alcohol oxycodone": 9536,
      "oxycodone kappa": 55322,
      "kappa receptor": 40597,
      "receptor binding": 68484,
      "role abuse": 72730,
      "oxycodone valued": 56070,
      "valued opioid": 85828,
      "analgesic administered": 10145,
      "administered strong": 8184,
      "opioid strong": 52375,
      "opioids ineffective": 52997,
      "case insufficient": 15177,
      "insufficient analgesia": 39121,
      "effects sedation": 28153,
      "nausea vomiting": 48788,
      "oxycodone beneficial": 54746,
      "oxycodone administered": 54683,
      "administered opioid": 8153,
      "patients severe": 59962,
      "pain patients": 57336,
      "unsuccessfully treated": 83951,
      "weak opioids": 86791,
      "opioids tramadol": 53343,
      "tramadol codeine": 82040,
      "codeine dihydrocodeine": 17225,
      "dihydrocodeine oxycodone": 24994,
      "oxycodone effective": 55013,
      "blood brain": 14107,
      "brain barrier": 14317,
      "higher concentrations": 35219,
      "concentrations brain": 18748,
      "brain plasma": 14358,
      "plasma oxycodone": 61945,
      "oxycodone displays": 54984,
      "displays high": 25479,
      "bioavailability oral": 13838,
      "oral administration": 53485,
      "morphine patients": 47872,
      "patients renal": 59880,
      "renal impairment": 70361,
      "impairment decreased": 36892,
      "oral controlled": 53504,
      "oxycodone formulation": 55102,
      "formulation introduced": 32345,
      "new product": 49364,
      "combination prolonged": 17605,
      "oxycodone prolonged": 55773,
      "release naloxone": 69893,
      "naloxone oxycodone": 48480,
      "naloxone tablets": 48519,
      "aim review": 9400,
      "pharmacodynamic pharmacokinetic": 61075,
      "pharmacokinetic properties": 61147,
      "properties drug": 65708,
      "drug interactions": 26664,
      "effects equianalgesic": 27912,
      "equianalgesic dose": 29256,
      "dose ratio": 26035,
      "ratio opioids": 67786,
      "oxycodone patients": 55652,
      "patients cancer": 59040,
      "pain potential": 57398,
      "potential role": 63223,
      "role oxycodone": 72755,
      "impact bowel": 36799,
      "approach management": 11463,
      "management pain": 43228,
      "pain involves": 56983,
      "pharmacologic non": 61199,
      "non pharmacologic": 49667,
      "patient characteristics": 58554,
      "pain analgesic": 56444,
      "mechanism action": 44124,
      "action pharmacodynamics": 7445,
      "pharmacodynamics pd": 61087,
      "onset duration": 51112,
      "duration action": 27148,
      "action pharmacokinetics": 7446,
      "pharmacokinetics pk": 61186,
      "pk single": 61588,
      "single agent": 76048,
      "non steroidal": 49686,
      "steroidal anti": 77342,
      "anti inflammatory": 11119,
      "inflammatory drugs": 38561,
      "drugs nsaids": 27009,
      "nsaids effective": 50102,
      "inflammatory pain": 38578,
      "pain acetaminophen": 56404,
      "mild pain": 46436,
      "migraine headache": 46418,
      "opioids remain": 53259,
      "option severe": 53463,
      "generally safe": 33023,
      "effective option": 27654,
      "opioids produce": 53227,
      "dose limiting": 25945,
      "limiting adverse": 41969,
      "effects abuse": 27799,
      "potential goal": 63169,
      "pain therapy": 57912,
      "maximum pain": 43599,
      "relief opioid": 70155,
      "opioid exposure": 51795,
      "approach use": 11484,
      "use analgesics": 84193,
      "release ir": 69873,
      "ir oral": 40242,
      "oral formulation": 53538,
      "oxycodone developed": 54958,
      "developed provide": 24192,
      "provide rapid": 66091,
      "rapid onset": 67389,
      "dose pain": 26002,
      "pain level": 57005,
      "reduce total": 68895,
      "exposure drug": 30761,
      "formulation management": 32349,
      "pain prescriptions": 57414,
      "prescriptions controlled": 64463,
      "oxycodone narcotic": 55526,
      "narcotic analgesic": 48588,
      "dramatic increase": 26433,
      "large private": 41146,
      "private insurance": 65192,
      "clinical benefits": 16760,
      "available drugs": 12799,
      "significantly greater": 75706,
      "systematic review": 79982,
      "clinical trials": 16939,
      "release controlled": 69813,
      "release preparations": 69994,
      "preparations oxycodone": 63782,
      "similar efficacy": 75918,
      "efficacy comparable": 28236,
      "effect profiles": 27540,
      "oxycodone agents": 54700,
      "lower costs": 42593,
      "costs patients": 20903,
      "patients requiring": 59910,
      "release opioid": 69904,
      "opioid treatment": 52438,
      "treatment controlled": 82524,
      "release morphine": 69891,
      "morphine methadone": 47755,
      "methadone considered": 45061,
      "appear effective": 11383,
      "effective oxycodone": 27658,
      "oxycodone cost": 54887,
      "oxycodone appropriate": 54728,
      "appropriate patients": 11510,
      "patients particularly": 59634,
      "release long": 69885,
      "acting opioid": 7396,
      "analgesics background": 10382,
      "control acute": 20269,
      "oxycodone pharmacokinetic": 55676,
      "pharmacokinetic parameters": 61123,
      "methods pooled": 45463,
      "oxycodone time": 55995,
      "concentration profiles": 18713,
      "adults data": 8560,
      "intravenous intramuscular": 39839,
      "using nonlinear": 85517,
      "nonlinear mixed": 49757,
      "mixed effects": 46791,
      "effects models": 28003,
      "used determine": 84909,
      "determine influence": 24017,
      "70 kg": 5562,
      "infants results": 38509,
      "24 weeks": 3290,
      "age 75": 9051,
      "75 years": 5723,
      "plasma concentrations": 61910,
      "compartment model": 18394,
      "model order": 47065,
      "elimination best": 28610,
      "best described": 13685,
      "oxycodone disposition": 54986,
      "parameter estimates": 58153,
      "clearance cl": 16711,
      "45 70": 4575,
      "volume distribution": 86392,
      "central compartment": 15585,
      "28 70": 3546,
      "kg total": 40813,
      "total body": 81783,
      "body weight": 14207,
      "minutes intramuscular": 46654,
      "minutes buccal": 46644,
      "buccal administration": 14469,
      "relative bioavailability": 69739,
      "lag time": 41080,
      "time minutes": 81292,
      "end year": 28832,
      "year life": 87448,
      "using total": 85643,
      "oxycodone clearance": 54782,
      "increasing year": 38130,
      "opioids known": 53010,
      "known study": 40933,
      "opioids community": 52806,
      "community pharmacies": 17925,
      "years respectively": 87657,
      "opioid disposal": 51722,
      "information sheet": 38672,
      "disposed opioids": 25496,
      "2017 2019": 2769,
      "years 2018": 87536,
      "2018 2019": 2808,
      "opioid 20": 51352,
      "20 mg": 2328,
      "mg oxycontin": 46145,
      "data different": 21946,
      "opioid mg": 51934,
      "medical institutions": 44366,
      "year study": 87503,
      "study period": 78380,
      "opioid 40": 51356,
      "oxycontin cost": 56132,
      "buccal tablet": 14471,
      "common reason": 17803,
      "disposal results": 25488,
      "results indicate": 71728,
      "studies suggest": 77854,
      "ms contin": 48079,
      "hepatitis virus": 34963,
      "deaths united": 22787,
      "infectious disease": 38518,
      "alarming rate": 9517,
      "role opioid": 72751,
      "opioid epidemic": 51768,
      "2010 introduction": 2560,
      "introduction abuse": 39917,
      "version oxycontin": 86091,
      "oxycontin oxycontin": 56167,
      "oxycontin reformulation": 56179,
      "users drug": 85237,
      "used difference": 84916,
      "difference differences": 24608,
      "differences methods": 24759,
      "using data": 85369,
      "states higher": 77106,
      "rates oxycontin": 67615,
      "oxycontin misuse": 56149,
      "misuse prior": 46741,
      "prior reformulation": 65168,
      "states reformulation": 77149,
      "misuse reformulation": 46746,
      "percent increase": 60465,
      "infection rates": 38514,
      "75 percent": 5719,
      "health consequences": 34701,
      "centers disease": 15566,
      "disease control": 25325,
      "abuse epidemic": 6719,
      "overdose deaths": 54277,
      "deaths largely": 22765,
      "excessive opioid": 30461,
      "cases opioid": 15248,
      "commonly abused": 17827,
      "abused substances": 6927,
      "pose significant": 62433,
      "significant risk": 75631,
      "risk opioid": 72611,
      "warnings fda": 86722,
      "risks associated": 72668,
      "associated using": 12462,
      "using medications": 85486,
      "time point": 81329,
      "studies evaluate": 77716,
      "interactions classes": 39387,
      "classes drugs": 16668,
      "drugs investigated": 26984,
      "depressant effects": 23560,
      "effects opioids": 28041,
      "opioids alter": 52721,
      "tolerance opioids": 81595,
      "opioids present": 53219,
      "present study": 64643,
      "study antinociceptive": 77954,
      "antinociceptive tolerance": 11254,
      "tolerance developed": 81582,
      "repeated administration": 70400,
      "administration oxycodone": 8325,
      "oxycodone reversed": 55855,
      "higher dose": 35230,
      "oxycodone induced": 55259,
      "doses diazepam": 26175,
      "did potentiate": 24474,
      "antinociceptive effect": 11239,
      "effect opioid": 27504,
      "opioid dose": 51730,
      "reversed oxycodone": 72241,
      "oxycodone antinociceptive": 54720,
      "oxycodone locomotor": 55339,
      "effects studies": 28168,
      "effect prescription": 27535,
      "developed chronic": 24173,
      "administration drugs": 8253,
      "drugs background": 26894,
      "development abuse": 24208,
      "formulations strategy": 32408,
      "deterrent formulation": 24108,
      "oxycodone extended": 55059,
      "release oxycontin": 69986,
      "oxycontin introduced": 56146,
      "introduced 2010": 39911,
      "reports demonstrated": 70722,
      "demonstrated reduced": 23362,
      "reduced abuse": 68904,
      "abuse diversion": 6709,
      "social media": 76355,
      "measured trends": 44000,
      "street price": 77465,
      "oxycontin assess": 56118,
      "reduction abuse": 69040,
      "abuse methods": 6776,
      "methods data": 45298,
      "poison center": 62146,
      "center program": 15539,
      "drug diversion": 26593,
      "diversion program": 25604,
      "program opioid": 65538,
      "treatment program": 82788,
      "survey key": 79715,
      "key informant": 40669,
      "patients program": 59706,
      "streetrx program": 77470,
      "program researched": 65541,
      "researched abuse": 71040,
      "diversion addiction": 25588,
      "addiction related": 7759,
      "related surveillance": 69689,
      "surveillance radars": 79684,
      "radars used": 66951,
      "used average": 84855,
      "rates abuse": 67549,
      "diversion oxycontin": 25600,
      "oxycontin compared": 56126,
      "2015 rates": 2718,
      "rates adjusted": 67553,
      "population using": 62397,
      "census data": 15512,
      "data drug": 21952,
      "drug availability": 26537,
      "results oxycontin": 71828,
      "oxycontin abuse": 56112,
      "declined significantly": 22870,
      "analgesics increased": 10437,
      "lesser extent": 41427,
      "abuse oral": 6796,
      "oral non": 53597,
      "non oral": 49662,
      "oral routes": 53664,
      "self administration": 74459,
      "declined following": 22867,
      "following reformulation": 32192,
      "geometric mean": 33121,
      "mean difference": 43750,
      "price reformulated": 64970,
      "reformulated product": 69206,
      "year reformulation": 87493,
      "following introduction": 32151,
      "continued decrease": 20133,
      "years background": 87572,
      "drugs used": 27097,
      "used treat": 85160,
      "pain fibromyalgia": 56779,
      "difficult treat": 24970,
      "different aetiologies": 24838,
      "substantial changes": 78844,
      "considered necessary": 19639,
      "interventions treat": 39684,
      "pain provide": 57442,
      "clinically relevant": 16988,
      "relevant oxycodone": 70066,
      "agonist widely": 9315,
      "manage severe": 43126,
      "pain review": 57650,
      "review assesses": 72258,
      "assesses evidence": 12098,
      "evidence oxycodone": 30241,
      "oxycodone using": 56068,
      "using current": 85368,
      "current standards": 21470,
      "designed reduce": 23842,
      "reduce bias": 68835,
      "objectives assess": 50542,
      "assess analgesic": 11907,
      "efficacy adverse": 28216,
      "events oxycodone": 30090,
      "oxycodone chronic": 54779,
      "chronic neuropathic": 16217,
      "search methods": 74117,
      "november 2013": 50031,
      "2013 searched": 2642,
      "searched central": 74138,
      "central medline": 15589,
      "databases reviewed": 22206,
      "studies reviews": 77835,
      "reviews searched": 72421,
      "searched clinical": 74141,
      "clinical trial": 16921,
      "clinicaltrials gov": 17016,
      "world health": 87306,
      "health organisation": 34739,
      "international clinical": 39477,
      "trials registry": 83193,
      "registry platform": 69407,
      "identify additional": 36487,
      "published unpublished": 66441,
      "unpublished data": 83923,
      "data selection": 22101,
      "selection criteria": 74407,
      "criteria included": 21199,
      "included randomised": 37532,
      "randomised controlled": 67012,
      "trials rcts": 83186,
      "double blind": 26336,
      "outcomes following": 54028,
      "following weeks": 32222,
      "weeks treatment": 86965,
      "studies weeks": 77875,
      "weeks longer": 86920,
      "longer used": 42394,
      "placebo active": 61647,
      "active comparator": 7485,
      "comparator data": 17992,
      "data collection": 21913,
      "collection analysis": 17495,
      "analysis review": 10757,
      "review authors": 72259,
      "authors independently": 12734,
      "independently extracted": 38179,
      "extracted efficacy": 30955,
      "adverse event": 8706,
      "event data": 29981,
      "data examined": 21961,
      "examined issues": 30385,
      "issues study": 40336,
      "study quality": 78439,
      "quality assessed": 66678,
      "assessed risk": 12055,
      "risk bias": 72528,
      "performed analysis": 60570,
      "analysis using": 10789,
      "minimal risk": 46580,
      "substantial pain": 78854,
      "pain intensity": 56877,
      "intention treat": 39342,
      "treat analysis": 82283,
      "200 participants": 2407,
      "participants comparison": 58287,
      "12 weeks": 1377,
      "weeks duration": 86910,
      "parallel design": 58127,
      "failed meet": 31141,
      "considered risk": 19648,
      "small numbers": 76291,
      "numbers participants": 50284,
      "considered likely": 19637,
      "limited clinical": 41920,
      "clinical utility": 16968,
      "main results": 42856,
      "results included": 71724,
      "painful diabetic": 58003,
      "neuralgia study": 49176,
      "study size": 78506,
      "ranged 45": 67346,
      "participants studies": 58371,
      "used cross": 84899,
      "cross design": 21248,
      "parallel group": 58128,
      "group design": 33733,
      "design study": 23807,
      "study duration": 78139,
      "duration weeks": 27194,
      "oxycodone cr": 54889,
      "cr used": 21114,
      "used studies": 85148,
      "doses titrated": 26290,
      "titrated maximum": 81472,
      "60 120": 5220,
      "120 mg": 1402,
      "mg daily": 45846,
      "daily mean": 21756,
      "mean doses": 43769,
      "37 45": 4179,
      "45 mg": 4589,
      "comparator study": 18000,
      "active placebo": 7529,
      "potential major": 63185,
      "study reported": 78461,
      "proportion participants": 65755,
      "participants experiencing": 58304,
      "50 pain": 4876,
      "relief improved": 70134,
      "30 pain": 3781,
      "relief reported": 70179,
      "reported moderate": 70588,
      "reported number": 70594,
      "number participants": 50215,
      "considered treatment": 19659,
      "effective study": 27705,
      "evidence efficacy": 30189,
      "efficacy outcome": 28310,
      "evidence indicated": 30199,
      "better patient": 13727,
      "satisfaction oxycodone": 73408,
      "oxycodone placebo": 55688,
      "placebo studies": 61832,
      "studies evidence": 77720,
      "group mean": 33851,
      "observation carried": 50594,
      "carried forward": 15136,
      "forward locf": 32420,
      "locf imputation": 42231,
      "small studies": 76306,
      "studies lasting": 77761,
      "lasting weeks": 41216,
      "weeks low": 86921,
      "low quality": 42541,
      "quality evidence": 66688,
      "evidence adverse": 30141,
      "events common": 30021,
      "common oxycodone": 17790,
      "cr placebo": 21107,
      "placebo adverse": 61658,
      "participants taking": 58374,
      "taking oxycodone": 80318,
      "placebo number": 61782,
      "number needed": 50182,
      "needed treat": 49039,
      "treat additional": 82276,
      "additional harmful": 7864,
      "harmful effect": 34589,
      "effect oxycodone": 27515,
      "oxycodone adverse": 54696,
      "events reported": 30108,
      "comparison placebo": 18376,
      "placebo oxycodone": 61791,
      "oxycodone versus": 56076,
      "versus placebo": 86147,
      "placebo rr": 61822,
      "48 95": 4697,
      "95 confidence": 6373,
      "confidence interval": 19435,
      "interval ci": 39574,
      "ci 18": 16408,
      "18 23": 2035,
      "23 low": 3100,
      "death reported": 22721,
      "reported oxycodone": 70607,
      "treatment adverse": 82433,
      "event withdrawals": 29999,
      "did differ": 24433,
      "differ significantly": 24547,
      "significantly groups": 75717,
      "participants oxycodone": 58336,
      "rr 69": 72964,
      "43 low": 4502,
      "lack efficacy": 41052,
      "frequent oxycodone": 32535,
      "placebo 11": 61616,
      "nnt prevent": 49526,
      "10 rr": 919,
      "03 45": 406,
      "45 low": 4586,
      "relevant studies": 70074,
      "studies chronic": 77661,
      "pain conditions": 56586,
      "authors conclusions": 12723,
      "evidence suggests": 30265,
      "suggests oxycodone": 79040,
      "treating people": 82409,
      "events typical": 30132,
      "typical opioids": 83389,
      "opioids appear": 52729,
      "widely prescribed": 87057,
      "oxycodone cause": 54770,
      "lethal respiratory": 41436,
      "respiratory depression": 71266,
      "depression compared": 23575,
      "compared effects": 18144,
      "healthy young": 34864,
      "volunteers pharmacokinetic": 86429,
      "pharmacodynamic pk": 61076,
      "pk pd": 61581,
      "pd modeling": 60291,
      "end points": 28806,
      "tested oxycodone": 80811,
      "oxycodone concentration": 54824,
      "concentration range": 18714,
      "male female": 43027,
      "female volunteers": 31380,
      "volunteers received": 86432,
      "received 20": 68096,
      "20 12": 2272,
      "12 40": 1251,
      "40 12": 4310,
      "12 mg": 1322,
      "mg oral": 46078,
      "oral oxycodone": 53613,
      "nociceptive assays": 49541,
      "assays pain": 11894,
      "pain pressure": 57420,
      "visit measured": 86264,
      "regular intervals": 69477,
      "analyses included": 10595,
      "carbon dioxide": 14969,
      "depression oxycodone": 23590,
      "onset offset": 51116,
      "30 40": 3688,
      "40 minutes": 4362,
      "effect site": 27562,
      "site concentration": 76157,
      "13 ng": 1494,
      "ng ml": 49430,
      "antinociceptive responses": 11253,
      "end tidal": 28827,
      "tidal carbon": 81174,
      "positive clinical": 62455,
      "similar better": 75903,
      "depression related": 23594,
      "related oxycodone": 69652,
      "oxycodone receptor": 55807,
      "receptor activation": 68453,
      "profile high": 65489,
      "modulation nociceptive": 47262,
      "nociceptive input": 49546,
      "oxycodone differs": 54971,
      "opioids fentanyl": 52908,
      "consistent negative": 19703,
      "manual verification": 43333,
      "paper presents": 58081,
      "results generalized": 71703,
      "birth patterns": 13882,
      "false positive": 31172,
      "positive rates": 62481,
      "method identified": 45181,
      "high accuracy": 35068,
      "health data": 34705,
      "data set": 22104,
      "based method": 13337,
      "false positives": 31174,
      "resulting positive": 71532,
      "positive predictive": 62478,
      "predictive value": 63578,
      "false negative": 31168,
      "negative rate": 49081,
      "rate 12": 67427,
      "linear time": 42036,
      "time series": 81370,
      "series models": 74658,
      "effective approach": 27600,
      "approach identify": 11459,
      "data quality": 22080,
      "clinical administrative": 16752,
      "administrative databases": 8399,
      "purpose investigate": 66534,
      "investigate impact": 40015,
      "acting oxycodone": 7421,
      "use opioid": 84541,
      "related harms": 69613,
      "administrative health": 8400,
      "data ontario": 22023,
      "ontario canada": 51127,
      "used measure": 85002,
      "differences opioids": 24770,
      "department ed": 23422,
      "ed visits": 27355,
      "visits opioid": 86286,
      "related overdose": 69648,
      "overdose poisoning": 54312,
      "substance use": 78809,
      "use following": 84374,
      "publicly insured": 66420,
      "study focused": 78211,
      "provincial drug": 66278,
      "drug insurance": 26658,
      "people 65": 60396,
      "low income": 42491,
      "dispensed oxycodone": 25432,
      "oxycodone prior": 55760,
      "models propensity": 47124,
      "propensity score": 65692,
      "score matched": 73757,
      "matched comparison": 43487,
      "comparison group": 18368,
      "non oxycodone": 49665,
      "oxycodone opioids": 55576,
      "opioids used": 53368,
      "used estimate": 84929,
      "main effects": 42827,
      "effects results": 28145,
      "results months": 71785,
      "months following": 47442,
      "following delisting": 32122,
      "delisting oxycontin": 23204,
      "milligrams morphine": 46478,
      "morphine equivalents": 47668,
      "equivalents mmes": 29365,
      "oxycodone relative": 55824,
      "group average": 33672,
      "average 13": 12858,
      "oxycodone months": 55465,
      "oxycodone 25": 54542,
      "25 chronic": 3349,
      "chronic oxycodone": 16252,
      "decline oxycodone": 22863,
      "oxycodone dispensing": 54982,
      "increase dispensing": 37744,
      "hydromorphone fentanyl": 36169,
      "important differences": 37004,
      "differences observed": 24765,
      "related opioid": 69642,
      "opioid poisoning": 52072,
      "use disorder": 84316,
      "disorder conclusions": 25372,
      "oxycodone impact": 55236,
      "quantities opioids": 66820,
      "oxycodone small": 55924,
      "population people": 62369,
      "increases use": 38088,
      "publicly funded": 66418,
      "formulations study": 32409,
      "study suggests": 78521,
      "specific prescription": 76613,
      "opioids led": 53014,
      "use particularly": 84604,
      "particularly chronic": 58408,
      "evidence changes": 30170,
      "related ed": 69594,
      "visits background": 86280,
      "background following": 13058,
      "following surgical": 32206,
      "surgical procedure": 79645,
      "female patient": 31370,
      "prescribed opioids": 63918,
      "opioids oxycodone": 53131,
      "extremely high": 30982,
      "high level": 35116,
      "involved treatment": 40114,
      "treatment medical": 82657,
      "case presentation": 15183,
      "presentation patient": 64681,
      "history substance": 35483,
      "general practitioner": 32983,
      "drug prescriptions": 26746,
      "years time": 87678,
      "reached 11": 67933,
      "000 mg": 26,
      "mg oxycodone": 46093,
      "oxycodone day": 54927,
      "high doses": 35091,
      "course months": 20993,
      "oxycodone treatment": 56027,
      "treatment initiated": 82628,
      "early stage": 27272,
      "patient history": 58656,
      "administration eventually": 8259,
      "care unit": 15086,
      "medical pharmacological": 44380,
      "evaluate effects": 29791,
      "effects dexmedetomidine": 27890,
      "dexmedetomidine dex": 24293,
      "inflammatory response": 38580,
      "tourniquet induced": 81922,
      "ischemia reperfusion": 40287,
      "mice used": 46328,
      "used construct": 84896,
      "mouse model": 48033,
      "randomly divided": 67231,
      "dex oxy": 24278,
      "oxy group": 54449,
      "morris water": 47977,
      "water maze": 86758,
      "maze test": 43620,
      "performed assess": 60571,
      "spatial learning": 76542,
      "learning memory": 41327,
      "nf \u03bab": 49426,
      "il 10": 36606,
      "mice hippocampus": 46290,
      "western blot": 86999,
      "spontaneous excitatory": 76756,
      "post synaptic": 62622,
      "currents sepscs": 21513,
      "significant effect": 75535,
      "effect compared": 27436,
      "compared group": 18167,
      "group dex": 33735,
      "oxy treatment": 54466,
      "05 significantly": 552,
      "significantly different": 75686,
      "frequency amplitude": 32512,
      "model mice": 47058,
      "effect tourniquet": 27573,
      "treatment alleviate": 82439,
      "synaptic transmission": 79912,
      "hippocampal neurons": 35429,
      "future studies": 32772,
      "studies needed": 77782,
      "needed examine": 49000,
      "examine effects": 30340,
      "mechanism involved": 44130,
      "aimed explore": 9454,
      "vivo vitro": 86383,
      "reveal mechanisms": 72210,
      "mechanisms related": 44152,
      "sigma receptor": 75379,
      "rat model": 67419,
      "oxycodone addition": 54679,
      "addition evaluated": 7800,
      "used assess": 84849,
      "rt qpcr": 73034,
      "related genes": 69611,
      "microvascular endothelial": 46386,
      "endothelial cells": 28869,
      "determined using": 24092,
      "using rt": 85601,
      "western blotting": 87001,
      "cell apoptosis": 15473,
      "oxycodone stimulated": 55938,
      "results indicated": 71732,
      "indicated oxycodone": 38241,
      "rat oxycodone": 67420,
      "oxycodone improved": 55240,
      "oxycodone administration": 54688,
      "molecular docking": 47281,
      "oxycodone elevated": 55023,
      "collectively oxycodone": 17505,
      "oxycodone alleviates": 54706,
      "previous studies": 64917,
      "studies demonstrated": 77692,
      "demonstrated significant": 23364,
      "significant reduction": 75611,
      "oral bioavailability": 53497,
      "administered concomitantly": 8113,
      "results 36": 71564,
      "50 lower": 4846,
      "lower auc": 42578,
      "authors investigated": 12741,
      "investigated possibility": 40050,
      "interaction oxycodone": 39377,
      "volunteers randomized": 86430,
      "randomized open": 67130,
      "open label": 51155,
      "way crossover": 86773,
      "crossover study": 21298,
      "receive oxycodone": 68065,
      "400 mg": 4391,
      "mg po": 46168,
      "starting oxycodone": 77021,
      "blood samples": 14151,
      "12 18": 1219,
      "18 24": 2036,
      "24 hours": 3210,
      "difference noted": 24637,
      "31 vs": 3881,
      "vs 31": 86561,
      "oxycodone regimens": 55819,
      "significantly delayed": 75682,
      "significant decrease": 75459,
      "study compared": 78007,
      "hydrocodone morphine": 36106,
      "ethanol oxycodone": 29681,
      "oxycodone significantly": 55909,
      "mouse tail": 48039,
      "tail withdrawal": 80251,
      "withdrawal assay": 87117,
      "morphine hydrocodone": 47717,
      "hydrocodone oxycodone": 36111,
      "administered orally": 8156,
      "tolerance seen": 81603,
      "following chronic": 32111,
      "chronic subcutaneous": 16347,
      "subcutaneous administration": 78599,
      "administration oral": 8320,
      "oxycodone following": 55098,
      "chronic oral": 16247,
      "ethanol kg": 29680,
      "kg significantly": 40806,
      "significantly reversed": 75859,
      "administration opioids": 8319,
      "opioids developed": 52848,
      "30 minutes": 3770,
      "minutes prior": 46662,
      "doses took": 26291,
      "took twice": 81679,
      "given orally": 33182,
      "tolerance oxycodone": 81596,
      "oxycodone investigated": 55302,
      "changes reflected": 15819,
      "brain oxycodone": 14352,
      "oxycodone concentrations": 54829,
      "tail immersion": 80248,
      "immersion test": 36759,
      "following administration": 32097,
      "administration acute": 8211,
      "chronic treatment": 16350,
      "concentrations significantly": 18813,
      "significantly lower": 75772,
      "concentrations oral": 18788,
      "kg reversed": 40798,
      "tolerance chronic": 81573,
      "oxycodone did": 54965,
      "did alter": 24405,
      "alter brain": 9681,
      "brain concentrations": 14329,
      "acute chronic": 7615,
      "oxycodone studies": 55946,
      "oxycodone neuronal": 55532,
      "oxycodone use": 56048,
      "use increased": 84427,
      "increased steadily": 38030,
      "despite high": 23883,
      "high cost": 35079,
      "use expenditures": 84365,
      "medicaid programs": 44332,
      "states objective": 77125,
      "objective estimate": 50405,
      "use medicaid": 84472,
      "medicaid beneficiaries": 44325,
      "design secondary": 23793,
      "secondary data": 74211,
      "data analysis": 21872,
      "medicaid prescription": 44331,
      "prescription dispensing": 64200,
      "dispensing records": 25460,
      "records 1996": 68717,
      "random effects": 66994,
      "effects meta": 27989,
      "meta analyses": 44887,
      "change rate": 15745,
      "rate cr": 67454,
      "use proportion": 84672,
      "proportion long": 65745,
      "oxycodone average": 54742,
      "oxycodone accounted": 54624,
      "beneficiaries study": 13610,
      "period use": 60806,
      "increased average": 37881,
      "21 states": 2983,
      "state specific": 77069,
      "use changes": 84231,
      "nonsignificant decrease": 49848,
      "use significant": 84727,
      "small significant": 76301,
      "significant change": 75437,
      "average cost": 12881,
      "cost long": 20879,
      "changes conclusions": 15780,
      "conclusions pa": 19150,
      "previously described": 64940,
      "effects suggesting": 28174,
      "oxycodone relatively": 55826,
      "policies needed": 62175,
      "needed identify": 49008,
      "identify effective": 36502,
      "prescription management": 64246,
      "opioids common": 52798,
      "common medications": 17768,
      "precipitated opioid": 63512,
      "misuse opioid": 46728,
      "study examined": 78197,
      "examined effects": 30378,
      "effects acute": 27805,
      "acute administration": 7607,
      "receptor mor": 68508,
      "mor agonist": 47494,
      "medium sized": 44724,
      "spiny neurons": 76732,
      "freely moving": 32500,
      "dopamine d1": 25718,
      "cre mice": 21135,
      "injections oxycodone": 38977,
      "oxycodone mg": 55407,
      "kg increased": 40737,
      "increased locomotor": 37942,
      "locomotor activity": 42241,
      "ca transients": 14659,
      "significantly reduced": 75842,
      "separate group": 74587,
      "mice injected": 46292,
      "neurons significantly": 49218,
      "increased oxycodone": 37971,
      "brain slices": 14365,
      "confirmed generalized": 19505,
      "inhibitory effects": 38821,
      "inhibitory postsynaptic": 38823,
      "postsynaptic currents": 63054,
      "currents results": 21512,
      "results demonstrate": 71657,
      "oxycodone background": 54743,
      "background purpose": 13183,
      "connectivity induced": 19547,
      "treatment analgesics": 82444,
      "results clinical": 71623,
      "studies investigating": 77757,
      "treatments patients": 82922,
      "sensory processing": 74575,
      "functional connectivity": 32693,
      "brain areas": 14316,
      "different treatment": 24931,
      "treatment oxycodone": 82725,
      "pure opioid": 66505,
      "opioid compared": 51592,
      "compared treatment": 18327,
      "treatment tapentadol": 82869,
      "systems methods": 80038,
      "methods healthy": 45344,
      "healthy male": 34823,
      "male volunteers": 43064,
      "volunteers included": 86421,
      "included randomized": 37535,
      "randomized double": 67095,
      "placebo controlled": 61673,
      "controlled cross": 20474,
      "cross study": 21273,
      "study received": 78454,
      "received tapentadol": 68296,
      "tapentadol 50": 80379,
      "mg extended": 45886,
      "oxycodone 10": 54491,
      "placebo twice": 61849,
      "twice daily": 83291,
      "daily 14": 21688,
      "14 days": 1585,
      "resting state": 71443,
      "state functional": 77043,
      "functional magnetic": 32701,
      "magnetic resonance": 42801,
      "resonance imaging": 71120,
      "data obtained": 22021,
      "analyses performed": 10601,
      "brain regions": 14361,
      "regions results": 69366,
      "results compared": 71636,
      "compared placebo": 18259,
      "placebo tapentadol": 61836,
      "tapentadol increased": 80423,
      "increased functional": 37922,
      "decreased functional": 22998,
      "anterior cingulate": 11102,
      "005 conclusions": 263,
      "conclusions study": 19217,
      "study shown": 78497,
      "central pain": 15609,
      "pain processing": 57436,
      "different tapentadol": 24925,
      "tapentadol oxycodone": 80451,
      "oxycodone treatments": 56033,
      "treatments compared": 82902,
      "different mechanism": 24884,
      "action studies": 7450,
      "studies larger": 77759,
      "larger sample": 41181,
      "sample sizes": 73317,
      "introduction opioid": 39939,
      "opioid prescribing": 52083,
      "prescribing rates": 64128,
      "continuing increase": 20154,
      "strategy reduce": 77443,
      "short term": 75188,
      "term opioid": 80644,
      "prescribing limited": 64076,
      "limited evidence": 41932,
      "objective aim": 50364,
      "study assess": 77959,
      "assess impact": 11936,
      "national policy": 48709,
      "mg discharge": 45874,
      "discharge prescriptions": 25165,
      "public hospitals": 66404,
      "hospitals using": 35676,
      "using electronic": 85389,
      "electronic prescribing": 28540,
      "proportion oxycodone": 65754,
      "prescriptions written": 64573,
      "10 tablets": 935,
      "tablets study": 80219,
      "interrupted time": 39537,
      "series design": 74656,
      "december 2018": 22828,
      "february 2021": 31313,
      "recommended quantity": 68637,
      "quantity oxycodone": 66841,
      "patients state": 59995,
      "september 2019": 74620,
      "effect june": 27470,
      "2020 results": 2909,
      "results 27": 71559,
      "27 month": 3499,
      "month period": 47399,
      "mg baseline": 45803,
      "approximately 50": 11572,
      "50 95": 4824,
      "95 ci": 6219,
      "ci 49": 16463,
      "51 oxycodone": 4958,
      "mg prescriptions": 46179,
      "prescriptions tablet": 64565,
      "tablet quantities": 80099,
      "quantities 10": 66818,
      "implementation state": 36943,
      "increased 95": 37867,
      "ci 10": 16384,
      "10 001": 655,
      "tablets 95": 80120,
      "ci 11": 16389,
      "11 001": 1086,
      "001 conclusions": 121,
      "restrictive prescribing": 71467,
      "policies state": 62177,
      "national level": 48699,
      "resulted decreased": 71502,
      "quantities oxycodone": 66821,
      "positive results": 62488,
      "tailored interventions": 80262,
      "ensure safe": 29043,
      "judicious opioid": 40502,
      "prescribing background": 64033,
      "background opioid": 13104,
      "analgesics used": 10514,
      "pain cause": 56516,
      "depression effect": 23581,
      "extensively studied": 30922,
      "induced respiratory": 38453,
      "remains difficult": 70292,
      "effect drug": 27447,
      "depression methods": 23583,
      "methods conducted": 45276,
      "conducted randomized": 19392,
      "randomized placebo": 67148,
      "controlled double": 20484,
      "blind crossover": 13929,
      "study 12": 77880,
      "12 healthy": 1284,
      "healthy adult": 34812,
      "males subjects": 43083,
      "subjects received": 78734,
      "received treatments": 68302,
      "treatments placebo": 82925,
      "oxycodone 30": 54548,
      "24 hour": 3203,
      "washout period": 86745,
      "period subjects": 60797,
      "minute ventilation": 46638,
      "respiratory rate": 71294,
      "tidal volume": 81176,
      "flow rate": 31934,
      "oxygen saturation": 56205,
      "pre dose": 63464,
      "dose 30": 25800,
      "30 60": 3696,
      "120 180": 1396,
      "180 minutes": 2126,
      "post dose": 62566,
      "primary endpoint": 65018,
      "60 minutes": 5263,
      "linear relationship": 42035,
      "results 60": 71577,
      "subjects mean": 78710,
      "placebo period": 61801,
      "period mean": 60744,
      "difference 95": 24582,
      "statistical significance": 77184,
      "time points": 81331,
      "points 30": 62120,
      "30 120": 3665,
      "dose 05": 25777,
      "oxycodone vs": 56084,
      "vs placebo": 86672,
      "placebo hours": 61761,
      "hours single": 35852,
      "single dose": 76076,
      "method predict": 45205,
      "predict relative": 63555,
      "depression objective": 23585,
      "objective prescription": 50467,
      "abuse poses": 6809,
      "poses significant": 62437,
      "significant public": 75607,
      "health concern": 34692,
      "address prescription": 7931,
      "investigated impact": 40042,
      "prescribing practices": 64115,
      "schedule ii": 73614,
      "ii controlled": 36557,
      "controlled substances": 20600,
      "design retrospective": 23780,
      "outpatient setting": 54141,
      "setting methods": 74786,
      "methods review": 45551,
      "review prescribing": 72337,
      "prescriptions schedule": 64559,
      "compared 10": 18063,
      "providers wrote": 66198,
      "oxycontin opana": 56157,
      "prescriptions 90": 64441,
      "90 pills": 6116,
      "pills dispensed": 61511,
      "results 10": 71537,
      "prescribers accounted": 64015,
      "38 percent": 4245,
      "dispensed 60": 25419,
      "average number": 12904,
      "prescriptions 14": 64430,
      "14 compared": 1581,
      "51 10": 4946,
      "controlled substance": 20597,
      "prescriptions compared": 64459,
      "compared total": 18323,
      "total number": 81849,
      "27 percent": 3507,
      "percent 10": 60446,
      "office visits": 50971,
      "24 percent": 3259,
      "provider opioid": 66176,
      "prescribing habits": 64062,
      "institution prescribing": 39082,
      "protein signaling": 65942,
      "signal transduction": 75386,
      "critical role": 21229,
      "role development": 72741,
      "development addiction": 24211,
      "related behaviors": 69562,
      "protein coupled": 65926,
      "coupled receptors": 20976,
      "including dopamine": 37610,
      "dopamine receptor": 25721,
      "receptor mu": 68513,
      "previously showed": 64958,
      "control morphine": 20369,
      "morphine analgesia": 47580,
      "promote development": 65662,
      "development morphine": 24234,
      "morphine tolerance": 47955,
      "analgesics fentanyl": 10422,
      "fentanyl methadone": 31522,
      "investigate role": 40026,
      "responses oxycodone": 71392,
      "oxycodone mor": 55466,
      "prescribed treatment": 63996,
      "treatment severe": 82836,
      "using mice": 85494,
      "mice lacking": 46293,
      "rewarding effects": 72438,
      "oxycodone pain": 55629,
      "pain free": 56795,
      "model neuropathic": 47059,
      "pain furthermore": 56803,
      "does affect": 25672,
      "affect analgesic": 8894,
      "oxycodone expression": 55058,
      "development oxycodone": 24243,
      "oxycodone tolerance": 56002,
      "acute pain": 7659,
      "pain models": 57203,
      "taken data": 80277,
      "data provide": 22069,
      "provide new": 66077,
      "new information": 49334,
      "rewarding analgesic": 72434,
      "analgesic actions": 10139,
      "oxycodone aim": 54702,
      "terminal cancer": 80684,
      "cancer patients": 14866,
      "positive effects": 62464,
      "treatment dyspnea": 82561,
      "studies focused": 77731,
      "opioid na\u00efve": 51975,
      "na\u00efve patients": 48838,
      "patients study": 60003,
      "study aimed": 77918,
      "aimed determine": 9443,
      "determine efficacy": 24009,
      "oxycodone infusion": 55273,
      "infusion opioid": 38716,
      "na\u00efve cancer": 48827,
      "patients dyspnea": 59232,
      "methods eligible": 45331,
      "eligible patients": 28590,
      "patients opioid": 59581,
      "cancer inpatients": 14791,
      "received continuous": 68128,
      "infusion treatment": 38733,
      "care palliative": 15053,
      "palliative care": 58033,
      "care team": 15085,
      "2013 december": 2628,
      "december 2016": 22826,
      "2016 retrospectively": 2759,
      "retrospectively investigated": 72180,
      "following continuous": 32115,
      "medical records": 44394,
      "records results": 68725,
      "results study": 71976,
      "study included": 78246,
      "included 19": 37386,
      "19 patients": 2190,
      "patients response": 59922,
      "response rate": 71361,
      "patients performance": 59642,
      "performance status": 60562,
      "median survival": 44285,
      "days adverse": 22485,
      "depression somnolence": 23600,
      "noted conclusion": 49986,
      "conclusion continuous": 18879,
      "treatment option": 82708,
      "option management": 53454,
      "management dyspnea": 43177,
      "formulations opioid": 32392,
      "effort required": 28435,
      "non medical": 49628,
      "medical use": 44413,
      "use study": 84757,
      "evaluated comparing": 29870,
      "release tablet": 70011,
      "commonly used": 17875,
      "used drug": 84923,
      "time required": 81360,
      "formulation drug": 32340,
      "drug release": 26772,
      "formulation maintained": 32347,
      "dose dumping": 25888,
      "tampering methods": 80352,
      "methods used": 45619,
      "used study": 85149,
      "study does": 78128,
      "access results": 7004,
      "results obtained": 71804,
      "described methods": 23657,
      "common drug": 17749,
      "medical users": 44424,
      "users following": 85241,
      "concurrent use": 19270,
      "increased risk": 38008,
      "risk respiratory": 72655,
      "depression death": 23579,
      "fda recognized": 31278,
      "data ability": 21856,
      "model developed": 47041,
      "diazepam used": 24373,
      "used combination": 84885,
      "combination opioid": 17575,
      "oxycodone compared": 54818,
      "opioid based": 51555,
      "current study": 21473,
      "study used": 78556,
      "used model": 85011,
      "model assess": 47027,
      "different drug": 24863,
      "drug classes": 26551,
      "quetiapine risperidone": 66915,
      "administered oxycodone": 8159,
      "oxycodone clinically": 54786,
      "given oxycodone": 33183,
      "oxycodone effect": 55012,
      "analyses indicated": 10596,
      "pharmacokinetic interactions": 61117,
      "resulting increased": 71529,
      "oxycodone exposure": 55056,
      "exposure increased": 30766,
      "recorded oxycodone": 68685,
      "oxycodone paroxetine": 55642,
      "expected effects": 30553,
      "drug exposure": 26627,
      "increased pharmacodynamic": 37982,
      "pharmacodynamic response": 61080,
      "response study": 71373,
      "study identified": 78235,
      "identified drug": 36436,
      "drug drug": 26599,
      "drug interaction": 26660,
      "animal model": 10995,
      "interaction studies": 39383,
      "objective recent": 50483,
      "recent years": 68435,
      "utilisation reported": 85714,
      "opioids australia": 52737,
      "details development": 23919,
      "oxycodone prescribing": 55743,
      "concepts opioid": 18820,
      "opioid stewardship": 52374,
      "developed used": 24197,
      "used facilitate": 84938,
      "prescribing practice": 64114,
      "context sensitive": 20112,
      "educational strategies": 27406,
      "outcome proportion": 53981,
      "oxycodone prescriptions": 55747,
      "emergency departments": 28687,
      "departments eds": 23453,
      "tablets surgery": 80221,
      "prescriptions given": 64491,
      "given patients": 33186,
      "patients required": 59905,
      "required opioids": 70850,
      "discharge results": 25172,
      "results cumulative": 71649,
      "demonstrated improved": 23345,
      "improved rates": 37130,
      "prescribing discharge": 64051,
      "62 vs": 5340,
      "vs 90": 86628,
      "surgical setting": 79650,
      "setting hospital": 74779,
      "prescribing increased": 64068,
      "increased significantly": 38026,
      "76 91": 5737,
      "proportion patients": 65759,
      "patients receiving": 59832,
      "receiving oxycodone": 68367,
      "36 vs": 4149,
      "vs 18": 86543,
      "18 001": 2024,
      "conclusions implementation": 19095,
      "quality improvement": 66705,
      "improvement projects": 37161,
      "significantly improved": 75749,
      "known topic": 40937,
      "increasing trend": 38126,
      "trend opioid": 82950,
      "prescribing misuse": 64082,
      "use known": 84445,
      "recent changes": 68390,
      "changes pharmaceutical": 15812,
      "pharmaceutical benefits": 61016,
      "benefits scheme": 13637,
      "help better": 34896,
      "better identify": 13716,
      "identify patients": 36515,
      "patients need": 59538,
      "need oxycodone": 48943,
      "oxycodone discharge": 54975,
      "does paper": 25685,
      "paper add": 58073,
      "add paper": 7725,
      "problem opioid": 65242,
      "reduction opioids": 69080,
      "management opioid": 43219,
      "implications practitioners": 36966,
      "paper provides": 58083,
      "provides practical": 66233,
      "starting point": 77022,
      "steps opioid": 77330,
      "pharmacodynamic relationships": 61079,
      "opioids consistently": 52814,
      "new therapeutics": 49380,
      "early studies": 27273,
      "development analgesics": 24213,
      "analgesics studies": 10504,
      "studies involving": 77758,
      "conducted determine": 19353,
      "form oral": 32288,
      "analytically blinded": 10808,
      "validated gas": 85787,
      "gas chromatographic": 32837,
      "chromatographic mass": 16146,
      "mass spectrometric": 43453,
      "specific method": 76603,
      "17 20": 1938,
      "plasma samples": 61956,
      "36 48": 4119,
      "48 hours": 4709,
      "hours following": 35776,
      "following single": 32198,
      "single 20": 76043,
      "mg 40": 45748,
      "mg dose": 45877,
      "dose study": 26083,
      "assessments included": 12151,
      "vital signs": 86343,
      "signs opioid": 75879,
      "opioid effect": 51756,
      "oxycodone oxymorphone": 55613,
      "vas drug": 86004,
      "drug effect": 26607,
      "12 hour": 1287,
      "duration pain": 27175,
      "demonstrated multiple": 23355,
      "involving patients": 40134,
      "patients various": 60173,
      "pain syndromes": 57897,
      "patients based": 59031,
      "based pharmacokinetic": 13353,
      "studies normal": 77791,
      "normal volunteers": 49912,
      "human abuse": 35937,
      "potential pharmacokinetics": 63206,
      "pk oxycodone": 61578,
      "oxycodone deterx": 54955,
      "deterx xtampza": 24134,
      "xtampza er": 87409,
      "er intact": 29426,
      "intact chewed": 39168,
      "administration design": 8245,
      "triple dummy": 83236,
      "dummy active": 27127,
      "controlled single": 20579,
      "dose period": 26008,
      "period crossover": 60717,
      "comparison study": 18382,
      "setting clinical": 74773,
      "clinical research": 16886,
      "adult nondependent": 8499,
      "nondependent recreational": 49729,
      "crushed immediate": 21332,
      "ir oxycodone": 40243,
      "oxycodone solution": 55925,
      "interventions oral": 39668,
      "intact oxycodone": 39173,
      "fasted fed": 31207,
      "chewed oxycodone": 15979,
      "crushed ir": 21337,
      "oxycodone fasted": 55067,
      "fasted placebo": 31210,
      "outcome measures": 53931,
      "ratings 100": 67688,
      "100 point": 1017,
      "point visual": 62113,
      "visual analog": 86302,
      "analog scales": 10542,
      "drug liking": 26678,
      "liking primary": 41867,
      "primary measure": 65040,
      "measure drug": 43938,
      "key secondary": 40678,
      "measure results": 43948,
      "pharmacodynamic pd": 61073,
      "pd analysis": 60289,
      "analysis included": 10698,
      "included 52": 37402,
      "subjects completed": 78688,
      "completed study": 18495,
      "pk analysis": 61574,
      "71 subjects": 5601,
      "subjects compared": 78687,
      "compared crushed": 18129,
      "squares mean": 76803,
      "mean maximum": 43790,
      "maximum effect": 43590,
      "effect max": 27480,
      "liking drug": 41856,
      "drug respectively": 26776,
      "ls mean": 42745,
      "difference standard": 24687,
      "standard error": 76904,
      "mean 13": 43657,
      "13 10": 1450,
      "10 points": 906,
      "12 points": 1356,
      "points results": 62141,
      "good effects": 33310,
      "feeling high": 31336,
      "treatments bioequivalent": 82898,
      "treatments based": 82897,
      "pk parameters": 61579,
      "study showed": 78494,
      "fed conditions": 31317,
      "conditions oxycodone": 19322,
      "statistically significantly": 77232,
      "lower abuse": 42573,
      "potential oral": 63201,
      "oral route": 53662,
      "compared ir": 18192,
      "oxycodone rationale": 55800,
      "rationale opioid": 67809,
      "epidemic remains": 29151,
      "pressing public": 64732,
      "years increasing": 87599,
      "increasing incidence": 38110,
      "incidence opioid": 37290,
      "opioid involved": 51879,
      "involved overdose": 40105,
      "like oxycodone": 41780,
      "oxycodone heroin": 55156,
      "heroin reasons": 35031,
      "reverse opioid": 72236,
      "stimulant drugs": 77354,
      "drugs including": 26977,
      "effects primarily": 28110,
      "receptor antagonism": 68472,
      "independent opioid": 38161,
      "receptors study": 68562,
      "fentanyl oxycodone": 31546,
      "oxycodone methods": 55400,
      "body plethysmography": 14204,
      "used characterize": 84874,
      "characterize fentanyl": 15894,
      "oxycodone effects": 55020,
      "effects respiration": 28140,
      "male swiss": 43061,
      "swiss webster": 79815,
      "webster mice": 86821,
      "tested effects": 80802,
      "evaluated ability": 29857,
      "ability reverse": 6558,
      "similar levels": 75941,
      "induced fentanyl": 38411,
      "oxycodone results": 55851,
      "results conclusions": 71640,
      "oxycodone fentanyl": 55072,
      "fentanyl dose": 31467,
      "dose dependently": 25874,
      "dependently reduced": 23547,
      "reduced respiratory": 68979,
      "minute volume": 46639,
      "ml min": 46876,
      "increased basal": 37883,
      "completely reversed": 18517,
      "doses tested": 26287,
      "despite limited": 23890,
      "limited efficacy": 41930,
      "reversing opioid": 72250,
      "combination naloxone": 17570,
      "oxymorphone potent": 56279,
      "potent opioid": 63109,
      "contribution oxycodone": 20249,
      "analgesia minor": 10024,
      "low peripheral": 42532,
      "low blood": 42454,
      "barrier permeability": 13257,
      "brain contribute": 14330,
      "oxymorphone levels": 56255,
      "analgesia brain": 9922,
      "brain cyp2d": 14331,
      "rat brain": 67417,
      "higher brain": 35211,
      "orally administered": 53690,
      "oxycodone metabolism": 55383,
      "brain microdialysis": 14348,
      "tail flick": 80241,
      "flick test": 31920,
      "mechanism based": 44127,
      "based inhibitor": 13328,
      "inhibitor inducing": 38795,
      "increased brain": 37888,
      "oxycodone levels": 55335,
      "001 oxycodone": 173,
      "brain oxymorphone": 14355,
      "fold 001": 31981,
      "001 decreased": 128,
      "induced brain": 38394,
      "fold brain": 31984,
      "metabolic ratios": 44912,
      "pre treatments": 63493,
      "treatments peak": 82923,
      "inversely correlated": 39994,
      "ex vivo": 30310,
      "cyp2d activity": 21586,
      "altering brain": 9705,
      "did affect": 24402,
      "analgesia oral": 10041,
      "oral oxymorphone": 53647,
      "oxymorphone auc": 56225,
      "60 groups": 5254,
      "levels response": 41604,
      "response suggesting": 71374,
      "reduced oxycodone": 68958,
      "oxycodone response": 55845,
      "objectives establish": 50557,
      "cerebrospinal fluid": 15644,
      "fluid csf": 31941,
      "oxycodone population": 55703,
      "population pharmacokinetic": 62370,
      "epidural epi": 29179,
      "administration methods": 8299,
      "methods study": 45587,
      "study conducted": 78024,
      "conducted 30": 19340,
      "subjects undergoing": 78749,
      "undergoing elective": 83529,
      "elective gynecological": 28493,
      "epidural analgesia": 29167,
      "parallel single": 58147,
      "iv placebo": 40402,
      "epi group": 29122,
      "group 18": 33577,
      "iv group": 40376,
      "group 12": 33564,
      "12 administered": 1272,
      "epidural catheter": 29177,
      "t12 l1": 80056,
      "spinal catheter": 76707,
      "plasma csf": 61923,
      "oxycodone analysis": 54715,
      "model built": 47032,
      "built using": 14479,
      "using nonmem": 85520,
      "results plasma": 71871,
      "concentrations evaluated": 18761,
      "evaluated using": 29927,
      "epidural space": 29192,
      "transfer plasma": 82179,
      "population parameters": 62367,
      "parameters plasma": 58169,
      "plasma clearance": 61897,
      "distribution volumes": 25571,
      "central peripheral": 15610,
      "based literature": 13330,
      "039 respectively": 439,
      "respectively conclusion": 71177,
      "concentration data": 18688,
      "purpose oxycodone": 66542,
      "major drug": 42943,
      "abuse especially": 6721,
      "contributes significantly": 20238,
      "significantly opioid": 75821,
      "deaths year": 22795,
      "year overdose": 87477,
      "depression studied": 23602,
      "tolerance develops": 81584,
      "prolonged exposure": 65613,
      "investigated role": 40055,
      "reverses oxycodone": 72246,
      "experimental approach": 30656,
      "cd mice": 15433,
      "kg day": 40710,
      "day oxycodone": 22352,
      "oxycodone days": 54928,
      "challenged oxycodone": 15700,
      "kg morphine": 40763,
      "assess level": 11938,
      "key results": 40675,
      "results oxycodone": 71822,
      "oxycodone treated": 56024,
      "treated mice": 82348,
      "mice developed": 46279,
      "developed tolerance": 24195,
      "oxycodone cross": 54914,
      "cross tolerance": 21278,
      "tolerance morphine": 81590,
      "morphine induced": 47730,
      "day 45": 22260,
      "treatment doses": 82557,
      "kg pregabalin": 40791,
      "\u03bcg kg": 87789,
      "tolerance resulting": 81602,
      "resulting significant": 71535,
      "significant respiratory": 75628,
      "tolerance mice": 81589,
      "mice treated": 46321,
      "treated oxycodone": 82363,
      "oxycodone 120": 54513,
      "day mice": 22337,
      "drug conclusion": 26564,
      "conclusion implications": 18914,
      "data suggest": 22127,
      "suggest oxycodone": 79005,
      "factor oxycodone": 31057,
      "oxycodone overdose": 55590,
      "deaths individuals": 22760,
      "misuse oxycodone": 46735,
      "oxycodone widely": 56093,
      "self medicate": 74489,
      "physical emotional": 61394,
      "pain physical": 57375,
      "pain dorsal": 56730,
      "examined oxycodone": 30397,
      "connectivity dorsal": 19546,
      "matrix using": 43540,
      "subjects randomized": 78726,
      "blind placebo": 13949,
      "controlled dose": 20483,
      "dose response": 26063,
      "healthy subjects": 34844,
      "placebo 10": 61613,
      "mg 20": 45724,
      "doses oxycodone": 26233,
      "oxycodone reduced": 55812,
      "reduced functional": 68929,
      "functional coupling": 32695,
      "relative placebo": 69758,
      "placebo differences": 61721,
      "doses findings": 26190,
      "multiple comparisons": 48266,
      "oxycodone produce": 55761,
      "purpose study": 66568,
      "study sought": 78507,
      "sought determine": 76484,
      "attenuate development": 12580,
      "oxycodone reward": 55857,
      "retaining analgesic": 72076,
      "effects experimental": 27921,
      "determine effect": 24006,
      "conditioned place": 19295,
      "place preference": 61600,
      "preference paradigm": 63627,
      "received saline": 68265,
      "saline oxycodone": 73265,
      "kg combination": 40703,
      "trials determine": 83136,
      "determine doses": 24002,
      "opioid reward": 52350,
      "nociceptive processes": 49553,
      "hot plate": 35681,
      "administered combination": 8111,
      "kg dose": 40720,
      "dose oxycodone": 25986,
      "oxycodone key": 55324,
      "results results": 71923,
      "rewarding aversive": 72435,
      "effective compared": 27605,
      "compared oxycodone": 18234,
      "oxycodone thermal": 55993,
      "thermal nociception": 81083,
      "plate assay": 61969,
      "responses observed": 71390,
      "conclusion findings": 18905,
      "findings suggest": 31825,
      "useful pain": 85209,
      "addiction treatment": 7774,
      "treatment settings": 82835,
      "common clinical": 17740,
      "clinical problem": 16873,
      "loss analgesic": 42430,
      "repeated dosing": 70408,
      "providing effective": 66258,
      "analgesia opioid": 10037,
      "dependent individuals": 23516,
      "inpatient study": 39032,
      "physically dependent": 61420,
      "dependent opioid": 23522,
      "induced analgesia": 38375,
      "analgesia oxycodone": 10044,
      "oxycodone maintenance": 55355,
      "mg orally": 46087,
      "times day": 81420,
      "days weeks": 22655,
      "weeks chronic": 86898,
      "pain ratings": 57472,
      "pressure pain": 64745,
      "pain test": 57905,
      "cold pressor": 17425,
      "pressor test": 64735,
      "60 mg": 5258,
      "maintenance dose": 42908,
      "agonist effects": 9285,
      "effects assessed": 27828,
      "analgesic response": 10330,
      "response oxycodone": 71356,
      "oxycodone 60": 54589,
      "placebo significantly": 61825,
      "liability measures": 41642,
      "measures data": 44053,
      "acute oxycodone": 7658,
      "dose needed": 25968,
      "acute analgesia": 7608,
      "analgesia adverse": 9906,
      "effects respiratory": 28141,
      "depression abuse": 23567,
      "abuse signals": 6873,
      "lower doses": 42602,
      "sensitivity opioid": 74560,
      "article describes": 11765,
      "experimental pain": 30668,
      "subjective physiological": 78661,
      "physiological responses": 61469,
      "weeks oxycodone": 86930,
      "maintenance oxycodone": 42912,
      "oxycodone produced": 55762,
      "euphoric effects": 29727,
      "effects miosis": 27995,
      "important cause": 36996,
      "cause acute": 15343,
      "ischemic stroke": 40289,
      "painful disorders": 58006,
      "disorders study": 25405,
      "study designed": 78095,
      "designed explore": 23837,
      "explore mechanism": 30725,
      "mechanism oxycodone": 44131,
      "brain microvascular": 14349,
      "endothelial cell": 28868,
      "results following": 71699,
      "following experiments": 32133,
      "detected using": 23951,
      "cells detected": 15493,
      "mrna protein": 48072,
      "protein expressions": 65936,
      "tight junction": 81180,
      "measured using": 44002,
      "inflammatory cytokines": 38556,
      "results revealed": 71926,
      "revealed oxycodone": 72220,
      "oxycodone attenuated": 54736,
      "inflammatory factor": 38574,
      "cells dose": 15494,
      "dose dependent": 25864,
      "dependent manner": 23518,
      "manner oxycodone": 43327,
      "oxycodone reduce": 55810,
      "cells induced": 15499,
      "oxycodone exhibited": 55052,
      "desirable effects": 23862,
      "conclusion oxycodone": 18947,
      "oxycodone relieved": 55830,
      "effective method": 27645,
      "background guidelines": 13059,
      "guidelines recommend": 34467,
      "morphine line": 47744,
      "line pharmacological": 41993,
      "pharmacological treatment": 61235,
      "treatment cancer": 82463,
      "trials opioids": 83173,
      "opioids performed": 53171,
      "demonstrate non": 23320,
      "non inferiority": 49612,
      "inferiority oxycodone": 38532,
      "patients methods": 59497,
      "label parallel": 40982,
      "group randomized": 33938,
      "randomized control": 67055,
      "control trial": 20436,
      "trial randomly": 83060,
      "patients regular": 59876,
      "regular oxycodone": 69480,
      "dose oral": 25980,
      "oral immediate": 53547,
      "morphine evaluated": 47683,
      "intensity numeric": 39275,
      "numeric rating": 50295,
      "rating scale": 67651,
      "scale 10": 73482,
      "events medication": 30067,
      "medication administration": 44454,
      "patients using": 60167,
      "using oxycodone": 85544,
      "using morphine": 85500,
      "oxycodone group": 55122,
      "intensity decreased": 39241,
      "decreased 75": 22972,
      "points 95": 62122,
      "72 78": 5611,
      "60 min": 5261,
      "interval 11": 39556,
      "120 min": 1408,
      "min morphine": 46537,
      "morphine group": 47705,
      "decreased 33": 22959,
      "25 60": 3338,
      "min differences": 46517,
      "requirement patients": 70874,
      "patients morphine": 59529,
      "group developed": 33734,
      "min patient": 46543,
      "significant adverse": 75423,
      "events conclusions": 30030,
      "oxycodone effectiveness": 55019,
      "significant safety": 75633,
      "safety concern": 73130,
      "trial registration": 83067,
      "registration umin": 69398,
      "tampering misuse": 80354,
      "properties new": 65716,
      "new formulations": 49332,
      "previously developed": 64941,
      "vitro laboratory": 86362,
      "reformulated oxycodone": 69200,
      "developed evaluate": 24175,
      "testing results": 80839,
      "formulation physical": 32360,
      "physical chemical": 61381,
      "real world": 68006,
      "test results": 80781,
      "results interpreted": 71737,
      "relative ease": 69745,
      "useful predicting": 85212,
      "deter drug": 23972,
      "different routes": 24919,
      "routes administration": 72853,
      "administration conclusions": 8232,
      "developed assess": 24170,
      "assessment drug": 12116,
      "drug formulations": 26636,
      "deterrence properties": 24102,
      "morphine reduce": 47907,
      "reduce chronic": 68836,
      "does oxycodone": 25684,
      "placebo methods": 61778,
      "methods multisite": 45392,
      "multisite randomized": 48311,
      "blind parallel": 13944,
      "parallel arm": 58126,
      "fixed dose": 31872,
      "dose trial": 26104,
      "trial oral": 83043,
      "oxycodone 15": 54518,
      "15 mg": 1748,
      "mg mg": 46049,
      "morphine mg": 47760,
      "doses day": 26169,
      "ethics committee": 29689,
      "2010 2014": 2542,
      "14 inpatient": 1602,
      "inpatient outpatient": 39020,
      "care services": 15078,
      "australia participants": 12692,
      "participants adults": 58278,
      "adults chronic": 8555,
      "medical research": 44399,
      "research council": 70994,
      "scale opioid": 73525,
      "primary end": 65014,
      "end point": 28802,
      "point proportion": 62106,
      "proportion people": 65776,
      "people greater": 60410,
      "intensity breathlessness": 39234,
      "100 mm": 999,
      "mm visual": 46939,
      "visual analogue": 86321,
      "analogue scale": 10551,
      "days secondary": 22617,
      "secondary end": 74218,
      "points average": 62126,
      "average worst": 12949,
      "life function": 41694,
      "harms results": 34597,
      "participants randomized": 58346,
      "74 oxycodone": 5676,
      "oxycodone 81": 54604,
      "placebo study": 61833,
      "study did": 78118,
      "did reach": 24483,
      "difference groups": 24616,
      "groups primary": 34277,
      "secondary outcomes": 74241,
      "placebo participants": 61798,
      "participants used": 58381,
      "used needed": 85028,
      "mean vs": 43906,
      "doses 001": 26115,
      "oxycodone participants": 55643,
      "participants reported": 58359,
      "nausea 001": 48755,
      "001 conclusion": 118,
      "benefit oxycodone": 13620,
      "future research": 32768,
      "opioid class": 51579,
      "class effect": 16658,
      "effect reduction": 27548,
      "reduction chronic": 69047,
      "background despite": 13036,
      "used pain": 85060,
      "management studies": 43268,
      "results evaluated": 71686,
      "methods women": 45633,
      "women aged": 87200,
      "surgery enrolled": 79386,
      "enrolled randomized": 29015,
      "double blinded": 26391,
      "blinded parallel": 14003,
      "group study": 34035,
      "study subjects": 78517,
      "subjects administered": 78679,
      "oxycodone epidural": 55027,
      "epidural oxycodone": 29189,
      "operation oxycodone": 51222,
      "administered single": 8181,
      "dose mg": 25958,
      "analysis oxycodone": 10722,
      "oxycodone major": 55356,
      "major metabolites": 42954,
      "primary outcomes": 65099,
      "peak concentration": 60303,
      "concentration max": 18701,
      "max time": 43561,
      "time peak": 81317,
      "auc oxycodone": 12636,
      "secondary outcome": 74237,
      "outcome analgesic": 53902,
      "efficacy measured": 28294,
      "measured total": 43999,
      "total dose": 81800,
      "dose rescue": 26061,
      "fentanyl postoperative": 31569,
      "postoperative hours": 62778,
      "hours results": 35843,
      "group median": 33856,
      "median oxycodone": 44265,
      "oxycodone cmax": 54791,
      "cmax auc": 17096,
      "fold higher": 31992,
      "higher respectively": 35316,
      "respectively compared": 71176,
      "compared iv": 18194,
      "group total": 34053,
      "fentanyl significantly": 31592,
      "lower epi": 42611,
      "seven subjects": 74879,
      "needed 16": 48966,
      "16 doses": 1871,
      "doses iv": 26207,
      "12 subjects": 1365,
      "unexpected adverse": 83717,
      "reported conclusions": 70526,
      "conclusions epidural": 19080,
      "provides higher": 66220,
      "csf concentrations": 21359,
      "better analgesic": 13703,
      "registration eudract": 69392,
      "background managing": 13082,
      "managing acute": 43281,
      "pain challenging": 56520,
      "surgeons patients": 79277,
      "despite making": 23892,
      "patient controlled": 58578,
      "controlled intravenous": 20500,
      "intravenous analgesia": 39816,
      "analgesia pcia": 10058,
      "solution oxycodone": 76445,
      "unique advantages": 83750,
      "practice study": 63417,
      "aimed compare": 9440,
      "pcia methods": 60278,
      "methods performed": 45453,
      "literature search": 42132,
      "pubmed embase": 66446,
      "cochrane central": 17166,
      "central register": 15611,
      "register controlled": 69370,
      "web science": 86813,
      "national knowledge": 48697,
      "knowledge infrastructure": 40886,
      "december 2020": 22830,
      "rcts comparing": 67912,
      "comparing efficacy": 18350,
      "oxycodone sufentanil": 55956,
      "sufentanil pcia": 78951,
      "outcome included": 53920,
      "ramsay sedation": 66988,
      "sedation scale": 74329,
      "scale patients": 73540,
      "patients satisfaction": 59936,
      "satisfaction effects": 73395,
      "results rcts": 71904,
      "rcts included": 67915,
      "included meta": 37484,
      "meta analysis": 44889,
      "analysis compared": 10655,
      "compared sufentanil": 18319,
      "sufentanil oxycodone": 78948,
      "oxycodone showed": 55899,
      "showed lower": 75270,
      "numerical rating": 50310,
      "scale scores": 73557,
      "scores mean": 73900,
      "difference md": 24625,
      "71 95": 5589,
      "ci 01": 16368,
      "01 41": 296,
      "41 001": 4410,
      "demonstrated better": 23332,
      "pain md": 57136,
      "22 95": 3028,
      "ci 58": 16472,
      "85 001": 5976,
      "ramsay score": 66987,
      "77 95": 5757,
      "ci 35": 16437,
      "19 001": 2155,
      "resulted fewer": 71506,
      "fewer effects": 31636,
      "odds ratio": 50904,
      "46 95": 4625,
      "35 60": 4068,
      "statistical difference": 77175,
      "degree patients": 23177,
      "13 95": 1476,
      "ci 88": 16505,
      "44 33": 4528,
      "drug consumption": 26566,
      "55 95": 5069,
      "ci 14": 16400,
      "14 18": 1555,
      "postoperative analgesia": 62698,
      "fewer adverse": 31629,
      "effects recommended": 28127,
      "especially abdominal": 29550,
      "primary objective": 65042,
      "improvement project": 37160,
      "reduce number": 68857,
      "number oxycodone": 50208,
      "tablets dispensed": 80149,
      "overnight stay": 54350,
      "patients discharge": 59201,
      "discharge secondary": 25173,
      "secondary objective": 74233,
      "reduce proportion": 68890,
      "inappropriate oxycodone": 37242,
      "prescriptions discharge": 64475,
      "series analysis": 74650,
      "analysis performed": 10730,
      "performed surgical": 60636,
      "hospital sydney": 35647,
      "period january": 60738,
      "january 2005": 40422,
      "august 2013": 12663,
      "july 2017": 40522,
      "linear trend": 42037,
      "ci 001": 16364,
      "tablets 100": 80110,
      "produced significant": 65404,
      "end month": 28799,
      "tablets decreased": 80141,
      "ci 39": 16443,
      "surgical cases": 79624,
      "trend monthly": 82948,
      "27 oxycodone": 3505,
      "oxycodone studied": 55945,
      "patients end": 59244,
      "end stage": 28815,
      "liver cirrhosis": 42173,
      "urine collected": 84067,
      "collected 24": 17445,
      "hours intravenous": 35786,
      "intravenous administration": 39813,
      "05 mg": 525,
      "kg oxycodone": 40775,
      "concentrations oxycodone": 18790,
      "oxycodone metabolites": 55388,
      "metabolites noroxycodone": 44974,
      "noroxycodone oxymorphone": 49935,
      "oxymorphone measured": 56257,
      "measured plasma": 43989,
      "plasma urine": 61961,
      "elimination half": 28612,
      "half life": 34515,
      "life oxycodone": 41714,
      "oxycodone 13": 54516,
      "hours range": 35838,
      "range 24": 67274,
      "hours patients": 35813,
      "patients cirrhosis": 59087,
      "clearance increased": 16714,
      "increased 26": 37845,
      "26 min": 3447,
      "range 15": 67259,
      "15 73": 1713,
      "73 min": 5654,
      "13 min": 1490,
      "98 min": 6467,
      "05 oxycodone": 533,
      "used patients": 85071,
      "stage disease": 76863,
      "deterrent oxycodone": 24124,
      "hydrochloride hcl": 36021,
      "hcl extended": 34637,
      "er tablets": 29475,
      "tablets developed": 80146,
      "pharmacokinetic pk": 61140,
      "pk study": 61590,
      "size range": 76186,
      "1000 \u03bcm": 1045,
      "resulted significant": 71517,
      "significant loss": 75573,
      "loss oxycodone": 42435,
      "hcl er": 34635,
      "minimal oxycodone": 46579,
      "ir tablets": 40261,
      "showed loss": 75268,
      "analytical procedures": 10803,
      "oxycodone phase": 55683,
      "content uniformity": 20102,
      "er ir": 29428,
      "particle size": 58395,
      "size distribution": 76184,
      "500 \u00b5m": 4928,
      "weight drug": 86977,
      "drug substance": 26795,
      "weight ratio": 86983,
      "oxycodone lost": 55342,
      "demonstrated oxycodone": 23358,
      "tablets did": 80147,
      "did result": 24495,
      "result significantly": 71492,
      "different release": 24918,
      "pain treated": 57932,
      "treated opioids": 82358,
      "opioids antidepressants": 52728,
      "serotonin norepinephrine": 74678,
      "norepinephrine reuptake": 49888,
      "pain relieving": 57606,
      "relieving effect": 70231,
      "mode action": 47016,
      "study investigated": 78273,
      "investigated oxycodone": 40048,
      "spinal supraspinal": 76726,
      "randomized cross": 67088,
      "study comparing": 78017,
      "day treatment": 22435,
      "pain transmission": 57931,
      "nociceptive withdrawal": 49554,
      "electrical stimulation": 28510,
      "anterior muscle": 11108,
      "days treatment": 22647,
      "curve aucs": 21525,
      "oxycodone increased": 55245,
      "increased auc": 37880,
      "04 oxycodone": 454,
      "activity increased": 7570,
      "activity decreased": 7564,
      "decreased 02": 22937,
      "level study": 41527,
      "nervous effects": 49141,
      "prevalence prescription": 64804,
      "abuse increased": 6736,
      "increased dramatically": 37906,
      "years united": 87684,
      "generally similar": 33026,
      "similar pattern": 75976,
      "pattern increasing": 60190,
      "seeking treatment": 74352,
      "opioid dependence": 51699,
      "study presents": 78428,
      "presents results": 64713,
      "internal quality": 39462,
      "project conducted": 65588,
      "conducted outpatient": 19383,
      "methadone maintenance": 45092,
      "sought examine": 76488,
      "testing methods": 80826,
      "patients provided": 59716,
      "urine samples": 84083,
      "week period": 86861,
      "samples analyzed": 73329,
      "enzyme multiplied": 29106,
      "multiplied immunoassay": 48307,
      "opiate assay": 51292,
      "assay 300": 11875,
      "300 ng": 3819,
      "supplemental oxycodone": 79165,
      "oxycodone test": 55990,
      "100 ng": 1004,
      "ml oxycodone": 46885,
      "emit assay": 28723,
      "samples positive": 73358,
      "positive oxycodone": 62475,
      "tested positive": 80812,
      "recent oxycodone": 68413,
      "oxycodone users": 56066,
      "users likely": 85250,
      "likely report": 41836,
      "report prescription": 70473,
      "primary drug": 64998,
      "drug intake": 26659,
      "treatment significantly": 82843,
      "significantly shorter": 75860,
      "shorter duration": 75208,
      "provide significantly": 66101,
      "opioid cocaine": 51583,
      "cocaine positive": 17161,
      "positive urine": 62502,
      "samples overall": 73351,
      "overall data": 54192,
      "illustrate potential": 36667,
      "importance monitoring": 36982,
      "future efforts": 32762,
      "question using": 66883,
      "methods findings": 45340,
      "implications clinical": 36960,
      "clinical issues": 16831,
      "medication dosing": 44492,
      "determining patient": 24099,
      "used particularly": 85066,
      "analgesia children": 9924,
      "cesarean section": 15674,
      "oxycodone developing": 54959,
      "developing brain": 24201,
      "remains seen": 70309,
      "exposure long": 30775,
      "cognitive dysfunction": 17323,
      "young children": 87717,
      "direct effect": 25045,
      "stem cells": 77315,
      "10 \u03bcg": 964,
      "\u03bcg ml": 87795,
      "ml 48": 46839,
      "effects significantly": 28157,
      "dose morphine": 25961,
      "morphine significant": 47923,
      "difference observed": 24640,
      "observed regarding": 50714,
      "doses \u03bcg": 26302,
      "ml \u03bcg": 46920,
      "oxycodone antagonist": 54717,
      "influence oxycodone": 38596,
      "oxycodone taken": 55984,
      "taken results": 80292,
      "indicated short": 38248,
      "term exposure": 80632,
      "exposure oxycodone": 30787,
      "oxycodone low": 55343,
      "medical services": 44402,
      "lack robust": 41058,
      "robust evidence": 72712,
      "evidence effectiveness": 30187,
      "overall health": 54204,
      "focus study": 31972,
      "study understand": 78551,
      "decision making": 22844,
      "policy decisions": 62183,
      "cases cases": 15226,
      "blood glucose": 14125,
      "test strips": 80786,
      "patients diabetes": 59186,
      "content analysis": 20097,
      "described using": 23662,
      "using framework": 85400,
      "key characteristics": 40663,
      "better understand": 13746,
      "services background": 74726,
      "background objectives": 13098,
      "objectives oxycodone": 50576,
      "used opioid": 85041,
      "300 fold": 3812,
      "fold greater": 31991,
      "administered intravenously": 8146,
      "gynecologic surgery": 34488,
      "surgery additionally": 79313,
      "additionally patients": 7908,
      "patients administered": 58947,
      "oxycodone lower": 55344,
      "lower pain": 42668,
      "pain scores": 57691,
      "scores needed": 73915,
      "needed rescue": 49033,
      "rescue analgesics": 70939,
      "effects compared": 27864,
      "compared intravenous": 18191,
      "routine clinical": 72860,
      "use methods": 84481,
      "cell culture": 15476,
      "culture models": 21380,
      "morphine study": 47934,
      "mechanisms underlying": 44154,
      "human neuroblastoma": 35965,
      "neuroblastoma cells": 49186,
      "increasing concentrations": 38096,
      "mm oxycodone": 46937,
      "24 48": 3164,
      "results morphine": 71786,
      "decreased cell": 22983,
      "cell viability": 15490,
      "morphine increased": 47726,
      "increased number": 37954,
      "oxycodone assessed": 54731,
      "flow cytometry": 31933,
      "transmission electron": 82225,
      "electron microscopy": 28528,
      "exposure opioids": 30783,
      "opioids evoked": 52896,
      "conclusions based": 19036,
      "clinical concentration": 16771,
      "epidural administration": 29165,
      "important opioid": 37019,
      "opioid antagonists": 51539,
      "naltrexone oxycodone": 48549,
      "obtained using": 50784,
      "carried using": 15141,
      "compared obtained": 18222,
      "showed good": 75248,
      "calculated data": 14689,
      "oxycodone objective": 55547,
      "abuse continues": 6668,
      "continues public": 20149,
      "oxycodone arir": 54730,
      "oxycodone tablet": 55975,
      "oral abuse": 53482,
      "abuse design": 6678,
      "blind double": 13935,
      "double dummy": 26403,
      "controlled way": 20651,
      "potential study": 63235,
      "pharmacodynamics pharmacokinetics": 61088,
      "pharmacokinetics crushed": 61164,
      "crushed intranasal": 21336,
      "intranasal oxycodone": 39755,
      "intact oral": 39172,
      "points included": 62132,
      "included mean": 37478,
      "liking emax": 41859,
      "analog scale": 10524,
      "scale primary": 73546,
      "desire drug": 23864,
      "drug overall": 26728,
      "overall drug": 54195,
      "drug high": 26643,
      "high good": 35105,
      "concentration time": 18722,
      "results subjects": 71989,
      "completed treatment": 18508,
      "treatment phase": 82761,
      "respectively 0001": 71143,
      "0001 significant": 78,
      "significant reductions": 75619,
      "reductions observed": 69113,
      "high overall": 35129,
      "liking good": 41860,
      "exhibited lower": 30514,
      "lower peak": 42676,
      "peak oxycodone": 60310,
      "oxycodone plasma": 55691,
      "concentration compared": 18685,
      "treatments tolerated": 82933,
      "tolerated adverse": 81618,
      "effects typical": 28187,
      "intranasal administration": 39748,
      "conclusions data": 19070,
      "indicate oxycodone": 38226,
      "potential reduce": 63215,
      "reduce abuse": 68829,
      "intranasal route": 39758,
      "route objective": 72843,
      "objective objective": 50447,
      "objective study": 50489,
      "study evaluate": 78160,
      "evaluate pharmacokinetics": 29831,
      "pharmacokinetics abuse": 61157,
      "potential different": 63157,
      "different formulations": 24870,
      "formulations oxycodone": 32396,
      "oxycodone design": 54945,
      "design participants": 23742,
      "participants completed": 58288,
      "completed day": 18465,
      "day placebo": 22372,
      "controlled trial": 20606,
      "naloxone challenge": 48435,
      "drug discrimination": 26586,
      "discrimination double": 25275,
      "study interventions": 78264,
      "interventions participants": 39671,
      "participants administered": 58276,
      "administered different": 8119,
      "different doses": 24860,
      "doses formulations": 26191,
      "oxycodone 40": 54570,
      "mg immediate": 45917,
      "ir 40": 40206,
      "mg controlled": 45835,
      "mg cr": 45839,
      "80 mg": 5846,
      "evaluate pharmacokinetic": 29830,
      "ratings drug": 67694,
      "liking high": 41863,
      "measures pharmacokinetic": 44082,
      "parameters determined": 58158,
      "hour dosing": 35696,
      "dosing interval": 26314,
      "interval primary": 39601,
      "drug effects": 26613,
      "effects questionnaire": 28122,
      "like drug": 41774,
      "high results": 35167,
      "results maximal": 71762,
      "area curve": 11625,
      "mg ir": 45934,
      "ir crushed": 40219,
      "cr greater": 21062,
      "greater 40": 33424,
      "maximal effect": 43572,
      "area effect": 11629,
      "effect curve": 27439,
      "curve similar": 21528,
      "similar formulations": 75922,
      "cr dose": 21058,
      "dose required": 26057,
      "required produce": 70857,
      "reports drug": 70724,
      "high approximately": 35072,
      "approximately twofold": 11592,
      "greater cr": 33437,
      "cr vs": 21115,
      "ir formulation": 40229,
      "cr tablet": 21110,
      "profile similar": 65507,
      "events consistent": 30031,
      "consistent opioid": 19705,
      "opioid administration": 51407,
      "oxycodone required": 55837,
      "required approximately": 70825,
      "doses produce": 26254,
      "subjective effects": 78648,
      "effects comparable": 27862,
      "comparable ir": 17959,
      "oxycodone rate": 55798,
      "rate drug": 67463,
      "drug delivery": 26576,
      "delivery central": 23215,
      "important predictor": 37023,
      "strength drug": 77473,
      "drug studies": 26794,
      "studies directly": 77702,
      "examined relationship": 30412,
      "relationship drug": 69715,
      "drug taking": 26799,
      "taking behavior": 80300,
      "administration purpose": 8353,
      "purpose present": 66546,
      "infusion rate": 38724,
      "dose opioid": 25973,
      "heroin dependent": 34996,
      "dependent participants": 23526,
      "participants 11": 58264,
      "completed week": 18513,
      "week inpatient": 86844,
      "study test": 78538,
      "participants received": 58351,
      "dose drug": 25887,
      "15 30": 1686,
      "60 90": 5239,
      "90 minutes": 6106,
      "random order": 67003,
      "sample session": 73313,
      "session participants": 74734,
      "sampled dose": 73322,
      "choice session": 16121,
      "conditions 40": 19304,
      "oxycodone served": 55895,
      "15 minutes": 1771,
      "subjective ratings": 78667,
      "good effect": 33307,
      "effect high": 27463,
      "results peak": 71860,
      "peak plasma": 60316,
      "plasma levels": 61937,
      "oxycodone generally": 55113,
      "end infusion": 28792,
      "minute infusion": 46635,
      "medications commonly": 44604,
      "treating pain": 82404,
      "pain present": 57415,
      "present results": 64633,
      "results provide": 71897,
      "support development": 79192,
      "reinforcing effects": 69523,
      "effects aim": 27816,
      "naloxone controlled": 48441,
      "cr combination": 21055,
      "december 2011": 22821,
      "evaluate impact": 29807,
      "people cancer": 60401,
      "cancer methods": 14793,
      "repatriation pharmaceutical": 70389,
      "dispensing data": 25443,
      "data linked": 22004,
      "cancer registry": 14904,
      "department veterans": 23445,
      "veterans affairs": 86175,
      "affairs dva": 8891,
      "card holders": 14977,
      "65 years": 5423,
      "cancer opioid": 14808,
      "opioid dispensings": 51721,
      "analysis model": 10710,
      "model changes": 47034,
      "monthly rates": 47422,
      "rates oxycodone": 67614,
      "cr tablets": 21111,
      "performed retrospective": 60623,
      "retrospective cohort": 72122,
      "study examine": 78192,
      "examine changes": 30335,
      "characteristics opioid": 15867,
      "opioid utilization": 52629,
      "time comparing": 81224,
      "initiating oxycodone": 38891,
      "dispensed month": 25426,
      "increased 20": 37832,
      "uptake oxycodone": 84021,
      "increased immediately": 37929,
      "immediately 17": 36744,
      "buprenorphine fentanyl": 14539,
      "fentanyl morphine": 31531,
      "morphine declined": 47636,
      "significantly likely": 75763,
      "cr formulation": 21059,
      "formulation likely": 32346,
      "likely use": 41847,
      "use immediate": 84416,
      "oxycodone 90": 54609,
      "90 days": 6093,
      "days following": 22524,
      "following initiation": 32143,
      "use weak": 84807,
      "weak opioid": 86787,
      "opioid 90": 51360,
      "days preceding": 22594,
      "time conclusions": 81226,
      "overall oxycodone": 54221,
      "findings highlight": 31785,
      "highlight need": 35375,
      "updated guidelines": 83983,
      "risk management": 72593,
      "treatment patients": 82746,
      "potentiation oxycodone": 63281,
      "oxycodone antinociception": 54719,
      "endothelin et": 28871,
      "imidazoline receptor": 36693,
      "receptor subtypes": 68528,
      "antinociception mice": 11228,
      "mice antinociceptive": 46271,
      "flick hot": 31916,
      "determined male": 24072,
      "combined administration": 17640,
      "antagonist used": 11074,
      "receptors respectively": 68560,
      "significant antinociceptive": 75430,
      "antinociceptive response": 11252,
      "report demonstrating": 70453,
      "receptors involved": 68544,
      "mice background": 46273,
      "background peripherally": 13157,
      "peripherally acting": 60888,
      "opioids particularly": 53152,
      "agonists effective": 9325,
      "effective treating": 27712,
      "receptors expressed": 68541,
      "study investigate": 78268,
      "investigate pharmacokinetic": 40021,
      "peripherally selective": 60895,
      "agonist cr665": 9282,
      "oxycodone non": 55537,
      "non selective": 49679,
      "opioid methods": 51933,
      "methods randomized": 45505,
      "study healthy": 78222,
      "volunteers administered": 86413,
      "cr665 36": 21117,
      "36 mg": 4134,
      "kg intravenous": 40747,
      "placebo intravenous": 61767,
      "intravenous oral": 39865,
      "pain tolerance": 57922,
      "tolerance thresholds": 81605,
      "volume water": 86403,
      "plasma drug": 61927,
      "drug concentration": 26557,
      "data used": 22150,
      "used generate": 84945,
      "pharmacokinetic models": 61121,
      "models used": 47133,
      "data using": 22154,
      "nonmem vi": 49796,
      "pharmacodynamic models": 61070,
      "models results": 47130,
      "model oxycodone": 47067,
      "oxycodone kinetics": 55325,
      "kinetics best": 40842,
      "described compartment": 23651,
      "drugs plasma": 27037,
      "plasma concentration": 61898,
      "linear model": 42022,
      "concentration analgesia": 18675,
      "analgesia delay": 9946,
      "ml ng": 46880,
      "ml plasma": 46892,
      "conclusion results": 18978,
      "peripheral selectivity": 60885,
      "background tapentadol": 13206,
      "tapentadol immediate": 80419,
      "indicated treatment": 38250,
      "severe acute": 74900,
      "pain clinical": 56550,
      "trials tapentadol": 83204,
      "tapentadol ir": 80425,
      "effectively reduced": 27737,
      "pain improved": 56848,
      "improved tolerability": 37135,
      "tolerability compared": 81522,
      "oxycodone ir": 55304,
      "doses providing": 26256,
      "providing comparable": 66253,
      "comparable analgesia": 17946,
      "analgesia objective": 10033,
      "objective analysis": 50374,
      "cost effectiveness": 20871,
      "effectiveness tapentadol": 27782,
      "ir providing": 40258,
      "outpatient treatment": 54151,
      "acute postsurgical": 7693,
      "pain perspective": 57370,
      "care health": 15027,
      "health plan": 34751,
      "methods markov": 45376,
      "markov model": 43440,
      "clinical economic": 16793,
      "economic outcomes": 27313,
      "outcomes tapentadol": 54102,
      "ir 100": 40196,
      "100 mg": 992,
      "mg compared": 45826,
      "ir 15": 40198,
      "mg treatment": 46247,
      "pain days": 56684,
      "days tapentadol": 22643,
      "ir 50": 40208,
      "ir 10": 40192,
      "pain 10": 56348,
      "10 days": 756,
      "changes pain": 15809,
      "occurrence opioid": 50861,
      "related adverse": 69546,
      "events aes": 30009,
      "opioid switching": 52390,
      "number quality": 50245,
      "quality adjusted": 66673,
      "adjusted life": 8030,
      "model obtained": 47061,
      "obtained clinical": 50764,
      "claims databases": 16630,
      "included drug": 37447,
      "drug costs": 26569,
      "sensitivity analyses": 74554,
      "analyses conducted": 10590,
      "model parameters": 47071,
      "parameters results": 58175,
      "cost pain": 20881,
      "pain medication": 57149,
      "medication patient": 44534,
      "higher tapentadol": 35330,
      "surgical pain": 79639,
      "pain setting": 57817,
      "23 vs": 3115,
      "vs 57": 86596,
      "57 respectively": 5137,
      "17 vs": 1990,
      "vs 21": 86547,
      "cost difference": 20864,
      "medical costs": 44354,
      "costs associated": 20894,
      "treatment aes": 82436,
      "lower mean": 42643,
      "mean treatment": 43896,
      "90 vs": 6118,
      "vs 55": 86594,
      "48 vs": 4750,
      "vs 144": 86536,
      "ir associated": 40213,
      "mean number": 43803,
      "number treatment": 50269,
      "treatment days": 82540,
      "days 30": 22470,
      "30 improvement": 3741,
      "improvement pain": 37155,
      "intensity opioid": 39282,
      "related aes": 69557,
      "pain 73": 56397,
      "73 vs": 5660,
      "vs 68": 86610,
      "03 vs": 422,
      "vs 92": 86630,
      "doses tapentadol": 26285,
      "lower treatment": 42718,
      "treatment costs": 82528,
      "costs greater": 20896,
      "greater effectiveness": 33442,
      "incremental cost": 38143,
      "effectiveness ratios": 27779,
      "ratios calculated": 67818,
      "suggest doses": 78989,
      "analgesia tapentadol": 10119,
      "cost effective": 20865,
      "effective alternative": 27586,
      "alternative oxycodone": 9731,
      "ir treatment": 40262,
      "pain objectives": 57269,
      "objectives identify": 50564,
      "identify prevalence": 36527,
      "prevalence oxycodone": 64797,
      "prescribed ed": 63858,
      "opioids following": 52917,
      "following ed": 32129,
      "admission methods": 8411,
      "methods retrospective": 45529,
      "retrospective cross": 72138,
      "hospital tasmania": 35649,
      "august 30": 12675,
      "september 2016": 74617,
      "patients received": 59761,
      "received ir": 68183,
      "oxycodone ed": 55011,
      "persistence opioid": 60915,
      "undertaken using": 83665,
      "real time": 68000,
      "patients aged": 58965,
      "aged 13": 9143,
      "13 years": 1513,
      "12 patients": 1351,
      "patients taking": 60032,
      "regularly prescribed": 69485,
      "opioids prior": 53226,
      "prior ed": 65145,
      "48 patients": 4739,
      "opioids months": 53064,
      "thirty patients": 81107,
      "opioids non": 53093,
      "pain conclusion": 56583,
      "suggest prescribing": 79013,
      "lower previous": 42689,
      "studies additionally": 77642,
      "chronic opioid": 16237,
      "given relatively": 33193,
      "low opioid": 42509,
      "approved indications": 11540,
      "related chronic": 69570,
      "pain following": 56786,
      "following months": 32162,
      "objective evaluate": 50406,
      "outcomes associated": 54012,
      "tapentadol er": 80397,
      "er vs": 29481,
      "vs oxycodone": 86667,
      "cr treatment": 21113,
      "treatment chronic": 82479,
      "pain cncp": 56555,
      "cncp methods": 17106,
      "study developed": 78117,
      "monte carlo": 47379,
      "carlo simulation": 15124,
      "patients having": 59348,
      "having moderate": 34609,
      "associated use": 12460,
      "use tapentadol": 84774,
      "effectiveness treatment": 27786,
      "treatment emergent": 82571,
      "emergent adverse": 28699,
      "event teae": 29994,
      "based published": 13369,
      "dosing patterns": 26323,
      "costs results": 20905,
      "results initial": 71735,
      "better outcomes": 13720,
      "initial oxycodone": 38861,
      "patients achieving": 58929,
      "achieving adequate": 7332,
      "adequate pain": 7961,
      "days days": 22508,
      "hours total": 35872,
      "total costs": 81792,
      "slightly higher": 76254,
      "higher initial": 35254,
      "nearly twice": 48873,
      "patients initial": 59409,
      "arm 29": 11666,
      "29 vs": 3618,
      "vs 15": 86537,
      "achieve adequate": 7290,
      "analyses tapentadol": 10615,
      "outcomes pain": 54068,
      "associated tapentadol": 12451,
      "patient response": 58747,
      "response tapentadol": 71375,
      "daily average": 21700,
      "average consumption": 12880,
      "limited use": 41966,
      "randomized trial": 67199,
      "practice settings": 63416,
      "safety long": 73162,
      "term therapy": 80670,
      "therapy oxycodone": 81041,
      "skin ulcers": 76209,
      "design open": 23732,
      "open study": 51200,
      "setting patients": 74807,
      "patients consecutive": 59132,
      "consecutive patients": 19562,
      "patients referred": 59872,
      "long standing": 42319,
      "study cases": 77982,
      "according world": 7066,
      "health organization": 34740,
      "organization guidelines": 53767,
      "guidelines oxycodone": 34454,
      "dosage 10": 25741,
      "10 20mg": 691,
      "mean period": 43838,
      "standard deviation": 76896,
      "evaluate efficacy": 29792,
      "safety opioid": 73174,
      "therapy following": 81014,
      "parameters recorded": 58173,
      "time intervals": 81279,
      "scale vas": 73570,
      "vas pain": 86009,
      "pittsburgh sleep": 61567,
      "sleep quality": 76232,
      "quality index": 66714,
      "index psqi": 38207,
      "sleep night": 76228,
      "assessment questionnaire": 12134,
      "disability index": 25073,
      "use rescue": 84695,
      "rescue therapy": 70975,
      "routine laboratory": 72863,
      "assessment results": 12135,
      "results month": 71784,
      "month therapy": 47414,
      "therapy patients": 81045,
      "patients experienced": 59276,
      "relief pain": 70160,
      "pain vas": 57970,
      "vas decreased": 86003,
      "decreased 93": 22974,
      "56 10": 5095,
      "10 0001": 654,
      "0001 better": 56,
      "better quality": 13734,
      "quality sleep": 66761,
      "increased 68": 37864,
      "75 0001": 5691,
      "72 95": 5614,
      "remained stable": 70274,
      "increase daily": 37739,
      "daily dosage": 21719,
      "dosage oxycodone": 25756,
      "observed effects": 50677,
      "constipation present": 19778,
      "effective safe": 27694,
      "safe treatment": 73105,
      "pain severe": 57820,
      "markedly improved": 43401,
      "improved patient": 37120,
      "patient compliance": 58568,
      "procedures effective": 65302,
      "necessary sensitive": 48891,
      "lacking study": 41067,
      "primary aims": 64987,
      "secondary aims": 74205,
      "interactions oxycodone": 39401,
      "oxycodone cyp3a": 54918,
      "healthy nondependent": 34833,
      "nondependent opioid": 49727,
      "subject double": 78626,
      "controlled inpatient": 20499,
      "study participants": 78359,
      "received following": 68150,
      "following oral": 32167,
      "oral doses": 53526,
      "mg days": 45869,
      "mg day": 45849,
      "oxycodone hours": 55167,
      "hour urine": 35721,
      "samples collected": 73332,
      "collected study": 17486,
      "study pharmacodynamic": 78403,
      "pharmacodynamic outcomes": 61071,
      "outcomes assessed": 54011,
      "experimental sessions": 30673,
      "sessions days": 74742,
      "10 hours": 771,
      "hours oxycodone": 35804,
      "oxycodone noroxycodone": 55538,
      "present drug": 64617,
      "slightly greater": 76252,
      "safely tolerated": 73110,
      "urinary concentrations": 84054,
      "16 hours": 1875,
      "decrease observed": 22906,
      "72 hours": 5618,
      "hours postdose": 35820,
      "overall low": 54209,
      "monitor adherence": 47306,
      "highly viscous": 35408,
      "currently development": 21494,
      "objective determine": 50397,
      "determine abuse": 23987,
      "conditions relative": 19328,
      "relative oxycodone": 69757,
      "oxycodone er": 55037,
      "er immediate": 29423,
      "fasted conditions": 31206,
      "placebo treatment": 61845,
      "treatment group": 82596,
      "evaluate abuse": 29765,
      "fed fasted": 31318,
      "design phase": 23747,
      "phase randomized": 61314,
      "dummy placebo": 27132,
      "active controlled": 7495,
      "setting single": 74821,
      "single site": 76140,
      "patients healthy": 59352,
      "healthy men": 34831,
      "men women": 44804,
      "18 50": 2051,
      "50 years": 4910,
      "users interventions": 85249,
      "er 40": 29391,
      "mg crushed": 45843,
      "crushed oxycodone": 21343,
      "measures primary": 44084,
      "endpoint drug": 28886,
      "pharmacodynamic parameters": 61072,
      "secondary endpoints": 74225,
      "endpoints included": 28911,
      "pharmacodynamic measures": 61067,
      "measures results": 44097,
      "results treatment": 72039,
      "potential compared": 63148,
      "parameters primary": 58170,
      "group showed": 34005,
      "similar results": 75991,
      "conclusions abuse": 19026,
      "known abuse": 40897,
      "including oxycodone": 37659,
      "associated reduced": 12400,
      "reduced risk": 68980,
      "risk potential": 72638,
      "potential abuse": 63120,
      "prevalent distressing": 64827,
      "symptoms patients": 79903,
      "terminally ill": 80688,
      "ill cancer": 36619,
      "effects morphine": 28006,
      "little known": 42160,
      "known effects": 40910,
      "effectiveness oxycodone": 27774,
      "injectable form": 38911,
      "compound oxycodone": 18603,
      "subcutaneous route": 78607,
      "136 patients": 1535,
      "patients effect": 59234,
      "varying degrees": 85994,
      "effects observed": 28030,
      "observed results": 50715,
      "continuous subcutaneous": 20188,
      "cancer background": 14763,
      "alo 02": 9653,
      "pellets extended": 60377,
      "surrounding sequestered": 79676,
      "sequestered naltrexone": 74636,
      "intended deter": 39204,
      "abuse objective": 6789,
      "potential intravenous": 63180,
      "solution compared": 76438,
      "users methods": 85254,
      "treatment phases": 82762,
      "treatments included": 82910,
      "included oxycodone": 37499,
      "mg plus": 46164,
      "naltrexone hydrochloride": 48542,
      "hydrochloride mg": 36029,
      "mg placebo": 46161,
      "sodium chloride": 76407,
      "injection primary": 38966,
      "peak effects": 60307,
      "max area": 43546,
      "results thirty": 72010,
      "thirty participants": 81105,
      "randomized treatment": 67196,
      "completed treatments": 18510,
      "treatments study": 82932,
      "differences max": 24755,
      "max drug": 43550,
      "resulted significantly": 71522,
      "lower scores": 42701,
      "scores oxycodone": 73936,
      "oxycodone drug": 55008,
      "58 vs": 5164,
      "high max": 35121,
      "vs 93": 86631,
      "12 vs": 1368,
      "133 respectively": 1527,
      "0001 comparisons": 57,
      "experienced adverse": 30599,
      "oxycodone 27": 54545,
      "versus intravenous": 86127,
      "02 12": 352,
      "conclusion intravenous": 18917,
      "potential assessed": 63136,
      "high intravenous": 35115,
      "users compared": 85231,
      "large inter": 41132,
      "inter individual": 39353,
      "individual variability": 38314,
      "response opioids": 71355,
      "opioids high": 52948,
      "high prevalence": 35151,
      "prevalence adverse": 64770,
      "events associated": 30014,
      "clinical importance": 16826,
      "able predict": 6572,
      "quantitative sensory": 66809,
      "sensory testing": 74576,
      "testing qst": 80838,
      "40 healthy": 4338,
      "predict analgesic": 63547,
      "effects oral": 28049,
      "latency onset": 41227,
      "intensity tolerance": 39320,
      "tolerance cold": 81576,
      "test cpt": 80761,
      "measuring heat": 44106,
      "heat cold": 34879,
      "cold pain": 17422,
      "pain thresholds": 57917,
      "inhibitory control": 38818,
      "like effect": 41776,
      "temporal summation": 80588,
      "summation ts": 79113,
      "results showed": 71946,
      "showed oxycodone": 75284,
      "significantly elevated": 75696,
      "pain significantly": 57839,
      "reduced pain": 68966,
      "heat pain": 34883,
      "reduction pain": 69085,
      "intensity response": 39305,
      "tolerance cpt": 81578,
      "38 11": 4226,
      "17 results": 1986,
      "qst potential": 66649,
      "response opioid": 71353,
      "treatment background": 82455,
      "background effective": 13041,
      "effective treatment": 27713,
      "pain rapid": 57462,
      "action important": 7430,
      "antinociceptive profile": 11249,
      "blind active": 13916,
      "design population": 23751,
      "population healthy": 62336,
      "volunteers methods": 86423,
      "methods female": 45339,
      "randomized receive": 67161,
      "receive 20": 68042,
      "500 mg": 4918,
      "electrical pain": 28508,
      "pain threshold": 57915,
      "time response": 81365,
      "data analysed": 21870,
      "pharmacodynamic model": 61068,
      "analgesia onset": 10036,
      "median 95": 44194,
      "analysis results": 10753,
      "produced rapid": 65403,
      "rapid increase": 67386,
      "pain analgesia": 56443,
      "67 versus": 5480,
      "30 16": 3667,
      "21 67": 2958,
      "oxycodone conclusions": 54838,
      "conclusions analgesic": 19030,
      "oxycodone successfully": 55955,
      "quantified using": 66782,
      "using mathematical": 85483,
      "mathematical model": 43533,
      "method allows": 45167,
      "allows quantification": 9650,
      "quantification variety": 66777,
      "data sets": 22106,
      "defined 30": 23121,
      "varied significantly": 85940,
      "15 min": 1770,
      "radiofrequency ablation": 66965,
      "recently introduced": 68444,
      "patient comfort": 58565,
      "painful procedure": 58010,
      "procedure purpose": 65281,
      "investigate analgesic": 39997,
      "safety single": 73220,
      "single intravenous": 76113,
      "injection oxycodone": 38962,
      "procedure patients": 65279,
      "methods total": 45611,
      "total 120": 81720,
      "american society": 9799,
      "society anesthesiologists": 76374,
      "anesthesiologists class": 10958,
      "class ii": 16660,
      "patients elective": 59242,
      "ultrasound guided": 83433,
      "guided percutaneous": 34412,
      "trial patients": 83047,
      "patients randomized": 59730,
      "receive single": 68076,
      "group continuous": 33709,
      "continuous infusion": 20169,
      "infusion remifentanil": 38725,
      "remifentanil group": 70323,
      "group groups": 33808,
      "groups received": 34285,
      "vas rescue": 86016,
      "rescue analgesic": 70934,
      "addition patient": 7824,
      "satisfaction scale": 73432,
      "determined results": 24085,
      "results vas": 72050,
      "vas score": 86020,
      "score group": 73748,
      "group significantly": 34015,
      "lower group": 42622,
      "group hours": 33818,
      "patients group": 59335,
      "group required": 33982,
      "analgesics significantly": 10501,
      "significantly later": 75762,
      "doses 24": 26133,
      "body movements": 14203,
      "complications including": 18561,
      "excessive sedation": 30463,
      "chest wall": 15975,
      "patients patient": 59635,
      "satisfaction score": 73433,
      "score significantly": 73789,
      "higher group": 35247,
      "group group": 33790,
      "group conclusion": 33696,
      "provides better": 66204,
      "patient experience": 58636,
      "procedural pain": 65263,
      "pain better": 56495,
      "better associated": 13706,
      "associated increase": 12296,
      "increase adverse": 37729,
      "effects objective": 28027,
      "study develop": 78116,
      "assess opioid": 11941,
      "prescribing behavior": 64035,
      "behavior evaluation": 13528,
      "acting er": 7381,
      "er la": 29431,
      "la opioid": 40963,
      "risk evaluation": 72555,
      "evaluation mitigation": 29956,
      "mitigation strategies": 46769,
      "strategies rems": 77424,
      "selected using": 74400,
      "published guidelines": 66429,
      "examined using": 30417,
      "medicare patients": 44439,
      "oxycodone ero": 55043,
      "july 2006": 40509,
      "2006 july": 2483,
      "included prescribing": 37517,
      "prescribing opioid": 64091,
      "opioid tolerant": 52431,
      "analgesics non": 10455,
      "non opioid": 49646,
      "tolerant patients": 81611,
      "patients prescribing": 59684,
      "drug screens": 26785,
      "days opioid": 22566,
      "opioid usage": 52457,
      "oxycodone equivalents": 55036,
      "days primary": 22597,
      "30 days": 3724,
      "prior opioid": 65158,
      "percent opioid": 60467,
      "met primary": 44879,
      "primary opioid": 65050,
      "prescription filled": 64221,
      "50 secondary": 4898,
      "prior prescription": 65164,
      "prescription days": 64194,
      "days supply": 22634,
      "consumed percent": 19844,
      "primary secondary": 65107,
      "treatment drug": 82558,
      "older patients": 51037,
      "patients likely": 59448,
      "likely opioid": 41822,
      "prescription conclusions": 64185,
      "changes prescribing": 15814,
      "prescribing behaviors": 64036,
      "behaviors opioid": 13564,
      "used evaluate": 84931,
      "85 years": 5992,
      "years likely": 87608,
      "prior receiving": 65167,
      "receiving prescriptions": 68374,
      "ero background": 29506,
      "background opioids": 13118,
      "opioids commonly": 52799,
      "manage chronic": 43118,
      "pain traditional": 57929,
      "traditional opioids": 81987,
      "opioids effective": 52872,
      "effective reducing": 27685,
      "reducing pain": 69025,
      "pain associated": 56472,
      "induced effects": 38409,
      "treatment effectiveness": 82567,
      "studies shown": 77843,
      "er lower": 29436,
      "lower incidence": 42628,
      "incidence gastrointestinal": 37276,
      "oxycodone controlled": 54880,
      "equianalgesic doses": 29258,
      "doses objective": 26225,
      "ii long": 36562,
      "opioids methods": 53050,
      "care costs": 15016,
      "acting formulations": 7385,
      "formulations tapentadol": 32410,
      "morphine hydromorphone": 47721,
      "hydromorphone oxymorphone": 36211,
      "oxymorphone fentanyl": 56244,
      "estimates incidence": 29649,
      "incidence prevalence": 37305,
      "base case": 13267,
      "assumed 10": 12507,
      "er 10": 29384,
      "10 decrease": 758,
      "way sensitivity": 86779,
      "sensitivity analysis": 74558,
      "reported results": 70642,
      "500 000": 4915,
      "000 members": 25,
      "formulary associated": 32319,
      "associated annual": 12221,
      "cost decreases": 20863,
      "lower daily": 42595,
      "consumption fewer": 19925,
      "er versus": 29478,
      "versus oxycodone": 86139,
      "leading reduced": 41312,
      "resource utilization": 71127,
      "months treatment": 47478,
      "analyses showed": 10611,
      "results sensitive": 71936,
      "sensitive drug": 74542,
      "conclusions results": 19200,
      "10 oxycodone": 884,
      "decrease overall": 22913,
      "mg hour": 45905,
      "cmax tmax": 17097,
      "difference 05": 24566,
      "auc 48": 12625,
      "48 59": 4691,
      "59 52": 5183,
      "52 vs": 4997,
      "vs 49": 86585,
      "levofloxacin oxycodone": 41625,
      "decrease auc": 22887,
      "early pain": 27261,
      "analgesic option": 10282,
      "aim evaluate": 9385,
      "evaluate analgesic": 29768,
      "pharmacokinetics single": 61191,
      "dose epidural": 25896,
      "multimodal analgesia": 48198,
      "women 60": 87196,
      "aged 23": 9177,
      "23 71": 3083,
      "71 years": 5603,
      "years undergoing": 87682,
      "group 31": 33597,
      "epidural saline": 29191,
      "kg iv": 40751,
      "group 29": 33592,
      "randomised double": 67020,
      "active control": 7493,
      "pharmacokinetic model": 61118,
      "developed using": 24198,
      "using population": 85567,
      "concentrations obtained": 18783,
      "obtained patients": 50774,
      "patients data": 59167,
      "data published": 22078,
      "studies primary": 77816,
      "rescue analgesia": 70925,
      "analgesia hours": 9990,
      "31 patients": 3876,
      "group 26": 33589,
      "26 29": 3428,
      "29 patients": 3612,
      "patients iv": 59427,
      "group needed": 33872,
      "needed fentanyl": 49002,
      "median interquartile": 44228,
      "interquartile range": 39514,
      "fentanyl doses": 31468,
      "group 008": 33536,
      "concentrations similar": 18814,
      "concentrations 100": 18737,
      "100 fold": 990,
      "population model": 62358,
      "model indicated": 47053,
      "oxycodone injected": 55282,
      "systemic circulation": 80021,
      "compared administration": 18094,
      "administration hours": 8273,
      "hours laparoscopic": 35789,
      "laparoscopic surgery": 41110,
      "old female": 51005,
      "local hospital": 42207,
      "immunoassay screen": 36773,
      "tricyclic antidepressants": 83216,
      "performed urine": 60645,
      "urine sample": 84082,
      "sample reported": 73312,
      "despite resuscitative": 23903,
      "pronounced dead": 65681,
      "specimens submitted": 76645,
      "drugs using": 27099,
      "chromatographic techniques": 16151,
      "techniques quantitation": 80549,
      "detection confirmation": 23954,
      "performed gas": 60591,
      "drug detected": 26582,
      "following concentrations": 32114,
      "gastric contents": 32853,
      "33 mg": 3994,
      "mg 33": 45745,
      "34 mg": 4025,
      "23 mg": 3102,
      "ml addition": 46847,
      "testing urine": 80846,
      "positive opiate": 62471,
      "opiate class": 51293,
      "class drugs": 16657,
      "case report": 15185,
      "report demonstrates": 70451,
      "demonstrates unusual": 23383,
      "cause death": 15347,
      "urine screening": 84086,
      "screening tests": 74050,
      "toxicological testing": 81945,
      "deaths study": 22786,
      "study measured": 78304,
      "effects single": 28162,
      "single 10": 76041,
      "dose immediate": 25926,
      "oxycodone healthy": 55154,
      "older 65": 51029,
      "middle aged": 46404,
      "aged 35": 9184,
      "55 years": 5083,
      "years adults": 87559,
      "suffering chronic": 78965,
      "daily pain": 21792,
      "pain seventy": 57819,
      "seventy participants": 74886,
      "completed separate": 18494,
      "study days": 78052,
      "days blind": 22491,
      "medication condition": 44474,
      "condition placebo": 19283,
      "minutes postdose": 46660,
      "pupil size": 66489,
      "physiological effects": 61460,
      "effects medication": 27987,
      "peaked approximately": 60328,
      "approximately 90": 11577,
      "90 120": 6074,
      "120 minutes": 1409,
      "01 significant": 326,
      "significant declines": 75458,
      "sustained attention": 79777,
      "working memory": 87297,
      "hour postdose": 35711,
      "postdose compared": 62645,
      "compared baseline": 18099,
      "baseline age": 13416,
      "age groups": 9077,
      "return baseline": 72186,
      "baseline hours": 13437,
      "age interaction": 9083,
      "groups exhibited": 34196,
      "exhibited similar": 30517,
      "older adults": 51031,
      "pharmacodynamic changes": 61059,
      "response 10": 71330,
      "similar observed": 75957,
      "aged adults": 9201,
      "perspective study": 60970,
      "study findings": 78210,
      "findings indicate": 31792,
      "avoid prescribing": 12962,
      "opioids older": 53115,
      "higher risk": 35317,
      "younger adults": 87732,
      "adults objective": 8571,
      "pharmacodynamics safety": 61091,
      "safety intranasally": 73159,
      "intranasally administered": 39763,
      "administered crushed": 8115,
      "crushed reformulated": 21346,
      "tablets orf": 80185,
      "placebo randomized": 61807,
      "positive placebo": 62476,
      "controlled crossover": 20477,
      "study enrolled": 78152,
      "enrolled healthy": 29000,
      "dependent recreational": 23531,
      "users recent": 85266,
      "history intranasal": 35461,
      "active treatments": 7540,
      "scales vas": 73592,
      "subjective drug": 78646,
      "intranasal irritation": 39753,
      "events vital": 30133,
      "signs laboratory": 75875,
      "laboratory tests": 41035,
      "assessed 24": 11980,
      "crushed orf": 21342,
      "yielded reduced": 87699,
      "crushed oc": 21341,
      "effects pharmacodynamic": 28088,
      "hours versus": 35875,
      "versus oc": 86135,
      "high vas": 35191,
      "values significantly": 85853,
      "lower 05": 42568,
      "orf versus": 53741,
      "unexpected safety": 83720,
      "observed compared": 50663,
      "compared oc": 18223,
      "administered orf": 8157,
      "orf associated": 53739,
      "associated lower": 12325,
      "lower delayed": 42598,
      "decreased drug": 22992,
      "intranasal tolerability": 39761,
      "potential intranasal": 63179,
      "abuse significant": 6874,
      "potential studies": 63234,
      "appropriate post": 11511,
      "post marketing": 62579,
      "marketing studies": 43427,
      "studies required": 77829,
      "impact reduction": 36850,
      "study real": 78453,
      "diversion purpose": 25605,
      "study document": 78125,
      "substantial increase": 78849,
      "use hydrocodone": 84407,
      "oxycodone addiction": 54677,
      "treatment population": 82767,
      "population study": 62391,
      "study consisted": 78039,
      "retrospective review": 72158,
      "review medical": 72320,
      "records patients": 68721,
      "patients admitted": 58951,
      "literature review": 42127,
      "review conducted": 72277,
      "conducted medical": 19375,
      "groups reports": 34296,
      "including drug": 37612,
      "abuse warning": 6909,
      "warning network": 86719,
      "survey drug": 79708,
      "144 patients": 1647,
      "patients 27": 58847,
      "prescription opiate": 64270,
      "opiate medications": 51303,
      "vicodin hydrocodone": 86199,
      "hydrocodone 53": 36051,
      "oxycodone 19": 54528,
      "physicians commonly": 61437,
      "dependence opiate": 23480,
      "medications included": 44629,
      "related diagnoses": 69588,
      "patients care": 59050,
      "care physicians": 15059,
      "drug dependence": 26579,
      "risk developing": 72543,
      "adverse consequences": 8620,
      "consequences prescription": 19595,
      "medications objective": 44651,
      "objective opioids": 50457,
      "opioids recommended": 53242,
      "severe cancer": 74918,
      "oxycodone commonly": 54808,
      "used opioids": 85051,
      "opioids metabolized": 53046,
      "metabolized liver": 44997,
      "cyp3a4 cyp2d6": 21635,
      "sectional study": 74287,
      "assess relationship": 11959,
      "relationship oxycodone": 69722,
      "cyp2d6 genotypes": 21606,
      "poor metaboliser": 62262,
      "metaboliser pm": 44917,
      "ultra rapid": 83422,
      "rapid metaboliser": 67387,
      "cohort patients": 17367,
      "pain methods": 57178,
      "methods patients": 45424,
      "patients genotyped": 59325,
      "metabolites determined": 44967,
      "determined pain": 24079,
      "pain assessed": 56461,
      "assessed using": 12080,
      "using brief": 85330,
      "brief pain": 14429,
      "pain inventory": 56974,
      "inventory bpi": 39976,
      "eortc qlq": 29118,
      "qlq c30": 66632,
      "c30 used": 14645,
      "assess symptoms": 11966,
      "symptoms tiredness": 79908,
      "tiredness nausea": 81445,
      "cognitive function": 17324,
      "function assessed": 32629,
      "mini mental": 46563,
      "mental state": 44828,
      "examination associations": 30324,
      "associations examined": 12494,
      "analyses variance": 10621,
      "variance anova": 85904,
      "covariance ancova": 21008,
      "ordinal logistic": 53733,
      "logistic regressions": 42279,
      "results sample": 71930,
      "sample consisted": 73299,
      "lower oxymorphone": 42667,
      "oxymorphone noroxymorphone": 56267,
      "concentrations oxymorphone": 18800,
      "oxymorphone oxycodone": 56273,
      "oxycodone ratios": 55801,
      "pm em": 62039,
      "intensity nausea": 39270,
      "nausea tiredness": 48785,
      "tiredness cognitive": 81443,
      "conclusion cyp2d6": 18886,
      "genotypes did": 33102,
      "influence pain": 38597,
      "control adverse": 20272,
      "nausea sedation": 48782,
      "study patients": 78363,
      "oxycodone cancer": 54764,
      "pain objective": 57258,
      "resistant opioids": 71103,
      "opioids play": 53181,
      "play important": 61990,
      "important role": 37030,
      "abuse behaviors": 6655,
      "chart review": 15926,
      "review examine": 72300,
      "examine reformulation": 30356,
      "reformulation oxycontin": 69216,
      "resistant properties": 71104,
      "impact oxycodone": 36828,
      "oxycodone positive": 55704,
      "urine drug": 84071,
      "receiving methadone": 68351,
      "maintenance therapy": 42920,
      "therapy mmt": 81027,
      "data time": 22142,
      "setting study": 74827,
      "female patients": 31372,
      "patients eligible": 59243,
      "diagnosis opioid": 24336,
      "opioid dependency": 51703,
      "positive uds": 62501,
      "period intervention": 60736,
      "noninterventional study": 49753,
      "study main": 78294,
      "outcome measure": 53925,
      "outcome number": 53959,
      "results demonstrated": 71658,
      "demonstrated marked": 23354,
      "marked reduction": 43395,
      "reduction oxycodone": 69084,
      "significant decreases": 75465,
      "relative baseline": 69737,
      "baseline oxycodone": 13446,
      "morphine related": 47910,
      "remained relatively": 70269,
      "relatively stable": 69792,
      "differences noted": 24760,
      "conclusions introduction": 19105,
      "associated statistically": 12444,
      "population methadone": 62354,
      "methadone maintained": 45091,
      "maintained patients": 42891,
      "despite oxycodone": 23893,
      "14 hydroxy": 1598,
      "hydroxy methoxy": 36238,
      "methoxy 17": 45638,
      "received drug": 68144,
      "reports documented": 70723,
      "relevance abuse": 70028,
      "abuse mechanism": 6771,
      "study characterize": 77985,
      "characterize analgesic": 15890,
      "oxycodone mechanism": 55378,
      "effects terms": 28180,
      "oxycodone potent": 55713,
      "potent antinociceptive": 63098,
      "antinociceptive effects": 11245,
      "plate tail": 61971,
      "flick assays": 31915,
      "acting mu": 7391,
      "discriminative stimulus": 25279,
      "positive reinforcer": 62482,
      "completely suppressed": 18518,
      "withdrawal signs": 87156,
      "signs morphine": 75878,
      "morphine dependent": 47640,
      "rhesus monkeys": 72448,
      "monkeys results": 47352,
      "suggest analgesic": 78984,
      "analgesic abuse": 10136,
      "liability effects": 41641,
      "oxycodone likely": 55337,
      "mediated mu": 44314,
      "receptors provide": 68559,
      "02 abuse": 358,
      "formulation consisting": 32336,
      "02 administered": 361,
      "following drug": 32127,
      "eligible participants": 28588,
      "ir 30": 40204,
      "mg primary": 46182,
      "measured visual": 44008,
      "effect emax": 27452,
      "scores versus": 74009,
      "60 vs": 5281,
      "respectively high": 71198,
      "25 vs": 3390,
      "vs 86": 86626,
      "27 vs": 3509,
      "respectively 28": 71156,
      "28 0001": 3531,
      "0001 adverse": 55,
      "events occurred": 30080,
      "occurred frequently": 50834,
      "frequently oxycodone": 32565,
      "02 placebo": 374,
      "scores drug": 73871,
      "positive subjective": 62491,
      "subjective measures": 78655,
      "abuse deterrence": 6680,
      "tolerability controlled": 81526,
      "treatment postoperative": 82771,
      "pain head": 56819,
      "head neck": 34649,
      "conducted prospective": 19388,
      "prospective observational": 65841,
      "83 patients": 5935,
      "patients moderate": 59518,
      "operations patients": 51238,
      "received general": 68153,
      "general anesthesia": 32958,
      "anesthesia propofol": 10936,
      "propofol fentanyl": 65735,
      "oxycodone 20": 54529,
      "12 12": 1211,
      "12 day": 1276,
      "day 10": 22238,
      "mg second": 46214,
      "assessed frequency": 12005,
      "frequency intensity": 32515,
      "intensity adverse": 39225,
      "effects intensity": 27957,
      "intensity postoperative": 39293,
      "verbal numeric": 86071,
      "numeric scale": 50305,
      "analgesia 12": 9892,
      "hours administration": 35748,
      "administration drug": 8252,
      "13 days": 1484,
      "days oxycodone": 22573,
      "oxycodone dose": 54990,
      "dose results": 26069,
      "results common": 71633,
      "common adverse": 17728,
      "events nausea": 30074,
      "vomiting dizziness": 86454,
      "dizziness pruritus": 25642,
      "constipation urinary": 19793,
      "urinary retention": 84060,
      "mild adverse": 46424,
      "hours use": 35874,
      "oxycodone significant": 55908,
      "pain remained": 57608,
      "end study": 28818,
      "rescue medication": 70948,
      "medication requested": 44559,
      "higher frequency": 35245,
      "frequency opioid": 32519,
      "dose reduced": 26041,
      "conclusion controlled": 18880,
      "safe tolerated": 73103,
      "tolerated caused": 81623,
      "caused significant": 15388,
      "decrease post": 22919,
      "post operative": 62588,
      "operative pain": 51262,
      "objective oxycodone": 50459,
      "oxycodone daily": 54922,
      "daily ood": 21771,
      "therapeutic efficacy": 80940,
      "safety compared": 73129,
      "compared established": 18157,
      "established oxycodone": 29589,
      "oxycodone twice": 56034,
      "daily otd": 21784,
      "design methods": 23723,
      "blind multicenter": 13943,
      "inferiority study": 38533,
      "conducted patients": 19385,
      "patients 68": 58892,
      "chronic malignant": 16205,
      "pain new": 57237,
      "total daily": 81793,
      "daily doses": 21737,
      "40 120": 4311,
      "times daily": 81417,
      "current pain": 21452,
      "pain 100": 56361,
      "pain assessments": 56471,
      "safety parameters": 73196,
      "treatment day": 82539,
      "run phase": 73040,
      "phase results": 61318,
      "difference analgesic": 24595,
      "ci difference": 16526,
      "difference daily": 24605,
      "mm vas": 46938,
      "difference 12": 24570,
      "relevant difference": 70052,
      "difference analgesia": 24594,
      "medication effect": 44494,
      "effect study": 27567,
      "study results": 78466,
      "difference adverse": 24591,
      "19 23": 2166,
      "23 patients": 3108,
      "experienced treatment": 30632,
      "treatment related": 82804,
      "ood otd": 51136,
      "analgesia use": 10127,
      "pain sedation": 57807,
      "reach statistical": 67930,
      "limited study": 41963,
      "study population": 78411,
      "population conclusion": 62319,
      "conclusion despite": 18890,
      "small number": 76290,
      "number patients": 50217,
      "patients short": 59973,
      "results support": 71998,
      "conclusion new": 18932,
      "efficacy pain": 28320,
      "life patients": 41719,
      "parkinson disease": 58228,
      "pain symptoms": 57893,
      "symptoms effectively": 79883,
      "different types": 24933,
      "distribution pain": 25564,
      "evaluated efficacy": 29879,
      "safety prolonged": 73212,
      "release oral": 69909,
      "combined naloxone": 17657,
      "fixed ratio": 31887,
      "oxn pr": 54420,
      "total 16": 81726,
      "patients history": 59363,
      "history pain": 35471,
      "pain minimum": 57198,
      "intensity numerical": 39278,
      "scale nrs": 73510,
      "received low": 68194,
      "dose oxn": 25983,
      "pr mg": 63336,
      "mg twice": 46249,
      "observed period": 50703,
      "period weeks": 60813,
      "weeks primary": 86944,
      "primary efficacy": 65003,
      "efficacy measure": 28291,
      "measure pain": 43940,
      "pain severity": 57824,
      "measured nrs": 43980,
      "secondary efficacy": 74214,
      "safety profile": 73203,
      "occurrence effects": 50858,
      "effects clinical": 27848,
      "clinical global": 16820,
      "global impression": 33226,
      "impression change": 37050,
      "sleep scale": 76237,
      "function index": 32651,
      "index bfi": 38188,
      "data collected": 21906,
      "collected analyzed": 17447,
      "using descriptive": 85376,
      "descriptive statistics": 23680,
      "patients completed": 59109,
      "study 14": 77882,
      "14 16": 1554,
      "reported significant": 70646,
      "relief observed": 70151,
      "observed reduction": 50713,
      "reduction nrs": 69070,
      "bpi scores": 14300,
      "dopaminergic therapy": 25730,
      "therapy required": 81060,
      "required significant": 70862,
      "significant changes": 75440,
      "changes observed": 15801,
      "observed bowel": 50654,
      "function constipation": 32639,
      "constipation symptoms": 19790,
      "symptoms measured": 79894,
      "measured bfi": 43960,
      "period similarly": 60793,
      "efficacious management": 28202,
      "patients pd": 59641,
      "patients did": 59190,
      "did experience": 24450,
      "experience significant": 30594,
      "significant effects": 75536,
      "effects constipation": 27877,
      "constipation sedation": 19784,
      "study provides": 78436,
      "provides evidence": 66215,
      "evidence opioids": 30233,
      "patients objective": 59563,
      "objective investigate": 50439,
      "investigate efficacy": 40009,
      "combination oxycodone": 17583,
      "oxycodone oc": 55552,
      "oc acetaminophen": 50796,
      "acetaminophen apap": 7152,
      "apap analgesic": 11348,
      "analgesic immediate": 10257,
      "release extended": 69853,
      "er components": 29412,
      "oc apap": 50799,
      "er patients": 29465,
      "pain using": 57961,
      "using established": 85391,
      "pain model": 57201,
      "research design": 70999,
      "trial adult": 83000,
      "adult patients": 8505,
      "included study": 37561,
      "study pain": 78355,
      "intensity score": 39308,
      "score 10": 73706,
      "10 numerical": 879,
      "bunionectomy surgery": 14484,
      "surgery randomized": 79547,
      "er placebo": 29466,
      "efficacy endpoint": 28261,
      "endpoint summed": 28904,
      "summed pain": 79115,
      "intensity difference": 39244,
      "difference 48": 24579,
      "total pain": 81877,
      "relief totpar": 70201,
      "dosing intervals": 26315,
      "time perceptible": 81320,
      "perceptible meaningful": 60526,
      "patients 30": 58852,
      "30 reduction": 3792,
      "intensity scores": 39310,
      "scores results": 73977,
      "patients enrolled": 59247,
      "131 completed": 1520,
      "study mean": 78300,
      "mean se": 43875,
      "er group": 29421,
      "group 66": 33636,
      "placebo group": 61732,
      "group 0001": 33525,
      "analyzed median": 10843,
      "median times": 44294,
      "relief significantly": 70186,
      "patients showed": 59974,
      "generally tolerated": 33027,
      "limitation study": 41897,
      "efficacious generally": 28200,
      "pain providing": 57445,
      "approximately 30": 11567,
      "sustained pain": 79780,
      "relief 12": 70092,
      "dosing period": 26324,
      "period objective": 60757,
      "objective relative": 50484,
      "relative analgesic": 69736,
      "single doses": 76095,
      "doses oral": 26230,
      "oxycodone oral": 55578,
      "morphine compared": 47614,
      "blind trial": 13992,
      "trial using": 83095,
      "using postoperative": 85569,
      "model methods": 47057,
      "following abdominal": 32094,
      "abdominal hysterectomy": 6525,
      "hysterectomy received": 36326,
      "received single": 68271,
      "single oral": 76130,
      "doses controlled": 26163,
      "morphine 45": 47559,
      "mg 90": 45777,
      "90 mg": 6103,
      "30 min": 3766,
      "hourly dosing": 35723,
      "dosing 12": 26304,
      "estimates relative": 29652,
      "relative potency": 69759,
      "oxycodone times": 55996,
      "morphine total": 47956,
      "confidence limits": 19486,
      "peak effect": 60305,
      "oxycodone doses": 55000,
      "doses 20": 26129,
      "mg comparable": 45825,
      "morphine doses": 47651,
      "mg respectively": 46204,
      "respectively total": 71255,
      "peak analgesic": 60301,
      "effects higher": 27940,
      "higher doses": 35232,
      "relief approximately": 70101,
      "patients reported": 59884,
      "similar opioids": 75959,
      "opioids conclusion": 52811,
      "conclusion oral": 18943,
      "potent oral": 63114,
      "morphine single": 47925,
      "patients oral": 59597,
      "oral morphine": 53572,
      "initial oral": 38860,
      "morphine dose": 47650,
      "recommended background": 68617,
      "vitro experiments": 86359,
      "metabolites oxycodone": 44979,
      "receptor agonists": 68470,
      "animal studies": 11000,
      "studies date": 77689,
      "failed demonstrate": 31140,
      "demonstrate significant": 23325,
      "demethylated metabolite": 23257,
      "metabolite oxymorphone": 44957,
      "clinical effects": 16799,
      "parent drug": 58193,
      "oxycodone pharmacodynamics": 55675,
      "examined methods": 30392,
      "healthy human": 34818,
      "human volunteers": 35979,
      "measurements included": 44019,
      "included time": 37567,
      "time course": 81229,
      "course plasma": 20999,
      "urinary excretion": 84055,
      "demethylation keto": 23261,
      "keto reduction": 40621,
      "miosis subjective": 46672,
      "subjective opioid": 78657,
      "opioid effects": 51758,
      "effects contribution": 27880,
      "pharmacodynamic modeling": 61069,
      "human study": 35974,
      "measurements opioid": 44025,
      "binding activation": 13812,
      "vivo studies": 86382,
      "brain distribution": 14337,
      "distribution oxycodone": 25563,
      "rats results": 67887,
      "urinary metabolites": 84059,
      "cytochrome p450": 21652,
      "p450 cyp": 56305,
      "cyp 3a": 21571,
      "mediated demethylation": 44307,
      "demethylation oxycodone": 23264,
      "noroxycodone noroxymorphone": 49933,
      "alpha beta": 9665,
      "45 21": 4568,
      "cyp2d6 mediated": 21611,
      "demethylation oxymorphone": 23266,
      "dose respectively": 26062,
      "respectively noroxycodone": 71219,
      "noroxymorphone major": 49948,
      "half lives": 34521,
      "longer oxycodone": 42381,
      "oxycodone uptake": 56045,
      "lower compared": 42586,
      "pupil constriction": 66486,
      "drug oxycodone": 26736,
      "contribute central": 20224,
      "central effects": 15586,
      "low potency": 42536,
      "potency low": 63076,
      "result poor": 71486,
      "cyp3a mediated": 21631,
      "metabolic pathway": 44907,
      "pathway oxycodone": 58516,
      "oxycodone humans": 55171,
      "central opioid": 15608,
      "objective chronic": 50385,
      "pain leading": 57001,
      "leading cause": 41300,
      "cause disability": 15351,
      "burden opioids": 14603,
      "opioids widely": 53392,
      "managing chronic": 43284,
      "pain high": 56824,
      "high incidence": 35110,
      "incidence effects": 37271,
      "effects main": 27976,
      "main reason": 42854,
      "reason discontinuation": 68014,
      "tolerability opioids": 81540,
      "opioids tapentadol": 53332,
      "direct comparison": 25043,
      "drugs available": 26892,
      "available literature": 12819,
      "effectiveness drugs": 27759,
      "drugs previously": 27045,
      "previously assessed": 64934,
      "assessed objective": 12024,
      "analysis clinical": 10648,
      "er treatment": 29477,
      "treatment musculoskeletal": 82673,
      "musculoskeletal pain": 48370,
      "indirect comparison": 38283,
      "methods structured": 45584,
      "conducted identify": 19366,
      "published data": 66427,
      "data health": 21977,
      "economic model": 27312,
      "model authors": 47028,
      "performed meta": 60603,
      "analysis selected": 10762,
      "treatment effect": 82563,
      "effect risk": 27553,
      "risk ratio": 72648,
      "ratio calculated": 67764,
      "calculated compared": 14688,
      "active treatment": 7538,
      "treatment cr": 82530,
      "following outcomes": 32178,
      "discontinuation rate": 25227,
      "rate adverse": 67442,
      "events gastrointestinal": 30048,
      "effects central": 27844,
      "nervous cns": 49136,
      "cns effects": 17117,
      "compare cost": 18011,
      "health states": 34776,
      "patients treatment": 60073,
      "treatment occurrence": 82693,
      "occurrence adverse": 50853,
      "treatment discontinuation": 82552,
      "treatment treatment": 82878,
      "events results": 30112,
      "results drugs": 71669,
      "showed significant": 75295,
      "significant clinical": 75444,
      "clinical advantage": 16753,
      "oxycodone tapentadol": 55989,
      "er resulted": 29469,
      "events secondary": 30119,
      "reduction constipation": 69050,
      "compared cr": 18127,
      "showed favorable": 75247,
      "life years": 41744,
      "qaly gain": 66624,
      "impact tapentadol": 36852,
      "events related": 30107,
      "conclusion tapentadol": 19010,
      "effective interventions": 27631,
      "er shown": 29470,
      "shown provide": 75350,
      "provide better": 66035,
      "better clinical": 13708,
      "clinical outcomes": 16851,
      "outcomes lower": 54047,
      "hydrochloride formulation": 36020,
      "indicated moderate": 38239,
      "pain designed": 56699,
      "intranasal intravenous": 39751,
      "opioids objectives": 53109,
      "objectives primary": 50579,
      "study determine": 78106,
      "tablets fasted": 80157,
      "secondary objectives": 74234,
      "effects pharmacokinetics": 28089,
      "bioavailability oxycodone": 13839,
      "marketed oxycodone": 43421,
      "evaluate single": 29848,
      "label single": 40998,
      "dose randomized": 26025,
      "healthy adults": 34815,
      "following treatments": 32219,
      "separated washout": 74592,
      "period days": 60722,
      "mg fasted": 45889,
      "mg high": 45903,
      "high fat": 35099,
      "fat high": 31227,
      "high calorie": 35073,
      "pharmacologic effects": 61195,
      "fed state": 31320,
      "90 cis": 6081,
      "80 125": 5826,
      "max auc": 43548,
      "enrolled study": 29024,
      "69 mean": 5522,
      "mean sd": 43856,
      "sd age": 74070,
      "age 32": 8992,
      "32 11": 3903,
      "11 years": 1159,
      "years mean": 87611,
      "mean weight": 43907,
      "weight 75": 86972,
      "kg plasma": 40788,
      "dose proportional": 26023,
      "auc auc": 12628,
      "concomitant food": 19249,
      "food intake": 32236,
      "oxycodone max": 55372,
      "based auc": 13284,
      "16 lower": 1878,
      "observed treatment": 50723,
      "monitored study": 47313,
      "study similar": 78500,
      "nausea headache": 48775,
      "abdominal pain": 6529,
      "dizziness common": 25632,
      "consistent known": 19700,
      "naltrexone blockade": 48540,
      "conclusions plasma": 19162,
      "dose pharmacokinetics": 26010,
      "increased overall": 37969,
      "fasting conditions": 31224,
      "reduction peak": 69091,
      "systemic exposure": 80024,
      "clinically significant": 16998,
      "oxycodone comparable": 54816,
      "details patient": 23924,
      "patient chronic": 58558,
      "analgesic therapy": 10343,
      "medical experts": 44363,
      "p450 enzyme": 56311,
      "enzyme methods": 29105,
      "methods case": 45266,
      "report results": 70477,
      "issues surrounding": 40338,
      "discussed conclusions": 25290,
      "treatment increase": 82623,
      "difficulties performing": 24972,
      "opioids objective": 53105,
      "objective assess": 50377,
      "assess clinical": 11916,
      "clinical efficacy": 16801,
      "efficacy controlled": 28241,
      "oxycodone cro": 54913,
      "12 dosing": 1280,
      "dosing schedule": 26332,
      "prospective randomised": 65855,
      "randomised placebo": 67030,
      "blinded study": 14020,
      "study 40": 77892,
      "asa physical": 11817,
      "physical status": 61412,
      "status iii": 77260,
      "women undergoing": 87251,
      "undergoing breast": 83514,
      "breast surgery": 14411,
      "surgery cancer": 79339,
      "general anaesthesia": 32954,
      "anaesthesia using": 9880,
      "performed surgery": 60635,
      "surgery groups": 79410,
      "received premedication": 68250,
      "premedication oral": 63722,
      "oral midazolam": 53568,
      "midazolam mg": 46395,
      "mg surgery": 46225,
      "tablet 20": 80087,
      "mg cro": 45842,
      "cro administered": 21236,
      "group placebo": 33913,
      "placebo tablet": 61834,
      "tablet administered": 80089,
      "tablet patients": 80098,
      "patients access": 58916,
      "access opioid": 6995,
      "opioid rescue": 52344,
      "medication iv": 44508,
      "iv patient": 40396,
      "controlled analgesia": 20445,
      "analgesia pca": 10054,
      "pca device": 60261,
      "measures area": 44044,
      "curve auc": 21518,
      "iv opioid": 40387,
      "rescue consumption": 70943,
      "consumption 24": 19874,
      "24 postoperatively": 3270,
      "postoperatively results": 63022,
      "iv pca": 40399,
      "consumption significantly": 20016,
      "cro group": 21238,
      "group 01": 33537,
      "required iv": 70845,
      "loading dose": 42196,
      "001 consumed": 124,
      "consumed opioid": 19835,
      "16 01": 1839,
      "01 24": 294,
      "vas scores": 86023,
      "scores rest": 73970,
      "rest significantly": 71431,
      "group 05": 33549,
      "05 vas": 560,
      "group 16": 33573,
      "16 04": 1840,
      "04 24": 444,
      "24 03": 3143,
      "postoperatively difference": 63000,
      "scores movement": 73906,
      "quality analgesia": 66677,
      "difference nausea": 24635,
      "nausea groups": 48774,
      "arterial hypotension": 11712,
      "group patients": 33900,
      "showed signs": 75309,
      "depression conclusions": 23576,
      "conclusions administration": 19028,
      "postoperative iv": 62783,
      "effective preventing": 27680,
      "pain breast": 56499,
      "effects background": 27835,
      "background objective": 13093,
      "opioids pharmacodynamic": 53172,
      "profile oxycodone": 65495,
      "oxycodone affected": 54698,
      "affected changes": 8915,
      "pain hyperalgesia": 56840,
      "hyperalgesia aim": 36258,
      "pharmacodynamic profiles": 61078,
      "profiles oxycodone": 65518,
      "oxycodone human": 55168,
      "human experimental": 35952,
      "received oral": 68224,
      "skin heat": 76201,
      "heat muscle": 34881,
      "muscle pressure": 48360,
      "minutes induction": 46653,
      "perfusion acid": 60654,
      "acid capsaicin": 7340,
      "venous blood": 86057,
      "samples obtained": 73350,
      "obtained quantification": 50780,
      "quantification oxycodone": 66775,
      "concentrations 10": 18736,
      "10 15": 673,
      "30 45": 3691,
      "45 60": 4573,
      "minutes drug": 46645,
      "oxycodone blood": 54750,
      "blood concentrations": 14115,
      "model given": 47051,
      "time dependent": 81247,
      "dependent changes": 23501,
      "pain measures": 57143,
      "placebo arm": 61661,
      "arm study": 11680,
      "course pain": 20998,
      "measures oxycodone": 44075,
      "taken time": 80294,
      "concentration effect": 18696,
      "effect relationship": 27550,
      "effect linear": 27474,
      "max model": 43554,
      "measures time": 44102,
      "administration placebo": 8337,
      "placebo pain": 61796,
      "measures linear": 44064,
      "linear concentration": 42011,
      "indicate initial": 38221,
      "peripheral analgesic": 60858,
      "animal human": 10993,
      "human studies": 35973,
      "suggest coadministration": 78986,
      "opioids different": 52853,
      "different receptor": 24917,
      "properties result": 65719,
      "enhanced analgesia": 28966,
      "analgesia fewer": 9974,
      "fewer opioid": 31649,
      "dual opioid": 27114,
      "opioid formulation": 51813,
      "ratio morphine": 67777,
      "evaluated analgesic": 29861,
      "effects safety": 28150,
      "safety management": 73164,
      "management acute": 43141,
      "acute moderate": 7639,
      "pain design": 56696,
      "flexible dosing": 31911,
      "clinic patients": 16743,
      "patients adults": 58956,
      "adults undergoing": 8584,
      "undergoing unilateral": 83590,
      "surgery following": 79402,
      "following surgery": 32201,
      "surgery patients": 79502,
      "severe intensity": 74949,
      "intensity pain": 39284,
      "pain point": 57382,
      "point likert": 62087,
      "likert scale": 41852,
      "scale 11": 73485,
      "11 point": 1143,
      "point numerical": 62093,
      "numerical pain": 50307,
      "pain rating": 57467,
      "18 12": 2031,
      "mg 48": 45754,
      "48 hour": 4704,
      "hour period": 35708,
      "period following": 60727,
      "surgery main": 79448,
      "sum pain": 79073,
      "intensity differences": 39249,
      "differences baseline": 24718,
      "use ibuprofen": 84410,
      "randomly assigned": 67216,
      "assigned treatment": 12182,
      "18 percent": 2103,
      "withdrew study": 87175,
      "study completion": 78019,
      "30 percent": 3787,
      "placebo mean": 61776,
      "mean dose": 43768,
      "oxycodone hour": 55166,
      "interval hours": 39599,
      "hours mg": 35795,
      "15 10": 1671,
      "mg groups": 45901,
      "groups respectively": 34298,
      "respectively mean": 71208,
      "dose compared": 25847,
      "placebo 12": 61617,
      "mg group": 45899,
      "group 11": 33562,
      "76 percent": 5745,
      "percent 001": 60445,
      "001 versus": 219,
      "placebo required": 61817,
      "occurrence nausea": 50860,
      "65 percent": 5419,
      "somnolence percent": 76467,
      "minimal changes": 46569,
      "conclusions 12": 19024,
      "formulation provided": 32363,
      "combination analgesic": 17545,
      "efficacy tolerability": 28401,
      "mg doses": 45879,
      "doses effective": 26185,
      "alternative treatment": 9745,
      "neurodegenerative diseases": 49190,
      "glial cells": 33216,
      "neuronal injury": 49212,
      "activation response": 7479,
      "response characterized": 71336,
      "inflammatory signaling": 38581,
      "factors opioid": 31119,
      "analgesic oxycodone": 10285,
      "oxycodone demonstrated": 54939,
      "efficacy peripheral": 28327,
      "activation proinflammatory": 7478,
      "lipopolysaccharide lps": 42069,
      "20 \u03bcg": 2392,
      "dependently inhibited": 23546,
      "protein expression": 65934,
      "expression levels": 30836,
      "levels proinflammatory": 41598,
      "proinflammatory cytokines": 65584,
      "tumor necrosis": 83277,
      "necrosis factor": 48902,
      "factor tnf": 31064,
      "interleukin il": 39447,
      "interleukin 1\u03b2": 39446,
      "increased expression": 37913,
      "nuclear factor": 50117,
      "oxycodone rat": 55797,
      "astrocytes increased": 12516,
      "neuroinflammation inhibiting": 49196,
      "response effective": 71344,
      "effective therapeutic": 27707,
      "therapeutic strategy": 80961,
      "evaluate differences": 29787,
      "differences patient": 24780,
      "healthcare resource": 34805,
      "healthcare costs": 34796,
      "ir formulations": 40230,
      "tapentadol tap": 80472,
      "tap ir": 80374,
      "oxy ir": 54455,
      "ir methods": 40236,
      "patients 18": 58834,
      "2009 31": 2522,
      "31 2011": 3845,
      "clinformatics data": 16737,
      "data mart": 22005,
      "claims database": 16626,
      "database patients": 22178,
      "patients assigned": 59014,
      "initial drug": 38848,
      "drug usage": 26827,
      "60 days": 5250,
      "follow period": 32026,
      "ir patients": 40254,
      "using exact": 85394,
      "key patient": 40672,
      "score matching": 73758,
      "patient demographics": 58608,
      "demographics clinical": 23296,
      "clinical characteristics": 16768,
      "test chi": 80757,
      "chi squared": 15990,
      "utilized evaluate": 85742,
      "healthcare utilization": 34810,
      "cohorts results": 17415,
      "results patient": 71839,
      "period significantly": 60791,
      "significantly differed": 75685,
      "overall study": 54260,
      "patients 10": 58821,
      "similar patient": 75974,
      "60 day": 5249,
      "day follow": 22312,
      "period patients": 60768,
      "patients took": 60050,
      "mean hospital": 43778,
      "hospital los": 35601,
      "21 vs": 2986,
      "vs 35": 86566,
      "35 days": 4079,
      "days 0001": 22456,
      "0001 lower": 65,
      "number hospitalizations": 50161,
      "07 vs": 610,
      "vs 10": 86519,
      "001 outpatient": 170,
      "healthcare charges": 34794,
      "vs 11": 86526,
      "index opioid": 38201,
      "vs 150": 86538,
      "characteristics patients": 15870,
      "different patients": 24906,
      "demographic clinical": 23276,
      "healthcare resources": 34807,
      "paper examines": 58078,
      "transition opioid": 82203,
      "prevalent misuse": 64829,
      "illicit opioids": 36645,
      "heroin fentanyl": 34998,
      "study effects": 78143,
      "effects substitution": 28173,
      "reformulation relative": 69219,
      "physiologically based": 61471,
      "pharmacokinetic pbpk": 61128,
      "pbpk modeling": 60256,
      "offers unique": 50965,
      "age specific": 9124,
      "assess ability": 11902,
      "pbpk model": 60254,
      "model predict": 47074,
      "plasma exposure": 61934,
      "opioid pain": 52034,
      "management adults": 43147,
      "adults children": 8553,
      "children methods": 16058,
      "following intravenous": 32147,
      "using combined": 85347,
      "method adult": 45166,
      "pk studies": 61589,
      "studies testing": 77866,
      "goodness fit": 33335,
      "fold error": 31988,
      "parameters calculated": 58155,
      "dose conversion": 25852,
      "conversion oxycodone": 20711,
      "model successfully": 47082,
      "successfully predicted": 78924,
      "predicted oxycodone": 63565,
      "observed auc": 50652,
      "auc max": 12634,
      "max max": 43552,
      "max 90": 43545,
      "fold difference": 31987,
      "model showed": 47079,
      "prediction performance": 63569,
      "pediatric populations": 60360,
      "50 fold": 4837,
      "fold range": 32000,
      "observed values": 50729,
      "model different": 47042,
      "intravenous doses": 39824,
      "doses given": 26192,
      "given children": 33157,
      "different ages": 24841,
      "compared standard": 18312,
      "standard mg": 76919,
      "increasing dose": 38102,
      "children conclusions": 16043,
      "conclusions current": 19069,
      "dose adjustment": 25821,
      "adjustment oxycodone": 8071,
      "design future": 23717,
      "pediatric clinical": 60347,
      "studies background": 77653,
      "pain major": 57044,
      "major challenges": 42932,
      "pediatric patients": 60356,
      "oxycodone shown": 55905,
      "shown good": 75339,
      "good pain": 33318,
      "relief postoperative": 70169,
      "relief children": 70108,
      "studies investigated": 77756,
      "oxycodone context": 54875,
      "context objective": 20109,
      "oxycodone pcia": 55665,
      "provide adequate": 66030,
      "safe postoperative": 73098,
      "relief comparison": 70117,
      "reference opioid": 69139,
      "opioid drug": 51743,
      "drug design": 26581,
      "multi center": 48143,
      "trial setting": 83086,
      "setting university": 74842,
      "university medical": 83869,
      "medical centers": 44342,
      "teaching hospitals": 80534,
      "hospitals china": 35669,
      "china participants": 16087,
      "participants patients": 58337,
      "month old": 47396,
      "old undergoing": 51019,
      "elective surgery": 28501,
      "surgery general": 79404,
      "intervention patients": 39638,
      "patients randomly": 59745,
      "randomly allocated": 67210,
      "oxycodone 89": 54608,
      "tramadol oxycodone": 82089,
      "dose end": 25895,
      "end surgery": 28820,
      "surgery mg": 79475,
      "kg respectively": 40796,
      "bolus doses": 14214,
      "10 min": 858,
      "min lockout": 46533,
      "lockout time": 42238,
      "outcomes primary": 54076,
      "adequate postoperative": 7968,
      "relief defined": 70123,
      "face legs": 31016,
      "legs activity": 41390,
      "activity consolability": 7561,
      "consolability flacc": 19730,
      "flacc score": 31893,
      "post anesthesia": 62557,
      "anesthesia care": 10902,
      "unit pacu": 83766,
      "measured 10": 43951,
      "min extubation": 46524,
      "extubation 10": 30994,
      "min discharge": 46518,
      "discharge pacu": 25153,
      "pacu analgesia": 56329,
      "analgesia currently": 9944,
      "doses rescue": 26263,
      "administered results": 8178,
      "oxycodone provided": 55781,
      "provided similar": 66158,
      "similar level": 75940,
      "flacc scores": 31895,
      "bolus dose": 14213,
      "pacu time": 56334,
      "analgesic drug": 10187,
      "bolus times": 14225,
      "activity score": 7588,
      "effects groups": 27935,
      "groups nausea": 34241,
      "groups patients": 34262,
      "patients oxycodone": 59612,
      "sedation levels": 74316,
      "compared tramadol": 18325,
      "tramadol group": 82064,
      "group conclusions": 33699,
      "analgesia achieved": 9900,
      "achieved intravenous": 7319,
      "effects tramadol": 28184,
      "patients trial": 60077,
      "registration study": 69394,
      "study registered": 78457,
      "www chictr": 87389,
      "chictr org": 15997,
      "org cn": 53747,
      "registration number": 69393,
      "date registration": 22218,
      "05 2018": 480,
      "06 01": 576,
      "mitragyna speciosa": 46778,
      "speciosa korth": 76649,
      "taken orally": 80288,
      "millions people": 46499,
      "eliminate opioid": 28604,
      "use analgesia": 84191,
      "manage opioid": 43120,
      "respiratory depressant": 71263,
      "overdose risk": 54316,
      "partial opioid": 58246,
      "opioid respiratory": 52347,
      "objectives compare": 50549,
      "compare respiratory": 18052,
      "respiratory effects": 71292,
      "oxycodone rats": 55802,
      "rats study": 67896,
      "previously published": 64954,
      "et al": 29669,
      "blood gases": 14124,
      "pharmacokinetics assessed": 61158,
      "assessed 12": 11977,
      "12 20": 1223,
      "20 40": 2288,
      "40 80": 4329,
      "80 240": 5827,
      "kg oral": 40770,
      "150 mg": 1807,
      "findings oxycodone": 31802,
      "administration produced": 8348,
      "significant dose": 75527,
      "dose related": 26045,
      "effects pronounced": 28115,
      "kg mitragynine": 40762,
      "threatening effects": 81145,
      "sedative like": 74338,
      "like effects": 41777,
      "produced oxycodone": 65399,
      "maximum oxycodone": 43598,
      "related conclusions": 69576,
      "conclusions consistent": 19059,
      "receptor agonism": 68456,
      "mitragynine produced": 46781,
      "doses times": 26289,
      "times higher": 81427,
      "humans objectives": 35986,
      "use disposal": 84336,
      "controlled drugs": 20491,
      "anecdotal evidence": 10896,
      "evidence study": 30263,
      "oral solution": 53666,
      "used simulate": 85131,
      "key findings": 40668,
      "dosing enteral": 26310,
      "loss volume": 42440,
      "loss observed": 42434,
      "used conclusions": 84893,
      "conclusions findings": 19084,
      "study support": 78523,
      "following recommendations": 32191,
      "hospital pharmacy": 35617,
      "provide oxycodone": 66087,
      "liquid formulation": 42091,
      "use enteral": 84352,
      "minimum required": 46615,
      "policy background": 62180,
      "background clinical": 13026,
      "clinical need": 16840,
      "potent opioids": 63113,
      "depression current": 23578,
      "effects tapentadol": 28177,
      "tapentadol mu": 80441,
      "agonist noradrenaline": 9294,
      "noradrenaline reuptake": 49873,
      "reuptake inhibitor": 72201,
      "inhibitor oxycodone": 38796,
      "oxycodone selective": 55871,
      "selective mu": 74432,
      "hypothesize tapentadol": 36306,
      "mg lesser": 46039,
      "mg methods": 46048,
      "receive oral": 68063,
      "oral tapentadol": 53674,
      "100 150": 982,
      "crossover double": 21288,
      "blind randomized": 13968,
      "randomized design": 67094,
      "main end": 42828,
      "point study": 62110,
      "study effect": 78142,
      "effect treatment": 27576,
      "prior following": 65146,
      "intake results": 39186,
      "results treatments": 72041,
      "typical opioid": 83387,
      "shift right": 75138,
      "mg significantly": 46217,
      "significantly larger": 75761,
      "effect tapentadol": 27568,
      "mg mean": 46044,
      "min 95": 46510,
      "mg 05": 45695,
      "conclusions exploratory": 19082,
      "exploratory study": 30715,
      "study observed": 78344,
      "observed tapentadol": 50722,
      "produce respiratory": 65365,
      "mg 150": 45717,
      "mg modest": 46058,
      "modest respiratory": 47227,
      "advantage oxycodone": 8608,
      "fully synthetic": 32616,
      "sol gel": 76415,
      "route used": 72851,
      "decreased increasing": 23003,
      "shown associated": 75328,
      "associated sustained": 12448,
      "vitro release": 86370,
      "release profile": 69996,
      "profile opioid": 65491,
      "period 12": 60680,
      "presented study": 64699,
      "novel approach": 50003,
      "formulations opioids": 32394,
      "clinical indication": 16827,
      "supply drugs": 79180,
      "case 35": 15153,
      "35 year": 4097,
      "old man": 51012,
      "injection oral": 38960,
      "hydrochloride oxycontin": 36031,
      "despite treatment": 23907,
      "association intravenous": 12480,
      "opana er": 51141,
      "er introduction": 29427,
      "introduction new": 39934,
      "illustrates practical": 36669,
      "detailed drug": 23914,
      "drug history": 26646,
      "highlights need": 35383,
      "clarify role": 16646,
      "cases drug": 15235,
      "drug associated": 26536,
      "pediatric burn": 60346,
      "improve patient": 37074,
      "increasingly common": 38133,
      "require minimal": 70806,
      "monitoring using": 47348,
      "using placebo": 85561,
      "blind design": 13934,
      "compared oral": 18231,
      "oral transmucosal": 53678,
      "transmucosal fentanyl": 82231,
      "fentanyl citrate": 31451,
      "approximately 10": 11556,
      "microg kg": 46358,
      "14 years": 1633,
      "pulse oximetry": 66470,
      "effects patient": 28081,
      "patient pain": 58699,
      "oxycodone resulted": 55849,
      "resulted similar": 71525,
      "similar outcome": 75963,
      "signs significant": 75882,
      "effective analgesics": 27598,
      "care children": 15009,
      "opiate withdrawal": 51315,
      "withdrawal induced": 87134,
      "uncommon clinical": 83483,
      "36 year": 4150,
      "old male": 51009,
      "male patient": 43045,
      "psychiatric history": 66326,
      "history treatment": 35487,
      "analgesic drugs": 10190,
      "prescribed oxycodone": 63940,
      "oxycodone intake": 55286,
      "course time": 21002,
      "follow patient": 32024,
      "oxycodone withdrawal": 56100,
      "data base": 21886,
      "base medical": 13269,
      "making rational": 43014,
      "clinical pharmacology": 16856,
      "affect opioid": 8905,
      "opioid plasma": 52069,
      "practice research": 63413,
      "aim characterize": 9376,
      "characterize pharmacokinetic": 15900,
      "tolerability transdermal": 81560,
      "transdermal oxycodone": 82163,
      "oxycodone patch": 55646,
      "patch containing": 58486,
      "containing tocopheryl": 20085,
      "tocopheryl phosphate": 81506,
      "phosphate mixture": 61366,
      "mixture tpm": 46814,
      "tpm patients": 81965,
      "tpm oxycodone": 81963,
      "oxycodone detected": 54951,
      "maximum plasma": 43604,
      "concentration 41": 18672,
      "34 ng": 4027,
      "profile consistent": 65481,
      "application method": 11425,
      "effect profile": 27537,
      "naltrexone treatment": 48550,
      "treatment limiting": 82641,
      "observed conclusion": 50665,
      "conclusion day": 18889,
      "acceptable safety": 6984,
      "background recent": 13191,
      "recent data": 68394,
      "liability opioids": 41643,
      "preclinical studies": 63534,
      "receptor selective": 68524,
      "selective agonists": 74424,
      "agonists oxycodone": 9340,
      "oxycodone activate": 54669,
      "increase release": 37798,
      "suppression opioid": 79246,
      "induced analgesic": 38377,
      "inhibit opioid": 38769,
      "induced glial": 38414,
      "glial activation": 33214,
      "enhance analgesic": 28950,
      "opioids doses": 52868,
      "enhances opioid": 28978,
      "aims purpose": 9495,
      "assess effects": 11930,
      "administration minocycline": 8302,
      "human research": 35969,
      "volunteers design": 86418,
      "study subject": 78516,
      "subject randomized": 78634,
      "outpatient study": 54145,
      "separate sessions": 74588,
      "received 100": 68093,
      "100 200": 984,
      "200 mg": 2397,
      "effects oxy": 28055,
      "settings participants": 74858,
      "participants 21": 58268,
      "21 45": 2954,
      "years age": 87560,
      "age non": 9093,
      "non treatment": 49693,
      "treatment seeking": 82828,
      "seeking non": 74350,
      "non dependent": 49592,
      "york state": 87710,
      "combination oxy": 17582,
      "oxy 40": 54439,
      "mg administered": 45796,
      "administered oxy": 8158,
      "attenuated oxy": 12589,
      "oxy induced": 54454,
      "compared oxy": 18233,
      "attenuate abuse": 12576,
      "agonists opioid": 9339,
      "opioid harm": 51833,
      "vary opioid": 85989,
      "opioid type": 52455,
      "observational study": 50624,
      "examined effect": 30377,
      "type oxycodone": 83341,
      "persistent postoperative": 60926,
      "community pharmacy": 17927,
      "patients dispensed": 59218,
      "discharge opioids": 25150,
      "january 2016": 40450,
      "2016 30": 2733,
      "september 2021": 74621,
      "2021 patients": 2916,
      "patients grouped": 59343,
      "opioid experience": 51789,
      "experience opioid": 30586,
      "having received": 34611,
      "received opioids": 68222,
      "discharge opioid": 25146,
      "modified release": 47242,
      "release immediate": 69870,
      "logistic regression": 42254,
      "regression models": 69448,
      "continued use": 20145,
      "days discharge": 22514,
      "risk factors": 72563,
      "836 patients": 5947,
      "31 opioid": 3875,
      "27 24": 3477,
      "24 opioid": 3254,
      "opioid experienced": 51790,
      "experienced patients": 30622,
      "patients met": 59492,
      "met criteria": 44868,
      "opioids significant": 53296,
      "release associated": 69808,
      "associated significantly": 12432,
      "lower odds": 42656,
      "oxycodone modified": 55460,
      "ci 81": 16497,
      "81 69": 5882,
      "94 opioid": 6194,
      "93 opioid": 6175,
      "patients patients": 59636,
      "patients underwent": 60139,
      "orthopaedic surgery": 53820,
      "regardless opioid": 69287,
      "tapentadol compared": 80391,
      "oxycodone largest": 55330,
      "use specifically": 84743,
      "specifically examined": 76626,
      "examined persistence": 30402,
      "appeared lower": 11393,
      "including patients": 37663,
      "undergoing orthopaedic": 83562,
      "surgery study": 79594,
      "study objective": 78328,
      "objective compare": 50387,
      "compare efficacy": 18021,
      "efficacy effects": 28257,
      "epidural morphine": 29187,
      "following major": 32160,
      "major abdominal": 42926,
      "abdominal surgery": 6531,
      "surgery design": 79369,
      "blind study": 13979,
      "department surgery": 23442,
      "surgery helsinki": 79412,
      "helsinki university": 34920,
      "university central": 83857,
      "central hospital": 15587,
      "hospital patients": 35613,
      "patients 44": 58868,
      "status ii": 77258,
      "ii iii": 36561,
      "iii patients": 36590,
      "patients scheduled": 59942,
      "scheduled elective": 73644,
      "elective major": 28496,
      "surgery interventions": 79428,
      "interventions thirty": 39683,
      "patients allocated": 58986,
      "groups 11": 34094,
      "11 patients": 1141,
      "received oxycodone": 68228,
      "oxycodone intravenously": 55297,
      "intravenously iv": 39895,
      "received morphine": 68203,
      "kg followed": 40728,
      "followed infusion": 32062,
      "kg hr": 40734,
      "hr oxycodone": 35896,
      "oxycodone bolus": 54754,
      "bolus 15": 14212,
      "03 mg": 418,
      "hr induction": 35894,
      "induction standardized": 38481,
      "standardized anesthesia": 76951,
      "anesthesia 24": 10899,
      "patients given": 59326,
      "epidural group": 29180,
      "control group": 20303,
      "group epidural": 33766,
      "measurements main": 44020,
      "results blood": 71615,
      "plasma opioid": 61943,
      "opioid concentrations": 51595,
      "postoperatively pain": 63012,
      "pain rest": 57639,
      "rest coughing": 71416,
      "coughing nausea": 20920,
      "nausea pruritus": 48779,
      "pruritus sedation": 66306,
      "sedation respiratory": 74326,
      "oxycodone provide": 55780,
      "provide similar": 66102,
      "similar analgesia": 75896,
      "analgesia effects": 9963,
      "effects occurred": 28033,
      "similarly groups": 76011,
      "depression seen": 23598,
      "seen groups": 74357,
      "groups hemodynamic": 34212,
      "remained normal": 70266,
      "normal limits": 49902,
      "limits conclusions": 41981,
      "dosages reported": 25770,
      "acute post": 7682,
      "morphine objective": 47790,
      "objective explore": 50432,
      "combined dexmedetomidine": 17643,
      "guided radiofrequency": 34413,
      "fentanyl group": 31483,
      "group oxycodone": 33887,
      "group 30": 33593,
      "30 patients": 3785,
      "group injected": 33831,
      "fentanyl \u03bcg": 31612,
      "kg patients": 40784,
      "injected oxycodone": 38921,
      "patients injected": 59413,
      "dose \u03bcg": 26110,
      "kg 10": 40683,
      "10 minutes": 864,
      "rate \u03bcg": 67524,
      "kg end": 40724,
      "end operation": 28800,
      "changes heart": 15790,
      "heart rate": 34870,
      "rate hr": 67473,
      "mean arterial": 43714,
      "arterial pressure": 11716,
      "pressure map": 64742,
      "pulse oxygen": 66472,
      "saturation spo": 73470,
      "bispectral index": 13888,
      "index bis": 38190,
      "different time": 24926,
      "points time": 62143,
      "time patients": 81316,
      "patients entering": 59255,
      "operating room": 51212,
      "operation t1": 51228,
      "operation t2": 51229,
      "operation t3": 51230,
      "minutes end": 46648,
      "operation t4": 51231,
      "effects nausea": 28014,
      "vomiting respiratory": 86473,
      "assessed visual": 12092,
      "scores recorded": 73963,
      "recorded t0": 68702,
      "hour postoperatively": 35715,
      "results patients": 71841,
      "kg compared": 40705,
      "compared t0": 18322,
      "hr groups": 35893,
      "groups decreased": 34173,
      "t2 05": 80058,
      "05 time": 557,
      "map hr": 43349,
      "significant groups": 75544,
      "groups incidence": 34217,
      "incidence nausea": 37281,
      "movements lower": 48058,
      "scores lower": 73898,
      "postoperatively 05": 62990,
      "05 conclusion": 499,
      "conclusion combination": 18871,
      "oxycodone dexmedetomidine": 54962,
      "used safely": 85119,
      "safely effectively": 73109,
      "effects purpose": 28119,
      "objective systematic": 50526,
      "review assess": 72257,
      "health related": 34764,
      "related quality": 69675,
      "life outcomes": 41713,
      "management moderate": 43206,
      "naloxone tapentadol": 48520,
      "effect treatments": 27578,
      "patients daily": 59166,
      "daily functioning": 21749,
      "methods literature": 45370,
      "sources including": 76505,
      "embase medline": 28649,
      "medline medline": 44740,
      "medline process": 44745,
      "process cochrane": 65335,
      "searched identify": 74150,
      "identify randomized": 36530,
      "trials investigating": 83152,
      "investigating tapentadol": 40067,
      "naloxone treatment": 48527,
      "network meta": 49160,
      "analysis conducted": 10660,
      "determine relative": 24046,
      "relative efficacy": 69747,
      "safety profiles": 73211,
      "treatments findings": 82908,
      "significantly better": 75660,
      "better tapentadol": 13739,
      "respect patient": 71137,
      "patient assessment": 58540,
      "assessment constipation": 12109,
      "total score": 81902,
      "score risk": 73782,
      "ratio 60": 67745,
      "60 95": 5244,
      "95 credible": 6400,
      "credible interval": 21160,
      "36 11": 4114,
      "lower risk": 42698,
      "interval 42": 39568,
      "98 oxycodone": 6471,
      "significantly superior": 75863,
      "headache fatigue": 34656,
      "dry mouth": 27101,
      "constipation nausea": 19765,
      "vomiting pain": 86465,
      "pain efficacy": 56746,
      "studies tapentadol": 77863,
      "difference oxycodone": 24649,
      "evaluation pain": 29960,
      "efficacy differences": 28248,
      "higher baseline": 35208,
      "baseline pain": 13447,
      "tapentadol studies": 80471,
      "implications oxycodone": 36964,
      "naloxone offers": 48469,
      "offers significant": 50964,
      "significant improvements": 75552,
      "fatigue headache": 31252,
      "release tapentadol": 70016,
      "patient daily": 58601,
      "life background": 41687,
      "background chronic": 13024,
      "increased 15": 37827,
      "15 years": 1803,
      "correlation opioid": 20833,
      "white matter": 87018,
      "demonstrated patients": 23359,
      "term use": 80677,
      "use prescription": 84649,
      "effect opioids": 27510,
      "opioids central": 52770,
      "fully understood": 32618,
      "investigated effect": 40038,
      "effect chronic": 27433,
      "chronic opioids": 16246,
      "using animal": 85307,
      "female rats": 31374,
      "oxycodone 24": 54541,
      "days addition": 22483,
      "receptor results": 68523,
      "results observed": 71803,
      "observed changes": 50660,
      "anti apoptotic": 11112,
      "stress response": 77491,
      "exposure using": 30800,
      "cells observed": 15500,
      "signaling opioid": 75389,
      "altogether data": 9755,
      "neuronal degeneration": 49210,
      "response leading": 71348,
      "objective misuse": 50446,
      "misuse prescription": 46738,
      "issue australia": 40320,
      "rapid rise": 67397,
      "rise prescription": 72492,
      "use associated": 84207,
      "increase overdose": 37772,
      "overdose death": 54274,
      "opioids especially": 52889,
      "especially oxycodone": 29562,
      "ed primary": 27349,
      "primary aim": 64985,
      "study identify": 78238,
      "administration patients": 8335,
      "patients ed": 59233,
      "incidence oxycodone": 37294,
      "prescribed patients": 63947,
      "discharge ed": 25119,
      "observational retrospective": 50620,
      "retrospective data": 72141,
      "analysis incidence": 10697,
      "health service": 34771,
      "slow release": 76263,
      "release sr": 70005,
      "prescribed year": 64006,
      "period 2015": 60697,
      "2018 included": 2822,
      "included results": 37544,
      "period resulted": 60787,
      "administration department": 8244,
      "prescriptions oxycodone": 64530,
      "prescriptions 1000": 64428,
      "frequently prescribed": 32568,
      "opioid medication": 51902,
      "ir mg": 40237,
      "prescriptions generated": 64490,
      "quantity 20": 66823,
      "higher incidence": 35252,
      "prescribing australian": 64032,
      "patient outcomes": 58698,
      "steps reduce": 77331,
      "reduce incidence": 68847,
      "increased prescribing": 37994,
      "prescribing tramadol": 64142,
      "emergency physicians": 28695,
      "breakthrough pain": 14397,
      "patients chronically": 59086,
      "oxycodone tramadol": 56009,
      "oxidative metabolism": 54395,
      "metabolism cyp2d6": 44928,
      "cyp2d6 cyp3a4": 21594,
      "performed determine": 60585,
      "control experimental": 20298,
      "control arm": 20275,
      "subject received": 78638,
      "received 10": 68089,
      "oxycodone orally": 55584,
      "oxymorphone concentrations": 56231,
      "concentrations measured": 18775,
      "mg tramadol": 46246,
      "calculated using": 14709,
      "using dose": 85383,
      "concentration curve": 18687,
      "concentrations max": 18773,
      "power detect": 63291,
      "20 difference": 2316,
      "study arms": 77958,
      "cl max": 16609,
      "compared study": 18317,
      "paired tests": 58025,
      "groups demonstrated": 34176,
      "doses tramadol": 26292,
      "impaired oxycodone": 36875,
      "objectives evaluate": 50559,
      "evaluate postoperative": 29832,
      "use benign": 84221,
      "minimally invasive": 46583,
      "surgery assess": 79325,
      "impact patient": 36835,
      "patient educational": 58627,
      "educational intervention": 27402,
      "regarding proper": 69277,
      "proper opioid": 65699,
      "provided preoperatively": 66151,
      "preoperatively patients": 63774,
      "underwent hysterectomy": 83683,
      "hysterectomy myomectomy": 36325,
      "laparoscopic procedures": 41104,
      "procedures opioid": 65317,
      "25 tablets": 3386,
      "tablets oxycodone": 80188,
      "oxycodone 5mg": 54588,
      "patient surveys": 58796,
      "surveys completed": 79748,
      "completed postoperative": 18484,
      "postoperative visits": 62983,
      "visits results": 86291,
      "consented patients": 19583,
      "median opioid": 44261,
      "use 35": 84154,
      "tablets iqr": 80169,
      "iqr 11": 40160,
      "11 25": 1106,
      "iqr 15": 40163,
      "75 18": 5695,
      "18 75": 2066,
      "75 ome": 5715,
      "48 75": 4695,
      "75 median": 5704,
      "operative day": 51247,
      "day use": 22441,
      "required refill": 70858,
      "5mg oxycodone": 5209,
      "oxycodone difference": 54969,
      "difference total": 24695,
      "use presence": 84660,
      "pelvic pain": 60381,
      "pain disorders": 56728,
      "overall satisfaction": 54256,
      "satisfaction pain": 73409,
      "33 patients": 3997,
      "increased awareness": 37882,
      "conclusion patients": 18954,
      "required 10": 70816,
      "regardless procedure": 69289,
      "satisfaction patient": 73418,
      "patient education": 58626,
      "simple method": 76019,
      "knowledge regarding": 40893,
      "regarding opioid": 69255,
      "medication disposal": 44489,
      "aims study": 9498,
      "aimed characterize": 9439,
      "characterize pharmacokinetics": 15902,
      "pharmacokinetics oxycodone": 61178,
      "age range": 9109,
      "methods seventy": 45575,
      "gestational age": 33136,
      "age 23": 8984,
      "23 42": 3081,
      "received intravenous": 68175,
      "hydrochloride trihydrate": 36040,
      "kg surgery": 40809,
      "samples taken": 73366,
      "unconjugated forms": 83488,
      "compounds determined": 18608,
      "determined urine": 24091,
      "noncompartmental analysis": 49722,
      "groups based": 34138,
      "age results": 9113,
      "patient age": 58536,
      "pharmacokinetic variability": 61154,
      "range 12": 67252,
      "significantly longer": 75768,
      "aged 24": 9180,
      "24 months": 3248,
      "months 12": 47427,
      "12 median": 1321,
      "constant age": 19739,
      "groups non": 34244,
      "markedly increased": 43402,
      "increased age": 37871,
      "major metabolite": 42953,
      "urine conclusions": 84070,
      "highlight importance": 35374,
      "importance careful": 36979,
      "careful dose": 15100,
      "dose titration": 26099,
      "oxycodone dual": 55010,
      "opioid combination": 51587,
      "versus individual": 86125,
      "individual components": 38289,
      "versus morphine": 86132,
      "morphine equivalent": 47655,
      "equivalent doses": 29307,
      "severe postoperative": 75010,
      "patients design": 59180,
      "centers patients": 15571,
      "patients hours": 59373,
      "reported pain": 70608,
      "intensity point": 39292,
      "mg morphine": 46059,
      "morphine 12": 47537,
      "differences 24": 24705,
      "hours dose": 35767,
      "study medication": 78306,
      "percentage patients": 60510,
      "severe nausea": 74956,
      "nausea emesis": 48773,
      "group compared": 33684,
      "compared individual": 18187,
      "mg 009": 45689,
      "009 oxycodone": 282,
      "mg 037": 45693,
      "mg 011": 45691,
      "54 vs": 5054,
      "vs 28": 86557,
      "35 30": 4063,
      "doses morphine": 26217,
      "comparable analgesic": 17948,
      "effects 50": 27798,
      "50 75": 4821,
      "percent reduction": 60487,
      "commonly associated": 17838,
      "associated opioids": 12365,
      "opioids nausea": 53082,
      "compared morphine": 18207,
      "equivalent dose": 29301,
      "dose groups": 25920,
      "groups conclusions": 34158,
      "superior analgesic": 79124,
      "comparable efficacy": 17954,
      "efficacy compared": 28237,
      "doses common": 26157,
      "50 percent": 4886,
      "pain tapentadol": 57903,
      "used analgesics": 84842,
      "shown oxycodone": 75344,
      "human brain": 35944,
      "brain limited": 14343,
      "aim investigate": 9391,
      "investigate effects": 40008,
      "oxycodone brain": 54757,
      "resonance spectroscopy": 71123,
      "21 healthy": 2971,
      "prefrontal cortex": 63652,
      "baseline 14": 13406,
      "mg tapentadol": 46237,
      "tapentadol 10": 80377,
      "oxycodone equipotent": 55031,
      "equipotent dose": 29272,
      "blind cross": 13927,
      "baseline decreased": 13426,
      "levels identified": 41568,
      "26 14": 3422,
      "14 vs": 1631,
      "35 18": 4058,
      "18 04": 2025,
      "oxycodone 26": 54544,
      "26 10": 3418,
      "10 vs": 950,
      "35 12": 4057,
      "12 05": 1204,
      "analgesics modulate": 10449,
      "st john": 76822,
      "john wort": 40480,
      "prone drug": 65677,
      "aims aim": 9472,
      "assess potential": 11953,
      "mediated metabolism": 44313,
      "design placebo": 23749,
      "controlled randomized": 20529,
      "phases intervals": 61326,
      "intervals weeks": 39618,
      "weeks conducted": 86899,
      "conducted 12": 19337,
      "healthy participants": 34836,
      "placebo administered": 61657,
      "administered 15": 8099,
      "15 days": 1729,
      "days oral": 22569,
      "day 14": 22245,
      "14 oxycodone": 1618,
      "behavioural analgesic": 13570,
      "analogue scales": 10564,
      "drug concentrations": 26559,
      "measured 48": 43958,
      "effects 12": 27793,
      "12 results": 1360,
      "oxycodone auc": 54738,
      "50 001": 4797,
      "self reported": 74492,
      "reported drug": 70534,
      "oxycodone measured": 55377,
      "12 decreased": 1278,
      "004 differences": 259,
      "threshold intensity": 81150,
      "observed conclusions": 50667,
      "greatly reduced": 33512,
      "reduced plasma": 68972,
      "oxycodone self": 55872,
      "clinical significance": 16902,
      "treating patients": 82406,
      "objective report": 50485,
      "report case": 70449,
      "case severe": 15208,
      "symptoms following": 79888,
      "addition oxycodone": 7821,
      "case summary": 15212,
      "70 year": 5573,
      "diagnostic criteria": 24342,
      "serotonin syndrome": 74688,
      "drugs resulted": 27066,
      "resulted resolution": 71515,
      "resolution symptoms": 71114,
      "naranjo probability": 48576,
      "probability scale": 65219,
      "probable relationship": 65224,
      "adverse reaction": 8837,
      "serotonergic drugs": 74669,
      "drugs previous": 27044,
      "previous reports": 64912,
      "reports involving": 70730,
      "involving oxycodone": 40133,
      "involving analgesics": 40122,
      "analgesics associated": 10380,
      "dextromethorphan tramadol": 24298,
      "synthetic opioids": 79959,
      "oxycodone does": 54988,
      "addition number": 7818,
      "interaction observed": 39373,
      "serotonin reuptake": 74682,
      "reuptake inhibitors": 72205,
      "clinical experience": 16814,
      "malignant disease": 43093,
      "disease chronic": 25322,
      "nonmalignant conditions": 49766,
      "opioids chronic": 52775,
      "chronic nonmalignant": 16231,
      "nonmalignant pain": 49770,
      "despite lack": 23887,
      "strong evidence": 77516,
      "evidence base": 30151,
      "patients develop": 59184,
      "develop tolerance": 24158,
      "repeated dose": 70406,
      "prescribing data": 64047,
      "data united": 22148,
      "united kingdom": 83775,
      "general practice": 32981,
      "pain reports": 57619,
      "oral transdermal": 53676,
      "pain median": 57147,
      "median number": 44250,
      "number days": 50150,
      "opioid pharmacotherapy": 52054,
      "thirty percent": 81114,
      "percent patients": 60473,
      "patients changed": 59059,
      "course treatment": 21003,
      "medications mean": 44644,
      "mean morphine": 43799,
      "hour dose": 35695,
      "dose increased": 25931,
      "increased beginning": 37884,
      "beginning end": 13521,
      "end opioid": 28801,
      "age gender": 9073,
      "fentanyl revealed": 31589,
      "greatest patients": 33504,
      "using fentanyl": 85397,
      "osmotic controlled": 53850,
      "oral delivery": 53513,
      "delivery oros": 23223,
      "oros hydromorphone": 53802,
      "release hydromorphone": 69869,
      "hydromorphone 24": 36153,
      "facilitate optimal": 31034,
      "optimal pain": 53426,
      "relief improve": 70133,
      "improve quality": 37085,
      "chronic osteoarthritis": 16248,
      "osteoarthritis pain": 53865,
      "pain daily": 56675,
      "daily oros": 21782,
      "administered times": 8189,
      "patients year": 60184,
      "initiating opioid": 38888,
      "hydromorphone er": 36165,
      "undergo dose": 83501,
      "dose adjustments": 25824,
      "events pain": 30091,
      "sleep problems": 76231,
      "score improved": 73754,
      "score treatment": 73803,
      "dependent distribution": 23508,
      "end titration": 28830,
      "pre treatment": 63492,
      "optimal dose": 53421,
      "dose non": 25969,
      "non compliant": 49590,
      "converted equianalgesic": 20725,
      "equianalgesic morphine": 29263,
      "using following": 85399,
      "hydromorphone morphine": 36193,
      "morphine ratio": 47902,
      "ratio oxycodone": 67787,
      "conversion ratios": 20714,
      "direct medical": 25050,
      "results year": 72061,
      "year mean": 87450,
      "mean daily": 43738,
      "daily morphine": 21762,
      "dose 90": 25814,
      "mg 14": 45713,
      "years qalys": 87646,
      "effectiveness ratio": 27777,
      "ratio icer": 67774,
      "qaly gained": 66625,
      "conversion ratio": 20712,
      "conclusion based": 18862,
      "based analyses": 13279,
      "objectives aim": 50537,
      "aim analysis": 9373,
      "analysis assess": 10638,
      "assess cost": 11921,
      "tapentadol pr": 80459,
      "pr prolonged": 63357,
      "cr controlled": 21056,
      "severe non": 74960,
      "malignant chronic": 43092,
      "patients controlled": 59155,
      "time horizon": 81270,
      "national health": 48685,
      "perspective uk": 60972,
      "patients continue": 59150,
      "line therapy": 42001,
      "line opioid": 41989,
      "poor tolerability": 62275,
      "patients failing": 59297,
      "health state": 34775,
      "data tolerability": 22143,
      "tolerability efficacy": 81533,
      "oxycodone obtained": 55551,
      "phase iii": 61292,
      "iii clinical": 36581,
      "patient records": 58729,
      "model results": 47078,
      "therapy tapentadol": 81071,
      "leads higher": 41317,
      "costs vs": 20911,
      "oxycodone overall": 55589,
      "overall population": 54230,
      "population included": 62340,
      "mean annual": 43709,
      "annual costs": 11013,
      "patient treated": 58801,
      "treated tapentadol": 82380,
      "respectively treatment": 71256,
      "oxycodone respectively": 55844,
      "sub group": 78577,
      "group opioid": 33880,
      "pain baseline": 56489,
      "remained unchanged": 70278,
      "study suggested": 78520,
      "line treatment": 42002,
      "instead oxycodone": 39065,
      "patients quality": 59722,
      "results use": 72047,
      "use different": 84312,
      "different sources": 24921,
      "data extrapolation": 21970,
      "introduction study": 39955,
      "adverse outcomes": 8832,
      "resource use": 71126,
      "use patients": 84611,
      "patients diagnosis": 59189,
      "diagnosis pain": 24337,
      "tapentadol prolonged": 80463,
      "release pr": 69987,
      "pr versus": 63381,
      "treated morphine": 82350,
      "morphine controlled": 47629,
      "care patients": 15057,
      "2011 december": 2580,
      "controls treated": 20675,
      "age pain": 9098,
      "pain duration": 56735,
      "pain site": 57846,
      "site pain": 76159,
      "pain aetiology": 56432,
      "times adverse": 81415,
      "vomiting compared": 86451,
      "cox proportional": 21029,
      "proportional hazards": 65785,
      "rates primary": 67628,
      "subset patients": 78790,
      "compared using": 18334,
      "using incidence": 85438,
      "incidence rate": 37307,
      "rate ratios": 67509,
      "regression results": 69456,
      "pain diagnosis": 56710,
      "43 oxycodone": 4504,
      "compared controls": 18125,
      "events tapentadol": 30127,
      "pr treatment": 63378,
      "treatment reduced": 82800,
      "cr primary": 21109,
      "pr associated": 63313,
      "significantly fewer": 75699,
      "adverse gastrointestinal": 8828,
      "gastrointestinal events": 32879,
      "cr patients": 21106,
      "secondary care": 74210,
      "care resource": 15074,
      "observational studies": 50623,
      "studies potential": 77814,
      "potential bias": 63143,
      "confounding indication": 19525,
      "funding gr\u00fcnenthal": 32735,
      "effective pain": 27660,
      "pain treatment": 57935,
      "understanding pharmacokinetic": 83646,
      "pharmacokinetic behavior": 61107,
      "age group": 9076,
      "pain little": 57025,
      "known pharmacokinetics": 40924,
      "pharmacokinetic modeling": 61119,
      "pharmacokinetic data": 61110,
      "data studies": 22121,
      "model described": 47040,
      "combined data": 17642,
      "data best": 21888,
      "compartment linear": 18392,
      "order absorption": 53703,
      "absorption rates": 6616,
      "route administration": 72838,
      "influence clearance": 38588,
      "cl volume": 16611,
      "following model": 32161,
      "describes population": 23667,
      "absolute bioavailability": 6593,
      "administration route": 8365,
      "coefficients variation": 17315,
      "19 respectively": 2196,
      "using model": 85498,
      "weight based": 86975,
      "based dose": 13309,
      "adjustment age": 8068,
      "age months": 9092,
      "months years": 47481,
      "dosing schedules": 26333,
      "isobolographic analysis": 40296,
      "analysis revealed": 10756,
      "coadministration morphine": 17122,
      "oxycodone produces": 55770,
      "designed determine": 23833,
      "coadministered healthy": 17119,
      "human subjects": 35975,
      "subjects methods": 78713,
      "randomized crossover": 67090,
      "study performed": 78378,
      "12 male": 1316,
      "determined intravenous": 24067,
      "intravenous infusions": 39834,
      "saline placebo": 73268,
      "placebo 15": 61622,
      "morphine sulphate": 47945,
      "hydrochloride combination": 36011,
      "dose ratios": 26039,
      "ratios drug": 67821,
      "drug metabolite": 26705,
      "metabolite concentrations": 44944,
      "measured high": 43967,
      "high performance": 35137,
      "performance liquid": 60553,
      "liquid chromatography": 42075,
      "chromatography ms": 16166,
      "ms ms": 48086,
      "ms results": 48093,
      "results placebo": 71870,
      "treatment significant": 82841,
      "differences active": 24709,
      "drug treatments": 26821,
      "responses drug": 71388,
      "drug treatment": 26818,
      "treatment mean": 82653,
      "decreased 74": 22971,
      "subjects treatment": 78748,
      "values 95": 85833,
      "69 59": 5515,
      "increasing oxycodone": 38114,
      "greater potency": 33480,
      "lower clearance": 42585,
      "morphine conclusions": 47618,
      "effects drugs": 27908,
      "use combination": 84248,
      "combination pain": 17595,
      "approved food": 11537,
      "release preparation": 69993,
      "preparation oxycodone": 63778,
      "oxycodone slow": 55923,
      "release properties": 69998,
      "abuse surveillance": 6888,
      "surveillance program": 79683,
      "named researched": 48555,
      "paper results": 58085,
      "abuse experts": 6722,
      "key informants": 40670,
      "drugs results": 27067,
      "indicate prescription": 38228,
      "abuse prevalent": 6843,
      "cases reported": 15259,
      "zip codes": 87765,
      "rank ordered": 67365,
      "ordered follows": 53727,
      "fentanyl buprenorphine": 31446,
      "abuse cases": 6658,
      "000 persons": 42,
      "digit zip": 24982,
      "zip code": 87764,
      "growth seen": 34382,
      "analgesics 10": 10360,
      "hydrocodone results": 36133,
      "indicate oxycontin": 38227,
      "problem country": 65237,
      "needs considered": 49056,
      "considered context": 19627,
      "abuse perspective": 6805,
      "past years": 58480,
      "epidemic study": 29154,
      "study report": 78460,
      "report systematic": 70479,
      "systematic data": 79975,
      "indicate opioid": 38224,
      "drug users": 26853,
      "users oxycontin": 85261,
      "hydrocodone products": 36130,
      "frequently abused": 32543,
      "need taken": 48961,
      "reduce prescription": 68889,
      "care needs": 15044,
      "appropriate use": 11519,
      "use drugs": 84347,
      "drugs treatment": 27094,
      "poorly studied": 62285,
      "tetrahydrocannabinol thc": 80877,
      "remains unknown": 70315,
      "combined opioid": 17661,
      "opioid studied": 52379,
      "studied effect": 77610,
      "effect thc": 27569,
      "oxycodone pretreatment": 55753,
      "methods randomised": 45504,
      "crossover trial": 21310,
      "trial healthy": 83027,
      "placebo oral": 61788,
      "mm hg": 46934,
      "intervals placebo": 39614,
      "results 18": 71547,
      "50 female": 4836,
      "30 decrease": 3734,
      "placebo effect": 61726,
      "20 23": 2278,
      "11 13": 1093,
      "83 oxycodone": 5934,
      "oxycodone second": 55865,
      "increased sedation": 38024,
      "sedation conclusions": 74309,
      "control placebo": 20392,
      "eu clinical": 29719,
      "trials register": 83190,
      "cancer induced": 14788,
      "induced bone": 38389,
      "bone pain": 14238,
      "pain cibp": 56545,
      "cibp challenging": 16543,
      "treat cibp": 82291,
      "cibp lack": 16547,
      "lack understanding": 41062,
      "cibp limits": 16549,
      "limits application": 41980,
      "application oxycodone": 11428,
      "oxycodone study": 55947,
      "treated spinal": 82377,
      "spinal dorsal": 76713,
      "rats cibp": 67843,
      "cibp performed": 16552,
      "proteins identified": 65945,
      "sham group": 75108,
      "cibp group": 16544,
      "cibp oxy": 16551,
      "reduction increase": 69061,
      "05 significant": 550,
      "group increased": 33826,
      "increased abundance": 37870,
      "group oxy": 33885,
      "reduced expression": 68927,
      "expression increased": 30835,
      "administration oxy": 8324,
      "dorsal horn": 25735,
      "horn neurons": 35549,
      "astrocytes microglia": 12517,
      "based observed": 13342,
      "potential drug": 63158,
      "drug target": 26802,
      "standard therapies": 76934,
      "therapies used": 80981,
      "used management": 84996,
      "management chronic": 43161,
      "pain widely": 57988,
      "widely adopted": 87055,
      "associated cancer": 12228,
      "considered important": 19632,
      "cancer neuropathic": 14798,
      "clock atc": 17048,
      "medication effective": 44495,
      "approach treating": 11482,
      "treating chronic": 82390,
      "pain guidelines": 56816,
      "american pain": 9797,
      "pain society": 57852,
      "preferred route": 63647,
      "administering opioids": 8197,
      "opioids oral": 53125,
      "concentrations blood": 18747,
      "therapy oral": 81039,
      "oral medication": 53565,
      "oral formulations": 53539,
      "opioids morphine": 53065,
      "oxycodone hydromorphone": 55216,
      "hydromorphone hydrocodone": 36175,
      "reduced dosing": 68921,
      "dosing frequency": 26311,
      "making easier": 43011,
      "dosing regimen": 26328,
      "increased compliance": 37892,
      "effective managing": 27639,
      "opioids share": 53293,
      "pharmacokinetics safety": 61190,
      "safety combination": 73128,
      "answer questions": 11053,
      "pain regimen": 57504,
      "doses sustained": 26282,
      "oxycodone enrolled": 55026,
      "day inpatient": 22325,
      "inpatient stay": 39031,
      "participants asked": 58281,
      "day days": 22295,
      "blood sampling": 14157,
      "sampling performed": 73371,
      "assessed daily": 11995,
      "investigations revealed": 40079,
      "revealed significant": 72225,
      "area plasma": 11634,
      "time curves": 81241,
      "significantly decreased": 75674,
      "decreased average": 22980,
      "27 95": 3486,
      "ci 46": 16456,
      "opioids significantly": 53297,
      "opioid levels": 51886,
      "combination allow": 17543,
      "treatment lower": 82645,
      "doses fewer": 26188,
      "effects introduction": 27960,
      "central role": 15614,
      "epidemic aim": 29126,
      "standardized perioperative": 76980,
      "perioperative pain": 60845,
      "pathway postoperative": 58517,
      "opioid requirements": 52339,
      "requirements men": 70884,
      "undergoing outpatient": 83563,
      "outpatient anterior": 54114,
      "institution methods": 39079,
      "patients undergoing": 60085,
      "single surgeon": 76142,
      "august 2017": 12669,
      "january 2021": 40459,
      "standardized nonopioid": 76973,
      "practice change": 63394,
      "october 2018": 50887,
      "transitioned oxycodone": 82208,
      "25 bupivacaine": 3346,
      "bupivacaine liposomal": 14503,
      "liposomal bupivacaine": 42071,
      "validated questionnaires": 85793,
      "questionnaires included": 66903,
      "included 72": 37405,
      "72 hour": 5616,
      "10 pain": 888,
      "management satisfaction": 43261,
      "consumption results": 20011,
      "total 116": 81714,
      "underwent outpatient": 83689,
      "did use": 24514,
      "opioids postoperatively": 53193,
      "78 patients": 5783,
      "patients used": 60163,
      "used tablets": 85153,
      "tablets median": 80173,
      "number unused": 50274,
      "unused tablets": 83968,
      "iqr 10": 40158,
      "use tablets": 84772,
      "preoperative opioid": 63747,
      "75 vs": 5722,
      "vs 25": 86553,
      "25 01": 3318,
      "overall patients": 54227,
      "reported higher": 70560,
      "higher satisfaction": 35321,
      "vs 01": 86510,
      "pain reduction": 57496,
      "80 vs": 5861,
      "vs 50": 86587,
      "50 01": 4798,
      "01 compared": 305,
      "conclusions opioid": 19132,
      "tablets opioid": 80183,
      "medication nonopioid": 44523,
      "care pathway": 15055,
      "pathway provides": 58518,
      "satisfactory pain": 73450,
      "control following": 20302,
      "following outpatient": 32179,
      "narcotic medication": 48598,
      "pain pathways": 57331,
      "perioperative patient": 60848,
      "patient counseling": 58599,
      "limit postoperative": 41889,
      "tolerance analgesic": 81569,
      "opioids demonstrated": 52840,
      "laboratory animals": 41024,
      "administration effect": 8255,
      "controlled laboratory": 20503,
      "laboratory conditions": 41026,
      "controlled study": 20584,
      "administered daily": 8116,
      "daily days": 21715,
      "days effects": 22521,
      "mg 70": 45764,
      "using session": 85609,
      "session cumulative": 74730,
      "cumulative dosing": 21394,
      "dosing procedure": 26326,
      "days daily": 22506,
      "daily dosing": 21745,
      "active oxycodone": 7523,
      "medication administered": 44453,
      "day day": 22292,
      "intermittent dosing": 39455,
      "phase placebo": 61312,
      "days intermittent": 22541,
      "day washout": 22447,
      "occurred phases": 50842,
      "administered healthy": 8131,
      "volunteers 10": 86412,
      "history drug": 35457,
      "dependence current": 23466,
      "drug use": 26828,
      "study analgesia": 77947,
      "analgesia assessed": 9917,
      "using cold": 85343,
      "pain drug": 56733,
      "effects measured": 27983,
      "using variety": 85659,
      "pupil diameter": 66487,
      "effects administered": 27808,
      "observed oxycodone": 50697,
      "tolerance did": 81585,
      "did develop": 24431,
      "oxycodone contrast": 54877,
      "contrast oxycodone": 20217,
      "ratings positive": 67705,
      "effects greater": 27933,
      "compared day": 18133,
      "miotic effects": 46674,
      "experimental conditions": 30659,
      "suggest tolerance": 79018,
      "effects therapeutic": 28182,
      "therapeutic doses": 80931,
      "oxycodone short": 55898,
      "dosing conditions": 26309,
      "intermittent administration": 39454,
      "administration enhance": 8257,
      "oxycodone increasing": 55252,
      "increasing drug": 38105,
      "drug positive": 26742,
      "effects related": 28135,
      "related abuse": 69543,
      "liability aims": 41637,
      "aims assess": 9475,
      "grunenthal aachen": 34384,
      "aachen germany": 6509,
      "study 54": 77898,
      "asa iii": 11816,
      "anesthesiologists classification": 10959,
      "classification physical": 16682,
      "status patients": 77264,
      "undergoing surgery": 83579,
      "surgery breast": 79337,
      "breast cancer": 14406,
      "anesthesia using": 10950,
      "allocated groups": 9612,
      "groups receiving": 34289,
      "receiving 20": 68314,
      "mg midazolam": 46053,
      "hours later": 35790,
      "later patients": 41238,
      "variables clinical": 85889,
      "differences mean": 24757,
      "mean values": 43899,
      "values pain": 85851,
      "rest pain": 71429,
      "scores coughing": 73857,
      "coughing 24": 20918,
      "hours operation": 35801,
      "equivalence margin": 29276,
      "determined 10": 24058,
      "10 visual": 949,
      "scale results": 73551,
      "regarding pain": 69265,
      "90 ci": 6080,
      "ci mean": 16532,
      "mean differences": 43764,
      "differences treatment": 24826,
      "treatment groups": 82601,
      "groups 24": 34104,
      "paracetamol given": 58099,
      "hour observation": 35704,
      "observation period": 50605,
      "significantly oxy": 75823,
      "group 32": 33598,
      "group 61": 33632,
      "61 32": 5307,
      "32 significant": 3939,
      "groups regarding": 34291,
      "regarding adverse": 69240,
      "nausea 13": 48758,
      "13 vomiting": 1510,
      "satisfaction scores": 73435,
      "scores patients": 73947,
      "patients general": 59321,
      "cancer oxycodone": 14811,
      "prescribed analgesic": 63818,
      "effects high": 27938,
      "high potential": 35146,
      "based dosage": 13308,
      "dosage formulation": 25750,
      "oc metabolites": 50807,
      "limited studies": 41962,
      "knowledge gap": 40884,
      "pharmacokinetic differences": 61111,
      "impact cyp2d6": 36803,
      "cyp2d6 activity": 21588,
      "metabolism excretion": 44931,
      "objectives study": 50589,
      "study compare": 77997,
      "phase ii": 61284,
      "ii metabolites": 36565,
      "changes time": 15824,
      "used predict": 85082,
      "ir tablet": 40260,
      "tablet oxycodone": 80097,
      "weeks later": 86918,
      "setting urine": 74848,
      "collected 10": 17444,
      "10 12": 668,
      "12 14": 1214,
      "48 72": 4692,
      "samples 100": 73325,
      "100 \u00b5l": 1028,
      "standard mixture": 76920,
      "acquity uplc": 7364,
      "uplc class": 83992,
      "class coupled": 16654,
      "coupled waters": 20981,
      "waters xevo": 86765,
      "xevo tqd": 87405,
      "using previously": 85574,
      "previously validated": 64965,
      "validated method": 85791,
      "cyp2d6 phenotypes": 21618,
      "poor metabolizers": 62265,
      "metabolizers pm": 45009,
      "pm intermediate": 62040,
      "intermediate metabolizers": 39450,
      "im extensive": 36672,
      "extensive metabolizers": 30916,
      "metabolizers em": 45004,
      "em ultrarapid": 28632,
      "ultrarapid metabolizers": 83426,
      "metabolizers um": 45011,
      "ir cr": 40217,
      "performed using": 60647,
      "paired test": 58024,
      "significance level": 75407,
      "level 05": 41445,
      "metabolite ratios": 44962,
      "metabolite parent": 44958,
      "ratios used": 67835,
      "early time": 27275,
      "drug metabolizing": 26709,
      "metabolizing enzymes": 45015,
      "interactions ddis": 39392,
      "information regarding": 38668,
      "influence opioids": 38595,
      "administration 15": 8206,
      "kg intraperitoneally": 40745,
      "quantitative real": 66805,
      "time polymerase": 81342,
      "polymerase chain": 62200,
      "chain reaction": 15687,
      "analyses used": 10617,
      "used identify": 84959,
      "significantly regulated": 75855,
      "regulated genes": 69493,
      "using metacore": 85489,
      "metacore computational": 45018,
      "computational platform": 18650,
      "taken findings": 80282,
      "repeated oxycodone": 70417,
      "administration rats": 8356,
      "rats demonstrate": 67852,
      "demonstrate oxycodone": 23323,
      "oxycodone alters": 54709,
      "alters expression": 9753,
      "medications illicit": 44627,
      "illicit drugs": 36637,
      "gastrointestinal tract": 32896,
      "drug absorption": 26498,
      "surface area": 79258,
      "case presented": 15184,
      "toxic effect": 81926,
      "drug adverse": 26529,
      "including bowel": 37596,
      "bowel obstruction": 14287,
      "airway obstruction": 9506,
      "effects oxymorphone": 28076,
      "oxymorphone extended": 56241,
      "release om": 69903,
      "release oc": 69902,
      "setting inpatient": 74780,
      "inpatient unit": 39034,
      "subjects healthy": 78702,
      "tablets placebo": 80197,
      "contained om": 20065,
      "mg oc": 46073,
      "range doses": 67311,
      "pain calculated": 56505,
      "opioid conversion": 51677,
      "conversion table": 20715,
      "table main": 80074,
      "addiction research": 7764,
      "research center": 70983,
      "center inventory": 15526,
      "positive negative": 62469,
      "mg versus": 46256,
      "mg low": 46041,
      "low doses": 42483,
      "er 30": 29389,
      "doses results": 26267,
      "thirty subjects": 81117,
      "effects lower": 27975,
      "morphine benzedrine": 47587,
      "benzedrine group": 13647,
      "001 high": 143,
      "nausea higher": 48776,
      "mg 001": 45682,
      "001 overall": 171,
      "drug 001": 26494,
      "mg 18": 45722,
      "dose group": 25918,
      "euphoric mood": 29729,
      "nausea somnolence": 48784,
      "somnolence vomiting": 76469,
      "use healthy": 84393,
      "doses single": 26275,
      "produced lower": 65394,
      "lower positive": 42678,
      "subjective objective": 78656,
      "objective effects": 50404,
      "combined opioids": 17662,
      "produce synergistic": 65370,
      "synergistic antinociceptive": 79931,
      "lowest effective": 42731,
      "opioid sparing": 52364,
      "sparing effects": 76530,
      "patients report": 59883,
      "report greater": 70459,
      "greater analgesia": 33429,
      "cannabis used": 14937,
      "opioids placebo": 53174,
      "studies assessed": 77651,
      "direct effects": 25046,
      "opioids combined": 52797,
      "study determined": 78115,
      "using validated": 85655,
      "experimental model": 30667,
      "pain effects": 56745,
      "cold water": 17430,
      "report pain": 70468,
      "hand water": 34555,
      "abuse related": 6860,
      "related effects": 69596,
      "administration determined": 8246,
      "increased pain": 37974,
      "oxycodone failed": 55065,
      "elicit analgesia": 28569,
      "analgesia combined": 9926,
      "did increase": 24456,
      "oxycodone active": 54670,
      "produced small": 65412,
      "significant increases": 75566,
      "increases oxycodone": 38068,
      "oxycodone suggesting": 55962,
      "findings support": 31828,
      "therapeutic use": 80967,
      "combinations pain": 17628,
      "pain background": 56480,
      "background approximately": 13015,
      "approximately 20": 11562,
      "20 30": 2281,
      "suffer chronic": 78957,
      "guidelines management": 34445,
      "use controlled": 84274,
      "opioids treat": 53354,
      "pain effective": 56743,
      "associated high": 12273,
      "high rates": 35159,
      "constipation oic": 19772,
      "effectiveness combination": 27753,
      "oxycodone management": 55367,
      "relief oic": 70154,
      "oic previously": 50990,
      "previously evaluated": 64943,
      "canada methods": 14749,
      "estimate cost": 29607,
      "cost utility": 20888,
      "naloxone compared": 48438,
      "managing pain": 43292,
      "costs related": 20904,
      "oic included": 50986,
      "included analysis": 37421,
      "analysis primary": 10741,
      "rates observed": 67602,
      "observed clinical": 50662,
      "conducted healthcare": 19363,
      "canadian dollars": 14755,
      "dollars results": 25702,
      "patient populations": 58708,
      "higher total": 35332,
      "treated patients": 82370,
      "patients compared": 59101,
      "patients improved": 59386,
      "improved clinical": 37100,
      "benefits terms": 13639,
      "patients analgesic": 58991,
      "analgesic costs": 10178,
      "costs slightly": 20906,
      "patients targin": 60040,
      "use resources": 84701,
      "management oic": 43217,
      "oxycodone ranged": 55794,
      "analysis cost": 10665,
      "results remained": 71913,
      "conclusion clinical": 18869,
      "clinical effectiveness": 16798,
      "pain oic": 57272,
      "oic compared": 50985,
      "resulted low": 71509,
      "low cost": 42464,
      "examine impact": 30345,
      "national clinical": 48672,
      "practice guidelines": 63400,
      "hospitalization opioid": 35658,
      "opioid toxicity": 52433,
      "analysis setting": 10764,
      "setting ontario": 74792,
      "2014 participants": 2671,
      "aged 15": 9144,
      "15 64": 1707,
      "64 years": 5395,
      "guidelines use": 34476,
      "november 2011": 50030,
      "outcomes explored": 54026,
      "rate opioid": 67489,
      "prevalence opioid": 64791,
      "prescriptions exceeding": 64484,
      "exceeding 200": 30436,
      "mg 400": 45750,
      "equivalents day": 29345,
      "department visits": 23449,
      "visits hospital": 86284,
      "hospital admissions": 35558,
      "period rate": 60782,
      "use declined": 84291,
      "users 10": 85225,
      "use significantly": 84728,
      "significantly impacted": 75742,
      "use impact": 84419,
      "users prevalence": 85265,
      "period 2014": 60696,
      "2014 40": 2655,
      "doses 200": 26131,
      "transdermal fentanyl": 82145,
      "period 18": 60686,
      "doses 400": 26139,
      "admissions increased": 8416,
      "increased 55": 37861,
      "period 14": 60682,
      "rate significantly": 67518,
      "59 conclusions": 5187,
      "pain led": 57004,
      "legislation did": 41369,
      "result significant": 71491,
      "change rates": 15746,
      "prescribing population": 64113,
      "safe prescribing": 73100,
      "opioids needed": 53086,
      "needed objective": 49015,
      "objective impact": 50437,
      "impact educational": 36808,
      "intervention ed": 39630,
      "discharge oxycodone": 25152,
      "prescribing number": 64088,
      "discharged patients": 25209,
      "number tablets": 50265,
      "tablets prescription": 80207,
      "outcomes included": 54031,
      "included quality": 37530,
      "assessment conducted": 12108,
      "tertiary referral": 80748,
      "referral hospital": 69153,
      "pre intervention": 63471,
      "intervention post": 39642,
      "post intervention": 62577,
      "intervention prescribing": 39645,
      "medical practitioners": 44385,
      "numbers used": 50287,
      "used obtain": 85039,
      "data oxycodone": 22035,
      "oxycodone containing": 54873,
      "containing prescriptions": 20084,
      "queensland health": 66871,
      "intervention included": 39635,
      "ed patient": 27338,
      "results pre": 71882,
      "intervention period": 39641,
      "ci 12": 16395,
      "ci 13": 16398,
      "13 31": 1464,
      "reduction mean": 69065,
      "mean total": 43889,
      "prescription decreased": 64195,
      "decreased 16": 22943,
      "16 sd": 1892,
      "sd 16": 74065,
      "12 sd": 1361,
      "10 sd": 922,
      "general practitioners": 32984,
      "practitioners 15": 63449,
      "15 95": 1719,
      "ci 21": 16412,
      "21 conclusions": 2965,
      "ed prescriber": 27347,
      "targeted intervention": 80497,
      "overall prescribing": 54232,
      "prescribing oxycodone": 64096,
      "improved communication": 37102,
      "discharge prescribing": 25163,
      "strategy used": 77446,
      "used ed": 84925,
      "medical staff": 44405,
      "patient safety": 58752,
      "analgesic effectiveness": 10210,
      "effectiveness safety": 27780,
      "safety new": 73170,
      "new oxycodone": 49351,
      "mg acetaminophen": 45784,
      "acetaminophen 325": 7125,
      "325 mg": 3950,
      "mg percocet": 46156,
      "formulations patients": 32399,
      "patients low": 59460,
      "low pain": 42518,
      "pain lbp": 56999,
      "nonsteroidal anti": 49853,
      "muscle relaxants": 48362,
      "cyclo oxygenase": 21551,
      "prn opioids": 65202,
      "opioids design": 52841,
      "design prospective": 23757,
      "prospective open": 65851,
      "week trial": 86876,
      "patients thirty": 60044,
      "women mean": 87221,
      "age 52": 9019,
      "52 years": 5003,
      "mean duration": 43773,
      "10 years": 961,
      "years interventions": 87603,
      "discontinued oxycodone": 25243,
      "dosed times": 26113,
      "meaningful pain": 43916,
      "acetaminophen dose": 7180,
      "mg tid": 46238,
      "650 mg": 5431,
      "effectiveness brief": 27750,
      "pain scale": 57659,
      "scale score": 73556,
      "dull deep": 27120,
      "deep pain": 23092,
      "pain quality": 57452,
      "lumbar spine": 42758,
      "events physical": 30098,
      "clinical laboratory": 16833,
      "tests results": 80863,
      "patients 85": 58905,
      "85 completed": 5982,
      "study discontinuations": 78122,
      "discontinuations adverse": 25235,
      "events patient": 30093,
      "mean oxycodone": 43821,
      "end treatment": 28831,
      "bpi pain": 14298,
      "intensity improved": 39259,
      "improved pain": 37116,
      "pain interference": 56962,
      "interference quality": 39427,
      "treatment safe": 82825,
      "events commonly": 30024,
      "expected opioid": 30555,
      "opioid mild": 51935,
      "mild moderate": 46426,
      "moderate intensity": 47150,
      "intensity conclusions": 39239,
      "conclusions primary": 19178,
      "primary purpose": 65105,
      "test effectiveness": 80768,
      "acetaminophen reduced": 7247,
      "acetaminophen clinical": 7161,
      "practice setting": 63415,
      "results trial": 72042,
      "trial suggest": 83093,
      "formulations effective": 32378,
      "chronic lbp": 16198,
      "patients 67": 58891,
      "relief tolerable": 70198,
      "tolerable effects": 81565,
      "tid dosing": 81172,
      "patients experience": 59272,
      "dosing oxycodone": 26319,
      "term controlled": 80624,
      "studies efficacy": 77706,
      "efficacy patient": 28323,
      "patient population": 58704,
      "study introduction": 78267,
      "estimated million": 29631,
      "opioids 50": 52680,
      "50 000": 4796,
      "longer term": 42388,
      "persistent opioid": 60918,
      "estimated 10": 29619,
      "10 opioid": 882,
      "develop persistent": 24153,
      "compare rates": 18051,
      "used postoperative": 85079,
      "postoperative opioids": 62830,
      "initial postoperative": 38866,
      "term outcomes": 80657,
      "outcomes methods": 54056,
      "methods analysis": 45249,
      "administrative data": 8398,
      "study include": 78245,
      "supply oxycodone": 79185,
      "home following": 35510,
      "following discharge": 32126,
      "surgical ward": 79659,
      "use months": 84496,
      "postdischarge opioid": 62640,
      "receive immediate": 68051,
      "hierarchical logistic": 35062,
      "use controlling": 84278,
      "ethics dissemination": 29690,
      "dissemination ethics": 25517,
      "ethics approval": 29687,
      "approval obtained": 11524,
      "monash university": 47300,
      "university human": 83866,
      "research ethics": 71003,
      "present project": 64627,
      "project findings": 65591,
      "findings peer": 31804,
      "peer reviewed": 60369,
      "reviewed journal": 72381,
      "journal article": 40494,
      "reporting studies": 70704,
      "conducted using": 19420,
      "routinely collected": 72868,
      "collected health": 17460,
      "clinical history": 16823,
      "history patient": 35473,
      "patient 37": 58530,
      "37 year": 4207,
      "chief complaint": 16001,
      "sickle cell": 75368,
      "cell crisis": 15475,
      "patient severe": 58781,
      "pain lower": 57039,
      "previous weeks": 64929,
      "weeks hospital": 86916,
      "discharged prescription": 25211,
      "prescription oxycodone": 64374,
      "oxycodone condition": 54841,
      "condition did": 19279,
      "did respond": 24494,
      "medicine pain": 44710,
      "patient multiple": 58684,
      "alcohol consumption": 9529,
      "illegal drug": 36622,
      "use physical": 84625,
      "physical examination": 61395,
      "findings patient": 31803,
      "patient normal": 58687,
      "family history": 31179,
      "laboratory findings": 41028,
      "findings table": 31830,
      "background aims": 13011,
      "nordic countries": 49886,
      "controls opioid": 20671,
      "previous research": 64913,
      "prescription strong": 64410,
      "opioids increasing": 52992,
      "study examines": 78202,
      "individuals receiving": 38354,
      "receiving ambulatory": 68323,
      "2006 2017": 2478,
      "publicly available": 66414,
      "available data": 12796,
      "national prescription": 48710,
      "methods repeated": 45524,
      "repeated cross": 70402,
      "sectional design": 74281,
      "year prevalence": 87489,
      "group reported": 33975,
      "denmark sweden": 23394,
      "period 2006": 60691,
      "prevalence weak": 64821,
      "codeine strong": 17288,
      "defined daily": 23126,
      "daily dose": 21722,
      "dose ddd": 25860,
      "opioids prescribed": 53204,
      "prescribed reported": 63974,
      "reported opioids": 70600,
      "2016 results": 2758,
      "results patterns": 71859,
      "opioids differ": 52850,
      "opioids 12": 52660,
      "population dispensed": 62328,
      "overall prevalence": 54235,
      "prevalence rates": 64809,
      "opioids compared": 52807,
      "largest proportion": 41197,
      "proportion population": 65777,
      "population conclusions": 62320,
      "conclusions significant": 19213,
      "norway sweden": 49973,
      "past 12": 58448,
      "12 years": 1391,
      "increasing prevalence": 38119,
      "oxycodone countries": 54888,
      "guide prescribing": 34408,
      "hospital stays": 35642,
      "importance objective": 36983,
      "compare use": 18061,
      "effectiveness different": 27757,
      "different opioids": 24898,
      "opioids postoperative": 53190,
      "materials methods": 43504,
      "patients evaluated": 59265,
      "total study": 81905,
      "divided groups": 25620,
      "groups group": 34207,
      "group 10": 33557,
      "naloxone mg": 48460,
      "group 20": 33581,
      "naloxone 10": 48423,
      "group tramadol": 34054,
      "treatment satisfaction": 82827,
      "evaluated results": 29917,
      "results discussion": 71665,
      "differences pain": 24776,
      "compared groups": 18172,
      "additional pain": 7878,
      "postoperative vomiting": 62985,
      "vomiting satisfaction": 86477,
      "differed significantly": 24563,
      "procedure specific": 65285,
      "analysis shown": 10768,
      "shown differences": 75335,
      "sub groups": 78578,
      "groups significant": 34319,
      "summary findings": 79099,
      "suggest postoperative": 79010,
      "regard pain": 69233,
      "parenteral morphine": 58206,
      "dying cancer": 27211,
      "patients terminal": 60041,
      "efficacy opioids": 28308,
      "oxycodone remains": 55831,
      "remains largely": 70295,
      "largely unknown": 41169,
      "unknown objectives": 83884,
      "objectives explore": 50562,
      "explore efficacy": 30722,
      "vs morphine": 86660,
      "morphine continuous": 47626,
      "infusion 24": 38696,
      "methods pre": 45472,
      "subgroup analysis": 78617,
      "analysis multicenter": 10711,
      "multicenter prospective": 48166,
      "study inclusion": 78255,
      "inclusion criteria": 37686,
      "criteria advanced": 21189,
      "advanced cancer": 8593,
      "care units": 15093,
      "eastern cooperative": 27285,
      "cooperative oncology": 20750,
      "oncology group": 51073,
      "group performance": 33911,
      "morphine initiated": 47735,
      "scores 24": 73831,
      "results analyzed": 71603,
      "164 patients": 1916,
      "days mean": 22551,
      "age 70": 9047,
      "70 years": 5575,
      "years 58": 87548,
      "58 patients": 5162,
      "patients 35": 58858,
      "lung cancer": 42762,
      "lung metastases": 42768,
      "scores decreased": 73859,
      "deviation oxycodone": 24263,
      "group difference": 33746,
      "difference means": 24628,
      "001 morphine": 159,
      "001 significant": 206,
      "significant group": 75542,
      "group differences": 33753,
      "differences existed": 24740,
      "seen patients": 74364,
      "morphine groups": 47709,
      "conclusion parenteral": 18952,
      "safe morphine": 73092,
      "morphine treatment": 47962,
      "patients future": 59320,
      "future randomized": 32767,
      "trials confirm": 83128,
      "safety opioids": 73178,
      "widely accepted": 87054,
      "standard therapy": 76935,
      "therapy treating": 81072,
      "treating acute": 82384,
      "pain frequent": 56797,
      "substantial burden": 78843,
      "optimal dosing": 53423,
      "adherence prescribed": 7996,
      "multimodal treatment": 48250,
      "pain lack": 56989,
      "lack knowledge": 41057,
      "potential benefit": 63140,
      "concerns effects": 18843,
      "added benefits": 7730,
      "results coadministration": 71626,
      "analgesia similar": 10110,
      "combination morphine": 17568,
      "treat acute": 82271,
      "pain independent": 56867,
      "morphine plus": 47877,
      "plus oxycodone": 62028,
      "excellent analgesia": 30440,
      "analgesia lower": 10010,
      "compared equianalgesic": 18150,
      "doses individual": 26203,
      "individual opioids": 38303,
      "trials morphine": 83165,
      "approximately 500": 11573,
      "500 subjects": 4927,
      "subjects moderate": 78714,
      "severe post": 75007,
      "post surgical": 62620,
      "pain received": 57478,
      "received multiple": 68207,
      "multiple doses": 48274,
      "oxycodone single": 55921,
      "single entity": 76101,
      "23 days": 3096,
      "phase phase": 61310,
      "phase clinical": 61276,
      "studies demonstrate": 77691,
      "demonstrate analgesic": 23311,
      "showing 50": 75324,
      "severe aes": 74911,
      "combination product": 17603,
      "morphine provide": 47896,
      "provide effective": 66051,
      "effective relief": 27689,
      "pain reducing": 57495,
      "aes patients": 8882,
      "past decades": 58463,
      "opioids pos": 53184,
      "particular oxycodone": 58404,
      "increased 14": 37826,
      "14 fold": 1597,
      "high consumption": 35078,
      "consumption pain": 19975,
      "pain relievers": 57605,
      "abuse substances": 6885,
      "resulted dramatic": 71504,
      "increase number": 37760,
      "related fatalities": 69606,
      "dependent subjects": 23536,
      "million population": 46495,
      "people dependent": 60404,
      "use 40": 84156,
      "users reported": 85269,
      "reported non": 70591,
      "non pain": 49666,
      "use misuse": 84491,
      "use pos": 84629,
      "slower rate": 76268,
      "assess risk": 11963,
      "po abuse": 62053,
      "abuse overdose": 6797,
      "overdose epidemic": 54290,
      "concluded risk": 18855,
      "europe limited": 29732,
      "dramatic rise": 26437,
      "rise opioid": 72489,
      "addiction overdose": 7751,
      "abuse involving": 6743,
      "nonoral administration": 49820,
      "oral versus": 53684,
      "nonoral abuse": 49819,
      "indicate oral": 38225,
      "97 opioid": 6443,
      "factors associated": 31071,
      "administration include": 8274,
      "longer duration": 42368,
      "duration opioid": 27168,
      "male gender": 43039,
      "relatively high": 69776,
      "high drug": 35095,
      "drug load": 26695,
      "onset effect": 51114,
      "formulations developed": 32376,
      "decrease likelihood": 22898,
      "reducing risk": 69032,
      "risk abuse": 72505,
      "appropriate patient": 11509,
      "patient selection": 58779,
      "patient monitoring": 58682,
      "management following": 43182,
      "painful orthopedic": 58007,
      "day surgery": 22424,
      "decrease need": 22902,
      "operative opioids": 51261,
      "reduce need": 68856,
      "surgical correction": 79626,
      "correction hallux": 20800,
      "hallux valgus": 34540,
      "patients planned": 59650,
      "surgery procedure": 79537,
      "pre operatively": 63480,
      "dexamethasone mg": 24287,
      "paracetamol oxycodone": 58111,
      "oxycodone capsules": 54767,
      "medication given": 44500,
      "study ended": 78149,
      "day pod": 22375,
      "endpoint cumulative": 28883,
      "cumulative oxycodone": 21401,
      "oxycodone consumption": 54850,
      "consumption secondary": 20015,
      "maximal pain": 43576,
      "daily oxycodone": 21785,
      "addition adverse": 7795,
      "effects documented": 27902,
      "documented results": 25667,
      "patients groups": 59344,
      "study total": 78544,
      "total median": 81834,
      "median range": 44279,
      "range oxycodone": 67330,
      "consumption study": 20026,
      "period 45": 60704,
      "mg dexamethasone": 45870,
      "dexamethasone group": 24284,
      "group 78": 33644,
      "175 mg": 2012,
      "differences oxycodone": 24774,
      "reported significantly": 70647,
      "significantly nausea": 75819,
      "pod pods": 62067,
      "differences seen": 24814,
      "seen weeks": 74368,
      "weeks post": 86936,
      "post operatively": 62609,
      "drug therapy": 26814,
      "therapy did": 81008,
      "differ groups": 24541,
      "combined paracetamol": 17665,
      "reduced total": 68982,
      "total oxycodone": 81873,
      "consumption following": 19926,
      "drugs increasingly": 26982,
      "increasingly prescribed": 38135,
      "prescribed pregnant": 63958,
      "pregnant women": 63699,
      "fetal brain": 31619,
      "hypothesized maternal": 36309,
      "maternal treatment": 43528,
      "oxy primary": 54462,
      "opioid center": 51569,
      "center current": 15515,
      "current crisis": 21431,
      "gene expression": 32942,
      "expression changes": 30829,
      "female mice": 31366,
      "treated daily": 82333,
      "daily mg": 21758,
      "mg oxy": 46090,
      "oxy kg": 54456,
      "kg saline": 40799,
      "saline solution": 73272,
      "solution control": 76439,
      "control ctl": 20287,
      "ctl weeks": 21365,
      "breeding gestation": 14423,
      "female offspring": 31369,
      "anxiety like": 11278,
      "physical activity": 61379,
      "qpcr analyses": 66644,
      "candidate gene": 14922,
      "expression patterns": 30839,
      "offspring developmental": 50980,
      "exposure oxy": 30786,
      "prenatal exposure": 63726,
      "sex dependent": 75069,
      "dependent differences": 23507,
      "differences expression": 24741,
      "expression genes": 30834,
      "genes encoding": 33059,
      "encoding opioid": 28769,
      "oxy exposure": 54448,
      "exposure induced": 30768,
      "induced changes": 38395,
      "epigenetic changes": 29196,
      "changes brain": 15778,
      "brain region": 14360,
      "cause concern": 15346,
      "work needed": 87279,
      "needed determine": 48995,
      "determine potential": 24039,
      "epigenetic mechanisms": 29198,
      "tapentadol opioid": 80449,
      "opioid mu": 51964,
      "agonism noradrenaline": 9270,
      "reuptake inhibition": 72198,
      "prescribing trends": 64143,
      "aimed investigate": 9457,
      "australian tertiary": 12707,
      "tertiary hospital": 80740,
      "hospital methods": 35602,
      "methods analysed": 45248,
      "expressed oral": 30821,
      "equivalents ome": 29369,
      "conducted retrospective": 19399,
      "54 patients": 5051,
      "hospital surgical": 35646,
      "results years": 72064,
      "19 reduction": 2195,
      "reduction total": 69104,
      "dispensing opioids": 25451,
      "ome milligrams": 51060,
      "specifically oxycodone": 76629,
      "oxycodone 37": 54567,
      "release 70": 69803,
      "prescriptions tapentadol": 64566,
      "increased 17": 37828,
      "17 2016": 1939,
      "21 2020": 2943,
      "surgical units": 79658,
      "97 patients": 6445,
      "tapentadol acute": 80382,
      "pain majority": 57050,
      "54 prescribed": 5052,
      "release sustained": 70009,
      "pain spinal": 57855,
      "prescriptions increased": 64502,
      "preferred opioid": 63641,
      "pain observed": 57270,
      "background aim": 13007,
      "compare opioid": 18035,
      "opioid piritramide": 52066,
      "mg ml": 46055,
      "given patient": 33185,
      "general surgery": 32989,
      "surgery trauma": 79607,
      "trauma surgery": 82264,
      "opioids safety": 53284,
      "procedures compared": 65295,
      "parenteral oral": 58211,
      "pain service": 57815,
      "analgesia evaluated": 9966,
      "quantitative data": 66798,
      "qualitative results": 66667,
      "satisfaction recorded": 73427,
      "august 2007": 12661,
      "231 patients": 3125,
      "31 december": 3866,
      "december 2012": 22822,
      "good good": 33315,
      "higher percentage": 35296,
      "group 96": 33658,
      "96 patients": 6424,
      "satisfied dissatisfied": 73457,
      "rate effects": 67465,
      "group approximately": 33670,
      "difference statistically": 24688,
      "vomiting vomiting": 86488,
      "vomiting reported": 86472,
      "reported mean": 70581,
      "effects typically": 28188,
      "seen opioid": 74362,
      "opioid pcia": 52048,
      "total patients": 81882,
      "group incidence": 33823,
      "directly compared": 25061,
      "piritramide oxycodone": 61564,
      "analgesia comparable": 9930,
      "comparable groups": 17955,
      "oxycodone combination": 54799,
      "mg subjects": 46224,
      "following bunionectomy": 32107,
      "hospitalized patients": 35667,
      "years moderate": 87618,
      "pain score": 57662,
      "interventions study": 39682,
      "surgery given": 79408,
      "efficacy variable": 28417,
      "mean sum": 43884,
      "difference spid": 24686,
      "spid scores": 76689,
      "baseline results": 13458,
      "total morphine": 81840,
      "dose med": 25950,
      "182 mg": 2137,
      "mg 92": 45779,
      "92 mg": 6154,
      "mg spid": 46222,
      "baseline 24": 13408,
      "hours spid": 35854,
      "hours significantly": 35849,
      "mg vs": 46259,
      "fewer subjects": 31669,
      "medication used": 44585,
      "medication longer": 44512,
      "median time": 44288,
      "time use": 81394,
      "oxygen desaturation": 56200,
      "mg cumulative": 45844,
      "median dose": 44216,
      "provided superior": 66162,
      "superior efficacy": 79126,
      "efficacy individual": 28279,
      "modest increase": 47225,
      "increase incidence": 37752,
      "according previous": 7058,
      "oxycodone advantages": 54695,
      "advantages morphine": 8614,
      "treatment visceral": 82885,
      "pain study": 57872,
      "investigated opioid": 40046,
      "consumption primary": 19997,
      "outcome pain": 53969,
      "relief effects": 70126,
      "morphine versus": 47968,
      "percutaneous nephrolithotomy": 60544,
      "using method": 85493,
      "pain component": 56580,
      "patients studied": 60001,
      "studied patients": 77625,
      "patients randomised": 59727,
      "randomised receive": 67034,
      "receive morphine": 68058,
      "treatment surgery": 82868,
      "surgery opioid": 79485,
      "scores effects": 73876,
      "nausea dizziness": 48771,
      "varied considerably": 85934,
      "considerably patients": 19619,
      "patients mean": 59479,
      "mean opioid": 43816,
      "consumption morphine": 19956,
      "group comparable": 33683,
      "93 mg": 6174,
      "versus 16": 86101,
      "16 15": 1846,
      "nausea significantly": 48783,
      "significantly frequent": 75705,
      "study morphine": 78313,
      "produced similar": 65411,
      "frequency nausea": 32517,
      "significantly patient": 75829,
      "patient reported": 58731,
      "reported morphine": 70590,
      "oxycodone superior": 55964,
      "superior treatment": 79149,
      "percutaneous kidney": 60542,
      "kidney stone": 40829,
      "global use": 33234,
      "increased fold": 37916,
      "decade study": 22807,
      "effect age": 27419,
      "pharmacokinetics intravenous": 61172,
      "renal function": 70356,
      "function elderly": 32644,
      "elderly patients": 28478,
      "methods compared": 45275,
      "compared pharmacokinetics": 18258,
      "mg intravenous": 45930,
      "oxycodone groups": 55142,
      "groups 10": 34092,
      "aged 20": 9173,
      "40 60": 4325,
      "60 70": 5230,
      "70 70": 5551,
      "70 90": 5557,
      "90 years": 6119,
      "surgery plasma": 79522,
      "noroxymorphone metabolites": 49950,
      "metabolites measured": 44971,
      "measured 24": 43957,
      "chromatography tandem": 16171,
      "tandem mass": 80358,
      "spectrometric method": 76655,
      "cyp 2d6": 21569,
      "2d6 genotype": 3650,
      "glomerular filtration": 33238,
      "filtration rate": 31736,
      "rate gfr": 67468,
      "gfr estimated": 33139,
      "age sex": 9114,
      "serum creatinine": 74698,
      "concentration patient": 18712,
      "patient results": 58749,
      "results pharmacokinetics": 71868,
      "showed age": 75228,
      "mean area": 43711,
      "time curve": 81233,
      "curve time": 21529,
      "time zero": 81400,
      "zero infinity": 87760,
      "infinity auc": 38541,
      "oxycodone 80": 54602,
      "body clearance": 14190,
      "drug plasma": 26739,
      "mean auc": 43720,
      "group age": 33668,
      "groups 60": 34118,
      "70 80": 5555,
      "80 years": 5863,
      "hours post": 35816,
      "higher 01": 35198,
      "01 patients": 320,
      "aged 80": 9197,
      "years patients": 87633,
      "40 years": 4386,
      "years noroxycodone": 87621,
      "noroxycodone auc": 49925,
      "auc increased": 12630,
      "compared patients": 18251,
      "significant sex": 75634,
      "sex related": 75087,
      "related differences": 69589,
      "41 patients": 4428,
      "patients extensive": 59293,
      "metabolizers cyp2d6": 45003,
      "effect cyp2d6": 27441,
      "genotype oxycodone": 33097,
      "assessed linear": 12014,
      "linear correlation": 42012,
      "coefficient determination": 17312,
      "distribution steady": 25566,
      "steady state": 77303,
      "05 19": 479,
      "29 oxycodone": 3611,
      "conclusions age": 19029,
      "age important": 9082,
      "important factor": 37008,
      "factor affecting": 31048,
      "aged 70": 9193,
      "average 40": 12870,
      "80 higher": 5843,
      "oxycodone young": 56106,
      "young adult": 87712,
      "dependent age": 23497,
      "age patient": 9100,
      "important titrate": 37036,
      "titrate analgesic": 81462,
      "analgesic dose": 10180,
      "dose individually": 25934,
      "individually particularly": 38327,
      "particularly elderly": 58409,
      "intravenous use": 39890,
      "use common": 84249,
      "common routes": 17806,
      "technology combines": 80555,
      "label randomized": 40994,
      "randomized period": 67145,
      "period treatment": 60805,
      "treatment crossover": 82532,
      "evaluate bioequivalence": 29775,
      "18 55": 2054,
      "years received": 87653,
      "effects doses": 27905,
      "using liquid": 85464,
      "mean ratios": 43851,
      "auc area": 12627,
      "area concentration": 11622,
      "90 confidence": 6082,
      "confidence intervals": 19479,
      "events mild": 30068,
      "therapy nausea": 81032,
      "occurred subjects": 50846,
      "subjects results": 78741,
      "provide alternative": 66032,
      "alternative conventional": 9718,
      "conventional immediate": 20693,
      "oxycodone formulations": 55104,
      "month follow": 47390,
      "observational prospective": 50616,
      "prospective multicenter": 65836,
      "multicenter study": 48172,
      "spinal cord": 76708,
      "patients neuropathic": 59543,
      "pain np": 57246,
      "np objectives": 50049,
      "assess effectiveness": 11928,
      "safety oxycodone": 73184,
      "difficult control": 24961,
      "intensity visual": 39327,
      "persisting month": 60934,
      "previously treated": 64961,
      "results 54": 71574,
      "57 patients": 5135,
      "patients recruited": 59870,
      "total 81": 81770,
      "men mean": 44800,
      "age 46": 9011,
      "46 patients": 4629,
      "oxycodone 83": 54606,
      "intensity vas": 39326,
      "score 13": 73711,
      "significantly 001": 75644,
      "001 study": 214,
      "study patient": 78362,
      "pain impact": 56845,
      "impact physical": 36840,
      "activity sleep": 7589,
      "eq 5d": 29224,
      "showed trend": 75322,
      "trend increase": 82945,
      "values increased": 85844,
      "significantly baseline": 75659,
      "62 001": 5330,
      "001 total": 216,
      "53 patients": 5024,
      "showed treatment": 75321,
      "constipation frequent": 19763,
      "treatment combination": 82502,
      "patients np": 59559,
      "decreases pain": 23063,
      "impact pain": 36829,
      "opioids relieve": 53258,
      "relieve acute": 70212,
      "little evidence": 42157,
      "evidence support": 30269,
      "term treatment": 80672,
      "chronic noncancer": 16225,
      "noncancer pain": 49707,
      "pain previous": 57423,
      "previous systematic": 64926,
      "systematic reviews": 79997,
      "data did": 21945,
      "did provide": 24482,
      "use patient": 84606,
      "patient level": 58670,
      "level data": 41456,
      "stability pain": 76827,
      "pain opioid": 57278,
      "physical function": 61397,
      "function pain": 32662,
      "treated 12": 82321,
      "12 months": 1333,
      "available studies": 12842,
      "included patient": 37504,
      "demographics baseline": 23295,
      "individual patient": 38305,
      "response time": 71377,
      "change baseline": 15723,
      "baseline final": 13433,
      "month observation": 47395,
      "patients stable": 59989,
      "stable pain": 76846,
      "pain stable": 57856,
      "stable lower": 76843,
      "lower opioid": 42659,
      "term benefit": 80619,
      "complete data": 18440,
      "level opioid": 41505,
      "secondary analysis": 74207,
      "patients measured": 59483,
      "addition pain": 7822,
      "patients successfully": 60011,
      "successfully titrated": 78926,
      "pain demonstrated": 56694,
      "demonstrated continued": 23333,
      "opioid self": 52361,
      "self reporting": 74503,
      "heroin users": 35039,
      "users design": 85236,
      "design cross": 23706,
      "sectional observational": 74283,
      "states current": 77087,
      "current past": 21453,
      "heroin use": 35038,
      "use participants": 84602,
      "greater 18": 33422,
      "completed survey": 18503,
      "survey main": 79718,
      "regarding prescription": 69275,
      "use prior": 84668,
      "heroin initiation": 35010,
      "including opioid": 37655,
      "opioid used": 52612,
      "diagnosis chronic": 24332,
      "pain results": 57648,
      "reported using": 70673,
      "using prescription": 85572,
      "heroin commonly": 34993,
      "initiation oxycodone": 38897,
      "oxycodone 92": 54611,
      "92 percent": 6157,
      "percent common": 60456,
      "cases prescriptions": 15256,
      "34 percent": 4032,
      "pain condition": 56585,
      "condition prior": 19284,
      "prior using": 65177,
      "using heroin": 85424,
      "heroin conclusions": 34994,
      "study supports": 78525,
      "supports role": 79234,
      "transition heroin": 82201,
      "use suggests": 84766,
      "oxycodone common": 54807,
      "common prescription": 17796,
      "used prior": 85089,
      "information prescription": 38662,
      "obtained combination": 50765,
      "analgesic agents": 10150,
      "offers advantages": 50959,
      "paracetamol acetaminophen": 58094,
      "central analgesic": 15579,
      "analgesic activity": 10140,
      "inflammatory drug": 38557,
      "drug nsaid": 26722,
      "opioid like": 51888,
      "oral fixed": 53533,
      "dose combination": 25839,
      "oxycodone paracetamol": 55635,
      "action useful": 7453,
      "combination offers": 17574,
      "individual drug": 38292,
      "drug doses": 26597,
      "doses used": 26299,
      "mechanisms action": 44134,
      "action opioid": 7437,
      "sparing effect": 76529,
      "good efficacy": 33311,
      "tolerability profile": 81547,
      "safety fixed": 73153,
      "range clinical": 67304,
      "settings patients": 74859,
      "patients osteoarthritis": 59601,
      "osteoarthritis chronic": 53858,
      "chronic musculoskeletal": 16213,
      "pain including": 56860,
      "neuropathic component": 49225,
      "pain elderly": 56749,
      "pain postoperative": 57393,
      "pain case": 56513,
      "given combination": 33158,
      "drugs large": 26987,
      "large variety": 41162,
      "dosages used": 25772,
      "chronic moderate": 16209,
      "introduction opioids": 39944,
      "analgesics treat": 10509,
      "treat moderate": 82298,
      "analgesia remain": 10091,
      "remain unclear": 70256,
      "unclear study": 83480,
      "brain activity": 14315,
      "tonic pain": 81658,
      "pain modified": 57207,
      "healthy males": 34830,
      "males included": 43077,
      "cross double": 21249,
      "recorded days": 68679,
      "treatment placebo": 82765,
      "37 mg": 4192,
      "rest tonic": 71433,
      "subjective pain": 78658,
      "pain unpleasantness": 57955,
      "pain recorded": 57485,
      "18 32": 2044,
      "decreased pain": 23020,
      "scores 05": 73821,
      "involved pain": 40107,
      "pain inhibition": 56872,
      "inhibition oxycodone": 38785,
      "opioid commonly": 51590,
      "oxycodone lead": 55331,
      "potentially inducing": 63261,
      "cardiac arrest": 14979,
      "sodium channel": 76406,
      "expressed human": 30819,
      "na channels": 48391,
      "used cell": 84873,
      "cell patch": 15484,
      "patch clamp": 58484,
      "voltage clamp": 86388,
      "protocols used": 66007,
      "used test": 85154,
      "oxycodone different": 54970,
      "stem cell": 77313,
      "oxycodone inhibited": 55277,
      "ic 50": 36381,
      "high concentrations": 35076,
      "concentrations effects": 18760,
      "effects lead": 27963,
      "lead reduced": 41298,
      "contrast effects": 20215,
      "conclusions implications": 19096,
      "oxycodone leads": 55332,
      "high patients": 35136,
      "patients long": 59456,
      "suffer severe": 78959,
      "effects induced": 27956,
      "analgesics known": 10440,
      "effects dizziness": 27901,
      "dizziness confusion": 25635,
      "lead increased": 41293,
      "risk experiencing": 72559,
      "effectiveness commonly": 27755,
      "used strong": 85144,
      "forearm fractures": 32255,
      "prior administration": 65134,
      "transdermal td": 82170,
      "buprenorphine td": 14591,
      "td fentanyl": 80527,
      "fentanyl oral": 31540,
      "morphine assessed": 47583,
      "health insurance": 34718,
      "combinations opioids": 17626,
      "opioids taken": 53331,
      "taken consideration": 80275,
      "available results": 12836,
      "present analysis": 64604,
      "buprenorphine dominant": 14537,
      "oxycodone showing": 55904,
      "life year": 41742,
      "opioids td": 53334,
      "oxycodone represents": 55835,
      "paravertebral block": 58180,
      "block pvb": 14060,
      "decrease postoperative": 22920,
      "postoperative nausea": 62802,
      "vomiting ponv": 86467,
      "surgery studies": 79593,
      "studies placebo": 77812,
      "60 patients": 5270,
      "scheduled breast": 73638,
      "cancer surgery": 14914,
      "surgery randomly": 79549,
      "given single": 33199,
      "single injection": 76107,
      "bupivacaine mg": 14504,
      "ml mg": 46875,
      "anesthesia patient": 10930,
      "investigators blinded": 40083,
      "sham block": 75106,
      "block performed": 14052,
      "medication primary": 44544,
      "outcome variable": 54002,
      "postanesthesia care": 62634,
      "rest 24": 71412,
      "24 control": 3193,
      "control patients": 20388,
      "patients 01": 58819,
      "90 min": 6105,
      "min 05": 46506,
      "performed better": 60573,
      "digit symbol": 24981,
      "min surgery": 46553,
      "surgery 05": 79294,
      "05 average": 496,
      "average peak": 12932,
      "750 ng": 5726,
      "ml patient": 46890,
      "bupivacaine injection": 14501,
      "surgery reduced": 79555,
      "reduced postoperative": 68974,
      "recovery anesthesia": 68737,
      "anesthesia background": 10901,
      "background prescription": 13168,
      "increased globally": 37924,
      "far higher": 31190,
      "second highest": 74186,
      "consumption rates": 20004,
      "rates following": 67579,
      "related harm": 69612,
      "control interventions": 20357,
      "2010 methods": 2564,
      "methods examined": 45335,
      "examined trends": 30416,
      "dispensing canada": 25441,
      "2005 2012": 2462,
      "potential effects": 63164,
      "interventions data": 39659,
      "annual dispensing": 11017,
      "opioids strong": 53313,
      "opioids representative": 53265,
      "sub sample": 78581,
      "retail pharmacies": 72070,
      "pharmacies canada": 61053,
      "compuscript converted": 18646,
      "converted defined": 20722,
      "doses ddd": 26170,
      "ddd examined": 22673,
      "intra inter": 39720,
      "total results": 81899,
      "dispensing driven": 25447,
      "opioids increased": 52986,
      "opioid dispensing": 51717,
      "2011 2012": 2573,
      "dispensing ratio": 25459,
      "weak strong": 86794,
      "opioids decreased": 52836,
      "dispensing levels": 25450,
      "formulations dispensed": 32377,
      "persisted previous": 60913,
      "increasing trends": 38127,
      "possible substitution": 62549,
      "substitution effects": 78878,
      "accurate assessment": 7100,
      "medication efficacy": 44497,
      "trials current": 83130,
      "limitations study": 41908,
      "rapidly absorbed": 67400,
      "metabolism urine": 44941,
      "methods double": 45316,
      "study 10": 77879,
      "consecutive days": 19558,
      "medication 30": 44449,
      "oxycodone examined": 55049,
      "urine followed": 84078,
      "life 50": 41682,
      "10 previously": 909,
      "previously reported": 64956,
      "doses hours": 26199,
      "intersubject variability": 39547,
      "16 10": 1842,
      "10 consecutive": 751,
      "overall effect": 54198,
      "20 05": 2267,
      "05 compared": 497,
      "compared days": 18134,
      "oxycodone pharmacodynamic": 55674,
      "responses conclusions": 71385,
      "time medication": 81290,
      "medication consumption": 44478,
      "96 hours": 6422,
      "new method": 49338,
      "method improve": 45182,
      "trials objectives": 83169,
      "medico legal": 44719,
      "legal case": 41363,
      "cpp oxycodone": 21044,
      "oxycodone present": 55750,
      "care patient": 15056,
      "patient fell": 58643,
      "standard medical": 76915,
      "develop recommendations": 24156,
      "recommendations future": 68603,
      "medicine physicians": 44711,
      "order avoid": 53706,
      "standards care": 76991,
      "care using": 15094,
      "using methadone": 85492,
      "regional hospital": 69356,
      "hospital pain": 35609,
      "pain clinic": 56549,
      "rotation used": 72823,
      "oxycodone addictive": 54678,
      "addictive disease": 7781,
      "results rotation": 71929,
      "legal consequences": 41364,
      "caused death": 15379,
      "death conclusion": 22702,
      "conclusion pain": 18951,
      "pain physicians": 57377,
      "methadone opioid": 45111,
      "opioid rotation": 52353,
      "substantial abuse": 78842,
      "newly developed": 49415,
      "ir oc": 40238,
      "apap methods": 11356,
      "volunteers recreational": 86433,
      "approved institutional": 11541,
      "institutional review": 39098,
      "review board": 72265,
      "provided written": 66169,
      "written informed": 87375,
      "informed consent": 38678,
      "doses intact": 26204,
      "15 650": 1709,
      "mg intact": 45926,
      "placebo peak": 61800,
      "area drug": 11628,
      "effect curves": 27440,
      "good drug": 33303,
      "using visual": 85662,
      "squares means": 76807,
      "means 95": 43922,
      "using analysis": 85304,
      "analysis variance": 10790,
      "er oc": 29445,
      "effects versus": 28194,
      "versus ir": 86128,
      "interval significantly": 39602,
      "lower oc": 42655,
      "mg 76": 45770,
      "72 80": 5612,
      "mg 85": 45776,
      "difference 13": 24571,
      "13 001": 1446,
      "mg 650": 45762,
      "lower subjective": 42707,
      "delayed onset": 23190,
      "compared intact": 18190,
      "phase study": 61321,
      "background morphine": 13083,
      "opioid patient": 52044,
      "pca oxycodone": 60267,
      "greater morphine": 33458,
      "morphine studied": 47931,
      "studied efficacy": 77612,
      "reconstruction breast": 68644,
      "lumbar spinal": 42756,
      "spinal fusion": 76718,
      "pca postoperative": 60269,
      "kg bolus": 40700,
      "doses patients": 26247,
      "patients assessed": 59008,
      "assessed pain": 12030,
      "pain visual": 57976,
      "concentration oxycodone": 18709,
      "morphine metabolites": 47754,
      "patients needed": 59539,
      "needed average": 48979,
      "average oxycodone": 12918,
      "recovery room": 68757,
      "vas incidence": 86006,
      "vomiting pruritus": 86468,
      "pruritus urinary": 66311,
      "concentrations morphine": 18779,
      "morphine glucuronide": 47700,
      "morphine administration": 47578,
      "conclusions dose": 19074,
      "dose intravenous": 25938,
      "morphine administered": 47577,
      "pca pump": 60271,
      "epidemic prescription": 29145,
      "prescribing medication": 64078,
      "patients discharged": 59202,
      "retrospective audit": 72111,
      "conducted surgical": 19415,
      "16 week": 1897,
      "intervention study": 39650,
      "period discharge": 60723,
      "prescribed proportion": 63962,
      "discharge median": 25137,
      "median milligrams": 44243,
      "milligrams oxycodone": 46480,
      "respectively results": 71242,
      "75 patients": 5718,
      "oxycodone 01": 54477,
      "01 median": 315,
      "patient post": 58709,
      "68 patients": 5501,
      "new conclusion": 49317,
      "reduced proportion": 68977,
      "patients supplied": 60021,
      "oxycodone supplied": 55967,
      "prescribing reduced": 64133,
      "cognitive functioning": 17326,
      "cancer non": 14800,
      "patients 20": 58839,
      "receiving sustained": 68379,
      "additional dose": 7854,
      "participants immediate": 58314,
      "release medication": 69890,
      "medication oxycodone": 44531,
      "morphine placebo": 47876,
      "drug placebo": 26738,
      "finally performance": 31755,
      "task assessed": 80517,
      "previous work": 64930,
      "opioid furthermore": 51823,
      "opioid did": 51711,
      "result increased": 71480,
      "opioid possibly": 52075,
      "lower levels": 42636,
      "carefully titrated": 15113,
      "release doses": 69829,
      "doses opioid": 26226,
      "drugs cause": 26901,
      "study using": 78561,
      "depressive symptoms": 23611,
      "education level": 27384,
      "levels influence": 41570,
      "impairment observed": 36904,
      "observed following": 50680,
      "background hydrocodone": 13063,
      "prescribed commonly": 63839,
      "pain differences": 56715,
      "differences risk": 24809,
      "initial prescription": 38867,
      "unknown study": 83891,
      "aims determine": 9479,
      "determine risk": 24048,
      "chronic use": 16352,
      "following prescription": 32186,
      "retrospective analysis": 72107,
      "analysis multiple": 10712,
      "health datasets": 34707,
      "state oregon": 77058,
      "patients ages": 58980,
      "ages 18": 9248,
      "18 older": 2097,
      "older received": 51043,
      "received initial": 68163,
      "2015 2017": 2689,
      "hospitalizations emergency": 35664,
      "use defined": 84293,
      "defined opioid": 23142,
      "prescriptions including": 64499,
      "index average": 38187,
      "average 30": 12866,
      "fatal non": 31234,
      "non fatal": 49597,
      "fatal opioid": 31236,
      "insurance claims": 39142,
      "hospital discharge": 35579,
      "discharge data": 25114,
      "data vital": 22157,
      "vital records": 86341,
      "index prescription": 38205,
      "prescription 14": 64150,
      "adjustment patient": 8072,
      "prescription characteristics": 64175,
      "odds developing": 50895,
      "use relative": 84687,
      "receiving hydrocodone": 68341,
      "adjusted odds": 8042,
      "ratio 95": 67753,
      "95 95": 6212,
      "ci 91": 16508,
      "91 00": 6129,
      "risk overdose": 72626,
      "adjusted hazard": 8022,
      "hazard ratio": 34614,
      "ratio ahr": 67761,
      "65 95": 5412,
      "ci 45": 16454,
      "87 oxycodone": 6024,
      "oxycodone monotherapy": 55462,
      "greatly increase": 33509,
      "ahr 18": 9359,
      "18 95": 2074,
      "ci 86": 16503,
      "compared hydrocodone": 18179,
      "hydrocodone acetaminophen": 36055,
      "acetaminophen oxycodone": 7220,
      "combined acetaminophen": 17638,
      "significant increase": 75558,
      "ahr 26": 9362,
      "26 95": 3438,
      "ci 06": 16377,
      "previously opioid": 64949,
      "patients risk": 59930,
      "higher hydrocodone": 35251,
      "higher oxycodone": 35282,
      "combination acetaminophen": 17541,
      "overdose related": 54314,
      "related deaths": 69580,
      "data chronic": 21901,
      "including effect": 37616,
      "oral medications": 53566,
      "poorly understood": 62287,
      "23 year": 3119,
      "male complex": 43026,
      "ineffective controlling": 38489,
      "pain despite": 56700,
      "aggressive titration": 9260,
      "inadequate pain": 37229,
      "control patient": 20385,
      "medications high": 44623,
      "lorazepam diazepam": 42416,
      "subcutaneous morphine": 78605,
      "morphine successfully": 47935,
      "produced immediate": 65390,
      "benzodiazepine use": 13650,
      "research needed": 71014,
      "important clinicians": 37000,
      "clinical response": 16892,
      "response objective": 71352,
      "objective opioid": 50455,
      "rheumatic disease": 72452,
      "pain controversial": 56669,
      "regarding efficacy": 69251,
      "efficacy toxicity": 28411,
      "use cohort": 84246,
      "pain defined": 56691,
      "methods opioid": 45414,
      "use studied": 84755,
      "studied retrospectively": 77630,
      "pharmacy records": 61263,
      "identified patients": 36454,
      "opioids previous": 53223,
      "years medical": 87615,
      "records reviewed": 68726,
      "reviewed determine": 72377,
      "reasons opioid": 68021,
      "opioid dosage": 51728,
      "patients interviewed": 59419,
      "history alcohol": 35450,
      "street drug": 77464,
      "abuse results": 6868,
      "results opioid": 71808,
      "prescriptions year": 64575,
      "pharmacy database": 61260,
      "consecutive months": 19559,
      "months opioid": 47456,
      "opioid treated": 52436,
      "received codeine": 68126,
      "codeine oxycodone": 17265,
      "oxycodone cohort": 54797,
      "133 patients": 1526,
      "treated group": 82338,
      "group 76": 33643,
      "studied opioids": 77620,
      "severity scores": 75051,
      "scores 10": 73822,
      "10 scale": 920,
      "scale 001": 73481,
      "effects reported": 28139,
      "initial dosage": 38835,
      "mg codeine": 45822,
      "day mean": 22332,
      "mean peak": 43836,
      "dose day": 25858,
      "32 patients": 3935,
      "medical complication": 44348,
      "addiction conclusion": 7741,
      "prolonged treatment": 65642,
      "pain codeine": 56559,
      "severity associated": 75036,
      "prolonged periods": 65619,
      "periods time": 60822,
      "opioid efficacy": 51764,
      "opioids patients": 53157,
      "patients defined": 59173,
      "pain previously": 57427,
      "previously shown": 64959,
      "rewarding properties": 72443,
      "properties investigated": 65710,
      "anti nociceptive": 11137,
      "drugs effect": 26948,
      "kg tramadol": 40814,
      "tramadol 10": 82021,
      "300 mg": 3813,
      "31 mg": 3870,
      "negative affect": 49061,
      "mechanical hypersensitivity": 44112,
      "carrageenan induced": 15133,
      "nociception assessed": 49537,
      "using conditioned": 85356,
      "place aversion": 61598,
      "aversion cpa": 12953,
      "paw pressure": 60241,
      "pressure test": 64747,
      "rewarding effect": 72436,
      "effect drugs": 27448,
      "drugs assessed": 26890,
      "preference cpp": 63621,
      "induced cpp": 38403,
      "showed large": 75266,
      "potency 10": 63068,
      "nociception oxycodone": 49539,
      "painful conditions": 58001,
      "pregabalin showed": 63684,
      "rewarding potency": 72442,
      "limited drugs": 41927,
      "drugs opioid": 27018,
      "opioid mechanism": 51898,
      "drugs different": 26936,
      "different mechanisms": 24886,
      "background update": 13211,
      "split separate": 76741,
      "pain considered": 56592,
      "considered effective": 19630,
      "examined opioids": 30396,
      "opioids review": 53278,
      "dose route": 26073,
      "pain adults": 56422,
      "adults search": 8576,
      "methods searched": 45560,
      "searched cochrane": 74143,
      "trials central": 83107,
      "january 2013": 40442,
      "december 2015": 22825,
      "update searched": 83980,
      "searched reference": 74161,
      "reference lists": 69132,
      "lists retrieved": 42106,
      "retrieved studies": 72096,
      "online clinical": 51095,
      "trial registries": 83079,
      "review included": 72312,
      "studies using": 77873,
      "add treatment": 7727,
      "treatment stable": 82850,
      "drug selection": 26789,
      "blind studies": 13978,
      "dose formulation": 25909,
      "pain data": 56677,
      "studies extracted": 77728,
      "pooled analysis": 62238,
      "analysis possible": 10737,
      "dichotomous data": 24375,
      "data calculate": 21893,
      "calculate risk": 14679,
      "numbers needed": 50281,
      "additional event": 7858,
      "event using": 29995,
      "using standard": 85623,
      "standard methods": 76916,
      "methods assessed": 45257,
      "assessed evidence": 12001,
      "evidence using": 30291,
      "using grade": 85414,
      "grade grading": 33372,
      "grading recommendations": 33385,
      "recommendations assessment": 68592,
      "assessment development": 12111,
      "development evaluation": 24224,
      "created summary": 21147,
      "results updated": 72044,
      "searches identified": 74166,
      "identified additional": 36420,
      "trial registry": 83082,
      "studies reporting": 77828,
      "neuralgia studies": 49175,
      "design used": 23816,
      "used active": 84831,
      "titrated effect": 81469,
      "added oxycodone": 7731,
      "oxycodone therapy": 55992,
      "pregabalin gabapentin": 63667,
      "reported outcomes": 70605,
      "equivalent moderate": 29318,
      "additional beneficial": 7844,
      "beneficial outcome": 13599,
      "outcome nnt": 53957,
      "reported group": 70551,
      "mean pain": 43825,
      "scores end": 73877,
      "treatment studies": 82859,
      "reported greater": 70548,
      "placebo similar": 61827,
      "result study": 71493,
      "adding oxycodone": 7791,
      "plus naloxone": 62026,
      "pregabalin did": 63664,
      "did additional": 24401,
      "additional effect": 7857,
      "harmful outcome": 34592,
      "oxycodone 11": 54510,
      "different groups": 24872,
      "treat prevent": 82315,
      "reported similar": 70653,
      "evidence low": 30220,
      "low outcomes": 42515,
      "study methods": 78310,
      "condition study": 19287,
      "data authors": 21883,
      "conclusions low": 19115,
      "treatment painful": 82741,
      "conditions adverse": 19308,
      "common objective": 17775,
      "narcotic use": 48614,
      "level pain": 41510,
      "medication usage": 44576,
      "identify demographic": 36499,
      "prospective cohort": 65817,
      "study tertiary": 78537,
      "tertiary care": 80732,
      "care center": 15006,
      "center methods": 15532,
      "tabs oxycodone": 80234,
      "medication use": 44578,
      "use survey": 84769,
      "postoperatively survey": 63030,
      "information collected": 38636,
      "collected regarding": 17478,
      "acetaminophen use": 7259,
      "use postoperative": 84631,
      "postoperative appointment": 62719,
      "patients asked": 59005,
      "use narcotic": 84508,
      "use pain": 84593,
      "pain levels": 57012,
      "10 time": 941,
      "use recorded": 84682,
      "recorded patients": 68690,
      "patients hour": 59372,
      "hour increments": 35701,
      "postoperatively postoperative": 63017,
      "postoperative visit": 62978,
      "visit results": 86269,
      "results pain": 71830,
      "postoperative day": 62733,
      "day pod1": 22378,
      "younger patients": 87739,
      "30 years": 3807,
      "years old": 87623,
      "younger female": 87736,
      "patients primary": 59700,
      "use women": 84814,
      "correlated higher": 20813,
      "higher narcotic": 35267,
      "use conclusion": 84258,
      "patients clinicians": 59093,
      "important knowledge": 37016,
      "pain expectations": 56769,
      "reduce narcotic": 68855,
      "narcotic prescribed": 48606,
      "prescribed providers": 63963,
      "patients level": 59445,
      "level evidence": 41466,
      "case series": 15201,
      "laryngoscope 131": 41202,
      "determine incidence": 24016,
      "addiction dependence": 7742,
      "design systematic": 23813,
      "review following": 72305,
      "prisma guidelines": 65187,
      "guidelines methods": 34448,
      "methods pubmed": 45498,
      "pubmed medline": 66452,
      "embase cinahl": 28638,
      "cinahl psycinfo": 16557,
      "psycinfo cochrane": 66370,
      "cochrane library": 17176,
      "inception january": 37250,
      "january 2020": 40458,
      "independent raters": 38164,
      "title abstract": 81458,
      "abstract text": 6626,
      "eligibility criteria": 28575,
      "criteria systematic": 21221,
      "review data": 72283,
      "data extraction": 21968,
      "bias assessment": 13762,
      "cochrane collaboration": 17169,
      "collaboration tool": 17434,
      "newcastle ottawa": 49401,
      "ottawa scale": 53891,
      "individual studies": 38310,
      "studies results": 77831,
      "incidence rates": 37311,
      "91 percent": 6142,
      "72 percent": 5625,
      "percent 44": 60451,
      "44 percent": 4546,
      "45 percent": 4597,
      "77 percent": 5765,
      "31 days": 3865,
      "assess incidence": 11937,
      "results systematic": 72005,
      "use leads": 84447,
      "small proportion": 76295,
      "proportion individuals": 65744,
      "exercise caution": 30498,
      "drawing conclusions": 26450,
      "conclusions included": 19098,
      "included articles": 37427,
      "studies area": 77649,
      "outcomes using": 54106,
      "adequate follow": 7959,
      "common outpatient": 17789,
      "outpatient procedure": 54139,
      "abdominal wall": 6535,
      "long lasting": 42315,
      "lasting pain": 41215,
      "minimal effects": 46573,
      "compared pvb": 18286,
      "peripheral neural": 60874,
      "entered prospective": 29062,
      "prospective single": 65879,
      "single blind": 76053,
      "standardized general": 76958,
      "general anesthetic": 32970,
      "anesthetic patients": 10970,
      "assigned receive": 12177,
      "preoperatively 24": 63766,
      "using ropivacaine": 85600,
      "ropivacaine 40": 72791,
      "40 ml": 4363,
      "verbal analog": 86070,
      "analog pain": 10521,
      "opioids surgery": 53329,
      "pvb group": 66606,
      "group 162": 33575,
      "70 mg": 5564,
      "need opioids": 48940,
      "group 39": 33607,
      "time pain": 81312,
      "pain discharge": 56723,
      "pvb patients": 66607,
      "patients 29": 58851,
      "compared 18": 18070,
      "patients 12": 58825,
      "12 mean": 1318,
      "mean time": 43886,
      "time oxycodone": 81308,
      "use similar": 84733,
      "similar groups": 75924,
      "18 oxycodone": 2100,
      "42 mg": 4463,
      "group 50": 33622,
      "antiemetic treatment": 11190,
      "group 21": 33584,
      "21 001": 2935,
      "study shows": 78498,
      "provides analgesia": 66203,
      "analgesia equivalent": 9965,
      "nerve block": 49111,
      "alternative method": 9724,
      "method postoperative": 45203,
      "introduction long": 39930,
      "term administration": 80613,
      "opiates patients": 51337,
      "insufficient clinical": 39122,
      "clinical evidence": 16812,
      "support efficacy": 79193,
      "tolerability methods": 81537,
      "analysis used": 10785,
      "used hospital": 84956,
      "hospital records": 35624,
      "doses combination": 26155,
      "cncp outpatient": 17107,
      "term efficacy": 80629,
      "efficacy patients": 28325,
      "september 2010": 74610,
      "2010 information": 2559,
      "duration therapy": 27187,
      "dynamic pain": 27216,
      "pain measured": 57138,
      "using numeric": 85526,
      "rating scales": 67682,
      "scales nrs": 73590,
      "age 66": 9043,
      "analyzed pain": 10849,
      "24 33": 3157,
      "sd pain": 74087,
      "pain reductions": 57500,
      "04 43": 445,
      "patients 23": 58843,
      "treated months": 82349,
      "177 patients": 2017,
      "patients 76": 58899,
      "23 months": 3104,
      "months pain": 47459,
      "reduction significant": 69101,
      "groups 0001": 34084,
      "improvements pain": 37176,
      "dose remained": 26052,
      "stable decreased": 76839,
      "decreased slightly": 23044,
      "discussion results": 25310,
      "support hypothesis": 79197,
      "based combination": 13299,
      "combination low": 17564,
      "patients obtaining": 59572,
      "larger studies": 41185,
      "studies use": 77872,
      "use opiates": 84540,
      "efficacious analgesics": 28198,
      "substances abuse": 78824,
      "abuse importance": 6733,
      "opioids cause": 52769,
      "cause severe": 15373,
      "severe respiratory": 75018,
      "products increased": 65450,
      "simultaneous use": 76036,
      "evaluated drugs": 29875,
      "similar effects": 75917,
      "quetiapine oxycodone": 66914,
      "oxycodone decreases": 54934,
      "design setting": 23796,
      "setting participants": 74800,
      "crossover clinical": 21285,
      "25 healthy": 3357,
      "interventions oxycodone": 39670,
      "randomized order": 67136,
      "increasing daily": 38099,
      "doses 100": 26120,
      "placebo main": 61773,
      "main outcomes": 42848,
      "outcomes measures": 54051,
      "day secondary": 22411,
      "results 25": 71557,
      "25 participants": 3376,
      "participants median": 58323,
      "median age": 44196,
      "years iqr": 87604,
      "iqr 30": 40172,
      "years 11": 87521,
      "completed trial": 18511,
      "trial mean": 83034,
      "vs 34": 86565,
      "min mean": 46534,
      "97 ci": 6439,
      "day 25": 22254,
      "35 min": 4085,
      "001 significantly": 211,
      "33 vs": 4001,
      "ci 28": 16425,
      "28 day": 3555,
      "day 34": 22257,
      "34 vs": 4039,
      "ci 37": 16439,
      "outcome mean": 53924,
      "decreased day": 22990,
      "paroxetine vs": 58233,
      "32 vs": 3941,
      "vs 41": 86575,
      "42 vs": 4477,
      "ci 67": 16482,
      "drug related": 26761,
      "conclusions relevance": 19188,
      "preliminary study": 63717,
      "study involving": 78282,
      "combined oxycodone": 17664,
      "did cause": 24414,
      "cause effect": 15353,
      "effect additional": 27415,
      "investigation needed": 40070,
      "needed characterize": 48989,
      "characterize effects": 15893,
      "determine clinical": 23996,
      "clinical relevance": 16883,
      "relevance findings": 70035,
      "registration clinicaltrials": 69389,
      "gov identifier": 33344,
      "assess effect": 11927,
      "effect oral": 27511,
      "heart failure": 34869,
      "methods results": 45528,
      "results oral": 71814,
      "oxycodone oxynorm": 55628,
      "interventions controlled": 39657,
      "days day": 22507,
      "interventions patients": 39673,
      "patients known": 59439,
      "grade iii": 33375,
      "iii iv": 36587,
      "invited participate": 40089,
      "participate participants": 58384,
      "receptor blockers": 68486,
      "participant rated": 58259,
      "nrs average": 50058,
      "previous 24": 64894,
      "severity score": 75050,
      "score baseline": 73732,
      "baseline day": 13424,
      "treatment primary": 82784,
      "study powered": 78419,
      "powered detect": 63293,
      "point change": 62081,
      "change severity": 15749,
      "active intervention": 7515,
      "types opioid": 83371,
      "nrs score": 50076,
      "group vs": 34072,
      "group 13": 33569,
      "13 29": 1463,
      "group 90": 33652,
      "response treatment": 71378,
      "concurrent drug": 19264,
      "therapy opioid": 81037,
      "administration did": 8248,
      "changes clinical": 15779,
      "clinical observations": 16842,
      "tolerated conclusion": 81627,
      "benefit placebo": 13623,
      "placebo relief": 61814,
      "trial registered": 83064,
      "www controlled": 87394,
      "trials com": 83118,
      "potentially fatal": 63255,
      "complication opioid": 18552,
      "study influence": 78260,
      "oxycodone intravenous": 55292,
      "21 28": 2947,
      "66 77": 5449,
      "combined intravenous": 17650,
      "intravenous infusion": 39833,
      "treatment results": 82820,
      "28 001": 3532,
      "001 vs": 224,
      "vs control": 86640,
      "caused decrease": 15381,
      "oxycodone ethanol": 55045,
      "oxycodone caused": 54771,
      "01 mean": 314,
      "mean 95": 43669,
      "33 27": 3981,
      "control 18": 20263,
      "min oxycodone": 46540,
      "15 12": 1675,
      "oxycodone causes": 54773,
      "patients systemic": 60030,
      "pain lead": 57000,
      "patient functional": 58645,
      "poor patient": 62272,
      "procedure pain": 65278,
      "associated negative": 12342,
      "healing pain": 34665,
      "key role": 40676,
      "case reports": 15195,
      "naloxone patients": 48483,
      "provided pain": 66145,
      "compliance redressing": 18536,
      "redressing wounds": 68827,
      "treat severe": 82316,
      "pain mechanisms": 57146,
      "explore oxycodone": 30727,
      "methods volunteers": 45630,
      "blinded way": 14025,
      "way placebo": 86777,
      "nerve stimulation": 49130,
      "assessment central": 12107,
      "effects treatments": 28186,
      "level ii": 41486,
      "level iii": 41490,
      "early late": 27258,
      "level iv": 41498,
      "ci 95": 16513,
      "decreased 95": 22975,
      "ci oxycodone": 16535,
      "25 95": 3342,
      "ci 22": 16414,
      "22 28": 3018,
      "12 95": 1263,
      "12 13": 1213,
      "66 95": 5452,
      "62 75": 5332,
      "28 95": 3549,
      "ci 27": 16423,
      "27 29": 3478,
      "12 28": 1244,
      "conclusions opioids": 19136,
      "effects present": 28106,
      "action drugs": 7429,
      "drugs effects": 26950,
      "methods thirty": 45608,
      "received mg": 68198,
      "kg fentanyl": 40726,
      "continuous infusions": 20175,
      "scores 11": 73826,
      "point numeric": 62090,
      "nrs 24": 50057,
      "body movement": 14200,
      "need additional": 48905,
      "additional analgesics": 7841,
      "analgesics recorded": 10488,
      "recorded 24": 68663,
      "pain nrs": 57247,
      "nrs scores": 50079,
      "fewer patients": 31661,
      "required additional": 70822,
      "analgesics group": 10427,
      "20 vs": 2388,
      "vs 13": 86531,
      "13 18": 1456,
      "average 24": 12863,
      "dezocine mg": 24306,
      "group mg": 33860,
      "observed group": 50681,
      "group 027": 33543,
      "operative nausea": 51253,
      "observed groups": 50682,
      "dizziness occurred": 25641,
      "occurred significantly": 50844,
      "significantly group": 75716,
      "better analgesia": 13700,
      "analgesia reduces": 10085,
      "reduces post": 69001,
      "operative opioid": 51256,
      "widespread use": 87086,
      "sharp rise": 75124,
      "oic opioid": 50989,
      "receptor antagonists": 68477,
      "antagonists proposed": 11086,
      "treat oic": 82302,
      "rapid opioid": 67394,
      "safety data": 73139,
      "data lacking": 21999,
      "reporting adverse": 70683,
      "naloxone large": 48457,
      "methods post": 45468,
      "marketing data": 43423,
      "events reporting": 30111,
      "reporting frequency": 70689,
      "assessed primary": 12045,
      "outcome reporting": 53988,
      "combination opioids": 17579,
      "quasi experimental": 66863,
      "considered significant": 19653,
      "significant results": 75630,
      "total 14": 81722,
      "adverse drug": 8621,
      "drug event": 26623,
      "event reports": 29993,
      "38 95": 4236,
      "43 453": 4495,
      "45 95": 4578,
      "ci 09": 16381,
      "tilidine naloxone": 81184,
      "92 95": 6152,
      "ci 65": 16480,
      "ci 89": 16506,
      "naloxone administration": 48429,
      "16 95": 1864,
      "ci 93": 16511,
      "93 45": 6171,
      "naloxone oral": 48474,
      "ci 63": 16478,
      "oxycodone 52": 54580,
      "adverse cardiovascular": 8619,
      "cardiovascular events": 14994,
      "events opioid": 30085,
      "antagonists used": 11091,
      "oic objective": 50988,
      "effects following": 27928,
      "administration buprenorphine": 8224,
      "design double": 23713,
      "treatment period": 82753,
      "period placebo": 60773,
      "single center": 76058,
      "participants healthy": 58313,
      "healthy individuals": 34822,
      "individuals self": 38358,
      "users confirmed": 85232,
      "test day": 80763,
      "interventions placebo": 39677,
      "300 600": 3810,
      "600 900": 5285,
      "diameter determined": 24351,
      "assessed predose": 12041,
      "moderately correlated": 47215,
      "baseline pupil": 13456,
      "34 37": 4019,
      "significant 05": 75418,
      "occurred hour": 50838,
      "respectively hours": 71200,
      "hours dosing": 35771,
      "mg conclusions": 45832,
      "oxycodone achieved": 54668,
      "achieved similar": 7324,
      "oa pain": 50351,
      "pain modulating": 57208,
      "decrease pain": 22914,
      "role opioidergic": 72753,
      "oa remains": 50354,
      "remains unclear": 70312,
      "unclear aim": 83473,
      "oxycodone serotonin": 55892,
      "serotonin noradrenaline": 74675,
      "inhibitor venlafaxine": 38800,
      "blinded placebo": 14005,
      "study 20": 77884,
      "20 healthy": 2318,
      "male participants": 43044,
      "age 24": 8986,
      "24 years": 3293,
      "thermal stimulation": 81086,
      "treatment control": 82522,
      "stimulus intensity": 77381,
      "included comparison": 37439,
      "unaffected oxycodone": 83455,
      "20 90": 2307,
      "90 respectively": 6117,
      "rating pain": 67650,
      "intensity observed": 39281,
      "placebo 001": 61609,
      "modulated oxycodone": 47258,
      "pharmacological mechanisms": 61221,
      "human beings": 35943,
      "characterize time": 15909,
      "morphine prescriptions": 47886,
      "type prescriber": 83347,
      "opioids prescriptions": 53218,
      "prescriptions morphine": 64518,
      "patient prescription": 58717,
      "years prescription": 87641,
      "defined time": 23154,
      "prescription patients": 64381,
      "received prescription": 68253,
      "months prior": 47468,
      "prior date": 65139,
      "classified strong": 16688,
      "investigate general": 40014,
      "preferences oxycodone": 63633,
      "morphine strong": 47928,
      "oxycodone hospital": 55164,
      "preference oxycodone": 63626,
      "34 95": 4022,
      "ci 29": 16426,
      "29 39": 3602,
      "responsible approximately": 71400,
      "patients conclusion": 59125,
      "great extent": 33414,
      "prescribed choice": 63833,
      "choice strong": 16122,
      "background pain": 13141,
      "pain common": 56566,
      "efficacy prolonged": 28335,
      "pr patients": 63354,
      "chronic severe": 16340,
      "47 secondary": 4665,
      "care centres": 15008,
      "enrolled patients": 29007,
      "pain average": 56478,
      "24 pain": 3256,
      "score assessed": 73731,
      "assessed 11": 11975,
      "scale pain": 73526,
      "pain bad": 56486,
      "bad imagine": 13221,
      "participants randomly": 58349,
      "pr placebo": 63355,
      "placebo 16": 61623,
      "16 weeks": 1898,
      "weeks starting": 86955,
      "starting dose": 77014,
      "mg naloxone": 46065,
      "daily patients": 21798,
      "patients investigators": 59425,
      "assignment primary": 12186,
      "endpoint average": 28878,
      "score 16": 73714,
      "analysis population": 10735,
      "202 patients": 2888,
      "patients 93": 58911,
      "assigned oxn": 12170,
      "placebo analysis": 61660,
      "population consisted": 62321,
      "88 patients": 6044,
      "patients versus": 60174,
      "106 patients": 1066,
      "mean average": 43721,
      "pr group": 63327,
      "group versus": 34067,
      "similar proportions": 75983,
      "proportions patients": 65792,
      "group adverse": 33665,
      "65 vs": 5421,
      "vs 76": 86618,
      "52 92": 4979,
      "57 vs": 5139,
      "vs 62": 86602,
      "related nausea": 69637,
      "nausea common": 48766,
      "related constipation": 69577,
      "based analysis": 13280,
      "week 16": 86826,
      "highlight potential": 35376,
      "efficacy oxn": 28312,
      "disease related": 25347,
      "funding mundipharma": 32736,
      "mundipharma research": 48356,
      "research background": 70982,
      "background pharmacokinetics": 13160,
      "hydroxy dihydrocodeinone": 36237,
      "disposition oxycodone": 25501,
      "study study": 78515,
      "study pharmacokinetics": 78406,
      "months methods": 47453,
      "given postoperatively": 33189,
      "intravenous bolus": 39818,
      "bolus mg": 14219,
      "hydrochloride patients": 36032,
      "patients younger": 60188,
      "week months": 86851,
      "months group": 47443,
      "group months": 33864,
      "group plasma": 33917,
      "concentrations 24": 18740,
      "noncompartmental methods": 49723,
      "results median": 71774,
      "range values": 67337,
      "cl 17": 16608,
      "40 15": 4312,
      "14 80": 1574,
      "min kg": 46530,
      "kg groups": 40732,
      "14 11": 1550,
      "11 respectively": 1150,
      "correlated age": 20810,
      "13 patients": 1501,
      "mechanical ventilation": 44118,
      "ventilation time": 86061,
      "study conclusions": 78022,
      "varied greatly": 85937,
      "oxycodone titrated": 56001,
      "titrated individually": 81471,
      "individually oxycodone": 38324,
      "opioid compound": 51593,
      "prescribed used": 64003,
      "current opioid": 21448,
      "antinociceptive respiratory": 11251,
      "respiratory depressive": 71288,
      "oxycodone mice": 55445,
      "moderate dose": 47140,
      "dose acute": 25818,
      "protein kinase": 65937,
      "kinase pkc": 40836,
      "acute prolonged": 7695,
      "prolonged oxycodone": 65616,
      "dorsal root": 25737,
      "root ganglia": 72783,
      "ganglia drg": 32829,
      "drg neurons": 26455,
      "acute exposure": 7634,
      "reduced neuronal": 68947,
      "neuronal excitability": 49211,
      "action potential": 7447,
      "measurable changes": 43931,
      "membrane potential": 44787,
      "exposure 10": 30750,
      "10 \u03bcm": 966,
      "oxycodone 18": 54527,
      "prevented oxycodone": 64860,
      "effect neuronal": 27496,
      "tolerance development": 81583,
      "development opioid": 24240,
      "arrestin knockout": 11699,
      "knockout mice": 40875,
      "mice oxycodone": 46303,
      "20 mm": 2364,
      "\u00b5m oxycodone": 87778,
      "following prolonged": 32189,
      "concluded oxycodone": 18854,
      "level single": 41526,
      "mechanisms objective": 44146,
      "formulation containing": 32338,
      "safety pharmacokinetics": 73200,
      "pharmacokinetics pks": 61189,
      "36 hours": 4129,
      "mg naltrexone": 46068,
      "naltrexone hcl": 48541,
      "hcl ir": 34640,
      "placebo single": 61828,
      "oral dose": 53521,
      "bipolar drug": 13875,
      "results 44": 71568,
      "randomized subjects": 67195,
      "treatment periods": 82757,
      "showed significantly": 75305,
      "001 median": 154,
      "placebo significant": 61824,
      "max observed": 43555,
      "objective measures": 50444,
      "effects overall": 28053,
      "maximum pupil": 43611,
      "lower max": 42641,
      "001 compared": 113,
      "demonstrated significantly": 23366,
      "decreased effects": 22994,
      "effects subjective": 28171,
      "greater nasal": 33460,
      "ir findings": 40228,
      "pk profile": 61587,
      "meaningful abuse": 43912,
      "frequently prescribe": 32566,
      "prescribe analgesics": 63795,
      "management dental": 43176,
      "dental pain": 23406,
      "pain overview": 57309,
      "analgesics prescribed": 10483,
      "2016 2020": 2732,
      "2020 collected": 2893,
      "collected data": 17454,
      "foundation pharmaceutical": 32426,
      "prescribed dentists": 63849,
      "practice dental": 63396,
      "dental specialists": 23412,
      "largest group": 41191,
      "opioids acetaminophen": 52699,
      "opioids nsaids": 53102,
      "prescribed groups": 63866,
      "oral maxillofacial": 53563,
      "maxillofacial surgeons": 43569,
      "codeine codeine": 17211,
      "codeine acetaminophen": 17208,
      "analgesics large": 10441,
      "opioids codeine": 52788,
      "different oral": 24899,
      "mu receptor": 48137,
      "intravenous patient": 39877,
      "prospective double": 65826,
      "randomized study": 67190,
      "patients tramadol": 60056,
      "tramadol compared": 82049,
      "oxycodone pca": 55664,
      "maxillofacial surgery": 43570,
      "twice day": 83307,
      "day post": 22380,
      "operatively patients": 51277,
      "received tramadol": 68300,
      "tramadol mg": 82082,
      "bolus oxycodone": 14223,
      "oxycodone 03": 54481,
      "immediate recovery": 36706,
      "opioid administered": 51405,
      "blind fashion": 13939,
      "increments pain": 38149,
      "assessed rest": 12050,
      "rest activity": 71413,
      "21 00": 2933,
      "00 09": 4,
      "09 00": 637,
      "effects recorded": 28129,
      "potency ratio": 63085,
      "groups vas": 34347,
      "scores pain": 73938,
      "adequate analgesia": 7958,
      "analgesia maxillofacial": 10014,
      "surgery risk": 79571,
      "group 44": 33614,
      "44 vs": 4549,
      "manage pain": 43121,
      "pain health": 56821,
      "january 2010": 40435,
      "recruited outpatient": 68793,
      "addicted percocet": 7735,
      "relief findings": 70130,
      "pressing need": 64731,
      "need expand": 48922,
      "growing concern": 34362,
      "increased prevalence": 37996,
      "oxycodone pills": 55685,
      "reddit social": 68822,
      "exposure fentanyl": 30763,
      "posts collected": 63043,
      "fentanyl related": 31583,
      "search terms": 74130,
      "relevant included": 70060,
      "included final": 37453,
      "final sample": 31748,
      "results 85": 71589,
      "pills identified": 61512,
      "contamination oxycodone": 20093,
      "testing strategies": 80843,
      "drugs aware": 26893,
      "harm reduction": 34580,
      "drug market": 26699,
      "market opioid": 43411,
      "drugs commonly": 26913,
      "exposure drugs": 30762,
      "gut microbiome": 34480,
      "drugs affect": 26879,
      "study date": 78050,
      "gut microbiota": 34481,
      "changes associated": 15774,
      "metabolic changes": 44905,
      "weeks prior": 86948,
      "prior breeding": 65138,
      "120 days": 1399,
      "females relative": 31398,
      "oxy exposed": 54447,
      "varied according": 85933,
      "according sex": 7063,
      "behavioral alterations": 13542,
      "effects adult": 27812,
      "products work": 65461,
      "oxy affects": 54441,
      "rodent model": 72718,
      "utero exposure": 85708,
      "exposure opioid": 30780,
      "drug lead": 26674,
      "effects evident": 27917,
      "mothers taking": 48010,
      "drugs important": 26975,
      "important tools": 37040,
      "addictive potential": 7787,
      "health complications": 34691,
      "complications respiratory": 18570,
      "brain hypoxia": 14339,
      "acute intoxication": 7636,
      "opioids result": 53275,
      "drug induced": 26650,
      "oxygen levels": 56204,
      "moving rats": 48062,
      "consider changes": 19603,
      "induced opioid": 38432,
      "doses exceeding": 26186,
      "mechanisms involved": 44143,
      "entry brain": 29087,
      "brain tissue": 14370,
      "present discuss": 64616,
      "data brain": 21892,
      "changes induced": 15794,
      "doses low": 26209,
      "self administered": 74454,
      "administered drug": 8124,
      "allowed compare": 9636,
      "compare effects": 18020,
      "drugs brain": 26898,
      "used high": 84954,
      "routes data": 72857,
      "data discussed": 21948,
      "volunteers completed": 86416,
      "cross trial": 21280,
      "trial oxycodone": 83044,
      "recorded analysis": 68670,
      "analysis number": 10715,
      "potential results": 63219,
      "results tapentadol": 72007,
      "89 001": 6055,
      "001 95": 105,
      "32 oxycodone": 3934,
      "increased latency": 37935,
      "003 95": 248,
      "35 21": 4060,
      "03 conclusion": 415,
      "decrease number": 22904,
      "tapentadol treatment": 80476,
      "effects spinal": 28167,
      "cord oxycodone": 20768,
      "possible opioid": 62541,
      "effect analgesic": 27421,
      "analgesic mechanisms": 10266,
      "generic drugs": 33046,
      "given purpose": 33191,
      "purpose analysis": 66518,
      "analysis examine": 10682,
      "impact introduction": 36817,
      "selected opioids": 74396,
      "include oxycodone": 37362,
      "er extended": 29416,
      "release fentanyl": 69856,
      "fentanyl transdermal": 31605,
      "transdermal patch": 82166,
      "marketing surveillance": 43428,
      "national sample": 48718,
      "generic formulations": 33051,
      "did significantly": 24502,
      "increase overall": 37771,
      "diversion did": 25593,
      "increase short": 37802,
      "term need": 80642,
      "warranted background": 86727,
      "opioids transition": 53351,
      "care hospital": 15028,
      "hospital home": 35594,
      "associated harm": 12270,
      "compare patients": 18041,
      "receiving tapentadol": 68380,
      "ir versus": 40264,
      "following orthopaedic": 32174,
      "opioids hospital": 52953,
      "setting major": 74785,
      "major metropolitan": 42958,
      "metropolitan tertiary": 45675,
      "hospital australia": 35567,
      "participants included": 58315,
      "included adult": 37411,
      "january 2018": 40456,
      "2018 30": 2811,
      "30 june": 3745,
      "june 2019": 40552,
      "2019 main": 2872,
      "measure proportion": 43945,
      "opioid prescribed": 52081,
      "prescribed changed": 63832,
      "study cohort": 77995,
      "cohort included": 17361,
      "100 patients": 1011,
      "oxycodone 99": 54614,
      "99 patients": 6493,
      "operatively hospitalisation": 51274,
      "66 years": 5462,
      "years sd": 87663,
      "sd 12": 74062,
      "56 female": 5101,
      "common surgeries": 17811,
      "total hip": 81810,
      "hip arthroplasty": 35416,
      "shoulder surgery": 75224,
      "26 13": 3421,
      "patients tapentadol": 60038,
      "tapentadol group": 80413,
      "group likely": 33839,
      "different opioid": 24894,
      "group 57": 33629,
      "versus difference": 86119,
      "ci 36": 16438,
      "36 59": 4121,
      "59 01": 5179,
      "01 adjusting": 302,
      "adjusting confounders": 8064,
      "tapentadol use": 80477,
      "use likely": 84454,
      "likely associated": 41797,
      "discharge 16": 25095,
      "ci 40": 16446,
      "40 01": 4307,
      "01 conclusions": 306,
      "associated increased": 12297,
      "increased likelihood": 37940,
      "likelihood opioid": 41790,
      "unwanted effects": 83973,
      "currently available": 21489,
      "alternative approach": 9716,
      "reduce opioid": 68858,
      "opioid needed": 51996,
      "comorbidity chronic": 17939,
      "pain anxiety": 56454,
      "likely responsible": 41844,
      "trials support": 83202,
      "effectiveness drug": 27758,
      "drug combination": 26553,
      "preclinical evidence": 63529,
      "using traditional": 85646,
      "animal models": 10996,
      "models nociception": 47118,
      "present studies": 64641,
      "studies examined": 77722,
      "examined prescription": 30406,
      "oxycodone 003": 54475,
      "operant behavior": 51204,
      "analgesia results": 10097,
      "related increases": 69622,
      "following oxycodone": 32181,
      "treatment did": 82548,
      "did produce": 24479,
      "produce significant": 65367,
      "significant antinociception": 75429,
      "antinociception combination": 11217,
      "shifted oxycodone": 75140,
      "additive effects": 7916,
      "effects limited": 27969,
      "dose range": 26028,
      "diazepam oxycodone": 24372,
      "oxycodone higher": 55159,
      "findings provide": 31810,
      "provide sufficient": 66103,
      "sufficient evidence": 78971,
      "relevant opioid": 70064,
      "sparing pain": 76533,
      "management especially": 43180,
      "especially considering": 29552,
      "drug class": 26550,
      "objectives opioid": 50573,
      "patients acute": 58934,
      "acute musculoskeletal": 7645,
      "impact opioid": 36822,
      "persistent use": 60931,
      "determined opioid": 24078,
      "pain randomized": 57457,
      "measured pain": 43986,
      "using 10": 85283,
      "analyzed data": 10825,
      "multivariable linear": 48320,
      "linear regression": 42028,
      "dependent variable": 23538,
      "independent variables": 38170,
      "controlling age": 20655,
      "sex results": 75089,
      "results 75": 71582,
      "apap mean": 11355,
      "good scores": 33331,
      "scores oxy": 73935,
      "commonly utilized": 17904,
      "dose analgesic": 25829,
      "summary current": 79098,
      "opioid equianalgesic": 51786,
      "meperidine tramadol": 44851,
      "codeine hydrocodone": 17241,
      "oxymorphone hydromorphone": 56249,
      "hydromorphone levorphanol": 36180,
      "fentanyl tapentadol": 31599,
      "tolerance opioid": 81591,
      "equianalgesic ratios": 29266,
      "baseline opioid": 13445,
      "databases including": 22201,
      "time max": 81282,
      "max results": 43557,
      "study opioid": 78346,
      "average 23": 12862,
      "tapentadol included": 80422,
      "minimum maximum": 46613,
      "maximum recommended": 43612,
      "recommended doses": 68620,
      "fentanyl hydromorphone": 31496,
      "hydromorphone oxycodone": 36203,
      "12 37": 1250,
      "37 oral": 4201,
      "oral tramadol": 53675,
      "oral hydromorphone": 53545,
      "hydromorphone intravenous": 36179,
      "iv hydromorphone": 40377,
      "06 mg": 587,
      "conclusion opioid": 18937,
      "opioid equianalgesia": 51785,
      "significant variation": 75641,
      "incomplete cross": 37702,
      "oral iv": 53556,
      "ratios opioids": 67826,
      "tramadol hydromorphone": 82071,
      "variation equianalgesic": 85914,
      "sex biological": 75062,
      "prevalence specific": 64816,
      "specific adverse": 76579,
      "reactions commonly": 67957,
      "large cohort": 41121,
      "cohort used": 17409,
      "used investigate": 84981,
      "sex differences": 75071,
      "reactions associated": 67954,
      "use codeine": 84243,
      "codeine tramadol": 17290,
      "participants right": 58365,
      "right drug": 72478,
      "right dose": 72477,
      "right study": 72479,
      "received opioid": 68218,
      "january 2004": 40421,
      "december 2017": 22827,
      "2017 reviewed": 2804,
      "61 women": 5320,
      "white median": 87023,
      "measures adverse": 44039,
      "section patient": 74272,
      "patient medical": 58678,
      "medical record": 44392,
      "risk adverse": 72513,
      "modelled using": 47101,
      "using logistic": 85469,
      "regression adjusted": 69413,
      "adjusted age": 8015,
      "age body": 9061,
      "body mass": 14195,
      "mass index": 43450,
      "race ethnicity": 66939,
      "reported adverse": 70499,
      "women men": 87225,
      "women likely": 87218,
      "report adverse": 70448,
      "oxycodone 95": 54613,
      "support importance": 79199,
      "02 capsules": 363,
      "opioid antagonist": 51536,
      "determine effects": 24008,
      "effects administration": 27810,
      "40 ethanol": 4336,
      "adults administered": 8538,
      "naltrexone block": 48539,
      "block results": 14065,
      "time maximum": 81283,
      "maximum concentration": 43583,
      "concentration 12": 18669,
      "ethanol decreased": 29679,
      "auc time": 12639,
      "zero extrapolated": 87758,
      "extrapolated infinity": 30976,
      "auc maximum": 12635,
      "concentration cmax": 18684,
      "cmax values": 17098,
      "values similar": 85854,
      "increased 13": 37825,
      "37 respectively": 4204,
      "administered 40": 8104,
      "intervals cis": 39610,
      "vomiting nausea": 86462,
      "headache somnolence": 34661,
      "oxycodone exposures": 55057,
      "administered 20": 8100,
      "tolerated background": 81621,
      "compare analgesic": 18005,
      "potency oxycodone": 63082,
      "resection methods": 71047,
      "undergoing laparoscopic": 83546,
      "morphine intravenous": 47738,
      "intravenous pca": 39880,
      "pca surgery": 60273,
      "surgery primary": 79533,
      "outcome opioid": 53965,
      "24 surgery": 3277,
      "surgery secondary": 79576,
      "time request": 81358,
      "request analgesia": 70784,
      "analgesia number": 10032,
      "sedation nausea": 74320,
      "depression bradycardia": 23573,
      "pain caused": 56517,
      "recorded results": 68694,
      "consumption 14": 19870,
      "83 morphine": 5933,
      "morphine consumption": 47620,
      "consumption 20": 19873,
      "20 14": 2275,
      "78 vs": 5786,
      "average time": 12939,
      "97 27": 6435,
      "higher morphine": 35263,
      "group 45": 33615,
      "45 vs": 4601,
      "vs 17": 86542,
      "17 19": 1937,
      "19 50": 2177,
      "50 vs": 4906,
      "19 12": 2160,
      "12 24": 1231,
      "24 40": 3162,
      "40 91": 4331,
      "91 vs": 6143,
      "13 04": 1448,
      "24 39": 3161,
      "vs 19": 86544,
      "19 13": 2161,
      "13 overall": 1498,
      "overall incidence": 54205,
      "incidence vomiting": 37327,
      "group 27": 33590,
      "difference visual": 24702,
      "score incidence": 73755,
      "incidence respiratory": 37313,
      "bradycardia groups": 14312,
      "types pain": 83374,
      "patients request": 59899,
      "analgesia incidence": 10002,
      "pain highest": 56828,
      "potent morphine": 63104,
      "oxycodone fewer": 55092,
      "chinese clinical": 16091,
      "http www": 35926,
      "2019 13": 2851,
      "13 00": 1444,
      "00 00": 1,
      "childhood adolescence": 16015,
      "migraine headaches": 46419,
      "report patient": 70470,
      "patient developed": 58617,
      "time age": 81205,
      "abdominal symptoms": 6533,
      "increased frequency": 37921,
      "determine use": 24055,
      "analgesic treatment": 10348,
      "treatment traumatic": 82877,
      "department methods": 23436,
      "prospective randomized": 65858,
      "controlled clinical": 20469,
      "community based": 17915,
      "based ed": 13314,
      "relief measured": 70140,
      "visual numeric": 86334,
      "numeric pain": 50290,
      "intensity scale": 39307,
      "exclusion criteria": 30485,
      "criteria follows": 21196,
      "follows age": 32226,
      "age younger": 9137,
      "younger 18": 87727,
      "drugs patients": 27034,
      "study drug": 78132,
      "drug control": 26568,
      "acetaminophen rescue": 7248,
      "analgesic pain": 10287,
      "pain diary": 56712,
      "outcome measurements": 53930,
      "hours treatment": 35873,
      "treatment use": 82881,
      "25 received": 3382,
      "received diclofenac": 68137,
      "groups similar": 34324,
      "score analgesic": 73730,
      "analgesic use": 10353,
      "greater improvement": 33450,
      "diclofenac group": 24387,
      "group 95": 33654,
      "groups 95": 34122,
      "rescue oxycodone": 70968,
      "20 95": 2308,
      "36 versus": 4148,
      "versus control": 86116,
      "group 42": 33612,
      "42 95": 4454,
      "complications associated": 18556,
      "appears safe": 11408,
      "background analgesic": 13014,
      "analgesic action": 10137,
      "action oxycodone": 7442,
      "contrast morphine": 20216,
      "mediated kappa": 44310,
      "surgery methods": 79459,
      "methods studied": 45585,
      "oxycodone 12": 54511,
      "25 patients": 3377,
      "nitrous oxide": 49504,
      "epidural anaesthesia": 29166,
      "sedation scores": 74331,
      "scores nausea": 73911,
      "vomiting scores": 86478,
      "days surgery": 22637,
      "surgery results": 79567,
      "higher patients": 35290,
      "day postoperative": 22383,
      "day significantly": 22416,
      "day 12": 22242,
      "day lower": 22330,
      "lower patients": 42673,
      "scores groups": 73879,
      "groups conclusion": 34156,
      "effective morphine": 27648,
      "purpose purpose": 66552,
      "opioid morphine": 51960,
      "methadone oxycodone": 45115,
      "fentanyl consumption": 31460,
      "2009 2016": 2519,
      "2016 identify": 2745,
      "recent trends": 68432,
      "trends methods": 82971,
      "data treatment": 22145,
      "settings private": 74861,
      "years 2009": 87532,
      "ministry health": 46620,
      "database data": 22167,
      "used calculate": 84863,
      "ddd 1000": 22669,
      "1000 inhabitants": 1033,
      "inhabitants day": 38758,
      "various drugs": 85965,
      "results consumption": 71647,
      "consumption opioids": 19962,
      "2016 trend": 2764,
      "fold fentanyl": 31989,
      "consumption 09": 19866,
      "1000 day": 1031,
      "67 methadone": 5476,
      "morphine 17": 47543,
      "17 ddd": 1965,
      "day 15": 22249,
      "trend observed": 82949,
      "observed use": 50727,
      "naloxone targin": 48522,
      "acetaminophen percocet": 7236,
      "pure oxycodone": 66507,
      "formulations conclusions": 32373,
      "conclusions increase": 19099,
      "associated substantial": 12446,
      "fentanyl prescriptions": 31573,
      "prescriptions decreases": 64470,
      "pethidine prescriptions": 60988,
      "prescriptions national": 64521,
      "national program": 48714,
      "safe use": 73106,
      "opioids treatment": 53356,
      "role mu": 72749,
      "mor mediated": 47502,
      "gaba transmission": 32784,
      "drug reward": 26779,
      "expressing neurons": 30825,
      "mice did": 46280,
      "oxycodone displayed": 54983,
      "control mice": 20365,
      "mice displayed": 46281,
      "oral consumption": 53503,
      "consumed oxycodone": 19839,
      "mice failed": 46286,
      "induced locomotor": 38421,
      "locomotor stimulation": 42243,
      "like responses": 41783,
      "following development": 32125,
      "oxycodone dependence": 54940,
      "littermate controls": 42142,
      "following treatment": 32218,
      "antagonist naloxone": 11065,
      "mediated behaviors": 44306,
      "analgesia data": 9945,
      "data reveal": 22098,
      "critical component": 21228,
      "component opioid": 18582,
      "67 year": 5481,
      "renal insufficiency": 70364,
      "admitted hospital": 8421,
      "morphine patient": 47869,
      "adverse opioid": 8829,
      "intensive care": 39332,
      "unit oxycodone": 83765,
      "oxycodone reliable": 55829,
      "recently developed": 68443,
      "effectively control": 27728,
      "control pain": 20383,
      "major orthopaedic": 42965,
      "analgesia provided": 10076,
      "spinal administration": 76699,
      "administration local": 8285,
      "local anesthetics": 42206,
      "opioids provides": 53233,
      "highest level": 35351,
      "therapy highly": 81019,
      "low molecular": 42503,
      "molecular weight": 47291,
      "weight heparin": 86981,
      "parenteral opioids": 58210,
      "allows patients": 9649,
      "perceived pain": 60443,
      "pain stimulus": 57864,
      "provide improved": 66073,
      "improved analgesic": 37097,
      "oral sustained": 53670,
      "opioids offer": 53114,
      "offer superior": 50952,
      "superior pain": 79134,
      "short duration": 75164,
      "agents provide": 9240,
      "provide opioid": 66082,
      "dose requirements": 26060,
      "surgery anesthesia": 79321,
      "immune function": 36764,
      "perioperative period": 60849,
      "study evaluated": 78176,
      "evaluated effects": 29878,
      "flurbiprofen axetil": 31960,
      "function patients": 32665,
      "undergoing radical": 83570,
      "radical resection": 66958,
      "colorectal cancer": 17523,
      "cancer crc": 14775,
      "randomized oxycodone": 67141,
      "group sufentanil": 34040,
      "group prescribed": 33931,
      "kg combined": 40704,
      "kg postoperative": 40789,
      "group received": 33943,
      "received sufentanil": 68289,
      "sufentanil \u03bcg": 78954,
      "outcome visual": 54004,
      "score secondary": 73784,
      "natural killer": 48738,
      "killer nk": 40831,
      "nk cells": 49508,
      "tnf level": 81501,
      "level interleukin": 41496,
      "peripheral blood": 60862,
      "consumption analgesics": 19894,
      "analgesics incidence": 10432,
      "similar group": 75923,
      "group vas": 34065,
      "cough group": 20915,
      "hours postsurgery": 35830,
      "cells higher": 15498,
      "group 48": 33620,
      "serum level": 74700,
      "tnf il": 81500,
      "il 12": 36607,
      "group lower": 33841,
      "addition incidence": 7807,
      "incidence postoperative": 37298,
      "pruritus lower": 66298,
      "lower time": 42714,
      "time flatus": 81263,
      "bowel movement": 14285,
      "earlier group": 27242,
      "applied patient": 11436,
      "analgesia effectively": 9962,
      "effectively reduce": 27736,
      "reduce pain": 68872,
      "pain help": 56823,
      "weeks days": 86903,
      "days life": 22547,
      "frequently use": 32582,
      "effects cancer": 27840,
      "patients objectives": 59565,
      "hydromorphone cancer": 36161,
      "methods secondary": 45566,
      "multicenter cohort": 48154,
      "utilizing standardized": 85747,
      "108 patients": 1073,
      "age 72": 9049,
      "34 32": 4018,
      "32 received": 3938,
      "respectively 24": 71154,
      "hours mean": 35793,
      "scores significantly": 73987,
      "error se": 29513,
      "se baseline": 74101,
      "baseline morphine": 13443,
      "morphine 001": 47527,
      "oxycodone 001": 54474,
      "respectively 48": 71159,
      "respectively significant": 71244,
      "mean scores": 43855,
      "similarly effective": 76010,
      "safe cancer": 73074,
      "highly selective": 35402,
      "cox inhibitor": 21027,
      "unique pharmacological": 83758,
      "pharmacological profile": 61227,
      "relatively short": 69788,
      "designed clinical": 23827,
      "52 weeks": 4999,
      "osteoarthritis oa": 53864,
      "rheumatoid arthritis": 72455,
      "efficacy oral": 28309,
      "decreasing pain": 23073,
      "improving functional": 37194,
      "functional status": 32717,
      "status greater": 77257,
      "greater placebo": 33478,
      "nonselective nsaids": 49846,
      "nsaids celecoxib": 50100,
      "daily single": 21805,
      "single multiple": 76123,
      "multiple dose": 48270,
      "designed trials": 23853,
      "trials patients": 83179,
      "associated primary": 12393,
      "primary dysmenorrhoea": 65000,
      "tension type": 80610,
      "type headache": 83327,
      "800 mg": 5866,
      "daily effective": 21746,
      "effective relieving": 27692,
      "relieving acute": 70228,
      "pain placebo": 57380,
      "mg effective": 45880,
      "selective cox": 74427,
      "cox inhibitors": 21028,
      "tolerated clinical": 81624,
      "trials similar": 83200,
      "similar overall": 75964,
      "selective inhibitors": 74430,
      "52 week": 4998,
      "patients oa": 59562,
      "approximately quarter": 11586,
      "ibuprofen 800": 36348,
      "mg times": 46239,
      "naproxen 500": 48564,
      "nervous adverse": 49134,
      "combination benzodiazepines": 17549,
      "benzodiazepines antidepressants": 13655,
      "antidepressants anticonvulsants": 11171,
      "aes oxycodone": 8881,
      "administration adverse": 8213,
      "event reporting": 29992,
      "data study": 22122,
      "aims explore": 9485,
      "provide reference": 66093,
      "methods extracted": 45337,
      "lower 95": 42570,
      "empirical bayes": 28736,
      "age distribution": 9070,
      "oxycodone mainly": 55352,
      "related drugs": 69592,
      "60 years": 5282,
      "risk aes": 72519,
      "oxycodone strongly": 55943,
      "strongly associated": 77576,
      "69 95": 5520,
      "ci 24": 16418,
      "24 21": 3149,
      "ci 53": 16467,
      "87 95": 6020,
      "ci 68": 16483,
      "associated mental": 12333,
      "08 95": 623,
      "ci 38": 16442,
      "38 10": 4225,
      "10 78": 726,
      "ic 33": 36380,
      "09 95": 641,
      "ci 76": 16491,
      "13 23": 1461,
      "23 95": 3085,
      "23 14": 3072,
      "87 43": 6018,
      "43 86": 4499,
      "74 95": 5672,
      "ci 15": 16401,
      "15 33": 1694,
      "prr 73": 66288,
      "89 95": 6058,
      "ci 17": 16405,
      "17 72": 1950,
      "86 95": 6005,
      "pharmacovigilance studies": 61255,
      "medication monitoring": 44518,
      "monitoring oxycodone": 47331,
      "aes background": 8870,
      "residents report": 71080,
      "driver opioid": 26465,
      "practices study": 63442,
      "surgical residents": 79649,
      "practices methods": 63428,
      "surveyed evaluate": 79744,
      "tablets prescribed": 80201,
      "prescribed common": 63837,
      "common procedures": 17802,
      "compared residents": 18293,
      "prescribing engagement": 64055,
      "engagement network": 28934,
      "prescribed frequency": 63863,
      "prescription practices": 64387,
      "assessed results": 12051,
      "results 72": 71581,
      "recommended opioid": 68632,
      "14 procedures": 1625,
      "reported prescribing": 70630,
      "prescribed significantly": 63980,
      "significantly recommended": 75838,
      "practices compared": 63425,
      "education regarding": 27395,
      "electronic medical": 28537,
      "concentrations generally": 18765,
      "toxicological interpretation": 81942,
      "autopsy cases": 12770,
      "cases lack": 15246,
      "limited information": 41934,
      "information exists": 38647,
      "postmortem concentrations": 62676,
      "concentrations matrices": 18772,
      "matrices blood": 43536,
      "blood pericardial": 14138,
      "pericardial fluid": 60667,
      "vitreous humor": 86351,
      "detection opioids": 23961,
      "detection methadone": 23960,
      "methadone buprenorphine": 45049,
      "buprenorphine oxycodone": 14574,
      "fentanyl tramadol": 31602,
      "postmortem samples": 62682,
      "skeletal muscle": 76191,
      "blood drug": 14119,
      "alternative matrices": 9722,
      "useful interpretation": 85206,
      "included cases": 37433,
      "opioid detected": 51709,
      "cases buprenorphine": 15225,
      "methadone concentrations": 45059,
      "quantitative analyses": 66796,
      "cases included": 15243,
      "alternative postmortem": 9738,
      "quantitative results": 66808,
      "interpreted caution": 39509,
      "caution background": 15409,
      "opioids continue": 52818,
      "prescribed chronic": 63834,
      "opioids provide": 53231,
      "short time": 75202,
      "lead dose": 41285,
      "effects difficult": 27897,
      "advantages using": 8617,
      "using pharmaceutical": 85557,
      "population chronic": 62317,
      "combining opioid": 17685,
      "effects lesser": 27964,
      "trial design": 83018,
      "design single": 23803,
      "center randomized": 15545,
      "arm open": 11668,
      "label exploratory": 40972,
      "population 60": 62300,
      "american college": 9792,
      "oxycodone sustained": 55970,
      "tablet times": 80106,
      "treatments treatment": 82934,
      "daily maximum": 21755,
      "given treatment": 33203,
      "weeks week": 86967,
      "week follow": 86840,
      "period main": 60743,
      "endpoint number": 28893,
      "number effects": 50160,
      "treatment using": 82883,
      "adverse effect": 8629,
      "following 10": 32093,
      "vomiting constipation": 86452,
      "secondary tertiary": 74261,
      "tertiary endpoints": 80739,
      "endpoints include": 28910,
      "include pain": 37363,
      "trial designed": 83020,
      "titration oxycodone": 81480,
      "reduce effects": 68841,
      "effects chronic": 27847,
      "trial register": 83063,
      "url https": 84097,
      "organization international": 53770,
      "evaluate clinical": 29778,
      "clinical effect": 16795,
      "effect safety": 27555,
      "hepatocellular carcinoma": 34966,
      "methods march": 45375,
      "march december": 43375,
      "undergoing percutaneous": 83566,
      "university cancer": 83856,
      "cancer hospital": 14785,
      "groups oxycodone": 34254,
      "group fentanyl": 33779,
      "group dezocine": 33738,
      "dezocine group": 24305,
      "20 cases": 2311,
      "cases group": 15239,
      "group respectively": 33987,
      "001 mg": 156,
      "kg dezocine": 40715,
      "map heart": 43346,
      "rate rr": 67516,
      "changes group": 15788,
      "began 10": 13517,
      "end surgical": 28826,
      "analgesia effect": 9959,
      "depression nausea": 23584,
      "recorded using": 68708,
      "anova repeated": 11045,
      "test test": 80787,
      "tests evaluate": 80857,
      "anesthetic effect": 10968,
      "completed patients": 18482,
      "points groups": 62130,
      "11 min": 1136,
      "min group": 46525,
      "t2 time": 80060,
      "group pain": 33894,
      "analogue scores": 10568,
      "waking group": 86692,
      "group cases": 33676,
      "intraoperative respiratory": 39781,
      "hemodynamic stability": 34940,
      "advantage terms": 8609,
      "terms postoperative": 80716,
      "compared immediate": 18182,
      "tablets crushed": 80139,
      "center single": 15552,
      "inpatient clinical": 39008,
      "unit toronto": 83773,
      "able discriminate": 6570,
      "receive 15": 68039,
      "crossover fashion": 21290,
      "primary subjective": 65113,
      "postdose drug": 62646,
      "included vas": 37573,
      "pupillometry subject": 66493,
      "subject rated": 78637,
      "subjects male": 78709,
      "percent white": 60504,
      "mean drug": 43771,
      "liking vas": 41870,
      "vas max": 86007,
      "70 vs": 5572,
      "47 vs": 4666,
      "vs 87": 86627,
      "vs 91": 86629,
      "effect lower": 27478,
      "treatment sequence": 82831,
      "treatments similar": 82928,
      "common opioids": 17783,
      "opioids observed": 53111,
      "observed treatments": 50726,
      "subjects experienced": 78697,
      "related symptoms": 69698,
      "tablets demonstrated": 80142,
      "demonstrated lower": 23353,
      "users background": 85228,
      "background prolonged": 13181,
      "physical mental": 61405,
      "mental health": 44819,
      "known risk": 40929,
      "use aim": 84184,
      "postoperative patients": 62934,
      "patients use": 60161,
      "oxycodone longer": 55341,
      "factors prolonged": 31127,
      "prolonged use": 65643,
      "method retrospective": 45211,
      "retrospective single": 72165,
      "nested case": 49145,
      "case control": 15166,
      "control study": 20426,
      "hospital study": 35643,
      "prescription discharge": 64199,
      "april 2018": 11609,
      "2018 june": 2827,
      "2020 primary": 2907,
      "oxycodone follow": 55096,
      "period 30": 60701,
      "outcome association": 53905,
      "potential risk": 63220,
      "factors oxycodone": 31120,
      "univariate multivariate": 83842,
      "multivariate logistic": 48346,
      "regression analyses": 69415,
      "determine association": 23989,
      "23 received": 3111,
      "received refill": 68256,
      "age adjusted": 9052,
      "01 95": 297,
      "interval 00": 39549,
      "length stay": 41405,
      "score higher": 73752,
      "14 01": 1548,
      "use continuous": 84271,
      "15 60": 1706,
      "oxycodone conclusion": 54837,
      "conclusion proportion": 18974,
      "oxycodone 23": 54540,
      "use potential": 84639,
      "potential misuse": 63191,
      "determined risk": 24086,
      "population future": 62332,
      "future interventions": 32763,
      "use purpose": 84675,
      "diclofenac 50": 24383,
      "diazepam 10": 24367,
      "useful adjuncts": 85196,
      "spinal anesthesia": 76705,
      "day case": 22275,
      "varicose vein": 85928,
      "repair methods": 70383,
      "methods asa": 45253,
      "outpatients age": 54158,
      "age 18": 8975,
      "18 60": 2056,
      "60 yr": 5283,
      "hour operation": 35705,
      "mg given": 45897,
      "given rescue": 33194,
      "needed oxycodone": 49020,
      "kg im": 40736,
      "im postoperative": 36674,
      "mg tablets": 46229,
      "asked record": 11846,
      "record postoperative": 68658,
      "quantity tablets": 66845,
      "tablets taken": 80224,
      "sd hours": 74080,
      "hours surgery": 35862,
      "end second": 28812,
      "second postoperative": 74193,
      "postoperative days": 62759,
      "days 23": 22468,
      "23 21": 3075,
      "12 17": 1217,
      "17 11": 1930,
      "11 15": 1095,
      "group 24": 33587,
      "23 12": 3071,
      "20 10": 2268,
      "10 17": 676,
      "17 16": 1935,
      "respectively ns": 71220,
      "groups 31": 34109,
      "31 67": 3859,
      "67 patients": 5479,
      "required postoperative": 70855,
      "postoperative diclofenac": 62768,
      "hours 05": 35728,
      "diclofenac premedication": 24395,
      "premedication reduced": 63724,
      "reduced analgesic": 68908,
      "analgesic requirements": 10327,
      "article reports": 11782,
      "elderly female": 28472,
      "opioid associated": 51551,
      "associated rate": 12399,
      "oxycodone ingestion": 55276,
      "factors likely": 31114,
      "likely contributed": 41803,
      "direct opioid": 25051,
      "induced inhibition": 38420,
      "related gene": 69610,
      "background previous": 13175,
      "20 years": 2390,
      "opioids medical": 53042,
      "opioids elderly": 52880,
      "study changes": 77983,
      "changes analgesic": 15772,
      "quality quantity": 66755,
      "quantity prescriptions": 66842,
      "prescriptions opioids": 64527,
      "analyzed results": 10855,
      "72 mg": 5622,
      "day patient": 22361,
      "naloxone tramadol": 48526,
      "increase total": 37812,
      "total consumption": 81788,
      "consumption drugs": 19921,
      "average daily": 12882,
      "daily cost": 21714,
      "cost analgesic": 20861,
      "compared 46": 18083,
      "increased 10": 37822,
      "10 conclusion": 749,
      "training program": 82011,
      "dramatically increased": 26439,
      "number children": 50145,
      "exposed opioids": 30744,
      "opioids including": 52976,
      "oxycodone number": 55546,
      "known mechanisms": 40916,
      "prenatal opioid": 63727,
      "neural circuits": 49167,
      "nucleus accumbens": 50125,
      "accumbens nac": 7088,
      "adolescence adulthood": 8435,
      "maternal oxycodone": 43525,
      "administration pregnancy": 8341,
      "adult male": 8492,
      "opioid exposed": 51794,
      "exposed offspring": 30743,
      "extinction oxycodone": 30935,
      "oxycodone conditioned": 54842,
      "work demonstrates": 87272,
      "demonstrates time": 23382,
      "play key": 61993,
      "morphine induces": 47732,
      "histamine liberation": 35436,
      "studies suggested": 77855,
      "suggested morphine": 79022,
      "initial effects": 38849,
      "used reference": 85105,
      "blinded fashion": 13999,
      "07 mg": 606,
      "14 mg": 1605,
      "min iv": 46528,
      "iv injection": 40379,
      "injection pain": 38964,
      "pain mean": 57137,
      "arterial blood": 11709,
      "blood pressure": 14143,
      "concentrations determined": 18755,
      "05 83": 488,
      "100 10": 980,
      "10 mm": 868,
      "05 respectively": 545,
      "parallel increase": 58144,
      "increase hr": 37751,
      "70 10": 5548,
      "simultaneous increase": 76035,
      "detected plasma": 23946,
      "immediate effect": 36699,
      "effect morphine": 27492,
      "effect seen": 27556,
      "morphine like": 47743,
      "blinded randomized": 14013,
      "evaluated morphine": 29898,
      "seen previously": 74365,
      "studies healthy": 77737,
      "painful stimulus": 58012,
      "morphine caused": 47595,
      "accompanied increased": 7024,
      "hemodynamic alterations": 34937,
      "background health": 13061,
      "promote quality": 65663,
      "appropriate prescription": 11514,
      "branded oxycodone": 14384,
      "medicare advantage": 44433,
      "plan study": 61868,
      "year following": 87441,
      "longitudinal cohort": 42398,
      "claims data": 16620,
      "data july": 21998,
      "december 31": 22832,
      "31 2014": 3847,
      "2014 conducted": 2660,
      "conducted study": 19413,
      "adults aged": 8542,
      "years chronic": 87576,
      "claims months": 16633,
      "index date": 38193,
      "years 2012": 87534,
      "2012 2014": 2590,
      "followed months": 32072,
      "patients overall": 59605,
      "approach results": 11479,
      "users study": 85273,
      "age 62": 9036,
      "62 years": 5342,
      "years 59": 87549,
      "female mean": 31364,
      "charlson comorbidity": 15922,
      "comorbidity index": 17940,
      "index score": 38208,
      "83 001": 5924,
      "001 patients": 182,
      "patients medical": 59486,
      "patients identified": 59375,
      "characteristics similar": 15882,
      "study years": 78570,
      "2012 2013": 2589,
      "respectively lower": 71204,
      "14 respectively": 1627,
      "years approximately": 87571,
      "approximately 40": 11569,
      "59 patients": 5190,
      "patients continued": 59151,
      "analysis indicated": 10701,
      "patients conclusions": 59126,
      "support consistent": 79189,
      "effect patient": 27525,
      "behavior result": 13538,
      "did lead": 24461,
      "lead higher": 41290,
      "lower patient": 42672,
      "costs study": 20908,
      "funding study": 32739,
      "time study": 81387,
      "morphine recommended": 47906,
      "recommended line": 68623,
      "pharmacological therapy": 61234,
      "therapy cancer": 80992,
      "opioids cancer": 52762,
      "physician reported": 61431,
      "practice opioid": 63407,
      "opioid cancer": 51565,
      "methods nationwide": 45395,
      "survey conducted": 79698,
      "randomly selected": 67241,
      "asked following": 11837,
      "use morphine": 84499,
      "morphine cancer": 47594,
      "opioid choice": 51575,
      "daily practice": 21802,
      "practice results": 63414,
      "results overall": 71816,
      "rate 71": 67438,
      "morphine needed": 47788,
      "needed opioid": 49016,
      "mean increase": 43780,
      "11 baseline": 1123,
      "42 low": 4461,
      "low moderate": 42500,
      "morphine 30": 47554,
      "oxycodone regardless": 55818,
      "regardless baseline": 69284,
      "fentanyl frequent": 31478,
      "cases oxycodone": 15250,
      "oxycodone preferred": 55732,
      "studies confirm": 77677,
      "safety effectiveness": 73142,
      "effectiveness opioid": 27767,
      "background electronic": 13050,
      "pain diaries": 56711,
      "increasing patients": 38118,
      "goal present": 33275,
      "pilot study": 61552,
      "evaluate feasibility": 29802,
      "telephone interviews": 80573,
      "interviews patients": 39696,
      "patients refractory": 59873,
      "refractory pain": 69226,
      "switched oxycodone": 79826,
      "oxycodone setting": 55896,
      "practice patients": 63409,
      "methods week": 45632,
      "consecutive weeks": 19571,
      "male patients": 43046,
      "patients answered": 58996,
      "telephone interview": 80572,
      "international classification": 39472,
      "daily activities": 21692,
      "activities results": 7553,
      "results weeks": 72058,
      "available 70": 12788,
      "70 participants": 5569,
      "physicians patients": 61444,
      "patients efficacy": 59240,
      "activities daily": 7549,
      "daily living": 21751,
      "good tolerability": 33333,
      "tolerability oxycodone": 81544,
      "findings reported": 31814,
      "reported clinical": 70518,
      "95 patients": 6405,
      "quality control": 66684,
      "conclusion standardized": 18996,
      "private payer": 65193,
      "payer claims": 60246,
      "months study": 47473,
      "patients claims": 59088,
      "drug 30": 26495,
      "days study": 22630,
      "medical drug": 44357,
      "reported patients": 70620,
      "18 64": 2059,
      "multivariate models": 48350,
      "estimate risk": 29615,
      "risk adjusted": 72512,
      "controlling patient": 20659,
      "characteristics results": 15879,
      "results oxymorphone": 71829,
      "lower drug": 42606,
      "mean follow": 43777,
      "days respectively": 22608,
      "aged 65": 9190,
      "medicare supplemental": 44441,
      "limitations patients": 41907,
      "patients concomitant": 59127,
      "concomitant use": 19255,
      "higher costs": 35224,
      "evaluate patients": 29827,
      "endoscopic retrograde": 28860,
      "retrograde cholangiopancreatography": 72100,
      "cholangiopancreatography ercp": 16128,
      "follow background": 32014,
      "background limited": 13075,
      "limited data": 41921,
      "data evaluating": 21960,
      "hp study": 35883,
      "retrospectively assessed": 72176,
      "response therapeutic": 71376,
      "telephone survey": 80574,
      "conducted obtain": 19378,
      "obtain information": 50753,
      "information results": 38670,
      "underwent total": 83701,
      "mean range": 43847,
      "range 11": 67251,
      "period years": 60814,
      "follow 15": 32009,
      "15 19": 1678,
      "19 27": 2169,
      "27 years": 3512,
      "patients 92": 58910,
      "92 received": 6158,
      "decreased 001": 22936,
      "001 yearly": 227,
      "care emergency": 15020,
      "emergency room": 28696,
      "room visits": 72781,
      "001 001": 94,
      "001 daily": 126,
      "oxycodone equivalent": 55033,
      "decreased 39": 22961,
      "complications included": 18560,
      "bleeding infection": 13909,
      "conclusions despite": 19072,
      "12 21": 1229,
      "21 patients": 2981,
      "associated decreased": 12244,
      "analgesic usage": 10352,
      "recurrent pancreatitis": 68818,
      "pancreatitis studies": 58062,
      "studies evaluating": 77719,
      "trial evaluated": 83024,
      "adjunctive analgesic": 8006,
      "analgesic cardiac": 10159,
      "cardiac surgery": 14983,
      "ninety patients": 49483,
      "elective coronary": 28489,
      "coronary artery": 20781,
      "artery bypass": 11723,
      "bypass grafting": 14632,
      "grafting cabg": 33398,
      "receive 75": 68045,
      "75 microg": 5710,
      "bolus ketamine": 14218,
      "followed continuous": 32052,
      "25 microg": 3367,
      "kg min": 40761,
      "48 44": 4687,
      "44 placebo": 4547,
      "normal saline": 49909,
      "saline bolus": 73256,
      "bolus infusion": 14216,
      "tracheal extubation": 81971,
      "extubation patients": 30997,
      "oxycodone patient": 55649,
      "analgesia device": 9949,
      "48 pain": 4738,
      "pain evaluated": 56761,
      "evaluated visual": 29936,
      "scale times": 73565,
      "quality recovery": 66756,
      "management adverse": 43148,
      "consumption 48": 19883,
      "48 postoperative": 4744,
      "ketamine group": 40610,
      "44 mg": 4542,
      "group 125": 33568,
      "22 mg": 3034,
      "mg 95": 45780,
      "interval difference": 39596,
      "scores did": 73863,
      "groups rest": 34305,
      "deep breath": 23090,
      "patients 26": 58846,
      "26 60": 3436,
      "compared 16": 18068,
      "16 35": 1857,
      "group satisfied": 33995,
      "analgesic management": 10265,
      "events similar": 30122,
      "patients ketamine": 59431,
      "small dose": 76275,
      "dose ketamine": 25942,
      "decreased opioid": 23014,
      "patients 48": 58872,
      "48 surgery": 4749,
      "surgery measured": 79457,
      "analgesics drug": 10416,
      "deaths consistent": 22748,
      "metropolitan areas": 45673,
      "reports opioid": 70734,
      "increase oxycodone": 37774,
      "reports increased": 70728,
      "noted frequently": 49987,
      "heroin cocaine": 34991,
      "dramatic increases": 26435,
      "abuse major": 6767,
      "growing problem": 34369,
      "determine impact": 24015,
      "shared decision": 75119,
      "postsurgical opioid": 63049,
      "women underwent": 87256,
      "invasive mis": 39969,
      "single tertiary": 76143,
      "care academic": 14997,
      "academic center": 6943,
      "center patients": 15537,
      "patients participants": 59629,
      "january 2019": 40457,
      "april 2020": 11611,
      "73 women": 5661,
      "study 36": 77891,
      "standard arm": 76890,
      "arm 37": 11667,
      "participants assigned": 58282,
      "30 tablets": 3798,
      "tablets patient": 80195,
      "outcome percentage": 53978,
      "excess opioid": 30452,
      "opioid tablets": 52393,
      "included total": 37568,
      "tablets used": 80228,
      "used frequency": 84943,
      "additional opioid": 7872,
      "tablets discharge": 80148,
      "prescribed results": 63976,
      "results age": 71595,
      "age race": 9108,
      "race body": 66936,
      "16 percent": 1889,
      "robotic assisted": 72708,
      "median iqr": 44233,
      "prescribed patient": 63946,
      "arm 15": 11664,
      "24 tablets": 3281,
      "tablets standard": 80217,
      "greater percentage": 33477,
      "73 percent": 5658,
      "56 percent": 5106,
      "03 01": 401,
      "01 difference": 307,
      "patients standard": 59992,
      "mean tablets": 43885,
      "tablets 50": 80118,
      "entire cohort": 29072,
      "tablets conclusions": 80132,
      "did decrease": 24428,
      "decrease total": 22931,
      "undergoing mis": 83555,
      "used 22": 84825,
      "standard 30": 76885,
      "fentanyl compared": 31456,
      "opioids transdermal": 53349,
      "transdermal buprenorphine": 82142,
      "model data": 47038,
      "data structured": 22120,
      "used derive": 84906,
      "probabilistic sensitivity": 65212,
      "fentanyl patients": 31565,
      "cost saving": 20884,
      "buprenorphine treatment": 14596,
      "treatment adults": 82432,
      "nonmalignant moderate": 49768,
      "alcohol intake": 9534,
      "intake bioavailability": 39179,
      "ood formulation": 51135,
      "ml 20": 46830,
      "oxycodone absorption": 54616,
      "absorption oxycodone": 6612,
      "showed peak": 75287,
      "taking opioids": 80316,
      "opioids evidence": 52895,
      "induced dose": 38407,
      "potential opioid": 63197,
      "extracted currently": 30950,
      "describes development": 23664,
      "use pharmaceutical": 84622,
      "despite limitations": 23889,
      "resistant opioid": 71102,
      "nonmedical use": 49782,
      "reduce use": 68896,
      "reduced opioid": 68951,
      "shown modulate": 75341,
      "modulate effects": 47253,
      "models study": 47132,
      "behavioral effects": 13545,
      "oxycodone male": 55363,
      "male rats": 43049,
      "rats trained": 67897,
      "trained intravenously": 82003,
      "intravenously self": 39900,
      "self administer": 74452,
      "kg infusion": 40743,
      "sessions following": 74745,
      "following acquisition": 32095,
      "rats exposed": 67858,
      "injection 10": 38933,
      "prior ivsa": 65156,
      "ivsa sessions": 40407,
      "fewer oxycodone": 31657,
      "oxycodone infusions": 55274,
      "rats following": 67860,
      "compared vehicle": 18338,
      "follow studies": 32035,
      "dependent effects": 23509,
      "different infusion": 24875,
      "infusion doses": 38705,
      "oxycodone preserved": 55752,
      "additional groups": 7863,
      "groups male": 34229,
      "female wistar": 31382,
      "wistar rats": 87113,
      "rats assessed": 67842,
      "oxycodone 100": 54505,
      "withdrawal latency": 87135,
      "combination compared": 17551,
      "additive antinociceptive": 7913,
      "effects produced": 28111,
      "data demonstrate": 21938,
      "oxycodone suggest": 55960,
      "suggest potential": 79011,
      "potential use": 63243,
      "enhance therapeutic": 28962,
      "efficacy reduce": 28341,
      "opioids introduction": 53005,
      "introduction oxycodone": 39946,
      "analgesics clinical": 10390,
      "clinical management": 16834,
      "present retrospective": 64636,
      "analysis aimed": 10637,
      "oxycodone achieve": 54667,
      "achieve effective": 7299,
      "effective control": 27608,
      "control moderate": 20366,
      "pain combined": 56565,
      "relevant reduction": 70073,
      "data patients": 22040,
      "10 20": 681,
      "mg evaluated": 45885,
      "dose days": 25859,
      "controlled pain": 20510,
      "pain initial": 56873,
      "intensity treatment": 39321,
      "results data": 71650,
      "data total": 22144,
      "93 patients": 6176,
      "average baseline": 12878,
      "population pain": 62366,
      "score reduced": 73779,
      "oxycodone 21": 54538,
      "21 60": 2957,
      "12 days": 1277,
      "mg combined": 45824,
      "conclusion low": 18922,
      "acetaminophen effective": 7182,
      "effective management": 27636,
      "treatment associated": 82452,
      "associated adverse": 12215,
      "reactions drug": 67960,
      "article processing": 11776,
      "processing charges": 65349,
      "safety quality": 73214,
      "combination therapy": 17613,
      "oxycodone plus": 55695,
      "plus pregabalin": 62033,
      "pregabalin versus": 63687,
      "oxycodone pregabalin": 55733,
      "pregabalin patients": 63675,
      "pain materials": 57134,
      "severe neuropathic": 74957,
      "despite use": 23908,
      "use various": 84801,
      "pharmacologic treatments": 61203,
      "prior study": 65172,
      "study entry": 78156,
      "treated cr": 82331,
      "intensity rated": 39297,
      "rated 11": 67527,
      "results combination": 71631,
      "combination cr": 17552,
      "monotherapy effective": 47375,
      "effective alleviating": 27585,
      "nrs value": 50085,
      "80 76": 5835,
      "respectively 003": 71147,
      "greater improvements": 33451,
      "improvements baseline": 37170,
      "91 patients": 6141,
      "receiving cr": 68328,
      "pregabalin treatment": 63686,
      "treatment effective": 82564,
      "effective effective": 27621,
      "dose reduction": 26042,
      "oxycodone 51": 54579,
      "profile compared": 65480,
      "conclusions combination": 19048,
      "pregabalin represent": 63682,
      "represent valuable": 70752,
      "valuable addition": 85812,
      "addition existing": 7801,
      "pain warrants": 57984,
      "warrants investigation": 86736,
      "investigation purpose": 40072,
      "goal studies": 33276,
      "studies determine": 77698,
      "determine relationship": 24045,
      "prescribed use": 64002,
      "non medically": 49638,
      "related use": 69704,
      "regional level": 69357,
      "level country": 41455,
      "gather information": 32907,
      "abuse treatment": 6896,
      "number cases": 50144,
      "cases prescription": 15255,
      "past 30": 58454,
      "days results": 22610,
      "strong correlation": 77514,
      "prescriptions filled": 64487,
      "relative therapeutic": 69770,
      "small urban": 76308,
      "urban suburban": 84036,
      "suburban rural": 78900,
      "rural areas": 73048,
      "rank order": 67362,
      "abuse shows": 6872,
      "buprenorphine products": 14583,
      "abused prescription": 6922,
      "analgesics hydrocodone": 10429,
      "data corrected": 21930,
      "exposure cases": 30755,
      "1000 persons": 1041,
      "filling prescription": 31724,
      "oxycodone drugs": 55009,
      "drugs grouped": 26969,
      "low levels": 42493,
      "abuse conclusion": 6664,
      "highly efficacious": 35396,
      "best possible": 13692,
      "risk benefit": 72526,
      "benefit ratio": 13624,
      "ratio drugs": 67767,
      "background efficacy": 13046,
      "tolerability oral": 81541,
      "pain analyzed": 56451,
      "severe severe": 75022,
      "pain musculoskeletal": 57220,
      "treated controlled": 82328,
      "controlled released": 20575,
      "released oxycodone": 70024,
      "oxycodone weeks": 56091,
      "severity pain": 75045,
      "associated pain": 12372,
      "nrs 10": 50054,
      "10 results": 918,
      "weeks physical": 86935,
      "physical therapy": 61418,
      "life improved": 41701,
      "improved significantly": 37132,
      "oxycodone impairment": 55238,
      "different aspects": 24847,
      "aspects life": 11861,
      "50 conclusion": 4831,
      "therapy pain": 81042,
      "oxycodone efficient": 55022,
      "different parts": 24903,
      "life objective": 41709,
      "impact increased": 36816,
      "access restrictions": 7003,
      "opioids er": 52888,
      "la opioids": 40965,
      "opioids health": 52940,
      "period 2009": 60692,
      "2009 30": 2521,
      "2012 methods": 2605,
      "study analyzed": 77952,
      "data adult": 21865,
      "study groups": 78220,
      "commercial medicare": 17711,
      "outpatient visits": 54156,
      "visits prescription": 86289,
      "test differences": 80764,
      "results mean": 71764,
      "month post": 47405,
      "outpatient visit": 54155,
      "001 higher": 144,
      "higher pre": 35307,
      "costs objective": 20900,
      "development new": 24236,
      "formulations extended": 32379,
      "er opioids": 29451,
      "deterrent technology": 24131,
      "appropriate access": 11496,
      "care pain": 15049,
      "patients avoid": 59023,
      "reformulated er": 69198,
      "extent patients": 30931,
      "methods analyzed": 45250,
      "truven marketscan": 83262,
      "data following": 21973,
      "continuous users": 20190,
      "users extended": 85239,
      "er oxymorphone": 29464,
      "period prior": 60780,
      "prior introduction": 65153,
      "products identified": 65447,
      "categorized based": 15305,
      "acting la": 7386,
      "treatment month": 82670,
      "identified using": 36480,
      "using icd": 85433,
      "icd cm": 36387,
      "diagnosis codes": 24333,
      "codes opioid": 17306,
      "abuse dependence": 6675,
      "pearson chi": 60333,
      "squared tests": 76801,
      "fisher exact": 31852,
      "exact tests": 30320,
      "tests used": 80866,
      "used compare": 84886,
      "patients avoided": 59024,
      "er opioid": 29449,
      "opioid sensitivity": 52362,
      "analyses examined": 10592,
      "used analysis": 84844,
      "analysis main": 10707,
      "rates diagnosed": 67568,
      "diagnosed opioid": 24323,
      "50 patients": 4882,
      "patients transitioned": 60057,
      "limitations observational": 41904,
      "observational research": 50618,
      "caution warranted": 15418,
      "warranted causal": 86728,
      "causal interpretation": 15333,
      "interpretation findings": 39501,
      "commercially insured": 17720,
      "research consider": 70993,
      "additional patient": 7883,
      "commercial insurance": 17707,
      "insurance medicare": 39151,
      "medicare medicaid": 44438,
      "conclusions patients": 19154,
      "patients switched": 60026,
      "opioids discontinued": 52860,
      "treatment suggesting": 82867,
      "systemic opioids": 80031,
      "world context": 87304,
      "evaluate effectiveness": 29789,
      "regular opioids": 69478,
      "care practice": 15063,
      "practice methods": 63402,
      "methods multicenter": 45388,
      "adult cancer": 8488,
      "patients starting": 59994,
      "intensity using": 39323,
      "using numerical": 85531,
      "hours 72": 35741,
      "starting opioids": 77019,
      "t1 t3": 80053,
      "common opioid": 17777,
      "aes results": 8884,
      "patients proportion": 59712,
      "68 95": 5494,
      "intervals ci": 39607,
      "75 95": 5701,
      "ci 70": 16485,
      "82 95": 5902,
      "76 87": 5736,
      "nrs baseline": 50059,
      "73 95": 5649,
      "99 95": 6484,
      "ci 71": 16486,
      "47 95": 4654,
      "common treatment": 17819,
      "emergent ae": 28706,
      "incidence severe": 37317,
      "10 study": 932,
      "period multivariate": 60753,
      "multivariate analysis": 48341,
      "analysis baseline": 10644,
      "positive correlation": 62459,
      "liver metastasis": 42182,
      "negative correlation": 49069,
      "regular systemic": 69482,
      "class medications": 16662,
      "general population": 32980,
      "used appropriately": 84847,
      "current article": 21427,
      "article aims": 11761,
      "medication class": 44468,
      "team based": 80539,
      "based approach": 13281,
      "clinically appropriate": 16974,
      "health services": 34772,
      "23 28": 3077,
      "type primary": 83348,
      "sleep disorder": 76216,
      "leading excessive": 41309,
      "daytime sleepiness": 22659,
      "aimed assess": 9435,
      "use self": 84723,
      "reported effect": 70539,
      "symptom severity": 79866,
      "methods systematically": 45604,
      "systematically reviewed": 80011,
      "reviewed literature": 72384,
      "literature opioid": 42119,
      "completed online": 18476,
      "online questionnaire": 51101,
      "use previous": 84665,
      "possible effects": 62536,
      "use reported": 84693,
      "systematic literature": 79976,
      "showed improvements": 75263,
      "recent opioid": 68411,
      "respondents used": 71315,
      "used 20": 84823,
      "codeine 20": 17197,
      "tramadol 20": 82024,
      "20 oxycodone": 2366,
      "fentanyl 20": 31418,
      "11 20": 1101,
      "pronounced oxycodone": 65682,
      "oxycodone codeine": 54794,
      "frequently used": 32583,
      "oxycodone lesser": 55334,
      "codeine associated": 17210,
      "frequently reported": 32575,
      "trials needed": 83166,
      "potential opioids": 63200,
      "therapeutic agents": 80917,
      "study estimate": 78159,
      "comparative safety": 17982,
      "long stay": 42320,
      "nursing home": 50341,
      "home residents": 35523,
      "study nursing": 78327,
      "residents initiating": 71075,
      "short acting": 75154,
      "hydrocodone tramadol": 36134,
      "2011 2013": 2574,
      "minimum data": 46609,
      "set medicare": 74756,
      "residents 65": 71070,
      "treatment episodes": 82581,
      "days prior": 22600,
      "opioid claims": 51578,
      "180 days": 2121,
      "hospitalization hip": 35657,
      "death competing": 22701,
      "inverse probability": 39988,
      "probability treatment": 65221,
      "treatment weighting": 82891,
      "hazard ratios": 34617,
      "ci results": 16538,
      "oxycodone 69": 54594,
      "hydrocodone 50": 36050,
      "hospitalizations 100": 35662,
      "100 person": 1014,
      "person years": 60944,
      "11 oxycodone": 1138,
      "ci hydrocodone": 16530,
      "models oxycodone": 47119,
      "similar rate": 75986,
      "ci 79": 16495,
      "lower fracture": 42620,
      "fracture rates": 32460,
      "rates hydrocodone": 67588,
      "67 95": 5472,
      "ci 56": 16470,
      "conclusions lower": 19117,
      "lower rate": 42695,
      "compared prior": 18281,
      "prior studies": 65171,
      "community dwelling": 17917,
      "overall fracture": 54203,
      "community settings": 17929,
      "limited risk": 41957,
      "random urine": 67005,
      "drug testing": 26806,
      "testing program": 80836,
      "drug tests": 26812,
      "errors methods": 29516,
      "clinical database": 16781,
      "abuse program": 6849,
      "program large": 65536,
      "children hospital": 16050,
      "hospital analyzed": 35563,
      "adolescent patients": 8445,
      "patients 13": 58827,
      "21 years": 2988,
      "drug test": 26804,
      "results collected": 71630,
      "2002 july": 2442,
      "july 2005": 40508,
      "2002 2006": 2438,
      "confirmed positive": 19506,
      "positive opioids": 62474,
      "opioids calculated": 52761,
      "potential false": 63166,
      "false negatives": 31171,
      "positive tests": 62499,
      "tests oxycodone": 80859,
      "result positive": 71487,
      "screen potential": 74026,
      "reviewed clinical": 72374,
      "clinical information": 16828,
      "information determine": 38642,
      "tests resulted": 80862,
      "prescription counter": 64189,
      "counter medication": 20934,
      "prescription medication": 64247,
      "use total": 84776,
      "total 85": 81771,
      "43 positive": 4507,
      "oxycodone 16": 54525,
      "produced positive": 65401,
      "procedures used": 65332,
      "testing drugs": 80819,
      "drugs substantial": 27084,
      "substantial risk": 78858,
      "hippocampus oxycodone": 35431,
      "oxycodone appears": 54725,
      "multiple opioid": 48288,
      "activity opioid": 7575,
      "receptor kor": 68503,
      "recent evidence": 68399,
      "evidence revealed": 30253,
      "activation opioid": 7473,
      "receptor dor": 68489,
      "dor kor": 25733,
      "vitro study": 86372,
      "study established": 78158,
      "oxycodone induce": 55258,
      "possible mechanisms": 62540,
      "inhibitory effect": 38819,
      "reactive oxygen": 67977,
      "oxygen species": 56208,
      "prevention treatment": 64885,
      "dose strengths": 26082,
      "strengths oxycodone": 77480,
      "tablets treatment": 80225,
      "controlled multicenter": 20505,
      "repeat dose": 70392,
      "study clinicaltrials": 77992,
      "pain post": 57386,
      "receive placebo": 68070,
      "placebo 30": 61629,
      "tablets 30": 80117,
      "tablets administered": 80122,
      "administered hours": 8135,
      "hours 48": 35738,
      "hours ketorolac": 35788,
      "ketorolac tromethamine": 40661,
      "available rescue": 12835,
      "endpoint sum": 28901,
      "scores 48": 73836,
      "spid 48": 76687,
      "48 following": 4703,
      "following initial": 32142,
      "initial dose": 38836,
      "drug secondary": 26786,
      "efficacy endpoints": 28264,
      "responder analysis": 71317,
      "analysis use": 10783,
      "medication safety": 44564,
      "safety evaluations": 73151,
      "evaluations included": 29971,
      "included adverse": 37413,
      "assessments results": 12155,
      "results doses": 71667,
      "demonstrated superior": 23374,
      "reductions pain": 69117,
      "intensity compared": 39237,
      "0001 oxycodone": 73,
      "mg 30": 45737,
      "intensity aes": 39228,
      "aes occurred": 8880,
      "group 134": 33570,
      "analgesia generally": 9982,
      "tolerated patients": 81636,
      "surgery aim": 79319,
      "aim aim": 9371,
      "aim present": 9395,
      "30 women": 3806,
      "67 years": 5483,
      "laparotomy administrated": 41114,
      "group 15": 33572,
      "15 oxycodone": 1780,
      "analgesia patients": 10049,
      "received paracetamol": 68239,
      "epidural infusion": 29181,
      "infusion postoperatively": 38722,
      "postoperatively primary": 63019,
      "outcome total": 53999,
      "dose fentanyl": 25905,
      "required fentanyl": 70836,
      "interval 01": 39551,
      "groups needed": 34243,
      "similar total": 75999,
      "infusion patient": 38719,
      "high groups": 35108,
      "groups administration": 34129,
      "tolerated conclusions": 81628,
      "administration pain": 8332,
      "systemic dexamethasone": 80022,
      "dexamethasone dxm": 24283,
      "fracture surgery": 32461,
      "surgery materials": 79453,
      "methods prospective": 45480,
      "randomized observer": 67128,
      "observer blinded": 50734,
      "blinded trial": 14024,
      "20 patients": 2369,
      "requiring surgical": 70917,
      "surgical intervention": 79634,
      "intervention conducted": 39626,
      "assessed postoperatively": 12039,
      "postoperatively using": 63032,
      "10 cm": 745,
      "cm visual": 17090,
      "vas time": 86029,
      "time analgesics": 81210,
      "analgesics acetaminophen": 10367,
      "acetaminophen hours": 7190,
      "oxycodone request": 55836,
      "auc 24": 12624,
      "hours postoperatively": 35823,
      "outcome data": 53912,
      "data analyzed": 21874,
      "using test": 85638,
      "student test": 77597,
      "tailed mann": 80257,
      "mann whitney": 43317,
      "whitney test": 87034,
      "value 05": 85820,
      "significance results": 75412,
      "exhibited significantly": 30516,
      "lower average": 42579,
      "average vas": 12942,
      "confounding variables": 19526,
      "remained significant": 70271,
      "03 conclusions": 416,
      "pain recommended": 57484,
      "pre emptive": 63465,
      "surgery purpose": 79545,
      "increased opioid": 37961,
      "opioid antinociception": 51547,
      "antinociception different": 11218,
      "different kinds": 24878,
      "pain typical": 57947,
      "opioids induced": 52996,
      "induced antinociception": 38382,
      "rats morphine": 67871,
      "morphine tramadol": 47957,
      "oxycodone magnesium": 55348,
      "50 \u03bcm": 4913,
      "mechanical stimuli": 44115,
      "model compared": 47036,
      "compared results": 18296,
      "kg enhanced": 40725,
      "enhanced analgesic": 28967,
      "administered opioids": 8154,
      "significantly faster": 75698,
      "faster effective": 31213,
      "40 oxycodone": 4370,
      "vitro studies": 86371,
      "greater extent": 33446,
      "approach treatment": 11483,
      "importance opioid": 36984,
      "prescribing common": 64041,
      "recent studies": 68422,
      "range analgesic": 67301,
      "analgesic prescription": 10300,
      "prescription patterns": 64383,
      "patterns following": 60207,
      "endoscopic sinus": 28863,
      "sinus surgery": 76149,
      "surgery ess": 79393,
      "efficacy different": 28249,
      "different analgesic": 24843,
      "analgesic regimens": 10319,
      "multi institutional": 48146,
      "randomized clinical": 67044,
      "trial conducted": 83014,
      "conducted tertiary": 19418,
      "participants underwent": 58379,
      "2019 march": 2873,
      "march 2020": 43370,
      "2020 data": 2896,
      "analyzed november": 10846,
      "received acetaminophen": 68111,
      "acetaminophen 650": 7138,
      "analgesic patients": 10288,
      "oxycodone rescue": 55840,
      "second line": 74187,
      "ibuprofen 600": 36346,
      "600 mg": 5286,
      "pain main": 57042,
      "baseline characteristics": 13421,
      "measures collected": 44050,
      "collected postoperative": 17475,
      "day primary": 22391,
      "outcome postoperative": 53979,
      "score pain": 73768,
      "pain brief": 56500,
      "interference scores": 39430,
      "scores collected": 73846,
      "total 118": 81715,
      "118 patients": 1190,
      "52 oxycodone": 4991,
      "46 16": 4618,
      "16 years": 1900,
      "black asian": 13900,
      "loss follow": 42433,
      "group 49": 33621,
      "similar demographic": 75910,
      "demographic characteristics": 23268,
      "63 oxycodone": 5364,
      "management acetaminophen": 43140,
      "37 consumed": 4189,
      "dose ibuprofen": 25925,
      "18 16": 2032,
      "required acetaminophen": 70820,
      "acetaminophen 28": 7122,
      "57 used": 5138,
      "used acetaminophen": 84830,
      "acetaminophen ibuprofen": 7194,
      "doses groups": 26194,
      "similar average": 75901,
      "acetaminophen 69": 7141,
      "69 vs": 5527,
      "vs 96": 86635,
      "vs 77": 86619,
      "use groups": 84385,
      "similar postoperative": 75980,
      "opioids users": 53379,
      "users nonusers": 85256,
      "showed clinically": 75233,
      "significant lower": 75576,
      "points conclusions": 62128,
      "acetaminophen acetaminophen": 7147,
      "ibuprofen ibuprofen": 36358,
      "did reduce": 24488,
      "reduce overall": 68869,
      "overall narcotic": 54213,
      "narcotic consumption": 48591,
      "consumption overall": 19970,
      "use low": 84461,
      "low groups": 42489,
      "groups trial": 34341,
      "compare postoperative": 18042,
      "anterior cruciate": 11103,
      "cruciate ligament": 21323,
      "ligament acl": 41756,
      "acl reconstruction": 7354,
      "reconstruction aclr": 68643,
      "receiving adductor": 68320,
      "adductor canal": 7945,
      "canal block": 14758,
      "block acb": 14037,
      "bupivacaine lb": 14502,
      "secondary purpose": 74260,
      "purpose compare": 66524,
      "undergoing aclr": 83510,
      "academic medical": 6951,
      "medical center": 44338,
      "november 21": 50041,
      "21 2019": 2942,
      "cohort received": 17375,
      "received acb": 68110,
      "20 tablets": 2383,
      "improvement initiative": 37152,
      "consumption postoperative": 19991,
      "days pain": 22577,
      "thrice daily": 81159,
      "daily using": 21813,
      "scale total": 73567,
      "total postoperative": 81889,
      "consumption reported": 20009,
      "converted oral": 20736,
      "equivalents omes": 29370,
      "subjects underwent": 78750,
      "met eligibility": 44870,
      "55 male": 5076,
      "male mean": 43041,
      "mean standard": 43879,
      "28 13": 3534,
      "years 52": 87543,
      "52 received": 4994,
      "47 received": 4664,
      "76 mean": 5741,
      "mean postoperative": 43840,
      "scores similar": 73993,
      "groups entire": 34192,
      "period 08": 60676,
      "consumption lower": 19948,
      "receiving lb": 68346,
      "median ome": 44260,
      "ome interquartile": 51057,
      "range 28": 67279,
      "63 vs": 5368,
      "vs 45": 86580,
      "average tablets": 12938,
      "tablets patients": 80196,
      "pain compared": 56575,
      "compared receiving": 18289,
      "block opioid": 14049,
      "consumption given": 19927,
      "received different": 68138,
      "numbers opioid": 50283,
      "prescribing patients": 64100,
      "completed opioid": 18478,
      "requested refills": 70794,
      "prescription size": 64408,
      "studies necessary": 77781,
      "consumption aclr": 19889,
      "contribute development": 20225,
      "subject groups": 78629,
      "investigated dose": 40036,
      "effects ibudilast": 27945,
      "glial cell": 33215,
      "dependent volunteers": 23540,
      "received placebo": 68244,
      "placebo ibudilast": 61762,
      "1st week": 2260,
      "day participants": 22360,
      "participants 10": 58263,
      "20 40mg": 2297,
      "bid placebo": 13788,
      "days week": 22654,
      "week analgesic": 86829,
      "70kg po": 5584,
      "analgesia measured": 10017,
      "threshold pain": 81152,
      "groups week": 34353,
      "week week": 86877,
      "week placebo": 86862,
      "group exhibited": 33769,
      "threshold subjective": 81154,
      "exhibited greater": 30510,
      "associated abuse": 12211,
      "did consistently": 24425,
      "suggest ibudilast": 78995,
      "enhance opioid": 28957,
      "objectives investigate": 50566,
      "symptoms opioid": 79897,
      "opioid potency": 52076,
      "aged 50": 9188,
      "reporting use": 70707,
      "opioids past": 53154,
      "adjusted multiple": 8039,
      "multiple linear": 48282,
      "2005 2013": 2463,
      "dataset national": 22214,
      "predictor variables": 63583,
      "variables included": 85896,
      "positive screen": 62489,
      "symptoms patient": 79902,
      "patient health": 58654,
      "health questionnaire": 34759,
      "score greater": 73747,
      "greater equal": 33445,
      "severe depression": 74942,
      "criterion variables": 21225,
      "analgesics codeine": 10391,
      "tramadol morphine": 82084,
      "morphine opioid": 47794,
      "results prevalence": 71888,
      "significantly associated": 75654,
      "high potency": 35143,
      "potency opioid": 63079,
      "use odds": 84535,
      "ci 16": 16404,
      "16 46": 1859,
      "post hoc": 62571,
      "remained significantly": 70272,
      "ci 59": 16474,
      "13 conclusions": 1482,
      "conclusions compared": 19052,
      "adults severe": 8579,
      "taking high": 80304,
      "symptoms severe": 79905,
      "use discharge": 84314,
      "surgery benign": 79334,
      "indications data": 38273,
      "data sources": 22111,
      "systematically searched": 80013,
      "searched medline": 74155,
      "october 2020": 50890,
      "study selection": 78478,
      "selection studies": 74422,
      "studies data": 77687,
      "gynecologic surgical": 34490,
      "surgical procedures": 79646,
      "outpatient opioids": 54131,
      "opioids consumed": 52815,
      "incidence persistent": 37296,
      "reviewers independently": 72397,
      "independently screened": 38184,
      "extracted data": 30951,
      "eligible studies": 28594,
      "thirty studies": 81116,
      "articles met": 11798,
      "met inclusion": 44876,
      "data extracted": 21966,
      "23 studies": 3112,
      "studies included": 77748,
      "included data": 37442,
      "data opioids": 22033,
      "consumed hospital": 19831,
      "discharge 12": 25094,
      "12 studies": 1364,
      "surgery average": 79329,
      "average morphine": 12898,
      "morphine milligram": 47767,
      "milligram equivalents": 46454,
      "equivalents mme": 29358,
      "mme used": 46980,
      "54 95": 5044,
      "tablets mg": 80176,
      "35 95": 4073,
      "ci 75": 16490,
      "12 tablets": 1366,
      "59 95": 5185,
      "ci 44": 16452,
      "44 74": 4535,
      "oxycodone laparoscopic": 55328,
      "laparoscopic hysterectomy": 41100,
      "ci 80": 16496,
      "14 tablets": 1629,
      "oxycodone abdominal": 54615,
      "22 mme": 3036,
      "mme 95": 46950,
      "12 32": 1248,
      "hours discharge": 35765,
      "days postdischarge": 22588,
      "use occurred": 84533,
      "occurred patients": 50841,
      "surgery outcome": 79490,
      "high heterogeneity": 35109,
      "average patients": 12931,
      "equivalent 15": 29282,
      "15 fewer": 1734,
      "fewer mg": 31642,
      "tablets equivalent": 80152,
      "weeks discharge": 86904,
      "discharge major": 25135,
      "major gynecologic": 42948,
      "findings help": 31784,
      "reduce medication": 68852,
      "medication diversion": 44491,
      "diversion misuse": 25597,
      "regional anesthesia": 69352,
      "anesthesia ra": 10938,
      "ambulatory hand": 9765,
      "hand surgery": 34554,
      "undergoing ambulatory": 83511,
      "brachial plexus": 14308,
      "plexus block": 62018,
      "block 50": 14036,
      "patients rated": 59757,
      "pain disability": 56721,
      "index surgery": 38211,
      "fast track": 31204,
      "pain adverse": 56428,
      "scores measured": 73901,
      "measured postoperative": 43990,
      "days 14": 22462,
      "14 patients": 1620,
      "documented pain": 25665,
      "consumption adverse": 19891,
      "effects pain": 28077,
      "satisfaction results": 73428,
      "results ra": 71901,
      "ra patients": 66932,
      "duration stay": 27183,
      "group 001": 33526,
      "001 time": 215,
      "time analgesic": 81208,
      "analgesic request": 10324,
      "001 opioid": 168,
      "consumption reduced": 20007,
      "discharge 001": 25090,
      "surgery lower": 79445,
      "patients spent": 59988,
      "spent time": 76683,
      "time hospital": 81271,
      "surgery 001": 79292,
      "experienced nausea": 30614,
      "vomiting recovery": 86471,
      "05 postoperative": 542,
      "despite significant": 23905,
      "hospital ambulatory": 35560,
      "surgery single": 79588,
      "single shot": 76138,
      "does reduce": 25690,
      "pain home": 56834,
      "home postoperative": 35519,
      "surgery compared": 79348,
      "compared ga": 18161,
      "does provide": 25689,
      "provide significant": 66100,
      "significant early": 75534,
      "benefits including": 13631,
      "including reduction": 37670,
      "hospital opioid": 35605,
      "overdoses deaths": 54326,
      "deaths continue": 22749,
      "problem usa": 65246,
      "significant portion": 75595,
      "related prescribed": 69669,
      "opioid addiction": 51399,
      "area research": 11640,
      "research opioid": 71021,
      "potential oxycodone": 63202,
      "widely abused": 87052,
      "abused opioid": 6919,
      "analgesic appears": 10154,
      "use high": 84396,
      "penetration cns": 60388,
      "providers consider": 66183,
      "risk addiction": 72511,
      "addiction opioids": 7750,
      "opioids prescribe": 53203,
      "drug used": 26852,
      "used alleviate": 84838,
      "alleviate acute": 9592,
      "oxycodone abused": 54621,
      "cns depression": 17114,
      "effects intravenous": 27958,
      "doses various": 26300,
      "rats high": 67865,
      "assess oxycodone": 11943,
      "oxycodone affects": 54699,
      "glucose levels": 33246,
      "levels nucleus": 41579,
      "maintain self": 42882,
      "administration behavior": 8223,
      "doses mg": 26215,
      "induced similar": 38458,
      "body temperature": 14206,
      "activation appears": 7468,
      "underlying mechanism": 83607,
      "increases brain": 38053,
      "blood oxygen": 14135,
      "likely mediate": 41816,
      "hypoxia induced": 36320,
      "oxycodone injections": 55284,
      "linked opioid": 42055,
      "humans known": 35984,
      "known objective": 40919,
      "developed abuse": 24164,
      "formulation extended": 32341,
      "hydrochloride sequestered": 36038,
      "capsules primary": 14959,
      "conditions pharmacokinetics": 19327,
      "concentrations used": 18817,
      "tolerability single": 81556,
      "doses alo": 26146,
      "methods irb": 45366,
      "irb approved": 40269,
      "study 24": 77887,
      "24 healthy": 3200,
      "adult volunteers": 8527,
      "volunteers aged": 86414,
      "years subject": 87676,
      "administered intact": 8140,
      "intact capsule": 39167,
      "administered fed": 8128,
      "fat breakfast": 31226,
      "120 hours": 1401,
      "parameters included": 58160,
      "included maximum": 37475,
      "cmax area": 17095,
      "profile time": 65513,
      "infinity aucinf": 38542,
      "quantifiable concentration": 66768,
      "time cmax": 81221,
      "parameters monitored": 58166,
      "tmax values": 81496,
      "values oxycodone": 85850,
      "similar treatments": 76003,
      "lack effect": 41051,
      "effect food": 27459,
      "fasted oxycodone": 31209,
      "oxycodone bioavailability": 54749,
      "test reference": 80779,
      "geometric means": 33123,
      "99 100": 6483,
      "respectively effect": 71191,
      "limits 80": 41979,
      "treatment based": 82458,
      "measurable plasma": 43932,
      "mg tolerated": 46243,
      "difference frequency": 24614,
      "sprinkled applesauce": 76788,
      "difficulty swallowing": 24975,
      "newly initiated": 49419,
      "initiated opioid": 38880,
      "increases risk": 38081,
      "remains determined": 70291,
      "determined drug": 24063,
      "negative effect": 49071,
      "cyp2d6 metabolizes": 21613,
      "partial effect": 58241,
      "effect tramadol": 27574,
      "investigate cyp2d6": 40002,
      "cyp2d6 inhibiting": 21608,
      "drugs contribute": 26924,
      "opioid treatments": 52454,
      "swedish national": 79812,
      "identified total": 36478,
      "total 167": 81731,
      "2006 31": 2480,
      "information dispensed": 38643,
      "dispensed drugs": 25424,
      "drugs use": 27096,
      "dispensed opioids": 25431,
      "opioids 28": 52672,
      "28 days": 3556,
      "related injury": 69626,
      "drugs compared": 26917,
      "compared earlier": 18142,
      "control period": 20391,
      "use 76": 84159,
      "76 95": 5738,
      "40 20": 4316,
      "20 times": 2384,
      "times risk": 81436,
      "risk increase": 72583,
      "17 95": 1953,
      "19 95": 2179,
      "ci 84": 16500,
      "04 95": 447,
      "ci 82": 16498,
      "morphine fentanyl": 47688,
      "opioid therapies": 52404,
      "use cyp2d6": 84287,
      "drugs associated": 26891,
      "cyp2d6 opioids": 21616,
      "use chronic": 84235,
      "patients adherent": 58945,
      "estimate number": 29609,
      "treatment design": 82547,
      "database study": 22188,
      "ibm marketscan": 36336,
      "marketscan commercial": 43433,
      "database opioid": 22177,
      "national mortality": 48703,
      "switching patients": 79838,
      "lower rates": 42696,
      "authors identified": 12732,
      "patients october": 59573,
      "october 2012": 50875,
      "march 2016": 43367,
      "proportion days": 65740,
      "days covered": 22505,
      "180 day": 2120,
      "treatment main": 82647,
      "percent versus": 60499,
      "001 fewer": 137,
      "fewer days": 31635,
      "patient mean": 58677,
      "versus 70": 86112,
      "70 days": 5561,
      "days 001": 22457,
      "conclusions treatment": 19236,
      "studies warranted": 77874,
      "objective investigated": 50442,
      "subjects ingested": 78707,
      "placebo days": 61716,
      "study day": 78051,
      "day ingested": 22322,
      "ingested 10": 38738,
      "48 pharmacodynamic": 4741,
      "oxycodone mean": 55374,
      "auc infinity": 12631,
      "infinity oxycodone": 38543,
      "range fold": 67316,
      "concentration fold": 18697,
      "ratio noroxycodone": 67779,
      "noroxycodone oxycodone": 49934,
      "001 oxymorphone": 176,
      "oxymorphone increased": 56254,
      "oxycodone modestly": 55459,
      "increasing exposure": 38107,
      "exposure oral": 30784,
      "oxycodone needed": 55528,
      "avoid opioid": 12959,
      "effects especially": 27914,
      "balance adequate": 13228,
      "measured use": 44001,
      "use narcotics": 84509,
      "narcotics pain": 48635,
      "pain inadequately": 56855,
      "inadequately controlled": 37235,
      "surgical experience": 79630,
      "objectives characterize": 50548,
      "association patient": 12486,
      "pain outcomes": 57305,
      "outcomes objective": 54060,
      "survey study": 79740,
      "july 2018": 40523,
      "2018 january": 2823,
      "plastic surgeons": 61965,
      "surgeons academic": 79265,
      "month surgery": 47413,
      "measures number": 44070,
      "outcomes number": 54059,
      "number narcotic": 50175,
      "narcotic prescription": 48608,
      "prescription refills": 64397,
      "refills patient": 69176,
      "perception pain": 60528,
      "pain surgical": 57890,
      "surgical outcome": 79638,
      "outcome oxycodone": 53968,
      "demographic information": 23285,
      "results recorded": 71909,
      "statistical analysis": 77171,
      "spearman rank": 76552,
      "order correlation": 53708,
      "correlation used": 20837,
      "variables 05": 85885,
      "05 considered": 505,
      "considered statistically": 19655,
      "104 patients": 1060,
      "patients surveyed": 60024,
      "lost follow": 42442,
      "follow participants": 32023,
      "included 50": 37400,
      "50 women": 4907,
      "age 38": 9000,
      "range 10": 67246,
      "10 40": 707,
      "40 tablets": 4379,
      "range 23": 67273,
      "pain perception": 57365,
      "significant negative": 75585,
      "functional outcome": 32704,
      "experienced pain": 30621,
      "functional improvement": 32698,
      "contrast patients": 20218,
      "association pain": 12485,
      "05 64": 486,
      "knowledge study": 40895,
      "study prospectively": 78432,
      "prospectively evaluate": 65898,
      "evaluate association": 29773,
      "association opioid": 12481,
      "success data": 78903,
      "data help": 21979,
      "help guide": 34903,
      "preoperative counseling": 63738,
      "counseling patients": 20924,
      "pain specific": 57854,
      "satisfaction level": 73403,
      "pharmacogenomics study": 61104,
      "study impact": 78243,
      "serve adjunct": 74709,
      "opioid fatalities": 51804,
      "fatalities oxycodone": 31244,
      "prescribed relief": 63971,
      "variant alleles": 85908,
      "oxycodone toxicity": 56008,
      "prevalence cyp2d6": 64778,
      "cyp2d6 polymorphisms": 21621,
      "hypothesized oxycodone": 36312,
      "drug metabolism": 26704,
      "medical examiner": 44360,
      "cases followed": 15238,
      "board approval": 14178,
      "obtained oxycodone": 50772,
      "oxycodone extracted": 55063,
      "extracted blood": 30947,
      "blood urine": 14159,
      "gc ms": 32917,
      "different control": 24855,
      "exact test": 30319,
      "genotyping cyp2d6": 33104,
      "interpretation oxycodone": 39504,
      "determination cause": 23980,
      "cause manner": 15359,
      "manner death": 43323,
      "forensic toxicology": 32265,
      "evaluated small": 29923,
      "studies treatment": 77870,
      "endogenous opioid": 28847,
      "exogenous opioids": 30536,
      "opioids drug": 52869,
      "screening tools": 74053,
      "electronic health": 28532,
      "health records": 34762,
      "interaction risk": 39381,
      "patient receiving": 58727,
      "treatment multiple": 82672,
      "patient received": 58726,
      "boluses infusion": 14227,
      "admission intensive": 8408,
      "purpose review": 66565,
      "discuss recent": 25286,
      "disease patients": 25338,
      "patients novel": 59558,
      "treatment strategies": 82853,
      "recent findings": 68402,
      "disease specific": 25350,
      "rotigotine transdermal": 72829,
      "monoamine oxidase": 47361,
      "beneficial effect": 13596,
      "effect pain": 27523,
      "pain sensations": 57811,
      "pharmacological therapies": 61232,
      "duloxetine effective": 27123,
      "injections considered": 38975,
      "deep brain": 23088,
      "brain stimulation": 14369,
      "patients suffering": 60017,
      "suffering pain": 78967,
      "pain summary": 57887,
      "summary pain": 79108,
      "dopaminergic drugs": 25728,
      "nonpharmacological interventions": 49828,
      "beneficial treatment": 13606,
      "pain 39": 56384,
      "mixed drug": 46786,
      "drug toxicity": 26816,
      "included methadone": 37486,
      "oxazepam oxycodone": 54384,
      "past medical": 58466,
      "abuse chronic": 6660,
      "chronic self": 16339,
      "self harm": 74486,
      "multiple hospital": 48280,
      "admissions drug": 8415,
      "drug overdoses": 26735,
      "drugs body": 26897,
      "small amounts": 76272,
      "case demonstrates": 15170,
      "currently used": 21510,
      "opioids national": 53081,
      "national institute": 48692,
      "institute drug": 39068,
      "number people": 50221,
      "framework developed": 32480,
      "infectious diseases": 38519,
      "model consisting": 47037,
      "40 opioid": 4369,
      "opioids model": 53056,
      "research focused": 71009,
      "general opioid": 32978,
      "models prescription": 47123,
      "combining data": 17681,
      "data substance": 22125,
      "abuse mental": 6773,
      "services administration": 74725,
      "people used": 60436,
      "used misused": 85009,
      "opioids data": 52830,
      "data centers": 21898,
      "control prevention": 20397,
      "estimate prescription": 29612,
      "prescription rates": 64393,
      "opioids additionally": 52705,
      "determine opioid": 24027,
      "largest impact": 41192,
      "likely lead": 41815,
      "lead addiction": 41278,
      "hydrocodone prescriptions": 36129,
      "background prospective": 13182,
      "effect pregabalin": 27532,
      "pregabalin oxycodone": 63672,
      "confusion pain": 19530,
      "seventy patients": 74887,
      "aged 75": 9195,
      "receive 150": 68041,
      "mg pregabalin": 46173,
      "75 mg": 5705,
      "daily postoperative": 21800,
      "intensity measured": 39263,
      "verbal rating": 86074,
      "scale vrs": 73585,
      "oxycodone 05": 54484,
      "orally 10": 53686,
      "assessed telephone": 12071,
      "operation results": 51226,
      "cumulative consumption": 21391,
      "extubation reduced": 31000,
      "consumption extubation": 19923,
      "fifth postoperative": 31686,
      "day reduced": 22399,
      "pregabalin group": 63668,
      "group time": 34046,
      "time extubation": 81260,
      "lower postoperative": 42679,
      "group significant": 34009,
      "difference respect": 24678,
      "state examination": 77042,
      "sedation score": 74330,
      "incidence pain": 37295,
      "pain movement": 57215,
      "movement significantly": 48054,
      "lower pregabalin": 42685,
      "months postoperative": 47464,
      "administration pregabalin": 8340,
      "pregabalin reduced": 63681,
      "consumption cardiac": 19903,
      "reduced incidence": 68934,
      "day increased": 22321,
      "increased time": 38038,
      "extubation compared": 30996,
      "operation patients": 51224,
      "patients pregabalin": 59665,
      "group experienced": 33771,
      "objective purpose": 50476,
      "prevalence correlates": 64777,
      "correlates opioid": 20822,
      "cohort rural": 17377,
      "rural opioid": 73051,
      "analgesic users": 10358,
      "rural appalachian": 73044,
      "appalachian kentucky": 11376,
      "results majority": 71756,
      "majority participants": 42991,
      "years interquartile": 87600,
      "lifetime prevalence": 41753,
      "injection drug": 38942,
      "analgesic formulations": 10255,
      "prevalence self": 64814,
      "reported 10": 70484,
      "10 26": 699,
      "respectively conclusions": 71180,
      "typically associated": 83392,
      "urban drug": 84028,
      "analgesics safe": 10499,
      "longitudinal course": 42400,
      "course opioid": 20994,
      "increasing access": 38091,
      "management study": 43269,
      "assessed total": 12074,
      "methods national": 45393,
      "data public": 22077,
      "public private": 66405,
      "2016 june": 2751,
      "consisted morphine": 19681,
      "morphine codeine": 47600,
      "codeine fentanyl": 17230,
      "fentanyl hydrocodone": 31489,
      "hydrocodone hydromorphone": 36084,
      "hydromorphone meperidine": 36183,
      "meperidine oxycodone": 44847,
      "non opioids": 49661,
      "opioids gabapentin": 52926,
      "gabapentin pregabalin": 32802,
      "pregabalin opioid": 63671,
      "opioid volumes": 52633,
      "analyzed separately": 10857,
      "opioids time": 53338,
      "regression modelling": 69447,
      "dependent variables": 23539,
      "compared pre": 18277,
      "pre versus": 63494,
      "versus post": 86154,
      "times greater": 81425,
      "vs mg": 86656,
      "findings similar": 31820,
      "76 vs": 5747,
      "vs 30": 86559,
      "pain reduce": 57488,
      "use public": 84674,
      "opioids responsible": 53274,
      "responsible opioid": 71402,
      "immune response": 36768,
      "known potential": 40925,
      "aim current": 9381,
      "current research": 21465,
      "investigate influence": 40016,
      "immune responses": 36769,
      "conditions methods": 19319,
      "administration morphine": 8305,
      "hapten conjugated": 34571,
      "nitric oxide": 49497,
      "treated buprenorphine": 82325,
      "morphine shown": 47922,
      "treatment opioids": 82707,
      "altered expression": 9696,
      "cell activation": 15471,
      "opioids studies": 53316,
      "great importance": 33415,
      "beneficial adverse": 13594,
      "patient condition": 58574,
      "research showed": 71028,
      "oxycodone exerts": 55051,
      "volume opioid": 86400,
      "majority opioids": 42987,
      "pain basis": 56492,
      "current guidelines": 21439,
      "lack data": 41049,
      "regarding long": 69253,
      "period months": 60751,
      "evaluate opioid": 29816,
      "medication misuse": 44517,
      "drug dependency": 26580,
      "particular emphasis": 58401,
      "release short": 70003,
      "opioid preparations": 52080,
      "investigate effect": 40004,
      "injury rats": 38991,
      "family member": 31181,
      "signaling pathway": 75391,
      "sprague dawley": 76768,
      "dawley sd": 22230,
      "sd rats": 74093,
      "rats randomly": 67879,
      "sham operation": 75111,
      "operation group": 51219,
      "group rats": 33941,
      "underwent thoracotomy": 83699,
      "group used": 34060,
      "associated protein": 12396,
      "measured quantitative": 43992,
      "quantitative polymerase": 66801,
      "reaction qpcr": 67948,
      "creatine kinase": 21152,
      "cardiac troponin": 14987,
      "showed compared": 75235,
      "increased 05": 37821,
      "05 differences": 511,
      "results relative": 71912,
      "increased compared": 37891,
      "group relative": 33973,
      "reduced 05": 68898,
      "differences relative": 24804,
      "qrt pcr": 66647,
      "mrna expression": 48070,
      "05 addition": 492,
      "assay results": 11883,
      "markedly elevated": 43399,
      "05 difference": 510,
      "results serum": 71937,
      "serum levels": 74702,
      "group statistically": 34031,
      "differences 05": 24704,
      "05 levels": 521,
      "levels serum": 41607,
      "oxycodone inhibits": 55279,
      "background prevalence": 13174,
      "prevalence drug": 64781,
      "drug alcohol": 26531,
      "trauma patients": 82263,
      "require narcotics": 70807,
      "reasonable option": 68016,
      "injection objective": 38959,
      "oral narcotics": 53596,
      "potential cause": 63144,
      "acute respiratory": 7699,
      "patients case": 59054,
      "20 year": 2389,
      "discharged hospital": 25203,
      "percocet endo": 60532,
      "endo pharmaceuticals": 28837,
      "tablets 24": 80116,
      "24 observation": 3252,
      "discharge emergency": 25120,
      "emergency medical": 28689,
      "level consciousness": 41453,
      "percocet tablets": 60538,
      "foreign body": 32260,
      "injection considered": 38941,
      "patients present": 59687,
      "failure patients": 31151,
      "patients suspected": 60025,
      "narcotic addiction": 48582,
      "important effects": 37006,
      "using various": 85660,
      "different databases": 24859,
      "databases searched": 22207,
      "terms opioids": 80711,
      "opioid agent": 51416,
      "electrocardiogram ecg": 28513,
      "interactions results": 39402,
      "results available": 71607,
      "opioids methadone": 53047,
      "high risk": 35168,
      "doses potential": 26250,
      "number opioids": 50201,
      "risk drugs": 72553,
      "doses opioids": 26228,
      "morphine buprenorphine": 47590,
      "low risk": 42551,
      "drugs produce": 27047,
      "sinus bradycardia": 76148,
      "atrial fibrillation": 12539,
      "various opioids": 85973,
      "methadone higher": 45080,
      "doses reduce": 26262,
      "risk high": 72579,
      "used cautiously": 84872,
      "opioid maintenance": 51893,
      "maintenance treatment": 42922,
      "background opiates": 13103,
      "traditional treatment": 81991,
      "opiates community": 51323,
      "led efforts": 41336,
      "efforts decrease": 28438,
      "postoperative opiate": 62810,
      "design analyzed": 23696,
      "opiate prescriptions": 51310,
      "prescriptions children": 64457,
      "intervention july": 39636,
      "july 2012": 40515,
      "february 2013": 31305,
      "2016 december": 2740,
      "2018 december": 2818,
      "patients contacted": 59148,
      "contacted phone": 20056,
      "use quality": 84677,
      "quality pain": 66751,
      "management results": 43260,
      "children underwent": 16078,
      "15 doses": 1732,
      "30 received": 3791,
      "appendectomy patients": 11415,
      "mean 05": 43653,
      "conclusions using": 19241,
      "using stepwise": 85628,
      "postdischarge pain": 62642,
      "pain children": 56528,
      "children undergoing": 16074,
      "laparoscopic appendectomy": 41090,
      "intervention resulted": 39647,
      "oxycodone community": 54815,
      "community study": 17930,
      "oxycodone acute": 54674,
      "rats methods": 67868,
      "methods male": 45374,
      "male sd": 43053,
      "groups control": 34166,
      "group effects": 33762,
      "cytokines release": 21672,
      "pulmonary edema": 66465,
      "toll like": 81647,
      "like receptor": 41781,
      "receptor tlr4": 68530,
      "significantly attenuated": 75658,
      "dry weight": 27102,
      "markedly decreased": 43398,
      "decreased oxycodone": 23019,
      "24 vs": 3288,
      "vs 80": 86622,
      "il 1\u03b2": 36608,
      "1\u03b2 tnf": 2262,
      "pg ml": 60997,
      "ml 61": 46842,
      "18 05": 2026,
      "significantly suppressed": 75865,
      "suppressed oxycodone": 79241,
      "treatment lung": 82646,
      "20 15": 2276,
      "15 05": 1670,
      "rats potential": 67874,
      "potential mechanism": 63187,
      "tlr4 activation": 81493,
      "cross blood": 21245,
      "brain derived": 14333,
      "derived neurotrophic": 23630,
      "neurotrophic factor": 49297,
      "factor bdnf": 31053,
      "study explore": 78207,
      "changes plasma": 15813,
      "therapy methods": 81026,
      "study group": 78214,
      "group included": 33825,
      "included 28": 37391,
      "28 patients": 3564,
      "chronic low": 16199,
      "treated opioid": 82354,
      "10 tramadol": 946,
      "included 11": 37376,
      "information opioid": 38657,
      "therapy recorded": 81057,
      "dose duration": 25889,
      "therapy data": 81006,
      "73 ng": 5655,
      "group 04": 33547,
      "levels did": 41555,
      "based type": 13397,
      "type opioid": 83335,
      "62 ng": 5336,
      "highest median": 35354,
      "oxycodone noted": 55544,
      "ml maximum": 46872,
      "57 ng": 5132,
      "ml respectively": 46897,
      "conclusion chronic": 18868,
      "specific changes": 76584,
      "tramadol buprenorphine": 82037,
      "levels examined": 41563,
      "examined patients": 30400,
      "opioid peptides": 52050,
      "opioids modulate": 53060,
      "potentially high": 63257,
      "patients surgery": 60022,
      "evaluate effect": 29788,
      "pathways associated": 58523,
      "laparotomy patients": 41115,
      "expression analyzed": 30827,
      "cells using": 15504,
      "control analgesia": 20274,
      "differential expression": 24940,
      "assay used": 11887,
      "investigate changes": 39999,
      "respectively patients": 71230,
      "patients satisfactory": 59938,
      "genes identified": 33062,
      "large number": 41138,
      "genes downregulated": 33058,
      "oxycodone statistically": 55934,
      "induced morphine": 38423,
      "cell activity": 15472,
      "activity suppressed": 7591,
      "maintained oxycodone": 42890,
      "expression profiles": 30840,
      "incision morphine": 37344,
      "purpose evaluate": 66531,
      "evaluate oral": 29821,
      "oral gabapentin": 53540,
      "photorefractive keratectomy": 61375,
      "keratectomy prk": 40605,
      "prospective nonrandomized": 65840,
      "nonrandomized clinical": 49838,
      "trial methods": 83035,
      "standard regimen": 76932,
      "prk patients": 65198,
      "surgery pain": 79495,
      "pain month": 57211,
      "percocet oxycodone": 60536,
      "pharmaceuticals chadds": 61049,
      "chadds ford": 15684,
      "mg 325": 45741,
      "days control": 22503,
      "completed pain": 18480,
      "pain assessment": 56469,
      "faces pain": 31023,
      "scale zero": 73586,
      "evening surgery": 29978,
      "surgery subsequent": 79599,
      "evening postoperative": 29977,
      "pfizer new": 60994,
      "dose administered": 25825,
      "hours procedure": 35836,
      "procedure oral": 65276,
      "oral pain": 53648,
      "medication days": 44484,
      "survey data": 79701,
      "141 patients": 1640,
      "patients cohort": 59096,
      "successful pain": 78913,
      "score defined": 73744,
      "superior postoperative": 79147,
      "days patients": 22579,
      "used significantly": 85127,
      "overall pain": 54222,
      "pain experience": 56770,
      "acetaminophen gabapentin": 7185,
      "cohorts respectively": 17414,
      "conclusions difference": 19073,
      "difference overall": 24647,
      "gabapentin oxycodone": 32799,
      "acetaminophen postoperative": 7239,
      "frequent use": 32536,
      "required background": 70827,
      "background postoperative": 13165,
      "pain continues": 56597,
      "especially patients": 29563,
      "pain surgery": 57889,
      "present prospective": 64630,
      "assess efficacy": 11931,
      "analgesia algorithm": 9910,
      "subgroup patients": 78619,
      "including controlled": 37605,
      "implemented different": 36946,
      "departments university": 23455,
      "university clinic": 83860,
      "administered preoperatively": 8171,
      "surgery day": 79364,
      "surgery 12": 79296,
      "maximum days": 43587,
      "days postoperatively": 22590,
      "inadequately managed": 37236,
      "managed pain": 43137,
      "vas 10": 85999,
      "10 rest": 917,
      "rest movement": 71426,
      "hydromorphone patient": 36214,
      "consent patients": 19580,
      "using standardized": 85626,
      "questionnaire preoperatively": 66896,
      "preoperatively days": 63770,
      "months surgery": 47477,
      "275 patients": 3523,
      "included present": 37519,
      "surgery 82": 79309,
      "surgery 30": 79306,
      "nrs pain": 50065,
      "received cr": 68132,
      "decreased 20": 22946,
      "30 day": 3716,
      "surgery 10": 79295,
      "events observed": 30078,
      "patients increased": 59403,
      "increased depression": 37902,
      "score surgery": 73800,
      "surgery reported": 79561,
      "pain non": 57240,
      "depressed patients": 23565,
      "patients 11": 58824,
      "ratings postoperative": 67706,
      "days conclusions": 22499,
      "conclusions present": 19174,
      "study demonstrated": 78058,
      "implementation oral": 36939,
      "regional analgesia": 69351,
      "analgesia effective": 9960,
      "effective feasible": 27623,
      "similar regardless": 75988,
      "surgery background": 79330,
      "background intravenous": 13073,
      "analgesia iv": 10006,
      "north america": 49955,
      "analgesic agent": 10149,
      "review compare": 72275,
      "methods authors": 45260,
      "used national": 85025,
      "medline database": 44731,
      "criteria randomized": 21212,
      "rcts published": 67918,
      "published english": 66428,
      "english language": 28941,
      "data abstracted": 21857,
      "studies meta": 77773,
      "effects model": 27998,
      "model used": 47085,
      "used results": 85117,
      "total 190": 81735,
      "total 12": 81719,
      "12 rcts": 1358,
      "sedation fatigue": 74313,
      "tramadol associated": 82035,
      "higher odds": 35276,
      "52 95": 4980,
      "ci 07": 16379,
      "14 lower": 1604,
      "43 95": 4500,
      "ci 19": 16410,
      "produce similar": 65369,
      "similar pain": 75970,
      "scores compared": 73850,
      "profile different": 65483,
      "relatively small": 69789,
      "small sample": 76296,
      "sample size": 73315,
      "purpose despite": 66528,
      "despite increasing": 23886,
      "increasing use": 38128,
      "2011 methods": 2585,
      "used pharmaceutical": 85075,
      "scheme dispensing": 73663,
      "dispensing claims": 25442,
      "rates dispensing": 67573,
      "cr formulations": 21060,
      "single ingredient": 76106,
      "study sample": 78475,
      "sample people": 73311,
      "treatment episode": 82580,
      "2009 2012": 2515,
      "2013 2016": 2619,
      "opioid utilisation": 52626,
      "patterns time": 60229,
      "time results": 81366,
      "associated fold": 12262,
      "fold increase": 31993,
      "growth rate": 34381,
      "resulting rapid": 71534,
      "new treatment": 49382,
      "observed increase": 50683,
      "tablet strength": 80103,
      "equal mg": 29232,
      "risk difference": 72544,
      "difference rd": 24675,
      "21 95": 2960,
      "19 22": 2165,
      "dispensing 90": 25439,
      "prior initiation": 65151,
      "rd 10": 67923,
      "10 conclusions": 750,
      "psychoactive drugs": 66333,
      "psychoactive drug": 66332,
      "licit illicit": 41668,
      "drugs prescribed": 27040,
      "death americans": 22692,
      "64 000": 5378,
      "000 people": 38,
      "review provide": 72342,
      "provide brief": 66041,
      "main classes": 42825,
      "drugs discuss": 26940,
      "total syntheses": 81907,
      "settings purpose": 74862,
      "intravenously injected": 39893,
      "oxycodone intraoperative": 55291,
      "intraoperative postoperative": 39779,
      "urinary catheter": 84053,
      "catheter related": 15316,
      "related bladder": 69563,
      "bladder discomfort": 13906,
      "discomfort crbd": 25219,
      "patients asa": 59004,
      "resection prostate": 71048,
      "observed patients": 50700,
      "group control": 33713,
      "45 received": 4599,
      "oxycodone 46": 54575,
      "46 received": 4630,
      "oxycodone end": 55024,
      "incidence severity": 37318,
      "severe crbd": 74941,
      "scores used": 74006,
      "assess pain": 11944,
      "period postoperative": 60774,
      "incidences nausea": 37332,
      "patients results": 59924,
      "incidence crbd": 37267,
      "lower oxycodone": 42665,
      "group 22": 33585,
      "49 vs": 4781,
      "10 22": 694,
      "40 vs": 4381,
      "vs 20": 86546,
      "11 24": 1105,
      "vs 001": 86502,
      "severity crbd": 75037,
      "severe lower": 74953,
      "group controlled": 33720,
      "020 compared": 382,
      "differences incidence": 24752,
      "postoperative adverse": 62696,
      "oxycodone effectively": 55018,
      "effectively prevent": 27735,
      "associated increasing": 12311,
      "rates harm": 67583,
      "despite reduced": 23900,
      "reduced use": 68985,
      "use reformulation": 84684,
      "resistant form": 71099,
      "opioids explored": 52905,
      "characteristics oxycodone": 15868,
      "oxycodone related": 55820,
      "harm design": 34578,
      "retrospective study": 72168,
      "patient care": 58548,
      "care records": 15070,
      "records related": 68724,
      "use january": 84444,
      "2013 september": 2643,
      "september 2018": 74619,
      "2018 setting": 2846,
      "setting victoria": 74849,
      "victoria australia": 86207,
      "australia cases": 12684,
      "temporal changes": 80586,
      "oxycodone presentations": 55751,
      "time 2013": 81196,
      "2013 2018": 2621,
      "health substance": 34782,
      "average age": 12873,
      "age 41": 9003,
      "41 16": 4412,
      "proportion females": 65743,
      "females oxycodone": 31396,
      "time average": 81214,
      "increase odds": 37763,
      "odds ratios": 50933,
      "05 95": 489,
      "01 10": 290,
      "temporal trends": 80590,
      "ci 85": 16502,
      "85 00": 5974,
      "81 95": 5883,
      "ci 66": 16481,
      "91 95": 6134,
      "greater risk": 33490,
      "risk alcohol": 72520,
      "06 95": 580,
      "01 11": 291,
      "use 05": 84137,
      "10 95": 731,
      "ci 05": 16376,
      "05 15": 478,
      "past history": 58465,
      "history psychiatric": 35478,
      "16 27": 1853,
      "analysis showed": 10766,
      "associated immediate": 12291,
      "effect sex": 27557,
      "accidental poisoning": 7019,
      "scale 28": 73492,
      "ci 04": 16372,
      "previous history": 64902,
      "80 95": 5836,
      "70 92": 5558,
      "year heroin": 87442,
      "illicit drug": 36630,
      "ci 23": 16415,
      "showed statistically": 75313,
      "changes following": 15786,
      "reformulation conclusions": 69212,
      "time including": 81274,
      "alcohol use": 9544,
      "extramedical use": 30972,
      "use non": 84514,
      "drug involvement": 26673,
      "cases year": 15270,
      "analyses revealed": 10610,
      "revealed presence": 72221,
      "methadone hydrocodone": 45081,
      "methadone associated": 45047,
      "associated mortality": 12338,
      "national trends": 48724,
      "death demographic": 22706,
      "cases positive": 15252,
      "positive result": 62487,
      "incidental finding": 37338,
      "increase observed": 37762,
      "observed number": 50694,
      "number positive": 50232,
      "positive cases": 62454,
      "national data": 48678,
      "data number": 22019,
      "25 deaths": 3353,
      "pharmacokinetic profiles": 61146,
      "28 29": 3539,
      "29 cases": 3607,
      "cases drugs": 15236,
      "drugs detected": 26932,
      "overlap range": 54342,
      "concentrations observed": 18782,
      "observed drug": 50675,
      "related death": 69578,
      "death groups": 22708,
      "groups mean": 34231,
      "mean median": 43793,
      "median concentrations": 44205,
      "hydrocodone related": 36132,
      "non drug": 49593,
      "inhibitor aim": 38791,
      "brain results": 14362,
      "differences effects": 24737,
      "showed decreased": 75237,
      "brain stem": 14368,
      "differential effects": 24939,
      "drugs combination": 26912,
      "effects potentially": 28098,
      "improve pain": 37070,
      "therapy objective": 81036,
      "virus hcv": 86248,
      "use rural": 84711,
      "rural drug": 73049,
      "remains poorly": 70304,
      "503 rural": 4933,
      "appalachian drug": 11374,
      "users recruited": 85267,
      "respondent driven": 71303,
      "driven sampling": 26463,
      "participants tested": 58375,
      "sociodemographic characteristics": 76391,
      "lifetime past": 41750,
      "day drug": 22306,
      "psychiatric disorders": 66325,
      "interviewer administered": 39692,
      "administered questionnaires": 8176,
      "months follow": 47441,
      "leaving final": 41330,
      "negative binomial": 49063,
      "binomial regression": 13829,
      "regression used": 69459,
      "follow results": 32033,
      "results despite": 71659,
      "overall decrease": 54193,
      "frequency similar": 32529,
      "adjusted incidence": 8028,
      "rate ratio": 67506,
      "ratio 07": 67714,
      "07 95": 602,
      "ci 72": 16487,
      "significant predictors": 75603,
      "predictors increased": 63587,
      "increased days": 37898,
      "months included": 47446,
      "use baseline": 84219,
      "marijuana use": 43385,
      "diagnostic statistical": 24343,
      "statistical manual": 77177,
      "manual mental": 43330,
      "mental disorders": 44816,
      "disorders fourth": 25393,
      "fourth edition": 32438,
      "using oxycontin": 85546,
      "baseline significantly": 13460,
      "follow conclusions": 32017,
      "positive drug": 62460,
      "targeted interventions": 80498,
      "epidemic objective": 29138,
      "objective quantify": 50482,
      "potential impact": 63172,
      "liability studies": 41653,
      "rates nonmedical": 67600,
      "endpoints overall": 28913,
      "liking moment": 41864,
      "moment drug": 47297,
      "use data": 84288,
      "obtained 2010": 50758,
      "national survey": 48720,
      "use health": 84388,
      "health nsduh": 34737,
      "use rates": 84678,
      "prescription volume": 64420,
      "drug opioid": 26725,
      "opioid controlled": 51675,
      "deterrent opioid": 24120,
      "formulations results": 32405,
      "results point": 71873,
      "point reduction": 62107,
      "reduction overall": 69083,
      "25 10": 3319,
      "10 05": 658,
      "standard errors": 76906,
      "11 12": 1092,
      "12 07": 1205,
      "percentage point": 60516,
      "point decrease": 62082,
      "11 percent": 1142,
      "reduction compared": 69048,
      "compared samples": 18303,
      "rates 21": 67547,
      "38 36": 4229,
      "36 percent": 4141,
      "conclusions reductions": 19186,
      "liking significantly": 41869,
      "use healthcare": 84391,
      "using drug": 85386,
      "consistent finding": 19699,
      "finding statistically": 31762,
      "abuse associated": 6653,
      "order obtain": 53716,
      "analgesic strategy": 10338,
      "cannabinoid receptor": 14929,
      "opiate analgesic": 51289,
      "chemical structure": 15952,
      "vitro radioligand": 86366,
      "radioligand binding": 66970,
      "binding experiments": 13818,
      "moderate high": 47148,
      "high affinity": 35071,
      "highest affinity": 35340,
      "11 19": 1100,
      "agonist properties": 9304,
      "35 gtp\u03b3s": 4080,
      "gtp\u03b3s binding": 34389,
      "binding assays": 13816,
      "receptor mediated": 68507,
      "mediated signaling": 44318,
      "signaling revealed": 75393,
      "rats 11": 67838,
      "antiallodynic effect": 11141,
      "effect similar": 27559,
      "parent drugs": 58197,
      "lead compounds": 41282,
      "antinociceptive properties": 11250,
      "analgesia challenging": 9923,
      "abuse considered": 6666,
      "growing public": 34372,
      "overprescribing major": 54354,
      "major contributor": 42937,
      "led development": 41334,
      "assessed follow": 12004,
      "showed improved": 75261,
      "analgesia prescribing": 10069,
      "years following": 87593,
      "following guideline": 32137,
      "guideline implementation": 34421,
      "analgesic medication": 10270,
      "april july": 11613,
      "100 unique": 1022,
      "unique patients": 83757,
      "patients chosen": 59064,
      "using computer": 85354,
      "computer generated": 18661,
      "randomisation patients": 67007,
      "hospital postoperative": 35619,
      "collected compared": 17452,
      "compared equivalent": 18152,
      "data previous": 22064,
      "highest overall": 35359,
      "rates achieved": 67552,
      "given discharge": 33166,
      "overall significant": 54259,
      "significant sustained": 75637,
      "2015 results": 2719,
      "results 2017": 71554,
      "high adherence": 35070,
      "adherence guidelines": 7993,
      "longer time": 42390,
      "period background": 60713,
      "information available": 38633,
      "requirement postoperative": 70875,
      "postoperative analgesic": 62710,
      "undergoing vaginal": 83593,
      "aim compare": 9378,
      "requirements patient": 70888,
      "standard protocol": 76930,
      "protocol postoperative": 65990,
      "management analgesic": 43150,
      "analgesic requirement": 10326,
      "used non": 85030,
      "nsaids oxycodone": 50104,
      "approximately half": 11581,
      "half dose": 34514,
      "dose patients": 26004,
      "19 21": 2164,
      "21 mg": 2974,
      "use nsaids": 84527,
      "reduced patients": 68970,
      "patients undergone": 60137,
      "days compared": 22496,
      "85 days": 5985,
      "0001 conclusions": 59,
      "randomised trials": 67038,
      "incidence constipation": 37266,
      "constipation associated": 19750,
      "associated oxycodone": 12369,
      "low oral": 42511,
      "bioavailability naloxone": 13837,
      "withdrawal symptoms": 87160,
      "incidence acute": 37253,
      "oral intravenous": 53554,
      "circumstances associated": 16579,
      "naloxone induced": 48455,
      "induced acute": 38371,
      "withdrawal methods": 87138,
      "methods observational": 45404,
      "observational case": 50607,
      "withdrawal following": 87132,
      "calls received": 14737,
      "poisons information": 62164,
      "information centre": 38634,
      "january 2012": 40440,
      "2012 december": 2597,
      "december 2014": 22824,
      "collected included": 17461,
      "demographics reported": 23303,
      "accidental exposure": 7015,
      "given results": 33196,
      "results 107": 71540,
      "exposures oxycodone": 30808,
      "crushed tablets": 21348,
      "tablets 14": 80113,
      "14 14": 1552,
      "14 cases": 1580,
      "cases respectively": 15260,
      "standing opioid": 76994,
      "symptoms oral": 79899,
      "relationship dose": 69714,
      "increased dose": 37904,
      "tablets injected": 80168,
      "injected intravenously": 38918,
      "acute withdrawal": 7710,
      "pass metabolism": 58438,
      "dose dose": 25885,
      "naloxone opioid": 48470,
      "opioid naloxone": 51974,
      "naloxone combination": 48436,
      "combination tablets": 17611,
      "symptoms diminished": 79882,
      "relief purpose": 70174,
      "purpose aim": 66515,
      "pharmacokinetic study": 61153,
      "study quantify": 78441,
      "quantify oxycodone": 66787,
      "neonates children": 49105,
      "children years": 16082,
      "intramuscular oxycodone": 39743,
      "obtained previously": 50778,
      "170 days": 1999,
      "days years": 22657,
      "measurements oxycodone": 44026,
      "repeated intravenous": 70410,
      "patients indicated": 59406,
      "10 50": 714,
      "50 ng": 4871,
      "ml high": 46861,
      "dose calculated": 25837,
      "rapidly birth": 67401,
      "subject variability": 78642,
      "dosing regimens": 26329,
      "repeated doses": 70407,
      "older people": 51038,
      "preclinical clinical": 63526,
      "efficacy associated": 28229,
      "outcomes older": 54063,
      "efficient sensitive": 28424,
      "sensitive method": 74546,
      "drugs metabolites": 26995,
      "inform drug": 38615,
      "drug dosing": 26598,
      "sensitive liquid": 74543,
      "spectrometry method": 76669,
      "method simultaneously": 45215,
      "respective metabolites": 71141,
      "preclinical model": 63531,
      "method validated": 45222,
      "optimal recovery": 53434,
      "recovery matrix": 68748,
      "matrix effect": 43538,
      "effect limit": 27473,
      "limit quantification": 41890,
      "quantification loq": 66772,
      "inter intra": 39356,
      "intra day": 39718,
      "day variability": 22444,
      "serum samples": 74705,
      "group treated": 34055,
      "treated chronic": 82326,
      "metabolite levels": 44951,
      "ml serum": 46910,
      "peak response": 60323,
      "observed concentrations": 50664,
      "drugs differences": 26935,
      "differences drug": 24735,
      "drug levels": 26676,
      "levels observed": 41583,
      "observed different": 50673,
      "method sensitive": 45212,
      "affect drug": 8897,
      "used understand": 85185,
      "inform prescribing": 38621,
      "prescribing improve": 64065,
      "improve outcomes": 37069,
      "background study": 13201,
      "evaluated prescribing": 29912,
      "prescribed strong": 63982,
      "opioids primary": 53225,
      "cancer cancer": 14765,
      "2000 2010": 2418,
      "prescriptions buprenorphine": 64455,
      "oxycodone issued": 55317,
      "prescriptions issued": 64504,
      "issued patients": 40331,
      "cancer medical": 14792,
      "use considered": 84267,
      "cancer use": 14918,
      "annual number": 11023,
      "prescriptions patients": 64535,
      "day oral": 22347,
      "dose measured": 25949,
      "estimates results": 29653,
      "87 non": 6023,
      "female 83": 31353,
      "age 67": 9045,
      "17 years": 1993,
      "years study": 87675,
      "higher non": 35270,
      "cancer group": 14784,
      "28 vs": 3576,
      "vs 12": 86528,
      "12 04": 1203,
      "vs 06": 86517,
      "24 oxycodone": 3255,
      "19 vs": 2197,
      "15 vs": 1796,
      "vs 008": 86508,
      "highest proportion": 35366,
      "prescribed low": 63884,
      "opioid doses": 51739,
      "39 groups": 4270,
      "followed dose": 32055,
      "51 100": 4947,
      "26 vs": 3456,
      "12 conclusions": 1275,
      "increase strong": 37804,
      "majority prescriptions": 42996,
      "prescriptions non": 64522,
      "pain morphine": 57214,
      "morphine frequently": 47697,
      "prescribed utilization": 64004,
      "oxycodone buprenorphine": 54760,
      "fentanyl increased": 31502,
      "increased markedly": 37945,
      "time background": 81215,
      "background studies": 13200,
      "studies carried": 77657,
      "drugs methods": 27000,
      "response pain": 71357,
      "responses blood": 71383,
      "blood circulation": 14112,
      "surgical wound": 79660,
      "analgesics nsaids": 10459,
      "nsaids opioids": 50103,
      "peri operative": 60657,
      "operative treatment": 51271,
      "children aged": 16032,
      "aged 12": 9141,
      "undergoing major": 83551,
      "major surgery": 42978,
      "doses diclofenac": 26176,
      "nsaid group": 50089,
      "infusion oxycodone": 38717,
      "opioid group": 51826,
      "continuous epidural": 20164,
      "infusion bupivacaine": 38699,
      "bupivacaine fentanyl": 14497,
      "peri operatively": 60658,
      "operatively pain": 51276,
      "results difference": 71661,
      "related analgesic": 69559,
      "blood opioid": 14132,
      "time related": 81353,
      "reactive protein": 67979,
      "group ii": 33819,
      "cell types": 15489,
      "pain treatments": 57940,
      "treatments using": 82936,
      "nsaid oxycodone": 50093,
      "systemic local": 80028,
      "probably clinically": 65226,
      "clinically unimportant": 17010,
      "background abuse": 13003,
      "opioids subsequent": 53320,
      "important public": 37025,
      "concern particularly": 18829,
      "scarce objective": 73601,
      "analgesics abuse": 10364,
      "taken account": 80269,
      "pharmacological characteristics": 61211,
      "administration extended": 8261,
      "extended immediate": 30849,
      "non injectable": 49616,
      "injectable opioid": 38912,
      "2013 included": 2631,
      "included opioids": 37496,
      "opioids mild": 53055,
      "moderately severe": 47217,
      "pain studied": 57868,
      "overlapping prescriptions": 54345,
      "prescriptions prescribers": 64546,
      "total dispensed": 81798,
      "results strong": 71968,
      "followed morphine": 32073,
      "having highest": 34606,
      "fentanyl respectively": 31587,
      "dosages morphine": 25767,
      "forms respectively": 32314,
      "morphine described": 47643,
      "release conclusion": 69812,
      "surveillance systems": 79690,
      "healthcare professionals": 34799,
      "misuse public": 46743,
      "sharp increase": 75123,
      "analgesic prescribing": 10297,
      "analyze opioid": 10817,
      "prescribing patterns": 64102,
      "health outcomes": 34749,
      "used data": 84900,
      "drug enforcement": 26617,
      "enforcement administration": 28926,
      "automated reports": 12756,
      "reports consolidated": 70717,
      "consolidated ordering": 19734,
      "counts oxycodone": 20967,
      "2006 2014": 2476,
      "opioid pill": 52057,
      "pill counts": 61491,
      "rates non": 67599,
      "non linear": 49621,
      "factors including": 31099,
      "research explore": 71007,
      "explore potential": 30728,
      "potential mechanisms": 63188,
      "opioid pills": 52058,
      "pharmacokinetics described": 61165,
      "target concentration": 80486,
      "concentration dependent": 18690,
      "dependent pain": 23525,
      "differ pain": 24544,
      "individuals methods": 38350,
      "range 20": 67267,
      "20 associated": 2310,
      "pharmacokinetic simulation": 61149,
      "given intravenous": 33175,
      "results 84": 71588,
      "maintenance dosing": 42909,
      "concentration decreased": 18689,
      "decreased age": 22977,
      "doses typical": 26297,
      "100 mcg": 991,
      "mcg kg": 43624,
      "dose 100": 25784,
      "kg maintenance": 40755,
      "age weight": 9133,
      "variability clearance": 85865,
      "range duration": 67313,
      "duration analgesic": 27154,
      "greater older": 33465,
      "buprenorphine partial": 14576,
      "ceiling effect": 15447,
      "depression buprenorphine": 23574,
      "severe require": 75015,
      "require daily": 70801,
      "daily clock": 21706,
      "clock long": 17049,
      "treatment alternative": 82441,
      "treatment options": 82711,
      "options inadequate": 53471,
      "conducted compare": 19348,
      "methods subjects": 45597,
      "subjects 19": 78675,
      "women ages": 87203,
      "41 years": 4436,
      "dependent opioids": 23523,
      "opioids determined": 52847,
      "test respiratory": 80780,
      "evaluated measuring": 29896,
      "assessment maximum": 12125,
      "maximum decrease": 43588,
      "administration treatment": 8389,
      "treatment treatments": 82879,
      "included 300": 37393,
      "using double": 85384,
      "crossover design": 21287,
      "statistical analyses": 77170,
      "using linear": 85458,
      "linear mixed": 42015,
      "min versus": 46559,
      "300 \u03bcg": 3823,
      "significantly reduce": 75839,
      "available prescription": 12830,
      "prescription dose": 64202,
      "dependent decrease": 23505,
      "option opioid": 53458,
      "pain trial": 57941,
      "oc opioid": 50808,
      "exerts analgesic": 30504,
      "receptors brain": 68536,
      "metabolized cyp450": 44994,
      "activity aim": 7556,
      "overall analgesic": 54185,
      "interactions cyp2d6": 39390,
      "published information": 66430,
      "concentrations oc": 18784,
      "behavior opioid": 13534,
      "receptor affinity": 68455,
      "contribution oc": 20247,
      "effect results": 27552,
      "effect administration": 27416,
      "respectively oxymorphone": 71227,
      "oxymorphone om": 56271,
      "higher affinity": 35202,
      "plays minor": 62008,
      "minor role": 46627,
      "77 52": 5756,
      "52 respectively": 4996,
      "remains major": 70299,
      "effect conclusion": 27438,
      "responsible analgesic": 71399,
      "om noroxymorphone": 51051,
      "site action": 76156,
      "authors report": 12746,
      "oxycodone 34": 54564,
      "34 year": 4040,
      "patient experienced": 58637,
      "visual hallucinations": 86333,
      "oxycodone stable": 55930,
      "combination drugs": 17556,
      "drugs report": 27061,
      "multiple medications": 48286,
      "associated risk": 12413,
      "prescribed methods": 63893,
      "cohort design": 17357,
      "veterans health": 86178,
      "health administration": 34668,
      "administration va": 8392,
      "prescribed codeine": 63835,
      "prevalent opioid": 64831,
      "2000 2001": 2414,
      "propensity scores": 65696,
      "using weighted": 85674,
      "duration use": 27191,
      "opioid initiation": 51871,
      "risk new": 72602,
      "diagnosis patients": 24338,
      "prescribed hydrocodone": 63869,
      "codeine compared": 17217,
      "12 43": 1252,
      "days exposed": 22522,
      "hoc analysis": 35496,
      "use conclusions": 84261,
      "conclusions codeine": 19047,
      "additional research": 7890,
      "copyright 2016": 20759,
      "2016 john": 2748,
      "john wiley": 40478,
      "wiley sons": 87101,
      "pain increased": 56864,
      "european countries": 29740,
      "time trends": 81393,
      "trends opioid": 82972,
      "europe methods": 29733,
      "data provided": 22075,
      "narcotics control": 48628,
      "consumption fentanyl": 19924,
      "union eu": 83748,
      "purpose united": 66593,
      "analysed using": 10579,
      "using joinpoint": 85449,
      "joinpoint regression": 40484,
      "regression analysis": 69421,
      "results 2014": 71552,
      "2014 2016": 2650,
      "2016 opioid": 2755,
      "use 10": 84138,
      "ddd 000": 22667,
      "000 000": 16,
      "000 inhabitants": 24,
      "countries opioid": 20957,
      "consumption increased": 19939,
      "16 491": 1860,
      "use steady": 84751,
      "mid 1990s": 46390,
      "mid late": 46391,
      "denmark finland": 23393,
      "years conclusions": 87581,
      "conclusions consumption": 19061,
      "consumption opioid": 19960,
      "sharply increased": 75126,
      "10 fold": 765,
      "comprehensive analysis": 18621,
      "analysis time": 10779,
      "trends geographic": 82966,
      "geographic variations": 33115,
      "variations opioid": 85925,
      "consumption use": 20035,
      "use european": 84358,
      "potency opioids": 63081,
      "opioids important": 52967,
      "important component": 37001,
      "management appropriate": 43151,
      "prescribed oral": 63936,
      "oral long": 53560,
      "cr oxymorphone": 21103,
      "fda approved": 31274,
      "tablets day": 80140,
      "values greater": 85843,
      "oxymorphone er": 56235,
      "er methods": 29440,
      "data large": 22000,
      "large commercially": 41122,
      "database analyzed": 22165,
      "analyzed identify": 10832,
      "july 2007": 40510,
      "2007 september": 2495,
      "september 30": 74622,
      "30 2009": 3670,
      "day titration": 22430,
      "titration period": 81481,
      "subjects included": 78704,
      "90 day": 6086,
      "day supply": 22423,
      "patients excluded": 59270,
      "period limitations": 60740,
      "opioids short": 53294,
      "short long": 75178,
      "period previous": 60777,
      "previous months": 64907,
      "months baseline": 47432,
      "old pregnant": 51017,
      "bivariate analyses": 13897,
      "wilcoxon rank": 87090,
      "rank sum": 67367,
      "characteristics including": 15864,
      "including age": 37589,
      "sex geographic": 75077,
      "geographic location": 33110,
      "drug group": 26640,
      "group evaluated": 33768,
      "using pearson": 85553,
      "chi square": 15985,
      "square test": 76795,
      "multivariate analyses": 48339,
      "using generalized": 85404,
      "generalized linear": 33003,
      "linear models": 42024,
      "patients observational": 59569,
      "link function": 42044,
      "tablet strengths": 80104,
      "findings results": 31815,
      "results final": 71694,
      "mean value": 43898,
      "milligrams mg": 46477,
      "001 mean": 152,
      "versus respectively": 86157,
      "lower strengths": 42705,
      "adjusting age": 8061,
      "use risk": 84708,
      "adjusted mean": 8035,
      "significance differences": 75405,
      "analyses conclusions": 10588,
      "day time": 22427,
      "consumed fewer": 19829,
      "fewer tablets": 31670,
      "day did": 22299,
      "did patients": 24473,
      "research necessary": 71013,
      "cost savings": 20885,
      "savings health": 73473,
      "ii opioid": 36566,
      "opioid activity": 51395,
      "inhibition used": 38789,
      "dual mechanism": 27112,
      "action thought": 7452,
      "effects complicate": 27869,
      "complicate pain": 18542,
      "active pharmaceutical": 7526,
      "fourth quarter": 32440,
      "quarter 2011": 66850,
      "tramadol hydrocodone": 82069,
      "center drug": 15519,
      "treatment center": 82470,
      "center programs": 15540,
      "programs combined": 65554,
      "health burden": 34673,
      "related tapentadol": 69699,
      "event rates": 29989,
      "abuse population": 6808,
      "population level": 62345,
      "opioids examined": 52899,
      "ii opioids": 36567,
      "opioids studied": 53315,
      "findings examining": 31781,
      "various opioid": 85972,
      "release role": 70002,
      "perspective article": 60961,
      "article presents": 11774,
      "results examination": 71688,
      "treatment centers": 82473,
      "suggest low": 78997,
      "objective present": 50469,
      "formulation adf": 32331,
      "opioid remoxy": 52332,
      "remoxy pain": 70347,
      "therapeutics san": 80973,
      "san mateo": 73376,
      "mateo ca": 43498,
      "king pharmaceuticals": 40847,
      "pharmaceuticals bristol": 61047,
      "bristol tn": 14441,
      "previous study": 64924,
      "particular features": 58402,
      "features prescription": 31298,
      "study method": 78309,
      "method applied": 45171,
      "products results": 65458,
      "demonstrated sufficient": 23373,
      "ratings overall": 67702,
      "drugs overall": 27023,
      "15 001": 1669,
      "model fit": 47049,
      "administration swallowing": 8383,
      "40 001": 4305,
      "data cross": 21932,
      "cross validation": 21281,
      "adf oxycontin": 7985,
      "pharma lp": 61009,
      "lp stamford": 42741,
      "ford pa": 32253,
      "vicodin abbott": 86196,
      "abbott laboratories": 6514,
      "laboratories abbott": 41019,
      "abbott park": 6517,
      "park il": 58226,
      "shows promise": 75363,
      "effects experienced": 27920,
      "experienced children": 30601,
      "children receiving": 16072,
      "receiving ibuprofen": 68342,
      "ibuprofen oxycodone": 36364,
      "following acute": 32096,
      "design observational": 23729,
      "observational cohort": 50608,
      "department patients": 23441,
      "aged 16": 9149,
      "prescribed ibuprofen": 63870,
      "oxycodone 61": 54590,
      "called days": 14731,
      "functional outcomes": 32707,
      "children using": 16079,
      "nausea 17": 48760,
      "17 001": 1926,
      "001 vomiting": 223,
      "vomiting 11": 86442,
      "001 drowsiness": 135,
      "ibuprofen children": 36351,
      "greater severity": 33495,
      "sd ibuprofen": 74081,
      "ibuprofen mean": 36361,
      "sd 13": 74063,
      "13 02": 1447,
      "02 day": 367,
      "constipation oxycodone": 19775,
      "sd 33": 74067,
      "days use": 22648,
      "increased odds": 37958,
      "odds experiencing": 50896,
      "31 95": 3861,
      "13 52": 1468,
      "higher pain": 35285,
      "12 01": 1202,
      "lower extremity": 42616,
      "extremity fracture": 30986,
      "01 34": 295,
      "extremity fractures": 30987,
      "associated frequent": 12265,
      "gastrointestinal aes": 32870,
      "functional limitations": 32700,
      "compared ibuprofen": 18181,
      "ibuprofen lower": 36360,
      "upper extremity": 84002,
      "clinicians consider": 17029,
      "fracture pain": 32456,
      "pain care": 56510,
      "children background": 16042,
      "buccal oxycodone": 14470,
      "outcomes children": 54015,
      "december 2001": 22819,
      "university teaching": 83872,
      "teaching hospital": 80532,
      "hospital finland": 35592,
      "patients total": 60053,
      "total 104": 81706,
      "days duration": 22519,
      "children pain": 16063,
      "scores higher": 73887,
      "higher 10": 35199,
      "volume normal": 86397,
      "findings indicated": 31794,
      "provisional diagnosis": 66281,
      "children received": 16071,
      "received study": 68285,
      "hour hours": 35700,
      "hours initial": 35785,
      "initial dosing": 38847,
      "dosing pain": 26320,
      "recorded baseline": 68671,
      "baseline 30": 13409,
      "minutes hours": 46652,
      "hours study": 35858,
      "administration main": 8290,
      "measures pain": 44077,
      "presence absence": 64581,
      "results demographic": 71656,
      "initial pain": 38863,
      "scores physical": 73948,
      "physical signs": 61411,
      "signs symptoms": 75883,
      "symptoms similar": 79906,
      "groups study": 34331,
      "study drugs": 78138,
      "greater oxycodone": 33470,
      "22 18": 3013,
      "cm 95": 17088,
      "interval 24": 39562,
      "24 cm": 3191,
      "88 oxycodone": 6043,
      "group remained": 33974,
      "17 patients": 1980,
      "group 14": 33571,
      "patients placebo": 59648,
      "exploratory laparotomy": 30714,
      "group patient": 33898,
      "group initially": 33830,
      "pain 14": 56370,
      "early administration": 27251,
      "clinical signs": 16903,
      "background increasing": 13066,
      "use extended": 84366,
      "case description": 15171,
      "precipitated withdrawal": 63515,
      "17 year": 1991,
      "adolescent female": 8441,
      "receiving extended": 68334,
      "release naltrexone": 69894,
      "dose medication": 25955,
      "days using": 22650,
      "conclusions case": 19038,
      "case suggests": 15211,
      "end dosing": 28788,
      "induced withdrawal": 38461,
      "strategies background": 77410,
      "background acute": 13004,
      "morbidity mortality": 47512,
      "mortality opioid": 47989,
      "therapy effective": 81012,
      "reactions patient": 67967,
      "administration analgesics": 8217,
      "analgesics oral": 10466,
      "alternative intravenous": 9721,
      "developed novel": 24186,
      "novel oral": 50018,
      "device enables": 24268,
      "pills patient": 61529,
      "methods medical": 45378,
      "orthopedic surgeries": 53835,
      "control cohort": 20282,
      "cohort 61": 17346,
      "44 received": 4548,
      "measures include": 44059,
      "score rest": 73780,
      "administered bolus": 8108,
      "initial nrs": 38853,
      "movement 05": 48043,
      "better pain": 13722,
      "effect rates": 27544,
      "rates comparable": 67563,
      "cohorts 11": 17411,
      "experienced effects": 30603,
      "higher oral": 35280,
      "cohort 19": 17340,
      "administered patients": 8166,
      "patients comparable": 59100,
      "32 mg": 3928,
      "mg 21": 45728,
      "21 14": 2938,
      "lower oral": 42662,
      "cohort 12": 17338,
      "mg 82": 45774,
      "oxycodone 004": 54476,
      "control conclusions": 20284,
      "conclusions oral": 19137,
      "provides pain": 66231,
      "analgesia background": 9920,
      "counterfeit prescription": 20946,
      "prescription pills": 64386,
      "population risk": 62384,
      "seizure data": 74378,
      "determine number": 24026,
      "number drug": 50158,
      "containing fentanyl": 20074,
      "fentanyl january": 31512,
      "december 2021": 22831,
      "fentanyl results": 31588,
      "2018 quarter": 2841,
      "94 001": 6186,
      "001 number": 165,
      "number pill": 50224,
      "96 01": 6418,
      "pills total": 61547,
      "doubled 13": 26413,
      "number pills": 50225,
      "increased 42": 37856,
      "90 001": 6070,
      "drugs containing": 26922,
      "fentanyl increasing": 31503,
      "counterfeit pills": 20945,
      "oxycodone alprazolam": 54708,
      "fentanyl purpose": 31579,
      "assessed clinical": 11990,
      "efficacy tolerance": 28410,
      "intravenous tramadol": 39888,
      "dose 10": 25780,
      "dose 24": 25797,
      "saline infusion": 73262,
      "tablet 12": 80086,
      "postoperatively patients": 63015,
      "access intravenous": 6992,
      "intravenous opioid": 39863,
      "medication results": 44563,
      "analgesia significantly": 10109,
      "higher cro": 35225,
      "patient rated": 58725,
      "rated quality": 67535,
      "24 001": 3139,
      "experienced significantly": 30628,
      "group 012": 33538,
      "012 patients": 335,
      "study protocol": 78434,
      "conclusions conclude": 19054,
      "administered twice": 8192,
      "twice 24": 83290,
      "satisfaction background": 73389,
      "background cardiac": 13023,
      "surgery sternotomy": 79592,
      "substantial postoperative": 78855,
      "general intravenous": 32975,
      "postoperative phase": 62949,
      "phase followed": 61282,
      "followed oral": 32077,
      "goal determine": 33273,
      "determine new": 24025,
      "new opioid": 49344,
      "opioid preparation": 52079,
      "provides adequate": 66200,
      "primary hypothesis": 65039,
      "compared patient": 18249,
      "efficacy similar": 28394,
      "similar oral": 75962,
      "total 51": 81754,
      "51 patients": 4959,
      "having elective": 34602,
      "randomised groups": 67025,
      "receiving different": 68331,
      "types analgesia": 83363,
      "morphine pain": 47868,
      "score visual": 73809,
      "surgery postoperative": 79526,
      "postoperative evening": 62771,
      "doses significantly": 26272,
      "interval 34": 39566,
      "38 vs": 4247,
      "vs 69": 86611,
      "respectively pain": 71228,
      "opioids suggesting": 53322,
      "painful procedures": 58011,
      "used prevent": 85088,
      "prevent overdose": 64848,
      "deaths illicit": 22755,
      "illicit use": 36656,
      "opioids little": 53023,
      "activity profile": 7583,
      "induced psychological": 38448,
      "psychological dependence": 66339,
      "aimed confirm": 9442,
      "dependence induced": 23471,
      "guanosine thio": 34395,
      "thio triphosphate": 81093,
      "binding assay": 13815,
      "30 30": 3683,
      "30 000": 3660,
      "000 nm": 29,
      "induced oxycodone": 38437,
      "fentanyl elicited": 31471,
      "concentration response": 18719,
      "response curves": 71340,
      "preference test": 63630,
      "test oxycodone": 80777,
      "01 mg": 316,
      "kg produced": 40792,
      "produced dose": 65376,
      "dependent increases": 23513,
      "increased place": 37984,
      "preference induced": 63624,
      "attenuated administration": 12584,
      "naloxone dose": 48446,
      "kg naloxone": 40766,
      "kg blocked": 40696,
      "blocked oxycodone": 14084,
      "kg induced": 40740,
      "dopamine release": 25723,
      "release nucleus": 69898,
      "lower dose": 42601,
      "dose 01": 25774,
      "kg did": 40719,
      "dependence oxycodone": 23483,
      "oxycodone antagonized": 54718,
      "antagonized naloxone": 11098,
      "lead better": 41279,
      "better understanding": 13751,
      "opioid acetaminophen": 51391,
      "acetaminophen combinations": 7170,
      "combinations methods": 17625,
      "using insurance": 85440,
      "conducted adult": 19344,
      "acetaminophen hydrocodone": 7191,
      "combinations included": 17624,
      "design employed": 23715,
      "initiation opioid": 38895,
      "acetaminophen combination": 7168,
      "acetaminophen group": 7186,
      "group risk": 33991,
      "post opioid": 62614,
      "acetaminophen treatment": 7255,
      "treatment compared": 82508,
      "group using": 34062,
      "using multivariate": 85508,
      "adjusting baseline": 8063,
      "differences groups": 24745,
      "groups results": 34306,
      "risk reduction": 72654,
      "period 11": 60679,
      "11 95": 1119,
      "12 month": 1330,
      "risk increased": 72584,
      "period 10": 60677,
      "14 95": 1575,
      "14 15": 1553,
      "period 17": 60685,
      "16 18": 1847,
      "group did": 33740,
      "did demonstrate": 24429,
      "demonstrate lower": 23316,
      "ratio opioid": 67784,
      "opioid opioid": 52006,
      "acetaminophen 95": 7143,
      "ci conclusions": 16523,
      "conclusions population": 19163,
      "population data": 62323,
      "data based": 21887,
      "based evidence": 13319,
      "evidence supporting": 30275,
      "elevated risk": 28564,
      "changes prescription": 15815,
      "use state": 84747,
      "state level": 77049,
      "factors contributing": 31086,
      "incompletely understood": 37705,
      "examined association": 30370,
      "opioid distribution": 51724,
      "comparison prescription": 18379,
      "prescription data": 64191,
      "pain fentanyl": 56777,
      "oxymorphone primarily": 56281,
      "primarily opioid": 64979,
      "disorder oud": 25382,
      "2007 2017": 2490,
      "2017 evaluated": 2781,
      "2007 2012": 2488,
      "2013 2017": 2620,
      "revealed statistically": 72227,
      "2012 2017": 2593,
      "greater decrease": 33438,
      "codeine oxymorphone": 17273,
      "prevalent opioids": 64832,
      "equivalents oxycodone": 29371,
      "pronounced changes": 65680,
      "additional study": 7897,
      "policy associated": 62179,
      "associated reductions": 12406,
      "used chronic": 84875,
      "pain studies": 57869,
      "known present": 40926,
      "receptors opioid": 68551,
      "various time": 85982,
      "intervals determined": 39611,
      "flick latency": 31919,
      "dependent increase": 23510,
      "increase tail": 37810,
      "increase analgesic": 37731,
      "effect produced": 27536,
      "used adjuvant": 84837,
      "opiate analgesia": 51288,
      "analgesia objectives": 10034,
      "pain highly": 56829,
      "highly prevalent": 35400,
      "prevalent problem": 64837,
      "problem older": 65240,
      "dying patients": 27213,
      "patients opioids": 59596,
      "opioids main": 53030,
      "analgesic moderate": 10275,
      "patients different": 59199,
      "specific population": 76611,
      "aim explore": 9388,
      "identify factors": 36503,
      "specific opioid": 76604,
      "pain older": 57273,
      "patients dying": 59231,
      "using online": 85535,
      "patients recorded": 59865,
      "factors considered": 31084,
      "completed questionnaire": 18488,
      "choice oxycodone": 16116,
      "second choice": 74180,
      "consideration opioid": 19622,
      "practice recommendations": 63412,
      "recommendations guidelines": 68604,
      "physicians long": 61440,
      "patients contrast": 59152,
      "morphine preferred": 47883,
      "patients fentanyl": 59303,
      "fentanyl second": 31590,
      "guidelines research": 34470,
      "spinal surgery": 76727,
      "surgery causes": 79341,
      "causes significant": 15401,
      "significant postoperative": 75599,
      "pain tested": 57906,
      "tested efficacy": 80804,
      "bilateral erector": 13793,
      "erector spinae": 29498,
      "allocated 60": 9611,
      "standard care": 76891,
      "block improved": 14046,
      "improved mean": 37112,
      "15 score": 1791,
      "score 24": 73717,
      "24 postoperative": 3267,
      "increase 95": 37724,
      "13 22": 1460,
      "iqr range": 40183,
      "block reduced": 14064,
      "reduced mean": 68939,
      "curve pain": 21527,
      "pain 24": 56377,
      "hours rest": 35842,
      "cumulative mean": 21396,
      "sd oxycodone": 74086,
      "24 27": 3155,
      "27 18": 3476,
      "18 mg": 2089,
      "mg control": 45833,
      "group 19": 33580,
      "26 mg": 3445,
      "block 20": 14033,
      "recovery reduced": 68755,
      "decompression surgery": 22877,
      "surgery present": 79532,
      "case histories": 15174,
      "autopsy findings": 12771,
      "toxicology findings": 81951,
      "fatal intoxications": 31233,
      "involving designer": 40126,
      "quantitative analysis": 66797,
      "postmortem fluids": 62678,
      "fluids tissues": 31946,
      "detected concentrations": 23939,
      "220 ng": 3050,
      "ml vitreous": 46917,
      "ng brain": 49428,
      "ml urine": 46915,
      "fatal intoxication": 31232,
      "second case": 74179,
      "fentanyl detected": 31464,
      "acetyl fentanyl": 7270,
      "fentanyl alprazolam": 31436,
      "fentanyl concentrations": 31458,
      "concentrations ng": 18780,
      "000 ng": 27,
      "63 ng": 5362,
      "39 ng": 4272,
      "49 ng": 4777,
      "21 ng": 2978,
      "28 000": 3530,
      "200 ng": 2406,
      "160 ng": 1907,
      "330 ng": 4004,
      "concentration 40": 18671,
      "40 ng": 4367,
      "ethanol concentration": 29678,
      "drug intoxication": 26671,
      "assessment treatment": 12145,
      "health practitioners": 34753,
      "using opiate": 85536,
      "medications treat": 44688,
      "medications including": 44630,
      "discussion medications": 25304,
      "medications increased": 44633,
      "addiction potential": 7754,
      "opiate treatment": 51311,
      "treatment including": 82622,
      "substance misuse": 78805,
      "examine role": 30361,
      "using opiates": 85537,
      "pain opiate": 57277,
      "objective orthopedic": 50458,
      "oxycodone ibuprofen": 55226,
      "demonstrated efficacy": 23337,
      "studies compared": 77667,
      "compared drugs": 18141,
      "children objective": 16060,
      "investigate effectiveness": 40006,
      "ibuprofen combination": 36352,
      "orthopedic injury": 53823,
      "injury related": 38992,
      "trial compared": 83007,
      "compared effectiveness": 18143,
      "children age": 16031,
      "years pain": 87631,
      "receive treatment": 68083,
      "treatment regimens": 82803,
      "scale baseline": 73498,
      "score time": 73801,
      "time compared": 81223,
      "groups using": 34344,
      "generalized estimating": 33000,
      "estimating equation": 29656,
      "time significant": 81377,
      "groups statistically": 34328,
      "differences demographics": 24731,
      "injury characteristics": 38988,
      "28 subjects": 3574,
      "subjects combination": 78686,
      "combination treatment": 17616,
      "effects conclusions": 27875,
      "analgesia mild": 10019,
      "moderate orthopedic": 47153,
      "effects given": 27932,
      "given opioid": 33179,
      "analgesic properties": 10305,
      "chronic post": 16329,
      "descending pain": 23647,
      "pain modulation": 57209,
      "opioids associated": 52734,
      "aimed evaluate": 9447,
      "cell line": 15481,
      "10 100": 661,
      "cell death": 15478,
      "superoxide dismutase": 79153,
      "dismutase sod": 25366,
      "glutathione transferase": 33260,
      "exposure did": 30759,
      "score compared": 73736,
      "exposure significantly": 30796,
      "significantly inhibited": 75760,
      "activities oxycodone": 7551,
      "showed naloxone": 75275,
      "interact different": 39363,
      "explain differences": 30698,
      "factors influence": 31107,
      "influence selection": 38601,
      "oxycodone primary": 55757,
      "primary drugs": 64999,
      "treatment programs": 82789,
      "qualitative interviews": 66665,
      "used examine": 84933,
      "examine influence": 30347,
      "characteristics drug": 15859,
      "use patterns": 84617,
      "related factors": 69603,
      "factors primary": 31126,
      "opioid selection": 52358,
      "drugs choice": 26905,
      "44 hydrocodone": 4541,
      "20 hydrocodone": 2320,
      "dose escalation": 25899,
      "high low": 35120,
      "women elderly": 87214,
      "friends family": 32600,
      "family members": 31182,
      "drugs high": 26971,
      "treatment approaches": 82446,
      "individual differences": 38290,
      "formulations adfs": 32370,
      "pharmaceutical formulations": 61026,
      "unpleasant effects": 83918,
      "pharmacodynamics opioid": 61083,
      "review comparative": 72274,
      "differences abuse": 24708,
      "pharmacodynamic differences": 61060,
      "differences focus": 24742,
      "comparing opioid": 18351,
      "opioid pharmacokinetics": 52052,
      "formulation pharmacokinetic": 32359,
      "differences reported": 24807,
      "physically manipulated": 61421,
      "fast release": 31203,
      "assessed 14": 11978,
      "comparative studies": 17983,
      "provided clinically": 66125,
      "equivalent analgesia": 29289,
      "analgesia clear": 9925,
      "suggests opioid": 79039,
      "phases subjects": 61330,
      "administration crushed": 8238,
      "crushed intact": 21335,
      "placebo primary": 61804,
      "primary endpoints": 65036,
      "reported maximum": 70580,
      "safety assessments": 73123,
      "results drug": 71668,
      "higher compared": 35217,
      "0001 drug": 62,
      "mg 60": 45757,
      "mg 0001": 45680,
      "0001 secondary": 77,
      "consistent results": 19716,
      "results fewer": 71692,
      "fewer participants": 31660,
      "02 oxycodone": 373,
      "pruritus somnolence": 66308,
      "somnolence dizziness": 76463,
      "dizziness conclusions": 25634,
      "injecting drugs": 38929,
      "pharmaceutical tablets": 61044,
      "inactive substances": 37224,
      "microcrystalline cellulose": 46351,
      "use present": 84661,
      "fourier transform": 32430,
      "transform infrared": 82185,
      "infrared spectroscopy": 38685,
      "cutaneous manifestations": 21537,
      "medications helpful": 44622,
      "animal experiments": 10991,
      "experiments clinical": 30680,
      "morphine previously": 47890,
      "oxycodone attenuates": 54737,
      "test effects": 80769,
      "caused chronic": 15378,
      "chronic pancreatitis": 16326,
      "material methods": 43501,
      "blinded cross": 13996,
      "study analgesic": 77948,
      "placebo tested": 61841,
      "mechanical thermal": 44116,
      "thermal electrical": 81081,
      "pain skin": 57848,
      "skin muscles": 76206,
      "assessed baseline": 11987,
      "min drug": 46521,
      "muscles oxycodone": 48365,
      "effective placebo": 27666,
      "placebo morphine": 61781,
      "12 001": 1201,
      "evoked pain": 30304,
      "oesophageal heat": 50943,
      "pain effect": 56742,
      "equal placebo": 29234,
      "attenuated pain": 12592,
      "effective attenuating": 27601,
      "mechanical pain": 44114,
      "analgesic morphine": 10277,
      "pain modalities": 57200,
      "skin muscle": 76205,
      "old boy": 51000,
      "clinical manifestations": 16836,
      "opioid intoxication": 51878,
      "presented discussed": 64689,
      "article report": 11781,
      "highlights use": 35385,
      "analgesics commonly": 10397,
      "prescribed needed": 63900,
      "needed prn": 49031,
      "acute painful": 7678,
      "patients actually": 58933,
      "surplus opioids": 79666,
      "source diversion": 76493,
      "diversion nonmedical": 25598,
      "nonmedical opioid": 49773,
      "understanding patterns": 83644,
      "actual opioid": 7600,
      "help clinicians": 34897,
      "patients safe": 59934,
      "safe opioid": 73093,
      "escalating opioid": 29525,
      "tolerance addiction": 81568,
      "addiction methods": 7747,
      "novel oxycodone": 50019,
      "oxycodone ingested": 55275,
      "events study": 30126,
      "study team": 78536,
      "naive individuals": 48398,
      "discharged emergency": 25194,
      "pain participants": 57327,
      "participants trained": 58377,
      "prn pain": 65204,
      "identified oxycodone": 36452,
      "time data": 81242,
      "study 26": 77888,
      "completing study": 18523,
      "individuals required": 38355,
      "opioids week": 53388,
      "utilization patterns": 85733,
      "days seven": 22622,
      "using opioids": 85540,
      "opioids days": 52833,
      "repair associated": 70379,
      "measure changes": 43936,
      "patterns opioid": 60214,
      "risks opioid": 72681,
      "using linked": 85463,
      "followed opioid": 32075,
      "abuse year": 6913,
      "initial exposure": 38850,
      "exposure tapentadol": 30798,
      "classification diseases": 16677,
      "diseases 9th": 25355,
      "abuse calculated": 6657,
      "risks developing": 72674,
      "outcome estimated": 53916,
      "estimated using": 29641,
      "higher proportions": 35312,
      "45 36": 4569,
      "44 37": 4529,
      "abuse age": 6649,
      "sex male": 75080,
      "mood disorders": 47483,
      "nonopioid medications": 49811,
      "medications pain": 44658,
      "pain risk": 57653,
      "factors developing": 31087,
      "oxycodone objectives": 55549,
      "patients initiating": 59412,
      "opioids long": 53025,
      "users pain": 85262,
      "drugs time": 27092,
      "time methods": 81291,
      "using marketscan": 85480,
      "2006 2015": 2477,
      "national commercial": 48673,
      "insurance database": 39146,
      "examined pain": 30399,
      "indications opioid": 38274,
      "median length": 44236,
      "cancer noncancer": 14804,
      "noncancer chronic": 49704,
      "pain active": 56409,
      "active ingredient": 7513,
      "adults initiating": 8565,
      "opioids 31": 52674,
      "days common": 22495,
      "fentanyl 23": 31422,
      "23 common": 3092,
      "pain 65": 56392,
      "users 16": 85227,
      "diagnosis cancer": 24331,
      "drugs approved": 26889,
      "administration 10": 8202,
      "years ago": 87569,
      "evidence cancer": 30169,
      "newer drugs": 49404,
      "drugs conclusions": 26919,
      "conclusions national": 19125,
      "sample adults": 73293,
      "common diagnosis": 17748,
      "therapy opioids": 81038,
      "frequently associated": 32545,
      "increasing concerns": 38098,
      "therapy findings": 81013,
      "provide context": 66047,
      "therapy prescribed": 81051,
      "background 2014": 13001,
      "hydrocodone combination": 36071,
      "combination products": 17604,
      "use diversion": 84339,
      "diversion methods": 25596,
      "radars poison": 66948,
      "data trends": 22146,
      "trends immediate": 82969,
      "prescriptions dispensed": 64476,
      "segmented regression": 74373,
      "results hydrocodone": 71716,
      "exposure rates": 30790,
      "significant different": 75524,
      "different oxycodone": 24900,
      "opioids schedule": 53285,
      "decreased 10": 22938,
      "14 0001": 1544,
      "quarter 95": 66852,
      "involving opioids": 40131,
      "misuse significant": 46749,
      "significant conclusions": 75448,
      "known morphine": 40917,
      "activity morphine": 7574,
      "morphine derived": 47642,
      "codeine hydromorphone": 17245,
      "natural opiates": 48743,
      "opiates morphine": 51330,
      "codeine synthetic": 17289,
      "synthetic derivatives": 79948,
      "derivatives hydromorphone": 23621,
      "naloxone naltrexone": 48466,
      "morphine displayed": 47649,
      "immunosuppressive effect": 36790,
      "effect dose": 27446,
      "related antinociceptive": 69560,
      "effect codeine": 27434,
      "kappa agonist": 40584,
      "antinociceptive activity": 11236,
      "antagonist bni": 11060,
      "antagonized antinociceptive": 11096,
      "antinociceptive drugs": 11238,
      "immunosuppressive effects": 36791,
      "antagonists naloxone": 11079,
      "immunosuppression hydromorphone": 36788,
      "effect opiates": 27503,
      "pain buprenorphine": 56504,
      "buprenorphine naloxone": 14566,
      "assessed oral": 12027,
      "pain history": 56832,
      "history opioid": 35468,
      "abuse participants": 6802,
      "participants 25": 58270,
      "doses 16": 26127,
      "16 mg": 1879,
      "maintenance period": 42913,
      "participants self": 58367,
      "administer oxycodone": 8092,
      "sessions drug": 74743,
      "clinical pain": 16853,
      "pain withdrawal": 57989,
      "whitney tests": 87035,
      "dose placebo": 26012,
      "oxycodone preference": 55731,
      "60 greater": 5253,
      "doses placebo": 26249,
      "dose factors": 25903,
      "symptoms pain": 79901,
      "reduce oxycodone": 68870,
      "inadequately treated": 37237,
      "using opioid": 85538,
      "little information": 42159,
      "drugs objective": 27014,
      "evaluate proportion": 29837,
      "setting retrospective": 74812,
      "abuse data": 6673,
      "automation reports": 12764,
      "consolidated orders": 19735,
      "nationally representative": 48727,
      "representative sample": 70759,
      "hospital emergency": 35588,
      "resulting drug": 71527,
      "abuse main": 6766,
      "mentions drug": 44838,
      "abuse number": 6788,
      "percentage population": 60517,
      "population results": 62383,
      "hydromorphone 19": 36152,
      "period total": 60803,
      "year opioid": 87475,
      "increased 32": 37850,
      "total drug": 81805,
      "806 oxycodone": 5875,
      "oxycodone 29": 54547,
      "increased morphine": 37950,
      "does appear": 25674,
      "consequences opioid": 19592,
      "aimed test": 9468,
      "impact prescribing": 36842,
      "providers methods": 66186,
      "records database": 68719,
      "identify new": 36510,
      "fentanyl controlled": 31461,
      "12 31": 1247,
      "proportion prescriptions": 65779,
      "prescriptions complied": 64460,
      "31 2008": 3844,
      "using interrupted": 85444,
      "indicator variable": 38278,
      "date results": 22219,
      "32 million": 3933,
      "prescriptions fentanyl": 64486,
      "patients meeting": 59490,
      "meeting inclusion": 44759,
      "entire study": 29076,
      "point near": 62089,
      "fit data": 31858,
      "plots revealed": 62021,
      "conclusions prescribing": 19170,
      "increased period": 37981,
      "did appear": 24410,
      "increase rate": 37797,
      "effective methods": 27647,
      "prescriber behavior": 64008,
      "future work": 32779,
      "background problems": 13179,
      "problems like": 65258,
      "anesthesia oxycodone": 10926,
      "hydrochloride semisynthetic": 36036,
      "therapeutic effect": 80935,
      "effect visceral": 27581,
      "results postoperative": 71877,
      "postoperative intravenous": 62782,
      "lower abdominal": 42572,
      "methods clinical": 45270,
      "ii patients": 36569,
      "elective general": 28492,
      "anesthesia randomly": 10941,
      "groups 30": 34108,
      "30 cases": 3711,
      "group iii": 33822,
      "150 ml": 1814,
      "respectively background": 71173,
      "background dose": 13038,
      "ml time": 46913,
      "time interval": 81278,
      "interval 10": 39555,
      "ml kg": 46867,
      "t1 t2": 80051,
      "t2 t3": 80059,
      "surgery including": 79425,
      "including mean": 37632,
      "pressure heart": 64740,
      "effective pressing": 27679,
      "ratio patient": 67789,
      "reactions results": 67972,
      "difference mean": 24626,
      "rate arterial": 67446,
      "arterial oxygen": 11713,
      "saturation adverse": 73469,
      "reactions groups": 67963,
      "groups time": 34335,
      "ii group": 36559,
      "05 t1": 556,
      "ratio significantly": 67799,
      "ratio 05": 67713,
      "scores group": 73878,
      "conclusion dose": 18891,
      "provide safe": 66096,
      "effective postoperative": 27672,
      "properties effective": 65709,
      "effective neuropathic": 27650,
      "efficacy tapentadol": 28400,
      "patients unclear": 60081,
      "japanese cancer": 40469,
      "31 2019": 3853,
      "2019 patients": 2878,
      "methadone 32": 45041,
      "fentanyl 26": 31424,
      "scores days": 73858,
      "secondary endpoint": 74224,
      "endpoint tolerability": 28907,
      "tolerability opioid": 81539,
      "opioids groups": 52936,
      "vrs score": 86499,
      "99 mean": 6490,
      "mean reduction": 43852,
      "score day": 73740,
      "greater tapentadol": 33497,
      "methadone fentanyl": 45071,
      "rate tapentadol": 67521,
      "group lowest": 33849,
      "tapentadol vs": 80479,
      "fentanyl vs": 31611,
      "vs hydromorphone": 86647,
      "hydromorphone vs": 36232,
      "vs vs": 86681,
      "10 respectively": 916,
      "respectively study": 71254,
      "suggests tapentadol": 79044,
      "efficacious cancer": 28199,
      "preferred option": 63643,
      "intensity evaluated": 39256,
      "evaluated pain": 29904,
      "validate findings": 85781,
      "using assessment": 85311,
      "paindetect questionnaire": 57999,
      "background data": 13035,
      "demonstrate opioid": 23322,
      "studies published": 77820,
      "subject methods": 78630,
      "database national": 22175,
      "registry patients": 69406,
      "dispensed prescription": 25434,
      "opioid po": 52070,
      "identified trends": 36479,
      "hospitalizations deaths": 35663,
      "annual prevalence": 11031,
      "po use": 62059,
      "dispensed pharmacies": 25433,
      "estimated results": 29637,
      "respectively 05": 71150,
      "significantly oxycodone": 75824,
      "increased 50": 37860,
      "50 67": 4819,
      "34 05": 4015,
      "mortality risk": 47994,
      "hr 95": 35891,
      "ci opioid": 16534,
      "15 40": 1700,
      "2000 2015": 2421,
      "use excluding": 84363,
      "fentanyl use": 31609,
      "related morbidity": 69633,
      "consumption order": 19968,
      "alarming increases": 9516,
      "increases opioid": 38066,
      "indication opioid": 38268,
      "monitoring opioid": 47329,
      "use introduction": 84441,
      "according american": 7035,
      "american association": 9791,
      "poison centers": 62150,
      "calls compared": 14734,
      "purpose investigation": 66536,
      "characterize nature": 15895,
      "center data": 15517,
      "2003 2007": 2445,
      "statistics used": 77250,
      "data results": 22095,
      "known substance": 40935,
      "24 25": 3153,
      "25 common": 3350,
      "combination hydrocodone": 17560,
      "oxycodone discussion": 54980,
      "medications substance": 44682,
      "opioids conclusions": 52812,
      "provide important": 66071,
      "important information": 37013,
      "abuse trends": 6903,
      "opioids increase": 52985,
      "increase risk": 37799,
      "increase mortality": 37758,
      "cause mortality": 15364,
      "mortality patients": 47990,
      "pain prescribed": 57407,
      "prescribed long": 63879,
      "participants retrospective": 58362,
      "tennessee medicaid": 80605,
      "medicaid patients": 44330,
      "pain evidence": 56766,
      "palliative end": 58050,
      "end life": 28794,
      "life care": 41688,
      "opioids analgesic": 52724,
      "control medications": 20363,
      "medications main": 44643,
      "measures total": 44103,
      "death certificates": 22699,
      "risk differences": 72548,
      "control medication": 20362,
      "opioids control": 52821,
      "age 48": 9012,
      "years 60": 87550,
      "group followed": 33784,
      "control treatment": 20435,
      "128 days": 1438,
      "64 95": 5386,
      "ci 26": 16422,
      "26 12": 3420,
      "deaths 95": 22738,
      "28 120": 3533,
      "000 person": 40,
      "risk hospital": 72581,
      "hospital deaths": 35578,
      "opioid 60": 51358,
      "90 95": 6078,
      "difference 67": 24581,
      "ci 30": 16429,
      "10 46": 710,
      "difference 28": 24577,
      "days therapy": 22644,
      "13 control": 1483,
      "mortality including": 47985,
      "including deaths": 37606,
      "causes overdose": 15396,
      "absolute risk": 6600,
      "findings considered": 31774,
      "harms benefits": 34595,
      "management complex": 43170,
      "pharmacotherapy treatment": 61252,
      "treatment plan": 82766,
      "plan patients": 61867,
      "loss pain": 42436,
      "sought identify": 76489,
      "identify relationships": 36533,
      "status opioid": 77261,
      "using pain": 85547,
      "understand impact": 83624,
      "physicians prescribe": 61447,
      "analgesics patients": 10478,
      "regarding abuse": 69239,
      "prescription pain": 64377,
      "spectrum opioid": 76676,
      "achieve high": 7300,
      "designed resist": 23844,
      "make drug": 43002,
      "article examines": 11767,
      "new products": 49365,
      "products clinical": 65444,
      "studies report": 77825,
      "oxycodone high": 55158,
      "high viscosity": 35194,
      "ratio 100": 67717,
      "100 morphine": 1003,
      "chewing crushing": 15982,
      "capsule controlled": 14954,
      "oxycodone designed": 54948,
      "drug injection": 26657,
      "prevent abuse": 64840,
      "abuse drug": 6714,
      "drug seeking": 26787,
      "seeking individuals": 74349,
      "particular drug": 58400,
      "drug drugs": 26606,
      "possible abuse": 62528,
      "warrant study": 86725,
      "background use": 13213,
      "increased greatly": 37926,
      "states past": 77140,
      "2010 16": 2537,
      "data 2013": 21850,
      "2013 methods": 2634,
      "programs researched": 65562,
      "trends 2002": 82959,
      "abuse products": 6848,
      "formulations prescription": 32402,
      "analgesics oxycodone": 10468,
      "centers substance": 15573,
      "college students": 17511,
      "increased substantially": 38033,
      "2002 2010": 2439,
      "programs reported": 65561,
      "large increases": 41129,
      "increases rates": 38080,
      "opioid diversion": 51725,
      "deaths rose": 22782,
      "rose fell": 72814,
      "reported nonmedical": 70592,
      "use did": 84308,
      "change significantly": 15750,
      "students conclusions": 77603,
      "postmarketing surveillance": 62669,
      "health hospital": 34713,
      "defined guidelines": 23140,
      "guidelines treatment": 34475,
      "evaluated use": 29926,
      "use new": 84512,
      "treatment protocol": 82790,
      "protocol designed": 65970,
      "minimize postoperative": 46599,
      "surgical treatment": 79656,
      "study involved": 78281,
      "september 2011": 74611,
      "2012 percutaneous": 2610,
      "invasive surgery": 39971,
      "received postoperative": 68248,
      "etoricoxib 120": 29715,
      "forms pain": 32312,
      "used evaluation": 84932,
      "pre postoperative": 63485,
      "pain 15": 56371,
      "results groups": 71708,
      "score similar": 73794,
      "reported case": 70512,
      "soft tissue": 76410,
      "proved effective": 66021,
      "management opioids": 43223,
      "opioids appropriately": 52730,
      "used japan": 84982,
      "depression present": 23593,
      "events deaths": 30038,
      "points using": 62144,
      "changes number": 15800,
      "proportion opioid": 65752,
      "number morphine": 50174,
      "annual consumption": 11012,
      "reported outcome": 70602,
      "following opioid": 32164,
      "events death": 30037,
      "death results": 22722,
      "rate fentanyl": 67467,
      "outcome death": 53913,
      "death increased": 22709,
      "increased 2010": 37837,
      "2010 highest": 2558,
      "oxycodone outcome": 55587,
      "events caused": 30019,
      "suggest opioid": 79002,
      "monitoring management": 47327,
      "management medical": 43198,
      "medical personnel": 44378,
      "fentanyl induced": 31505,
      "induced adverse": 38372,
      "evaluate combined": 29780,
      "combined oral": 17663,
      "2x10 mg": 3658,
      "respect postoperative": 71138,
      "postoperative mobilization": 62790,
      "radical retropubic": 66959,
      "retropubic prostatectomy": 72104,
      "prostatectomy rrp": 65914,
      "methods consecutive": 45289,
      "paracetamol tablet": 58117,
      "eda group": 27360,
      "group infiltration": 33829,
      "25 40": 3335,
      "ml 25": 46833,
      "bupivacaine wound": 14512,
      "hydrochloride 10": 36005,
      "mg tablet": 46226,
      "groups compared": 34146,
      "compared respect": 18294,
      "respect pain": 71136,
      "hospital stay": 35631,
      "operation time": 51232,
      "results analgesic": 71598,
      "provided satisfactory": 66153,
      "satisfactory analgesia": 73448,
      "scores remained": 73967,
      "significantly 0001": 75643,
      "group operation": 33879,
      "operation day": 51216,
      "day significant": 22414,
      "median vas": 44299,
      "scores respectively": 73969,
      "respectively 27": 71155,
      "27 median": 3496,
      "scores ranged": 73962,
      "oxy groups": 54453,
      "difference postoperative": 24667,
      "groups 06": 34091,
      "median duration": 44218,
      "duration hospital": 27161,
      "conclusion postoperative": 18967,
      "costs taken": 20909,
      "account background": 7072,
      "use likelihood": 84453,
      "unknown methods": 83881,
      "design data": 23709,
      "healthcare claims": 34795,
      "patients presenting": 59691,
      "term prescription": 80664,
      "days initial": 22540,
      "prescription included": 64240,
      "included 120": 37378,
      "probit regression": 65232,
      "model effect": 47045,
      "average treatment": 12941,
      "use observed": 84532,
      "potential confounders": 63152,
      "confounders including": 19522,
      "including morphine": 37637,
      "10 14": 671,
      "14 treated": 1630,
      "use vs": 84805,
      "vs 95": 86633,
      "sensitivity subgroup": 74564,
      "subgroup analyses": 78615,
      "detected conclusions": 23940,
      "conclusions long": 19113,
      "greater patients": 33476,
      "oxycodone despite": 54950,
      "multiple types": 48303,
      "pain especially": 56759,
      "lead development": 41284,
      "tolerance withdrawal": 81608,
      "exposure including": 30765,
      "changes contribute": 15782,
      "contribute opioid": 20227,
      "effect tolerance": 27571,
      "known opioids": 40923,
      "opioids altering": 52722,
      "induce clinically": 38366,
      "intracellular ca": 39728,
      "factor alpha": 31049,
      "activation specific": 7480,
      "test hypothesis": 80772,
      "hypothesis used": 36301,
      "used animal": 84846,
      "increased levels": 37939,
      "activation using": 7481,
      "pathway 24": 58511,
      "24 treatment": 3285,
      "combined vivo": 17675,
      "vitro data": 86354,
      "prolonged opioid": 65614,
      "contribute drug": 20226,
      "changes neuronal": 15797,
      "neuronal plasticity": 49213,
      "role management": 72745,
      "medications authors": 44595,
      "rates tapentadol": 67642,
      "ir compared": 40215,
      "diversion opioid": 25599,
      "informants patients": 38630,
      "patients skip": 59985,
      "june 2011": 40543,
      "000 unique": 47,
      "unique recipients": 83759,
      "recipients dispensed": 68566,
      "dispensed drug": 25423,
      "rates time": 67643,
      "regression model": 69444,
      "rate versus": 67523,
      "versus time": 86160,
      "results 24": 71556,
      "ir low": 40235,
      "low population": 42533,
      "population based": 62303,
      "similar rates": 75987,
      "rates tramadol": 67644,
      "market share": 43414,
      "conclusions rates": 19183,
      "report report": 70476,
      "66 year": 5460,
      "old patient": 51015,
      "bone metastases": 14237,
      "opiate analgesics": 51290,
      "day months": 22339,
      "nasal spray": 48657,
      "200 microg": 2403,
      "microg puff": 46363,
      "weight loss": 86982,
      "complete resolution": 18452,
      "blurred vision": 14172,
      "drug reaction": 26756,
      "pharmacodynamic interaction": 61066,
      "selective serotonin": 74440,
      "fentanyl treatment": 31608,
      "treatment serotonin": 82832,
      "estimated 04": 29618,
      "combination medications": 17566,
      "medications increase": 44631,
      "impairment cognitive": 36888,
      "cognitive disorders": 17322,
      "depressed pain": 23564,
      "analgesics risk": 10498,
      "conclusion clinicians": 18870,
      "inhibitor antidepressants": 38792,
      "pain specialists": 57853,
      "help reduce": 34912,
      "consequences patients": 19594,
      "treating opioid": 82399,
      "proof concept": 65685,
      "examined potential": 30404,
      "cb1 receptor": 15430,
      "receptor partial": 68516,
      "partial agonist": 58236,
      "session followed": 74733,
      "sessions testing": 74751,
      "test dose": 80765,
      "substituted oxycodone": 78873,
      "order produce": 53719,
      "observer participant": 50735,
      "ratings opioid": 67701,
      "agonist opioid": 9298,
      "psychomotor cognitive": 66351,
      "cognitive performance": 17329,
      "performance results": 60560,
      "produced prototypic": 65402,
      "prototypic opioid": 66016,
      "increasing subjective": 38125,
      "effects indicative": 27955,
      "produced effects": 65384,
      "similar placebo": 75978,
      "placebo 20": 61624,
      "doses produced": 26255,
      "produced modest": 65397,
      "performance identified": 60552,
      "dose conclusion": 25849,
      "suppression effects": 79245,
      "limited duration": 41928,
      "visits emergency": 86281,
      "patients usually": 60172,
      "usually treated": 85699,
      "drugs acetaminophen": 26870,
      "opioids skeletal": 53302,
      "compare functional": 18028,
      "pain week": 57985,
      "ed visit": 27354,
      "10 day": 754,
      "day course": 22288,
      "naproxen cyclobenzaprine": 48567,
      "naproxen oxycodone": 48569,
      "conducted urban": 19419,
      "urban ed": 84030,
      "bronx new": 14457,
      "york city": 87708,
      "patients presented": 59689,
      "eligible enrollment": 28580,
      "ed discharge": 27330,
      "item questionnaire": 40346,
      "related functional": 69607,
      "functional impairment": 32697,
      "april 2012": 11600,
      "patients approached": 58998,
      "eligible participation": 28589,
      "cyclobenzaprine oxycodone": 21553,
      "follow completed": 32015,
      "completed december": 18466,
      "participants given": 58311,
      "given 20": 33152,
      "mg taken": 46236,
      "day randomized": 22396,
      "60 tablets": 5279,
      "mg participants": 46152,
      "participants instructed": 58317,
      "tablets hours": 80162,
      "hours needed": 35798,
      "received standardized": 68284,
      "10 minute": 863,
      "prior discharge": 65141,
      "outcome improvement": 53919,
      "discharge week": 25185,
      "week later": 86845,
      "later results": 41239,
      "characteristics comparable": 15852,
      "groups baseline": 34139,
      "20 interquartile": 2323,
      "range iqr": 67318,
      "iqr 17": 40166,
      "17 21": 1940,
      "21 oxycodone": 2980,
      "20 iqr": 2325,
      "17 22": 1941,
      "98 ci": 6463,
      "ci 77": 16493,
      "77 oxycodone": 5762,
      "acetaminophen vs": 7261,
      "28 oxycodone": 3563,
      "45 conclusions": 4580,
      "relevance patients": 70037,
      "presenting ed": 64702,
      "acetaminophen naproxen": 7208,
      "did improve": 24454,
      "improve functional": 37061,
      "use additional": 84172,
      "additional medications": 7869,
      "background long": 13077,
      "term management": 80639,
      "pain opioids": 57294,
      "stable time": 76851,
      "dose increases": 25932,
      "increases drug": 38057,
      "toxic effects": 81927,
      "clinical correlates": 16776,
      "acetaminophen commonly": 7172,
      "prescribed short": 63979,
      "outpatient pharmacy": 54136,
      "new england": 49323,
      "june 30": 40555,
      "doses dose": 26181,
      "use long": 84458,
      "cancer diagnoses": 14776,
      "diseases ninth": 25356,
      "ninth revision": 49492,
      "revision clinical": 72427,
      "clinical modification": 16839,
      "months mean": 47452,
      "prescribed daily": 63845,
      "dose tablets": 26092,
      "day range": 22397,
      "range 13": 67256,
      "13 tablets": 1508,
      "daily prescribed": 21803,
      "prescribed mean": 63888,
      "dose time": 26097,
      "likely patients": 41824,
      "higher mean": 35261,
      "dose associated": 25831,
      "older age": 51034,
      "human immunodeficiency": 35954,
      "immunodeficiency virus": 36778,
      "virus hiv": 86249,
      "prescribed benzodiazepines": 63824,
      "benzodiazepine prescriptions": 13649,
      "prescriptions associated": 64450,
      "alcohol abuse": 9525,
      "received long": 68192,
      "term oxycodone": 80658,
      "management patients": 43233,
      "cause opioid": 15365,
      "opioid deaths": 51695,
      "2017 2017": 2767,
      "combined non": 17658,
      "fentanyl analogs": 31439,
      "84 opioid": 5961,
      "drug deaths": 26574,
      "increase deaths": 37741,
      "oral prescription": 53655,
      "availability illicit": 12781,
      "population opioids": 62365,
      "important tool": 37039,
      "issue opioid": 40325,
      "deaths caused": 22746,
      "opioids buprenorphine": 52753,
      "buprenorphine tramadol": 14592,
      "tramadol tapentadol": 82113,
      "conventional opioids": 20697,
      "narrative review": 48642,
      "review clinical": 72273,
      "evidence regarding": 30251,
      "schedule iv": 73627,
      "iv drug": 40374,
      "low abuse": 42446,
      "effects including": 27949,
      "p450 2d6": 56302,
      "metabolizer status": 45001,
      "tapentadol appears": 80383,
      "buprenorphine schedule": 14586,
      "schedule iii": 73623,
      "depression reported": 23595,
      "buprenorphine addition": 14518,
      "administration single": 8373,
      "formulation buprenorphine": 32333,
      "opioids safer": 53283,
      "safer option": 73114,
      "dose bupivacaine": 25836,
      "bupivacaine spinal": 14511,
      "sufentanil patients": 78949,
      "transurethral resection": 82248,
      "30 normal": 3777,
      "saline group": 73259,
      "30 oxycodone": 3780,
      "kg normal": 40768,
      "kg administered": 40691,
      "procedures group": 65304,
      "bupivacaine ml": 14507,
      "ml normal": 46882,
      "ml total": 46914,
      "bupivacaine 25": 14491,
      "spinal block": 76706,
      "perioperative analgesic": 60827,
      "assessed study": 12066,
      "study carried": 77981,
      "september 2014": 74614,
      "2014 results": 2674,
      "results time": 72017,
      "sensory block": 74572,
      "block recovery": 14063,
      "block analgesic": 14039,
      "longer group": 42374,
      "group fewer": 33781,
      "postoperative analgesics": 62717,
      "16 24": 1851,
      "operation significantly": 51227,
      "efficient safe": 28423,
      "safe method": 73091,
      "method decrease": 45177,
      "anesthesia combined": 10905,
      "combined intrathecal": 17649,
      "abuse united": 6904,
      "2017 2018": 2768,
      "identify opioid": 36511,
      "opioid molecules": 51953,
      "higher level": 35255,
      "design national": 23728,
      "variables related": 85898,
      "percentages patients": 60520,
      "dependence results": 23488,
      "million people": 46493,
      "pr used": 63380,
      "used hydrocodone": 84958,
      "hydrocodone 33": 36048,
      "33 percent": 3998,
      "percent oxycodone": 60470,
      "relieving pain": 70238,
      "pain 48": 56388,
      "48 percent": 4740,
      "feel good": 31331,
      "15 percent": 1785,
      "medical prescription": 44386,
      "used frequently": 84944,
      "used higher": 84955,
      "higher amounts": 35203,
      "amounts prescribed": 9838,
      "prescribed conclusions": 63841,
      "lower expected": 42614,
      "people united": 60431,
      "point prevalence": 62105,
      "associated misuse": 12334,
      "prescriptions medical": 64512,
      "medical supervision": 44407,
      "use medications": 84475,
      "dependence misuse": 23475,
      "abuse use": 6906,
      "age onset": 9096,
      "onset oxycodone": 51120,
      "fentanyl does": 31466,
      "background fentanyl": 13057,
      "fentanyl methamphetamine": 31527,
      "death rates": 22717,
      "2018 2021": 2810,
      "substances prescription": 78836,
      "aims characterize": 9476,
      "english speaking": 28943,
      "prescription methods": 64252,
      "methods employed": 45333,
      "mixed methods": 46797,
      "methods design": 45312,
      "design longitudinal": 23722,
      "samples oxycodone": 73352,
      "immunoassay based": 36772,
      "characterize drug": 15892,
      "contents results": 20105,
      "results 40": 71567,
      "obtained prescription": 50777,
      "prescription single": 64407,
      "pills 19": 61498,
      "obtained 11": 50756,
      "sold controlled": 76417,
      "sold oxycodone": 76419,
      "oxycodone samples": 55863,
      "samples contained": 73339,
      "fentanyl heroin": 31487,
      "heroin methamphetamine": 35015,
      "counterfeit medications": 20944,
      "health risk": 34768,
      "fentanyl based": 31444,
      "opioids key": 53008,
      "medications based": 44597,
      "overdose surveillance": 54320,
      "death rate": 22716,
      "used cancer": 84865,
      "relief studies": 70192,
      "investigated use": 40060,
      "use aimed": 84186,
      "codeine phosphate": 17277,
      "2018 used": 2849,
      "data presented": 22063,
      "compared regions": 18292,
      "average rate": 12934,
      "consumption highest": 19931,
      "consumption 11": 19868,
      "11 28": 1107,
      "53 14": 5015,
      "consumption 16": 19871,
      "reviews published": 72417,
      "literature regarding": 42125,
      "effectiveness effects": 27760,
      "burn patients": 14615,
      "patients conducted": 59130,
      "conducted systematic": 19416,
      "study characteristics": 77984,
      "results interventions": 71742,
      "review identified": 72311,
      "identified studies": 36473,
      "patients ranged": 59755,
      "examined studies": 30414,
      "studies showed": 77842,
      "pain use": 57957,
      "associated systemic": 12450,
      "systemic opioid": 80030,
      "medications compared": 44607,
      "intranasal fentanyl": 39749,
      "equivalent oral": 29325,
      "non invasive": 49619,
      "invasive analgesic": 39966,
      "burn pain": 14614,
      "limited sample": 41958,
      "pain combination": 56563,
      "common condition": 17746,
      "undertreatment pain": 83668,
      "pain suffering": 57884,
      "pain detection": 56702,
      "study strong": 78513,
      "retest reliability": 72084,
      "study validate": 78567,
      "blind randomised": 13965,
      "people advanced": 60397,
      "pain second": 57805,
      "aim examine": 9387,
      "assessing pain": 12104,
      "able demonstrate": 6568,
      "difference study": 24692,
      "study revealed": 78470,
      "difference pain": 24652,
      "compared treated": 18326,
      "treated placebo": 82373,
      "high number": 35124,
      "possible reasons": 62545,
      "early onset": 27260,
      "study efficacy": 78144,
      "patients liver": 59453,
      "drugs taken": 27088,
      "high degradation": 35080,
      "decrease oral": 22912,
      "oral application": 53496,
      "play role": 61997,
      "impaired hepatic": 36873,
      "hepatic clearance": 34950,
      "article relevant": 11780,
      "morphine naloxone": 47787,
      "high pass": 35132,
      "pass effect": 58437,
      "combination high": 17559,
      "naloxone approved": 48430,
      "objectives objective": 50568,
      "cerebrovascular events": 15648,
      "events patients": 30096,
      "research database": 70996,
      "cases defined": 15231,
      "patients hospitalized": 59371,
      "case controls": 15169,
      "conditional logistic": 19289,
      "confounder adjusted": 19520,
      "associated current": 12240,
      "therapy compared": 80997,
      "compared past": 18248,
      "events detected": 30039,
      "rate 19": 67428,
      "19 48": 2175,
      "14 19": 1556,
      "1000 person": 1039,
      "04 22": 443,
      "22 oxycodone": 3037,
      "significant impact": 75547,
      "04 21": 442,
      "21 25": 2945,
      "ci 03": 16371,
      "association oxycodone": 12483,
      "events findings": 30045,
      "evidence use": 30288,
      "neuromuscular block": 49206,
      "pain laparoscopic": 56992,
      "surgery limited": 79442,
      "limited existing": 41933,
      "conflicting results": 19515,
      "design randomised": 23768,
      "university affiliated": 83853,
      "affiliated hospital": 8942,
      "hospital participants": 35610,
      "randomly receive": 67239,
      "asked rate": 11843,
      "rate pain": 67497,
      "min using": 46556,
      "10 severe": 925,
      "postanaesthesia care": 62630,
      "pacu patients": 56331,
      "mg 10": 45697,
      "min pain": 46541,
      "rest wound": 71436,
      "wound compression": 87357,
      "compression point": 18633,
      "minimum effective": 46612,
      "analgesia dose": 9955,
      "oxycodone determined": 54954,
      "oxycodone secondary": 55866,
      "included area": 37426,
      "wound pain": 87365,
      "shoulder pain": 75223,
      "surgery duration": 79383,
      "groups area": 34135,
      "time similar": 81379,
      "variables associated": 85888,
      "associated postoperative": 12381,
      "mean vas": 43900,
      "patients reached": 59759,
      "groups moderate": 34238,
      "higher proportion": 35309,
      "proportion cases": 65739,
      "positively correlated": 62511,
      "tapentadol new": 80445,
      "new class": 49314,
      "class analgesics": 16651,
      "inhibitory actions": 38816,
      "areas pain": 11649,
      "adults cancer": 8551,
      "pain recent": 57481,
      "shown effective": 75336,
      "oxycodone randomized": 55792,
      "randomized multicenter": 67121,
      "multicenter double": 48157,
      "results effective": 71671,
      "effective opioid": 27652,
      "having lower": 34607,
      "binding affinity": 13814,
      "trial comparing": 83012,
      "comparing tapentadol": 18360,
      "tapentadol tapentadol": 80473,
      "duloxetine patients": 27124,
      "patients chemotherapy": 59061,
      "chemotherapy induced": 15966,
      "induced peripheral": 38442,
      "peripheral neuropathy": 60877,
      "range pain": 67332,
      "life measures": 41706,
      "similar adverse": 75894,
      "considered alternative": 19625,
      "especially opioid": 29561,
      "issue background": 40321,
      "following orthopedic": 32175,
      "distress patients": 25548,
      "analgesics treatment": 10510,
      "numerous studies": 50330,
      "research topics": 71034,
      "literature data": 42115,
      "data retrieved": 22096,
      "science citation": 73678,
      "citation index": 16590,
      "science wos": 73682,
      "surgery recruited": 79553,
      "index total": 38212,
      "countries obtained": 20956,
      "vosviewer software": 86495,
      "software results": 76412,
      "articles retrieved": 11803,
      "2021 11": 2911,
      "san diego": 73374,
      "states department": 77090,
      "department health": 23433,
      "health human": 34714,
      "human services": 35972,
      "anesthesia analgesia": 10900,
      "29 respectively": 3613,
      "regarding different": 69246,
      "occurrence keywords": 50859,
      "outcomes oxycodone": 54067,
      "oxycodone total": 56006,
      "hip replacement": 35423,
      "observed study": 50719,
      "analysis provide": 10747,
      "detailed information": 23916,
      "hyperthermia rats": 36278,
      "rats effect": 67855,
      "unknown present": 83887,
      "carried study": 15140,
      "study role": 78473,
      "et receptors": 29671,
      "receptors morphine": 68549,
      "respectively morphine": 71215,
      "produce changes": 65359,
      "used medications": 85006,
      "p450 3a4": 56304,
      "method present": 45206,
      "administering fentanyl": 8195,
      "potentiate fentanyl": 63273,
      "fentanyl toxicity": 31601,
      "pain palliative": 57323,
      "interaction objective": 39372,
      "trends prescribing": 82981,
      "treatment problems": 82786,
      "problems associated": 65255,
      "associated drugs": 12255,
      "related mortality": 69635,
      "mortality data": 47984,
      "australia design": 12686,
      "adjusted using": 8059,
      "using australian": 85312,
      "australian bureau": 12696,
      "bureau statistics": 14609,
      "resident population": 71067,
      "prospectively collected": 65892,
      "data national": 22014,
      "national hospital": 48689,
      "heroin opioids": 35020,
      "alcohol drug": 9530,
      "national minimum": 48700,
      "national coronial": 48675,
      "coronial information": 20793,
      "deaths oxycodone": 22774,
      "oxycodone underlying": 56041,
      "underlying cause": 83602,
      "numbers prescriptions": 50286,
      "10 year": 958,
      "year age": 87430,
      "iii treatment": 36601,
      "declined oxycodone": 22868,
      "prescriptions highest": 64495,
      "years 2005": 87528,
      "2005 06": 2457,
      "morphine remained": 47912,
      "stable oxycodone": 76845,
      "deaths recorded": 22777,
      "prescriptions australia": 64452,
      "particularly older": 58415,
      "reflect appropriate": 69186,
      "appropriate prescribing": 11513,
      "prescribing pain": 64098,
      "ageing population": 9210,
      "use appropriate": 84203,
      "mortality associated": 47981,
      "australia continued": 12685,
      "continued need": 20137,
      "pain prescribing": 57409,
      "potential harms": 63171,
      "harms associated": 34594,
      "medications introduction": 44637,
      "introduction aims": 39923,
      "presenting treatment": 64709,
      "pharmaceutical opioid": 61031,
      "principal drug": 65126,
      "drug concern": 26563,
      "codeine users": 17300,
      "treatment needs": 82679,
      "retrospective case": 72112,
      "case review": 15199,
      "135 patients": 1533,
      "new south": 49374,
      "south wales": 76511,
      "codeine 53": 17205,
      "morphine 82": 47565,
      "82 compared": 5907,
      "compared differences": 18137,
      "differences demographic": 24730,
      "characteristics pain": 15869,
      "history mental": 35463,
      "use history": 84402,
      "examined results": 30413,
      "results people": 71861,
      "codeine likely": 17249,
      "likely female": 41809,
      "66 vs": 5459,
      "vs 37": 86570,
      "37 001": 4168,
      "43 vs": 4510,
      "vs 22": 86548,
      "49 001": 4767,
      "001 difference": 130,
      "difference age": 24593,
      "codeine group": 17239,
      "mean 38": 43665,
      "38 years": 4249,
      "39 years": 4279,
      "years opioid": 87628,
      "substitution therapy": 78879,
      "received groups": 68156,
      "likely treated": 41846,
      "buprenorphine methadone": 14559,
      "interval 27": 39564,
      "27 001": 3473,
      "001 likely": 150,
      "discussion conclusions": 25303,
      "differences codeine": 24724,
      "patients strong": 60000,
      "patients work": 60182,
      "sedation management": 74317,
      "change determine": 15729,
      "online survey": 51103,
      "survey sent": 79735,
      "responses received": 71393,
      "nurse practitioners": 50335,
      "pediatric adult": 60345,
      "66 patients": 5457,
      "patients eighty": 59241,
      "200 patients": 2408,
      "premedication oxycodone": 63723,
      "fentanyl frequently": 31479,
      "used oral": 85056,
      "oral po": 53653,
      "opioid premedication": 52078,
      "used long": 84989,
      "protocol 24": 65953,
      "55 patients": 5079,
      "time 25": 81198,
      "39 44": 4263,
      "management needs": 43212,
      "anesthesia providers": 10937,
      "specific cases": 76583,
      "need completed": 48915,
      "demonstrate effective": 23314,
      "effective means": 27642,
      "outcomes background": 54014,
      "examine relative": 30359,
      "relative abuse": 69734,
      "liability reinforcing": 41648,
      "reinforcing efficacy": 69527,
      "blind subject": 13988,
      "subject placebo": 78632,
      "mg week": 46265,
      "week study": 86872,
      "sessions conducted": 74739,
      "conducted 48": 19341,
      "intervals examine": 39613,
      "administration following": 8268,
      "following day": 32121,
      "intranasal placebo": 39756,
      "mg buprenorphine": 45813,
      "observer rated": 50736,
      "rated physiological": 67534,
      "physiological measures": 61464,
      "collected assess": 17448,
      "magnitude opioid": 42813,
      "antagonist effects": 11064,
      "progressive ratio": 65577,
      "administration procedure": 8346,
      "procedure assessed": 65270,
      "drug versus": 26859,
      "versus money": 86131,
      "results active": 71592,
      "active doses": 7507,
      "produced opioid": 65398,
      "effects increased": 27954,
      "increased ratings": 38001,
      "ratings liking": 67700,
      "placebo effects": 61727,
      "buprenorphine buprenorphine": 14524,
      "effects hour": 27942,
      "hour post": 35710,
      "buprenorphine active": 14517,
      "buprenorphine self": 14588,
      "administered placebo": 8167,
      "placebo buprenorphine": 61666,
      "doses conclusions": 26160,
      "data confirm": 21925,
      "withdrawal effects": 87129,
      "effects likely": 27966,
      "compared buprenorphine": 18100,
      "buprenorphine opioid": 14571,
      "guideline prescribing": 34422,
      "provide guidance": 66067,
      "opioid new": 51998,
      "new pain": 49354,
      "pain episodes": 56758,
      "tramadol decreased": 82052,
      "decreased 18": 22944,
      "18 months": 2095,
      "months vs": 47479,
      "decrease associated": 22886,
      "physician specialty": 61433,
      "provider type": 66180,
      "nationally distributed": 48726,
      "identified electronic": 36437,
      "health record": 34760,
      "record ehr": 68657,
      "ehr data": 28448,
      "new prescription": 49363,
      "prescription schedule": 64402,
      "models estimated": 47113,
      "specialty emergency": 76574,
      "hospital primary": 35621,
      "adjusting covariates": 8065,
      "prescriptions common": 64458,
      "common surgical": 17813,
      "anesthesia pain": 10929,
      "tramadol prescriptions": 82104,
      "common primary": 17799,
      "opioid vs": 52634,
      "emergency care": 28669,
      "hydrocodone vs": 36138,
      "85 95": 5979,
      "start opioid": 77002,
      "tramadol prescribing": 82103,
      "prescribing guidelines": 64061,
      "specialists frequently": 76567,
      "prescribing purpose": 64126,
      "death methods": 22711,
      "select opioid": 74384,
      "analgesics oas": 10460,
      "oas heroin": 50356,
      "heroin using": 35040,
      "series analyses": 74649,
      "october 2014": 50880,
      "dispensing declined": 25445,
      "30 study": 3795,
      "dispensing decreased": 25446,
      "dosage units": 25764,
      "units codeine": 83832,
      "morphine dispensing": 47648,
      "dispensing increased": 25449,
      "rates statistically": 67639,
      "immediate drop": 36698,
      "increases codeine": 38055,
      "heroin involved": 35011,
      "rates overdose": 67612,
      "rates increased": 67590,
      "increased study": 38031,
      "associated accelerated": 12213,
      "smaller increases": 76313,
      "fatal overdose": 31239,
      "did detect": 24430,
      "heroin abuse": 34981,
      "dynamic nature": 27215,
      "case involving": 15179,
      "high methadone": 35122,
      "methadone blood": 45048,
      "concentrations cause": 18750,
      "death unrelated": 22728,
      "unrelated drug": 83926,
      "240 mg": 3295,
      "day history": 22318,
      "history prior": 35477,
      "suicide attempts": 79049,
      "examination revealed": 30329,
      "mg dl": 45875,
      "methadone concentration": 45058,
      "causes death": 15395,
      "methadone related": 45124,
      "contributed death": 20232,
      "death pneumonia": 22714,
      "likely cause": 41798,
      "growing number": 34367,
      "number similar": 50256,
      "based drug": 13311,
      "emerged major": 28663,
      "issue united": 40327,
      "increases abuse": 38052,
      "changes medication": 15796,
      "medication prescribing": 44541,
      "changes drug": 15783,
      "easy access": 27290,
      "pain appears": 56457,
      "associated clinically": 12232,
      "clinical practices": 16869,
      "minimize risks": 46601,
      "risks addiction": 72665,
      "development guidelines": 24230,
      "early detection": 27255,
      "detection management": 23959,
      "abuse opiate": 6792,
      "states particularly": 77139,
      "best practices": 13694,
      "development prevention": 24249,
      "prevention strategies": 64884,
      "strategies reduce": 77423,
      "common causes": 17739,
      "respiratory distress": 71289,
      "distress syndrome": 25550,
      "pulmonary emboli": 66466,
      "cardiac disease": 14980,
      "disease presented": 25340,
      "treatment required": 82809,
      "endotracheal intubation": 28876,
      "echocardiogram demonstrated": 27304,
      "artery disease": 11730,
      "disease pulmonary": 25345,
      "imaging revealed": 36688,
      "signs aspiration": 75873,
      "days patient": 22578,
      "respiratory function": 71293,
      "function improved": 32649,
      "demonstrates novel": 23379,
      "setting acute": 74766,
      "tramadol commonly": 82048,
      "abuse using": 6908,
      "nationwide registers": 48733,
      "aimed characterise": 9438,
      "oxycodone mixed": 55457,
      "tramadol poisonings": 82101,
      "poisonings identified": 62162,
      "hazards regression": 34621,
      "comorbidities patients": 17936,
      "days total": 22646,
      "total 205": 81740,
      "patients died": 59196,
      "risk higher": 72580,
      "higher following": 35243,
      "oxycodone ahr": 54701,
      "2017 conclusion": 2774,
      "lower mortality": 42649,
      "risk compared": 72539,
      "drugs class": 26907,
      "cyclooxygenase inhibitors": 21560,
      "analgesic anti": 10151,
      "relief acute": 70098,
      "arthritis pain": 11732,
      "efficacy treatment": 28414,
      "treatment various": 82884,
      "products objective": 65455,
      "individuals prescribed": 38353,
      "2018 linked": 2829,
      "drug monitoring": 26714,
      "monitoring program": 47335,
      "program pdmp": 65539,
      "2014 2017": 2651,
      "state death": 77039,
      "death certificate": 22697,
      "certificate data": 15666,
      "2018 study": 2848,
      "ambulatory cancer": 9764,
      "opioid prescribers": 52082,
      "payment opioid": 60251,
      "potential measures": 63186,
      "composite score": 18598,
      "developed based": 24171,
      "observed opioid": 50695,
      "overdose opioid": 54304,
      "total 17": 81732,
      "tramadol 23": 82028,
      "included composite": 37440,
      "overdose index": 54297,
      "day period": 22367,
      "period average": 60712,
      "scores 28": 73834,
      "compared long": 18196,
      "75 73": 5699,
      "adjusted analyses": 8017,
      "qualitatively similar": 66670,
      "composite measure": 18597,
      "higher tramadol": 35333,
      "sources suggest": 76508,
      "suggest significant": 79014,
      "differ opioid": 24543,
      "examine abuse": 30332,
      "liability oxycodone": 41644,
      "pain met": 57173,
      "dsm iv": 27106,
      "criteria opioid": 21205,
      "patient unit": 58806,
      "given oral": 33181,
      "kg maintained": 40754,
      "sublingual buprenorphine": 78755,
      "medications administered": 44591,
      "blind conditions": 13924,
      "overall positive": 54231,
      "effects non": 28024,
      "drug abusing": 26513,
      "individuals oxycodone": 38352,
      "related reduction": 69679,
      "reduction effects": 69057,
      "acutely administered": 7712,
      "potential analgesic": 63133,
      "investigate use": 40031,
      "pain abuse": 56401,
      "opioids use": 53367,
      "pain growing": 56815,
      "good evidence": 33312,
      "study directly": 78120,
      "stable dose": 76840,
      "prescribing strategy": 64139,
      "strategy opioid": 77440,
      "escalating dose": 29522,
      "arm parallel": 11671,
      "parallel randomized": 58146,
      "pragmatic clinical": 63454,
      "affairs hospital": 8892,
      "hospital 12": 35556,
      "pain primary": 57429,
      "evaluations pain": 29972,
      "functional disability": 32696,
      "application treatment": 11429,
      "strategies opioid": 77417,
      "differences primary": 24794,
      "usual pain": 85693,
      "pain functional": 56801,
      "self rated": 74490,
      "rated pain": 67532,
      "27 patients": 3506,
      "course study": 21001,
      "differences rate": 24797,
      "study demonstrate": 78057,
      "carefully selected": 15112,
      "selected patients": 74397,
      "patients significant": 59979,
      "risk problematic": 72642,
      "problematic opioid": 65252,
      "reported acute": 70494,
      "strategy background": 77430,
      "regimens opioid": 69337,
      "increasing opioid": 38113,
      "opioids frequently": 52920,
      "needed basis": 48982,
      "dose frequency": 25911,
      "frequency patient": 32525,
      "wide variability": 87047,
      "physician prescribing": 61430,
      "use needed": 84511,
      "events provide": 30100,
      "provide opportunity": 66083,
      "determine feasibility": 24013,
      "patterns patients": 60223,
      "ed acute": 27326,
      "fracture methods": 32455,
      "hospital ed": 35586,
      "acute extremity": 7635,
      "received hip": 68158,
      "ed study": 27351,
      "discharged home": 25197,
      "home used": 35525,
      "ingest oxycodone": 38736,
      "needed pain": 49023,
      "data open": 22025,
      "open ended": 51148,
      "follow appointment": 32010,
      "attitudes beliefs": 12603,
      "results recruited": 71910,
      "87 96": 6022,
      "stopped using": 77393,
      "reporting pain": 70699,
      "pain focus": 56784,
      "pills study": 61543,
      "participants continued": 58291,
      "continued opioids": 20140,
      "opioids end": 52882,
      "80 10": 5823,
      "10 reported": 914,
      "willingness continue": 87104,
      "continue use": 20128,
      "improve medication": 37065,
      "adherence monitoring": 7994,
      "90 10": 6073,
      "feasible method": 31290,
      "pain develop": 56705,
      "interventions opioid": 39667,
      "opioids pose": 53185,
      "significant increased": 75564,
      "drug events": 26624,
      "identify significant": 36538,
      "predictors associated": 63586,
      "risk life": 72588,
      "examine predictors": 30354,
      "predictors opioid": 63591,
      "data sample": 22099,
      "included age": 37417,
      "misuse substance": 46751,
      "disorder number": 25380,
      "concurrent opioids": 19268,
      "use benzodiazepines": 84222,
      "protective factors": 65921,
      "factors reduced": 31128,
      "female gender": 31360,
      "use antidepressants": 84196,
      "factors increased": 31103,
      "taking opioid": 80313,
      "opioid benzodiazepine": 51561,
      "implications practice": 36965,
      "people use": 60433,
      "use prescribed": 84646,
      "opioids self": 53290,
      "opioids clinically": 52786,
      "uptake inhibition": 84018,
      "sedatives opioids": 74342,
      "analgesic approved": 10156,
      "approved europe": 11533,
      "management severe": 43262,
      "pain authors": 56477,
      "daily bid": 21701,
      "utility model": 85724,
      "alternative strong": 9743,
      "strong oral": 77560,
      "nonmalignant malignant": 49767,
      "severe nonmalignant": 74962,
      "pain oros": 57297,
      "cost incremental": 20878,
      "compared er": 18154,
      "effectiveness oros": 27770,
      "malignant nonmalignant": 43097,
      "investigated differences": 40035,
      "opioids experimental": 52904,
      "pain healthy": 56822,
      "males participated": 43081,
      "placebo 14": 61620,
      "pain induced": 56870,
      "results decreased": 71655,
      "pain day": 56683,
      "006 oxycodone": 271,
      "action involved": 7431,
      "sedation analgesia": 74307,
      "liver cancer": 42172,
      "remains controversial": 70290,
      "controversial aim": 20677,
      "haemodynamic stability": 34503,
      "fentanyl fen": 31473,
      "sedation methods": 74319,
      "methods adults": 45244,
      "society anaesthesiologists": 76368,
      "anaesthesiologists physical": 9882,
      "successfully performed": 78923,
      "observed mean": 50690,
      "mean blood": 43725,
      "groups despite": 34178,
      "longer durations": 42373,
      "group highest": 33817,
      "highest nrs": 35355,
      "surgery hour": 79418,
      "surgery significantly": 79585,
      "lower oxy": 42664,
      "group surgery": 34043,
      "movement respiratory": 48052,
      "experience lower": 30580,
      "aims current": 9478,
      "epidemic united": 29155,
      "accidental deaths": 7014,
      "using world": 85684,
      "individual case": 38287,
      "used worldwide": 85191,
      "drugs considered": 26921,
      "medication recorded": 44548,
      "june 2021": 40554,
      "99 ci": 6488,
      "using quasi": 85583,
      "neural network": 49168,
      "cluster analysis": 17083,
      "performed identify": 60596,
      "similar reported": 75989,
      "65 75": 5409,
      "cis opioids": 16586,
      "similar opioid": 75958,
      "highest reported": 35368,
      "risk opioids": 72625,
      "australia canada": 12683,
      "hypothesize oxycodone": 36305,
      "oc recycling": 50809,
      "local opioid": 42211,
      "gives rise": 33206,
      "pilot test": 61554,
      "oc mass": 50805,
      "mass transport": 43473,
      "model derived": 47039,
      "quantifiable measure": 66769,
      "estimates oc": 29651,
      "recovery days": 68742,
      "defined rate": 23153,
      "oc stopped": 50810,
      "random sample": 67004,
      "sample opioid": 73309,
      "opioid intolerant": 51877,
      "subjects history": 78703,
      "opioid illicit": 51838,
      "use comorbidities": 84253,
      "silico subjects": 75889,
      "values mean": 85846,
      "sd weight": 74096,
      "cyp2d6 em": 21599,
      "em phenotype": 28631,
      "dose oc": 25972,
      "time steady": 81384,
      "oc dose": 50803,
      "fell 61": 31341,
      "compared single": 18310,
      "vs days": 86642,
      "associated significant": 12423,
      "dose orally": 25981,
      "oc dosing": 50804,
      "gave rise": 32915,
      "accompanied reduction": 7026,
      "cell surface": 15487,
      "binding sites": 13823,
      "development include": 24233,
      "humans objective": 35985,
      "evaluate cost": 29784,
      "hip surgery": 35426,
      "societal perspective": 76365,
      "patients major": 59469,
      "surgery cost": 79358,
      "effectiveness analysis": 27747,
      "events quality": 30103,
      "treatment arm": 82447,
      "willingness pay": 87105,
      "conducted examine": 19359,
      "conclusions tapentadol": 19232,
      "analgesia respiratory": 10095,
      "depression despite": 23580,
      "codeine widely": 17302,
      "pediatric tertiary": 60362,
      "tertiary medical": 80745,
      "prescribers potentially": 64022,
      "effects measures": 27985,
      "retrospective prospective": 72157,
      "determine frequency": 24014,
      "compared similar": 18309,
      "interventions included": 39662,
      "education prescribers": 27391,
      "months age": 47429,
      "age appropriate": 9058,
      "appropriate medication": 11503,
      "medication patients": 44536,
      "key process": 40674,
      "codeine use": 17298,
      "use reduced": 84683,
      "formulary january": 32320,
      "conclusions lessons": 19109,
      "lessons learned": 41429,
      "translation study": 82217,
      "emergency physician": 28694,
      "guidelines aimed": 34428,
      "aimed reducing": 9465,
      "inappropriate opioid": 37241,
      "number type": 50270,
      "program data": 65533,
      "data january": 21997,
      "2010 december": 2554,
      "opioids hydrocodone": 52955,
      "hydromorphone primary": 36219,
      "statewide prescription": 77162,
      "prescription total": 64415,
      "total opioids": 81869,
      "analysis compare": 10653,
      "compare pre": 18045,
      "opioids number": 53103,
      "prescriptions greater": 64492,
      "supply opioids": 79183,
      "opioids results": 53276,
      "beginning january": 13522,
      "2010 number": 2565,
      "month 95": 47383,
      "implementation guidelines": 36934,
      "associated 12": 12208,
      "reduction 95": 69038,
      "total prescriptions": 81896,
      "prescriptions month": 64515,
      "estimated effect": 29625,
      "monthly prescriptions": 47421,
      "associated reduction": 12404,
      "reduction prescribing": 69093,
      "associated decrease": 12243,
      "decrease quantity": 22926,
      "quantity opioid": 66833,
      "guidelines occurred": 34450,
      "parallel opioid": 58145,
      "geographic areas": 33107,
      "objective examine": 50429,
      "examine prescribing": 30355,
      "single blinded": 76054,
      "ambulatory surgery": 9773,
      "surgery center": 79342,
      "patients women": 60181,
      "women scheduled": 87244,
      "scheduled undergo": 73657,
      "scheduled ambulatory": 73636,
      "tablet number": 80096,
      "number prescription": 50238,
      "tablets tablets": 80223,
      "received prescriptions": 68255,
      "prescriptions acetaminophen": 64444,
      "telephone surveys": 80576,
      "used days": 84903,
      "standardized effect": 76953,
      "effect sizes": 27565,
      "sizes study": 76189,
      "detect difference": 23927,
      "comparing primary": 18359,
      "groups 47": 34113,
      "47 patients": 4663,
      "survey median": 79721,
      "taken day": 80279,
      "group interquartile": 33832,
      "group 36": 33604,
      "36 patients": 4140,
      "groups reported": 34293,
      "reported taking": 70663,
      "tablets fewer": 80158,
      "additional prescriptions": 7886,
      "prescriptions pain": 64533,
      "fewer unused": 31673,
      "tablets tablet": 80222,
      "group day": 33725,
      "day conclusion": 22281,
      "conclusion prescribing": 18970,
      "patients minor": 59517,
      "study present": 78426,
      "prescribed drug": 63856,
      "participants data": 58296,
      "data french": 21975,
      "french national": 32505,
      "2010 2015": 2543,
      "2015 2019": 2690,
      "nervous drugs": 49140,
      "detection quantification": 23963,
      "level drug": 41462,
      "drug dispensed": 26589,
      "expressed defined": 30814,
      "population given": 62333,
      "given drug": 33167,
      "use level": 84450,
      "drug findings": 26633,
      "included approximately": 37425,
      "approximately 200": 11563,
      "year opioids": 87476,
      "drugs diazepam": 26933,
      "diazepam oxazepam": 24371,
      "increased opioids": 37967,
      "benzodiazepines drugs": 13661,
      "increase proportion": 37795,
      "28 40": 3541,
      "ddd 100": 22668,
      "drugs study": 27082,
      "occurs drugs": 50867,
      "drugs opioids": 27019,
      "opioids analgesics": 52725,
      "analgesic medications": 10272,
      "laboratory studies": 41032,
      "ability reduce": 6557,
      "medications used": 44694,
      "used clinically": 84880,
      "model useful": 47090,
      "humans results": 35988,
      "medications reduce": 44669,
      "induced hyperalgesia": 38416,
      "hyperalgesia model": 36260,
      "assess time": 11969,
      "measures drug": 44054,
      "efficacy effect": 28255,
      "novel analgesic": 50001,
      "oxycodone 2010": 54536,
      "2010 2016": 2544,
      "sex age": 75058,
      "2016 study": 2762,
      "study cross": 78046,
      "sectional comparative": 74279,
      "comparative analysis": 17978,
      "dispensings oxycodone": 25466,
      "2016 number": 2754,
      "behavior increased": 13530,
      "30 44": 3690,
      "exposure strong": 30797,
      "oxycodone prevent": 55754,
      "prevent misuse": 64845,
      "misuse potential": 46737,
      "studies provided": 77819,
      "emergence agitation": 28666,
      "children following": 16047,
      "sevoflurane anaesthesia": 75055,
      "oxycodone premedication": 55737,
      "affected incidence": 8917,
      "measured compared": 43961,
      "130 patients": 1517,
      "using point": 85562,
      "point scale": 62109,
      "min recovery": 46546,
      "recovery discharge": 68743,
      "results used": 72048,
      "objective patients": 50466,
      "received opiates": 68217,
      "examination results": 30328,
      "use alternative": 84188,
      "cyclooxygenase cox": 21558,
      "benefit patients": 13622,
      "compared traditional": 18324,
      "inflammatory medications": 38575,
      "neurosurgical patients": 49289,
      "randomized single": 67182,
      "blinded prospective": 14011,
      "seven patients": 74869,
      "assigned control": 12165,
      "experimental group": 30662,
      "medications results": 44671,
      "narcotics group": 48631,
      "scores increased": 73895,
      "increased length": 37936,
      "use compared": 84254,
      "increased hospitalization": 37928,
      "hospitalization costs": 35654,
      "conclusion use": 19016,
      "inhibitors addition": 38802,
      "decrease effects": 22894,
      "associated narcotic": 12340,
      "tampering diversion": 80350,
      "developing opioid": 24205,
      "therapeutic effectiveness": 80938,
      "abuse desirable": 6679,
      "areas covered": 11643,
      "antagonists opioid": 11081,
      "intended reduce": 39207,
      "dosage form": 25747,
      "performed comprehensive": 60577,
      "search using": 74132,
      "using available": 85318,
      "identify clinical": 36496,
      "utilizing opioid": 85746,
      "agonist combination": 9281,
      "safety abuse": 73118,
      "studies identified": 77745,
      "products containing": 65445,
      "expert opinion": 30688,
      "opinion clinical": 51344,
      "clinical impact": 16824,
      "epidemiological studies": 29161,
      "conducted order": 19382,
      "remain cautious": 70245,
      "opioids best": 52751,
      "current practice": 21455,
      "opioid risk": 52351,
      "management background": 43152,
      "data exist": 21965,
      "aims investigate": 9488,
      "effects analgesic": 27820,
      "explore association": 30718,
      "effect effects": 27451,
      "effects methods": 27991,
      "methods single": 45578,
      "measurements performed": 44029,
      "results including": 71726,
      "statistical significant": 77187,
      "treatment effects": 82568,
      "effects areas": 27827,
      "associations treatment": 12500,
      "treatment induced": 82626,
      "used detect": 84908,
      "acute analgesic": 7609,
      "analgesic treatments": 10351,
      "valuable tool": 85817,
      "effects potential": 28097,
      "predict treatment": 63556,
      "treatment outcomes": 82722,
      "outcomes research": 54088,
      "needed introduction": 49011,
      "medications given": 44621,
      "given current": 33161,
      "crisis surgeons": 21181,
      "minimize opioid": 46598,
      "avoid use": 12964,
      "bleeding risk": 13910,
      "sought evaluate": 76487,
      "ibuprofen pain": 36370,
      "pain bleeding": 56496,
      "cohort pilot": 17372,
      "undergoing ess": 83534,
      "patients self": 59953,
      "acetaminophen prn": 7244,
      "prn oxycodone": 65203,
      "intervention arm": 39624,
      "ibuprofen acetaminophen": 36350,
      "measures included": 44060,
      "included pain": 37500,
      "10 point": 902,
      "rate 10": 67424,
      "number opiate": 50187,
      "pills consumed": 61503,
      "consumed results": 19848,
      "study 15": 77883,
      "control 24": 20264,
      "intervention overall": 39637,
      "arm reported": 11675,
      "reported decreased": 70532,
      "days 95": 22478,
      "decreased postoperative": 23029,
      "postoperative bleeding": 62720,
      "opiate consumption": 51294,
      "consumption similar": 20019,
      "patients consuming": 59147,
      "consuming average": 19861,
      "pills oxycodone": 61525,
      "compared acetaminophen": 18092,
      "additionally significant": 7909,
      "cohort compared": 17349,
      "compared cohort": 18108,
      "furthermore study": 32754,
      "showed opioid": 75281,
      "regardless pain": 69288,
      "regimen prescribed": 69323,
      "trial needed": 83037,
      "2b opioid": 3637,
      "epidemic affected": 29125,
      "recent surge": 68430,
      "relative lack": 69751,
      "lack information": 41056,
      "information characterizing": 38635,
      "related drug": 69590,
      "fastest growing": 31221,
      "fentanyl norfentanyl": 31536,
      "concentrations ranged": 18808,
      "ml 53": 46841,
      "ml mean": 46873,
      "concentrations 17": 18739,
      "11 10": 1089,
      "10 ng": 874,
      "polydrug use": 62194,
      "methamphetamine amphetamines": 45140,
      "21 cocaine": 2964,
      "positivity rates": 62514,
      "drugs drug": 26943,
      "investigations reported": 40078,
      "reported illicit": 70566,
      "oxycodone 44": 54573,
      "alprazolam 24": 9669,
      "24 cases": 3190,
      "study provide": 78435,
      "health risks": 34769,
      "associated sleep": 12441,
      "circadian rhythm": 16567,
      "study set": 78485,
      "evaluate influence": 29811,
      "spinal general": 76720,
      "knee surgery": 40871,
      "inducing properties": 38473,
      "monitored pre": 47312,
      "included 20": 37387,
      "orthopaedic operations": 53816,
      "receive spinal": 68078,
      "evening morning": 29976,
      "saliva samples": 73277,
      "diminished postoperative": 25024,
      "significant decline": 75457,
      "recommendations pain": 68608,
      "physician patient": 61428,
      "treated pain": 82369,
      "aberrant drug": 6544,
      "large doses": 41126,
      "results differences": 71664,
      "conclusions avoid": 19035,
      "physicians advised": 61435,
      "procedures objective": 65316,
      "investigate safety": 40027,
      "safety satisfaction": 73218,
      "satisfaction patients": 73419,
      "pain research": 57630,
      "label extension": 40973,
      "extension ole": 30910,
      "patients consented": 59134,
      "entered ole": 29059,
      "received tablets": 68295,
      "tablets er": 80153,
      "dose 12": 25787,
      "hours 14": 35733,
      "physical examinations": 61396,
      "vital sign": 86342,
      "global assessments": 33222,
      "clinic visit": 16746,
      "146 patients": 1652,
      "64 patients": 5391,
      "patients 43": 58867,
      "events including": 30059,
      "including nausea": 37644,
      "17 vomiting": 1989,
      "changes vital": 15828,
      "patients satisfied": 59939,
      "satisfied satisfied": 73462,
      "limitations include": 41902,
      "14 day": 1582,
      "results er": 71684,
      "model acute": 47022,
      "decreased analgesic": 22979,
      "oxycodone breakthrough": 54758,
      "improved analgesia": 37096,
      "oxycodone inactive": 55241,
      "inactive metabolites": 37223,
      "morphine oxymorphone": 47865,
      "surrogate measures": 79672,
      "measures quantify": 44094,
      "need develop": 48917,
      "develop new": 24150,
      "new analgesic": 49308,
      "surgical pleth": 79643,
      "pleth index": 62015,
      "14 min": 1608,
      "pain group": 56813,
      "variables extracted": 85894,
      "receiver operating": 68308,
      "operating characteristic": 51209,
      "characteristic curve": 15843,
      "final model": 31746,
      "model predictions": 47075,
      "89 patients": 6061,
      "used develop": 84913,
      "pain numerical": 57254,
      "patients postoperative": 59657,
      "validation studies": 85800,
      "needed evaluate": 48999,
      "potentially harmful": 63256,
      "term long": 80637,
      "term effects": 80628,
      "prescription aim": 64163,
      "aim assess": 9375,
      "type opioids": 83340,
      "regional variation": 69361,
      "variation prescribing": 85921,
      "prescribing design": 64050,
      "retrospective observational": 72145,
      "available government": 12808,
      "government data": 33350,
      "data various": 22156,
      "various sources": 85978,
      "analysed opioid": 10574,
      "february 2014": 31306,
      "2014 total": 2680,
      "calculated standardised": 14704,
      "comparisons results": 18389,
      "equivalent milligrams": 29314,
      "period opioids": 60761,
      "66 0001": 5445,
      "greater social": 33496,
      "56 0001": 5093,
      "0001 conclusion": 58,
      "conclusion long": 18920,
      "prescribing increasing": 64069,
      "increasing despite": 38101,
      "poor efficacy": 62256,
      "efficacy non": 28302,
      "best practice": 13693,
      "national registry": 48716,
      "patients high": 59357,
      "high opioid": 35125,
      "use improve": 84421,
      "epidemiological data": 29160,
      "regarding patterns": 69269,
      "woman history": 87186,
      "history chronic": 35453,
      "exacerbation pain": 30316,
      "double usual": 26411,
      "patient acute": 58532,
      "acute compartment": 7625,
      "compartment syndrome": 18399,
      "right arm": 72475,
      "opioids increasingly": 52993,
      "prescribed frequently": 63864,
      "frequently involved": 32555,
      "nature opioid": 48750,
      "design post": 23753,
      "analysis data": 10668,
      "collected retrospective": 17479,
      "record review": 68659,
      "2008 2011": 2499,
      "2012 2015": 2591,
      "hospitals participants": 35671,
      "participants total": 58376,
      "total 10": 81703,
      "type medication": 83331,
      "opioids involved": 53007,
      "identify risk": 36536,
      "factors results": 31132,
      "involved opioids": 40104,
      "probably contributed": 65227,
      "factors identified": 31096,
      "levels morphine": 41578,
      "higher elderly": 35237,
      "related opioids": 69646,
      "frequency low": 32516,
      "recommend use": 68585,
      "use findings": 84373,
      "interventions focus": 39661,
      "especially elderly": 29554,
      "thoracic epidural": 81119,
      "recovery bowel": 68740,
      "postoperative prolonged": 62956,
      "naloxone potentially": 48488,
      "potentially useful": 63270,
      "analgesic step": 10337,
      "oxycodone decrease": 54931,
      "gastrointestinal function": 32882,
      "undergoing open": 83556,
      "center trial": 15558,
      "september 2015": 74616,
      "february 2017": 31309,
      "known allergy": 40901,
      "day patients": 22363,
      "naloxone placebo": 48485,
      "intensity rest": 39306,
      "rating score": 67684,
      "hours primary": 35833,
      "endpoint duration": 28888,
      "function median": 32656,
      "time defecation": 81246,
      "hours 95": 35744,
      "27 compared": 3489,
      "compared 28": 18077,
      "naloxone group": 48453,
      "30 placebo": 3789,
      "naloxone did": 48443,
      "oxycodone led": 55333,
      "led delayed": 41333,
      "different placebo": 24912,
      "prescribed postoperative": 63954,
      "analgesia following": 9981,
      "following pediatric": 32184,
      "pediatric surgery": 60361,
      "surgery result": 79564,
      "leftover opioid": 41354,
      "leftover opioids": 41356,
      "opioids overall": 53127,
      "community opioid": 17924,
      "opioid burden": 51564,
      "initial opioid": 38854,
      "evaluate extent": 29800,
      "analgesics following": 10424,
      "ambulatory surgeries": 9772,
      "state mandated": 77052,
      "restrictive opioid": 71465,
      "disposal rates": 25487,
      "rates methods": 67594,
      "study personnel": 78402,
      "discharged opioid": 25205,
      "prescription following": 64227,
      "surgery parents": 79500,
      "parents completed": 58218,
      "survey regarding": 79728,
      "data survey": 22140,
      "data medical": 22007,
      "doses prescribed": 26251,
      "prescribed left": 63876,
      "185 patients": 2142,
      "patients 62": 58883,
      "rate prescribed": 67503,
      "prescribed median": 63889,
      "median 12": 44173,
      "12 opioid": 1345,
      "iqr 12": 40161,
      "18 consumed": 2084,
      "13 90": 1474,
      "parents reported": 58222,
      "83 prescribed": 5936,
      "significant proportion": 75606,
      "surgery half": 79411,
      "parents disposed": 58219,
      "disposed leftover": 25495,
      "medication commonly": 44470,
      "opioids 53": 52681,
      "unlocked location": 83900,
      "experience pain": 30587,
      "medication conclusions": 44473,
      "proportion prescribed": 65778,
      "opioids left": 53015,
      "majority parents": 42990,
      "safety risks": 73217,
      "opioids home": 52952,
      "general agreement": 32953,
      "need perform": 48947,
      "screening test": 74049,
      "supporting effectiveness": 79224,
      "77 patients": 5764,
      "patients affected": 58962,
      "individual pain": 38304,
      "experience risk": 30590,
      "characteristics prior": 15876,
      "starting treatment": 77026,
      "results maximum": 71763,
      "analysis lower": 10706,
      "major reduction": 42974,
      "maximum vas": 43618,
      "treatment quality": 82792,
      "better patients": 13728,
      "therapy chronic": 80994,
      "patients background": 59027,
      "analgesia including": 10003,
      "alpha adrenergic": 9663,
      "shown affect": 75327,
      "methods analgesic": 45247,
      "flick latencies": 31918,
      "latencies measured": 41225,
      "min results": 46549,
      "produced mild": 65395,
      "action morphine": 7434,
      "oxycodone clonidine": 54790,
      "induced increases": 38419,
      "morphine inhibited": 47734,
      "conclusions report": 19198,
      "analgesia morphine": 10029,
      "adrenergic agonists": 8477,
      "agonists documented": 9324,
      "adrenergic agonist": 8476,
      "male sprague": 43056,
      "dawley rats": 22223,
      "rats treated": 67901,
      "respectively key": 71203,
      "findings morphine": 31796,
      "produced hyperthermia": 65389,
      "adrenergic antagonist": 8478,
      "rats oxycodone": 67873,
      "induced apoptosis": 38386,
      "molecular mechanism": 47286,
      "evident oxycodone": 30298,
      "decreased expression": 22996,
      "tissue rats": 81452,
      "rats vitro": 67904,
      "induced anti": 38378,
      "akt pathway": 9512,
      "pathway inhibitor": 58513,
      "inguinal hernia": 38753,
      "hernia repair": 34974,
      "associated short": 12421,
      "return normal": 72190,
      "normal activity": 49898,
      "control important": 20352,
      "following laparoscopic": 32157,
      "methods institutional": 45363,
      "44 patients": 4544,
      "elective laparoscopic": 28494,
      "laparoscopic inguinal": 41101,
      "prospectively randomized": 65902,
      "randomized groups": 67116,
      "mg bupivacaine": 45812,
      "received normal": 68214,
      "fixed time": 31889,
      "analgesics required": 10495,
      "group demographic": 33730,
      "type surgery": 83359,
      "significantly differ": 75683,
      "groups average": 34136,
      "average pain": 12920,
      "levels significantly": 41608,
      "attenuated group": 12585,
      "vs respectively": 86675,
      "surgery furthermore": 79403,
      "analgesic intake": 10261,
      "intake significantly": 39187,
      "decreased group": 22999,
      "despite growing": 23882,
      "growing concerns": 34363,
      "pharmaceutical opioids": 61038,
      "lead harm": 41289,
      "research examining": 71006,
      "vary different": 85988,
      "opioids established": 52891,
      "case descriptions": 15172,
      "82 year": 5913,
      "period 2013": 60695,
      "framework analysis": 32479,
      "analysis identify": 10696,
      "cases use": 15269,
      "drug types": 26823,
      "similar approximately": 75900,
      "55 female": 5074,
      "35 54": 4066,
      "54 years": 5056,
      "contextual factors": 20117,
      "psychological distress": 66340,
      "physical pain": 61407,
      "suicidal intent": 79046,
      "analysis patients": 10727,
      "patients complex": 59120,
      "data highlight": 21980,
      "highlight complex": 35373,
      "use subsequent": 84759,
      "harm objectives": 34579,
      "estimate oxycodone": 29611,
      "required pain": 70853,
      "week postoperative": 86865,
      "benign disease": 13642,
      "disease methods": 25331,
      "study english": 78150,
      "speaking women": 76548,
      "women 18": 87192,
      "older undergoing": 51044,
      "baseline daily": 13422,
      "daily weeks": 21817,
      "weeks postoperatively": 86939,
      "postoperatively addition": 62992,
      "recorded number": 68684,
      "tablets pain": 80193,
      "medications taken": 44684,
      "taken daily": 80276,
      "weeks postoperative": 86938,
      "postoperative results": 62964,
      "results eighty": 71674,
      "eighty women": 28462,
      "64 10": 5379,
      "years vs": 87688,
      "vs 47": 86583,
      "47 years": 4670,
      "iqr vs": 40184,
      "vs iqr": 86651,
      "51 vs": 4963,
      "vs 79": 86621,
      "lower baseline": 42582,
      "15 women": 1801,
      "group consumed": 33705,
      "consumed significantly": 19850,
      "tablets postoperatively": 80200,
      "postoperatively median": 63004,
      "iqr 18": 40167,
      "took oxycodone": 81674,
      "consume oxycodone": 19821,
      "oxycodone minimally": 55453,
      "pain multidimensional": 57219,
      "review pathophysiology": 72331,
      "opioids children": 52774,
      "management neuropathic": 43213,
      "antihyperalgesic efficacy": 11207,
      "response relationship": 71368,
      "relationship morphine": 69719,
      "18 respectively": 2106,
      "oxycodone 10mg": 54509,
      "morphine 20mg": 47547,
      "12 25": 1241,
      "oxycodone 20mg": 54537,
      "morphine highest": 47715,
      "highest dose": 35344,
      "dose 40": 25804,
      "considered clinically": 19626,
      "difference placebo": 24664,
      "observed dose": 50674,
      "points 001": 62118,
      "001 doses": 134,
      "hyperalgesia developed": 36259,
      "vs baseline": 86636,
      "onset analgesic": 51110,
      "effects hours": 27943,
      "hours morphine": 35797,
      "morphine 20": 47546,
      "mg hours": 45906,
      "doses conclusion": 26159,
      "conclusion study": 18998,
      "response relationships": 71369,
      "relationships analgesic": 69730,
      "antihyperalgesic effects": 11206,
      "breathing pattern": 14417,
      "pattern opioid": 60192,
      "intravenous morphine": 39857,
      "infusion administered": 38698,
      "cross fashion": 21250,
      "included pulse": 37528,
      "total amounts": 81778,
      "drugs given": 26967,
      "35 mg": 4083,
      "sd morphine": 74084,
      "41 mg": 4426,
      "min respiratory": 46548,
      "rate increase": 67476,
      "background longer": 13078,
      "people chronic": 60402,
      "term effect": 80627,
      "month open": 47397,
      "crossover randomized": 21294,
      "trial rct": 83061,
      "days morphine": 22557,
      "placebo thirty": 61842,
      "continued opioid": 20138,
      "breathlessness intensity": 14419,
      "intensity 10": 39217,
      "worst average": 87337,
      "combined using": 17674,
      "single measure": 76117,
      "measure primary": 43944,
      "primary analysis": 64989,
      "analysis groups": 10692,
      "analysis covariance": 10666,
      "secondary measures": 74231,
      "sf 12": 75097,
      "12 health": 1282,
      "health survey": 34785,
      "months results": 47470,
      "extent opioid": 30927,
      "improvement global": 37151,
      "change mean": 15731,
      "opioids versus": 53385,
      "12 physical": 1353,
      "physical component": 61384,
      "component improved": 18577,
      "improved opioid": 37113,
      "unchanged conclusions": 83469,
      "opioids given": 52933,
      "data effective": 21957,
      "needed background": 48981,
      "gabapentin effective": 32796,
      "objective test": 50528,
      "prophylactic administration": 65724,
      "administration gabapentin": 8270,
      "obese patients": 50358,
      "reduces postoperative": 69003,
      "postoperative oxycodone": 62837,
      "113 patients": 1175,
      "laparoscopic sleeve": 41107,
      "sleeve gastrectomy": 76241,
      "anesthesia patients": 10931,
      "gabapentin group": 32797,
      "dose gabapentin": 25912,
      "1200 mg": 1415,
      "matching placebo": 43495,
      "time end": 81259,
      "end anesthesia": 28783,
      "group 110": 33563,
      "65 minutes": 5416,
      "36 95": 4123,
      "mean 12": 43656,
      "31 10": 3840,
      "placebo 26": 61628,
      "mg gabapentin": 45896,
      "difference mg": 24632,
      "ci 08": 16380,
      "mean nrs": 43800,
      "intensity 12": 39221,
      "hours placebo": 35814,
      "15 81": 1715,
      "003 conclusions": 250,
      "demand oxycodone": 23252,
      "oxycodone delayed": 54935,
      "dose requirement": 26058,
      "requirement oxycodone": 70873,
      "centrally acting": 15621,
      "acting analgesics": 7376,
      "multimodal analgesic": 48209,
      "effects profile": 28112,
      "tramadol similar": 82109,
      "similar analgesic": 75897,
      "analgesic profile": 10304,
      "single mechanism": 76118,
      "analgesic compared": 10168,
      "mice produced": 46306,
      "desmethyl tramadol": 23867,
      "tramadol tramadol": 82117,
      "tramadol opioid": 82086,
      "opioid nonopioid": 52001,
      "reference compounds": 69129,
      "estimated dose": 29624,
      "tramadol potent": 82102,
      "tramadol opioids": 82087,
      "noxious stimulus": 50047,
      "increased naloxone": 37951,
      "tramadol doses": 82056,
      "doses effect": 26184,
      "synergistic effect": 79933,
      "induction observed": 38480,
      "codeine morphine": 17254,
      "morphine drug": 47652,
      "tramadol celecoxib": 82038,
      "pharmaceutical ingredients": 61028,
      "ingredients apis": 38751,
      "atypical opioid": 12622,
      "opioid tramadol": 52435,
      "cyclooxygenase inhibitor": 21559,
      "ratio study": 67801,
      "study non": 78324,
      "plus acetaminophen": 62024,
      "ratio 17": 67720,
      "ed 50": 27322,
      "kg thermal": 40811,
      "effects postoperative": 28093,
      "tramadol acetaminophen": 82032,
      "mechanical allodynia": 44110,
      "allodynia thermal": 9624,
      "thermal hyperalgesia": 81082,
      "motor coordination": 48024,
      "potential gastrointestinal": 63168,
      "gastrointestinal transit": 32897,
      "observed administration": 50648,
      "synergistic analgesic": 79929,
      "showed similar": 75310,
      "pain ed": 56741,
      "50 ratios": 4892,
      "ratios compared": 67819,
      "compared strong": 18314,
      "pain alternative": 56440,
      "careful medical": 15101,
      "help determine": 34899,
      "medical problems": 44387,
      "prior admission": 65135,
      "chemical physical": 15950,
      "second day": 74181,
      "patient medication": 58679,
      "medication profile": 44545,
      "included early": 37450,
      "process obtaining": 65337,
      "obtaining medication": 50786,
      "recommendations management": 68606,
      "presented background": 64686,
      "elderly population": 28483,
      "effects various": 28192,
      "korea veterans": 40947,
      "veterans hospital": 86181,
      "hospital performed": 35615,
      "performed data": 60583,
      "binomial variables": 13831,
      "variables describing": 85890,
      "describing patient": 23669,
      "patient related": 58730,
      "related characteristics": 69569,
      "constructed associations": 19809,
      "associations variables": 12504,
      "variables frequency": 85895,
      "determined odds": 24075,
      "ratio adjusted": 67758,
      "ratio aor": 67762,
      "aor calculated": 11340,
      "univariate multivariable": 83839,
      "multivariable analyses": 48316,
      "analyses respectively": 10607,
      "attributable risk": 12608,
      "patients 28": 58850,
      "gastrointestinal problems": 32886,
      "effects 20": 27794,
      "use 12": 84139,
      "increased 80": 37865,
      "compared codeine": 18107,
      "ci 92": 16510,
      "day opioid": 22344,
      "findings significant": 31819,
      "significant implications": 75549,
      "dose short": 26076,
      "pose risk": 62432,
      "carefully monitor": 15110,
      "monitor patients": 47308,
      "starting opioid": 77018,
      "older population": 51042,
      "muscle relaxant": 48361,
      "analgesic given": 10256,
      "unusual case": 83970,
      "experienced symptoms": 30631,
      "symptoms resolved": 79904,
      "clinicians monitor": 17031,
      "regimen background": 69298,
      "clinicians increasingly": 17030,
      "actual pain": 7601,
      "assessed patient": 12034,
      "medication lead": 44509,
      "office based": 50967,
      "based primary": 13366,
      "pain additional": 56415,
      "prescribe medication": 63798,
      "seeking behavior": 74348,
      "request oxycodone": 70787,
      "pain 001": 56345,
      "001 multivariable": 161,
      "multivariable models": 48331,
      "11 31": 1108,
      "patient physician": 58703,
      "physician characteristics": 61424,
      "gender race": 32938,
      "did strong": 24511,
      "strong associations": 77513,
      "associations drug": 12493,
      "strategy managing": 77437,
      "managing patients": 43295,
      "pain avoiding": 56479,
      "avoiding opioid": 12974,
      "opioid overuse": 52023,
      "patients make": 59470,
      "request opioid": 70785,
      "far likely": 31191,
      "strategies used": 77428,
      "assess patients": 11948,
      "varied widely": 85942,
      "indicate need": 38222,
      "need development": 48918,
      "development better": 24215,
      "traumatic brain": 82266,
      "brain injury": 14341,
      "injury tbi": 38998,
      "recent study": 68429,
      "potentially significant": 63268,
      "prescribed post": 63952,
      "cohort post": 17374,
      "31 19": 3843,
      "15 31": 1692,
      "frequently followed": 32554,
      "conclusions presence": 19173,
      "including opioids": 37657,
      "recovered significantly": 68730,
      "assessment significant": 12140,
      "state opioid": 77057,
      "monitor opioid": 47307,
      "combination data": 17554,
      "methods aimed": 45245,
      "analgesic consumption": 10170,
      "calculated percent": 14697,
      "percent differences": 60462,
      "month drug": 47387,
      "drug type": 26822,
      "type morphine": 83333,
      "buprenorphine codeine": 14527,
      "september 2013": 74613,
      "reviewing medical": 72400,
      "july 2013": 40516,
      "2013 results": 2641,
      "results percent": 71862,
      "drugs larger": 26988,
      "consumption compared": 19905,
      "compared year": 18343,
      "total percent": 81883,
      "percent difference": 60461,
      "mg year": 46267,
      "hospital electronic": 35587,
      "estimate opioid": 29610,
      "consumption population": 19989,
      "short period": 75185,
      "time objective": 81297,
      "compare safety": 18057,
      "low high": 42490,
      "neck pain": 48899,
      "oxycodone conducted": 54846,
      "using iqvia": 85448,
      "database 2006": 22161,
      "studying opioid": 78572,
      "self inflicted": 74488,
      "disorders opioid": 25396,
      "patients followed": 59311,
      "time varying": 81398,
      "cox regression": 21033,
      "tramadol 16": 82023,
      "hydrocodone 61": 36053,
      "61 oxycodone": 5316,
      "oxycodone 22": 54539,
      "outcomes compared": 54018,
      "dose hydrocodone": 25923,
      "hydrocodone compared": 36074,
      "difference risk": 24680,
      "risk observed": 72609,
      "observed low": 50687,
      "tramadol low": 82078,
      "ratio 85": 67752,
      "higher risks": 35320,
      "disorder low": 25376,
      "injuries opioid": 38985,
      "disorder compared": 25371,
      "benefits pain": 13633,
      "objectives current": 50551,
      "current evidence": 21435,
      "evidence shows": 30257,
      "hydrochloride prolonged": 36033,
      "effective opioids": 27653,
      "evaluate compare": 29782,
      "tapentadol versus": 80478,
      "formulations methods": 32388,
      "methods cost": 45293,
      "payer perspective": 60247,
      "administration tapentadol": 8387,
      "results reported": 71915,
      "reported terms": 70666,
      "35 000": 4055,
      "year results": 87497,
      "1000 individuals": 1032,
      "higher associated": 35205,
      "naloxone associated": 48432,
      "associated highest": 12286,
      "patient conclusion": 58572,
      "results pharmacoeconomic": 71866,
      "promote use": 65666,
      "comparison oxycodone": 18373,
      "formulations background": 32371,
      "donor site": 25712,
      "requiring opioids": 70907,
      "opioids method": 53049,
      "effect bupivacaine": 27427,
      "20 ml": 2357,
      "given hour": 33172,
      "catheters placed": 15323,
      "study consisting": 78040,
      "bupivacaine group": 14499,
      "needed times": 49038,
      "opioids 72": 52684,
      "difference seen": 24682,
      "drugs conclusion": 26918,
      "conclusion conclude": 18876,
      "significantly reduces": 75851,
      "pain need": 57228,
      "need narcotic": 48935,
      "increased drug": 37909,
      "drug companies": 26555,
      "formulations intended": 32383,
      "crushing dissolving": 21352,
      "tablets capsules": 80128,
      "ir opioids": 40241,
      "opioids available": 52742,
      "crushing dissolution": 21351,
      "making difficult": 43010,
      "difficult prepare": 24967,
      "nasal discomfort": 48652,
      "identified risk": 36466,
      "opioids require": 53267,
      "alternative opioids": 9730,
      "finding effective": 31761,
      "switching rotation": 79840,
      "patients respond": 59919,
      "experience intolerable": 30579,
      "intolerable adverse": 39703,
      "poor response": 62274,
      "response adverse": 71333,
      "need aware": 48910,
      "affect efficacy": 8898,
      "needs compared": 49055,
      "risk patients": 72629,
      "prevention cdc": 64871,
      "prescribing guideline": 64060,
      "opioid codeine": 51584,
      "18 month": 2093,
      "month periods": 47404,
      "guideline release": 34424,
      "decreased relative": 23034,
      "depression anxiety": 23570,
      "participants cross": 58292,
      "million adults": 46484,
      "adults 18": 8537,
      "months 18": 47428,
      "2016 eligible": 2743,
      "condition patients": 19282,
      "received new": 68212,
      "2014 september": 2675,
      "september 14": 74608,
      "14 2017": 1560,
      "age patients": 9101,
      "patients 52": 58875,
      "years 61": 87551,
      "prevalence new": 64790,
      "prescriptions drug": 64479,
      "follows codeine": 32227,
      "vs hydrocodone": 86646,
      "45 oxycodone": 4594,
      "22 vs": 3045,
      "vs 24": 86552,
      "24 tramadol": 3284,
      "vs 23": 86549,
      "overall odds": 54215,
      "odds prescribed": 50902,
      "ratios 95": 67814,
      "91 98": 6136,
      "82 90": 5901,
      "respectively odds": 71222,
      "prescribed schedule": 63977,
      "similar patients": 75975,
      "disorders conclusions": 25392,
      "months publication": 47469,
      "14 decrease": 1596,
      "prescriptions observed": 64524,
      "prescribed high": 63867,
      "tapentadol lower": 80438,
      "low affinity": 42449,
      "affinity mu": 8945,
      "aim retrospective": 9399,
      "compare risk": 18055,
      "ir using": 40263,
      "using claims": 85340,
      "2010 followed": 2557,
      "followed year": 32090,
      "proportion subjects": 65780,
      "subjects developed": 78691,
      "developed opioid": 24187,
      "revision codes": 72429,
      "pooled using": 62248,
      "using random": 85586,
      "exposed oxycodone": 30746,
      "group tapentadol": 34044,
      "lower tapentadol": 42708,
      "oxycodone odds": 55556,
      "ratio 35": 67729,
      "interval 21": 39560,
      "risk oxycodone": 72627,
      "oxycodone continued": 54876,
      "change time": 15754,
      "compared risk": 18300,
      "receiving opioid": 68360,
      "year follow": 87440,
      "prescribers patients": 64019,
      "patients aware": 59025,
      "introduction use": 39958,
      "po dependence": 62055,
      "rapidly increasing": 67404,
      "guidelines based": 34430,
      "based research": 13375,
      "aimed examine": 9453,
      "po dependent": 62056,
      "treatment daily": 82534,
      "daily oral": 21778,
      "equivalent ome": 29323,
      "standard dose": 76901,
      "conversion tables": 20718,
      "doses based": 26152,
      "days 28": 22469,
      "results participants": 71835,
      "sd 10": 74060,
      "69 reported": 5526,
      "methadone group": 45078,
      "21 mean": 2973,
      "mg ome": 46074,
      "ome sd": 51063,
      "prior treatment": 65175,
      "methadone dose": 45062,
      "dose 45": 25808,
      "mg sd": 46213,
      "61 mg": 5313,
      "day 28": 22255,
      "group 23": 33586,
      "23 mean": 3101,
      "dose 14": 25790,
      "sd mg": 74083,
      "day 18": 22251,
      "ome opioid": 51061,
      "dose conclusions": 25850,
      "varied substantially": 85941,
      "use conversion": 84279,
      "selection opioid": 74421,
      "morphine dependence": 47639,
      "pain wound": 57992,
      "wound healing": 87359,
      "prk methods": 65197,
      "study 60": 77899,
      "flap group": 31899,
      "defect size": 23100,
      "size measured": 76185,
      "measured daily": 43962,
      "significantly postoperative": 75833,
      "groups 33": 34110,
      "group 41": 33611,
      "hour compared": 35693,
      "94 hour": 6192,
      "statistically clinically": 77191,
      "significant advantage": 75421,
      "scores difference": 73867,
      "time groups": 81269,
      "groups background": 34137,
      "background oral": 13128,
      "administration intravenous": 8281,
      "prevent postoperative": 64850,
      "tested hypothesis": 80806,
      "incidence ponv": 37297,
      "tropisetron mg": 83243,
      "standard general": 76910,
      "anesthetic technique": 10973,
      "analgesia used": 10128,
      "need rescue": 48951,
      "rescue antiemetic": 70940,
      "antiemetic medication": 11188,
      "15 32": 1693,
      "32 39": 3910,
      "respectively incidence": 71201,
      "ponv 24": 62234,
      "24 group": 3198,
      "group 68": 33638,
      "vomiting significantly": 86481,
      "satisfaction significantly": 73438,
      "conclusions initial": 19103,
      "vomiting lower": 86461,
      "anti emetic": 11117,
      "usage patients": 84127,
      "dose rate": 26034,
      "prostate cancer": 65911,
      "institutional ethics": 39093,
      "approval retrospectively": 11526,
      "retrospectively reviewed": 72183,
      "reviewed records": 72390,
      "45 patients": 4595,
      "january 2003": 40419,
      "intra postoperative": 39724,
      "analgesics anti": 10376,
      "drugs administered": 26875,
      "patients hospital": 59369,
      "doses parenteral": 26246,
      "purposes study": 66597,
      "dose median": 25954,
      "patients 69": 58893,
      "patients 56": 58878,
      "56 received": 5107,
      "received intraoperative": 68173,
      "intraoperative morphine": 39776,
      "mg patients": 46155,
      "96 received": 6426,
      "received regular": 68257,
      "regular postoperative": 69481,
      "patients 80": 58901,
      "additional postoperative": 7884,
      "administration overall": 8323,
      "overall mean": 54210,
      "mean 45": 43666,
      "included 14": 37381,
      "postoperative course": 62729,
      "fourteen patients": 32434,
      "regular oral": 69479,
      "oral paracetamol": 53651,
      "opioids required": 53268,
      "opioids numerous": 53104,
      "centrally active": 15627,
      "active drugs": 7510,
      "drugs metabolized": 26996,
      "sex estrous": 75074,
      "estrous cycle": 29666,
      "cycle differences": 21545,
      "differences brain": 24722,
      "analgesia investigated": 10005,
      "propranolol cyp2d": 65809,
      "specific mechanism": 76601,
      "administering oxycodone": 8198,
      "oxymorphone negative": 56263,
      "negative control": 49067,
      "sham operated": 75110,
      "females received": 31397,
      "received treatment": 68301,
      "estradiol progesterone": 29663,
      "using tail": 85633,
      "brain drug": 14338,
      "microdialysis data": 46353,
      "versus vehicle": 86163,
      "oxycodone greater": 55121,
      "greater increases": 33452,
      "concentrations analgesia": 18742,
      "greater decreases": 33439,
      "ratios vivo": 67836,
      "brain males": 14344,
      "females estrus": 31390,
      "compared females": 18159,
      "females diestrus": 31389,
      "sex cycle": 75068,
      "treatment following": 82590,
      "altered brain": 9694,
      "individual variation": 38315,
      "variation response": 85922,
      "substrate drugs": 78885,
      "introduction adequate": 39921,
      "recovery following": 68744,
      "colorectal surgery": 17526,
      "transversus abdominis": 82252,
      "abdominis plane": 6537,
      "plane tap": 61875,
      "tap blocks": 80371,
      "improving pain": 37198,
      "abdominal operations": 6527,
      "improving postoperative": 37204,
      "laparoscopic colorectal": 41098,
      "trial involving": 83030,
      "surgery performed": 79521,
      "using ultrasound": 85651,
      "ultrasound guidance": 83432,
      "control primary": 20401,
      "analogue score": 10565,
      "score vas": 73806,
      "function time": 32684,
      "time return": 81368,
      "return gut": 72188,
      "gut function": 34479,
      "function length": 32655,
      "length hospital": 41398,
      "stay postoperative": 77287,
      "postoperative complications": 62726,
      "complications occurred": 18565,
      "blockade difference": 14077,
      "control vs": 20440,
      "daily vas": 21814,
      "outcome time": 53998,
      "satisfaction conclusion": 73393,
      "safe intervention": 73089,
      "burn injuries": 14612,
      "treatment interventions": 82631,
      "interventions outcomes": 39669,
      "limited objective": 41947,
      "objective provide": 50475,
      "range motion": 67324,
      "outcomes regarding": 54082,
      "regarding use": 69281,
      "admitted inpatient": 8422,
      "inpatient rehabilitation": 39029,
      "burn injury": 14613,
      "injury treated": 39000,
      "patients weeks": 60179,
      "degrees 95": 23180,
      "seen week": 74366,
      "week treatment": 86875,
      "treatment average": 82454,
      "improvement 11": 37142,
      "11 degrees": 1129,
      "patients average": 59019,
      "mm 95": 46929,
      "treatment 12": 82416,
      "improved patients": 37122,
      "patients week": 60178,
      "week average": 86830,
      "opioid heroin": 51834,
      "australia assess": 12682,
      "reformulation oxycodone": 69213,
      "stratified sex": 77457,
      "sex setting": 75090,
      "records examined": 68720,
      "using fixed": 85398,
      "free text": 32493,
      "text fields": 80883,
      "variable pre": 85882,
      "oxycodone reformulation": 55817,
      "findings 30": 31767,
      "2012 october": 2608,
      "heroin related": 35032,
      "july 2008": 40511,
      "june 2018": 40551,
      "related increase": 69620,
      "events 100": 30002,
      "people year": 60438,
      "opioid ed": 51754,
      "2008 2018": 2504,
      "ci 108": 16388,
      "2014 2018": 2652,
      "april 2014": 11602,
      "2014 june": 2665,
      "2018 compared": 2816,
      "compared respective": 18295,
      "pre april": 63459,
      "trend continued": 82941,
      "ci 005": 16367,
      "appears trend": 11412,
      "increasing heroin": 38109,
      "increase decrease": 37742,
      "opioids changes": 52771,
      "changes reflect": 15818,
      "affects quality": 8938,
      "retrospectively evaluated": 72179,
      "opioids administered": 52707,
      "terminal stage": 80686,
      "stage cancer": 76861,
      "94 years": 6199,
      "assessed administration": 11982,
      "administration using": 8391,
      "support team": 79216,
      "concomitantly treated": 19259,
      "scores 22": 73830,
      "receiving morphine": 68355,
      "morphine receiving": 47904,
      "fentanyl 18": 31417,
      "concomitant opioid": 19253,
      "associated point": 12380,
      "14 20": 1557,
      "patients effectiveness": 59238,
      "dose did": 25882,
      "significantly affect": 75650,
      "treatment effectively": 82566,
      "effectively alleviate": 27725,
      "modeling simulation": 47098,
      "aged years": 9208,
      "models predict": 47122,
      "predict drug": 63550,
      "drug clearance": 26552,
      "methods drugs": 45322,
      "drugs included": 26976,
      "drugs selected": 27070,
      "individual subjects": 38312,
      "age clearance": 9067,
      "data drugs": 21956,
      "route renal": 72847,
      "renal hepatic": 70358,
      "models age": 47108,
      "maximum possible": 43608,
      "possible effect": 62535,
      "age dependent": 9069,
      "clearance values": 16718,
      "values compared": 85837,
      "compared observed": 18221,
      "prediction error": 63568,
      "mean individual": 43781,
      "drugs data": 26929,
      "validation data": 85798,
      "different age": 24839,
      "study indicated": 78258,
      "provide accurate": 66027,
      "purpose prospective": 66550,
      "prospective studies": 65883,
      "studies effect": 77705,
      "effect dexamethasone": 27443,
      "neck surgery": 48900,
      "despite widespread": 23909,
      "dexamethasone setting": 24290,
      "setting aim": 74768,
      "perioperative use": 60854,
      "authors hypothesized": 12731,
      "enhance recovery": 28960,
      "pain nausea": 57224,
      "methods ninety": 45398,
      "included prospective": 37524,
      "group 51": 33623,
      "received dexamethasone": 68135,
      "days 42": 22473,
      "42 patients": 4468,
      "did receive": 24486,
      "receive dexamethasone": 68050,
      "protein crp": 65933,
      "results significantly": 71957,
      "significantly pain": 75828,
      "group 030": 33546,
      "postoperatively lower": 63003,
      "recovery patients": 68752,
      "required significantly": 70863,
      "patients control": 59153,
      "lower study": 42706,
      "use lower": 84463,
      "lower total": 42715,
      "routine use": 72866,
      "dexamethasone pain": 24288,
      "neck cancer": 48898,
      "prevent patient": 64849,
      "pain clinician": 56553,
      "nonopioid analgesics": 49807,
      "managing moderate": 43287,
      "careful selection": 15105,
      "selection effective": 74418,
      "analgesic regimen": 10309,
      "regimen based": 69299,
      "type pain": 83342,
      "patient expected": 58633,
      "expected prevent": 30559,
      "prevent stress": 64854,
      "stress anxiety": 77485,
      "anxiety associated": 11268,
      "associated breakthrough": 12225,
      "clinician develop": 17022,
      "develop variety": 24160,
      "variety effective": 85950,
      "safe analgesic": 73071,
      "regimens based": 69331,
      "based estimates": 13316,
      "estimates anticipated": 29643,
      "anticipated pain": 11157,
      "intensity use": 39322,
      "pharmacological principles": 61226,
      "excessive alcohol": 30459,
      "intake drugs": 39180,
      "cannabinoid cb1": 14927,
      "studies addressed": 77643,
      "potential utility": 63246,
      "utility combining": 85723,
      "drugs especially": 26952,
      "availability novel": 12783,
      "types drugs": 83366,
      "yl methyl": 87705,
      "drugs effective": 26949,
      "alcohol self": 9538,
      "ec 50": 27298,
      "rats repeated": 67886,
      "rats data": 67849,
      "support feasibility": 79196,
      "aimed prescribing": 9463,
      "hospital secondary": 35628,
      "knowledge opioid": 40888,
      "opioid pharmacology": 52053,
      "limiting opioid": 41975,
      "use design": 84300,
      "sectional survey": 74292,
      "survey patients": 79727,
      "requiring opioid": 70905,
      "analgesia performed": 10059,
      "semi structured": 74510,
      "questionnaire administered": 66888,
      "nursing staff": 50345,
      "associated having": 12272,
      "dose opioids": 25979,
      "opioids limited": 53020,
      "understanding opioid": 83638,
      "use included": 84424,
      "large numbers": 41140,
      "preparations prescription": 63783,
      "doses administered": 26145,
      "formulations conclusion": 32372,
      "conclusion majority": 18924,
      "relief maximum": 70138,
      "reported barriers": 70510,
      "included staff": 37556,
      "titration opioid": 81479,
      "included poor": 37512,
      "considerable overlap": 19611,
      "overlap exists": 54341,
      "therapeutic toxic": 80966,
      "toxic concentrations": 81924,
      "concentrations study": 18815,
      "aims quantify": 9496,
      "quantify opioid": 66785,
      "opioid mortality": 51963,
      "use fentanyl": 84371,
      "oxycodone evaluate": 55046,
      "evaluate utility": 29853,
      "death cases": 22696,
      "january 2001": 40417,
      "2001 31": 2435,
      "detection fentanyl": 23955,
      "postmortem toxicology": 62684,
      "single opioid": 76129,
      "deaths opioid": 22771,
      "opioid present": 52217,
      "deaths increased": 22757,
      "independent manner": 38160,
      "manner non": 43326,
      "deaths background": 22744,
      "fentanyl high": 31488,
      "opioid increasingly": 51845,
      "large proportion": 41147,
      "drug supply": 26797,
      "deaths including": 22756,
      "patients concomitantly": 59128,
      "pediatric opioid": 60352,
      "spectrometry used": 76673,
      "used confirm": 84894,
      "main findings": 42831,
      "presence opioids": 64597,
      "fentanyl exposure": 31472,
      "illicit tablets": 36655,
      "pills objective": 61522,
      "thyroid surgery": 81167,
      "patients 59": 58880,
      "59 women": 5191,
      "18 70": 2063,
      "years underwent": 87683,
      "placebo 35": 61631,
      "minutes surgery": 46663,
      "surgery surgery": 79603,
      "surgery oxycodone": 79492,
      "provided rescue": 66152,
      "analgesia main": 10011,
      "hours secondary": 35846,
      "31 34": 3857,
      "34 patients": 4031,
      "patients etoricoxib": 59261,
      "group given": 33788,
      "25 35": 3333,
      "35 patients": 4090,
      "16 34": 1856,
      "analgesics mean": 10447,
      "difference 24": 24574,
      "24 95": 3181,
      "ci 47": 16457,
      "conclusion etoricoxib": 18900,
      "mg reduced": 46199,
      "did opioid": 24468,
      "exposure associated": 30752,
      "lower weight": 42725,
      "neonatal opioid": 49098,
      "withdrawal syndrome": 87164,
      "syndrome nows": 79918,
      "term adverse": 80614,
      "opioids addition": 52704,
      "pre clinical": 63461,
      "post natal": 62585,
      "exposure birth": 30754,
      "gestation birth": 33134,
      "results short": 71945,
      "sex specific": 75091,
      "specific increase": 76594,
      "weight gain": 86978,
      "male mice": 43043,
      "caused increased": 15385,
      "increased weight": 38048,
      "evidence long": 30218,
      "social behavioral": 76352,
      "memory deficits": 44791,
      "opioid cessation": 51573,
      "results highlight": 71712,
      "term consequences": 80623,
      "explored objectives": 30732,
      "compare effectiveness": 18017,
      "effectiveness oral": 27769,
      "group ox": 33884,
      "epidural bupivacaine": 29176,
      "pain advanced": 56426,
      "advanced stage": 8601,
      "peripheral arterial": 60861,
      "disease paod": 25336,
      "prior surgery": 65173,
      "surgery discharged": 79382,
      "groups pain": 34257,
      "scores median": 73903,
      "conditions pain": 19323,
      "effects patients": 28084,
      "good excellent": 33313,
      "excellent results": 30443,
      "results confirmed": 71643,
      "confirmed studies": 19510,
      "larger samples": 41184,
      "conclusions perioperative": 19159,
      "perioperative setting": 60852,
      "infusion local": 38711,
      "local anaesthetics": 42202,
      "non surgical": 49691,
      "oxycodone suggested": 55961,
      "control severe": 20419,
      "common types": 17823,
      "error rate": 29512,
      "narcotic prescriptions": 48609,
      "web based": 86810,
      "based dosing": 13310,
      "000 prescriptions": 45,
      "hospital providers": 35622,
      "providers prescribe": 66189,
      "adults ages": 8545,
      "discharge methods": 25139,
      "january 2007": 40424,
      "14 2014": 1559,
      "based patient": 13350,
      "medication drug": 44493,
      "prescriptions based": 64454,
      "stored data": 77399,
      "previously established": 64942,
      "prescriber compared": 64009,
      "patient weight": 58815,
      "range 21": 67270,
      "age 36": 8996,
      "regardless age": 69283,
      "oxycodone 73": 54597,
      "acetaminophen codeine": 7162,
      "containing acetaminophen": 20069,
      "liquid formulations": 42092,
      "formulations prescribed": 32401,
      "age 16": 8973,
      "children 12": 16019,
      "84 received": 5966,
      "received tablet": 68294,
      "tablet formulations": 80095,
      "dispensed dose": 25422,
      "dose patient": 26003,
      "varied 10": 85930,
      "prescribed weight": 64005,
      "30 kg": 3747,
      "kg conclusions": 40706,
      "common handwritten": 17759,
      "handwritten prescriptions": 34567,
      "codeine commonly": 17213,
      "pediatric pain": 60353,
      "pain practice": 57401,
      "independent formulation": 38159,
      "large quantities": 41149,
      "underscores need": 83619,
      "pediatric population": 60359,
      "urgent need": 84043,
      "prescribed medication": 63890,
      "carry systematic": 15145,
      "opiate dependence": 51295,
      "psychiatric symptoms": 66329,
      "methods following": 45341,
      "search strategy": 74128,
      "tramadol fentanyl": 82061,
      "fentanyl remifentanil": 31585,
      "heroin methadone": 35013,
      "results 12": 71543,
      "present symptoms": 64670,
      "suspension opioid": 79768,
      "opioid therapeutic": 52403,
      "preliminary findings": 63713,
      "scarce critical": 73599,
      "opioids prevent": 53222,
      "patient mental": 58680,
      "literature concerning": 42113,
      "studied outcome": 77622,
      "symptoms improved": 79891,
      "practice aims": 63392,
      "aims prescription": 9491,
      "drug misuse": 26712,
      "misuse usa": 46752,
      "1990s 2010": 2228,
      "need new": 48937,
      "medications involved": 44638,
      "user characteristics": 85222,
      "needed address": 48973,
      "epidemic methods": 29134,
      "using real": 85592,
      "profile drug": 65484,
      "misuse using": 46753,
      "results multiple": 71788,
      "multiple sources": 48299,
      "bias results": 13773,
      "results research": 71918,
      "research findings": 71008,
      "remarkably consistent": 70318,
      "consistent multiple": 19702,
      "multiple data": 48268,
      "commonly misused": 17854,
      "misused opioid": 46756,
      "medications hydrocodone": 44626,
      "fentanyl prescription": 31572,
      "prescription form": 64228,
      "oxymorphone tapentadol": 56286,
      "similar number": 75956,
      "decrease 2011": 22882,
      "multiple drugs": 48277,
      "introduction tamper": 39956,
      "conclusions rapid": 19181,
      "rapid expansion": 67381,
      "analgesics objective": 10461,
      "objective review": 50487,
      "studies examining": 77724,
      "opioids characteristics": 52772,
      "review methods": 72325,
      "searched databases": 74146,
      "databases inception": 22200,
      "february 2020": 31312,
      "2020 conducted": 2895,
      "included observational": 37491,
      "pain used": 57960,
      "analgesics opioids": 10465,
      "weak codeine": 86785,
      "development evaluations": 24229,
      "overall quality": 54237,
      "quality results": 66759,
      "results pooled": 71874,
      "meta regression": 44902,
      "regression determined": 69437,
      "use results": 84704,
      "reported data": 70530,
      "data opioid": 22027,
      "use people": 84618,
      "moderate risk": 47162,
      "moderate quality": 47158,
      "evidence people": 30245,
      "opioids 17": 52662,
      "evidence common": 30176,
      "common use": 17824,
      "use strong": 84752,
      "opioids 95": 52689,
      "geographic region": 33111,
      "02 lower": 370,
      "europe north": 29734,
      "conclusions review": 19208,
      "data million": 22010,
      "pain reporting": 57618,
      "reporting opioid": 70697,
      "pain reported": 57617,
      "background severe": 13195,
      "burden patients": 14605,
      "patients leads": 59441,
      "overprescription opioids": 54358,
      "health concerns": 34699,
      "provides novel": 66229,
      "patients time": 60045,
      "opioid intake": 51873,
      "intake reducing": 39185,
      "reducing effects": 69014,
      "effects enhanced": 27911,
      "medication using": 44586,
      "methods arm": 45251,
      "arm randomized": 11673,
      "trial 96": 82999,
      "patients 24": 58844,
      "24 patients": 3258,
      "group scheduled": 33998,
      "scheduled total": 73655,
      "knee replacement": 40869,
      "replacement tkr": 70434,
      "groups postoperative": 34269,
      "interventions treatment": 39685,
      "standardized medication": 76968,
      "physiotherapy postoperative": 61478,
      "pre postoperatively": 63487,
      "difference post": 24666,
      "preoperative pain": 63753,
      "experienced greater": 30605,
      "greater postoperative": 33479,
      "ci 69": 16484,
      "respectively difference": 71185,
      "difference compared": 24603,
      "ci 98": 16516,
      "98 76": 6458,
      "significant opioid": 75589,
      "groups 01": 34088,
      "83 mg": 5932,
      "morphine sulfate": 47936,
      "consumption patients": 19984,
      "satisfied treatment": 73463,
      "09 conclusions": 643,
      "doctor patient": 25656,
      "significantly improve": 75745,
      "improve postoperative": 37079,
      "management trial": 43275,
      "serve important": 74711,
      "acute pancreatitis": 7680,
      "pain acute": 56411,
      "duration magnitude": 27163,
      "african american": 8958,
      "gastrointestinal motility": 32885,
      "testing patient": 80829,
      "patient study": 58789,
      "designed assess": 23826,
      "efficacy systemic": 28398,
      "gel formulation": 32925,
      "inflammation induced": 38549,
      "pl injection": 61596,
      "freund complete": 32593,
      "complete adjuvant": 18438,
      "mechanical hyperalgesia": 44111,
      "pressure thresholds": 64749,
      "just prior": 40568,
      "days later": 22546,
      "later analgesic": 41234,
      "injection 50": 38934,
      "50 \u03bcg": 4912,
      "systemic oxycodone": 80032,
      "exposure assessed": 30751,
      "topical application": 81696,
      "assessed vitro": 12096,
      "vitro using": 86373,
      "cells oxycodone": 15502,
      "alleviate moderate": 9594,
      "internet searches": 39491,
      "objectives estimate": 50558,
      "estimate effect": 29608,
      "design experiments": 23716,
      "experiments conducted": 30681,
      "using different": 85379,
      "video based": 86217,
      "patient symptoms": 58797,
      "patient diagnosed": 58618,
      "chronic knee": 16197,
      "knee osteoarthritis": 40867,
      "half patients": 34526,
      "requested oxycodone": 70791,
      "oxycodone half": 55144,
      "osteoarthritis patients": 53866,
      "patients specifically": 59987,
      "pain subjects": 57880,
      "numbers available": 50279,
      "medications prescribed": 44663,
      "outcomes results": 54091,
      "results 19": 71548,
      "patients requesting": 59901,
      "receive prescription": 68074,
      "request 001": 70782,
      "001 percent": 185,
      "compared 24": 18075,
      "likely receive": 41832,
      "receive strong": 68081,
      "nonselective nonsteroidal": 49843,
      "factors influenced": 31110,
      "prescribing decisions": 64048,
      "purpose research": 66560,
      "non opiate": 49645,
      "understood studies": 83659,
      "studies assess": 77650,
      "study compares": 78016,
      "oral opiate": 53598,
      "opiate pain": 51306,
      "used proxy": 85092,
      "patients instructed": 59416,
      "instructed acetaminophen": 39104,
      "pain moderate": 57204,
      "used oxycodone": 85058,
      "acetaminophen patients": 7235,
      "pain controlled": 56667,
      "compared cohorts": 18109,
      "square tests": 76799,
      "subjects pain": 78720,
      "disorders oxycodone": 25399,
      "subjects diabetes": 78692,
      "differences using": 24830,
      "reference group": 69131,
      "poorly controlled": 62280,
      "pain 18": 56372,
      "07 oxycodone": 608,
      "85 conclusion": 5984,
      "meloxicam oxycodone": 44769,
      "effective controlling": 27609,
      "androgen deficiency": 10894,
      "opioids daily": 52829,
      "daily chronic": 21702,
      "studies long": 77764,
      "greater odds": 33464,
      "equipotent doses": 29273,
      "doses short": 26269,
      "patients large": 59440,
      "large integrated": 41130,
      "integrated health": 39194,
      "care delivery": 15019,
      "delivery study": 23228,
      "men ages": 44798,
      "18 80": 2068,
      "opioid chronic": 51576,
      "serum total": 74706,
      "total testosterone": 81911,
      "testosterone levels": 80851,
      "levels measured": 41575,
      "subjects prescribed": 78724,
      "regression controlling": 69436,
      "age hypertension": 9081,
      "included 159": 37382,
      "234 97": 3130,
      "33 95": 3986,
      "29 16": 3595,
      "33 oxycodone": 3996,
      "ci 87": 16504,
      "increased doses": 37905,
      "doses hydrocodone": 26200,
      "18 10": 2027,
      "mg increase": 45924,
      "increase drug": 37746,
      "ci 00": 16363,
      "02 associated": 362,
      "certain opioids": 15655,
      "studies studies": 77852,
      "pharmacologic agents": 61193,
      "number studies": 50262,
      "studies focusing": 77732,
      "methods obtaining": 45407,
      "evaluating oral": 29947,
      "analgesics opioid": 10463,
      "use current": 84286,
      "current medications": 21444,
      "treat opioid": 82303,
      "limited abuse": 41913,
      "agonists including": 9330,
      "withdrawal clinical": 87120,
      "clinical preclinical": 16870,
      "studies opioid": 77795,
      "dependence strategy": 23489,
      "dependence repeated": 23487,
      "receptor positive": 68519,
      "positive allosteric": 62449,
      "allosteric modulators": 9628,
      "modulators pams": 47266,
      "receptor signaling": 68526,
      "rodent models": 72719,
      "models pain": 47120,
      "naloxone precipitated": 48503,
      "dependent mice": 23521,
      "regimen oxycodone": 69317,
      "challenged naloxone": 15699,
      "displayed withdrawal": 25476,
      "signs included": 75874,
      "induced diarrhea": 38406,
      "jumping behavior": 40534,
      "receptor type": 68531,
      "type receptor": 83353,
      "mice suggesting": 46315,
      "collectively results": 17506,
      "completely blocked": 18516,
      "oxycodone dependent": 54941,
      "suggest cb": 78985,
      "offer novel": 50949,
      "novel strategy": 50021,
      "strategy treat": 77444,
      "significance statement": 75413,
      "statement opioid": 77074,
      "crisis current": 21169,
      "allosteric modulator": 9627,
      "represent viable": 70753,
      "viable strategy": 86189,
      "withdrawal authors": 87119,
      "pain cp": 56670,
      "methyl aspartate": 45641,
      "briefly use": 14436,
      "evaluation study": 29967,
      "ice packs": 36390,
      "standard pain": 76923,
      "design institutional": 23719,
      "board approved": 14182,
      "involved patients": 40109,
      "receive standard": 68079,
      "enhanced recovery": 28973,
      "recovery surgery": 68763,
      "setting academic": 74761,
      "academic tertiary": 6955,
      "care centers": 15007,
      "february 2019": 31311,
      "november 2020": 50040,
      "considered patients": 19643,
      "pain current": 56673,
      "use week": 84808,
      "planned overnight": 61884,
      "excluded primary": 30478,
      "data available": 21884,
      "opioid requirement": 52336,
      "milligram equivalent": 46451,
      "equivalent difference": 29300,
      "groups demographic": 34174,
      "demographic variables": 23292,
      "requirements different": 70879,
      "scores different": 73868,
      "eighty percent": 28458,
      "percent subjects": 60492,
      "subjects reported": 78740,
      "reported feeling": 70545,
      "controlled subjects": 20596,
      "reported did": 70533,
      "eighty seven": 28460,
      "seven percent": 74872,
      "use ice": 84411,
      "prescribed 20": 63806,
      "used discharge": 84920,
      "discharge conclusion": 25113,
      "conclusion ice": 18909,
      "control reduce": 20410,
      "usage compared": 84114,
      "infants born": 38503,
      "neonatal abstinence": 49096,
      "abstinence syndrome": 6620,
      "2000 2012": 2420,
      "brain development": 14336,
      "study presented": 78427,
      "rate opioids": 67493,
      "morphine heroin": 47711,
      "using human": 85432,
      "heroin administered": 34985,
      "administered dose": 8122,
      "highest oxycodone": 35360,
      "46 10": 4617,
      "preferred drug": 63639,
      "drug short": 26792,
      "term pain": 80659,
      "needed understand": 49045,
      "understand potential": 83628,
      "growth opioid": 34380,
      "exposure likely": 30774,
      "fentanyl study": 31596,
      "study demonstrates": 78059,
      "opioids like": 53017,
      "like heroin": 41779,
      "providing clinicians": 66252,
      "clinicians necessary": 17032,
      "necessary information": 48886,
      "pregnancy rising": 63693,
      "rising opioid": 72499,
      "mixture exposure": 46811,
      "exposure individual": 30767,
      "individual opioid": 38302,
      "investigated opioids": 40047,
      "oxycodone highest": 55160,
      "change observed": 15734,
      "potential intact": 63176,
      "intact manipulated": 39171,
      "deterrent extended": 24106,
      "marketed morphine": 43418,
      "sulfate er": 79065,
      "tablets methods": 80174,
      "crossover single": 21295,
      "center study": 15555,
      "morphine er": 47680,
      "received dose": 68140,
      "endpoints assessed": 28909,
      "liking visual": 41873,
      "abuse quotient": 6852,
      "quotient aq": 66927,
      "pharmacokinetic parameter": 61122,
      "associated drug": 12254,
      "max significantly": 43559,
      "er compared": 29408,
      "mean aq": 43710,
      "16 morphine": 1883,
      "er 45": 29393,
      "orally morphine": 53696,
      "er morphine": 29441,
      "morphine product": 47895,
      "lower potential": 42683,
      "misuse chewing": 46716,
      "non ad": 49565,
      "er products": 29467,
      "delivery systems": 23229,
      "systems provide": 80042,
      "provide pain": 66088,
      "relief patients": 70167,
      "patients intolerant": 59420,
      "morphine long": 47745,
      "acting oral": 7419,
      "analgesia convenient": 9941,
      "analgesic doses": 10184,
      "optimal opioid": 53425,
      "dose finding": 25906,
      "enhance pain": 28958,
      "limiting drug": 41972,
      "effects avoiding": 27834,
      "prescription clinical": 64178,
      "practice background": 63393,
      "evaluate current": 29786,
      "practice patterns": 63410,
      "influence patterns": 38598,
      "patterns overall": 60220,
      "thumb carpometacarpal": 81165,
      "osteoarthritis methods": 53863,
      "methods online": 45408,
      "containing 14": 20067,
      "active members": 7516,
      "members american": 44775,
      "ligament reconstruction": 41758,
      "44 26": 4526,
      "years experience": 87589,
      "24 17": 3147,
      "hand surgeons": 34553,
      "prescribe oxycodone": 63801,
      "postoperatively compared": 62995,
      "treatment choice": 82478,
      "choice use": 16125,
      "rise particularly": 72491,
      "particularly younger": 58426,
      "procedures hand": 65305,
      "oxymorphone immediate": 56252,
      "placebo efficacy": 61728,
      "ir placebo": 40257,
      "safety patients": 73199,
      "pain single": 57845,
      "dose phase": 26011,
      "300 patients": 3822,
      "providing pain": 66265,
      "significant analgesic": 75427,
      "occurred 45": 50828,
      "45 min": 4591,
      "min 20": 46507,
      "05 discontinuations": 512,
      "discontinuations lack": 25237,
      "placebo treated": 61844,
      "requiring rescue": 70911,
      "allowed receive": 9639,
      "analgesia 48": 9896,
      "groups opioid": 34248,
      "generally mild": 33022,
      "mg provided": 46184,
      "provided significant": 66154,
      "relief compared": 70115,
      "relief maintained": 70137,
      "days safety": 22614,
      "profile comparable": 65479,
      "comparable oxycodone": 17964,
      "ir background": 40214,
      "mor dor": 47499,
      "reported provide": 70635,
      "pretreatment oxycodone": 64763,
      "oxycodone attenuate": 54735,
      "tight junctions": 81181,
      "groups rats": 34283,
      "pretreated oxycodone": 64760,
      "min intravenous": 46527,
      "24 later": 3240,
      "protocol results": 65995,
      "oxycodone upregulated": 56043,
      "upregulated expression": 84012,
      "oxycodone partly": 55645,
      "appears act": 11398,
      "act opioid": 7368,
      "protective effect": 65920,
      "24 year": 3291,
      "28 hours": 3557,
      "month prior": 47408,
      "prior presentation": 65165,
      "pain refractory": 57502,
      "analgesia ed": 9958,
      "experienced significant": 30626,
      "significant relief": 75627,
      "relief intravenous": 70135,
      "intravenous lidocaine": 39854,
      "lidocaine infusion": 41670,
      "revealed large": 72215,
      "pain limited": 57021,
      "narcotic analgesia": 48587,
      "shown promise": 75347,
      "variety acute": 85949,
      "conditions background": 19312,
      "background currently": 13034,
      "currently limited": 21500,
      "patients noncancer": 59553,
      "noncancer cancer": 49702,
      "hospital setting": 35629,
      "dihydrocodeine fentanyl": 24989,
      "examined number": 30395,
      "opioids annual": 52727,
      "dose individual": 25933,
      "individual level": 38297,
      "prescriptions prescribed": 64545,
      "cancer diagnosis": 14777,
      "oxycodone 38": 54568,
      "noncancer group": 49706,
      "group majority": 33850,
      "doses 50": 26140,
      "opioids 90": 52687,
      "days year": 22656,
      "group 17": 33576,
      "finding study": 31764,
      "41 opioid": 4427,
      "opioids noncancer": 53096,
      "pain 21": 56374,
      "days average": 22489,
      "qt prolongation": 66651,
      "given high": 33170,
      "high prescription": 35150,
      "prescription rate": 64391,
      "rate increasing": 67478,
      "understanding effects": 83633,
      "effects treatment": 28185,
      "investigate clinical": 40001,
      "clinical features": 16816,
      "overdose design": 54286,
      "thirty seven": 81115,
      "overdoses identified": 54329,
      "2001 2011": 2433,
      "use length": 84449,
      "stay los": 77280,
      "extracted clinical": 30948,
      "combination ir": 17562,
      "age 40": 9001,
      "49 years": 4783,
      "dose ir": 25941,
      "oxycodone 70": 54595,
      "mg iqr": 45933,
      "iqr 40": 40175,
      "range 200": 67269,
      "range 30": 67281,
      "sr oxycodone": 76814,
      "oxycodone benzodiazepines": 54747,
      "52 38": 4976,
      "20 17": 2277,
      "34 25": 4017,
      "naloxone infusion": 48456,
      "infusion higher": 38708,
      "higher overall": 35281,
      "oxycodone 33": 54563,
      "median los": 44238,
      "12 35": 1249,
      "15 iqr": 1742,
      "24 period": 3260,
      "iqr 20": 40168,
      "conclusion addition": 18857,
      "depression opioid": 23589,
      "sr formulation": 76811,
      "use naloxone": 84507,
      "longer los": 42379,
      "obtaining opioids": 50789,
      "opioids multiple": 53080,
      "action tapentadol": 7451,
      "abused opioids": 6921,
      "opioids aim": 52718,
      "subjects exposed": 78698,
      "oxycodone recent": 55806,
      "included followed": 37456,
      "year primary": 87490,
      "subjects opioid": 78718,
      "total 112": 81710,
      "oxycodone 42": 54572,
      "subjects oxycodone": 78719,
      "group subjects": 34039,
      "group adjusted": 33663,
      "interval oxycodone": 39600,
      "group 28": 33591,
      "events involved": 30061,
      "tapentadol results": 80468,
      "substantially lower": 78861,
      "oxycodone perspective": 55673,
      "obtaining opioid": 50787,
      "background multimodal": 13084,
      "nociceptive inflammatory": 49544,
      "inflammatory neuropathic": 38576,
      "different classes": 24851,
      "relief using": 70206,
      "combination therapies": 17612,
      "provides effective": 66209,
      "comprehensive pain": 18627,
      "pain scoring": 57800,
      "patients multimodal": 59532,
      "management index": 43190,
      "study consecutive": 78036,
      "patients classified": 59089,
      "classified according": 16686,
      "according presence": 7056,
      "group 72": 33641,
      "mg paracetamol": 46149,
      "paracetamol 325": 58092,
      "weeks patients": 86934,
      "group receiving": 33968,
      "treatment maximum": 82652,
      "2400 mg": 3299,
      "period pain": 60764,
      "limitation patients": 41896,
      "using western": 85675,
      "western ontario": 87003,
      "ontario mcmaster": 51129,
      "mcmaster universities": 43630,
      "universities osteoarthritis": 83849,
      "osteoarthritis index": 53859,
      "index womac": 38213,
      "allodynia hyperalgesia": 9623,
      "vas results": 86018,
      "results group": 71707,
      "group 64": 33635,
      "group 83": 33648,
      "reported improvement": 70568,
      "category pain": 15310,
      "sleep patients": 76230,
      "spontaneous pain": 76759,
      "burning pain": 14619,
      "37 58": 4182,
      "did complete": 24421,
      "complete study": 18453,
      "effective tool": 27711,
      "assessment pain": 12128,
      "symptoms majority": 79893,
      "compliant patients": 18540,
      "pain rescue": 57629,
      "significant improvement": 75550,
      "rel 1017": 69537,
      "opioid inactive": 51842,
      "methadone low": 45090,
      "nmda receptor": 49518,
      "showed rapid": 75291,
      "antidepressant effects": 11167,
      "conducted evaluate": 19358,
      "study utilized": 78565,
      "design assess": 23697,
      "25 mg": 3362,
      "proposed therapeutic": 65800,
      "dose 150": 25792,
      "mg maximum": 46043,
      "maximum tolerated": 43616,
      "tolerated dose": 81629,
      "dose evaluated": 25900,
      "evaluated study": 29924,
      "positive controls": 62458,
      "intravenous ketamine": 39848,
      "ketamine mg": 40611,
      "40 min": 4361,
      "min ketamine": 46529,
      "included oral": 37497,
      "oral dextromethorphan": 53516,
      "endpoint maximum": 28890,
      "vas total": 86030,
      "completed oxycodone": 18479,
      "population studies": 62390,
      "doses ranging": 26260,
      "meaningful statistically": 43919,
      "001 lower": 151,
      "control results": 20414,
      "max scores": 43558,
      "lower vs": 42724,
      "studies indicate": 77753,
      "new medications": 49337,
      "medications opioid": 44653,
      "disorders oud": 25398,
      "studies undertaken": 77871,
      "trained discriminate": 81998,
      "032 mg": 429,
      "saline 10": 73254,
      "ratio fr": 67770,
      "10 schedule": 921,
      "reinforcement results": 69518,
      "agonists fentanyl": 9328,
      "fentanyl pretreatment": 31574,
      "stimulus effects": 77380,
      "kg effective": 40723,
      "effective blocking": 27602,
      "fold lower": 31998,
      "doses did": 26177,
      "did modify": 24463,
      "food maintained": 32237,
      "maintained responding": 42892,
      "dose tested": 26094,
      "decreased response": 23037,
      "response rates": 71366,
      "rates results": 67633,
      "results extend": 71690,
      "effects heroin": 27937,
      "data suggests": 22136,
      "fentanyl opioids": 31539,
      "provide novel": 66080,
      "therapeutic option": 80952,
      "option treatment": 53465,
      "treatment oud": 82719,
      "perioperative management": 60836,
      "chronic therapy": 16349,
      "remains substantial": 70311,
      "problem patients": 65243,
      "effects minimized": 27994,
      "analgesic combinations": 10165,
      "substantial evidence": 78847,
      "evidence supports": 30277,
      "combination analgesics": 17547,
      "doses combined": 26156,
      "patient specific": 58784,
      "specific manner": 76599,
      "additive synergistic": 7920,
      "acetaminophen aspirin": 7155,
      "aspirin ibuprofen": 11869,
      "clinical challenges": 16767,
      "potential therapeutic": 63237,
      "article address": 11760,
      "address safety": 7934,
      "prescription dosage": 64201,
      "dosage forms": 25748,
      "pharmacokinetics including": 61171,
      "opiate opioid": 51304,
      "opioid combinations": 51589,
      "oxycodone propoxyphene": 55779,
      "remains significant": 70310,
      "problem worldwide": 65247,
      "agonist currently": 9283,
      "currently investigation": 21498,
      "novel opioid": 50017,
      "treatment study": 82860,
      "study reports": 78462,
      "safety outcomes": 73183,
      "adults opioid": 8572,
      "maintained oral": 42889,
      "mg qid": 46193,
      "administered session": 8179,
      "decreased 40": 22962,
      "mg heart": 45902,
      "rate blood": 67447,
      "assessed repeatedly": 12049,
      "sinus tachycardia": 76152,
      "reduction 30": 69036,
      "anxiety occurred": 11279,
      "increases heart": 38058,
      "miosis conclusion": 46668,
      "safety results": 73216,
      "results important": 71720,
      "important implications": 37011,
      "implications future": 36963,
      "cord injury": 20767,
      "authors knowledge": 12742,
      "knowledge report": 40894,
      "natural history": 48737,
      "drug overdose": 26731,
      "early intervention": 27257,
      "clinical diagnosis": 16789,
      "altered level": 9698,
      "failure background": 31146,
      "associated considerable": 12237,
      "considerable postoperative": 19613,
      "presence opioid": 64596,
      "patients symptomatic": 60028,
      "fourth degree": 32437,
      "blind prospective": 13964,
      "randomized morphine": 67119,
      "oxycodone vehicle": 56075,
      "time dose": 81254,
      "kappa delta": 40585,
      "delta opioid": 23238,
      "furthermore significant": 32753,
      "significant 001": 75417,
      "analgesic administration": 10146,
      "administration significantly": 8372,
      "increased 001": 37820,
      "increase 001": 37718,
      "001 observed": 166,
      "patient group": 58652,
      "compared mg": 18204,
      "patient groups": 58653,
      "administration low": 8289,
      "receptors located": 68547,
      "mortality studies": 47996,
      "studies comprehensively": 77670,
      "harms opioid": 34596,
      "opioid types": 52456,
      "population wide": 62400,
      "wide indicator": 87042,
      "supply adjusted": 79177,
      "adjusted rates": 8052,
      "setting australia": 74770,
      "primary analyses": 64988,
      "data australian": 21882,
      "australian jurisdictions": 12701,
      "calculated supply": 14705,
      "used multinomial": 85016,
      "multinomial logistic": 48254,
      "regression compare": 69434,
      "compare demographic": 18014,
      "use characteristics": 84232,
      "highest rates": 35367,
      "000 oral": 31,
      "equivalent mg": 29312,
      "000 oxycodone": 34,
      "lowest rates": 42736,
      "rates fentanyl": 67578,
      "associated severe": 12417,
      "accidental overdose": 7017,
      "naloxone administered": 48428,
      "likely involve": 41814,
      "conclusions australia": 19034,
      "australia rates": 12693,
      "rates characteristics": 67560,
      "large changes": 41120,
      "certain opioid": 15654,
      "immune functions": 36767,
      "functions study": 32728,
      "study undertaken": 78552,
      "undertaken determine": 83664,
      "patients rheumatoid": 59927,
      "arthritis ra": 11733,
      "ra methods": 66930,
      "self controlled": 74482,
      "controlled case": 20467,
      "patients ra": 59726,
      "enrolled tennessee": 29025,
      "person comparisons": 60940,
      "periods opioid": 60819,
      "versus non": 86133,
      "use performed": 84619,
      "conditional poisson": 19291,
      "age use": 9132,
      "disease modifying": 25332,
      "proton pump": 66009,
      "pump inhibitors": 66479,
      "additional analyses": 7842,
      "associated new": 12346,
      "use use": 84793,
      "opioid dosages": 51729,
      "account potential": 7076,
      "compared non": 18214,
      "ratio irr": 67775,
      "39 95": 4266,
      "interval 95": 39572,
      "ci 52": 16466,
      "ci 33": 16433,
      "42 respectively": 4475,
      "comparisons patients": 18388,
      "ra opioid": 66931,
      "placebo control": 61671,
      "army medical": 11689,
      "washington dc": 86742,
      "trial comprised": 83013,
      "active duty": 7511,
      "aged 21": 9176,
      "received gabapentin": 68152,
      "gabapentin 300": 32787,
      "days beginning": 22490,
      "beginning days": 13520,
      "surgery current": 79359,
      "levels assessed": 41545,
      "surgery daily": 79360,
      "days repeated": 22606,
      "measures analysis": 44040,
      "anova used": 11047,
      "scores time": 74000,
      "test used": 80789,
      "determine difference": 24001,
      "10 groups": 769,
      "placebo repeated": 61815,
      "measures anova": 44043,
      "pain time": 57918,
      "35 oxycodone": 4089,
      "use gabapentin": 84379,
      "higher placebo": 35298,
      "standardized postoperative": 76982,
      "gabapentin use": 32807,
      "use led": 84448,
      "control compared": 20283,
      "placebo dose": 61723,
      "risk minimization": 72597,
      "especially important": 29558,
      "new drugs": 49321,
      "paper describes": 58077,
      "proper use": 65701,
      "minimizing risk": 46607,
      "potential drugs": 63163,
      "including subgroups": 37677,
      "subgroups population": 78622,
      "medical ethics": 44359,
      "medications treatments": 44693,
      "treatments pain": 82921,
      "anxiety disorders": 11276,
      "risk factor": 72560,
      "factor opioid": 31056,
      "aimed identify": 9455,
      "predictors long": 63588,
      "adults diagnosis": 8563,
      "point care": 62078,
      "care methods": 15043,
      "using quebec": 85584,
      "administrative claims": 8395,
      "study random": 78444,
      "sample adult": 73291,
      "18 yr": 2117,
      "dec 31": 22801,
      "31 2016": 3849,
      "use 90": 84161,
      "120 cumulative": 1398,
      "days 12": 22461,
      "12 mo": 1329,
      "potential predictors": 63209,
      "sociodemographic factors": 76394,
      "prescriber specialty": 64012,
      "used multivariable": 85020,
      "multivariable logistic": 48325,
      "regression assess": 69430,
      "assess association": 11911,
      "use used": 84796,
      "used area": 84848,
      "area receiver": 11637,
      "curve determine": 21526,
      "determine predictive": 24040,
      "predictive performance": 63576,
      "patients initiated": 59411,
      "associated factors": 12258,
      "adjusted analysis": 8018,
      "prescription acetaminophen": 64159,
      "ratio 30": 67726,
      "30 95": 3707,
      "ci 99": 16517,
      "02 95": 356,
      "ci 31": 16430,
      "pain 41": 56386,
      "41 95": 4417,
      "90 morphine": 6108,
      "mme day": 46959,
      "day 24": 22253,
      "predictive model": 63574,
      "interpretation study": 39506,
      "associated long": 12320,
      "limiting doses": 41971,
      "90 mme": 6107,
      "care objective": 15045,
      "frequency severity": 32528,
      "overdose methods": 54301,
      "parameters including": 58163,
      "cardiovascular effects": 14993,
      "unit icu": 83764,
      "database results": 22183,
      "mg median": 46047,
      "age 37": 8999,
      "25 48": 3336,
      "48 years": 4753,
      "patients medications": 59489,
      "16 vs": 1895,
      "systolic bp": 80048,
      "004 patients": 260,
      "patients intubated": 59424,
      "patients developed": 59185,
      "patients 63": 58884,
      "conclusion duloxetine": 18893,
      "care admission": 15002,
      "overdose background": 54270,
      "remains challenging": 70288,
      "clear guidelines": 16704,
      "current status": 21471,
      "status pain": 77263,
      "pharmacological non": 61222,
      "non pharmacological": 49668,
      "pharmacological treatments": 61236,
      "pubmed cochrane": 66443,
      "cochrane database": 17171,
      "database october": 22176,
      "october 31": 50891,
      "2019 included": 2867,
      "hoc analyses": 35495,
      "label studies": 41000,
      "increases pain": 38069,
      "efficacy duloxetine": 28253,
      "label trial": 41007,
      "naloxone pr": 48489,
      "pain protocol": 57439,
      "protocol analysis": 65957,
      "showed reduction": 75293,
      "rotigotine patch": 72828,
      "pain scales": 57661,
      "non significant": 49684,
      "limb pain": 41879,
      "research area": 70979,
      "optimizing pain": 53446,
      "recommendations regarding": 68612,
      "regarding treatment": 69280,
      "weak future": 86786,
      "prospective audit": 65813,
      "ketamine opioid": 40616,
      "opioid anti": 51545,
      "hypothesis study": 36299,
      "control obtained": 20375,
      "18 patients": 2102,
      "agent therapy": 9224,
      "responders non": 71321,
      "non responders": 49677,
      "results according": 71591,
      "clinical criteria": 16778,
      "criteria 12": 21186,
      "rate highest": 67471,
      "uncontrolled pain": 83493,
      "approach safe": 11480,
      "inpatient palliative": 39024,
      "superior results": 79148,
      "compared gold": 18165,
      "gold standard": 33284,
      "approach purpose": 11474,
      "institutional prescribing": 39096,
      "trends hydrocodone": 82967,
      "hydrocodone containing": 36077,
      "evaluated methods": 29897,
      "2014 patients": 2672,
      "prescribed following": 63862,
      "codeine containing": 17219,
      "acetaminophen morphine": 7207,
      "products oxycodone": 65456,
      "acetaminophen tramadol": 7254,
      "month study": 47411,
      "total 38": 81749,
      "prescriptions processed": 64549,
      "overall reduction": 54245,
      "proportional use": 65790,
      "codeine observed": 17263,
      "increase codeine": 37736,
      "accompanied increases": 7025,
      "settings background": 74854,
      "background major": 13081,
      "major effect": 42944,
      "levels pain": 41589,
      "effective convenient": 27611,
      "designed evaluate": 23834,
      "safety oral": 73181,
      "included treatment": 37570,
      "placebo groups": 61756,
      "groups selected": 34313,
      "randomization patients": 67040,
      "groups analgesic": 34132,
      "acetaminophen patient": 7234,
      "orally 30": 53688,
      "5mg kg": 5208,
      "nm laser": 49515,
      "recorded visual": 68711,
      "31 58": 3858,
      "min treatment": 46554,
      "52 compared": 4985,
      "compared 17": 18069,
      "17 12": 1931,
      "score 05": 73705,
      "05 adverse": 493,
      "reported study": 70660,
      "study oral": 78349,
      "ineffective pain": 38490,
      "goal limiting": 33274,
      "age region": 9110,
      "region methods": 69344,
      "methods drug": 45321,
      "female age": 31354,
      "33 reported": 3999,
      "location results": 42225,
      "common substances": 17810,
      "reported heroin": 70555,
      "crack cocaine": 21121,
      "overall number": 54214,
      "heroin buprenorphine": 34989,
      "stimulants cocaine": 77357,
      "cocaine crack": 17146,
      "cocaine methamphetamine": 17154,
      "women significantly": 87247,
      "increased involvement": 37934,
      "lower percentage": 42677,
      "individuals age": 38333,
      "age 60": 9032,
      "18 29": 2042,
      "29 22": 3597,
      "improved treatment": 37138,
      "treatment needed": 82678,
      "needed prevent": 49027,
      "provided unique": 66163,
      "data source": 22108,
      "opioid exposures": 51800,
      "states special": 77150,
      "agents objective": 9231,
      "assess changes": 11914,
      "changes exposures": 15784,
      "exposures prescription": 30809,
      "analgesics heroin": 10428,
      "reported poison": 70625,
      "texas poison": 80880,
      "included opioid": 37494,
      "months months": 47454,
      "specific opioids": 76608,
      "opioids large": 53013,
      "characterized patient": 15913,
      "exposures decreased": 30804,
      "increase age": 37730,
      "age 20": 8982,
      "misuse increased": 46722,
      "patients age": 58963,
      "years reported": 87655,
      "heroin exposures": 34997,
      "limited reports": 41955,
      "hydrocodone followed": 36083,
      "hydrocodone decreased": 36079,
      "diversion conclusion": 25592,
      "conclusion increased": 18915,
      "temporally associated": 80592,
      "pain affects": 56435,
      "optimal treatment": 53436,
      "analgesia relatively": 10090,
      "relatively little": 69778,
      "opioids sought": 53306,
      "sought compare": 76483,
      "matched cohort": 43485,
      "cohort analysis": 17348,
      "used health": 84951,
      "care utilization": 15095,
      "utilization data": 85728,
      "january 1996": 40413,
      "1996 december": 2235,
      "participants medicare": 58326,
      "medicare beneficiaries": 44435,
      "states new": 77123,
      "therapy nonmalignant": 81033,
      "including codeine": 37600,
      "hydrocodone bitartrate": 36066,
      "tramadol hydrochloride": 82068,
      "hydrochloride cancer": 36010,
      "home care": 35508,
      "care main": 15039,
      "measures incidence": 44058,
      "ratios rrs": 67832,
      "rrs 95": 73023,
      "composite end": 18596,
      "opioid groups": 51830,
      "groups groups": 34211,
      "risk cardiovascular": 72538,
      "days start": 22627,
      "62 95": 5333,
      "27 06": 3474,
      "hydrocodone 30": 36046,
      "exposure risk": 30794,
      "risk fracture": 72576,
      "tramadol rr": 82108,
      "rr 21": 72907,
      "16 28": 1854,
      "44 66": 4533,
      "users risk": 85270,
      "risk gastrointestinal": 72577,
      "gastrointestinal safety": 32888,
      "events did": 30040,
      "oxycodone rr": 55859,
      "rr 43": 72927,
      "47 00": 4646,
      "22 45": 3023,
      "events older": 30083,
      "vary significantly": 85990,
      "decade pain": 22805,
      "control research": 20413,
      "review examines": 72302,
      "opioid policies": 52073,
      "examined characteristics": 30372,
      "patients currently": 59165,
      "oxycodone admitted": 54692,
      "inpatient detoxification": 39009,
      "dependence patients": 23484,
      "patients categorized": 59056,
      "categorized according": 15304,
      "use 48": 84157,
      "medical condition": 44350,
      "condition 15": 19275,
      "15 patients": 1783,
      "03 lower": 417,
      "age alcohol": 9053,
      "abuse common": 6662,
      "common patients": 17794,
      "prescribed pain": 63943,
      "states drug": 77095,
      "change hydrocodone": 15730,
      "iii ii": 36585,
      "decrease drug": 22892,
      "research suggests": 71032,
      "prescribing dispensing": 64052,
      "research assessing": 70981,
      "overdoses accidental": 54325,
      "accidental exposures": 7016,
      "analyze changes": 10813,
      "reported california": 70511,
      "methods collected": 45273,
      "2019 conducted": 2860,
      "conducted interrupted": 19367,
      "heroin additional": 34984,
      "exposures resulting": 30810,
      "major health": 42949,
      "health effects": 34709,
      "increased fentanyl": 37914,
      "reduce drug": 68839,
      "drug exposures": 26628,
      "effective strategy": 27704,
      "strategy improve": 77435,
      "improve public": 37084,
      "data intentional": 21995,
      "effects racemic": 28123,
      "present report": 64632,
      "best authors": 13682,
      "single patient": 76134,
      "52 year": 5000,
      "history depression": 35456,
      "close patient": 17068,
      "patient transferred": 58800,
      "airway management": 9505,
      "supportive care": 79231,
      "initiated patient": 38883,
      "12 lead": 1314,
      "lead ecg": 41288,
      "cardiac monitoring": 14981,
      "specific treatment": 76621,
      "duration effects": 27160,
      "interactions drugs": 39393,
      "outpatient pain": 54134,
      "iliac crest": 36614,
      "report use": 70480,
      "use home": 84403,
      "paravertebral nerve": 58183,
      "block catheter": 14040,
      "scores low": 73897,
      "reported high": 70557,
      "high pain": 35131,
      "control satisfaction": 20416,
      "analgesia strategy": 10113,
      "medical recreational": 44398,
      "increasingly important": 38134,
      "adolescent exposure": 8440,
      "vehicle twice": 86047,
      "postnatal day": 62687,
      "day pnd": 22374,
      "intake assessed": 39177,
      "groups following": 34200,
      "intravenous self": 39883,
      "oxycodone adults": 54694,
      "repeated exposure": 70409,
      "despite similar": 23906,
      "similar plasma": 75979,
      "enhanced potency": 28972,
      "rats consumed": 67846,
      "alter oxycodone": 9682,
      "administration sex": 8370,
      "sex increased": 75079,
      "severe burn": 74917,
      "patients undergo": 60083,
      "sedatives analgesics": 74341,
      "demonstrate feasibility": 23315,
      "feasibility efficacy": 31284,
      "morphine derivatives": 47641,
      "short half": 75175,
      "outcome duration": 53915,
      "20 11": 2271,
      "11 38": 1109,
      "statistically different": 77193,
      "17 17": 1936,
      "17 days": 1964,
      "days 32": 22471,
      "showed difference": 75240,
      "phase 18": 61271,
      "analgesia repeated": 10093,
      "patients failed": 59296,
      "demonstrated opioids": 23357,
      "little effect": 42156,
      "approaches used": 11494,
      "opioids differential": 52854,
      "study systematically": 78530,
      "systematically evaluate": 80008,
      "cytotoxicity cell": 21677,
      "obtained healthy": 50769,
      "effects clinically": 27849,
      "relevant concentrations": 70050,
      "oxycodone diamorphine": 54963,
      "diamorphine codeine": 24354,
      "blood flow": 14121,
      "results methadone": 71779,
      "il il": 36610,
      "escherichia coli": 29535,
      "conclusions preliminary": 19168,
      "preliminary studies": 63716,
      "therapeutic opioids": 80951,
      "little direct": 42155,
      "understanding prescription": 83651,
      "lack consistent": 41048,
      "compared conventional": 18126,
      "opioids evaluate": 52893,
      "uk methods": 83410,
      "survey non": 79723,
      "program online": 65537,
      "population national": 62359,
      "national surveys": 48723,
      "surveys analyzed": 79746,
      "45 000": 4562,
      "000 total": 46,
      "compared national": 18212,
      "national prevalence": 48713,
      "prevalence estimates": 64782,
      "population drug": 62329,
      "data included": 21987,
      "included patients": 37506,
      "entering treatment": 29067,
      "exposures results": 30811,
      "opioids similar": 53300,
      "similar patterns": 75977,
      "largest number": 41196,
      "adjusted availability": 8019,
      "abuse occurs": 6791,
      "including tramadol": 37680,
      "absolute number": 6598,
      "opioids availability": 52741,
      "injection rare": 38968,
      "results case": 71617,
      "abusing prescription": 6938,
      "naloxone resulted": 48516,
      "day withdrawal": 22452,
      "withdrawal period": 87141,
      "patient family": 58641,
      "contacted months": 20055,
      "drugs alcohol": 26881,
      "discussion conclusion": 25302,
      "conclusion review": 18983,
      "review literature": 72316,
      "severe cases": 74925,
      "thoracic paravertebral": 81121,
      "anesthesia postoperative": 10934,
      "analgesia thoracic": 10121,
      "report describes": 70454,
      "dural puncture": 27144,
      "puncture headache": 66484,
      "headache following": 34657,
      "following bilateral": 32105,
      "paravertebral blocks": 58182,
      "blocks postoperative": 14098,
      "umbilical hernia": 83441,
      "healthcare providers": 34801,
      "variations drug": 85924,
      "observational setting": 50622,
      "controlled prescription": 20523,
      "medication distribution": 44490,
      "participants drug": 58297,
      "analysed sex": 10578,
      "substances involved": 78832,
      "non controlled": 49591,
      "opioids stimulants": 53312,
      "substances reported": 78837,
      "evaluated drug": 29874,
      "induced deaths": 38404,
      "identified results": 36465,
      "elevated oxycodone": 28561,
      "substances opioids": 78833,
      "opioids accounted": 52698,
      "involving buprenorphine": 40123,
      "methadone tramadol": 45131,
      "prescriptions hydrocodone": 64496,
      "hydrocodone 56": 36052,
      "56 oxycodone": 5104,
      "buprenorphine increased": 14554,
      "58 2012": 5153,
      "fentanyl analogues": 31441,
      "identified conclusions": 36432,
      "conclusions overall": 19141,
      "overall profile": 54236,
      "40 heroin": 4339,
      "oxycodone older": 55559,
      "observed prescription": 50710,
      "deaths involving": 22763,
      "continue increase": 20123,
      "hepatically metabolized": 34961,
      "metabolized opioid": 44998,
      "recent reports": 68418,
      "high oxycodone": 35130,
      "low efficacy": 42485,
      "codeine opioid": 17264,
      "agonist methods": 9289,
      "healthy non": 34832,
      "completed 14": 18461,
      "200 400": 2395,
      "collected self": 17483,
      "administration sessions": 8368,
      "volunteers given": 86420,
      "oxycodone readily": 55804,
      "intermediate levels": 39449,
      "levels drug": 41558,
      "taking drugs": 80303,
      "dependently increased": 23545,
      "placebo magnitude": 61772,
      "mu opioids": 48136,
      "opioids higher": 52949,
      "providing new": 66264,
      "opium poppy": 53401,
      "strategy developed": 77433,
      "pseudomonas putida": 66319,
      "putida m10": 66602,
      "copy number": 20757,
      "important step": 37035,
      "demonstrates potential": 23380,
      "opioids background": 52744,
      "children associated": 16041,
      "modes postoperative": 47223,
      "rectus sheath": 68811,
      "sheath block": 75128,
      "block rsb": 14068,
      "local anaesthetic": 42200,
      "infiltration surgical": 38539,
      "surgical site": 79651,
      "randomized prospective": 67158,
      "compare duration": 18016,
      "duration analgesia": 27152,
      "analgesia based": 9921,
      "based time": 13394,
      "time rescue": 81362,
      "compare quality": 18050,
      "faces scale": 31027,
      "group completed": 33694,
      "study statistically": 78511,
      "perioperative opioid": 60838,
      "09 17": 638,
      "17 mg": 1975,
      "interval 05": 39552,
      "09 mg": 644,
      "kg 008": 40682,
      "compared postoperative": 18275,
      "kg 95": 40687,
      "interval 07": 39554,
      "significance groups": 75406,
      "groups difference": 34183,
      "difference time": 24694,
      "min statistically": 46550,
      "provides superior": 66240,
      "superior analgesia": 79123,
      "comparing postoperative": 18358,
      "undergoing abdominal": 83509,
      "rsb aim": 73028,
      "pain sleep": 57849,
      "cytokine levels": 21669,
      "levels patients": 41592,
      "performed preoperatively": 60613,
      "postoperatively methods": 63006,
      "study prospective": 78431,
      "controlled randomised": 20528,
      "randomised parallel": 67028,
      "surgery randomised": 79546,
      "randomised treatment": 67036,
      "treatment intervention": 82630,
      "anaesthesia adjunct": 9865,
      "preoperative postoperative": 63757,
      "objective trial": 50532,
      "trial evaluate": 83023,
      "32 versus": 3940,
      "group allocation": 33669,
      "pcia oxycodone": 60279,
      "post anaesthesia": 62554,
      "anaesthesia care": 9866,
      "pcia bolus": 60277,
      "bolus injection": 14217,
      "postoperative night": 62808,
      "night patients": 49475,
      "versus postoperative": 86155,
      "postoperative sleep": 62966,
      "tumour necrosis": 83282,
      "surgery 24": 79304,
      "analgesic technique": 10342,
      "answer following": 11050,
      "following questions": 32190,
      "block postoperative": 14054,
      "block duration": 14044,
      "extend analgesic": 30846,
      "analgesic time": 10344,
      "clinical applications": 16756,
      "june 2015": 40547,
      "reports adverse": 70711,
      "drug reactions": 26757,
      "march 2015": 43366,
      "2015 21": 2693,
      "21 cases": 2963,
      "cases 10": 15215,
      "regional pharmacovigilance": 69358,
      "pharmacovigilance center": 61254,
      "opioids combination": 52796,
      "combination avoided": 17548,
      "invasive surgical": 39972,
      "surgical techniques": 79655,
      "patients require": 59902,
      "require opioid": 70808,
      "analgesia significant": 10107,
      "effects toxicity": 28183,
      "using multimodal": 85503,
      "analgesia pregabalin": 10066,
      "methods present": 45477,
      "included 60": 37403,
      "assisted laparoscopic": 12196,
      "laparoscopic radical": 41105,
      "radical prostatectomy": 66957,
      "received multimodal": 68205,
      "pregabalin 150": 63656,
      "acetaminophen 975": 7145,
      "975 mg": 6453,
      "mg celecoxib": 45816,
      "celecoxib 400": 15451,
      "orally hours": 53694,
      "hours start": 35856,
      "compared 30": 18078,
      "received standard": 68281,
      "standard postoperative": 76926,
      "intravenous ketorolac": 39851,
      "ketorolac 15": 40636,
      "intraoperative opioid": 39777,
      "measured mean": 43975,
      "73 mg": 5653,
      "65 mg": 5415,
      "mg 01": 45690,
      "reduced 10": 68899,
      "vs 26": 86554,
      "26 56": 3434,
      "56 mg": 5102,
      "034 mean": 433,
      "vs 75": 86617,
      "operative time": 51269,
      "blood loss": 14128,
      "antiemetic use": 11191,
      "postoperative creatinine": 62730,
      "stay similar": 77295,
      "treatment complications": 82515,
      "occurred group": 50836,
      "review indicated": 72315,
      "analgesic approach": 10155,
      "pregabalin celecoxib": 63662,
      "undergoing robotic": 83573,
      "associated non": 12347,
      "analgesics established": 10420,
      "people using": 60437,
      "opioid injection": 51872,
      "detailed examination": 23915,
      "cohort people": 17369,
      "people regularly": 60423,
      "regularly tamper": 69487,
      "tamper pharmaceutical": 80330,
      "data drawn": 21950,
      "national opioid": 48704,
      "wales nsw": 86694,
      "south australia": 76510,
      "face face": 31015,
      "structured interviews": 77591,
      "data use": 22149,
      "sedative drugs": 74336,
      "drugs illicit": 26974,
      "illicit substances": 36654,
      "greater use": 33499,
      "use injection": 84434,
      "methadone tablets": 45129,
      "engagement opioid": 28935,
      "substitution treatment": 78881,
      "rates pain": 67617,
      "pain based": 56488,
      "opioids regards": 53250,
      "administration compared": 8230,
      "people tamper": 60427,
      "opioids potentially": 53198,
      "differences prescribing": 24793,
      "prescribing regulatory": 64135,
      "regulatory mechanisms": 69506,
      "complaint emergency": 18428,
      "increasing availability": 38095,
      "local anesthetic": 42205,
      "decreased need": 23012,
      "known adverse": 40899,
      "pediatric emergency": 60350,
      "component recovery": 18585,
      "cornerstone postoperative": 20777,
      "effects adverse": 27813,
      "decreasing opioid": 23071,
      "directly impacted": 25062,
      "use single": 84737,
      "intraoperative injection": 39771,
      "release liposomal": 69883,
      "literature objective": 42118,
      "days posterior": 22589,
      "aims evaluate": 9481,
      "day total": 22431,
      "equivalent narcotic": 29319,
      "narcotic usage": 48612,
      "trial 100": 82994,
      "clinic subjects": 16745,
      "years scheduled": 87660,
      "epidural anesthesia": 29174,
      "bupivacaine exparel": 14496,
      "ml placebo": 46891,
      "used injected": 84976,
      "injected immediately": 38917,
      "immediately postoperative": 36749,
      "recorded postoperative": 68692,
      "day pain": 22357,
      "contacted telephone": 20057,
      "overall morphine": 54212,
      "narcotics compared": 48626,
      "2014 august": 2657,
      "study 49": 77895,
      "49 patients": 4779,
      "scores study": 73997,
      "group postoperative": 33922,
      "day study": 22421,
      "placebo median": 61777,
      "range 59": 67294,
      "range 06": 67245,
      "cumulative pain": 21406,
      "scores postoperative": 73956,
      "10 placebo": 900,
      "range 14": 67257,
      "multivariate model": 48349,
      "study placebo": 78409,
      "difference morphine": 24633,
      "range 45": 67289,
      "range 37": 67285,
      "81 conclusion": 5885,
      "pain decrease": 56688,
      "compared saline": 18302,
      "aim determine": 9384,
      "concurrent validity": 19272,
      "maintenance programs": 42919,
      "past month": 58468,
      "14 opioid": 1615,
      "used past": 85067,
      "self report": 74491,
      "respondents completed": 71307,
      "methadone 49": 45043,
      "generic extended": 33047,
      "reported abuse": 70493,
      "oxycontin methadone": 56147,
      "pain debilitating": 56687,
      "cell disease": 15479,
      "remain effective": 70248,
      "vaso occlusive": 86036,
      "common cause": 17737,
      "pseudo addiction": 66316,
      "outpatient clinics": 54117,
      "reviewed analyzed": 72373,
      "narcotic utilization": 48621,
      "patients sickle": 59976,
      "psychological functioning": 66343,
      "reports pain": 70736,
      "function primary": 32672,
      "taking oral": 80317,
      "reported treatment": 70669,
      "oxycodone 35": 54565,
      "methadone 11": 45035,
      "11 morphine": 1137,
      "reactions pain": 67966,
      "001 visual": 220,
      "intensity ratings": 39300,
      "use medication": 84474,
      "pain affective": 56434,
      "response patients": 71358,
      "treated oxycontin": 82368,
      "clear differences": 16701,
      "acting narcotics": 7394,
      "patients managed": 59474,
      "management context": 43172,
      "providers patients": 66188,
      "background nonmedical": 13090,
      "illicit opioid": 36643,
      "opioid increasing": 51844,
      "illicit prescription": 36648,
      "opioids people": 53168,
      "people inject": 60413,
      "inject drugs": 38908,
      "drugs pwid": 27051,
      "data derived": 21940,
      "derived prospective": 23633,
      "cohort studies": 17379,
      "acetaminophen vicodin": 7260,
      "dilaudid hydromorphone": 25005,
      "minutes versus": 46665,
      "availability identified": 12780,
      "multivariable generalized": 48319,
      "estimating equations": 29657,
      "calendar year": 14722,
      "year increase": 87444,
      "05 12": 477,
      "12 morphine": 1340,
      "percocet vicodin": 60539,
      "values 05": 85831,
      "availability prescription": 12785,
      "opioids continued": 52819,
      "continued increase": 20135,
      "years sample": 87659,
      "availability heroin": 12779,
      "combination illicit": 17561,
      "addiction patients": 7753,
      "misusing opioids": 46759,
      "mild severe": 46437,
      "symptoms associated": 79873,
      "risk increasing": 72585,
      "effective agent": 27584,
      "managing opioid": 43291,
      "presentation case": 64677,
      "opioids context": 52817,
      "pain presented": 57418,
      "presented severe": 64697,
      "severe opioid": 74964,
      "prescribe high": 63797,
      "treatment oxycontin": 82731,
      "oxycontin extended": 56139,
      "daily acetaminophen": 21691,
      "codeine 300": 17201,
      "mg 25": 45733,
      "kg ketamine": 40752,
      "ketamine oral": 40617,
      "treatment gradually": 82595,
      "reduced patient": 68969,
      "reduced dosage": 68918,
      "dosage opioid": 25754,
      "symptoms conclusion": 79878,
      "used instead": 84977,
      "potentially addictive": 63249,
      "pharmacological management": 61219,
      "worsened pain": 87333,
      "medical conditions": 44351,
      "conditions patients": 19324,
      "received diagnosis": 68136,
      "self reports": 74504,
      "chronically administered": 16359,
      "administered prescription": 8172,
      "medications study": 44680,
      "sample patients": 73310,
      "patients taken": 60031,
      "patients selected": 59952,
      "medications inpatient": 44636,
      "inpatient setting": 39030,
      "criteria study": 21220,
      "iv diagnosis": 40373,
      "abstinence opioid": 6619,
      "patient census": 58550,
      "2001 2003": 2430,
      "significant findings": 75540,
      "scores improved": 73893,
      "discharge mean": 25136,
      "mean discharge": 43767,
      "discharge pain": 25154,
      "average days": 12888,
      "produced higher": 65388,
      "higher levels": 35256,
      "discharge patients": 25157,
      "medications patients": 44660,
      "patients dsm": 59230,
      "individuals experience": 38345,
      "known effective": 40909,
      "treat condition": 82295,
      "attention given": 12567,
      "given fact": 33168,
      "analgesics frequently": 10425,
      "abused drugs": 6916,
      "drugs misuse": 27001,
      "prominent patients": 65650,
      "designed prevent": 23840,
      "opioids currently": 52828,
      "article review": 11783,
      "review various": 72370,
      "various types": 85984,
      "advances opioid": 8604,
      "help mitigate": 34909,
      "mitigate risk": 46764,
      "legitimate need": 41383,
      "need pain": 48944,
      "good clinical": 33297,
      "review quantitative": 72347,
      "quantitative qualitative": 66804,
      "practice treatment": 63418,
      "treatment response": 82816,
      "diversion prescribed": 25602,
      "prescribed opiates": 63904,
      "methods medline": 45381,
      "google scholar": 33339,
      "relevant abuse": 70042,
      "abuse prescribed": 6835,
      "prescribed opiate": 63903,
      "opiate medication": 51302,
      "medication identified": 44503,
      "relevant articles": 70045,
      "text papers": 80887,
      "papers retrieved": 58087,
      "criteria review": 21217,
      "review results": 72353,
      "included review": 37545,
      "different countries": 24858,
      "countries reported": 20962,
      "treatment responses": 82817,
      "research implications": 71010,
      "need prescribe": 48949,
      "prescribe opioids": 63800,
      "dispensing prescription": 25454,
      "medication abuse": 44451,
      "abuse limited": 6764,
      "abuse individual": 6739,
      "change according": 15719,
      "economic costs": 27310,
      "rapidly growing": 67402,
      "problem united": 65244,
      "states methods": 77119,
      "economic burden": 27308,
      "burden nonmedical": 14601,
      "medical complications": 44349,
      "criminal justice": 21165,
      "drug level": 26675,
      "estimated total": 29640,
      "total cost": 81791,
      "53 billion": 5019,
      "drugs oxycontin": 27027,
      "hydrocodone propoxyphene": 36131,
      "propoxyphene methadone": 65804,
      "accounted thirds": 7081,
      "billion annually": 13802,
      "annually lost": 11034,
      "vast majority": 86040,
      "spatial distribution": 76541,
      "distribution opioid": 25561,
      "health interventions": 34722,
      "interventions methods": 39665,
      "using patient": 85549,
      "treatment facilities": 82584,
      "new mexico": 49340,
      "asi mv": 11828,
      "opioid volume": 52632,
      "identified clusters": 36429,
      "geographic differences": 33109,
      "collected patients": 17472,
      "according opioid": 7052,
      "indicating abuse": 38258,
      "interviewed patients": 39690,
      "001 relative": 197,
      "relative risk": 69763,
      "partly responsible": 58431,
      "rr 001": 72884,
      "significant challenges": 75436,
      "overdose fatalities": 54292,
      "health emergency": 34710,
      "measure abuse": 43934,
      "opioids reduce": 53246,
      "data determine": 21943,
      "efficacy reported": 28349,
      "nktr 181": 49511,
      "potential novel": 63195,
      "novel abuse": 49999,
      "deterrent opioids": 24123,
      "relieve pain": 70217,
      "subject abuse": 78624,
      "decrease abuse": 22883,
      "affecting patient": 8928,
      "patient access": 58531,
      "reviewed using": 72393,
      "reviewed journals": 72383,
      "web sites": 86816,
      "use profiles": 84671,
      "profiles results": 65519,
      "results reviewed": 71928,
      "deterrent characteristics": 24104,
      "physical barrier": 61380,
      "include new": 37359,
      "promote safe": 65664,
      "educational initiatives": 27401,
      "conclusions outcomes": 19140,
      "indicate adf": 38218,
      "effective use": 27722,
      "world war": 87318,
      "war ii": 86707,
      "oxycontin addiction": 56115,
      "treatment mmt": 82659,
      "primary treatment": 65118,
      "use canada": 84228,
      "treatment data": 82536,
      "data scarce": 22100,
      "users repeatedly": 85268,
      "patterns cohort": 60198,
      "cohort participants": 17366,
      "regression significant": 69458,
      "significant baseline": 75433,
      "drug heroin": 26642,
      "use housing": 84405,
      "lower prevalence": 42688,
      "prevalence levels": 64789,
      "levels opioid": 41584,
      "lower frequency": 42621,
      "use days": 84290,
      "days observed": 22560,
      "study highlights": 78228,
      "highlights potential": 35384,
      "potential factors": 63165,
      "reductions drug": 69110,
      "use related": 84686,
      "report 38": 70442,
      "scientific literature": 73688,
      "decades study": 22811,
      "study seeks": 78477,
      "subsequent discussions": 78777,
      "2019 using": 2886,
      "using quantitative": 85582,
      "analysis determine": 10672,
      "associated prescribing": 12387,
      "prescribing guidance": 64059,
      "changed time": 15766,
      "results using": 72049,
      "using time": 85640,
      "analysis identified": 10695,
      "opioids second": 53287,
      "series used": 74666,
      "analgesics recognized": 10487,
      "effects evaluated": 27915,
      "2019 focused": 2866,
      "article conclusion": 11764,
      "conclusion changes": 18867,
      "impacted clinical": 36858,
      "researchers clinicians": 71045,
      "guidelines objective": 34449,
      "social economic": 76353,
      "authors evaluated": 12728,
      "evaluated primary": 29914,
      "prospective evaluation": 65833,
      "following implementation": 32141,
      "guidelines evidence": 34438,
      "special attention": 76557,
      "prescriptions quantity": 64552,
      "oxycontin morphine": 56153,
      "equivalent daily": 29293,
      "results statistically": 71963,
      "decrease average": 22888,
      "number schedule": 50252,
      "pills prescribed": 61533,
      "state regulations": 77067,
      "based guidelines": 13325,
      "guidelines primary": 34464,
      "practice decrease": 63395,
      "preventive measures": 64890,
      "opioids reducing": 53248,
      "use overdose": 84579,
      "access prescription": 7000,
      "opioids indicated": 52995,
      "associated prolonged": 12395,
      "shown opioids": 75343,
      "potassium channels": 63064,
      "study oxycodone": 78353,
      "doses associated": 26150,
      "methods chronic": 45269,
      "treated methadone": 82347,
      "recruited cross": 68791,
      "activity presence": 7581,
      "cells expressing": 15497,
      "age treatment": 9128,
      "mg higher": 45904,
      "revealed low": 72217,
      "potassium current": 63065,
      "oxycodone capable": 54766,
      "prescription analgesic": 64165,
      "states 2006": 77078,
      "effects current": 27882,
      "effects relative": 28136,
      "potency oxymorphone": 63083,
      "identical doses": 36407,
      "oxymorphone 10": 56218,
      "oxymorphone produced": 56282,
      "produced approximately": 65374,
      "magnitude effects": 42812,
      "measures respiratory": 44096,
      "effects 40": 27797,
      "mg oxymorphone": 46146,
      "related subjective": 69684,
      "greater effects": 33443,
      "liability similar": 41652,
      "similar oxycodone": 75966,
      "published clinical": 66426,
      "clinical equianalgesic": 16810,
      "consistent observed": 19704,
      "measures assessed": 44047,
      "human laboratory": 35958,
      "laboratory objective": 41029,
      "safety tapentadol": 73228,
      "cr management": 21065,
      "related cancer": 69566,
      "korean patients": 40951,
      "er 25": 29388,
      "mg bid": 45804,
      "hcl cr": 34634,
      "weeks double": 86906,
      "blind treatment": 13989,
      "treatment clinicaltrials": 82496,
      "inferiority efficacy": 38530,
      "cr based": 21054,
      "mean change": 43731,
      "change average": 15721,
      "intensity 11": 39218,
      "events teaes": 30128,
      "recorded study": 68700,
      "patients screened": 59948,
      "difference change": 24599,
      "change pain": 15738,
      "intensity baseline": 39233,
      "study treatment": 78547,
      "upper limit": 84007,
      "limit 95": 41884,
      "er provided": 29468,
      "provided analgesic": 66122,
      "non inferior": 49608,
      "inferior oxycodone": 38526,
      "patients reporting": 59895,
      "similar tapentadol": 75996,
      "168 oxycodone": 1921,
      "gastrointestinal teaes": 32892,
      "group 55": 33626,
      "cr group": 21063,
      "group 67": 33637,
      "bid provides": 13789,
      "provided oxycodone": 66143,
      "pain tolerated": 57925,
      "tolerated overall": 81634,
      "better gastrointestinal": 13713,
      "gastrointestinal tolerability": 32893,
      "cr opioid": 21073,
      "led epidemic": 41337,
      "review suggests": 72362,
      "epidemic requires": 29152,
      "lived experience": 42170,
      "review evaluates": 72296,
      "rates chronic": 67561,
      "post surgery": 62619,
      "analysis essential": 10679,
      "essential understand": 29577,
      "abuse present": 6840,
      "present opioid": 64624,
      "shows patient": 75362,
      "main goal": 42832,
      "involvement central": 40116,
      "et mechanisms": 29670,
      "mechanisms morphine": 44145,
      "investigated interaction": 40043,
      "micro opioid": 46338,
      "agonist u50": 9310,
      "u50 488h": 83401,
      "oxycodone micro": 55447,
      "micro kappa": 46337,
      "antinociception tolerance": 11233,
      "produce analgesia": 65357,
      "change body": 15728,
      "significantly enhanced": 75697,
      "enhanced antinociception": 28968,
      "antinociception response": 11232,
      "55 38": 5066,
      "38 oxycodone": 4242,
      "61 72": 5308,
      "effect mice": 27487,
      "mice tolerant": 46317,
      "oxycodone tolerant": 56003,
      "tolerant mice": 81610,
      "37 48": 4180,
      "48 43": 4686,
      "treated vehicle": 82382,
      "naloxone completely": 48440,
      "oxycodone potentiation": 55722,
      "delta kappa": 23233,
      "kappa selective": 40599,
      "selective non": 74435,
      "antagonists useful": 11092,
      "abuse particularly": 6803,
      "hydrocodone increased": 36099,
      "increased past": 37976,
      "states highest": 77107,
      "year 2000": 87423,
      "year 2005": 87424,
      "regional poison": 69360,
      "years 2000": 87527,
      "2002 2003": 2437,
      "significant positive": 75597,
      "higher rate": 35314,
      "correlation noted": 20830,
      "rate decreased": 67456,
      "indicated management": 38236,
      "pain purpose": 57447,
      "utility analysis": 85720,
      "morphine 037": 47529,
      "expected number": 30554,
      "despite conservative": 23873,
      "year qaly": 87492,
      "led increased": 41340,
      "increased cost": 37897,
      "head head": 34645,
      "trade offs": 81979,
      "provide consistent": 66046,
      "use individual": 84431,
      "background pharmaceutical": 13158,
      "overdose rates": 54313,
      "increased recent": 38004,
      "rates 1000": 67545,
      "heroin oxycodone": 35023,
      "oxycodone injection": 55283,
      "clinical severity": 16901,
      "sydney medically": 79846,
      "medically supervised": 44428,
      "supervised injecting": 79156,
      "injecting centre": 38923,
      "centre msic": 15632,
      "using glasgow": 85413,
      "overdoses occurred": 54331,
      "occurred times": 50848,
      "overdoses higher": 54328,
      "48 differences": 4701,
      "overdose associated": 54269,
      "consciousness need": 19553,
      "greater rate": 33484,
      "opioids management": 53036,
      "methods january": 45368,
      "20 min": 2355,
      "opioids nonsteroidal": 53099,
      "point ordinal": 62099,
      "study overall": 78352,
      "overall response": 54247,
      "rate 48": 67435,
      "71 respectively": 5600,
      "respectively reported": 71241,
      "tylenol codeine": 83316,
      "95 64": 6209,
      "64 respectively": 5393,
      "morphine ms": 47784,
      "24 respectively": 3273,
      "33 respectively": 4000,
      "36 13": 4115,
      "13 respectively": 1505,
      "fentanyl patch": 31560,
      "respectively methadone": 71211,
      "respectively male": 71207,
      "greater degree": 33440,
      "alpha 05": 9662,
      "differences detected": 24733,
      "years practice": 87639,
      "practice number": 63404,
      "positive relationship": 62485,
      "correlation coefficient": 20826,
      "significance pain": 75409,
      "management practice": 43244,
      "higher confidence": 35220,
      "need increase": 48932,
      "level opioids": 41508,
      "opioids general": 52928,
      "adequately manage": 7978,
      "analgesia reduce": 10081,
      "methods eighty": 45326,
      "eighty patients": 28454,
      "divided group": 25619,
      "block oxycodone": 14050,
      "group primary": 33935,
      "score coughing": 73738,
      "consumption recorded": 20005,
      "complications opioid": 18566,
      "analgesia satisfaction": 10102,
      "results nrs": 71795,
      "vs group": 86645,
      "vs 05": 86516,
      "05 24": 482,
      "group reduced": 33970,
      "reduced compared": 68914,
      "10 19": 679,
      "11 18": 1099,
      "18 vs": 2107,
      "additional analgesia": 7839,
      "05 analgesic": 495,
      "analgesic satisfaction": 10334,
      "001 group": 141,
      "pcia provided": 60280,
      "satisfactory postoperative": 73453,
      "analgesia reduced": 10084,
      "patients following": 59315,
      "22 12": 3009,
      "12 2019": 1228,
      "agonists objectives": 9337,
      "potentiate opioid": 63274,
      "analgesia humans": 9991,
      "using laboratory": 85453,
      "models methods": 47117,
      "completed subject": 18500,
      "randomized outpatient": 67137,
      "study sessions": 78483,
      "sessions completed": 74738,
      "total test": 81909,
      "test conditions": 80758,
      "sensory threshold": 74579,
      "participant observer": 58257,
      "produced miosis": 65396,
      "analgesic responses": 10333,
      "pressure tolerance": 64750,
      "oxycodone subjective": 55950,
      "05 placebo": 541,
      "placebo mg": 61780,
      "study indicates": 78259,
      "did enhance": 24447,
      "impairment related": 36906,
      "effects data": 27885,
      "appropriate opioid": 11504,
      "opioid adjuvant": 51404,
      "treatment buprenorphine": 82462,
      "buprenorphine considered": 14535,
      "considered safe": 19649,
      "oud treatment": 53899,
      "prescriptions increase": 64500,
      "misused abused": 46755,
      "use buprenorphine": 84226,
      "prescription use": 64417,
      "diverted medication": 25610,
      "analgesic opioid": 10279,
      "directly compare": 25060,
      "using buprenorphine": 85333,
      "potential objective": 63196,
      "products including": 65448,
      "including buprenorphine": 37597,
      "methods web": 45631,
      "2012 2016": 2592,
      "using web": 85673,
      "internet monitoring": 39490,
      "categories use": 15299,
      "avoid withdrawal": 12965,
      "high use": 35188,
      "results posts": 71880,
      "selected posts": 74399,
      "posts revealed": 63046,
      "posts mentioning": 63045,
      "likely oxycodone": 41823,
      "management 001": 43139,
      "buprenorphine related": 14584,
      "related posts": 69668,
      "posts discussed": 63044,
      "despite differences": 23876,
      "differences overall": 24772,
      "overall pattern": 54229,
      "conclusions analysis": 19031,
      "based discussion": 13307,
      "post online": 62586,
      "online drug": 51099,
      "patterns associated": 60196,
      "findings presented": 31809,
      "actual use": 7602,
      "management oxycodone": 43227,
      "findings consistent": 31775,
      "medication assisted": 44460,
      "associated harms": 12271,
      "clinical records": 16882,
      "unique opportunity": 83756,
      "aims compare": 9477,
      "rates pharmaceutical": 67621,
      "naloxone morphine": 48464,
      "pethidine tramadol": 60989,
      "tapentadol compare": 80390,
      "context surrounding": 20113,
      "australian market": 12702,
      "fewer studies": 31668,
      "data clinical": 21902,
      "data form": 21974,
      "form basis": 32276,
      "large national": 41137,
      "national database": 48679,
      "alcohol related": 9537,
      "rates presentations": 67626,
      "different pharmaceutical": 24909,
      "related cases": 69567,
      "eastern health": 27288,
      "analysis findings": 10687,
      "submitted peer": 78765,
      "peer review": 60368,
      "understanding risk": 83652,
      "findings national": 31797,
      "national dataset": 48681,
      "opioids year": 53396,
      "pain sufficiently": 57885,
      "utilisation study": 85715,
      "available analysis": 12790,
      "prescription different": 64198,
      "oxycodone hci": 55146,
      "data ims": 21984,
      "costs opioids": 20901,
      "opioids differed": 52851,
      "followed oxycodone": 32078,
      "treatment fentanyl": 82586,
      "differences period": 24782,
      "treated long": 82346,
      "previous data": 64900,
      "suggest tapentadol": 79017,
      "action relatively": 7448,
      "abuse different": 6708,
      "opioids help": 52942,
      "considering potential": 19667,
      "potential risks": 63222,
      "risks benefits": 72672,
      "results urine": 72045,
      "provide unique": 66108,
      "answer question": 11052,
      "investigate different": 40003,
      "different rates": 24915,
      "urine specimens": 84088,
      "specimens collected": 76639,
      "opioids reviewed": 53279,
      "study tapentadol": 78533,
      "oxymorphone tramadol": 56289,
      "tramadol drug": 82057,
      "drug dispensing": 26590,
      "data including": 21989,
      "mme dispensed": 46961,
      "162 patients": 1913,
      "patients examined": 59267,
      "tapentadol common": 80389,
      "udt results": 83404,
      "results cohort": 71628,
      "specimens positive": 76644,
      "ranged 12": 67341,
      "12 percent": 1352,
      "percent tapentadol": 60494,
      "resulted change": 71500,
      "abuse conclusions": 6665,
      "conclusions sample": 19211,
      "factors potentially": 31122,
      "consistent previous": 19712,
      "ongoing line": 51084,
      "treatment management": 82650,
      "severe central": 74926,
      "obstructive sleep": 50749,
      "sleep apnea": 76212,
      "objectives determine": 50554,
      "central sleep": 15616,
      "apnea patients": 11367,
      "16 patients": 1888,
      "continuous positive": 20182,
      "apnea hypopnea": 11365,
      "hypopnea index": 36285,
      "11 final": 1130,
      "oxyhemoglobin saturation": 56215,
      "seventeen patients": 74883,
      "minimum months": 46614,
      "hours conclusions": 35760,
      "conclusions chronic": 19042,
      "patients remain": 59878,
      "term studies": 80669,
      "improves quality": 37188,
      "use oral": 84575,
      "sources pubmed": 76507,
      "medline search": 44752,
      "search 1966": 74105,
      "oxymorphone oxymorphone": 56276,
      "provided data": 66128,
      "selection data": 74415,
      "oxymorphone pain": 56277,
      "management considered": 43171,
      "non english": 49596,
      "data excluded": 21964,
      "excluded data": 30476,
      "data synthesis": 22141,
      "unlike opioids": 83895,
      "liver metabolism": 42181,
      "metabolism oral": 44935,
      "severe hepatic": 74948,
      "hepatic impairment": 34953,
      "cyp3a4 2c9": 21634,
      "mediated drug": 44308,
      "40 increase": 4340,
      "increase plasma": 37783,
      "patients 57": 58879,
      "rate absorption": 67441,
      "primary adverse": 64984,
      "constipation conclusions": 19757,
      "approved treatment": 11549,
      "pain oxymorphone": 57315,
      "efficacy profile": 28334,
      "pure opioids": 66506,
      "morphine studies": 47933,
      "comparative efficacy": 17981,
      "opioids necessary": 53085,
      "geographic demographic": 33108,
      "demographic factors": 23284,
      "drugs buprenorphine": 26899,
      "using researched": 85595,
      "surveillance poison": 79682,
      "public healthcare": 66403,
      "annual incidence": 11018,
      "total prescription": 81895,
      "year state": 87502,
      "population density": 62326,
      "high school": 35179,
      "positive trends": 62500,
      "rate prescription": 67504,
      "rate increased": 67477,
      "study strongly": 78514,
      "influenced hydrocodone": 38604,
      "rates high": 67584,
      "understanding trends": 83654,
      "resources prevention": 71130,
      "prevention efforts": 64872,
      "objective trends": 50530,
      "codeine dextropropoxyphene": 17222,
      "2000 2008": 2416,
      "explanations changes": 30704,
      "changes consumption": 15781,
      "data 2000": 21848,
      "2008 period": 2511,
      "administration data": 8241,
      "data converted": 21927,
      "day results": 22406,
      "consumption strong": 20023,
      "requiring special": 70913,
      "increased 47": 37859,
      "consumption 32": 19881,
      "2008 oxycodone": 2508,
      "levels increased": 41569,
      "consumption rose": 20013,
      "pethidine codeine": 60984,
      "changes pattern": 15811,
      "characterized increased": 15912,
      "genetic variants": 33084,
      "known affect": 40900,
      "pharmacokinetics efficacy": 61168,
      "substrates inhibitors": 78890,
      "currently reported": 21507,
      "control cells": 20280,
      "observed substantial": 50721,
      "substantial differences": 78845,
      "inhibitory potency": 38825,
      "safer use": 73115,
      "use individuals": 84432,
      "impairment memory": 36899,
      "prior drug": 65143,
      "drug administered": 26519,
      "reported following": 70546,
      "memory tasks": 44792,
      "administered 10": 8094,
      "placebo separate": 61823,
      "separate test": 74589,
      "following opioids": 32166,
      "range measures": 67323,
      "measures showed": 44098,
      "showed drug": 75243,
      "standard doses": 76902,
      "outpatient basis": 54116,
      "objective previous": 50471,
      "previous literature": 64904,
      "literature suggests": 42137,
      "opioids early": 52871,
      "early 1990s": 27249,
      "increased morbidity": 37949,
      "analyze trends": 10818,
      "use medical": 84473,
      "classes opioid": 16670,
      "analysis drug": 10675,
      "network dawn": 49159,
      "results analysis": 71601,
      "opioids remained": 53261,
      "drug mentions": 26702,
      "use selected": 84722,
      "selected opioid": 74395,
      "opioid classes": 51581,
      "morphine 48": 47562,
      "48 oxycodone": 4737,
      "conclusion using": 19018,
      "method analysis": 45169,
      "rates drug": 67574,
      "use substances": 84763,
      "drug safety": 26780,
      "safety studies": 73222,
      "studies regarding": 77824,
      "regarding comparative": 69244,
      "opioid compounds": 51594,
      "compounds important": 18612,
      "balance pain": 13232,
      "management ongoing": 43218,
      "ongoing opioid": 51085,
      "use nmu": 84513,
      "world data": 87305,
      "addiction severity": 7770,
      "severity index": 75040,
      "index multimedia": 38197,
      "multimedia version": 48194,
      "version asi": 86087,
      "comparator opioid": 17995,
      "adults assessed": 8546,
      "assessed substance": 12067,
      "using asi": 85309,
      "2010 2018": 2546,
      "2018 population": 2837,
      "drug utilization": 26858,
      "studied patient": 77624,
      "diversion results": 25606,
      "results past": 71836,
      "nmu prescription": 49524,
      "opioid reported": 52334,
      "43 tramadol": 4509,
      "group prevalence": 33934,
      "prevalence past": 64799,
      "lower morphine": 42648,
      "times lower": 81430,
      "opioids injection": 53003,
      "14 34": 1568,
      "34 times": 4036,
      "tramadol likely": 82077,
      "obtained patient": 50773,
      "dealers family": 22687,
      "conclusion tramadol": 19014,
      "opioids likely": 53019,
      "likely diverted": 41806,
      "risk non": 72605,
      "enforcement agency": 28928,
      "low potential": 42538,
      "communication drug": 17909,
      "illegal prescription": 36626,
      "strengths limitations": 77479,
      "implementing similar": 36955,
      "programs methods": 65557,
      "max 71": 43544,
      "examined drugs": 30376,
      "drugs classified": 26908,
      "administration schedule": 8367,
      "stimulants sedatives": 77359,
      "second half": 74185,
      "completed results": 18493,
      "substances drugs": 78829,
      "single drug": 76098,
      "involved illicit": 40098,
      "involved non": 40102,
      "drugs gabapentin": 26964,
      "half 51": 34512,
      "decreased 51": 22967,
      "increased 89": 37866,
      "illegal drugs": 36624,
      "opioids illicit": 52963,
      "especially alprazolam": 29551,
      "source information": 76495,
      "misuse addiction": 46712,
      "addiction objective": 7749,
      "objective identify": 50436,
      "different pharmacological": 24911,
      "pharmacological strategies": 61230,
      "pharmacological approaches": 61210,
      "gabapentin compared": 32791,
      "control condition": 20285,
      "dummy subject": 27135,
      "subject crossover": 78625,
      "subjects participants": 78721,
      "stable doses": 76841,
      "doses methadone": 26214,
      "recruited setting": 68798,
      "setting outpatient": 74794,
      "outpatient opioid": 54126,
      "inner city": 39003,
      "sydney australia": 79845,
      "ratings subjective": 67709,
      "physiological cognitive": 61459,
      "difference primary": 24670,
      "interindividual variability": 39441,
      "differences subjective": 24822,
      "identified including": 36439,
      "including lower": 37630,
      "satisfaction additional": 73385,
      "effects detected": 27889,
      "administration increased": 8275,
      "gabapentin conclusions": 32792,
      "conclusions evidence": 19081,
      "evidence objective": 30229,
      "improvement analgesia": 37143,
      "condition compared": 19278,
      "research required": 71026,
      "required optimize": 70851,
      "unmet needs": 83909,
      "involving oral": 40132,
      "current standard": 21468,
      "epidural injection": 29186,
      "period postoperatively": 60775,
      "indwelling epidural": 38486,
      "epidural catheters": 29178,
      "er endo": 29414,
      "ii trials": 36576,
      "review discusses": 72286,
      "agents administered": 9226,
      "drugs studies": 27081,
      "morphine morphine": 47779,
      "morphine remains": 47913,
      "properties opioid": 65717,
      "different morphine": 24890,
      "morphine preclinical": 47882,
      "preclinical models": 63532,
      "models human": 47114,
      "concerning effects": 18839,
      "effects fentanyl": 27925,
      "different methods": 24888,
      "large range": 41151,
      "range opioid": 67326,
      "participants available": 58283,
      "common effect": 17751,
      "decade seen": 22806,
      "rise number": 72488,
      "number infants": 50163,
      "infants exposed": 38506,
      "opioids utero": 53382,
      "provide insight": 66075,
      "insight potential": 39052,
      "potential areas": 63135,
      "present review": 64638,
      "review summarizes": 72364,
      "findings animal": 31769,
      "exposure morphine": 30779,
      "duration treatment": 27188,
      "treatment key": 82634,
      "finally significant": 31756,
      "significant gaps": 75541,
      "gaps current": 32834,
      "future directions": 32761,
      "discussed studies": 25295,
      "use examine": 84360,
      "examine relationship": 30358,
      "misusing prescription": 46760,
      "oxycontin percocet": 56170,
      "using stage": 85622,
      "opioids positive": 53186,
      "estimates suggest": 29654,
      "epidemic proportions": 29149,
      "world recent": 87314,
      "analogs commonly": 10547,
      "commonly observed": 17855,
      "furanyl fentanyl": 32743,
      "postmortem casework": 62675,
      "contributes opioid": 20237,
      "induced fatalities": 38410,
      "case study": 15209,
      "man dead": 43111,
      "san francisco": 73375,
      "toxicology screening": 81956,
      "detect oxycodone": 23930,
      "blood positive": 14142,
      "showed presence": 75290,
      "samples revealed": 73361,
      "anilino phenethyl": 10987,
      "phenethyl piperidine": 61341,
      "piperidine anpp": 61561,
      "analytes detected": 10798,
      "detected urine": 23950,
      "urine vitreous": 84094,
      "detected case": 23937,
      "fentanyl overdose": 31545,
      "unknown drug": 83878,
      "drug entities": 26621,
      "toxicological analysis": 81940,
      "analysis provides": 10748,
      "fentanyl metabolite": 31521,
      "monitoring programs": 47341,
      "abuse monitoring": 6783,
      "hydromorphone methadone": 36186,
      "oxycodone considered": 54847,
      "case coded": 15165,
      "abuse intentional": 6740,
      "intentional misuse": 39347,
      "comparative data": 17979,
      "hydrocodone 75": 36054,
      "75 100": 5693,
      "dawn emergency": 22233,
      "ed data": 27329,
      "people aged": 60399,
      "18 25": 2039,
      "35 44": 4064,
      "year olds": 87474,
      "misuse opioids": 46733,
      "20 69": 2302,
      "conclusions comparing": 19053,
      "data dawn": 21936,
      "yielded comparable": 87697,
      "comparable results": 17970,
      "including hydrocodone": 37623,
      "hydrocodone commonly": 36072,
      "drug results": 26778,
      "timely geographically": 81408,
      "abuse effects": 6718,
      "postmortem opioid": 62680,
      "parent metabolite": 58198,
      "blood concentration": 14114,
      "concentration ratios": 18716,
      "ratios determined": 67820,
      "determined fentanyl": 24065,
      "related accidental": 69545,
      "opioids partially": 53150,
      "metabolized cyp3a4": 44993,
      "cyp3a4 enzyme": 21636,
      "diazepam alprazolam": 24369,
      "opioid metabolite": 51929,
      "follows fentanyl": 32228,
      "hydrocodone dihydrocodeine": 36081,
      "dihydrocodeine methadone": 24992,
      "methadone eddp": 45064,
      "parent opioid": 58199,
      "concentrations analyzed": 18745,
      "deaths excluding": 22751,
      "present known": 64621,
      "decreased median": 23009,
      "48 01": 4682,
      "concentration ratio": 18715,
      "ratio reduced": 67795,
      "reduced 35": 68901,
      "did statistically": 24510,
      "affect fentanyl": 8901,
      "factors affecting": 31068,
      "affecting opioid": 8926,
      "effects specific": 28165,
      "purpose prescription": 66545,
      "burden disease": 14600,
      "including mortality": 37643,
      "consumption key": 19943,
      "potential correlations": 63154,
      "correlations levels": 20840,
      "levels consumption": 41551,
      "british columbia": 14443,
      "columbia bc": 17529,
      "annual population": 11030,
      "population standardized": 62388,
      "annual defined": 11014,
      "doses 1000": 26122,
      "1000 population": 1042,
      "population day": 62324,
      "drugs dispensed": 26941,
      "based representative": 13374,
      "retail pharmacy": 72071,
      "pharmacy sales": 61265,
      "sales data": 73248,
      "2005 2009": 2460,
      "2009 results": 2531,
      "consistently higher": 19723,
      "higher use": 35335,
      "strong correlations": 77515,
      "mortality levels": 47986,
      "drugs hydromorphone": 26973,
      "reflect similar": 69189,
      "high increasing": 35111,
      "efforts reduce": 28442,
      "single level": 76116,
      "association reoperations": 12489,
      "reoperations years": 70376,
      "summary background": 79096,
      "data preoperative": 22056,
      "spine surgery": 76729,
      "surgery linked": 79443,
      "linked worse": 42057,
      "worse postoperative": 87330,
      "postoperative outcomes": 62834,
      "outcomes studies": 54098,
      "studies determined": 77699,
      "duration type": 27189,
      "opiate use": 51313,
      "acute months": 7642,
      "months subacute": 47474,
      "subacute acute": 78584,
      "acute use": 7707,
      "months chronic": 47433,
      "chronic subacute": 16344,
      "subacute use": 78589,
      "surgery determined": 79377,
      "association preoperative": 12487,
      "medications surgery": 44683,
      "surgery commonly": 79347,
      "opioid hydrocodone": 51835,
      "50 acute": 4828,
      "use 24": 84150,
      "year reoperation": 87494,
      "reoperation rate": 70372,
      "rate compared": 67450,
      "compared 25": 18076,
      "25 15": 3322,
      "chronic preoperative": 16333,
      "preoperative use": 63762,
      "use tramadol": 84778,
      "analysis controlling": 10664,
      "sex charlson": 75063,
      "01 01": 287,
      "increased reoperations": 38006,
      "associated reoperations": 12410,
      "subacute chronic": 78587,
      "medications associated": 44592,
      "patients preoperatively": 59668,
      "evidence background": 30150,
      "adf opioid": 7983,
      "use relatively": 84688,
      "adf opioids": 7984,
      "community pharmacists": 17926,
      "survey asked": 79696,
      "available time": 12845,
      "results respondents": 71919,
      "oxycontin adf": 56116,
      "range 46": 67290,
      "range 56": 67293,
      "reducing opioid": 69020,
      "abuse swallowing": 6890,
      "background large": 13074,
      "cancer experience": 14779,
      "experience moderate": 30583,
      "tapentadol novel": 80446,
      "novel centrally": 50004,
      "acting analgesic": 7373,
      "comparable morphine": 17961,
      "relief cancer": 70105,
      "use clinical": 84240,
      "embase january": 28648,
      "july 2015": 40518,
      "retrieved papers": 72094,
      "review articles": 72255,
      "trials conducted": 83127,
      "additional trials": 7901,
      "trials identified": 83147,
      "electronic searches": 28546,
      "searches language": 74167,
      "rcts tapentadol": 67921,
      "active controls": 7506,
      "adults moderate": 8568,
      "validated assessment": 85785,
      "assessment tool": 12144,
      "10 participants": 893,
      "standard form": 76907,
      "form assessed": 32273,
      "bias extracted": 13765,
      "design participant": 23739,
      "participant details": 58254,
      "details interventions": 23921,
      "outcomes including": 54042,
      "including analgesic": 37594,
      "analgesic outcome": 10283,
      "withdrawals adverse": 87170,
      "events main": 30064,
      "design included": 23718,
      "initial titration": 38872,
      "titration phase": 81482,
      "determine maximum": 24023,
      "effective tolerated": 27709,
      "dose followed": 25908,
      "followed maintenance": 32066,
      "maintenance phase": 42916,
      "medication taken": 44571,
      "doses ranged": 26259,
      "ranged 50": 67347,
      "medication morphine": 44519,
      "studies overall": 77799,
      "participants enrolled": 58301,
      "enriched enrolment": 28991,
      "randomised titration": 67035,
      "phase trial": 61322,
      "rating scores": 67686,
      "scores patient": 73942,
      "patient global": 58647,
      "scores use": 74005,
      "measures efficacy": 44055,
      "events withdrawals": 30135,
      "studies enrolled": 77712,
      "efficacy study": 28397,
      "medication fewer": 44499,
      "20 participants": 2368,
      "study high": 78227,
      "bias open": 13769,
      "label design": 40971,
      "insufficient data": 39124,
      "data pooling": 22052,
      "comparable treatment": 17974,
      "study response": 78465,
      "high treatment": 35187,
      "placebo arms": 61663,
      "morphine 50": 47563,
      "50 placebo": 4890,
      "relief tapentadol": 70196,
      "tapentadol effective": 80396,
      "morphine low": 47747,
      "evidence treatment": 30286,
      "50 90": 4823,
      "tapentadol morphine": 80440,
      "terms adverse": 80700,
      "consciousness appetite": 19551,
      "appetite thirst": 11417,
      "conclusions information": 19102,
      "effectiveness tolerability": 27784,
      "tolerability tapentadol": 81557,
      "tapentadol limited": 80437,
      "limited available": 41919,
      "studies moderate": 77780,
      "small size": 76302,
      "data pain": 22036,
      "relief adverse": 70099,
      "events comparable": 30025,
      "man chronic": 43109,
      "pain diabetes": 56707,
      "diabetes hypertension": 24310,
      "pain triggered": 57945,
      "health problems": 34757,
      "problems including": 65257,
      "prescription mg": 64254,
      "tablets enrolled": 80151,
      "follow visit": 32039,
      "filled prescription": 31710,
      "prescription did": 64197,
      "did return": 24499,
      "doses use": 26298,
      "symptoms finally": 79887,
      "months later": 47449,
      "opioids analgesia": 52723,
      "health systems": 34789,
      "implement opioid": 36925,
      "opioid minimization": 51936,
      "use increase": 84426,
      "particularly patients": 58420,
      "data outpatient": 22034,
      "studies tested": 77865,
      "comparator cohort": 17989,
      "minimize confounding": 46596,
      "patients baseline": 59032,
      "included 25": 37390,
      "received median": 68197,
      "median days": 44210,
      "rate 23": 67430,
      "days rate": 22605,
      "term nsaid": 80643,
      "treatment reason": 82797,
      "choose opioids": 16135,
      "opioids lieu": 53016,
      "severity acute": 75032,
      "pain differs": 56717,
      "hysterectomy methods": 36324,
      "non randomized": 49674,
      "consumption oxycodone": 19971,
      "women 20": 87195,
      "performed standardized": 60633,
      "oxycodone consumed": 54849,
      "main secondary": 42866,
      "endpoints pain": 28914,
      "scores numeric": 73920,
      "stay results": 77290,
      "opioid patients": 52047,
      "period surgery": 60800,
      "surgery difference": 79379,
      "difference significant": 24684,
      "significant time": 75638,
      "point oxycodone": 62100,
      "18 21": 2034,
      "20 25": 2280,
      "026 pain": 393,
      "lower laparoscopic": 42635,
      "laparoscopic approach": 41092,
      "026 conclusion": 392,
      "reduced need": 68946,
      "need analgesics": 48908,
      "impact age": 36796,
      "identified data": 36434,
      "data patient": 22038,
      "trough concentrations": 83250,
      "concentrations clinical": 18751,
      "laboratory test": 41033,
      "test values": 80793,
      "medications collected": 44603,
      "administration used": 8390,
      "data population": 22053,
      "statistical models": 77181,
      "mixed effect": 46788,
      "effect modeling": 27489,
      "modeling nonmem": 47096,
      "software used": 76413,
      "including limited": 37627,
      "concomitant medications": 19252,
      "patients 36": 58859,
      "women 64": 87198,
      "consumed patients": 19843,
      "patients 60": 58881,
      "60 60": 5226,
      "clearance kg": 16716,
      "hours half": 35779,
      "oxycodone previously": 55755,
      "risk pharmacokinetic": 72634,
      "pharmacokinetic drug": 61112,
      "60 75": 5234,
      "depth analysis": 23615,
      "larger initiative": 41176,
      "spectrometry gc": 76660,
      "detection gc": 23956,
      "time frame": 81267,
      "tablet fentanyl": 80093,
      "identified psychoactive": 36458,
      "importance analyzing": 36978,
      "develop evaluate": 24146,
      "benefit tolerability": 13627,
      "tolerability analgesic": 81516,
      "drugs clinical": 26909,
      "trials evaluated": 83140,
      "combining different": 17682,
      "30 50": 3694,
      "reduction adverse": 69041,
      "tested using": 80816,
      "data randomized": 22081,
      "subjects chronic": 78684,
      "composite scores": 18599,
      "scores calculated": 73845,
      "calculated mean": 14691,
      "days subject": 22631,
      "expected study": 30562,
      "validity demonstrated": 85803,
      "significant correlation": 75452,
      "patients global": 59328,
      "scores tapentadol": 73998,
      "scores statistically": 73995,
      "20 pain": 2367,
      "reduction demonstrated": 69054,
      "effect size": 27564,
      "valid responsive": 85777,
      "overall efficacy": 54199,
      "trials objective": 83168,
      "tolerability dosing": 81531,
      "dosing role": 26331,
      "ir extended": 40225,
      "source medline": 76496,
      "medline pubmed": 44747,
      "pubmed search": 66455,
      "studies additional": 77641,
      "additional references": 7887,
      "references obtained": 69147,
      "obtained bibliographies": 50761,
      "bibliographies study": 13782,
      "reviewed data": 72375,
      "ir er": 40220,
      "er tablet": 29474,
      "june 2006": 40539,
      "agonist structurally": 9307,
      "hydromorphone oral": 36201,
      "10 oxymorphone": 887,
      "extensively metabolized": 30921,
      "metabolized oxymorphone": 44999,
      "oxymorphone glucuronide": 56247,
      "superior placebo": 79137,
      "er superior": 29472,
      "equivalent oxycodone": 29326,
      "oxymorphone exhibits": 56240,
      "morphine clinical": 47598,
      "coadministration ethanol": 17121,
      "variability drug": 85866,
      "indicated relief": 38245,
      "er indicated": 29425,
      "persistent pain": 60922,
      "initial doses": 38846,
      "hours ir": 35787,
      "dosage adjustment": 25742,
      "adjustment recommended": 8073,
      "impairment child": 36885,
      "child pugh": 16012,
      "pugh class": 66461,
      "impairment creatinine": 36890,
      "creatinine clearance": 21155,
      "elderly conclusion": 28471,
      "newest oral": 49411,
      "opioid enter": 51765,
      "enter crowded": 29051,
      "crowded marketplace": 21314,
      "marketplace totaling": 43430,
      "schedule opioids": 73629,
      "opioids does": 52867,
      "appear unique": 11387,
      "unique assets": 83752,
      "assets liabilities": 12160,
      "liabilities considered": 41633,
      "considered oral": 19641,
      "inflammatory analgesic": 38551,
      "placebo patients": 61799,
      "initial results": 38869,
      "valdecoxib 10": 85761,
      "day effective": 22308,
      "effective naproxen": 27649,
      "college rheumatology": 17509,
      "rheumatology 20": 72461,
      "20 response": 2378,
      "rate similar": 67519,
      "valdecoxib 20": 85764,
      "provided effective": 66129,
      "naproxen sodium": 48571,
      "sodium 550": 76403,
      "550 mg": 5086,
      "dose valdecoxib": 26107,
      "valdecoxib 40": 85766,
      "plus paracetamol": 62031,
      "acetaminophen 1000": 7114,
      "1000 mg": 1035,
      "rofecoxib oxycodone": 72728,
      "paracetamol oral": 58110,
      "oral surgery": 53668,
      "10 80": 727,
      "hip knee": 35421,
      "laparoscopic cholecystectomy": 41095,
      "valdecoxib generally": 85769,
      "generally lower": 33021,
      "specifically developed": 76625,
      "selective inhibitor": 74429,
      "relief oxycodone": 70159,
      "long duration": 42311,
      "provides valuable": 66244,
      "valuable alternative": 85813,
      "receptor opioid": 68515,
      "explored using": 30734,
      "mor agonism": 47493,
      "sigma antagonism": 75378,
      "potent analgesic": 63092,
      "test mice": 80774,
      "local peripheral": 42213,
      "activity test": 7592,
      "agonist pre": 9302,
      "pre 084": 63458,
      "oxycodone providing": 55787,
      "providing evidence": 66261,
      "based prescription": 13364,
      "studies drug": 77704,
      "drug compared": 26556,
      "community objective": 17923,
      "assess consistency": 11920,
      "different approaches": 24846,
      "methods years": 45636,
      "2004 2010": 2453,
      "using negative": 85512,
      "obtained drug": 50766,
      "ims health": 37214,
      "consistency results": 19688,
      "respectively adjusted": 71164,
      "abuse analyses": 6651,
      "analyze effects": 10815,
      "effects multimodal": 28012,
      "regimen postoperative": 69321,
      "pain function": 56800,
      "function adverse": 32622,
      "effects satisfaction": 28151,
      "satisfaction compared": 73392,
      "undergoing tka": 83584,
      "tka randomized": 81488,
      "periarticular injection": 60664,
      "wound closure": 87355,
      "mg ketorolac": 45942,
      "tramadol ketorolac": 82076,
      "narcotics needed": 48634,
      "postoperative data": 62732,
      "time physical": 81325,
      "medication related": 44555,
      "multimodal group": 48215,
      "lower vas": 42721,
      "scores earlier": 73875,
      "management protocol": 43249,
      "improves pain": 37184,
      "early recovery": 27271,
      "recovery objective": 68749,
      "objective measure": 50443,
      "impact prescription": 36844,
      "programs pdmps": 65559,
      "2010 2013": 2541,
      "physician level": 61427,
      "design using": 23819,
      "fixed effects": 31882,
      "effects study": 28170,
      "hydrocodone opioids": 36109,
      "principal findings": 65128,
      "findings prescription": 31807,
      "percent decrease": 60459,
      "decrease days": 22890,
      "prescribed physician": 63950,
      "reductions hydrocodone": 69111,
      "percent percent": 60481,
      "percent respectively": 60489,
      "small increase": 76281,
      "increase prescribing": 37787,
      "associated changes": 12229,
      "did require": 24492,
      "require use": 70813,
      "conclusions prescription": 19171,
      "medicare population": 44440,
      "smaller effect": 76312,
      "widespread opioid": 87084,
      "abuse problem": 6847,
      "effort combat": 28430,
      "evaluating abuse": 29944,
      "laboratory based": 41025,
      "based vitro": 13404,
      "studies pharmacokinetic": 77810,
      "pharmacokinetic studies": 61151,
      "studies human": 77744,
      "adf product": 7986,
      "available evidence": 12804,
      "currently facing": 21496,
      "facing opioid": 31044,
      "pain fifth": 56780,
      "fifth vital": 31688,
      "overdose mortality": 54302,
      "opioids mainly": 53031,
      "mainly oxycodone": 42872,
      "increased 2009": 37836,
      "study data": 78048,
      "following time": 32211,
      "people opioid": 60417,
      "prescriptions number": 64523,
      "people treated": 60430,
      "people died": 60405,
      "died opioid": 24527,
      "data years": 22159,
      "drug information": 26654,
      "project database": 65589,
      "related hospital": 69616,
      "2008 2017": 2503,
      "hospital data": 35576,
      "data data": 21935,
      "alcohol drugs": 9532,
      "entire population": 29073,
      "2017 overall": 2799,
      "nearly doubled": 48867,
      "2008 2015": 2502,
      "2015 number": 2713,
      "care opioid": 15047,
      "heroin increased": 35008,
      "2008 2014": 2501,
      "21 deaths": 2970,
      "deaths 100": 22732,
      "increased 65": 37863,
      "guidelines implemented": 34443,
      "escalation opioid": 29530,
      "medical centre": 44343,
      "centre study": 15635,
      "design case": 23700,
      "report description": 70456,
      "relevant literature": 70063,
      "lower limbs": 42637,
      "combinations pregabalin": 17630,
      "oxycontin failed": 56142,
      "alleviate neuropathic": 9596,
      "pain years": 57996,
      "years post": 87636,
      "subcutaneous injections": 78603,
      "subcutaneously injected": 78609,
      "conclusion subcutaneous": 19008,
      "effects case": 27842,
      "refractory neuropathic": 69224,
      "use type": 84785,
      "epidemic opioid": 29140,
      "represents advance": 70765,
      "impact opioids": 36825,
      "non adf": 49569,
      "abusable opioid": 6637,
      "low rate": 42546,
      "influx blood": 38611,
      "analgesia low": 10009,
      "regardless formulation": 69285,
      "formulation route": 32364,
      "administration nktr": 8309,
      "181 novel": 2132,
      "reduce rate": 68891,
      "181 demonstrated": 2131,
      "oxycodone hot": 55165,
      "plate latency": 61970,
      "acetic acid": 7267,
      "potential self": 63226,
      "administration progressive": 8351,
      "break point": 14390,
      "models behavioral": 47111,
      "vitro vivo": 86374,
      "presented demonstrate": 64688,
      "entry kinetics": 29088,
      "analysis nma": 10714,
      "effectiveness opioids": 27768,
      "events incidence": 30056,
      "constipation trial": 19792,
      "withdrawal rate": 87148,
      "rate patient": 67500,
      "satisfaction treatment": 73444,
      "overall adverse": 54183,
      "events constipation": 30033,
      "better tolerability": 13740,
      "satisfaction higher": 73401,
      "naloxone followed": 48450,
      "followed fentanyl": 32058,
      "results agreement": 71596,
      "comparison opioid": 18371,
      "drugs management": 26993,
      "associated low": 12324,
      "strong analgesics": 77511,
      "frail elderly": 32473,
      "use multiple": 84506,
      "relevant drug": 70055,
      "age related": 9111,
      "related changes": 69568,
      "drug response": 26777,
      "harmful drug": 34588,
      "effects result": 28143,
      "physicians face": 61439,
      "patients review": 59926,
      "based recommendations": 13371,
      "prescribing strong": 64140,
      "search performed": 74122,
      "individual drugs": 38294,
      "information obtained": 38656,
      "morphine evidence": 47684,
      "recommendations formulated": 68600,
      "using set": 85612,
      "patients methadone": 59495,
      "strong negative": 77523,
      "interaction potential": 39378,
      "potential associated": 63137,
      "risk accumulation": 72508,
      "addition methadone": 7811,
      "variability pharmacokinetics": 85873,
      "useful analgesic": 85201,
      "elderly opioids": 28476,
      "oral dosage": 53519,
      "transdermal formulations": 82159,
      "formulations preferred": 32400,
      "safety concerns": 73131,
      "effectiveness long": 27766,
      "rates adverse": 67554,
      "patients newly": 59546,
      "newly prescribed": 49420,
      "data conducted": 21924,
      "time adverse": 81204,
      "adverse outcome": 8831,
      "outcome patients": 53977,
      "patients new": 59545,
      "methadone extended": 45070,
      "morphine transdermal": 47958,
      "ed encounters": 27332,
      "diagnoses opioid": 24327,
      "hazards models": 34620,
      "used adjust": 84836,
      "cancer results": 14911,
      "subjects patients": 78723,
      "oxycodone 55": 54582,
      "likely adjusted": 41796,
      "ratio hr": 67771,
      "involving opioid": 40130,
      "adjusted hr": 8027,
      "41 lower": 4425,
      "risk constipation": 72540,
      "risk death": 72541,
      "ci 54": 16468,
      "compared prescribed": 18278,
      "fentanyl associated": 31442,
      "ci 02": 16370,
      "57 95": 5126,
      "03 40": 405,
      "morphine additional": 47576,
      "additional studies": 7895,
      "needed confirm": 48991,
      "confirm findings": 19492,
      "associated different": 12253,
      "level consumption": 41454,
      "china reported": 16089,
      "consumption trends": 20034,
      "trends prescription": 82982,
      "patterns opioids": 60219,
      "compare results": 18054,
      "results selected": 71933,
      "opioids included": 52974,
      "doses ddds": 26172,
      "pearson correlation": 60338,
      "results ddds": 71653,
      "79 18": 5796,
      "asian countries": 11831,
      "10 47": 711,
      "20 32": 2285,
      "intravenous opioids": 39864,
      "predominantly fentanyl": 63603,
      "increase consumption": 37738,
      "consumption conclusion": 19907,
      "increased 40": 37854,
      "higher average": 35206,
      "increase pain": 37777,
      "need highly": 48927,
      "ongoing prescription": 51091,
      "pain clinics": 56554,
      "cited significant": 16598,
      "significant contributors": 75450,
      "contributors opioid": 20256,
      "included primary": 37520,
      "legislation better": 41368,
      "better regulate": 13737,
      "operation pain": 51223,
      "examined changes": 30371,
      "marginally significant": 43379,
      "study documented": 78126,
      "implementation florida": 36933,
      "florida pain": 31929,
      "interventions initial": 39664,
      "continued surveillance": 20144,
      "clearly warranted": 16726,
      "high patient": 35134,
      "burden pain": 14604,
      "preparations increased": 63781,
      "pain mechanism": 57145,
      "does involve": 25681,
      "concern harms": 18822,
      "setting evidence": 74777,
      "pain modulatory": 57210,
      "clinically useful": 17014,
      "useful patients": 85211,
      "understanding role": 83653,
      "pharmacoepidemiological studies": 61095,
      "research studies": 71031,
      "studies summarized": 77857,
      "analgesic study": 10340,
      "individual factors": 38295,
      "clinical pharmacokinetics": 16855,
      "gabapentin used": 32808,
      "used dose": 84922,
      "plasma disposition": 61924,
      "disposition noroxycodone": 25500,
      "cancer cachexia": 14764,
      "fentanyl affected": 31433,
      "affected polymorphisms": 8921,
      "cyp3a5 abcb1": 21644,
      "magnesium oxide": 42798,
      "db study": 22662,
      "advantage using": 8610,
      "disorders risk": 25401,
      "29 95": 3605,
      "27 17": 3475,
      "variation plasma": 85920,
      "exposure free": 30764,
      "inhibitory concentration": 38817,
      "critically ill": 21231,
      "ill patients": 36620,
      "patients studies": 60002,
      "use medicines": 84476,
      "settings opioid": 74857,
      "receptors mors": 68550,
      "expressed different": 30817,
      "role mor": 72748,
      "relatively unknown": 69795,
      "address question": 7933,
      "genetically engineered": 33090,
      "striatal dopamine": 77497,
      "induced hyperlocomotion": 38418,
      "neurons resulted": 49217,
      "administration assessed": 8219,
      "behavior using": 13540,
      "mice underwent": 46327,
      "underwent extinction": 83679,
      "extinction training": 30936,
      "training drug": 82010,
      "drug delivered": 26575,
      "selective mor": 74431,
      "associated behaviors": 12223,
      "behaviors background": 13557,
      "evidence animal": 30143,
      "infections unclear": 38516,
      "unclear risk": 83478,
      "initiating long": 38887,
      "analgesics previously": 10485,
      "properties methods": 65714,
      "medicaid enrollees": 44329,
      "multivariable poisson": 48332,
      "calculate adjusted": 14676,
      "using long": 85472,
      "properties morphine": 65715,
      "history using": 35489,
      "exposure propensity": 30788,
      "individual long": 38298,
      "acting morphine": 7390,
      "opioid results": 52349,
      "results 61": 71578,
      "240 patients": 3297,
      "initiating opioids": 38890,
      "opioids immunosuppressive": 52965,
      "users lower": 85252,
      "78 ci": 5781,
      "ci 60": 16475,
      "morphine conclusion": 47617,
      "dramatically united": 26443,
      "studies systematically": 77862,
      "systematically examined": 80010,
      "relative reinforcing": 69761,
      "controlled patient": 20514,
      "designed compare": 23829,
      "effects intravenously": 27959,
      "25 12": 3320,
      "25 50": 3337,
      "morphine 25": 47552,
      "kg buprenorphine": 40701,
      "125 mg": 1427,
      "kg heroin": 40733,
      "125 25": 1426,
      "completers maintained": 18521,
      "doses 30": 26137,
      "received drugs": 68145,
      "drugs tested": 27091,
      "tested drugs": 80801,
      "drugs doses": 26942,
      "drugs produced": 27048,
      "produced statistically": 65413,
      "increases positive": 38073,
      "ratings feel": 67697,
      "effect like": 27471,
      "drug general": 26638,
      "order potency": 53718,
      "producing effects": 65423,
      "buprenorphine heroin": 14549,
      "heroin morphine": 35016,
      "contrast buprenorphine": 20214,
      "buprenorphine drug": 14538,
      "drug self": 26790,
      "levels dose": 41557,
      "tested data": 80799,
      "suggest abuse": 78980,
      "despite fact": 23881,
      "appear similar": 11386,
      "date limited": 22217,
      "limited drug": 41926,
      "patient data": 58602,
      "factors related": 31129,
      "drug efficacy": 26616,
      "reactions observed": 67964,
      "health professionals": 34758,
      "physicians pharmacists": 61446,
      "major findings": 42946,
      "cachectic cancer": 14665,
      "high plasma": 35140,
      "oxycodone reduction": 55814,
      "reduction cyp3a": 69053,
      "cyp3a activity": 21629,
      "patients potentially": 59662,
      "elevated serum": 28565,
      "receptor drd2": 68490,
      "antiemetic efficacy": 11186,
      "induced nausea": 38426,
      "having high": 34604,
      "prolactin secretion": 65599,
      "secretion oxycodone": 74266,
      "patients genetic": 59324,
      "atp binding": 12532,
      "binding cassette": 13817,
      "subfamily member": 78612,
      "member abcb1": 44771,
      "decreased kidney": 23004,
      "kidney function": 40826,
      "chronic inflammation": 16194,
      "inflammation increased": 38548,
      "increased plasma": 37987,
      "alter plasma": 9687,
      "prednisolone did": 63598,
      "median milk": 44241,
      "milk plasma": 46443,
      "infant dose": 38501,
      "intentional exposures": 39346,
      "period 2003": 60689,
      "vs non": 86663,
      "periods study": 60821,
      "period 25": 60700,
      "showed decrease": 75236,
      "sd mean": 74082,
      "showed increase": 75264,
      "mean study": 43883,
      "mean percent": 43837,
      "day week": 22449,
      "days significant": 22623,
      "drugs temporally": 27090,
      "temporally related": 80593,
      "examiner cases": 30419,
      "southwestern virginia": 76516,
      "years fentanyl": 87591,
      "increased 2000": 37833,
      "23 cases": 3091,
      "cases attributed": 15224,
      "transdermal patches": 82168,
      "transdermal transmucosal": 82172,
      "administration fentanyl": 8265,
      "using solid": 85617,
      "solid phase": 76430,
      "phase extraction": 61281,
      "ms electron": 48080,
      "electron impact": 28526,
      "impact ionization": 36818,
      "ionization mode": 40146,
      "quantitation performed": 66794,
      "using selected": 85604,
      "selected ion": 74388,
      "ion monitoring": 40142,
      "monitoring gc": 47324,
      "ms method": 48085,
      "method linear": 45185,
      "linear 50": 42010,
      "50 microg": 4864,
      "limit quantitation": 41892,
      "microg fentanyl": 46357,
      "fentanyl blood": 31445,
      "16 53": 1861,
      "fentanyl patches": 31561,
      "number case": 50143,
      "abuse suggest": 6886,
      "opioid similar": 52363,
      "report drug": 70457,
      "medications fail": 44620,
      "use nonprescribed": 84523,
      "nonprescribed medications": 49833,
      "prescribed physicians": 63951,
      "use illicit": 84413,
      "patient inappropriate": 58662,
      "inappropriate use": 37244,
      "patient management": 58676,
      "management use": 43276,
      "use external": 84369,
      "prescription monitoring": 64257,
      "programs improve": 65555,
      "management methods": 43202,
      "methods urine": 45617,
      "urine toxicology": 84092,
      "toxicology testing": 81957,
      "patient prescribed": 58713,
      "authors review": 12748,
      "review use": 72369,
      "use urine": 84790,
      "monitoring patients": 47334,
      "present evidence": 64618,
      "studies suggests": 77856,
      "behavior patients": 13537,
      "potential problems": 63213,
      "testing authors": 80818,
      "authors conclude": 12722,
      "urgently needed": 84049,
      "testing patients": 80830,
      "record daily": 68653,
      "daily opioid": 21772,
      "levels level": 41572,
      "level level": 41499,
      "data inform": 21993,
      "inform opioid": 38617,
      "prescription guidelines": 64231,
      "understanding postoperative": 83648,
      "prescriptions methods": 64513,
      "undergoing level": 83548,
      "participating institutions": 58392,
      "march 2018": 43369,
      "dependence defined": 23467,
      "daily use": 21812,
      "starting postoperative": 77024,
      "day daily": 22291,
      "automated text": 12759,
      "text messaging": 80885,
      "facilitate clinical": 31031,
      "use converted": 84280,
      "mg equivalents": 45883,
      "weeks patient": 86933,
      "cessation opioid": 15676,
      "questions asked": 66906,
      "state prescription": 77061,
      "factors patients": 31121,
      "consumption analyzed": 19895,
      "results 57": 71575,
      "completed daily": 18464,
      "sample 50": 73289,
      "50 10": 4799,
      "patients 66": 58890,
      "median postdischarge": 44275,
      "use pills": 84626,
      "pills range": 61540,
      "cumulative opioid": 21397,
      "groups median": 34234,
      "pill consumption": 61489,
      "consumption 10": 19867,
      "10 interquartile": 774,
      "vs interquartile": 86649,
      "thirteen patients": 81099,
      "27 did": 3490,
      "opioids discharge": 52858,
      "took opioids": 81673,
      "ceased opioids": 15443,
      "quartile opioid": 66860,
      "consumption vs": 20041,
      "006 conclusion": 270,
      "12 oxycodone": 1346,
      "equivalents discharge": 29347,
      "discharge prescription": 25164,
      "education appropriate": 27379,
      "disposal opioid": 25486,
      "addiction prescription": 7755,
      "prescription illicit": 64238,
      "drugs growing": 26970,
      "people suffer": 60426,
      "recently released": 68448,
      "agonists methadone": 9334,
      "naltrexone naloxone": 48545,
      "naloxone combinations": 48437,
      "naloxone shown": 48518,
      "agonists increased": 9331,
      "risk diversion": 72551,
      "existing medications": 30527,
      "used therapy": 85157,
      "disease scd": 25349,
      "current future": 21438,
      "guidelines exist": 34440,
      "based treatment": 13395,
      "strategies pain": 77419,
      "management pediatric": 43236,
      "extant literature": 30844,
      "approaches management": 11490,
      "pain findings": 56783,
      "findings reveal": 31816,
      "management interventions": 43192,
      "psychosocial interventions": 66363,
      "cognitive behavioral": 17320,
      "analgesics nonsteroidal": 10456,
      "medications morphine": 44646,
      "oxycodone date": 54926,
      "management children": 43160,
      "physiological processes": 61468,
      "management requires": 43259,
      "comprehensive treatment": 18629,
      "additional clinical": 7849,
      "warranted ensure": 86732,
      "safe efficacious": 73088,
      "enzyme metabolizes": 29104,
      "buprenorphine bup": 14523,
      "treatment opiate": 82696,
      "competitive inhibitors": 18415,
      "investigation determine": 40069,
      "effect 20": 27411,
      "opiates administered": 51319,
      "pregnant patients": 63697,
      "therapeutic indications": 80945,
      "opiates increased": 51327,
      "fentanyl 25": 31423,
      "25 microm": 3368,
      "agonists morphine": 9335,
      "heroin hydromorphone": 35004,
      "oxymorphone hydrocodone": 56248,
      "caused increase": 15384,
      "did inhibit": 24458,
      "50 values": 4905,
      "fentanyl sufentanil": 31597,
      "affect maternal": 8904,
      "maternal neonatal": 43522,
      "neonatal outcome": 49101,
      "evaluate incidence": 29810,
      "obtain data": 50752,
      "april 2004": 11599,
      "2004 march": 2455,
      "medical devices": 44356,
      "tapentadol methadone": 80439,
      "time onset": 81299,
      "analysis detected": 10671,
      "morphine showed": 47921,
      "old patients": 51016,
      "patients median": 59484,
      "median daily": 44208,
      "dose transdermal": 26101,
      "distribution opioids": 25562,
      "failure type": 31153,
      "type median": 83330,
      "oxycodone transdermal": 56021,
      "fentanyl 11": 31412,
      "12 respectively": 1359,
      "respectively 50": 71160,
      "50 cases": 4829,
      "reported 30": 70486,
      "important monitor": 37017,
      "patients carefully": 59051,
      "week month": 86850,
      "administered morphine": 8151,
      "belongs class": 13587,
      "cells opioid": 15501,
      "opioid characteristics": 51574,
      "structurally related": 77582,
      "bell shaped": 13584,
      "shaped curve": 75115,
      "response curve": 71339,
      "50 12": 4805,
      "12 microm": 1327,
      "50 20": 4808,
      "classical opioid": 16674,
      "effect observed": 27501,
      "evidence non": 30227,
      "preoperative analgesia": 63736,
      "analgesia epidural": 9964,
      "phantom pain": 61007,
      "pain published": 57446,
      "report 41": 70443,
      "41 year": 4434,
      "local recurrence": 42214,
      "squamous cell": 76791,
      "cell carcinoma": 15474,
      "pain syndrome": 57896,
      "requiring oxycodone": 70908,
      "infusion morphine": 38715,
      "morphine bupivacaine": 47589,
      "hours preoperatively": 35832,
      "discontinued postoperative": 25246,
      "oxycodone gradually": 55120,
      "gradually decreased": 33390,
      "discontinued prior": 25248,
      "epidural pain": 29190,
      "management prevention": 43246,
      "prevention postoperative": 64880,
      "need provide": 48950,
      "combination oral": 17580,
      "subcutaneous intravenous": 78604,
      "intravenous epidural": 39826,
      "fentanyl potent": 31571,
      "potent synthetic": 63117,
      "general regional": 32985,
      "management persistent": 43237,
      "forensic medicine": 32263,
      "america europe": 9785,
      "fentanyl recreational": 31580,
      "mixed heroin": 46796,
      "hydrocodone alprazolam": 36060,
      "standard drug": 76903,
      "drug fentanyl": 26632,
      "patients naloxone": 59535,
      "onset fentanyl": 51115,
      "new effective": 49322,
      "effective harm": 27629,
      "objective abuse": 50362,
      "morphine tapentadol": 47952,
      "agonism norepinephrine": 9273,
      "result differences": 71474,
      "differences receptor": 24801,
      "receptor pharmacology": 68518,
      "initial step": 38871,
      "testing hypothesis": 80821,
      "sentinel sample": 74584,
      "individuals assessed": 38336,
      "treatment navippro": 82677,
      "38 states": 4246,
      "states january": 77112,
      "september 2012": 74612,
      "2012 examined": 2599,
      "examined prevalence": 30407,
      "prescription adjusted": 64161,
      "adjusted prevalence": 8049,
      "day abuse": 22265,
      "er formulations": 29420,
      "comparators results": 18003,
      "abuse reported": 6865,
      "abuse prevalence": 6842,
      "prevalence tapentadol": 64819,
      "er abuse": 29396,
      "er low": 29435,
      "low prescription": 42540,
      "lowest observed": 42734,
      "observed lowest": 50689,
      "adjusted risk": 8056,
      "er comparators": 29407,
      "06 conclusions": 586,
      "study prescription": 78425,
      "ii analgesics": 36554,
      "drug formulation": 26635,
      "psychoactive effects": 66334,
      "narcotic analgesics": 48589,
      "pharmaceutical products": 61043,
      "specific drug": 76586,
      "administration time": 8388,
      "course effects": 20988,
      "effects pharmaceutical": 28087,
      "vary widely": 85991,
      "tampering attempts": 80347,
      "attempts frequently": 12552,
      "use successful": 84765,
      "narcotic drugs": 48596,
      "drugs codeine": 26911,
      "time release": 81354,
      "dose formulations": 25910,
      "alternate routes": 9708,
      "administration development": 8247,
      "development successful": 24251,
      "scope practice": 73694,
      "methods available": 45262,
      "users internet": 85248,
      "background patients": 13147,
      "opioids 24": 52670,
      "surgery june": 79437,
      "tablet formulation": 80094,
      "formulation oxymorphone": 32357,
      "surgery objective": 79478,
      "assessed efficacy": 12000,
      "tolerability multiple": 81538,
      "fixed doses": 31880,
      "pain abdominal": 56399,
      "multicenter randomized": 48167,
      "controlled parallel": 20511,
      "incision patients": 37345,
      "patients discontinued": 59211,
      "point categorical": 62079,
      "categorical scale": 15293,
      "50 mm": 4866,
      "mm 100": 46924,
      "100 worst": 1025,
      "worst pain": 87339,
      "pain imaginable": 56843,
      "30 hours": 3740,
      "hours abdominal": 35745,
      "receive oxymorphone": 68069,
      "included efficacy": 37451,
      "efficacy assessments": 28228,
      "dose evaluation": 25902,
      "assessed 15": 11979,
      "minute intervals": 46636,
      "hourly hours": 35724,
      "efficacy end": 28258,
      "study discontinuation": 78121,
      "assessment tolerability": 12143,
      "tolerability based": 81520,
      "study demographic": 78055,
      "327 patients": 3971,
      "age study": 9126,
      "42 years": 4481,
      "mg 17": 45721,
      "17 hours": 1971,
      "20 hours": 2319,
      "mg 24": 45730,
      "significantly effective": 75693,
      "placebo hour": 61760,
      "hour single": 35717,
      "groups significantly": 34322,
      "current average": 21428,
      "pain intensities": 56876,
      "respectively squares": 71250,
      "intensity significantly": 39312,
      "compared received": 18288,
      "placebo 39": 61632,
      "39 50": 4264,
      "50 respectively": 4896,
      "respectively 005": 71148,
      "emergent aes": 28707,
      "groups 82": 34121,
      "17 14": 1933,
      "81 13": 5881,
      "13 11": 1451,
      "83 12": 5925,
      "12 11": 1210,
      "respectively proportions": 71238,
      "reporting treatment": 70706,
      "46 38": 4621,
      "51 42": 4950,
      "compared 34": 18080,
      "group ns": 33875,
      "study limitation": 78287,
      "did allow": 24404,
      "effect did": 27444,
      "population undergoing": 62393,
      "given hours": 33173,
      "hours provided": 35837,
      "analgesia moderate": 10026,
      "synthetic routes": 79963,
      "nalbuphine buprenorphine": 48411,
      "starting material": 77017,
      "mainly associated": 42869,
      "search new": 74121,
      "new selective": 49372,
      "agents result": 9242,
      "selective determination": 74428,
      "determination opiate": 23982,
      "opiate alkaloids": 51287,
      "biological matrices": 13852,
      "effect parent": 27524,
      "oxime formation": 54403,
      "hydrocodone 14": 36045,
      "formation monitored": 32297,
      "reversed phase": 72242,
      "phase hplc": 61283,
      "oxime products": 54405,
      "98 conclusion": 6465,
      "conclusion survey": 19009,
      "different ratios": 24916,
      "hydrocodone codeine": 36067,
      "tramadol frequently": 82062,
      "opioids affect": 52713,
      "taking hydrocodone": 80305,
      "tramadol methods": 82081,
      "study 201": 77885,
      "age cancer": 9064,
      "filled prescriptions": 31712,
      "prescriptions study": 64563,
      "study opioids": 78348,
      "opioids adverse": 52711,
      "defined emergency": 23137,
      "department visit": 23448,
      "hospital admission": 35557,
      "death related": 22719,
      "score adjusted": 73727,
      "results incidence": 71723,
      "events 10": 30001,
      "events 13": 30004,
      "codeine 58": 17206,
      "317 tramadol": 3896,
      "98 03": 6457,
      "94 81": 6187,
      "tramadol consistently": 82051,
      "possible overdose": 62542,
      "opioids incidence": 52971,
      "consistently greater": 19721,
      "hydrocodone immediate": 36097,
      "acetaminophen prescribed": 7241,
      "patterns use": 60231,
      "use including": 84425,
      "including long": 37628,
      "treatment dose": 82556,
      "days continuous": 22501,
      "continuous use": 20189,
      "assessed patients": 12035,
      "acetaminophen compared": 7174,
      "database january": 22173,
      "january 2008": 40425,
      "2008 september": 2512,
      "small percentage": 76293,
      "treatment long": 82642,
      "number large": 50167,
      "nearly times": 48872,
      "morphine 22": 47548,
      "treatment increased": 82624,
      "meeting criteria": 44758,
      "use approximately": 84204,
      "160 000": 1902,
      "20 60": 2300,
      "received doses": 68143,
      "approximately 15": 11561,
      "prescribed total": 63991,
      "prescription time": 64414,
      "consider benefits": 19602,
      "benefits risks": 13635,
      "use products": 84670,
      "pain adequately": 56416,
      "adequately managed": 7979,
      "managed opioid": 43134,
      "tapentadol reported": 80467,
      "improved adverse": 37095,
      "events ae": 30008,
      "analgesics similar": 10502,
      "levels analgesia": 41543,
      "used line": 84984,
      "care payer": 15058,
      "fentanyl tdf": 31600,
      "medical treatment": 44410,
      "patient discontinued": 58623,
      "discontinued treatment": 25250,
      "switched alternative": 79823,
      "opioid data": 51692,
      "utility values": 85726,
      "trials clinical": 83114,
      "switching opioids": 79835,
      "pain unit": 57951,
      "results tested": 72009,
      "tapentadol patients": 80458,
      "greater efficacy": 33444,
      "compared comparator": 18114,
      "pay threshold": 60244,
      "20 000": 2264,
      "based findings": 13321,
      "findings present": 31808,
      "commonly accepted": 17835,
      "hydromorphone opioid": 36199,
      "performed patient": 60608,
      "hydromorphone administration": 36156,
      "reversed symptoms": 72244,
      "demonstrated introduction": 23349,
      "introduction prescription": 39949,
      "article explores": 11768,
      "damaging effects": 21823,
      "oral health": 53543,
      "old caucasian": 51001,
      "university pennsylvania": 83871,
      "school dental": 73668,
      "dental medicine": 23403,
      "approximately tablets": 11587,
      "management outcome": 43225,
      "dental treatment": 23414,
      "treatment patient": 82745,
      "patient included": 58663,
      "generic formulation": 33050,
      "little research": 42167,
      "research examined": 71005,
      "examined extent": 30380,
      "examined patterns": 30401,
      "patterns prescription": 60226,
      "naloxone terms": 48525,
      "associated clinical": 12231,
      "clinical conditions": 16773,
      "commercial health": 17705,
      "2011 2015": 2575,
      "naloxone assessed": 48431,
      "patients prescription": 59685,
      "prescription buprenorphine": 64173,
      "conditions associated": 19310,
      "months patients": 47460,
      "patients common": 59097,
      "common pain": 17792,
      "prescribed buprenorphine": 63827,
      "results number": 71796,
      "prescription increased": 64241,
      "substantially study": 78865,
      "approximately 25": 11565,
      "25 000": 3316,
      "2011 39": 2578,
      "clinical condition": 16772,
      "condition associated": 19276,
      "percentage prescriptions": 60518,
      "naloxone observed": 48468,
      "pain particularly": 57328,
      "caused persistent": 15387,
      "conditions acute": 19307,
      "genetic factors": 33072,
      "based clinical": 13295,
      "standard treatment": 76936,
      "patients cp": 59160,
      "surgery endoscopic": 79385,
      "opioid ibuprofen": 51837,
      "ibuprofen naproxen": 36362,
      "ap cp": 11344,
      "replacement therapy": 70432,
      "beneficial patients": 13603,
      "patients abdominal": 58914,
      "cp patients": 21037,
      "pancreatic cancer": 58059,
      "clinicians need": 17033,
      "treatment methods": 82658,
      "timely manner": 81409,
      "manner background": 43322,
      "addressing opioid": 7940,
      "disorder treatment": 25388,
      "policies programs": 62176,
      "growing opioid": 34368,
      "assessing impact": 12102,
      "policy change": 62181,
      "regarding opioids": 69261,
      "disorder opioid": 25381,
      "anti drug": 11116,
      "canadian federal": 14756,
      "oxycontin drug": 56135,
      "early 2000s": 27250,
      "closely linked": 17074,
      "implemented conclusion": 36945,
      "using evidence": 85392,
      "address opioid": 7928,
      "despite increased": 23884,
      "increased attention": 37879,
      "curbing opioid": 21419,
      "multiple concurrent": 48267,
      "concurrent opioid": 19267,
      "prescriptions dental": 64471,
      "patients limited": 59450,
      "limited methods": 41944,
      "authors reviewed": 12749,
      "used descriptive": 84907,
      "descriptive analyses": 23677,
      "dental opioid": 23404,
      "opioids initial": 53001,
      "frequently dispensed": 32549,
      "younger 21": 87729,
      "prescriptions identified": 64497,
      "time frames": 81268,
      "dentists prescribed": 23418,
      "high volume": 35195,
      "practical implications": 63387,
      "care addiction": 15000,
      "importance secure": 36988,
      "storage disposal": 77397,
      "disposal leftover": 25485,
      "american academy": 9787,
      "academy otolaryngology": 6965,
      "otolaryngology head": 53885,
      "practice guideline": 63399,
      "analgesia common": 9927,
      "national guidelines": 48684,
      "new zealand": 49394,
      "guidelines group": 34442,
      "health medical": 34732,
      "database pubmed": 22181,
      "library embase": 41662,
      "isi web": 40291,
      "reviews randomized": 72418,
      "conclusion nsaids": 18933,
      "nsaids provide": 50105,
      "highly effective": 35393,
      "analgesia postoperative": 10062,
      "use nonopioid": 84522,
      "potent analgesics": 63094,
      "opioids unacceptable": 53364,
      "risk bleeding": 72536,
      "mg ibuprofen": 45916,
      "ibuprofen significantly": 36374,
      "opioid regimens": 52294,
      "nsaids acetaminophen": 50099,
      "acetaminophen provides": 7246,
      "greater safety": 33492,
      "multimodal nonopioid": 48218,
      "nonopioid analgesia": 49803,
      "reserved severe": 71057,
      "severe refractory": 75014,
      "pain state": 57859,
      "state art": 77032,
      "pain regimens": 57507,
      "order accelerate": 53704,
      "route delivery": 72842,
      "combat opioid": 17535,
      "epidemic usa": 29157,
      "usa drug": 84107,
      "drug manufacturers": 26698,
      "barriers crushing": 13260,
      "crushing chewing": 21350,
      "drug extraction": 26630,
      "opioid agents": 51417,
      "review article": 72254,
      "provides comprehensive": 66206,
      "available extended": 12805,
      "formulations objective": 32391,
      "nature extent": 48749,
      "study analysis": 77950,
      "analysis electronic": 10678,
      "drug management": 26697,
      "management medication": 43199,
      "medical surgical": 44408,
      "melbourne victoria": 44766,
      "year main": 87449,
      "discrepancy quantity": 25268,
      "quantity medication": 66829,
      "direct cost": 25044,
      "overall rates": 54244,
      "rates hospital": 67587,
      "medications useful": 44696,
      "treatment oral": 82715,
      "ci 83": 16499,
      "83 89": 5927,
      "ondansetron mg": 51078,
      "53 95": 5017,
      "generally low": 33020,
      "temazepam diazepam": 80579,
      "32 95": 3920,
      "ci 32": 16431,
      "range 25": 67276,
      "ci 25": 16420,
      "25 26": 3328,
      "39 39": 4261,
      "cause pain": 15367,
      "pain dysfunction": 56737,
      "measures fail": 44057,
      "clinical radiographic": 16880,
      "use large": 84446,
      "large patient": 41143,
      "patient cohort": 58563,
      "cohort methods": 17364,
      "study treated": 78546,
      "treated single": 82376,
      "single fellowship": 76103,
      "fellowship trained": 31345,
      "trained foot": 82001,
      "foot ankle": 32242,
      "orthopaedic surgeon": 53817,
      "visit patients": 86268,
      "regular use": 69483,
      "ibuprofen days": 36354,
      "oxycodone reserved": 55842,
      "mean preoperative": 43844,
      "respectively postoperative": 71234,
      "postoperatively patient": 63013,
      "91 mean": 6138,
      "oxycodone pill": 55684,
      "good method": 33317,
      "low postoperative": 42535,
      "postoperative narcotic": 62798,
      "evidence level": 30204,
      "study single": 78502,
      "analgesia protocols": 10075,
      "surgery reduce": 79554,
      "use limited": 84455,
      "analgesia protocol": 10074,
      "inpatient post": 39026,
      "post discharge": 62563,
      "discharge outpatient": 25151,
      "review patients": 72332,
      "admitted level": 8428,
      "level trauma": 41531,
      "trauma center": 82260,
      "september 2017": 74618,
      "2017 february": 2782,
      "february 2018": 31310,
      "multimodal protocol": 48245,
      "protocol pre": 65991,
      "2018 april": 2814,
      "april 2019": 11610,
      "protocol post": 65989,
      "post cohort": 62562,
      "performed outpatient": 60607,
      "injury results": 38995,
      "total inpatient": 81818,
      "130 mg": 1516,
      "mg 44": 45753,
      "intravenous hydromorphone": 39832,
      "mg pre": 46172,
      "mg post": 46169,
      "inpatient oxycodone": 39023,
      "decreased 45": 22964,
      "increased mg": 37947,
      "patients post": 59654,
      "prescribed fewer": 63860,
      "fewer mmes": 31644,
      "discharge 05": 25092,
      "05 number": 529,
      "prescribed gabapentin": 63865,
      "conclusion implementation": 18912,
      "protocol decreased": 65969,
      "decreased total": 23050,
      "total mme": 81836,
      "mme daily": 46958,
      "daily mme": 21761,
      "pain protocols": 57441,
      "protocols lead": 66003,
      "lead increase": 41292,
      "cause serotonin": 15372,
      "number different": 50155,
      "mechanisms including": 44142,
      "inhibition cytochrome": 38781,
      "interactions involving": 39396,
      "involved cases": 40093,
      "including monoamine": 37636,
      "oxidase inhibitors": 54392,
      "inhibitors selective": 38808,
      "inhibitors serotonin": 38811,
      "class opioid": 16663,
      "pain medicines": 57170,
      "meperidine methadone": 44842,
      "models including": 47115,
      "including studies": 37676,
      "important insights": 37014,
      "transfected human": 82177,
      "tramadol meperidine": 82079,
      "methadone tapentadol": 45130,
      "receptor ligand": 68505,
      "ligand binding": 41761,
      "assays revealed": 11896,
      "receptors interaction": 68543,
      "ht 2a": 35907,
      "toxicity patients": 81937,
      "used intravenous": 84980,
      "sublingual sufentanil": 78758,
      "formulation patient": 32358,
      "lockout interval": 42237,
      "method opioid": 45192,
      "opioid delivery": 51697,
      "delivery compared": 23219,
      "onset time": 51125,
      "covered paper": 21016,
      "paper focuses": 58080,
      "safety feasibility": 73152,
      "sublingual formulation": 78757,
      "pain paper": 57325,
      "paper based": 58076,
      "expert commentary": 30686,
      "pain substantial": 57883,
      "states aimed": 77079,
      "postoperative setting": 62965,
      "chronic pelvic": 16327,
      "pain undergoing": 57950,
      "surgical excision": 79629,
      "excision endometriosis": 30470,
      "urban academic": 84026,
      "academic university": 6958,
      "university hospital": 83861,
      "hospital january": 35596,
      "use collected": 84247,
      "collected patient": 17470,
      "reported survey": 70662,
      "survey given": 79711,
      "weeks follow": 86913,
      "visit data": 86260,
      "robotic surgery": 72710,
      "benign gynecologic": 13643,
      "gynecologic indications": 34484,
      "158 patients": 1834,
      "39 patients": 4275,
      "average 105": 12857,
      "mme equivalent": 46963,
      "mg difference": 45873,
      "significant conclusion": 75447,
      "used times": 85158,
      "higher perceived": 35294,
      "pain providers": 57443,
      "level prescription": 41519,
      "pharmaceutical drugs": 61024,
      "injecting drug": 38925,
      "users idu": 85245,
      "methamphetamine users": 45152,
      "ecstasy users": 27320,
      "2006 2009": 2473,
      "2006 2007": 2471,
      "2007 2008": 2485,
      "2008 2009": 2497,
      "heroin principal": 35030,
      "used idu": 84965,
      "prescriptions use": 64569,
      "morphine lower": 47748,
      "lower proportion": 42691,
      "injected methadone": 38919,
      "compared previous": 18279,
      "years higher": 87596,
      "extra medical": 30938,
      "occurred groups": 50837,
      "groups level": 34225,
      "medical pharmaceutical": 44379,
      "control strategies": 20424,
      "opioids generally": 52929,
      "opioid toxicology": 52434,
      "toxicology laboratories": 81952,
      "play major": 61995,
      "major role": 42975,
      "large scale": 41152,
      "buprenorphine used": 14597,
      "used alternative": 84839,
      "alternative pharmacotherapy": 9737,
      "risk toxicity": 72663,
      "used cns": 84881,
      "cns depressants": 17113,
      "injected morphine": 38920,
      "hydrocodone fentanyl": 36082,
      "fentanyl increasingly": 31504,
      "testing programs": 80837,
      "study purpose": 78438,
      "use month": 84495,
      "abusers methods": 6931,
      "completed month": 18472,
      "follow assessment": 32012,
      "demographic drug": 23282,
      "use social": 84739,
      "social network": 76356,
      "network characteristics": 49158,
      "results lifetime": 71750,
      "nearly half": 48868,
      "half 46": 34511,
      "46 used": 4632,
      "used diverted": 84921,
      "50 daily": 4833,
      "friends 31": 32599,
      "follow included": 32019,
      "generalized anxiety": 32998,
      "anxiety disorder": 11275,
      "disorder past": 25385,
      "good quality": 33326,
      "work evaluate": 87275,
      "access treatment": 7007,
      "time different": 81251,
      "acetaminophen containing": 7177,
      "containing medications": 20077,
      "medications methods": 44645,
      "family medicine": 31180,
      "residency programs": 71064,
      "asked participate": 11841,
      "survey participants": 79726,
      "administered questionnaire": 8175,
      "questionnaire questions": 66897,
      "education provided": 27394,
      "provided patients": 66150,
      "multiple choice": 48264,
      "percocet acetaminophen": 60531,
      "correctly identified": 20805,
      "ninety percent": 49488,
      "information provided": 38666,
      "provided limited": 66140,
      "conclusions physicians": 19160,
      "physicians prescribing": 61448,
      "acetaminophen products": 7245,
      "public awareness": 66375,
      "reduction strategy": 69103,
      "drugs low": 26991,
      "low study": 42557,
      "practice design": 63397,
      "frequent opioid": 32534,
      "opioid tablet": 52392,
      "education post": 27389,
      "questionnaires administered": 66901,
      "terms perceived": 80715,
      "ease use": 27278,
      "use overall": 84578,
      "usually used": 85700,
      "methods pharmaceutical": 45461,
      "tablets increases": 80167,
      "time injection": 81276,
      "clients supervised": 16734,
      "background canadian": 13019,
      "care facilities": 15022,
      "health canada": 34674,
      "street value": 77468,
      "facilities january": 31041,
      "2012 september": 2613,
      "2017 conducted": 2775,
      "analyses opioid": 10597,
      "drug lost": 26696,
      "equivalents daily": 29344,
      "daily defined": 21716,
      "defined doses": 23135,
      "results 64": 71580,
      "interpretation large": 39502,
      "milligrams opioids": 46479,
      "period 2000": 60687,
      "regulatory barriers": 69504,
      "according guidelines": 7045,
      "day fentanyl": 22311,
      "consumption decreased": 19914,
      "analgesics consumption": 10405,
      "differences opioid": 24768,
      "result drug": 71475,
      "data mining": 22011,
      "drug combinations": 26554,
      "high dimensional": 35082,
      "risk existing": 72558,
      "ddis associated": 22678,
      "drugs reported": 27062,
      "analysis confirmed": 10663,
      "simvastatin atorvastatin": 76039,
      "tool allows": 81681,
      "select drug": 74382,
      "strategy identify": 77434,
      "identify high": 36507,
      "tool potential": 81688,
      "care availability": 15004,
      "mortality attributed": 47982,
      "attributed prescription": 12614,
      "differences related": 24803,
      "assessed methods": 12015,
      "community engagement": 17919,
      "data demographics": 21937,
      "health status": 34778,
      "oxycodone collected": 54798,
      "community members": 17922,
      "north central": 49960,
      "health needs": 34736,
      "participants 18": 58266,
      "use past": 84605,
      "statistics chi": 77243,
      "ratios aor": 67817,
      "aor ci": 11341,
      "examine sex": 30362,
      "age 45": 9009,
      "60 female": 5252,
      "respondents endorsed": 71308,
      "lifetime use": 41754,
      "strongest risk": 77574,
      "96 95": 6420,
      "ci 34": 16436,
      "history cancer": 35452,
      "associated prescription": 12388,
      "use varied": 84798,
      "sex conclusions": 75067,
      "provide additional": 66028,
      "additional information": 7866,
      "opioid sedative": 52357,
      "use especially": 84356,
      "especially women": 29566,
      "women needed": 87227,
      "medications reported": 44670,
      "reported cause": 70515,
      "medications similar": 44678,
      "concentrations free": 18764,
      "serum plasma": 74704,
      "equilibrium dialysis": 29269,
      "spectrometry methods": 76670,
      "lower concentrations": 42588,
      "positive hydrocodone": 62466,
      "age matched": 9087,
      "matched controls": 43489,
      "pregabalin effect": 63666,
      "showed reduced": 75292,
      "concentrations samples": 18811,
      "particular opioid": 58403,
      "advantages opioid": 8615,
      "copyright 2017": 20762,
      "2017 john": 2784,
      "epidemic focused": 29131,
      "national attention": 48668,
      "opioid overprescribing": 52021,
      "time state": 81381,
      "opioid filling": 51807,
      "filling surrounding": 31726,
      "arthroplasty tha": 11743,
      "cumulative perioperative": 21409,
      "volumes rates": 86406,
      "equivalents oe": 29368,
      "undergoing primary": 83568,
      "primary tha": 65114,
      "days pre": 22593,
      "pre operative": 63476,
      "operative 90": 51242,
      "days post": 22583,
      "surgery year": 79622,
      "volumes remained": 86407,
      "decreased considerably": 22987,
      "similar 2010": 75893,
      "legislation targeting": 41378,
      "targeting duration": 80502,
      "duration volume": 27192,
      "decreases opioid": 23059,
      "prescription filling": 64222,
      "opioid legislation": 51883,
      "legislation large": 41371,
      "cumulative 90": 21389,
      "compared 20": 18071,
      "20 states": 2382,
      "descriptive study": 23687,
      "opioid limiting": 51890,
      "limiting legislation": 41974,
      "legislation larger": 41372,
      "causal relationships": 15336,
      "relationships inferred": 69731,
      "iii retrospective": 36595,
      "retrospective prognostic": 72154,
      "prognostic cohort": 65528,
      "study background": 77978,
      "states district": 77093,
      "district columbia": 25574,
      "cannabis use": 14936,
      "street prices": 77467,
      "cannabis methamphetamine": 14934,
      "methamphetamine cocaine": 45141,
      "cocaine heroin": 17148,
      "amphetamine alprazolam": 9846,
      "crowdsourced data": 21317,
      "information drug": 38644,
      "forensic laboratory": 32262,
      "differences design": 24732,
      "changes outcomes": 15807,
      "reported quality": 70636,
      "quality primary": 66754,
      "defined using": 23156,
      "using effective": 85388,
      "93 95": 6172,
      "ci 51": 16465,
      "including heroin": 37622,
      "conclusions recreational": 19185,
      "associated illegal": 12288,
      "states including": 77109,
      "opioids analyzed": 52726,
      "noncancer patients": 49715,
      "safety signals": 73219,
      "wide variety": 87050,
      "signal detection": 75384,
      "induced neurotoxicity": 38430,
      "neurotoxicity oin": 49292,
      "patients respiratory": 59918,
      "morphine exhibited": 47686,
      "onset oin": 51117,
      "morphine 13": 47538,
      "respectively opioids": 71224,
      "purpose opioids": 66538,
      "opioids inhibit": 53000,
      "noradrenaline transporter": 49878,
      "transporter net": 82245,
      "net inhibition": 49152,
      "effects different": 27894,
      "opioids human": 52954,
      "binding affinities": 13813,
      "ht 2c": 35909,
      "clinical cases": 16765,
      "methadone racemic": 45122,
      "racemic methadone": 66943,
      "tapentadol inhibited": 80424,
      "plasma estimated": 61933,
      "concentrations patients": 18803,
      "tramadol methadone": 82080,
      "monoacetylmorphine buprenorphine": 47356,
      "heroin hydrocodone": 35002,
      "micromolar range": 46373,
      "range opioids": 67327,
      "opioids interact": 53004,
      "potentially clinically": 63252,
      "involved methadone": 40101,
      "28 non": 3562,
      "driving influence": 26469,
      "combined effects": 17647,
      "effects multiple": 28013,
      "opioids employed": 52881,
      "benzodiazepines hypnotics": 13663,
      "road traffic": 72701,
      "impairment blood": 36884,
      "blood alcohol": 14104,
      "alcohol concentrations": 9528,
      "15 different": 1731,
      "opioids based": 52746,
      "drug na\u00efve": 26721,
      "na\u00efve users": 48854,
      "used establish": 84928,
      "conversion factors": 20708,
      "equivalents results": 29377,
      "alprazolam bromazepam": 9673,
      "flunitrazepam lorazepam": 31948,
      "lorazepam nitrazepam": 42418,
      "nordiazepam oxazepam": 49884,
      "zolpidem zopiclone": 87768,
      "february 2016": 31308,
      "2016 calculated": 2737,
      "evaluated opioid": 29901,
      "icd codes": 36388,
      "pills opioid": 61523,
      "compared incidence": 18186,
      "wilcoxon test": 87096,
      "continuous variables": 20193,
      "associated chronic": 12230,
      "443 33": 4556,
      "male 69": 43019,
      "duty military": 27199,
      "pills 20": 61499,
      "range 240": 67275,
      "likely prescribe": 41826,
      "77 vs": 5767,
      "providers likely": 66184,
      "opioid active": 51394,
      "vs 42": 86576,
      "42 0001": 4445,
      "providers prescribed": 66190,
      "median 20": 44177,
      "20 pills": 2375,
      "pills prescription": 61538,
      "prescription commonly": 64180,
      "wound catheter": 87354,
      "wound infusion": 87363,
      "bupivacaine followed": 14498,
      "postoperative need": 62807,
      "single centre": 76073,
      "centre prospective": 15633,
      "major university": 42980,
      "recruited study": 68799,
      "study 50": 77896,
      "analysis interventions": 10703,
      "saline injected": 73263,
      "infusion ml": 38714,
      "ml following": 46859,
      "paracetamol non": 58103,
      "drugs morphine": 27003,
      "morphine required": 47915,
      "25 75": 3340,
      "18 bupivacaine": 2081,
      "equal groups": 29230,
      "groups mg": 34237,
      "postoperatively significantly": 63028,
      "higher number": 35273,
      "detected time": 23949,
      "presence nausea": 64594,
      "staphylococcus aureus": 76998,
      "majority cases": 42983,
      "injection provides": 38967,
      "detected 12": 23935,
      "samples used": 73367,
      "injection hydromorphone": 38950,
      "methicillin sensitive": 45160,
      "methicillin resistant": 45157,
      "vehicle control": 86045,
      "reduction number": 69071,
      "strategy objectives": 77439,
      "introduction extended": 39926,
      "release abuse": 69805,
      "new methods": 49339,
      "studies methods": 77777,
      "methods model": 45384,
      "reductions abuse": 69109,
      "related events": 69602,
      "opioid cost": 51678,
      "opioid market": 51896,
      "brand generic": 14381,
      "market abuse": 43408,
      "opioids estimated": 52892,
      "lower annual": 42577,
      "annual medical": 11020,
      "associated largest": 12317,
      "highest number": 35356,
      "opioid replacement": 52333,
      "medical cost": 44352,
      "net savings": 49154,
      "opioid price": 52220,
      "non abuse": 49561,
      "defined pain": 23144,
      "major complication": 42935,
      "open inguinal": 51152,
      "hospital evaluated": 35590,
      "received total": 68299,
      "ml bupivacaine": 46851,
      "level 10": 41446,
      "discharge recovery": 25170,
      "quantity consumed": 66824,
      "days narcotics": 22558,
      "results ninety": 71790,
      "bupivacaine infiltration": 14500,
      "room pain": 72776,
      "pain vs": 57981,
      "001 shorter": 205,
      "shorter recovery": 75214,
      "fewer narcotics": 31648,
      "vs 27": 86556,
      "013 conclusion": 338,
      "implemented novel": 36948,
      "nerve blockade": 49118,
      "pain immediately": 56844,
      "immediately operation": 36746,
      "months postoperatively": 47465,
      "furthermore method": 32750,
      "room stay": 72778,
      "identify changes": 36493,
      "pos illicit": 62428,
      "large observational": 41141,
      "involving illicit": 40128,
      "2006 2010": 2474,
      "aspirin oxycodone": 11870,
      "morphine acetaminophen": 47570,
      "codeine methadone": 17252,
      "reporting using": 70708,
      "using pos": 85568,
      "measured levels": 43974,
      "individual characteristics": 38288,
      "characteristics cohort": 15850,
      "increases observed": 38065,
      "abuse heroin": 6729,
      "remained constant": 70260,
      "constant adjusted": 19738,
      "codeine greater": 17238,
      "study required": 78463,
      "required determine": 70830,
      "context use": 20114,
      "policy responses": 62185,
      "purpose case": 66523,
      "reported summary": 70661,
      "sought treatment": 76490,
      "patient home": 58657,
      "home medications": 35511,
      "included following": 37457,
      "release used": 70017,
      "week day": 86834,
      "initial laboratory": 38852,
      "dl patient": 25649,
      "secondary acute": 74202,
      "acute renal": 7696,
      "renal failure": 70354,
      "failure patient": 31150,
      "patient urine": 58807,
      "200 ml": 2404,
      "ml hr": 46862,
      "sodium bicarbonate": 76405,
      "therapy urine": 81074,
      "day 42": 22259,
      "scale revealed": 73554,
      "clinical availability": 16758,
      "authors hypothesize": 12730,
      "prostaglandin e2": 65909,
      "vascular surgery": 86033,
      "surgery spinal": 79590,
      "cyclooxygenase selective": 21561,
      "elective lower": 28495,
      "fluid obtained": 31943,
      "obtained baseline": 50760,
      "start surgery": 77005,
      "surgical incision": 79632,
      "receive intravenous": 68053,
      "parecoxib 40": 58187,
      "ketorolac 30": 40637,
      "mg preservative": 46180,
      "preservative free": 64717,
      "administered intravenous": 8143,
      "intravenous fentanyl": 39827,
      "concentrations increased": 18768,
      "surgery intravenous": 79432,
      "scores reduced": 73966,
      "reduced drug": 68923,
      "drug groups": 26641,
      "ward pain": 86710,
      "patients lower": 59462,
      "pain tonsillectomy": 57926,
      "tonsillectomy commonly": 81664,
      "following tonsillectomy": 32213,
      "tonsillectomy children": 81663,
      "children opioids": 16062,
      "genetic variations": 33088,
      "associated deaths": 12241,
      "metabolized cyp2d6": 44992,
      "metabolizers extensive": 45005,
      "active opioid": 7521,
      "opioid metabolites": 51931,
      "especially young": 29567,
      "history sleep": 35482,
      "depression adverse": 23569,
      "cyp2d6 genetic": 21603,
      "genetic testing": 33082,
      "using alternative": 85303,
      "alternative analgesics": 9715,
      "states evaluated": 77099,
      "practices primary": 63435,
      "general surgeons": 32988,
      "surgeons pain": 79276,
      "management specialists": 43265,
      "evaluation prescribing": 29964,
      "30 2019": 3677,
      "number prescribed": 50234,
      "orthopedic surgeon": 53832,
      "equivalent mme": 29316,
      "significantly declined": 75673,
      "care medical": 15041,
      "practices reduce": 63440,
      "prescribed research": 63975,
      "research warranted": 71038,
      "warranted determine": 86731,
      "alternative therapies": 9744,
      "opioids alleviate": 52720,
      "alleviate patient": 9601,
      "potentially lethal": 63263,
      "june 10": 40538,
      "10 2010": 689,
      "weekly reports": 86885,
      "alarming increase": 9515,
      "involving prescription": 40135,
      "patients including": 59402,
      "including benzodiazepines": 37595,
      "benzodiazepines muscle": 13666,
      "painful crisis": 58002,
      "despite advances": 23870,
      "analgesics pain": 10470,
      "management protocols": 43251,
      "protocols patients": 66005,
      "acute care": 7613,
      "care setting": 15079,
      "setting objective": 74791,
      "objective article": 50376,
      "evaluate evidence": 29797,
      "management using": 43278,
      "alternatives morphine": 9751,
      "adolescents young": 8464,
      "opioids acute": 52702,
      "acute setting": 7702,
      "required ensure": 70833,
      "safety patient": 73197,
      "study randomized": 78447,
      "showed mor": 75274,
      "models acute": 47105,
      "produces analgesic": 65420,
      "relevant adverse": 70043,
      "intestinal transit": 39699,
      "behavioral signs": 13552,
      "withdrawal results": 87152,
      "analgesics basis": 10383,
      "clinical candidate": 16761,
      "compared pain": 18246,
      "preincisional local": 63706,
      "controls received": 20673,
      "preoperative bupivacaine": 63737,
      "block plus": 14053,
      "rofecoxib 50": 72724,
      "mg preoperatively": 46177,
      "iv fentanyl": 40375,
      "administered postoperatively": 8169,
      "discharge time": 25182,
      "10 analgesic": 740,
      "use satisfaction": 84715,
      "lower maximum": 42642,
      "scores worst": 74019,
      "pain postanesthesia": 57387,
      "02 24": 355,
      "24 versus": 3287,
      "01 required": 322,
      "required 28": 70818,
      "24 discharge": 3196,
      "discharge 04": 25091,
      "hospital recovery": 35625,
      "recovery time": 68767,
      "scores opioid": 73929,
      "oxycodone facilitated": 55064,
      "medical opioid": 44374,
      "examine patterns": 30350,
      "patterns trends": 60230,
      "determinants opioid": 23978,
      "raw data": 67906,
      "data prescription": 22059,
      "iqvia compuscript": 40186,
      "strong weak": 77564,
      "opioid categories": 51567,
      "methods dispensing": 45314,
      "opioid category": 51568,
      "year assessed": 87433,
      "examine possible": 30352,
      "time strong": 81386,
      "peaking 2011": 60330,
      "half reported": 34529,
      "reported lower": 70577,
      "2020 compared": 2894,
      "opioids declined": 52834,
      "heterogeneity opioid": 35052,
      "questions opioid": 66908,
      "related health": 69614,
      "health policy": 34752,
      "intravenous acetaminophen": 39810,
      "quantity opioids": 66838,
      "administered 48": 8106,
      "affording patients": 8954,
      "patients adequate": 58942,
      "analgesia women": 10134,
      "retrospective chart": 72117,
      "review setting": 72356,
      "setting tertiary": 74834,
      "care community": 15013,
      "community hospital": 17921,
      "addition acetaminophen": 7794,
      "january march": 40463,
      "addition opioids": 7820,
      "2012 time": 2614,
      "addition intravenous": 7808,
      "groups given": 34206,
      "opioids group": 52935,
      "surgery time": 79605,
      "time hours": 81273,
      "min opioids": 46539,
      "days intravenous": 22544,
      "24 mg": 3242,
      "mg multimodal": 46064,
      "mg opioids": 46077,
      "group 003": 33533,
      "26 total": 3455,
      "total perioperative": 81884,
      "preoperative intraoperative": 63744,
      "room postoperative": 72777,
      "39 mg": 4271,
      "conclusion multimodal": 18927,
      "approach perioperative": 11472,
      "management includes": 43187,
      "total average": 81780,
      "average opioids": 12915,
      "administered postoperative": 8168,
      "retrospective design": 72143,
      "obstetric gynecologic": 50742,
      "gynecologic surgeries": 34487,
      "low detection": 42465,
      "detection rates": 23965,
      "rates opioids": 67611,
      "post mortem": 62583,
      "mortem cases": 48001,
      "cases state": 15265,
      "samples different": 73342,
      "12 2016": 1227,
      "samples previously": 73360,
      "samples analysed": 73328,
      "lc ms": 41266,
      "evaluate changes": 29776,
      "prescribing prevalence": 64124,
      "opiates opioids": 51334,
      "showed number": 75279,
      "fentanyl fold": 31477,
      "frequently detected": 32548,
      "methadone 39": 45042,
      "2011 2017": 2576,
      "tramadol 31": 82029,
      "methadone greater": 45077,
      "average higher": 12892,
      "significant regional": 75624,
      "regional differences": 69354,
      "collect data": 17442,
      "postmortem case": 62673,
      "postmortem redistribution": 62681,
      "computed tomography": 18655,
      "tomography ct": 81652,
      "ct guided": 21361,
      "samples using": 73368,
      "cases involving": 15244,
      "use methadone": 84480,
      "concentration changes": 18683,
      "kidney liver": 40827,
      "liver spleen": 42187,
      "collected utilizing": 17490,
      "approximately 24": 11564,
      "28 15": 3535,
      "samples body": 73331,
      "body regions": 14205,
      "blood analysis": 14106,
      "conducted liquid": 19372,
      "spectrometry significant": 76672,
      "indicate occurrence": 38223,
      "relevant forensic": 70058,
      "main metabolite": 42833,
      "metabolite methadone": 44952,
      "methadone ethylidene": 45067,
      "ethylidene dimethyl": 29704,
      "dimethyl diphenylpyrrolidine": 25018,
      "diphenylpyrrolidine eddp": 25032,
      "passive diffusion": 58443,
      "results fentanyl": 71691,
      "trend significant": 82952,
      "proved valuable": 66022,
      "irritable bowel": 40281,
      "bowel syndrome": 14288,
      "reporting january": 70696,
      "disability compared": 25072,
      "compared data": 18132,
      "kruskal wallis": 40958,
      "rank test": 67369,
      "test analysis": 80754,
      "53 cases": 5020,
      "treatment complication": 82514,
      "agents significantly": 9243,
      "lower proportions": 42692,
      "recent report": 68417,
      "ratio used": 67805,
      "large medical": 41135,
      "10 therapeutic": 940,
      "total population": 81888,
      "used 45": 84827,
      "opioid non": 51999,
      "used greater": 84946,
      "multidisciplinary patient": 48181,
      "patient gender": 58646,
      "gender specific": 32939,
      "suggest opioids": 79004,
      "generally indicated": 33019,
      "analgesic ladder": 10262,
      "treatment guidelines": 82613,
      "infrequent opioid": 38688,
      "opioid extended": 51801,
      "propoxyphene codeine": 65803,
      "tramadol strong": 82110,
      "numerous factors": 50329,
      "related intensity": 69627,
      "intensity duration": 39254,
      "cancer care": 14766,
      "purpose opioid": 66537,
      "prescribing changed": 64038,
      "changing opioid": 15832,
      "opioid regulations": 52295,
      "ontario residents": 51132,
      "residents aged": 71071,
      "relatively constant": 69775,
      "patients observed": 59570,
      "observed change": 50659,
      "patients relative": 59877,
      "annual increase": 11019,
      "period significant": 60790,
      "changes seen": 15821,
      "decreasing use": 23076,
      "groups changes": 34141,
      "similar drug": 75915,
      "classes conclusion": 16667,
      "conclusion overall": 18945,
      "remain unchanged": 70255,
      "impact changes": 36802,
      "changes quality": 15816,
      "symptom control": 79861,
      "control cancer": 20279,
      "patients needs": 59542,
      "physicians offices": 61442,
      "regulatory concern": 69505,
      "abuse high": 6730,
      "risk population": 72637,
      "assess abuse": 11903,
      "treatment prescription": 82778,
      "subjects used": 78751,
      "used buprenorphine": 84862,
      "30 35": 3687,
      "35 percent": 4091,
      "quarter 2006": 66849,
      "considerably lower": 19618,
      "number individuals": 50162,
      "individuals using": 38361,
      "20 percent": 2373,
      "interpretation data": 39500,
      "altering effects": 9706,
      "percent total": 60495,
      "total sample": 81900,
      "opioid detoxification": 51710,
      "compare pain": 18040,
      "received institutional": 68168,
      "10 men": 785,
      "renal lesions": 70365,
      "11 men": 1131,
      "68 years": 5506,
      "analgesic sedative": 10335,
      "procedure compared": 65272,
      "standard anesthesia": 76889,
      "consisted ml": 19680,
      "ml lidocaine": 46868,
      "conscious sedation": 19549,
      "consisted 50": 19674,
      "fentanyl mg": 31528,
      "compare clinical": 18010,
      "clinical factors": 16815,
      "factors drug": 31090,
      "terms patient": 80714,
      "central versus": 15618,
      "groups cryoablation": 34168,
      "rf group": 72446,
      "cryoablation group": 21354,
      "patient required": 58746,
      "required general": 70838,
      "additional narcotics": 7870,
      "image guided": 36679,
      "prospective trials": 65889,
      "validated pain": 85792,
      "modulate opioid": 47254,
      "use dependence": 84299,
      "dependence withdrawal": 23492,
      "target drug": 80488,
      "identify potential": 36521,
      "potential interaction": 63177,
      "800 000": 5865,
      "000 urine": 48,
      "collected pain": 17467,
      "levels evaluated": 41559,
      "evaluated determine": 29873,
      "determine presence": 24042,
      "11 carboxy": 1124,
      "carboxy tetrahydrocannabinol": 14973,
      "thc cooh": 80899,
      "statistical differences": 77176,
      "concentrations results": 18810,
      "conclusion opioids": 18940,
      "opioids investigated": 53006,
      "buprenorphine marijuana": 14558,
      "despite large": 23888,
      "increases pharmaceutical": 38071,
      "dependence related": 23486,
      "characteristics treatment": 15884,
      "people receiving": 60422,
      "receiving treatment": 68386,
      "treatment pharmaceutical": 82760,
      "dependence baseline": 23465,
      "characteristics design": 15856,
      "treatment services": 82833,
      "opioids pain": 53144,
      "responses regarding": 71394,
      "sd 11": 74061,
      "lifetime heroin": 41748,
      "57 oxycodone": 5134,
      "oxycodone 49": 54577,
      "49 codeine": 4775,
      "opioids reported": 53263,
      "reported past": 70617,
      "past year": 58474,
      "reported chronic": 70516,
      "pain half": 56817,
      "half 52": 34513,
      "52 reported": 4995,
      "group older": 33878,
      "related treatment": 69703,
      "treatment expectations": 82583,
      "iv pain": 40395,
      "pain positive": 57385,
      "study describes": 78062,
      "emerging treatment": 28713,
      "associated pharmaceutical": 12379,
      "epidemic continues": 29129,
      "continues impact": 20147,
      "new strategies": 49377,
      "combat epidemic": 17534,
      "study analyze": 77951,
      "based descriptive": 13305,
      "program study": 65546,
      "access drug": 6989,
      "identify respond": 36535,
      "drug distribution": 26592,
      "data 2015": 21852,
      "analyzed drugs": 10829,
      "agency dea": 9213,
      "dea schedule": 22680,
      "pharmaceutical company": 61022,
      "marijuana 11": 43381,
      "bath salts": 13486,
      "methamphetamine amphetamine": 45139,
      "15 buprenorphine": 1723,
      "benzodiazepines alprazolam": 13654,
      "versus 11": 86096,
      "females 005": 31385,
      "005 conclusion": 262,
      "information health": 38650,
      "providers regarding": 66194,
      "individuals history": 38348,
      "history past": 35472,
      "review perioperative": 72335,
      "acetaminophen dipyrone": 7179,
      "opioids weak": 53386,
      "tramadol tilidine": 82115,
      "main aim": 42823,
      "relationship analgesic": 69712,
      "clinical decisions": 16786,
      "patients preoperative": 59667,
      "gastrointestinal cardiovascular": 32873,
      "perioperative administration": 60824,
      "pain discussed": 56726,
      "purpose oral": 66541,
      "oral use": 53683,
      "use primary": 84666,
      "administration non": 8311,
      "stronger opioids": 77568,
      "opioids previously": 53224,
      "previously studied": 64960,
      "prevalence patterns": 64802,
      "pill use": 61495,
      "seeking opioid": 74351,
      "users history": 85244,
      "pill intact": 61493,
      "median maximum": 44239,
      "maximum number": 43595,
      "pills taken": 61545,
      "time 20": 81195,
      "frequently endorsed": 32551,
      "tablets containing": 80135,
      "indicate ingestion": 38220,
      "prevention intervention": 64874,
      "efforts targeting": 28445,
      "determine proportion": 24044,
      "prescribed surgeons": 63984,
      "medicine opioid": 44708,
      "guidelines developed": 34435,
      "types care": 83365,
      "prescriptions limited": 64507,
      "using nationwide": 85511,
      "nationwide insurance": 48731,
      "study adults": 77914,
      "years primary": 87643,
      "outcome change": 53908,
      "change opioid": 15736,
      "prescription share": 64404,
      "undergoing surgical": 83582,
      "dental care": 23399,
      "amounts opioid": 9836,
      "opioid filled": 51806,
      "filled results": 31713,
      "filled opioid": 31706,
      "receiving surgery": 68378,
      "surgery emergency": 79384,
      "15 2010": 1680,
      "2016 001": 2727,
      "001 greatest": 140,
      "greatest increases": 33502,
      "patients filled": 59304,
      "initial prescriptions": 38868,
      "prescriptions emergency": 64482,
      "emergency medicine": 28691,
      "patients surgical": 60023,
      "total oral": 81870,
      "period surgical": 60801,
      "received highest": 68157,
      "based guideline": 13324,
      "guideline development": 34420,
      "dental prescribing": 23408,
      "opioid morbidity": 51958,
      "studies news": 77790,
      "news media": 49422,
      "reporting increased": 70692,
      "effects substance": 28172,
      "use documented": 84340,
      "major roles": 42976,
      "media reporting": 44167,
      "media reports": 44168,
      "reports prescription": 70738,
      "increases overdose": 38067,
      "ecological study": 27306,
      "monthly time": 47423,
      "unintentional poisoning": 83745,
      "poisoning deaths": 62158,
      "opioid substances": 52382,
      "using multiple": 85504,
      "multiple cause": 48261,
      "death data": 22705,
      "national center": 48669,
      "center health": 15522,
      "health statistics": 34777,
      "monthly counts": 47418,
      "mortality rates": 47992,
      "opioids seven": 53292,
      "seven year": 74880,
      "number articles": 50141,
      "oxycontin significant": 56184,
      "significant association": 75431,
      "reports deaths": 70720,
      "preceding fatal": 63502,
      "mortality conclusions": 47983,
      "key factors": 40666,
      "factors influencing": 31111,
      "psychoactive substances": 66335,
      "finding suggests": 31765,
      "suggests need": 79038,
      "reporting prescription": 70701,
      "large percentage": 41144,
      "experience increased": 30577,
      "end dose": 28785,
      "pain linked": 57023,
      "formulations long": 32384,
      "performed systematic": 60637,
      "review evaluate": 72293,
      "chronic cancer": 16184,
      "pain identified": 56842,
      "pain btp": 56503,
      "btp frequency": 14465,
      "final analysis": 31740,
      "analysis 14": 10625,
      "14 studies": 1628,
      "formulations showed": 32406,
      "morphine 23": 47549,
      "showed patients": 75286,
      "experienced fewer": 30604,
      "fewer episodes": 31638,
      "episodes btp": 29206,
      "action opioids": 7441,
      "compared short": 18305,
      "studies examine": 77721,
      "examine incidence": 30346,
      "incidence end": 37274,
      "rescue medicine": 70962,
      "pain taking": 57900,
      "vs long": 86652,
      "physiological changes": 61458,
      "drug disposition": 26591,
      "porto systemic": 62424,
      "systemic shunting": 80033,
      "metabolism drug": 44929,
      "increased oral": 37968,
      "result impaired": 71478,
      "drug binding": 26539,
      "body composition": 14191,
      "affected various": 8923,
      "liver disease": 42175,
      "drugs difficult": 26939,
      "lack evidence": 41053,
      "antiplatelet activity": 11257,
      "likely occur": 41820,
      "reduced doses": 68920,
      "safe patients": 73097,
      "patients non": 59550,
      "alcoholic liver": 9549,
      "affected presence": 8922,
      "presence hepatic": 64591,
      "reduction analgesic": 69043,
      "effect expected": 27455,
      "tramadol alfentanil": 82034,
      "decreased moderate": 23010,
      "impairment highly": 36895,
      "oxycodone important": 55239,
      "patients hepatic": 59354,
      "intervals used": 39617,
      "phenylpiperidine opioids": 61355,
      "sufentanil remifentanil": 78953,
      "disease opioid": 25334,
      "hepatic encephalopathy": 34951,
      "careful monitoring": 15102,
      "purpose use": 66595,
      "media attention": 44165,
      "june december": 40560,
      "nationwide registries": 48734,
      "2014 2019": 2653,
      "rates prevalence": 67627,
      "total use": 81914,
      "analgesics time": 10507,
      "time described": 81249,
      "treatment duration": 82560,
      "results early": 71670,
      "2019 total": 2885,
      "tramadol use": 82118,
      "use decreased": 84292,
      "markedly use": 43403,
      "quarterly prevalence": 66855,
      "decreased 32": 22958,
      "2014 18": 2647,
      "18 1000": 2029,
      "prevalence increased": 64788,
      "users decreased": 85234,
      "use stable": 84744,
      "june 2017": 40550,
      "use continued": 84270,
      "unintended effects": 83741,
      "utilization opioids": 85731,
      "opioids related": 53252,
      "regarding postoperative": 69272,
      "design patients": 23744,
      "level use": 41537,
      "consecutive adult": 19555,
      "subjects met": 78711,
      "134 patients": 1530,
      "patients 61": 58882,
      "tablets postoperative": 80198,
      "fewer 15": 31626,
      "medication opioid": 44526,
      "consumption positively": 19990,
      "correlated postoperative": 20816,
      "pain 01": 56346,
      "correlated use": 20820,
      "use acetaminophen": 84168,
      "specific procedures": 76616,
      "procedures performed": 65320,
      "postoperative steroids": 62969,
      "smoking history": 76338,
      "history current": 35455,
      "current smokers": 21467,
      "001 required": 200,
      "opioids 02": 52654,
      "02 conclusions": 366,
      "approach postoperative": 11473,
      "surgery reduces": 79556,
      "reduces number": 68995,
      "sufficient pain": 78973,
      "90 patients": 6112,
      "patients immediate": 59376,
      "performed use": 60646,
      "use systemic": 84770,
      "systemic steroids": 80034,
      "smoking status": 76340,
      "prescriptions background": 64453,
      "background high": 13062,
      "remain common": 70247,
      "common patient": 17793,
      "needed dosing": 48997,
      "managing postoperative": 43296,
      "determine pain": 24034,
      "related clinical": 69572,
      "outcomes patients": 54072,
      "age 10": 8966,
      "years adult": 87558,
      "analgesia pain": 10045,
      "management strategy": 43267,
      "strategy methods": 77438,
      "study act": 77908,
      "staff patients": 76858,
      "patients families": 59298,
      "traditional pain": 81989,
      "control needed": 20370,
      "needed analgesics": 48977,
      "retrospectively compared": 72178,
      "initiation patient": 38898,
      "decreased 14": 22941,
      "used patient": 85068,
      "analgesia mean": 10016,
      "opioid consumed": 51597,
      "14 98": 1579,
      "98 mg": 6466,
      "27 mg": 3497,
      "13 58": 1471,
      "58 mg": 5161,
      "morphine 33": 47558,
      "standardized use": 76988,
      "medication consumed": 44477,
      "mortality morbidity": 47988,
      "studies documented": 77703,
      "population levels": 62351,
      "2011 design": 2582,
      "correlations annual": 20839,
      "levels strong": 41611,
      "alcohol treatment": 9543,
      "treatment information": 82627,
      "examined study": 30415,
      "strong significant": 77563,
      "significant correlations": 75454,
      "correlations observed": 20841,
      "98 95": 6459,
      "00 001": 2,
      "003 oxycodone": 251,
      "oxycodone 93": 54612,
      "ci 57": 16471,
      "86 59": 6004,
      "00 95": 9,
      "ci 96": 16514,
      "001 discussion": 133,
      "strongly correlated": 77577,
      "findings randomized": 31812,
      "oral parenteral": 53652,
      "los hospital": 42428,
      "hospitalization outpatient": 35659,
      "home methods": 35512,
      "diaries follow": 24357,
      "diary days": 24361,
      "periods oxycodone": 60820,
      "codeine frequently": 17236,
      "medication average": 44463,
      "days groups": 22529,
      "cumulative time": 21411,
      "trial significantly": 83088,
      "lowest doses": 42730,
      "beneficial effects": 13597,
      "75 ropivacaine": 5721,
      "ropivacaine postoperative": 72806,
      "postoperative inflammatory": 62780,
      "hemodynamic response": 34939,
      "methods seven": 45573,
      "15 ml": 1774,
      "ml 75": 46843,
      "ropivacaine group": 72794,
      "received routine": 68264,
      "pro inflammatory": 65206,
      "inflammatory cytokine": 38554,
      "levels plasma": 41594,
      "72 postoperatively": 5629,
      "response skin": 71372,
      "skin incision": 76204,
      "measured results": 43993,
      "il levels": 36611,
      "decreased plasma": 23027,
      "48 postoperatively": 4746,
      "postoperatively groups": 63002,
      "conclusion preoperative": 18969,
      "cerebral aneurysms": 15642,
      "controlled postoperative": 20521,
      "03 2017": 404,
      "calcium channel": 14673,
      "channel blockers": 15835,
      "potentiate analgesic": 63272,
      "properties local": 65712,
      "examined analgesic": 30368,
      "effects administering": 27809,
      "undergoing upper": 83591,
      "received brachial": 68122,
      "epinephrine microg": 29202,
      "microg ml": 46361,
      "received iv": 68184,
      "solution group": 76443,
      "analgesic duration": 10193,
      "increased patients": 37980,
      "plexus blocks": 62019,
      "groups 005": 34087,
      "total 24": 81744,
      "24 acetaminophen": 3184,
      "groups 002": 34086,
      "conclude addition": 18851,
      "block lidocaine": 14047,
      "prolong duration": 65606,
      "duration sensory": 27182,
      "anesthesia effect": 10907,
      "24 analgesic": 3188,
      "lidocaine morphine": 41672,
      "prolongs duration": 65647,
      "use serotonin": 84725,
      "rare complication": 67407,
      "autonomic instability": 12768,
      "effects include": 27947,
      "methadone meperidine": 45098,
      "codeine combination": 17212,
      "drugs antidepressants": 26887,
      "attention paid": 12569,
      "pharmacological antagonism": 61208,
      "drugs frequently": 26962,
      "treatment post": 82768,
      "patient complications": 58570,
      "brain review": 14363,
      "review recent": 72351,
      "based data": 13304,
      "intracranial surgery": 39735,
      "surgery especially": 79392,
      "performed end": 60588,
      "surgery local": 79444,
      "adequate short": 7974,
      "relief opioids": 70157,
      "increase effects": 37747,
      "codeine non": 17261,
      "non narcotics": 49643,
      "tramadol paracetamol": 82098,
      "supplemental opioid": 79164,
      "deaths related": 22778,
      "illicit non": 36642,
      "use uncommon": 84787,
      "sleep apnoea": 76214,
      "30 subjects": 3796,
      "subjects clinical": 78685,
      "sleep related": 76235,
      "review addresses": 72252,
      "sleep disordered": 76217,
      "disordered breathing": 25390,
      "use discussion": 84315,
      "discussion regarding": 25309,
      "medications safe": 44673,
      "making process": 43013,
      "process opioid": 65338,
      "complex clinical": 18528,
      "public safety": 66406,
      "abuse recent": 6858,
      "abuse prevention": 6844,
      "use furthermore": 84378,
      "proposed means": 65798,
      "raise concerns": 66978,
      "guidelines postoperative": 34462,
      "measure postoperative": 43942,
      "use minimally": 84489,
      "factors predict": 31123,
      "predict patient": 63554,
      "patient low": 58674,
      "opioid user": 52615,
      "prospective survey": 65887,
      "based study": 13384,
      "study including": 78254,
      "hospitals patients": 35672,
      "anxiety depression": 11271,
      "depression pain": 23591,
      "pain catastrophizing": 56514,
      "weeks surgery": 86957,
      "opioid acute": 51397,
      "150 morphine": 1815,
      "equivalents equivalent": 29349,
      "equivalent 20": 29286,
      "median patient": 44272,
      "patient postoperative": 58710,
      "37 morphine": 4197,
      "equivalent tablets": 29333,
      "patients leftover": 59443,
      "opioids weeks": 53389,
      "included history": 37462,
      "anticipated postoperative": 11159,
      "medication needs": 44522,
      "factors help": 31095,
      "help identify": 34904,
      "likely high": 41810,
      "user defined": 85223,
      "equivalents conclusion": 29342,
      "surgeons prescribed": 79279,
      "prescribed times": 63990,
      "needed patients": 49025,
      "preoperative risk": 63759,
      "excess prescription": 30455,
      "experiencing opioid": 30647,
      "29 states": 3614,
      "states washington": 77159,
      "opioids received": 53239,
      "state drug": 77040,
      "data linear": 22003,
      "assessed associations": 11986,
      "level time": 41529,
      "covariates prescription": 21012,
      "socio economic": 76388,
      "setting united": 74839,
      "states participants": 77136,
      "drug prescription": 26745,
      "fee service": 31325,
      "provide health": 66069,
      "adjusted number": 8041,
      "iii opioids": 36589,
      "iii opioid": 36588,
      "prescriptions 29": 64438,
      "conclusion state": 18997,
      "appears associated": 11399,
      "legitimate opioid": 41386,
      "trends large": 82970,
      "highest opioid": 35357,
      "prescriptions 2012": 64435,
      "period prevalence": 60776,
      "results 62": 71579,
      "identified study": 36474,
      "prescriptions decreased": 64467,
      "seasonal variation": 74176,
      "multivariable regression": 48334,
      "odds opioid": 50900,
      "prescribed discharge": 63850,
      "discharge month": 25141,
      "period 001": 60675,
      "significant interaction": 75570,
      "black patients": 13901,
      "odds receiving": 50939,
      "opioid discharge": 51712,
      "discharge compared": 25112,
      "compared white": 18340,
      "white patients": 87028,
      "interval 001": 39550,
      "conclusion large": 18919,
      "opioid recent": 52231,
      "evidence indicates": 30200,
      "program associated": 65532,
      "relationship opioid": 69720,
      "race background": 66935,
      "reported increase": 70572,
      "home patients": 35517,
      "insufficient evidence": 39125,
      "agents used": 9245,
      "variations use": 85926,
      "use time": 84775,
      "prescribed objective": 63902,
      "scheduled analgesic": 73637,
      "2000 2011": 2419,
      "association age": 12471,
      "secondary analyses": 74206,
      "study samples": 78476,
      "setting subjects": 74833,
      "methods trend": 45616,
      "results odds": 71805,
      "receiving pain": 68368,
      "compared 2000": 18072,
      "increase 34": 37723,
      "34 57": 4021,
      "buprenorphine morphine": 14562,
      "001 non": 162,
      "decreased 2000": 22947,
      "2000 2004": 2415,
      "2004 2009": 2452,
      "received fewer": 68149,
      "analgesics compared": 10401,
      "patients dementia": 59174,
      "differences analgesic": 24713,
      "use paracetamol": 84601,
      "paracetamol strong": 58115,
      "cognitive impairment": 17328,
      "impairment objective": 36903,
      "2012 objective": 2606,
      "testing individuals": 80824,
      "individuals initiating": 38349,
      "analgesics design": 10412,
      "setting sentinel": 74819,
      "sentinel distributed": 74582,
      "distributed database": 25554,
      "insured members": 39160,
      "members patients": 44781,
      "age 65": 9041,
      "january 2009": 40429,
      "2009 december": 2524,
      "december 2013": 22823,
      "new users": 49386,
      "analgesics claim": 10387,
      "test 30": 80752,
      "results identified": 71718,
      "criteria met": 21204,
      "64 percent": 5392,
      "hydromorphone 40": 36155,
      "40 percent": 4374,
      "episodes identified": 29208,
      "analgesics percent": 10481,
      "percent vs": 60500,
      "vs 14": 86533,
      "14 percent": 1623,
      "23 percent": 3109,
      "areas improving": 11647,
      "practices introduction": 63427,
      "agonist used": 9312,
      "tablet single": 80101,
      "mean plasma": 43839,
      "plasma elimination": 61930,
      "covered review": 21017,
      "review focuses": 72304,
      "pain phase": 57373,
      "phase studies": 61320,
      "tablet containing": 80091,
      "containing 15": 20068,
      "reviewed expert": 72378,
      "various acute": 85958,
      "pain states": 57860,
      "vomiting sedation": 86479,
      "healthcare facilities": 34797,
      "acting vs": 7426,
      "vs short": 86676,
      "total serum": 81904,
      "kaiser permanente": 40577,
      "permanente northern": 60900,
      "northern california": 49966,
      "california kpnc": 14729,
      "participants eighty": 58298,
      "age 26": 8989,
      "79 years": 5803,
      "opioid months": 51955,
      "laboratory results": 41030,
      "results average": 71608,
      "average total": 12940,
      "population showed": 62385,
      "receiving daily": 68330,
      "250 ng": 3398,
      "receiving long": 68347,
      "34 46": 4020,
      "34 12": 4016,
      "using short": 85613,
      "dl mean": 25648,
      "128 ng": 1439,
      "vs median": 86655,
      "opioids 78": 52685,
      "index significantly": 38210,
      "ratio 13": 67719,
      "24 006": 3140,
      "ratio 02": 67712,
      "receiving chronic": 68326,
      "chronic daily": 16189,
      "opioid year": 52650,
      "studies group": 77736,
      "consumption data": 19910,
      "july 2016": 40519,
      "new tool": 49381,
      "illicit fentanyl": 36640,
      "potential severe": 63227,
      "death used": 22730,
      "users high": 85242,
      "medicinal products": 44701,
      "occurred united": 50849,
      "states europe": 77098,
      "involved polysubstance": 40110,
      "polysubstance use": 62228,
      "reports case": 70713,
      "fatalities involving": 31243,
      "available information": 12816,
      "eventual death": 30137,
      "metabolites detected": 44966,
      "biological fluids": 13851,
      "reported concentrations": 70524,
      "years american": 87570,
      "primary concern": 64996,
      "relative value": 69772,
      "physician contacts": 61425,
      "major medical": 42952,
      "write prescription": 87369,
      "patient life": 58672,
      "pill based": 61488,
      "related medications": 69632,
      "pain larger": 56998,
      "patient suffering": 58792,
      "analyze abuse": 10812,
      "various aspects": 85961,
      "administration effects": 8256,
      "effects effects": 27909,
      "opioid followed": 51811,
      "followed codeine": 32051,
      "intake frequently": 39181,
      "mode administration": 47017,
      "administration followed": 8267,
      "support caregivers": 79187,
      "modes administration": 47222,
      "ferric carboxymaltose": 31617,
      "11 16": 1096,
      "lidocaine prilocaine": 41677,
      "conjugate vaccine": 19536,
      "polyethylene glycol": 62196,
      "available single": 12837,
      "agent combination": 9216,
      "withdrawn market": 87173,
      "recommendation based": 68589,
      "concern risk": 18833,
      "risk associated": 72522,
      "clinical benefit": 16759,
      "drug previously": 26748,
      "search conducted": 74107,
      "50 opioid": 4874,
      "using pubmed": 85580,
      "acetaminophen analgesics": 7151,
      "used including": 84972,
      "qtc interval": 66653,
      "level effect": 41463,
      "sublingual administration": 78754,
      "analgesics mainstay": 10444,
      "mainstay pain": 42877,
      "hospice patients": 35553,
      "patients longer": 59459,
      "route available": 72841,
      "hepatic pass": 34957,
      "metabolism pharmacokinetic": 44937,
      "hydromorphone superior": 36225,
      "buprenorphine potent": 14582,
      "partial mu": 58243,
      "appears promising": 11405,
      "medications new": 44649,
      "use increasing": 84429,
      "various methods": 85970,
      "medications number": 44650,
      "methods described": 45309,
      "formulations using": 32413,
      "propoxyphene pentazocine": 65806,
      "route abuse": 72837,
      "medication medication": 44515,
      "potential abusers": 63126,
      "abusers targeted": 6935,
      "patients prior": 59701,
      "identify proportion": 36529,
      "users evidence": 85238,
      "dosage strength": 25762,
      "methods identified": 45354,
      "identified new": 36449,
      "years enrolled": 87588,
      "medical pharmacy": 44381,
      "pharmacy coverage": 61259,
      "assessed proportion": 12046,
      "using definitions": 85375,
      "day consecutive": 22283,
      "days immediately": 22535,
      "immediately prior": 36751,
      "index 30": 38186,
      "25 mcg": 3361,
      "respectively aged": 71167,
      "aged 25": 9181,
      "25 34": 3331,
      "34 years": 4042,
      "years highest": 87597,
      "did evidence": 24448,
      "minimum standard": 46616,
      "suggest need": 79001,
      "regarding appropriate": 69243,
      "polymorphisms cytochrome": 62216,
      "demethylation codeine": 23260,
      "required analgesic": 70824,
      "dihydrocodeine hydrocodone": 24990,
      "potency efficacy": 63074,
      "stimulate mu": 77361,
      "mu delta": 48107,
      "agonist stimulated": 9306,
      "guanosine 35": 34392,
      "35 thio": 4092,
      "triphosphate 35": 83231,
      "mu receptors": 48139,
      "delta receptors": 23243,
      "fold potent": 31999,
      "30 100": 3664,
      "efficacy morphine": 28299,
      "morphine produced": 47892,
      "efficacy potency": 28329,
      "potency codeine": 63070,
      "activate mu": 7459,
      "increased efficacy": 37911,
      "efficacy decreased": 28245,
      "delta receptor": 23242,
      "showed greater": 75254,
      "differences efficacy": 24738,
      "understand relationship": 83629,
      "following dental": 32124,
      "local infiltration": 42208,
      "procedure used": 65290,
      "dental prostheses": 23411,
      "receive opioid": 68060,
      "266 mg": 3467,
      "mg end": 45881,
      "bupivacaine epinephrine": 14495,
      "near end": 48857,
      "tablets ibuprofen": 80165,
      "mg needed": 46069,
      "10 numeric": 876,
      "10 worst": 954,
      "reports treatment": 70741,
      "events collected": 30020,
      "group 35": 33603,
      "35 time": 4094,
      "significantly cumulative": 75671,
      "follow patients": 32025,
      "seventy seven": 74894,
      "group 80": 33646,
      "80 control": 5840,
      "reduction opioid": 69072,
      "incidence treatment": 37324,
      "comparable patients": 17966,
      "analyzed changes": 10822,
      "covid 19": 21021,
      "19 pandemic": 2189,
      "surveillance streetrx": 79688,
      "price milligram": 64969,
      "opioids april": 52731,
      "potency drugs": 63073,
      "increased 23": 37842,
      "drugs hydrocodone": 26972,
      "increased 12": 37824,
      "opioid demand": 51698,
      "opioids measures": 53040,
      "measures taken": 44101,
      "access medications": 6993,
      "disorder associated": 25368,
      "analgesics morphine": 10450,
      "codeine semi": 17285,
      "enzymes involved": 29114,
      "transcripts corresponding": 82136,
      "biosynthetic pathways": 13868,
      "pathway intermediates": 58514,
      "product formation": 65429,
      "provide update": 66109,
      "old white": 51020,
      "white man": 87017,
      "man presented": 43112,
      "16 ng": 1884,
      "trending downward": 82957,
      "spontaneous resolution": 76760,
      "patient admitted": 58535,
      "teenagers young": 80558,
      "based current": 13301,
      "evidence evidence": 30190,
      "evidence available": 30148,
      "available support": 12843,
      "support long": 79201,
      "improved quality": 37128,
      "joint pain": 40490,
      "failed benefit": 31139,
      "include morphine": 37358,
      "adjunct medication": 8003,
      "medication including": 44505,
      "related behavior": 69561,
      "monitoring intervention": 47326,
      "buprenorphine similar": 14590,
      "limited number": 41946,
      "opiate dependent": 51296,
      "combination buprenorphine": 17550,
      "treatment pregnant": 82776,
      "syndrome occur": 79919,
      "problem countries": 65236,
      "naloxone potential": 48487,
      "heroin prescription": 35026,
      "prescription opiates": 64272,
      "opiates oxycodone": 51335,
      "accept treatment": 6975,
      "traditional opiate": 81985,
      "use difficult": 84313,
      "article reviews": 11784,
      "clinical guidelines": 16822,
      "treatment review": 82823,
      "aspects opioids": 11863,
      "use gabapentinoids": 84380,
      "pain difficult": 56718,
      "limits quality": 41982,
      "life common": 41689,
      "yr old": 87747,
      "grade iv": 33377,
      "experienced severe": 30624,
      "refractory line": 69222,
      "antidepressants selective": 11178,
      "remained high": 70264,
      "control time": 20433,
      "role opioids": 72754,
      "pain secondary": 57806,
      "patients improving": 59388,
      "improving function": 37193,
      "function quality": 32673,
      "sulfate oxycodone": 79068,
      "limits use": 41983,
      "use acute": 84171,
      "pain settings": 57818,
      "reduced effects": 68924,
      "burden opioid": 14602,
      "2010 conclusions": 2551,
      "therapy based": 80991,
      "preclinical findings": 63530,
      "intraoperative local": 39773,
      "cleft lip": 16728,
      "lip repair": 42064,
      "associated perioperative": 12377,
      "information primary": 38665,
      "performed united": 60643,
      "2010 2020": 2548,
      "local anesthesia": 42204,
      "treatment lidocaine": 82639,
      "narcotic administration": 48583,
      "administration study": 8379,
      "underwent primary": 83690,
      "repair decreased": 70380,
      "decreased years": 23055,
      "years overall": 87629,
      "overall 21": 54179,
      "received lidocaine": 68190,
      "received local": 68191,
      "administration perioperative": 8336,
      "001 11": 96,
      "11 vs": 1156,
      "utilization postoperative": 85734,
      "receiving bupivacaine": 68325,
      "vs conclusions": 86638,
      "conclusions children": 19041,
      "undergoing cleft": 83519,
      "decreased perioperative": 23026,
      "potential methods": 63190,
      "controlling postoperative": 20660,
      "non narcotic": 49640,
      "narcotic medications": 48599,
      "surgery july": 79435,
      "usage complications": 84115,
      "patient initial": 58665,
      "patients separated": 59956,
      "measures addition": 44037,
      "information following": 38648,
      "measures recorded": 44095,
      "used total": 85159,
      "consumption refills": 20008,
      "surgical complications": 79625,
      "complications related": 18569,
      "analgesic adverse": 10147,
      "included 17": 37383,
      "acetaminophen tablets": 7253,
      "controls 14": 20665,
      "cohort 17": 17339,
      "mg ci": 45821,
      "ci 55": 16469,
      "0001 mean": 66,
      "reduced average": 68913,
      "average 26": 12865,
      "26 ome": 3448,
      "001 postoperative": 191,
      "group 02": 33541,
      "addition celecoxib": 7797,
      "decrease incidence": 22896,
      "appears effective": 11401,
      "effective decreasing": 27612,
      "increased decades": 37899,
      "opioids nonmedical": 53098,
      "nonmedical purposes": 49781,
      "therapy costs": 81003,
      "costs long": 20898,
      "dose daily": 25856,
      "therapeutic alternatives": 80918,
      "year prior": 87491,
      "initiative implemented": 38904,
      "claims based": 16618,
      "generic versions": 33053,
      "percentage change": 60507,
      "paid claims": 56343,
      "implementation opioid": 36937,
      "opioid management": 51895,
      "2002 overall": 2443,
      "17 0001": 1925,
      "0001 overall": 72,
      "stable average": 76838,
      "52 82": 4978,
      "compared 59": 18084,
      "state medicaid": 77053,
      "significant overall": 75590,
      "decrease opioid": 22907,
      "specifically targeted": 76630,
      "therapeutic class": 80927,
      "authorization process": 12716,
      "medication management": 44513,
      "management guidelines": 43184,
      "types prescribed": 83376,
      "searches conducted": 74165,
      "language restrictions": 41086,
      "measuring opioid": 44107,
      "using risk": 85599,
      "bias tool": 13775,
      "individual study": 38311,
      "investigated study": 40059,
      "study level": 78285,
      "level factors": 41483,
      "overall evidence": 54200,
      "evidence quality": 30250,
      "using grading": 85419,
      "42 studies": 4476,
      "identified majority": 36444,
      "states america": 77081,
      "studies low": 77767,
      "estimate proportion": 29614,
      "opioids 30": 52673,
      "28 32": 3540,
      "32 42": 3913,
      "evidence strong": 30260,
      "21 15": 2939,
      "15 studies": 1793,
      "prescribing associated": 64031,
      "prescribing recent": 64130,
      "states high": 77105,
      "fentanyl used": 31610,
      "used inappropriately": 84970,
      "ingestion just": 38744,
      "reports suggest": 70740,
      "suggest higher": 78994,
      "treatment inadequate": 82620,
      "crisis research": 21178,
      "research aims": 70978,
      "identifying novel": 36543,
      "enhanced efficacy": 28970,
      "efficacy fentanyl": 28268,
      "methods series": 45572,
      "antagonize effects": 11094,
      "studies followed": 77733,
      "vivo pharmacological": 86380,
      "determine ability": 23986,
      "antinociception hot": 11223,
      "highly potent": 35397,
      "studies revealed": 77832,
      "concentrations apparent": 18746,
      "80 min": 5853,
      "kg ip": 40750,
      "antinociception induced": 11227,
      "fully effective": 32614,
      "preventing oxycodone": 64866,
      "kg ineffective": 40742,
      "deficits caused": 23114,
      "kor agonist": 40942,
      "u50 488": 83400,
      "methods developed": 45313,
      "agents treatment": 9244,
      "mor antagonist": 47497,
      "antagonist activity": 11057,
      "activity vitro": 7593,
      "genetic polymorphisms": 33079,
      "drug metabolising": 26703,
      "cytochromes p450": 21666,
      "major cyp": 42938,
      "polymorphisms cyp2d6": 62215,
      "cyp2d6 cyp2c19": 21592,
      "cyp2c19 cyp2c9": 21578,
      "prescribed drugs": 63857,
      "antidepressants antipsychotics": 11175,
      "metaboliser um": 44918,
      "um phenotype": 83438,
      "venlafaxine amitriptyline": 86055,
      "prodrug opioids": 65353,
      "oxycodone pms": 55699,
      "pms cyp2d6": 62047,
      "codeine cyp2d6": 17220,
      "cyp2d6 pm": 21619,
      "effects cyp2d6": 27884,
      "cyp2d6 genotyping": 21607,
      "cyp2c19 responsible": 21580,
      "inhibitors ppis": 38807,
      "active metabolite": 7517,
      "ph values": 61002,
      "rates higher": 67585,
      "involved metabolism": 40100,
      "dose reductions": 26043,
      "polymorphism associated": 62212,
      "time reach": 81347,
      "higher frequencies": 35244,
      "risk nsaid": 72607,
      "associated gastrointestinal": 12267,
      "gastrointestinal bleeding": 32871,
      "impact terms": 36853,
      "require lower": 70805,
      "therapeutic plasma": 80955,
      "dosing guidelines": 26313,
      "derivatives oxycodone": 23623,
      "anticancer drug": 11152,
      "genes involved": 33064,
      "information pertaining": 38660,
      "recent developments": 68398,
      "young population": 87723,
      "population received": 62380,
      "little attention": 42145,
      "used medicines": 85007,
      "sale prescription": 73245,
      "illicit market": 36641,
      "opiates like": 51328,
      "like fentanyl": 41778,
      "medical specialities": 44404,
      "giving rise": 33208,
      "dependence diversion": 23468,
      "cases death": 15230,
      "current clinical": 21430,
      "analgesia ambulatory": 9914,
      "ambulatory surgical": 9776,
      "context opioid": 20110,
      "ambulatory patients": 9769,
      "patients provide": 59715,
      "achieve early": 7298,
      "early mobilization": 27259,
      "stay hospital": 77279,
      "analgesia strategies": 10112,
      "local analgesia": 42203,
      "analgesia acetaminophen": 9899,
      "acetaminophen nonsteroidal": 7213,
      "aspartate receptor": 11856,
      "multimodal strategy": 48248,
      "regarding effects": 69250,
      "effects risks": 28148,
      "weaker opioids": 86799,
      "tramadol used": 82119,
      "education postoperative": 27390,
      "pharmacological activities": 61206,
      "recent advances": 68388,
      "proteomics metabolomics": 65951,
      "candidates vitro": 14925,
      "differences oral": 24771,
      "release products": 69995,
      "products used": 65460,
      "searches medline": 74168,
      "medline 1966": 44728,
      "using key": 85451,
      "key search": 40677,
      "terms opioid": 80710,
      "relevant information": 70061,
      "articles identified": 11797,
      "evaluated information": 29893,
      "information deemed": 38639,
      "deemed relevant": 23085,
      "clarified clinical": 16643,
      "recognition treatment": 68570,
      "major focus": 42947,
      "review pain": 72330,
      "oral modified": 53570,
      "patients better": 59036,
      "differences available": 24715,
      "available oral": 12828,
      "assessed current": 11994,
      "medical management": 44368,
      "population patients": 62368,
      "percent female": 60464,
      "female average": 31355,
      "age 53": 9021,
      "53 years": 5026,
      "years common": 87578,
      "joint disease": 40489,
      "headache migraine": 34659,
      "pain frequently": 56798,
      "15 hydrocodone": 1736,
      "affective disorders": 8932,
      "disorders reported": 25400,
      "reported 36": 70488,
      "36 patient": 4139,
      "patient charts": 58557,
      "abuse alcohol": 6650,
      "treat patients": 82310,
      "cocaine amphetamines": 17139,
      "amphetamines opiates": 9853,
      "related substances": 69688,
      "profound effects": 65524,
      "organ systems": 53755,
      "method administration": 45165,
      "administration injection": 8278,
      "injection inhalation": 38952,
      "systemic effects": 80023,
      "cocaine use": 17163,
      "hypoxic brain": 36322,
      "heroin associated": 34988,
      "methylenedioxymethamphetamine mdma": 45658,
      "mdma ecstasy": 43646,
      "results systemic": 72006,
      "changes ketamine": 15795,
      "systematic approach": 79972,
      "analyzed determine": 10828,
      "determine factors": 24011,
      "term high": 80634,
      "posttraumatic stress": 63057,
      "stress disorder": 77488,
      "10 average": 742,
      "alprazolam clonazepam": 9674,
      "clonazepam diazepam": 17057,
      "younger age": 87733,
      "age drug": 9071,
      "independently predicted": 38183,
      "predicted high": 63562,
      "challenges pain": 15705,
      "usage opioids": 84126,
      "level using": 41538,
      "opioids evaluated": 52894,
      "morphine rate": 47901,
      "rate lower": 67481,
      "codeine meperidine": 17251,
      "meperidine pentazocine": 44849,
      "greater high": 33448,
      "opioids hydromorphone": 52960,
      "potency relative": 63087,
      "relative morphine": 69753,
      "rates reported": 67632,
      "equivalent opioid": 29324,
      "prescriptive use": 64579,
      "prescription analgesics": 64166,
      "class measured": 16661,
      "predictable based": 63559,
      "safety pharmacology": 73201,
      "wide variations": 87049,
      "comparison data": 18365,
      "data difficult": 21947,
      "blood gas": 14122,
      "assessing effect": 12100,
      "effect different": 27445,
      "different vehicles": 24935,
      "times post": 81431,
      "gas measurements": 32846,
      "multiple opioids": 48290,
      "opioids furthermore": 52925,
      "determined intra": 24066,
      "conditions highly": 19316,
      "highly sensitive": 35403,
      "data strongly": 22119,
      "developed countries": 24174,
      "newer strategies": 49408,
      "strategies treat": 77426,
      "treat addiction": 82275,
      "developing countries": 24202,
      "similar issues": 75939,
      "current data": 21432,
      "concerns arisen": 18842,
      "addictive effects": 7783,
      "effects like": 27965,
      "therapeutically valuable": 80970,
      "valuable drugs": 85814,
      "naturally occurring": 48747,
      "semisynthetic derivatives": 74520,
      "oxymorphone buprenorphine": 56226,
      "severe effects": 74943,
      "effects limiting": 27970,
      "naltrexone used": 48551,
      "biological actions": 13850,
      "receptor types": 68532,
      "types mu": 83368,
      "coupled receptor": 20975,
      "receptor family": 68492,
      "considerable effort": 19610,
      "complications improve": 18559,
      "structure activity": 77586,
      "activity relationships": 7585,
      "manage acute": 43114,
      "receive medications": 68055,
      "vice versa": 86194,
      "combinations drugs": 17622,
      "drugs pain": 27028,
      "interactions opioids": 39400,
      "important understand": 37041,
      "potential interactions": 63178,
      "opioids drugs": 52870,
      "interactions occur": 39398,
      "occur pharmacokinetic": 50824,
      "interactions including": 39395,
      "including effects": 37617,
      "metabolic pathways": 44909,
      "drug transport": 26817,
      "knowledge metabolism": 40887,
      "metabolism opioids": 44934,
      "increased years": 38050,
      "cyp enzymes": 21574,
      "2d6 3a4": 3648,
      "metabolism commonly": 44925,
      "like codeine": 41773,
      "regarding role": 69279,
      "proteins drug": 65944,
      "additive interactions": 7917,
      "sedative effects": 74337,
      "endogenous opioids": 28849,
      "physiological functions": 61463,
      "effects important": 27946,
      "mainly based": 42870,
      "based case": 13292,
      "interindividual differences": 39440,
      "role potential": 72764,
      "current literature": 21443,
      "drug discovery": 26585,
      "discovery development": 25264,
      "portal http": 62417,
      "methyl ester": 45646,
      "darbepoetin alfa": 21834,
      "eslicarbazepine acetate": 29539,
      "hpv 16": 35889,
      "toxicity resulting": 81938,
      "concentration related": 18717,
      "recent research": 68419,
      "research clearly": 70987,
      "effects occur": 28031,
      "uptake inhibitors": 84020,
      "frequently produce": 32573,
      "15 cases": 1724,
      "cases moderate": 15247,
      "drugs acting": 26871,
      "acting different": 7377,
      "oxidase inhibitor": 54391,
      "known drugs": 40908,
      "deaths occurring": 22770,
      "help ensure": 34900,
      "clinical situations": 16905,
      "dextromethorphan propoxyphene": 24297,
      "pain contributed": 56598,
      "potent analogues": 63097,
      "fentanyl structurally": 31595,
      "ah 7921": 9354,
      "7921 mt": 5808,
      "mt 45": 48102,
      "antagonist doses": 11063,
      "opioid mediated": 51901,
      "mediated pathway": 44316,
      "present unique": 64674,
      "acute toxicity": 7706,
      "life parent": 41717,
      "iii analgesic": 36579,
      "profile analgesic": 65475,
      "efficacy prescription": 28333,
      "drug coverage": 26570,
      "label use": 41008,
      "review performed": 72334,
      "locations oxycodone": 42229,
      "involved deaths": 40097,
      "chronic acute": 16182,
      "fewer prescribed": 31665,
      "pain given": 56806,
      "opioid public": 52225,
      "case 57": 15159,
      "57 year": 5140,
      "intrathecal morphine": 39795,
      "pain intrathecal": 56970,
      "years patient": 87632,
      "intrathecal pump": 39804,
      "improved dramatically": 37105,
      "morphine withdrawal": 47973,
      "studies evaluated": 77717,
      "evaluated influence": 29892,
      "levels present": 41596,
      "relevant patient": 70069,
      "reviews literature": 72414,
      "concentrations opioids": 18787,
      "opioids detected": 52845,
      "detected patients": 23945,
      "potentially relevant": 63266,
      "relevant clinical": 70048,
      "data concentrations": 21922,
      "concentrations commonly": 18752,
      "searching pubmed": 74171,
      "total 42": 81751,
      "42 relevant": 4473,
      "review concentrations": 72276,
      "previous clinical": 64899,
      "studies 10": 77634,
      "ml fentanyl": 46858,
      "fentanyl 50": 31427,
      "500 ng": 4925,
      "methadone 25": 45039,
      "ml morphine": 46879,
      "dependent patient": 23527,
      "vitro potential": 86365,
      "clinical context": 16775,
      "related occurrence": 69641,
      "nitrogen atom": 49500,
      "metabolites various": 44989,
      "species model": 76577,
      "systems results": 80043,
      "results decades": 71654,
      "oxycodone derived": 54943,
      "anti cancer": 11113,
      "regulatory proteins": 69507,
      "proteins involved": 65946,
      "content related": 20101,
      "overview recent": 54368,
      "indole alkaloid": 38363,
      "using commonly": 85351,
      "examine factors": 30343,
      "longer acting": 42366,
      "opioids experienced": 52903,
      "methods prescription": 45475,
      "study poats": 78410,
      "treatment research": 82811,
      "analysis examines": 10684,
      "clinical opiate": 16844,
      "withdrawal scale": 87154,
      "scale cows": 73501,
      "dose higher": 25922,
      "higher scores": 35324,
      "contrary hypothesis": 20211,
      "score lower": 73756,
      "cows scores": 21024,
      "compared did": 18135,
      "09 vs": 645,
      "12 77": 1261,
      "13 56": 1469,
      "56 001": 5094,
      "did predict": 24476,
      "participants primary": 58344,
      "severity withdrawal": 75053,
      "evidence moderate": 30224,
      "moderate opioid": 47152,
      "withdrawal findings": 87131,
      "findings add": 31768,
      "used difficulties": 84919,
      "representing small": 70763,
      "prescribers opioids": 64018,
      "opioids despite": 52844,
      "despite data": 23875,
      "data suggesting": 22135,
      "pain oral": 57296,
      "unclear opioid": 83476,
      "care settings": 15081,
      "january december": 40460,
      "exposures opioids": 30807,
      "measures proportion": 44091,
      "greater proportion": 33482,
      "written english": 87374,
      "dental prescriptions": 23409,
      "opioids 11": 52659,
      "million prescriptions": 46496,
      "prescriptions 28": 64437,
      "prescriptions difference": 64473,
      "32 001": 3901,
      "codeine derivative": 17221,
      "sole opioid": 76425,
      "containing hydrocodone": 20076,
      "23 oxycodone": 3106,
      "prescriptions long": 64508,
      "relevance study": 70040,
      "greater frequency": 33447,
      "background drug": 13039,
      "pregabalin combination": 63663,
      "estimate prevalence": 29613,
      "mmt methods": 46995,
      "included current": 37441,
      "patients 300": 58855,
      "large tertiary": 41155,
      "center university": 15562,
      "pregabalin tested": 63685,
      "urine tests": 84091,
      "2017 data": 2776,
      "urine results": 84081,
      "patients characteristics": 59060,
      "retrieved patients": 72095,
      "patients records": 59869,
      "results pregabalin": 71883,
      "group higher": 33812,
      "score 21": 73716,
      "vs 03": 86513,
      "higher prevalence": 35308,
      "13 vs": 1511,
      "vs 02": 86511,
      "psychiatric diagnosis": 66324,
      "41 03": 4411,
      "urine opiates": 84079,
      "39 vs": 4278,
      "vs 0005": 86501,
      "0005 oxycodone": 88,
      "81 oxycodone": 5887,
      "positive 95": 62445,
      "conclusions high": 19092,
      "abusers non": 6932,
      "non abusers": 49564,
      "population background": 62302,
      "injured patients": 38983,
      "trial aimed": 83001,
      "minimizing opioid": 46605,
      "urban trauma": 84040,
      "pragmatic randomized": 63456,
      "randomized comparative": 67053,
      "comparative effectiveness": 17980,
      "effectiveness trial": 27787,
      "adult trauma": 8526,
      "oral acetaminophen": 53483,
      "acetaminophen 48": 7133,
      "hours celecoxib": 35755,
      "celecoxib pregabalin": 15465,
      "followed naproxen": 32074,
      "tramadol needed": 82085,
      "multi modal": 48149,
      "lidocaine patches": 41676,
      "needed opioids": 49017,
      "total mmes": 81839,
      "operations performed": 51240,
      "performed patients": 60609,
      "61 mmes": 5315,
      "vs 48": 86584,
      "range 22": 67272,
      "22 74": 3026,
      "vs 67": 86609,
      "interval 86": 39570,
      "scores seen": 73982,
      "widely available": 87056,
      "achieved adequate": 7314,
      "control background": 20277,
      "pain cnp": 56558,
      "options patients": 53474,
      "consensus based": 19574,
      "drugs country": 26926,
      "necessary guide": 48884,
      "guide clinical": 34403,
      "decisions objective": 22855,
      "objective develop": 50403,
      "brazil methods": 14387,
      "methods systematic": 45600,
      "review meta": 72322,
      "considering efficacy": 19664,
      "treatment 20": 82417,
      "20 included": 2321,
      "included qualitative": 37529,
      "based systematic": 13390,
      "gabapentin duloxetine": 32795,
      "line drugs": 41988,
      "opioids particular": 53151,
      "delta tetrahydrocannabinol": 23244,
      "drugs central": 26903,
      "conclusions studies": 19216,
      "treatment cns": 82500,
      "recommendations based": 68597,
      "approach individualized": 11461,
      "profile adverse": 65473,
      "addiction risk": 7769,
      "patients comorbidities": 59099,
      "order entry": 53712,
      "medications initial": 44635,
      "medication orders": 44528,
      "self identified": 74487,
      "methods nearly": 45396,
      "nearly year": 48874,
      "year retrospective": 87498,
      "period identified": 60733,
      "chart reviews": 15934,
      "revealed limited": 72216,
      "near real": 48859,
      "january 2014": 40445,
      "2014 april": 2656,
      "outpatient drug": 54118,
      "included medication": 37483,
      "drug dosage": 26595,
      "release versus": 70018,
      "conclusion drugs": 18892,
      "represent important": 70744,
      "important source": 37034,
      "common symptom": 17814,
      "impact quality": 36847,
      "advanced diseases": 8598,
      "review ascertain": 72256,
      "methods non": 45400,
      "databases medline": 22204,
      "medline cochrane": 44730,
      "trials published": 83185,
      "august 2015": 12666,
      "terms used": 80724,
      "used search": 85122,
      "search included": 74113,
      "scientific evidence": 73686,
      "management important": 43185,
      "patients outpatients": 59604,
      "use transmucosal": 84782,
      "main problem": 42853,
      "50 elderly": 4835,
      "dwelling patients": 27202,
      "aged care": 9205,
      "patient complicated": 58569,
      "trials evaluating": 83143,
      "evaluating efficacy": 29946,
      "population groups": 62334,
      "stepwise approach": 77334,
      "needed manage": 49013,
      "pain short": 57829,
      "patients minimal": 59516,
      "evidence surrounding": 30279,
      "newer opioid": 49405,
      "opioid tapentadol": 52402,
      "tapentadol acts": 80381,
      "tramadol evidence": 82059,
      "established safety": 29593,
      "paracetamol morphine": 58102,
      "abuse surveys": 6889,
      "results measures": 71773,
      "abuse buprenorphine": 6656,
      "increased 2005": 37834,
      "measures national": 44069,
      "results adjusted": 71593,
      "abuse measures": 6770,
      "abuse continuous": 6671,
      "continuous monitoring": 20176,
      "monitoring surveillance": 47345,
      "finding balance": 31759,
      "balance risk": 13233,
      "expanded treatment": 30540,
      "remains challenge": 70286,
      "challenge post": 15694,
      "post herpetic": 62568,
      "herpetic neuralgia": 35044,
      "neuralgia phn": 49174,
      "treatment phn": 82764,
      "treatment intractable": 82632,
      "intractable phn": 39738,
      "time consuming": 81228,
      "available treatments": 12849,
      "intolerable effects": 39705,
      "used drugs": 84924,
      "high quality": 35153,
      "quality studies": 66762,
      "relieving neuropathic": 70236,
      "escalating doses": 29523,
      "produce pain": 65364,
      "role central": 72735,
      "central sensitization": 15615,
      "activated microglia": 7462,
      "produce cytokines": 65360,
      "second generation": 74183,
      "microglial activation": 46367,
      "growing body": 34359,
      "attenuates morphine": 12594,
      "neuropathic mice": 49227,
      "synergetic effect": 79927,
      "prevent development": 64843,
      "morphine antinociceptive": 47581,
      "improve efficacy": 37059,
      "activation microglia": 7470,
      "electronic prescription": 28541,
      "programs pmps": 65560,
      "health surveillance": 34784,
      "pmp data": 62044,
      "evaluate trends": 29851,
      "usage methods": 84124,
      "fiscal year": 31849,
      "year 1996": 87422,
      "2006 analyzed": 2482,
      "estimates based": 29647,
      "based individual": 13327,
      "refills results": 69179,
      "steadily increased": 77301,
      "increased 1996": 37831,
      "87 used": 6027,
      "used prescribers": 85083,
      "greater number": 33462,
      "number pharmacies": 50222,
      "defined use": 23155,
      "highly associated": 35390,
      "medical non": 44370,
      "opioids inform": 52998,
      "inform public": 38624,
      "pain remains": 57609,
      "analgesics important": 10431,
      "proven efficacy": 66025,
      "management cancer": 43158,
      "variety settings": 85956,
      "safety oxymorphone": 73192,
      "rapid effective": 67380,
      "er chronic": 29403,
      "pain trials": 57944,
      "weeks dose": 86905,
      "dose year": 26109,
      "titrated doses": 81468,
      "effective generally": 27626,
      "experienced opioid": 30617,
      "oxymorphone metabolism": 56258,
      "treatment certain": 82474,
      "explore impact": 30724,
      "implementing prescription": 36954,
      "sectional data": 74280,
      "setting data": 74776,
      "state pennsylvania": 77059,
      "statistics run": 77249,
      "opioid research": 52346,
      "nearly million": 48871,
      "million opioid": 46490,
      "fewer opioids": 31655,
      "decreasing average": 23068,
      "average percent": 12933,
      "000 fewer": 22,
      "conclusion fewer": 18904,
      "prescribed overall": 63939,
      "type prescribed": 83346,
      "prescribed remained": 63972,
      "remained similar": 70273,
      "largest decrease": 41188,
      "high throughput": 35185,
      "throughput screening": 81163,
      "lead compound": 41281,
      "effects animal": 27824,
      "sciatic nerve": 73674,
      "nerve ligation": 49129,
      "pain reduced": 57491,
      "reduced gastrointestinal": 68931,
      "gastrointestinal effects": 32877,
      "occur patients": 50823,
      "hematological malignancies": 34925,
      "malignancies including": 43089,
      "acute myeloid": 7647,
      "myeloid leukemia": 48379,
      "surgical treatments": 79657,
      "bleeding risks": 13911,
      "56 year": 5109,
      "preoperative laboratory": 63746,
      "septic shock": 74625,
      "incision drainage": 37343,
      "therapy started": 81070,
      "observed day": 50669,
      "day 21": 22252,
      "observed bone": 50653,
      "bone marrow": 14236,
      "cell transplants": 15488,
      "prevent fatal": 64844,
      "surgical interventions": 79635,
      "interventions including": 39663,
      "standardized patients": 76979,
      "common severe": 17807,
      "medication dispensed": 44488,
      "dispensed opioid": 25428,
      "dependence addiction": 23459,
      "students used": 77604,
      "educating patients": 27377,
      "education training": 27398,
      "fentanyl opioid": 31538,
      "receptors mor": 68548,
      "mor agonists": 47496,
      "agonists used": 9342,
      "used decades": 84904,
      "associated numerous": 12351,
      "numerous effects": 50328,
      "addiction respiratory": 7767,
      "activity developed": 7565,
      "virtual screening": 86244,
      "protocol including": 65977,
      "including receptor": 37669,
      "molecular dynamics": 47282,
      "simulations used": 76031,
      "agonist effect": 9284,
      "receptors results": 68561,
      "point development": 62083,
      "deaths associated": 22741,
      "characterize prescription": 15907,
      "region physician": 69346,
      "using truven": 85648,
      "truven health": 83257,
      "health analytics": 34670,
      "analytics marketscan": 10810,
      "included subjects": 37564,
      "12 64": 1258,
      "oxymorphone methadone": 56259,
      "tramadol increased": 82075,
      "varies considerably": 85944,
      "nearly 20": 48864,
      "20 opioid": 2365,
      "nearly 50": 48865,
      "50 prescriptions": 4891,
      "prescribers tramadol": 64024,
      "0001 tramadol": 81,
      "family practice": 31186,
      "vs 32": 86563,
      "32 internal": 3924,
      "vs 16": 86540,
      "medicine non": 44707,
      "prescriptions 2015": 64436,
      "receiving tramadol": 68383,
      "differences exist": 24739,
      "regions physician": 69365,
      "tramadol pain": 82097,
      "little consensus": 42148,
      "met review": 44881,
      "existing evidence": 30525,
      "gaps understanding": 32835,
      "studies reviewed": 77834,
      "base limited": 13268,
      "pain applied": 56458,
      "applied study": 11441,
      "dopaminergic medications": 25729,
      "shown positive": 75345,
      "results future": 71701,
      "descriptive data": 23679,
      "improvement efforts": 37149,
      "north carolina": 49959,
      "nursing homes": 50343,
      "data repository": 22092,
      "years data": 87582,
      "type possible": 83345,
      "disproportionately associated": 25506,
      "error oxycodone": 29511,
      "exploratory analysis": 30713,
      "tools help": 81691,
      "determine value": 24056,
      "information multi": 38655,
      "multi state": 48152,
      "determine prevalence": 24043,
      "opioid defined": 51696,
      "abusers 69": 6930,
      "abusers oxycodone": 6934,
      "40 morphine": 4366,
      "heroin 13": 34980,
      "hydromorphone 16": 36151,
      "16 fentanyl": 1872,
      "comparatively low": 17987,
      "methadone treatment": 45132,
      "age chronic": 9065,
      "pain reason": 57476,
      "reported history": 70565,
      "characteristics predict": 15872,
      "factors contribute": 31085,
      "feasibility using": 31287,
      "providing information": 66263,
      "aggravating factors": 9252,
      "methods survey": 45599,
      "task force": 80518,
      "face validity": 31020,
      "content validity": 20103,
      "questionnaire completed": 66889,
      "respondents predominantly": 71312,
      "factors included": 31098,
      "emotional distress": 28726,
      "management modalities": 43204,
      "medications acetaminophen": 44590,
      "oxycodone preparations": 55739,
      "role emotional": 72744,
      "patients impaired": 59380,
      "impaired renal": 36876,
      "hepatic function": 34952,
      "pre existing": 63467,
      "published articles": 66425,
      "pain effectively": 56744,
      "small group": 76280,
      "studies case": 77658,
      "reports included": 70727,
      "organ dysfunction": 53752,
      "presence renal": 64600,
      "impairment drugs": 36894,
      "alfentanil buprenorphine": 9559,
      "fentanyl ketamine": 31513,
      "remifentanil sufentanil": 70324,
      "significantly prolonged": 75837,
      "bupivacaine clonidine": 14492,
      "require specific": 70812,
      "presence chronic": 64585,
      "chronic renal": 16337,
      "failure risk": 31152,
      "drugs subject": 27083,
      "significantly impaired": 75744,
      "used caution": 84869,
      "caution close": 15410,
      "avoided risk": 12972,
      "higher population": 35303,
      "mmt program": 46997,
      "review new": 72326,
      "1997 1999": 2237,
      "age 34": 8993,
      "years 65": 87552,
      "65 male": 5414,
      "admission patients": 8412,
      "patients 83": 58904,
      "groups identified": 34214,
      "identified 24": 36418,
      "24 used": 3286,
      "used heroin": 84953,
      "heroin group": 35001,
      "significantly younger": 75871,
      "26 years": 3458,
      "reported regular": 70641,
      "tablets consumed": 80133,
      "consumed daily": 19827,
      "daily 23": 21690,
      "tablets respectively": 80212,
      "ongoing pain": 51090,
      "better elucidate": 13711,
      "relationships pain": 69732,
      "pain mental": 57171,
      "order develop": 53711,
      "prescriptions total": 64568,
      "hypothesis opioid": 36296,
      "legislation reduced": 41377,
      "study retrospectively": 78468,
      "filling patients": 31722,
      "undergoing total": 83585,
      "commercially available": 17715,
      "available insurance": 12817,
      "database 2010": 22163,
      "initial discharge": 38834,
      "discharge 90": 25102,
      "day cumulative": 22290,
      "equivalents filled": 29352,
      "time states": 81383,
      "linear logistic": 42013,
      "reductions initial": 69112,
      "initial cumulative": 38830,
      "filling volume": 31727,
      "legislation legislation": 41373,
      "volume largest": 86395,
      "compared states": 18313,
      "volume specific": 86401,
      "large significant": 41153,
      "volume magnitude": 86396,
      "states enacted": 77097,
      "age pre": 9103,
      "use higher": 84397,
      "greater opioid": 33466,
      "use postoperatively": 84635,
      "exceptionally high": 30447,
      "cause fatal": 15355,
      "fatal effects": 31231,
      "effects mainly": 27980,
      "review summarize": 72363,
      "alternative strategies": 9742,
      "potential pathway": 63203,
      "pathway selective": 58519,
      "related receptors": 69678,
      "pharmacological profiles": 61228,
      "drugs targeting": 27089,
      "receptors potential": 68554,
      "agents objectives": 9232,
      "hyperalgesia oih": 36261,
      "pain sensitivity": 57813,
      "analgesia explored": 9969,
      "managed chronic": 43131,
      "therapy results": 81062,
      "results survey": 72002,
      "survey response": 79732,
      "76 reported": 5746,
      "patients oih": 59574,
      "associated development": 12251,
      "development oih": 24239,
      "42 42": 4450,
      "44 fentanyl": 4540,
      "morphine 84": 47566,
      "opioid likely": 51889,
      "commonly managed": 17853,
      "15 000": 1667,
      "000 children": 18,
      "annually united": 11035,
      "children experience": 16046,
      "relieved pain": 70221,
      "nonpharmacologic therapies": 49826,
      "pain symptom": 57891,
      "single analgesic": 76051,
      "remain mainstay": 70250,
      "effectively treat": 27741,
      "opioids pediatric": 53167,
      "pediatric palliative": 60354,
      "methadone results": 45125,
      "unrelieved pain": 83930,
      "pain end": 56755,
      "methadone prescribed": 45121,
      "use effects": 84350,
      "role treating": 72767,
      "treating episodes": 82393,
      "states food": 77102,
      "tramadol does": 82055,
      "children risk": 16073,
      "overuse opioids": 54365,
      "states canada": 77084,
      "come scrutiny": 17688,
      "methods longitudinal": 45372,
      "longitudinal analysis": 42397,
      "milligram morphine": 46470,
      "prescription guideline": 64230,
      "guideline adherence": 34417,
      "analyses evaluated": 10591,
      "prescription results": 64401,
      "followed tramadol": 32084,
      "prescriptions prescriptions": 64547,
      "95 cases": 6216,
      "cases 90": 15220,
      "87 patients": 6025,
      "day conclusions": 22282,
      "available guidelines": 12810,
      "prescribed quantities": 63966,
      "improve opioid": 37067,
      "smaller quantities": 76315,
      "quantities greater": 66819,
      "adults associated": 8549,
      "associated number": 12350,
      "substantial medical": 78852,
      "cognitive decline": 17321,
      "limited success": 41964,
      "screening approaches": 74040,
      "likely present": 41830,
      "general hospital": 32974,
      "problematic alcohol": 65249,
      "assessment management": 12124,
      "female presented": 31373,
      "metropolitan hospital": 45674,
      "symptoms including": 79892,
      "severe anxiety": 74913,
      "assessment revealed": 12136,
      "use number": 84528,
      "treatment approach": 82445,
      "opioid dispensations": 51716,
      "income quintile": 37700,
      "based administrative": 13271,
      "changes total": 15825,
      "equivalents dispensed": 29348,
      "dispensed 1000": 25416,
      "results 2005": 71549,
      "increased 31": 37849,
      "increase use": 37817,
      "use stronger": 84754,
      "opioids consumption": 52816,
      "opioids did": 52849,
      "differences total": 24825,
      "total level": 81831,
      "consumption times": 20031,
      "times high": 81426,
      "analgesics cornerstone": 10409,
      "higher lower": 35257,
      "income countries": 37699,
      "countries study": 20963,
      "perspective opioid": 60969,
      "consumption providing": 19999,
      "statistics calculated": 77241,
      "opioids ability": 52691,
      "opioids total": 53341,
      "major problem": 42967,
      "consequences including": 19591,
      "risk persistent": 72630,
      "hospital readmission": 35623,
      "postoperative periods": 62948,
      "pain improvements": 56849,
      "provides overview": 66230,
      "include use": 37370,
      "use preoperative": 84645,
      "analgesia continuous": 9938,
      "plane block": 61871,
      "release epidural": 69831,
      "use intravenous": 84440,
      "formulations morphine": 32389,
      "analgesia conclusion": 9933,
      "postoperative oral": 62831,
      "objective past": 50465,
      "care implemented": 15031,
      "methods search": 45557,
      "prescriptions primary": 64548,
      "drugs require": 27063,
      "require special": 70811,
      "occurred time": 50847,
      "consumption accounting": 19888,
      "increase oral": 37770,
      "morphine choice": 47596,
      "choice drug": 16112,
      "updates previous": 83989,
      "analysis trends": 10781,
      "data 1997": 21846,
      "research questions": 71024,
      "including fentanyl": 37619,
      "class compared": 16653,
      "compared trends": 18330,
      "abuse studied": 6881,
      "studied opioid": 77619,
      "opioids growing": 52937,
      "medical practice": 44383,
      "including drugs": 37613,
      "drugs opiates": 27017,
      "strongly dependent": 77578,
      "molecular mechanics": 47285,
      "step forward": 77321,
      "scale background": 73497,
      "increasing worldwide": 38129,
      "trends consumption": 82963,
      "2010 2019": 2547,
      "consumption human": 19935,
      "use region": 84685,
      "used mixed": 85010,
      "models assess": 47109,
      "consumption used": 20036,
      "used regression": 85106,
      "region results": 69348,
      "opioids region": 53251,
      "pethidine oxycodone": 60987,
      "codeine conclusion": 17218,
      "collection reporting": 17500,
      "data providing": 22076,
      "access pain": 6999,
      "drugs studied": 27080,
      "studied interaction": 77615,
      "molecular modeling": 47289,
      "impact drug": 36805,
      "release results": 70001,
      "occurs spontaneously": 50868,
      "indicated effect": 38234,
      "vitro drug": 86357,
      "release profiles": 69997,
      "potentially impact": 63258,
      "impact drugs": 36807,
      "samples submitted": 73364,
      "analyses present": 10605,
      "clinical laboratories": 16832,
      "60 000": 5218,
      "recently published": 68447,
      "sample adulteration": 73292,
      "prescription non": 64266,
      "active prescription": 7534,
      "antibody based": 11150,
      "based screening": 13379,
      "positive benzodiazepines": 62453,
      "benzodiazepines oxycodone": 13669,
      "communication pain": 17910,
      "management clinic": 43167,
      "validity testing": 85805,
      "specimens liquid": 76640,
      "urine specimen": 84087,
      "medication list": 44510,
      "raising question": 66982,
      "case highlights": 15173,
      "specimen validity": 76635,
      "testing laboratory": 80825,
      "samples pain": 73353,
      "approach opioid": 11467,
      "opioid dosing": 51742,
      "raising questions": 66983,
      "effect combination": 27435,
      "doses similar": 26274,
      "effects reduced": 28131,
      "opioids reduction": 53249,
      "induced postoperative": 38446,
      "important clinical": 36998,
      "clinical implications": 16825,
      "given adverse": 33155,
      "effects expected": 27919,
      "pain information": 56871,
      "improving opioid": 37195,
      "opioid response": 52348,
      "pain process": 57435,
      "needed better": 48984,
      "near future": 48858,
      "introduction chronic": 39925,
      "western world": 87008,
      "severe intractable": 74950,
      "pain presents": 57419,
      "impact patients": 36836,
      "life physical": 41721,
      "physical functioning": 61400,
      "functioning pain": 32724,
      "pain persistent": 57368,
      "admission hospital": 8406,
      "therapies pain": 80979,
      "levels evidence": 41560,
      "supporting use": 79228,
      "relevant journals": 70062,
      "study type": 78550,
      "excluded results": 30480,
      "medical therapies": 44409,
      "therapies including": 80978,
      "including oral": 37658,
      "enzyme preparations": 29108,
      "analysis current": 10667,
      "pain lacking": 56990,
      "research topic": 71033,
      "antagonists shown": 11087,
      "effect introduction": 27469,
      "introduction pain": 39947,
      "patients frequently": 59316,
      "recommended treatments": 68638,
      "treatments condition": 82904,
      "potential targets": 63236,
      "critical aspects": 21227,
      "design patient": 23743,
      "outcomes evaluated": 54024,
      "discussed expert": 25292,
      "preliminary results": 63714,
      "reports indicate": 70729,
      "repetitive transcranial": 70423,
      "transcranial magnetic": 82127,
      "magnetic stimulation": 42806,
      "stimulation rtms": 77373,
      "naloxone prolonged": 48506,
      "population treated": 62392,
      "treated according": 82322,
      "according type": 7065,
      "proper selection": 65700,
      "study outcomes": 78351,
      "outcomes follow": 54027,
      "recommendations background": 68596,
      "misuse dependence": 46717,
      "investigate prevalence": 40024,
      "current prescription": 21459,
      "clinical interview": 16829,
      "past current": 58459,
      "current dependence": 21433,
      "analgesics assessed": 10379,
      "agreed participate": 9348,
      "participate survey": 58386,
      "subjects 43": 78676,
      "cases severe": 15263,
      "11 cases": 1125,
      "oxycodone typically": 56037,
      "typically reported": 83395,
      "conclusions research": 19199,
      "possible risk": 62546,
      "factors prescription": 31125,
      "vulnerable population": 86689,
      "treatment algorithms": 82438,
      "single specialty": 76141,
      "chronic abdominal": 16180,
      "using combination": 85346,
      "management treatment": 43274,
      "treatment somatic": 82846,
      "somatic visceral": 76455,
      "series patients": 74660,
      "causes chronic": 15392,
      "received bilateral": 68120,
      "based pain": 13349,
      "pain location": 57030,
      "location using": 42227,
      "combination 25": 17540,
      "25 bupivicaine": 3347,
      "clonidine 50": 17061,
      "50 mcg": 4848,
      "single physician": 76135,
      "treatment included": 82621,
      "included combination": 37438,
      "combination gabapentin": 17558,
      "hydrocodone apap": 36061,
      "oxycodone apap": 54723,
      "opioid regimen": 52293,
      "pre injection": 63470,
      "mme post": 46974,
      "68 total": 5503,
      "decreased mean": 23008,
      "pain year": 57994,
      "urban safety": 84033,
      "safety net": 73168,
      "net hospital": 49151,
      "added urine": 7732,
      "standard urine": 76938,
      "results identify": 71719,
      "value presumptive": 85825,
      "results methods": 71781,
      "methods included": 45358,
      "january june": 40462,
      "june 2016": 40548,
      "2016 analyzed": 2734,
      "immunoassay tests": 36774,
      "testing samples": 80842,
      "samples confirmed": 73338,
      "fentanyl fentanyl": 31474,
      "true positives": 83253,
      "results 11": 71541,
      "samples 10": 73324,
      "samples screened": 73363,
      "screened fentanyl": 74029,
      "value positive": 85824,
      "patients confirmed": 59131,
      "likely positive": 41825,
      "barbiturates benzodiazepines": 13248,
      "benzodiazepines cocaine": 13659,
      "cocaine methadone": 17152,
      "methadone opiates": 45110,
      "common associated": 17734,
      "testing positive": 80832,
      "high confirmation": 35077,
      "especially older": 29560,
      "testing used": 80847,
      "change treatment": 15756,
      "approach patient": 11471,
      "ess study": 29571,
      "series planned": 74661,
      "planned data": 61881,
      "collection setting": 17501,
      "center subjects": 15556,
      "methods prospectively": 45497,
      "evaluated postoperative": 29910,
      "included use": 37572,
      "surgery use": 79614,
      "use endoscopic": 84351,
      "underwent bilateral": 83677,
      "discharged 30": 25190,
      "pain narcotic": 57222,
      "total 64": 81762,
      "completed surveys": 18506,
      "surveys mean": 79750,
      "use day": 84289,
      "pills patients": 61530,
      "demographic surgical": 23289,
      "surgical factors": 79631,
      "low use": 42563,
      "did report": 24491,
      "report higher": 70460,
      "level postoperative": 41515,
      "requiring narcotics": 70904,
      "narcotics postoperative": 48637,
      "reduced opiate": 68950,
      "opiate prescription": 51309,
      "use ess": 84357,
      "postoperative patient": 62932,
      "postoperative management": 62787,
      "prospective clinical": 65814,
      "clinical study": 16918,
      "conducted june": 19371,
      "december 2019": 22829,
      "life qol": 41723,
      "days pods": 22582,
      "nose scores": 49980,
      "outcomes postoperative": 54073,
      "domains pain": 25706,
      "oxycodone usage": 56047,
      "showed greatest": 75255,
      "returned normal": 72194,
      "trends pain": 82979,
      "domains general": 25705,
      "general activity": 32950,
      "work mood": 87278,
      "pain qol": 57450,
      "impairment conclusions": 36889,
      "experience using": 30597,
      "validated clinical": 85786,
      "instrument allows": 39114,
      "counseling set": 20926,
      "accurate patient": 7102,
      "patient expectations": 58631,
      "expectations postoperative": 30550,
      "pain usually": 57965,
      "usually managed": 85696,
      "pain require": 57620,
      "disease states": 25352,
      "management medications": 43200,
      "infants children": 38504,
      "children adolescents": 16023,
      "use agents": 84183,
      "evidence provided": 30249,
      "preferring opioid": 63650,
      "available opioids": 12827,
      "fentanyl derivatives": 31462,
      "buprenorphine butorphanol": 14525,
      "butorphanol nalbuphine": 14626,
      "based age": 13275,
      "opioids population": 53183,
      "neonatal population": 49102,
      "risks medications": 72678,
      "comparable seen": 17973,
      "sought assess": 76479,
      "authors conducted": 12725,
      "trial 63": 82997,
      "63 patients": 5365,
      "patients isolated": 59426,
      "randomly received": 67240,
      "received perioperative": 68243,
      "analgesics paracetamol": 10472,
      "paracetamol times": 58118,
      "postoperative 24": 62692,
      "using vas": 85661,
      "significance 05": 75403,
      "fracture patients": 32457,
      "effects 10": 27791,
      "mg single": 46220,
      "remains common": 70289,
      "following inpatient": 32144,
      "modern medicine": 47219,
      "article highlights": 11772,
      "promising new": 65655,
      "management recent": 43253,
      "surgery eras": 79389,
      "analgesia mma": 10025,
      "essential component": 29574,
      "persistent concern": 60917,
      "concern opioid": 18827,
      "opioid alternatives": 51438,
      "iv acetaminophen": 40365,
      "acetaminophen non": 7210,
      "popular recent": 62291,
      "recent meta": 68409,
      "use perioperative": 84620,
      "transcutaneous electrical": 82138,
      "electrical nerve": 28505,
      "herbal preparations": 34970,
      "role acute": 72732,
      "pain services": 57816,
      "evidence practice": 30247,
      "era opioid": 29485,
      "lines evidence": 42042,
      "right balance": 72476,
      "states reached": 77148,
      "drug united": 26825,
      "common source": 17809,
      "available misuse": 12823,
      "postoperative prescriptions": 62954,
      "prescriptions high": 64494,
      "school seniors": 73670,
      "legitimate prescriptions": 41388,
      "leftover doses": 41352,
      "patients postoperatively": 59660,
      "postoperatively prescribed": 63018,
      "opioids remainder": 53260,
      "literature presented": 42121,
      "perspective current": 60967,
      "strategies dealing": 77412,
      "review includes": 72314,
      "includes data": 37583,
      "electronic survey": 28547,
      "prescriptions provide": 64550,
      "provide treatment": 66107,
      "prescriptions varied": 64572,
      "narcotic prescribing": 48607,
      "disposal unused": 25490,
      "problem long": 65238,
      "resources directed": 71129,
      "facilitate safe": 31035,
      "harmful effects": 34590,
      "reflect clinical": 69188,
      "demonstrate method": 23317,
      "methods eighteen": 45325,
      "contributing factor": 20241,
      "identified compared": 36431,
      "hospital drug": 35585,
      "content analyzed": 20098,
      "use 13": 84141,
      "common high": 17761,
      "medications oxycodone": 44657,
      "midazolam propofol": 46398,
      "parenteral preparations": 58214,
      "method applicable": 45170,
      "peripheral stimulation": 60886,
      "interaction morphine": 39371,
      "woman presented": 87189,
      "sweating tachycardia": 79808,
      "nausea previous": 48778,
      "lower extremities": 42615,
      "days earlier": 22520,
      "left breast": 41346,
      "short course": 75163,
      "morphine prescribed": 47884,
      "supportive measures": 79232,
      "morphine discontinued": 47647,
      "interaction probability": 39379,
      "score patient": 73770,
      "mechanism underlying": 44132,
      "underlying interaction": 83606,
      "clinicians carefully": 17028,
      "strategy involves": 77436,
      "universal precautions": 83846,
      "procedures help": 65306,
      "help physicians": 34910,
      "therapy safe": 81064,
      "patient risk": 58751,
      "selecting appropriate": 74402,
      "monitoring patient": 47333,
      "aberrant behaviors": 6543,
      "treatment failure": 82585,
      "involves use": 40119,
      "potential reduced": 63216,
      "practices based": 63423,
      "help minimize": 34908,
      "pain prescription": 57411,
      "remain important": 70249,
      "absence strong": 6590,
      "prescribing abuse": 64027,
      "practice postoperative": 63411,
      "common problem": 17800,
      "sevoflurane anesthesia": 75056,
      "children included": 16054,
      "included 75": 37406,
      "kg clonidine": 40702,
      "clonidine microg": 17063,
      "anesthesia induction": 10916,
      "induction anesthesia": 38476,
      "anesthesia induced": 10915,
      "maintained sevoflurane": 42893,
      "20 microg": 2354,
      "kg diclofenac": 40716,
      "diclofenac mg": 24391,
      "treated iv": 82343,
      "kg time": 40812,
      "time achieve": 81201,
      "pain discomfort": 56725,
      "scale used": 73569,
      "32 25": 3908,
      "placebo 62": 61639,
      "26 patients": 3451,
      "patients 05": 58820,
      "54 13": 5038,
      "13 24": 1462,
      "24 adverse": 3187,
      "effects noted": 28025,
      "groups 80": 34120,
      "differ placebo": 24545,
      "placebo respect": 61818,
      "period patient": 60767,
      "route opioid": 72844,
      "discharge diagnosis": 25117,
      "treated naloxone": 82352,
      "17 45": 1946,
      "codeine heroin": 17240,
      "common long": 17764,
      "presence ethanol": 64590,
      "occurred approximately": 50831,
      "department opioid": 23439,
      "identified background": 36424,
      "background social": 13198,
      "economic consequences": 27309,
      "population health": 62335,
      "baby boomers": 12996,
      "alcohol substance": 9540,
      "socioeconomic disadvantage": 76398,
      "descriptive analysis": 23678,
      "maximum likelihood": 43592,
      "focused individual": 31974,
      "binge drinking": 13827,
      "use simultaneously": 84736,
      "report social": 70478,
      "insurance status": 39155,
      "employment status": 28748,
      "generally higher": 33018,
      "aor 51": 11309,
      "51 95": 4951,
      "cocaine aor": 17140,
      "aor 39": 11300,
      "aor 33": 11297,
      "ci 74": 16489,
      "74 12": 5670,
      "crack use": 21123,
      "use aor": 84199,
      "aor 56": 11315,
      "56 95": 5099,
      "related measures": 69631,
      "exhibited highest": 30513,
      "score 97": 73726,
      "97 95": 6437,
      "ci 64": 16479,
      "increased social": 38029,
      "rates substance": 67640,
      "attention needed": 12568,
      "differentially affected": 24943,
      "120 women": 1413,
      "intervention group": 39633,
      "eras protocol": 29493,
      "protocol primary": 65992,
      "outcome length": 53922,
      "length hospitalization": 41404,
      "operative bleeding": 51245,
      "bleeding time": 13912,
      "results women": 72059,
      "women discharged": 87210,
      "discharged 24": 25187,
      "88 vs": 6045,
      "55 001": 5064,
      "22 hours": 3033,
      "hours 001": 35726,
      "ready discharge": 67995,
      "time 15": 81193,
      "groups observed": 34246,
      "follow time": 32037,
      "month conclusion": 47384,
      "conclusion eras": 18898,
      "modulate response": 47255,
      "response reward": 71371,
      "use despite": 84303,
      "harmful consequences": 34587,
      "plays critical": 62002,
      "fentanyl cocaine": 31452,
      "receptors dor": 68540,
      "new psychoactive": 49366,
      "substances illegally": 78830,
      "activity relationship": 7584,
      "mor kor": 47501,
      "structural features": 77580,
      "features associated": 31297,
      "addiction introduction": 7744,
      "misuse related": 46747,
      "use sought": 84741,
      "database identified": 22168,
      "patients diagnosed": 59188,
      "2016 using": 2765,
      "using international": 85442,
      "classification disease": 16676,
      "outpatient prescription": 54138,
      "using generic": 85411,
      "analyzed opioid": 10847,
      "identified median": 36447,
      "claims patient": 16636,
      "mean patient": 43834,
      "receiving opioids": 68362,
      "common prescriptions": 17798,
      "significant number": 75587,
      "quantified opioid": 66781,
      "states using": 77158,
      "using state": 85627,
      "prescription database": 64192,
      "program database": 65534,
      "prescriptions regardless": 64557,
      "37 months": 4196,
      "change results": 15748,
      "results rescheduling": 71917,
      "associated hydrocodone": 12287,
      "hydrocodone level": 36100,
      "change 26": 15716,
      "decrease prescriptions": 22923,
      "codeine prescribing": 17279,
      "increased level": 37938,
      "ci 003": 16366,
      "associated level": 12318,
      "change 14": 15715,
      "prescriptions 10": 64426,
      "associated declines": 12242,
      "codeine results": 17284,
      "prescribing specialties": 64138,
      "affected oxycodone": 8919,
      "monkeys trained": 47353,
      "food reinforced": 32239,
      "doses decreased": 26173,
      "morphine generally": 47699,
      "decreased number": 23013,
      "trials completed": 83126,
      "animals humans": 11002,
      "impulsivity tasks": 37211,
      "states continues": 77086,
      "continues increase": 20148,
      "care professionals": 15064,
      "deaths benzodiazepines": 22745,
      "relatively safe": 69787,
      "deaths attributed": 22743,
      "benzodiazepines occurred": 13668,
      "benzodiazepines 89": 13652,
      "2003 2009": 2446,
      "prescriptions drugs": 64480,
      "highest increase": 35349,
      "drug unintentional": 26824,
      "unintentional overdoses": 83744,
      "analgesics combination": 10395,
      "patterns patient": 60222,
      "patient usage": 58808,
      "usage health": 84117,
      "inform patients": 38619,
      "determine minimally": 24024,
      "clinically important": 16977,
      "important difference": 37003,
      "data methods": 22009,
      "trial morphine": 83036,
      "intensity assessed": 39229,
      "baseline end": 13431,
      "end intervention": 28793,
      "day using": 22443,
      "using 11": 85289,
      "change nrs": 15733,
      "calculated results": 14701,
      "95 cis": 6372,
      "average nrs": 12900,
      "score 001": 73702,
      "reactions adrs": 67953,
      "safety issue": 73161,
      "spontaneously reported": 76763,
      "adr reporting": 8473,
      "reports adrs": 70710,
      "suspected drug": 79765,
      "suspected adr": 79764,
      "medication assessed": 44459,
      "criteria results": 21216,
      "35 20": 4059,
      "related prescribing": 69670,
      "monitoring treatment": 47346,
      "common drugs": 17750,
      "unsafe use": 83939,
      "drugs purpose": 27049,
      "successful use": 78917,
      "lung disease": 42766,
      "summary 48": 79091,
      "48 year": 4751,
      "resistant staphylococcus": 71106,
      "included long": 37472,
      "spinal stenosis": 76725,
      "iron deficiency": 40273,
      "deficiency anemia": 23107,
      "lung function": 42767,
      "lung transplantation": 42769,
      "time admission": 81203,
      "admission included": 8407,
      "supplemental oxygen": 79166,
      "oral methadone": 53567,
      "methadone oral": 45114,
      "exacerbation patient": 30317,
      "patient started": 58786,
      "methadone ketamine": 45089,
      "using modified": 85499,
      "score observed": 73764,
      "morphine effective": 47654,
      "pain thoracic": 57914,
      "condition characterized": 19277,
      "using new": 85515,
      "clinical case": 16764,
      "step step": 77327,
      "presented results": 64696,
      "results intraoperative": 71743,
      "improvements functional": 37173,
      "functional capacity": 32691,
      "scores noted": 73916,
      "patients visual": 60175,
      "oswestry disability": 53878,
      "24 10": 3145,
      "points respectively": 62140,
      "sf 36": 75099,
      "36 physical": 4142,
      "function score": 32678,
      "score changed": 73735,
      "patient stopped": 58788,
      "mg used": 46255,
      "patient decreased": 58606,
      "decreased use": 23051,
      "patient continued": 58576,
      "opioids 100": 52658,
      "100 microg": 996,
      "microg transdermal": 46364,
      "readily available": 67985,
      "available treatment": 12847,
      "comparison studies": 18381,
      "procedure opioids": 65275,
      "formulation opioid": 32350,
      "oxymorphone analgesic": 56222,
      "pain systematic": 57898,
      "search published": 74124,
      "studies oral": 77798,
      "pain conducted": 56590,
      "conducted studies": 19412,
      "according standard": 7064,
      "criteria evaluated": 21195,
      "performed examine": 60590,
      "examine effect": 30337,
      "oxymorphone compared": 56230,
      "quality controlled": 66686,
      "duration 12": 27146,
      "subjects suffering": 78745,
      "studies high": 77742,
      "studies respectively": 77830,
      "analysis suggests": 10775,
      "interval 17": 39558,
      "17 08": 1928,
      "08 69": 622,
      "efficacy oxymorphone": 28319,
      "pain result": 57646,
      "pathophysiological mechanisms": 58507,
      "depends type": 23552,
      "treatment requires": 82810,
      "multimodal procedure": 48242,
      "specific analgesia": 76581,
      "analgesia addition": 9904,
      "perioperative complications": 60831,
      "improving patient": 37200,
      "optimal postoperative": 53430,
      "management represents": 43258,
      "represents important": 70769,
      "years known": 87606,
      "known groups": 40911,
      "pregabalin lidocaine": 63669,
      "lidocaine ketamine": 41671,
      "article discusses": 11766,
      "analgesic methods": 10274,
      "glycoprotein gp": 33266,
      "efflux transporter": 28428,
      "tolerant rats": 81612,
      "shown clinically": 75331,
      "clinically employed": 16976,
      "development central": 24216,
      "studies focus": 77730,
      "gp substrate": 33358,
      "substrate activity": 78884,
      "medicine clinic": 44705,
      "stage iv": 76865,
      "non hodgkin": 49606,
      "hodgkin lymphoma": 35500,
      "term drug": 80626,
      "therapy consisted": 81002,
      "reported adherence": 70498,
      "overall patient": 54225,
      "preceding months": 63503,
      "months significant": 47471,
      "clinical status": 16906,
      "status significant": 77268,
      "therapeutic range": 80959,
      "tobacco use": 81503,
      "use alcohol": 84187,
      "later patient": 41237,
      "taking prescribed": 80322,
      "increased 29": 37847,
      "component relative": 18586,
      "condition drug": 19280,
      "knowledge case": 40882,
      "reports concerning": 70716,
      "taken concomitantly": 80274,
      "dietary supplements": 24536,
      "include acetaminophen": 37350,
      "acetaminophen nsaids": 7216,
      "ibuprofen treatment": 36376,
      "administered needed": 8152,
      "improving analgesia": 37192,
      "effects renal": 28138,
      "gi tract": 33144,
      "population needed": 62360,
      "needed severe": 49035,
      "hydrocodone using": 36137,
      "using oral": 85543,
      "factors interfere": 31113,
      "inability tolerate": 37217,
      "slow absorption": 76262,
      "patients considered": 59136,
      "considered primary": 19644,
      "pain hospital": 56835,
      "studies defined": 77690,
      "recent systematic": 68431,
      "aimed develop": 9445,
      "prevalence use": 64820,
      "used norwegian": 85035,
      "norwegian prescription": 49975,
      "prescription register": 64400,
      "31 october": 3874,
      "october 2019": 50888,
      "users opioids": 85260,
      "365 days": 4162,
      "days apart": 22487,
      "days 90": 22477,
      "women used": 87258,
      "buprenorphine frequently": 14548,
      "users continued": 85233,
      "identify clinically": 36497,
      "level supporting": 41528,
      "therapeutic approaches": 80920,
      "inhibitor cyp3a4": 38793,
      "cyp3a4 substrates": 21642,
      "increased clearance": 37890,
      "given opioids": 33180,
      "conclusions clinicians": 19046,
      "drugs extensively": 26956,
      "hepatic metabolism": 34956,
      "identification management": 36412,
      "patients individuals": 59407,
      "medication refill": 44552,
      "refill rates": 69167,
      "analgesic protocol": 10306,
      "data 58": 21854,
      "order set": 53722,
      "new order": 49349,
      "consisted 10": 19670,
      "mg 100": 45705,
      "mg 28": 45735,
      "prescriptions refills": 64556,
      "provider results": 66179,
      "mme prescribed": 46975,
      "mg non": 46072,
      "ci 235": 16417,
      "108 mg": 1072,
      "ci 135": 16399,
      "126 mg": 1433,
      "85 difference": 5986,
      "rates conclusions": 67565,
      "manage postoperative": 43124,
      "pain difference": 56714,
      "difference opioid": 24642,
      "opioid refill": 52288,
      "results warrant": 72057,
      "pain satisfaction": 57657,
      "grey literature": 33519,
      "published january": 66432,
      "2014 july": 2664,
      "july 2019": 40528,
      "experimental studies": 30674,
      "evaluated risk": 29919,
      "bias included": 13767,
      "study authors": 77977,
      "related outcomes": 69647,
      "experimental design": 30661,
      "10 using": 948,
      "24 studies": 3276,
      "reported decrease": 70531,
      "doses 14": 26126,
      "80 increased": 5844,
      "13 studies": 1506,
      "studies tramadol": 77869,
      "studies codeine": 77665,
      "equivalents 10": 29338,
      "increase morphine": 37757,
      "approach findings": 11458,
      "16 conclusions": 1869,
      "conclusions hydrocodone": 19094,
      "reductions prescribing": 69120,
      "prescribing use": 64144,
      "major source": 42977,
      "concern patient": 18830,
      "patient surgeon": 58794,
      "medications currently": 44611,
      "direct visualization": 25052,
      "study 13": 77881,
      "using spinal": 85621,
      "spinal needle": 76723,
      "ml liposomal": 46869,
      "endpoints total": 28920,
      "total opiate": 81859,
      "scores assessed": 73843,
      "follow data": 32018,
      "average visual": 12943,
      "score postoperative": 73773,
      "day average": 22271,
      "mg patient": 46154,
      "patient conclusions": 58573,
      "conclusions pilot": 19161,
      "pain early": 56738,
      "present time": 64673,
      "limited pharmacological": 41952,
      "pharmacological options": 61225,
      "efficacy opioid": 28306,
      "group specialized": 34025,
      "specialized register": 76570,
      "june 2014": 40546,
      "2014 using": 2681,
      "alfentanil fentanyl": 9560,
      "methadone nalbuphine": 45108,
      "nalbuphine oxycodone": 48412,
      "levorphanol oxymorphone": 41630,
      "criteria randomised": 21209,
      "analysis authors": 10640,
      "independently assessed": 38172,
      "assessed studies": 12063,
      "relevant trials": 70075,
      "remains lack": 70294,
      "determine opioids": 24030,
      "evidence needed": 30225,
      "needed guide": 49006,
      "morphine based": 47586,
      "based analgesia": 13276,
      "hand assisted": 34548,
      "donor nephrectomy": 25711,
      "respectively case": 71175,
      "group consisted": 33702,
      "regard sex": 69234,
      "age bmi": 9060,
      "standardized multimodal": 76970,
      "controlled oxycodone": 20509,
      "treatment acetaminophen": 82423,
      "lower median": 42647,
      "median cumulative": 44207,
      "56 vs": 5108,
      "nausea 18": 48761,
      "18 45": 2050,
      "shorter time": 75215,
      "time postoperative": 81345,
      "postoperative care": 62722,
      "min 001": 46504,
      "stay vs": 77297,
      "11 days": 1128,
      "reduces need": 68992,
      "need opioid": 48938,
      "recovery introduction": 68747,
      "opioids improve": 52969,
      "life pain": 41715,
      "study characterizes": 77988,
      "matrix patch": 43539,
      "likert scales": 41853,
      "highly valued": 35406,
      "decreasing order": 23072,
      "60 percent": 5274,
      "patch gel": 58493,
      "10 59": 720,
      "conclusions fentanyl": 19083,
      "formulation canada": 32334,
      "fentanyl matrix": 31520,
      "diversion tampering": 25607,
      "transdermal opioid": 82160,
      "management programs": 43248,
      "polymorphic cytochrome": 62209,
      "cytochrome 450": 21651,
      "reactions drugs": 67961,
      "using developed": 85378,
      "based population": 13357,
      "allele frequencies": 9585,
      "identified potential": 36457,
      "17 drugs": 1967,
      "polymorphic cyp": 62207,
      "cyp enzyme": 21573,
      "information used": 38675,
      "cyp2c9 cyp2c19": 21583,
      "cyp2c19 cyp2d6": 21579,
      "enzymes clinical": 29111,
      "pharmacologic effect": 61194,
      "poor intermediate": 62260,
      "44 28": 4527,
      "amitriptyline nortriptyline": 9824,
      "nortriptyline codeine": 49970,
      "approach applied": 11454,
      "work required": 87286,
      "potential clinical": 63146,
      "identify drugs": 36501,
      "greatest potential": 33505,
      "test drugs": 80767,
      "greatly increased": 33510,
      "small increases": 76284,
      "concentrations analgesics": 18743,
      "analgesics tested": 10506,
      "tested fentanyl": 80805,
      "suggest patients": 79008,
      "compared analgesics": 18098,
      "clinical decision": 16782,
      "decision support": 22849,
      "support tools": 79217,
      "prescriptions using": 64571,
      "prescriptions analyzed": 64447,
      "identify prescribing": 36524,
      "28 week": 3578,
      "prescriptions 83": 64440,
      "intervention control": 39627,
      "respectively 01": 71149,
      "rates groups": 67581,
      "similar time": 75998,
      "prescriptions majority": 64511,
      "modest reduction": 47226,
      "using structured": 85631,
      "optimal timing": 53435,
      "bariatric surgery": 13252,
      "prior incision": 65149,
      "narcotic requirements": 48611,
      "completion surgery": 18525,
      "2019 2020": 2852,
      "doses medd": 26212,
      "lb group": 41263,
      "pod vs": 62068,
      "008 conclusions": 277,
      "required fewer": 70837,
      "objective pain": 50463,
      "common symptoms": 17815,
      "recent literature": 68406,
      "use oncology": 84538,
      "oncology patients": 51076,
      "pain databases": 56680,
      "databases data": 22196,
      "literature using": 42139,
      "embase google": 28646,
      "published 2008": 66422,
      "key words": 40679,
      "studies met": 77768,
      "aspects pain": 11865,
      "status quality": 77266,
      "tolerated efficacious": 81631,
      "pain typically": 57948,
      "superiority tapentadol": 79151,
      "opioids low": 53028,
      "noninferiority trials": 49750,
      "trials comparing": 83122,
      "studies conclusion": 77671,
      "tolerated alternative": 81620,
      "pain prospective": 57438,
      "small samples": 76300,
      "research centers": 70986,
      "lack detailed": 41050,
      "review published": 72346,
      "published research": 66438,
      "pharmacotherapy pain": 61251,
      "medline cinahl": 44729,
      "embase psycinfo": 28652,
      "searched articles": 74137,
      "met following": 44873,
      "50 subjects": 4900,
      "pharmacologic treatment": 61202,
      "treatment improvement": 82619,
      "trials assessed": 83104,
      "quality using": 66766,
      "physiotherapy evidence": 61476,
      "evidence database": 30180,
      "new studies": 49379,
      "following categories": 32110,
      "categories analgesics": 15295,
      "analgesics anticonvulsants": 10377,
      "anticonvulsants antidepressants": 11164,
      "evidence new": 30226,
      "duloxetine venlafaxine": 27125,
      "new evidence": 49324,
      "evidence conclusions": 30177,
      "remain studied": 70254,
      "mixed pain": 46807,
      "related prescription": 69671,
      "developed included": 24179,
      "included abuse": 37408,
      "participants recreational": 58356,
      "174 participants": 2009,
      "study 80": 77906,
      "80 participants": 5856,
      "participants study": 58372,
      "common reasons": 17804,
      "asked specific": 11850,
      "year oxycodone": 87478,
      "morphine commonly": 47611,
      "hydrocodone use": 36136,
      "reported various": 70676,
      "chewed crushed": 15978,
      "drugs prescription": 27042,
      "marijuana alcohol": 43382,
      "opioids family": 52906,
      "canada united": 14751,
      "known opioid": 40920,
      "oxymorphone opioid": 56272,
      "clinical agents": 16755,
      "tools opioid": 81692,
      "pharmacological effects": 61213,
      "mor delta": 47498,
      "dor kappa": 25732,
      "potent agonists": 63090,
      "agonists antagonists": 9319,
      "therapeutic properties": 80958,
      "group position": 33920,
      "opioid ligands": 51887,
      "work development": 87274,
      "new approach": 49310,
      "morphinan skeleton": 47524,
      "compounds high": 18611,
      "high efficacy": 35097,
      "affinity selectivity": 8947,
      "antinociceptive agents": 11237,
      "achieve better": 7296,
      "function opioid": 32659,
      "open new": 51194,
      "new avenues": 49312,
      "options available": 53469,
      "pain optimal": 57295,
      "requires understanding": 70896,
      "search carried": 74106,
      "terms included": 80709,
      "results search": 71931,
      "pain literature": 57024,
      "acting short": 7424,
      "opioids variety": 53384,
      "pain appear": 56456,
      "pain seen": 57809,
      "activities pain": 7552,
      "term clinical": 80621,
      "make informed": 43003,
      "informed decisions": 38680,
      "tramadol hcl": 82065,
      "scheduled drug": 73643,
      "developed independent": 24180,
      "potential changes": 63145,
      "changes abuse": 15771,
      "products available": 65443,
      "asked indicate": 11838,
      "tramadol identified": 82074,
      "commonly diverted": 17848,
      "remained low": 70265,
      "abuse increase": 6735,
      "abuse introduction": 6742,
      "abuse rates": 6854,
      "lower observed": 42654,
      "tramadol risk": 82107,
      "management plan": 43238,
      "potential background": 63139,
      "alternative route": 9739,
      "intravenous subcutaneous": 39886,
      "oral rectal": 53659,
      "rectal administration": 68803,
      "patients key": 59436,
      "key features": 40667,
      "administration combined": 8226,
      "combined rapid": 17668,
      "aim paper": 9394,
      "review based": 72264,
      "nasal mucosa": 48655,
      "systematically evaluated": 80009,
      "results pharmacokinetic": 71867,
      "volunteers reported": 86434,
      "fentanyl alfentanil": 31434,
      "alfentanil sufentanil": 9562,
      "butorphanol oxycodone": 14627,
      "mean times": 43888,
      "fentanyl pethidine": 31567,
      "studied postoperative": 77627,
      "vary 12": 85987,
      "12 22": 1230,
      "24 60": 3173,
      "interindividual variation": 39442,
      "variation pharmacokinetics": 85919,
      "pharmacokinetics clinical": 61163,
      "clinical outcome": 16848,
      "pca adverse": 60259,
      "administration experience": 8260,
      "outpatients chronic": 54161,
      "reported conclusion": 70525,
      "improve clinical": 37057,
      "outcome background": 53907,
      "improve recovery": 37088,
      "surgeries study": 79289,
      "psychological symptoms": 66346,
      "life hrqol": 41700,
      "completed questionnaires": 18489,
      "year surgery": 87505,
      "life satisfaction": 41732,
      "hospital anxiety": 35564,
      "depression scale": 23597,
      "equally high": 29244,
      "points higher": 62131,
      "use better": 84223,
      "relief use": 70205,
      "medication 12": 44447,
      "intensity similar": 39315,
      "patients benign": 59035,
      "population 12": 62298,
      "population decreased": 62325,
      "decreased patients": 23025,
      "patients malignant": 59473,
      "satisfaction lower": 73405,
      "decreased groups": 23000,
      "satisfaction increased": 73402,
      "similarly low": 76013,
      "correlated pain": 20815,
      "preoperative evaluation": 63741,
      "professionals patients": 65467,
      "patients psychological": 59719,
      "retrospectively registered": 72181,
      "remain poorly": 70251,
      "concomitant analgesics": 19248,
      "march 2021": 43371,
      "morphine contrast": 47628,
      "celecoxib acetaminophen": 15454,
      "analgesics observed": 10462,
      "analysis adjusted": 10634,
      "adjusted sex": 8057,
      "assess trends": 11971,
      "trends use": 82990,
      "analyzed evaluate": 10830,
      "evaluate patterns": 29828,
      "patterns long": 60209,
      "use delivery": 84297,
      "medications evaluated": 44619,
      "evaluated included": 29890,
      "unadjusted adjusted": 83452,
      "adjusted models": 8038,
      "hospital factors": 35591,
      "evaluating use": 29950,
      "medications risk": 44672,
      "risk severe": 72660,
      "determined based": 24061,
      "study criteria": 78045,
      "methadone use": 45134,
      "decreased 2006": 22948,
      "used delivery": 84905,
      "clinical recommendations": 16881,
      "women opioid": 87230,
      "buprenorphine associated": 14521,
      "decreased maternal": 23007,
      "post traumatic": 62625,
      "testing study": 80844,
      "frequently administered": 32544,
      "short stay": 75187,
      "obtained 25": 50759,
      "discharged day": 25191,
      "oxycodone new": 55535,
      "25 14": 3321,
      "occurred conclusions": 50832,
      "ra associated": 66929,
      "purpose recent": 66559,
      "states likely": 77115,
      "likely related": 41835,
      "derivatives study": 23625,
      "study program": 78430,
      "individuals entering": 38342,
      "entering substance": 29064,
      "month use": 47416,
      "high fentanyl": 35103,
      "findings total": 31836,
      "use rose": 84709,
      "rose modestly": 72815,
      "fentanyl products": 31578,
      "mean 10": 43654,
      "10 25": 696,
      "products nearly": 65453,
      "assess prevalence": 11954,
      "prevalence illicit": 64786,
      "recent increases": 68405,
      "use entirely": 84353,
      "likely represent": 41841,
      "fentanyl abuse": 31429,
      "abuse growing": 6728,
      "efforts identify": 28439,
      "abuse long": 6765,
      "drugs pattern": 27035,
      "therapeutic intervention": 80946,
      "experience patients": 30589,
      "successful treatment": 78916,
      "intranasal opioid": 39754,
      "referral center": 69152,
      "chief complaints": 16004,
      "complaints patients": 18431,
      "reported previous": 70633,
      "patients exhibited": 59271,
      "patients compliant": 59122,
      "improvement symptoms": 37167,
      "antifungal therapy": 11200,
      "treatment objective": 82689,
      "population design": 62327,
      "database ims": 22169,
      "age year": 9135,
      "year use": 87513,
      "17 percent": 1982,
      "percent 30": 60449,
      "days 10": 22460,
      "10 percent": 897,
      "percent 90": 60452,
      "days supplied": 22633,
      "43 percent": 4506,
      "percent received": 60485,
      "oxycodone 17": 54526,
      "equivalent total": 29334,
      "71 percent": 5597,
      "50 99": 4827,
      "99 mg": 6491,
      "claims 100": 16616,
      "individuals cancer": 38340,
      "cancer older": 14807,
      "patients significantly": 59981,
      "opioids 05": 52656,
      "22 percent": 3039,
      "percent 20": 60447,
      "claims conclusions": 16619,
      "increased slightly": 38028,
      "women patients": 87234,
      "doses younger": 26301,
      "patients men": 59491,
      "common likely": 17763,
      "medications little": 44640,
      "research conducted": 70992,
      "retrospectively analyzed": 72175,
      "harmful opioid": 34591,
      "did involve": 24460,
      "help explain": 34901,
      "results authors": 71606,
      "authors included": 12733,
      "21 percent": 2982,
      "52 percent": 4993,
      "opioids 40": 52677,
      "percent 41": 60450,
      "41 percent": 4429,
      "compared 22": 18074,
      "78 percent": 5785,
      "percent opioids": 60469,
      "significantly common": 75668,
      "compared 12": 18065,
      "given intravenously": 33177,
      "vs percent": 86671,
      "percent morphine": 60466,
      "confusion immediate": 19529,
      "reported opioid": 70595,
      "frequently cause": 32546,
      "incorporated pain": 37711,
      "guidelines education": 34436,
      "based medication": 13332,
      "care participants": 15054,
      "state north": 77055,
      "reporting evaluation": 70688,
      "conducted assess": 19345,
      "potential prevent": 63212,
      "number specific": 50257,
      "help improve": 34906,
      "results 23": 71555,
      "number times": 50267,
      "patient impact": 58661,
      "requiring monitoring": 70903,
      "human error": 35951,
      "lorazepam oxycodone": 42419,
      "20 sites": 2381,
      "completed evaluation": 18470,
      "easy use": 27291,
      "conclusions web": 19242,
      "methods standardized": 45583,
      "standardized questionnaires": 76987,
      "members children": 44778,
      "demographic data": 23279,
      "current treatment": 21482,
      "residual pain": 71084,
      "received 53": 68106,
      "demographic differences": 23281,
      "total 77": 81768,
      "agreed patients": 9349,
      "drowsiness fatigue": 26490,
      "16 05": 1841,
      "year commonly": 87435,
      "drugs significantly": 27073,
      "significantly affected": 75651,
      "conclusion pediatric": 18958,
      "decision prescribe": 22847,
      "data needed": 22018,
      "needed facilitate": 49001,
      "cost benefit": 20862,
      "modalities used": 47013,
      "managing patient": 43293,
      "adjuvant analgesics": 8078,
      "paracetamol nonsteroidal": 58106,
      "nonsteroidal antiinflammatory": 49857,
      "antiinflammatory drugs": 11211,
      "originally developed": 53794,
      "drugs celecoxib": 26902,
      "highly specific": 35405,
      "advance treatment": 8590,
      "treatment neuropathic": 82680,
      "anti depressant": 11114,
      "new drug": 49319,
      "classes modulate": 16669,
      "background substance": 13205,
      "cause morbidity": 15361,
      "mortality united": 47997,
      "assisted treatment": 12204,
      "naloxone used": 48529,
      "modification therapy": 47232,
      "injection administered": 38936,
      "healthcare provider": 34800,
      "purpose quality": 66556,
      "methods veterans": 45627,
      "range age": 67300,
      "age 42": 9006,
      "42 33": 4449,
      "following primary": 32187,
      "primary opioids": 65053,
      "47 oxycodone": 4661,
      "001 small": 213,
      "discussion recent": 25308,
      "risk medication": 72595,
      "2016 2019": 2731,
      "based prescribing": 13362,
      "used linear": 84985,
      "trends results": 82986,
      "13 million": 1489,
      "prescriptions 12": 64429,
      "20 39": 2287,
      "05 tramadol": 559,
      "codeine increased": 17248,
      "increased 24": 37843,
      "24 05": 3144,
      "respectively opioid": 71223,
      "decreased 27": 22953,
      "population year": 62403,
      "2019 proportion": 2882,
      "days decreased": 22510,
      "decreased 54": 22968,
      "prescriptions 50": 64439,
      "50 mme": 4867,
      "day decreased": 22297,
      "states experienced": 77101,
      "especially high": 29557,
      "risk prescribing": 72641,
      "interventions warranted": 39686,
      "purpose tapentadol": 66592,
      "dual acting": 27111,
      "inferior analgesic": 38524,
      "oxycodone better": 54748,
      "evidence tapentadol": 30280,
      "evaluated effectiveness": 29877,
      "patient type": 58803,
      "na\u00efve opioid": 48834,
      "84 patients": 5964,
      "august 2016": 12668,
      "patients achieved": 58922,
      "relevant pain": 70067,
      "relief days": 70121,
      "days median": 22552,
      "patients nociceptive": 59548,
      "nociceptive pain": 49552,
      "decreased baseline": 22981,
      "end maintenance": 28797,
      "vomiting tapentadol": 86485,
      "pain varying": 57969,
      "including nociceptive": 37650,
      "nociceptive neuropathic": 49548,
      "components tapentadol": 18593,
      "considered line": 19638,
      "use moderate": 84494,
      "aims increase": 9487,
      "increase prescription": 37789,
      "pain concern": 56581,
      "possible diversion": 62533,
      "diversion prescription": 25603,
      "recent media": 68407,
      "sample chronic": 73294,
      "methods participants": 45422,
      "recruited australia": 68790,
      "included questions": 37531,
      "conditions included": 19317,
      "included chronic": 37435,
      "chronic neck": 16216,
      "currently prescribed": 21504,
      "participant reported": 58260,
      "reported receiving": 70638,
      "supplied opioids": 79174,
      "opioids younger": 53399,
      "95 99": 6215,
      "medication odds": 44525,
      "ratio 77": 67750,
      "45 17": 4565,
      "including tampering": 37679,
      "alternative routes": 9740,
      "conclusion people": 18959,
      "studies investigate": 77755,
      "investigate extent": 40012,
      "healthcare issue": 34798,
      "ability patients": 6555,
      "patients participate": 59631,
      "anxiety patients": 11282,
      "pain important": 56846,
      "include patients": 37365,
      "caused cancer": 15377,
      "cancer treatment": 14916,
      "pain europe": 56760,
      "role treatment": 72768,
      "accumulating evidence": 7093,
      "evidence potential": 30246,
      "potential toxicity": 63238,
      "traditional non": 81984,
      "selective nsaids": 74436,
      "use particular": 84603,
      "pain issues": 56984,
      "nsaid related": 50094,
      "use mild": 84487,
      "mild opioids": 46435,
      "underlying disease": 83605,
      "treatment common": 82507,
      "providing adequate": 66247,
      "purpose based": 66522,
      "clinical abuse": 16749,
      "liability assessments": 41638,
      "methods recruited": 45522,
      "anonymous survey": 11040,
      "related issues": 69629,
      "patients potent": 59661,
      "highly correlated": 35391,
      "commonly given": 17849,
      "toxicity overdose": 81935,
      "source drug": 76494,
      "sample conclusions": 73298,
      "formulations high": 32381,
      "use potent": 84637,
      "significant growing": 75545,
      "reduced theoretical": 68981,
      "injection snorting": 38971,
      "safety benefits": 73127,
      "potential cost": 63155,
      "numbers abuse": 50278,
      "admissions substance": 8417,
      "using identified": 85434,
      "year 2006": 87425,
      "developed theoretical": 24194,
      "drug therapeutic": 26813,
      "specifically designed": 76624,
      "common methods": 17770,
      "methods abuse": 45237,
      "abuse including": 6734,
      "including injection": 37626,
      "snorting chewing": 76347,
      "results potential": 71881,
      "privately insured": 65195,
      "range approximately": 67303,
      "different possible": 24914,
      "following breast": 32106,
      "preemptive administration": 63608,
      "efficacious reducing": 28204,
      "reducing incidence": 69016,
      "incidence neuropathic": 37287,
      "pain rat": 57463,
      "examined efficacy": 30379,
      "efficacy administering": 28215,
      "placebo weeks": 61855,
      "mastectomy axillary": 43479,
      "pca morphine": 60266,
      "morphine 24": 47550,
      "surgery acetaminophen": 79311,
      "month months": 47394,
      "presence pain": 64599,
      "pain chest": 56527,
      "movement lower": 48048,
      "55 vs": 5080,
      "arm pain": 11670,
      "pain 45": 56387,
      "pain 51": 56389,
      "noted groups": 49988,
      "groups regard": 34290,
      "reduces incidence": 68989,
      "increasingly utilized": 38140,
      "used perioperative": 85074,
      "impact time": 36854,
      "state legislation": 77048,
      "study retrospective": 78467,
      "day perioperative": 22369,
      "using large": 85454,
      "baseline patient": 13451,
      "patient operative": 58689,
      "operative characteristics": 51246,
      "student tests": 77600,
      "tests analysis": 80853,
      "regression utilized": 69470,
      "utilized analyze": 85741,
      "legislation opioid": 41376,
      "perioperative time": 60853,
      "period initial": 60735,
      "filling oxycodone": 31718,
      "equivalents decreased": 29346,
      "significantly 2010": 75647,
      "2019 41": 2853,
      "vs 61": 86600,
      "vs 125": 86530,
      "ankle surgeons": 11006,
      "results encourage": 71680,
      "appropriate pain": 11507,
      "potential administered": 63127,
      "opioids targeted": 53333,
      "iv abuse": 40363,
      "risks adverse": 72666,
      "health events": 34711,
      "reduce potential": 68887,
      "experienced drug": 30602,
      "strategy potential": 77442,
      "states include": 77108,
      "described data": 23655,
      "data human": 21981,
      "abuse adf": 6648,
      "products studies": 65459,
      "opioids decrease": 52835,
      "opioids represents": 53266,
      "providing access": 66246,
      "needed medication": 49014,
      "epidemic purpose": 29150,
      "studies assessing": 77652,
      "admitted intensive": 8424,
      "sought characterize": 76482,
      "outcomes patient": 54071,
      "population materials": 62352,
      "study adult": 77912,
      "patient hospital": 58658,
      "patients 107": 58823,
      "iqr 23": 40170,
      "benzodiazepines common": 13660,
      "smoking chronic": 76337,
      "pain alcoholism": 56439,
      "84 median": 5960,
      "icu length": 36398,
      "stay days": 77274,
      "eighteen patients": 28450,
      "died hospital": 24526,
      "discharged nursing": 25204,
      "iqr days": 40180,
      "overdose common": 54272,
      "relatively young": 69796,
      "associated relatively": 12407,
      "impact outcomes": 36826,
      "efficacy perioperative": 28326,
      "care postoperative": 15062,
      "acetaminophen needed": 7209,
      "care plus": 15061,
      "intravenous dexamethasone": 39822,
      "days determine": 22511,
      "score number": 73763,
      "mean visual": 43901,
      "score opioid": 73765,
      "lower dexamethasone": 42599,
      "day compared": 22276,
      "96 vs": 6427,
      "vs 64": 86604,
      "40 002": 4306,
      "group demonstrated": 33732,
      "97 88": 6436,
      "observed days": 50670,
      "conclusion single": 18994,
      "transduction pathways": 82175,
      "mor activation": 47492,
      "fully understand": 32617,
      "underlying opioid": 83609,
      "current therapies": 21480,
      "investigate opioid": 40019,
      "behavioral phenotypes": 13549,
      "validated applied": 85784,
      "mor expression": 47500,
      "expression brain": 30828,
      "respect function": 71133,
      "differences behavioral": 24719,
      "behavioral responses": 13551,
      "responses morphine": 71389,
      "compared wild": 18341,
      "wild type": 87098,
      "type mice": 83332,
      "oprm1 gene": 53415,
      "receptor density": 68487,
      "rna sequencing": 72694,
      "neurons following": 49216,
      "utility new": 85725,
      "greatly facilitate": 33508,
      "attributed opioids": 12611,
      "drug objective": 26723,
      "substances using": 78840,
      "multiple drug": 48276,
      "results fifths": 71693,
      "drug opioids": 26726,
      "opioids followed": 52916,
      "63 opioids": 5363,
      "opioids 42": 52678,
      "44 oxycodone": 4543,
      "oxycodone 54": 54581,
      "addition common": 7798,
      "require greater": 70804,
      "ability enhance": 6551,
      "prevention guidelines": 64873,
      "adult opioid": 8502,
      "paucity evidence": 60236,
      "evidence guidelines": 30192,
      "guidelines inform": 34444,
      "prescribing pediatrics": 64111,
      "develop guidelines": 24147,
      "use objectives": 84531,
      "hospital compare": 35571,
      "received greater": 68155,
      "days methods": 22554,
      "review oral": 72328,
      "prescribed acute": 63814,
      "january 2017": 40453,
      "2017 december": 2777,
      "31 2017": 3851,
      "2017 patients": 2800,
      "hematology oncology": 34927,
      "results opioids": 71813,
      "days interquartile": 22542,
      "range days": 67308,
      "days opioids": 22568,
      "prescribed days": 63847,
      "prescriptions days": 64466,
      "common diagnoses": 17747,
      "burn trauma": 14616,
      "143 patients": 1644,
      "received days": 68134,
      "younger 001": 87726,
      "001 differences": 131,
      "differences sex": 24815,
      "sex ethnicity": 75076,
      "prescribing characteristics": 64039,
      "patients providers": 59717,
      "providers background": 66182,
      "background standard": 13199,
      "protocol minimize": 65980,
      "2017 methods": 2794,
      "methods june": 45369,
      "total 29": 81746,
      "group catheter": 33677,
      "catheter inserted": 15313,
      "induction general": 38478,
      "anesthesia epidural": 10912,
      "infusion started": 38732,
      "received intermittent": 68171,
      "rescue opioids": 70967,
      "consumption day": 19913,
      "iqr 14": 40162,
      "14 33": 1567,
      "19 mg": 2185,
      "conclusion compared": 18875,
      "law 38": 41248,
      "physician reports": 61432,
      "reports medical": 70732,
      "pharmacological approach": 61209,
      "approach pain": 11469,
      "carried clinical": 15135,
      "compliance law": 18534,
      "assessed age": 11984,
      "age 71": 9048,
      "measurement pain": 44017,
      "points lower": 62133,
      "37 34": 4177,
      "time increased": 81275,
      "achieved oxycodone": 7321,
      "normal release": 49906,
      "clinical problems": 16874,
      "drugs currently": 26927,
      "available recent": 12833,
      "recent guidelines": 68404,
      "need improved": 48931,
      "treatment decisions": 82542,
      "decisions based": 22853,
      "based solely": 13381,
      "fact different": 31046,
      "different causative": 24848,
      "combining drugs": 17683,
      "risk drug": 72552,
      "inhibition single": 38786,
      "single molecule": 76121,
      "molecule mechanisms": 47294,
      "mechanisms contributing": 44140,
      "shown opioid": 75342,
      "opioid agonism": 51418,
      "primarily responsible": 64981,
      "analgesia acute": 9902,
      "tapentadol similar": 80470,
      "produced significantly": 65409,
      "fewer gastrointestinal": 31639,
      "treatment discontinuations": 82553,
      "stable year": 76852,
      "year safety": 87499,
      "safety study": 73223,
      "limitations currently": 41899,
      "available analgesics": 12789,
      "undertaken assess": 83663,
      "assess degree": 11923,
      "asked complete": 11836,
      "opioids patient": 53155,
      "calculated patients": 14696,
      "great deal": 33413,
      "abuse patterns": 6804,
      "significant morbidity": 75579,
      "psychiatric problems": 66328,
      "intensity common": 39236,
      "provide reliable": 66094,
      "reliable high": 70082,
      "provide valid": 66112,
      "valid reliable": 85776,
      "reliable information": 70083,
      "patterns abuse": 60195,
      "mandated risk": 43301,
      "drugs shown": 27071,
      "shown prolong": 75346,
      "include opioids": 37361,
      "inhalational anesthetics": 38762,
      "preparations used": 63786,
      "narrow therapeutic": 48647,
      "possible drug": 62534,
      "lead clinical": 41280,
      "potency buprenorphine": 63069,
      "effective antiemetics": 27599,
      "ht3 receptor": 35916,
      "particularly vulnerable": 58424,
      "risk potentially": 72639,
      "fatalities associated": 31242,
      "hydrochloride increasingly": 36027,
      "september 2005": 74609,
      "cocaine benzoylecognine": 17143,
      "associated illicit": 12289,
      "younger people": 87742,
      "61 years": 5321,
      "fentanyl 17": 31416,
      "17 ng": 1977,
      "ml vs": 46919,
      "vs ng": 86661,
      "ml lower": 46871,
      "postmortem blood": 62672,
      "vs deaths": 86644,
      "use wide": 84812,
      "concentrations fentanyl": 18763,
      "concentration ng": 18706,
      "fentanyl strongly": 31594,
      "poly drug": 62189,
      "commonly detected": 17844,
      "users morphine": 85255,
      "oxycodone 14": 54517,
      "methadone 14": 45036,
      "greater 10": 33421,
      "pattern licit": 60191,
      "objectives hypothesis": 50563,
      "largely unexplored": 41168,
      "evaluated incidence": 29888,
      "acetaminophen paracetamol": 7231,
      "design authors": 23698,
      "study need": 78320,
      "surgery adverse": 79315,
      "events recorded": 30104,
      "71 placebo": 5598,
      "patients acetaminophen": 58920,
      "required rescue": 70860,
      "surgery severe": 79584,
      "insufficient patients": 39132,
      "followed closely": 32050,
      "need efficient": 48921,
      "efficient analgesia": 28421,
      "phase recovery": 61317,
      "recovery background": 68739,
      "methods children": 45267,
      "studied study": 77631,
      "parallel groups": 58143,
      "anaesthetic technique": 9886,
      "management used": 43277,
      "endpoints postoperative": 28919,
      "results children": 71622,
      "compared open": 18224,
      "postoperative mornings": 62793,
      "resulted reduced": 71514,
      "doses mean": 26211,
      "difference doses": 24611,
      "95 cent": 6217,
      "interval doses": 39597,
      "mean length": 43784,
      "stay significantly": 77293,
      "versus days": 86118,
      "difference days": 24606,
      "001 children": 112,
      "wound infection": 87360,
      "infection conclusion": 38513,
      "pain shorter": 57832,
      "stay open": 77282,
      "particularly involving": 58414,
      "treated hospital": 82342,
      "analyzed trends": 10862,
      "hospitals united": 35673,
      "states opioids": 77134,
      "2000 2019": 2422,
      "used observational": 85038,
      "study hospital": 78231,
      "mmes calculated": 46984,
      "oral conversion": 53510,
      "mme person": 46973,
      "calculated compare": 14687,
      "compare data": 18013,
      "year 2012": 87427,
      "peaked 2012": 60327,
      "50 greater": 4839,
      "buprenorphine seen": 14587,
      "hospital use": 35650,
      "methadone 58": 45044,
      "new jersey": 49336,
      "39 states": 4277,
      "crisis objective": 21174,
      "determine drug": 24004,
      "buprenorphine nalbuphine": 14565,
      "sex ratio": 75086,
      "ratio 74": 67748,
      "treatment conclusion": 82517,
      "conclusion work": 19020,
      "indicating opioid": 38263,
      "patients progressive": 59707,
      "disease objective": 25333,
      "series study": 74665,
      "dosage opioids": 25755,
      "scored according": 73815,
      "clinical course": 16777,
      "patients 86": 58906,
      "primary causes": 64995,
      "complication chronic": 18548,
      "morphine used": 47967,
      "used 12": 84820,
      "final dose": 31744,
      "mg range": 46194,
      "range 36": 67284,
      "001 severe": 204,
      "events background": 30016,
      "background emergency": 13051,
      "ed patients": 27339,
      "pain challenge": 56519,
      "determine patients": 24036,
      "oud methods": 53895,
      "complaint chronic": 18426,
      "pain enrolled": 56757,
      "reviewed medical": 72385,
      "monitoring database": 47319,
      "database information": 22172,
      "bivariate analysis": 13898,
      "analysis comparing": 10656,
      "comparing differences": 18347,
      "groups multivariate": 34240,
      "results 45": 71569,
      "preference opioid": 63625,
      "dose increase": 25930,
      "include small": 37368,
      "reported measures": 70582,
      "convenience sample": 20686,
      "bias conclusion": 13763,
      "characteristics emergency": 15861,
      "consider evidence": 19604,
      "implicit bias": 36972,
      "study objectives": 78342,
      "cohort discharged": 17358,
      "opioids examine": 52897,
      "factors predictive": 31124,
      "sample ed": 73301,
      "years discharged": 87585,
      "opioid participants": 52043,
      "additional prescription": 7885,
      "opioids prescription": 53215,
      "85 patients": 5988,
      "follow ups": 32038,
      "36 42": 4118,
      "42 reported": 4474,
      "days difference": 22513,
      "scores analgesic": 73841,
      "treatment discharge": 82551,
      "taking prescription": 80324,
      "reported 39": 70489,
      "14 36": 1569,
      "taking pain": 80321,
      "13 36": 1466,
      "risk substance": 72662,
      "prevalent cohort": 64825,
      "patients heterogeneous": 59356,
      "misuse study": 46750,
      "operating time": 51213,
      "intraoperative blood": 39767,
      "loss postoperative": 42437,
      "single health": 76105,
      "women requiring": 87243,
      "arm 19": 11665,
      "arms 28": 11684,
      "minutes vs": 46666,
      "37 18": 4173,
      "91 63": 6132,
      "loss significantly": 42438,
      "group 62": 33633,
      "63 12": 5352,
      "05 21": 481,
      "54 ml": 5049,
      "006 significant": 272,
      "66 mg": 5455,
      "mg 77": 45771,
      "hours vs": 35876,
      "vs 60": 86599,
      "60 05": 5219,
      "05 48": 485,
      "hours 88": 35743,
      "overall complication": 54190,
      "complication rates": 18554,
      "safe alternative": 73070,
      "yr received": 87748,
      "analgesics rescue": 10496,
      "analgesia consisted": 9934,
      "pain just": 56986,
      "wong baker": 87260,
      "baker faces": 13224,
      "kg group": 40731,
      "group 006": 33535,
      "parents rated": 58221,
      "larger dose": 41173,
      "moderate severity": 47212,
      "vomiting 10": 86441,
      "10 nausea": 873,
      "similar treatment": 76001,
      "changes hemodynamic": 15792,
      "tolerated effective": 81630,
      "analgesia group": 9986,
      "receiving mg": 68354,
      "efficacy early": 28254,
      "oral analgesia": 53490,
      "intra abdominal": 39714,
      "gynecologic oncology": 34485,
      "methods year": 45634,
      "versus traditional": 86162,
      "patients initially": 59410,
      "received parenteral": 68241,
      "pca dose": 60263,
      "minute lockout": 46637,
      "patients began": 59033,
      "morphine received": 47903,
      "received scheduled": 68266,
      "dose 20": 25794,
      "hours additional": 35747,
      "needed breakthrough": 48987,
      "morphine pca": 47875,
      "day scheduled": 22409,
      "scheduled oral": 73651,
      "doses continued": 26162,
      "continued 24": 20130,
      "time patient": 81315,
      "mg results": 46207,
      "stay pain": 77284,
      "major postoperative": 42966,
      "complications conclusions": 18558,
      "surgery safe": 79574,
      "evaluated prevalence": 29913,
      "use mental": 84477,
      "year methods": 87451,
      "risk er": 72554,
      "variables significantly": 85901,
      "major depressive": 42939,
      "depressive episode": 23610,
      "pain reliever": 57602,
      "reliever misuse": 70223,
      "codeine products": 17281,
      "including nicotine": 37649,
      "implement interventions": 36923,
      "health objective": 34738,
      "assess factors": 11935,
      "setting national": 74789,
      "national pharmaceutical": 48706,
      "pharmaceutical database": 61023,
      "health marketscan": 34728,
      "commercial claims": 17701,
      "claims encounters": 16631,
      "medicare claims": 44437,
      "prescriptions january": 64505,
      "2016 patients": 2756,
      "patients previous": 59695,
      "previous opioid": 64908,
      "week surgery": 86874,
      "surgery cohort": 79345,
      "prescription 12": 64148,
      "assess associations": 11912,
      "measure opioid": 43939,
      "prescription details": 64196,
      "98 patients": 6472,
      "cohort 57": 17342,
      "hydrocodone mg": 36104,
      "mg frequently": 45895,
      "average duration": 12890,
      "duration opioids": 27171,
      "prescribed 49": 63811,
      "associated total": 12453,
      "prescribed day": 63846,
      "postoperative week": 62986,
      "opioids 20": 52666,
      "patients additional": 58941,
      "increases likelihood": 38060,
      "use 15": 84143,
      "22 respectively": 3042,
      "day 40": 22258,
      "40 mme": 4365,
      "background peripheral": 13154,
      "use ultrasound": 84786,
      "studies studied": 77851,
      "result reduced": 71489,
      "improved outcomes": 37114,
      "ankle surgery": 11007,
      "surgery included": 79424,
      "103 patients": 1058,
      "patients stratified": 59999,
      "scales 12": 73589,
      "postoperatively days": 62999,
      "use weight": 84811,
      "prn opioid": 65201,
      "variance used": 85906,
      "groups proportion": 34280,
      "reported visual": 70677,
      "point results": 62108,
      "levels groups": 41566,
      "groups 12": 34095,
      "levels 24": 41540,
      "significantly morphine": 75817,
      "ga group": 32782,
      "conclusions use": 19240,
      "beneficial postoperative": 13604,
      "surgery pediatric": 79520,
      "evidence iii": 30195,
      "retrospective comparative": 72135,
      "comparative study": 17984,
      "open abdominal": 51146,
      "hysterectomy study": 36327,
      "historical control": 35444,
      "patients 2008": 58841,
      "2008 2010": 2498,
      "pca compared": 60260,
      "po acetaminophen": 62054,
      "acetaminophen 1g": 7117,
      "1g iv": 2249,
      "iv administered": 40366,
      "administered 45": 8105,
      "injected bupivacaine": 38914,
      "control regimen": 20411,
      "regimen consisted": 69304,
      "24h postoperatively": 3312,
      "6h 48h": 5537,
      "48h postoperatively": 4765,
      "basal rate": 13265,
      "acetaminophen 10": 7111,
      "6h needed": 5539,
      "cohort 105": 17337,
      "compared historical": 18177,
      "historical postoperative": 35445,
      "postoperative morphine": 62794,
      "cancer stage": 14913,
      "database prescription": 22180,
      "methodology use": 45231,
      "use assess": 84205,
      "used self": 85123,
      "period overall": 60762,
      "53 10": 5014,
      "37 95": 4184,
      "ci 50": 16464,
      "50 53": 4816,
      "ci 20": 16411,
      "respectively observed": 71221,
      "increased rate": 37999,
      "rate low": 67480,
      "70 95": 5559,
      "37 13": 4170,
      "13 morphine": 1492,
      "extent oxycodone": 30930,
      "agonists associated": 9320,
      "conclusions approach": 19033,
      "successfully identified": 78922,
      "observed drugs": 50676,
      "drugs known": 26986,
      "suggest current": 78988,
      "screening tool": 74051,
      "tool drugs": 81683,
      "present article": 64605,
      "adjuvant opioids": 8084,
      "pain sickle": 57834,
      "31 year": 3882,
      "male history": 43040,
      "multiple joint": 48281,
      "signs physical": 75880,
      "bilirubin mg": 13798,
      "intravenous fluids": 39830,
      "fentanyl patient": 31562,
      "methadone analgesic": 45046,
      "course hospitalization": 20991,
      "pain resolved": 57634,
      "day later": 22328,
      "infusion ketamine": 38710,
      "aspartate nmda": 11854,
      "published reports": 66437,
      "search revealed": 74127,
      "17 cases": 1957,
      "showed improvement": 75262,
      "dosage patient": 25758,
      "leading discontinuation": 41308,
      "discontinuation drug": 25223,
      "option pain": 53459,
      "disease randomized": 25346,
      "trial required": 83083,
      "required establish": 70834,
      "available therapies": 12844,
      "older persons": 51041,
      "pain characteristic": 56525,
      "treatment model": 82663,
      "generally accepted": 33009,
      "possible initial": 62538,
      "initial assessment": 38829,
      "assessment possible": 12132,
      "underlying causes": 83603,
      "causes pain": 15397,
      "based non": 13339,
      "used widely": 85190,
      "moderate adverse": 47136,
      "analgesics strong": 10503,
      "strong pain": 77561,
      "continuous pain": 20180,
      "analgesic preparations": 10295,
      "recommended drugs": 68621,
      "carefully monitored": 15111,
      "adjuvant drugs": 8081,
      "effective especially": 27622,
      "pain diabetic": 56708,
      "result decreased": 71473,
      "function improvement": 32650,
      "improvement mood": 37154,
      "mood sleep": 47484,
      "center retrospective": 15550,
      "academic urban": 6960,
      "overdose developed": 54288,
      "defined acute": 23123,
      "onset respiratory": 51124,
      "gas exchange": 32845,
      "results adults": 71594,
      "23 years": 3122,
      "median total": 44295,
      "dose naloxone": 25964,
      "mg interquartile": 45927,
      "clinically apparent": 16973,
      "days iqr": 22545,
      "extracorporeal membrane": 30943,
      "membrane oxygenation": 44786,
      "administration recreational": 8357,
      "care clinicians": 15012,
      "clinicians aware": 17027,
      "effect naloxone": 27494,
      "management particularly": 43231,
      "major challenge": 42931,
      "current pharmacotherapy": 21454,
      "administration analgesic": 8216,
      "morphine structurally": 47929,
      "receptor subtype": 68527,
      "global opioid": 33229,
      "aim improve": 9390,
      "improve treatment": 37092,
      "treatment efficacy": 82569,
      "review presents": 72338,
      "potent analgesia": 63091,
      "fewer undesirable": 31671,
      "undesirable effects": 83707,
      "effects targeted": 28179,
      "safety monitoring": 73167,
      "access drugs": 6990,
      "aims present": 9493,
      "present different": 64615,
      "health authorities": 34672,
      "events identified": 30055,
      "methadone opioids": 45113,
      "benzodiazepines cannabis": 13657,
      "cannabis cocaine": 14933,
      "particularly specific": 58422,
      "prescriptions period": 64540,
      "methadone naloxone": 45109,
      "french society": 32506,
      "undergoing cardiac": 83517,
      "sedation leading": 74315,
      "longer hospital": 42376,
      "intravenous methadone": 39855,
      "cardiopulmonary bypass": 14990,
      "comparing patient": 18356,
      "surgery prior": 79535,
      "prior institution": 65152,
      "methadone usage": 45133,
      "days non": 22559,
      "outcome intraoperative": 53921,
      "measured morphine": 43976,
      "patients postintervention": 59655,
      "postintervention group": 62666,
      "significantly opioids": 75822,
      "hours conclusion": 35759,
      "use intraoperative": 84439,
      "appears reasonable": 11407,
      "potential benefits": 63141,
      "opioids sedatives": 53289,
      "total hospital": 81816,
      "repair ihr": 70381,
      "postoperative cumulative": 62731,
      "tap block": 80370,
      "block recently": 14062,
      "anesthesia technique": 10949,
      "efficacy block": 28231,
      "block used": 14073,
      "transabdominal preperitoneal": 82123,
      "remains low": 70298,
      "study investigating": 78280,
      "conducted data": 19351,
      "838 patients": 5949,
      "patients operated": 59580,
      "using technique": 85637,
      "june 2007": 40540,
      "72 patients": 5624,
      "insufficient information": 39128,
      "medication protocol": 44546,
      "protocol patients": 65985,
      "block group": 14045,
      "differ statistically": 24550,
      "gender bmi": 32931,
      "experienced postoperative": 30623,
      "001 received": 195,
      "oxycodone piritramide": 55687,
      "acetaminophen 001": 7110,
      "approach reduce": 11475,
      "pain emergency": 56752,
      "potential prescription": 63210,
      "study trends": 78549,
      "prescribing pediatric": 64110,
      "eds past": 27370,
      "decade methods": 22803,
      "2001 2010": 2432,
      "ambulatory medical": 9766,
      "care survey": 15083,
      "related visits": 69705,
      "visits identified": 86285,
      "visits pediatric": 86288,
      "19 opioid": 2187,
      "category year": 15311,
      "included codeine": 37437,
      "nonopioid pain": 49813,
      "investigated results": 40053,
      "stratified drug": 77450,
      "overall use": 54263,
      "pediatric ed": 60348,
      "increased 11": 37823,
      "11 14": 1094,
      "use schedule": 84717,
      "analgesic increased": 10260,
      "particularly adolescents": 58407,
      "balancing pain": 13238,
      "newly formulated": 49416,
      "blocks action": 14090,
      "taken directed": 80280,
      "euphoria opioids": 29725,
      "precipitate opioid": 63509,
      "withdrawal opioid": 87139,
      "patient objective": 58688,
      "50 year": 4908,
      "dependent male": 23517,
      "developed acute": 24166,
      "withdrawal taking": 87166,
      "disc disease": 25086,
      "relief trial": 70203,
      "patient returned": 58750,
      "oxymorphone time": 56288,
      "risk involved": 72587,
      "withdrawal treated": 87167,
      "1st 2nd": 2256,
      "medical advice": 44334,
      "best knowledge": 13690,
      "dose 25": 25798,
      "bupivacaine ropivacaine": 14510,
      "plus ibuprofen": 62025,
      "ibuprofen paracetamol": 36371,
      "hours rescue": 35841,
      "regimen used": 69328,
      "scale visual": 73582,
      "age years": 9136,
      "pain degree": 56692,
      "53 vs": 5025,
      "vs 36": 86569,
      "patients mild": 59514,
      "vs 65": 86605,
      "65 05": 5404,
      "rescue treatment": 70976,
      "pain 30": 56379,
      "pain 05": 56347,
      "05 02": 473,
      "02 respectively": 376,
      "time mobilization": 81294,
      "groups 25": 34106,
      "25 17": 3324,
      "time discharge": 81252,
      "home days": 35509,
      "days 05": 22459,
      "05 05": 474,
      "analgesia control": 9939,
      "control post": 20393,
      "equianalgesic potency": 29265,
      "potency ratios": 63086,
      "frequentist network": 32538,
      "comparing opioids": 18352,
      "search medline": 74115,
      "criteria rcts": 21215,
      "resulting pain": 71531,
      "using cochrane": 85342,
      "cochrane risk": 17184,
      "results 52": 71572,
      "16 opioids": 1887,
      "analgesic potencies": 10291,
      "95 percent": 6406,
      "48 22": 4684,
      "37 26": 4176,
      "66 50": 5448,
      "11 01": 1087,
      "46 84": 4624,
      "05 73": 487,
      "10 morphine": 872,
      "oxycodone 65": 54591,
      "55 56": 5067,
      "95 pethidine": 6407,
      "12 10": 1207,
      "opioids potent": 53195,
      "acting drugs": 7379,
      "background epidemic": 13054,
      "states prompted": 77146,
      "inpatient opioid": 39014,
      "decreased time": 23048,
      "center january": 15529,
      "31 2020": 3854,
      "mme administered": 46952,
      "administered hospitalization": 8134,
      "log transformed": 42249,
      "determine average": 23992,
      "average patient": 12930,
      "year patients": 87480,
      "mechanically ventilated": 44121,
      "results thousand": 72016,
      "72 oxycodone": 5623,
      "10 fentanyl": 763,
      "time conclusion": 81225,
      "administration absence": 8209,
      "immersion assay": 36758,
      "acute thermal": 7704,
      "thermal pain": 81084,
      "using stopwatch": 85629,
      "time measurement": 81289,
      "greatly reduce": 33511,
      "latency water": 41228,
      "water temperature": 86763,
      "assay conducted": 11877,
      "data recorded": 22085,
      "observed previously": 50712,
      "previously unreported": 64963,
      "experiment using": 30654,
      "observed significantly": 50718,
      "water control": 86755,
      "detected significant": 23948,
      "strain differences": 77404,
      "baseline latency": 13438,
      "introduction limited": 39929,
      "studies analyzed": 77645,
      "limited english": 41931,
      "literature lacks": 42116,
      "opioid risks": 52352,
      "risks study": 72684,
      "dependency overdose": 23495,
      "overdose risks": 54317,
      "quantitatively coded": 66816,
      "non verbal": 49696,
      "common effects": 17753,
      "effects discussed": 27899,
      "effects 23": 27795,
      "identify patient": 36514,
      "providing patient": 66267,
      "patients regarding": 59875,
      "cnp patients": 17111,
      "outweigh risks": 54170,
      "review examined": 72301,
      "patients analysis": 58992,
      "analysis studies": 10773,
      "trials 12": 83099,
      "month duration": 47388,
      "duration morphine": 27167,
      "used objective": 85037,
      "sleep measures": 76227,
      "leg movements": 41360,
      "increased sleep": 38027,
      "rapid eye": 67382,
      "eye movement": 31002,
      "movement rem": 48050,
      "rem sleep": 70243,
      "associated improved": 12293,
      "standardised mean": 76941,
      "unclear high": 83474,
      "overall risk": 54252,
      "bias studies": 13774,
      "effect background": 27424,
      "based analgesics": 13278,
      "routinely prescribed": 72871,
      "approach methods": 11465,
      "prospectively enrolled": 65895,
      "depression surgery": 23603,
      "peak pain": 60315,
      "medication requirements": 44561,
      "median 30": 44189,
      "30 opioid": 3778,
      "pain pills": 57378,
      "pills surgery": 61544,
      "10 patients": 895,
      "mg 32": 45740,
      "median 27": 44186,
      "27 pills": 3508,
      "pills left": 61514,
      "period median": 60749,
      "levels procedures": 41597,
      "94 day": 6191,
      "26 range": 3453,
      "range 52": 67292,
      "day median": 22334,
      "mme days": 46960,
      "surgery appears": 79323,
      "requirements pain": 70887,
      "based surgeon": 13387,
      "judicious prescribing": 40503,
      "surgery represents": 79562,
      "opioid overprescription": 52022,
      "october 2013": 50876,
      "2013 july": 2633,
      "proportion total": 65781,
      "market results": 43413,
      "schedule change": 73611,
      "change statistically": 15752,
      "yearly increase": 87517,
      "opioids represent": 53264,
      "opioids sold": 53305,
      "product availability": 65426,
      "2016 conclusions": 2738,
      "particularly oxycodone": 58419,
      "background cancer": 13020,
      "related neuropathic": 69638,
      "pain unresponsive": 57956,
      "novel drugs": 50009,
      "drugs required": 27065,
      "use adjuvant": 84176,
      "relieving cancer": 70230,
      "center open": 15533,
      "included 38": 37397,
      "japanese patients": 40471,
      "patients advanced": 58957,
      "cancer received": 14901,
      "primary tumor": 65119,
      "tapentadol doses": 80395,
      "adjuvant analgesic": 8077,
      "analgesic prescriptions": 10301,
      "outcomes adverse": 54009,
      "assessed days": 11996,
      "results eighteen": 71672,
      "38 patients": 4243,
      "13 94": 1475,
      "switching oral": 79836,
      "score decreased": 73742,
      "78 78": 5777,
      "patients clinically": 59092,
      "clinically improved": 16981,
      "switching tapentadol": 79841,
      "usually mild": 85697,
      "common terminology": 17816,
      "terminology criteria": 80696,
      "criteria adverse": 21190,
      "safety margin": 73165,
      "treatment increasing": 82625,
      "states limited": 77116,
      "make difficult": 43001,
      "difficult determine": 24962,
      "investigated relationship": 40052,
      "use consistent": 84268,
      "consistent predictors": 19709,
      "obtain prescription": 50754,
      "drugs past": 27031,
      "benzodiazepines illicit": 13664,
      "multilevel models": 48192,
      "variance opioid": 85905,
      "drugs benzodiazepines": 26895,
      "ratio 36": 67732,
      "abuse compared": 6663,
      "ratio 49": 67740,
      "49 95": 4770,
      "10 48": 712,
      "strength association": 77472,
      "association abuse": 12469,
      "deaths 2012": 22735,
      "deaths 2014": 22736,
      "sold pills": 76422,
      "prevalence characteristics": 64774,
      "invited complete": 40088,
      "provide urine": 66110,
      "sample test": 73319,
      "participants analyzed": 58280,
      "statistical methods": 77180,
      "used multiple": 85019,
      "multiple substances": 48301,
      "59 heroin": 5188,
      "use frequently": 84376,
      "29 tested": 3615,
      "report using": 70481,
      "reported use": 70672,
      "78 001": 5773,
      "001 use": 218,
      "fentanyl detection": 31465,
      "conclusions proportion": 19179,
      "need targeted": 48962,
      "strategies increased": 77416,
      "naloxone overdose": 48475,
      "common nursing": 17773,
      "nh residents": 49463,
      "evaluate factors": 29801,
      "medication information": 44506,
      "models adjusted": 47107,
      "residents nhs": 71076,
      "analgesics results": 10497,
      "excruciating pain": 30496,
      "vs moderate": 86658,
      "pain documented": 56729,
      "64 vs": 5394,
      "16 long": 1876,
      "fentanyl common": 31453,
      "use factors": 84370,
      "analgesics included": 10435,
      "included severe": 37551,
      "aor 57": 11318,
      "ci 41": 16447,
      "41 80": 4416,
      "disease aor": 25319,
      "aor 55": 11312,
      "79 95": 5797,
      "scores aor": 73842,
      "pharmacologic management": 61197,
      "guidelines pain": 34455,
      "identify people": 36518,
      "death study": 22725,
      "patients factors": 59294,
      "misuse index": 46723,
      "index pomi": 38204,
      "scores methods": 73904,
      "2019 eligible": 2864,
      "pain consented": 56591,
      "consented participate": 19582,
      "62 women": 5341,
      "age 58": 9028,
      "years 16": 87525,
      "paracetamol tramadol": 58119,
      "opioids 32": 52675,
      "median morphine": 44246,
      "day iqr": 22327,
      "75 20": 5696,
      "20 80": 2305,
      "score 01": 73703,
      "mme 01": 46947,
      "analysis age": 10636,
      "78 95": 5779,
      "26 40": 3433,
      "mg 65": 45761,
      "scores conclusions": 73853,
      "refer pain": 69125,
      "replacement thr": 70433,
      "opioid rates": 52230,
      "center united": 15560,
      "april 30": 11612,
      "2015 april": 2695,
      "30 2018": 3675,
      "average mme": 12895,
      "age 64": 9040,
      "18 85": 2071,
      "patients primarily": 59699,
      "caucasian white": 15331,
      "white 78": 87013,
      "sample 12": 73287,
      "95 respectively": 6408,
      "opioid moderate": 51950,
      "times likely": 81429,
      "180 patients": 2127,
      "period 40": 60703,
      "range 270": 67278,
      "period having": 60729,
      "predicted opioid": 63564,
      "aim identify": 9389,
      "perioperative factors": 60833,
      "associated delayed": 12250,
      "delayed time": 23194,
      "following hysterectomy": 32140,
      "2018 single": 2847,
      "single academic": 76045,
      "hospital results": 35626,
      "overall median": 54211,
      "median postoperative": 44276,
      "postoperative time": 62973,
      "distribution time": 25569,
      "characteristics groups": 15863,
      "likely older": 41821,
      "history previous": 35476,
      "longer postoperative": 42387,
      "compared equal": 18149,
      "use hydromorphone": 84409,
      "acetaminophen postoperatively": 7240,
      "morphine milliequivalents": 47765,
      "conclusions following": 19089,
      "historic data": 35442,
      "recommend prescription": 68584,
      "prescription low": 64242,
      "duration study": 27184,
      "study assesses": 77975,
      "performed cross": 60580,
      "based sample": 13378,
      "patient visits": 58814,
      "2015 truven": 2723,
      "marketscan research": 43437,
      "research databases": 70997,
      "patients recent": 59864,
      "data standardized": 22114,
      "equivalents recorded": 29375,
      "supply opioid": 79182,
      "percent prescribed": 60483,
      "recommended morphine": 68631,
      "18 34": 2045,
      "years men": 87616,
      "equivalents increased": 29354,
      "patients overprescribed": 59606,
      "health conditions": 34700,
      "illness associated": 36662,
      "procedures prolonged": 65321,
      "identified chronic": 36428,
      "based cohort": 13296,
      "setting adult": 74767,
      "province ontario": 66275,
      "yr admitted": 87746,
      "april 2002": 11598,
      "exposure chronic": 30756,
      "use year": 84815,
      "prescription duration": 64219,
      "day hospital": 22320,
      "results primary": 71890,
      "outcome difference": 53914,
      "prior hospital": 65147,
      "range 17": 67262,
      "dose 36": 25803,
      "reduction prescriptions": 69094,
      "prescribed months": 63894,
      "objective current": 50394,
      "examines opioid": 30425,
      "growing epidemic": 34365,
      "concern study": 18834,
      "community health": 17920,
      "including use": 37683,
      "based self": 13380,
      "modeling used": 47099,
      "ratios ors": 67827,
      "ors 95": 53812,
      "50 reported": 4894,
      "users significantly": 85272,
      "non users": 49695,
      "likely reported": 41840,
      "half sample": 34531,
      "investigate relationship": 40025,
      "provide useful": 66111,
      "narcotics used": 48640,
      "used analgesia": 84840,
      "surgery agents": 79318,
      "intercostal nerve": 39408,
      "implant based": 36916,
      "based breast": 13288,
      "breast reconstruction": 14409,
      "reconstruction methods": 68645,
      "performed operative": 60606,
      "complications recorded": 18568,
      "recorded consumption": 68675,
      "oxycodone recorded": 55809,
      "recorded data": 68677,
      "did results": 24498,
      "reduction length": 69063,
      "days versus": 22651,
      "consumption intravenous": 19941,
      "morphine 15": 47540,
      "versus 12": 86097,
      "12 68": 1260,
      "22 24": 3016,
      "versus 31": 86105,
      "mg 026": 45692,
      "reduction consumption": 69051,
      "versus 17": 86102,
      "mg 007": 45688,
      "14 patient": 1619,
      "hospital length": 35598,
      "clinical question": 16877,
      "question level": 66879,
      "evidence therapeutic": 30281,
      "therapeutic iii": 80943,
      "metabolite oxycodone": 44956,
      "oxycodone highly": 55161,
      "potent narcotic": 63108,
      "nervous available": 49135,
      "available immediate": 12813,
      "er formulation": 29418,
      "crush resistant": 21330,
      "deter misuse": 23973,
      "previously healthy": 64944,
      "hearing loss": 34866,
      "oxymorphone presented": 56280,
      "reported snorting": 70655,
      "department evaluation": 23432,
      "aspiration pneumonia": 11867,
      "experienced similar": 30630,
      "presentation emergency": 64679,
      "completely understood": 18519,
      "second published": 74196,
      "report acute": 70447,
      "clinical suspicion": 16919,
      "june 2012": 40544,
      "aged 17": 9151,
      "selected month": 74393,
      "according categories": 7036,
      "goods administration": 33337,
      "enrolled 56": 28998,
      "29 31": 3599,
      "31 label": 3869,
      "37 patients": 4202,
      "commonly administered": 17836,
      "44 cases": 4539,
      "indication treatment": 38270,
      "medicine administered": 44704,
      "administration common": 8227,
      "used label": 84983,
      "medicines recommended": 44717,
      "use demonstrated": 84298,
      "specimens analyzed": 76638,
      "spectrometry lc": 76665,
      "specimens tested": 76646,
      "reported medication": 70584,
      "use 66": 84158,
      "positive specimens": 62490,
      "unreported use": 83933,
      "respectively non": 71218,
      "clonazepam higher": 17058,
      "cohort 05": 17335,
      "cohort higher": 17360,
      "vs 46": 86582,
      "46 05": 4616,
      "plus opioid": 62027,
      "opioids po": 53182,
      "dramatically north": 26440,
      "2007 methods": 2493,
      "linked population": 42056,
      "level medication": 41502,
      "receiving 30": 68315,
      "mmt opioid": 46996,
      "included proportion": 37522,
      "factors independently": 31105,
      "independently associated": 38177,
      "effects regression": 28134,
      "individuals 27": 38330,
      "po prescriptions": 62058,
      "originated non": 53796,
      "non mmt": 49639,
      "prescriptions person": 64541,
      "person year": 60943,
      "increases morphine": 38061,
      "positively associated": 62510,
      "age higher": 9080,
      "morbidity higher": 47511,
      "prescriptions physicians": 64542,
      "new online": 49343,
      "reported individual": 70574,
      "methods new": 45397,
      "tool available": 81682,
      "new reporting": 49369,
      "errors likely": 29515,
      "likely caused": 41799,
      "product given": 65430,
      "rr 22": 72910,
      "medication overdoses": 44530,
      "rr 32": 72918,
      "include warfarin": 37371,
      "rr 58": 72951,
      "09 18": 639,
      "97 oxycodone": 6444,
      "oxycodone combinations": 54804,
      "48 ci": 4699,
      "collected nursing": 17465,
      "reduce harm": 68843,
      "continuous quality": 20185,
      "efforts background": 28437,
      "background evaluated": 13055,
      "profile low": 65490,
      "kg intrathecal": 40746,
      "morphine postoperative": 47878,
      "various surgical": 85980,
      "methods reviewed": 45553,
      "reviewed pain": 72387,
      "hospital philadelphia": 35618,
      "march 2006": 43358,
      "patients prospectively": 59713,
      "followed 24": 32048,
      "48 intrathecal": 4731,
      "187 patients": 2150,
      "examined mean": 30391,
      "10 median": 784,
      "score evaluated": 73745,
      "evaluated numeric": 29899,
      "iqr iqr": 40181,
      "rescue opioid": 70963,
      "opioid 22": 51353,
      "19 24": 2168,
      "24 24": 3150,
      "70 patients": 5570,
      "patients 37": 58861,
      "receive opioids": 68062,
      "117 patients": 1187,
      "opioids 59": 52682,
      "managed oxycodone": 43136,
      "pain managed": 57052,
      "combination iv": 17563,
      "postdural puncture": 62649,
      "headache patients": 34660,
      "assisted ventilation": 12205,
      "administration observed": 8315,
      "useful safe": 85213,
      "conducted investigate": 19370,
      "caregivers children": 15116,
      "tests performed": 80860,
      "performed compare": 60576,
      "examine use": 30366,
      "use pharmacologic": 84624,
      "pharmacologic therapies": 61201,
      "codeine 32": 17203,
      "70 63": 5550,
      "33 years": 4002,
      "years using": 87687,
      "therapy use": 81075,
      "compared children": 18102,
      "analgesics analgesic": 10375,
      "nonopioid analgesic": 49804,
      "using greater": 85422,
      "greater numbers": 33463,
      "conventional pain": 20700,
      "role pain": 72757,
      "studies provide": 77818,
      "evidence pain": 30242,
      "national regional": 48715,
      "consumption studied": 20025,
      "analgesics past": 10475,
      "use 19": 84145,
      "19 years": 2199,
      "used extract": 84937,
      "anatomical therapeutic": 10881,
      "therapeutic chemical": 80924,
      "chemical classification": 15948,
      "opioids 2000": 52667,
      "using defined": 85373,
      "mg 1000": 45707,
      "31 12": 3841,
      "12 fold": 1281,
      "mg 19": 45723,
      "value 001": 85819,
      "annual opioid": 11025,
      "despite considerable": 23874,
      "low signal": 42555,
      "sub optimal": 78579,
      "increases consumption": 38056,
      "analgesics controlled": 10406,
      "analgesia minimizing": 10022,
      "requirements following": 70881,
      "following ambulatory": 32100,
      "treatment used": 82882,
      "used adjunct": 84835,
      "provide analgesia": 66033,
      "anatomic location": 10879,
      "risks present": 72682,
      "series demonstrate": 74655,
      "demonstrate use": 23327,
      "electromagnetic field": 28523,
      "surgery case": 79340,
      "moderately painful": 47216,
      "bilateral breast": 13792,
      "resting pain": 71441,
      "scale median": 73506,
      "avoided opioid": 12969,
      "oxycodone postoperative": 55707,
      "conclusions cases": 19039,
      "cases demonstrate": 15232,
      "feasible effective": 31289,
      "characteristics clinical": 15849,
      "study children": 77989,
      "states participating": 77138,
      "prescription main": 64243,
      "encounters associated": 28775,
      "filled days": 31702,
      "likely prescribed": 41827,
      "results 113": 71542,
      "dental surgery": 23413,
      "outpatient surgery": 54148,
      "surgery 21": 79303,
      "inpatient discharge": 39010,
      "discharge 10": 25093,
      "percent conclusions": 60457,
      "relatively rare": 69786,
      "opioids filled": 52915,
      "research critical": 70995,
      "understand drivers": 83622,
      "drivers prescribing": 26467,
      "practices clinical": 63424,
      "indications appropriate": 38272,
      "prevalence pain": 64798,
      "pain needed": 57230,
      "needed study": 49037,
      "prescription habits": 64232,
      "moderate efficacy": 47145,
      "efficacy strong": 28396,
      "musculoskeletal conditions": 48368,
      "patterns non": 60211,
      "database including": 22171,
      "prescribed morphine": 63895,
      "morphine significantly": 47924,
      "mean 35": 43664,
      "equivalent day": 29299,
      "pain principal": 57432,
      "treatment weeks": 82890,
      "treatment benefit": 82459,
      "mean months": 43798,
      "evaluate pain": 29824,
      "opioids 001": 52653,
      "conclusions non": 19130,
      "doses according": 26144,
      "according national": 7050,
      "affected opioid": 8918,
      "deaths west": 22791,
      "west virginia": 86995,
      "virginia wv": 86240,
      "wv united": 87385,
      "wv drug": 87382,
      "deaths 2005": 22734,
      "performed including": 60597,
      "demographic toxicological": 23291,
      "deaths deaths": 22750,
      "deaths fentanyl": 22752,
      "deaths prescription": 22775,
      "deaths overdoses": 22773,
      "overdoses 11": 54324,
      "opioid presence": 52216,
      "deaths respectively": 22780,
      "fentanyl involvement": 31510,
      "replaced oxycodone": 70428,
      "oxycodone diazepam": 54964,
      "decedents prescription": 22816,
      "drugs recent": 27053,
      "health threat": 34792,
      "drug tampering": 26801,
      "practices aim": 63422,
      "increase availability": 37733,
      "availability drug": 12778,
      "enhance drug": 28956,
      "combination paracetamol": 17596,
      "following procedures": 32188,
      "procedures reported": 65322,
      "containing codeine": 20073,
      "analysed liquid": 10572,
      "chromatography coupled": 16154,
      "coupled tandem": 20978,
      "ms separation": 48095,
      "separation analytes": 74599,
      "mm 50": 46927,
      "mm \u03bcm": 46943,
      "gradient elution": 33383,
      "formic acid": 32303,
      "acid water": 7344,
      "mrm mode": 48068,
      "99 opioid": 6492,
      "paracetamol associated": 58095,
      "opioid content": 51674,
      "use mixtures": 84493,
      "ignored important": 36551,
      "characterize population": 15903,
      "population methods": 62355,
      "icd 10": 36386,
      "treated january": 82344,
      "charts reviewed": 15937,
      "43 years": 4511,
      "initiated opioids": 38881,
      "prescription adherence": 64160,
      "adherence pain": 7995,
      "opioid frequently": 51821,
      "significant higher": 75546,
      "higher consumption": 35221,
      "therapy conclusion": 80998,
      "drugs treat": 27093,
      "pain low": 57037,
      "substantial efficacy": 78846,
      "efficacy acute": 28214,
      "extent opioids": 30928,
      "opioids affected": 52714,
      "county level": 20969,
      "level analysis": 41448,
      "analysis opioid": 10718,
      "program pmp": 65540,
      "15 completed": 1727,
      "number pharmacists": 50223,
      "agreed opioid": 9347,
      "use pmp": 84627,
      "16 day": 1870,
      "half opioid": 34525,
      "involved prescription": 40112,
      "consistently use": 19724,
      "continues substantial": 20152,
      "necessary minimize": 48888,
      "depression total": 23604,
      "developed general": 24177,
      "general medical": 32976,
      "medical psychiatric": 44390,
      "trials acute": 83102,
      "release vs": 70020,
      "acute low": 7637,
      "pain 666": 56393,
      "666 analyses": 5467,
      "psychometric properties": 66348,
      "internal consistency": 39457,
      "consistency convergent": 19686,
      "convergent validity": 20703,
      "confirmatory factor": 19499,
      "factor analysis": 31050,
      "performed test": 60640,
      "predictive validity": 63577,
      "good psychometric": 33324,
      "displayed good": 25471,
      "good convergent": 33300,
      "fit priori": 31859,
      "priori factor": 65181,
      "factor structure": 31062,
      "structure highly": 77588,
      "result analgesic": 71471,
      "treatment conclude": 82516,
      "valid instrument": 85775,
      "pain population": 57384,
      "perspective considered": 60964,
      "considered results": 19645,
      "results recent": 71905,
      "responsive efficient": 71405,
      "efficient assessment": 28422,
      "bupivacaine morphine": 14508,
      "systemic morphine": 80029,
      "morphine quality": 47900,
      "quality postoperative": 66753,
      "outcomes context": 54020,
      "context enhanced": 20107,
      "undergoing general": 83537,
      "anaesthesia randomly": 9876,
      "allocated receive": 9618,
      "morphine followed": 47696,
      "oxycodone spinal": 55928,
      "spinal group": 76722,
      "pca group": 60264,
      "outcome consumption": 53910,
      "function dietary": 32642,
      "discharge length": 25132,
      "consumption spinal": 20022,
      "group 005": 33534,
      "reported elderly": 70542,
      "spinal analgesia": 76704,
      "stay conclusions": 77273,
      "morphine associated": 47584,
      "source pharmaceutical": 76500,
      "synthetic drugs": 79949,
      "buprenorphine naltrexone": 14569,
      "morphinan alkaloid": 47523,
      "pathway specific": 58521,
      "protein level": 65939,
      "protein levels": 65940,
      "levels correlated": 41552,
      "morphine levels": 47742,
      "levels substantial": 41613,
      "respectively contrast": 71183,
      "genes using": 33068,
      "previously characterized": 64935,
      "provides insight": 66224,
      "potential metabolic": 63189,
      "used reduce": 85102,
      "recovery qor": 68754,
      "gastrointestinal surgery": 32889,
      "surgery established": 79396,
      "established aim": 29582,
      "evaluate ability": 29764,
      "postoperative qor": 62958,
      "receive ultrasound": 68086,
      "ml 375": 46837,
      "375 ropivacaine": 4216,
      "ropivacaine saline": 72807,
      "saline primary": 73269,
      "qor 15": 66638,
      "consumption incidence": 19938,
      "difference 16": 24573,
      "11 21": 1104,
      "group cumulative": 33724,
      "48 48": 4688,
      "group rest": 33988,
      "undergoing gastrointestinal": 83535,
      "likely younger": 41849,
      "adults receive": 8575,
      "use older": 84537,
      "poisoning cases": 62157,
      "2015 2020": 2692,
      "national poison": 48707,
      "poison data": 62155,
      "examine associations": 30334,
      "medical outcomes": 44375,
      "level care": 41449,
      "care clinical": 15011,
      "types opioids": 83372,
      "years proportion": 87645,
      "opioid cases": 51566,
      "cases received": 15258,
      "received naloxone": 68209,
      "rate illicit": 67475,
      "31 compared": 3864,
      "receiving naloxone": 68359,
      "therapy prescription": 81052,
      "rates older": 67604,
      "managed non": 43133,
      "especially low": 29559,
      "unknown opioids": 83886,
      "importance access": 36977,
      "life saving": 41735,
      "conclusions increased": 19100,
      "prevent opioid": 64846,
      "adults use": 8588,
      "based surveillance": 13388,
      "hospital sample": 35627,
      "results based": 71611,
      "estimated emergency": 29626,
      "2016 2017": 2728,
      "2017 nearly": 2797,
      "40 54": 4324,
      "use 38": 84155,
      "32 44": 3914,
      "concurrent illicit": 19265,
      "27 35": 3480,
      "use visits": 84802,
      "35 common": 4078,
      "effects 30": 27796,
      "30 common": 3714,
      "help target": 34913,
      "treatment substance": 82863,
      "dispensing patterns": 25453,
      "cohort setting": 17378,
      "applicable patient": 11421,
      "maximum opioid": 43596,
      "procedure opioid": 65274,
      "use substance": 84760,
      "frequency opioids": 32522,
      "quantity dispensed": 66825,
      "10th 90th": 1082,
      "90th percentile": 6127,
      "multivariate regression": 48351,
      "calculate odds": 14677,
      "examine association": 30333,
      "result total": 71496,
      "total 61": 81761,
      "criteria analysis": 21192,
      "commonly hydrocodone": 17850,
      "oral mme": 53569,
      "mme dose": 46962,
      "dose dispensed": 25884,
      "00 36": 8,
      "18 37": 2048,
      "aor 62": 11323,
      "47 80": 4652,
      "prescription compared": 64182,
      "proportion women": 65783,
      "substantial variation": 78859,
      "patients concurrent": 59129,
      "anti depressants": 11115,
      "purpose results": 66561,
      "determine demographic": 24000,
      "characteristics predictive": 15874,
      "database searched": 22184,
      "allocation ratio": 9621,
      "binary logistic": 13807,
      "regression employed": 69438,
      "employed identify": 28741,
      "female sex": 31375,
      "ratio 41": 67737,
      "renal disease": 70351,
      "oxycodone 76": 54601,
      "13 33": 1465,
      "needed use": 49047,
      "needed analgesia": 48976,
      "administered oral": 8155,
      "route 33": 72836,
      "improvement initiatives": 37153,
      "prescribing patient": 64099,
      "importance overuse": 36986,
      "increasingly recognized": 38136,
      "recognized problem": 68574,
      "published 2015": 66424,
      "use services": 84726,
      "articles reviewed": 11804,
      "evidence review": 30254,
      "review english": 72290,
      "language articles": 41084,
      "january 2015": 40447,
      "2015 december": 2699,
      "31 2015": 3848,
      "2015 reviewed": 2720,
      "using criteria": 85363,
      "findings included": 31791,
      "13 2010": 1459,
      "therapy administered": 80987,
      "opioids overdose": 53128,
      "61 patients": 5318,
      "identified medical": 36448,
      "medical practices": 44384,
      "use treatment": 84783,
      "13 opioids": 1497,
      "scored high": 73816,
      "scale 100": 73484,
      "use harm": 84386,
      "injection fentanyl": 38948,
      "medically prescribed": 44427,
      "form heroin": 32282,
      "51 respectively": 4961,
      "users low": 85251,
      "pethidine methadone": 60986,
      "measures considered": 44052,
      "rising trend": 72502,
      "drug active": 26516,
      "overdose objective": 54303,
      "containing analgesics": 20070,
      "specifically focusing": 76627,
      "hospital based": 35569,
      "patients knowledge": 59438,
      "assessed person": 12036,
      "oxycodone 28": 54546,
      "identified 17": 36416,
      "maximum dose": 43589,
      "dose 11": 25785,
      "11 17": 1098,
      "able identify": 6571,
      "prescription significant": 64405,
      "information patients": 38659,
      "patients awareness": 59026,
      "27 50": 3482,
      "high variability": 35190,
      "receiving acetaminophen": 68319,
      "determine long": 24020,
      "term outcome": 80656,
      "approved retrospective": 11545,
      "tertiary pediatric": 80747,
      "measures postoperative": 44083,
      "postoperative stay": 62968,
      "patients 55": 58877,
      "11 45": 1111,
      "45 discharged": 4583,
      "home pod": 35518,
      "oral diet": 53517,
      "patients 38": 58862,
      "acetaminophen pain": 7229,
      "required oxycodone": 70852,
      "time 47": 81200,
      "patients 50": 58874,
      "future treatment": 32778,
      "required treatment": 70866,
      "procedures conclusions": 65296,
      "patients tolerate": 60048,
      "tolerate treatment": 81616,
      "diet time": 24534,
      "hospital boston": 35570,
      "deeper structures": 23094,
      "multimodal treatments": 48251,
      "treatments including": 82911,
      "including surgical": 37678,
      "poorly treated": 62286,
      "develop novel": 24151,
      "agents opioids": 9233,
      "choice clinical": 16111,
      "pain mu": 57217,
      "undesired effects": 83709,
      "dependence tolerance": 23490,
      "body evidence": 14192,
      "systems level": 80037,
      "associated commonly": 12234,
      "used mu": 85014,
      "opioids include": 52972,
      "opioids lacking": 53011,
      "work area": 87269,
      "provide support": 66106,
      "based medicine": 13333,
      "supporting clinical": 79223,
      "clinical opioid": 16847,
      "analyzed treatment": 10861,
      "prescribed agents": 63817,
      "described sample": 23660,
      "tested associations": 80797,
      "pharmacological clinical": 61212,
      "clinical variables": 16970,
      "prescribed average": 63822,
      "doses high": 26195,
      "prescriptions 16": 64431,
      "agents combined": 9228,
      "combined compared": 17641,
      "compared middle": 18205,
      "quartile dose": 66859,
      "prescriptions adjusted": 64445,
      "younger likely": 87737,
      "17 13": 1932,
      "11 60": 1117,
      "60 likely": 5256,
      "concurrent oxycodone": 19269,
      "03 95": 410,
      "recommended guidelines": 68622,
      "prescriptions psychoactive": 64551,
      "management objective": 43215,
      "efficacy preoperative": 28332,
      "preoperative gabapentin": 63742,
      "levels postoperative": 41595,
      "academic institution": 6950,
      "2019 january": 2869,
      "received 600": 68109,
      "gabapentin did": 32793,
      "medication log": 44511,
      "test wilcoxon": 80794,
      "results seven": 71939,
      "control 28": 20265,
      "groups total": 34339,
      "total med": 81833,
      "19 groups": 2183,
      "25 16": 3323,
      "16 44": 1858,
      "gabapentin groups": 32798,
      "81 mean": 5886,
      "mild opioid": 46434,
      "remain significant": 70253,
      "significant national": 75583,
      "national concern": 48674,
      "patients 32": 58856,
      "orthopaedic surgeons": 53818,
      "surgeons medicare": 79275,
      "using medicare": 85484,
      "prescribed orthopaedic": 63938,
      "medications opioids": 44656,
      "separately results": 74594,
      "prescriptions 96": 64443,
      "prescribing conclusion": 64043,
      "surgeons highest": 79272,
      "highest prescribers": 35365,
      "highlighting importance": 35379,
      "based ecological": 13312,
      "determine correlates": 23997,
      "use sample": 84713,
      "survey completed": 79697,
      "april 2017": 11608,
      "2017 logistic": 2789,
      "significant associations": 75432,
      "year prescription": 87486,
      "non prescribed": 49670,
      "partially mediated": 58251,
      "mediated relationship": 44317,
      "association drugs": 12472,
      "drugs amphetamines": 26884,
      "negatively correlated": 49087,
      "rates past": 67618,
      "implemented opioid": 36949,
      "fentanyl analogue": 31440,
      "fentanyl showed": 31591,
      "varied fold": 85935,
      "risks fentanyl": 72675,
      "opioids typically": 53361,
      "typically prescribed": 83394,
      "prescribed transdermal": 63992,
      "pain requires": 57623,
      "drug addiction": 26518,
      "negative results": 49082,
      "samples subsequently": 73365,
      "opioids metabolites": 53045,
      "results confirmatory": 71642,
      "care plans": 15060,
      "confirmed drug": 19504,
      "levels fentanyl": 41564,
      "inappropriate prescribing": 37243,
      "drug analysis": 26534,
      "prevalence chronic": 64775,
      "pain long": 57031,
      "term basis": 80618,
      "prescribed analgesics": 63819,
      "2009 2010": 2514,
      "material method": 43500,
      "2010 data": 2553,
      "results 90": 71590,
      "indicated chronic": 38233,
      "opioids 33": 52676,
      "non steroid": 49685,
      "followed buprenorphine": 32049,
      "codeine paracetamol": 17274,
      "medications conclusion": 44608,
      "conclusion number": 18934,
      "used benzodiazepines": 84859,
      "pain increase": 56863,
      "fatal overdoses": 31240,
      "overdoses involving": 54330,
      "multifactorial issue": 48187,
      "abuse useful": 6907,
      "comprehensive opioid": 18624,
      "naltrexone opioid": 48547,
      "march 2011": 43360,
      "currently unknown": 21509,
      "resistant abuse": 71093,
      "consisted immediate": 19675,
      "likely abuse": 41795,
      "clear determined": 16700,
      "incremental step": 38147,
      "pediatric urologists": 60364,
      "prescribed postoperatively": 63956,
      "patients help": 59353,
      "sought better": 76480,
      "understand postoperative": 83626,
      "correlate postoperative": 20807,
      "consumed following": 19830,
      "pediatric urologic": 60363,
      "urologic procedures": 84100,
      "procedures patients": 65319,
      "require opioids": 70810,
      "participate patients": 58385,
      "enrolled prospective": 29012,
      "patients parents": 59627,
      "text message": 80884,
      "child pain": 16011,
      "doses pain": 26244,
      "procedure types": 65289,
      "scores 01": 73820,
      "highest postoperative": 35363,
      "overall average": 54187,
      "low patients": 42531,
      "prescribed narcotics": 63898,
      "consumed average": 19826,
      "scores number": 73918,
      "number narcotics": 50178,
      "surgery type": 79611,
      "opioids overprescribed": 53129,
      "type conclusions": 83322,
      "use varies": 84799,
      "procedure type": 65288,
      "type number": 83334,
      "narcotics prescribed": 48638,
      "potential inform": 63175,
      "inform future": 38616,
      "response efforts": 71346,
      "objective summarize": 50525,
      "embase central": 28637,
      "2020 december": 2899,
      "comparing period": 18357,
      "period vs": 60808,
      "data assessed": 21881,
      "methodological quality": 45225,
      "results findings": 71697,
      "studies 13": 77637,
      "13 65": 1472,
      "17 61": 1948,
      "results increased": 71727,
      "138 80": 1540,
      "studies heroin": 77740,
      "12 62": 1257,
      "unchanged decreased": 83470,
      "decreased study": 23045,
      "measures opioid": 44072,
      "reduction efforts": 69058,
      "prospero registration": 65906,
      "oud opioid": 53897,
      "potential respiratory": 63217,
      "examining opioid": 30427,
      "30 2021": 3679,
      "225 participants": 3060,
      "63 male": 5360,
      "oud studies": 53898,
      "buprenorphine maintained": 14556,
      "healthy persons": 34840,
      "comparison groups": 18369,
      "additional doses": 7855,
      "seven studies": 74878,
      "analgesia despite": 9948,
      "despite receiving": 23898,
      "clinically used": 17011,
      "greater abuse": 33428,
      "potency compounds": 63071,
      "required achieve": 70821,
      "vulnerable opioid": 86688,
      "clinical methodological": 16837,
      "implications treatment": 36970,
      "growing evidence": 34366,
      "based guidance": 13323,
      "exists support": 30533,
      "utilization hypothesis": 85729,
      "arthroscopic surgery": 11755,
      "partial meniscectomy": 58242,
      "absolutely necessary": 6605,
      "necessary pain": 48889,
      "included multimodal": 37488,
      "discharge study": 25179,
      "trial level": 83031,
      "evidence methods": 30223,
      "undergoing arthroscopic": 83512,
      "arthroscopic partial": 11750,
      "oxycodone included": 55242,
      "points month": 62135,
      "medication effects": 44496,
      "50 reduction": 4893,
      "successful outcome": 78912,
      "105 patients": 1062,
      "95 91": 6211,
      "group 47": 33617,
      "47 group": 4658,
      "successfully completed": 78920,
      "study significant": 78499,
      "groups vs": 34352,
      "45 days": 4581,
      "prescription significantly": 64406,
      "tablets remaining": 80210,
      "prescribed tablets": 63987,
      "tablets vs": 80231,
      "vs 82": 86624,
      "tablets 001": 80108,
      "tablets conclusion": 80130,
      "minimal number": 46576,
      "opioids knee": 53009,
      "difference number": 24639,
      "regimen patients": 69319,
      "setting multimodal": 74787,
      "control significantly": 20422,
      "unused opioids": 83963,
      "circulating community": 16574,
      "information substances": 38674,
      "information drugs": 38645,
      "gain better": 32812,
      "injected clients": 38915,
      "comparison results": 18380,
      "substances used": 78839,
      "used week": 85189,
      "week february": 86839,
      "content analysed": 20096,
      "substance present": 78808,
      "reported literature": 70575,
      "laboratory analysis": 41023,
      "users self": 85271,
      "messaging based": 44864,
      "objective data": 50396,
      "data approach": 21880,
      "approach used": 11485,
      "needle syringe": 49051,
      "detection harmful": 23957,
      "better inform": 13717,
      "important assess": 36995,
      "real life": 67999,
      "dedicated drug": 23080,
      "dependence aim": 23460,
      "aim article": 9374,
      "demonstrate utility": 23328,
      "using 2015": 85296,
      "patients described": 59178,
      "buprenorphine 39": 14515,
      "generic buprenorphine": 33043,
      "syrup form": 79970,
      "analgesic opioids": 10281,
      "clearly demonstrated": 16725,
      "useful data": 85204,
      "data regional": 22088,
      "levels objective": 41582,
      "health harms": 34712,
      "aimed establish": 9446,
      "associations opioid": 12495,
      "13 subjects": 1507,
      "patient clinical": 58561,
      "data 60": 21855,
      "60 consecutive": 5248,
      "prescription specific": 64409,
      "39 oxycodone": 4274,
      "care indications": 15034,
      "repeat prescriptions": 70395,
      "prescriptions pre": 64544,
      "included older": 37492,
      "prescriber patient": 64011,
      "patient male": 58675,
      "requests opioid": 70797,
      "rarely reported": 67411,
      "risk mitigation": 72600,
      "pain demographic": 56693,
      "management purpose": 43252,
      "skilled nursing": 76195,
      "nursing facility": 50340,
      "adult 18": 8484,
      "quaternary care": 66868,
      "31 2018": 3852,
      "2018 primary": 2839,
      "receipt opioid": 68033,
      "exposures included": 30805,
      "diagnosis related": 24339,
      "opioids day": 52832,
      "inpatient hospital": 39011,
      "patients 70": 58894,
      "years 50": 87541,
      "approximately 70": 11575,
      "discharge 68": 25100,
      "68 oxycodone": 5500,
      "opioid day": 51693,
      "warranted objective": 86733,
      "assessed opioid": 12025,
      "addition standard": 7828,
      "standard multimodal": 76921,
      "controlled setting": 20578,
      "tertiary academic": 80728,
      "total 90": 81773,
      "subjects presenting": 78725,
      "presenting surgery": 64708,
      "block primary": 14056,
      "activities assessment": 7545,
      "assessment scores": 12139,
      "analgesia utilized": 10132,
      "groups included": 34220,
      "eighty subjects": 28461,
      "group 40": 33608,
      "analysis demonstrated": 10670,
      "demonstrated difference": 23335,
      "hour postoperative": 35712,
      "equivalent consumption": 29292,
      "consumption block": 19898,
      "block sham": 14070,
      "sham groups": 75109,
      "groups 27": 34107,
      "differences secondary": 24811,
      "outcomes conclusions": 54019,
      "conclusions continuous": 19064,
      "plane blocks": 61872,
      "pain open": 57276,
      "consumption improve": 19936,
      "functional activity": 32688,
      "activity levels": 7572,
      "use background": 84217,
      "background ongoing": 13100,
      "prevent adverse": 64842,
      "therapy frequently": 81015,
      "using treatment": 85647,
      "20 used": 2387,
      "using urine": 85654,
      "use prescribing": 84648,
      "90 06": 6072,
      "recommended use": 68639,
      "case non": 15180,
      "episodes severe": 29213,
      "taking buprenorphine": 80301,
      "given total": 33202,
      "started mg": 77007,
      "subsequently patient": 78786,
      "greater 90": 33427,
      "rate mg": 67484,
      "prescribed label": 63875,
      "increasing frequency": 38108,
      "frequency pain": 32524,
      "control opioid": 20376,
      "usual doses": 85692,
      "better treat": 13744,
      "opioids monitoring": 53061,
      "hours background": 35754,
      "acetaminophen common": 7171,
      "opioid paracetamol": 52042,
      "paracetamol combination": 58097,
      "duration days": 27157,
      "currently recommended": 21506,
      "recommended maximum": 68626,
      "recommended dose": 68619,
      "prescriptions excess": 64485,
      "dysfunction methods": 27222,
      "study examining": 78205,
      "outcomes examined": 54025,
      "results large": 71747,
      "beneficiaries receiving": 13608,
      "guidelines contained": 34433,
      "multiple factors": 48278,
      "including type": 37682,
      "dextropropoxyphene oxycodone": 24302,
      "paracetamol opioid": 58109,
      "physician assistant": 61423,
      "cases 23": 15218,
      "prescription 90": 64156,
      "prescribed dispensed": 63852,
      "excessive doses": 30460,
      "doses paracetamol": 26245,
      "benefit manager": 13617,
      "data objectives": 22020,
      "opioids display": 52863,
      "use behaviors": 84220,
      "specific types": 76622,
      "behaviors current": 13559,
      "gap literature": 32832,
      "72 women": 5634,
      "women chronic": 87207,
      "clinic participants": 16742,
      "white women": 87031,
      "women average": 87204,
      "age 51": 9017,
      "51 years": 4965,
      "women taking": 87249,
      "likely men": 41817,
      "unused medication": 83959,
      "effectiveness pain": 27775,
      "04 trend": 458,
      "women observed": 87228,
      "vs 08": 86518,
      "women use": 87257,
      "differ sex": 24546,
      "identify aberrant": 36486,
      "best predict": 13695,
      "specific risk": 76620,
      "use need": 84510,
      "consecutive patient": 19561,
      "scoring based": 74022,
      "organization analgesic": 53765,
      "table used": 80078,
      "used standardize": 85137,
      "standardize opioid": 76947,
      "results 370": 71565,
      "decrease mean": 22899,
      "equivalent prescribed": 29332,
      "88 mg": 6042,
      "99 001": 6482,
      "different 05": 24835,
      "assessing opioid": 12103,
      "pain complex": 56578,
      "disease burden": 25320,
      "patients hip": 59362,
      "knee oa": 40866,
      "pain receiving": 57480,
      "analysis real": 10752,
      "opioids considered": 52813,
      "considered disease": 19629,
      "analgesia assessments": 9918,
      "nrs scale": 50074,
      "barthel index": 13262,
      "patients analyzed": 58993,
      "72 years": 5635,
      "sd 14": 74064,
      "14 76": 1573,
      "treated fentanyl": 82337,
      "13 point": 1503,
      "days sd": 22616,
      "barthel scores": 13263,
      "year treatment": 87511,
      "2013 patient": 2636,
      "36 months": 4137,
      "severe agitation": 74912,
      "single mg": 76119,
      "australian state": 12706,
      "depression respiratory": 23596,
      "rate 11": 67426,
      "breaths min": 14421,
      "room air": 72773,
      "outcomes proportion": 54079,
      "rate 100": 67425,
      "reversal respiratory": 72232,
      "score 15": 73713,
      "15 results": 1790,
      "july 2021": 40531,
      "171 patients": 2003,
      "years total": 87679,
      "14 morphine": 1611,
      "morphine 11": 47536,
      "agitation anxiety": 9267,
      "naloxone reversed": 48517,
      "ci 94": 16512,
      "conclusion severe": 18990,
      "administration mg": 8300,
      "naloxone rarely": 48511,
      "rarely required": 67412,
      "review prospectively": 72341,
      "underwent single": 83694,
      "2014 october": 2668,
      "effect perioperative": 27529,
      "discharge patient": 25156,
      "prior research": 65169,
      "research demonstrated": 70998,
      "demonstrated opioid": 23356,
      "control methods": 20364,
      "patients complete": 59106,
      "complete press": 18449,
      "press ganey": 64727,
      "hospital consumer": 35573,
      "consumer assessment": 19856,
      "assessment healthcare": 12120,
      "providers systems": 66195,
      "systems hcahps": 80036,
      "survey information": 79713,
      "prescriptions recorded": 64554,
      "converted milligram": 20727,
      "hcahps scores": 34626,
      "scores converted": 73855,
      "48 10": 4683,
      "inpatient opioids": 39019,
      "102 106": 1053,
      "106 mme": 1065,
      "mme average": 46953,
      "consumption hospital": 19932,
      "similarly statistically": 76015,
      "control opioids": 20379,
      "date surgery": 22220,
      "control increased": 20354,
      "study correlation": 78044,
      "correlation patient": 20835,
      "decrease mme": 22900,
      "role patient": 72758,
      "iii background": 36580,
      "cncp remains": 17109,
      "remains public": 70307,
      "treatment cncp": 82499,
      "patients cncp": 59095,
      "patients consulting": 59138,
      "sociodemographic data": 76392,
      "po misuse": 62057,
      "dsm criteria": 27105,
      "analysis order": 10721,
      "order identify": 53714,
      "115 patients": 1181,
      "included majority": 37474,
      "18 82": 2070,
      "strong group": 77518,
      "group 56": 33627,
      "56 42": 5098,
      "likely current": 41805,
      "oxycodone report": 55833,
      "dependent conclusions": 23502,
      "43 patients": 4505,
      "identify predictors": 36523,
      "undergoing minimally": 83553,
      "patients planning": 59651,
      "single institution": 76108,
      "review surveys": 72365,
      "surveys week": 79753,
      "week post": 86863,
      "opioids converted": 52823,
      "modified poisson": 47240,
      "used quantify": 85094,
      "eligible women": 28601,
      "79 cases": 5799,
      "cases 71": 15219,
      "30 75": 3704,
      "75 mme": 5711,
      "mme iqr": 46968,
      "iqr 52": 40177,
      "mme women": 46981,
      "21 used": 2984,
      "inpatient week": 39036,
      "follow median": 32021,
      "pills mg": 61517,
      "oxycodone 45": 54574,
      "15 pills": 1787,
      "complete follow": 18444,
      "10 pills": 899,
      "22 pills": 3041,
      "pills 36": 61500,
      "36 participants": 4138,
      "prescription 30": 64153,
      "30 pills": 3788,
      "10 60": 721,
      "median inpatient": 44226,
      "multivariable analysis": 48318,
      "analysis conclusions": 10659,
      "relative use": 69771,
      "use inpatient": 84437,
      "inpatient use": 39035,
      "strongest predictor": 77573,
      "predictor post": 63581,
      "opioid needs": 51997,
      "buprenorphine transdermal": 14594,
      "adults methods": 8566,
      "analysis 16": 10626,
      "16 placebo": 1890,
      "uncontrolled studies": 83494,
      "evaluated safety": 29920,
      "profile patients": 65504,
      "patients exposed": 59291,
      "btds compared": 14462,
      "profiles associated": 65515,
      "associated btds": 12227,
      "years younger": 87692,
      "safety analyses": 73120,
      "aes laboratory": 8875,
      "laboratory values": 41040,
      "electrocardiograms results": 28515,
      "constipation peripheral": 19777,
      "significant treatment": 75639,
      "treatment similar": 82845,
      "similar trend": 76004,
      "btds active": 14461,
      "controls oxycodone": 20672,
      "oxy apap": 54443,
      "apap hydrocodone": 11351,
      "groups statistical": 34327,
      "test treatment": 80788,
      "conducted active": 19343,
      "aes clinically": 8871,
      "liver enzymes": 42177,
      "ast alt": 12512,
      "viable option": 86188,
      "risks older": 72679,
      "adults background": 8550,
      "eliminate need": 28603,
      "reduce post": 68877,
      "studied controlled": 77608,
      "controlled fashion": 20498,
      "irb approval": 40268,
      "2011 april": 2579,
      "april 2013": 11601,
      "2013 91": 2625,
      "fixation patients": 31869,
      "demographics intraoperative": 23299,
      "time recorded": 81350,
      "score mean": 73760,
      "mean score": 43854,
      "return work": 72191,
      "scores reported": 73968,
      "patients 91": 58909,
      "14 months": 1610,
      "average size": 12936,
      "acetaminophen mg": 7202,
      "usage tablets": 84131,
      "work days": 87270,
      "post op": 62587,
      "62 patients": 5339,
      "range 43": 67287,
      "rapid recovery": 67395,
      "summary product": 79109,
      "product characteristics": 65427,
      "observed methods": 50691,
      "patients prescriptions": 59686,
      "prescribed 30": 63808,
      "treatment drugs": 82559,
      "characteristics determined": 15857,
      "cyp3a4 inhibitors": 21639,
      "inhibitors inducers": 38805,
      "cyp2d6 inhibitors": 21610,
      "database contained": 22166,
      "405 eligible": 4403,
      "patients 72": 58896,
      "diabetes mellitus": 24311,
      "received concomitant": 68127,
      "drug patients": 26737,
      "drugs potential": 27038,
      "potential safety": 63225,
      "interactions alter": 39385,
      "opioid background": 51554,
      "including florida": 37621,
      "florida 2009": 31928,
      "electronic databases": 28530,
      "data controlled": 21926,
      "substances commonly": 78827,
      "abused medications": 6917,
      "serve tool": 74714,
      "practitioners prescribing": 63452,
      "drug caused": 26544,
      "caused deaths": 15380,
      "florida prescription": 31931,
      "substances oxycodone": 78834,
      "oxycodone 56": 54583,
      "alprazolam 35": 9670,
      "florida pdmp": 31930,
      "implemented pharmacists": 36951,
      "prior implementation": 65148,
      "approximately 26": 11566,
      "mail survey": 42819,
      "survey survey": 79742,
      "survey items": 79714,
      "state results": 77068,
      "18 completed": 2083,
      "survey majority": 79720,
      "implementation results": 36942,
      "relevant outcomes": 70065,
      "prescribing pharmaceutical": 64112,
      "drugs order": 27022,
      "order reduce": 53721,
      "evaluated factors": 29884,
      "information medical": 38654,
      "medical histories": 44364,
      "2020 august": 2890,
      "august 2020": 12673,
      "identify independent": 36508,
      "opioids 60": 52683,
      "included hydromorphone": 37466,
      "oxycodone adjusted": 54681,
      "higher maximum": 35259,
      "prescriptions aor": 64448,
      "aor 03": 11293,
      "67 15": 5470,
      "15 90": 1718,
      "higher dosages": 35229,
      "identify optimal": 36512,
      "optimal prescribing": 53433,
      "term impacts": 80635,
      "states participated": 77137,
      "prescription prior": 64389,
      "military health": 46441,
      "health clinics": 34690,
      "clinics patients": 17043,
      "inventory short": 39983,
      "short form": 75165,
      "outcomes study": 54099,
      "36 item": 4131,
      "item short": 40347,
      "deviation age": 24262,
      "years majority": 87609,
      "pain 60": 56390,
      "35 tramadol": 4095,
      "tramadol 34": 82030,
      "took opioid": 81672,
      "opioid 44": 51357,
      "opioids discussion": 52861,
      "poor pain": 62268,
      "severity interference": 75043,
      "record data": 68656,
      "midst national": 46410,
      "use children": 84234,
      "operations methods": 51237,
      "age underwent": 9131,
      "underwent ambulatory": 83674,
      "surgery 2010": 79302,
      "2010 2017": 2545,
      "current procedural": 21461,
      "procedural terminology": 65264,
      "terminology codes": 80695,
      "information 18": 38632,
      "18 commonly": 2082,
      "setting ambulatory": 74769,
      "ambulatory procedures": 9770,
      "procedures decreased": 65298,
      "total analgesic": 81779,
      "morphine decreased": 47637,
      "decreased 19": 22945,
      "19 15": 2162,
      "15 intravenous": 1741,
      "use remained": 84689,
      "use 14": 84142,
      "perioperative analgesia": 60826,
      "purpose determine": 66529,
      "determine time": 24053,
      "methods population": 45464,
      "common cancers": 17736,
      "rates months": 67595,
      "months life": 47450,
      "investigated using": 40061,
      "ci 43": 16451,
      "years significantly": 87671,
      "age 50": 9015,
      "prevalence ratio": 64810,
      "ratio pr": 67791,
      "pr range": 63362,
      "men receive": 44803,
      "opioid pr": 52077,
      "morphine diamorphine": 47644,
      "62 compared": 5335,
      "conclusion morphine": 18926,
      "treating cancer": 82388,
      "pain united": 57952,
      "lower older": 42658,
      "people opioids": 60418,
      "spinae plane": 76695,
      "plane esp": 61873,
      "esp block": 29545,
      "recently shown": 68451,
      "shown effectively": 75337,
      "consumption breast": 19899,
      "data limited": 22002,
      "procedure methods": 65273,
      "groups esp": 34193,
      "blocks performed": 14097,
      "outcome assessment": 53904,
      "improvement quality": 37162,
      "recovery 40": 68734,
      "qor 40": 66640,
      "included postoperative": 37513,
      "vas 24": 86002,
      "hour opioid": 35706,
      "consumption patient": 19981,
      "esp group": 29546,
      "group 186": 33579,
      "medians interquartile": 44301,
      "interquartile ranges": 39532,
      "32 30": 3909,
      "30 18": 3669,
      "25 observed": 3373,
      "observed lower": 50688,
      "group statistical": 34029,
      "alleviated pain": 9603,
      "surgery did": 79378,
      "did observe": 24466,
      "group trial": 34056,
      "used medication": 85005,
      "trials adults": 83103,
      "testing prior": 80834,
      "prior oral": 65162,
      "drugs affecting": 26880,
      "trials testing": 83206,
      "targeted drug": 80495,
      "quality extracted": 66703,
      "induced drug": 38408,
      "trials using": 83208,
      "neuropsychological tests": 49286,
      "evidence drug": 30185,
      "results trials": 72043,
      "68 trials": 5504,
      "trials drugs": 83138,
      "drugs evidence": 26953,
      "narcotic agents": 48584,
      "lorazepam mg": 42417,
      "antidepressants benzodiazepines": 11176,
      "drug discontinuation": 26584,
      "analgesics effective": 10418,
      "study evaluates": 78187,
      "visits 2015": 86276,
      "120 morphine": 1410,
      "patient demographic": 58607,
      "demographic medical": 23286,
      "medical characteristics": 44344,
      "equivalents using": 29380,
      "regression clustering": 69432,
      "analysis assessed": 10639,
      "2021 results": 2917,
      "visits 28": 86277,
      "pain substance": 57882,
      "misuse associated": 46715,
      "women older": 87229,
      "routine dental": 72861,
      "receive codeine": 68049,
      "conclusions nearly": 19127,
      "prescribing higher": 64063,
      "higher potency": 35306,
      "groups addressed": 34128,
      "striking increase": 77503,
      "increase prevalence": 37794,
      "neurological deficits": 49201,
      "model study": 47081,
      "maternal opioid": 43523,
      "use management": 84466,
      "oud humans": 53894,
      "humans following": 35983,
      "oud moud": 53896,
      "opioids pregnancy": 53201,
      "pregnancy maternal": 63690,
      "offspring exposed": 50981,
      "use pregnancy": 84643,
      "late adolescence": 41222,
      "neurons ventral": 49219,
      "ventral tegmental": 86065,
      "tegmental area": 80562,
      "area vta": 11641,
      "vta mice": 86684,
      "mice exposed": 46284,
      "provide critical": 66048,
      "causal relationship": 15335,
      "relationship maternal": 69718,
      "analysed prescription": 10576,
      "prescription databases": 64193,
      "tertiary hospitals": 80741,
      "dihydrocodeine tramadol": 24995,
      "2011 31": 2577,
      "measures main": 44065,
      "number short": 50255,
      "days long": 22549,
      "users majority": 85253,
      "18 received": 2105,
      "initial daily": 38832,
      "dose 50": 25810,
      "primarily prescribed": 64980,
      "adjusted model": 8037,
      "opioid daily": 51690,
      "doses prescription": 26252,
      "opioids initiated": 53002,
      "initiated non": 38879,
      "conclusions majority": 19118,
      "majority opioid": 42986,
      "patients tertiary": 60042,
      "progression long": 65573,
      "higher opioid": 35277,
      "anti addiction": 11111,
      "effects limit": 27967,
      "limit clinical": 41887,
      "clinical potential": 16858,
      "negative allosteric": 49062,
      "represent novel": 70749,
      "ligands hypothesized": 41765,
      "using vivo": 85669,
      "accumbens shell": 7089,
      "key component": 40664,
      "mesocorticolimbic reward": 44859,
      "evoked dopamine": 30303,
      "effect blocked": 27426,
      "induced reward": 38455,
      "cpp assay": 21042,
      "blockade morphine": 14078,
      "morphine cpp": 47631,
      "reduced oral": 68956,
      "oxycodone water": 56088,
      "bottle choice": 14258,
      "choice paradigm": 16118,
      "therapeutic potential": 80957,
      "novel drug": 50008,
      "drug candidates": 26542,
      "preventing opioid": 64863,
      "background 1999": 13000,
      "1999 2010": 2245,
      "number deaths": 50152,
      "overdose increased": 54296,
      "increased approximately": 37875,
      "period hydrocodone": 60732,
      "analysis 10": 10624,
      "2014 hydrocodone": 2662,
      "did substantially": 24512,
      "increased rates": 38000,
      "study conclusion": 78021,
      "conclusion total": 19013,
      "relatively unchanged": 69794,
      "change prescribing": 15744,
      "substituting tramadol": 78876,
      "similar medications": 75949,
      "alternative approaches": 9717,
      "approaches needed": 11492,
      "lack standardized": 41060,
      "policy changes": 62182,
      "inpatients receiving": 39041,
      "study 75": 77905,
      "risk investigated": 72586,
      "model based": 47029,
      "total 220": 81743,
      "patient days": 58605,
      "73 hydromorphone": 5652,
      "19 04": 2157,
      "ci 42": 16448,
      "42 80": 4453,
      "12 09": 1206,
      "study investigates": 78279,
      "explain increased": 30699,
      "severe psychological": 75013,
      "drug reporting": 26774,
      "factors differences": 31089,
      "groups findings": 34199,
      "nature use": 48753,
      "use involving": 84442,
      "group findings": 33783,
      "importance drug": 36980,
      "indicates important": 38252,
      "differences substance": 24823,
      "functioning measured": 32723,
      "trials network": 83167,
      "effectiveness buprenorphine": 27751,
      "oxycodone 68": 54593,
      "65 respectively": 5420,
      "higher women": 35338,
      "evidenced higher": 30295,
      "alcohol 01": 9524,
      "scores women": 74018,
      "higher drug": 35235,
      "women endorsed": 87215,
      "problems conclusions": 65256,
      "differences clinical": 24723,
      "clinical profiles": 16875,
      "profiles opioid": 65517,
      "impairment associated": 36882,
      "enhance understanding": 28963,
      "treatment efforts": 82570,
      "associated risks": 12414,
      "limited long": 41939,
      "create opioid": 21141,
      "individuals dispensed": 38341,
      "bc canada": 13494,
      "canada 1996": 14747,
      "use based": 84218,
      "based review": 13377,
      "patterns po": 60224,
      "findings date": 31778,
      "cohort includes": 17362,
      "million individuals": 46489,
      "40 50": 4322,
      "prevalence higher": 64785,
      "likely higher": 41811,
      "higher social": 35325,
      "overall findings": 54201,
      "therapy future": 81016,
      "future plans": 32766,
      "assessed prevalence": 12044,
      "11 states": 1151,
      "continuously enrolled": 20197,
      "versus oe": 86136,
      "older ages": 51036,
      "ages 10": 9247,
      "10 18": 677,
      "chronic conditions": 16188,
      "conditions 49": 19305,
      "medication classes": 44469,
      "31 001": 3839,
      "range common": 67305,
      "codeine 21": 17198,
      "associated follow": 12264,
      "follow visits": 32041,
      "visits 30": 86278,
      "subsequent studies": 78780,
      "fueled prescription": 32609,
      "distribution patterns": 25565,
      "analyses include": 10594,
      "converted morphine": 20730,
      "analyses completed": 10587,
      "completed 2017": 18462,
      "2017 results": 2803,
      "peaked 2011": 60326,
      "21 morphine": 2977,
      "morphine 18": 47544,
      "increase buprenorphine": 37735,
      "substantial inter": 78851,
      "rhode island": 72465,
      "mg person": 46157,
      "association identified": 12476,
      "identified state": 36471,
      "disorder prescription": 25386,
      "needed continue": 48993,
      "opioid access": 51390,
      "pain minimizing": 57197,
      "nsaids diclofenac": 50101,
      "diclofenac ibuprofen": 24389,
      "inflammatory antipyretic": 38553,
      "renal toxicity": 70367,
      "safety objective": 73173,
      "inhibitor valdecoxib": 38799,
      "interactions contraindications": 39389,
      "summarized methods": 79088,
      "methods articles": 45252,
      "identified searches": 36468,
      "1966 december": 2213,
      "international pharmaceutical": 39484,
      "pharmaceutical abstracts": 61015,
      "lists identified": 42105,
      "identified articles": 36423,
      "reviewed additional": 72372,
      "product information": 65431,
      "results fourteen": 71700,
      "treatment osteoarthritis": 82716,
      "osteoarthritis studies": 53872,
      "acetaminophen significantly": 7250,
      "reviews clinical": 72406,
      "001 05": 95,
      "platelet function": 61979,
      "function bleeding": 32635,
      "time platelet": 81327,
      "platelet aggregation": 61978,
      "allergic reactions": 9588,
      "conclusions clinical": 19045,
      "valdecoxib effective": 85768,
      "osteoarthritis rheumatoid": 53869,
      "toxicity conventional": 81932,
      "reserved patients": 71056,
      "nsaid induced": 50091,
      "induced gastrointestinal": 38413,
      "epidemic nonmedical": 29135,
      "urological procedures": 84102,
      "procedures common": 65294,
      "surgeries performed": 79288,
      "compare prescribed": 18047,
      "urological surgery": 84103,
      "surgery determine": 79376,
      "prescribing consumption": 64044,
      "prescribed consumed": 63842,
      "40 patients": 4371,
      "77 years": 5768,
      "age opioid": 9097,
      "oxycodone dosed": 54999,
      "number doses": 50156,
      "30 interquartile": 3742,
      "respondents reported": 71314,
      "iqr 29": 40171,
      "83 did": 5931,
      "doses consumed": 26161,
      "regression showed": 69457,
      "consumed patient": 19841,
      "age type": 9129,
      "type procedure": 83349,
      "score use": 73804,
      "therapy days": 81007,
      "69 81": 5519,
      "consumed 86": 19825,
      "72 83": 5613,
      "disposal instructions": 25484,
      "leftover medication": 41353,
      "opioid sufficient": 52388,
      "patients adjusting": 58946,
      "designed study": 23846,
      "repair patients": 70385,
      "therapy versus": 81077,
      "versus standard": 86159,
      "17 received": 1983,
      "received rofecoxib": 68260,
      "controls 17": 20666,
      "surgery anesthetic": 79322,
      "fentanyl iv": 31511,
      "discharge versus": 25184,
      "05 oral": 532,
      "use 34": 84153,
      "doses 02": 26116,
      "use outpatient": 84577,
      "outpatients undergoing": 54163,
      "undergoing inguinal": 83541,
      "report moderate": 70462,
      "therapy included": 81020,
      "discharge background": 25108,
      "evaluated potential": 29911,
      "analgesia improve": 9996,
      "recovery assessed": 68738,
      "assessed quality": 12047,
      "undergo elective": 83502,
      "cholecystectomy randomized": 16131,
      "tap group": 80372,
      "block multimodal": 14048,
      "25 ropivacaine": 3384,
      "block using": 14074,
      "saline groups": 73261,
      "analgesia regimen": 10088,
      "regimen consisting": 69305,
      "40 score": 4377,
      "surgery data": 79362,
      "using independent": 85439,
      "independent test": 38169,
      "group 161": 33574,
      "median difference": 44213,
      "40 30": 4318,
      "26 32": 3430,
      "32 control": 3923,
      "does improve": 25678,
      "analgesic outcomes": 10284,
      "support routine": 79214,
      "block surgery": 14072,
      "prescribed manage": 63885,
      "use australian": 84214,
      "australian new": 12703,
      "position statement": 62441,
      "objectives included": 50565,
      "opioids surgical": 53330,
      "study time": 78541,
      "opioid 16": 51350,
      "prescribing decreased": 64049,
      "26 001": 3415,
      "oxycodone 31": 54556,
      "14 001": 1545,
      "immediate decline": 36697,
      "increased incidence": 37931,
      "35 71": 4070,
      "rr 44": 72930,
      "44 95": 4536,
      "51 28": 4949,
      "prescribing observed": 64090,
      "females respond": 31399,
      "remains limited": 70297,
      "mice studied": 46314,
      "role physical": 72762,
      "behavior following": 13529,
      "serum drug": 74699,
      "months old": 47455,
      "c57bl mice": 14653,
      "control high": 20349,
      "group weeks": 34079,
      "reduced physical": 68971,
      "grip strength": 33521,
      "gait speed": 32821,
      "increased anxiety": 37874,
      "mice ages": 46270,
      "001 young": 228,
      "females 05": 31386,
      "treated animals": 82324,
      "induced functional": 38412,
      "sex groups": 75078,
      "groups age": 34131,
      "improve management": 37064,
      "opioid reduction": 52287,
      "education program": 27393,
      "program decrease": 65535,
      "decrease discharge": 22891,
      "surgical oncology": 79636,
      "study aim": 77917,
      "year later": 87447,
      "later methods": 41235,
      "prospective quality": 65853,
      "tumor sites": 83279,
      "cancer center": 14767,
      "2017 july": 2787,
      "2018 july": 2825,
      "august 2018": 12670,
      "evaluable patients": 29761,
      "patients pre": 59663,
      "522 45": 5007,
      "median 24": 44179,
      "pre patients": 63482,
      "patients 001": 58818,
      "frequency patients": 32526,
      "001 discharge": 132,
      "later opioid": 41236,
      "negative health": 49073,
      "opioid abstinence": 51362,
      "good predictor": 33323,
      "data prospective": 22068,
      "followed years": 32091,
      "years years": 87691,
      "years prior": 87644,
      "follow interview": 32020,
      "20 total": 2386,
      "categories opioid": 15298,
      "health social": 34774,
      "social functioning": 76354,
      "social support": 76360,
      "retention treatment": 72082,
      "treatment help": 82614,
      "individuals treated": 38359,
      "usually performed": 85698,
      "intraoperative anesthetic": 39766,
      "time surgery": 81388,
      "surgery decrease": 79366,
      "decrease perioperative": 22918,
      "conducted october": 19379,
      "october 2015": 50883,
      "2015 june": 2711,
      "assigned following": 12167,
      "following groups": 32136,
      "groups general": 34203,
      "anesthesia group": 10913,
      "received ropivacaine": 68263,
      "postoperatively group": 63001,
      "postoperative 48": 62693,
      "48 results": 4748,
      "24 65": 3175,
      "years included": 87598,
      "final study": 31750,
      "sample significant": 73314,
      "time administration": 81202,
      "administration patient": 8334,
      "analgesia groups": 9988,
      "52 29": 4975,
      "respectively preoperative": 71235,
      "postoperative group": 62774,
      "group end": 33764,
      "postoperatively conclusions": 62997,
      "conclusions concluded": 19055,
      "analgesia time": 10122,
      "surgery trial": 79608,
      "patient use": 58809,
      "gynecologic procedures": 34486,
      "procedures design": 65299,
      "design survey": 23812,
      "classification iii": 16681,
      "setting urban": 74847,
      "hospital subjects": 35645,
      "147 patients": 1655,
      "april 2016": 11607,
      "2016 interventions": 2747,
      "survey opioid": 79724,
      "procedures patient": 65318,
      "telephone asked": 80567,
      "mg hydromorphone": 45913,
      "hydromorphone mg": 36191,
      "mean 22": 43661,
      "30 laparoscopic": 3748,
      "16 tablets": 1893,
      "01 statistically": 327,
      "patients participated": 59632,
      "survey 64": 79693,
      "used half": 84950,
      "mean 25": 43663,
      "tablets using": 80230,
      "range 60": 67295,
      "60 33": 5225,
      "mean 24": 43662,
      "41 used": 4432,
      "practices patient": 63432,
      "patient opioid": 58692,
      "surgery patient": 79501,
      "prescribe fewer": 63796,
      "invasive approach": 39967,
      "half prescribed": 34528,
      "opioid availability": 51553,
      "use harms": 84387,
      "comprehensive overview": 18626,
      "indicators opioid": 38280,
      "identify relevant": 36534,
      "relevant publications": 70070,
      "identify pertinent": 36519,
      "use comparison": 84255,
      "mid level": 46392,
      "relatively moderate": 69784,
      "compared neighboring": 18213,
      "regulations opioid": 69500,
      "restricted opioid": 71458,
      "codeine remains": 17283,
      "limited national": 41945,
      "increases non": 38062,
      "background efforts": 13048,
      "states purpose": 77147,
      "variability opioid": 85867,
      "states trauma": 77153,
      "trauma centers": 82262,
      "intraclass correlation": 39732,
      "multilevel generalized": 48190,
      "injury severity": 38996,
      "score prior": 73775,
      "results centers": 71621,
      "45 mmes": 4593,
      "day equivalent": 22309,
      "mg hydrocodone": 45911,
      "hydrocodone day": 36078,
      "variation opioid": 85917,
      "day despite": 22298,
      "efforts minimize": 28440,
      "exposure injury": 30770,
      "limit analgesic": 41886,
      "specific effect": 76588,
      "choosing opioid": 16138,
      "risk ratios": 72652,
      "effects using": 28191,
      "opioids equianalgesic": 52886,
      "comparable pain": 17965,
      "scores quality": 73960,
      "effects direct": 27898,
      "different interventions": 24877,
      "indirect comparisons": 38284,
      "evidence used": 30290,
      "used enhance": 84927,
      "events sedation": 30120,
      "sedation mean": 74318,
      "differences scores": 24810,
      "point patient": 62102,
      "registered prospero": 69381,
      "results sixteen": 71961,
      "opioid interventions": 51876,
      "morphine primary": 47891,
      "buprenorphine significantly": 14589,
      "fentanyl lower": 31517,
      "pruritus respiratory": 66301,
      "meperidine fentanyl": 44841,
      "fentanyl oxymorphone": 31557,
      "oxymorphone caused": 56227,
      "caused significantly": 15389,
      "lower satisfaction": 42699,
      "oxycodone alfentanil": 54705,
      "remifentanil fentanyl": 70322,
      "treatment likely": 82640,
      "incidence pruritus": 37306,
      "pruritus nausea": 66299,
      "considerable differences": 19609,
      "better worse": 13753,
      "differences drugs": 24736,
      "drugs observed": 27015,
      "sedation patient": 74324,
      "choosing appropriate": 16137,
      "background low": 13080,
      "control objectives": 20374,
      "objectives aimed": 50541,
      "aimed study": 9467,
      "people end": 60408,
      "therapy ltot": 81023,
      "october 2005": 50873,
      "2005 june": 2467,
      "000 dispensed": 21,
      "91 days": 6137,
      "days starting": 22628,
      "study end": 78148,
      "women included": 87216,
      "included median": 37481,
      "median follow": 44224,
      "patients 46": 58870,
      "23 morphine": 3105,
      "16 codeine": 1868,
      "codeine 16": 17196,
      "range 16": 67261,
      "indication pain": 38269,
      "despite evidence": 23879,
      "evidence supported": 30274,
      "supported use": 79221,
      "opioids relief": 53255,
      "rarely prescribed": 67410,
      "morphine prescribing": 47885,
      "purpose postdischarge": 66543,
      "contributing factors": 20242,
      "abdominal orthopedic": 6528,
      "using bc": 85322,
      "bc ministry": 13495,
      "assembled cohort": 11899,
      "appendectomy la": 11414,
      "cholecystectomy lc": 16130,
      "arthroplasty tka": 11744,
      "linear modeling": 42023,
      "opioid rate": 52229,
      "rate 30": 67431,
      "prior use": 65176,
      "opioid dispensation": 51715,
      "rose steadily": 72816,
      "tha tka": 80895,
      "2016 rates": 2757,
      "rates 69": 67548,
      "year tramadol": 87510,
      "increased year": 38049,
      "2007 2014": 2489,
      "mean mme": 43797,
      "58 64": 5155,
      "mme patient": 46970,
      "postdischarge abdominal": 62639,
      "clinical challenge": 16766,
      "clinicians patients": 17035,
      "expert clinicians": 30685,
      "convened assess": 20684,
      "assess relative": 11961,
      "relative benefit": 69738,
      "benefit safety": 13626,
      "17 effect": 1968,
      "relevant benefits": 70046,
      "benefits safety": 13636,
      "79 100": 5795,
      "tramadol ibuprofen": 82073,
      "showed pain": 75285,
      "reduction quality": 69096,
      "life scores": 41736,
      "alternative pharmacological": 9736,
      "symptoms high": 79890,
      "quality clinical": 66681,
      "trials systematic": 83203,
      "systematic comprehensive": 79974,
      "multimodal mechanisms": 48217,
      "epidemic north": 29136,
      "opioids effort": 52879,
      "maintain stable": 42884,
      "support improvements": 79200,
      "recommended product": 68636,
      "inter patient": 39359,
      "patient variability": 58811,
      "systematically studied": 80018,
      "studied objective": 77618,
      "characterize use": 15910,
      "study took": 78542,
      "pain addiction": 56413,
      "addiction mental": 7746,
      "assessments completed": 12149,
      "intervals results": 39615,
      "01 longer": 313,
      "vs 39": 86573,
      "01 differences": 308,
      "compared use": 18333,
      "standard intervals": 76914,
      "doses increased": 26202,
      "metabolism study": 44940,
      "data analyses": 21871,
      "group self": 34002,
      "usual care": 85688,
      "participants 81": 58274,
      "81 white": 5890,
      "67 female": 5475,
      "data 12": 21842,
      "electronic records": 28545,
      "trial participants": 83046,
      "opioid number": 52005,
      "year total": 87509,
      "period 53": 60707,
      "prescriptions patient": 64534,
      "prescribed type": 63999,
      "codeine plus": 17278,
      "plus tramadol": 62034,
      "average annual": 12876,
      "prescriptions strong": 64561,
      "year annual": 87432,
      "post results": 62617,
      "results objective": 71802,
      "analgesics currently": 10410,
      "application opioids": 11426,
      "concerns related": 18847,
      "related gastrointestinal": 69609,
      "gastrointestinal central": 32874,
      "tapentadol centrally": 80386,
      "action micro": 7432,
      "inhibition considered": 38778,
      "partial solution": 58248,
      "issues methods": 40333,
      "experience gastrointestinal": 30576,
      "commonly constipation": 17842,
      "limit use": 41893,
      "appears provide": 11406,
      "tolerability conclusions": 81525,
      "associated effects": 12256,
      "addiction present": 7758,
      "present potential": 64626,
      "satisfactory analgesic": 73449,
      "profile associated": 65476,
      "review focus": 72303,
      "exhaustive review": 30507,
      "review current": 72281,
      "literature treatment": 42138,
      "received increasing": 68161,
      "increasing attention": 38094,
      "attention past": 12571,
      "examined national": 30394,
      "national ambulatory": 48665,
      "1999 2000": 2244,
      "visits time": 86295,
      "vs 33": 86564,
      "rr 74": 72970,
      "95 chronic": 6218,
      "vs 29": 86558,
      "ci 97": 16515,
      "rr 95": 73009,
      "52 48": 4977,
      "morphine chronic": 47597,
      "number outpatient": 50207,
      "attention pain": 12570,
      "hospital patient": 35612,
      "evidence exists": 30191,
      "patients oud": 59603,
      "academic hospital": 6948,
      "2021 march": 2914,
      "march 2022": 43372,
      "protocol consisting": 65965,
      "abstracted data": 6628,
      "platform primary": 61983,
      "outcome safety": 53990,
      "cohort results": 17376,
      "identified white": 36481,
      "median doses": 44217,
      "equivalents 24": 29340,
      "rate 44": 67434,
      "los days": 42426,
      "cases discharged": 15234,
      "compared 33": 18079,
      "longer patients": 42383,
      "naloxone efficacy": 48448,
      "outcomes remains": 54086,
      "remains established": 70293,
      "background open": 13102,
      "analgesia commonly": 9928,
      "alternative methods": 9725,
      "open radical": 51199,
      "guided single": 34414,
      "ml ropivacaine": 46899,
      "ropivacaine 20": 72789,
      "ml group": 46860,
      "analgesia ropivacaine": 10099,
      "basic analgesia": 13472,
      "paracetamol 1000": 58090,
      "recorded day": 68678,
      "days pod": 22581,
      "vomiting results": 86475,
      "total 20": 81737,
      "patients epidural": 59256,
      "included analyses": 37420,
      "versus mg": 86130,
      "mg 16": 45719,
      "15 versus": 1795,
      "11 52": 1115,
      "versus 18": 86103,
      "14 43": 1570,
      "doses 12": 26123,
      "23 versus": 3113,
      "versus 10": 86095,
      "20 respectively": 2377,
      "consumption 19": 19872,
      "mg 31": 45739,
      "consumption did": 19915,
      "infusion ropivacaine": 38728,
      "opioid interactions": 51875,
      "prescribing drug": 64053,
      "2015 august": 2697,
      "took medications": 81671,
      "medications discharge": 44614,
      "data retrospectively": 22097,
      "retrospectively collected": 72177,
      "use concurrent": 84265,
      "results presented": 71887,
      "intervals 95": 39604,
      "index number": 38200,
      "prescribing results": 64136,
      "results 15": 71546,
      "users opioid": 85257,
      "negatively associated": 49086,
      "beta blocking": 13698,
      "effects receptor": 28126,
      "receptor theory": 68529,
      "fixed proportion": 31885,
      "proportion mixtures": 65750,
      "common receptor": 17805,
      "dependent decreases": 23506,
      "efficacy agonist": 28223,
      "dose effect": 25893,
      "effect functions": 27460,
      "study tested": 78539,
      "effects fixed": 27927,
      "warm water": 86714,
      "water tail": 86759,
      "withdrawal procedure": 87147,
      "monkeys fentanyl": 47351,
      "056 mg": 570,
      "kg naltrexone": 40767,
      "naltrexone 032": 48535,
      "fentanyl produced": 31575,
      "dependent antinociception": 23499,
      "50 54": 4817,
      "largest dose": 41190,
      "produce antinociception": 65358,
      "evaluated utility": 29935,
      "binding vitro": 13824,
      "highest efficacy": 35346,
      "efficacy 17": 28209,
      "17 cyclopropylmethyl": 1961,
      "cyclopropylmethyl 14\u03b2": 21564,
      "14\u03b2 dihyroxy": 1663,
      "dihyroxy 5\u03b1": 24999,
      "5\u03b1 epoxy": 5214,
      "epoxy 6\u03b1": 29218,
      "6\u03b1 isoquinolyl": 5543,
      "isoquinolyl acetamindo": 40310,
      "morphine nalbuphine": 47786,
      "basic research": 13473,
      "block provides": 14059,
      "perineural dexamethasone": 60673,
      "received ultrasound": 68303,
      "10 ml": 865,
      "iv dexamethasone": 40372,
      "150 \u03bcg": 1819,
      "blocks containing": 14091,
      "containing buprenorphine": 20072,
      "neuraxial anesthesia": 49178,
      "patients assessors": 59013,
      "assessors blinded": 12158,
      "blinded group": 14000,
      "group assignment": 33671,
      "movement 24": 48044,
      "hours median": 35794,
      "group longer": 33840,
      "pain versus": 57973,
      "60 respectively": 5278,
      "respectively nausea": 71217,
      "conclusions pain": 19151,
      "analgesia improved": 9997,
      "dexamethasone prolonged": 24289,
      "pain experienced": 56772,
      "compare outcomes": 18038,
      "care facility": 15023,
      "participants adult": 58277,
      "cardiac surgical": 14986,
      "multimodal regimens": 48247,
      "regimen included": 69308,
      "intraoperative fentanyl": 39770,
      "multimodal regimen": 48246,
      "included preoperative": 37515,
      "infusion postoperative": 38721,
      "outcomes measured": 54049,
      "measured included": 43972,
      "surrogate marker": 79671,
      "time bowel": 81218,
      "median oral": 44263,
      "mg 75": 45768,
      "75 150": 5694,
      "160 240": 1903,
      "reduced median": 68942,
      "ome mg": 51059,
      "estimated difference": 29623,
      "versus opioid": 86137,
      "hours opioid": 35802,
      "conclusions multimodal": 19121,
      "use cardiac": 84229,
      "objective primary": 50472,
      "quantify postoperative": 66788,
      "completed preoperative": 18485,
      "postoperative surveys": 62972,
      "control setting": 20418,
      "total 100": 81704,
      "100 women": 1024,
      "pain interventions": 56969,
      "discharge surgery": 25181,
      "92 patients": 6155,
      "preoperative survey": 63761,
      "rates ranged": 67629,
      "ranged 70": 67348,
      "80 mean": 5845,
      "28 average": 3554,
      "prescribed 10": 63803,
      "increase postoperative": 37785,
      "procedure associated": 65271,
      "trend greater": 82943,
      "vs 155": 86539,
      "fewer postoperative": 31664,
      "postoperative narcotics": 62801,
      "previous surgery": 64925,
      "pain self": 57810,
      "represent subset": 70750,
      "increased postoperative": 37988,
      "requirements background": 70877,
      "analgesia provides": 10077,
      "surgery regional": 79558,
      "regional anaesthesia": 69350,
      "anaesthesia used": 9879,
      "continuous nerve": 20177,
      "acting local": 7387,
      "favourable safety": 31268,
      "safety toxicity": 73238,
      "rate ml": 67486,
      "reduces opioid": 68997,
      "evaluate recovery": 29839,
      "blinded manner": 14001,
      "lidocaine saline": 41678,
      "cumulated intravenous": 21387,
      "analgesia 72": 9897,
      "score recorded": 73778,
      "recorded times": 68704,
      "hours nrs": 35800,
      "rest deep": 71419,
      "oxycodone requirement": 55838,
      "hours 12": 35729,
      "surgery preoperative": 79530,
      "peak expiratory": 60308,
      "expiratory flow": 30694,
      "values days": 85839,
      "analgesia important": 9995,
      "quality care": 66680,
      "improves analgesia": 37181,
      "european clinical": 29737,
      "trials database": 83132,
      "number 2018": 50134,
      "opioids exert": 52901,
      "interaction opioid": 39375,
      "receptors present": 68555,
      "peripheral central": 60863,
      "primarily mediated": 64978,
      "objective methods": 50445,
      "assessment opioid": 12127,
      "effects increase": 27953,
      "processes responsible": 65346,
      "analgesia aim": 9909,
      "assessment spinal": 12141,
      "method literature": 45186,
      "november 2014": 50032,
      "original articles": 53783,
      "effects supraspinal": 28175,
      "level following": 41485,
      "methods evaluated": 45334,
      "positron emission": 62516,
      "emission tomography": 28720,
      "tomography pet": 81654,
      "used research": 85116,
      "research clinical": 70988,
      "invasive method": 39968,
      "method estimate": 45180,
      "estimate brain": 29605,
      "oxygen level": 56201,
      "level dependent": 41458,
      "dependent bold": 23500,
      "bold signal": 14210,
      "imaging technique": 36689,
      "receptor distribution": 68488,
      "responses assessed": 71382,
      "sural nerve": 79256,
      "presented methods": 64694,
      "centrally mediated": 15629,
      "drug development": 26583,
      "studies clinical": 77663,
      "measurement opioid": 44016,
      "used biomarker": 84860,
      "biomarker opioid": 13858,
      "different levels": 24880,
      "potential used": 63244,
      "acts opioid": 7598,
      "antagonists potentiate": 11085,
      "antinociception effect": 11220,
      "antinociception antinociceptive": 11216,
      "treated tramadol": 82381,
      "mice pretreated": 46305,
      "partially blocked": 58250,
      "naloxone yohimbine": 48532,
      "antinociception indicating": 11226,
      "mice results": 46310,
      "involvement opioid": 40117,
      "antinociception opioid": 11229,
      "presenting emergency": 64703,
      "presented acute": 64685,
      "acute non": 7651,
      "21 2018": 2941,
      "receiving 400": 68317,
      "placebo addition": 61656,
      "scale range": 73547,
      "10 secondary": 923,
      "scores hours": 73890,
      "hours similar": 35851,
      "absolute difference": 6595,
      "difference points": 24665,
      "points median": 62134,
      "iqr 21": 40169,
      "hours preceding": 35831,
      "reported effects": 70541,
      "effects conclusion": 27874,
      "zealand clinical": 87751,
      "ed methods": 27333,
      "methods electronic": 45330,
      "ii medications": 36564,
      "medications codeine": 44602,
      "products non": 65454,
      "used logistic": 84987,
      "explore relationship": 30729,
      "relationship prescription": 69727,
      "prescription type": 64416,
      "sex race": 75082,
      "58 95": 5156,
      "prescription received": 64395,
      "11 ci": 1126,
      "vs post": 86674,
      "45 001": 4563,
      "001 did": 129,
      "58 60": 5154,
      "controlling demographic": 20657,
      "patients remained": 59879,
      "led substantial": 41344,
      "prescriptions ed": 64481,
      "increase prescriptions": 37791,
      "evaluate relationship": 29840,
      "relationship preoperative": 69726,
      "decompressive surgery": 22879,
      "preoperative visit": 63763,
      "visit opioid": 86265,
      "form health": 32279,
      "survey sf": 79737,
      "36 scores": 4146,
      "patients divided": 59221,
      "morphine meperidine": 47752,
      "codeine propoxyphene": 17282,
      "groups preoperative": 34274,
      "outcomes scores": 54093,
      "using paired": 85548,
      "categorized follows": 15306,
      "16 opioid": 1886,
      "na\u00efve strong": 48852,
      "similar respect": 75990,
      "marital status": 43389,
      "24 month": 3247,
      "component summary": 18589,
      "summary scores": 79111,
      "point improvement": 62086,
      "success rates": 78907,
      "treatment arms": 82448,
      "conclusions preoperative": 19169,
      "adversely affect": 8854,
      "careful patient": 15103,
      "good results": 33328,
      "population objective": 62362,
      "patients nonmalignant": 59555,
      "prescriptions years": 64577,
      "analysis efficacy": 10677,
      "toxicity patient": 81936,
      "patient interviews": 58666,
      "addiction behaviors": 7739,
      "behaviors patients": 13565,
      "patients months": 59528,
      "propoxyphene tramadol": 65807,
      "sedation reported": 74325,
      "reported 58": 70492,
      "patients rarely": 59756,
      "medication significant": 44565,
      "increase mean": 37756,
      "12 30": 1245,
      "day 30": 22256,
      "oral codeine": 53500,
      "codeine mg": 17253,
      "analgesia did": 9951,
      "occurred 19": 50826,
      "problems patients": 65260,
      "data efficacy": 21958,
      "provide objective": 66081,
      "physicians treating": 61449,
      "medications background": 44596,
      "investigate trends": 40029,
      "dispensing varied": 25462,
      "varied geographically": 85936,
      "socioeconomic status": 76399,
      "analysis prescription": 10739,
      "medication surveillance": 44570,
      "surveillance data": 79681,
      "group medications": 33859,
      "methadone hydromorphone": 45083,
      "tapentadol fentanyl": 80412,
      "large metropolitan": 41136,
      "national state": 48719,
      "methods report": 45527,
      "opioids state": 53308,
      "dispensing rates": 25456,
      "prescriptions assessed": 64449,
      "assessed association": 11985,
      "months overall": 47457,
      "rate study": 67520,
      "lower socioeconomic": 42702,
      "ratio rr": 67796,
      "rr 88": 73001,
      "88 95": 6040,
      "33 58": 3983,
      "estimated opioid": 29634,
      "state presence": 77066,
      "cancer centres": 14769,
      "20 decrease": 2315,
      "rr 80": 72983,
      "sd 17": 74066,
      "measures introduced": 44063,
      "patients palliative": 59625,
      "funding national": 32738,
      "health study": 34781,
      "ed opioid": 27336,
      "association initial": 12477,
      "claims optum": 16635,
      "optum clinformatics": 53477,
      "clinformatics datamart": 16739,
      "patients older": 59575,
      "older 18": 51027,
      "determined patient": 24080,
      "patient state": 58787,
      "filling opioid": 31716,
      "days index": 22537,
      "total 30": 81747,
      "criteria patients": 21207,
      "patients 25": 58845,
      "range 75": 67297,
      "15 interquartile": 1738,
      "20 days": 2314,
      "level prescribing": 41518,
      "mg adjusted": 45795,
      "adjusted rate": 8050,
      "rate prolonged": 67505,
      "ci did": 16525,
      "prescription conclusion": 64183,
      "prescribing ed": 64054,
      "highly variable": 35407,
      "225 mme": 3059,
      "safer opioid": 73113,
      "purpose current": 66527,
      "current epidemic": 21434,
      "increased fourfold": 37920,
      "medications signs": 44677,
      "hypotension bradycardia": 36287,
      "testing important": 80822,
      "tool monitoring": 81686,
      "use interpretation": 84438,
      "screening confirmatory": 74043,
      "guidelines opioid": 34451,
      "therapy including": 81021,
      "ensure adequate": 29042,
      "targeting patients": 80504,
      "systems play": 80041,
      "various forms": 85968,
      "forms opioid": 32310,
      "decrease patient": 22917,
      "scores narcotic": 73909,
      "following robot": 32194,
      "robot assisted": 72705,
      "prostatectomy ralp": 65913,
      "mixture liposomal": 46812,
      "celecoxib 200": 15449,
      "group 100": 33560,
      "receive tap": 68082,
      "assessed scale": 12061,
      "24 post": 3264,
      "surgery intra": 79431,
      "intra post": 39722,
      "time ambulation": 81206,
      "arrival surgical": 11703,
      "analyzed patient": 10850,
      "immediate post": 36701,
      "000 pain": 35,
      "patients difference": 59198,
      "001 respectively": 201,
      "respectively average": 71172,
      "block patients": 14051,
      "68 vs": 5505,
      "intra operative": 39721,
      "used fentanyl": 84939,
      "morphine vs": 47970,
      "mg 000": 45679,
      "000 hydromorphone": 23,
      "used mg": 85008,
      "mg 003": 45686,
      "total time": 81912,
      "41 vs": 4433,
      "immediately post": 36747,
      "add significant": 7726,
      "cornerstone pain": 20775,
      "risk acute": 72509,
      "retrospective population": 72150,
      "end results": 28811,
      "database 2008": 22162,
      "treatment enrolled": 82579,
      "patients 811": 58902,
      "150 patients": 1818,
      "patients 15": 58830,
      "prescriptions months": 64517,
      "treatment odds": 82694,
      "ratio 28": 67723,
      "radiation treatment": 66955,
      "84 95": 5957,
      "44 10": 4524,
      "10 24": 695,
      "45 91": 4577,
      "50 oxycodone": 4875,
      "17 62": 1949,
      "10 67": 725,
      "symptom management": 79865,
      "treatment completion": 82512,
      "regarding pharmaceutical": 69270,
      "increase treatment": 37816,
      "treatment demand": 82545,
      "use heroin": 84394,
      "heroin opioid": 35019,
      "included cochrane": 37436,
      "trials cochrane": 83117,
      "2015 issue": 2710,
      "1966 2015": 2211,
      "2015 embase": 2703,
      "embase ovid": 28650,
      "1982 2015": 2221,
      "2015 isi": 2707,
      "psycinfo ovid": 66371,
      "trials examining": 83145,
      "maintenance opioid": 42911,
      "codeine versus": 17301,
      "versus different": 86120,
      "agonists buprenorphine": 9321,
      "buprenorphine maintenance": 14557,
      "used standard": 85135,
      "standard cochrane": 76895,
      "procedures main": 65314,
      "trials met": 83162,
      "participants moderate": 58327,
      "evidence studies": 30262,
      "difference methadone": 24631,
      "rr 37": 72925,
      "opioid positive": 52074,
      "rr 81": 72986,
      "56 18": 5096,
      "18 low": 2088,
      "events rr": 30113,
      "treatment terms": 82873,
      "rr 63": 72955,
      "63 95": 5357,
      "rr 54": 72945,
      "difference smd": 24685,
      "maintenance detoxification": 42907,
      "treatment retention": 82822,
      "rr 33": 72919,
      "label study": 41001,
      "use maintenance": 84464,
      "appeared effective": 11392,
      "2017 march": 2792,
      "participants currently": 58295,
      "median 28": 44188,
      "day dosing": 22303,
      "10 total": 945,
      "participants 23": 58269,
      "23 participants": 3107,
      "negative consequences": 49066,
      "impact treatment": 36856,
      "physical health": 61403,
      "review evidence": 72297,
      "treatment resistant": 82813,
      "october 2017": 50886,
      "tolerability safety": 81554,
      "safety assessed": 73122,
      "aes adverse": 8867,
      "events saes": 30116,
      "15 36": 1697,
      "age participants": 9099,
      "placebo reducing": 61811,
      "risk rr": 72657,
      "24 43": 3163,
      "recommendation assessment": 68587,
      "evaluation grade": 29954,
      "person using": 60942,
      "achieving complete": 7336,
      "rr 17": 72904,
      "25 32": 3330,
      "306 patients": 3832,
      "rr 73": 72967,
      "33 26": 3980,
      "aes rr": 8885,
      "rr 55": 72948,
      "ci 48": 16460,
      "reported 50": 70491,
      "studies 95": 77639,
      "reported improved": 70567,
      "improved qol": 37127,
      "adjuvant treatment": 8087,
      "rct evidence": 67909,
      "rcts examining": 67914,
      "syndromes cannabinoids": 79925,
      "potency prescription": 63084,
      "rates patients": 67620,
      "calculated according": 14683,
      "according centers": 7037,
      "standardized opioid": 76976,
      "included 44": 37399,
      "18 000": 2023,
      "respectively median": 71210,
      "median mme": 44245,
      "23 38": 3080,
      "opioid 65": 51359,
      "65 patients": 5418,
      "period conclusions": 60716,
      "start patients": 77004,
      "patients higher": 59360,
      "epidemic background": 29128,
      "background headache": 13060,
      "registry included": 69405,
      "inpatient postdischarge": 39027,
      "died received": 24528,
      "use determine": 84304,
      "related risk": 69680,
      "factors inpatient": 31112,
      "hospitalization 12": 35653,
      "12 53": 1256,
      "discharge commonly": 25111,
      "30 morphine": 3776,
      "morphine 26": 47553,
      "hydromorphone patients": 36215,
      "range 64": 67296,
      "74 vs": 5678,
      "years 001": 87519,
      "year 95": 87428,
      "10 28": 700,
      "received inpatient": 68164,
      "additional risk": 7893,
      "43 23": 4494,
      "refill prescriptions": 69163,
      "months post": 47461,
      "use does": 84341,
      "does necessarily": 25683,
      "necessarily lead": 48876,
      "high rate": 35158,
      "compared clinical": 18104,
      "symptom burden": 79859,
      "institution implementation": 39075,
      "2018 post": 2838,
      "symptom burdens": 79860,
      "42 days": 4459,
      "discharge using": 25183,
      "md anderson": 43636,
      "anderson symptom": 10891,
      "symptom inventory": 79864,
      "white non": 87025,
      "83 women": 5940,
      "65 women": 5422,
      "reduction morphine": 69068,
      "dose prescribed": 26020,
      "discharge 83": 25101,
      "groups rate": 34282,
      "refill requests": 69169,
      "including patient": 37662,
      "activity interference": 7571,
      "affective interference": 8933,
      "associated differences": 12252,
      "comprehensive picture": 18628,
      "additional support": 7898,
      "recommendations reduce": 68610,
      "agonist norepinephrine": 9297,
      "directly prior": 25065,
      "conversion oral": 20710,
      "50 250": 4809,
      "controlled methods": 20504,
      "label phase": 40986,
      "iii study": 36600,
      "included week": 37579,
      "screening period": 74046,
      "opioid week": 52639,
      "week open": 86854,
      "label treatment": 41006,
      "score days": 73741,
      "prior randomization": 65166,
      "control previous": 20400,
      "receive twice": 68084,
      "daily treatment": 21811,
      "er 100": 29385,
      "100 500": 989,
      "day morphine": 22340,
      "morphine sustained": 47946,
      "140 mg": 1637,
      "assay sensitivity": 11884,
      "estimated based": 29620,
      "ratio tapentadol": 67802,
      "fentanyl 10": 31409,
      "10 03": 657,
      "primary effectiveness": 65001,
      "effectiveness endpoint": 27761,
      "endpoint proportion": 28897,
      "patients maintained": 59468,
      "baseline mean": 13440,
      "days doses": 22518,
      "medication day": 44483,
      "patients 42": 58866,
      "70 89": 5556,
      "week patient": 86859,
      "48 50": 4689,
      "reported overall": 70606,
      "improved improved": 37110,
      "minimally improved": 46582,
      "week compared": 86833,
      "53 15": 5016,
      "15 28": 1685,
      "28 reporting": 3572,
      "effectiveness analyses": 27746,
      "morphine sr": 47926,
      "35 99": 4077,
      "treatment overall": 82723,
      "overall safety": 54253,
      "er associated": 29400,
      "gastrointestinal treatment": 32898,
      "38 19": 4228,
      "vs 54": 86592,
      "54 27": 5040,
      "including constipation": 37604,
      "constipation 12": 19745,
      "12 50": 1254,
      "vomiting 50": 86445,
      "overall results": 54249,
      "control improved": 20353,
      "improved gastrointestinal": 37108,
      "tolerability versus": 81563,
      "sr patients": 76815,
      "controlled previous": 20525,
      "improve understanding": 37093,
      "compare prevalence": 18048,
      "treatment measured": 82655,
      "using clinical": 85341,
      "longitudinal study": 42403,
      "male c57bl": 43022,
      "c57bl 6j": 14652,
      "mice administered": 46269,
      "doses different": 26179,
      "assessments performed": 12154,
      "12 15": 1215,
      "15 18": 1677,
      "21 24": 2944,
      "different effects": 24867,
      "therapeutic drug": 80932,
      "drug regimens": 26760,
      "months high": 47445,
      "months oxycodone": 47458,
      "treatment low": 82644,
      "43 72": 4498,
      "01 16": 293,
      "41 74": 4415,
      "74 05": 5669,
      "05 odds": 530,
      "assessment increased": 12123,
      "increased low": 37944,
      "13 74": 1473,
      "aor 63": 11326,
      "15 54": 1704,
      "54 treatment": 5053,
      "allows analysis": 9646,
      "rate change": 67449,
      "provides greater": 66219,
      "greater sensitivity": 33494,
      "mice greater": 46289,
      "greater chance": 33434,
      "exposure results": 30793,
      "consistent clinical": 19693,
      "studies demonstrating": 77696,
      "regimens induce": 69335,
      "observed using": 50728,
      "research regarding": 71025,
      "identify prescription": 36526,
      "frequently misused": 32558,
      "assess differences": 11925,
      "examine trends": 30364,
      "individuals opioid": 38351,
      "used nationally": 85026,
      "representative data": 70757,
      "2019 national": 2876,
      "2019 analyzed": 2856,
      "analyzed february": 10831,
      "february 15": 31303,
      "15 2021": 1681,
      "physician did": 61426,
      "use greater": 84383,
      "told use": 81514,
      "annual average": 11010,
      "women 13": 87191,
      "13 14": 1452,
      "40 95": 4332,
      "respectively prevalence": 71237,
      "oud buprenorphine": 53893,
      "pain 20": 56373,
      "adults misused": 8567,
      "buprenorphine likely": 14555,
      "vs 53": 86591,
      "57 001": 5124,
      "adults past": 8573,
      "buprenorphine multivariable": 14564,
      "aor 95": 11338,
      "stimulant use": 77355,
      "prevalence buprenorphine": 64773,
      "reporting past": 70700,
      "findings underscore": 31837,
      "underscore need": 83617,
      "buprenorphine based": 14522,
      "associated conditions": 12236,
      "mental illness": 44827,
      "common feature": 17754,
      "feature childhood": 31292,
      "adolescence world": 8436,
      "world young": 87320,
      "young people": 87720,
      "people pain": 60419,
      "chronic world": 16355,
      "guidelines pharmacological": 34458,
      "treatments children": 82899,
      "children persisting": 16066,
      "persisting pain": 60935,
      "pain acknowledge": 56406,
      "acknowledge pain": 7348,
      "children major": 16055,
      "concern high": 18823,
      "high significance": 35182,
      "significance parts": 75410,
      "parts world": 58435,
      "past pain": 58471,
      "pain largely": 56995,
      "largely dismissed": 41164,
      "dismissed frequently": 25362,
      "frequently left": 32556,
      "left untreated": 41349,
      "views children": 86227,
      "pain changed": 56522,
      "time relief": 81355,
      "designed suite": 23848,
      "suite seven": 79056,
      "seven reviews": 74875,
      "reviews chronic": 72403,
      "pain looking": 57034,
      "looking antidepressants": 42409,
      "antidepressants antiepileptic": 11172,
      "antiepileptic drugs": 11195,
      "drugs non": 27005,
      "opioids paracetamol": 53149,
      "evidence children": 30171,
      "pharmacological interventions": 61218,
      "morbidity children": 47508,
      "adolescents world": 8462,
      "world today": 87317,
      "paediatric population": 56339,
      "nerve damage": 49124,
      "worldwide treatment": 87325,
      "receptors central": 68537,
      "nervous mu": 49143,
      "mixed agonist": 46785,
      "antagonists partial": 11083,
      "partial agonists": 58238,
      "generally available": 33010,
      "available healthcare": 12811,
      "healthcare settings": 34808,
      "settings high": 74855,
      "countries access": 20952,
      "access restricted": 7002,
      "include buprenorphine": 37351,
      "used varying": 85188,
      "varying doses": 85995,
      "paediatric patients": 56338,
      "transmucosal transdermal": 82233,
      "transdermal oral": 82162,
      "opioids acceptable": 52695,
      "acceptable grade": 6980,
      "grade adverse": 33365,
      "recommended method": 68627,
      "dose gradually": 25915,
      "gradually titrated": 33392,
      "effect child": 27430,
      "child objectives": 16008,
      "events opioids": 30087,
      "adolescents aged": 8454,
      "aged birth": 9202,
      "birth 17": 13878,
      "years setting": 87666,
      "setting search": 74816,
      "central cochrane": 15581,
      "library medline": 41665,
      "medline ovid": 44742,
      "ovid embase": 54372,
      "ovid inception": 54375,
      "2016 searched": 2760,
      "searched online": 74158,
      "registries selection": 69400,
      "blinding dose": 14027,
      "route treating": 72850,
      "adolescents comparing": 8458,
      "studies eligibility": 77707,
      "eligibility planned": 28576,
      "planned use": 61885,
      "use dichotomous": 84305,
      "ratio number": 67781,
      "assessed grade": 12006,
      "evaluation planned": 29961,
      "planned create": 61878,
      "create summary": 21143,
      "studies eligible": 77710,
      "low downgraded": 42484,
      "support refute": 79210,
      "refute use": 69229,
      "efficacy harm": 28274,
      "harm use": 34583,
      "codeine effective": 17229,
      "conclusions efficacy": 19078,
      "adolescents background": 8457,
      "pocket costs": 62062,
      "barrier treatment": 13258,
      "currently receiving": 21505,
      "clients currently": 16733,
      "52 followed": 4987,
      "compared participants": 18247,
      "coefficient 33": 17311,
      "42 79": 4452,
      "36 72": 4122,
      "conclusions participants": 19152,
      "newer treatment": 49409,
      "receiving fewer": 68337,
      "receiving effective": 68333,
      "care background": 15005,
      "following databases": 32119,
      "register central": 69369,
      "medline databases": 44732,
      "checked reference": 15942,
      "references relevant": 69150,
      "included rcts": 37540,
      "adults adolescents": 8540,
      "identified rcts": 36463,
      "treatment non": 82682,
      "treatment comparison": 82510,
      "low certainty": 42455,
      "certainty evidence": 15658,
      "28 86": 3548,
      "participants low": 58320,
      "use measured": 84470,
      "moderate certainty": 47138,
      "study difference": 78119,
      "use mean": 84469,
      "difference 41": 24578,
      "41 days": 4421,
      "days higher": 22530,
      "rr 13": 72895,
      "66 93": 5451,
      "rr 66": 72961,
      "smd 19": 76321,
      "rr 02": 72885,
      "ci 73": 16488,
      "rr 50": 72939,
      "rates treatment": 67645,
      "arms authors": 11685,
      "buprenorphine did": 14536,
      "buprenorphine appears": 14520,
      "findings importance": 31788,
      "tolerance increased": 81587,
      "claims patients": 16637,
      "appear opioid": 11384,
      "measure prevalence": 43943,
      "evidence opioid": 30231,
      "2016 data": 2739,
      "included 131": 37380,
      "continuous enrollment": 20163,
      "advantage insurance": 8607,
      "medication 20": 44448,
      "2017 august": 2773,
      "august 31": 12676,
      "data prescriptions": 22061,
      "occurred women": 50851,
      "women 62": 87197,
      "prior initiating": 65150,
      "initiating therapy": 38892,
      "including 31": 37586,
      "data present": 22062,
      "episodes occurred": 29212,
      "tolerance present": 81601,
      "relevance cohort": 70029,
      "medications did": 44613,
      "contribute substantial": 20230,
      "additional evidence": 7861,
      "tolerance data": 81579,
      "understand clinical": 83621,
      "patients associated": 59017,
      "potentially inappropriate": 63259,
      "prescribing introduction": 64071,
      "despite risk": 23904,
      "melbourne australia": 44765,
      "prior distribution": 65142,
      "structured telephone": 77592,
      "november 22": 50042,
      "injected drugs": 38916,
      "monthly past": 47419,
      "past months": 58470,
      "word mouth": 87264,
      "treatment characteristics": 82476,
      "epidemic led": 29132,
      "led similar": 41343,
      "opioids uk": 53363,
      "initiation escalation": 38894,
      "opioids contribute": 52820,
      "prescribing behaviour": 64037,
      "use studies": 84756,
      "practices prescribers": 63434,
      "dose potency": 26018,
      "factors long": 31115,
      "use iv": 84443,
      "opioid included": 51843,
      "opioids identified": 52962,
      "identified mean": 36445,
      "years 57": 87546,
      "57 female": 5129,
      "year morphine": 87452,
      "200 mme": 2405,
      "category higher": 15309,
      "respectively following": 71195,
      "users year": 85277,
      "model following": 47050,
      "70 001": 5547,
      "74 years": 5679,
      "aor 77": 11332,
      "59 001": 5178,
      "aor 72": 11329,
      "65 79": 5410,
      "48 58": 4690,
      "58 001": 5151,
      "compared population": 18274,
      "average study": 12937,
      "study limited": 78290,
      "limited patients": 41951,
      "high mme": 35123,
      "surgery history": 79417,
      "prescribers high": 64017,
      "observed findings": 50679,
      "aims opioid": 9490,
      "properties deter": 65706,
      "abuse abuse": 6639,
      "design conduct": 23704,
      "meaningful changes": 43913,
      "outcomes reported": 54087,
      "reported prevalence": 70632,
      "prevalence frequency": 64784,
      "access study": 7006,
      "use improved": 84422,
      "adults taking": 8583,
      "pentazocine pethidine": 60394,
      "tapentadol tramadol": 80474,
      "2020 intervention": 2902,
      "randomized usual": 67204,
      "day long": 22329,
      "delivered nurse": 23208,
      "months main": 47451,
      "measurement information": 44015,
      "information pain": 38658,
      "score range": 73776,
      "range 40": 67286,
      "indicates worst": 38256,
      "minimal clinically": 46570,
      "difference proportion": 24672,
      "discontinued opioids": 25242,
      "measured self": 43994,
      "age 61": 9034,
      "completed 12": 18459,
      "care groups": 15025,
      "94 89": 6188,
      "89 15": 6056,
      "opioid discontinuation": 51714,
      "care group": 15024,
      "group odds": 33876,
      "ratio 55": 67742,
      "10 99": 739,
      "14 28": 1565,
      "305 participants": 3830,
      "participants intervention": 58318,
      "group usual": 34063,
      "received additional": 68113,
      "additional medical": 7867,
      "possible probable": 62544,
      "shortness breath": 75218,
      "hot flushes": 35680,
      "fever pain": 31623,
      "pain small": 57851,
      "small intestinal": 76285,
      "suicide attempt": 79048,
      "pain nonmalignant": 57244,
      "group individual": 33827,
      "interference daily": 39422,
      "daily life": 21750,
      "life activities": 41683,
      "org identifier": 53750,
      "pain fever": 56778,
      "recently approved": 68440,
      "adjunctive opioid": 8009,
      "analgesics reduction": 10492,
      "aim work": 9431,
      "placebo 24": 61625,
      "hours subjects": 35861,
      "adult subjects": 8523,
      "subjects aged": 78680,
      "years randomized": 87647,
      "groups iv": 34223,
      "100 ml": 997,
      "65 ml": 5417,
      "subjects remained": 78739,
      "group iv": 33838,
      "mg q6h": 46191,
      "enrolled open": 29005,
      "choice opioid": 16114,
      "intensity pi": 39291,
      "scale point": 73541,
      "restricted morphine": 71457,
      "oral rescue": 53660,
      "efficacy analyses": 28224,
      "intent treat": 39337,
      "pi pain": 61481,
      "relief pr": 70171,
      "weighted sum": 86987,
      "sum pi": 79077,
      "pi differences": 61480,
      "model time": 47083,
      "time meaningful": 81286,
      "stopwatch method": 77395,
      "pr second": 63368,
      "spontaneous adverse": 76751,
      "subjects screened": 78742,
      "study arm": 77957,
      "mg 42": 45752,
      "itt population": 40359,
      "244 women": 3305,
      "white mean": 87019,
      "78 years": 5787,
      "35 lb": 4082,
      "contract research": 20201,
      "research organization": 71022,
      "withdrawal consent": 87122,
      "early discharge": 27256,
      "subjects participated": 78722,
      "elective open": 28497,
      "pr scores": 63367,
      "003 12": 247,
      "global evaluations": 33224,
      "compared combined": 18110,
      "combined placebo": 17667,
      "pr double": 63322,
      "dose significantly": 26077,
      "compared subjects": 18318,
      "group constipation": 33704,
      "headache frequency": 34658,
      "frequency treatment": 32530,
      "aes teaes": 8886,
      "unrelated study": 83927,
      "placebo tolerated": 61843,
      "dependence growing": 23470,
      "attention deficit": 12564,
      "deficit hyperactivity": 23111,
      "hyperactivity disorder": 36256,
      "eating disorder": 27294,
      "risk aberrant": 72504,
      "novel formulation": 50010,
      "trial used": 83094,
      "methamphetamine use": 45151,
      "using 14": 85293,
      "28 previously": 3566,
      "responded treatment": 71301,
      "15 week": 1799,
      "placebo week": 61854,
      "given access": 33154,
      "access sessions": 7005,
      "therapy treatment": 81073,
      "outcomes efficacy": 54023,
      "use safety": 84712,
      "safety treatment": 73239,
      "outcomes total": 54104,
      "12 week": 1369,
      "week active": 86828,
      "period percentage": 60771,
      "21 days": 2967,
      "days abstinence": 22482,
      "withdrawal dependence": 87123,
      "additionally study": 7911,
      "dissemination study": 25520,
      "study approved": 77955,
      "australia hrec": 12689,
      "pre results": 63489,
      "overdose emergency": 54289,
      "home naloxone": 35513,
      "members people": 44782,
      "need widespread": 48964,
      "000 deaths": 20,
      "deaths worldwide": 22794,
      "rapid growth": 67385,
      "deaths heroin": 22753,
      "prison release": 65189,
      "include pre": 37367,
      "nasal sprays": 48658,
      "speed onset": 76680,
      "choosing right": 16139,
      "ongoing debate": 51082,
      "naloxone provided": 48510,
      "greater impact": 33449,
      "objectives examine": 50561,
      "type treatment": 83361,
      "design dose": 23712,
      "10 criteria": 752,
      "100 250": 986,
      "mg weeks": 46266,
      "followed week": 32088,
      "250 100": 3394,
      "participants followed": 58309,
      "week 12": 86824,
      "outcomes safety": 54092,
      "safety drug": 73140,
      "week participants": 86858,
      "included change": 37434,
      "potential non": 63194,
      "non prescription": 49671,
      "use adherence": 84173,
      "trial week": 83096,
      "iqr 16": 40165,
      "013 conclusions": 339,
      "tolerated study": 81640,
      "syringe programmes": 79967,
      "therapy ost": 81040,
      "increasing evidence": 38106,
      "therapy combination": 80996,
      "database systematic": 22189,
      "reviews effects": 72411,
      "health technology": 34790,
      "technology assessment": 80554,
      "global health": 33225,
      "cinahl web": 16561,
      "november 2015": 50034,
      "results review": 71927,
      "studies did": 77700,
      "authors provide": 12744,
      "reviews eligible": 72412,
      "studies cross": 77683,
      "sectional surveys": 74293,
      "control studies": 20425,
      "trials measured": 83158,
      "reduced exposure": 68926,
      "exposure reported": 30792,
      "drugs defined": 26930,
      "analysis followed": 10688,
      "followed standard": 32083,
      "bias domains": 13764,
      "missing data": 46698,
      "europe australia": 29731,
      "years follow": 87592,
      "judged studies": 40499,
      "quality low": 66750,
      "low evidence": 42486,
      "evidence current": 30178,
      "reduces risk": 69008,
      "50 risk": 4897,
      "intervention effect": 39631,
      "effect remained": 27551,
      "proportion female": 65742,
      "main drug": 42826,
      "evidence high": 30193,
      "rr 79": 72980,
      "based studies": 13383,
      "region high": 69342,
      "combined high": 17648,
      "reduction risk": 69099,
      "heterogeneity studies": 35053,
      "oxycontin controlled release": 56130,
      "controlled release oxycodone": 20552,
      "release oxycodone hydrochloride": 69944,
      "purdue pharma stamford": 66502,
      "pharma stamford ct": 61013,
      "food drug administration": 32233,
      "drug administration fda": 26522,
      "moderate severe chronic": 47174,
      "severe chronic pain": 74934,
      "prescription drug abuse": 64204,
      "health care providers": 34683,
      "specific effects drug": 76590,
      "altered mental status": 9701,
      "recreational use oxycodone": 68784,
      "oxycodone clinical use": 54784,
      "clinical use 1917": 16966,
      "acute postoperative pain": 7686,
      "used manage cancer": 84993,
      "cancer related pain": 14908,
      "pain chronic non": 56539,
      "chronic non cancer": 16221,
      "non cancer related": 49586,
      "controlled studies performed": 20583,
      "postoperative pain cancer": 62851,
      "pain cancer pain": 56507,
      "osteoarthritis related pain": 53868,
      "pain neuropathic pain": 57235,
      "neuropathic pain postherpetic": 49253,
      "pain postherpetic neuralgia": 57391,
      "postherpetic neuralgia diabetic": 62658,
      "neuralgia diabetic neuropathy": 49172,
      "pharmacodynamic effects oxycodone": 61064,
      "typical mu opioid": 83385,
      "mu opioid agonist": 48117,
      "opioid agonist oxycodone": 51427,
      "closely resembles morphine": 17078,
      "overdose including prescription": 54294,
      "including prescription opioids": 37665,
      "prescription opioids heroin": 64336,
      "opioids heroin illicitly": 52945,
      "heroin illicitly manufactured": 35006,
      "illicitly manufactured fentanyl": 36660,
      "opioids moderate severe": 53058,
      "moderate severe pain": 47189,
      "opioid prescription medications": 52154,
      "highly prescribed opioid": 35399,
      "prescribed opioid medications": 63913,
      "treating moderate severe": 82395,
      "opioid use disorders": 52506,
      "opioid use abuse": 52467,
      "crisis united states": 21183,
      "united states opioid": 83810,
      "medical care providers": 44336,
      "total joint arthroplasty": 81823,
      "joint arthroplasty pain": 40488,
      "arthroplasty pain control": 11739,
      "pain control surgery": 56663,
      "early postoperative period": 27269,
      "opioid misuse epidemic": 51940,
      "epidemic orthopedic surgeons": 29143,
      "medications long acting": 44642,
      "long acting opioids": 42300,
      "acting opioids oxycontin": 7415,
      "multimodal pain control": 48227,
      "narcotic pain medications": 48602,
      "alternative pain management": 9734,
      "pain management strategies": 57121,
      "reduce postoperative opioid": 68882,
      "postoperative opioid consumption": 62814,
      "peripheral nerve blocks": 60870,
      "recommend evidence based": 68581,
      "pain related complaints": 57510,
      "oxycontin purdue pharma": 56175,
      "north american newspapers": 49958,
      "social problem associated": 76358,
      "27 north american": 3503,
      "law enforcement agencies": 41250,
      "public health crisis": 66384,
      "public health safety": 66400,
      "results significant differences": 71954,
      "oxycodone semi synthetic": 55882,
      "semi synthetic opioid": 74513,
      "analgesic effects oxycodone": 10221,
      "immediate release formulations": 36716,
      "drug administration approved": 26521,
      "release form oxycodone": 69859,
      "oxycodone immediate release": 55230,
      "doses 10 30": 26118,
      "10 30 mg": 703,
      "12 year period": 1390,
      "liquid liquid extraction": 42095,
      "gas chromatography nitrogen": 32843,
      "chromatography nitrogen phosphorus": 16169,
      "nitrogen phosphorus detection": 49502,
      "gas chromatography mass": 32841,
      "chromatography mass spectrometry": 16162,
      "oxycodone d3 used": 54921,
      "used internal standard": 84979,
      "11 mg kg": 1133,
      "reformulated oxycontin oxycodone": 69204,
      "oxycontin oxycodone hcl": 56163,
      "oxycodone hcl controlled": 55148,
      "hcl controlled release": 34631,
      "healthy recreational opioid": 34842,
      "recreational opioid users": 68779,
      "aged 18 years": 9168,
      "18 years older": 2113,
      "opioid use assessed": 52470,
      "females mean age": 31395,
      "age 35 years": 8995,
      "years range 18": 87652,
      "range 18 51": 67264,
      "major public health": 42969,
      "public health issue": 66391,
      "cohort study assessed": 17385,
      "brand extended release": 14379,
      "extended release er": 30860,
      "release er oxycodone": 69847,
      "oxycontin comparator opioids": 56125,
      "july 2009 june": 40513,
      "2009 june 2010": 2527,
      "brand er oxycodone": 14377,
      "oxycodone abuse deterrent": 54618,
      "abuse deterrent properties": 6704,
      "er oxycodone comparators": 29453,
      "prescribers pharmacies conclusions": 64021,
      "oxycodone semisynthetic opioid": 55885,
      "semisynthetic opioid analgesic": 74523,
      "widely used clinical": 87062,
      "used clinical practice": 84879,
      "10 times potent": 943,
      "times potent oxycodone": 81434,
      "article provides updated": 11779,
      "role peripheral opioid": 72760,
      "peripheral opioid analgesia": 60880,
      "analgesia discussed present": 9953,
      "oxycontin commonly prescribed": 56123,
      "commonly prescribed medications": 17864,
      "medications chronic pain": 44600,
      "tamper resistant formulation": 80339,
      "prescribed treat chronic": 63994,
      "treat chronic pain": 82290,
      "patients chronic pain": 59080,
      "pain management practices": 57104,
      "oxycontin oxycodone hydrochloride": 56165,
      "oxycodone hydrochloride extended": 55182,
      "hydrochloride extended release": 36017,
      "extended release tablets": 30903,
      "identify characteristics associated": 36495,
      "increased 2015 2016": 37840,
      "original formulation oxycontin": 53787,
      "formulation abuse deterrent": 32329,
      "increasingly used treatment": 38139,
      "used treatment acute": 85175,
      "acute cancer chronic": 7611,
      "cancer chronic non": 14771,
      "chronic non malignant": 16223,
      "non malignant pain": 49626,
      "malignant pain oxycodone": 43102,
      "selective opioid receptor": 74438,
      "opioid receptor agonist": 52238,
      "opioid crisis canada": 51682,
      "opioid naive patients": 51970,
      "total opioid prescriptions": 81867,
      "users prescription opioids": 85264,
      "changes opioid related": 15806,
      "opioid related hospitalizations": 52319,
      "administration opioid analgesics": 8318,
      "opioid analgesics use": 51533,
      "drug screen results": 26783,
      "using gas chromatography": 85402,
      "high levels oxycodone": 35118,
      "provide overview analgesic": 66086,
      "year old woman": 87470,
      "patient presented emergency": 58720,
      "presented emergency department": 64691,
      "following total knee": 32216,
      "total knee arthroplasty": 81826,
      "acute myocardial infarction": 7650,
      "positive airway pressure": 62447,
      "increasing number opioid": 38112,
      "opioid dependent patients": 51707,
      "management postoperative pain": 43241,
      "oxycodone naloxone oxn": 55508,
      "pain management surgical": 57125,
      "management surgical patients": 43272,
      "studies randomized controlled": 77822,
      "randomized controlled trials": 67079,
      "eligible inclusion review": 28585,
      "included studies reported": 37559,
      "bowel function evaluated": 14274,
      "studies patients treated": 77808,
      "patients treated oxn": 60068,
      "bowel function compared": 14270,
      "compared control groups": 18121,
      "adverse events conclusion": 8742,
      "pain control achieved": 56601,
      "effects opioid induced": 28037,
      "opioid induced constipation": 51857,
      "prescription opioid abuse": 64274,
      "public health problem": 66394,
      "release oxycodone oxycontin": 69962,
      "methods cross sectional": 45295,
      "cross sectional analysis": 21255,
      "significantly higher rates": 75740,
      "tamper resistant formulations": 80340,
      "tapentadol hydrochloride extended": 80417,
      "release er 50": 69835,
      "er 50 mg": 29395,
      "study design randomized": 78085,
      "oxycontin 40 mg": 56110,
      "study setting studies": 78491,
      "new york ny": 49392,
      "measurements primary outcome": 44032,
      "primary outcome study": 65094,
      "tablets primary outcome": 80209,
      "extended release oxycodone": 30891,
      "release oxycodone tablets": 69979,
      "tapentadol extended release": 80410,
      "extended release intravenous": 30879,
      "immediate postoperative period": 36705,
      "faster onset pain": 31215,
      "onset pain relief": 51122,
      "tolerate oral intake": 81615,
      "morphine widely used": 47972,
      "control postoperative pain": 20396,
      "kappa mu opioid": 40589,
      "mu opioid receptors": 48133,
      "pain report oxycodone": 57616,
      "oxycodone safe effective": 55861,
      "safe effective analgesic": 73076,
      "oxycodone associated greater": 54733,
      "pain control fewer": 56615,
      "severe adverse events": 74909,
      "new old drug": 49342,
      "postoperative pain control": 62857,
      "potential adverse effects": 63131,
      "opioid abuse misuse": 51373,
      "abuse misuse diversion": 6780,
      "designed deter abuse": 23832,
      "remoxy extended release": 70340,
      "extended release formulation": 30874,
      "strong opioid oxycodone": 77535,
      "review efficacy safety": 72288,
      "efficacy safety tolerability": 28392,
      "generic controlled release": 33045,
      "controlled release cr": 20536,
      "release cr oxycodone": 69822,
      "oxycodone hydrocodone methadone": 55208,
      "hydrocodone methadone morphine": 36102,
      "poison control centers": 62154,
      "rates 100 000": 67543,
      "100 000 population": 978,
      "000 patients calculated": 37,
      "using poisson regression": 85565,
      "opioids statistically significant": 53310,
      "statistically significant differences": 77212,
      "cr oxycodone followed": 21086,
      "abuse prescription opioid": 6838,
      "prescription opioid drugs": 64297,
      "opioid drugs oxycodone": 51752,
      "abuse liability prescription": 6756,
      "liability prescription opioids": 41647,
      "prescription opioids study": 64371,
      "differences pharmacokinetic pharmacodynamic": 24786,
      "findings study suggest": 31823,
      "significant difference incidence": 75474,
      "incidence adverse effects": 37257,
      "gastrointestinal adverse reactions": 32869,
      "paucity data regarding": 60235,
      "new abuse deterrent": 49306,
      "abuse deterrent formulations": 6690,
      "oxytrex pain therapeutics": 56296,
      "oxycodone ultra low": 56039,
      "ultra low dose": 83418,
      "development physical dependence": 24247,
      "physical dependence analgesic": 61388,
      "dependence analgesic tolerance": 23462,
      "treatment moderate severe": 82665,
      "evaluate safety efficacy": 29844,
      "safety efficacy oxycodone": 73148,
      "clinical studies conducted": 16908,
      "conducted healthy volunteers": 19365,
      "healthy volunteers patients": 34857,
      "low dose naltrexone": 42472,
      "protein coupling opioid": 65931,
      "coupling opioid receptors": 20986,
      "opioid tolerance dependence": 52428,
      "opioid receptor activity": 52234,
      "agonist antagonist combination": 9279,
      "tolerance physical dependence": 81600,
      "background oxycodone strong": 13136,
      "oxycodone strong opioid": 55940,
      "mu kappa opioid": 48114,
      "kappa opioid receptors": 40596,
      "opioid receptors pharmacological": 52281,
      "analgesic potency morphine": 10293,
      "malignant non malignant": 43096,
      "established wide range": 29598,
      "provide evidence based": 66062,
      "using medline embase": 85488,
      "medline embase cochrane": 44737,
      "embase cochrane databases": 28644,
      "pharmacokinetics pharmacodynamics oxycodone": 61184,
      "data support use": 22139,
      "oxycodone visceral pain": 56080,
      "opioid receptors oxycodone": 52280,
      "pain 12 hours": 56367,
      "relief moderate severe": 70145,
      "pain improving quality": 56852,
      "improving quality life": 37206,
      "conclusions oxycodone provides": 19148,
      "oxycodone provides significant": 55786,
      "significant pain relief": 75592,
      "alternative morphine oxycodone": 9727,
      "opioids united states": 53366,
      "sustained release opioids": 79791,
      "cr morphine cr": 21070,
      "morphine cr oxycodone": 47633,
      "oxycodone similar morphine": 55920,
      "oxycodone valued opioid": 56071,
      "opioid analgesic administered": 51449,
      "administered strong opioid": 8185,
      "strong opioid strong": 77538,
      "opioid strong opioids": 52377,
      "strong opioids ineffective": 77550,
      "case insufficient analgesia": 15178,
      "adverse effects sedation": 8699,
      "patients severe pain": 59968,
      "severe pain patients": 74996,
      "codeine dihydrocodeine oxycodone": 17228,
      "blood brain barrier": 14108,
      "brain plasma oxycodone": 14359,
      "oxycodone displays high": 54985,
      "morphine patients renal": 47873,
      "patients renal impairment": 59882,
      "oral controlled release": 53505,
      "release oxycodone formulation": 69939,
      "oxycodone formulation introduced": 55103,
      "combination prolonged release": 17606,
      "prolonged release oxycodone": 65627,
      "release oxycodone prolonged": 69972,
      "oxycodone prolonged release": 55774,
      "prolonged release naloxone": 65624,
      "naloxone oxycodone naloxone": 48481,
      "oxycodone naloxone tablets": 55518,
      "equianalgesic dose ratio": 29257,
      "clinical studies oxycodone": 16915,
      "oxycodone patients cancer": 55653,
      "patients cancer pain": 59044,
      "cancer pain potential": 14847,
      "potential role oxycodone": 63224,
      "chronic pain management": 16285,
      "impact bowel function": 36800,
      "pharmacologic non pharmacologic": 61200,
      "mechanism action pharmacodynamics": 44126,
      "onset duration action": 51113,
      "pharmacokinetics pk single": 61188,
      "non steroidal anti": 49687,
      "steroidal anti inflammatory": 77343,
      "anti inflammatory drugs": 11127,
      "inflammatory drugs nsaids": 38564,
      "drugs nsaids effective": 27011,
      "generally safe effective": 33024,
      "safe effective option": 73080,
      "limiting adverse effects": 41970,
      "effects abuse potential": 27801,
      "abuse potential goal": 6818,
      "maximum pain relief": 43601,
      "pain relief opioid": 57556,
      "immediate release ir": 36718,
      "release ir oral": 69878,
      "rapid onset action": 67390,
      "immediate release controlled": 36711,
      "release controlled release": 69814,
      "controlled release preparations": 20571,
      "immediate release oxycodone": 36731,
      "lower costs patients": 42594,
      "controlled release opioid": 20548,
      "opioid treatment controlled": 52445,
      "treatment controlled release": 82525,
      "controlled release morphine": 20547,
      "controlled release long": 20545,
      "release long acting": 69886,
      "long acting opioid": 42293,
      "acting opioid analgesics": 7399,
      "opioid analgesics background": 51484,
      "background oxycodone used": 13138,
      "control acute postoperative": 20270,
      "using nonlinear mixed": 85518,
      "nonlinear mixed effects": 49760,
      "mixed effects models": 46794,
      "compartment model order": 18395,
      "elimination best described": 28611,
      "28 70 kg": 3547,
      "total body weight": 81785,
      "using total body": 85644,
      "years 2018 2019": 87537,
      "20 mg oxycontin": 2348,
      "year study period": 87504,
      "40 mg oxycontin": 4354,
      "deaths united states": 22788,
      "role opioid epidemic": 72752,
      "2010 introduction abuse": 2561,
      "introduction abuse deterrent": 39918,
      "used difference differences": 84917,
      "methods using data": 45624,
      "rates oxycontin misuse": 67616,
      "oxycontin misuse prior": 56150,
      "misuse prior reformulation": 46742,
      "oxycontin misuse reformulation": 56152,
      "public health consequences": 66383,
      "centers disease control": 15567,
      "opioid abuse epidemic": 51369,
      "commonly abused substances": 17834,
      "prescription opioid analgesics": 64286,
      "interactions classes drugs": 39388,
      "depressant effects opioids": 23561,
      "repeated administration oxycodone": 70401,
      "antinociceptive effect opioid": 11241,
      "effect opioid dose": 27507,
      "development abuse deterrent": 24209,
      "deterrent formulations strategy": 24116,
      "prescription opioid misuse": 64301,
      "opioid misuse abuse": 51938,
      "abuse deterrent formulation": 6686,
      "deterrent formulation oxycodone": 24112,
      "oxycodone extended release": 55060,
      "extended release oxycontin": 30899,
      "data poison center": 22048,
      "poison center program": 62149,
      "drug diversion program": 26594,
      "opioid treatment program": 52451,
      "program researched abuse": 65542,
      "researched abuse diversion": 71041,
      "abuse diversion addiction": 6710,
      "diversion addiction related": 25589,
      "addiction related surveillance": 7761,
      "related surveillance radars": 69690,
      "surveillance radars used": 79687,
      "abuse diversion oxycontin": 6712,
      "abuse opioid analgesics": 6794,
      "opioid analgesics increased": 51504,
      "non oral routes": 49664,
      "street price reformulated": 77466,
      "drugs used treat": 27098,
      "neuropathic pain fibromyalgia": 49244,
      "strong opioid agonist": 77525,
      "agonist widely used": 9316,
      "manage severe pain": 43127,
      "objectives assess analgesic": 50543,
      "assess analgesic efficacy": 11908,
      "analgesic efficacy adverse": 10226,
      "efficacy adverse events": 28220,
      "adverse events oxycodone": 8784,
      "chronic neuropathic pain": 16218,
      "searched central medline": 74139,
      "central medline embase": 15590,
      "studies reviews searched": 77836,
      "searched clinical trial": 74142,
      "world health organisation": 87307,
      "international clinical trials": 39478,
      "clinical trials registry": 16960,
      "trials registry platform": 83194,
      "data selection criteria": 22102,
      "selection criteria included": 74408,
      "criteria included randomised": 21200,
      "included randomised controlled": 37533,
      "randomised controlled trials": 67017,
      "controlled trials rcts": 20642,
      "following weeks treatment": 32223,
      "placebo active comparator": 61648,
      "active comparator data": 7489,
      "comparator data collection": 17993,
      "data collection analysis": 21914,
      "collection analysis review": 17498,
      "analysis review authors": 10758,
      "review authors independently": 72260,
      "authors independently extracted": 12737,
      "independently extracted efficacy": 38181,
      "extracted efficacy adverse": 30956,
      "efficacy adverse event": 28218,
      "adverse event data": 8707,
      "event data examined": 29982,
      "data examined issues": 21962,
      "examined issues study": 30386,
      "issues study quality": 40337,
      "assessed risk bias": 12056,
      "intention treat analysis": 39343,
      "12 weeks duration": 1381,
      "main results included": 42858,
      "results included studies": 71725,
      "painful diabetic neuropathy": 58004,
      "postherpetic neuralgia study": 62661,
      "parallel group design": 58129,
      "release oxycodone oxycodone": 69961,
      "oxycodone cr used": 54912,
      "120 mg daily": 1403,
      "proportion participants experiencing": 65757,
      "50 pain relief": 4880,
      "pain relief improved": 57543,
      "pain relief reported": 57575,
      "observation carried forward": 50595,
      "carried forward locf": 15137,
      "forward locf imputation": 32421,
      "studies lasting weeks": 77762,
      "weeks low quality": 86922,
      "low quality evidence": 42542,
      "quality evidence adverse": 66689,
      "evidence adverse events": 30142,
      "adverse events common": 8736,
      "oxycodone cr placebo": 54908,
      "placebo adverse event": 61659,
      "taking oxycodone cr": 80319,
      "number needed treat": 50184,
      "needed treat additional": 49040,
      "treat additional harmful": 82281,
      "oxycodone adverse events": 54697,
      "adverse events reported": 8801,
      "comparison placebo oxycodone": 18377,
      "oxycodone versus placebo": 56078,
      "versus placebo rr": 86152,
      "95 confidence interval": 6374,
      "confidence interval ci": 19458,
      "interval ci 18": 39584,
      "ci 18 23": 16409,
      "treatment adverse event": 82434,
      "adverse event withdrawals": 8720,
      "did differ significantly": 24437,
      "differ significantly groups": 24548,
      "03 45 low": 407,
      "45 low quality": 4587,
      "neuropathic pain conditions": 49240,
      "adverse events typical": 8823,
      "widely prescribed opioid": 87059,
      "prescribed opioid oxycodone": 63914,
      "lethal respiratory depression": 41437,
      "respiratory depression compared": 71273,
      "pharmacokinetic pharmacodynamic pk": 61135,
      "pharmacodynamic pk pd": 61077,
      "male female volunteers": 43036,
      "mg oral oxycodone": 46086,
      "immediate release tablets": 36739,
      "30 40 minutes": 3689,
      "effect site concentration": 27563,
      "13 ng ml": 1495,
      "end tidal carbon": 28828,
      "tidal carbon dioxide": 81175,
      "false positive rates": 31173,
      "positive predictive value": 62479,
      "false negative rate": 31169,
      "time series models": 81376,
      "long acting oxycodone": 42308,
      "oxycodone prescription opioid": 55746,
      "prescription opioid use": 64315,
      "opioid use opioid": 52550,
      "use opioid related": 84551,
      "opioid related harms": 52315,
      "health data ontario": 34706,
      "data ontario canada": 22024,
      "emergency department ed": 28672,
      "department ed visits": 23431,
      "ed visits opioid": 27356,
      "opioid related overdose": 52325,
      "models propensity score": 47125,
      "propensity score matched": 65694,
      "matched comparison group": 43488,
      "oxycodone opioids used": 55577,
      "following delisting oxycontin": 32123,
      "morphine equivalents mmes": 47674,
      "substance use disorder": 78811,
      "use disorder conclusions": 84319,
      "opioid formulations study": 51817,
      "specific prescription opioids": 76615,
      "opioid use particularly": 52558,
      "related ed visits": 69595,
      "following surgical procedure": 32207,
      "prescribed opioids oxycodone": 63931,
      "history substance abuse": 35484,
      "mg oxycodone day": 46110,
      "dex oxy group": 24279,
      "morris water maze": 47978,
      "group dex oxy": 33736,
      "future studies needed": 32776,
      "studies needed examine": 77786,
      "microvascular endothelial cells": 46387,
      "results indicated oxycodone": 71733,
      "previous studies demonstrated": 64918,
      "healthy volunteers randomized": 34858,
      "randomized open label": 67131,
      "way crossover study": 86774,
      "blood samples drawn": 14155,
      "12 18 24": 1220,
      "18 24 hours": 2037,
      "significant difference noted": 75478,
      "prescription opioids oxycodone": 64355,
      "opioids oxycodone hydrocodone": 53137,
      "oxycodone hydrocodone morphine": 55209,
      "tail withdrawal assay": 80252,
      "morphine hydrocodone oxycodone": 47720,
      "hydrocodone oxycodone significantly": 36122,
      "chronic subcutaneous administration": 16348,
      "administration oral oxycodone": 8321,
      "oxycodone following chronic": 55099,
      "kg significantly reversed": 40808,
      "brain oxycodone concentrations": 14353,
      "tail immersion test": 80250,
      "following chronic treatment": 32112,
      "oxycodone concentrations significantly": 54835,
      "chronic oxycodone did": 16253,
      "did alter brain": 24406,
      "oxycodone use increased": 56051,
      "design secondary data": 23794,
      "secondary data analysis": 74212,
      "dispensing records 1996": 25461,
      "random effects meta": 66995,
      "rate cr oxycodone": 67455,
      "proportion long acting": 65746,
      "medicaid beneficiaries study": 44326,
      "beneficiaries study period": 13611,
      "study period use": 78399,
      "cost long acting": 20880,
      "opioid misuse opioid": 51945,
      "present study examined": 64659,
      "study examined effects": 78198,
      "oxycodone opioid receptor": 55571,
      "opioid receptor mor": 52261,
      "receptor mor agonist": 68509,
      "injections oxycodone mg": 38978,
      "oxycodone mg kg": 55421,
      "mg kg increased": 45982,
      "kg increased locomotor": 40738,
      "increased locomotor activity": 37943,
      "significantly increased oxycodone": 75757,
      "inhibitory effects oxycodone": 38822,
      "inhibitory postsynaptic currents": 38824,
      "oxycodone background purpose": 54744,
      "results clinical studies": 71624,
      "clinical studies investigating": 16912,
      "methods healthy male": 45345,
      "healthy male volunteers": 34828,
      "included randomized double": 37538,
      "randomized double blind": 67096,
      "placebo controlled cross": 61678,
      "controlled cross study": 20475,
      "study received tapentadol": 78455,
      "tapentadol 50 mg": 80380,
      "mg extended release": 45887,
      "release oxycodone 10": 69920,
      "oxycodone 10 mg": 54496,
      "10 mg extended": 814,
      "placebo twice daily": 61850,
      "daily 14 days": 21689,
      "resting state functional": 71444,
      "functional magnetic resonance": 32702,
      "magnetic resonance imaging": 42802,
      "results compared placebo": 71639,
      "compared placebo tapentadol": 18272,
      "increased functional connectivity": 37923,
      "005 conclusions study": 264,
      "conclusions study shown": 19226,
      "treatments compared placebo": 82903,
      "different mechanism action": 24885,
      "larger sample sizes": 41183,
      "introduction opioid prescribing": 39941,
      "opioid prescribing rates": 52124,
      "short term opioid": 75195,
      "opioid prescribing limited": 52107,
      "objective aim study": 50367,
      "aim study assess": 9404,
      "study assess impact": 77966,
      "discharge prescriptions written": 25166,
      "tablets study period": 80220,
      "interrupted time series": 39538,
      "time series design": 81375,
      "results 27 month": 71560,
      "27 month period": 3500,
      "50 95 ci": 4825,
      "95 ci 49": 6305,
      "95 ci 10": 6238,
      "ci 10 001": 16385,
      "95 ci 11": 6240,
      "ci 11 001": 16390,
      "opioid prescribing background": 52086,
      "background opioid analgesics": 13105,
      "opioid analgesics used": 51534,
      "analgesics used treat": 10515,
      "used treat pain": 85170,
      "induced respiratory depression": 38454,
      "respiratory depression methods": 71278,
      "methods conducted randomized": 45281,
      "conducted randomized placebo": 19396,
      "randomized placebo controlled": 67149,
      "placebo controlled double": 61685,
      "controlled double blind": 20485,
      "double blind crossover": 26348,
      "blind crossover study": 13931,
      "males subjects received": 43084,
      "subjects received treatments": 78736,
      "oxycodone 30 mg": 54552,
      "washout period subjects": 86747,
      "60 120 180": 5221,
      "120 180 minutes": 1397,
      "period mean difference": 60745,
      "mean difference 95": 43757,
      "difference 95 ci": 24583,
      "time points 30": 81334,
      "30 mg oxycodone": 3765,
      "hours single dose": 35853,
      "objective prescription opioid": 50468,
      "significant public health": 75608,
      "public health concern": 66377,
      "address prescription drug": 7932,
      "primary care providers": 64994,
      "schedule ii controlled": 73616,
      "outpatient setting methods": 54142,
      "number prescriptions schedule": 50242,
      "average number prescriptions": 12908,
      "total number prescriptions": 81856,
      "provider opioid prescribing": 66177,
      "opioid prescribing habits": 52102,
      "addiction related behaviors": 7760,
      "protein coupled receptors": 65928,
      "including dopamine receptor": 37611,
      "mu opioid receptor": 48122,
      "development morphine tolerance": 24235,
      "opioid analgesics fentanyl": 51497,
      "treatment severe pain": 82840,
      "severe pain conditions": 74974,
      "rewarding effects oxycodone": 72441,
      "model neuropathic pain": 47060,
      "affect analgesic efficacy": 8895,
      "analgesic efficacy oxycodone": 10242,
      "acute pain chronic": 7664,
      "neuropathic pain models": 49247,
      "data provide new": 22073,
      "provide new information": 66079,
      "terminal cancer patients": 80685,
      "opioid na\u00efve patients": 51984,
      "na\u00efve patients study": 48846,
      "patients study aimed": 60004,
      "study aimed determine": 77925,
      "aimed determine efficacy": 9444,
      "determine efficacy safety": 24010,
      "opioid na\u00efve cancer": 51977,
      "na\u00efve cancer patients": 48828,
      "methods eligible patients": 45332,
      "patients opioid na\u00efve": 59586,
      "medical records results": 44396,
      "results study included": 71981,
      "cancer patients performance": 14886,
      "patients performance status": 59643,
      "days adverse events": 22486,
      "respiratory depression somnolence": 71286,
      "treatment option management": 82709,
      "controlled release formulations": 20544,
      "non medical use": 49631,
      "controlled release tablet": 20572,
      "tampering methods used": 80353,
      "non medical users": 49637,
      "concurrent use opioids": 19271,
      "increased risk respiratory": 38021,
      "risk respiratory depression": 72656,
      "respiratory depression death": 71277,
      "different drug classes": 24864,
      "oxycodone clinically relevant": 54787,
      "oxycodone significantly increased": 55913,
      "increased oxycodone exposure": 37972,
      "drug drug interaction": 26601,
      "drug interaction studies": 26663,
      "prescription opioids australia": 64327,
      "primary outcome proportion": 65088,
      "emergency departments eds": 28688,
      "given patients required": 33187,
      "patients required opioids": 59907,
      "proportion patients receiving": 65770,
      "patients receiving oxycodone": 59854,
      "001 conclusions implementation": 122,
      "quality improvement projects": 66711,
      "long term opioid": 42339,
      "term opioid use": 80650,
      "opioid use known": 52529,
      "pharmaceutical benefits scheme": 61017,
      "does paper add": 25686,
      "paper add paper": 58074,
      "pain management opioid": 57089,
      "paper provides practical": 58084,
      "pharmacokinetic pharmacodynamic relationships": 61138,
      "gas chromatographic mass": 32838,
      "chromatographic mass spectrometric": 16147,
      "36 48 hours": 4120,
      "48 hours following": 4712,
      "single 20 mg": 76044,
      "20 mg 40": 2333,
      "mg 40 mg": 45749,
      "plasma oxycodone oxymorphone": 61950,
      "duration pain control": 27176,
      "human abuse potential": 35938,
      "abuse potential pharmacokinetics": 6826,
      "pharmacokinetics pk oxycodone": 61187,
      "oxycodone deterx xtampza": 54956,
      "deterx xtampza er": 24135,
      "xtampza er intact": 87414,
      "design randomized double": 23773,
      "dummy active placebo": 27128,
      "active placebo controlled": 7530,
      "placebo controlled single": 61699,
      "controlled single dose": 20580,
      "single dose period": 76087,
      "study setting clinical": 78487,
      "setting clinical research": 74774,
      "adult nondependent recreational": 8500,
      "nondependent recreational opioid": 49730,
      "crushed immediate release": 21333,
      "release ir oxycodone": 69879,
      "ir oxycodone solution": 40251,
      "intact oxycodone deterx": 39174,
      "chewed oxycodone deterx": 15980,
      "crushed ir oxycodone": 21340,
      "oxycodone fasted placebo": 55068,
      "main outcome measures": 42839,
      "100 point visual": 1018,
      "point visual analog": 62114,
      "visual analog scales": 86318,
      "drug liking primary": 26687,
      "pharmacodynamic pd analysis": 61074,
      "subjects completed study": 78689,
      "maximum effect max": 43591,
      "drug liking drug": 26679,
      "ls mean difference": 42746,
      "conclusions study showed": 19225,
      "fasted fed conditions": 31208,
      "statistically significantly lower": 77237,
      "significantly lower abuse": 75775,
      "lower abuse potential": 42574,
      "abuse potential oral": 6824,
      "compared ir oxycodone": 18193,
      "opioid epidemic remains": 51779,
      "pressing public health": 64733,
      "health crisis united": 34703,
      "opioid involved overdose": 51880,
      "opioid receptors study": 52285,
      "male swiss webster": 43062,
      "swiss webster mice": 79816,
      "fentanyl oxycodone results": 31555,
      "dose dependently reduced": 25880,
      "potent opioid receptor": 63111,
      "contribution oxycodone analgesia": 20250,
      "brain barrier permeability": 14320,
      "orally administered oxycodone": 53692,
      "tail flick test": 80247,
      "mechanism based inhibitor": 44128,
      "increased brain oxycodone": 37889,
      "brain oxycodone levels": 14354,
      "fold brain plasma": 31985,
      "brain cyp2d activity": 14332,
      "cerebrospinal fluid csf": 15645,
      "intravenous iv oxycodone": 39847,
      "methods study conducted": 45588,
      "epi group 18": 29123,
      "model built using": 47033,
      "background purpose oxycodone": 13185,
      "opioid overdose deaths": 52012,
      "overdose deaths year": 54285,
      "respiratory depression studied": 71287,
      "reverses oxycodone induced": 72247,
      "mg kg day": 45965,
      "kg day oxycodone": 40711,
      "day oxycodone days": 22353,
      "mg kg morphine": 45999,
      "kg morphine 10": 40764,
      "morphine 10 mg": 47532,
      "10 mg kg": 822,
      "tolerance oxycodone cross": 81597,
      "oxycodone cross tolerance": 54915,
      "cross tolerance morphine": 21279,
      "20 mg kg": 2342,
      "day oxycodone treatment": 22355,
      "significant respiratory depression": 75629,
      "mice treated oxycodone": 46326,
      "oxycodone 120 mg": 54514,
      "data suggest oxycodone": 22131,
      "suggest oxycodone induced": 79006,
      "oxycodone widely prescribed": 56095,
      "prescribed opioid analgesic": 63907,
      "current study examined": 21478,
      "examined oxycodone effects": 30398,
      "state functional connectivity": 77044,
      "functional connectivity dorsal": 32694,
      "double blind placebo": 26365,
      "blind placebo controlled": 13952,
      "placebo controlled dose": 61684,
      "placebo 10 mg": 61614,
      "10 mg 20": 792,
      "mg 20 mg": 45726,
      "20 mg oxycodone": 2347,
      "reduced functional coupling": 68930,
      "background purpose study": 13186,
      "study sought determine": 78509,
      "effects experimental approach": 27922,
      "conditioned place preference": 19298,
      "place preference paradigm": 61604,
      "saline oxycodone mg": 73266,
      "mg kg combination": 45960,
      "mg kg dose": 45970,
      "hot plate assay": 35682,
      "conclusion findings suggest": 18906,
      "useful pain management": 85210,
      "common clinical problem": 17742,
      "loss analgesic efficacy": 42431,
      "providing effective analgesia": 66259,
      "effective analgesia opioid": 27592,
      "opioid dependent individuals": 51705,
      "oxycodone induced analgesia": 55260,
      "induced analgesia oxycodone": 38376,
      "30 mg orally": 3764,
      "cold pressor test": 17426,
      "dose oxycodone 30": 25987,
      "30 60 mg": 3700,
      "opioid agonist effects": 51424,
      "analgesic response oxycodone": 10332,
      "compared placebo significantly": 18271,
      "abuse liability measures": 6752,
      "analgesia adverse effects": 9907,
      "adverse effects respiratory": 8695,
      "effects respiratory depression": 28142,
      "respiratory depression abuse": 71267,
      "important cause acute": 36997,
      "oxycodone widely used": 56096,
      "widely used treat": 87075,
      "explore mechanism oxycodone": 30726,
      "brain microvascular endothelial": 14350,
      "cells dose dependent": 15495,
      "dose dependent manner": 25873,
      "line pharmacological treatment": 41994,
      "demonstrate non inferiority": 23321,
      "cancer patients methods": 14878,
      "patients methods conducted": 59499,
      "open label parallel": 51170,
      "label parallel group": 40983,
      "parallel group randomized": 58137,
      "randomized control trial": 67057,
      "single dose oral": 76082,
      "oral immediate release": 53548,
      "release oxycodone morphine": 69952,
      "intensity numeric rating": 39276,
      "numeric rating scale": 50296,
      "rating scale 10": 67652,
      "adverse events medication": 8770,
      "points 95 confidence": 62124,
      "confidence interval 11": 19443,
      "min morphine group": 46538,
      "patients morphine group": 59530,
      "significant adverse events": 75425,
      "adverse events conclusions": 8744,
      "clinical trial registration": 16932,
      "trial registration umin": 83078,
      "formulation physical chemical": 32361,
      "different routes administration": 24920,
      "double blind parallel": 26361,
      "oxycodone 15 mg": 54520,
      "15 mg mg": 1761,
      "immediate release morphine": 36724,
      "14 inpatient outpatient": 1603,
      "palliative care services": 58046,
      "medical research council": 44400,
      "primary end point": 65015,
      "end point proportion": 28804,
      "100 mm visual": 1000,
      "visual analogue scale": 86323,
      "secondary end points": 74220,
      "end points average": 28808,
      "quality life function": 66724,
      "difference groups primary": 24619,
      "groups primary outcome": 34279,
      "opioid class effect": 51580,
      "used pain management": 85063,
      "pain management studies": 57123,
      "enrolled randomized double": 29016,
      "randomized double blinded": 67111,
      "blinded parallel group": 14004,
      "parallel group study": 58139,
      "administered single dose": 8182,
      "single dose mg": 76081,
      "dose mg kg": 25959,
      "analysis oxycodone major": 10723,
      "oxycodone major metabolites": 55358,
      "concentration max time": 18702,
      "time peak concentration": 81318,
      "analgesic efficacy measured": 10237,
      "postoperative hours results": 62779,
      "oxycodone cmax auc": 54792,
      "lower epi group": 42612,
      "unexpected adverse events": 83718,
      "events reported conclusions": 30109,
      "better analgesic efficacy": 13704,
      "trial registration eudract": 83074,
      "managing acute postoperative": 43282,
      "patient controlled intravenous": 58596,
      "controlled intravenous analgesia": 20501,
      "intravenous analgesia pcia": 39817,
      "clinical practice study": 16868,
      "study aimed compare": 77923,
      "pubmed embase cochrane": 66448,
      "embase cochrane central": 28642,
      "cochrane central register": 17167,
      "central register controlled": 15612,
      "register controlled trials": 69371,
      "national knowledge infrastructure": 48698,
      "oxycodone sufentanil pcia": 55958,
      "ramsay sedation scale": 66989,
      "included meta analysis": 37485,
      "compared sufentanil oxycodone": 18320,
      "oxycodone showed lower": 55901,
      "numerical rating scale": 50311,
      "rating scale scores": 67677,
      "mean difference md": 43761,
      "22 95 ci": 3029,
      "95 ci 58": 6314,
      "77 95 ci": 5758,
      "95 ci 35": 6283,
      "46 95 ci": 4626,
      "degree patients satisfaction": 23178,
      "13 95 ci": 1477,
      "95 ci 88": 6345,
      "55 95 ci": 5070,
      "95 ci 14": 6250,
      "fewer adverse effects": 31630,
      "adverse effects recommended": 8689,
      "quality improvement project": 66710,
      "time series analysis": 81372,
      "immediate release tablet": 36738,
      "95 ci 001": 6221,
      "average number oxycodone": 12905,
      "number oxycodone tablets": 50213,
      "95 ci 39": 6288,
      "patients end stage": 59246,
      "collected 24 hours": 17446,
      "05 mg kg": 526,
      "mg kg oxycodone": 46008,
      "kg oxycodone hydrochloride": 40779,
      "concentrations oxycodone metabolites": 18791,
      "oxycodone metabolites noroxycodone": 55389,
      "metabolites noroxycodone oxymorphone": 44975,
      "noroxycodone oxymorphone measured": 49938,
      "elimination half life": 28613,
      "half life oxycodone": 34517,
      "24 hours patients": 3222,
      "abuse deterrent oxycodone": 6701,
      "oxycodone hydrochloride hcl": 55185,
      "hydrochloride hcl extended": 36024,
      "hcl extended release": 34638,
      "release er tablets": 69852,
      "resulted significant loss": 71518,
      "significant loss oxycodone": 75574,
      "oxycodone hcl er": 55151,
      "hcl er tablets": 34636,
      "particle size distribution": 58396,
      "severe pain treated": 75004,
      "serotonin norepinephrine reuptake": 74679,
      "pain relieving effect": 57607,
      "randomized cross study": 67089,
      "central nervous effects": 15599,
      "prevalence prescription opioid": 64807,
      "opioid abuse increased": 51370,
      "recent years united": 68437,
      "years united states": 87685,
      "patients seeking treatment": 59950,
      "treatment opioid dependence": 82702,
      "samples analyzed using": 73330,
      "enzyme multiplied immunoassay": 29107,
      "300 ng ml": 3820,
      "100 ng ml": 1005,
      "ng ml oxycodone": 49450,
      "likely report prescription": 41837,
      "report prescription opioid": 70474,
      "positive urine samples": 62507,
      "widely used particularly": 87074,
      "effect oxycodone developing": 27517,
      "oxycodone developing brain": 54960,
      "exposure long term": 30776,
      "high dose oxycodone": 35089,
      "10 \u03bcg ml": 965,
      "significant difference observed": 75479,
      "ml \u03bcg ml": 46921,
      "indicated short term": 38249,
      "lack robust evidence": 41059,
      "background objectives oxycodone": 13099,
      "commonly used opioid": 17887,
      "opioid treatment moderate": 52447,
      "surgery additionally patients": 79314,
      "oxycodone lower pain": 55345,
      "lower pain scores": 42670,
      "pain scores needed": 57742,
      "adverse effects compared": 8647,
      "intravenous administration oxycodone": 39814,
      "use methods used": 84485,
      "cell culture models": 15477,
      "human neuroblastoma cells": 35966,
      "results morphine oxycodone": 71787,
      "transmission electron microscopy": 82226,
      "conclusions based results": 19037,
      "important opioid antagonists": 37020,
      "opioid abuse continues": 51365,
      "abuse continues public": 6669,
      "continues public health": 20150,
      "non oral abuse": 49663,
      "double blind double": 26354,
      "blind double dummy": 13936,
      "double dummy active": 26404,
      "placebo controlled way": 61712,
      "controlled way crossover": 20652,
      "abuse potential study": 6833,
      "end points included": 28809,
      "drug liking emax": 26681,
      "mm visual analog": 46940,
      "visual analog scale": 86306,
      "analog scale primary": 10530,
      "drug overall drug": 26729,
      "overall drug liking": 54196,
      "liking drug high": 41857,
      "drug high good": 26644,
      "results subjects completed": 71990,
      "significant reductions observed": 75621,
      "drug liking good": 26682,
      "liking good effects": 41862,
      "peak oxycodone plasma": 60313,
      "oxycodone plasma concentrations": 55694,
      "intranasal route objective": 39759,
      "objective objective study": 50448,
      "objective study evaluate": 50509,
      "study evaluate pharmacokinetics": 78173,
      "placebo controlled trial": 61707,
      "drug discrimination double": 26587,
      "discrimination double blind": 25276,
      "study interventions participants": 78265,
      "administered different doses": 8120,
      "different doses formulations": 24861,
      "oxycodone 40 mg": 54571,
      "mg immediate release": 45918,
      "ir 40 mg": 40207,
      "40 mg controlled": 4345,
      "mg controlled release": 45836,
      "ratings drug liking": 67695,
      "drug liking high": 26684,
      "pharmacokinetic parameters determined": 61125,
      "12 hour dosing": 1288,
      "hour dosing interval": 35697,
      "drug effects questionnaire": 26615,
      "reports drug liking": 70725,
      "adverse events consistent": 8745,
      "events consistent opioid": 30032,
      "comparable ir oxycodone": 17960,
      "ir oxycodone rate": 40250,
      "drug delivery central": 26577,
      "delivery central nervous": 23216,
      "drug taking behavior": 26800,
      "40 mg oxycodone": 4352,
      "mg oxycodone administered": 46108,
      "oxycodone administered intravenously": 54686,
      "15 30 60": 1689,
      "30 60 90": 3697,
      "60 90 minutes": 5243,
      "liking good effect": 41861,
      "good effect high": 33308,
      "self administration results": 74477,
      "plasma levels oxycodone": 61938,
      "extended release opioid": 30886,
      "opioid medications commonly": 51913,
      "medications commonly prescribed": 44605,
      "pain present results": 57417,
      "oxycodone naloxone controlled": 55497,
      "naloxone controlled release": 48442,
      "repatriation pharmaceutical benefits": 70390,
      "department veterans affairs": 23446,
      "veterans affairs dva": 86176,
      "65 years older": 5428,
      "oxycodone cr tablets": 54909,
      "performed retrospective cohort": 60627,
      "retrospective cohort study": 72125,
      "study examine changes": 78194,
      "rate oxycodone cr": 67496,
      "increased immediately 17": 37930,
      "buprenorphine fentanyl morphine": 14546,
      "mg oxycodone cr": 46109,
      "oxycodone 90 days": 54610,
      "opioid 90 days": 51361,
      "90 days preceding": 6100,
      "findings highlight need": 31787,
      "opioid treatment patients": 52450,
      "treatment patients cancer": 82747,
      "present study conducted": 64647,
      "study conducted determine": 78025,
      "tail flick hot": 80243,
      "flick hot plate": 31917,
      "determined male swiss": 24073,
      "receptor antagonist used": 68476,
      "oxycodone produced significant": 55767,
      "produced significant antinociceptive": 65405,
      "agonists effective treating": 9326,
      "objective study investigate": 50519,
      "methods randomized placebo": 45516,
      "crossover study healthy": 21305,
      "study healthy male": 78224,
      "male volunteers administered": 43065,
      "cr665 36 mg": 21118,
      "36 mg kg": 4135,
      "mg kg intravenous": 45989,
      "kg intravenous oxycodone": 40748,
      "pain tolerance thresholds": 57924,
      "plasma drug concentration": 61928,
      "data using nonmem": 22155,
      "population pharmacokinetic pharmacodynamic": 62373,
      "pharmacokinetic pharmacodynamic models": 61133,
      "compartment model oxycodone": 18397,
      "model oxycodone kinetics": 47069,
      "oxycodone kinetics best": 55326,
      "kinetics best described": 40843,
      "best described compartment": 13686,
      "described compartment model": 23654,
      "concentration analgesia delay": 18676,
      "ml ng ml": 46881,
      "ng ml plasma": 49452,
      "tapentadol immediate release": 80420,
      "moderate severe acute": 47165,
      "severe acute pain": 74903,
      "acute pain clinical": 7665,
      "clinical trials tapentadol": 16964,
      "trials tapentadol ir": 83205,
      "improved tolerability compared": 37136,
      "tolerability compared oxycodone": 81523,
      "compared oxycodone ir": 18241,
      "doses providing comparable": 26257,
      "providing comparable analgesia": 66254,
      "oxycodone ir providing": 55314,
      "methods markov model": 45377,
      "clinical economic outcomes": 16794,
      "tapentadol ir 100": 80426,
      "ir 100 mg": 40197,
      "mg compared oxycodone": 45827,
      "ir 15 mg": 40199,
      "mg treatment acute": 46248,
      "acute postsurgical pain": 7694,
      "tapentadol ir 50": 80428,
      "ir 50 mg": 40211,
      "50 mg compared": 4852,
      "oxycodone ir 10": 55305,
      "ir 10 mg": 40193,
      "10 mg treatment": 852,
      "occurrence opioid related": 50862,
      "opioid related adverse": 52299,
      "related adverse events": 69553,
      "adverse events aes": 8726,
      "number quality adjusted": 50246,
      "quality adjusted life": 66674,
      "model parameters results": 47072,
      "higher tapentadol ir": 35331,
      "tapentadol ir oxycodone": 80432,
      "ir oxycodone ir": 40248,
      "23 vs 57": 3117,
      "medical costs associated": 44355,
      "tapentadol ir associated": 80431,
      "improvement pain intensity": 37156,
      "pain intensity opioid": 56922,
      "pain 73 vs": 56398,
      "doses tapentadol ir": 26286,
      "lower treatment costs": 42719,
      "incremental cost effectiveness": 38144,
      "cost effectiveness ratios": 20877,
      "suggest doses providing": 78990,
      "comparable analgesia tapentadol": 17947,
      "analgesia tapentadol ir": 10120,
      "cost effective alternative": 20866,
      "oxycodone ir treatment": 55315,
      "methods retrospective cross": 45541,
      "retrospective cross sectional": 72139,
      "use opioid na\u00efve": 84548,
      "patients aged 13": 58966,
      "opioids non cancer": 53094,
      "non cancer pain": 49578,
      "chronic opioid use": 16242,
      "opioid use following": 52514,
      "ir oxycodone given": 40246,
      "er vs oxycodone": 29482,
      "vs oxycodone cr": 86668,
      "oxycodone cr treatment": 54911,
      "treatment chronic non": 82483,
      "cancer pain cncp": 14822,
      "pain cncp methods": 56556,
      "monte carlo simulation": 47380,
      "patients having moderate": 59350,
      "having moderate severe": 34610,
      "outcomes associated use": 54013,
      "treatment emergent adverse": 82572,
      "emergent adverse event": 28700,
      "adverse event teae": 8718,
      "initial oxycodone cr": 38862,
      "proportion patients achieving": 65762,
      "patients achieving adequate": 58930,
      "achieving adequate pain": 7333,
      "adequate pain relief": 7966,
      "achieve adequate pain": 7291,
      "outcomes pain relief": 54069,
      "efficacy safety long": 28364,
      "safety long term": 73163,
      "long term therapy": 42353,
      "design open study": 23735,
      "setting patients consecutive": 74808,
      "patients consecutive patients": 59133,
      "according world health": 7067,
      "world health organization": 87308,
      "health organization guidelines": 34743,
      "twice daily mean": 83297,
      "evaluate efficacy safety": 29794,
      "efficacy safety opioid": 28367,
      "safety opioid therapy": 73176,
      "analog scale vas": 10539,
      "scale vas pain": 73575,
      "pittsburgh sleep quality": 61568,
      "sleep quality index": 76233,
      "quality index psqi": 66715,
      "better quality sleep": 13736,
      "daily dosage oxycodone": 21720,
      "dosage oxycodone required": 25757,
      "conclusion oxycodone showed": 18949,
      "improved patient compliance": 37121,
      "nondependent opioid users": 49728,
      "subject double blind": 78627,
      "placebo controlled inpatient": 61690,
      "study participants received": 78361,
      "following oral doses": 32169,
      "80 mg day": 5850,
      "24 hour urine": 3209,
      "urine samples collected": 84084,
      "samples collected study": 73337,
      "10 hours oxycodone": 772,
      "oxycodone er immediate": 55038,
      "er immediate release": 29424,
      "compared placebo treatment": 18273,
      "objective evaluate abuse": 50407,
      "evaluate abuse potential": 29766,
      "fed fasted conditions": 31319,
      "phase randomized double": 61315,
      "dummy placebo active": 27133,
      "placebo active controlled": 61652,
      "active controlled way": 7504,
      "crossover study setting": 21308,
      "study setting single": 78490,
      "men women aged": 44805,
      "women aged 18": 87201,
      "er 40 mg": 29392,
      "crushed oxycodone ir": 21344,
      "oxycodone ir 40": 55307,
      "outcome measures primary": 53949,
      "measures primary endpoint": 44088,
      "primary endpoint drug": 65023,
      "endpoint drug liking": 28887,
      "secondary endpoints included": 74227,
      "abuse potential compared": 6815,
      "potential compared oxycodone": 63149,
      "parameters primary endpoint": 58171,
      "treatment group showed": 82599,
      "similar results conclusions": 75992,
      "known abuse potential": 40898,
      "oxycodone ir crushed": 55310,
      "terminally ill cancer": 80689,
      "adverse effects observed": 8676,
      "subcutaneous administration oxycodone": 78600,
      "pellets extended release": 60378,
      "surrounding sequestered naltrexone": 79677,
      "intended deter abuse": 39205,
      "opioid users methods": 52624,
      "methods randomized double": 45510,
      "mg oxycodone hydrochloride": 46120,
      "20 mg plus": 2350,
      "20 mg mg": 2343,
      "primary end points": 65017,
      "results thirty participants": 72011,
      "participants randomized treatment": 58348,
      "differences max drug": 24756,
      "max drug liking": 43551,
      "resulted significantly lower": 71524,
      "significantly lower scores": 75809,
      "experienced adverse events": 30600,
      "alo 02 12": 9654,
      "abuse potential assessed": 6813,
      "large inter individual": 41133,
      "inter individual variability": 39354,
      "prevalence adverse events": 64771,
      "adverse events associated": 8730,
      "events associated use": 30015,
      "present study used": 64667,
      "quantitative sensory testing": 66810,
      "sensory testing qst": 74577,
      "predict analgesic effects": 63548,
      "analgesic effects oral": 10219,
      "effects oral oxycodone": 28051,
      "oxycodone compared placebo": 54823,
      "pain intensity tolerance": 56954,
      "pressor test cpt": 64736,
      "heat cold pain": 34880,
      "temporal summation ts": 80589,
      "results showed oxycodone": 71948,
      "tolerance cold pain": 81577,
      "pain significantly reduced": 57844,
      "significantly reduced pain": 75848,
      "reduced pain intensity": 68967,
      "reduction pain intensity": 69086,
      "pain intensity response": 56939,
      "treatment background effective": 82456,
      "effective treatment acute": 27714,
      "treatment acute pain": 82429,
      "double blind active": 26337,
      "crossover study design": 21302,
      "study design population": 78077,
      "population healthy volunteers": 62337,
      "healthy volunteers methods": 34854,
      "volunteers randomized receive": 86431,
      "randomized receive 20": 67166,
      "receive 20 mg": 68043,
      "electrical pain threshold": 28509,
      "median 95 ci": 44195,
      "procedure purpose study": 65282,
      "purpose study investigate": 66585,
      "study investigate analgesic": 78269,
      "single intravenous injection": 76114,
      "intravenous injection oxycodone": 39837,
      "patients methods total": 59511,
      "american society anesthesiologists": 9802,
      "society anesthesiologists class": 76378,
      "ultrasound guided percutaneous": 83434,
      "randomized controlled trial": 67069,
      "controlled trial patients": 20614,
      "trial patients randomized": 83048,
      "patients randomized receive": 59739,
      "randomized receive single": 67178,
      "group continuous infusion": 33712,
      "results vas score": 72051,
      "score group significantly": 73749,
      "group significantly lower": 34018,
      "significantly lower group": 75785,
      "lower group hours": 42626,
      "patients group required": 59341,
      "patient satisfaction score": 58774,
      "satisfaction score significantly": 73434,
      "score significantly higher": 73792,
      "significantly higher group": 75727,
      "higher group group": 35249,
      "adverse effects objective": 8675,
      "objective study develop": 50507,
      "opioid prescribing behavior": 52087,
      "extended release long": 30882,
      "long acting er": 42285,
      "acting er la": 7382,
      "er la opioid": 29432,
      "risk evaluation mitigation": 72556,
      "evaluation mitigation strategies": 29957,
      "mitigation strategies rems": 46770,
      "release oxycodone ero": 69936,
      "la opioid analgesics": 40964,
      "non opioid tolerant": 49656,
      "opioid tolerant patients": 52432,
      "mg oxycodone equivalents": 46114,
      "background opioids commonly": 13119,
      "opioids commonly used": 52803,
      "commonly used manage": 17882,
      "used manage chronic": 84994,
      "manage chronic pain": 43119,
      "opioids effective reducing": 52874,
      "effective reducing pain": 27687,
      "associated opioid induced": 12356,
      "opioid induced effects": 51860,
      "lower incidence gastrointestinal": 42630,
      "incidence gastrointestinal adverse": 37277,
      "gastrointestinal adverse events": 32867,
      "oxycodone controlled release": 54882,
      "equianalgesic doses objective": 29261,
      "schedule ii long": 73618,
      "ii long acting": 36563,
      "health care costs": 34676,
      "care costs patients": 15017,
      "long acting formulations": 42289,
      "formulations tapentadol oxycodone": 32411,
      "tapentadol oxycodone morphine": 80453,
      "oxycodone morphine hydromorphone": 55475,
      "morphine hydromorphone oxymorphone": 47724,
      "way sensitivity analysis": 86780,
      "tapentadol er versus": 80407,
      "er versus oxycodone": 29479,
      "versus oxycodone cr": 86143,
      "conclusions results suggest": 19206,
      "receive oxycodone mg": 68068,
      "significant difference 05": 75468,
      "evaluate analgesic efficacy": 29771,
      "single dose epidural": 76080,
      "aged 23 71": 9178,
      "23 71 years": 3084,
      "mg kg iv": 45993,
      "randomised double blind": 67021,
      "blind active control": 13917,
      "data published studies": 22079,
      "studies primary outcome": 77817,
      "patients iv group": 59428,
      "median interquartile range": 44229,
      "plasma concentrations similar": 61922,
      "year old female": 87457,
      "performed gas chromatography": 60592,
      "ng ml addition": 49440,
      "case report demonstrates": 15189,
      "report demonstrates unusual": 70452,
      "single 10 mg": 76042,
      "10 mg dose": 812,
      "dose immediate release": 25927,
      "older 65 years": 51030,
      "participants completed separate": 58289,
      "medication condition placebo": 44475,
      "10 mg oxycodone": 833,
      "mg oxycodone plasma": 46135,
      "plasma oxycodone concentration": 61946,
      "90 120 minutes": 6075,
      "suffering chronic pain": 78966,
      "middle aged adults": 46405,
      "opioids older adults": 53116,
      "potential pharmacokinetics pharmacodynamics": 63207,
      "pharmacokinetics pharmacodynamics safety": 61185,
      "safety intranasally administered": 73160,
      "crushed reformulated oxycontin": 21347,
      "controlled release tablets": 20573,
      "release tablets orf": 70013,
      "placebo randomized double": 61808,
      "positive placebo controlled": 62477,
      "placebo controlled crossover": 61680,
      "controlled crossover study": 20479,
      "crossover study enrolled": 21303,
      "study enrolled healthy": 78153,
      "enrolled healthy adult": 29001,
      "dependent recreational opioid": 23532,
      "analog scales vas": 10543,
      "adverse events vital": 8824,
      "events vital signs": 30134,
      "vital signs laboratory": 86344,
      "signs laboratory tests": 75876,
      "assessed 24 hours": 11981,
      "24 hours postdose": 3225,
      "significantly lower 05": 75774,
      "orf versus oc": 53742,
      "intranasally administered orf": 39764,
      "peak plasma concentrations": 60320,
      "abuse potential studies": 6832,
      "post marketing studies": 62581,
      "misuse abuse diversion": 46706,
      "abuse diversion purpose": 6713,
      "purpose study document": 66578,
      "use hydrocodone oxycodone": 84408,
      "retrospective review medical": 72160,
      "review medical records": 72321,
      "medical records patients": 44395,
      "literature review conducted": 42128,
      "drug abuse warning": 26509,
      "abuse warning network": 6910,
      "prescription opiate medications": 64271,
      "moderate severe cancer": 47171,
      "severe cancer pain": 74919,
      "cancer pain oxycodone": 14842,
      "pain oxycodone commonly": 57311,
      "oxycodone commonly used": 54812,
      "commonly used opioids": 17889,
      "cross sectional study": 21264,
      "study assess relationship": 77968,
      "assess relationship oxycodone": 11960,
      "poor metaboliser pm": 62263,
      "ultra rapid metaboliser": 83423,
      "cancer pain methods": 14834,
      "pain methods patients": 57186,
      "serum concentrations oxycodone": 74695,
      "pain assessed using": 56464,
      "assessed using brief": 12083,
      "using brief pain": 85331,
      "brief pain inventory": 14430,
      "pain inventory bpi": 56975,
      "eortc qlq c30": 29119,
      "c30 used assess": 14646,
      "used assess symptoms": 84853,
      "assess symptoms tiredness": 11967,
      "symptoms tiredness nausea": 79909,
      "cognitive function assessed": 17325,
      "mini mental state": 46564,
      "examination associations examined": 30325,
      "ordinal logistic regressions": 53735,
      "serum concentrations oxymorphone": 74697,
      "concentrations oxymorphone oxycodone": 18801,
      "oxymorphone oxycodone ratios": 56275,
      "pain intensity nausea": 56915,
      "intensity nausea tiredness": 39271,
      "nausea tiredness cognitive": 48786,
      "tiredness cognitive function": 81444,
      "pain control adverse": 56602,
      "patients treated oxycodone": 60069,
      "oxycodone cancer pain": 54765,
      "cancer pain objective": 14839,
      "play important role": 61991,
      "chart review examine": 15928,
      "examine reformulation oxycontin": 30357,
      "tamper resistant properties": 80342,
      "positive urine drug": 62503,
      "urine drug screens": 84074,
      "dependent patients receiving": 23529,
      "patients receiving methadone": 59844,
      "receiving methadone maintenance": 68352,
      "methadone maintenance therapy": 45094,
      "maintenance therapy mmt": 42921,
      "setting study conducted": 74828,
      "male female patients": 43031,
      "study main outcome": 78295,
      "main outcome measure": 42837,
      "results results demonstrated": 71924,
      "statistically significant decreases": 77207,
      "remained relatively stable": 70270,
      "associated statistically significant": 12445,
      "statistically significant reduction": 77228,
      "14 hydroxy methoxy": 1599,
      "hydroxy methoxy 17": 36239,
      "abuse mechanism action": 6772,
      "characterize analgesic effects": 15891,
      "oxycodone mechanism action": 55379,
      "results indicate oxycodone": 71729,
      "oxycodone potent antinociceptive": 55715,
      "potent antinociceptive effects": 63100,
      "hot plate tail": 35684,
      "plate tail flick": 61972,
      "tail flick assays": 80242,
      "acting mu opioid": 7392,
      "served positive reinforcer": 74718,
      "withdrawal signs morphine": 87157,
      "rhesus monkeys results": 72450,
      "abuse liability effects": 6751,
      "mediated mu opioid": 44315,
      "opioid receptors provide": 52284,
      "alo 02 abuse": 9655,
      "02 abuse deterrent": 359,
      "blind placebo active": 13950,
      "alo 02 administered": 9657,
      "healthy nondependent recreational": 34834,
      "opioid users following": 52620,
      "mg mg oxycodone": 46051,
      "ir 30 mg": 40205,
      "measured visual analog": 44009,
      "versus oxycodone ir": 86144,
      "adverse events occurred": 8778,
      "events occurred frequently": 30082,
      "alo 02 placebo": 9659,
      "consistent opioid therapy": 19706,
      "objective evaluate safety": 50428,
      "evaluate safety tolerability": 29845,
      "tolerability controlled release": 81527,
      "release oxycodone treatment": 69984,
      "treatment postoperative pain": 82772,
      "pain head neck": 56820,
      "methods conducted prospective": 45279,
      "conducted prospective observational": 19390,
      "patients moderate severe": 59520,
      "operations patients received": 51239,
      "patients received general": 59780,
      "received general anesthesia": 68154,
      "release oxycodone 20": 69922,
      "oxycodone 20 mg": 54531,
      "20 mg 12": 2332,
      "day 10 mg": 22240,
      "10 mg second": 846,
      "intensity adverse effects": 39226,
      "adverse effects intensity": 8660,
      "intensity postoperative pain": 39294,
      "use rescue analgesia": 84696,
      "analgesia 12 hours": 9893,
      "12 hours administration": 1296,
      "hours administration drug": 35749,
      "oxycodone dose results": 54998,
      "common adverse events": 17732,
      "adverse events nausea": 8775,
      "events nausea vomiting": 30075,
      "nausea vomiting dizziness": 48797,
      "vomiting dizziness pruritus": 86456,
      "constipation urinary retention": 19794,
      "postoperative pain remained": 62914,
      "higher frequency opioid": 35246,
      "opioid dose reduced": 51735,
      "conclusion controlled release": 18881,
      "safe tolerated caused": 73104,
      "post operative pain": 62601,
      "pain objective oxycodone": 57266,
      "oxycodone daily ood": 54923,
      "established oxycodone twice": 29590,
      "oxycodone twice daily": 56035,
      "twice daily otd": 83298,
      "design methods randomized": 23725,
      "double blind multicenter": 26360,
      "non inferiority study": 49615,
      "study conducted patients": 78030,
      "total daily doses": 81795,
      "120 mg day": 1404,
      "results significant difference": 71953,
      "significant difference analgesic": 75469,
      "95 ci difference": 6361,
      "rescue medication effect": 70951,
      "patients experienced treatment": 59284,
      "treatment related aes": 82808,
      "use rescue medication": 84697,
      "did reach statistical": 24484,
      "reach statistical significance": 67931,
      "safety efficacy pain": 73149,
      "quality life patients": 66737,
      "evaluated efficacy safety": 29880,
      "efficacy safety prolonged": 28381,
      "safety prolonged release": 73213,
      "prolonged release oral": 65625,
      "formulation oxycodone hydrochloride": 32352,
      "intensity numerical rating": 39279,
      "rating scale nrs": 67657,
      "low dose oxn": 42479,
      "dose oxn pr": 25984,
      "mg twice daily": 46250,
      "weeks primary efficacy": 86945,
      "primary efficacy measure": 65009,
      "efficacy measure pain": 28293,
      "clinical global impression": 16821,
      "global impression change": 33227,
      "bowel function index": 14276,
      "function index bfi": 32652,
      "using descriptive statistics": 85377,
      "patients completed study": 59115,
      "pain relief observed": 57553,
      "observed bowel function": 50655,
      "bowel function constipation": 14271,
      "function constipation symptoms": 32640,
      "constipation symptoms measured": 19791,
      "low dose oral": 42478,
      "pain symptoms patients": 57895,
      "patients did experience": 59191,
      "study provides evidence": 78437,
      "opioids used treat": 53373,
      "objective investigate efficacy": 50441,
      "investigate efficacy safety": 40010,
      "combination oxycodone oc": 17590,
      "oxycodone oc acetaminophen": 55553,
      "oc acetaminophen apap": 50797,
      "acetaminophen apap analgesic": 7153,
      "apap analgesic immediate": 11349,
      "analgesic immediate release": 10258,
      "immediate release extended": 36714,
      "release extended release": 69854,
      "release er components": 69841,
      "severe pain using": 75005,
      "research design methods": 71000,
      "controlled trial adult": 20607,
      "adult patients included": 8514,
      "patients included study": 59400,
      "study pain intensity": 78356,
      "pain intensity score": 56942,
      "intensity score 10": 39309,
      "10 numerical rating": 880,
      "surgery randomized receive": 79548,
      "measures primary efficacy": 44085,
      "primary efficacy endpoint": 65007,
      "endpoint summed pain": 28905,
      "summed pain intensity": 79116,
      "pain intensity difference": 56897,
      "intensity difference 48": 39245,
      "difference 48 hours": 24580,
      "total pain relief": 81878,
      "pain relief totpar": 57593,
      "time perceptible meaningful": 81321,
      "proportion patients 30": 65760,
      "30 reduction pain": 3793,
      "pain intensity scores": 56944,
      "scores results total": 73979,
      "pain relief significantly": 57581,
      "efficacious generally tolerated": 28201,
      "sustained pain relief": 79781,
      "pain relief 12": 57516,
      "hour dosing period": 35698,
      "oxycodone oral controlled": 55579,
      "double blind trial": 26389,
      "pain model methods": 57202,
      "severe pain following": 74978,
      "received single oral": 68276,
      "single oral doses": 76133,
      "doses controlled release": 26164,
      "morphine 45 mg": 47560,
      "release oxycodone times": 69981,
      "oxycodone times potent": 56000,
      "doses 20 mg": 26130,
      "release oxycodone controlled": 69927,
      "oral morphine oral": 53587,
      "morphine oral oxycodone": 47800,
      "opioid receptor agonists": 52244,
      "healthy human volunteers": 34821,
      "time course plasma": 81231,
      "course plasma concentrations": 21000,
      "demethylation keto reduction": 23262,
      "opioid receptor binding": 52251,
      "cytochrome p450 cyp": 21656,
      "p450 cyp 3a": 56308,
      "demethylation oxycodone noroxycodone": 23265,
      "noroxymorphone major metabolites": 49949,
      "elimination half lives": 28616,
      "significantly lower compared": 75779,
      "parent drug oxycodone": 58195,
      "metabolic pathway oxycodone": 44908,
      "opioid effects oxycodone": 51762,
      "objective chronic pain": 50386,
      "chronic pain leading": 16282,
      "pain leading cause": 57002,
      "leading cause disability": 41303,
      "opioids widely used": 53394,
      "effects main reason": 27977,
      "main reason discontinuation": 42855,
      "meta analysis clinical": 44890,
      "tapentadol er oxycodone": 80404,
      "treatment musculoskeletal pain": 82674,
      "meta analysis selected": 44900,
      "treatment tapentadol er": 82870,
      "treatment cr oxycodone": 82531,
      "discontinuation rate adverse": 25228,
      "rate adverse events": 67443,
      "adverse events gastrointestinal": 8758,
      "effects central nervous": 27845,
      "central nervous cns": 15595,
      "compare cost effectiveness": 18012,
      "occurrence adverse events": 50855,
      "adverse events results": 8805,
      "adverse events secondary": 8812,
      "compared cr oxycodone": 18128,
      "adjusted life years": 8033,
      "lower incidence adverse": 42629,
      "incidence adverse events": 37259,
      "adverse events related": 8800,
      "conclusion tapentadol er": 19011,
      "tapentadol er shown": 80406,
      "oxycodone hydrochloride formulation": 55184,
      "intranasal intravenous abuse": 39752,
      "abuse prescription opioids": 6839,
      "prescription opioids objectives": 64352,
      "objectives primary objective": 50582,
      "primary objective study": 65046,
      "objective study determine": 50505,
      "relative bioavailability oxycodone": 69740,
      "methods open label": 45411,
      "open label single": 51181,
      "label single dose": 40999,
      "single dose randomized": 76091,
      "crossover study conducted": 21300,
      "study conducted healthy": 78027,
      "received following treatments": 68151,
      "washout period days": 86746,
      "mg mg mg": 46050,
      "mg fasted conditions": 45890,
      "high fat high": 35101,
      "fat high calorie": 31228,
      "pharmacologic effects oxycodone": 61196,
      "effects oxycodone dose": 28061,
      "mean sd age": 43857,
      "sd age 32": 74071,
      "32 11 years": 3904,
      "years mean weight": 87614,
      "max auc auc": 43549,
      "concomitant food intake": 19250,
      "emergent adverse events": 28702,
      "consistent known effects": 19701,
      "single dose pharmacokinetics": 76089,
      "systemic exposure oxycodone": 80027,
      "opioid analgesic therapy": 51471,
      "assess clinical efficacy": 11917,
      "clinical efficacy controlled": 16802,
      "efficacy controlled release": 28242,
      "release oxycodone cro": 69930,
      "randomised placebo controlled": 67031,
      "controlled double blinded": 20488,
      "double blinded study": 26398,
      "asa physical status": 11818,
      "physical status iii": 61415,
      "women undergoing breast": 87252,
      "general anaesthesia using": 32957,
      "received premedication oral": 68251,
      "release oxycodone group": 69942,
      "tablet 20 mg": 80088,
      "20 mg cro": 2337,
      "patients access opioid": 58917,
      "opioid rescue medication": 52345,
      "iv patient controlled": 40397,
      "patient controlled analgesia": 58579,
      "controlled analgesia pca": 20458,
      "analgesia pca device": 10055,
      "outcome measures area": 53933,
      "measures area curve": 44045,
      "area curve auc": 11626,
      "24 postoperatively results": 3271,
      "opioid consumption significantly": 51662,
      "consumption significantly lower": 20018,
      "required iv opioid": 70846,
      "vas scores rest": 86027,
      "scores rest significantly": 73975,
      "rest significantly lower": 71432,
      "05 vas scores": 561,
      "cro group 16": 21239,
      "pain scores movement": 57738,
      "observed treatment group": 50724,
      "treatment group patients": 82597,
      "respiratory depression conclusions": 71274,
      "background objective oxycodone": 13094,
      "aim study investigate": 9424,
      "pharmacokinetic pharmacodynamic profiles": 61137,
      "oxycodone human experimental": 55169,
      "human experimental pain": 35953,
      "experimental pain model": 30670,
      "methods healthy subjects": 45350,
      "healthy subjects received": 34847,
      "received oral oxycodone": 68227,
      "oral oxycodone 15": 53617,
      "15 mg placebo": 1765,
      "skin heat muscle": 76202,
      "heat muscle pressure": 34882,
      "perfusion acid capsaicin": 60655,
      "venous blood samples": 86058,
      "obtained quantification oxycodone": 50781,
      "15 30 45": 1687,
      "30 45 60": 3692,
      "60 90 120": 5240,
      "minutes drug administration": 46646,
      "drug administration results": 26527,
      "administration results oxycodone": 8362,
      "oxycodone blood concentrations": 54751,
      "placebo arm study": 61662,
      "pain measures oxycodone": 57144,
      "peripheral analgesic effect": 60859,
      "analgesic effect oxycodone": 10205,
      "animal human studies": 10994,
      "fewer opioid related": 31652,
      "ratio morphine oxycodone": 67778,
      "management acute moderate": 43142,
      "acute moderate severe": 7640,
      "pain design randomized": 56697,
      "dose response study": 26068,
      "following surgery patients": 32204,
      "surgery patients required": 79518,
      "moderate severe intensity": 47181,
      "point likert scale": 62088,
      "scale 11 point": 73486,
      "11 point numerical": 1146,
      "point numerical pain": 62094,
      "numerical pain rating": 50308,
      "pain rating scale": 57468,
      "hour period following": 35709,
      "period following surgery": 60728,
      "following surgery main": 32203,
      "surgery main outcome": 79449,
      "sum pain intensity": 79074,
      "pain intensity differences": 56901,
      "intensity differences baseline": 39252,
      "randomly assigned treatment": 67230,
      "dose morphine oxycodone": 25963,
      "10 mg 12": 789,
      "groups respectively mean": 34301,
      "versus placebo 12": 86149,
      "12 mg group": 1324,
      "associated opioid use": 12363,
      "conclusions 12 mg": 19025,
      "analgesic efficacy tolerability": 10252,
      "opioid analgesic oxycodone": 51463,
      "dose dependently inhibited": 25879,
      "mrna protein expression": 48073,
      "protein expression levels": 65935,
      "levels proinflammatory cytokines": 41599,
      "tumor necrosis factor": 83278,
      "necrosis factor tnf": 48903,
      "results suggest oxycodone": 71995,
      "healthcare resource utilization": 34806,
      "release ir formulations": 69877,
      "oxycodone oxy ir": 55600,
      "methods patients 18": 45425,
      "patients 18 years": 58835,
      "clinformatics data mart": 16738,
      "claims database patients": 16629,
      "propensity score matching": 65695,
      "patient demographics clinical": 58609,
      "demographics clinical characteristics": 23297,
      "follow period patients": 32029,
      "vs 35 days": 86567,
      "index opioid prescription": 38202,
      "demographic clinical characteristics": 23277,
      "illicit opioids heroin": 36646,
      "opioids heroin fentanyl": 52944,
      "physiologically based pharmacokinetic": 61472,
      "based pharmacokinetic pbpk": 13354,
      "pharmacokinetic pbpk modeling": 61130,
      "objective study assess": 50496,
      "study assess ability": 77960,
      "plasma exposure oxycodone": 61935,
      "widely used opioid": 87067,
      "used opioid pain": 85047,
      "opioid pain management": 52035,
      "adults children methods": 8554,
      "oxycodone following intravenous": 55100,
      "following intravenous oral": 32149,
      "intravenous oral administration": 39866,
      "pk parameters calculated": 61580,
      "pbpk model successfully": 60255,
      "following oral administration": 32168,
      "dose adjustment oxycodone": 25823,
      "management acute postoperative": 43145,
      "postoperative pain major": 62883,
      "patients oral oxycodone": 59598,
      "good pain relief": 33320,
      "relief postoperative pain": 70170,
      "postoperative pain relief": 62912,
      "pain relief children": 57526,
      "pain relief comparison": 57531,
      "opioid drug design": 51744,
      "clinical trial setting": 16938,
      "participants patients aged": 58338,
      "year old undergoing": 87467,
      "undergoing elective surgery": 83532,
      "elective surgery general": 28502,
      "surgery general anesthesia": 79406,
      "patients randomly allocated": 59746,
      "postoperative opioid analgesic": 62813,
      "tramadol oxycodone administered": 82090,
      "end surgery mg": 28821,
      "surgery mg kg": 79476,
      "mg kg respectively": 46023,
      "outcomes primary outcome": 54077,
      "adequate postoperative pain": 7970,
      "pain relief defined": 57535,
      "face legs activity": 31017,
      "legs activity consolability": 41391,
      "activity consolability flacc": 7562,
      "consolability flacc score": 19731,
      "flacc score 10": 31894,
      "post anesthesia care": 62558,
      "anesthesia care unit": 10903,
      "care unit pacu": 15089,
      "measured 10 min": 43952,
      "10 min extubation": 859,
      "extubation 10 min": 30995,
      "min discharge pacu": 46519,
      "oxycodone provided similar": 55782,
      "significant differences noted": 75508,
      "analgesic drug consumption": 10188,
      "groups nausea vomiting": 34242,
      "patients oxycodone group": 59614,
      "oxycodone group showed": 55139,
      "adequate postoperative analgesia": 7969,
      "postoperative analgesia achieved": 62699,
      "analgesia achieved intravenous": 9901,
      "patients trial registration": 60078,
      "trial registration study": 83076,
      "registration study registered": 69395,
      "www chictr org": 87390,
      "chictr org cn": 15998,
      "mitragyna speciosa korth": 46779,
      "eliminate opioid use": 28605,
      "compare respiratory effects": 18053,
      "20 40 80": 2291,
      "mg kg oral": 46004,
      "150 mg kg": 1810,
      "kg oral oxycodone": 40772,
      "oral oxycodone hydrochloride": 53629,
      "administration produced significant": 8349,
      "produced significant dose": 65406,
      "significant dose related": 75529,
      "respiratory depressant effects": 71264,
      "mg kg mitragynine": 45998,
      "life threatening effects": 41740,
      "sedative like effects": 74339,
      "opioid receptor agonism": 52235,
      "oxycodone oral solution": 55583,
      "findings study support": 31824,
      "respiratory depression current": 71276,
      "tapentadol mu opioid": 80442,
      "receptor agonist noradrenaline": 68462,
      "agonist noradrenaline reuptake": 9295,
      "noradrenaline reuptake inhibitor": 49876,
      "selective mu opioid": 74433,
      "methods healthy volunteers": 45351,
      "randomized receive oral": 67173,
      "100 150 mg": 983,
      "150 mg oxycodone": 1811,
      "mg oxycodone 20": 46098,
      "20 mg placebo": 2349,
      "crossover double blind": 21289,
      "double blind randomized": 26371,
      "blind randomized design": 13974,
      "main end point": 42829,
      "typical opioid effects": 83388,
      "20 mg significantly": 2351,
      "mg mean difference": 46045,
      "mg 05 conclusions": 45696,
      "produce respiratory depression": 65366,
      "mg 150 mg": 45718,
      "controlled release opioids": 20549,
      "case 35 year": 15154,
      "35 year old": 4098,
      "year old man": 87463,
      "oxycodone hydrochloride oxycontin": 55192,
      "case illustrates practical": 15176,
      "improve patient satisfaction": 37076,
      "double blind design": 26353,
      "oral transmucosal fentanyl": 53679,
      "transmucosal fentanyl citrate": 82232,
      "oral oxycodone mg": 53633,
      "36 year old": 4151,
      "year old male": 87460,
      "old male patient": 51011,
      "oxycodone morphine patients": 55479,
      "patients chronic non": 59072,
      "aim characterize pharmacokinetic": 9377,
      "characterize pharmacokinetic profile": 15901,
      "safety tolerability transdermal": 73236,
      "tolerability transdermal oxycodone": 81561,
      "transdermal oxycodone patch": 82164,
      "oxycodone patch containing": 55647,
      "patch containing tocopheryl": 58487,
      "containing tocopheryl phosphate": 20086,
      "tocopheryl phosphate mixture": 81507,
      "phosphate mixture tpm": 61367,
      "mixture tpm patients": 46815,
      "results oxycodone detected": 71824,
      "maximum plasma concentration": 43605,
      "plasma concentration 41": 61899,
      "34 ng ml": 4028,
      "safety profile consistent": 73206,
      "tpm oxycodone patch": 81964,
      "background recent data": 13192,
      "recent data suggest": 68395,
      "effects abuse liability": 27800,
      "abuse liability opioids": 6753,
      "preclinical studies demonstrated": 63535,
      "opioid receptor selective": 52266,
      "receptor selective agonists": 68525,
      "opioid induced analgesic": 51851,
      "enhance analgesic effects": 28951,
      "analgesic effects opioids": 10218,
      "rewarding effects opioids": 72440,
      "opioid induced analgesia": 51850,
      "purpose present study": 66547,
      "study assess effects": 77962,
      "effects oxycodone human": 28065,
      "subject randomized double": 78635,
      "100 200 mg": 985,
      "21 45 years": 2955,
      "45 years age": 4604,
      "years age non": 87565,
      "non treatment seeking": 49694,
      "new york state": 49393,
      "oxy 40 mg": 54440,
      "attenuated oxy induced": 12590,
      "positive subjective effects": 62494,
      "attenuate abuse liability": 12577,
      "persistent postoperative opioid": 60927,
      "postoperative opioid use": 62825,
      "january 2016 30": 40451,
      "modified release immediate": 47243,
      "release immediate release": 69871,
      "logistic regression models": 42270,
      "90 days discharge": 6096,
      "opioid experienced patients": 51793,
      "immediate release opioids": 36729,
      "associated significantly lower": 12438,
      "significantly lower odds": 75795,
      "oxycodone modified release": 55461,
      "95 ci 81": 6337,
      "patients patients underwent": 59640,
      "tapentadol compared oxycodone": 80392,
      "study objective compare": 78331,
      "objective compare efficacy": 50388,
      "compare efficacy effects": 18022,
      "morphine oxycodone pain": 47848,
      "major abdominal surgery": 42927,
      "surgery design randomized": 79372,
      "double blind study": 26379,
      "blind study setting": 13985,
      "department surgery helsinki": 23443,
      "surgery helsinki university": 79413,
      "helsinki university central": 34921,
      "university central hospital": 83858,
      "central hospital patients": 15588,
      "physical status ii": 61413,
      "patients scheduled elective": 59945,
      "patients received oxycodone": 59808,
      "oxycodone intravenously iv": 55298,
      "groups received morphine": 34286,
      "mg kg followed": 45974,
      "mg kg hr": 45980,
      "oxycodone bolus 15": 54755,
      "15 mg kg": 1757,
      "03 mg kg": 419,
      "induction standardized anesthesia": 38482,
      "group patients given": 33904,
      "measurements main results": 44021,
      "plasma opioid concentrations": 61944,
      "pain rest coughing": 57641,
      "nausea pruritus sedation": 48780,
      "dose ratio morphine": 26036,
      "respiratory depression seen": 71285,
      "oxycodone group groups": 55131,
      "remained normal limits": 70267,
      "normal limits conclusions": 49903,
      "acute post operative": 7683,
      "operative pain analgesic": 51263,
      "methods patients underwent": 45452,
      "fentanyl group group": 31484,
      "group group oxycodone": 33799,
      "group oxycodone group": 33888,
      "oxycodone group group": 55130,
      "group group 30": 33792,
      "group 30 patients": 33594,
      "group patients group": 33905,
      "patients group injected": 59338,
      "fentanyl \u03bcg kg": 31613,
      "\u03bcg kg patients": 87793,
      "kg patients group": 40785,
      "mg kg patients": 46015,
      "dose \u03bcg kg": 26111,
      "\u03bcg kg 10": 87790,
      "kg 10 minutes": 40684,
      "rate \u03bcg kg": 67525,
      "changes heart rate": 15791,
      "heart rate hr": 34874,
      "mean arterial pressure": 43717,
      "arterial pressure map": 11719,
      "pulse oxygen saturation": 66473,
      "oxygen saturation spo": 56207,
      "bispectral index bis": 13889,
      "different time points": 24929,
      "minutes end operation": 46649,
      "incidence effects nausea": 37272,
      "effects nausea vomiting": 28017,
      "nausea vomiting respiratory": 48810,
      "vomiting respiratory depression": 86474,
      "assessed visual analogue": 12094,
      "analogue scale vas": 10558,
      "scale vas scores": 73579,
      "vas scores recorded": 86026,
      "postoperatively results patients": 63023,
      "results patients group": 71847,
      "incidence nausea vomiting": 37284,
      "lower group group": 42625,
      "05 conclusion combination": 500,
      "conclusion combination oxycodone": 18872,
      "combination oxycodone dexmedetomidine": 17586,
      "used safely effectively": 85120,
      "objective systematic review": 50527,
      "clinical efficacy safety": 16807,
      "health related quality": 34765,
      "related quality life": 69676,
      "quality life outcomes": 66735,
      "management moderate severe": 43207,
      "chronic pain oxycodone": 16294,
      "pain oxycodone naloxone": 57312,
      "oxycodone naloxone tapentadol": 55519,
      "medline medline process": 44741,
      "medline process cochrane": 44746,
      "searched identify randomized": 74151,
      "identify randomized controlled": 36531,
      "controlled trials investigating": 20637,
      "tapentadol oxycodone naloxone": 80454,
      "oxycodone naloxone treatment": 55522,
      "naloxone treatment patients": 48528,
      "network meta analysis": 49161,
      "meta analysis conducted": 44891,
      "efficacy safety profiles": 28380,
      "significantly better tapentadol": 75666,
      "patient assessment constipation": 58541,
      "assessment constipation symptoms": 12110,
      "ratio 60 95": 67746,
      "95 credible interval": 6401,
      "significantly lower risk": 75808,
      "constipation nausea vomiting": 19768,
      "nausea vomiting pain": 48804,
      "difference oxycodone naloxone": 24651,
      "oxycodone naloxone offers": 55506,
      "extended release tapentadol": 30904,
      "quality life background": 66721,
      "chronic opioid therapy": 16240,
      "long term use": 42359,
      "use prescription opioids": 84656,
      "opioid receptor results": 52265,
      "chronic opioid administration": 16238,
      "stress response leading": 77492,
      "misuse prescription opioids": 46739,
      "prescription opioids significant": 64369,
      "health issue australia": 34724,
      "rise prescription opioid": 72493,
      "opioid use associated": 52471,
      "primary aim study": 64986,
      "aim study identify": 9423,
      "oral oxycodone administration": 53625,
      "methods study designed": 45589,
      "retrospective data analysis": 72142,
      "frequently prescribed opioid": 32571,
      "prescribed opioid medication": 63912,
      "oxycodone ir mg": 55312,
      "reduce incidence opioid": 68848,
      "breakthrough pain patients": 14400,
      "pain patients chronically": 57342,
      "subject received 10": 78639,
      "received 10 mg": 68090,
      "10 mg immediate": 819,
      "release oxycodone orally": 69958,
      "calculated using dose": 14710,
      "peak plasma oxycodone": 60321,
      "plasma oxycodone concentrations": 61948,
      "oxycodone concentrations max": 54832,
      "concentrations max time": 18774,
      "peak oxycodone concentrations": 60311,
      "statistically significant difference": 77208,
      "significant difference groups": 75473,
      "objectives evaluate postoperative": 50560,
      "opioid use benign": 52475,
      "patient educational intervention": 58628,
      "opioid use disposal": 52509,
      "patients underwent hysterectomy": 60144,
      "25 tablets oxycodone": 3387,
      "10 tablets oxycodone": 939,
      "oral morphine equivalents": 53580,
      "postoperative visits results": 62984,
      "opioid use 35": 52465,
      "tablets iqr 15": 80171,
      "post operative day": 62591,
      "difference total opioid": 24696,
      "total opioid use": 81868,
      "pain chronic pain": 56541,
      "overall satisfaction pain": 54257,
      "satisfaction pain control": 73410,
      "regarding opioid epidemic": 69257,
      "aims study aimed": 9499,
      "study aimed characterize": 77922,
      "age 23 42": 8985,
      "received intravenous oxycodone": 68179,
      "oxycodone hydrochloride trihydrate": 55197,
      "mg kg surgery": 46031,
      "blood samples taken": 14156,
      "plasma concentrations oxycodone": 61916,
      "concentrations oxycodone noroxycodone": 18793,
      "oxycodone noroxycodone oxymorphone": 55540,
      "noroxycodone oxymorphone noroxymorphone": 49939,
      "findings highlight importance": 31786,
      "compare efficacy safety": 18024,
      "release morphine oxycodone": 69892,
      "versus individual components": 86126,
      "morphine equivalent doses": 47663,
      "moderate severe postoperative": 47210,
      "severe postoperative pain": 75011,
      "postoperative pain patients": 62906,
      "pain patients design": 57344,
      "reported pain intensity": 70609,
      "pain intensity point": 56930,
      "12 mg oxycodone": 1326,
      "mg oxycodone mg": 46124,
      "oxycodone mg morphine": 55429,
      "mg morphine mg": 46062,
      "oxycodone mg administered": 55414,
      "intensity differences 24": 39250,
      "differences 24 hours": 24706,
      "24 hours dose": 3216,
      "hours dose study": 35768,
      "dose study medication": 26089,
      "moderate severe nausea": 47186,
      "mg morphine equivalent": 46060,
      "analgesic effects 50": 10215,
      "commonly associated opioids": 17839,
      "opioids nausea vomiting": 53083,
      "group compared morphine": 33688,
      "morphine equivalent dose": 47659,
      "dose groups conclusions": 25921,
      "pain tapentadol oxycodone": 57904,
      "commonly used analgesics": 17876,
      "studies shown oxycodone": 77845,
      "human brain limited": 35945,
      "effects tapentadol oxycodone": 28178,
      "magnetic resonance spectroscopy": 42805,
      "baseline 14 days": 13407,
      "50 mg tapentadol": 4862,
      "double blind cross": 26346,
      "blind cross study": 13928,
      "10 vs 35": 952,
      "background chronic pain": 13025,
      "st john wort": 76823,
      "prone drug interactions": 65678,
      "aims aim study": 9473,
      "study assess potential": 77967,
      "cyp3a mediated metabolism": 21632,
      "receptor agonist oxycodone": 68465,
      "design placebo controlled": 23750,
      "placebo controlled randomized": 61696,
      "phases intervals weeks": 61327,
      "intervals weeks conducted": 39619,
      "weeks conducted 12": 86900,
      "conducted 12 healthy": 19338,
      "15 mg day": 1753,
      "mg day 14": 45853,
      "day 14 oxycodone": 22248,
      "behavioural analgesic effects": 13571,
      "visual analogue scales": 86329,
      "plasma drug concentrations": 61929,
      "drug concentrations measured": 26561,
      "self reported drug": 74494,
      "reported drug effect": 70535,
      "drug effect oxycodone": 26610,
      "pain threshold intensity": 57916,
      "greatly reduced plasma": 33513,
      "reduced plasma concentrations": 68973,
      "plasma concentrations oral": 61914,
      "concentrations oral oxycodone": 18789,
      "oral oxycodone self": 53640,
      "oxycodone decreased significantly": 54933,
      "treating patients chronic": 82407,
      "chronic pain objective": 16288,
      "pain objective report": 57267,
      "objective report case": 50486,
      "report case severe": 70450,
      "70 year old": 5574,
      "200 mg day": 2400,
      "resulted resolution symptoms": 71516,
      "naranjo probability scale": 48577,
      "serotonin reuptake inhibitors": 74685,
      "disease chronic pain": 25323,
      "opioids chronic nonmalignant": 52780,
      "chronic nonmalignant pain": 16232,
      "strong evidence base": 77517,
      "opioid prescribing data": 52093,
      "patients received oral": 59806,
      "extended release opioids": 30889,
      "median number days": 44251,
      "number days opioid": 50151,
      "24 hour dose": 3204,
      "extended release morphine": 30884,
      "morphine oxycodone fentanyl": 47822,
      "patients using fentanyl": 60168,
      "osmotic controlled release": 53851,
      "controlled release oral": 20550,
      "release oral delivery": 69910,
      "oral delivery oros": 53514,
      "delivery oros hydromorphone": 23224,
      "optimal pain relief": 53428,
      "pain relief improve": 57542,
      "managing chronic osteoarthritis": 43285,
      "chronic osteoarthritis pain": 16251,
      "daily oros hydromorphone": 21783,
      "oros hydromorphone er": 53803,
      "hydromorphone er oxycodone": 36166,
      "adverse events pain": 8785,
      "ratio oxycodone morphine": 67788,
      "mean daily morphine": 43741,
      "daily morphine equivalent": 21763,
      "life years qalys": 41745,
      "cost effectiveness ratio": 20875,
      "effectiveness ratio icer": 27778,
      "conversion ratio oxycodone": 20713,
      "assess cost effectiveness": 11922,
      "effectiveness tapentadol pr": 27783,
      "pr prolonged release": 63358,
      "compared oxycodone cr": 18239,
      "oxycodone cr controlled": 54895,
      "cr controlled release": 21057,
      "severe non malignant": 74961,
      "non malignant chronic": 49624,
      "chronic pain patients": 16299,
      "patients controlled release": 59156,
      "national health service": 48688,
      "phase iii clinical": 61293,
      "iii clinical trials": 36583,
      "associated opioid treatment": 12362,
      "line treatment patients": 42006,
      "treatment patients severe": 82750,
      "patients severe non": 59966,
      "patients quality life": 59723,
      "tapentadol prolonged release": 80464,
      "prolonged release pr": 65632,
      "morphine controlled release": 47630,
      "cr oxycodone cr": 21081,
      "primary care patients": 64993,
      "pain duration pain": 56736,
      "nausea vomiting compared": 48795,
      "cox proportional hazards": 21030,
      "adverse events tapentadol": 8818,
      "tapentadol pr treatment": 80462,
      "conclusion tapentadol pr": 19012,
      "tapentadol pr associated": 80460,
      "pr associated significantly": 63314,
      "associated significantly fewer": 12435,
      "significantly fewer adverse": 75700,
      "oxycodone cr patients": 54907,
      "primary secondary care": 65108,
      "care resource use": 15075,
      "effective pain treatment": 27664,
      "understanding pharmacokinetic behavior": 83647,
      "oxycodone commonly prescribed": 54810,
      "commonly prescribed opioid": 17865,
      "pain little known": 57027,
      "little known pharmacokinetics": 42163,
      "population pharmacokinetic modeling": 62372,
      "data best described": 21889,
      "described compartment linear": 23652,
      "compartment linear model": 18393,
      "clearance cl volume": 16712,
      "cl volume distribution": 16612,
      "pharmacokinetic profile oxycodone": 61145,
      "isobolographic analysis revealed": 40297,
      "coadministration morphine oxycodone": 17123,
      "study designed determine": 78099,
      "healthy human subjects": 34819,
      "human subjects methods": 35976,
      "randomized crossover study": 67092,
      "15 mg oxycodone": 1763,
      "oxycodone hydrochloride combination": 55179,
      "measured high performance": 43968,
      "high performance liquid": 35138,
      "performance liquid chromatography": 60554,
      "liquid chromatography ms": 42084,
      "chromatography ms ms": 16167,
      "ms ms results": 48089,
      "increasing oxycodone doses": 38115,
      "effects morphine oxycodone": 28008,
      "approved food drug": 11538,
      "sustained release preparation": 79795,
      "named researched abuse": 48556,
      "use drug abuse": 84344,
      "drug abuse experts": 26503,
      "abuse prescription drugs": 6837,
      "drugs results indicate": 27068,
      "results indicate prescription": 71730,
      "indicate prescription drug": 38229,
      "drug abuse prevalent": 26506,
      "rank ordered follows": 67366,
      "hydrocodone oxycodone methadone": 36118,
      "morphine hydromorphone fentanyl": 47722,
      "hydromorphone fentanyl buprenorphine": 36170,
      "100 000 persons": 977,
      "digit zip code": 24983,
      "opioid analgesic abuse": 51447,
      "recreational drug users": 68775,
      "use drugs treatment": 84348,
      "drugs treatment pain": 27095,
      "controlled crossover trial": 20481,
      "healthy volunteers administered": 34851,
      "oral oxycodone 20": 53619,
      "eu clinical trials": 29720,
      "clinical trials register": 16958,
      "treatment cancer induced": 82464,
      "cancer induced bone": 14789,
      "induced bone pain": 38390,
      "bone pain cibp": 14239,
      "pain cibp challenging": 56546,
      "used treat cibp": 85166,
      "treat cibp lack": 82292,
      "cibp lack understanding": 16548,
      "cibp limits application": 16550,
      "treated spinal dorsal": 82378,
      "rats cibp performed": 67844,
      "05 significant differences": 551,
      "cibp group oxy": 16545,
      "group oxy group": 33886,
      "oxy group compared": 54451,
      "spinal dorsal horn": 76714,
      "dorsal horn neurons": 25736,
      "management chronic pain": 43166,
      "treatment chronic pain": 82487,
      "non cancer neuropathic": 49576,
      "cancer neuropathic pain": 14799,
      "treating chronic pain": 82391,
      "american pain society": 9798,
      "release oral formulations": 69912,
      "opioids morphine oxycodone": 53074,
      "morphine oxycodone hydromorphone": 47832,
      "reduced dosing frequency": 68922,
      "effective managing chronic": 27640,
      "managing chronic pain": 43286,
      "twice daily doses": 83295,
      "doses sustained release": 26283,
      "sustained release morphine": 79788,
      "day inpatient stay": 22326,
      "times day days": 81421,
      "area plasma concentration": 11635,
      "plasma concentration time": 61906,
      "concentration time curves": 18727,
      "morphine oxycodone exposure": 47821,
      "pain significantly decreased": 57840,
      "significantly decreased average": 75675,
      "lower doses fewer": 42603,
      "doses fewer effects": 26189,
      "opioid epidemic aim": 51769,
      "aim evaluate efficacy": 9386,
      "standardized perioperative pain": 76981,
      "perioperative pain management": 60847,
      "postoperative opioid requirements": 62824,
      "opioid requirements men": 52343,
      "methods patients undergoing": 45445,
      "patients undergoing outpatient": 60119,
      "pain management satisfaction": 57118,
      "opioid consumption results": 51660,
      "consumption results total": 20012,
      "study period patients": 78392,
      "patients did use": 59194,
      "did use opioids": 24515,
      "use opioids postoperatively": 84567,
      "78 patients used": 5784,
      "median number unused": 44258,
      "tablets iqr 10": 80170,
      "preoperative opioid use": 63750,
      "reported higher satisfaction": 70563,
      "vs 50 01": 86588,
      "satisfactory pain control": 73451,
      "pain control following": 56617,
      "postoperative opioid prescribing": 62819,
      "tolerance analgesic effects": 81572,
      "placebo controlled study": 61702,
      "subjective physiological effects": 78662,
      "effects commonly prescribed": 27860,
      "mg 70 kg": 45765,
      "using session cumulative": 85610,
      "session cumulative dosing": 74731,
      "cumulative dosing procedure": 21395,
      "effects oxycodone compared": 28059,
      "day washout period": 22448,
      "administered healthy volunteers": 8132,
      "healthy volunteers 10": 34850,
      "history drug dependence": 35459,
      "using cold pressor": 85344,
      "effects measured using": 27984,
      "tolerance did develop": 81586,
      "subjective effects oxycodone": 78652,
      "positive subjective drug": 62492,
      "subjective drug effects": 78647,
      "subjective effects related": 78653,
      "related abuse liability": 69544,
      "abuse liability aims": 6747,
      "20 mg controlled": 2335,
      "grunenthal aachen germany": 34385,
      "society anesthesiologists classification": 76379,
      "classification physical status": 16683,
      "physical status patients": 61416,
      "status patients undergoing": 77265,
      "patients undergoing surgery": 60128,
      "undergoing surgery breast": 83580,
      "surgery breast cancer": 79338,
      "surgery patients randomly": 79513,
      "randomly allocated groups": 67212,
      "allocated groups receiving": 9615,
      "release oxycodone oxy": 69959,
      "oxycodone oxy group": 55599,
      "pain scores rest": 57774,
      "pain scores coughing": 57712,
      "24 hours operation": 3220,
      "scale results patients": 73552,
      "results patients enrolled": 71846,
      "differences treatment groups": 24827,
      "groups 24 hours": 34105,
      "significant differences treatment": 75520,
      "nausea 13 vomiting": 48759,
      "patient satisfaction scores": 58775,
      "postoperative pain management": 62884,
      "high potential abuse": 35147,
      "phase ii metabolites": 61289,
      "10 mg cr": 806,
      "24 48 72": 3166,
      "internal standard mixture": 39464,
      "acquity uplc class": 7365,
      "uplc class coupled": 83993,
      "class coupled waters": 16655,
      "coupled waters xevo": 20982,
      "waters xevo tqd": 86766,
      "using previously validated": 85575,
      "poor metabolizers pm": 62266,
      "extensive metabolizers em": 30918,
      "ultrarapid metabolizers um": 83428,
      "significance level 05": 75408,
      "drug metabolizing enzymes": 26710,
      "drug drug interactions": 26602,
      "drug interactions ddis": 26667,
      "study determine influence": 78111,
      "oxycodone administration 15": 54689,
      "administration 15 mg": 8207,
      "mg kg intraperitoneally": 45988,
      "twice daily days": 83294,
      "quantitative real time": 66806,
      "real time polymerase": 68004,
      "time polymerase chain": 81343,
      "polymerase chain reaction": 62201,
      "using metacore computational": 85490,
      "metacore computational platform": 45019,
      "major metabolites noroxycodone": 42955,
      "noroxycodone oxymorphone oxycodone": 49941,
      "repeated oxycodone administration": 70418,
      "oxycodone administration rats": 54690,
      "medications illicit drugs": 44628,
      "drug adverse effects": 26530,
      "oxymorphone extended release": 56242,
      "versus oxycodone controlled": 86141,
      "15 30 mg": 1691,
      "chronic pain calculated": 16261,
      "addiction research center": 7765,
      "research center inventory": 70984,
      "15 mg versus": 1767,
      "er 30 mg": 29390,
      "results thirty subjects": 72015,
      "morphine benzedrine group": 47588,
      "high dose group": 35085,
      "produce synergistic antinociceptive": 65371,
      "synergistic antinociceptive effects": 79932,
      "opioid dose opioid": 51733,
      "opioid sparing effects": 52367,
      "opioids placebo controlled": 53177,
      "placebo controlled studies": 61701,
      "low dose oxycodone": 42481,
      "administered oxycodone mg": 8160,
      "oxycodone mg po": 55439,
      "abuse related effects": 6862,
      "self administration determined": 74462,
      "oxycodone increased pain": 55248,
      "increased pain threshold": 37975,
      "05 oxycodone did": 536,
      "oxycodone did increase": 54968,
      "oxycodone abuse liability": 54619,
      "suffer chronic pain": 78958,
      "guidelines management chronic": 34446,
      "use controlled release": 84275,
      "associated high rates": 12278,
      "high rates opioid": 35162,
      "induced constipation oic": 38401,
      "effectiveness combination oxycodone": 27754,
      "combination oxycodone naloxone": 17589,
      "oxycodone naloxone compared": 55495,
      "naloxone compared oxycodone": 48439,
      "oic included analysis": 50987,
      "included analysis primary": 37423,
      "patients compared oxycodone": 59102,
      "oxycodone treated patients": 56025,
      "treated patients improved": 82371,
      "costs slightly higher": 20907,
      "cr oxycodone resulted": 21098,
      "clinical practice guidelines": 16864,
      "high dose opioid": 35087,
      "setting ontario canada": 74793,
      "aged 15 64": 9145,
      "15 64 years": 1708,
      "opioids chronic non": 52776,
      "rate opioid use": 67492,
      "prevalence opioid prescriptions": 64793,
      "mg 400 mg": 45751,
      "mg morphine equivalents": 46061,
      "morphine equivalents day": 47671,
      "rates opioid related": 67610,
      "emergency department visits": 28685,
      "department visits hospital": 23450,
      "study period rate": 78393,
      "period rate opioid": 60783,
      "users 10 000": 85226,
      "opioid use significantly": 52592,
      "doses 200 mg": 26132,
      "hospital admissions increased": 35559,
      "study period 14": 78382,
      "legislation did result": 41370,
      "did result significant": 24497,
      "significant change rates": 75438,
      "change rates opioid": 15747,
      "impact educational intervention": 36809,
      "educational intervention ed": 27403,
      "secondary outcomes included": 74245,
      "outcomes included quality": 54038,
      "tertiary referral hospital": 80750,
      "intervention post intervention": 39643,
      "oxycodone containing prescriptions": 54874,
      "pre intervention period": 63472,
      "discharged patients prescribed": 25210,
      "patients prescribed oxycodone": 59681,
      "prescribed oxycodone compared": 63941,
      "95 ci 12": 6245,
      "95 ci 13": 6248,
      "mean total number": 43893,
      "15 95 ci": 1720,
      "95 ci 21": 6260,
      "patient safety opioid": 58753,
      "objective evaluate analgesic": 50408,
      "evaluate analgesic effectiveness": 29770,
      "analgesic effectiveness safety": 10211,
      "effectiveness safety new": 27781,
      "safety new oxycodone": 73171,
      "new oxycodone 10": 49352,
      "10 mg acetaminophen": 798,
      "mg acetaminophen 325": 45787,
      "acetaminophen 325 mg": 7126,
      "325 mg percocet": 3962,
      "patients low pain": 59461,
      "low pain lbp": 42522,
      "nonsteroidal anti inflammatory": 49854,
      "prospective open label": 65852,
      "men women mean": 44808,
      "women mean age": 87222,
      "mean age 52": 43688,
      "age 52 years": 9020,
      "discontinued oxycodone acetaminophen": 25244,
      "clinically meaningful pain": 16985,
      "meaningful pain relief": 43917,
      "oxycodone acetaminophen dose": 54639,
      "neuropathic pain scale": 49261,
      "dull deep pain": 27121,
      "pain quality life": 57453,
      "adverse events physical": 8791,
      "laboratory tests results": 41036,
      "85 completed study": 5983,
      "study discontinuations adverse": 78123,
      "discontinuations adverse events": 25236,
      "adverse events patient": 8787,
      "treatment significantly reduced": 82844,
      "bpi pain intensity": 14299,
      "pain intensity improved": 56908,
      "improved pain relief": 37118,
      "pain interference quality": 56964,
      "interference quality life": 39428,
      "tolerated adverse events": 81619,
      "adverse events commonly": 8738,
      "mild moderate intensity": 46428,
      "primary purpose study": 65106,
      "effective treatment moderate": 27717,
      "pain relief tolerable": 57590,
      "relief tolerable effects": 70199,
      "pain patients experience": 57346,
      "long term controlled": 42330,
      "efficacy safety new": 28366,
      "persistent opioid use": 60919,
      "patients prescribed opioids": 59680,
      "develop persistent opioid": 24154,
      "opioid use study": 52597,
      "opioid use commonly": 52482,
      "commonly used postoperative": 17895,
      "longer term outcomes": 42389,
      "primary outcome measure": 65069,
      "opioid use months": 52539,
      "receive immediate release": 68052,
      "immediate release tapentadol": 36740,
      "regression models used": 69452,
      "opioid use controlling": 52487,
      "ethics dissemination ethics": 29693,
      "dissemination ethics approval": 25518,
      "ethics approval obtained": 29688,
      "monash university human": 47301,
      "university human research": 83867,
      "human research ethics": 35970,
      "research ethics committee": 71004,
      "present project findings": 64628,
      "project findings peer": 65592,
      "findings peer reviewed": 31805,
      "peer reviewed journal": 60370,
      "reviewed journal article": 72382,
      "studies conducted using": 77676,
      "routinely collected health": 72869,
      "37 year old": 4208,
      "sickle cell crisis": 75369,
      "patient severe pain": 58782,
      "illegal drug use": 36623,
      "publicly available data": 66415,
      "methods repeated cross": 45525,
      "repeated cross sectional": 70403,
      "cross sectional design": 21258,
      "tramadol codeine strong": 82045,
      "defined daily dose": 23128,
      "daily dose ddd": 21726,
      "mean doses oxycodone": 43770,
      "slow release opioids": 76264,
      "aim study compare": 9410,
      "opioids postoperative pain": 53192,
      "postoperative pain treatment": 62928,
      "total study population": 81906,
      "divided groups group": 25623,
      "group 10 mg": 33558,
      "mg oxycodone naloxone": 46127,
      "group 20 mg": 33583,
      "oxycodone naloxone 10": 55489,
      "naloxone 10 mg": 48424,
      "10 mg group": 816,
      "maximum pain intensity": 43600,
      "pain intensity pain": 56924,
      "satisfaction pain management": 73414,
      "differences pain intensity": 24777,
      "reported pain interference": 70611,
      "additional pain medication": 7880,
      "summary findings suggest": 79100,
      "release oral oxycodone": 69916,
      "dying cancer patients": 27212,
      "cancer patients terminal": 14893,
      "remains largely unknown": 70296,
      "oxycodone vs morphine": 56086,
      "morphine continuous infusion": 47627,
      "continuous infusion 24": 20170,
      "infusion 24 hours": 38697,
      "prospective observational study": 65847,
      "study inclusion criteria": 78256,
      "advanced cancer patients": 8594,
      "cancer patients admitted": 14868,
      "palliative care units": 58049,
      "eastern cooperative oncology": 27286,
      "cooperative oncology group": 20751,
      "oncology group performance": 51074,
      "group performance status": 33912,
      "scores 24 hours": 73832,
      "24 hours results": 3230,
      "mean age 70": 43704,
      "standard deviation oxycodone": 76898,
      "significant group differences": 75543,
      "oxycodone morphine groups": 55473,
      "equally effective safe": 29242,
      "efficacy safety opioids": 28369,
      "background opioids widely": 13126,
      "incidence opioid related": 37293,
      "combination morphine oxycodone": 17569,
      "morphine oxycodone used": 47862,
      "used treat acute": 85161,
      "treat acute pain": 82274,
      "compared equianalgesic doses": 18151,
      "controlled trials morphine": 20640,
      "subjects moderate severe": 78715,
      "moderate severe post": 47209,
      "post surgical pain": 62621,
      "received multiple doses": 68208,
      "doses morphine oxycodone": 26218,
      "demonstrate analgesic efficacy": 23312,
      "analgesic efficacy comparable": 10232,
      "morphine oxycodone compared": 47813,
      "doses oxycodone morphine": 26240,
      "morphine provide effective": 47897,
      "provide effective relief": 66057,
      "effective relief moderate": 27690,
      "medical use prescription": 44421,
      "prescription opioids pos": 64361,
      "medical use abuse": 44414,
      "resulted dramatic increase": 71505,
      "opioid pain relievers": 52040,
      "rise opioid related": 72490,
      "opioid related abuse": 52298,
      "abuse addiction overdose": 6643,
      "prescription opioids increasing": 64344,
      "data indicate oral": 21991,
      "longer duration opioid": 42372,
      "risk abuse addiction": 72506,
      "multimodal pain management": 48228,
      "pain management following": 57070,
      "correction hallux valgus": 20801,
      "operative day pod": 51248,
      "primary endpoint cumulative": 65021,
      "endpoint cumulative oxycodone": 28884,
      "cumulative oxycodone consumption": 21403,
      "pain scores oxycodone": 57755,
      "daily oxycodone doses": 21790,
      "adverse effects documented": 8654,
      "effects documented results": 27903,
      "documented results patients": 25668,
      "study period 45": 78384,
      "mg placebo group": 46162,
      "group patients reported": 33907,
      "patients reported significantly": 59892,
      "reported significantly lower": 70650,
      "significantly lower pain": 75800,
      "did differ groups": 24434,
      "total oxycodone consumption": 81874,
      "prescribed pregnant women": 63959,
      "hypothesized maternal treatment": 36310,
      "maternal treatment oxycodone": 43529,
      "treatment oxycodone oxy": 82729,
      "oxycodone oxy primary": 55602,
      "oxy primary opioid": 54463,
      "primary opioid center": 65051,
      "opioid center current": 51570,
      "center current crisis": 15516,
      "gene expression changes": 32944,
      "female mice treated": 31367,
      "mice treated daily": 46322,
      "treated daily mg": 82334,
      "daily mg oxy": 21759,
      "mg oxy kg": 46091,
      "oxy kg saline": 54457,
      "kg saline solution": 40800,
      "saline solution control": 73273,
      "solution control ctl": 76440,
      "control ctl weeks": 20288,
      "male female offspring": 43030,
      "gene expression patterns": 32945,
      "sex dependent differences": 75070,
      "genes encoding opioid": 33060,
      "encoding opioid receptors": 28770,
      "opioid receptors involved": 52273,
      "epigenetic changes brain": 29197,
      "work needed determine": 87280,
      "receptor agonism noradrenaline": 68457,
      "agonism noradrenaline reuptake": 9271,
      "noradrenaline reuptake inhibition": 49874,
      "study aimed investigate": 77933,
      "expressed oral morphine": 30822,
      "morphine equivalents ome": 47675,
      "conducted retrospective review": 19407,
      "immediate release 70": 36709,
      "immediate release sustained": 36736,
      "release sustained release": 70010,
      "background aim study": 13008,
      "morphine oxycodone 10": 47802,
      "10 mg ml": 826,
      "materials methods data": 43505,
      "acute pain service": 7674,
      "data regarding opioid": 22087,
      "regarding opioid consumption": 69256,
      "patient satisfaction recorded": 58770,
      "effects oxycodone group": 28063,
      "group difference statistically": 33751,
      "difference statistically significant": 24689,
      "significantly lower incidence": 75791,
      "compare efficacy tolerability": 18026,
      "morphine oxycodone combination": 47811,
      "years moderate severe": 87619,
      "primary efficacy variable": 65012,
      "intensity difference spid": 39248,
      "mean total morphine": 43892,
      "total morphine equivalent": 81842,
      "equivalent dose med": 29302,
      "48 hours significantly": 4724,
      "doses rescue medication": 26264,
      "median time use": 44292,
      "time use rescue": 81395,
      "efficacy individual components": 28280,
      "increase incidence adverse": 37753,
      "according previous studies": 7059,
      "morphine treatment visceral": 47963,
      "treatment visceral pain": 82886,
      "consumption primary outcome": 19998,
      "primary outcome pain": 65079,
      "outcome pain relief": 53973,
      "pain relief effects": 57538,
      "morphine versus oxycodone": 47969,
      "patients randomised receive": 59729,
      "surgery opioid consumption": 79486,
      "opioid consumption pain": 51639,
      "consumption pain scores": 19979,
      "pain scores effects": 57724,
      "mean opioid consumption": 43817,
      "opioid consumption morphine": 51633,
      "morphine oxycodone group": 47828,
      "study morphine oxycodone": 78314,
      "morphine oxycodone produced": 47853,
      "percutaneous kidney stone": 60543,
      "objective oxycodone widely": 50461,
      "used opioid analgesic": 85043,
      "global use increased": 33235,
      "pharmacokinetics intravenous oxycodone": 61173,
      "function elderly patients": 32645,
      "mg intravenous oxycodone": 45931,
      "oxycodone groups 10": 55143,
      "patients aged 20": 58973,
      "aged 20 40": 9174,
      "20 40 60": 2289,
      "40 60 70": 4326,
      "60 70 70": 5231,
      "surgery plasma concentrations": 79523,
      "oxymorphone noroxymorphone metabolites": 56270,
      "liquid chromatography tandem": 42086,
      "chromatography tandem mass": 16172,
      "tandem mass spectrometric": 80359,
      "mass spectrometric method": 43455,
      "p450 cyp 2d6": 56306,
      "glomerular filtration rate": 33239,
      "filtration rate gfr": 31737,
      "rate gfr estimated": 67469,
      "oxycodone showed age": 55900,
      "mean area plasma": 43712,
      "concentration time curve": 18723,
      "time curve time": 81239,
      "curve time zero": 21530,
      "time zero infinity": 81403,
      "zero infinity auc": 87761,
      "total body clearance": 81784,
      "age groups 60": 9078,
      "70 70 80": 5552,
      "hours post dose": 35817,
      "aged 80 years": 9198,
      "years patients aged": 87634,
      "sex related differences": 75088,
      "differences pharmacokinetic parameters": 24785,
      "extensive metabolizers cyp2d6": 30917,
      "cyp2d6 genotype oxycodone": 21605,
      "volume distribution steady": 86393,
      "distribution steady state": 25567,
      "patients aged 70": 58977,
      "aged 70 years": 9194,
      "young adult patients": 87713,
      "dependent age patient": 23498,
      "important titrate analgesic": 37037,
      "titrate analgesic dose": 81463,
      "analgesic dose individually": 10181,
      "dose individually particularly": 25935,
      "individually particularly elderly": 38328,
      "ir oxycodone hcl": 40247,
      "open label randomized": 51178,
      "randomized period treatment": 67146,
      "treatment crossover study": 82533,
      "release oxycodone hcl": 69943,
      "aged 18 55": 9159,
      "18 55 years": 2055,
      "15 mg doses": 1754,
      "plasma samples taken": 61959,
      "analyzed using liquid": 10868,
      "using liquid chromatography": 85465,
      "tandem mass spectrometry": 80361,
      "geometric mean ratios": 33122,
      "area concentration time": 11623,
      "90 confidence intervals": 6084,
      "adverse events mild": 8771,
      "events mild moderate": 30069,
      "conventional immediate release": 20694,
      "release oxycodone formulations": 69941,
      "patients neuropathic pain": 59544,
      "neuropathic pain np": 49248,
      "objectives assess effectiveness": 50545,
      "assess effectiveness safety": 11929,
      "safety oxycodone treatment": 73188,
      "intensity visual analog": 39328,
      "pain intensity vas": 56958,
      "treatment related adverse": 82805,
      "related adverse event": 69551,
      "conclusion oxycodone treatment": 18950,
      "impact pain physical": 36833,
      "relieve acute pain": 70213,
      "long term treatment": 42355,
      "term treatment chronic": 80673,
      "treatment chronic noncancer": 82485,
      "chronic noncancer pain": 16226,
      "previous systematic reviews": 64927,
      "patient level data": 58671,
      "patients treated 12": 60059,
      "formulations oxycodone hydrocodone": 32397,
      "pain physical function": 57376,
      "change baseline final": 15725,
      "patients stable pain": 59990,
      "long term benefit": 42326,
      "pain level opioid": 57008,
      "objective study examined": 50515,
      "design cross sectional": 23707,
      "cross sectional observational": 21260,
      "sectional observational study": 74284,
      "observational study setting": 50634,
      "united states current": 83786,
      "18 years age": 2110,
      "completed survey main": 18504,
      "survey main outcome": 79719,
      "regarding prescription opioid": 69276,
      "opioid use prior": 52578,
      "reported using prescription": 70674,
      "using prescription opioids": 85573,
      "chronic pain condition": 16267,
      "conclusions study supports": 19228,
      "study supports role": 78526,
      "transition heroin use": 82202,
      "common prescription opioid": 17797,
      "anti inflammatory drug": 11123,
      "inflammatory drug nsaid": 38559,
      "semisynthetic opioid agonist": 74522,
      "oral fixed dose": 53534,
      "fixed dose combination": 31873,
      "dose combination oxycodone": 25843,
      "combination oxycodone paracetamol": 17592,
      "individual drug doses": 38293,
      "mechanisms action opioid": 44138,
      "opioid sparing effect": 52366,
      "efficacy tolerability profile": 28408,
      "efficacy safety fixed": 28360,
      "safety fixed dose": 73154,
      "wide range clinical": 87045,
      "chronic musculoskeletal pain": 16214,
      "musculoskeletal pain including": 48371,
      "chronic pain elderly": 16274,
      "pain elderly patients": 56750,
      "elderly patients cancer": 28480,
      "patients cancer related": 59047,
      "pain postoperative pain": 57396,
      "postoperative pain neuropathic": 62894,
      "neuropathic pain case": 49234,
      "chronic moderate severe": 16210,
      "treat moderate severe": 82299,
      "methods healthy males": 45347,
      "placebo oxycodone 10": 61792,
      "rest tonic pain": 71434,
      "tonic pain recorded": 81659,
      "decreased pain scores": 23022,
      "pain scores 05": 57692,
      "synthetic opioid commonly": 79954,
      "opioid commonly used": 51591,
      "commonly used treatment": 17903,
      "used treatment severe": 85184,
      "treatment severe acute": 82837,
      "severe acute chronic": 74901,
      "acute chronic pain": 7620,
      "chronic pain treatment": 16321,
      "pain treatment oxycodone": 57939,
      "cell patch clamp": 15485,
      "patients long term": 59457,
      "patients treated opioids": 60065,
      "commonly used strong": 17898,
      "used strong opioids": 85146,
      "fentanyl oral oxycodone": 31543,
      "oral oxycodone oral": 53637,
      "oxycodone oral morphine": 55582,
      "cost effective treatment": 20869,
      "effective treatment option": 27719,
      "paravertebral block pvb": 58181,
      "decrease postoperative pain": 22921,
      "postoperative pain postoperative": 62908,
      "postoperative nausea vomiting": 62803,
      "nausea vomiting ponv": 48806,
      "studies placebo controlled": 77813,
      "60 patients scheduled": 5272,
      "patients scheduled breast": 59943,
      "scheduled breast cancer": 73639,
      "breast cancer surgery": 14407,
      "bupivacaine mg ml": 14506,
      "mg kg saline": 46026,
      "general anesthesia patient": 32965,
      "study patients given": 78368,
      "iv opioid medication": 40388,
      "primary outcome variable": 65098,
      "postanesthesia care unit": 62635,
      "pain rest 24": 57640,
      "750 ng ml": 5727,
      "reduced postoperative pain": 68975,
      "postoperative pain opioid": 62900,
      "pain opioid consumption": 57280,
      "background prescription opioid": 13169,
      "prescription opioid analgesic": 64284,
      "methods examined trends": 45336,
      "opioids strong opioids": 53314,
      "compuscript converted defined": 18647,
      "converted defined daily": 20723,
      "defined daily doses": 23130,
      "daily doses ddd": 21739,
      "strong opioids increased": 77549,
      "strong opioid dispensing": 77529,
      "weak strong opioids": 86795,
      "possible substitution effects": 62550,
      "methods double blind": 45317,
      "10 previously reported": 910,
      "days oxycodone given": 22575,
      "clinical trials objectives": 16952,
      "medico legal case": 44720,
      "chronic pain patient": 16298,
      "methadone opioid rotation": 45112,
      "background prescription opioids": 13171,
      "er oxycodone oc": 29461,
      "ir oc apap": 40239,
      "blind active placebo": 13920,
      "healthy volunteers recreational": 34861,
      "prescription opioid users": 64320,
      "approved institutional review": 11542,
      "institutional review board": 39099,
      "provided written informed": 66170,
      "written informed consent": 87376,
      "participants received single": 58353,
      "received single doses": 68274,
      "single doses intact": 76096,
      "er ir oc": 29429,
      "15 650 mg": 1710,
      "650 mg intact": 5434,
      "high good drug": 35106,
      "good drug effects": 33306,
      "measured using visual": 44006,
      "using visual analogue": 85666,
      "means 95 confidence": 43923,
      "compared using analysis": 18335,
      "using analysis variance": 85306,
      "er oc apap": 29446,
      "mg 650 mg": 45763,
      "crushed ir oc": 21338,
      "opioid patient controlled": 52045,
      "analgesia pca oxycodone": 10056,
      "lumbar spinal fusion": 42757,
      "pain patients randomized": 57354,
      "microg kg oxycodone": 46360,
      "patients assessed pain": 59011,
      "assessed pain visual": 12032,
      "pain visual analogue": 57979,
      "plasma concentration oxycodone": 61903,
      "results study patients": 71983,
      "patients needed average": 59540,
      "average oxycodone morphine": 12919,
      "nausea vomiting pruritus": 48807,
      "pruritus urinary retention": 66312,
      "plasma concentrations morphine": 61913,
      "dose intravenous oxycodone": 25940,
      "intravenous oxycodone morphine": 39873,
      "oxycodone morphine administered": 55469,
      "epidemic prescription opioid": 29146,
      "pre post intervention": 63484,
      "proportion patients prescribed": 65768,
      "median milligrams oxycodone": 44244,
      "milligrams oxycodone prescribed": 46481,
      "cancer non cancer": 14801,
      "cross study patients": 21277,
      "study patients 20": 78364,
      "immediate release opioid": 36728,
      "acute opioid induced": 7655,
      "did result increased": 24496,
      "conclusion results suggest": 18981,
      "immediate release doses": 36713,
      "doses opioid drugs": 26227,
      "sustained release opioid": 79790,
      "risk opioid related": 72618,
      "related adverse outcomes": 69556,
      "study aims determine": 77941,
      "na\u00efve patients methods": 48842,
      "patients methods retrospective": 59505,
      "methods retrospective analysis": 45530,
      "patients ages 18": 58981,
      "ages 18 older": 9249,
      "prescription oxycodone hydrocodone": 64375,
      "opioid prescriptions opioid": 52201,
      "hospitalizations emergency department": 35665,
      "opioid use defined": 52492,
      "use defined opioid": 84294,
      "opioid prescriptions including": 52191,
      "fatal non fatal": 31235,
      "non fatal opioid": 49598,
      "fatal opioid overdose": 31237,
      "hospital discharge data": 35580,
      "adjusted odds ratio": 8043,
      "odds ratio 95": 50925,
      "interval ci 91": 39595,
      "ci 91 00": 16509,
      "adjusted hazard ratio": 8023,
      "hazard ratio ahr": 34615,
      "65 95 ci": 5413,
      "95 ci 45": 6299,
      "ahr 18 95": 9360,
      "18 95 ci": 2075,
      "95 ci 86": 6343,
      "hydrocodone acetaminophen oxycodone": 36057,
      "oxycodone combined acetaminophen": 54806,
      "ahr 26 95": 9363,
      "26 95 ci": 3439,
      "95 ci 06": 6233,
      "previously opioid na\u00efve": 64951,
      "patients risk developing": 59931,
      "oxycodone combination acetaminophen": 54800,
      "overdose related deaths": 54315,
      "23 year old": 3120,
      "chronic pain despite": 16271,
      "inadequate pain control": 37230,
      "pain control patient": 56635,
      "objective opioid treatment": 50456,
      "opioid treatment chronic": 52443,
      "opioid use cohort": 52479,
      "methods opioid use": 45417,
      "opioid use studied": 52595,
      "medical records reviewed": 44397,
      "records reviewed determine": 68727,
      "results opioid prescriptions": 71812,
      "opioid prescriptions year": 52214,
      "opioid treated patients": 52437,
      "pain severity scores": 57828,
      "scores 10 scale": 73825,
      "30 mg codeine": 3755,
      "development tolerance opioids": 24253,
      "effect oxycodone 10": 27516,
      "mg kg tramadol": 46034,
      "kg tramadol 10": 40815,
      "300 mg kg": 3815,
      "mg kg pregabalin": 46020,
      "31 mg kg": 3871,
      "assessed using conditioned": 12085,
      "using conditioned place": 85357,
      "conditioned place aversion": 19296,
      "place aversion cpa": 61599,
      "paw pressure test": 60242,
      "rewarding effect drugs": 72437,
      "place preference cpp": 61601,
      "similar morphine oxycodone": 75951,
      "morphine oxycodone tramadol": 47859,
      "taken data suggest": 80278,
      "drugs different mechanisms": 26937,
      "different mechanisms action": 24887,
      "neuropathic pain opioid": 49249,
      "commonly used treat": 17900,
      "dose route administration": 26074,
      "pain adults search": 56425,
      "adults search methods": 8577,
      "search methods searched": 74118,
      "methods searched cochrane": 45563,
      "searched cochrane central": 74144,
      "controlled trials central": 20624,
      "trials central medline": 83110,
      "searched reference lists": 74162,
      "reference lists retrieved": 69135,
      "lists retrieved studies": 42108,
      "retrieved studies reviews": 72097,
      "online clinical trial": 51096,
      "clinical trial registries": 16935,
      "review included studies": 72313,
      "included studies using": 37560,
      "oxycodone combination naloxone": 54802,
      "double blind studies": 26378,
      "studies weeks duration": 77876,
      "pain data collection": 56678,
      "dichotomous data calculate": 24376,
      "data calculate risk": 21894,
      "calculate risk ratio": 14680,
      "numbers needed treat": 50282,
      "treat additional event": 82279,
      "additional event using": 7859,
      "event using standard": 29996,
      "using standard methods": 85624,
      "standard methods assessed": 76917,
      "assessed evidence using": 12002,
      "evidence using grade": 30292,
      "grade grading recommendations": 33373,
      "grading recommendations assessment": 33386,
      "recommendations assessment development": 68593,
      "assessment development evaluation": 12112,
      "created summary findings": 21148,
      "summary findings table": 79101,
      "findings table main": 31831,
      "table main results": 80075,
      "main results updated": 42864,
      "clinical trial registry": 16937,
      "postherpetic neuralgia studies": 62660,
      "modified release oxycodone": 47245,
      "treat additional beneficial": 82277,
      "additional beneficial outcome": 7845,
      "beneficial outcome nnt": 13600,
      "group mean pain": 33855,
      "mean pain scores": 43832,
      "reported greater pain": 70549,
      "additional harmful outcome": 7865,
      "placebo significantly different": 61826,
      "significantly different groups": 75690,
      "studies reported similar": 77827,
      "quality evidence low": 66693,
      "quality evidence oxycodone": 66695,
      "treatment painful diabetic": 82742,
      "conditions adverse events": 19309,
      "patient pain level": 58700,
      "pain medication usage": 57161,
      "study design prospective": 78079,
      "design prospective cohort": 23758,
      "prospective cohort study": 65821,
      "tertiary care center": 80735,
      "pain medication use": 57162,
      "information collected regarding": 38637,
      "opioid use narcotic": 52542,
      "use pain levels": 84595,
      "postoperative visit results": 62982,
      "postoperative day pod1": 62748,
      "pain significantly higher": 57842,
      "acetaminophen oxycodone use": 7226,
      "higher narcotic use": 35268,
      "narcotic use conclusion": 48616,
      "postoperative pain expectations": 62866,
      "patients level evidence": 59446,
      "noncancer pain cncp": 49708,
      "design systematic review": 23814,
      "systematic review following": 79990,
      "pubmed medline embase": 66453,
      "medline embase cinahl": 44735,
      "inception january 2020": 37251,
      "title abstract text": 81459,
      "criteria systematic review": 21222,
      "cochrane collaboration tool": 17170,
      "newcastle ottawa scale": 49402,
      "future studies area": 32773,
      "long lasting pain": 42317,
      "methods patients scheduled": 45442,
      "prospective single blind": 65880,
      "blind study patients": 13983,
      "study patients underwent": 78376,
      "anesthetic patients randomly": 10971,
      "patients randomly assigned": 59749,
      "randomly assigned receive": 67225,
      "ropivacaine 40 ml": 72792,
      "analog pain scores": 10523,
      "72 hours results": 5620,
      "use opioids surgery": 84569,
      "used opioids compared": 85052,
      "time oxycodone use": 81310,
      "oxycodone use similar": 56055,
      "use similar groups": 84734,
      "conclusions study shows": 19227,
      "peripheral nerve block": 60868,
      "long term administration": 42322,
      "opiates patients chronic": 51338,
      "patients chronic noncancer": 59075,
      "insufficient clinical evidence": 39123,
      "clinical evidence support": 16813,
      "evidence support efficacy": 30270,
      "support efficacy tolerability": 79195,
      "long term efficacy": 42333,
      "pain measured using": 57139,
      "measured using numeric": 44004,
      "using numeric rating": 85529,
      "numeric rating scales": 50303,
      "rating scales nrs": 67683,
      "results thirty patients": 72013,
      "mean sd pain": 43867,
      "reduction significant groups": 69102,
      "daily dose remained": 21733,
      "dose remained stable": 26053,
      "remained stable decreased": 70275,
      "study support hypothesis": 78524,
      "combination low doses": 17565,
      "severe respiratory depression": 75019,
      "effects objective study": 28028,
      "oxycodone compared oxycodone": 54820,
      "design setting participants": 23797,
      "crossover clinical trial": 21286,
      "increasing daily doses": 38100,
      "doses 100 mg": 26121,
      "400 mg placebo": 4395,
      "placebo main outcomes": 61774,
      "main outcomes measures": 42849,
      "compared placebo oxycodone": 18269,
      "vs 35 min": 86568,
      "97 ci 001": 6440,
      "001 significantly decreased": 212,
      "significantly decreased day": 75677,
      "drug related adverse": 26762,
      "compared oxycodone significantly": 18243,
      "oxycodone significantly decreased": 55911,
      "clinical relevance findings": 16884,
      "trial registration clinicaltrials": 83072,
      "registration clinicaltrials gov": 69390,
      "clinicaltrials gov identifier": 17019,
      "effect oral opioids": 27512,
      "blind crossover trial": 13932,
      "invited participate participants": 40090,
      "point numerical rating": 62096,
      "score baseline day": 73733,
      "baseline day day": 13425,
      "treatment primary outcome": 82785,
      "study powered detect": 78420,
      "thirty patients randomized": 81111,
      "placebo group vs": 61755,
      "opioid administration did": 51408,
      "www controlled trials": 87395,
      "controlled trials com": 20628,
      "oral oxycodone intravenous": 53631,
      "mg oxycodone tablet": 46141,
      "treatment results oxycodone": 82821,
      "oxycodone induced respiratory": 55269,
      "oxycodone caused significant": 54772,
      "significant increase number": 75560,
      "mean 95 ci": 43670,
      "healing pain management": 34666,
      "safety oxycodone naloxone": 73186,
      "oxycodone naloxone patients": 55510,
      "provided pain relief": 66146,
      "increased compliance redressing": 37893,
      "compliance redressing wounds": 18537,
      "present study aimed": 64644,
      "study aimed explore": 77931,
      "double blinded way": 26401,
      "decreased 95 ci": 22976,
      "95 ci oxycodone": 6368,
      "25 95 ci": 3343,
      "95 ci 22": 6262,
      "12 95 ci": 1264,
      "66 95 ci": 5453,
      "28 95 ci": 3550,
      "95 ci 27": 6271,
      "effects present study": 28107,
      "present study compared": 64646,
      "efficacy oxycodone fentanyl": 28317,
      "methods thirty patients": 45609,
      "patients received mg": 59795,
      "received mg kg": 68199,
      "kg oxycodone group": 40778,
      "\u03bcg kg fentanyl": 87792,
      "kg fentanyl group": 40727,
      "primary outcomes pain": 65101,
      "outcomes pain scores": 54070,
      "pain scores 11": 57695,
      "scores 11 point": 73827,
      "11 point numeric": 1144,
      "point numeric rating": 62091,
      "scale nrs 24": 73513,
      "analgesics recorded 24": 10489,
      "patients required additional": 59906,
      "mg group mg": 45900,
      "post operative nausea": 62596,
      "operative nausea vomiting": 51254,
      "oxycodone provides better": 55785,
      "reduces post operative": 69002,
      "post operative opioid": 62598,
      "operative opioid consumption": 51257,
      "widespread use opioids": 87087,
      "particularly opioid induced": 58417,
      "constipation oic opioid": 19773,
      "opioid receptor antagonists": 52248,
      "receptor antagonists proposed": 68481,
      "post marketing data": 62580,
      "adverse events reporting": 8804,
      "considered significant results": 19654,
      "adverse drug event": 8623,
      "38 95 ci": 4237,
      "95 ci 28": 6272,
      "45 95 ci": 4579,
      "95 ci 09": 6236,
      "95 ci 67": 6322,
      "92 95 ci": 6153,
      "95 ci 65": 6320,
      "95 95 ci": 6213,
      "95 ci 89": 6346,
      "16 95 ci": 1865,
      "95 ci 93": 6350,
      "95 ci 63": 6318,
      "opioid antagonists used": 51544,
      "effects following administration": 27929,
      "oxycodone design double": 54946,
      "design double blind": 23714,
      "treatment period placebo": 82756,
      "ir oxycodone 30": 40245,
      "oxycodone 30 60": 54549,
      "pupil diameter determined": 66488,
      "baseline pupil diameter": 13457,
      "decrease pain intensity": 22915,
      "aim study evaluate": 9416,
      "oxycodone serotonin noradrenaline": 55893,
      "serotonin noradrenaline reuptake": 74676,
      "reuptake inhibitor venlafaxine": 72204,
      "double blinded placebo": 26394,
      "blinded placebo controlled": 14006,
      "healthy male participants": 34826,
      "mean age 24": 43674,
      "age 24 years": 8987,
      "mg oxycodone 37": 46102,
      "pain intensity observed": 56921,
      "compared placebo 001": 18260,
      "aim study characterize": 9408,
      "strong opioids prescriptions": 77558,
      "prescription patients received": 64382,
      "patients received prescription": 59818,
      "classified strong opioid": 16689,
      "oxycodone morphine strong": 55480,
      "patients opioid naive": 59585,
      "34 95 ci": 4023,
      "95 ci 29": 6273,
      "prescriptions oxycodone morphine": 64531,
      "choice strong opioid": 16123,
      "background pain common": 13142,
      "analgesic efficacy prolonged": 10243,
      "efficacy prolonged release": 28336,
      "release oxycodone naloxone": 69953,
      "naloxone oxn pr": 48477,
      "oxn pr patients": 54429,
      "chronic severe pain": 16343,
      "severe pain methods": 74986,
      "average 24 pain": 12864,
      "pain score assessed": 57669,
      "assessed 11 point": 11976,
      "rating scale pain": 67668,
      "scale pain 10": 73527,
      "pain 10 pain": 56352,
      "10 pain bad": 890,
      "pain bad imagine": 56487,
      "participants randomly assigned": 58350,
      "oxn pr placebo": 54430,
      "dose oxycodone mg": 25993,
      "oxycodone mg naloxone": 55431,
      "mg naloxone mg": 46066,
      "naloxone mg twice": 48462,
      "twice daily patients": 83302,
      "primary endpoint average": 65019,
      "analysis population consisted": 10736,
      "oxn pr group": 54425,
      "group versus placebo": 34068,
      "versus placebo group": 86150,
      "placebo group difference": 61740,
      "group difference 95": 33747,
      "similar proportions patients": 75984,
      "group adverse events": 33666,
      "group placebo group": 33915,
      "efficacy oxn pr": 28313,
      "parkinson disease related": 58229,
      "disease related pain": 25348,
      "funding mundipharma research": 32737,
      "background pharmacokinetics oxycodone": 13161,
      "bolus mg kg": 14220,
      "oxycodone hydrochloride patients": 55193,
      "plasma samples collected": 61958,
      "ml min kg": 46877,
      "min kg groups": 46531,
      "mechanical ventilation time": 44119,
      "dose oxycodone titrated": 26000,
      "individually oxycodone semisynthetic": 38325,
      "current opioid epidemic": 21450,
      "protein kinase pkc": 65938,
      "aims study assess": 9500,
      "dorsal root ganglia": 25738,
      "root ganglia drg": 72784,
      "development opioid tolerance": 24242,
      "oxycodone significantly reduced": 55915,
      "healthy male female": 34824,
      "mg oxycodone hcl": 46116,
      "oxycodone hcl ir": 55153,
      "single oral dose": 76131,
      "peak effect max": 60306,
      "bipolar drug liking": 13876,
      "analog scale results": 10532,
      "completed treatment periods": 18509,
      "showed significantly higher": 75307,
      "drug effects overall": 26614,
      "showed significantly lower": 75308,
      "001 compared oxycodone": 114,
      "oxycodone ir findings": 55311,
      "frequently prescribe analgesics": 32567,
      "general practice dental": 32982,
      "oral maxillofacial surgeons": 53564,
      "strong opioids oxycodone": 77555,
      "oxycodone frequently prescribed": 55108,
      "weak opioids codeine": 86792,
      "opioid mu receptor": 51965,
      "mu receptor agonist": 48138,
      "intravenous patient controlled": 39878,
      "prospective double blind": 65827,
      "blind randomized study": 13977,
      "randomized study involving": 67193,
      "surgery patients given": 79507,
      "mg twice day": 46254,
      "day post operatively": 22382,
      "tramadol mg kg": 82083,
      "mg kg bolus": 45958,
      "oxycodone 03 mg": 54482,
      "double blind fashion": 26356,
      "pain assessed rest": 56462,
      "00 09 00": 5,
      "groups vas scores": 34348,
      "vas scores pain": 86025,
      "analgesia maxillofacial surgery": 10015,
      "surgery risk respiratory": 79572,
      "pain relief findings": 57539,
      "reddit social media": 68823,
      "opioid drugs commonly": 51750,
      "drugs commonly prescribed": 26914,
      "ctl weeks prior": 21366,
      "weeks prior breeding": 86949,
      "mothers taking oxycodone": 48011,
      "freely moving rats": 32501,
      "heroin fentanyl oxycodone": 35000,
      "fentanyl oxycodone morphine": 31554,
      "wide range doses": 87046,
      "associated opioid abuse": 12353,
      "study investigate effects": 78272,
      "10 mg tapentadol": 850,
      "release tablets placebo": 70015,
      "003 95 ci": 249,
      "spinal cord oxycodone": 76710,
      "er extended release": 29417,
      "extended release fentanyl": 30873,
      "fentanyl transdermal patch": 31606,
      "post marketing surveillance": 62582,
      "diversion did increase": 25594,
      "patients receiving tapentadol": 59859,
      "receiving tapentadol ir": 68381,
      "tapentadol ir versus": 80435,
      "ir versus oxycodone": 40265,
      "methods retrospective cohort": 45538,
      "orthopaedic surgery patients": 53821,
      "surgery patients receiving": 79517,
      "outcome measure proportion": 53927,
      "measure proportion patients": 43946,
      "hospital discharge results": 35584,
      "results study cohort": 71977,
      "study cohort included": 77996,
      "patients received tapentadol": 59829,
      "post operatively hospitalisation": 62610,
      "mean age 66": 43701,
      "age 66 years": 9044,
      "total hip arthroplasty": 81811,
      "48 95 ci": 4698,
      "95 ci 36": 6284,
      "95 ci 40": 6291,
      "associated increased likelihood": 12300,
      "increased likelihood opioid": 37941,
      "antinociceptive effect opioids": 11242,
      "fatal opioid overdoses": 31238,
      "clinical trials support": 16963,
      "present studies examined": 64642,
      "studies examined prescription": 77723,
      "dose related increases": 26048,
      "following oxycodone treatment": 32183,
      "did produce significant": 24481,
      "produce significant antinociception": 65368,
      "clinically relevant opioid": 16994,
      "opioid sparing pain": 52370,
      "sparing pain management": 76534,
      "pain management especially": 57068,
      "patients acute musculoskeletal": 58937,
      "acute musculoskeletal pain": 7646,
      "impact opioid induced": 36823,
      "methods patients acute": 45427,
      "patients acute pain": 58939,
      "pain randomized receive": 57458,
      "randomized receive oxycodone": 67174,
      "receive oxycodone acetaminophen": 68066,
      "measured pain using": 43987,
      "multivariable linear regression": 48323,
      "linear regression models": 42031,
      "age sex results": 9121,
      "tramadol codeine hydrocodone": 82041,
      "hydrocodone morphine oxycodone": 36108,
      "morphine oxycodone oxymorphone": 47845,
      "oxycodone oxymorphone hydromorphone": 55617,
      "opioid equianalgesic ratios": 51787,
      "maximum recommended doses": 43613,
      "fentanyl hydromorphone oxycodone": 31501,
      "oxycodone morphine hydrocodone": 55474,
      "morphine oral hydromorphone": 47799,
      "incomplete cross tolerance": 37703,
      "commonly prescribed opioids": 17867,
      "occurrence adverse reactions": 50857,
      "use codeine tramadol": 84245,
      "codeine tramadol oxycodone": 17294,
      "tramadol oxycodone hydrocodone": 82093,
      "design retrospective cohort": 23785,
      "cohort study setting": 17401,
      "participants right study": 58366,
      "received opioid prescription": 68219,
      "31 december 2017": 3867,
      "white median age": 87024,
      "primary secondary outcome": 65109,
      "secondary outcome measures": 74238,
      "outcome measures adverse": 53932,
      "risk adverse reactions": 72518,
      "using logistic regression": 85470,
      "regression adjusted age": 69414,
      "age body mass": 9062,
      "body mass index": 14198,
      "conclusions findings support": 19088,
      "alo 02 capsules": 9658,
      "sequestered naltrexone hcl": 74637,
      "study determine effects": 78108,
      "20 40 ethanol": 2293,
      "pharmacokinetics oxycodone methods": 61179,
      "time maximum concentration": 81284,
      "time curve auc": 81234,
      "curve auc time": 21521,
      "auc time zero": 12640,
      "time zero extrapolated": 81401,
      "zero extrapolated infinity": 87759,
      "extrapolated infinity auc": 30977,
      "maximum concentration cmax": 43585,
      "confidence intervals cis": 19485,
      "generally tolerated background": 33028,
      "tolerated background objective": 81622,
      "background objective study": 13096,
      "objective study compare": 50499,
      "study compare analgesic": 77998,
      "analgesic potency oxycodone": 10294,
      "oxycodone versus morphine": 56077,
      "patients undergoing laparoscopic": 60108,
      "surgery primary outcome": 79534,
      "primary outcome opioid": 65076,
      "opioid consumption 24": 51600,
      "consumption 24 surgery": 19880,
      "24 surgery secondary": 3280,
      "surgery secondary outcomes": 79581,
      "outcomes included time": 54039,
      "time request analgesia": 81359,
      "sedation nausea vomiting": 74321,
      "respiratory depression bradycardia": 71271,
      "recorded results oxycodone": 68695,
      "results oxycodone consumption": 71823,
      "compared morphine group": 18209,
      "longer oxycodone group": 42382,
      "group incidence nausea": 33824,
      "incidence nausea higher": 37283,
      "higher morphine group": 35266,
      "morphine group oxycodone": 47707,
      "analogue scale score": 10556,
      "incidence respiratory depression": 37314,
      "oxycodone potent morphine": 55717,
      "chinese clinical trial": 16092,
      "trial registration number": 83075,
      "http www chictr": 35927,
      "report patient developed": 70471,
      "study objective determine": 78333,
      "effective analgesic treatment": 27597,
      "emergency department methods": 28681,
      "department methods conducted": 23437,
      "conducted prospective randomized": 19391,
      "prospective randomized double": 65863,
      "placebo controlled clinical": 61676,
      "controlled clinical trial": 20470,
      "pain relief measured": 57547,
      "relief measured using": 70141,
      "numeric pain intensity": 50291,
      "pain intensity scale": 56941,
      "exclusion criteria follows": 30486,
      "criteria follows age": 21197,
      "younger 18 years": 87728,
      "inflammatory drugs patients": 38571,
      "use oxycodone acetaminophen": 84581,
      "occurrence adverse effects": 50854,
      "adverse effects results": 8697,
      "patients enrolled study": 59251,
      "significantly greater improvement": 75709,
      "group 95 confidence": 33656,
      "compared control group": 18117,
      "control group 95": 20316,
      "group 95 ci": 33655,
      "ci difference groups": 16527,
      "difference groups 95": 24617,
      "groups 95 ci": 34123,
      "rescue oxycodone acetaminophen": 70969,
      "20 95 ci": 2309,
      "versus control group": 86117,
      "42 95 ci": 4455,
      "appears safe effective": 11409,
      "analgesic action oxycodone": 10138,
      "mediated kappa opioid": 44311,
      "morphine mg day": 47761,
      "oxycodone mg day": 55416,
      "12 mg day": 1323,
      "vas pain scores": 86011,
      "scores rest coughing": 73972,
      "scores nausea vomiting": 73912,
      "nausea vomiting scores": 48813,
      "recorded days surgery": 68680,
      "days surgery results": 22641,
      "received oxycodone mg": 68236,
      "patients received morphine": 59797,
      "day postoperative day": 22384,
      "day significantly higher": 22417,
      "significantly higher patients": 75735,
      "mg day 12": 45851,
      "lower patients received": 42674,
      "significant differences seen": 75518,
      "scores groups conclusion": 73881,
      "purpose purpose study": 66553,
      "purpose study assess": 66571,
      "years 2009 2016": 87533,
      "data used calculate": 22151,
      "doses ddd 1000": 26171,
      "1000 inhabitants day": 1034,
      "various drugs results": 85966,
      "results consumption opioids": 71648,
      "consumption opioids increased": 19963,
      "ddd 1000 day": 22670,
      "17 ddd 1000": 1966,
      "use oxycodone naloxone": 84589,
      "oxycodone naloxone targin": 55521,
      "oxycodone acetaminophen percocet": 54655,
      "increase opioid consumption": 37767,
      "ensure safe use": 29044,
      "use opioids treatment": 84574,
      "receptor mor mediated": 68512,
      "low dose opioid": 42475,
      "oxycodone induced locomotor": 55267,
      "opioid antagonist naloxone": 51537,
      "67 year old": 5482,
      "secondary end stage": 74223,
      "adverse opioid effects": 8830,
      "intensive care unit": 39334,
      "care unit oxycodone": 15088,
      "effectively control pain": 27729,
      "pain major orthopaedic": 57047,
      "highest level pain": 35352,
      "low molecular weight": 42504,
      "molecular weight heparin": 47292,
      "oral sustained release": 53671,
      "offer superior pain": 50953,
      "superior pain control": 79135,
      "opioid dose requirements": 51737,
      "study evaluated effects": 78180,
      "immune function patients": 36765,
      "function patients undergoing": 32668,
      "patients undergoing radical": 60125,
      "undergoing radical resection": 83571,
      "colorectal cancer crc": 17524,
      "group prescribed oxycodone": 33932,
      "oxycodone hydrochloride mg": 55190,
      "hydrochloride mg kg": 36030,
      "mg kg combined": 45961,
      "mg kg postoperative": 46018,
      "kg postoperative analgesia": 40790,
      "received sufentanil \u03bcg": 68290,
      "sufentanil \u03bcg kg": 78955,
      "scale vas score": 73578,
      "score secondary outcomes": 73787,
      "natural killer nk": 48739,
      "killer nk cells": 40832,
      "level interleukin il": 41497,
      "analgesics incidence adverse": 10433,
      "incidence adverse reactions": 37262,
      "group vas scores": 34066,
      "group 12 24": 33565,
      "12 24 hours": 1237,
      "12 24 48": 1233,
      "48 72 hours": 4693,
      "nk cells higher": 49509,
      "incidence postoperative nausea": 37300,
      "applied patient controlled": 11437,
      "reduce pain intensity": 68874,
      "effects cancer patients": 27841,
      "cancer patients objectives": 14883,
      "oxycodone hydromorphone cancer": 55218,
      "methods secondary analysis": 45567,
      "multicenter cohort study": 48155,
      "cancer patients moderate": 14881,
      "palliative care physicians": 58041,
      "24 48 hours": 3168,
      "48 hours results": 4722,
      "patients mean age": 59480,
      "mean age 72": 43705,
      "received morphine oxycodone": 68204,
      "standard error se": 76905,
      "groups respectively significant": 34304,
      "significant differences mean": 75507,
      "scores groups 24": 73880,
      "effective safe cancer": 27697,
      "designed clinical trials": 23828,
      "patients osteoarthritis oa": 59602,
      "400 mg day": 4392,
      "acute pain associated": 7662,
      "pain associated primary": 56475,
      "associated primary dysmenorrhoea": 12394,
      "tension type headache": 80611,
      "effective relieving acute": 27693,
      "relieving acute pain": 70229,
      "generally tolerated clinical": 33030,
      "tolerated clinical trials": 81625,
      "clinical trials similar": 16962,
      "ibuprofen 800 mg": 36349,
      "mg times daily": 46240,
      "naproxen 500 mg": 48565,
      "500 mg twice": 4923,
      "central nervous adverse": 15593,
      "oxycodone combination oxycodone": 54803,
      "adverse event reporting": 8716,
      "study aims explore": 77943,
      "oxycodone combination benzodiazepines": 54801,
      "lower 95 ci": 42571,
      "oxycodone strongly associated": 55944,
      "69 95 ci": 5521,
      "95 ci 24": 6266,
      "95 ci 53": 6309,
      "87 95 ci": 6021,
      "95 ci 68": 6323,
      "08 95 ci": 624,
      "95 ci 38": 6287,
      "09 95 ci": 642,
      "95 ci 76": 6331,
      "23 95 ci": 3086,
      "74 95 ci": 5673,
      "95 ci 15": 6251,
      "ci 15 33": 16403,
      "89 95 ci": 6059,
      "95 ci 17": 6255,
      "86 95 ci": 6006,
      "opioid prescribing practices": 52121,
      "study compared opioid": 78013,
      "oxycodone tablets prescribed": 55981,
      "tablets prescribed common": 80202,
      "prescribed common procedures": 63838,
      "opioid prescribing engagement": 52098,
      "prescribing engagement network": 64056,
      "median number tablets": 44257,
      "recommended opioid prescribing": 68633,
      "opioid prescription practices": 52159,
      "regarding opioid prescribing": 69258,
      "electronic medical record": 28538,
      "limited information exists": 41936,
      "blood pericardial fluid": 14139,
      "buprenorphine oxycodone fentanyl": 14575,
      "oxycodone fentanyl tramadol": 55090,
      "blood drug concentrations": 14120,
      "methadone oxycodone fentanyl": 45116,
      "results interpreted caution": 71738,
      "widely prescribed chronic": 87058,
      "noncancer pain despite": 49710,
      "time pain relief": 81313,
      "population chronic pain": 62318,
      "chronic pain methods": 16286,
      "design single center": 23804,
      "single center randomized": 76064,
      "arm open label": 11669,
      "open label exploratory": 51160,
      "intervention patients randomized": 39639,
      "oxycodone sustained release": 55971,
      "sustained release sr": 79796,
      "nausea vomiting constipation": 48796,
      "include pain relief": 37364,
      "number oxycodone doses": 50209,
      "health organization international": 34745,
      "organization international clinical": 53771,
      "objective evaluate clinical": 50410,
      "evaluate clinical effect": 29779,
      "clinical effect safety": 16797,
      "safety oxycodone hydrochloride": 73185,
      "patients undergoing percutaneous": 60121,
      "randomly divided groups": 67233,
      "divided groups oxycodone": 25625,
      "groups oxycodone group": 34255,
      "group fentanyl group": 33780,
      "group dezocine group": 33739,
      "group group 20": 33791,
      "mg kg fentanyl": 45973,
      "001 mg kg": 157,
      "mg kg dezocine": 45968,
      "dezocine mg kg": 24307,
      "pressure map heart": 64743,
      "map heart rate": 43347,
      "respiratory rate rr": 71295,
      "respiratory depression nausea": 71279,
      "postoperative pain scores": 62919,
      "pain scores recorded": 57770,
      "scores recorded using": 73965,
      "completed patients patients": 18483,
      "groups significant differences": 34321,
      "time points groups": 81337,
      "group lower group": 33844,
      "group group pain": 33802,
      "visual analogue scores": 86332,
      "group group group": 33797,
      "postoperative pain score": 62918,
      "group group significantly": 33806,
      "intraoperative respiratory depression": 39782,
      "terms postoperative pain": 80717,
      "postoperative pain objective": 62897,
      "pain objective evaluate": 57263,
      "compared immediate release": 18183,
      "opioid users design": 52619,
      "single center single": 76069,
      "center single dose": 15553,
      "dose randomized double": 26026,
      "blind active controlled": 13918,
      "setting inpatient clinical": 74781,
      "randomized receive 15": 67163,
      "receive 15 mg": 68040,
      "effect max drug": 27481,
      "subjects randomized treatment": 78729,
      "mean drug liking": 43772,
      "drug liking vas": 26690,
      "liking vas max": 41871,
      "opioid users background": 52617,
      "physical mental health": 61406,
      "little known risk": 42165,
      "use aim study": 84185,
      "determine risk factors": 24049,
      "risk factors prolonged": 72575,
      "retrospective single center": 72166,
      "nested case control": 49146,
      "case control study": 15168,
      "study population consisted": 78412,
      "adult patients received": 8517,
      "oxycodone prescription discharge": 55745,
      "2020 primary outcome": 2908,
      "outcome proportion patients": 53982,
      "period 30 days": 60702,
      "days secondary outcome": 22618,
      "potential risk factors": 63221,
      "risk factors oxycodone": 72572,
      "multivariate logistic regression": 48347,
      "logistic regression analyses": 42255,
      "regression analyses performed": 69418,
      "01 95 confidence": 300,
      "confidence interval 00": 19436,
      "scale pain score": 73535,
      "pain score higher": 57674,
      "conclusion proportion patients": 18975,
      "determined risk factors": 24087,
      "prolonged use purpose": 65644,
      "diclofenac 50 mg": 24384,
      "diazepam 10 mg": 24368,
      "methods asa physical": 45254,
      "outpatients age 18": 54159,
      "age 18 60": 8976,
      "18 60 yr": 2058,
      "given rescue medication": 33195,
      "patients received diclofenac": 59776,
      "mg kg im": 45981,
      "im postoperative pain": 36675,
      "pain using visual": 57963,
      "results vas scores": 72052,
      "end second postoperative": 28813,
      "second postoperative days": 74195,
      "patients required postoperative": 59908,
      "diclofenac premedication reduced": 24396,
      "prescription opioids medical": 64348,
      "opioids medical use": 53044,
      "use opioids elderly": 84561,
      "use opioids increased": 84563,
      "increase total consumption": 37813,
      "average daily cost": 12883,
      "opioids including oxycodone": 52981,
      "little known mechanisms": 42162,
      "prenatal opioid exposure": 63728,
      "acute opioid exposure": 7654,
      "nucleus accumbens nac": 50126,
      "maternal oxycodone self": 43526,
      "oxycodone self administration": 55875,
      "self administration pregnancy": 74471,
      "adult male female": 8495,
      "oxycodone conditioned place": 54843,
      "work demonstrates time": 87273,
      "play key role": 61994,
      "healthy volunteers received": 34860,
      "07 mg kg": 607,
      "14 mg kg": 1606,
      "mean arterial blood": 43715,
      "arterial blood pressure": 11711,
      "double blinded randomized": 26396,
      "randomized study evaluated": 67192,
      "studies healthy volunteers": 77738,
      "longitudinal cohort study": 42399,
      "cohort study using": 17405,
      "2011 december 31": 2581,
      "december 31 2014": 22834,
      "adults aged 18": 8543,
      "mean age 62": 43697,
      "age 62 years": 9037,
      "charlson comorbidity index": 15923,
      "patient characteristics similar": 58556,
      "recommended line pharmacological": 68624,
      "patients used opioid": 60165,
      "used opioid morphine": 85046,
      "response rate 71": 71363,
      "na\u00efve patients mean": 48841,
      "study evaluate feasibility": 78170,
      "patients refractory pain": 59874,
      "female male patients": 31362,
      "impact pain daily": 36830,
      "pain daily activities": 56676,
      "daily activities results": 21695,
      "activities daily living": 7550,
      "methods patients aged": 45429,
      "patients aged 18": 58970,
      "drug 30 days": 26496,
      "aged 18 64": 9161,
      "endoscopic retrograde cholangiopancreatography": 28861,
      "retrograde cholangiopancreatography ercp": 72101,
      "background limited data": 13076,
      "telephone survey conducted": 80575,
      "results patients underwent": 71858,
      "patients underwent total": 60155,
      "pain scores decreased": 57714,
      "emergency room visits": 28697,
      "associated decreased pain": 12247,
      "pain analgesic usage": 56448,
      "clinical trial evaluated": 16928,
      "adjunctive analgesic cardiac": 8007,
      "analgesic cardiac surgery": 10160,
      "ninety patients scheduled": 49485,
      "scheduled elective coronary": 73645,
      "elective coronary artery": 28490,
      "coronary artery bypass": 20782,
      "artery bypass grafting": 11726,
      "bypass grafting cabg": 14633,
      "followed continuous infusion": 32053,
      "microg kg min": 46359,
      "extubation patients access": 30998,
      "access opioid oxycodone": 6996,
      "opioid oxycodone patient": 52031,
      "oxycodone patient controlled": 55650,
      "controlled analgesia device": 20448,
      "pain evaluated visual": 56764,
      "evaluated visual analog": 29937,
      "analog scale times": 10537,
      "scale times daily": 73566,
      "patient satisfaction pain": 58766,
      "adverse effects recorded": 8691,
      "oxycodone consumption 48": 54855,
      "48 postoperative hours": 4745,
      "mg 95 confidence": 45782,
      "confidence interval difference": 19478,
      "pain scores did": 57715,
      "scores did differ": 73864,
      "differ groups rest": 24542,
      "adverse events similar": 8813,
      "patients ketamine group": 59432,
      "placebo group conclusion": 61739,
      "decreased opioid consumption": 23015,
      "opioid analgesics drug": 51495,
      "drug abuse related": 26507,
      "objective determine impact": 50399,
      "shared decision making": 75120,
      "postsurgical opioid prescribing": 63050,
      "minimally invasive mis": 46585,
      "design randomized controlled": 23772,
      "controlled trial setting": 20618,
      "trial setting single": 83087,
      "single tertiary care": 76144,
      "tertiary care academic": 80733,
      "30 tablets oxycodone": 3801,
      "tablets oxycodone mg": 80191,
      "measures primary outcome": 44089,
      "primary outcome percentage": 65086,
      "excess opioid tablets": 30453,
      "number tablets prescribed": 50266,
      "outcomes included total": 54040,
      "included total opioid": 37569,
      "opioid tablets used": 52401,
      "opioid tablets discharge": 52396,
      "number opioid tablets": 50198,
      "opioid tablets prescribed": 52398,
      "race body mass": 66937,
      "oxycodone prescribed patient": 55742,
      "total number oxycodone": 81854,
      "mean number oxycodone": 43809,
      "decrease total number": 22932,
      "oxycodone tablets used": 55983,
      "patients undergoing mis": 60114,
      "standard 30 tablets": 76886,
      "transdermal fentanyl compared": 82147,
      "probabilistic sensitivity analysis": 65215,
      "transdermal fentanyl patients": 82157,
      "adjusted life year": 8031,
      "nonmalignant moderate severe": 49769,
      "pain objective study": 57268,
      "study determine effect": 78107,
      "bioavailability oxycodone oxycodone": 13840,
      "label randomized crossover": 40995,
      "abuse potential opioid": 6822,
      "nonmedical use prescription": 49788,
      "behavioral effects oxycodone": 13547,
      "effects oxycodone male": 28067,
      "oxycodone male rats": 55366,
      "rats trained intravenously": 67899,
      "trained intravenously self": 82004,
      "intravenously self administer": 39901,
      "mg kg infusion": 45986,
      "mg kg groups": 45978,
      "dose dependent effects": 25868,
      "groups male female": 34230,
      "male female wistar": 43037,
      "female wistar rats": 31383,
      "50 mg ml": 4857,
      "mg ml oxycodone": 46057,
      "ml oxycodone 100": 46886,
      "oxycodone 100 mg": 54508,
      "tail withdrawal latency": 80253,
      "additive antinociceptive effects": 7914,
      "kg oxycodone mg": 40781,
      "suggest potential use": 79012,
      "used opioid analgesics": 85044,
      "opioid analgesics clinical": 51486,
      "clinical management pain": 16835,
      "present retrospective analysis": 64637,
      "dose oxycodone achieve": 25989,
      "clinically relevant reduction": 16997,
      "pain methods data": 57179,
      "methods data patients": 45306,
      "combination oxycodone 10": 17584,
      "oxycodone 10 20": 54493,
      "10 20 mg": 687,
      "total daily dose": 81794,
      "pain intensity treatment": 56955,
      "using numeric pain": 85527,
      "numeric pain rating": 50293,
      "rating scale results": 67674,
      "baseline pain score": 13449,
      "pain score reduced": 57680,
      "doses oxycodone mg": 26238,
      "325 mg acetaminophen": 3954,
      "conclusion low dose": 18923,
      "low dose combination": 42468,
      "combination oxycodone acetaminophen": 17585,
      "effective management moderate": 27637,
      "treatment associated adverse": 82453,
      "adverse reactions drug": 8842,
      "article processing charges": 11777,
      "study compare efficacy": 78001,
      "efficacy safety quality": 28383,
      "safety quality life": 73215,
      "oxycodone plus pregabalin": 55698,
      "cr oxycodone pregabalin": 21096,
      "oxycodone pregabalin patients": 55734,
      "pain materials methods": 57135,
      "materials methods patients": 43511,
      "moderate severe neuropathic": 47187,
      "severe neuropathic pain": 74958,
      "neuropathic pain despite": 49241,
      "treated cr oxycodone": 82332,
      "pain intensity rated": 56933,
      "intensity rated 11": 39298,
      "rated 11 point": 67528,
      "combination cr oxycodone": 17553,
      "oxycodone monotherapy effective": 55463,
      "significantly greater improvements": 75710,
      "receiving cr oxycodone": 68329,
      "treatment effective effective": 82565,
      "safety profile compared": 73205,
      "pregabalin represent valuable": 63683,
      "use opioid analgesics": 84543,
      "gather information prescription": 32908,
      "information prescription drug": 38663,
      "drug abuse treatment": 26508,
      "past 30 days": 58458,
      "exposure opioid analgesics": 30782,
      "abused prescription opioid": 6924,
      "opioid analgesics hydrocodone": 51502,
      "risk benefit ratio": 72527,
      "background efficacy tolerability": 13047,
      "efficacy tolerability oral": 28405,
      "release oxycodone therapy": 69980,
      "observational study patients": 50632,
      "patients severe severe": 59972,
      "controlled released oxycodone": 20576,
      "scale nrs 10": 73511,
      "results pain intensity": 71831,
      "quality life improved": 66728,
      "life improved significantly": 41702,
      "release oxycodone efficient": 69934,
      "effective pain relief": 27663,
      "quality life objective": 66732,
      "life objective evaluate": 41710,
      "objective evaluate impact": 50421,
      "er la opioids": 29434,
      "cohort study analyzed": 17384,
      "claims data adult": 16621,
      "data adult patients": 21866,
      "conclusions results study": 19204,
      "results study suggest": 71988,
      "formulations extended release": 32380,
      "release er opioids": 69846,
      "opioids abuse deterrent": 52693,
      "abuse deterrent technology": 6707,
      "care pain patients": 15051,
      "following introduction reformulated": 32152,
      "introduction reformulated er": 39952,
      "continuous users extended": 20191,
      "users extended release": 85240,
      "long acting la": 42290,
      "opioid treatment month": 52449,
      "opioid abuse dependence": 51367,
      "pearson chi squared": 60336,
      "chi squared tests": 15991,
      "fisher exact tests": 31854,
      "tests used compare": 80867,
      "rates diagnosed opioid": 67569,
      "diagnosed opioid abuse": 24324,
      "opioid abuse results": 51381,
      "higher patients compared": 35291,
      "limitations observational research": 41905,
      "observational research design": 50619,
      "caution warranted causal": 15419,
      "warranted causal interpretation": 86729,
      "causal interpretation findings": 15334,
      "er oxycodone er": 29458,
      "commercial insurance medicare": 17709,
      "insurance medicare medicaid": 39152,
      "rates opioid abuse": 67606,
      "higher patients switched": 35293,
      "prescription opioids abuse": 64324,
      "treatment cancer related": 82468,
      "palliative care practice": 58042,
      "methods multicenter prospective": 45389,
      "adult cancer patients": 8489,
      "cancer patients starting": 14891,
      "oxycodone hydromorphone fentanyl": 55220,
      "intensity using numerical": 39324,
      "using numerical rating": 85532,
      "hours 72 hours": 35742,
      "common opioid related": 17781,
      "68 95 confidence": 5496,
      "95 confidence intervals": 6396,
      "confidence intervals ci": 19483,
      "75 95 ci": 5702,
      "95 ci 70": 6325,
      "82 95 ci": 5903,
      "ci 76 87": 16492,
      "73 95 ci": 5650,
      "95 ci 46": 6300,
      "99 95 ci": 6485,
      "95 ci 71": 6326,
      "47 95 ci": 4655,
      "common treatment emergent": 17820,
      "treatment emergent ae": 82575,
      "period multivariate analysis": 60754,
      "mental health services": 44823,
      "opioid use self": 52590,
      "use self reported": 84724,
      "methods systematically reviewed": 45605,
      "systematically reviewed literature": 80012,
      "opioid use previous": 52577,
      "opioid use reported": 52584,
      "systematic literature review": 79977,
      "tramadol 20 oxycodone": 82025,
      "controlled trials needed": 20641,
      "objectives aim study": 50538,
      "nursing home residents": 50342,
      "short acting oxycodone": 75162,
      "oxycodone hydrocodone tramadol": 55214,
      "minimum data set": 46610,
      "data set medicare": 22105,
      "inverse probability treatment": 39989,
      "probability treatment weighting": 65222,
      "100 person years": 1015,
      "95 ci hydrocodone": 6365,
      "95 ci 79": 6335,
      "67 95 ci": 5473,
      "95 ci 56": 6312,
      "objective study estimate": 50508,
      "urine drug testing": 84076,
      "drug testing program": 26808,
      "substance abuse program": 78799,
      "21 years age": 2989,
      "urine drug test": 84075,
      "drug test results": 26805,
      "confirmed positive opioids": 19507,
      "potential false negatives": 63167,
      "prescription counter medication": 64190,
      "use total 85": 84777,
      "drugs substantial risk": 27085,
      "activity opioid receptor": 7576,
      "opioid receptor kor": 52258,
      "recent evidence revealed": 68401,
      "activation opioid receptor": 7474,
      "opioid receptor dor": 52253,
      "reactive oxygen species": 67978,
      "taken findings indicate": 80283,
      "objective evaluate efficacy": 50417,
      "tablets treatment moderate": 80226,
      "postoperative pain following": 62867,
      "pain following bunionectomy": 56788,
      "repeat dose study": 70393,
      "dose study clinicaltrials": 26084,
      "study clinicaltrials gov": 77993,
      "severe pain post": 74997,
      "randomized receive placebo": 67176,
      "placebo 30 mg": 61630,
      "hours 48 hours": 35739,
      "efficacy endpoint sum": 28262,
      "endpoint sum pain": 28902,
      "scores 48 hours": 73837,
      "48 hours spid": 4725,
      "hours spid 48": 35855,
      "initial dose study": 38844,
      "dose study drug": 26087,
      "study drug secondary": 78137,
      "secondary efficacy endpoints": 74215,
      "analysis use rescue": 10784,
      "rescue medication safety": 70957,
      "included adverse events": 37414,
      "doses oxycodone hcl": 26235,
      "reductions pain intensity": 69118,
      "pain intensity compared": 56891,
      "intensity compared placebo": 39238,
      "0001 oxycodone hcl": 74,
      "mg 30 mg": 45738,
      "provide effective analgesia": 66052,
      "analgesia generally tolerated": 9983,
      "generally tolerated patients": 33032,
      "aim present study": 9396,
      "compare analgesic efficacy": 18008,
      "intravenous oxycodone dose": 39871,
      "15 oxycodone mg": 1781,
      "multimodal analgesia patients": 48201,
      "analgesia patients received": 10052,
      "patients received paracetamol": 59815,
      "primary outcome total": 65096,
      "group mean difference": 33854,
      "difference 95 confidence": 24589,
      "confidence interval 01": 19438,
      "epidural infusion patient": 29184,
      "postoperative opioid oxycodone": 62818,
      "opioid oxycodone consumption": 52026,
      "surgery materials methods": 79454,
      "materials methods prospective": 43512,
      "methods prospective randomized": 45491,
      "randomized observer blinded": 67129,
      "requiring surgical intervention": 70918,
      "using 10 cm": 85284,
      "10 cm visual": 746,
      "scale vas time": 73580,
      "24 hours postoperatively": 3226,
      "data analyzed using": 21878,
      "tailed mann whitney": 80258,
      "mann whitney test": 43318,
      "significantly lower average": 75778,
      "significantly increased opioid": 75756,
      "orally administered opioids": 53691,
      "importance opioid epidemic": 36985,
      "opioid prescribing common": 52089,
      "recent studies shown": 68426,
      "prescription patterns following": 64384,
      "endoscopic sinus surgery": 28864,
      "sinus surgery ess": 76150,
      "different analgesic regimens": 24844,
      "randomized clinical trial": 67045,
      "clinical trial conducted": 16926,
      "2019 march 2020": 2874,
      "2020 data analyzed": 2897,
      "data analyzed november": 21876,
      "participants received acetaminophen": 58352,
      "acetaminophen 650 mg": 7139,
      "patients randomized oxycodone": 59738,
      "rescue oxycodone mg": 70971,
      "second line therapy": 74190,
      "ibuprofen 600 mg": 36347,
      "collected postoperative day": 17476,
      "postoperative day primary": 62752,
      "day primary outcome": 22393,
      "primary outcome postoperative": 65087,
      "analog scale score": 10533,
      "pain brief pain": 56501,
      "pain severity pain": 57825,
      "severity pain interference": 75046,
      "total 118 patients": 81716,
      "group groups similar": 33809,
      "groups similar demographic": 34325,
      "similar demographic characteristics": 75911,
      "adequate pain management": 7965,
      "acetaminophen 69 vs": 7142,
      "95 ci 37": 6285,
      "analog scale scores": 10534,
      "clinical trial patients": 16931,
      "use low groups": 84462,
      "groups trial registration": 34342,
      "purpose study compare": 66573,
      "study compare postoperative": 78003,
      "compare postoperative pain": 18044,
      "anterior cruciate ligament": 11104,
      "cruciate ligament acl": 21324,
      "ligament acl reconstruction": 41757,
      "patients receiving adductor": 59835,
      "receiving adductor canal": 68321,
      "adductor canal block": 7946,
      "canal block acb": 14759,
      "liposomal bupivacaine lb": 42073,
      "cohort study patients": 17398,
      "study patients undergoing": 78375,
      "academic medical center": 6952,
      "325 mg oxycodone": 3959,
      "mg oxycodone acetaminophen": 46106,
      "reduction opioids prescribed": 69081,
      "quality improvement initiative": 66707,
      "narcotic consumption postoperative": 48592,
      "consumption postoperative days": 19993,
      "rating scale total": 67679,
      "total postoperative opioid": 81890,
      "opioid consumption reported": 51659,
      "converted oral morphine": 20737,
      "morphine equivalents omes": 47676,
      "met eligibility criteria": 44871,
      "mean standard deviation": 43880,
      "mean postoperative pain": 43842,
      "pain scores similar": 57784,
      "scores similar groups": 73994,
      "opioid consumption lower": 51628,
      "lower patients receiving": 42675,
      "ome interquartile range": 51058,
      "similar postoperative pain": 75981,
      "postoperative pain compared": 62856,
      "opioid consumption given": 51622,
      "reduce opioid prescribing": 68863,
      "opioid prescribing patients": 52116,
      "patients completed opioid": 59111,
      "opioid consumption aclr": 51605,
      "tolerance opioid induced": 81593,
      "study investigated dose": 78275,
      "physiological effects oxycodone": 61461,
      "multiple linear regression": 48283,
      "predictor variables included": 63584,
      "patient health questionnaire": 58655,
      "analgesics codeine tramadol": 10394,
      "analgesics fentanyl oxycodone": 10423,
      "results prevalence rates": 71889,
      "high potency opioid": 35144,
      "opioid use odds": 52547,
      "use odds ratio": 84536,
      "interval ci 16": 39582,
      "potency opioid medications": 63080,
      "prescription opioid medication": 64299,
      "opioid medication used": 51908,
      "opioid use discharge": 52498,
      "searched medline embase": 74156,
      "study selection studies": 78481,
      "gynecologic surgical procedures": 34491,
      "outpatient opioids consumed": 54132,
      "opioid use disorder": 52499,
      "reviewers independently screened": 72398,
      "articles met inclusion": 11799,
      "met inclusion criteria": 44877,
      "morphine milligram equivalents": 47770,
      "milligram equivalents mme": 46461,
      "equivalents mme used": 29364,
      "54 95 ci": 5045,
      "tablets mg oxycodone": 80177,
      "35 95 ci": 4074,
      "95 ci 75": 6330,
      "59 95 ci": 5186,
      "95 ci 44": 6297,
      "ci 44 74": 16453,
      "oxycodone laparoscopic hysterectomy": 55329,
      "95 ci 80": 6336,
      "mme 95 ci": 46951,
      "24 hours discharge": 3215,
      "10 tablets mg": 937,
      "mg oxycodone discharge": 46111,
      "14 days postdischarge": 1590,
      "opioid use occurred": 52546,
      "fewer mg oxycodone": 31643,
      "mg oxycodone tablets": 46142,
      "reduce medication diversion": 68853,
      "purpose study determine": 66576,
      "regional anesthesia ra": 69353,
      "surgery methods patients": 79464,
      "patients undergoing ambulatory": 60087,
      "surgery randomly assigned": 79550,
      "brachial plexus block": 14309,
      "surgery patients rated": 79515,
      "pain visual analog": 57977,
      "analog scale pain": 10526,
      "pain disability index": 56722,
      "pain adverse effects": 56429,
      "measured postoperative days": 43991,
      "postoperative days 14": 62760,
      "opioid consumption adverse": 51606,
      "consumption adverse effects": 19892,
      "adverse effects pain": 8682,
      "group 001 time": 33530,
      "time analgesic request": 81209,
      "opioid consumption reduced": 51657,
      "patients experienced nausea": 59280,
      "experienced nausea vomiting": 30616,
      "nausea vomiting recovery": 48809,
      "significant reduction pain": 75615,
      "home postoperative day": 35520,
      "postoperative day 14": 62735,
      "day 14 days": 22246,
      "14 days surgery": 1595,
      "opioid analgesic agents": 51451,
      "oxycodone widely abused": 56094,
      "abused opioid analgesic": 6920,
      "levels nucleus accumbens": 41580,
      "maintain self administration": 42883,
      "self administration behavior": 74461,
      "doses mg kg": 26216,
      "brain hypoxia induced": 14340,
      "developed abuse deterrent": 24165,
      "deterrent formulation extended": 24110,
      "formulation extended release": 32342,
      "doses alo 02": 26147,
      "methods irb approved": 45367,
      "period crossover study": 60718,
      "crossover study 24": 21299,
      "healthy adult volunteers": 34814,
      "adult volunteers aged": 8528,
      "volunteers aged 18": 86415,
      "administered intact capsule": 8141,
      "high fat breakfast": 35100,
      "plasma samples analyzed": 61957,
      "48 hours postdose": 4716,
      "pharmacokinetic parameters included": 61126,
      "parameters included maximum": 58161,
      "included maximum plasma": 37476,
      "plasma concentration cmax": 61900,
      "tmax values oxycodone": 81497,
      "40 mg tolerated": 4360,
      "conclusion results indicate": 18979,
      "alternative treatment option": 9746,
      "aim investigate cyp2d6": 9392,
      "2006 31 december": 2481,
      "drug use 76": 26829,
      "76 95 ci": 5739,
      "20 times risk": 2385,
      "17 95 ci": 1954,
      "19 95 ci": 2180,
      "95 ci 84": 6340,
      "04 95 ci": 448,
      "95 ci 82": 6338,
      "oxycodone morphine fentanyl": 55471,
      "morphine fentanyl buprenorphine": 47689,
      "opioids objective compare": 53106,
      "use chronic pain": 84238,
      "opioid overdose death": 52011,
      "patients opioid treatment": 59592,
      "proportion days covered": 65741,
      "treatment main outcome": 82648,
      "average daily dose": 12884,
      "oxycodone methods healthy": 55401,
      "healthy subjects ingested": 34846,
      "cross study day": 21274,
      "day ingested 10": 22323,
      "ingested 10 mg": 38739,
      "48 pharmacodynamic effects": 4742,
      "effects recorded results": 28130,
      "oxycodone mean area": 55375,
      "curve auc infinity": 21519,
      "auc infinity oxycodone": 12632,
      "infinity oxycodone increased": 38544,
      "oxycodone increased fold": 55246,
      "increased fold range": 37917,
      "fold range fold": 32001,
      "peak plasma concentration": 60317,
      "plasma concentration fold": 61901,
      "fold 001 compared": 31982,
      "001 compared placebo": 115,
      "ratio noroxycodone oxycodone": 67780,
      "001 oxymorphone increased": 177,
      "effects oxycodone modestly": 28070,
      "exposure oral oxycodone": 30785,
      "lower doses oxycodone": 42605,
      "doses oxycodone needed": 26241,
      "avoid opioid related": 12960,
      "related adverse effects": 69549,
      "current opioid crisis": 21449,
      "pain inadequately controlled": 56856,
      "patient reported pain": 58739,
      "reported pain outcomes": 70613,
      "survey study conducted": 79741,
      "july 2018 january": 40524,
      "2018 january 2019": 2824,
      "consecutive patients underwent": 19566,
      "surgeons academic medical": 79266,
      "surgery main outcomes": 79450,
      "measures number oxycodone": 44071,
      "prescription refills patient": 64398,
      "refills patient reported": 69177,
      "statistical analysis performed": 77172,
      "analysis performed using": 10732,
      "spearman rank order": 76553,
      "rank order correlation": 67363,
      "order correlation used": 53709,
      "variables 05 considered": 85886,
      "05 considered statistically": 507,
      "considered statistically significant": 19656,
      "statistically significant results": 77231,
      "lost follow participants": 42443,
      "women mean sd": 87223,
      "sd age 38": 74074,
      "men mean sd": 44801,
      "range 10 40": 67247,
      "40 tablets oxycodone": 4380,
      "significant sex differences": 75635,
      "narcotic use patients": 48619,
      "use patients undergoing": 84616,
      "statistically significant negative": 77227,
      "patients experienced pain": 59282,
      "study prospectively evaluate": 78433,
      "evaluate association opioid": 29774,
      "association opioid use": 12482,
      "opioid use patient": 52560,
      "use patient reported": 84610,
      "patient satisfaction level": 58762,
      "satisfaction level evidence": 73404,
      "metabolized cytochrome p450": 44996,
      "prevalence cyp2d6 polymorphisms": 64779,
      "review board approval": 72266,
      "gc ms results": 32921,
      "significantly different control": 75689,
      "different control group": 24856,
      "fisher exact test": 31853,
      "cause manner death": 15360,
      "electronic health records": 28535,
      "interaction risk opioid": 39382,
      "risk opioid withdrawal": 72624,
      "received single dose": 68272,
      "single dose oxycodone": 76085,
      "admission intensive care": 8409,
      "purpose review review": 66566,
      "rotigotine transdermal patch": 72830,
      "effective treatment chronic": 27715,
      "deep brain stimulation": 23089,
      "patients suffering pain": 60019,
      "past medical history": 58467,
      "abused prescription opioids": 6926,
      "national institute drug": 48693,
      "institute drug abuse": 39069,
      "data substance abuse": 22126,
      "substance abuse mental": 78797,
      "abuse mental health": 6774,
      "health services administration": 34773,
      "data centers disease": 21899,
      "disease control prevention": 25326,
      "controlled study investigated": 20591,
      "study investigated effect": 78276,
      "pregabalin oxycodone consumption": 63673,
      "oxycodone consumption postoperative": 54866,
      "cardiac surgery patients": 14984,
      "surgery patients methods": 79510,
      "patients methods seventy": 59507,
      "methods seventy patients": 45576,
      "patients aged 75": 58979,
      "randomized receive 150": 67165,
      "150 mg pregabalin": 1812,
      "75 mg pregabalin": 5709,
      "daily postoperative days": 21801,
      "placebo pain intensity": 61797,
      "pain intensity measured": 56910,
      "verbal rating scale": 86075,
      "received oxycodone 05": 68229,
      "oxycodone 05 mg": 54485,
      "10 15 mg": 674,
      "postoperative pain assessed": 62846,
      "oxycodone consumption extubation": 54860,
      "fifth postoperative day": 31687,
      "group time extubation": 34047,
      "scores significantly lower": 73991,
      "lower postoperative day": 42680,
      "day placebo group": 22373,
      "placebo group significant": 61751,
      "group significant difference": 34010,
      "significant difference respect": 75492,
      "mental state examination": 44829,
      "pain movement significantly": 57216,
      "movement significantly lower": 48055,
      "significantly lower pregabalin": 75804,
      "lower pregabalin group": 42686,
      "opioid consumption cardiac": 51613,
      "consumption cardiac surgery": 19904,
      "group experienced pain": 33774,
      "objective purpose study": 50479,
      "purpose study examine": 66583,
      "opioid analgesic users": 51474,
      "rural appalachian kentucky": 73047,
      "years interquartile range": 87601,
      "injection drug use": 38944,
      "oral opioid analgesic": 53600,
      "prevalence self reported": 64815,
      "respectively conclusions opioid": 71181,
      "conclusions opioid analgesic": 19133,
      "rural opioid users": 73052,
      "urban drug users": 84029,
      "course opioid analgesic": 20995,
      "use pain management": 84597,
      "pain management study": 57124,
      "total opioid prescribing": 81865,
      "january 2016 june": 40452,
      "morphine codeine fentanyl": 47601,
      "codeine fentanyl hydrocodone": 17231,
      "fentanyl hydrocodone hydromorphone": 31490,
      "hydrocodone hydromorphone meperidine": 36085,
      "opioids gabapentin pregabalin": 52927,
      "gabapentin pregabalin opioid": 32803,
      "claims data analyzed": 16623,
      "data analyzed separately": 21877,
      "pre versus post": 63495,
      "vs 30 mg": 86560,
      "pain reduce opioid": 57490,
      "reduce opioid use": 68868,
      "opioid use public": 52579,
      "effects morphine fentanyl": 28007,
      "mice treated morphine": 46324,
      "beneficial adverse effects": 13595,
      "adverse effects patient": 8685,
      "majority opioids prescribed": 42988,
      "opioids prescribed treat": 53213,
      "treat chronic non": 82288,
      "regarding long term": 69254,
      "term use opioids": 80680,
      "release short acting": 70004,
      "short acting opioid": 75158,
      "study investigate effect": 78270,
      "investigate effect oxycodone": 40005,
      "materials methods total": 43517,
      "sprague dawley sd": 76775,
      "dawley sd rats": 22231,
      "rats randomly divided": 67880,
      "quantitative polymerase chain": 66802,
      "chain reaction qpcr": 15689,
      "results showed compared": 71947,
      "significantly increased compared": 75754,
      "group statistically significant": 34032,
      "significant differences 05": 75498,
      "group 05 conclusions": 33553,
      "adequate pain control": 7962,
      "patients case report": 59055,
      "percocet endo pharmaceuticals": 60533,
      "emergency medical services": 28690,
      "patients history substance": 59366,
      "opioids tramadol oxycodone": 53345,
      "high doses opioids": 35092,
      "opioids morphine buprenorphine": 53066,
      "opioid maintenance treatment": 51894,
      "2016 december 2017": 2741,
      "2018 december 2018": 2819,
      "medication use quality": 44582,
      "quality pain management": 66752,
      "pain management results": 57117,
      "pain children undergoing": 56535,
      "rats methods male": 67869,
      "male sd rats": 43054,
      "groups control group": 34167,
      "control group oxycodone": 20332,
      "toll like receptor": 81648,
      "like receptor tlr4": 41782,
      "results oxycodone significantly": 71827,
      "il 1\u03b2 tnf": 36609,
      "oxycodone treatment reduced": 56031,
      "cross blood brain": 21246,
      "brain derived neurotrophic": 14334,
      "derived neurotrophic factor": 23631,
      "neurotrophic factor bdnf": 49298,
      "aim study explore": 9422,
      "term opioid therapy": 80645,
      "opioid therapy methods": 52416,
      "patients chronic low": 59068,
      "chronic low pain": 16200,
      "tramadol oxycodone morphine": 82096,
      "control group included": 20329,
      "opioid therapy recorded": 52424,
      "daily dose duration": 21728,
      "dose duration opioid": 25890,
      "73 ng ml": 5656,
      "control group 04": 20306,
      "62 ng ml": 5337,
      "ng ml maximum": 49446,
      "57 ng ml": 5133,
      "ng ml respectively": 49455,
      "endogenous opioid peptides": 28848,
      "study evaluate effect": 78165,
      "effect morphine oxycodone": 27493,
      "gene expression analyzed": 32943,
      "oxycodone statistically significant": 55935,
      "statistically significant increases": 77225,
      "gene expression profiles": 32946,
      "photorefractive keratectomy prk": 61376,
      "nonrandomized clinical trial": 49839,
      "clinical trial methods": 16930,
      "percocet oxycodone acetaminophen": 60537,
      "endo pharmaceuticals chadds": 28838,
      "pharmaceuticals chadds ford": 61050,
      "mg 325 mg": 45742,
      "days control group": 22504,
      "control group patients": 20334,
      "patients completed pain": 59112,
      "completed pain assessment": 18481,
      "faces pain scale": 31026,
      "cohort patients received": 17368,
      "pfizer new york": 60995,
      "oral pain medication": 53650,
      "survey data collected": 79702,
      "results data collected": 71651,
      "second postoperative day": 74194,
      "postoperative days patients": 62762,
      "patients oxycodone acetaminophen": 59613,
      "gabapentin oxycodone acetaminophen": 32800,
      "oxycodone acetaminophen postoperative": 54657,
      "background postoperative pain": 13166,
      "use opioids especially": 84562,
      "suffer severe pain": 78960,
      "severe pain surgery": 75003,
      "study assess efficacy": 77963,
      "cr oxycodone immediate": 21089,
      "non opioid analgesic": 49648,
      "surgery day surgery": 79365,
      "scale vas 10": 73571,
      "preoperatively days postoperatively": 63771,
      "12 months surgery": 1339,
      "surgery results total": 79570,
      "scale nrs pain": 73515,
      "nrs pain scores": 50069,
      "respectively patients received": 71231,
      "patients received cr": 59773,
      "received cr oxycodone": 68133,
      "adverse events observed": 8777,
      "immediate postoperative pain": 36704,
      "postoperative pain non": 62896,
      "persistent postoperative pain": 60929,
      "pain 12 months": 56368,
      "pain ratings postoperative": 57474,
      "ratings postoperative days": 67707,
      "conclusions present study": 19176,
      "present study demonstrated": 64648,
      "controlled analgesia iv": 20451,
      "analgesia iv pca": 10007,
      "criteria randomized controlled": 21213,
      "rcts published english": 67919,
      "studies meta analysis": 77774,
      "meta analysis performed": 44895,
      "random effects model": 66996,
      "effects model used": 28001,
      "scale pain scores": 73537,
      "48 hours postoperatively": 4717,
      "associated higher odds": 12281,
      "52 95 confidence": 4983,
      "43 95 ci": 4501,
      "95 ci 19": 6258,
      "similar pain scores": 75973,
      "pain scores compared": 57709,
      "relatively small sample": 69790,
      "small sample size": 76297,
      "benefits scheme dispensing": 13638,
      "oral oxycodone cr": 53627,
      "cr formulations oxycodone": 21061,
      "associated fold increase": 12263,
      "new treatment episodes": 49383,
      "risk difference rd": 72547,
      "21 95 ci": 2961,
      "opioid dispensing 90": 51718,
      "dispensing 90 days": 25440,
      "dose oxycodone naloxone": 25995,
      "leading cause death": 41301,
      "cause death americans": 15348,
      "50 years age": 4911,
      "intravenously injected oxycodone": 39894,
      "catheter related bladder": 15317,
      "related bladder discomfort": 69564,
      "bladder discomfort crbd": 13907,
      "methods patients asa": 45432,
      "placebo group oxycodone": 61745,
      "mild moderate severe": 46431,
      "moderate severe crbd": 47178,
      "used assess pain": 84851,
      "assess pain intensity": 11945,
      "incidences nausea vomiting": 37333,
      "results compared control": 71638,
      "control group incidence": 20328,
      "significantly lower oxycodone": 75798,
      "lower oxycodone group": 42666,
      "49 vs 10": 4782,
      "40 vs 20": 4382,
      "compared group vas": 18170,
      "001 significant differences": 209,
      "significant differences incidence": 75506,
      "incidence postoperative adverse": 37299,
      "postoperative adverse effects": 62697,
      "adverse effects groups": 8658,
      "groups conclusion oxycodone": 34157,
      "adverse effects background": 8644,
      "tamper resistant form": 80338,
      "design retrospective study": 23791,
      "patient care records": 58549,
      "2013 september 2018": 2644,
      "setting victoria australia": 74850,
      "victoria australia cases": 86208,
      "time 2013 2018": 81197,
      "mental health substance": 44825,
      "health substance use": 34783,
      "average age 41": 12874,
      "05 95 confidence": 491,
      "95 ci 85": 6342,
      "81 95 ci": 5884,
      "95 ci 66": 6321,
      "91 95 ci": 6135,
      "06 95 ci": 581,
      "95 ci 01": 6224,
      "ci 01 11": 16369,
      "05 95 ci": 490,
      "10 95 ci": 732,
      "95 ci 05": 6232,
      "95 ci 16": 6254,
      "series analysis showed": 74652,
      "95 ci 04": 6228,
      "80 95 ci": 5837,
      "illicit drug use": 36635,
      "95 ci 23": 6263,
      "showed statistically significant": 75314,
      "use non opioid": 84515,
      "oxycodone related deaths": 55822,
      "cases year period": 15271,
      "methadone hydrocodone oxycodone": 45082,
      "mean median concentrations": 43794,
      "drug related deaths": 26769,
      "antinociceptive effects oxycodone": 11247,
      "effects oxycodone opioid": 28072,
      "norepinephrine reuptake inhibitor": 49890,
      "reuptake inhibitor aim": 72202,
      "day treatment oxycodone": 22436,
      "hepatitis virus hcv": 34964,
      "rural drug users": 73050,
      "remains poorly understood": 70306,
      "503 rural appalachian": 4934,
      "rural appalachian drug": 73045,
      "appalachian drug users": 11375,
      "drug users recruited": 26857,
      "respondent driven sampling": 71304,
      "lifetime past 30": 41751,
      "past 30 day": 58455,
      "leaving final sample": 41331,
      "final sample size": 31749,
      "negative binomial regression": 49064,
      "binomial regression used": 13830,
      "used determine effect": 84912,
      "adjusted incidence rate": 8029,
      "incidence rate ratio": 37309,
      "ratio 07 95": 67715,
      "07 95 ci": 603,
      "95 ci 72": 6327,
      "significant predictors increased": 75604,
      "diagnostic statistical manual": 24344,
      "statistical manual mental": 77178,
      "manual mental disorders": 43331,
      "mental disorders fourth": 44817,
      "disorders fourth edition": 25394,
      "significantly fewer days": 75701,
      "abuse liability studies": 6762,
      "rates nonmedical use": 67601,
      "use prescription drugs": 84652,
      "prescription drugs associated": 64218,
      "drug liking moment": 26685,
      "liking moment drug": 41865,
      "moment drug liking": 47298,
      "national survey drug": 48721,
      "survey drug use": 79709,
      "drug use health": 26835,
      "use health nsduh": 84389,
      "nonmedical use rates": 49792,
      "model used assess": 47086,
      "abuse deterrent opioid": 6697,
      "deterrent opioid formulations": 24122,
      "drug liking significantly": 26689,
      "finding statistically significant": 31763,
      "vitro radioligand binding": 86367,
      "35 gtp\u03b3s binding": 4081,
      "growing public health": 34373,
      "overprescribing major contributor": 54355,
      "analgesia prescribing practices": 10070,
      "dispensing data obtained": 25444,
      "using computer generated": 85355,
      "patients medical records": 59487,
      "time period background": 81323,
      "limited information available": 41935,
      "patients undergoing vaginal": 60136,
      "compare postoperative analgesic": 18043,
      "postoperative analgesic requirements": 62716,
      "acute pain management": 7670,
      "days patients used": 22580,
      "patients used non": 60164,
      "used non steroidal": 85033,
      "mg compared patients": 45828,
      "significantly reduced patients": 75849,
      "days compared patients": 22497,
      "0001 conclusions patients": 60,
      "oral oxycodone naloxone": 53635,
      "low oral bioavailability": 42512,
      "oral bioavailability naloxone": 53498,
      "acute opioid withdrawal": 7656,
      "opioid withdrawal symptoms": 52647,
      "following oral oxycodone": 32172,
      "withdrawal symptoms following": 87162,
      "following oral intravenous": 32170,
      "oral intravenous administration": 53555,
      "administration oxycodone naloxone": 8328,
      "methods observational case": 45405,
      "opioid withdrawal following": 52643,
      "withdrawal following oxycodone": 87133,
      "poisons information centre": 62165,
      "january 2012 december": 40441,
      "data collected included": 21907,
      "collected included patient": 17462,
      "patient demographics reported": 58612,
      "conclusion oxycodone naloxone": 18948,
      "pain relief purpose": 57571,
      "population pharmacokinetic study": 62374,
      "children years age": 16083,
      "obtained previously published": 50779,
      "previously published studies": 64955,
      "population pharmacokinetic model": 62371,
      "oxycodone plasma concentration": 55693,
      "model used simulate": 47089,
      "intravenous oxycodone administration": 39869,
      "50 ng ml": 4872,
      "ng ml high": 49442,
      "dose calculated using": 25838,
      "conclusions oxycodone clearance": 19145,
      "efficient sensitive method": 28425,
      "sensitive liquid chromatography": 74544,
      "mass spectrometry method": 43468,
      "limit quantification loq": 41891,
      "inter intra day": 39357,
      "intra day variability": 39719,
      "drug metabolite levels": 26706,
      "ng ml serum": 49456,
      "background study evaluated": 13204,
      "non cancer cancer": 49573,
      "sectional study conducted": 74288,
      "fentanyl morphine oxycodone": 31534,
      "patients cancer medical": 59042,
      "annual number prescriptions": 11024,
      "dose ddd 1000": 25861,
      "day oral morphine": 22348,
      "oral morphine equivalent": 53575,
      "mean age 67": 43703,
      "study period mean": 78388,
      "28 vs 12": 3577,
      "patients prescribed low": 59673,
      "low opioid doses": 42510,
      "50 mg day": 4854,
      "15 vs 19": 1797,
      "increase strong opioid": 37805,
      "strong opioid prescribing": 77536,
      "cancer pain morphine": 14838,
      "oxycodone buprenorphine fentanyl": 54761,
      "treatment pain methods": 82735,
      "aged 12 years": 9142,
      "undergoing major surgery": 83552,
      "continuous infusion oxycodone": 20174,
      "infusion oxycodone opioid": 38718,
      "group continuous epidural": 33710,
      "continuous epidural infusion": 20166,
      "epidural infusion bupivacaine": 29182,
      "infusion bupivacaine fentanyl": 38700,
      "children undergoing surgery": 16077,
      "surgery general anaesthesia": 79405,
      "opioid analgesics abuse": 51477,
      "extended immediate release": 30850,
      "non injectable opioid": 49617,
      "mild moderate pain": 46430,
      "results strong opioid": 71969,
      "strong opioid analgesics": 77527,
      "oxycodone fentanyl respectively": 55087,
      "200 mg oxycodone": 2402,
      "opioid misuse public": 51946,
      "misuse public health": 46744,
      "increase opioid analgesic": 37766,
      "opioid analgesic prescribing": 51466,
      "opioid prescribing patterns": 52117,
      "drug enforcement administration": 26618,
      "automated reports consolidated": 12757,
      "reports consolidated ordering": 70718,
      "future research explore": 32770,
      "oxycodone pharmacokinetics described": 55678,
      "increased risk adverse": 38009,
      "risk adverse effects": 72515,
      "parenteral oxycodone results": 58213,
      "duration analgesic effect": 27155,
      "respiratory depression buprenorphine": 71272,
      "use patients chronic": 84612,
      "chronic pain severe": 16312,
      "pain severe require": 57822,
      "severe require daily": 75016,
      "require daily clock": 70802,
      "daily clock long": 21707,
      "clock long term": 17050,
      "term opioid treatment": 80647,
      "opioid treatment alternative": 52440,
      "treatment alternative treatment": 82442,
      "alternative treatment options": 9747,
      "treatment options inadequate": 82713,
      "immediate release oral": 36730,
      "men women ages": 44807,
      "using double blind": 85385,
      "randomized crossover design": 67091,
      "analyses performed using": 10604,
      "using linear mixed": 85459,
      "linear mixed effects": 42017,
      "mixed effects model": 46792,
      "60 mg oxycodone": 5260,
      "did significantly reduce": 24509,
      "significant dose dependent": 75528,
      "dose dependent decrease": 25866,
      "pain trial registration": 57942,
      "oxycodone oc opioid": 55555,
      "exerts analgesic effect": 30505,
      "overall analgesic effect": 54186,
      "drug interactions cyp2d6": 26665,
      "concentrations oc metabolites": 18785,
      "plays minor role": 62009,
      "parent drug metabolite": 58194,
      "authors report case": 12747,
      "34 year old": 4041,
      "equivalent dose pain": 29305,
      "type opioid prescribed": 83336,
      "retrospective cohort design": 72124,
      "veterans health administration": 86179,
      "health administration va": 34669,
      "codeine hydrocodone oxycodone": 17244,
      "oxycodone 30 days": 54551,
      "27 95 ci": 3487,
      "oxycodone significantly associated": 55910,
      "post hoc analysis": 62573,
      "additional research needed": 7891,
      "research needed determine": 71017,
      "copyright 2016 john": 20760,
      "2016 john wiley": 2749,
      "john wiley sons": 40479,
      "trends opioid consumption": 82973,
      "total opioid consumption": 81862,
      "european union eu": 29752,
      "purpose united states": 66594,
      "using joinpoint regression": 85450,
      "joinpoint regression analysis": 40485,
      "regression analysis results": 69425,
      "analysis results 2014": 10754,
      "results 2014 2016": 71553,
      "opioid use 10": 52461,
      "countries opioid consumption": 20958,
      "opioid consumption increased": 51625,
      "conclusions consumption opioid": 19062,
      "consumption opioid analgesics": 19961,
      "opioid consumption use": 51670,
      "use european countries": 84359,
      "high potency opioids": 35145,
      "opioids important component": 52968,
      "pain management appropriate": 57054,
      "oral long acting": 53561,
      "acting opioids oxycodone": 7414,
      "opioids oxycodone controlled": 53133,
      "twice daily dosing": 83296,
      "oxycodone cr oxymorphone": 54904,
      "cr oxymorphone er": 21104,
      "large commercially insured": 41123,
      "subjects included study": 78706,
      "90 day supply": 6091,
      "short long acting": 75179,
      "18 years old": 2112,
      "wilcoxon rank sum": 87091,
      "characteristics including age": 15865,
      "including age sex": 37590,
      "using pearson chi": 85554,
      "pearson chi square": 60334,
      "chi square test": 15986,
      "using generalized linear": 85407,
      "generalized linear models": 33007,
      "period opioid medication": 60760,
      "opioid medication use": 51907,
      "oxymorphone er 40": 56236,
      "adjusting age sex": 8062,
      "medication use risk": 44584,
      "adjusted mean difference": 8036,
      "statistical significance differences": 77185,
      "sensitivity analyses conclusions": 74555,
      "patients taking oxycodone": 60036,
      "cost savings health": 20886,
      "chronic pain syndromes": 16317,
      "schedule ii opioid": 73621,
      "norepinephrine reuptake inhibition": 49889,
      "used management moderate": 84997,
      "dual mechanism action": 27113,
      "reduce opioid related": 68865,
      "opioid related effects": 52309,
      "effects complicate pain": 27870,
      "complicate pain management": 18543,
      "fourth quarter 2011": 32441,
      "oxycodone hydromorphone oxymorphone": 55224,
      "poison center drug": 62147,
      "center drug diversion": 15520,
      "treatment center programs": 82471,
      "center programs combined": 15541,
      "schedule ii opioids": 73622,
      "opioid formulations extended": 51815,
      "perspective article presents": 60962,
      "article presents results": 11775,
      "objective present study": 50470,
      "deterrent formulation adf": 24109,
      "remoxy pain therapeutics": 70348,
      "pain therapeutics san": 57910,
      "therapeutics san mateo": 80974,
      "san mateo ca": 73377,
      "king pharmaceuticals bristol": 40848,
      "pharmaceuticals bristol tn": 61048,
      "features prescription opioid": 31299,
      "prescription opioids used": 64372,
      "prescription opioid abusers": 64281,
      "preferred route administration": 63648,
      "data cross validation": 21933,
      "revealed significant differences": 72226,
      "purdue pharma lp": 66500,
      "pharma lp stamford": 61010,
      "lp stamford ct": 42742,
      "chadds ford pa": 15685,
      "vicodin abbott laboratories": 86197,
      "abbott laboratories abbott": 6515,
      "laboratories abbott park": 41020,
      "abbott park il": 6518,
      "intensity adverse events": 39227,
      "ibuprofen oxycodone pain": 36366,
      "oxycodone pain management": 55631,
      "clinical characteristics associated": 16769,
      "observational cohort study": 50609,
      "emergency department patients": 28683,
      "aged 16 years": 9150,
      "called days discharge": 14732,
      "reported greater severity": 70550,
      "oxycodone mean sd": 55376,
      "use oxycodone associated": 84582,
      "oxycodone associated increased": 54734,
      "associated increased odds": 12302,
      "31 95 ci": 3862,
      "higher pain scores": 35287,
      "lower extremity fracture": 42617,
      "95 ci 07": 6234,
      "lower extremity fractures": 42618,
      "upper extremity fractures": 84003,
      "pain care children": 56511,
      "objective evaluate effects": 50416,
      "oxycodone pain relief": 55632,
      "design prospective randomized": 23766,
      "setting university teaching": 74845,
      "university teaching hospital": 83873,
      "aged 15 years": 9147,
      "pain scores higher": 57727,
      "volume normal saline": 86398,
      "received study medication": 68286,
      "dosing pain scores": 26321,
      "baseline 30 minutes": 13412,
      "hours study drug": 35859,
      "study drug administration": 78133,
      "administration main outcome": 8291,
      "outcome measures pain": 53943,
      "measures pain intensity": 44078,
      "initial pain scores": 38865,
      "pain scores physical": 57760,
      "significantly greater oxycodone": 75711,
      "greater oxycodone group": 33471,
      "placebo group 12": 61736,
      "mean difference 13": 43751,
      "patients placebo group": 59649,
      "placebo group patients": 61747,
      "background increasing use": 13067,
      "use extended release": 84367,
      "17 year old": 1992,
      "receiving extended release": 68335,
      "extended release naltrexone": 30885,
      "end dosing interval": 28789,
      "background acute postoperative": 13005,
      "adverse reactions patient": 8846,
      "methods medical records": 45379,
      "oxycodone iv pca": 55320,
      "scale nrs score": 73520,
      "nrs score rest": 50078,
      "results patient demographics": 71840,
      "better pain control": 13723,
      "14 mg oxycodone": 1607,
      "mg 82 mg": 45775,
      "pain control conclusions": 56608,
      "provides pain control": 66232,
      "pca postoperative analgesia": 60270,
      "postoperative analgesia background": 62700,
      "counterfeit prescription pills": 20947,
      "prospective randomised double": 65856,
      "cro group received": 21240,
      "group received 10": 33944,
      "10 mg cro": 808,
      "initial dose 10": 38837,
      "dose 10 mg": 25781,
      "group received intravenous": 33952,
      "group received placebo": 33961,
      "received placebo tablet": 68246,
      "rescue medication results": 70956,
      "significantly higher cro": 75724,
      "pain scores groups": 57725,
      "group experienced significantly": 33775,
      "experienced significantly nausea": 30629,
      "fewer adverse events": 31632,
      "substantial postoperative pain": 78856,
      "intravenous iv opioids": 39846,
      "opioid use morphine": 52540,
      "use morphine equivalents": 84501,
      "compared patient controlled": 18250,
      "analgesic efficacy similar": 10250,
      "methods total 51": 45614,
      "total 51 patients": 81755,
      "patients having elective": 59349,
      "surgery enrolled study": 79388,
      "patients randomised groups": 59728,
      "iv morphine pain": 40386,
      "score visual analogue": 73810,
      "results total opioid": 72037,
      "dose morphine equivalent": 25962,
      "doses significantly lower": 26273,
      "significantly lower oral": 75796,
      "geometric means 95": 33124,
      "confidence interval 34": 19452,
      "respectively pain scores": 71229,
      "naloxone opioid receptor": 48472,
      "opioid receptor antagonist": 52245,
      "abuse potential opioids": 6823,
      "induced psychological dependence": 38449,
      "study aimed confirm": 77924,
      "used opioid receptor": 85049,
      "guanosine thio triphosphate": 34396,
      "gtp\u03b3s binding assay": 34390,
      "hydrocodone morphine fentanyl": 36107,
      "concentration response curves": 18720,
      "place preference test": 61605,
      "preference test oxycodone": 63631,
      "oxycodone 01 mg": 54478,
      "01 mg kg": 317,
      "mg kg produced": 46021,
      "kg produced dose": 40793,
      "produced dose dependent": 65377,
      "dose dependent increases": 25871,
      "increased place preference": 37985,
      "place preference induced": 61603,
      "induced oxycodone mg": 38438,
      "mg kg significantly": 46029,
      "mg kg naloxone": 46002,
      "naloxone mg kg": 48461,
      "mg kg induced": 45984,
      "dopamine release nucleus": 25724,
      "release nucleus accumbens": 69899,
      "dose 01 mg": 25775,
      "mg kg did": 45969,
      "release oxycodone results": 69975,
      "patients prescribed opioid": 59677,
      "prescribed opioid acetaminophen": 63906,
      "using insurance claims": 85441,
      "insurance claims database": 39144,
      "oxycodone acetaminophen hydrocodone": 54643,
      "acetaminophen hydrocodone acetaminophen": 7192,
      "opioid acetaminophen combination": 51392,
      "group control group": 33714,
      "control group opioid": 20331,
      "acetaminophen group compared": 7187,
      "compared opioid group": 18228,
      "12 95 confidence": 1269,
      "interval ci 12": 39579,
      "11 95 ci": 1120,
      "12 month period": 1332,
      "14 95 ci": 1576,
      "group did demonstrate": 33741,
      "ratio opioid opioid": 67785,
      "acetaminophen 95 ci": 7144,
      "95 ci conclusions": 6358,
      "opioids used pain": 53370,
      "morphine hydrocodone hydromorphone": 47718,
      "hydrocodone hydromorphone oxycodone": 36092,
      "hydromorphone oxycodone oxymorphone": 36208,
      "oxycodone oxymorphone primarily": 55622,
      "use disorder oud": 84323,
      "2007 2017 evaluated": 2491,
      "revealed statistically significant": 72228,
      "morphine equivalents oxycodone": 47677,
      "used chronic pain": 84876,
      "chronic pain studies": 16314,
      "pain studies demonstrated": 57870,
      "known present study": 40927,
      "present study performed": 64662,
      "tail flick latency": 80246,
      "dose dependent increase": 25869,
      "dependent increase tail": 23511,
      "increase tail flick": 37811,
      "pain highly prevalent": 56830,
      "problem older adults": 65241,
      "analgesic moderate severe": 10276,
      "treatment pain older": 82737,
      "pain older patients": 57274,
      "sectional study using": 74291,
      "physicians long term": 61441,
      "causes significant postoperative": 15402,
      "significant postoperative pain": 75600,
      "bilateral erector spinae": 13794,
      "randomly allocated 60": 67211,
      "24 postoperative hours": 3268,
      "increase 95 ci": 37725,
      "median iqr range": 44234,
      "control group vs": 20346,
      "area curve pain": 11627,
      "mean sd oxycodone": 43866,
      "oxycodone consumption 24": 54853,
      "mg control group": 45834,
      "control group 19": 20311,
      "postmortem fluids tissues": 62679,
      "220 ng ml": 3051,
      "ng ml vitreous": 49459,
      "ml vitreous humor": 46918,
      "ng ml urine": 49457,
      "concentrations ng ml": 18781,
      "000 ng ml": 28,
      "21 ng ml": 2979,
      "330 ng ml": 4005,
      "40 ng ml": 4368,
      "mixed drug intoxication": 46787,
      "patients using opiate": 60171,
      "investigate effectiveness oxycodone": 40007,
      "oxycodone ibuprofen combination": 55227,
      "orthopedic injury related": 53824,
      "injury related pain": 38993,
      "related pain children": 69657,
      "clinical trial compared": 16925,
      "age 18 years": 8979,
      "compared treatment groups": 18328,
      "using generalized estimating": 85405,
      "generalized estimating equation": 33001,
      "results treatment groups": 72040,
      "significant differences groups": 75504,
      "treatment groups statistically": 82609,
      "groups statistically significant": 34329,
      "significant differences demographics": 75501,
      "combination treatment group": 17617,
      "group reported adverse": 33976,
      "reported adverse effects": 70500,
      "adverse effects conclusions": 8650,
      "effects conclusions oxycodone": 27876,
      "mild moderate orthopedic": 46429,
      "used treat chronic": 85164,
      "use opioids associated": 84556,
      "opioids associated adverse": 52735,
      "associated adverse effects": 12216,
      "study aimed evaluate": 77927,
      "superoxide dismutase sod": 79154,
      "showed naloxone oxycodone": 75276,
      "factors influence selection": 31109,
      "drug treatment programs": 26819,
      "used examine influence": 84934,
      "demographic characteristics drug": 23269,
      "characteristics drug use": 15860,
      "drug use patterns": 26845,
      "deterrent formulations adfs": 24114,
      "sustained release formulation": 79786,
      "pharmacodynamic effects assessed": 61063,
      "evidence suggests opioid": 30266,
      "sequestered naltrexone hydrochloride": 74638,
      "treatment phases subjects": 82763,
      "placebo primary endpoints": 61805,
      "max area effect": 43547,
      "safety assessments included": 73124,
      "40 mg significantly": 4358,
      "significantly higher compared": 75720,
      "higher compared placebo": 35218,
      "0001 drug liking": 63,
      "mg significantly lower": 46219,
      "40 60 mg": 4328,
      "compared crushed oxycodone": 18130,
      "pruritus somnolence dizziness": 66309,
      "somnolence dizziness conclusions": 76464,
      "fourier transform infrared": 32431,
      "transform infrared spectroscopy": 82186,
      "injection drug abuse": 38943,
      "animal experiments clinical": 10992,
      "profile oxycodone compared": 65496,
      "oxycodone compared morphine": 54819,
      "effects oxycodone morphine": 28071,
      "experimental pain patients": 30671,
      "pain patients pain": 57352,
      "material methods patients": 43502,
      "blinded cross study": 13997,
      "analgesic effects morphine": 10217,
      "morphine 30 mg": 47555,
      "mechanical thermal electrical": 44117,
      "assessed baseline 30": 11988,
      "baseline 30 60": 13410,
      "60 90 min": 5242,
      "min drug administration": 46522,
      "skin muscles oxycodone": 76207,
      "001 morphine oxycodone": 160,
      "year old boy": 87455,
      "opioid analgesics commonly": 51488,
      "analgesics commonly prescribed": 10398,
      "acute painful conditions": 7679,
      "nonmedical opioid use": 49774,
      "opioid naive individuals": 51968,
      "discharged emergency department": 25195,
      "real time data": 68001,
      "discharge emergency department": 25121,
      "objectives study compared": 50591,
      "behavior opioid abuse": 13535,
      "release oxycodone immediate": 69948,
      "materials methods retrospective": 43515,
      "study using linked": 78563,
      "opioid abuse year": 51387,
      "exposure tapentadol oxycodone": 30799,
      "international classification diseases": 39474,
      "classification diseases 9th": 16678,
      "opioid abuse addiction": 51364,
      "abuse addiction dependence": 6642,
      "logistic regression results": 42272,
      "proportions patients oxycodone": 65793,
      "ratio 95 confidence": 67755,
      "age 18 64": 8978,
      "risk factors developing": 72566,
      "opioid use oxycodone": 52553,
      "opioids long term": 53027,
      "initiation opioid therapy": 38896,
      "commercial insurance database": 17708,
      "proportion long term": 65747,
      "noncancer chronic pain": 49705,
      "opioids prescribed oxycodone": 53210,
      "10 years ago": 962,
      "compared patients received": 18253,
      "conclusions national sample": 19126,
      "opioid therapy findings": 52413,
      "surveillance radars poison": 79685,
      "radars poison center": 66949,
      "opioids schedule ii": 53286,
      "quarter 95 ci": 66853,
      "drugs commonly used": 26915,
      "used treatment pain": 85183,
      "codeine hydromorphone oxycodone": 17247,
      "natural opiates morphine": 48744,
      "opiates morphine codeine": 51331,
      "morphine codeine synthetic": 47608,
      "derivatives hydromorphone oxycodone": 23622,
      "potent antinociceptive drugs": 63099,
      "antagonists naloxone naltrexone": 11080,
      "antagonized antinociceptive effect": 11097,
      "chronic pain buprenorphine": 16260,
      "assessed oral oxycodone": 12028,
      "chronic pain history": 16279,
      "history opioid abuse": 35469,
      "doses 16 mg": 26128,
      "participants self administer": 58368,
      "self administer oxycodone": 74453,
      "10 20 40": 685,
      "pain withdrawal symptoms": 57990,
      "mann whitney tests": 43319,
      "oxycodone dose placebo": 54997,
      "factors associated oxycodone": 31080,
      "withdrawal symptoms pain": 87163,
      "using opioid analgesics": 85539,
      "pain little information": 57026,
      "related opioid analgesics": 69644,
      "used treat severe": 85172,
      "treat severe pain": 82317,
      "design setting retrospective": 23801,
      "automation reports consolidated": 12765,
      "reports consolidated orders": 70719,
      "nationally representative sample": 48729,
      "hospital emergency department": 35589,
      "drug abuse main": 26504,
      "drug abuse number": 26505,
      "period total number": 60804,
      "medical use opioid": 44415,
      "opioid analgesics treat": 51530,
      "purpose study aimed": 66569,
      "using interrupted time": 85445,
      "fentanyl oxycodone cr": 31548,
      "meeting inclusion criteria": 44760,
      "rate drug related": 67464,
      "related overdose deaths": 69649,
      "background problems like": 13180,
      "postoperative pain common": 62854,
      "general anesthesia oxycodone": 32963,
      "anesthesia oxycodone hydrochloride": 10927,
      "oxycodone hydrochloride semisynthetic": 55195,
      "hydrochloride semisynthetic opioid": 36037,
      "therapeutic effect visceral": 80936,
      "effect visceral pain": 27582,
      "different doses oxycodone": 24862,
      "patients methods clinical": 59498,
      "methods clinical trial": 45271,
      "ii patients scheduled": 36570,
      "general anesthesia randomly": 32967,
      "anesthesia randomly divided": 10944,
      "30 cases group": 3712,
      "group oxycodone hydrochloride": 33890,
      "75 mg kg": 5707,
      "t1 t2 t3": 80052,
      "including mean arterial": 37633,
      "arterial pressure heart": 11717,
      "pressure heart rate": 64741,
      "ramsay sedation score": 66990,
      "adverse reactions results": 8851,
      "blood pressure heart": 14145,
      "heart rate arterial": 34871,
      "arterial oxygen saturation": 11714,
      "oxygen saturation adverse": 56206,
      "adverse reactions groups": 8843,
      "groups time point": 34336,
      "05 compared group": 498,
      "group ii group": 33820,
      "ii group iii": 36560,
      "lower group 05": 42624,
      "ramsay sedation scores": 66991,
      "group group ii": 33798,
      "provide safe effective": 66097,
      "safe effective postoperative": 73084,
      "effective postoperative analgesia": 27673,
      "postoperative analgesia lower": 62702,
      "fewer adverse reactions": 31633,
      "tapentadol opioid receptor": 80450,
      "effective neuropathic pain": 27651,
      "cancer patients unclear": 14894,
      "japanese cancer patients": 40470,
      "january 2013 december": 40443,
      "2013 december 31": 2629,
      "december 31 2019": 22840,
      "groups significant difference": 34320,
      "significantly greater tapentadol": 75715,
      "tapentadol group oxycodone": 80414,
      "methadone fentanyl hydromorphone": 45073,
      "vs hydromorphone vs": 86648,
      "vs vs vs": 86682,
      "pain intensity evaluated": 56905,
      "opioid overdose epidemic": 52014,
      "prescription opioid po": 64309,
      "related hospitalizations deaths": 69619,
      "prevalence weak opioid": 64822,
      "strong opioid use": 77541,
      "opioid use increased": 52524,
      "opioid use chronic": 52478,
      "opioid related deaths": 52308,
      "opioid related morbidity": 52321,
      "related morbidity mortality": 69634,
      "increase opioid related": 37769,
      "monitoring opioid use": 47330,
      "opioid use introduction": 52528,
      "descriptive statistics used": 23686,
      "known substance abuse": 40936,
      "data provide important": 22072,
      "provide important information": 66072,
      "prescribed long acting": 63880,
      "setting participants retrospective": 74805,
      "participants retrospective cohort": 58363,
      "palliative end life": 58051,
      "end life care": 28795,
      "adjusted hazard ratios": 8026,
      "11 years 60": 1160,
      "acting opioid group": 7402,
      "64 95 ci": 5387,
      "95 ci 26": 6270,
      "deaths 95 ci": 22739,
      "000 person years": 41,
      "risk hospital deaths": 72582,
      "90 95 ci": 6079,
      "95 ci 30": 6275,
      "72 95 ci": 5615,
      "ci 24 39": 16419,
      "30 days therapy": 3733,
      "acting opioids chronic": 7410,
      "opioids chronic noncancer": 52778,
      "noncancer pain compared": 49709,
      "associated significantly increased": 12437,
      "significantly increased risk": 75758,
      "absolute risk difference": 6601,
      "better understand impact": 13748,
      "opioid analgesics patients": 51521,
      "analgesics patients moderate": 10479,
      "use prescription pain": 84658,
      "formulations opioid analgesics": 32393,
      "safety effectiveness drugs": 73143,
      "release oxycodone tablet": 69977,
      "capsule controlled release": 14955,
      "release oxycodone designed": 69931,
      "oxycodone designed resist": 54949,
      "background use prescription": 13215,
      "use prescription opioid": 84654,
      "prescription opioid medications": 64300,
      "united states past": 83817,
      "states past decades": 77141,
      "programs researched abuse": 65563,
      "opioid analgesics oxycodone": 51514,
      "analgesics oxycodone hydrocodone": 10469,
      "oxycodone hydrocodone hydromorphone": 55207,
      "poison centers substance": 62151,
      "centers substance abuse": 15574,
      "substance abuse treatment": 78800,
      "abuse treatment centers": 6897,
      "opioid diversion abuse": 51726,
      "rate opioid related": 67491,
      "reported nonmedical use": 70593,
      "use did change": 84309,
      "did change significantly": 24417,
      "minimize postoperative pain": 46600,
      "methods study involved": 45592,
      "minimally invasive surgery": 46586,
      "patients received postoperative": 59817,
      "etoricoxib 120 mg": 29716,
      "day 15 days": 22250,
      "pre postoperative pain": 63486,
      "postoperative pain 15": 62843,
      "pain days following": 56685,
      "days following surgery": 22525,
      "surgery 30 days": 79307,
      "effective pain management": 27662,
      "pain management opioids": 57091,
      "respiratory depression present": 71283,
      "adverse events deaths": 8750,
      "adverse event reports": 8717,
      "following opioid related": 32165,
      "adverse events caused": 8734,
      "induced adverse events": 38374,
      "evaluate combined oral": 29781,
      "respect postoperative pain": 71139,
      "pain control postoperative": 56641,
      "radical retropubic prostatectomy": 66960,
      "retropubic prostatectomy rrp": 72105,
      "methods consecutive patients": 45290,
      "consecutive patients scheduled": 19564,
      "ml 25 bupivacaine": 46834,
      "oxycodone hydrochloride 10": 55175,
      "hydrochloride 10 mg": 36008,
      "10 mg tablet": 848,
      "groups compared respect": 34151,
      "eda group experienced": 27361,
      "respectively significant difference": 71246,
      "significant difference postoperative": 75489,
      "median duration hospital": 44219,
      "duration hospital stay": 27162,
      "costs taken account": 20910,
      "taken account background": 80270,
      "long term prescription": 42348,
      "120 days supply": 1400,
      "regression used model": 69467,
      "patients prescribed hydrocodone": 59671,
      "opioid use observed": 52545,
      "including morphine milligram": 37640,
      "ci 10 14": 16386,
      "vs 95 ci": 86634,
      "oxycodone patients received": 55661,
      "sensitivity subgroup analyses": 74565,
      "conclusions long term": 19114,
      "background oxycodone opioid": 13133,
      "oxycodone opioid prescribed": 55570,
      "types pain especially": 83375,
      "chronic opioid exposure": 16239,
      "contribute opioid induced": 20229,
      "induce clinically significant": 38367,
      "test hypothesis used": 80773,
      "demonstrated increased levels": 23347,
      "combined vivo vitro": 17676,
      "vivo vitro data": 86384,
      "drug induced changes": 26651,
      "important role management": 37031,
      "prescribing opioid analgesics": 64092,
      "analgesics abuse diversion": 10366,
      "ir compared oxycodone": 40216,
      "rates prescription opioid": 67624,
      "opioid abuse diversion": 51368,
      "survey key informants": 79716,
      "key informants patients": 40671,
      "unique recipients dispensed": 83760,
      "recipients dispensed drug": 68567,
      "using linear regression": 85460,
      "linear regression model": 42030,
      "case report report": 15194,
      "66 year old": 5461,
      "year old patient": 87466,
      "opiate analgesics oxycodone": 51291,
      "adverse drug reaction": 8625,
      "selective serotonin reuptake": 74443,
      "serotonin reuptake inhibitor": 74683,
      "different opioid analgesics": 24895,
      "reuptake inhibitor antidepressants": 72203,
      "study examined potential": 78201,
      "receptor partial agonist": 68517,
      "symptoms opioid withdrawal": 79898,
      "blind randomized placebo": 13975,
      "opioid agonist opioid": 51426,
      "psychomotor cognitive performance": 66352,
      "results oxycodone produced": 71826,
      "oxycodone produced prototypic": 55766,
      "produced effects similar": 65385,
      "visits emergency departments": 86282,
      "inflammatory drugs acetaminophen": 38562,
      "opioids skeletal muscle": 53303,
      "skeletal muscle relaxants": 76192,
      "compare functional outcomes": 18029,
      "functional outcomes pain": 32708,
      "10 day course": 755,
      "group study conducted": 34036,
      "study conducted urban": 78033,
      "bronx new york": 14458,
      "new york city": 49391,
      "related functional impairment": 69608,
      "cyclobenzaprine oxycodone acetaminophen": 21554,
      "follow completed december": 32016,
      "interventions participants given": 39672,
      "oxycodone mg acetaminophen": 55412,
      "mg participants instructed": 46153,
      "tablets hours needed": 80163,
      "outcomes measures primary": 54053,
      "primary outcome improvement": 65064,
      "characteristics comparable groups": 15853,
      "placebo group 20": 61737,
      "20 interquartile range": 2324,
      "interquartile range iqr": 39528,
      "oxycodone acetaminophen group": 54641,
      "11 oxycodone acetaminophen": 1140,
      "group group difference": 33796,
      "group difference mean": 33749,
      "77 oxycodone acetaminophen": 5763,
      "conclusions relevance patients": 19195,
      "oxycodone acetaminophen naproxen": 54649,
      "improve functional outcomes": 37062,
      "pain week follow": 57986,
      "findings support use": 31829,
      "long term management": 42337,
      "term management chronic": 80640,
      "chronic pain opioids": 16292,
      "oxycodone acetaminophen commonly": 54636,
      "acetaminophen commonly prescribed": 7173,
      "use long acting": 84459,
      "tricyclic antidepressants anticonvulsants": 83217,
      "classification diseases ninth": 16679,
      "diseases ninth revision": 25357,
      "ninth revision clinical": 49493,
      "revision clinical modification": 72428,
      "received oxycodone acetaminophen": 68233,
      "acting opioids patients": 7416,
      "opioids patients cancer": 53158,
      "mean daily dose": 43739,
      "daily dose associated": 21725,
      "human immunodeficiency virus": 35955,
      "immunodeficiency virus hiv": 36779,
      "patients received long": 59794,
      "long term oxycodone": 42346,
      "mean daily doses": 43740,
      "management patients cancer": 43234,
      "opioid prescription management": 52153,
      "drugs oxycodone hydrocodone": 27026,
      "dramatic increase opioid": 26434,
      "availability illicit opioids": 12782,
      "opioids fentanyl analogs": 52909,
      "treatment pain opioid": 82738,
      "health issue opioid": 34725,
      "buprenorphine tramadol tapentadol": 14593,
      "conventional opioids morphine": 20698,
      "low abuse potential": 42448,
      "cytochrome p450 2d6": 21653,
      "following administration single": 32099,
      "administration single dose": 8374,
      "treatment pain objectives": 82736,
      "low dose bupivacaine": 42467,
      "sufentanil patients undergoing": 78950,
      "transurethral resection prostate": 82249,
      "60 patients undergoing": 5273,
      "allocated groups oxycodone": 9613,
      "normal saline group": 49910,
      "saline group group": 73260,
      "kg normal saline": 40769,
      "kg administered intravenously": 40692,
      "group group patients": 33803,
      "group patients received": 33906,
      "ml normal saline": 46883,
      "perioperative analgesic requirements": 60828,
      "september 2014 results": 74615,
      "group fewer patients": 33782,
      "postoperative pain reduce": 62909,
      "abuse united states": 6905,
      "15 percent patients": 1786,
      "percent patients used": 60480,
      "people united states": 60432,
      "associated misuse abuse": 12335,
      "overdose death rates": 54275,
      "mixed methods design": 46798,
      "sold controlled substances": 76418,
      "public health risk": 66398,
      "opioid overdose surveillance": 52019,
      "used cancer pain": 84866,
      "cancer pain relief": 14853,
      "pain relief studies": 57585,
      "pain use analgesics": 57958,
      "opioid medications compared": 51914,
      "morphine hydromorphone oxycodone": 47723,
      "limited sample size": 41959,
      "double blind randomised": 26369,
      "difference study groups": 24693,
      "opioid therapy patients": 52422,
      "patients liver cirrhosis": 59454,
      "buprenorphine fentanyl hydromorphone": 14543,
      "fentanyl hydromorphone morphine": 31499,
      "high pass effect": 35133,
      "methadone oxycodone tramadol": 45118,
      "objectives objective study": 50570,
      "conditional logistic regression": 19290,
      "adjusted odds ratios": 8046,
      "1000 person years": 1040,
      "ci 04 22": 16374,
      "ci 04 21": 16373,
      "95 ci 03": 6227,
      "respectively conclusions study": 71182,
      "association oxycodone naloxone": 12484,
      "postoperative pain laparoscopic": 62881,
      "pain laparoscopic surgery": 56994,
      "pain objective aim": 57259,
      "study setting university": 78493,
      "setting university affiliated": 74843,
      "university affiliated hospital": 83854,
      "hospital participants patients": 35611,
      "patients asked rate": 59007,
      "asked rate pain": 11844,
      "rate pain 10": 67498,
      "pain 10 min": 56350,
      "10 min using": 861,
      "min using visual": 46557,
      "pain 10 severe": 56356,
      "10 severe pain": 926,
      "postanaesthesia care unit": 62631,
      "unit pacu patients": 83768,
      "patients received intravenous": 59787,
      "intravenous oxycodone mg": 39872,
      "oxycodone mg 10": 55408,
      "mg 10 min": 45702,
      "min pain intensity": 46542,
      "rest wound compression": 71437,
      "wound compression point": 87358,
      "oxycodone secondary endpoints": 55867,
      "pain vas scores": 57971,
      "associated postoperative pain": 12384,
      "postoperative pain including": 62875,
      "score significantly different": 73790,
      "significantly higher proportion": 75739,
      "higher proportion cases": 35310,
      "new class analgesics": 49315,
      "adults cancer pain": 8552,
      "cancer pain recent": 14850,
      "pain recent findings": 57482,
      "randomized multicenter double": 67122,
      "multicenter double blind": 48158,
      "patients taking opioids": 60035,
      "having lower opioid": 34608,
      "receptor binding affinity": 68485,
      "randomized trial comparing": 67200,
      "patients chemotherapy induced": 59062,
      "chemotherapy induced peripheral": 15967,
      "induced peripheral neuropathy": 38443,
      "quality life measures": 66731,
      "similar adverse effects": 75895,
      "background pain following": 13145,
      "pain following orthopedic": 56792,
      "following orthopedic surgery": 32176,
      "orthopedic surgery methods": 53837,
      "science citation index": 73679,
      "web science wos": 86815,
      "vosviewer software results": 86496,
      "united states department": 83788,
      "states department health": 77091,
      "department health human": 23434,
      "health human services": 34715,
      "total hip replacement": 81813,
      "unknown present study": 83888,
      "treated morphine oxycodone": 82351,
      "oxycodone morphine induced": 55476,
      "did produce changes": 24480,
      "et receptors involved": 29672,
      "cytochrome p450 3a4": 21655,
      "pain palliative care": 57324,
      "oxycodone related mortality": 55823,
      "using australian bureau": 85313,
      "australian bureau statistics": 12697,
      "prospectively collected data": 65893,
      "data national hospital": 22015,
      "alcohol drug treatment": 9531,
      "national minimum data": 48701,
      "morphine oxycodone primary": 47851,
      "national coronial information": 48676,
      "10 year age": 959,
      "year age group": 87431,
      "morphine oxycodone iv": 47837,
      "related deaths recorded": 69583,
      "reflect appropriate prescribing": 69187,
      "morbidity mortality associated": 47513,
      "oxycodone relatively low": 55827,
      "pain prescribing opioids": 57410,
      "principal drug concern": 65127,
      "methods retrospective case": 45532,
      "new south wales": 49375,
      "pain history mental": 56833,
      "history mental health": 35464,
      "strong opioid group": 77531,
      "opioid substitution therapy": 52384,
      "confidence interval 27": 19450,
      "prescription opioid dependent": 64292,
      "management patients undergoing": 43235,
      "fentanyl frequently used": 31480,
      "examine relative abuse": 30360,
      "relative abuse liability": 69735,
      "abuse liability reinforcing": 6758,
      "short acting opioids": 75159,
      "double blind subject": 26385,
      "subject placebo controlled": 78633,
      "sessions conducted 48": 74740,
      "self administration following": 74465,
      "intranasal placebo oxycodone": 39757,
      "observer rated physiological": 50737,
      "physiological measures collected": 61467,
      "opioid agonist antagonist": 51423,
      "self administration procedure": 74472,
      "drug versus money": 26860,
      "increased ratings liking": 38002,
      "self administered placebo": 74457,
      "opioids chronic pain": 52782,
      "new opioid prescriptions": 49347,
      "electronic health record": 28533,
      "health record ehr": 34761,
      "prescription schedule ii": 64403,
      "opioids codeine hydrocodone": 52789,
      "85 95 ci": 5980,
      "opioid therapy oxycodone": 52419,
      "safe opioid prescribing": 73094,
      "opioid prescribing purpose": 52122,
      "misuse abuse overdose": 46709,
      "opioid analgesics oas": 51511,
      "time series analyses": 81371,
      "rates overdose death": 67613,
      "death rates increased": 22718,
      "increased study period": 38032,
      "mg times day": 46241,
      "issue united states": 40328,
      "opioid analgesics treatment": 51531,
      "acute pain appears": 7661,
      "non opioid analgesics": 49649,
      "high rates abuse": 35160,
      "united states particularly": 83816,
      "acute respiratory distress": 7700,
      "respiratory distress syndrome": 71290,
      "proportional hazards regression": 65787,
      "hazards regression model": 34622,
      "regression model used": 69445,
      "model used estimate": 47087,
      "patients morphine oxycodone": 59531,
      "lower mortality risk": 42650,
      "mortality risk compared": 47995,
      "analgesic anti inflammatory": 10152,
      "widely used analgesics": 87061,
      "objective study sought": 50521,
      "potential opioid misuse": 63199,
      "prescribed long term": 63883,
      "acting oxycodone methods": 7422,
      "oxycodone methods retrospective": 55404,
      "cohort study conducted": 17387,
      "study conducted using": 78034,
      "prescription drug monitoring": 64213,
      "drug monitoring program": 26715,
      "monitoring program pdmp": 47339,
      "death certificate data": 22698,
      "data 2013 2018": 21851,
      "overdose opioid related": 54305,
      "day period average": 22368,
      "abuse liability oxycodone": 6754,
      "oxycodone patients chronic": 55655,
      "oral oxycodone 10": 53614,
      "double blind conditions": 26343,
      "non drug abusing": 49594,
      "produced dose related": 65382,
      "dose related reduction": 26051,
      "oxycodone data suggest": 54925,
      "chronic pain abuse": 16255,
      "use opioid medications": 84547,
      "noncancer pain growing": 49711,
      "pragmatic clinical trial": 63455,
      "veterans affairs hospital": 86177,
      "pain primary outcomes": 57431,
      "primary outcomes included": 65100,
      "pain related functional": 57513,
      "rated pain relief": 67533,
      "results study demonstrate": 71979,
      "risk problematic opioid": 72643,
      "significant differences primary": 75516,
      "medications increase opioid": 44632,
      "opioid abuse overdose": 51374,
      "opioids frequently prescribed": 52921,
      "patients discharged emergency": 59206,
      "department ed acute": 23423,
      "ed acute extremity": 27327,
      "opioids end study": 52883,
      "end study period": 28819,
      "real time opioid": 68003,
      "background opioids pose": 13123,
      "significant increased risk": 75565,
      "risk adverse drug": 72514,
      "adverse drug events": 8624,
      "risk life threatening": 72589,
      "methods post hoc": 45469,
      "design used examine": 23818,
      "administration adverse events": 8214,
      "logistic regression used": 42273,
      "included age gender": 37418,
      "use morphine fentanyl": 84502,
      "morphine fentanyl oxycodone": 47692,
      "use prescribed opioids": 84647,
      "extended release oral": 30890,
      "acting opioid analgesic": 7398,
      "management severe pain": 43263,
      "widely used oral": 87071,
      "twice daily bid": 83293,
      "treatment chronic severe": 82490,
      "chronic severe nonmalignant": 16341,
      "severe nonmalignant pain": 74963,
      "pain oros hydromorphone": 57298,
      "compared er oxycodone": 18156,
      "effectiveness oros hydromorphone": 27771,
      "malignant nonmalignant pain": 43100,
      "present study investigated": 64661,
      "study investigated differences": 78274,
      "twice daily oxycodone": 83299,
      "daily oxycodone 10": 21786,
      "50 mg placebo": 4861,
      "placebo 14 days": 61621,
      "pain baseline 14": 56490,
      "mechanisms action involved": 44135,
      "controversial aim study": 20678,
      "effects oxycodone oxy": 28073,
      "american society anaesthesiologists": 9800,
      "society anaesthesiologists physical": 76369,
      "anaesthesiologists physical status": 9883,
      "included study patients": 37563,
      "patients significant differences": 59980,
      "significant differences observed": 75511,
      "mean blood pressure": 43726,
      "hours surgery significantly": 35870,
      "surgery significantly lower": 79586,
      "significantly lower oxy": 75797,
      "body movement respiratory": 14201,
      "movement respiratory depression": 48053,
      "experience lower postoperative": 30581,
      "lower postoperative pain": 42682,
      "opioid epidemic united": 51782,
      "epidemic united states": 29156,
      "high risk opioid": 35174,
      "risk opioid use": 72622,
      "using world health": 85685,
      "opioids used worldwide": 53377,
      "oxycodone fentanyl morphine": 55083,
      "drug abuse dependence": 26500,
      "opioids oxycodone fentanyl": 53135,
      "local opioid receptors": 42212,
      "pilot test hypothesis": 61555,
      "oc mass transport": 50806,
      "healthy male subjects": 34827,
      "opioid illicit drug": 51839,
      "mean sd weight": 43874,
      "cyp2d6 em phenotype": 21600,
      "administration single oral": 8375,
      "time steady state": 81385,
      "vs days 001": 86643,
      "single dose orally": 76083,
      "dose orally administered": 25982,
      "opioid tolerance development": 52429,
      "objective evaluate cost": 50412,
      "evaluate cost effectiveness": 29785,
      "surgery methods study": 79474,
      "conducted using australian": 19421,
      "cost effectiveness analysis": 20873,
      "effectiveness analysis conducted": 27748,
      "analysis conducted using": 10662,
      "adverse events quality": 8796,
      "conclusions tapentadol ir": 19235,
      "analgesia respiratory depression": 10096,
      "codeine widely used": 17303,
      "conclusions lessons learned": 19110,
      "study evaluate association": 78164,
      "opioid prescribing number": 52112,
      "number type opioid": 50271,
      "opioid prescriptions dispensed": 52185,
      "monitoring program data": 47337,
      "january 2010 december": 40436,
      "2010 december 31": 2555,
      "prescribed opioids hydrocodone": 63928,
      "opioids hydrocodone oxycodone": 52957,
      "hydrocodone oxycodone tramadol": 36123,
      "hydromorphone primary outcome": 36220,
      "number opioid prescriptions": 50195,
      "days supply opioids": 22635,
      "supply opioids results": 79184,
      "number prescriptions dispensed": 50241,
      "reduction 95 ci": 69039,
      "total prescriptions month": 81897,
      "95 ci 18": 6257,
      "opioid prescribing guidelines": 52101,
      "quantity opioid prescriptions": 66836,
      "study objective examine": 78335,
      "blinded randomized trial": 14019,
      "ambulatory surgery center": 9774,
      "women scheduled undergo": 87245,
      "patients received prescriptions": 59819,
      "medication use pain": 44580,
      "pain primary outcome": 57430,
      "primary outcome number": 65073,
      "outcome number oxycodone": 53960,
      "survey median number": 79722,
      "median number oxycodone": 44254,
      "group interquartile range": 33833,
      "interquartile range 10": 39515,
      "day significant differences": 22415,
      "pain scores significantly": 57781,
      "fewer unused tablets": 31674,
      "oxycodone acetaminophen ibuprofen": 54645,
      "sectional study setting": 74290,
      "population level drug": 62347,
      "expressed defined daily": 30815,
      "opioids buprenorphine methadone": 52759,
      "methadone morphine oxycodone": 45104,
      "efficacy effect profile": 28256,
      "study cross sectional": 78047,
      "cross sectional comparative": 21256,
      "potential misuse abuse": 63192,
      "subjects received oxycodone": 78735,
      "abuse potential oxycodone": 6825,
      "treatment pain background": 82733,
      "study determine frequency": 78110,
      "postoperative pain use": 62929,
      "anti inflammatory medications": 11135,
      "methods randomized single": 45518,
      "randomized single blinded": 67184,
      "randomly assigned control": 67217,
      "assigned control group": 12166,
      "control group 13": 20310,
      "pain medications results": 57167,
      "statistically significantly higher": 77235,
      "scale scores increased": 73558,
      "increased length stay": 37937,
      "group conclusion use": 33698,
      "provide better pain": 66038,
      "misuse abuse addiction": 46704,
      "opioid antagonists opioid": 51543,
      "expert opinion clinical": 30689,
      "formulations prescription opioids": 32403,
      "limited data exist": 41923,
      "study aims investigate": 77944,
      "selective serotonin norepinephrine": 74441,
      "changes analgesic effect": 15773,
      "healthy subjects treatment": 34848,
      "treatment days oxycodone": 82541,
      "oxycodone doses 10": 55001,
      "doses 10 mg": 26119,
      "statistical significant differences": 77188,
      "outcomes research needed": 54089,
      "management pain following": 43230,
      "given current opioid": 33162,
      "opioid crisis surgeons": 51687,
      "methods prospective cohort": 45481,
      "cohort pilot study": 17373,
      "patients undergoing ess": 60102,
      "oxycodone outcome measures": 55588,
      "outcome measures included": 53939,
      "measures included pain": 44061,
      "pain 10 point": 56354,
      "thirty patients completed": 81108,
      "days 95 ci": 22479,
      "95 ci 95": 6352,
      "consumption similar groups": 20020,
      "similar groups patients": 75933,
      "pills oxycodone mg": 61526,
      "additionally significant difference": 7910,
      "study showed opioid": 78495,
      "opioid pills consumed": 52059,
      "retrospective study conducted": 72169,
      "study conducted examine": 78026,
      "ng ml mean": 49447,
      "11 10 ng": 1090,
      "10 ng ml": 875,
      "drugs drug classes": 26944,
      "results study provide": 71987,
      "provide better understanding": 66040,
      "public health risks": 66399,
      "spinal general anaesthesia": 76721,
      "aberrant drug related": 6545,
      "drug related behaviors": 26767,
      "release oxycodone acetaminophen": 69924,
      "dose combination analgesic": 25841,
      "pain research design": 57631,
      "open label extension": 51161,
      "label extension ole": 40974,
      "tablets er oc": 80154,
      "mg total dose": 46245,
      "12 hours 14": 1292,
      "hours 14 days": 35734,
      "events physical examinations": 30099,
      "gastrointestinal events including": 32880,
      "events including nausea": 30060,
      "changes vital signs": 15829,
      "safety tolerability profile": 73234,
      "model acute pain": 47023,
      "significantly improved analgesia": 75750,
      "hydromorphone morphine oxymorphone": 36198,
      "aim study develop": 9415,
      "surgical pleth index": 79644,
      "receiver operating characteristic": 68309,
      "operating characteristic curve": 51210,
      "pain numerical rating": 57255,
      "patients postoperative pain": 59659,
      "studies needed evaluate": 77785,
      "opioids widely prescribed": 53393,
      "short term long": 75192,
      "term long term": 80638,
      "long term effects": 42332,
      "cancer pain major": 14832,
      "retrospective observational study": 72149,
      "publicly available government": 66416,
      "available government data": 12809,
      "total opioid prescribed": 81864,
      "equivalent milligrams morphine": 29315,
      "study period opioids": 78390,
      "conclusion long term": 18921,
      "high opioid use": 35128,
      "opioid use improve": 52522,
      "old woman history": 51024,
      "history chronic pain": 35454,
      "chronic pain spinal": 16313,
      "acute compartment syndrome": 7626,
      "related opioid use": 69645,
      "design post hoc": 23754,
      "hoc analysis data": 35497,
      "analysis data collected": 10669,
      "data collected retrospective": 21910,
      "identify risk factors": 36537,
      "elderly patients conclusions": 28481,
      "especially elderly patients": 29555,
      "postoperative prolonged release": 62957,
      "oxycodone oxycodone naloxone": 55607,
      "ninety patients undergoing": 49487,
      "patients undergoing open": 60115,
      "parallel group placebo": 58135,
      "group placebo controlled": 33914,
      "single center trial": 76072,
      "postoperative day patients": 62744,
      "day patients received": 22365,
      "naloxone placebo 12": 48486,
      "placebo 12 hours": 61618,
      "pain intensity rest": 56940,
      "primary endpoint duration": 65025,
      "treated oxycodone naloxone": 82367,
      "10 days oxycodone": 757,
      "oxycodone group compared": 55126,
      "group compared placebo": 33690,
      "compared placebo group": 18265,
      "oxycodone group 30": 55125,
      "oxycodone naloxone group": 55502,
      "group 30 placebo": 33595,
      "30 placebo group": 3790,
      "oxycodone naloxone did": 55499,
      "commonly prescribed postoperative": 17872,
      "opioid analgesics following": 51499,
      "restrictive opioid prescribing": 71466,
      "aimed evaluate opioid": 9451,
      "opioid disposal rates": 51723,
      "pediatric patients discharged": 60357,
      "patients discharged opioid": 59210,
      "discharged opioid prescription": 25206,
      "opioid prescription following": 52149,
      "survey regarding opioid": 79729,
      "regarding opioid use": 69259,
      "opioid doses prescribed": 51740,
      "parents disposed leftover": 58220,
      "leftover opioid medication": 41355,
      "risk opioid misuse": 72616,
      "study assess effect": 77961,
      "chronic opioid treatment": 16241,
      "observational prospective study": 50617,
      "experience risk opioid": 30591,
      "scores pain medication": 73940,
      "respectively conclusion results": 71178,
      "treatment quality life": 82793,
      "opioid therapy chronic": 52408,
      "noncancer pain patients": 49712,
      "pain patients background": 57339,
      "tail flick latencies": 80245,
      "analgesic effect morphine": 10203,
      "morphine oxycodone conclusions": 47815,
      "male sprague dawley": 43057,
      "sprague dawley rats": 76769,
      "dawley rats treated": 22229,
      "morphine oxycodone induced": 47836,
      "oxycodone induced anti": 55261,
      "inguinal hernia repair": 38754,
      "early postoperative pain": 27268,
      "pain control important": 56619,
      "methods institutional review": 45364,
      "44 patients undergoing": 4545,
      "patients undergoing elective": 60098,
      "undergoing elective laparoscopic": 83530,
      "laparoscopic inguinal hernia": 41102,
      "prospectively randomized groups": 65903,
      "group received normal": 33957,
      "received normal saline": 68215,
      "assessed using visual": 12090,
      "using visual analog": 85663,
      "fixed time intervals": 31890,
      "recorded results patients": 68697,
      "results patients included": 71848,
      "group demographic characteristics": 33731,
      "did significantly differ": 24506,
      "significantly differ groups": 75684,
      "group compared group": 33686,
      "use pharmaceutical opioids": 84623,
      "2013 2018 used": 2623,
      "35 54 years": 4067,
      "54 years old": 5057,
      "pharmaceutical opioid use": 61037,
      "study english speaking": 78151,
      "english speaking women": 28944,
      "speaking women 18": 76549,
      "women 18 years": 87193,
      "years older undergoing": 87627,
      "medications taken daily": 44685,
      "weeks primary outcome": 86947,
      "64 10 years": 5380,
      "lower baseline pain": 42583,
      "group consumed significantly": 33707,
      "consumed significantly oxycodone": 19851,
      "oxycodone tablets postoperatively": 55980,
      "postoperatively median iqr": 63005,
      "median iqr vs": 44235,
      "oxycodone days discharge": 54929,
      "days discharge median": 22515,
      "oxycodone minimally invasive": 55454,
      "management neuropathic pain": 43214,
      "study evaluate analgesic": 78162,
      "dose response relationship": 26066,
      "30 mg 12": 3750,
      "dose 40 mg": 25805,
      "end points 001": 28807,
      "20 30 mg": 2283,
      "30 mg hours": 3758,
      "oxycodone doses conclusion": 55003,
      "conclusion study demonstrated": 18999,
      "dose response relationships": 26067,
      "mg mean sd": 46046,
      "mean sd morphine": 43864,
      "mg oxycodone oxycodone": 46129,
      "background longer term": 13079,
      "objective aim assess": 50365,
      "month open label": 47398,
      "controlled trial rct": 20617,
      "analysis groups compared": 10693,
      "groups compared using": 34153,
      "using analysis covariance": 85305,
      "secondary measures included": 74232,
      "12 health survey": 1283,
      "sf 12 physical": 75098,
      "12 physical component": 1354,
      "objective test hypothesis": 50529,
      "postoperative oxycodone consumption": 62838,
      "methods study enrolled": 45590,
      "laparoscopic sleeve gastrectomy": 41108,
      "general anesthesia patients": 32966,
      "group received single": 33965,
      "results mean time": 71771,
      "36 95 ci": 4124,
      "10 mg placebo": 841,
      "26 10 mg": 3419,
      "mean difference mg": 43762,
      "mg 95 ci": 45781,
      "95 ci 08": 6235,
      "mean nrs pain": 43801,
      "nrs pain intensity": 50066,
      "pain intensity 12": 56882,
      "intensity 12 hours": 39222,
      "12 hours placebo": 1303,
      "dose requirement oxycodone": 26059,
      "tramadol codeine morphine": 82043,
      "common clinical practice": 17741,
      "active pharmaceutical ingredients": 7527,
      "pharmaceutical ingredients apis": 61029,
      "strong opioids morphine": 77551,
      "50 mg kg": 4856,
      "mg kg thermal": 46032,
      "effects postoperative pain": 28096,
      "allodynia thermal hyperalgesia": 9625,
      "efficacy safety data": 28359,
      "synergistic analgesic effects": 79930,
      "showed similar efficacy": 75311,
      "ed 50 ratios": 27323,
      "compared strong opioids": 18315,
      "risk factors associated": 72564,
      "factors associated opioid": 31077,
      "opioid induced adverse": 51848,
      "korea veterans hospital": 40948,
      "veterans hospital performed": 86182,
      "hospital performed data": 35616,
      "male patients aged": 43047,
      "patients aged 65": 58975,
      "aged 65 years": 9191,
      "years older received": 87626,
      "morphine oxycodone codeine": 47810,
      "binomial variables describing": 13832,
      "variables describing patient": 85891,
      "describing patient related": 23670,
      "drug related characteristics": 26768,
      "constructed associations variables": 19810,
      "associations variables frequency": 12505,
      "determined odds ratio": 24076,
      "odds ratio adjusted": 50929,
      "ratio adjusted odds": 67759,
      "odds ratio aor": 50931,
      "ratio aor calculated": 67763,
      "multivariable analyses respectively": 48317,
      "events gastrointestinal problems": 30049,
      "adverse effects 20": 8636,
      "patients opioid use": 59593,
      "opioid use 12": 52462,
      "using morphine oxycodone": 85502,
      "60 mg day": 5259,
      "95 ci 92": 6349,
      "opioid combination therapy": 51588,
      "clinical use opioid": 16967,
      "short term use": 75201,
      "opioid pain medications": 52037,
      "opioid pain medication": 52036,
      "pain medication lead": 57153,
      "based primary care": 13367,
      "drug seeking behavior": 26788,
      "ci 11 31": 16393,
      "findings indicate need": 31793,
      "traumatic brain injury": 82267,
      "brain injury tbi": 14342,
      "opioids commonly prescribed": 52802,
      "commonly prescribed post": 17871,
      "claims data used": 16625,
      "total opioid analgesic": 81861,
      "opioid analgesic consumption": 51454,
      "cancer patients compared": 14872,
      "electronic medical records": 28539,
      "oxycodone fentanyl buprenorphine": 55073,
      "fentanyl buprenorphine codeine": 31447,
      "conclusion study showed": 19005,
      "short period time": 75186,
      "objective compare safety": 50392,
      "initial opioid prescription": 38856,
      "tramadol hydrocodone oxycodone": 82070,
      "substance use disorders": 78813,
      "use disorders opioid": 84329,
      "cox regression models": 21034,
      "regression models estimated": 69449,
      "dose oxycodone associated": 25990,
      "associated higher risk": 12284,
      "higher risk opioid": 35318,
      "risk opioid overdose": 72617,
      "disorder low dose": 25377,
      "future research background": 32769,
      "hydrochloride prolonged release": 36034,
      "evaluate compare efficacy": 29783,
      "results reported terms": 71916,
      "formulation oxycodone naloxone": 32354,
      "oxycodone naloxone associated": 55492,
      "results postoperative pain": 71879,
      "72 hours postoperatively": 5619,
      "20 patients results": 2371,
      "group significantly reduced": 34020,
      "placebo group needed": 61744,
      "significantly reduces postoperative": 75853,
      "reduces postoperative pain": 69004,
      "postoperative pain need": 62893,
      "rates opioid prescribing": 67608,
      "opioid prescribing opioid": 52114,
      "pain management needs": 57085,
      "tamper resistant opioid": 80341,
      "intolerable adverse events": 39704,
      "affect efficacy tolerability": 8899,
      "high abuse potential": 35067,
      "high risk patients": 35176,
      "control prevention cdc": 20398,
      "opioid prescribing guideline": 52100,
      "opioids design setting": 52842,
      "setting participants cross": 74803,
      "participants cross sectional": 58293,
      "2016 eligible patients": 2744,
      "eligible patients 18": 28591,
      "patients received new": 59800,
      "included study mean": 37562,
      "study mean sd": 78301,
      "odds ratios 95": 50934,
      "95 ci 91": 6348,
      "prescribed schedule ii": 63978,
      "oxycodone prescriptions observed": 55748,
      "relatively low affinity": 69781,
      "low affinity mu": 42450,
      "affinity mu opioid": 8946,
      "study compare risk": 78005,
      "compare risk opioid": 18056,
      "risk opioid abuse": 72612,
      "oxycodone ir using": 55316,
      "outcome proportion subjects": 53983,
      "logistic regression model": 42269,
      "pooled using random": 62249,
      "using random effects": 85587,
      "higher oxycodone group": 35284,
      "lower tapentadol oxycodone": 42712,
      "tapentadol oxycodone odds": 80455,
      "oxycodone odds ratio": 55557,
      "odds ratio 35": 50913,
      "ratio 35 95": 67730,
      "35 95 confidence": 4075,
      "confidence interval 21": 19447,
      "opioid po dependence": 52071,
      "current guidelines based": 21440,
      "study aimed examine": 77930,
      "retrospective case series": 72115,
      "daily oral morphine": 21779,
      "morphine equivalent ome": 47664,
      "calculated using standard": 14711,
      "male mean age": 43042,
      "mean age 41": 43679,
      "age 41 years": 9004,
      "41 years sd": 4437,
      "years sd 10": 87664,
      "dose 45 mg": 25809,
      "20 mg day": 2339,
      "mg day 28": 45855,
      "treatment mean dose": 82654,
      "pain wound healing": 57993,
      "keratectomy prk methods": 40606,
      "study 60 patients": 77900,
      "60 patients received": 5271,
      "difference pain scores": 24656,
      "statistically clinically significant": 77192,
      "group pain scores": 33897,
      "pain scores difference": 57718,
      "prevent postoperative nausea": 64851,
      "patients methods prospective": 59502,
      "methods prospective double": 45483,
      "10 mg orally": 832,
      "standard general anesthetic": 76911,
      "general anesthetic technique": 32971,
      "rescue antiemetic medication": 70941,
      "medication recorded 24": 44549,
      "incidence vomiting significantly": 37328,
      "vomiting significantly lower": 86482,
      "satisfaction significantly higher": 73439,
      "24 postoperative period": 3269,
      "usage patients undergoing": 84128,
      "institutional ethics committee": 39094,
      "45 patients undergoing": 4596,
      "collected data regarding": 17455,
      "patients hospital stay": 59370,
      "converted oral oxycodone": 20739,
      "parenteral morphine equivalents": 58207,
      "received regular postoperative": 68258,
      "patients included 14": 59392,
      "thirty patients received": 81112,
      "patients received intraoperative": 59785,
      "centrally active drugs": 15628,
      "drugs metabolized cytochrome": 26997,
      "sex estrous cycle": 75075,
      "cycle differences brain": 21546,
      "using tail flick": 85634,
      "metabolite concentrations measured": 44945,
      "brain oxymorphone oxycodone": 14357,
      "brain males females": 14345,
      "males females estrus": 43075,
      "altered brain oxycodone": 9695,
      "oxycodone concentration response": 54825,
      "inter individual variation": 39355,
      "drugs including opioids": 26980,
      "transversus abdominis plane": 82253,
      "abdominis plane tap": 6539,
      "laparoscopic colorectal surgery": 41099,
      "blind randomized clinical": 13969,
      "using ultrasound guidance": 85652,
      "control primary outcome": 20402,
      "outcome postoperative pain": 53980,
      "postoperative pain measured": 62887,
      "secondary outcomes assessed": 74242,
      "visual analogue score": 86330,
      "analogue score vas": 10566,
      "return gut function": 72189,
      "length hospital stay": 41399,
      "hospital stay postoperative": 35637,
      "patient satisfaction results": 58771,
      "satisfaction results total": 73431,
      "patient satisfaction conclusion": 58757,
      "patients admitted inpatient": 58952,
      "admitted inpatient rehabilitation": 8423,
      "seen week treatment": 74367,
      "degrees 95 ci": 23181,
      "mm 95 ci": 46930,
      "pharmaceutical opioid heroin": 61033,
      "care emergency department": 15021,
      "events 100 000": 30003,
      "100 000 people": 975,
      "000 people year": 39,
      "pre april 2014": 63460,
      "affects quality life": 8939,
      "opioid treatment dyspnea": 52446,
      "effects various opioids": 28193,
      "stage cancer patients": 76862,
      "14 20 patients": 1558,
      "dose did significantly": 25883,
      "did significantly affect": 24503,
      "cancer patients background": 14871,
      "children aged years": 16040,
      "maximum possible effect": 43609,
      "different age groups": 24840,
      "head neck surgery": 34651,
      "despite widespread use": 23910,
      "methods ninety patients": 45399,
      "prospective double blinded": 65830,
      "blinded randomized controlled": 14014,
      "patients study group": 60008,
      "42 patients did": 4469,
      "patients did receive": 59192,
      "reactive protein crp": 67980,
      "total oxycodone dose": 81875,
      "patients control group": 59154,
      "control group 001": 20304,
      "levels significantly lower": 41609,
      "adverse effects postoperative": 8687,
      "head neck cancer": 34650,
      "opioid nonopioid analgesics": 52004,
      "managing moderate severe": 43288,
      "careful selection effective": 15106,
      "selection effective analgesic": 74419,
      "effective analgesic regimen": 27595,
      "analgesic regimen based": 10310,
      "regimen based type": 69300,
      "based type pain": 13398,
      "type pain patient": 83343,
      "pain patient expected": 57333,
      "patient expected prevent": 58634,
      "expected prevent stress": 30560,
      "prevent stress anxiety": 64855,
      "stress anxiety associated": 77486,
      "anxiety associated breakthrough": 11269,
      "associated breakthrough pain": 12226,
      "clinician develop variety": 17023,
      "develop variety effective": 24161,
      "variety effective safe": 85951,
      "effective safe analgesic": 27695,
      "safe analgesic regimens": 73072,
      "analgesic regimens based": 10320,
      "regimens based estimates": 69332,
      "based estimates anticipated": 13317,
      "estimates anticipated pain": 29644,
      "anticipated pain intensity": 11158,
      "pain intensity use": 56956,
      "cannabinoid cb1 receptor": 14928,
      "potential utility combining": 63247,
      "alcohol self administration": 9539,
      "rats data support": 67850,
      "data support feasibility": 22138,
      "alcohol use disorder": 9545,
      "objective study aimed": 50490,
      "study aimed prescribing": 77936,
      "limiting opioid use": 41976,
      "opioid use design": 52497,
      "cross sectional survey": 21269,
      "patients requiring opioid": 59911,
      "opioid analgesia performed": 51445,
      "australian tertiary referral": 12708,
      "teaching hospital patients": 80533,
      "hospital patients patients": 35614,
      "pain relief maximum": 57545,
      "opioid dose titration": 51738,
      "considerable overlap exists": 19612,
      "fentanyl methadone oxycodone": 31526,
      "overdose deaths increased": 54280,
      "drug concentrations cause": 26560,
      "mass spectrometry used": 43472,
      "objective assess efficacy": 50379,
      "controlled randomized trial": 20534,
      "18 70 years": 2064,
      "surgery interventions patients": 79429,
      "interventions patients randomized": 39674,
      "surgery oxycodone mg": 79494,
      "mg administered intravenously": 45797,
      "rescue analgesia main": 70928,
      "analgesia main outcome": 10012,
      "outcome measures oxycodone": 53941,
      "measures oxycodone consumption": 44076,
      "24 hours secondary": 3231,
      "group given oxycodone": 33789,
      "oxycodone rescue analgesia": 55841,
      "mean difference 24": 43753,
      "difference 24 95": 24575,
      "24 95 ci": 3182,
      "95 ci 47": 6301,
      "conclusion etoricoxib 120": 18901,
      "neonatal opioid withdrawal": 49099,
      "opioid withdrawal syndrome": 52648,
      "withdrawal syndrome nows": 87165,
      "pre clinical studies": 63462,
      "oxycodone oxy exposure": 55598,
      "evidence long term": 30219,
      "conclusions findings suggest": 19087,
      "results highlight potential": 71714,
      "long term consequences": 42329,
      "compare effectiveness oral": 18018,
      "slow release oxycodone": 76265,
      "control moderate severe": 20367,
      "severe pain advanced": 74969,
      "pain advanced stage": 56427,
      "design observational retrospective": 23730,
      "observational retrospective analysis": 50621,
      "patients treated pain": 60071,
      "days prior surgery": 22603,
      "pain intensity using": 56957,
      "effects patient satisfaction": 28083,
      "results groups pain": 71709,
      "groups pain control": 34258,
      "good excellent results": 33314,
      "results confirmed studies": 71644,
      "studies larger samples": 77760,
      "control severe pain": 20420,
      "weight based dosing": 86976,
      "hospital discharge methods": 35582,
      "based patient age": 13351,
      "liquid formulations prescribed": 42093,
      "children 12 years": 16020,
      "common handwritten prescriptions": 17760,
      "codeine commonly prescribed": 17216,
      "prescribed oral opioid": 63937,
      "patients objective study": 59564,
      "carry systematic review": 15146,
      "morphine buprenorphine oxycodone": 47592,
      "oxycodone tramadol fentanyl": 56012,
      "reported case reports": 70513,
      "patient mental status": 58681,
      "clinical practice aims": 16862,
      "prescription drug misuse": 64211,
      "multiple data sources": 48269,
      "oxycodone methadone buprenorphine": 55395,
      "methadone buprenorphine tramadol": 45054,
      "hydromorphone oxymorphone tapentadol": 36213,
      "introduction tamper resistant": 39957,
      "misuse opioid analgesics": 46729,
      "opioid analgesics objective": 51512,
      "opioids characteristics associated": 52773,
      "systematic review methods": 79994,
      "searched databases inception": 74147,
      "adults chronic noncancer": 8558,
      "assessment development evaluations": 12115,
      "opioid use results": 52587,
      "data opioid use": 22032,
      "opioid use people": 52565,
      "moderate risk bias": 47163,
      "interval ci 23": 39587,
      "moderate quality evidence": 47159,
      "ci 11 24": 16392,
      "quality evidence common": 66691,
      "use strong opioids": 84753,
      "opioids 95 ci": 52690,
      "europe north america": 29735,
      "reporting opioid use": 70698,
      "reported taking opioids": 70665,
      "did change time": 24419,
      "scheduled total knee": 73656,
      "total knee replacement": 81829,
      "knee replacement tkr": 40870,
      "groups postoperative days": 34270,
      "pain opioid requirements": 57287,
      "pain significantly different": 57841,
      "95 ci 69": 6324,
      "95 ci 98": 6355,
      "significantly improve postoperative": 75746,
      "improve postoperative pain": 37081,
      "pain management trial": 57128,
      "study designed assess": 78096,
      "efficacy systemic exposure": 28399,
      "freund complete adjuvant": 32594,
      "alleviate moderate severe": 9595,
      "adverse effects associated": 8642,
      "oral administration opioid": 53488,
      "pain medications prescribed": 57166,
      "likely receive strong": 41834,
      "nonselective nonsteroidal anti": 49844,
      "patients instructed acetaminophen": 59417,
      "pain moderate severe": 57205,
      "oxycodone acetaminophen oxycodone": 54651,
      "acetaminophen oxycodone acetaminophen": 7221,
      "chi square tests": 15989,
      "poorly controlled pain": 62281,
      "18 95 confidence": 2078,
      "interval ci 05": 39575,
      "effective controlling pain": 27610,
      "daily chronic pain": 21703,
      "chronic pain previous": 16308,
      "pain previous studies": 57426,
      "studies long acting": 77765,
      "acting opioids associated": 7409,
      "associated greater odds": 12269,
      "prescribed opioids associated": 63920,
      "large integrated health": 41131,
      "health care delivery": 34678,
      "serum total testosterone": 74707,
      "study included 159": 78249,
      "33 95 ci": 3987,
      "ci 29 16": 16427,
      "95 ci 87": 6344,
      "10 mg increase": 821,
      "01 95 ci": 298,
      "95 ci 00": 6220,
      "opioids associated increased": 52736,
      "transdermal fentanyl methadone": 82148,
      "clinical studies evaluating": 16910,
      "current medications treat": 21445,
      "medications treat opioid": 44689,
      "treat opioid withdrawal": 82307,
      "limited abuse liability": 41914,
      "clinical preclinical studies": 16871,
      "receptor positive allosteric": 68520,
      "positive allosteric modulators": 62451,
      "allosteric modulators pams": 9629,
      "naloxone precipitated withdrawal": 48504,
      "withdrawal signs opioid": 87158,
      "male female mice": 43029,
      "cannabinoid receptor type": 14930,
      "strategy treat opioid": 77445,
      "significance statement opioid": 75414,
      "statement opioid use": 77075,
      "medications used treat": 44695,
      "positive allosteric modulator": 62450,
      "mouse model oxycodone": 48034,
      "model oxycodone dependence": 47068,
      "viable strategy treat": 86190,
      "study objective evaluate": 78334,
      "standard pain management": 76924,
      "design institutional review": 23720,
      "review board approved": 72269,
      "subjects randomized receive": 78728,
      "randomized receive standard": 67179,
      "enhanced recovery surgery": 28974,
      "surgery pain management": 79498,
      "setting academic tertiary": 74762,
      "academic tertiary care": 6956,
      "tertiary care centers": 80736,
      "centers patients patients": 15572,
      "patients patients undergoing": 59639,
      "excluded primary outcome": 30479,
      "main results pain": 42860,
      "using morphine milligram": 85501,
      "morphine milligram equivalent": 47768,
      "requirements different groups": 70880,
      "postoperative day pod": 62745,
      "percent subjects reported": 60493,
      "prescribed 20 tablets": 63807,
      "tablets used discharge": 80229,
      "conclusion ice packs": 18910,
      "pain control reduce": 56649,
      "reduce postoperative pain": 68884,
      "pain opioid usage": 57289,
      "neonatal abstinence syndrome": 49097,
      "morphine heroin fentanyl": 47712,
      "heroin fentanyl methadone": 34999,
      "liquid chromatography mass": 42082,
      "short long term": 75181,
      "long term pain": 42347,
      "needed understand potential": 49046,
      "abuse potential intact": 6820,
      "abuse deterrent extended": 6684,
      "deterrent extended release": 24107,
      "marketed morphine sulfate": 43419,
      "morphine sulfate er": 47939,
      "tablets methods randomized": 80175,
      "crossover single center": 21296,
      "single center study": 76071,
      "study included adult": 78252,
      "drug liking visual": 26692,
      "liking visual analog": 41874,
      "abuse quotient aq": 6853,
      "thirty participants completed": 81106,
      "participants completed study": 58290,
      "significantly lower treatment": 75812,
      "demonstrated significantly lower": 23368,
      "significantly lower drug": 75783,
      "lower drug liking": 42607,
      "er morphine product": 29444,
      "provide pain relief": 66089,
      "pain relief patients": 57566,
      "morphine long acting": 47746,
      "long acting oral": 42307,
      "analgesia convenient dosing": 9942,
      "enhance pain relief": 28959,
      "related effects avoiding": 69597,
      "associated opioid prescription": 12359,
      "clinical practice background": 16863,
      "purpose study evaluate": 66579,
      "methods online survey": 45409,
      "members american society": 44777,
      "blind parallel group": 13945,
      "oxymorphone immediate release": 56253,
      "single dose phase": 76090,
      "10 20 30": 682,
      "mg oxycodone ir": 46122,
      "providing pain relief": 66266,
      "analgesic dose response": 10183,
      "30 mg doses": 3757,
      "05 discontinuations lack": 513,
      "patients requiring rescue": 59915,
      "requiring rescue medication": 70912,
      "multiple dose phase": 48272,
      "events similar groups": 30123,
      "pain relief compared": 57529,
      "relief compared placebo": 70116,
      "compared placebo relief": 18270,
      "days safety profile": 22615,
      "oxycodone ir background": 55309,
      "activity opioid receptors": 7577,
      "oxycodone 30 min": 54554,
      "oxycodone upregulated expression": 56044,
      "act opioid receptors": 7369,
      "24 year old": 3292,
      "old female patient": 51006,
      "female patient presented": 31371,
      "limited data available": 41922,
      "patterns opioid prescribing": 60216,
      "duration opioid use": 27169,
      "opioid use patients": 52562,
      "noncancer cancer pain": 49703,
      "pain methods retrospective": 57190,
      "groups results total": 34309,
      "opioid prescriptions prescribed": 52209,
      "doses 50 mg": 26141,
      "50 mg morphine": 4858,
      "chronic use opioids": 16353,
      "use opioids 90": 84554,
      "opioids 90 days": 52688,
      "90 days year": 6101,
      "opioids noncancer pain": 53097,
      "90 days average": 6094,
      "limited data oxycodone": 41924,
      "nervous cns depression": 49137,
      "overdose design retrospective": 54287,
      "design retrospective review": 23790,
      "length stay los": 41411,
      "extracted clinical database": 30949,
      "age 40 years": 9002,
      "obtaining opioid prescriptions": 50788,
      "background multimodal pain": 13087,
      "nociceptive inflammatory neuropathic": 49545,
      "pain relief using": 57598,
      "provides effective pain": 66212,
      "malignant pain using": 43103,
      "pain management index": 57075,
      "methods prospective observational": 45486,
      "study consecutive patients": 78037,
      "groups received oxycodone": 34287,
      "paracetamol 325 mg": 58093,
      "intensity evaluated using": 39257,
      "evaluated using visual": 29933,
      "using western ontario": 85676,
      "western ontario mcmaster": 87004,
      "ontario mcmaster universities": 51130,
      "mcmaster universities osteoarthritis": 43631,
      "universities osteoarthritis index": 83850,
      "osteoarthritis index womac": 53860,
      "15 days treatment": 1730,
      "group 83 patients": 33649,
      "patients reported improvement": 59889,
      "did complete study": 24422,
      "study group respectively": 78219,
      "pain symptoms majority": 57894,
      "significant improvement pain": 75551,
      "nmda receptor antagonist": 49519,
      "controlled crossover design": 20478,
      "dose 150 mg": 25793,
      "maximum tolerated dose": 43617,
      "intravenous ketamine mg": 39849,
      "ketamine mg kg": 40612,
      "primary endpoint maximum": 65027,
      "endpoint maximum effect": 28891,
      "study drug liking": 78135,
      "vas max scores": 86008,
      "significantly lower vs": 75813,
      "medications opioid use": 44654,
      "use disorders oud": 84331,
      "rats trained discriminate": 67898,
      "032 mg kg": 430,
      "fixed ratio fr": 31888,
      "results opioid agonists": 71809,
      "opioid antagonist naltrexone": 51538,
      "discriminative stimulus effects": 25280,
      "32 mg kg": 3929,
      "mg kg effective": 45972,
      "10 fold lower": 766,
      "food maintained responding": 32238,
      "highest dose tested": 35345,
      "behavioral effects heroin": 13546,
      "therapy chronic pain": 80995,
      "adverse effects minimized": 8666,
      "dose combination analgesics": 25842,
      "demonstrated efficacy safety": 23338,
      "acetaminophen aspirin ibuprofen": 7156,
      "background opioid dependence": 13109,
      "health problem worldwide": 34756,
      "oral oxycodone 30": 53621,
      "heart rate blood": 34872,
      "rate blood pressure": 67448,
      "produced significant increases": 65408,
      "increases heart rate": 38059,
      "agonist effects miosis": 9286,
      "results important implications": 71721,
      "important implications future": 37012,
      "spinal cord injury": 76709,
      "case report case": 15188,
      "altered level consciousness": 9699,
      "associated considerable postoperative": 12238,
      "considerable postoperative pain": 19614,
      "postoperative pain study": 62924,
      "morphine oxycodone administered": 47804,
      "postoperative pain methods": 62890,
      "double blind prospective": 26368,
      "prospective randomized placebo": 65868,
      "controlled trial conducted": 20611,
      "patients randomized morphine": 59735,
      "kappa delta opioid": 40586,
      "delta opioid receptor": 23239,
      "kappa opioid agonist": 40591,
      "opioid receptors located": 52276,
      "population wide indicator": 62401,
      "pharmaceutical opioid related": 61036,
      "opioid related harm": 52314,
      "supply adjusted rates": 79178,
      "design retrospective observational": 23787,
      "calculated supply adjusted": 14706,
      "poisson regression used": 62169,
      "regression used multinomial": 69468,
      "used multinomial logistic": 85017,
      "multinomial logistic regression": 48255,
      "logistic regression compare": 42265,
      "regression compare demographic": 69435,
      "substance use characteristics": 78810,
      "100 000 oral": 973,
      "000 oral morphine": 32,
      "oxycodone single ingredient": 55922,
      "australia rates characteristics": 12694,
      "study undertaken determine": 78554,
      "use associated increased": 84211,
      "associated increased risk": 12307,
      "patients rheumatoid arthritis": 59928,
      "rheumatoid arthritis ra": 72457,
      "arthritis ra methods": 11734,
      "self controlled case": 74483,
      "controlled case series": 20468,
      "enrolled tennessee medicaid": 29026,
      "conditional poisson regression": 19292,
      "proton pump inhibitors": 66011,
      "risks associated new": 72669,
      "opioid use use": 52603,
      "sensitivity analyses performed": 74556,
      "opioid use compared": 52483,
      "rate ratio irr": 67507,
      "confidence interval 95": 19456,
      "interval 95 ci": 39573,
      "acting opioid use": 7407,
      "95 ci 52": 6308,
      "95 ci 33": 6279,
      "purpose compare efficacy": 66525,
      "compare efficacy oral": 18023,
      "army medical center": 11690,
      "methods single center": 45579,
      "gabapentin 300 mg": 32788,
      "300 mg placebo": 3817,
      "times daily days": 81418,
      "pain levels assessed": 57015,
      "levels assessed using": 41546,
      "visual analog pain": 86303,
      "analog pain scale": 10522,
      "hours surgery daily": 35864,
      "days repeated measures": 22607,
      "repeated measures analysis": 70412,
      "measures analysis variance": 44041,
      "analysis variance anova": 10791,
      "maximum pain scores": 43603,
      "pain scores time": 57787,
      "test used determine": 80791,
      "severe pain 10": 74967,
      "results patients received": 71854,
      "placebo repeated measures": 61816,
      "repeated measures anova": 70414,
      "showed significant difference": 75298,
      "oxycodone acetaminophen use": 54666,
      "group significantly higher": 34017,
      "significantly higher placebo": 75736,
      "higher placebo group": 35299,
      "standardized postoperative pain": 76984,
      "postoperative pain regimen": 62910,
      "pain control compared": 56607,
      "compared placebo dose": 18264,
      "abuse potential drugs": 6817,
      "patients prescribed medications": 59675,
      "known risk factor": 40930,
      "risk factor opioid": 72561,
      "predictors long term": 63589,
      "adults diagnosis cancer": 8564,
      "methods using quebec": 45625,
      "conducted retrospective cohort": 19403,
      "study random sample": 78445,
      "opioid use 90": 52466,
      "used multivariable logistic": 85021,
      "multivariable logistic regression": 48326,
      "logistic regression assess": 42263,
      "regression assess association": 69431,
      "area receiver operating": 11638,
      "odds ratio 30": 50911,
      "ratio 30 95": 67727,
      "30 95 confidence": 3709,
      "02 95 ci": 357,
      "95 ci 31": 6276,
      "41 95 ci": 4418,
      "dose 90 morphine": 25815,
      "90 morphine milligram": 6109,
      "chronic pain diagnosis": 16273,
      "associated long term": 12321,
      "care unit icu": 15087,
      "intensive care admission": 39333,
      "clear guidelines management": 16705,
      "pharmacological non pharmacological": 61223,
      "post hoc analyses": 62572,
      "open label studies": 51183,
      "open label trial": 51189,
      "trial oxycodone naloxone": 83045,
      "oxycodone naloxone pr": 55512,
      "randomized controlled studies": 67066,
      "controlled studies needed": 20582,
      "analgesic response adverse": 10331,
      "response adverse effects": 71334,
      "opioid anti inflammatory": 51546,
      "chronic pain clinical": 16265,
      "pain control obtained": 56629,
      "patients reported pain": 59891,
      "pain analgesic requirement": 56447,
      "responders non responders": 71322,
      "patients reported adverse": 59885,
      "approach safe effective": 11481,
      "inpatient palliative care": 39025,
      "compared gold standard": 18166,
      "oral opioid analgesics": 53601,
      "oxycodone oxycodone acetaminophen": 55605,
      "month study period": 47412,
      "study period total": 78398,
      "total number opioid": 81850,
      "use codeine containing": 84244,
      "designed evaluate efficacy": 23835,
      "efficacy safety oral": 28370,
      "orally 30 min": 53689,
      "30 60 min": 3701,
      "placebo group significantly": 61753,
      "vas score treatment": 86022,
      "05 adverse events": 494,
      "events reported study": 30110,
      "use prescription drug": 84650,
      "young adults 18": 87715,
      "opioid analgesics heroin": 51501,
      "reported poison centers": 70626,
      "opioids codeine tramadol": 52792,
      "age 20 years": 8983,
      "reported heroin exposures": 70556,
      "codeine oxycodone tramadol": 17272,
      "health care utilization": 34687,
      "opioid therapy nonmalignant": 52417,
      "therapy nonmalignant pain": 81034,
      "care main outcome": 15040,
      "outcome measures incidence": 53938,
      "rate ratios rrs": 67510,
      "ratios rrs 95": 67833,
      "rrs 95 confidence": 73024,
      "62 95 ci": 5334,
      "30 days opioid": 3728,
      "opioid exposure risk": 51799,
      "rr 21 95": 72908,
      "30 days oxycodone": 3729,
      "rr 43 95": 72928,
      "ci 47 00": 16458,
      "events older adults": 30084,
      "pain control research": 56652,
      "medical record review": 44393,
      "cr oxycodone dependence": 21082,
      "age alcohol use": 9054,
      "united states drug": 83790,
      "schedule iii ii": 73624,
      "conducted interrupted time": 19368,
      "major health effects": 42951,
      "associated significant decrease": 12424,
      "associated significant reduction": 12430,
      "best authors knowledge": 13683,
      "52 year old": 5001,
      "10 mg day": 810,
      "30 mg day": 3756,
      "12 lead ecg": 1315,
      "paravertebral nerve block": 58184,
      "pain scores low": 57732,
      "patients reported high": 59886,
      "reported high pain": 70558,
      "pain control satisfaction": 56654,
      "multimodal analgesia strategy": 48207,
      "patients background purpose": 59030,
      "male female rats": 43032,
      "postnatal day pnd": 62688,
      "intravenous self administration": 39884,
      "self administration oxycodone": 74470,
      "control group significant": 20343,
      "did alter oxycodone": 24407,
      "alter oxycodone self": 9683,
      "patients methods performed": 59501,
      "short half life": 75176,
      "primary outcome duration": 65062,
      "results eighty seven": 71677,
      "studies demonstrated opioids": 77694,
      "study systematically evaluate": 78531,
      "clinically relevant concentrations": 16990,
      "buprenorphine methadone oxycodone": 14561,
      "codeine morphine oxycodone": 17259,
      "misuse abuse prescription": 46710,
      "opioids similar patterns": 53301,
      "past 12 months": 58450,
      "opioids including tramadol": 52983,
      "abusing prescription opioids": 6939,
      "day withdrawal period": 22453,
      "prescription opioids opioid": 64354,
      "thoracic paravertebral block": 81122,
      "anesthesia postoperative analgesia": 10935,
      "case report describes": 15191,
      "umbilical hernia repair": 83442,
      "prescriptions controlled substances": 64464,
      "primary outcome measures": 65071,
      "drug induced deaths": 26652,
      "observed prescription opioids": 50711,
      "deaths involving opioids": 22764,
      "200 400 mg": 2396,
      "400 mg oxycodone": 4394,
      "oxycodone 20 40": 54530,
      "20 40 mg": 2294,
      "self administration sessions": 74478,
      "high doses tramadol": 35094,
      "dose dependently increased": 25878,
      "drugs conclusions study": 26920,
      "conclusions study demonstrates": 19219,
      "opioids higher doses": 52950,
      "pseudomonas putida m10": 66320,
      "codeine morphine hydromorphone": 17257,
      "hydromorphone hydrocodone oxycodone": 36176,
      "rectus sheath block": 68812,
      "sheath block rsb": 75129,
      "blinded randomized prospective": 14018,
      "primary objective compare": 65043,
      "objective compare use": 50393,
      "use opioid medication": 84546,
      "opioid medication patients": 51906,
      "secondary objectives compare": 74235,
      "group completed study": 33695,
      "completed study statistically": 18498,
      "study statistically significant": 78512,
      "group mean 13": 33852,
      "mean 13 mg": 43658,
      "13 mg kg": 1488,
      "17 mg kg": 1976,
      "confidence interval 05": 19439,
      "mg kg 008": 45948,
      "compared postoperative opioid": 18276,
      "mg kg 95": 45951,
      "kg 95 confidence": 40689,
      "confidence interval 07": 19441,
      "statistical significance groups": 77186,
      "groups difference time": 34184,
      "rescue analgesic administration": 70935,
      "min statistically significant": 46551,
      "provides superior analgesia": 66241,
      "statistically significant improvement": 77222,
      "used postoperative pain": 85081,
      "relief patients undergoing": 70168,
      "patients undergoing abdominal": 60086,
      "rsb aim present": 73029,
      "present study evaluate": 64657,
      "study evaluate postoperative": 78174,
      "evaluate postoperative pain": 29833,
      "levels patients undergoing": 41593,
      "randomised parallel group": 67029,
      "single blinded trial": 76056,
      "trial patients undergoing": 83049,
      "post anaesthesia care": 62555,
      "anaesthesia care unit": 9867,
      "postoperative night patients": 62809,
      "consumption 24 hours": 19878,
      "24 hours surgery": 3233,
      "hours surgery postoperative": 35868,
      "postoperative sleep quality": 62967,
      "tumour necrosis factor": 83283,
      "surgery 24 48": 79305,
      "answer following questions": 11051,
      "adverse drug reactions": 8626,
      "regional pharmacovigilance center": 69359,
      "minimally invasive surgical": 46587,
      "invasive surgical techniques": 39973,
      "postoperative pain despite": 62864,
      "patients require opioid": 59903,
      "require opioid analgesia": 70809,
      "analgesia significant effects": 10108,
      "methods present retrospective": 45478,
      "study included 60": 78250,
      "included 60 patients": 37404,
      "robotic assisted laparoscopic": 72709,
      "assisted laparoscopic radical": 12197,
      "laparoscopic radical prostatectomy": 41106,
      "pregabalin 150 mg": 63657,
      "acetaminophen 975 mg": 7146,
      "mg celecoxib 400": 45819,
      "celecoxib 400 mg": 15452,
      "400 mg orally": 4393,
      "mg orally hours": 46088,
      "patients received standard": 59825,
      "received standard postoperative": 68283,
      "postoperative analgesic regimen": 62715,
      "15 mg hours": 1755,
      "mg hours oxycodone": 45909,
      "hours oxycodone mg": 35807,
      "325 mg tablets": 3963,
      "mg tablets hours": 46230,
      "hours needed pain": 35799,
      "pain results patients": 57649,
      "mean postoperative opioid": 43841,
      "use significantly reduced": 84732,
      "mg vs 26": 46262,
      "26 56 mg": 3435,
      "75 mg 001": 5706,
      "multimodal analgesic approach": 48210,
      "undergoing robotic assisted": 83574,
      "associated non medical": 12348,
      "medical use pharmaceutical": 44419,
      "opioid analgesics established": 51496,
      "using pharmaceutical opioids": 85558,
      "patterns opioid use": 60217,
      "people regularly tamper": 60424,
      "regularly tamper pharmaceutical": 69488,
      "tamper pharmaceutical opioids": 80331,
      "opioids australia design": 52738,
      "australia design methods": 12687,
      "design methods data": 23724,
      "methods data drawn": 45302,
      "south wales nsw": 76512,
      "morphine methadone tablets": 47758,
      "opioid substitution treatment": 52386,
      "people tamper pharmaceutical": 60428,
      "complaint emergency department": 18429,
      "pediatric emergency department": 60351,
      "background effective postoperative": 13044,
      "effective postoperative pain": 27674,
      "previous studies reported": 64919,
      "extended release liposomal": 30880,
      "release liposomal bupivacaine": 69884,
      "pain postoperative day": 57394,
      "postoperative day total": 62756,
      "liposomal bupivacaine exparel": 42072,
      "postoperative day pain": 62741,
      "day pain scores": 22359,
      "pain scores patients": 57759,
      "patients contacted telephone": 59149,
      "compared groups results": 18173,
      "100 patients enrolled": 1012,
      "patients randomized study": 59743,
      "pain scores study": 57786,
      "placebo group postoperative": 61748,
      "group postoperative day": 33923,
      "interquartile range 59": 39524,
      "interquartile range 20": 39522,
      "cumulative pain scores": 21408,
      "pain scores postoperative": 57765,
      "scores postoperative day": 73957,
      "interquartile range 14": 39518,
      "significant difference morphine": 75477,
      "medication usage compared": 44577,
      "methadone maintenance programs": 45093,
      "14 opioid analgesics": 1616,
      "generic extended release": 33048,
      "release oxycodone pain": 69963,
      "sickle cell disease": 75370,
      "patients sickle cell": 59977,
      "oral pain management": 53649,
      "percent patients reported": 60479,
      "patients reported treatment": 59894,
      "001 visual analog": 221,
      "pain intensity ratings": 56935,
      "patients treated oxycontin": 60070,
      "pain patients sickle": 57358,
      "short acting narcotics": 75157,
      "care providers patients": 15069,
      "background nonmedical use": 13091,
      "illicit prescription opioids": 36651,
      "opioids people inject": 53169,
      "people inject drugs": 60414,
      "inject drugs pwid": 38909,
      "methods data derived": 45300,
      "data derived prospective": 21941,
      "derived prospective cohort": 23634,
      "prospective cohort studies": 65820,
      "vicodin hydrocodone acetaminophen": 86200,
      "generalized estimating equations": 33002,
      "13 95 confidence": 1478,
      "availability prescription opioids": 12786,
      "illicit prescription opioid": 36649,
      "overdose background opioids": 54271,
      "symptoms associated opioid": 79874,
      "associated opioid withdrawal": 12364,
      "opioid medication effective": 51904,
      "oxycontin extended release": 56140,
      "mg daily oxycodone": 45848,
      "acetaminophen codeine 300": 7163,
      "codeine 300 mg": 17202,
      "mg 25 mg": 45734,
      "pain received mg": 57479,
      "mg kg ketamine": 45994,
      "ketamine oral solution": 40618,
      "prescription opioid dependence": 64291,
      "administered prescription opioid": 8173,
      "dsm iv diagnosis": 27107,
      "study patients randomly": 78373,
      "patients randomly selected": 59754,
      "self reported pain": 74498,
      "reported pain scores": 70615,
      "pain scores improved": 57731,
      "days oxycodone cr": 22574,
      "patients experienced significant": 59283,
      "opioid medications patients": 51921,
      "opioid analgesics frequently": 51500,
      "new opioid formulations": 49345,
      "new formulation extended": 49330,
      "legitimate need pain": 41384,
      "need pain control": 48945,
      "clinical research implications": 16888,
      "prescription medication abuse": 64248,
      "growing problem united": 34370,
      "problem united states": 65245,
      "united states methods": 83804,
      "oxycontin oxycodone hydrocodone": 56166,
      "oxycodone hydrocodone propoxyphene": 55213,
      "billion annually lost": 13803,
      "public health interventions": 66390,
      "interventions methods using": 39666,
      "data used determine": 22152,
      "001 relative risk": 198,
      "prescription opioid addiction": 64282,
      "opioid addiction overdose": 51400,
      "public health emergency": 66386,
      "reduce opioid abuse": 68859,
      "deterrent formulations opioids": 24115,
      "low abuse liability": 42447,
      "novel abuse deterrent": 50000,
      "abuse deterrent opioids": 6700,
      "patients treated opioid": 60063,
      "treated opioid analgesics": 82355,
      "peer reviewed journals": 60372,
      "abuse deterrent characteristics": 6682,
      "promote safe effective": 65665,
      "safe effective use": 73087,
      "world war ii": 87319,
      "methadone maintenance treatment": 45096,
      "maintenance treatment mmt": 42923,
      "illicit opioid use": 36644,
      "drug use lower": 26842,
      "study highlights potential": 78230,
      "drug use related": 26848,
      "opioids methods conducted": 53051,
      "using time series": 85641,
      "2014 september 30": 2676,
      "guidelines evidence based": 34439,
      "opioid prescriptions quantity": 52210,
      "morphine equivalent daily": 47656,
      "equivalent daily dosage": 29294,
      "results statistically significant": 71964,
      "statistically significant increase": 77224,
      "significant increase total": 75561,
      "increase total number": 37815,
      "decrease average number": 22889,
      "number schedule ii": 50253,
      "opioid pills prescribed": 52062,
      "pills prescribed patient": 61536,
      "average morphine equivalent": 12899,
      "conclusions study reports": 19224,
      "evidence based guidelines": 30157,
      "aims study evaluate": 9502,
      "nonmalignant pain patients": 49771,
      "pain patients treated": 57360,
      "patients treated methadone": 60061,
      "recruited cross sectional": 68792,
      "higher oxycodone dose": 35283,
      "united states 2006": 83777,
      "effects current study": 27883,
      "current study aimed": 21475,
      "mg oxycodone 10": 46094,
      "40 mg placebo": 4355,
      "experimental pain measures": 30669,
      "compared oxycodone oxymorphone": 18242,
      "oxycodone oxymorphone produced": 55623,
      "oxycodone abuse related": 54620,
      "abuse related subjective": 6863,
      "abuse liability similar": 6761,
      "similar oxycodone data": 75967,
      "effects opioids results": 28045,
      "study evaluated efficacy": 78181,
      "efficacy safety tapentadol": 28390,
      "safety tapentadol extended": 73229,
      "release er compared": 69839,
      "er compared oxycodone": 29409,
      "compared oxycodone controlled": 18237,
      "release cr management": 69818,
      "cr management moderate": 21066,
      "cancer pain research": 14854,
      "active controlled study": 7503,
      "controlled study included": 20590,
      "related pain patients": 69663,
      "oxycodone hcl cr": 55150,
      "weeks double blind": 86907,
      "double blind treatment": 26386,
      "treatment clinicaltrials gov": 82497,
      "outcome measures study": 53954,
      "study designed evaluate": 78100,
      "non inferiority efficacy": 49613,
      "oxycodone cr based": 54894,
      "average pain intensity": 12922,
      "pain intensity 11": 56880,
      "intensity 11 point": 39219,
      "rating scale baseline": 67653,
      "adverse events teaes": 8819,
      "squares mean difference": 76804,
      "difference change pain": 24600,
      "change pain intensity": 15739,
      "pain intensity baseline": 56890,
      "er oxycodone cr": 29456,
      "06 95 confidence": 584,
      "upper limit 95": 84008,
      "limit 95 ci": 41885,
      "non inferior oxycodone": 49611,
      "percentage patients reporting": 60515,
      "treatment groups incidence": 82606,
      "incidence gastrointestinal teaes": 37278,
      "lower tapentadol er": 42709,
      "tapentadol er group": 80403,
      "oxycodone cr group": 54897,
      "conclusions tapentadol er": 19234,
      "mg bid provides": 45807,
      "provided oxycodone hcl": 66144,
      "better gastrointestinal tolerability": 13714,
      "gastrointestinal tolerability profile": 32894,
      "tolerability profile oxycodone": 81549,
      "profile oxycodone cr": 65498,
      "oxycodone cr opioid": 54902,
      "opioid epidemic requires": 51780,
      "prevention treatment opioid": 64887,
      "treatment opioid abuse": 82698,
      "micro opioid receptor": 46340,
      "agonist u50 488h": 9311,
      "kappa opioid receptor": 40592,
      "oxycodone micro kappa": 55448,
      "oxycodone induced changes": 55263,
      "antagonist naloxone completely": 11066,
      "non selective opioid": 49681,
      "receptor antagonists useful": 68483,
      "showed significant positive": 75303,
      "significant positive correlation": 75598,
      "management chronic moderate": 43162,
      "compared long acting": 18197,
      "cost utility analysis": 20889,
      "utility analysis performed": 85721,
      "life year qaly": 41743,
      "background pharmaceutical opioid": 13159,
      "pharmaceutical opioid overdose": 61034,
      "opioid overdose rates": 52018,
      "increased recent years": 38005,
      "non fatal overdose": 49599,
      "sydney medically supervised": 79847,
      "medically supervised injecting": 44429,
      "supervised injecting centre": 79157,
      "injecting centre msic": 38924,
      "opioids management chronic": 53037,
      "opioids nonsteroidal anti": 53100,
      "overall response rate": 54248,
      "response rate 48": 71362,
      "morphine ms contin": 47785,
      "pain management practice": 57103,
      "based patient controlled": 13352,
      "analgesia reduce postoperative": 10082,
      "opioid consumption patients": 51644,
      "consumption patients undergoing": 19985,
      "methods eighty patients": 45328,
      "eighty patients undergoing": 28456,
      "randomly divided group": 67232,
      "group primary outcome": 33936,
      "nrs pain score": 50067,
      "opioid consumption recorded": 51655,
      "compared group group": 18169,
      "group median interquartile": 33857,
      "group vs group": 34077,
      "group reduced compared": 33971,
      "reduced compared group": 68915,
      "10 19 vs": 680,
      "group 05 analgesic": 33550,
      "higher group 001": 35248,
      "group 001 group": 33529,
      "satisfactory postoperative analgesia": 73454,
      "reduced oxycodone consumption": 68959,
      "preclinical studies reported": 63537,
      "effects opioid agonists": 28035,
      "agonists objectives aim": 9338,
      "aim study determine": 9413,
      "potentiate opioid analgesia": 63275,
      "opioid analgesia humans": 51444,
      "methods healthy participants": 45348,
      "healthy participants 10": 34837,
      "drug use pain": 26844,
      "completed subject double": 18501,
      "controlled randomized outpatient": 20532,
      "randomized outpatient study": 67138,
      "outpatient study sessions": 54146,
      "study sessions completed": 78484,
      "10 mg total": 851,
      "total test conditions": 81910,
      "participant observer rated": 58258,
      "physiological effects results": 61462,
      "effects results oxycodone": 28146,
      "oxycodone subjective effects": 55951,
      "subjective effects drug": 78649,
      "effects drug liking": 27907,
      "conclusions study indicates": 19221,
      "effects oxycodone increased": 28066,
      "related subjective effects": 69685,
      "effects background opioid": 27836,
      "background opioid use": 13116,
      "considered safe effective": 19650,
      "small sample sizes": 76298,
      "opioid addiction treatment": 51402,
      "use oxycodone er": 84585,
      "buprenorphine related posts": 14585,
      "study aims compare": 77940,
      "rates pharmaceutical opioid": 67622,
      "buprenorphine codeine fentanyl": 14531,
      "codeine fentanyl oxycodone": 17235,
      "oxycodone naloxone morphine": 55504,
      "commonly used pharmaceutical": 17893,
      "used pharmaceutical opioids": 85076,
      "adjusted rates presentations": 8053,
      "regression used compare": 69463,
      "different pharmaceutical opioids": 24910,
      "oxycodone related cases": 55821,
      "opioids year period": 53397,
      "therapy patients chronic": 81046,
      "treatment fentanyl morphine": 82587,
      "prescription opioids patients": 64360,
      "opioids patients chronic": 53159,
      "chronic pain treated": 16320,
      "results urine drug": 72046,
      "retrospective study examined": 72172,
      "urine specimens collected": 84090,
      "hydrocodone oxycodone hydromorphone": 36116,
      "equivalents mme dispensed": 29359,
      "findings consistent previous": 31776,
      "treatment management chronic": 82651,
      "obstructive sleep apnea": 50750,
      "central sleep apnea": 15617,
      "sleep apnea patients": 76213,
      "opioids methods patients": 53052,
      "patients opioid therapy": 59589,
      "continuous positive airway": 20183,
      "apnea hypopnea index": 11366,
      "long term studies": 42352,
      "improves quality life": 37189,
      "acute chronic moderate": 7618,
      "data sources pubmed": 22113,
      "medline search 1966": 44753,
      "study selection data": 78479,
      "selection data extraction": 74416,
      "safety efficacy oral": 73147,
      "pain management considered": 57064,
      "treat acute chronic": 82272,
      "increase plasma concentrations": 37784,
      "adverse effects similar": 8701,
      "treatment acute chronic": 82425,
      "buprenorphine fentanyl hydrocodone": 14541,
      "hydrocodone hydromorphone morphine": 36089,
      "hydromorphone morphine methadone": 36194,
      "using researched abuse": 85596,
      "prescription opioid drug": 64296,
      "objective trends opioid": 50531,
      "buprenorphine codeine dextropropoxyphene": 14528,
      "2000 2008 period": 2417,
      "consumption strong opioids": 20024,
      "hydromorphone oxycodone hydrocodone": 36205,
      "palliative care patients": 58040,
      "present study designed": 64649,
      "effects single oral": 28163,
      "oral dose morphine": 53522,
      "oxycodone healthy volunteers": 55155,
      "materials methods double": 43506,
      "administered 10 mg": 8095,
      "10 mg morphine": 827,
      "mg oxycodone placebo": 46133,
      "medical use opioids": 44417,
      "classes opioid analgesics": 16671,
      "analgesics commonly used": 10399,
      "sustained release formulations": 79787,
      "setting retrospective analysis": 74813,
      "retrospective analysis drug": 72110,
      "warning network dawn": 86720,
      "pain management ongoing": 57088,
      "ongoing opioid epidemic": 51087,
      "opioid epidemic objective": 51776,
      "nonmedical use nmu": 49784,
      "real world data": 68007,
      "addiction severity index": 7771,
      "severity index multimedia": 75041,
      "index multimedia version": 38198,
      "multimedia version asi": 48195,
      "version asi mv": 86088,
      "study design used": 78094,
      "adults assessed substance": 8547,
      "assessed substance abuse": 12068,
      "using asi mv": 85310,
      "results past 30": 71837,
      "prevalence past 30": 64800,
      "significantly lower morphine": 75794,
      "morphine oxycodone hydrocodone": 47831,
      "significantly lower rate": 75807,
      "drug enforcement agency": 26619,
      "low potential abuse": 42539,
      "background opioid epidemic": 13110,
      "female mean age": 31365,
      "involved illicit drugs": 40099,
      "controlled prescription drugs": 20524,
      "study objective identify": 78336,
      "randomized controlled double": 67060,
      "double dummy subject": 26409,
      "dummy subject crossover": 27136,
      "crossover study subjects": 21309,
      "test used examine": 80792,
      "results difference primary": 71662,
      "difference primary outcome": 24671,
      "increased drug liking": 37910,
      "morphine fentanyl hydromorphone": 47690,
      "indwelling epidural catheters": 38487,
      "opana er endo": 51142,
      "er endo pharmaceuticals": 29415,
      "opioid drugs studies": 51753,
      "opioids frequently used": 52922,
      "primary objective review": 65045,
      "preclinical models human": 63533,
      "common effect opioid": 17752,
      "number infants exposed": 50164,
      "exposed opioids utero": 30745,
      "provide insight potential": 66076,
      "morphine methadone buprenorphine": 47756,
      "data national survey": 22016,
      "use health survey": 84390,
      "misusing prescription opioids": 46761,
      "world recent years": 87315,
      "drug induced fatalities": 26653,
      "old man dead": 51013,
      "anilino phenethyl piperidine": 10988,
      "phenethyl piperidine anpp": 61342,
      "urine vitreous humor": 84095,
      "illicit drug users": 36636,
      "methods data collected": 45299,
      "involving buprenorphine fentanyl": 40124,
      "hydrocodone hydromorphone methadone": 36087,
      "hydromorphone methadone morphine": 36188,
      "morphine oxycodone considered": 47816,
      "abuse intentional misuse": 6741,
      "rates abuse misuse": 67550,
      "dawn emergency department": 22234,
      "people aged 18": 60400,
      "aged 18 25": 9156,
      "yielded comparable results": 87698,
      "fentanyl hydrocodone methadone": 31493,
      "hydrocodone methadone oxycodone": 36103,
      "effects specific opioids": 28166,
      "british columbia bc": 14444,
      "hydromorphone morphine oxycodone": 36195,
      "annual defined daily": 11015,
      "daily doses 1000": 21738,
      "1000 population day": 1043,
      "medications study design": 44681,
      "study design retrospective": 78088,
      "cohort study objective": 17396,
      "study objective aim": 78329,
      "summary background data": 79097,
      "data preoperative opioid": 22057,
      "duration type opioid": 27190,
      "type opioid used": 83339,
      "acute months subacute": 7643,
      "months subacute acute": 47475,
      "subacute acute use": 78585,
      "acute use use": 7708,
      "use use months": 84794,
      "use months chronic": 84497,
      "months chronic subacute": 47434,
      "chronic subacute use": 16345,
      "subacute use use": 78590,
      "used determine association": 84910,
      "determine association preoperative": 23990,
      "opioid medications surgery": 51924,
      "na\u00efve patients year": 48849,
      "patients year reoperation": 60185,
      "year reoperation rate": 87495,
      "reoperation rate compared": 70373,
      "rate compared 25": 67451,
      "chronic preoperative use": 16334,
      "age sex charlson": 9115,
      "sex charlson comorbidity": 75064,
      "associated increased reoperations": 12306,
      "oxycodone tramadol associated": 56010,
      "subacute chronic use": 78588,
      "dose opioid medications": 25977,
      "opioid medications associated": 51910,
      "medications associated increased": 44593,
      "preoperative opioid cessation": 63748,
      "level evidence background": 41468,
      "effective reducing opioid": 27686,
      "people advanced cancer": 60398,
      "cancer experience moderate": 14780,
      "experience moderate severe": 30584,
      "tapentadol novel centrally": 80447,
      "novel centrally acting": 50005,
      "centrally acting analgesic": 15622,
      "acting opioid receptor": 7404,
      "comparable morphine oxycodone": 17962,
      "morphine oxycodone objectives": 47843,
      "analgesic efficacy tapentadol": 10251,
      "relief cancer pain": 70106,
      "cancer pain adults": 14814,
      "medline embase january": 44738,
      "lists retrieved papers": 42107,
      "clinical trials conducted": 16943,
      "additional trials identified": 7902,
      "trials identified electronic": 83148,
      "identified electronic searches": 36438,
      "trials rcts tapentadol": 83189,
      "tapentadol compared placebo": 80393,
      "compared placebo active": 18262,
      "adults moderate severe": 8569,
      "independently extracted data": 38180,
      "extracted data using": 30954,
      "standard form assessed": 76908,
      "form assessed risk": 32274,
      "risk bias extracted": 72530,
      "data study design": 22123,
      "study design participant": 78072,
      "design participant details": 23740,
      "participant details interventions": 58255,
      "details interventions outcomes": 23922,
      "withdrawals adverse events": 87171,
      "adverse events main": 8768,
      "events main results": 30065,
      "effective tolerated dose": 27710,
      "500 mg day": 4919,
      "scores patient global": 73943,
      "patient global impression": 58650,
      "efficacy reported adverse": 28350,
      "reported adverse events": 70501,
      "adverse events withdrawals": 8826,
      "rescue medication fewer": 70953,
      "high risk bias": 35169,
      "bias open label": 13770,
      "open label design": 51159,
      "comparable treatment groups": 17975,
      "treatment groups study": 82611,
      "pain relief tapentadol": 57588,
      "adverse event rates": 8713,
      "consciousness appetite thirst": 19552,
      "effectiveness tolerability tapentadol": 27785,
      "data pain relief": 22037,
      "pain relief adverse": 57521,
      "relief adverse events": 70100,
      "adverse events comparable": 8739,
      "morphine oxycodone groups": 47829,
      "man chronic pain": 43110,
      "prescription mg oxycodone": 64255,
      "active comparator cohort": 7486,
      "comparator cohort study": 17990,
      "oxycodone patients treated": 55662,
      "results analysis included": 71602,
      "analysis patients treated": 10728,
      "consumption oxycodone pain": 19974,
      "oxycodone pain scores": 55633,
      "standardized general anesthesia": 76959,
      "groups primary endpoint": 34278,
      "cumulative oxycodone consumed": 21402,
      "secondary endpoints pain": 74228,
      "endpoints pain scores": 28916,
      "pain scores numeric": 57746,
      "scores numeric rating": 73921,
      "hospital stay results": 35638,
      "stay results patients": 77291,
      "026 pain scores": 394,
      "pain scores lower": 57733,
      "60 min surgery": 5262,
      "data patient demographics": 22039,
      "laboratory test values": 41034,
      "nonlinear mixed effect": 49758,
      "mixed effect modeling": 46789,
      "risk pharmacokinetic drug": 72635,
      "pharmacokinetic drug interactions": 61115,
      "60 75 years": 5235,
      "75 years age": 5724,
      "mass spectrometry gc": 43460,
      "spectrometry gc ms": 76661,
      "analgesic drugs clinical": 10191,
      "clinical trials evaluated": 16946,
      "trials evaluated efficacy": 83141,
      "evaluated efficacy tolerability": 29883,
      "30 50 pain": 3695,
      "50 pain reduction": 4878,
      "drug related aes": 26765,
      "data randomized double": 22082,
      "comparing tapentadol extended": 18361,
      "pain efficacy tolerability": 56748,
      "mean number days": 43804,
      "demonstrated significant correlation": 23365,
      "patients global impression": 59329,
      "change baseline pain": 15726,
      "baseline pain scores": 13450,
      "scores tapentadol er": 73999,
      "significantly higher oxycodone": 75733,
      "pain reduction demonstrated": 57497,
      "standardized effect size": 76954,
      "tapentadol er compared": 80401,
      "er compared placebo": 29411,
      "23 95 confidence": 3089,
      "clinical trials objective": 16951,
      "pharmacodynamics pharmacokinetics efficacy": 61089,
      "pharmacokinetics efficacy tolerability": 61169,
      "efficacy tolerability dosing": 28403,
      "tolerability dosing role": 81532,
      "release ir extended": 69874,
      "ir extended release": 40226,
      "data source medline": 22109,
      "source medline pubmed": 76497,
      "medline pubmed search": 44748,
      "additional references obtained": 7888,
      "references obtained bibliographies": 69148,
      "obtained bibliographies study": 50762,
      "bibliographies study selection": 13783,
      "reviewed data synthesis": 72376,
      "receptor agonist structurally": 68466,
      "agonist structurally similar": 9308,
      "acute pain studies": 7675,
      "oxymorphone er superior": 56238,
      "er superior placebo": 29473,
      "oxycodone cr morphine": 54900,
      "expected opioid effects": 30557,
      "opioid effects comparable": 51760,
      "effects comparable oxycodone": 27863,
      "morphine clinical trials": 47599,
      "indicated relief moderate": 38246,
      "pain oxymorphone er": 57316,
      "20 mg hours": 2341,
      "mg 12 hours": 45710,
      "dosage adjustment recommended": 25743,
      "hepatic impairment child": 34954,
      "impairment child pugh": 36886,
      "child pugh class": 16013,
      "renal impairment creatinine": 70362,
      "impairment creatinine clearance": 36891,
      "newest oral opioid": 49412,
      "oral opioid enter": 53605,
      "opioid enter crowded": 51766,
      "enter crowded marketplace": 29052,
      "crowded marketplace totaling": 21315,
      "does appear unique": 25675,
      "appear unique assets": 11388,
      "unique assets liabilities": 83753,
      "assets liabilities considered": 12161,
      "liabilities considered oral": 41634,
      "considered oral opioids": 19642,
      "persistent pain moderate": 60924,
      "anti inflammatory analgesic": 11120,
      "inflammatory analgesic properties": 38552,
      "versus placebo patients": 86151,
      "40 mg day": 4347,
      "valdecoxib 10 mg": 85762,
      "mg day effective": 45856,
      "american college rheumatology": 9793,
      "college rheumatology 20": 17510,
      "valdecoxib 20 40": 85765,
      "provided effective pain": 66131,
      "naproxen sodium 550": 48572,
      "sodium 550 mg": 76404,
      "valdecoxib 40 mg": 85767,
      "provided similar analgesia": 66159,
      "10 mg plus": 842,
      "mg plus paracetamol": 46166,
      "plus paracetamol acetaminophen": 62032,
      "acetaminophen 1000 mg": 7115,
      "time rescue medication": 81363,
      "oxycodone paracetamol oral": 55639,
      "10 80 mg": 728,
      "hip knee arthroplasty": 35422,
      "pain laparoscopic cholecystectomy": 56993,
      "valdecoxib generally tolerated": 85770,
      "provided similar pain": 66160,
      "similar pain relief": 75972,
      "pain relief oxycodone": 57560,
      "long duration action": 42312,
      "rapid onset analgesia": 67391,
      "analgesia opioid sparing": 10038,
      "pain acute pain": 56412,
      "mor agonist oxycodone": 47495,
      "agonist pre 084": 9303,
      "prescription opioids hydrocodone": 64339,
      "using negative binomial": 85513,
      "statistically significantly increased": 77236,
      "multimodal analgesic regimen": 48213,
      "analgesic regimen postoperative": 10316,
      "regimen postoperative pain": 69322,
      "function adverse effects": 32623,
      "adverse effects satisfaction": 8698,
      "thirty patients undergoing": 81113,
      "patients undergoing tka": 60130,
      "15 mg ketorolac": 1756,
      "time physical therapy": 81326,
      "medication related adverse": 44556,
      "lower vas scores": 42723,
      "higher satisfaction scores": 35322,
      "pain management protocol": 57107,
      "drug monitoring programs": 26718,
      "monitoring programs pdmps": 47342,
      "oxycodone hydrocodone opioids": 55211,
      "nonopioid analgesics opioids": 49808,
      "conclusions prescription drug": 19172,
      "opioid abuse problem": 51377,
      "studies pharmacokinetic studies": 77811,
      "currently facing opioid": 21497,
      "pain fifth vital": 56781,
      "fifth vital sign": 31689,
      "opioid prescriptions number": 52200,
      "treated opioid use": 82356,
      "people died opioid": 60406,
      "data opioid related": 22031,
      "opioid related hospital": 52317,
      "related hospital admissions": 69617,
      "number prescription opioid": 50239,
      "number opioid related": 50197,
      "opioid related mortality": 52323,
      "deaths 100 000": 22733,
      "study design case": 78065,
      "neuropathic pain treated": 49266,
      "neuropathic pain associated": 49233,
      "alleviate neuropathic pain": 9597,
      "neuropathic pain years": 49269,
      "neuropathic pain conclusion": 49239,
      "neuropathic pain related": 49259,
      "analgesics treatment pain": 10512,
      "epidemic opioid misuse": 29141,
      "opioid misuse diversion": 51939,
      "opioids oxycodone morphine": 53141,
      "mu opioid agonists": 48120,
      "influx blood brain": 38612,
      "formulation route administration": 32365,
      "administration nktr 181": 8310,
      "nktr 181 novel": 49513,
      "nktr 181 demonstrated": 49512,
      "hot plate latency": 35683,
      "reduced abuse potential": 68906,
      "self administration progressive": 74474,
      "administration progressive ratio": 8352,
      "vitro vivo studies": 86375,
      "reduced abuse liability": 68905,
      "meta analysis nma": 44894,
      "adverse events incidence": 8763,
      "patient satisfaction treatment": 58778,
      "overall adverse events": 54184,
      "adverse events constipation": 8747,
      "oxycodone naloxone combination": 55494,
      "treatment chronic malignant": 82482,
      "clinically relevant drug": 16992,
      "drug drug drug": 26600,
      "age related changes": 9112,
      "opioids buprenorphine fentanyl": 52757,
      "fentanyl hydromorphone methadone": 31497,
      "morphine oxycodone tapentadol": 47858,
      "evidence based recommendations": 30165,
      "literature search performed": 42135,
      "analgesic treatment chronic": 10349,
      "oral dosage forms": 53520,
      "rates adverse events": 67555,
      "adverse events patients": 8789,
      "methods retrospective observational": 45544,
      "retrospective observational cohort": 72146,
      "administrative claims data": 8396,
      "oxycodone er morphine": 55040,
      "morphine transdermal fentanyl": 47959,
      "diagnoses opioid related": 24328,
      "proportional hazards models": 65786,
      "patients cancer results": 59049,
      "hazard ratio hr": 34616,
      "71 95 ci": 5590,
      "95 ci 54": 6310,
      "95 ci 02": 6226,
      "greater risk overdose": 33491,
      "57 95 ci": 5127,
      "conclusions results support": 19207,
      "additional studies needed": 7896,
      "studies needed confirm": 77784,
      "needed confirm findings": 48992,
      "prescription patterns opioids": 64385,
      "daily doses ddds": 21741,
      "total consumption opioids": 81789,
      "increase pain control": 37778,
      "ongoing prescription opioid": 51092,
      "significant contributors opioid": 75451,
      "statewide prescription drug": 77163,
      "prescription opioid diversion": 64295,
      "increased opioid use": 37966,
      "dose opioid antagonists": 25975,
      "therapy cancer pain": 80993,
      "cancer pain patients": 14843,
      "effects pain relief": 28079,
      "plasma disposition noroxycodone": 61925,
      "29 95 ci": 3606,
      "critically ill patients": 21232,
      "opioid receptors mors": 52278,
      "opioid morphine oxycodone": 51962,
      "oxycodone induced hyperlocomotion": 55266,
      "self administration assessed": 74460,
      "underwent extinction training": 83680,
      "evidence animal human": 30144,
      "methods conducted retrospective": 45283,
      "used multivariable poisson": 85023,
      "multivariable poisson regression": 48333,
      "poisson regression models": 62168,
      "patients using long": 60169,
      "using long acting": 85473,
      "oxycodone oxymorphone tramadol": 55627,
      "individual long acting": 38299,
      "opioids long acting": 53026,
      "long acting morphine": 42292,
      "oxycodone users lower": 56067,
      "dramatically united states": 26444,
      "relative reinforcing effects": 69762,
      "reinforcing effects commonly": 69524,
      "effects commonly abused": 27858,
      "study designed compare": 78097,
      "70 kg buprenorphine": 5563,
      "12 25 mg": 1242,
      "mg day oral": 45857,
      "doses 30 mg": 26138,
      "produced statistically significant": 65414,
      "related increases positive": 69623,
      "increases positive subjective": 38074,
      "positive subjective ratings": 62496,
      "subjective ratings feel": 78668,
      "ratings feel good": 67698,
      "feel good drug": 31332,
      "good drug effect": 33304,
      "drug effect like": 26608,
      "effect like drug": 27472,
      "heroin morphine oxycodone": 35018,
      "data suggest abuse": 22128,
      "suggest abuse liability": 78982,
      "morphine oxycodone heroin": 47830,
      "efficacy adverse reactions": 28222,
      "adverse reactions observed": 8844,
      "cachectic cancer patients": 14666,
      "cancer patients high": 14875,
      "oxycodone reduction cyp3a": 55815,
      "serum level interleukin": 74701,
      "treatment opioid induced": 82703,
      "opioid induced nausea": 51863,
      "prolactin secretion oxycodone": 65600,
      "atp binding cassette": 12533,
      "high plasma concentration": 35141,
      "decreased kidney function": 23005,
      "did alter plasma": 24409,
      "median milk plasma": 44242,
      "milk plasma concentration": 46444,
      "plasma concentration ratio": 61905,
      "prescription opioids buprenorphine": 64329,
      "year period 2003": 87482,
      "trends abuse misuse": 82961,
      "abuse misuse prescription": 6781,
      "medical examiner cases": 44361,
      "fentanyl transdermal patches": 31607,
      "using solid phase": 85618,
      "solid phase extraction": 76431,
      "gc ms electron": 32918,
      "ms electron impact": 48081,
      "electron impact ionization": 28527,
      "using selected ion": 85605,
      "selected ion monitoring": 74389,
      "ion monitoring gc": 40143,
      "monitoring gc ms": 47325,
      "gc ms method": 32920,
      "blood concentrations ranged": 14118,
      "use illicit drugs": 84415,
      "patient chronic pain": 58559,
      "prescription monitoring programs": 64260,
      "urine toxicology testing": 84093,
      "patient prescribed oxycodone": 58715,
      "chronic pain including": 16280,
      "patients chronic opioid": 59077,
      "toxicology testing authors": 81958,
      "design prospective observational": 23762,
      "observational study objective": 50630,
      "record daily opioid": 68654,
      "daily opioid use": 21776,
      "opioid use pain": 52554,
      "pain levels level": 57016,
      "opioid prescription guidelines": 52150,
      "understanding postoperative opioid": 83649,
      "patients undergoing level": 60110,
      "patients opioid dependence": 59583,
      "opioid dependence defined": 51701,
      "starting postoperative day": 77025,
      "scale pain levels": 73532,
      "automated text messaging": 12760,
      "facilitate clinical applications": 31032,
      "opioid use converted": 52488,
      "use converted oral": 84283,
      "oxycodone mg equivalents": 55417,
      "risk factors patients": 72573,
      "results 57 patients": 71576,
      "cumulative opioid use": 21400,
      "10 interquartile range": 775,
      "vs interquartile range": 86650,
      "range 18 respectively": 67265,
      "patients 27 did": 58848,
      "27 did use": 3491,
      "patients took opioids": 60051,
      "opioids postoperative day": 53191,
      "patients use opioids": 60162,
      "use opioids patients": 84566,
      "12 oxycodone mg": 1349,
      "opioid addiction prescription": 51401,
      "prescription illicit drugs": 64239,
      "administration opioid agonists": 8317,
      "opioid agonists methadone": 51432,
      "studies demonstrated efficacy": 77693,
      "cell disease scd": 15480,
      "based guidelines exist": 13326,
      "treatment strategies pain": 82854,
      "pain management pediatric": 57100,
      "approaches management pain": 11491,
      "pain management interventions": 57076,
      "analgesics nonsteroidal anti": 10457,
      "opioid medications morphine": 51916,
      "medications morphine oxycodone": 44647,
      "gold standard pain": 33285,
      "pain management children": 57059,
      "pain management requires": 57116,
      "pain functional outcomes": 56802,
      "ic 50 values": 36382,
      "proper use opioids": 65702,
      "opioids morphine fentanyl": 53069,
      "years old patients": 87624,
      "doses oral morphine": 26231,
      "oral morphine oxycodone": 53590,
      "mg oral morphine": 46084,
      "dose transdermal fentanyl": 26102,
      "120 mg oral": 1406,
      "median time onset": 44289,
      "oral oxycodone transdermal": 53642,
      "oxycodone transdermal fentanyl": 56022,
      "patients administered morphine": 58949,
      "case report 41": 15186,
      "report 41 year": 70444,
      "41 year old": 4435,
      "discontinued postoperative day": 25247,
      "day 10 days": 22239,
      "pain management prevention": 57105,
      "prevention postoperative pain": 64881,
      "potent synthetic opioid": 63118,
      "general regional anesthesia": 32986,
      "north america europe": 49956,
      "fentanyl recreational drug": 31581,
      "sold oxycodone hydrocodone": 76420,
      "oxycodone hydrocodone alprazolam": 55201,
      "rapid onset fentanyl": 67392,
      "effective harm reduction": 27630,
      "objective abuse prescription": 50363,
      "prescription opioid pain": 64307,
      "analgesic mechanisms action": 10267,
      "action opioid receptor": 7439,
      "receptor agonism norepinephrine": 68459,
      "agonism norepinephrine reuptake": 9274,
      "individuals assessed substance": 38337,
      "abuse treatment navippro": 6898,
      "states january 2011": 77113,
      "2012 examined prevalence": 2600,
      "examined prevalence prescription": 30408,
      "prevalence prescription adjusted": 64805,
      "prescription adjusted prevalence": 64162,
      "30 day abuse": 3717,
      "release er formulations": 69844,
      "oxymorphone hydromorphone hydrocodone": 56250,
      "fentanyl oxycodone tramadol": 31556,
      "oxycodone tramadol buprenorphine": 56011,
      "schedule ii analgesics": 73615,
      "use misuse prescription": 84492,
      "illicit drug abuse": 36631,
      "drug abuse drug": 26501,
      "time course effects": 81230,
      "recreational drug use": 68774,
      "narcotic drugs codeine": 48597,
      "alternate routes administration": 9709,
      "48 hours surgery": 4727,
      "treatment acute moderate": 82427,
      "severe pain single": 75002,
      "surgery objective study": 79479,
      "objective study assessed": 50498,
      "abdominal surgery methods": 6532,
      "surgery methods multicenter": 79462,
      "methods multicenter randomized": 45390,
      "multicenter randomized double": 48170,
      "placebo controlled parallel": 61691,
      "controlled parallel group": 20512,
      "18 years undergoing": 2115,
      "point categorical scale": 62080,
      "severe pain intensity": 74983,
      "mm 100 mm": 46925,
      "pain 100 worst": 56362,
      "100 worst pain": 1026,
      "worst pain imaginable": 87344,
      "randomized receive oxymorphone": 67175,
      "mg placebo hours": 46163,
      "dose study included": 26088,
      "primary efficacy end": 65004,
      "efficacy end point": 28259,
      "study demographic characteristics": 78056,
      "demographic characteristics similar": 23274,
      "characteristics similar groups": 15883,
      "active treatments compared": 7541,
      "15 mg 24": 1749,
      "mg 24 hours": 45732,
      "mg significantly effective": 46218,
      "significantly effective placebo": 75694,
      "hour single dose": 35718,
      "active treatment groups": 7539,
      "current average pain": 21429,
      "pain intensity significantly": 56946,
      "intensity significantly lower": 39314,
      "significantly lower patients": 75802,
      "15 mg compared": 1751,
      "treatment emergent aes": 82576,
      "placebo groups respectively": 61758,
      "groups respectively proportions": 34302,
      "respectively proportions patients": 71239,
      "patients reporting treatment": 59898,
      "groups respectively compared": 34300,
      "analgesia moderate severe": 10027,
      "oxycodone naloxone naltrexone": 55505,
      "analgesic effect parent": 10207,
      "oxycodone hydrocodone 14": 55199,
      "oxime formation monitored": 54404,
      "reversed phase hplc": 72243,
      "hydrocodone codeine oxycodone": 36068,
      "oxycodone tramadol frequently": 56013,
      "tramadol frequently prescribed": 82063,
      "pharmacodynamic differences opioids": 61061,
      "12 17 years": 1218,
      "17 years age": 1994,
      "opioids adverse events": 52712,
      "defined emergency department": 23138,
      "emergency department visit": 28684,
      "death related opioid": 22720,
      "events opioid related": 30086,
      "propensity score adjusted": 65693,
      "adverse events 10": 8722,
      "acting opioids incidence": 7412,
      "hydrocodone immediate release": 36098,
      "including long term": 37629,
      "90 days continuous": 6095,
      "compared opioid analgesics": 18227,
      "january 2008 september": 40428,
      "hydrocodone acetaminophen patients": 36059,
      "treatment long term": 82643,
      "increased number patients": 37955,
      "er morphine er": 29442,
      "morphine er oxycodone": 47681,
      "er oxycodone patients": 29463,
      "20 60 mg": 2301,
      "patients prescribed long": 59672,
      "adults severe chronic": 8580,
      "chronic pain adequately": 16256,
      "pain adequately managed": 56417,
      "adequately managed opioid": 7980,
      "managed opioid analgesics": 43135,
      "adverse events ae": 8725,
      "potent opioid analgesics": 63110,
      "opioid analgesics similar": 51526,
      "similar levels analgesia": 75942,
      "commonly used line": 17881,
      "line treatment severe": 42007,
      "treatment severe chronic": 82838,
      "severe chronic nonmalignant": 74932,
      "transdermal fentanyl tdf": 82158,
      "second line opioid": 74188,
      "line opioid data": 41990,
      "randomized clinical trials": 67049,
      "clinical trials clinical": 16941,
      "opioids health care": 52941,
      "health care resource": 34685,
      "patients severe chronic": 59963,
      "willingness pay threshold": 87106,
      "compared oxycodone tapentadol": 18244,
      "better quality life": 13735,
      "introduction prescription opioid": 39950,
      "school dental medicine": 73669,
      "treating opioid use": 82401,
      "commercial health insurance": 17706,
      "results number patients": 71797,
      "increased substantially study": 38034,
      "substantially study period": 78866,
      "substantial increase number": 78850,
      "increase number patients": 37761,
      "prescribed opioid use": 63916,
      "genetic factors associated": 33073,
      "clinicians need aware": 17034,
      "use disorder treatment": 84327,
      "use disorder opioid": 84322,
      "methods authors reviewed": 45261,
      "dental opioid prescriptions": 23405,
      "younger 21 years": 87730,
      "opioid prescriptions identified": 52190,
      "opioid medications objective": 51919,
      "american academy otolaryngology": 9789,
      "academy otolaryngology head": 6966,
      "otolaryngology head neck": 53886,
      "national health medical": 48686,
      "health medical research": 34733,
      "cochrane library embase": 17177,
      "isi web science": 40292,
      "systematic reviews randomized": 80002,
      "reviews randomized controlled": 72419,
      "analgesia postoperative pain": 10064,
      "200 mg ibuprofen": 2401,
      "provides effective postoperative": 66214,
      "safety opioid based": 73175,
      "postoperative pain regimens": 62911,
      "combat opioid epidemic": 17536,
      "opioid epidemic usa": 51784,
      "available extended release": 12806,
      "95 ci 83": 6339,
      "53 95 ci": 5018,
      "32 95 ci": 3921,
      "95 ci 32": 6277,
      "95 ci 25": 6268,
      "ci 25 26": 16421,
      "39 95 ci": 4267,
      "ci 39 39": 16444,
      "aim current study": 9382,
      "current study evaluate": 21477,
      "patient cohort methods": 58564,
      "single fellowship trained": 76104,
      "fellowship trained foot": 31346,
      "trained foot ankle": 82002,
      "narcotic pain medication": 48601,
      "medication recorded results": 44550,
      "recorded results total": 68698,
      "postoperatively patient satisfaction": 63014,
      "mg oxycodone pill": 46131,
      "postoperative narcotic use": 62800,
      "narcotic use level": 48617,
      "use level evidence": 84451,
      "level evidence level": 41472,
      "evidence level iii": 30208,
      "cohort study single": 17402,
      "background multimodal analgesia": 13085,
      "multimodal analgesia protocols": 48204,
      "opioid use limited": 52531,
      "multimodal analgesia protocol": 48203,
      "outpatient opioid use": 54130,
      "methods retrospective review": 45546,
      "retrospective review patients": 72162,
      "patients admitted level": 58954,
      "admitted level trauma": 8429,
      "level trauma center": 41532,
      "2018 april 2019": 2815,
      "multimodal pain protocols": 48234,
      "inhibition cytochrome p450": 38782,
      "drug interactions involving": 26669,
      "opioid analgesic drugs": 51457,
      "monoamine oxidase inhibitors": 47362,
      "inhibitors selective serotonin": 38809,
      "reuptake inhibitors serotonin": 72206,
      "inhibitors serotonin norepinephrine": 38812,
      "norepinephrine reuptake inhibitors": 49892,
      "including morphine hydromorphone": 37639,
      "method opioid delivery": 45193,
      "areas covered paper": 11644,
      "united states aimed": 83778,
      "states aimed identify": 77080,
      "opioids used postoperative": 53372,
      "patients history chronic": 59364,
      "chronic pelvic pain": 16328,
      "academic university hospital": 6959,
      "opioid use collected": 52480,
      "patient reported survey": 58742,
      "surgery benign gynecologic": 79335,
      "benign gynecologic indications": 13644,
      "used average 105": 84856,
      "significant difference opioids": 75481,
      "opioids used patients": 53371,
      "statistically significant conclusion": 77203,
      "conclusion patients undergoing": 18957,
      "control patient population": 20386,
      "injecting drug users": 38927,
      "drug users idu": 26854,
      "extra medical use": 30939,
      "play major role": 61996,
      "used cns depressants": 84882,
      "opioid abusers methods": 51389,
      "completed month follow": 18473,
      "demographic drug use": 23283,
      "month period results": 47401,
      "month follow period": 47391,
      "generalized anxiety disorder": 32999,
      "30 day use": 3722,
      "day use oxycontin": 22442,
      "future work evaluate": 32780,
      "harm reduction strategy": 34582,
      "low study aimed": 42558,
      "opioid tablets increases": 52397,
      "clients supervised injecting": 16735,
      "health care facilities": 34679,
      "codeine fentanyl hydromorphone": 17233,
      "morphine oxycodone reported": 47855,
      "daily defined doses": 21717,
      "oxycodone study period": 55948,
      "large quantities opioids": 41150,
      "fentanyl methadone buprenorphine": 31523,
      "results opioid consumption": 71810,
      "opioid consumption rates": 51654,
      "2008 oxycodone consumption": 2509,
      "oxycodone consumption increased": 54863,
      "attributed prescription opioids": 12615,
      "sex differences related": 75073,
      "substance use including": 78817,
      "participants 18 years": 58267,
      "opioid use past": 52559,
      "descriptive statistics chi": 23682,
      "statistics chi square": 77244,
      "regression used calculate": 69461,
      "used calculate adjusted": 84864,
      "odds ratios aor": 50936,
      "sex specific effects": 75092,
      "mean age 45": 43682,
      "age 45 years": 9010,
      "96 95 ci": 6421,
      "95 ci 34": 6282,
      "associated prescription opioid": 12389,
      "opioid use varied": 52604,
      "non opioid pain": 49655,
      "hydrocodone oxycodone morphine": 36119,
      "oxycodone morphine methadone": 55477,
      "mass spectrometry methods": 43469,
      "positive hydrocodone oxycodone": 62467,
      "oxycodone morphine group": 55472,
      "age matched controls": 9088,
      "concentrations samples positive": 18812,
      "non opioid medications": 49653,
      "copyright 2017 john": 20763,
      "2017 john wiley": 2785,
      "background opioid misuse": 13113,
      "time state level": 81382,
      "opioid filling surrounding": 51808,
      "hip arthroplasty tha": 35417,
      "methods national database": 45394,
      "cumulative perioperative opioid": 21410,
      "perioperative opioid filling": 60839,
      "mg equivalents oe": 45884,
      "patients undergoing primary": 60123,
      "undergoing primary tha": 83569,
      "pre operative 90": 63477,
      "90 days post": 6097,
      "days post operative": 22586,
      "initial opioid filling": 38855,
      "cumulative opioid filling": 21399,
      "initial opioid prescriptions": 38857,
      "legislation targeting duration": 41379,
      "opioid prescription filling": 52146,
      "states opioid legislation": 77128,
      "10 oxycodone mg": 885,
      "cumulative 90 day": 21390,
      "90 day opioid": 6087,
      "day opioid filling": 22345,
      "opioid limiting legislation": 51891,
      "causal relationships inferred": 15337,
      "level iii retrospective": 41493,
      "iii retrospective prognostic": 36597,
      "retrospective prognostic cohort": 72155,
      "prognostic cohort study": 65529,
      "cohort study background": 17386,
      "states district columbia": 77094,
      "cannabis methamphetamine cocaine": 14935,
      "cocaine heroin oxycodone": 17149,
      "difference differences design": 24609,
      "interval ci 15": 39581,
      "93 95 ci": 6173,
      "95 ci 51": 6307,
      "opioids including heroin": 52978,
      "widely used treatment": 87076,
      "used treatment moderate": 85180,
      "severe pain cancer": 74972,
      "cancer noncancer patients": 14806,
      "opioid induced neurotoxicity": 51865,
      "induced neurotoxicity oin": 38431,
      "fentanyl tramadol oxycodone": 31604,
      "time onset oin": 81300,
      "transdermal fentanyl oral": 82149,
      "background purpose opioids": 13184,
      "effects different opioids": 27896,
      "methadone racemic methadone": 45123,
      "monoacetylmorphine buprenorphine codeine": 47357,
      "buprenorphine codeine dihydrocodeine": 14530,
      "heroin hydrocodone hydromorphone": 35003,
      "morphine equivalents results": 47679,
      "flunitrazepam lorazepam nitrazepam": 31949,
      "opioids methadone oxycodone": 53048,
      "chronic pain common": 16266,
      "pain common reason": 56569,
      "opioid medications prescribed": 51922,
      "number pills opioid": 50228,
      "active duty military": 7512,
      "hydrocodone tramadol codeine": 36135,
      "iqr 15 30": 40164,
      "providers likely prescribe": 66185,
      "providers prescribed median": 66191,
      "median 20 pills": 44178,
      "prescription commonly prescribed": 64181,
      "opioid chronic pain": 51577,
      "wound infusion bupivacaine": 87364,
      "opioids patients undergoing": 53165,
      "single centre prospective": 76074,
      "continuous infusion ml": 20173,
      "paracetamol non steroidal": 58104,
      "inflammatory drugs morphine": 38563,
      "morphine oxycodone needed": 47842,
      "outcomes included pain": 54036,
      "included pain scores": 37502,
      "scores rest activity": 73971,
      "postoperative period significantly": 62946,
      "10 mg 25": 795,
      "higher number patients": 35275,
      "presence nausea vomiting": 64595,
      "drug use associated": 26832,
      "immediate release hydromorphone": 36717,
      "release oxycodone cr": 69929,
      "introduction extended release": 39927,
      "extended release abuse": 30855,
      "release abuse deterrent": 69806,
      "methods model developed": 45385,
      "opioid cost effectiveness": 51679,
      "release oxycodone extended": 69937,
      "annual medical cost": 11021,
      "medical cost savings": 44353,
      "non abuse deterrent": 49562,
      "sought determine effect": 76485,
      "open inguinal hernia": 51153,
      "patients group received": 59339,
      "pain level 10": 57006,
      "discharge recovery room": 25171,
      "consumed oxycodone mg": 19840,
      "results ninety patients": 71791,
      "randomized study patients": 67194,
      "study patients received": 78374,
      "recovery room pain": 68759,
      "recovery room stay": 68761,
      "pos illicit drugs": 62429,
      "oxycodone hydromorphone oxycodone": 55223,
      "acetaminophen codeine methadone": 7166,
      "ordinal logistic regression": 53734,
      "study period 2006": 78383,
      "drugs abuse heroin": 26866,
      "remained constant adjusted": 70261,
      "study required determine": 78464,
      "extended release used": 30905,
      "mg dl patient": 45876,
      "acute renal failure": 7697,
      "renal failure patient": 70355,
      "probability scale revealed": 65220,
      "undergoing elective lower": 83531,
      "cerebrospinal fluid obtained": 15646,
      "surgical incision patients": 79633,
      "randomized receive intravenous": 67170,
      "parecoxib 40 mg": 58188,
      "mg ketorolac 30": 45945,
      "ketorolac 30 mg": 40638,
      "mg preservative free": 46181,
      "patients administered intravenous": 58948,
      "intravenous ketorolac 30": 39852,
      "pain scores reduced": 57772,
      "groups compared placebo": 34150,
      "required postoperative intravenous": 70856,
      "oxycodone consumption reduced": 54868,
      "codeine tramadol hydrocodone": 17291,
      "metabolizers extensive metabolizers": 45006,
      "active opioid metabolites": 7522,
      "especially young children": 29568,
      "respiratory depression adverse": 71269,
      "united states evaluated": 83793,
      "practices primary care": 63436,
      "pain management specialists": 57120,
      "significantly increased number": 75755,
      "number prescribed schedule": 50236,
      "total morphine milligram": 81845,
      "milligram equivalent mme": 46452,
      "increase overdose deaths": 37773,
      "overdose deaths involving": 54281,
      "benzodiazepines muscle relaxants": 13667,
      "management acute pain": 43144,
      "opioid analgesics pain": 51516,
      "pain management protocols": 57109,
      "acute care setting": 7614,
      "care setting objective": 15080,
      "evaluate evidence use": 29798,
      "evidence use opioids": 30289,
      "adolescents young adults": 8465,
      "efficacy safety patient": 28377,
      "safety patient satisfaction": 73198,
      "study randomized controlled": 78448,
      "animal models acute": 10997,
      "models acute chronic": 47106,
      "relevant adverse events": 70044,
      "results provide evidence": 71898,
      "pain study compared": 57873,
      "controls received standard": 20674,
      "received standard care": 68282,
      "anesthesia randomly assigned": 10942,
      "rofecoxib 50 mg": 72725,
      "time pain scores": 81314,
      "pain scores 10": 57693,
      "use satisfaction scores": 84716,
      "pain scores worst": 57798,
      "scores worst pain": 74020,
      "pain postanesthesia care": 57388,
      "required 28 oxycodone": 70819,
      "decreases pain scores": 23064,
      "pain scores opioid": 57751,
      "scores opioid use": 73933,
      "scores 24 surgery": 73833,
      "high rates chronic": 35161,
      "data prescription opioid": 22060,
      "prescription opioid dispensing": 64294,
      "iqvia compuscript converted": 40187,
      "000 population day": 44,
      "opioid related health": 52316,
      "objective examine impact": 50430,
      "patients adequate analgesia": 58943,
      "design retrospective chart": 23783,
      "retrospective chart review": 72118,
      "chart review setting": 15931,
      "review setting tertiary": 72358,
      "setting tertiary care": 74835,
      "care community hospital": 15014,
      "50 patients received": 4883,
      "patients received opioids": 59804,
      "opioids fentanyl morphine": 52912,
      "fentanyl morphine hydromorphone": 31532,
      "received intravenous acetaminophen": 68176,
      "2012 time period": 2615,
      "main results patients": 42861,
      "groups mean age": 34232,
      "years mean sd": 87613,
      "group postoperative days": 33924,
      "reduced opioid use": 68955,
      "total perioperative period": 81885,
      "recovery room postoperative": 68760,
      "group 001 conclusion": 33527,
      "conclusion multimodal approach": 18928,
      "administration intravenous acetaminophen": 8282,
      "limitations study include": 41909,
      "post mortem cases": 62584,
      "different time periods": 24928,
      "lc ms ms": 41267,
      "ms ms method": 48088,
      "prescription opioids main": 64347,
      "evaluate changes prescribing": 29777,
      "pharmacy claims data": 61258,
      "prescription rates increased": 64394,
      "opioid abuse significant": 51384,
      "significant regional differences": 75625,
      "computed tomography ct": 18656,
      "tomography ct guided": 81653,
      "opioid use methadone": 52535,
      "tramadol codeine oxycodone": 82044,
      "codeine oxycodone hydrocodone": 17267,
      "kidney liver spleen": 40828,
      "conducted liquid chromatography": 19373,
      "mass spectrometry significant": 43471,
      "methadone ethylidene dimethyl": 45068,
      "ethylidene dimethyl diphenylpyrrolidine": 29705,
      "dimethyl diphenylpyrrolidine eddp": 25019,
      "proved valuable tool": 66023,
      "irritable bowel syndrome": 40282,
      "patient age sex": 58538,
      "reports adverse events": 70712,
      "significantly lower proportions": 75806,
      "non opioid group": 49652,
      "opioids results showed": 53277,
      "chronic opioid users": 16245,
      "opioid non opioid": 52000,
      "opioid extended release": 51802,
      "chronic pain used": 16324,
      "codeine tramadol strong": 17297,
      "tramadol strong opioid": 82111,
      "strong opioid morphine": 77533,
      "pain cancer patients": 56509,
      "non cancer patients": 49585,
      "cancer patients study": 14892,
      "opioid prescribing changed": 52088,
      "residents aged 65": 71072,
      "opioid prescription rate": 52160,
      "mean daily opioid": 43744,
      "daily opioid dose": 21775,
      "daily dose time": 21736,
      "high risk population": 35177,
      "treatment prescription opioid": 82781,
      "abuse treatment programs": 6902,
      "related increase number": 69621,
      "subjects used buprenorphine": 78752,
      "hydrocodone oxycodone number": 36120,
      "methadone oxycodone hydrocodone": 45117,
      "received institutional review": 68169,
      "records patients underwent": 68723,
      "study period 10": 78381,
      "50 microg fentanyl": 4865,
      "fentanyl mg midazolam": 31529,
      "student test used": 77598,
      "test used compare": 80790,
      "group vs mg": 34078,
      "required general anesthesia": 70839,
      "group required additional": 33983,
      "opioid use dependence": 52496,
      "drug testing results": 26809,
      "collected pain management": 17468,
      "pain management patients": 57098,
      "codeine morphine hydrocodone": 17255,
      "oxycodone oxymorphone fentanyl": 55615,
      "marijuana use associated": 43386,
      "statistically significant lower": 77226,
      "increases pharmaceutical opioid": 38072,
      "pharmaceutical opioid dependence": 61032,
      "related mortality studies": 69636,
      "opioid dependence baseline": 51700,
      "drug treatment services": 26820,
      "pharmaceutical opioids pain": 61040,
      "results mean age": 71765,
      "lifetime heroin use": 41749,
      "reported past year": 70618,
      "reported chronic pain": 70517,
      "chronic pain half": 16277,
      "reported moderate severe": 70589,
      "moderate severe depression": 47179,
      "study objective opioid": 78338,
      "opioid epidemic continues": 51771,
      "epidemic continues impact": 29130,
      "united states new": 83807,
      "states new strategies": 77124,
      "epidemic objective study": 29139,
      "objective study analyze": 50495,
      "use study design": 84758,
      "design population based": 23752,
      "population based descriptive": 62310,
      "based descriptive study": 13306,
      "study using data": 78562,
      "drug abuse epidemic": 26502,
      "data health care": 21978,
      "patients risk overdose": 59932,
      "enforcement agency dea": 28929,
      "agency dea schedule": 9214,
      "use non opioids": 84517,
      "opioids weak opioids": 53387,
      "opioids tramadol tilidine": 53347,
      "tramadol tilidine naloxone": 82116,
      "hydromorphone fentanyl methadone": 36171,
      "relationship analgesic efficacy": 69713,
      "analgesic efficacy effects": 10235,
      "non medical prescription": 49630,
      "treatment seeking opioid": 82829,
      "completed online survey": 18477,
      "opioid users history": 52621,
      "number pills taken": 50231,
      "conclusions results indicate": 19202,
      "objective determine proportion": 50402,
      "opioid prescribing increased": 52104,
      "opioid prescriptions limited": 52196,
      "nationwide insurance claims": 48732,
      "18 64 years": 2060,
      "primary outcome change": 65058,
      "naive patients undergoing": 48407,
      "patients undergoing surgical": 60129,
      "opioid prescriptions filled": 52187,
      "prescriptions filled opioid": 64489,
      "patients receiving surgery": 59858,
      "surgery patients filled": 79505,
      "prescriptions emergency medicine": 64483,
      "total oral morphine": 81871,
      "study period surgical": 78397,
      "patients received highest": 59782,
      "evidence based guideline": 30156,
      "opioid morbidity mortality": 51959,
      "news media reports": 49423,
      "monthly time series": 47424,
      "poisoning deaths involving": 62159,
      "using multiple cause": 85505,
      "multiple cause death": 48262,
      "cause death data": 15349,
      "national center health": 48670,
      "center health statistics": 15523,
      "involving prescription opioids": 40136,
      "prescription opioids increased": 64342,
      "opioids increased dramatically": 52988,
      "nonmedical use oxycontin": 49787,
      "end dose pain": 28787,
      "pain patients using": 57362,
      "formulations long acting": 32385,
      "performed systematic review": 60638,
      "systematic review evaluate": 79988,
      "studies patients chronic": 77806,
      "patients chronic cancer": 59066,
      "cancer noncancer pain": 14805,
      "breakthrough pain btp": 14398,
      "compared patients placebo": 18252,
      "compared short acting": 18306,
      "short acting formulations": 75156,
      "incidence end dose": 37275,
      "chronic pain taking": 16318,
      "vs long acting": 86653,
      "porto systemic shunting": 62425,
      "lack evidence based": 41054,
      "patients severe hepatic": 59965,
      "appears safe patients": 11410,
      "alcoholic liver disease": 9550,
      "large number opioid": 41139,
      "presence hepatic impairment": 64592,
      "decreased moderate severe": 23011,
      "patients hepatic impairment": 59355,
      "phenylpiperidine opioids fentanyl": 61356,
      "opioids fentanyl sufentanil": 52914,
      "fentanyl sufentanil remifentanil": 31598,
      "regarding postoperative pain": 69273,
      "pain opioid use": 57290,
      "study design patients": 78074,
      "pain level use": 57011,
      "academic medical centers": 6954,
      "consecutive adult patients": 19556,
      "adult patients undergoing": 8519,
      "subjects met criteria": 78712,
      "combination oxycodone mg": 17587,
      "tablets postoperative days": 80199,
      "opioid consumption positively": 51648,
      "difference postoperative pain": 24669,
      "higher average pain": 35207,
      "opioids 02 conclusions": 52655,
      "evidence based approach": 30154,
      "reduces number unused": 68996,
      "sufficient pain control": 78974,
      "patients immediate postoperative": 59377,
      "postoperative period following": 62938,
      "use acetaminophen use": 84170,
      "use systemic steroids": 84771,
      "larger opioid prescriptions": 41178,
      "managing postoperative pain": 43297,
      "clinical outcomes patients": 16852,
      "age 10 years": 8967,
      "using patient controlled": 85550,
      "controlled analgesia pain": 20457,
      "analgesia pain management": 10046,
      "pain management strategy": 57122,
      "plan study act": 61869,
      "use patient controlled": 84607,
      "pain control needed": 56626,
      "controlled analgesia results": 20465,
      "mean pain score": 43831,
      "pain score time": 57685,
      "used patient controlled": 85069,
      "33 mg oxycodone": 3995,
      "controlled analgesia postoperative": 20462,
      "lower mean pain": 42644,
      "aims prescription opioid": 9492,
      "drug alcohol treatment": 26532,
      "98 95 confidence": 6461,
      "95 ci 57": 6313,
      "00 95 ci": 10,
      "95 ci 96": 6353,
      "controlled multicenter study": 20506,
      "frequently used oxycodone": 32586,
      "used oral medication": 85057,
      "pain control patients": 56638,
      "control patients undergoing": 20390,
      "methods seven patients": 45574,
      "ropivacaine group received": 72796,
      "pro inflammatory cytokine": 65207,
      "inflammatory cytokine levels": 38555,
      "postoperative pain intensity": 62877,
      "12 24 surgery": 1239,
      "24 surgery compared": 3278,
      "consumption oxycodone lower": 19973,
      "controlled postoperative pain": 20522,
      "postoperative pain better": 62850,
      "patients undergoing upper": 60134,
      "undergoing upper extremity": 83592,
      "orthopedic surgery patients": 53838,
      "surgery patients received": 79516,
      "patients received brachial": 59768,
      "received brachial plexus": 68123,
      "epinephrine microg ml": 29203,
      "patients randomized groups": 59734,
      "groups group received": 34210,
      "group received iv": 33953,
      "solution group received": 76444,
      "received iv morphine": 68187,
      "iv morphine mg": 40384,
      "patients rated pain": 59758,
      "instructed acetaminophen 325": 39105,
      "oxycodone mg tablet": 55441,
      "brachial plexus blocks": 14310,
      "24 acetaminophen oxycodone": 3185,
      "prolong duration sensory": 65608,
      "24 analgesic use": 3189,
      "opioids fentanyl methadone": 52911,
      "recent evidence based": 68400,
      "adequate short term": 7975,
      "pain relief opioids": 57558,
      "long term outcomes": 42345,
      "opioid use related": 52581,
      "sleep disordered breathing": 76218,
      "decision making process": 22846,
      "release oxycodone products": 69971,
      "pain severe pain": 57821,
      "release opioid analgesics": 69905,
      "guidelines postoperative opioid": 34463,
      "postoperative opioid prescriptions": 62821,
      "study opioid prescribing": 78347,
      "use minimally invasive": 84490,
      "women undergoing laparoscopic": 87253,
      "undergoing laparoscopic hysterectomy": 83547,
      "anxiety depression pain": 11272,
      "depression pain catastrophizing": 23592,
      "weeks surgery patients": 86960,
      "surgery patients surveyed": 79519,
      "medication use results": 44583,
      "ninety percent patients": 49489,
      "percent patients prescribed": 60475,
      "median opioid prescription": 44262,
      "150 morphine milligram": 1816,
      "milligram equivalents equivalent": 46457,
      "equivalents equivalent 20": 29350,
      "equivalent 20 tablets": 29287,
      "37 morphine milligram": 4198,
      "opioids weeks surgery": 53391,
      "included history chronic": 37463,
      "preoperative pain score": 63754,
      "anticipated postoperative pain": 11160,
      "postoperative pain medication": 62888,
      "pain medication needs": 57155,
      "help identify patients": 34905,
      "opioids needed patients": 53087,
      "patients opioid prescriptions": 59588,
      "opioid prescriptions based": 52178,
      "preoperative risk factors": 63760,
      "prescription opioids background": 64328,
      "experiencing opioid epidemic": 30648,
      "states washington dc": 77160,
      "associated reduction opioids": 12405,
      "state level opioid": 77050,
      "level opioid prescription": 41507,
      "setting united states": 74840,
      "united states participants": 83814,
      "provide health care": 66070,
      "schedule iii opioids": 73626,
      "schedule iii opioid": 73625,
      "united states objective": 83809,
      "legitimate opioid prescriptions": 41387,
      "opioid prescribing trends": 52128,
      "opioid related death": 52307,
      "trends opioid prescriptions": 82976,
      "identified study period": 36475,
      "opioid prescriptions decreased": 52181,
      "prescriptions decreased oxycodone": 64468,
      "lower odds receiving": 42657,
      "confidence interval 001": 19437,
      "monitoring program associated": 47336,
      "associated reduced opioid": 12403,
      "reduced opioid prescribing": 68953,
      "relationship opioid prescriptions": 69721,
      "randomised controlled trial": 67015,
      "receiving pain medication": 68369,
      "strong opioids fentanyl": 77547,
      "opioids fentanyl buprenorphine": 52910,
      "buprenorphine morphine oxycodone": 14563,
      "morphine oxycodone increased": 47835,
      "001 non steroidal": 163,
      "analgesic drug prescription": 10189,
      "paracetamol strong opioids": 58116,
      "2012 objective assess": 2607,
      "study setting sentinel": 78489,
      "sentinel distributed database": 74583,
      "commercially insured members": 17723,
      "january 2009 december": 40430,
      "opioid analgesics claim": 51485,
      "30 days prior": 3731,
      "extended release hydromorphone": 30876,
      "use urine drug": 84791,
      "compared er la": 18155,
      "results suggest potential": 71996,
      "analgesic prescribing practices": 10299,
      "opioid agonist used": 51428,
      "tablet single dose": 80102,
      "plasma elimination half": 61931,
      "areas covered review": 11645,
      "pain phase studies": 57374,
      "reviewed expert opinion": 72379,
      "provide effective pain": 66053,
      "typical opioids nausea": 83390,
      "nausea vomiting sedation": 48814,
      "pain objective objective": 57264,
      "objective study examine": 50514,
      "opioid use including": 52523,
      "vs short acting": 86677,
      "chronic pain use": 16322,
      "setting retrospective cohort": 74814,
      "kaiser permanente northern": 40578,
      "permanente northern california": 60901,
      "northern california kpnc": 49967,
      "january 2009 june": 40431,
      "outcome measures total": 53955,
      "receiving long acting": 68348,
      "odds ratio 13": 50907,
      "odds ratio 02": 50906,
      "95 ci 99": 6356,
      "used treat moderate": 85168,
      "opioid consumption data": 51617,
      "patterns opioid consumption": 60215,
      "potential severe adverse": 63228,
      "severe adverse effects": 74908,
      "adverse effects including": 8659,
      "heroin cocaine methamphetamine": 34992,
      "users high risk": 85243,
      "occurred united states": 50850,
      "united states europe": 83792,
      "involved polysubstance use": 40111,
      "case reports case": 15196,
      "reports case series": 70714,
      "morphine oxycodone opioids": 47844,
      "frequently used opioids": 32585,
      "11 16 18": 1097,
      "available single agent": 12838,
      "analgesics mainstay pain": 10445,
      "mainstay pain management": 42878,
      "oral route available": 53663,
      "hepatic pass metabolism": 34958,
      "oxycodone hydromorphone superior": 55225,
      "partial mu opioid": 58244,
      "study non medical": 78325,
      "opioid medications new": 51918,
      "combination opioid agonist": 17576,
      "patients prior opioid": 59702,
      "purpose study identify": 66584,
      "day consecutive days": 22284,
      "aged 25 34": 9182,
      "25 34 years": 3332,
      "findings suggest need": 31826,
      "education regarding appropriate": 27396,
      "polymorphisms cytochrome p450": 62217,
      "dihydrocodeine hydrocodone oxycodone": 24991,
      "mu delta opioid": 48110,
      "opioid receptor mediated": 52260,
      "guanosine 35 thio": 34393,
      "35 thio triphosphate": 4093,
      "thio triphosphate 35": 81094,
      "approximately 10 fold": 11557,
      "exhibited greater efficacy": 30511,
      "research needed understand": 71019,
      "severe pain reported": 74999,
      "patients randomized open": 59736,
      "postsurgical pain management": 63052,
      "patients scheduled undergo": 59947,
      "assigned receive opioid": 12179,
      "end surgery patients": 28824,
      "oxycodone mg tablets": 55443,
      "10 numeric rating": 877,
      "pain 10 worst": 56358,
      "10 worst pain": 955,
      "adverse events collected": 8735,
      "results patients randomized": 71853,
      "control group 35": 20315,
      "group reported significantly": 33980,
      "cumulative pain control": 21407,
      "pain control group": 56618,
      "control group conclusion": 20318,
      "seventy seven percent": 74896,
      "seven percent patients": 74874,
      "80 control group": 5841,
      "control group experienced": 20326,
      "group experienced treatment": 33777,
      "experienced treatment emergent": 30633,
      "higher percentage patients": 35297,
      "conclusion patients receiving": 18956,
      "patients receiving opioid": 59850,
      "reduction opioid consumption": 69074,
      "opioid consumption overall": 51637,
      "incidence treatment emergent": 37325,
      "comparable patients receiving": 17967,
      "covid 19 pandemic": 21022,
      "related surveillance streetrx": 69693,
      "surveillance streetrx program": 79689,
      "linear regression results": 42032,
      "statistically significant conclusions": 77204,
      "use disorder associated": 84317,
      "morphine codeine semi": 47606,
      "codeine semi synthetic": 17286,
      "semi synthetic derivatives": 74512,
      "oxycodone opioid antagonist": 55568,
      "year old white": 87468,
      "old white man": 51021,
      "16 ng ml": 1885,
      "days prior admission": 22601,
      "teenagers young adults": 80559,
      "term treatment patients": 80675,
      "based current evidence": 13302,
      "evidence available support": 30149,
      "support long term": 79202,
      "improved quality life": 37129,
      "group patients chronic": 33901,
      "oxycodone tramadol hydrocodone": 56014,
      "drug related behavior": 26766,
      "treatment pregnant women": 82777,
      "abuse significant public": 6875,
      "health problem countries": 34755,
      "pain difficult treat": 56720,
      "neuropathic pain refractory": 49258,
      "tricyclic antidepressants selective": 83219,
      "antidepressants selective serotonin": 11179,
      "pain control time": 56664,
      "neuropathic pain secondary": 49262,
      "function quality life": 32674,
      "morphine sulfate oxycodone": 47942,
      "sulfate oxycodone hydrochloride": 79069,
      "commonly used pain": 17890,
      "data clinical studies": 21904,
      "cleft lip repair": 16729,
      "performed united states": 60644,
      "patients underwent primary": 60150,
      "lip repair decreased": 42065,
      "patients received lidocaine": 59792,
      "patients received local": 59793,
      "narcotic utilization postoperative": 48622,
      "day significantly lower": 22418,
      "children undergoing cleft": 16075,
      "undergoing cleft lip": 83520,
      "associated decreased perioperative": 12249,
      "pain non narcotic": 57243,
      "non narcotic medications": 49642,
      "surgery design setting": 79374,
      "surgery july 2018": 79436,
      "week postoperative visit": 86866,
      "postoperative visit patients": 62981,
      "outcomes measures addition": 54052,
      "opioid consumption refills": 51658,
      "analgesic adverse effects": 10148,
      "oxycodone acetaminophen tablets": 54664,
      "ci 11 18": 16391,
      "nausea vomiting significantly": 48815,
      "vomiting significantly reduced": 86483,
      "control group 02": 20305,
      "prescription opioids nonmedical": 64351,
      "costs long acting": 20899,
      "analysis performed determine": 10731,
      "prior authorization process": 65137,
      "prescribed opioid types": 63915,
      "risk bias tool": 72535,
      "level factors associated": 41484,
      "using grading recommendations": 85420,
      "united states america": 83780,
      "low risk bias": 42553,
      "pain prescribed opioids": 57408,
      "30 95 ci": 3708,
      "quality evidence strong": 66696,
      "evidence strong opioids": 30261,
      "opioid prescribing associated": 52085,
      "cause opioid induced": 15366,
      "receptor antagonist naloxone": 68474,
      "fentanyl induced respiratory": 31506,
      "opioid induced antinociception": 51852,
      "induced antinociception hot": 38383,
      "antinociception hot plate": 11224,
      "mg kg ip": 45992,
      "effective preventing oxycodone": 27683,
      "preventing oxycodone induced": 64867,
      "oxycodone induced antinociception": 55262,
      "kor agonist u50": 40943,
      "activity vitro vivo": 7594,
      "cytochromes p450 cyp": 21667,
      "commonly prescribed drugs": 17863,
      "pump inhibitors ppis": 66480,
      "associated lower doses": 12326,
      "therapeutic plasma concentrations": 80956,
      "opiates like fentanyl": 51329,
      "fentanyl oxycodone buprenorphine": 31547,
      "abuse dependence diversion": 6676,
      "present review aims": 64639,
      "effect patient satisfaction": 27526,
      "multimodal analgesia strategies": 48206,
      "acetaminophen nonsteroidal anti": 7214,
      "methyl aspartate receptor": 45644,
      "chronic pain data": 16270,
      "searches medline 1966": 74169,
      "evaluated information deemed": 29894,
      "information deemed relevant": 38640,
      "deemed relevant included": 23086,
      "oral modified release": 53571,
      "drug release properties": 26773,
      "age 53 years": 9022,
      "frequently prescribed opioids": 32572,
      "opioids oxycodone acetaminophen": 53132,
      "treat patients chronic": 82311,
      "pain use drugs": 57959,
      "opioids heroin oxycodone": 52947,
      "heroin oxycodone methadone": 35024,
      "oxycodone methadone fentanyl": 55396,
      "crack cocaine use": 21122,
      "determine factors associated": 24012,
      "posttraumatic stress disorder": 63058,
      "10 average daily": 743,
      "alprazolam clonazepam diazepam": 9675,
      "age drug abuse": 9072,
      "associated high dose": 12274,
      "opioid abuse major": 51372,
      "challenges pain management": 15706,
      "data drug abuse": 21953,
      "low potency opioids": 42537,
      "morphine equivalent opioid": 47665,
      "statistically significant association": 77200,
      "arterial blood gas": 11710,
      "blood gas measurements": 14123,
      "therapeutic use opioids": 80968,
      "synthetic opioid tramadol": 79958,
      "potent analgesic effects": 63093,
      "therapeutically valuable drugs": 80971,
      "derivatives oxycodone oxymorphone": 23624,
      "oxycodone oxymorphone buprenorphine": 55614,
      "receptor types mu": 68533,
      "types mu delta": 83369,
      "mu delta kappa": 48108,
      "protein coupled receptor": 65927,
      "structure activity relationships": 77587,
      "drugs pain management": 27029,
      "drugs drug interactions": 26946,
      "drug interactions occur": 26670,
      "cyp 2d6 3a4": 21570,
      "metabolism commonly used": 44926,
      "opioids like codeine": 53018,
      "analgesic sedative effects": 10336,
      "recent clinical trials": 68392,
      "drugs acting different": 26872,
      "acting different mechanisms": 7378,
      "morphine codeine oxycodone": 47603,
      "overdose deaths united": 54283,
      "ah 7921 mt": 9355,
      "7921 mt 45": 5809,
      "opioids present unique": 53220,
      "half life parent": 34518,
      "life parent opioid": 41718,
      "acting opioid treatment": 7406,
      "adverse effect profile": 8632,
      "effect profile analgesic": 27538,
      "prescription drug coverage": 64210,
      "retrospective review performed": 72163,
      "chronic pain given": 16275,
      "opioid public health": 52226,
      "case 57 year": 15160,
      "57 year old": 5141,
      "treated chronic pain": 82327,
      "pain intrathecal morphine": 56971,
      "oral oxycodone patient": 53639,
      "article reviews literature": 11785,
      "studies included review": 77751,
      "ng ml fentanyl": 49441,
      "500 ng ml": 4926,
      "250 ng ml": 3399,
      "ng ml morphine": 49448,
      "10 100 ng": 662,
      "oxycodone 100 000": 54506,
      "100 000 ng": 970,
      "examine factors associated": 30344,
      "methods prescription opioid": 45476,
      "addiction treatment study": 7775,
      "treatment study poats": 82862,
      "treatment research design": 82812,
      "er oxycodone ir": 29460,
      "oxycodone ir oxycodone": 55313,
      "clinical opiate withdrawal": 16845,
      "opiate withdrawal scale": 51316,
      "withdrawal scale cows": 87155,
      "objective compare opioid": 50391,
      "compare opioid prescribing": 18036,
      "prescriptions opioids dispensed": 64528,
      "january december 31": 40461,
      "december 31 2016": 22836,
      "outcomes measures proportion": 54055,
      "rates opioid prescriptions": 67609,
      "opioid prescriptions results": 52212,
      "higher number opioid": 35274,
      "prescriptions long acting": 64509,
      "conclusions relevance study": 19197,
      "opioids significantly greater": 53298,
      "treatment mmt methods": 82660,
      "sectional study included": 74289,
      "tertiary medical center": 80746,
      "results patients characteristics": 71843,
      "patients group higher": 59337,
      "conclusions high prevalence": 19093,
      "abusers non abusers": 6933,
      "multimodal pain regimens": 48236,
      "urban trauma center": 84041,
      "acetaminophen 48 hours": 7134,
      "48 hours celecoxib": 4711,
      "oral morphine milligram": 53585,
      "milligram equivalents mmes": 46466,
      "day secondary outcomes": 22412,
      "opioid prescribing discharge": 52096,
      "discharge pain scores": 25155,
      "pain scores results": 57778,
      "interquartile range 15": 39520,
      "interquartile range 22": 39523,
      "fewer prescribed opioids": 31666,
      "prescribed opioids discharge": 63926,
      "clinically significant difference": 17001,
      "significant difference pain": 75486,
      "pain scores seen": 57780,
      "acute pain control": 7666,
      "pain control background": 56605,
      "neuropathic pain cnp": 49236,
      "evidence based treatment": 30166,
      "treatment options patients": 82714,
      "methods systematic review": 45601,
      "systematic review meta": 79992,
      "review meta analysis": 72323,
      "considering efficacy adverse": 19665,
      "second line treatment": 74191,
      "based systematic review": 13391,
      "drugs central nervous": 26904,
      "profile adverse effects": 65474,
      "near real time": 48860,
      "extended release versus": 30906,
      "release versus oxycodone": 70019,
      "represent important source": 70745,
      "negative impact quality": 49078,
      "impact quality life": 36848,
      "life patients cancer": 41720,
      "systematic review ascertain": 79983,
      "clinical trials published": 16956,
      "mechanism action opioids": 44125,
      "community dwelling patients": 17918,
      "management pain elderly": 43229,
      "trials evaluating efficacy": 83144,
      "insufficient evidence support": 39126,
      "evidence support use": 30273,
      "established safety profiles": 29594,
      "post herpetic neuralgia": 62569,
      "herpetic neuralgia phn": 35045,
      "morphine oxycodone widely": 47863,
      "widely used drugs": 87065,
      "chronic pain number": 16287,
      "high quality studies": 35156,
      "relieving neuropathic pain": 70237,
      "neuropathic pain especially": 49243,
      "attenuates morphine tolerance": 12595,
      "morphine antinociceptive tolerance": 47582,
      "monitoring programs pmps": 47343,
      "public health surveillance": 66401,
      "evaluate trends opioid": 29852,
      "trends opioid prescribing": 82974,
      "opioid prescribing dispensing": 52097,
      "results number prescriptions": 71798,
      "used greater number": 84947,
      "medical non medical": 44371,
      "inform public health": 38625,
      "severe pain different": 74977,
      "studies evaluated efficacy": 77718,
      "efficacy safety oxymorphone": 28374,
      "ir patients moderate": 40255,
      "safety oxymorphone er": 73193,
      "12 weeks dose": 1380,
      "effective generally tolerated": 27627,
      "opioid experienced opioid": 51791,
      "experienced opioid na\u00efve": 30619,
      "impact opioid prescribing": 36824,
      "cross sectional data": 21257,
      "million opioid prescriptions": 46491,
      "opioid prescriptions given": 52189,
      "decrease opioid prescriptions": 22909,
      "fewer opioids prescribed": 31656,
      "prescribed oxycodone hydrocodone": 63942,
      "high throughput screening": 35186,
      "sciatic nerve ligation": 73676,
      "acute myeloid leukemia": 7648,
      "56 year old": 5110,
      "old man presented": 51014,
      "stem cell transplants": 77314,
      "opioid receptors mor": 52277,
      "addiction respiratory depression": 7768,
      "starting point development": 77023,
      "region physician specialty": 69347,
      "using truven health": 85649,
      "truven health analytics": 83258,
      "health analytics marketscan": 34671,
      "years 2012 2015": 87535,
      "inclusion criteria included": 37688,
      "prescription opioids including": 64341,
      "opioids including hydrocodone": 52979,
      "codeine oxycodone oxymorphone": 17270,
      "oxycodone oxymorphone methadone": 55618,
      "oxymorphone methadone fentanyl": 56260,
      "32 internal medicine": 3925,
      "patients receiving tramadol": 59861,
      "evidence base limited": 30152,
      "quality improvement efforts": 66706,
      "low population density": 42534,
      "age chronic pain": 9066,
      "chronic pain pain": 16295,
      "characteristics predict treatment": 15873,
      "acetaminophen ibuprofen naproxen": 7195,
      "patients impaired renal": 59381,
      "impaired renal hepatic": 36878,
      "renal hepatic function": 70359,
      "studies case reports": 77659,
      "case reports included": 15198,
      "buprenorphine fentanyl ketamine": 14545,
      "oxycodone tramadol used": 56020,
      "chronic renal failure": 16338,
      "used caution close": 84870,
      "caution close patient": 15411,
      "close patient monitoring": 17069,
      "characterize prescription opioid": 15908,
      "mean age 34": 43678,
      "years 65 male": 87553,
      "used prescription opioids": 85085,
      "heroin prescription opioids": 35028,
      "group significantly younger": 34021,
      "mean age 26": 43676,
      "age 26 years": 8990,
      "opioid group reported": 51829,
      "non opioid drugs": 49651,
      "opioid drugs associated": 51748,
      "pain mental health": 57172,
      "study evaluate impact": 78171,
      "perioperative opioid prescriptions": 60842,
      "opioid prescriptions total": 52213,
      "reduced opioid prescription": 68954,
      "study retrospectively evaluated": 78469,
      "prescription filling patients": 64225,
      "filling patients undergoing": 31723,
      "patients undergoing total": 60131,
      "undergoing total knee": 83588,
      "commercially available insurance": 17718,
      "available insurance database": 12818,
      "insurance database 2010": 39147,
      "database 2010 2018": 22164,
      "discharge 90 day": 25103,
      "states opioid limiting": 77130,
      "multivariable linear logistic": 48321,
      "linear logistic regression": 42014,
      "significant reductions initial": 75620,
      "initial cumulative opioid": 38831,
      "opioid legislation legislation": 51884,
      "legislation legislation targeting": 41374,
      "duration volume largest": 27193,
      "large significant reductions": 41154,
      "pre operative opioid": 63478,
      "operative opioid use": 51260,
      "opioid use higher": 52518,
      "opioid use postoperatively": 52571,
      "prescribed treatment moderate": 63997,
      "peripheral opioid receptors": 60881,
      "objectives opioid induced": 50574,
      "opioid induced hyperalgesia": 51861,
      "induced hyperalgesia oih": 38417,
      "managed chronic pain": 43132,
      "chronic pain opioid": 16290,
      "pain opioid therapy": 57288,
      "results survey response": 72003,
      "survey response rate": 79733,
      "dose opioid therapy": 25978,
      "chronic pain conditions": 16268,
      "pain conditions associated": 56587,
      "opioid dose reduction": 51736,
      "annually united states": 11036,
      "pain symptom control": 57892,
      "control fewer effects": 20301,
      "effectively treat pain": 27742,
      "pediatric palliative care": 60355,
      "united states food": 83795,
      "states food drug": 77103,
      "united states canada": 83783,
      "analysis conducted adult": 10661,
      "milligram morphine equivalents": 46472,
      "opioid prescription results": 52164,
      "followed tramadol acetaminophen": 32085,
      "tramadol acetaminophen oxycodone": 82033,
      "improve opioid prescribing": 37068,
      "older adults associated": 51032,
      "problematic alcohol use": 65250,
      "alcohol use disorders": 9546,
      "old female presented": 51008,
      "examine patterns opioid": 30351,
      "population based administrative": 62304,
      "based administrative data": 13272,
      "total morphine equivalents": 81844,
      "dispensed 1000 population": 25417,
      "consumption increased oxycodone": 19940,
      "level opioid consumption": 41506,
      "opioid analgesics cornerstone": 51493,
      "opioid consumption providing": 51651,
      "postoperative pain remains": 62915,
      "remains major problem": 70300,
      "increased risk persistent": 38019,
      "length stay hospital": 41410,
      "preoperative intraoperative postoperative": 63745,
      "manage acute postoperative": 43115,
      "analgesic efficacy safety": 10247,
      "traditional pain management": 81990,
      "review provides overview": 72345,
      "abdominis plane block": 6538,
      "extended release epidural": 30858,
      "release epidural morphine": 69832,
      "formulations morphine oxycodone": 32390,
      "morphine oxycodone patient": 47849,
      "palliative care implemented": 58034,
      "overall opioid consumption": 54217,
      "drugs require special": 27064,
      "prescribed opioid analgesics": 63908,
      "severe pain including": 74982,
      "opioids growing public": 52938,
      "semi synthetic opioids": 74516,
      "pharmaceutical opioids use": 61041,
      "impact drug release": 36806,
      "vitro drug release": 86358,
      "curbing opioid dependence": 21420,
      "tested positive benzodiazepines": 80813,
      "pain management clinic": 57061,
      "specimens liquid chromatography": 76641,
      "specimen validity testing": 76636,
      "morphine oxycodone given": 47827,
      "reduction opioid induced": 69076,
      "opioid induced postoperative": 51867,
      "important clinical implications": 36999,
      "reduction adverse effects": 69042,
      "research needed better": 71015,
      "needed better elucidate": 48985,
      "impact patients quality": 36837,
      "quality life physical": 66739,
      "pharmacological therapies pain": 61233,
      "antagonists shown promise": 11088,
      "discussed expert opinion": 25293,
      "preliminary results indicate": 63715,
      "repetitive transcranial magnetic": 70424,
      "transcranial magnetic stimulation": 82128,
      "magnetic stimulation rtms": 42807,
      "oxycodone naloxone prolonged": 55515,
      "naloxone prolonged release": 48507,
      "prolonged release tablets": 65638,
      "aimed investigate prevalence": 9462,
      "current prescription opioid": 21460,
      "opioid analgesics including": 51503,
      "possible risk factors": 62547,
      "risk factors prescription": 72574,
      "drug misuse abuse": 26713,
      "safe prescribing practices": 73101,
      "chronic abdominal pain": 16181,
      "treatment somatic visceral": 82847,
      "somatic visceral pain": 76456,
      "case series patients": 15203,
      "causes chronic abdominal": 15393,
      "morphine equivalents mme": 47673,
      "urban safety net": 84034,
      "safety net hospital": 73169,
      "predictive value presumptive": 63579,
      "positive drug test": 62462,
      "barbiturates benzodiazepines cocaine": 13249,
      "cocaine methadone opiates": 17153,
      "testing used results": 80848,
      "opiate use patients": 51314,
      "regarding pain management": 69266,
      "surgery ess study": 79394,
      "ess study design": 29572,
      "design case series": 23701,
      "case series planned": 15204,
      "series planned data": 74662,
      "planned data collection": 61882,
      "data collection setting": 21917,
      "setting tertiary referral": 74837,
      "center subjects methods": 15557,
      "exclusion criteria included": 30487,
      "patients discharged 30": 59205,
      "oxycodone acetaminophen 325": 54630,
      "use postoperative days": 84632,
      "postoperative days results": 62765,
      "days results total": 22613,
      "results total 64": 72033,
      "total 64 patients": 81763,
      "patients completed surveys": 59117,
      "completed surveys mean": 18507,
      "day postoperative period": 22387,
      "demographic surgical factors": 23290,
      "level postoperative day": 41516,
      "pain management background": 57055,
      "management methods prospective": 43203,
      "prospective clinical study": 65815,
      "study conducted june": 78029,
      "plastic surgeons patients": 61966,
      "quality life qol": 66740,
      "postoperative days pods": 62764,
      "results patients showed": 71857,
      "postoperative period pain": 62939,
      "period pain management": 60765,
      "pain usually managed": 57966,
      "oral acetaminophen ibuprofen": 53484,
      "severe pain require": 75000,
      "infants children adolescents": 38505,
      "currently available opioids": 21491,
      "hydromorphone methadone buprenorphine": 36187,
      "buprenorphine butorphanol nalbuphine": 14526,
      "morphine studied opioid": 47932,
      "trial 63 patients": 82998,
      "postoperative pain severity": 62922,
      "cm visual analogue": 17091,
      "logistic regression analysis": 42258,
      "pain compared controls": 56576,
      "possible adverse effects": 62531,
      "effects 10 mg": 27792,
      "mg single dose": 46221,
      "pain remains common": 57611,
      "following inpatient outpatient": 32145,
      "recovery surgery eras": 68764,
      "multimodal analgesia mma": 48200,
      "controlling postoperative pain": 20661,
      "intravenous iv acetaminophen": 39841,
      "acetaminophen non steroidal": 7211,
      "transcutaneous electrical nerve": 82139,
      "electrical nerve stimulation": 28506,
      "era opioid epidemic": 29486,
      "non opioid based": 49650,
      "newer opioid formulations": 49406,
      "introduction opioid epidemic": 39940,
      "united states reached": 83825,
      "drug united states": 26826,
      "high school seniors": 35180,
      "oxycodone acetaminophen codeine": 54633,
      "problem long term": 65239,
      "content analyzed results": 20099,
      "case report patient": 15192,
      "old woman presented": 51025,
      "prescribed pain control": 63944,
      "drug interaction probability": 26661,
      "interaction probability scale": 39380,
      "improve pain management": 37072,
      "appropriate opioid therapy": 11505,
      "evaluate efficacy tolerability": 29796,
      "pain prescription opioid": 57412,
      "important public health": 37026,
      "public health problems": 66397,
      "present study evaluated": 64658,
      "tropisetron mg kg": 83244,
      "mg kg clonidine": 45959,
      "anesthesia induction anesthesia": 10917,
      "kg diclofenac mg": 40717,
      "diclofenac mg kg": 24392,
      "postoperative pain treated": 62927,
      "pain treated iv": 57933,
      "mg kg time": 46033,
      "compared placebo 62": 18261,
      "adverse effects noted": 8673,
      "kg significantly reduced": 40807,
      "significantly reduced incidence": 75844,
      "did differ placebo": 24436,
      "objective determine frequency": 50398,
      "retrospective case control": 72113,
      "ci 17 45": 16407,
      "common opioids codeine": 17784,
      "common long acting": 17765,
      "alcohol substance use": 9541,
      "health insurance status": 34720,
      "aor 51 95": 11310,
      "51 95 ci": 4952,
      "aor 39 95": 11301,
      "aor 33 95": 11298,
      "95 ci 74": 6329,
      "aor 56 95": 11316,
      "56 95 ci": 5100,
      "97 95 ci": 6438,
      "95 ci 64": 6319,
      "associated higher rates": 12283,
      "rates substance use": 67641,
      "center randomized controlled": 15546,
      "protocol primary outcome": 65993,
      "primary outcome length": 65066,
      "secondary outcomes postoperative": 74254,
      "opioid use postoperative": 52568,
      "use postoperative pain": 84634,
      "discharged 24 hours": 25188,
      "use oxycodone lower": 84587,
      "mg vs mg": 46264,
      "conclusion eras protocol": 18899,
      "opioid receptor family": 52254,
      "plays critical role": 62003,
      "hydrocodone oxycodone fentanyl": 36115,
      "delta opioid receptors": 23240,
      "opioid receptors dor": 52272,
      "new psychoactive substances": 49367,
      "opioid misuse related": 51948,
      "opioid prescription use": 52167,
      "prescription use patients": 64418,
      "claims database identified": 16627,
      "using international classification": 85443,
      "international classification disease": 39473,
      "mean patient age": 43835,
      "percent patients received": 60477,
      "patients received opioid": 59801,
      "patient receiving opioids": 58728,
      "opioid prescriptions month": 52198,
      "significant number patients": 75588,
      "opioid prescriptions associated": 52176,
      "opioid use data": 52490,
      "united states using": 83829,
      "state prescription drug": 77062,
      "monitoring program database": 47338,
      "schedule ii iii": 73617,
      "95 ci 003": 6223,
      "united states continues": 83785,
      "health care professionals": 34681,
      "fold increase deaths": 31994,
      "analgesic prescribing patterns": 10298,
      "prescribing patterns patient": 64108,
      "usage health care": 84118,
      "clinically important difference": 16978,
      "statistically significant changes": 77201,
      "using 11 point": 85290,
      "numerical rating scales": 50321,
      "calculated results thirty": 14702,
      "completed study interventions": 18497,
      "change average nrs": 15722,
      "drug reactions adrs": 26758,
      "results study period": 71984,
      "summary 48 year": 79092,
      "48 year old": 4752,
      "methicillin resistant staphylococcus": 45158,
      "resistant staphylococcus aureus": 71107,
      "iron deficiency anemia": 40274,
      "years chronic pain": 87577,
      "fentanyl oral morphine": 31542,
      "oral morphine sulfate": 53592,
      "clinically significant improvements": 17004,
      "pain scores noted": 57743,
      "patients visual analog": 60176,
      "oswestry disability index": 53879,
      "chronic malignant nonmalignant": 16206,
      "pain controlled release": 56668,
      "controlled release formulation": 20542,
      "aim review assess": 9401,
      "systematic search published": 80006,
      "duration 12 weeks": 27147,
      "low pain chronic": 42519,
      "chronic pain osteoarthritis": 16293,
      "chronic cancer pain": 16185,
      "cancer pain studies": 14857,
      "confidence interval 17": 19445,
      "effective pain control": 27661,
      "control patients cancer": 20389,
      "oxycodone equipotent doses": 55032,
      "type surgery performed": 83360,
      "multimodal procedure specific": 48243,
      "procedure specific analgesia": 65286,
      "optimal postoperative pain": 53432,
      "pain management represents": 57115,
      "postoperative pain therapy": 62925,
      "oxycodone tolerant rats": 56004,
      "numerous studies shown": 50331,
      "gp substrate activity": 33359,
      "non hodgkin lymphoma": 49607,
      "long term drug": 42331,
      "months significant changes": 47472,
      "tobacco use alcohol": 81504,
      "weeks later patient": 86919,
      "needed severe pain": 49036,
      "weak opioid codeine": 86788,
      "opioid codeine oxycodone": 51585,
      "data opioid dispensations": 22029,
      "tramadol oxycodone buprenorphine": 82091,
      "opioid users continued": 52618,
      "multimodal analgesic protocol": 48211,
      "new order set": 49350,
      "mg primary outcome": 46183,
      "opioid prescriptions refills": 52211,
      "equivalent mme prescribed": 29317,
      "95 ci 235": 6265,
      "95 ci 135": 6249,
      "total mme prescribed": 81838,
      "opioid prescription rates": 52162,
      "rates significantly decreased": 67635,
      "manage postoperative pain": 43125,
      "opioid refill rates": 52289,
      "objective evaluate opioid": 50424,
      "evaluate opioid prescribing": 29818,
      "published january 2014": 66433,
      "january 2014 july": 40446,
      "risk bias included": 72532,
      "opioid related outcomes": 52324,
      "results studies identified": 71972,
      "morphine equivalents 10": 47669,
      "background pain control": 13144,
      "improving pain control": 37199,
      "20 ml liposomal": 2361,
      "ml liposomal bupivacaine": 46870,
      "pain scores assessed": 57706,
      "patients met inclusion": 59493,
      "patients adequate follow": 58944,
      "average visual analog": 12944,
      "pain score postoperative": 57679,
      "postoperative day postoperative": 62750,
      "postoperative day average": 62736,
      "postoperative pain early": 62865,
      "limited pharmacological options": 41953,
      "safety efficacy opioid": 73146,
      "group specialized register": 34026,
      "morphine buprenorphine codeine": 47591,
      "hydromorphone levorphanol oxymorphone": 36181,
      "clinical trials identified": 16949,
      "databases medline embase": 22205,
      "selection criteria randomised": 74411,
      "criteria randomised controlled": 21210,
      "opioids compared placebo": 52808,
      "collection analysis authors": 17496,
      "analysis authors independently": 10641,
      "authors independently assessed": 12735,
      "independently assessed studies": 38173,
      "placebo controlled trials": 61710,
      "continuous infusion local": 20172,
      "control group consisted": 20319,
      "regard sex age": 69235,
      "sex age bmi": 75059,
      "consumption morphine equivalents": 19957,
      "42 mg 15": 4464,
      "lower incidence nausea": 42631,
      "incidence nausea 18": 37282,
      "postoperative care unit": 62723,
      "reduces need opioid": 68993,
      "need opioid treatment": 48939,
      "postoperative recovery introduction": 62961,
      "improve quality life": 37086,
      "quality life pain": 66736,
      "recreational opioid abusers": 68777,
      "using point likert": 85563,
      "analyses used compare": 10618,
      "risk management programs": 72594,
      "commonly used drugs": 17879,
      "polymorphic cyp enzyme": 62208,
      "cyp2c9 cyp2c19 cyp2d6": 21584,
      "poor intermediate metabolizers": 62261,
      "ultrarapid metabolizers cyp2d6": 83427,
      "amitriptyline nortriptyline codeine": 9825,
      "nortriptyline codeine oxycodone": 49971,
      "increased risk developing": 38011,
      "morphine did increase": 47646,
      "clinical decision support": 16784,
      "decision support tools": 22850,
      "study evaluate effectiveness": 78166,
      "identify prescribing patterns": 36525,
      "week study period": 86873,
      "control groups respectively": 20348,
      "bariatric surgery patients": 13253,
      "42 patients received": 4471,
      "equivalent daily doses": 29297,
      "daily doses medd": 21743,
      "15 vs 20": 1798,
      "surgery background objective": 79331,
      "objective pain common": 50464,
      "pain common symptoms": 56570,
      "pain databases data": 56681,
      "databases data treatment": 22197,
      "pubmed cochrane library": 66444,
      "embase google scholar": 28647,
      "using key words": 85452,
      "studies met inclusion": 77771,
      "health status quality": 34779,
      "status quality life": 77267,
      "mild adverse reactions": 46425,
      "trials comparing tapentadol": 83125,
      "prospective observational studies": 65846,
      "physiotherapy evidence database": 61477,
      "analgesics anticonvulsants antidepressants": 10378,
      "neuropathic pain post": 49252,
      "related prescription opioid": 69672,
      "participants recreational opioid": 58357,
      "past year oxycodone": 58476,
      "acetaminophen codeine morphine": 7167,
      "morphine commonly used": 47612,
      "prescription opioids high": 64338,
      "prescription opioids family": 64334,
      "canada united states": 14753,
      "opioid agonists oxycodone": 51435,
      "opioid antagonists naloxone": 51541,
      "commonly used clinical": 17877,
      "achieve better understanding": 7297,
      "open new avenues": 51195,
      "available treatment patients": 12848,
      "option management moderate": 53455,
      "methods literature search": 45371,
      "using pubmed search": 85581,
      "search terms included": 74131,
      "opioid controlled release": 51676,
      "morphine oxymorphone hydromorphone": 47866,
      "oxymorphone hydromorphone oxycodone": 56251,
      "hydromorphone oxycodone fentanyl": 36204,
      "oxycodone fentanyl results": 55088,
      "studies chronic pain": 77662,
      "long acting short": 42309,
      "acting short acting": 7425,
      "conditions patients chronic": 19325,
      "opioids patients receiving": 53164,
      "patients receiving long": 59841,
      "acting opioid formulations": 7401,
      "long term clinical": 42328,
      "make informed decisions": 43004,
      "provided unique opportunity": 66164,
      "hydrocodone oxycodone combination": 36114,
      "abuse potential background": 6814,
      "methods review based": 45552,
      "fentanyl alfentanil sufentanil": 31435,
      "interindividual variation pharmacokinetics": 39443,
      "analgesia effective alternative": 9961,
      "effective alternative intravenous": 27588,
      "clinical studies needed": 16913,
      "surgeries study aimed": 79290,
      "quality life hrqol": 66727,
      "surgery methods prospective": 79466,
      "cohort study enrolled": 17391,
      "surgery patients completed": 79504,
      "life satisfaction scale": 41734,
      "hospital anxiety depression": 35565,
      "anxiety depression scale": 11274,
      "pain analgesic use": 56449,
      "better pain relief": 13725,
      "pain relief use": 57597,
      "use pain medication": 84598,
      "surgery pain intensity": 79497,
      "pain intensity similar": 56949,
      "intensity similar groups": 39316,
      "life satisfaction increased": 41733,
      "groups time points": 34337,
      "pain year surgery": 57995,
      "analgesics codeine fentanyl": 10392,
      "concomitant use non": 19256,
      "non narcotic analgesics": 49641,
      "adjusted sex age": 8058,
      "release formulations oxycodone": 69865,
      "formulations oxycodone morphine": 32398,
      "unadjusted adjusted models": 83453,
      "acting opioids increased": 7413,
      "opioids increased significantly": 52990,
      "acting opioids used": 7418,
      "increased use methadone": 38042,
      "women opioid use": 87231,
      "united states likely": 83800,
      "fentanyl derivatives study": 31463,
      "individuals entering substance": 38343,
      "entering substance abuse": 29065,
      "abuse treatment opioid": 6899,
      "treatment opioid use": 82704,
      "past month use": 58469,
      "use rose modestly": 84710,
      "methods retrospective chart": 45535,
      "tertiary referral center": 80749,
      "showed significant improvement": 75301,
      "use results prevalence": 84705,
      "percent 90 days": 60453,
      "percent received oxycodone": 60486,
      "higher doses opioids": 35234,
      "20 percent opioid": 2374,
      "percent vs percent": 60503,
      "state north carolina": 77056,
      "survey conducted assess": 79699,
      "outcome measures number": 53940,
      "improve medication safety": 37066,
      "use opioids treat": 84572,
      "opioids treat pain": 53355,
      "pain management use": 57129,
      "prescribed opioids codeine": 63922,
      "opioids codeine oxycodone": 52791,
      "decision prescribe opioids": 22848,
      "managing patient pain": 43294,
      "analgesics paracetamol nonsteroidal": 10473,
      "nonsteroidal antiinflammatory drugs": 49858,
      "treatment neuropathic pain": 82681,
      "leading cause morbidity": 41306,
      "cause morbidity mortality": 15362,
      "morbidity mortality united": 47514,
      "mortality united states": 47998,
      "states opioid use": 77133,
      "medication assisted treatment": 44461,
      "buprenorphine naloxone used": 14568,
      "purpose quality improvement": 66557,
      "median range age": 44280,
      "used linear regression": 84986,
      "opioid prescriptions 12": 52174,
      "conclusion opioid prescribing": 18938,
      "non inferior analgesic": 49609,
      "methods retrospective study": 45547,
      "retrospective study evaluated": 72171,
      "study evaluated effectiveness": 78179,
      "safety tolerability tapentadol": 73235,
      "opioid na\u00efve opioid": 51981,
      "na\u00efve opioid tolerant": 48837,
      "clinically relevant pain": 16995,
      "relevant pain relief": 70068,
      "pain relief days": 57533,
      "relief days median": 70122,
      "patients nociceptive pain": 59549,
      "intensity significantly decreased": 39313,
      "decreased baseline end": 22982,
      "end maintenance period": 28798,
      "adverse events opioid": 8781,
      "nausea vomiting tapentadol": 48819,
      "severe cancer related": 74923,
      "related pain introduction": 69661,
      "recent media coverage": 68408,
      "sample chronic pain": 73295,
      "pain patients prescribed": 57353,
      "prescribed opioids reported": 63935,
      "prescribed opioids pain": 63933,
      "odds ratio 77": 50923,
      "ratio 77 95": 67751,
      "conclusion people chronic": 18960,
      "chronic pain major": 16284,
      "depression anxiety patients": 23571,
      "chronic pain chronic": 16264,
      "cancer pain chronic": 14820,
      "pain chronic cancer": 56537,
      "cancer pain important": 14827,
      "cancer pain associated": 14816,
      "role treatment chronic": 72769,
      "non selective nsaids": 49680,
      "patients high risk": 59358,
      "high risk nsaid": 35172,
      "risk nsaid related": 72608,
      "use mild opioids": 84488,
      "tramadol strong opioids": 82112,
      "opioids morphine hydromorphone": 53072,
      "cancer pain cancer": 14818,
      "cancer pain related": 14852,
      "providing adequate pain": 66249,
      "abuse liability assessments": 6748,
      "results hydrocodone oxycodone": 71717,
      "new drug formulations": 49320,
      "use potent opioids": 84638,
      "use abuse deterrent": 84163,
      "potential cost savings": 63156,
      "admissions substance abuse": 8418,
      "incidence neuropathic pain": 37288,
      "neuropathic pain rat": 49256,
      "pain rat model": 57464,
      "morphine 24 hours": 47551,
      "24 hours following": 3218,
      "hours following surgery": 35777,
      "following surgery acetaminophen": 32202,
      "acetaminophen oxycodone tablets": 7225,
      "tablets pain scores": 80194,
      "difference postoperative opioid": 24668,
      "use pain scores": 84600,
      "scores movement lower": 73907,
      "scores time intervals": 74001,
      "differences noted groups": 24761,
      "commonly used perioperative": 17892,
      "perioperative pain control": 60846,
      "perioperative opioid prescribing": 60840,
      "evaluate impact time": 29808,
      "impact time state": 36855,
      "90 day perioperative": 6089,
      "day perioperative opioid": 22370,
      "baseline patient operative": 13453,
      "patient operative characteristics": 58690,
      "tests analysis variance": 80854,
      "logistic regression utilized": 42278,
      "prescription filling oxycodone": 64223,
      "filling oxycodone mg": 31719,
      "decreased significantly 2010": 23041,
      "foot ankle surgeons": 32243,
      "appropriate pain management": 11508,
      "abuse potential administered": 6811,
      "potential administered intravenously": 63128,
      "risks adverse outcomes": 72667,
      "adverse outcomes including": 8834,
      "outcomes including mortality": 54043,
      "potential abuse prescription": 63122,
      "united states include": 83797,
      "effort combat opioid": 28431,
      "opioid epidemic purpose": 51778,
      "admitted intensive care": 8425,
      "population materials methods": 62353,
      "study adult patients": 77913,
      "adult patients admitted": 8508,
      "hospital opioid overdose": 35607,
      "commonly abused opioids": 17830,
      "chronic pain alcoholism": 16258,
      "icu length stay": 36399,
      "length stay days": 41407,
      "opioid overdose common": 52010,
      "chronic pain background": 16259,
      "standard care postoperative": 76894,
      "oxycodone acetaminophen needed": 54650,
      "postoperative days determine": 62761,
      "scale 10 pain": 73483,
      "pain score number": 57676,
      "opioid tablets consumed": 52394,
      "tablets consumed results": 80134,
      "results mean visual": 71772,
      "mean visual analog": 43902,
      "score opioid use": 73766,
      "use significantly lower": 84731,
      "significantly lower dexamethasone": 75780,
      "lower dexamethasone group": 42600,
      "postoperative day compared": 62737,
      "day compared control": 22277,
      "significantly lower total": 75810,
      "significant differences pain": 75513,
      "pain score opioid": 57677,
      "conclusion single dose": 18995,
      "significantly reduce postoperative": 75841,
      "opioids opioid receptors": 53122,
      "signal transduction pathways": 75387,
      "mechanisms underlying opioid": 44155,
      "oxycodone heroin fentanyl": 55157,
      "differences behavioral responses": 24720,
      "compared wild type": 18342,
      "wild type mice": 87099,
      "drug objective study": 26724,
      "objective study identify": 50517,
      "control prevention guidelines": 20399,
      "inform opioid prescribing": 38618,
      "prescribing patterns opioids": 64107,
      "opioids acute pain": 52703,
      "characteristics patients received": 15871,
      "opioid analgesics prescribed": 51523,
      "prescribed acute pain": 63815,
      "january 2017 december": 40454,
      "2017 december 31": 2779,
      "december 31 2017": 22838,
      "opioid prescription discharge": 52143,
      "opioids prescribed median": 53209,
      "median days interquartile": 44211,
      "days interquartile range": 22543,
      "interquartile range days": 39527,
      "acetaminophen combination products": 7169,
      "patients received days": 59775,
      "overall prescribing patterns": 54233,
      "days median days": 22553,
      "induction general anesthesia": 38479,
      "patients received intermittent": 59784,
      "controlled analgesia oxycodone": 20456,
      "received oral acetaminophen": 68225,
      "administered intravenous morphine": 8144,
      "intravenous morphine equivalents": 39858,
      "overall patient satisfaction": 54226,
      "effective safe postoperative": 27699,
      "safe postoperative analgesia": 73099,
      "increased use opioids": 38043,
      "strong opioids opioid": 77553,
      "opioids opioid na\u00efve": 53120,
      "drugs currently available": 26928,
      "short term efficacy": 75190,
      "term efficacy opioids": 80630,
      "combining drugs different": 17684,
      "increased risk drug": 38012,
      "reuptake inhibition single": 72199,
      "inhibition single molecule": 38787,
      "single molecule mechanisms": 76122,
      "analgesia acute pain": 9903,
      "clinical trials patients": 16955,
      "oxycodone produced significantly": 55769,
      "fewer gastrointestinal effects": 31640,
      "year safety study": 87500,
      "safety study tapentadol": 73225,
      "limitations currently available": 41900,
      "analgesics treatment chronic": 10511,
      "present study undertaken": 64666,
      "study undertaken assess": 78553,
      "opioid drugs buprenorphine": 51749,
      "buprenorphine fentanyl heroin": 14540,
      "opioids patient population": 53156,
      "moderate intensity common": 47151,
      "mandated risk evaluation": 43302,
      "ht3 receptor antagonist": 35917,
      "risk potentially fatal": 72640,
      "deaths associated illicit": 22742,
      "vs 61 years": 86601,
      "17 ng ml": 1978,
      "vs ng ml": 86662,
      "ng ml lower": 49445,
      "use wide range": 84813,
      "blood concentrations fentanyl": 14116,
      "concentration ng ml": 18707,
      "associated illicit use": 12290,
      "evaluated incidence severity": 29889,
      "incidence severity pain": 37322,
      "pain efficacy safety": 56747,
      "design authors conducted": 23699,
      "conducted prospective double": 19389,
      "normal saline placebo": 49911,
      "study need rescue": 78321,
      "need rescue analgesic": 48953,
      "surgery adverse events": 79316,
      "adverse events recorded": 8797,
      "events recorded results": 30105,
      "71 placebo group": 5599,
      "significantly fewer patients": 75703,
      "group required rescue": 33985,
      "required rescue analgesia": 70861,
      "patients needed oxycodone": 59541,
      "groups incidence adverse": 34218,
      "events common adverse": 30022,
      "associated significant postoperative": 12428,
      "provides adequate pain": 66201,
      "children methods children": 16059,
      "methods children aged": 45268,
      "prospective randomized single": 65870,
      "pain management used": 57130,
      "need rescue analgesia": 48952,
      "rescue analgesia oxycodone": 70930,
      "hospital stay significantly": 35640,
      "stay significantly shorter": 77294,
      "postoperative pain shorter": 62923,
      "hospital stay open": 35636,
      "hospitals united states": 35674,
      "united states opioids": 83813,
      "hydromorphone meperidine methadone": 36184,
      "meperidine methadone morphine": 44843,
      "equivalents mmes calculated": 29366,
      "class effect opioids": 16659,
      "case series study": 15207,
      "terminally ill patients": 80690,
      "mean age patients": 43707,
      "used 12 patients": 84821,
      "route opioid administration": 72845,
      "events occurred conclusions": 30081,
      "conclusions low dose": 19116,
      "adverse events background": 8732,
      "events background emergency": 30017,
      "background emergency department": 13052,
      "department ed patients": 23426,
      "disorder oud methods": 25383,
      "chief complaint chronic": 16002,
      "complaint chronic pain": 18427,
      "state prescription monitoring": 77064,
      "001 95 ci": 106,
      "95 ci 55": 6311,
      "include small sample": 37369,
      "conclusion patients chronic": 18955,
      "prior opioid therapy": 65159,
      "ed patients received": 27345,
      "received prescription opioids": 68254,
      "opioids examine factors": 52898,
      "observational study enrolled": 50628,
      "sample ed patients": 73302,
      "ed patients aged": 27341,
      "questions opioid use": 66909,
      "opioid use misuse": 52538,
      "prescription opioids prescription": 64363,
      "pain scores analgesic": 57705,
      "taking prescription opioids": 80325,
      "past 12 month": 58449,
      "substance abuse associated": 78796,
      "intraoperative blood loss": 39768,
      "blood loss postoperative": 14129,
      "university hospital patients": 83863,
      "blood loss significantly": 14130,
      "significant difference mean": 75476,
      "mean oxycodone use": 43824,
      "66 mg vs": 5456,
      "hospital stay similar": 35641,
      "significant difference overall": 75484,
      "rates groups conclusion": 67582,
      "randomized multicenter study": 67124,
      "examined analgesic efficacy": 30369,
      "status ii patients": 77259,
      "morphine patient controlled": 47870,
      "controlled analgesia oral": 20454,
      "analgesia oral analgesics": 10042,
      "rescue analgesia consisted": 70927,
      "equivalent dose oxycodone": 29304,
      "dose oxycodone patients": 25996,
      "wong baker faces": 87261,
      "baker faces pain": 13225,
      "faces pain rating": 31024,
      "mg kg group": 45977,
      "mild moderate severity": 46433,
      "similar treatment groups": 76002,
      "treatment groups significant": 82608,
      "controlled analgesia group": 20450,
      "intra abdominal surgery": 39715,
      "methods year period": 45635,
      "received parenteral morphine": 68242,
      "analgesia pca pump": 10057,
      "dose 20 mg": 25795,
      "10 mg hours": 817,
      "mg hours needed": 45907,
      "needed breakthrough pain": 48988,
      "continued 24 hours": 20131,
      "differences groups demographic": 24746,
      "groups demographic clinical": 34175,
      "bowel function length": 14278,
      "substance use mental": 78819,
      "use mental health": 84478,
      "age 65 years": 9042,
      "increased risk er": 38013,
      "regression analysis showed": 69427,
      "major depressive episode": 42942,
      "pain reliever misuse": 57603,
      "mental health problems": 44821,
      "prescribing patterns following": 64106,
      "truven health marketscan": 83260,
      "health marketscan commercial": 34729,
      "marketscan commercial claims": 43434,
      "commercial claims encounters": 17704,
      "filled opioid prescriptions": 31708,
      "opioid prescriptions january": 52194,
      "january 2011 december": 40438,
      "patients previous opioid": 59696,
      "previous opioid prescriptions": 64910,
      "filled opioid prescription": 31707,
      "prescription 12 months": 64149,
      "12 months following": 1335,
      "univariate multivariate analysis": 83844,
      "multivariate analysis performed": 48344,
      "outcome measure opioid": 53926,
      "use results study": 84706,
      "hydrocodone mg frequently": 36105,
      "duration opioids prescribed": 27172,
      "equivalents mme prescribed": 29362,
      "mg tablets oxycodone": 46232,
      "opioid use 15": 52463,
      "background peripheral nerve": 13155,
      "patients general anesthesia": 59322,
      "foot ankle surgery": 32244,
      "pain levels measured": 57017,
      "levels measured visual": 41576,
      "opioid use recorded": 52580,
      "analysis variance used": 10792,
      "groups proportion patients": 34281,
      "reported visual analog": 70678,
      "time point results": 81330,
      "group higher pain": 33815,
      "higher pain levels": 35286,
      "pain levels 24": 57013,
      "levels 24 hours": 41541,
      "compared ga group": 18162,
      "group significantly greater": 34016,
      "significantly greater proportion": 75714,
      "population level evidence": 62348,
      "level evidence iii": 41470,
      "iii retrospective comparative": 36596,
      "retrospective comparative study": 72136,
      "comparative study objective": 17985,
      "study objective study": 78341,
      "multimodal pain protocol": 48233,
      "design study design": 23809,
      "cancer patients undergoing": 14895,
      "undergoing open abdominal": 83557,
      "acetaminophen 1g iv": 7118,
      "pain control regimen": 56650,
      "6h 48h postoperatively": 5538,
      "oxycodone acetaminophen 10": 54626,
      "conclusion multimodal pain": 18929,
      "37 95 ci": 4185,
      "95 ci 50": 6306,
      "95 ci 20": 6259,
      "exposure associated increased": 30753,
      "associated increased rate": 12305,
      "70 95 ci": 5560,
      "low dose ketamine": 42470,
      "pain sickle cell": 57835,
      "31 year old": 3883,
      "disease presented emergency": 25341,
      "vital signs physical": 86347,
      "bilirubin mg dl": 13799,
      "fentanyl patient controlled": 31563,
      "methyl aspartate nmda": 45642,
      "aspartate nmda receptor": 11855,
      "significant reduction opioid": 75614,
      "reduction opioid dosage": 69075,
      "option pain control": 53460,
      "regarding adverse effects": 69241,
      "treatment cancer pain": 82466,
      "underlying causes pain": 83604,
      "non opioid opioid": 49654,
      "opioid analgesics nsaids": 51510,
      "moderate pain patients": 47157,
      "pain patients history": 57347,
      "moderate adverse effects": 47137,
      "opioid analgesics opioid": 51513,
      "analgesics opioid analgesics": 10464,
      "oxycodone codeine tramadol": 54796,
      "strong pain relief": 77562,
      "pain diabetic neuropathy": 56709,
      "recreational opioid use": 68778,
      "single center retrospective": 76067,
      "setting academic urban": 74764,
      "academic urban safety": 6961,
      "median age 23": 44197,
      "mg interquartile range": 45928,
      "seven patients received": 74870,
      "extracorporeal membrane oxygenation": 30944,
      "pain management particularly": 57096,
      "morphine structurally related": 47930,
      "highly effective opioid": 35394,
      "activation opioid receptors": 7476,
      "global opioid crisis": 33230,
      "analgesia fewer undesirable": 9979,
      "fewer undesirable effects": 31672,
      "multiple opioid receptors": 48289,
      "potential abuse dependence": 63121,
      "benzodiazepines cannabis cocaine": 13658,
      "pediatric patients undergoing": 60358,
      "patients undergoing cardiac": 60091,
      "undergoing cardiac surgery": 83518,
      "longer hospital stays": 42377,
      "18 years underwent": 2116,
      "surgery prior institution": 79536,
      "primary outcome intraoperative": 65065,
      "measured morphine equivalents": 43977,
      "hours postoperatively postoperative": 35827,
      "postoperative day secondary": 62754,
      "pain sedation scores": 57808,
      "oxycodone results patients": 55853,
      "patients groups similar": 59347,
      "patients postintervention group": 59656,
      "group required significantly": 33986,
      "significantly lower doses": 75782,
      "opioid use non": 52543,
      "opioids 24 hours": 52671,
      "24 hours conclusion": 3213,
      "future studies assess": 32774,
      "total hospital stay": 81817,
      "hernia repair ihr": 34975,
      "reduce postoperative cumulative": 68881,
      "plane tap block": 61876,
      "observational study investigating": 50629,
      "insufficient information regarding": 39129,
      "did differ statistically": 24440,
      "postoperative pain analgesic": 62844,
      "abuse potential prescription": 6828,
      "potential prescription opioids": 63211,
      "opioid prescribing pediatric": 52119,
      "eds past decade": 27371,
      "past decade methods": 58461,
      "decade methods data": 22804,
      "national hospital ambulatory": 48690,
      "hospital ambulatory medical": 35561,
      "ambulatory medical care": 9767,
      "medical care survey": 44337,
      "related visits identified": 69706,
      "pain related ed": 57511,
      "ed visits pediatric": 27357,
      "codeine hydrocodone hydromorphone": 17242,
      "stratified drug enforcement": 77451,
      "results overall use": 71819,
      "pediatric ed visits": 60349,
      "001 significant increase": 210,
      "significant increase use": 75563,
      "use schedule iii": 84718,
      "conclusions opioid use": 19135,
      "balancing pain relief": 13239,
      "adverse effects opioid": 8677,
      "effects opioid analgesics": 28036,
      "deterrent opioid formulation": 24121,
      "centrally acting opioid": 15626,
      "precipitate opioid withdrawal": 63510,
      "50 year old": 4909,
      "opioid dependent male": 51706,
      "developed acute opioid": 24167,
      "severe chronic low": 74930,
      "oxycodone 80 mg": 54603,
      "inadequate pain relief": 37231,
      "pain relief trial": 57595,
      "patient family members": 58642,
      "continuous epidural analgesia": 20165,
      "postoperative oxycodone tramadol": 62840,
      "48 hours rescue": 4721,
      "scale visual analog": 73583,
      "mean age years": 43708,
      "respectively significant group": 71247,
      "group difference pain": 33750,
      "19 vs 42": 2198,
      "40 vs 23": 4383,
      "vs 65 05": 86606,
      "72 hours surgery": 5621,
      "moderate pain 05": 47155,
      "frequentist network meta": 32539,
      "rcts comparing opioids": 67913,
      "search medline embase": 74116,
      "embase cochrane library": 28645,
      "cochrane risk bias": 17185,
      "united states prompted": 83823,
      "implementation opioid prescribing": 36938,
      "total mme administered": 81837,
      "linear models used": 42025,
      "models used determine": 47134,
      "ninety patients included": 49484,
      "patients included analysis": 59393,
      "patients administered opioid": 58950,
      "reduction opioid administration": 69073,
      "tail immersion assay": 80249,
      "acute thermal pain": 7705,
      "withdrawal latency water": 87136,
      "latency water temperature": 41229,
      "thermal pain thresholds": 81085,
      "overdose risks associated": 54318,
      "risks associated opioid": 72670,
      "effects opioid therapy": 28039,
      "rapid eye movement": 67383,
      "eye movement rem": 31003,
      "movement rem sleep": 48051,
      "suggest opioid therapy": 79003,
      "standardised mean difference": 76942,
      "risk bias studies": 72534,
      "background opioid based": 13108,
      "opioid based analgesics": 51557,
      "prospectively enrolled patients": 65896,
      "enrolled patients completed": 29008,
      "chronic pain surgery": 16315,
      "opioid pain pills": 52038,
      "325 mg 32": 3953,
      "median 27 pills": 44187,
      "study period median": 78389,
      "measured morphine milligram": 43978,
      "reduce opioid overprescription": 68862,
      "sale prescription opioids": 73246,
      "change statistically significant": 15753,
      "prescription opioids particularly": 64358,
      "opioids particularly oxycodone": 53153,
      "cancer related neuropathic": 14906,
      "related neuropathic pain": 69639,
      "use adjuvant analgesics": 84177,
      "study objective investigate": 78337,
      "single center open": 76060,
      "non randomized study": 49675,
      "randomized study conducted": 67191,
      "university hospital study": 83864,
      "patients advanced cancer": 58958,
      "rating scale primary": 67673,
      "outcomes adverse events": 54010,
      "38 patients enrolled": 4244,
      "pain score decreased": 57673,
      "prior opioid use": 65160,
      "common terminology criteria": 17817,
      "terminology criteria adverse": 80697,
      "criteria adverse events": 21191,
      "conclusions tapentadol appears": 19233,
      "associated opioid analgesics": 12354,
      "united states limited": 83801,
      "states limited data": 77117,
      "opioid analgesic medication": 51459,
      "opioid analgesic use": 51472,
      "drugs past year": 27032,
      "past year use": 58479,
      "odds ratio 36": 50915,
      "ratio 36 95": 67733,
      "36 95 confidence": 4125,
      "compared using drug": 18337,
      "ratio 49 95": 67741,
      "49 95 confidence": 4772,
      "confidence interval 10": 19442,
      "drug overdose deaths": 26732,
      "people use drugs": 60434,
      "study aimed assess": 77920,
      "use frequently reported": 84377,
      "29 tested positive": 3616,
      "use significantly associated": 84729,
      "health concern risk": 34695,
      "common nursing home": 17774,
      "use methods identified": 84483,
      "pain vs moderate": 57982,
      "vs moderate pain": 86659,
      "16 long acting": 1877,
      "aor 57 95": 11319,
      "95 ci 41": 6292,
      "aor 55 95": 11313,
      "factors associated increased": 31074,
      "analgesic use included": 10355,
      "79 95 ci": 5798,
      "pharmacologic management pain": 61198,
      "guidelines pain management": 34456,
      "prescription opioids associated": 64326,
      "opioid misuse index": 51941,
      "misuse index pomi": 46724,
      "2019 eligible patients": 2865,
      "adults chronic non": 8556,
      "mean age 58": 43691,
      "median morphine milligram": 44247,
      "multivariate analysis age": 48342,
      "68 95 ci": 5495,
      "78 95 ci": 5780,
      "proportion patients high": 65767,
      "refer pain specialists": 69126,
      "patients total hip": 60054,
      "hip replacement thr": 35425,
      "pain purpose study": 57448,
      "opioid prescriptions patients": 52204,
      "prescriptions patients undergoing": 64536,
      "retrospective cohort analysis": 72123,
      "center united states": 15561,
      "median age 64": 44200,
      "18 85 years": 2072,
      "moderate high risk": 47149,
      "receive opioid prescription": 68061,
      "perioperative factors associated": 60834,
      "included final analysis": 37454,
      "demographic characteristics groups": 23271,
      "oxycodone acetaminophen postoperatively": 54658,
      "low dose opioids": 42477,
      "performed cross sectional": 60581,
      "population based sample": 62314,
      "2015 truven health": 2724,
      "health marketscan research": 34731,
      "marketscan research databases": 43438,
      "morphine equivalents recorded": 47678,
      "percent prescribed opioids": 60484,
      "aged 18 34": 9157,
      "18 34 years": 2046,
      "morphine equivalents increased": 47672,
      "remained unchanged conclusions": 70279,
      "population based cohort": 62308,
      "based cohort study": 13297,
      "elderly patients 65": 28479,
      "opioid use year": 52611,
      "opioid prescription duration": 52144,
      "results primary outcome": 71894,
      "proportion patients filled": 65764,
      "patients filled opioid": 59305,
      "difference morphine equivalent": 24634,
      "median daily dose": 44209,
      "32 mg morphine": 3930,
      "opioid prescription filled": 52145,
      "conclusions chronic opioid": 19043,
      "health concern study": 34696,
      "study design cross": 78068,
      "descriptive statistics calculated": 23681,
      "odds ratios ors": 50937,
      "ratios ors 95": 67828,
      "ors 95 confidence": 53813,
      "significantly likely report": 75766,
      "prescription opioids compared": 64331,
      "implant based breast": 36917,
      "based breast reconstruction": 13289,
      "breast reconstruction methods": 14410,
      "chart review performed": 15930,
      "patients included patients": 59399,
      "included patients undergoing": 37510,
      "reduction length stay": 69064,
      "morphine 15 mg": 47541,
      "24 mg versus": 3245,
      "patients undergoing unilateral": 60133,
      "intercostal nerve block": 39409,
      "consumption pain medication": 19978,
      "hospital length stay": 35599,
      "clinical question level": 16878,
      "question level evidence": 66880,
      "level evidence therapeutic": 41479,
      "evidence therapeutic iii": 30282,
      "semisynthetic opioid receptor": 74525,
      "active metabolite oxycodone": 7518,
      "central nervous available": 15594,
      "available immediate release": 12814,
      "release er formulation": 69842,
      "er formulation oxymorphone": 29419,
      "deter misuse abuse": 23974,
      "emergency department evaluation": 28680,
      "presentation emergency department": 64680,
      "objective determine prevalence": 50401,
      "ed patients methods": 27343,
      "aged 17 years": 9152,
      "selected month study": 74394,
      "ci 29 31": 16428,
      "commonly used label": 17880,
      "urine specimens analyzed": 84089,
      "mass spectrometry lc": 43465,
      "spectrometry lc ms": 76666,
      "reported medication list": 70585,
      "pain patient population": 57335,
      "patient population background": 58705,
      "increased dramatically north": 37907,
      "dramatically north america": 26441,
      "population level medication": 62349,
      "30 days continuous": 3725,
      "factors independently associated": 31106,
      "generalized linear mixed": 33004,
      "mixed effects regression": 46795,
      "originated non mmt": 53797,
      "ci 09 18": 16382,
      "continuous quality improvement": 20186,
      "background evaluated efficacy": 13056,
      "efficacy safety profile": 28379,
      "intrathecal morphine postoperative": 39800,
      "morphine postoperative pain": 47880,
      "various surgical procedures": 85981,
      "morphine postoperative analgesia": 47879,
      "children hospital philadelphia": 16052,
      "intrathecal morphine administration": 39796,
      "patients examined mean": 59268,
      "range iqr 10": 67319,
      "iqr 10 median": 40159,
      "median maximum pain": 44240,
      "maximum pain score": 43602,
      "pain score 24": 57666,
      "mean time rescue": 43887,
      "time rescue opioid": 81364,
      "117 patients received": 1188,
      "postdural puncture headache": 62650,
      "study conducted investigate": 78028,
      "therapies pain management": 80980,
      "frequently used pain": 32587,
      "used pain medications": 85064,
      "use significantly higher": 84730,
      "nonopioid analgesic use": 49806,
      "significant difference opioid": 75480,
      "years 13 years": 87523,
      "opioid analgesics past": 51518,
      "analgesics past decades": 10476,
      "anatomical therapeutic chemical": 10882,
      "therapeutic chemical classification": 80926,
      "morphine fentanyl pethidine": 47694,
      "oxycodone strong opioids": 55942,
      "using defined daily": 85374,
      "optimal pain management": 53427,
      "opioid analgesics controlled": 51491,
      "analgesia minimizing opioid": 10023,
      "opioid requirements following": 52340,
      "following ambulatory surgery": 32101,
      "present case series": 64611,
      "case series demonstrate": 15202,
      "breast surgery patients": 14412,
      "resting pain scores": 71442,
      "pain scores measured": 57735,
      "measured 10 numeric": 43953,
      "rating scale median": 67655,
      "treatment period patients": 82754,
      "avoided opioid use": 12970,
      "opioid use entirely": 52512,
      "mg oxycodone postoperative": 46136,
      "oxycodone postoperative day": 55709,
      "effects adverse events": 27814,
      "new opioid prescription": 49346,
      "opioid prescription main": 52152,
      "better understand drivers": 13747,
      "prescribing practices clinical": 64116,
      "pain management guidelines": 57072,
      "strong opioids chronic": 77543,
      "cancer pain recommended": 14851,
      "health insurance database": 34719,
      "insurance database including": 39149,
      "patients aged 16": 58968,
      "strong opioid prescription": 77537,
      "results patients receiving": 71855,
      "fentanyl fentanyl analogs": 31475,
      "related deaths west": 69586,
      "deaths west virginia": 22792,
      "west virginia wv": 86996,
      "virginia wv united": 86241,
      "wv united states": 87386,
      "wv drug related": 87383,
      "related deaths 2005": 69581,
      "heroin related deaths": 35033,
      "deaths prescription opioid": 22776,
      "prescription opioid related": 64313,
      "drugs recent years": 27055,
      "analysed liquid chromatography": 10573,
      "liquid chromatography coupled": 42077,
      "chromatography coupled tandem": 16155,
      "coupled tandem mass": 20979,
      "ms ms separation": 48090,
      "mm 50 mm": 46928,
      "formic acid water": 32304,
      "methods observational study": 45406,
      "treated january 2011": 82345,
      "opioids medical prescription": 53043,
      "opioid frequently used": 51822,
      "statistically significant higher": 77221,
      "analysis opioid prescriptions": 10720,
      "prescription monitoring program": 64258,
      "monitoring program pmp": 47340,
      "results significantly greater": 71958,
      "involved prescription opioids": 40113,
      "prescription opioids decreased": 64332,
      "nonmedical use opioids": 49785,
      "depression total 14": 23605,
      "study tapentadol immediate": 78534,
      "acute low pain": 7638,
      "pain 666 analyses": 56394,
      "internal consistency convergent": 39458,
      "consistency convergent validity": 19687,
      "confirmatory factor analysis": 19500,
      "factor analysis conducted": 31051,
      "analyses performed test": 10603,
      "showed good psychometric": 75252,
      "good psychometric properties": 33325,
      "displayed good convergent": 25472,
      "good convergent validity": 33301,
      "fit priori factor": 31860,
      "priori factor structure": 65182,
      "factor structure highly": 31063,
      "perspective considered results": 60965,
      "considered results recent": 19646,
      "results recent studies": 71906,
      "recent studies data": 68423,
      "studies data suggest": 77688,
      "provide valid responsive": 66113,
      "valid responsive efficient": 85778,
      "responsive efficient assessment": 71406,
      "trials clinical research": 83115,
      "clinical research examining": 16887,
      "context enhanced recovery": 20108,
      "patients undergoing general": 60105,
      "anaesthesia randomly allocated": 9877,
      "randomly allocated receive": 67215,
      "primary outcome consumption": 65059,
      "consumption opioids postoperative": 19964,
      "postoperative days secondary": 62766,
      "days secondary outcomes": 22619,
      "secondary outcomes pain": 74253,
      "bowel function dietary": 14273,
      "discharge length hospital": 25133,
      "results postoperative opioid": 71878,
      "opioid consumption spinal": 51665,
      "significantly postoperative days": 75834,
      "excessive sedation respiratory": 30464,
      "sedation respiratory depression": 74327,
      "reported elderly patients": 70543,
      "hospital stay conclusions": 35632,
      "associated postoperative opioid": 12382,
      "acute pain opioid": 7671,
      "quality recovery qor": 66758,
      "established aim study": 29583,
      "study evaluate ability": 78161,
      "gastrointestinal surgery methods": 32890,
      "surgery methods eighty": 79460,
      "receive ultrasound guided": 68087,
      "20 ml 375": 2358,
      "ml 375 ropivacaine": 46838,
      "saline primary outcome": 73270,
      "qor 15 score": 66639,
      "outcomes postoperative pain": 54074,
      "intensity opioid consumption": 39283,
      "control group mean": 20330,
      "mean difference 16": 43752,
      "oxycodone consumption significantly": 54869,
      "24 24 48": 3151,
      "24 48 48": 3165,
      "control group rest": 20342,
      "scale scores significantly": 73561,
      "postoperative period patients": 62941,
      "period patients undergoing": 60770,
      "patients undergoing gastrointestinal": 60103,
      "undergoing gastrointestinal surgery": 83536,
      "given high rates": 33171,
      "high rates prescription": 35163,
      "opioid use older": 52549,
      "national poison data": 48708,
      "regression used examine": 69464,
      "cases involving oxycodone": 15245,
      "prescription opioid poisoning": 64311,
      "methods used data": 45620,
      "concurrent illicit drug": 19266,
      "illicit drug alcohol": 36632,
      "ci 27 35": 16424,
      "treatment substance use": 82864,
      "opioids prescribed long": 53207,
      "objective study opioid": 50520,
      "maximum opioid prescription": 43597,
      "opioid prescription 12": 52132,
      "use substance use": 84761,
      "10th 90th percentile": 1083,
      "multivariate regression analyses": 48352,
      "regression analyses used": 69420,
      "calculate odds ratios": 14678,
      "ratios 95 confidence": 67815,
      "met criteria analysis": 44869,
      "use aor 62": 84200,
      "aor 62 95": 11324,
      "ci 47 80": 16459,
      "opioid prescription compared": 52137,
      "potential opioid induced": 63198,
      "group patients did": 33902,
      "total sample size": 81901,
      "binary logistic regression": 13808,
      "logistic regression employed": 42267,
      "odds ratio 41": 50919,
      "ratio 41 95": 67738,
      "41 95 confidence": 4419,
      "identified risk factors": 36467,
      "quality improvement initiatives": 66708,
      "review english language": 72291,
      "english language articles": 28942,
      "january 2015 december": 40448,
      "2015 december 31": 2701,
      "december 31 2015": 22835,
      "prescriptions increase risk": 64501,
      "determine long term": 24021,
      "long term outcome": 42344,
      "board approved retrospective": 14183,
      "retrospective study setting": 72173,
      "medical center patients": 44341,
      "center patients patients": 15538,
      "outcome measures postoperative": 53948,
      "discharged home postoperative": 25200,
      "discharged home pod": 25199,
      "acetaminophen pain control": 7230,
      "oral diet time": 53518,
      "children hospital boston": 16051,
      "remains poorly treated": 70305,
      "severe pain mu": 74987,
      "pain mu opioid": 57218,
      "physical dependence tolerance": 61392,
      "growing body evidence": 34360,
      "commonly used mu": 17885,
      "opioids include morphine": 52973,
      "meperidine oxycodone fentanyl": 44848,
      "evidence based medicine": 30159,
      "identify factors associated": 36504,
      "factors associated high": 31072,
      "commonly prescribed agents": 17862,
      "univariate multivariate analyses": 83843,
      "patients prescribed average": 59670,
      "doses high dose": 26196,
      "interval ci 17": 39583,
      "ci 17 13": 16406,
      "ci 11 60": 16394,
      "03 95 ci": 411,
      "reported pain levels": 70612,
      "surgery study design": 79595,
      "review setting academic": 72357,
      "600 mg oral": 5288,
      "mg oral gabapentin": 46083,
      "use acetaminophen ibuprofen": 84169,
      "acetaminophen ibuprofen oxycodone": 7196,
      "oxycodone needed pain": 55530,
      "patients completed daily": 59110,
      "pain medication log": 57154,
      "pain measured visual": 57140,
      "use morphine equivalent": 84500,
      "used data analysis": 84901,
      "data analysis results": 21873,
      "results seven patients": 71940,
      "score decreased significantly": 73743,
      "decreased significantly groups": 23043,
      "orthopaedic surgeons medicare": 53819,
      "daily doses opioid": 21744,
      "fentanyl morphine methadone": 31533,
      "significant reduction total": 75617,
      "reduction total opioid": 69105,
      "daily doses hydrocodone": 21742,
      "surgeons highest prescribers": 79273,
      "efforts reduce opioid": 28443,
      "study examine association": 78193,
      "population based ecological": 62312,
      "based ecological study": 13313,
      "2017 logistic regression": 2790,
      "regression used identify": 69465,
      "used identify significant": 84964,
      "past year heroin": 58475,
      "past year prescription": 58477,
      "year prescription opioid": 87487,
      "prescription opioid oxycodone": 64306,
      "opioid oxycodone hydrocodone": 52028,
      "oxycodone hydrocodone use": 55215,
      "use non prescribed": 84518,
      "partially mediated relationship": 58252,
      "prescription opioids fentanyl": 64335,
      "implemented opioid prescribing": 36950,
      "determine opioid prescribing": 24028,
      "12 oxycodone 10": 1347,
      "fentanyl fentanyl analogues": 31476,
      "increase opioid prescribing": 37768,
      "opioids typically prescribed": 53362,
      "2015 december 2015": 2700,
      "false negative results": 31170,
      "urine samples subsequently": 84085,
      "pain long term": 57032,
      "long term basis": 42325,
      "national prescription database": 48712,
      "number patients received": 50219,
      "comprehensive opioid risk": 18625,
      "naltrexone opioid antagonist": 48548,
      "tamper resistant abuse": 80334,
      "resistant abuse deterrent": 71094,
      "consisted immediate release": 19676,
      "opioids prescribed postoperatively": 53212,
      "sought better understand": 76481,
      "better understand postoperative": 13750,
      "understand postoperative pain": 83627,
      "postoperative pain levels": 62882,
      "correlate postoperative pain": 20808,
      "number opioids consumed": 50202,
      "patients require opioids": 59904,
      "enrolled prospective cohort": 29013,
      "highest postoperative day": 35364,
      "day pain score": 22358,
      "pain scores number": 57744,
      "conclusions findings indicate": 19086,
      "number narcotics prescribed": 50181,
      "outcomes regarding opioid": 54083,
      "pubmed embase central": 66447,
      "2020 december 2021": 2900,
      "misuse opioid use": 46731,
      "studies extracted data": 77729,
      "extracted data assessed": 30952,
      "included studies 13": 37558,
      "testing results 10": 80840,
      "prospero registration number": 65907,
      "treating acute pain": 82387,
      "abuse potential respiratory": 6830,
      "methods conducted systematic": 45288,
      "conducted systematic review": 19417,
      "experimental pain studies": 30672,
      "severe pain opioid": 74992,
      "pain opioid na\u00efve": 57285,
      "potential respiratory depression": 63218,
      "evidence based guidance": 30155,
      "decrease opioid utilization": 22910,
      "discharge study design": 25180,
      "trial level evidence": 83032,
      "level evidence methods": 41477,
      "patients undergoing arthroscopic": 60088,
      "arthroscopic partial meniscectomy": 11751,
      "multimodal pain medications": 48232,
      "time points month": 81338,
      "mean number tablets": 43812,
      "significant reduction number": 75613,
      "postoperative pain time": 62926,
      "patients did require": 59193,
      "did require opioids": 24493,
      "tablets conclusion patients": 80131,
      "minimal number opioids": 46577,
      "opioid prescription included": 52151,
      "pain control significantly": 56658,
      "gain better understanding": 32813,
      "reported drug use": 70537,
      "tramadol oxycodone fentanyl": 82092,
      "public health harms": 66387,
      "understanding opioid prescribing": 83639,
      "associations opioid prescribing": 12496,
      "opioid prescribing design": 52095,
      "demographic data collected": 23280,
      "opioid analgesic prescription": 51468,
      "time results overall": 81367,
      "patients frequently prescribed": 59319,
      "palliative care indications": 58035,
      "pain management purpose": 57110,
      "skilled nursing facility": 76196,
      "increased risk opioid": 38015,
      "adult 18 years": 8485,
      "december 31 2018": 22839,
      "2018 primary outcome": 2840,
      "receipt opioid prescription": 68034,
      "length stay results": 41414,
      "prescribed opioid discharge": 63909,
      "discharge patients prescribed": 25159,
      "milligram equivalents day": 46456,
      "cancer chronic pain": 14773,
      "pain pain score": 57321,
      "undergoing open inguinal": 83558,
      "addition standard multimodal": 7829,
      "tertiary academic medical": 80729,
      "total 90 patients": 81774,
      "methods subjects presenting": 45598,
      "opioid consumption 48": 51603,
      "consumption 48 hours": 19884,
      "hours surgery secondary": 35869,
      "scores opioid related": 73931,
      "results eighty subjects": 71678,
      "48 hour postoperative": 4707,
      "hour postoperative oxycodone": 35713,
      "oxycodone equivalent consumption": 55034,
      "reduction pain scores": 69088,
      "pain scores 24": 57698,
      "differences secondary outcomes": 24812,
      "secondary outcomes conclusions": 74243,
      "significantly reduce opioid": 75840,
      "reduce opioid consumption": 68860,
      "setting multimodal analgesia": 74788,
      "background ongoing opioid": 13101,
      "analgesic use patients": 10356,
      "patients suffering chronic": 60018,
      "opioid therapy frequently": 52414,
      "opioid use prescribing": 52573,
      "40 years age": 4387,
      "reported significantly fewer": 70649,
      "acute pain design": 7667,
      "old male history": 51010,
      "oxycodone hydrocodone acetaminophen": 55200,
      "patients history opioid": 59365,
      "pain difficult control": 56719,
      "common cause acute": 17738,
      "study determine opioid": 78112,
      "dysfunction methods retrospective": 27223,
      "2009 31 december": 2523,
      "million prescriptions opioid": 46497,
      "beneficiaries receiving opioid": 13609,
      "multiple factors including": 48279,
      "prescription 90 days": 64157,
      "women chronic pain": 87208,
      "women average age": 87205,
      "age 51 years": 9018,
      "taking prescribed opioid": 80323,
      "women significantly likely": 87248,
      "alternative routes administration": 9741,
      "use oxycodone morphine": 84588,
      "health organization analgesic": 34741,
      "organization analgesic ladder": 53766,
      "conversion table used": 20716,
      "table used standardize": 80079,
      "used standardize opioid": 85138,
      "standardize opioid analgesic": 76948,
      "opioid analgesic doses": 51455,
      "morphine oxycodone methadone": 47839,
      "significant decrease mean": 75460,
      "morphine equivalent prescribed": 47666,
      "95 ci 77": 6333,
      "001 significant decrease": 207,
      "strong opioid discharge": 77528,
      "significantly different 05": 75687,
      "showed significant increase": 75302,
      "significant decrease total": 75464,
      "chronic pain introduction": 16281,
      "study patients aged": 78365,
      "strong opioids considered": 77546,
      "use healthcare resources": 84392,
      "age 72 years": 9050,
      "years sd 14": 87665,
      "pain intensity decreased": 56894,
      "scores decreased significantly": 73861,
      "increase proportion patients": 37796,
      "years patients treated": 87635,
      "respiratory depression respiratory": 71284,
      "secondary outcomes proportion": 74256,
      "reversal respiratory depression": 72233,
      "patients median age": 59485,
      "18 80 years": 2069,
      "single mg dose": 76120,
      "dose naloxone reversed": 25965,
      "95 ci 94": 6351,
      "following administration mg": 32098,
      "study design single": 78092,
      "retrospective review prospectively": 72164,
      "data patients underwent": 22042,
      "patients underwent single": 60152,
      "underwent single level": 83695,
      "october 2014 october": 50881,
      "2014 october 2019": 2669,
      "objective investigate effect": 50440,
      "prior research demonstrated": 65170,
      "pain control methods": 56625,
      "patients complete press": 59107,
      "complete press ganey": 18450,
      "hospital consumer assessment": 35574,
      "consumer assessment healthcare": 19857,
      "assessment healthcare providers": 12121,
      "healthcare providers systems": 34802,
      "providers systems hcahps": 66196,
      "inpatient opioid prescriptions": 39016,
      "converted milligram morphine": 20728,
      "scale results total": 73553,
      "inclusion criteria study": 37690,
      "average opioids prescribed": 12916,
      "opioids prescribed discharge": 53206,
      "pain control opioid": 56630,
      "control opioid consumption": 20377,
      "opioid consumption hospital": 51624,
      "similarly statistically significant": 76016,
      "pain control increased": 56621,
      "mme prescribed discharge": 46976,
      "pain cncp remains": 56557,
      "remains public health": 70308,
      "pain management pain": 57095,
      "sociodemographic data medical": 76393,
      "post discharge opioid": 62564,
      "discharge opioid use": 25149,
      "undergoing minimally invasive": 83554,
      "operative opioid usage": 51259,
      "week week post": 86879,
      "week post operative": 86864,
      "opioids converted oral": 52824,
      "modified poisson regression": 47241,
      "pills mg oxycodone": 61518,
      "pills range 10": 61541,
      "inpatient opioid use": 39017,
      "chronic pain older": 16289,
      "evaluated safety tolerability": 29921,
      "tolerability profile patients": 81551,
      "patients 65 years": 58887,
      "65 years age": 5424,
      "younger patients 65": 87740,
      "events aes laboratory": 30010,
      "results overall incidence": 71817,
      "clinically significant increases": 17005,
      "risks older adults": 72680,
      "older adults background": 51033,
      "reduce post operative": 68878,
      "patients followed year": 59314,
      "oxycodone acetaminophen mg": 54646,
      "acetaminophen mg 325": 7203,
      "proportion patients treated": 65775,
      "chronic pain prescribed": 16306,
      "summary product characteristics": 79110,
      "hydromorphone oxycodone tramadol": 36210,
      "prescribed 30 days": 63809,
      "days opioid prescription": 22567,
      "405 eligible patients": 4404,
      "disease patients received": 25339,
      "patients received concomitant": 59770,
      "commonly abused medications": 17829,
      "abuse drug related": 6716,
      "chart review conducted": 15927,
      "2020 august 2020": 2891,
      "multivariable regression used": 48336,
      "used identify independent": 84962,
      "sustained release oral": 79792,
      "release oral morphine": 69913,
      "49 95 ci": 4771,
      "needed identify optimal": 49009,
      "united states participated": 83815,
      "methods patients chronic": 45433,
      "pain inventory short": 56979,
      "inventory short form": 39984,
      "medical outcomes study": 44376,
      "36 item short": 4132,
      "item short form": 40348,
      "standard deviation age": 76897,
      "10 years common": 963,
      "midst national opioid": 46411,
      "national opioid crisis": 48705,
      "opioid analgesic medications": 51460,
      "study aims characterize": 77939,
      "retrospective review conducted": 72159,
      "current procedural terminology": 21462,
      "procedural terminology codes": 65265,
      "opioid analgesic opioid": 51462,
      "opioid use perioperative": 52566,
      "decreased study period": 23046,
      "hydromorphone oral oxycodone": 36202,
      "oral oxycodone use": 53643,
      "characteristics associated opioid": 15848,
      "prescribing patients cancer": 64101,
      "end life patients": 28796,
      "methods population based": 45465,
      "cohort study used": 17403,
      "study used data": 78557,
      "95 ci 43": 6296,
      "age 60 years": 9033,
      "age 50 years": 9016,
      "prevalence ratio pr": 64811,
      "likely men receive": 41818,
      "treating cancer pain": 82389,
      "cancer pain united": 14861,
      "older people opioids": 51040,
      "erector spinae plane": 29499,
      "spinae plane esp": 76696,
      "plane esp block": 61874,
      "opioid consumption breast": 51610,
      "consumption breast surgery": 19900,
      "quality recovery 40": 66757,
      "included postoperative pain": 37514,
      "24 hour opioid": 3205,
      "hour opioid consumption": 35707,
      "opioid consumption patient": 51643,
      "consumption patient controlled": 19982,
      "results overall patients": 71818,
      "groups patients group": 34263,
      "esp group satisfied": 29547,
      "treatment group statistical": 82600,
      "groups conclusions compared": 34159,
      "patients undergoing breast": 60090,
      "oral administration drugs": 53486,
      "tricyclic antidepressants benzodiazepines": 83218,
      "associated opioid overprescribing": 12358,
      "primary outcome association": 65056,
      "demographic medical characteristics": 23287,
      "milligram equivalents using": 46469,
      "assessed opioid prescriptions": 12026,
      "opioid prescriptions days": 52180,
      "receive oxycodone hydrocodone": 68067,
      "opioid use women": 52610,
      "maternal opioid use": 43524,
      "opioid use pregnancy": 52572,
      "neurons ventral tegmental": 49220,
      "ventral tegmental area": 86066,
      "tegmental area vta": 80563,
      "opioids data provide": 52831,
      "effects opioid use": 28040,
      "study included patients": 78253,
      "included patients aged": 37507,
      "days long term": 22550,
      "term opioid users": 80654,
      "daily dose results": 21735,
      "na\u00efve patients received": 48845,
      "received opioid prescriptions": 68221,
      "prescriptions study period": 64564,
      "opioid users majority": 52623,
      "prescribed opioids days": 63925,
      "opioid use increasing": 52525,
      "opioid daily doses": 51691,
      "progression long term": 65574,
      "term use opioid": 80679,
      "higher opioid doses": 35279,
      "effects limit clinical": 27968,
      "nucleus accumbens shell": 50127,
      "preference cpp assay": 63622,
      "deaths opioid overdose": 22772,
      "number opioids prescribed": 50203,
      "reduced total opioid": 68983,
      "total number opioids": 81852,
      "opioids prescribed year": 53214,
      "total opioid prescription": 81866,
      "interval ci 42": 39590,
      "60 95 ci": 5245,
      "risk non fatal": 72606,
      "illicit drug reporting": 36634,
      "polysubstance use factors": 62229,
      "use associated greater": 84209,
      "differences substance use": 24824,
      "differences opioid use": 24769,
      "clinical trials network": 16950,
      "opioids significantly higher": 53299,
      "significantly higher women": 75741,
      "prevention treatment efforts": 64886,
      "limited long term": 41940,
      "create opioid prescribing": 21142,
      "patterns po use": 60225,
      "pain chronic use": 56542,
      "chronic pain related": 16311,
      "overall findings suggest": 54202,
      "adverse outcomes background": 8833,
      "outpatient opioid exposure": 54128,
      "health care needs": 34680,
      "10 18 years": 678,
      "vs 31 001": 86562,
      "methods data obtained": 45304,
      "data obtained drug": 22022,
      "converted morphine milligram": 20734,
      "treat opioid use": 82305,
      "use disorder prescription": 84325,
      "disorder prescription opioid": 25387,
      "treating opioid addiction": 82400,
      "diclofenac ibuprofen naproxen": 24390,
      "anti inflammatory antipyretic": 11122,
      "adverse effects potential": 8688,
      "potential drug interactions": 63162,
      "international pharmaceutical abstracts": 39485,
      "reference lists identified": 69134,
      "articles reviewed additional": 11805,
      "effective placebo treatment": 27668,
      "severe pain primary": 74998,
      "oxycodone plus acetaminophen": 55696,
      "platelet function bleeding": 61980,
      "bleeding time platelet": 13913,
      "time platelet aggregation": 81328,
      "treatment osteoarthritis rheumatoid": 82717,
      "osteoarthritis rheumatoid arthritis": 53870,
      "severe pain associated": 74970,
      "opioid prescribing consumption": 52091,
      "prescribing consumption methods": 64045,
      "10 14 days": 672,
      "opioid prescriptions oxycodone": 52202,
      "median number doses": 44252,
      "number doses prescribed": 50157,
      "30 interquartile range": 3743,
      "linear regression showed": 42033,
      "showed significant association": 75296,
      "pain score use": 57686,
      "opioid therapy days": 52412,
      "day opioid use": 22346,
      "hernia repair patients": 34976,
      "received rofecoxib 50": 68261,
      "17 received placebo": 1984,
      "iv oxycodone mg": 40393,
      "pain pain scores": 57322,
      "days surgery pain": 22638,
      "surgery pain scores": 79499,
      "lower treatment group": 42720,
      "oral analgesic use": 53493,
      "undergoing inguinal hernia": 83542,
      "report moderate severe": 70463,
      "reduced pain scores": 68968,
      "background previous research": 13176,
      "following laparoscopic cholecystectomy": 32158,
      "patients age 18": 58964,
      "18 60 years": 2057,
      "years scheduled undergo": 87661,
      "scheduled undergo elective": 73658,
      "laparoscopic cholecystectomy randomized": 41097,
      "control group treated": 20345,
      "multimodal analgesia regimen": 48205,
      "ibuprofen oxycodone primary": 36368,
      "oxycodone primary outcome": 55759,
      "qor 40 score": 66641,
      "score 24 hours": 73719,
      "analyzed using independent": 10866,
      "thirty patients group": 81110,
      "tap group 15": 80373,
      "24 control group": 3194,
      "control group postoperative": 20336,
      "postoperative qor 40": 62959,
      "hours surgery did": 35865,
      "median difference 95": 44214,
      "differences groups pain": 24748,
      "australian new zealand": 12704,
      "acute pain study": 7676,
      "aimed evaluate impact": 9450,
      "secondary objectives included": 74236,
      "surgical patients prescribed": 79641,
      "opioid prescribing decreased": 52094,
      "vs 26 001": 86555,
      "vs 14 001": 86534,
      "associated increased incidence": 12299,
      "52 95 ci": 4981,
      "rr 44 95": 72931,
      "44 95 ci": 4537,
      "males females respond": 43076,
      "discharge opioid prescriptions": 25148,
      "methods prospective quality": 45489,
      "prospective quality improvement": 65854,
      "identified patients undergoing": 36455,
      "cancer center patients": 14768,
      "2017 july 2018": 2788,
      "2018 july 2019": 2826,
      "patients 10 mg": 58822,
      "mg oxycodone pills": 46132,
      "negative health consequences": 49074,
      "oxycodone opioid analgesics": 55567,
      "injection drug users": 38947,
      "drug users likely": 26855,
      "opioid use lower": 52532,
      "use injection drug": 84435,
      "drug use increasing": 26840,
      "longer duration analgesic": 42371,
      "surgery methods randomized": 79470,
      "seventy seven patients": 74895,
      "seven patients undergoing": 74871,
      "randomly assigned following": 67219,
      "assigned following groups": 12168,
      "groups general anesthesia": 34204,
      "general anesthesia group": 32960,
      "group received ropivacaine": 33963,
      "24 65 years": 3176,
      "group end surgery": 33765,
      "surgery trial registration": 79609,
      "tertiary care hospital": 80737,
      "2015 april 2016": 2696,
      "contacted telephone asked": 20058,
      "telephone asked participate": 80568,
      "01 statistically significant": 328,
      "consumption significantly different": 20017,
      "patient opioid consumption": 58693,
      "fewer opioid tablets": 31654,
      "minimally invasive approach": 46584,
      "use opioids background": 84557,
      "opioid use harms": 52517,
      "stronger opioids oxycodone": 77569,
      "opioid use effects": 52511,
      "increases non medical": 38063,
      "population level opioid": 62350,
      "acute pain related": 7673,
      "understanding opioid use": 83640,
      "background efforts reduce": 13049,
      "united states purpose": 83824,
      "united states trauma": 83827,
      "observational study performed": 50633,
      "opioids oral morphine": 53126,
      "multilevel generalized linear": 48191,
      "generalized linear model": 33005,
      "injury severity score": 38997,
      "mg hydrocodone day": 45912,
      "significant differences opioid": 75512,
      "opioid exposure injury": 51797,
      "effects opioids used": 28046,
      "opioids used treatment": 53376,
      "opioid effects patient": 51763,
      "effects patient controlled": 28082,
      "risk ratios rrs": 72653,
      "methods search medline": 45558,
      "controlled trials comparing": 20630,
      "trials comparing opioids": 83124,
      "pain scores quality": 57768,
      "secondary end point": 74219,
      "pruritus respiratory depression": 66302,
      "pruritus nausea vomiting": 66300,
      "population based study": 62315,
      "based study patients": 13385,
      "2005 june 30": 2468,
      "june 30 2009": 40556,
      "dispensed opioid prescriptions": 25429,
      "interquartile range 16": 39521,
      "use opioids relief": 84568,
      "purpose postdischarge opioid": 66544,
      "methods using bc": 45622,
      "using bc ministry": 85323,
      "bc ministry health": 13496,
      "laparoscopic appendectomy la": 41091,
      "laparoscopic cholecystectomy lc": 41096,
      "knee arthroplasty tka": 40858,
      "generalized linear modeling": 33006,
      "percentages patients dispensed": 60521,
      "patients dispensed opioids": 59219,
      "rate 30 days": 67432,
      "30 days surgery": 3732,
      "surgery type opioid": 79612,
      "results opioid dispensation": 71811,
      "pharmacological management chronic": 61220,
      "reduction quality life": 69097,
      "quality life scores": 66747,
      "neuropathic pain symptoms": 49264,
      "high quality clinical": 35154,
      "opioid epidemic north": 51774,
      "epidemic north america": 29137,
      "release opioid products": 69907,
      "inter patient variability": 39360,
      "study characterize use": 77986,
      "release opioid formulations": 69906,
      "chronic pain high": 16278,
      "pain high risk": 56825,
      "setting study took": 74831,
      "study took place": 78543,
      "study data collected": 78049,
      "use associated higher": 84210,
      "people chronic pain": 60403,
      "usual care patients": 85690,
      "opioids tramadol buprenorphine": 53344,
      "oxycodone fentanyl tapentadol": 55089,
      "mean number opioid": 43807,
      "opioid prescriptions patient": 52203,
      "patient prescribed opioid": 58714,
      "patients prescribed strong": 59682,
      "40 patients received": 4372,
      "prescriptions strong opioids": 64562,
      "management chronic non": 43164,
      "gastrointestinal central nervous": 32875,
      "related effects patient": 69599,
      "tapentadol centrally acting": 80387,
      "acting analgesic mechanisms": 7374,
      "mechanisms action micro": 44136,
      "action micro opioid": 7433,
      "opioid agonism norepinephrine": 51419,
      "cancer pain opioids": 14841,
      "results majority patients": 71757,
      "commonly constipation nausea": 17843,
      "constipation nausea somnolence": 19767,
      "effects analgesic tolerance": 27821,
      "analgesic tolerance dependence": 10346,
      "tolerance dependence addiction": 81581,
      "opioid associated adverse": 51552,
      "associated adverse events": 12218,
      "profile associated tapentadol": 65477,
      "cancer pain review": 14856,
      "review current literature": 72282,
      "received increasing attention": 68162,
      "attention past decade": 12572,
      "national ambulatory medical": 48666,
      "rr 74 95": 72971,
      "95 ci 97": 6354,
      "rr 95 ci": 73010,
      "total number outpatient": 81853,
      "pain short acting": 57830,
      "acting opioid agonist": 7397,
      "2021 march 2022": 2915,
      "escalating doses oxycodone": 29524,
      "oxycodone oral hydromorphone": 55581,
      "primary outcome safety": 65093,
      "12 months prior": 1338,
      "los days compared": 42427,
      "analgesia commonly used": 9929,
      "method postoperative analgesia": 45204,
      "methods randomized controlled": 45508,
      "controlled trial compared": 20610,
      "epidural analgesia postoperative": 29170,
      "postoperative pain open": 62899,
      "adult patients aged": 8509,
      "aged 18 85": 9167,
      "guided single injection": 34415,
      "75 mg ml": 5708,
      "ml ropivacaine 20": 46900,
      "ropivacaine 20 ml": 72790,
      "epidural analgesia ropivacaine": 29172,
      "paracetamol 1000 mg": 58091,
      "postoperative days pod": 62763,
      "postoperative pain nausea": 62891,
      "pain nausea vomiting": 57226,
      "nausea vomiting results": 48812,
      "patients epidural analgesia": 59257,
      "epidural analgesia group": 29169,
      "consumption did differ": 19916,
      "epidural infusion ropivacaine": 29185,
      "identify prevalence opioid": 36528,
      "patients factors associated": 59295,
      "2015 august 2016": 2698,
      "aged 75 years": 9196,
      "confidence intervals 95": 19480,
      "intervals 95 ci": 39605,
      "adjusted age sex": 8016,
      "opioid prescribing results": 52126,
      "compared non users": 18216,
      "strong opioids prescribed": 77557,
      "opioids opioid users": 53123,
      "related adverse drug": 69547,
      "adverse drug effects": 8622,
      "fixed proportion mixtures": 31886,
      "dose effect functions": 25894,
      "present study tested": 64664,
      "study tested hypothesis": 78540,
      "warm water tail": 86715,
      "water tail withdrawal": 86761,
      "tail withdrawal procedure": 80255,
      "rhesus monkeys fentanyl": 72449,
      "056 mg kg": 571,
      "mg kg naltrexone": 46003,
      "naltrexone 032 mg": 48536,
      "fentanyl produced dose": 31576,
      "dose dependent antinociception": 25865,
      "efficacy 17 cyclopropylmethyl": 28210,
      "17 cyclopropylmethyl 14\u03b2": 1962,
      "cyclopropylmethyl 14\u03b2 dihyroxy": 21565,
      "14\u03b2 dihyroxy 5\u03b1": 1664,
      "dihyroxy 5\u03b1 epoxy": 25000,
      "5\u03b1 epoxy 6\u03b1": 5215,
      "epoxy 6\u03b1 isoquinolyl": 29219,
      "6\u03b1 isoquinolyl acetamindo": 5544,
      "sciatic nerve block": 73675,
      "patients received ultrasound": 59830,
      "received ultrasound guided": 68304,
      "intravenous iv dexamethasone": 39843,
      "assignment primary outcome": 12187,
      "outcome pain movement": 53972,
      "45 vs 30": 4602,
      "worst pain experienced": 87342,
      "opioid use intravenous": 52527,
      "future research needed": 32771,
      "research needed confirm": 71016,
      "large tertiary care": 41156,
      "interventions patients received": 39676,
      "regimen included preoperative": 69309,
      "outcomes measured included": 54050,
      "included opioid use": 37495,
      "time bowel movement": 81219,
      "median oral morphine": 44264,
      "150 mg 75": 1808,
      "mg 15 001": 45715,
      "conclusions multimodal analgesic": 19122,
      "opioid use cardiac": 52476,
      "surgical patients study": 79642,
      "study objective primary": 78339,
      "objective primary objective": 50473,
      "patient characteristics associated": 58555,
      "based study subjects": 13386,
      "pain control setting": 56656,
      "main results total": 42863,
      "results total 100": 72019,
      "total 100 patients": 81705,
      "92 patients patients": 6156,
      "patients completed preoperative": 59113,
      "completed preoperative survey": 18486,
      "mean number pills": 43811,
      "average number pills": 12907,
      "number pills prescribed": 50229,
      "pills prescribed 10": 61534,
      "associated significant increase": 12426,
      "pain lower postoperative": 57040,
      "lower postoperative opioid": 42681,
      "increased postoperative opioid": 37989,
      "long acting local": 42291,
      "acting local anaesthetic": 7388,
      "provides effective analgesia": 66210,
      "effective analgesia reduces": 27593,
      "randomised double blinded": 67024,
      "double blinded manner": 26393,
      "intravenous morphine patient": 39859,
      "12 weeks surgery": 1387,
      "peak expiratory flow": 60309,
      "hours postoperatively compared": 35824,
      "european clinical trials": 29738,
      "clinical trials database": 16945,
      "opioids potent analgesics": 53196,
      "interaction opioid receptors": 39376,
      "opioid receptors opioid": 52279,
      "opioid receptors present": 52282,
      "peripheral central nervous": 60864,
      "analgesic effects primarily": 10223,
      "review provide overview": 72343,
      "method literature search": 45187,
      "literature search conducted": 42133,
      "november 2014 june": 50033,
      "june 2016 using": 40549,
      "original articles published": 53784,
      "positron emission tomography": 62517,
      "emission tomography pet": 28721,
      "widely used non": 87066,
      "blood oxygen level": 14136,
      "oxygen level dependent": 56202,
      "level dependent bold": 41459,
      "centrally mediated effects": 15630,
      "opioid receptor activation": 52233,
      "receptor antagonists potentiate": 68480,
      "antinociceptive effects morphine": 11246,
      "morphine oxycodone effects": 47819,
      "naloxone opioid antagonist": 48471,
      "endothelin et receptors": 28872,
      "mice results demonstrate": 46311,
      "efficacy safety single": 28385,
      "safety single dose": 73221,
      "patients presenting emergency": 59693,
      "presenting emergency department": 64704,
      "low pain design": 42521,
      "design randomised double": 23769,
      "patients presented acute": 59690,
      "eligible patients randomised": 28593,
      "receiving 400 mg": 68318,
      "10 secondary outcomes": 924,
      "rescue analgesia adverse": 70926,
      "analgesia adverse events": 9908,
      "pain scores hours": 57730,
      "points 95 ci": 62123,
      "median length stay": 44237,
      "group oxycodone use": 33893,
      "pain emergency department": 56753,
      "new zealand clinical": 49395,
      "zealand clinical trials": 87752,
      "department ed methods": 23425,
      "used identify patients": 84963,
      "patients aged 15": 58967,
      "15 years older": 1804,
      "schedule ii medications": 73620,
      "used logistic regression": 84988,
      "age sex race": 9118,
      "sex race ethnicity": 75085,
      "ci 58 60": 16473,
      "study evaluate relationship": 78175,
      "surgery methods retrospective": 79472,
      "short form health": 75171,
      "form health survey": 32280,
      "health survey sf": 34786,
      "survey sf 36": 79739,
      "sf 36 scores": 75100,
      "collected patients divided": 17473,
      "scores compared groups": 73851,
      "compared groups using": 18175,
      "results patients categorized": 71842,
      "36 physical component": 4143,
      "physical component summary": 61386,
      "component summary scores": 18591,
      "careful patient selection": 15104,
      "patient population objective": 58706,
      "clinic patients opioid": 16744,
      "patients nonmalignant pain": 59556,
      "efficacy toxicity patient": 28412,
      "different patients different": 24907,
      "pain severity score": 57827,
      "significant increase mean": 75559,
      "12 30 mg": 1246,
      "tolerance opioid analgesia": 81592,
      "conclusion study provides": 19004,
      "physicians treating patients": 61450,
      "investigate trends opioid": 40030,
      "opioids including morphine": 52980,
      "morphine methadone hydromorphone": 47757,
      "annual opioid prescriptions": 11027,
      "opioid prescriptions 10": 52172,
      "prescriptions 10 000": 64427,
      "palliative care pain": 58039,
      "opioid dispensing rates": 51720,
      "major metropolitan areas": 42959,
      "opioid prescriptions assessed": 52175,
      "dispensing rates increased": 25457,
      "10 000 inhabitants": 653,
      "lower socioeconomic status": 42703,
      "rate ratio rr": 67508,
      "rr 88 95": 73002,
      "88 95 ci": 6041,
      "ci 33 58": 16434,
      "rr 80 95": 72984,
      "patients palliative care": 59626,
      "association initial opioid": 12478,
      "prolonged opioid use": 65615,
      "opioid use methods": 52536,
      "insurance claims optum": 39145,
      "optum clinformatics datamart": 53478,
      "patients older 18": 59576,
      "older 18 years": 51028,
      "filling opioid prescriptions": 31717,
      "180 days index": 2122,
      "results total 30": 72029,
      "inclusion criteria patients": 37689,
      "median total mme": 44296,
      "interquartile range 75": 39526,
      "15 interquartile range": 1739,
      "interquartile range 12": 39516,
      "range 12 20": 67254,
      "95 ci did": 6360,
      "did opioid prescription": 24469,
      "opioid prescription conclusion": 52138,
      "prescription conclusion opioid": 64184,
      "ed patients treated": 27346,
      "safe effective opioid": 73079,
      "fentanyl hydrocodone oxycodone": 31495,
      "receiving long term": 68350,
      "drug testing important": 26807,
      "opioids aim study": 52719,
      "pain scores narcotic": 57740,
      "narcotic use 24": 48615,
      "following robot assisted": 32195,
      "robot assisted laparoscopic": 72706,
      "mixture liposomal bupivacaine": 46813,
      "mg celecoxib 200": 45817,
      "celecoxib 200 mg": 15450,
      "24 post surgery": 3266,
      "intra post operative": 39723,
      "24 pain scores": 3257,
      "vs 10 mg": 86522,
      "oral oxycodone acetaminophen": 53623,
      "used pain control": 85061,
      "pain scores different": 57719,
      "scores different time": 73870,
      "different time intervals": 24927,
      "cornerstone pain management": 20776,
      "pain management cancer": 57058,
      "risk acute chronic": 72510,
      "treatment study design": 82861,
      "retrospective population based": 72151,
      "univariate multivariable logistic": 83840,
      "opioid prescriptions months": 52199,
      "opioid use treatment": 52602,
      "treatment odds ratio": 82695,
      "odds ratio 28": 50909,
      "ratio 28 95": 67724,
      "28 95 confidence": 3552,
      "continued opioid use": 20139,
      "84 95 ci": 5958,
      "1966 2015 embase": 2212,
      "2015 embase ovid": 2704,
      "2015 isi web": 2708,
      "controlled trials examining": 20636,
      "partial opioid agonists": 58247,
      "opioid agonists buprenorphine": 51430,
      "treatment data collection": 82537,
      "used standard cochrane": 85136,
      "main results identified": 42857,
      "trials met inclusion": 83163,
      "quality evidence studies": 66698,
      "self reported opioid": 74497,
      "reported opioid use": 70599,
      "risk ratio rr": 72651,
      "rr 37 95": 72926,
      "37 95 confidence": 4186,
      "rr 81 95": 72987,
      "rr 69 95": 72965,
      "adverse events rr": 8806,
      "rr 63 95": 72956,
      "63 95 ci": 5358,
      "rr 54 95": 72946,
      "mean difference smd": 43763,
      "rr 33 95": 72920,
      "treatment adverse events": 82435,
      "open label study": 51184,
      "low moderate quality": 42501,
      "people use opioids": 60435,
      "2017 march 2018": 2793,
      "medline embase psycinfo": 44739,
      "tolerability safety assessed": 81555,
      "aes adverse events": 8868,
      "adverse events saes": 8809,
      "effective placebo reducing": 27667,
      "relative risk rr": 69764,
      "recommendation assessment development": 68588,
      "development evaluation grade": 24225,
      "rr 17 95": 72905,
      "rr 73 95": 72968,
      "rr 55 95": 72949,
      "95 ci 48": 6304,
      "58 patients reported": 5163,
      "aim compare opioid": 9379,
      "prescribing rates patients": 64129,
      "cohort study adults": 17383,
      "administrative health records": 8401,
      "canada united kingdom": 14752,
      "dosages morphine milligram": 25768,
      "according centers disease": 7038,
      "10 year period": 960,
      "prescribing patterns patients": 64109,
      "multivariable regression models": 48335,
      "related risk factors": 69681,
      "inpatient postdischarge opioid": 39028,
      "postdischarge opioid use": 62641,
      "interquartile range 64": 39525,
      "year 95 confidence": 87429,
      "cm 95 ci": 17089,
      "additional risk factors": 7894,
      "risk factors increased": 72567,
      "factors increased opioid": 31104,
      "increased opioid prescriptions": 37965,
      "opioid prescriptions discharge": 52184,
      "discharge patients received": 25160,
      "months post discharge": 47462,
      "gynecologic surgery methods": 34489,
      "surgery single institution": 79589,
      "single institution implementation": 76109,
      "md anderson symptom": 43637,
      "anderson symptom inventory": 10892,
      "analyzed using linear": 10867,
      "83 women underwent": 5941,
      "difference opioid prescribing": 24643,
      "30 days discharge": 3727,
      "operative opioid prescribing": 51258,
      "provide comprehensive picture": 66045,
      "different opioid prescribing": 24897,
      "recommendations reduce opioid": 68611,
      "tolerability tapentadol extended": 81558,
      "analgesic opioid receptor": 10280,
      "receptor agonist norepinephrine": 68464,
      "objective current study": 50395,
      "50 250 mg": 4810,
      "250 mg twice": 3396,
      "therapy patients moderate": 81047,
      "methods randomized open": 45514,
      "open label phase": 51173,
      "phase iii study": 61299,
      "week open label": 86855,
      "open label treatment": 51188,
      "strong opioid analgesic": 77526,
      "mean pain intensity": 43826,
      "pain control previous": 56643,
      "randomized receive twice": 67180,
      "receive twice daily": 68085,
      "twice daily treatment": 83306,
      "tapentadol er 100": 80398,
      "morphine sustained release": 47947,
      "primary effectiveness endpoint": 65002,
      "endpoint proportion patients": 28898,
      "rescue medication day": 70950,
      "results tapentadol er": 72008,
      "patients tapentadol er": 60039,
      "overall safety profile": 54254,
      "safety profile similar": 73210,
      "previous studies tapentadol": 64923,
      "studies tapentadol er": 77864,
      "tapentadol er associated": 80399,
      "er associated lower": 29401,
      "associated lower incidence": 12327,
      "gastrointestinal treatment emergent": 32899,
      "overall results indicate": 54250,
      "strong opioids tapentadol": 77559,
      "safe effective pain": 73081,
      "pain control improved": 56620,
      "improved gastrointestinal tolerability": 37109,
      "morphine sr patients": 47927,
      "previous opioid use": 64911,
      "study aims assess": 77938,
      "treatment measured using": 82656,
      "male c57bl 6j": 43023,
      "interval ci 43": 39591,
      "ci 12 10": 16396,
      "aor 63 95": 11327,
      "provided clinically relevant": 66126,
      "used nationally representative": 85027,
      "nationally representative data": 48728,
      "40 95 ci": 4333,
      "likely report using": 41839,
      "aor 95 ci": 11339,
      "drug use aor": 26831,
      "ci conclusions relevance": 16524,
      "conclusions relevance findings": 19193,
      "relevance findings suggest": 70036,
      "findings underscore need": 31838,
      "pain common feature": 56567,
      "common feature childhood": 17755,
      "feature childhood adolescence": 31293,
      "childhood adolescence world": 16016,
      "adolescence world young": 8437,
      "world young people": 87321,
      "young people pain": 87721,
      "people pain chronic": 60420,
      "pain chronic world": 56543,
      "chronic world health": 16356,
      "organization guidelines pharmacological": 53768,
      "guidelines pharmacological treatments": 34459,
      "pharmacological treatments children": 61237,
      "treatments children persisting": 82900,
      "children persisting pain": 16067,
      "persisting pain acknowledge": 60936,
      "pain acknowledge pain": 56407,
      "acknowledge pain children": 7349,
      "pain children major": 56533,
      "children major public": 16056,
      "health concern high": 34693,
      "concern high significance": 18824,
      "high significance parts": 35183,
      "significance parts world": 75411,
      "past pain largely": 58472,
      "pain largely dismissed": 56996,
      "largely dismissed frequently": 41165,
      "dismissed frequently left": 25363,
      "frequently left untreated": 32557,
      "views children pain": 86228,
      "children pain changed": 16064,
      "pain changed time": 56523,
      "changed time relief": 15767,
      "time relief pain": 81356,
      "relief pain seen": 70163,
      "designed suite seven": 23849,
      "suite seven reviews": 79057,
      "seven reviews chronic": 74876,
      "reviews chronic non": 72404,
      "cancer pain looking": 14830,
      "pain looking antidepressants": 57035,
      "looking antidepressants antiepileptic": 42410,
      "antidepressants antiepileptic drugs": 11173,
      "antiepileptic drugs non": 11196,
      "drugs non steroidal": 27006,
      "inflammatory drugs opioids": 38569,
      "drugs opioids paracetamol": 27020,
      "review evidence children": 72298,
      "evidence children pain": 30172,
      "morbidity children adolescents": 47509,
      "children adolescents world": 16029,
      "adolescents world today": 8463,
      "associated pain major": 12374,
      "pain major health": 57045,
      "major health concern": 42950,
      "used worldwide treatment": 85192,
      "worldwide treatment pain": 87326,
      "opioid receptors central": 52270,
      "receptors central nervous": 68538,
      "central nervous mu": 15601,
      "mu kappa delta": 48112,
      "antagonists partial agonists": 11084,
      "opioids generally available": 52930,
      "generally available healthcare": 33011,
      "available healthcare settings": 12812,
      "countries access restricted": 20953,
      "include buprenorphine codeine": 37352,
      "oxycodone tramadol opioids": 56017,
      "tramadol opioids used": 82088,
      "relief children using": 70109,
      "children using opioids": 16080,
      "using opioids acceptable": 85541,
      "opioids acceptable grade": 52696,
      "acceptable grade adverse": 6981,
      "grade adverse effects": 33366,
      "effects recommended method": 28128,
      "dose gradually titrated": 25916,
      "gradually titrated effect": 33393,
      "effect child objectives": 27431,
      "child objectives assess": 16009,
      "adverse events opioids": 8782,
      "events opioids used": 30088,
      "pain children adolescents": 56529,
      "children adolescents aged": 16024,
      "adolescents aged birth": 8455,
      "aged birth 17": 9203,
      "birth 17 years": 13879,
      "17 years setting": 1995,
      "years setting search": 87667,
      "setting search methods": 74817,
      "trials central cochrane": 83108,
      "central cochrane library": 15582,
      "cochrane library medline": 17180,
      "medline ovid embase": 44743,
      "ovid embase ovid": 54373,
      "embase ovid inception": 28651,
      "reviews searched online": 72422,
      "searched online clinical": 74159,
      "trial registries selection": 83080,
      "registries selection criteria": 69401,
      "blinding dose route": 14028,
      "dose route treating": 26075,
      "children adolescents comparing": 16027,
      "adolescents comparing opioids": 8459,
      "comparing opioids placebo": 18353,
      "opioids placebo active": 53175,
      "assessed studies eligibility": 12064,
      "studies eligibility planned": 77708,
      "eligibility planned use": 28577,
      "planned use dichotomous": 61886,
      "use dichotomous data": 84306,
      "risk ratio number": 72649,
      "ratio number needed": 67782,
      "methods assessed grade": 45258,
      "assessed grade grading": 12007,
      "development evaluation planned": 24227,
      "evaluation planned create": 29962,
      "planned create summary": 61879,
      "create summary findings": 21144,
      "main results studies": 42862,
      "results studies eligible": 71971,
      "studies eligible inclusion": 77711,
      "rated quality evidence": 67536,
      "evidence low downgraded": 30222,
      "authors conclusions evidence": 12724,
      "controlled trials support": 20648,
      "support refute use": 79211,
      "refute use opioids": 69230,
      "efficacy harm use": 28275,
      "harm use opioids": 34584,
      "opioids morphine codeine": 53067,
      "children adolescents background": 16026,
      "opioid drug use": 51746,
      "methadone buprenorphine buprenorphine": 45050,
      "buprenorphine naloxone treatment": 14567,
      "58 95 ci": 5157,
      "95 ci 42": 6293,
      "ci 42 79": 16450,
      "checked reference lists": 15943,
      "criteria included rcts": 21202,
      "versus non opioid": 86134,
      "studies compared buprenorphine": 77668,
      "low certainty evidence": 42456,
      "participants low certainty": 58321,
      "substance use measured": 78818,
      "moderate certainty evidence": 47139,
      "opioid use mean": 52533,
      "mean difference 41": 43756,
      "rr 13 95": 72896,
      "rr 66 95": 72962,
      "rr 02 95": 72886,
      "95 ci 73": 6328,
      "rr 50 95": 72940,
      "treatment arms authors": 82449,
      "arms authors conclusions": 11686,
      "release fentanyl products": 69857,
      "safe use patients": 73107,
      "increased risk overdose": 38018,
      "insurance claims data": 39143,
      "medical pharmacy claims": 44382,
      "31 2016 data": 3850,
      "days continuous enrollment": 22502,
      "commercial medicare advantage": 17712,
      "medicare advantage insurance": 44434,
      "prescription 14 days": 64151,
      "conclusions relevance cohort": 19189,
      "relevance cohort study": 70030,
      "potentially inappropriate prescribing": 63260,
      "risk adverse outcomes": 72517,
      "monthly past months": 47420,
      "drug use drug": 26833,
      "use drug treatment": 84346,
      "treatment characteristics results": 82477,
      "opioid epidemic led": 51773,
      "high dose opioids": 35088,
      "opioid use studies": 52596,
      "risk factors long": 72569,
      "factors long term": 31116,
      "adult patients cancer": 8511,
      "identified mean age": 36446,
      "mean age 51": 43687,
      "years 57 female": 87547,
      "respectively following opioid": 71196,
      "opioid users year": 52625,
      "aor 77 95": 11333,
      "aor 72 95": 11330,
      "background aims opioid": 13012,
      "properties deter abuse": 65707,
      "abuse abuse deterrent": 6640,
      "hydromorphone methadone oxycodone": 36190,
      "pain study conducted": 57874,
      "primary care centers": 64991,
      "randomized usual care": 67205,
      "12 months main": 1336,
      "measures primary outcomes": 44090,
      "patient reported outcomes": 58738,
      "minimal clinically important": 46571,
      "difference proportion participants": 24673,
      "measured self report": 43995,
      "mean age 61": 43695,
      "age 61 years": 9035,
      "12 month follow": 1331,
      "care groups group": 15026,
      "12 months opioid": 1337,
      "group odds ratio": 33877,
      "ratio 55 95": 67743,
      "participants intervention group": 58319,
      "group received additional": 33949,
      "additional medical care": 7868,
      "patient reported use": 58743,
      "pain interference daily": 56963,
      "pain management moderate": 57083,
      "objective aim work": 50373,
      "intravenous acetaminophen compared": 39811,
      "acetaminophen compared placebo": 7175,
      "placebo 24 hours": 61626,
      "severe pain abdominal": 74968,
      "laparoscopic surgery methods": 41111,
      "subjects aged 18": 78681,
      "aged 18 80": 9165,
      "enrolled open label": 29006,
      "pain intensity pi": 56929,
      "analog scale point": 10529,
      "pi pain relief": 61482,
      "pain relief pr": 57568,
      "sum pi differences": 79078,
      "spontaneous adverse event": 76752,
      "tests results total": 80864,
      "white mean sd": 87021,
      "contract research organization": 20202,
      "24 hours treatment": 3235,
      "compared combined placebo": 18111,
      "received iv acetaminophen": 68185,
      "emergent aes teaes": 28708,
      "analgesic efficacy compared": 10233,
      "efficacy compared placebo": 28239,
      "attention deficit hyperactivity": 12565,
      "deficit hyperactivity disorder": 23112,
      "blind randomised controlled": 13966,
      "secondary outcomes total": 74259,
      "treatment period percentage": 82755,
      "measures abuse liability": 44036,
      "ethics dissemination study": 29695,
      "dissemination study approved": 25521,
      "hospital sydney australia": 35648,
      "family members people": 31184,
      "members people use": 44783,
      "overdose deaths heroin": 54279,
      "100 250 mg": 987,
      "needle syringe programmes": 49052,
      "substitution therapy ost": 78880,
      "cochrane database systematic": 17172,
      "database systematic reviews": 22190,
      "health technology assessment": 34791,
      "cinahl web science": 16562,
      "cohort studies cross": 17380,
      "studies cross sectional": 77684,
      "cross sectional surveys": 21270,
      "case control studies": 15167,
      "risk bias domains": 72529,
      "person years follow": 60945,
      "50 95 confidence": 4826,
      "rr 79 95": 72981,
      "oxycontin controlled release oxycodone": 56131,
      "controlled release oxycodone hydrochloride": 20562,
      "purdue pharma stamford ct": 66503,
      "food drug administration fda": 32235,
      "moderate severe chronic pain": 47177,
      "oxycodone clinical use 1917": 54785,
      "pain chronic non cancer": 56540,
      "non cancer related pain": 49587,
      "postoperative pain cancer pain": 62852,
      "neuropathic pain postherpetic neuralgia": 49254,
      "pain postherpetic neuralgia diabetic": 57392,
      "postherpetic neuralgia diabetic neuropathy": 62659,
      "typical mu opioid agonist": 83386,
      "mu opioid agonist oxycodone": 48119,
      "overdose including prescription opioids": 54295,
      "including prescription opioids heroin": 37666,
      "prescription opioids heroin illicitly": 64337,
      "opioids heroin illicitly manufactured": 52946,
      "heroin illicitly manufactured fentanyl": 35007,
      "opioids moderate severe pain": 53059,
      "treating moderate severe pain": 82396,
      "total joint arthroplasty pain": 81824,
      "long acting opioids oxycontin": 42305,
      "alternative pain management strategies": 9735,
      "reduce postoperative opioid consumption": 68883,
      "27 north american newspapers": 3504,
      "oxycontin purdue pharma stamford": 56177,
      "oxycodone semi synthetic opioid": 55883,
      "food drug administration approved": 32234,
      "gas chromatography nitrogen phosphorus": 32844,
      "chromatography nitrogen phosphorus detection": 16170,
      "gas chromatography mass spectrometry": 32842,
      "reformulated oxycontin oxycodone hcl": 69205,
      "oxycontin oxycodone hcl controlled": 56164,
      "oxycodone hcl controlled release": 55149,
      "healthy recreational opioid users": 34843,
      "aged 18 years older": 9169,
      "major public health issue": 42972,
      "brand extended release er": 14380,
      "extended release er oxycodone": 30869,
      "oxycodone semisynthetic opioid analgesic": 55887,
      "widely used clinical practice": 87063,
      "10 times potent oxycodone": 944,
      "prescribed treat chronic pain": 63995,
      "oxycodone hydrochloride extended release": 55183,
      "hydrochloride extended release tablets": 36019,
      "formulation abuse deterrent properties": 32330,
      "acute cancer chronic non": 7612,
      "cancer chronic non malignant": 14772,
      "chronic non malignant pain": 16224,
      "non malignant pain oxycodone": 49627,
      "using gas chromatography mass": 85403,
      "patient presented emergency department": 58721,
      "following total knee arthroplasty": 32217,
      "pain management surgical patients": 57126,
      "studies randomized controlled trials": 77823,
      "effects opioid induced constipation": 28038,
      "controlled release oxycodone oxycontin": 20564,
      "tapentadol hydrochloride extended release": 80418,
      "extended release er 50": 30861,
      "release er 50 mg": 69836,
      "faster onset pain relief": 31216,
      "controlled release cr oxycodone": 20540,
      "rates 100 000 population": 67544,
      "abuse liability prescription opioids": 6757,
      "new abuse deterrent formulations": 49307,
      "oxycodone ultra low dose": 56040,
      "physical dependence analgesic tolerance": 61389,
      "treatment moderate severe chronic": 82667,
      "ultra low dose naltrexone": 83419,
      "protein coupling opioid receptors": 65932,
      "background oxycodone strong opioid": 13137,
      "mu kappa opioid receptors": 48115,
      "relief moderate severe pain": 70146,
      "pain improving quality life": 56853,
      "conclusions oxycodone provides significant": 19149,
      "cr morphine cr oxycodone": 21071,
      "administered strong opioid strong": 8186,
      "strong opioid strong opioids": 77539,
      "opioid strong opioids ineffective": 52378,
      "patients severe pain patients": 59970,
      "morphine patients renal impairment": 47874,
      "oral controlled release oxycodone": 53508,
      "controlled release oxycodone formulation": 20560,
      "release oxycodone formulation introduced": 69940,
      "combination prolonged release oxycodone": 17607,
      "prolonged release oxycodone prolonged": 65631,
      "release oxycodone prolonged release": 69973,
      "oxycodone prolonged release naloxone": 55775,
      "oxycodone patients cancer pain": 55654,
      "non steroidal anti inflammatory": 49688,
      "steroidal anti inflammatory drugs": 77345,
      "anti inflammatory drugs nsaids": 11130,
      "inflammatory drugs nsaids effective": 38566,
      "immediate release ir oral": 36722,
      "immediate release controlled release": 36712,
      "controlled release long acting": 20546,
      "release long acting opioid": 69888,
      "long acting opioid analgesics": 42295,
      "control acute postoperative pain": 20271,
      "using nonlinear mixed effects": 85519,
      "using total body weight": 85645,
      "2010 introduction abuse deterrent": 2562,
      "oxycontin misuse prior reformulation": 56151,
      "development abuse deterrent formulations": 24210,
      "abuse deterrent formulations strategy": 6693,
      "abuse deterrent formulation oxycodone": 6689,
      "program researched abuse diversion": 65543,
      "researched abuse diversion addiction": 71042,
      "abuse diversion addiction related": 6711,
      "diversion addiction related surveillance": 25590,
      "addiction related surveillance radars": 7762,
      "related surveillance radars used": 69692,
      "oxycodone strong opioid agonist": 55941,
      "objectives assess analgesic efficacy": 50544,
      "assess analgesic efficacy adverse": 11909,
      "analgesic efficacy adverse events": 10228,
      "searched central medline embase": 74140,
      "international clinical trials registry": 39479,
      "clinical trials registry platform": 16961,
      "data selection criteria included": 22103,
      "selection criteria included randomised": 74409,
      "criteria included randomised controlled": 21201,
      "included randomised controlled trials": 37534,
      "randomised controlled trials rcts": 67018,
      "placebo active comparator data": 61650,
      "active comparator data collection": 7490,
      "comparator data collection analysis": 17994,
      "data collection analysis review": 21916,
      "collection analysis review authors": 17499,
      "analysis review authors independently": 10759,
      "review authors independently extracted": 72262,
      "authors independently extracted efficacy": 12739,
      "independently extracted efficacy adverse": 38182,
      "extracted efficacy adverse event": 30957,
      "efficacy adverse event data": 28219,
      "adverse event data examined": 8708,
      "event data examined issues": 29983,
      "data examined issues study": 21963,
      "examined issues study quality": 30387,
      "main results included studies": 42859,
      "observation carried forward locf": 50596,
      "carried forward locf imputation": 15138,
      "weeks low quality evidence": 86923,
      "low quality evidence adverse": 42543,
      "quality evidence adverse events": 66690,
      "number needed treat additional": 50185,
      "needed treat additional harmful": 49043,
      "95 confidence interval ci": 6394,
      "confidence interval ci 18": 19467,
      "interval ci 18 23": 39585,
      "did differ significantly groups": 24438,
      "03 45 low quality": 408,
      "45 low quality evidence": 4588,
      "pharmacokinetic pharmacodynamic pk pd": 61136,
      "end tidal carbon dioxide": 28829,
      "opioid use opioid related": 52552,
      "emergency department ed visits": 28679,
      "substance use disorder conclusions": 78812,
      "12 18 24 hours": 1221,
      "prescription opioids oxycodone hydrocodone": 64356,
      "design secondary data analysis": 23795,
      "medicaid beneficiaries study period": 44327,
      "opioid receptor mor agonist": 52262,
      "injections oxycodone mg kg": 38979,
      "oxycodone mg kg increased": 55423,
      "mg kg increased locomotor": 45983,
      "kg increased locomotor activity": 40739,
      "methods healthy male volunteers": 45346,
      "included randomized double blind": 37539,
      "placebo controlled cross study": 61679,
      "mg extended release oxycodone": 45888,
      "release oxycodone 10 mg": 69921,
      "10 mg extended release": 815,
      "functional magnetic resonance imaging": 32703,
      "objective aim study assess": 50368,
      "interrupted time series design": 39541,
      "results 27 month period": 71561,
      "95 ci 11 001": 6241,
      "background opioid analgesics used": 13107,
      "analgesics used treat pain": 10516,
      "conducted randomized placebo controlled": 19397,
      "randomized placebo controlled double": 67152,
      "placebo controlled double blind": 61686,
      "controlled double blind crossover": 20486,
      "double blind crossover study": 26350,
      "60 120 180 minutes": 5222,
      "period mean difference 95": 60746,
      "mean difference 95 ci": 43758,
      "significant public health concern": 75609,
      "mu opioid receptor mor": 48131,
      "affect analgesic efficacy oxycodone": 8896,
      "data provide new information": 22074,
      "opioid na\u00efve patients study": 51991,
      "patients study aimed determine": 60005,
      "study aimed determine efficacy": 77926,
      "opioid na\u00efve cancer patients": 51978,
      "cancer patients performance status": 14887,
      "increased risk respiratory depression": 38022,
      "given patients required opioids": 33188,
      "proportion patients receiving oxycodone": 65771,
      "long term opioid use": 42342,
      "does paper add paper": 25687,
      "oral controlled release tablet": 53509,
      "gas chromatographic mass spectrometric": 32839,
      "20 mg 40 mg": 2334,
      "human abuse potential pharmacokinetics": 35940,
      "oxycodone deterx xtampza er": 54957,
      "design randomized double blind": 23774,
      "dummy active placebo controlled": 27129,
      "placebo controlled single dose": 61700,
      "study setting clinical research": 78488,
      "adult nondependent recreational opioid": 8501,
      "nondependent recreational opioid users": 49731,
      "crushed immediate release ir": 21334,
      "immediate release ir oxycodone": 36723,
      "release ir oxycodone solution": 69881,
      "100 point visual analog": 1019,
      "significantly lower abuse potential": 75776,
      "public health crisis united": 66385,
      "health crisis united states": 34704,
      "male swiss webster mice": 43063,
      "potent opioid receptor agonist": 63112,
      "blood brain barrier permeability": 14110,
      "mg kg day oxycodone": 45966,
      "kg day oxycodone days": 40712,
      "oxycodone mg kg morphine": 55427,
      "mg kg morphine 10": 46000,
      "morphine 10 mg kg": 47533,
      "tolerance oxycodone cross tolerance": 81598,
      "resting state functional connectivity": 71445,
      "randomized double blind placebo": 67107,
      "double blind placebo controlled": 26367,
      "blind placebo controlled dose": 13954,
      "10 mg 20 mg": 793,
      "mg 20 mg oxycodone": 45727,
      "conditioned place preference paradigm": 19300,
      "saline oxycodone mg kg": 73267,
      "oxycodone 30 mg oxycodone": 54553,
      "adverse effects respiratory depression": 8696,
      "oxycodone widely used treat": 56098,
      "brain microvascular endothelial cells": 14351,
      "cells dose dependent manner": 15496,
      "open label parallel group": 51171,
      "label parallel group randomized": 40984,
      "oral immediate release oxycodone": 53550,
      "intensity numeric rating scale": 39277,
      "numeric rating scale 10": 50297,
      "points 95 confidence interval": 62125,
      "95 confidence interval 11": 6382,
      "difference groups primary outcome": 24620,
      "enrolled randomized double blinded": 29018,
      "unexpected adverse events reported": 83719,
      "adverse events reported conclusions": 8802,
      "clinical trial registration eudract": 16934,
      "managing acute postoperative pain": 43283,
      "patient controlled intravenous analgesia": 58597,
      "controlled intravenous analgesia pcia": 20502,
      "embase cochrane central register": 28643,
      "cochrane central register controlled": 17168,
      "central register controlled trials": 15613,
      "randomized controlled trials rcts": 67084,
      "numerical rating scale scores": 50319,
      "55 95 ci 14": 5071,
      "interrupted time series analysis": 39540,
      "average number oxycodone tablets": 12906,
      "05 mg kg oxycodone": 528,
      "mg kg oxycodone hydrochloride": 46011,
      "concentrations oxycodone metabolites noroxycodone": 18792,
      "oxycodone metabolites noroxycodone oxymorphone": 55390,
      "elimination half life oxycodone": 28614,
      "oxycodone hydrochloride hcl extended": 55187,
      "hydrochloride hcl extended release": 36025,
      "hcl extended release er": 34639,
      "extended release er tablets": 30872,
      "oxycodone hcl er tablets": 55152,
      "recent years united states": 68438,
      "100 ng ml oxycodone": 1006,
      "likely report prescription opioid": 41838,
      "effect oxycodone developing brain": 27518,
      "opioid treatment moderate severe": 52448,
      "treatment moderate severe pain": 82668,
      "oxycodone lower pain scores": 55346,
      "lower pain scores needed": 42671,
      "fewer adverse effects compared": 31631,
      "prescription opioid abuse continues": 64275,
      "opioid abuse continues public": 51366,
      "abuse continues public health": 6670,
      "continues public health concern": 20151,
      "randomized double blind double": 67102,
      "double blind double dummy": 26355,
      "blind double dummy active": 13937,
      "double dummy active placebo": 26405,
      "active placebo controlled way": 7533,
      "placebo controlled way crossover": 61713,
      "human abuse potential study": 35942,
      "100 mm visual analog": 1001,
      "mm visual analog scale": 46941,
      "visual analog scale primary": 86310,
      "drug overall drug liking": 26730,
      "overall drug liking drug": 54197,
      "drug liking drug high": 26680,
      "liking drug high good": 41858,
      "peak oxycodone plasma concentrations": 60314,
      "objective objective study evaluate": 50452,
      "drug discrimination double blind": 26588,
      "mg immediate release ir": 45919,
      "40 mg controlled release": 4346,
      "mg controlled release cr": 45837,
      "ratings drug liking high": 67696,
      "12 hour dosing interval": 1289,
      "adverse events consistent opioid": 8746,
      "drug delivery central nervous": 26578,
      "15 30 60 90": 1690,
      "drug liking good effect": 26683,
      "oxycodone naloxone controlled release": 55498,
      "department veterans affairs dva": 23447,
      "performed retrospective cohort study": 60628,
      "tail flick hot plate": 80244,
      "determined male swiss webster": 24074,
      "objective objective study investigate": 50454,
      "methods randomized placebo controlled": 45517,
      "way crossover study healthy": 86776,
      "crossover study healthy male": 21306,
      "healthy male volunteers administered": 34829,
      "cr665 36 mg kg": 21119,
      "mg kg intravenous oxycodone": 45990,
      "compartment model oxycodone kinetics": 18398,
      "model oxycodone kinetics best": 47070,
      "oxycodone kinetics best described": 55327,
      "kinetics best described compartment": 40844,
      "best described compartment model": 13688,
      "tapentadol immediate release ir": 80421,
      "treatment moderate severe acute": 82666,
      "moderate severe acute pain": 47167,
      "severe acute pain clinical": 74904,
      "improved tolerability compared oxycodone": 37137,
      "tolerability compared oxycodone ir": 81524,
      "doses providing comparable analgesia": 26258,
      "tapentadol ir 100 mg": 80427,
      "tapentadol ir 50 mg": 80430,
      "ir 50 mg compared": 40212,
      "50 mg compared oxycodone": 4853,
      "oxycodone ir 10 mg": 55306,
      "ir 10 mg treatment": 40195,
      "10 mg treatment acute": 853,
      "occurrence opioid related adverse": 50863,
      "opioid related adverse events": 52304,
      "number quality adjusted life": 50247,
      "tapentadol ir oxycodone ir": 80433,
      "incremental cost effectiveness ratios": 38146,
      "suggest doses providing comparable": 78991,
      "providing comparable analgesia tapentadol": 66255,
      "oxycodone immediate release ir": 55232,
      "methods retrospective cross sectional": 45542,
      "opioid use opioid na\u00efve": 52551,
      "use opioid na\u00efve patients": 84549,
      "opioids non cancer pain": 53095,
      "chronic non cancer pain": 16222,
      "er vs oxycodone cr": 29483,
      "treatment chronic non cancer": 82484,
      "non cancer pain cncp": 49581,
      "patients having moderate severe": 59351,
      "treatment emergent adverse event": 82573,
      "emergent adverse event teae": 28701,
      "proportion patients achieving adequate": 65763,
      "patients achieving adequate pain": 58931,
      "achieving adequate pain relief": 7335,
      "achieve adequate pain relief": 7293,
      "efficacy safety long term": 28365,
      "setting patients consecutive patients": 74809,
      "according world health organization": 7068,
      "world health organization guidelines": 87310,
      "efficacy safety opioid therapy": 28368,
      "visual analog scale vas": 86317,
      "analog scale vas pain": 10540,
      "pittsburgh sleep quality index": 61569,
      "sleep quality index psqi": 76234,
      "subject double blind placebo": 78628,
      "blind placebo controlled inpatient": 13956,
      "oxycodone extended release er": 55061,
      "oxycodone er immediate release": 55039,
      "phase randomized double blind": 61316,
      "dummy placebo active controlled": 27134,
      "placebo active controlled way": 61655,
      "active controlled way crossover": 7505,
      "controlled way crossover study": 20653,
      "men women aged 18": 44806,
      "oxycodone ir 40 mg": 55308,
      "outcome measures primary endpoint": 53951,
      "primary endpoint drug liking": 65024,
      "abuse potential compared oxycodone": 6816,
      "parameters primary endpoint drug": 58172,
      "pellets extended release oxycodone": 60379,
      "methods randomized double blind": 45511,
      "adverse events associated use": 8731,
      "quantitative sensory testing qst": 66811,
      "analgesic effects oral oxycodone": 10220,
      "cold pressor test cpt": 17427,
      "randomized double blind active": 67097,
      "randomized receive 20 mg": 67167,
      "single intravenous injection oxycodone": 76115,
      "american society anesthesiologists class": 9804,
      "randomized controlled trial patients": 67076,
      "controlled trial patients randomized": 20615,
      "score group significantly lower": 73750,
      "group significantly lower group": 34019,
      "significantly lower group hours": 75789,
      "significantly higher group group": 75728,
      "extended release long acting": 30883,
      "release long acting er": 69887,
      "long acting er la": 42286,
      "risk evaluation mitigation strategies": 72557,
      "evaluation mitigation strategies rems": 29958,
      "extended release oxycodone ero": 30894,
      "er la opioid analgesics": 29433,
      "background opioids commonly used": 13120,
      "commonly used manage chronic": 17883,
      "used manage chronic pain": 84995,
      "opioids effective reducing pain": 52875,
      "tapentadol extended release er": 80411,
      "oxycodone controlled release cr": 54883,
      "schedule ii long acting": 73619,
      "health care costs patients": 34677,
      "tapentadol er versus oxycodone": 80408,
      "er versus oxycodone cr": 29480,
      "aged 23 71 years": 9179,
      "oxycodone mg kg iv": 55425,
      "double blind active control": 26338,
      "performed gas chromatography mass": 60593,
      "case report demonstrates unusual": 15190,
      "dose immediate release oxycodone": 25929,
      "placebo 10 mg oxycodone": 61615,
      "10 mg oxycodone plasma": 837,
      "abuse potential pharmacokinetics pharmacodynamics": 6827,
      "potential pharmacokinetics pharmacodynamics safety": 63208,
      "hcl controlled release tablets": 34633,
      "controlled release tablets orf": 20574,
      "placebo randomized double blind": 61809,
      "placebo controlled crossover study": 61682,
      "controlled crossover study enrolled": 20480,
      "crossover study enrolled healthy": 21304,
      "study enrolled healthy adult": 78154,
      "dependent recreational opioid users": 23533,
      "visual analog scales vas": 86319,
      "adverse events vital signs": 8825,
      "vital signs laboratory tests": 86345,
      "misuse abuse diversion purpose": 46707,
      "retrospective review medical records": 72161,
      "drug abuse warning network": 26510,
      "moderate severe cancer pain": 47172,
      "study assess relationship oxycodone": 77969,
      "patients cancer pain methods": 59045,
      "cancer pain methods patients": 14836,
      "serum concentrations oxycodone metabolites": 74696,
      "pain assessed using brief": 56465,
      "assessed using brief pain": 12084,
      "using brief pain inventory": 85332,
      "brief pain inventory bpi": 14431,
      "c30 used assess symptoms": 14647,
      "used assess symptoms tiredness": 84854,
      "assess symptoms tiredness nausea": 11968,
      "pain intensity nausea tiredness": 56916,
      "intensity nausea tiredness cognitive": 39272,
      "nausea tiredness cognitive function": 48787,
      "positive urine drug screens": 62505,
      "opioid dependent patients receiving": 51708,
      "patients receiving methadone maintenance": 59845,
      "receiving methadone maintenance therapy": 68353,
      "methadone maintenance therapy mmt": 45095,
      "14 hydroxy methoxy 17": 1600,
      "oxycodone potent antinociceptive effects": 55716,
      "hot plate tail flick": 35685,
      "plate tail flick assays": 61973,
      "acting mu opioid receptor": 7393,
      "mu opioid receptor agonist": 48125,
      "mu opioid receptors provide": 48135,
      "alo 02 abuse deterrent": 9656,
      "02 abuse deterrent formulation": 360,
      "double blind placebo active": 26366,
      "blind placebo active controlled": 13951,
      "healthy nondependent recreational opioid": 34835,
      "recreational opioid users following": 68782,
      "measured visual analog scales": 44011,
      "adverse events occurred frequently": 8780,
      "tolerability controlled release oxycodone": 81528,
      "controlled release oxycodone treatment": 20570,
      "methods conducted prospective observational": 45280,
      "patients moderate severe pain": 59525,
      "patients received general anesthesia": 59781,
      "controlled release oxycodone 20": 20554,
      "release oxycodone 20 mg": 69923,
      "oxycodone 20 mg 12": 54532,
      "adverse events nausea vomiting": 8776,
      "events nausea vomiting dizziness": 30076,
      "conclusion controlled release oxycodone": 18882,
      "established oxycodone twice daily": 29591,
      "oxycodone twice daily otd": 56036,
      "did reach statistical significance": 24485,
      "evaluated efficacy safety prolonged": 29881,
      "efficacy safety prolonged release": 28382,
      "intensity numerical rating scale": 39280,
      "numerical rating scale nrs": 50314,
      "low dose oxn pr": 42480,
      "weeks primary efficacy measure": 86946,
      "primary efficacy measure pain": 65011,
      "bowel function index bfi": 14277,
      "bowel function constipation symptoms": 14272,
      "function constipation symptoms measured": 32641,
      "opioids used treat pain": 53375,
      "combination oxycodone oc acetaminophen": 17591,
      "oxycodone oc acetaminophen apap": 55554,
      "oc acetaminophen apap analgesic": 50798,
      "acetaminophen apap analgesic immediate": 7154,
      "apap analgesic immediate release": 11350,
      "analgesic immediate release extended": 10259,
      "immediate release extended release": 36715,
      "release extended release er": 69855,
      "extended release er components": 30864,
      "moderate severe pain using": 47207,
      "research design methods randomized": 71001,
      "blind placebo controlled trial": 13962,
      "pain intensity score 10": 56943,
      "10 numerical rating scale": 881,
      "main outcome measures primary": 42844,
      "outcome measures primary efficacy": 53950,
      "measures primary efficacy endpoint": 44086,
      "endpoint summed pain intensity": 28906,
      "summed pain intensity difference": 79117,
      "pain intensity difference 48": 56898,
      "intensity difference 48 hours": 39246,
      "total pain relief totpar": 81880,
      "30 reduction pain intensity": 3794,
      "oxycodone oral controlled release": 55580,
      "oral controlled release morphine": 53507,
      "randomized double blind trial": 67110,
      "moderate severe pain following": 47198,
      "received single oral doses": 68278,
      "doses controlled release oxycodone": 26165,
      "controlled release oxycodone controlled": 20556,
      "release oxycodone controlled release": 69928,
      "oxycodone controlled release morphine": 54884,
      "oral morphine oral oxycodone": 53589,
      "time course plasma concentrations": 81232,
      "cytochrome p450 cyp 3a": 21658,
      "chronic pain leading cause": 16283,
      "pain leading cause disability": 57003,
      "effects main reason discontinuation": 27978,
      "treatment tapentadol er oxycodone": 82872,
      "discontinuation rate adverse events": 25229,
      "quality adjusted life years": 66676,
      "objectives primary objective study": 50583,
      "primary objective study determine": 65049,
      "open label single dose": 51182,
      "way crossover study conducted": 86775,
      "crossover study conducted healthy": 21301,
      "high fat high calorie": 35102,
      "mean sd age 32": 43858,
      "treatment emergent adverse events": 82574,
      "assess clinical efficacy controlled": 11918,
      "clinical efficacy controlled release": 16803,
      "efficacy controlled release oxycodone": 28243,
      "controlled release oxycodone cro": 20558,
      "placebo controlled double blinded": 61687,
      "controlled double blinded study": 20489,
      "asa physical status iii": 11820,
      "controlled release oxycodone group": 20561,
      "iv patient controlled analgesia": 40398,
      "patient controlled analgesia pca": 58589,
      "controlled analgesia pca device": 20459,
      "main outcome measures area": 42840,
      "outcome measures area curve": 53934,
      "measures area curve auc": 44046,
      "vas scores rest significantly": 86028,
      "scores rest significantly lower": 73976,
      "oxycodone human experimental pain": 55170,
      "oral oxycodone 15 mg": 53618,
      "oxycodone 15 mg placebo": 54523,
      "skin heat muscle pressure": 76203,
      "15 30 45 60": 1688,
      "60 90 120 minutes": 5241,
      "minutes drug administration results": 46647,
      "drug administration results oxycodone": 26528,
      "peripheral analgesic effect oxycodone": 60860,
      "fewer opioid related adverse": 31653,
      "management acute moderate severe": 43143,
      "acute moderate severe pain": 7641,
      "pain design randomized double": 56698,
      "11 point numerical pain": 1147,
      "point numerical pain rating": 62095,
      "numerical pain rating scale": 50309,
      "sum pain intensity differences": 79076,
      "pain intensity differences baseline": 56903,
      "immediate release ir formulations": 36721,
      "methods patients 18 years": 45426,
      "illicit opioids heroin fentanyl": 36647,
      "physiologically based pharmacokinetic pbpk": 61473,
      "based pharmacokinetic pbpk modeling": 13356,
      "oxycodone widely used opioid": 56097,
      "widely used opioid pain": 87069,
      "used opioid pain management": 85048,
      "following intravenous oral administration": 32150,
      "management acute postoperative pain": 43146,
      "randomized double blind parallel": 67105,
      "end surgery mg kg": 28822,
      "adequate postoperative pain relief": 7972,
      "face legs activity consolability": 31018,
      "legs activity consolability flacc": 41392,
      "activity consolability flacc score": 7563,
      "consolability flacc score 10": 19732,
      "post anesthesia care unit": 62559,
      "anesthesia care unit pacu": 10904,
      "patients oxycodone group showed": 59615,
      "patients trial registration study": 60079,
      "trial registration study registered": 83077,
      "www chictr org cn": 87391,
      "mg kg oral oxycodone": 46006,
      "kg oral oxycodone hydrochloride": 40773,
      "administration produced significant dose": 8350,
      "produced significant dose related": 65407,
      "tapentadol mu opioid receptor": 80443,
      "opioid receptor agonist noradrenaline": 52239,
      "receptor agonist noradrenaline reuptake": 68463,
      "agonist noradrenaline reuptake inhibitor": 9296,
      "selective mu opioid receptor": 74434,
      "methods healthy volunteers randomized": 45352,
      "healthy volunteers randomized receive": 34859,
      "mg oxycodone 20 mg": 46099,
      "double blind randomized design": 26375,
      "oxycodone 20 mg significantly": 54534,
      "case 35 year old": 15155,
      "extended release oxycodone hydrochloride": 30896,
      "release oxycodone hydrochloride oxycontin": 69947,
      "oral transmucosal fentanyl citrate": 53680,
      "oral oxycodone mg kg": 53634,
      "year old male patient": 87462,
      "patients chronic non cancer": 59073,
      "safety tolerability transdermal oxycodone": 73237,
      "tolerability transdermal oxycodone patch": 81562,
      "transdermal oxycodone patch containing": 82165,
      "oxycodone patch containing tocopheryl": 55648,
      "patch containing tocopheryl phosphate": 58488,
      "containing tocopheryl phosphate mixture": 20087,
      "tocopheryl phosphate mixture tpm": 81508,
      "phosphate mixture tpm patients": 61368,
      "mu opioid receptor selective": 48132,
      "opioid receptor selective agonists": 52267,
      "analgesic effects oxycodone human": 10222,
      "subject randomized double blind": 78636,
      "persistent postoperative opioid use": 60928,
      "modified release immediate release": 47244,
      "study objective compare efficacy": 78332,
      "objective compare efficacy effects": 50389,
      "surgery design randomized double": 79373,
      "randomized double blind study": 67108,
      "double blind study setting": 26384,
      "department surgery helsinki university": 23444,
      "surgery helsinki university central": 79414,
      "helsinki university central hospital": 34922,
      "university central hospital patients": 83859,
      "asa physical status ii": 11819,
      "dose ratio morphine oxycodone": 26037,
      "remained normal limits conclusions": 70268,
      "acute post operative pain": 7684,
      "post operative pain analgesic": 62602,
      "fentanyl group group oxycodone": 31485,
      "group group oxycodone group": 33800,
      "group oxycodone group group": 33889,
      "group group 30 patients": 33793,
      "\u03bcg kg patients group": 87794,
      "oxycodone mg kg patients": 55428,
      "mean arterial pressure map": 43719,
      "pulse oxygen saturation spo": 66474,
      "incidence effects nausea vomiting": 37273,
      "nausea vomiting respiratory depression": 48811,
      "assessed visual analogue scale": 12095,
      "visual analogue scale vas": 86328,
      "analogue scale vas scores": 10562,
      "05 conclusion combination oxycodone": 501,
      "conclusion combination oxycodone dexmedetomidine": 18873,
      "health related quality life": 34766,
      "management moderate severe chronic": 43210,
      "searched identify randomized controlled": 74152,
      "identify randomized controlled trials": 36532,
      "randomized controlled trials investigating": 67083,
      "oxycodone naloxone treatment patients": 55523,
      "patient assessment constipation symptoms": 58542,
      "15 mg kg oxycodone": 1760,
      "public health issue australia": 66392,
      "rise prescription opioid use": 72494,
      "prescription opioid use associated": 64316,
      "subject received 10 mg": 78640,
      "10 mg immediate release": 820,
      "mg immediate release oxycodone": 45920,
      "peak plasma oxycodone concentrations": 60322,
      "oxycodone concentrations max time": 54833,
      "peak oxycodone concentrations max": 60312,
      "statistically significant difference groups": 77209,
      "overall satisfaction pain control": 54258,
      "plasma concentrations oxycodone noroxycodone": 61918,
      "concentrations oxycodone noroxycodone oxymorphone": 18794,
      "oxycodone noroxycodone oxymorphone noroxymorphone": 55541,
      "objective compare efficacy safety": 50390,
      "immediate release morphine oxycodone": 36725,
      "moderate severe postoperative pain": 47211,
      "oxycodone mg morphine mg": 55430,
      "pain intensity differences 24": 56902,
      "intensity differences 24 hours": 39251,
      "hours dose study medication": 35769,
      "patients moderate severe nausea": 59523,
      "severe adverse events aes": 74910,
      "management moderate severe acute": 43208,
      "oxycodone commonly used analgesics": 54813,
      "randomized double blind cross": 67100,
      "double blind cross study": 26347,
      "aim study assess potential": 9407,
      "opioid receptor agonist oxycodone": 52241,
      "phases intervals weeks conducted": 61328,
      "intervals weeks conducted 12": 39620,
      "weeks conducted 12 healthy": 86901,
      "mg day 14 oxycodone": 45854,
      "self reported drug effect": 74495,
      "reported drug effect oxycodone": 70536,
      "greatly reduced plasma concentrations": 33514,
      "plasma concentrations oral oxycodone": 61915,
      "treating patients chronic pain": 82408,
      "patients chronic pain objective": 59083,
      "opioids chronic nonmalignant pain": 52781,
      "osmotic controlled release oral": 53852,
      "controlled release oral delivery": 20551,
      "release oral delivery oros": 69911,
      "oral delivery oros hydromorphone": 53515,
      "oros hydromorphone er oxycodone": 53804,
      "daily morphine equivalent dose": 21764,
      "adjusted life years qalys": 8034,
      "incremental cost effectiveness ratio": 38145,
      "cost effectiveness ratio icer": 20876,
      "oxycodone cr controlled release": 54896,
      "phase iii clinical trials": 61295,
      "patients severe non malignant": 59967,
      "tapentadol prolonged release pr": 80465,
      "release cr oxycodone cr": 69823,
      "morphine cr oxycodone cr": 47634,
      "gastrointestinal adverse events tapentadol": 32868,
      "tapentadol pr associated significantly": 80461,
      "associated significantly fewer adverse": 12436,
      "oxycodone commonly prescribed opioid": 54811,
      "pain little known pharmacokinetics": 57028,
      "data best described compartment": 21890,
      "best described compartment linear": 13687,
      "described compartment linear model": 23653,
      "clearance cl volume distribution": 16713,
      "healthy human subjects methods": 34820,
      "15 mg oxycodone hydrochloride": 1764,
      "measured high performance liquid": 43969,
      "high performance liquid chromatography": 35139,
      "performance liquid chromatography ms": 60558,
      "liquid chromatography ms ms": 42085,
      "approved food drug administration": 11539,
      "named researched abuse diversion": 48557,
      "results indicate prescription drug": 71731,
      "indicate prescription drug abuse": 38230,
      "prescription drug abuse prevalent": 64206,
      "use drugs treatment pain": 84349,
      "oral oxycodone 20 mg": 53620,
      "eu clinical trials register": 29721,
      "treatment cancer induced bone": 82465,
      "cancer induced bone pain": 14790,
      "induced bone pain cibp": 38391,
      "bone pain cibp challenging": 14240,
      "used treat cibp lack": 85167,
      "treat cibp lack understanding": 82293,
      "cibp group oxy group": 16546,
      "spinal dorsal horn neurons": 76715,
      "non cancer neuropathic pain": 49577,
      "opioids morphine oxycodone hydromorphone": 53076,
      "effective managing chronic pain": 27641,
      "sustained release morphine oxycodone": 79789,
      "area plasma concentration time": 11636,
      "lower doses fewer effects": 42604,
      "methods patients undergoing outpatient": 45450,
      "opioid consumption results total": 51661,
      "patients did use opioids": 59195,
      "did use opioids postoperatively": 24516,
      "blind placebo controlled study": 13961,
      "commonly prescribed opioid oxycodone": 17866,
      "using session cumulative dosing": 85611,
      "session cumulative dosing procedure": 74732,
      "using cold pressor test": 85345,
      "positive subjective effects oxycodone": 62495,
      "positive subjective drug effects": 62493,
      "enhance analgesic effects oxycodone": 28952,
      "20 mg controlled release": 2336,
      "mg controlled release oxycodone": 45838,
      "randomized double blinded study": 67114,
      "american society anesthesiologists classification": 9805,
      "physical status patients undergoing": 61417,
      "undergoing surgery breast cancer": 83581,
      "surgery patients randomly allocated": 79514,
      "patients randomly allocated groups": 59747,
      "randomly allocated groups receiving": 67213,
      "significant differences treatment groups": 75521,
      "acquity uplc class coupled": 7366,
      "uplc class coupled waters": 83994,
      "class coupled waters xevo": 16656,
      "coupled waters xevo tqd": 20983,
      "drug drug interactions ddis": 26605,
      "quantitative real time polymerase": 66807,
      "real time polymerase chain": 68005,
      "time polymerase chain reaction": 81344,
      "using metacore computational platform": 85491,
      "oxycodone major metabolites noroxycodone": 55359,
      "major metabolites noroxycodone oxymorphone": 42956,
      "versus oxycodone controlled release": 86142,
      "randomized double blind crossover": 67101,
      "addiction research center inventory": 7766,
      "produce synergistic antinociceptive effects": 65372,
      "guidelines management chronic pain": 34447,
      "use controlled release cr": 84276,
      "opioid induced constipation oic": 51859,
      "oxycodone naloxone compared oxycodone": 55496,
      "aged 15 64 years": 9146,
      "opioids chronic non cancer": 52777,
      "emergency department visits hospital": 28686,
      "study period rate opioid": 78394,
      "significant change rates opioid": 75439,
      "impact educational intervention ed": 36810,
      "analgesic effectiveness safety new": 10212,
      "safety new oxycodone 10": 73172,
      "new oxycodone 10 mg": 49353,
      "oxycodone 10 mg acetaminophen": 54497,
      "10 mg acetaminophen 325": 799,
      "mg acetaminophen 325 mg": 45788,
      "acetaminophen 325 mg percocet": 7129,
      "nonsteroidal anti inflammatory drugs": 49856,
      "men women mean age": 44809,
      "mean age 52 years": 43689,
      "clinically meaningful pain relief": 16986,
      "study discontinuations adverse events": 78124,
      "pain interference quality life": 56965,
      "effective treatment moderate severe": 27718,
      "pain relief tolerable effects": 57591,
      "chronic pain patients experience": 16300,
      "develop persistent opioid use": 24155,
      "ethics dissemination ethics approval": 29694,
      "dissemination ethics approval obtained": 25519,
      "monash university human research": 47302,
      "university human research ethics": 83868,
      "human research ethics committee": 35971,
      "present project findings peer": 64629,
      "project findings peer reviewed": 65593,
      "findings peer reviewed journal": 31806,
      "peer reviewed journal article": 60371,
      "37 year old man": 4209,
      "methods repeated cross sectional": 45526,
      "defined daily dose ddd": 23129,
      "objective aim study compare": 50369,
      "10 mg oxycodone naloxone": 836,
      "mg oxycodone naloxone 10": 46128,
      "oxycodone naloxone 10 mg": 55490,
      "continuous infusion 24 hours": 20171,
      "advanced cancer patients admitted": 8595,
      "eastern cooperative oncology group": 27287,
      "cooperative oncology group performance": 20752,
      "oncology group performance status": 51075,
      "occurrence adverse events aes": 50856,
      "used treat acute pain": 85163,
      "demonstrate analgesic efficacy comparable": 23313,
      "provide effective relief moderate": 66058,
      "effective relief moderate severe": 27691,
      "medical use prescription opioids": 44423,
      "non medical use abuse": 49632,
      "release long acting opioids": 69889,
      "post operative day pod": 62592,
      "primary endpoint cumulative oxycodone": 65022,
      "adverse effects documented results": 8655,
      "reported significantly lower pain": 70651,
      "significantly lower pain scores": 75801,
      "hypothesized maternal treatment oxycodone": 36311,
      "maternal treatment oxycodone oxy": 43530,
      "treatment oxycodone oxy primary": 82730,
      "oxycodone oxy primary opioid": 55603,
      "oxy primary opioid center": 54464,
      "primary opioid center current": 65052,
      "opioid center current crisis": 51571,
      "female mice treated daily": 31368,
      "mice treated daily mg": 46323,
      "treated daily mg oxy": 82335,
      "daily mg oxy kg": 21760,
      "mg oxy kg saline": 46092,
      "oxy kg saline solution": 54458,
      "kg saline solution control": 40801,
      "saline solution control ctl": 73274,
      "solution control ctl weeks": 76441,
      "genes encoding opioid receptors": 33061,
      "mu opioid receptor agonism": 48124,
      "opioid receptor agonism noradrenaline": 52236,
      "receptor agonism noradrenaline reuptake": 68458,
      "agonism noradrenaline reuptake inhibition": 9272,
      "expressed oral morphine equivalents": 30823,
      "oral morphine equivalents ome": 53582,
      "immediate release sustained release": 36737,
      "background aim study compare": 13009,
      "morphine oxycodone 10 mg": 47803,
      "group difference statistically significant": 33752,
      "women aged 18 years": 87202,
      "years moderate severe pain": 87620,
      "sum pain intensity difference": 79075,
      "pain intensity difference spid": 56900,
      "total morphine equivalent dose": 81843,
      "morphine equivalent dose med": 47660,
      "median time use rescue": 44293,
      "time use rescue medication": 81396,
      "morphine treatment visceral pain": 47964,
      "primary outcome pain relief": 65083,
      "opioid consumption pain scores": 51642,
      "consumption pain scores effects": 19980,
      "objective oxycodone widely used": 50462,
      "widely used opioid analgesic": 87068,
      "patients aged 20 40": 58974,
      "aged 20 40 60": 9175,
      "20 40 60 70": 2290,
      "40 60 70 70": 4327,
      "surgery plasma concentrations oxycodone": 79524,
      "liquid chromatography tandem mass": 42087,
      "chromatography tandem mass spectrometric": 16173,
      "tandem mass spectrometric method": 80360,
      "cytochrome p450 cyp 2d6": 21657,
      "glomerular filtration rate gfr": 33240,
      "filtration rate gfr estimated": 31738,
      "mean area plasma concentration": 43713,
      "plasma concentration time curve": 61907,
      "concentration time curve time": 18726,
      "time curve time zero": 81240,
      "curve time zero infinity": 21531,
      "time zero infinity auc": 81404,
      "60 70 70 80": 5232,
      "volume distribution steady state": 86394,
      "patients aged 70 years": 58978,
      "important titrate analgesic dose": 37038,
      "titrate analgesic dose individually": 81464,
      "analgesic dose individually particularly": 10182,
      "dose individually particularly elderly": 25936,
      "aged 18 55 years": 9160,
      "analyzed using liquid chromatography": 10869,
      "using liquid chromatography tandem": 85468,
      "chromatography tandem mass spectrometry": 16174,
      "area concentration time curve": 11624,
      "adverse events mild moderate": 8772,
      "events mild moderate intensity": 30070,
      "objectives assess effectiveness safety": 50546,
      "intensity visual analog scale": 39329,
      "treatment related adverse event": 82806,
      "long term treatment chronic": 42356,
      "treatment chronic noncancer pain": 82486,
      "cross sectional observational study": 21261,
      "completed survey main outcome": 18505,
      "nonsteroidal anti inflammatory drug": 49855,
      "anti inflammatory drug nsaid": 11125,
      "oxycodone semisynthetic opioid agonist": 55886,
      "oral fixed dose combination": 53535,
      "fixed dose combination oxycodone": 31877,
      "efficacy safety fixed dose": 28361,
      "safety fixed dose combination": 73155,
      "chronic musculoskeletal pain including": 16215,
      "patients cancer related pain": 59048,
      "postoperative pain neuropathic pain": 62895,
      "chronic moderate severe pain": 16211,
      "treat moderate severe pain": 82300,
      "placebo oxycodone 10 mg": 61793,
      "semi synthetic opioid commonly": 74515,
      "synthetic opioid commonly used": 79955,
      "severe acute chronic pain": 74902,
      "acute chronic pain treatment": 7624,
      "commonly used strong opioids": 17899,
      "oral oxycodone oral morphine": 53638,
      "postoperative nausea vomiting ponv": 62805,
      "patients scheduled breast cancer": 59944,
      "scheduled breast cancer surgery": 73640,
      "reduced postoperative pain opioid": 68976,
      "postoperative pain opioid consumption": 62901,
      "compuscript converted defined daily": 18648,
      "converted defined daily doses": 20724,
      "defined daily doses ddd": 23132,
      "methods double blind placebo": 45318,
      "release er oxycodone oc": 69849,
      "er oxycodone oc acetaminophen": 29462,
      "double blind active placebo": 26340,
      "blind active placebo controlled": 13921,
      "approved institutional review board": 11543,
      "provided written informed consent": 66171,
      "participants received single doses": 58354,
      "received single doses intact": 68275,
      "er ir oc apap": 29430,
      "15 650 mg intact": 1711,
      "drug high good drug": 26645,
      "high good drug effects": 35107,
      "measured using visual analogue": 44007,
      "crushed ir oc apap": 21339,
      "opioid patient controlled analgesia": 52046,
      "controlled analgesia pca oxycodone": 20460,
      "pain patients randomized receive": 57355,
      "patients assessed pain visual": 59012,
      "assessed pain visual analogue": 12033,
      "pain visual analogue scale": 57980,
      "effects nausea vomiting pruritus": 28020,
      "cancer non cancer pain": 14802,
      "controlled cross study patients": 20476,
      "risk opioid related adverse": 72619,
      "opioid related adverse outcomes": 52305,
      "opioid na\u00efve patients methods": 51988,
      "patients ages 18 older": 58982,
      "opioid use defined opioid": 52493,
      "adjusted odds ratio 95": 8044,
      "confidence interval ci 91": 19477,
      "adjusted hazard ratio ahr": 8024,
      "ahr 18 95 ci": 9361,
      "18 95 ci 86": 2077,
      "ahr 26 95 ci": 9364,
      "previously opioid na\u00efve patients": 64952,
      "oxycodone 10 mg kg": 54500,
      "mg kg tramadol 10": 46035,
      "assessed using conditioned place": 12086,
      "conditioned place aversion cpa": 19297,
      "using conditioned place preference": 85358,
      "conditioned place preference cpp": 19299,
      "drugs different mechanisms action": 26938,
      "adults search methods searched": 8578,
      "search methods searched cochrane": 74120,
      "methods searched cochrane central": 45564,
      "searched cochrane central register": 74145,
      "register controlled trials central": 69372,
      "controlled trials central medline": 20626,
      "trials central medline embase": 83111,
      "searched reference lists retrieved": 74163,
      "reference lists retrieved studies": 69137,
      "lists retrieved studies reviews": 42109,
      "online clinical trial registries": 51097,
      "pain data collection analysis": 56679,
      "dichotomous data calculate risk": 24377,
      "data calculate risk ratio": 21895,
      "needed treat additional event": 49042,
      "treat additional event using": 82280,
      "additional event using standard": 7860,
      "event using standard methods": 29997,
      "using standard methods assessed": 85625,
      "assessed evidence using grade": 12003,
      "grade grading recommendations assessment": 33374,
      "grading recommendations assessment development": 33387,
      "recommendations assessment development evaluation": 68594,
      "summary findings table main": 79102,
      "findings table main results": 31832,
      "needed treat additional beneficial": 49041,
      "treat additional beneficial outcome": 82278,
      "additional beneficial outcome nnt": 7846,
      "treat additional harmful outcome": 82282,
      "low quality evidence oxycodone": 42544,
      "treatment painful diabetic neuropathy": 82743,
      "study design prospective cohort": 78080,
      "design prospective cohort study": 23759,
      "steroidal anti inflammatory drug": 77344,
      "chronic noncancer pain cncp": 16227,
      "anesthetic patients randomly assigned": 10972,
      "patients randomly assigned receive": 59751,
      "time oxycodone use similar": 81311,
      "oxycodone use similar groups": 56056,
      "patients chronic noncancer pain": 59076,
      "evidence support efficacy tolerability": 30271,
      "measured using numeric rating": 44005,
      "numeric rating scales nrs": 50304,
      "daily dose remained stable": 21734,
      "placebo main outcomes measures": 61775,
      "drug related adverse events": 26764,
      "trial registration clinicaltrials gov": 83073,
      "registration clinicaltrials gov identifier": 69391,
      "double blind crossover trial": 26351,
      "11 point numerical rating": 1148,
      "point numerical rating scale": 62097,
      "www controlled trials com": 87396,
      "oxycodone induced respiratory depression": 55270,
      "safety oxycodone naloxone patients": 73187,
      "increased compliance redressing wounds": 37894,
      "28 95 ci 27": 3551,
      "18 95 ci 12": 2076,
      "patients received mg kg": 59796,
      "received mg kg oxycodone": 68200,
      "mg kg oxycodone group": 46010,
      "pain scores 11 point": 57696,
      "scores 11 point numeric": 73828,
      "11 point numeric rating": 1145,
      "point numeric rating scale": 62092,
      "numeric rating scale nrs": 50299,
      "rating scale nrs 24": 67660,
      "post operative nausea vomiting": 62597,
      "operative nausea vomiting ponv": 51255,
      "post operative opioid consumption": 62599,
      "particularly opioid induced constipation": 58418,
      "induced constipation oic opioid": 38402,
      "oxycodone design double blind": 54947,
      "oxycodone 30 60 mg": 54550,
      "oxycodone serotonin noradrenaline reuptake": 55894,
      "serotonin noradrenaline reuptake inhibitor": 74677,
      "noradrenaline reuptake inhibitor venlafaxine": 49877,
      "randomized double blinded placebo": 67113,
      "double blinded placebo controlled": 26395,
      "blinded placebo controlled cross": 14008,
      "mean age 24 years": 43675,
      "received 10 mg oxycodone": 68092,
      "placebo twice daily days": 61851,
      "analgesic efficacy prolonged release": 10244,
      "efficacy prolonged release oxycodone": 28337,
      "prolonged release oxycodone naloxone": 65628,
      "release oxycodone naloxone oxn": 69955,
      "oxycodone naloxone oxn pr": 55509,
      "naloxone oxn pr patients": 48478,
      "rating scale pain 10": 67669,
      "scale pain 10 pain": 73528,
      "pain 10 pain bad": 56353,
      "10 pain bad imagine": 891,
      "oxycodone mg naloxone mg": 55432,
      "mg naloxone mg twice": 46067,
      "group difference 95 ci": 33748,
      "treatment related adverse events": 82807,
      "parkinson disease related pain": 58230,
      "ml min kg groups": 46878,
      "individually oxycodone semisynthetic opioid": 38326,
      "dorsal root ganglia drg": 25739,
      "mg oxycodone hydrochloride hcl": 46121,
      "mg oxycodone hcl ir": 46118,
      "point visual analog scale": 62115,
      "visual analog scale results": 86312,
      "opioid mu receptor agonist": 51966,
      "intravenous patient controlled analgesia": 39879,
      "prospective double blind randomized": 65829,
      "double blind randomized study": 26377,
      "oxycodone 03 mg kg": 54483,
      "10 mg oxycodone mg": 835,
      "surgery risk respiratory depression": 79573,
      "control ctl weeks prior": 20289,
      "ctl weeks prior breeding": 21367,
      "aim study investigate effects": 9426,
      "patients receiving tapentadol ir": 59860,
      "receiving tapentadol ir versus": 68382,
      "tapentadol ir versus oxycodone": 80436,
      "ir versus oxycodone ir": 40266,
      "methods retrospective cohort study": 45540,
      "main outcome measure proportion": 42838,
      "outcome measure proportion patients": 53928,
      "results study cohort included": 71978,
      "mean age 66 years": 43702,
      "associated increased likelihood opioid": 12301,
      "prescription opioid analgesic oxycodone": 64285,
      "significant dose related increases": 75530,
      "opioid sparing pain management": 52371,
      "patients acute musculoskeletal pain": 58938,
      "multivariable linear regression models": 48324,
      "morphine oxycodone oxymorphone hydromorphone": 47846,
      "oral morphine oral hydromorphone": 53588,
      "codeine tramadol oxycodone hydrocodone": 17295,
      "design retrospective cohort study": 23786,
      "retrospective cohort study setting": 72132,
      "primary secondary outcome measures": 65110,
      "age body mass index": 9063,
      "release oxycodone hydrochloride hcl": 69946,
      "surrounding sequestered naltrexone hcl": 79678,
      "objective study determine effects": 50506,
      "concentration time curve auc": 18724,
      "time curve auc time": 81236,
      "curve auc time zero": 21522,
      "time zero extrapolated infinity": 81402,
      "90 confidence intervals cis": 6085,
      "generally tolerated background objective": 33029,
      "background objective study compare": 13097,
      "objective study compare analgesic": 50500,
      "methods patients undergoing laparoscopic": 45449,
      "opioid consumption 24 surgery": 51602,
      "surgery secondary outcomes included": 79582,
      "secondary outcomes included time": 74249,
      "sedation nausea vomiting respiratory": 74322,
      "recorded results oxycodone consumption": 68696,
      "morphine group oxycodone group": 47708,
      "visual analogue scale score": 86326,
      "chinese clinical trial registry": 16093,
      "http www chictr org": 35928,
      "emergency department methods conducted": 28682,
      "prospective randomized double blinded": 65865,
      "blinded placebo controlled clinical": 14007,
      "placebo controlled clinical trial": 61677,
      "pain relief measured using": 57548,
      "numeric pain intensity scale": 50292,
      "anti inflammatory drugs patients": 11132,
      "group 95 confidence interval": 33657,
      "compared control group 95": 18118,
      "95 ci difference groups": 6362,
      "difference groups 95 ci": 24618,
      "42 95 ci 22": 4456,
      "mediated kappa opioid receptors": 44312,
      "analogue scale vas pain": 10560,
      "scale vas pain scores": 73577,
      "vas pain scores rest": 86012,
      "pain scores rest coughing": 57776,
      "recorded days surgery results": 68681,
      "patients received oxycodone mg": 59813,
      "scores nausea vomiting pruritus": 73913,
      "purpose purpose study assess": 66554,
      "daily doses ddd 1000": 21740,
      "opioid receptor mor mediated": 52264,
      "low molecular weight heparin": 42505,
      "oral sustained release opioids": 53673,
      "offer superior pain control": 50954,
      "immune function patients undergoing": 36766,
      "function patients undergoing radical": 32669,
      "patients undergoing radical resection": 60126,
      "oxycodone hydrochloride mg kg": 55191,
      "mg kg postoperative analgesia": 46019,
      "received sufentanil \u03bcg kg": 68291,
      "analog scale vas score": 10541,
      "score secondary outcomes included": 73788,
      "natural killer nk cells": 48740,
      "analgesics incidence adverse reactions": 10434,
      "group 12 24 48": 33566,
      "12 24 48 72": 1234,
      "24 48 72 hours": 3167,
      "applied patient controlled intravenous": 11438,
      "morphine oxycodone hydromorphone cancer": 47833,
      "cancer patients moderate severe": 14882,
      "pain associated primary dysmenorrhoea": 56476,
      "generally tolerated clinical trials": 33031,
      "tolerated clinical trials similar": 81626,
      "500 mg twice daily": 4924,
      "74 95 ci 15": 5674,
      "95 ci 15 33": 6253,
      "oxycodone tablets prescribed common": 55982,
      "tablets prescribed common procedures": 80203,
      "opioid prescribing engagement network": 52099,
      "chronic noncancer pain despite": 16229,
      "oxycodone sustained release sr": 55972,
      "world health organization international": 87311,
      "health organization international clinical": 34746,
      "organization international clinical trials": 53772,
      "objective evaluate clinical effect": 50411,
      "randomly divided groups oxycodone": 67235,
      "groups oxycodone group group": 34256,
      "arterial pressure map heart": 11720,
      "pressure map heart rate": 64744,
      "map heart rate hr": 43348,
      "postoperative pain scores recorded": 62921,
      "pain scores recorded using": 57771,
      "group group significantly lower": 33807,
      "compared immediate release oxycodone": 18185,
      "recreational opioid users design": 68781,
      "single center single dose": 76070,
      "center single dose randomized": 15554,
      "single dose randomized double": 76092,
      "dose randomized double blind": 26027,
      "double blind active controlled": 26339,
      "randomized receive 15 mg": 67164,
      "effect max drug liking": 27482,
      "drug liking vas max": 26691,
      "recreational opioid users background": 68780,
      "nested case control study": 49147,
      "primary outcome proportion patients": 65089,
      "logistic regression analyses performed": 42257,
      "01 95 confidence interval": 301,
      "95 confidence interval 00": 6375,
      "numeric rating scale pain": 50300,
      "rating scale pain score": 67671,
      "methods asa physical status": 45255,
      "outpatients age 18 60": 54160,
      "age 18 60 yr": 8977,
      "im postoperative pain relief": 36676,
      "using visual analogue scale": 85667,
      "end second postoperative days": 28814,
      "prescription opioids medical use": 64349,
      "maternal oxycodone self administration": 43527,
      "oxycodone self administration pregnancy": 55879,
      "oxycodone conditioned place preference": 54844,
      "mean arterial blood pressure": 43716,
      "adults aged 18 years": 8544,
      "mean age 62 years": 43698,
      "opioid na\u00efve patients mean": 51987,
      "impact pain daily activities": 36831,
      "oxycodone controlled release oxycodone": 54885,
      "methods patients aged 18": 45430,
      "patients aged 18 64": 58971,
      "endoscopic retrograde cholangiopancreatography ercp": 28862,
      "mean pain scores decreased": 43833,
      "prospective randomized double blind": 65864,
      "adjunctive analgesic cardiac surgery": 8008,
      "ninety patients scheduled elective": 49486,
      "patients scheduled elective coronary": 59946,
      "scheduled elective coronary artery": 73646,
      "elective coronary artery bypass": 28491,
      "coronary artery bypass grafting": 20784,
      "artery bypass grafting cabg": 11727,
      "extubation patients access opioid": 30999,
      "patients access opioid oxycodone": 58918,
      "access opioid oxycodone patient": 6997,
      "opioid oxycodone patient controlled": 52032,
      "oxycodone patient controlled analgesia": 55651,
      "patient controlled analgesia device": 58582,
      "pain evaluated visual analog": 56765,
      "evaluated visual analog scale": 29938,
      "visual analog scale times": 86316,
      "analog scale times daily": 10538,
      "patient satisfaction pain management": 58768,
      "cumulative oxycodone consumption 48": 21405,
      "mg 95 confidence interval": 45783,
      "95 confidence interval difference": 6395,
      "pain scores did differ": 57716,
      "scores did differ groups": 73865,
      "did differ groups rest": 24435,
      "controlled trial setting single": 20619,
      "30 tablets oxycodone mg": 3802,
      "outcome measures primary outcome": 53952,
      "secondary outcomes included total": 74250,
      "outcomes included total opioid": 54041,
      "number opioid tablets prescribed": 50200,
      "race body mass index": 66938,
      "number oxycodone tablets used": 50214,
      "quality adjusted life year": 66675,
      "severe chronic pain objective": 74937,
      "open label randomized crossover": 51179,
      "nonmedical use prescription opioids": 49790,
      "effects oxycodone male rats": 28068,
      "rats trained intravenously self": 67900,
      "trained intravenously self administer": 82005,
      "oxycodone 15 mg kg": 54521,
      "15 mg kg infusion": 1758,
      "male female wistar rats": 43038,
      "mg kg oxycodone mg": 46013,
      "kg oxycodone mg kg": 40782,
      "oxycodone commonly used opioid": 54814,
      "commonly used opioid analgesics": 17888,
      "oxycodone 10 20 mg": 54495,
      "using numeric pain rating": 85528,
      "numeric pain rating scale": 50294,
      "aim study compare efficacy": 9412,
      "study compare efficacy safety": 78002,
      "efficacy safety quality life": 28384,
      "cr oxycodone pregabalin patients": 21097,
      "patients moderate severe neuropathic": 59524,
      "moderate severe neuropathic pain": 47188,
      "severe neuropathic pain despite": 74959,
      "pain intensity rated 11": 56934,
      "intensity rated 11 point": 39299,
      "rated 11 point numerical": 67529,
      "gather information prescription drug": 32909,
      "information prescription drug abuse": 38664,
      "controlled release oxycodone therapy": 20569,
      "rating scale nrs 10": 67658,
      "quality life improved significantly": 66729,
      "quality life objective evaluate": 66733,
      "retrospective cohort study analyzed": 72126,
      "claims data adult patients": 16622,
      "conclusions results study suggest": 19205,
      "extended release er opioids": 30868,
      "following introduction reformulated er": 32153,
      "continuous users extended release": 20192,
      "pearson chi squared tests": 60337,
      "rates diagnosed opioid abuse": 67570,
      "limitations observational research design": 41906,
      "caution warranted causal interpretation": 15420,
      "warranted causal interpretation findings": 86730,
      "commercial insurance medicare medicaid": 17710,
      "morphine oxycodone hydromorphone fentanyl": 47834,
      "intensity using numerical rating": 39325,
      "using numerical rating scale": 85533,
      "common opioid related adverse": 17782,
      "95 confidence intervals ci": 6398,
      "82 95 ci 76": 5904,
      "95 ci 76 87": 6332,
      "73 95 ci 46": 5651,
      "opioid use self reported": 52591,
      "methods systematically reviewed literature": 45606,
      "minimum data set medicare": 46611,
      "inverse probability treatment weighting": 39990,
      "objective objective study estimate": 50451,
      "objective evaluate efficacy safety": 50418,
      "tablets treatment moderate severe": 80227,
      "treatment moderate severe postoperative": 82669,
      "severe postoperative pain following": 75012,
      "postoperative pain following bunionectomy": 62869,
      "dose study clinicaltrials gov": 26085,
      "patients aged 18 years": 58972,
      "moderate severe pain post": 47204,
      "patients randomized receive placebo": 59742,
      "primary efficacy endpoint sum": 65008,
      "efficacy endpoint sum pain": 28263,
      "endpoint sum pain intensity": 28903,
      "48 hours spid 48": 4726,
      "initial dose study drug": 38845,
      "use rescue medication safety": 84699,
      "included adverse events aes": 37415,
      "reductions pain intensity compared": 69119,
      "pain intensity compared placebo": 56892,
      "severe pain following bunionectomy": 74979,
      "study compare analgesic efficacy": 77999,
      "multimodal analgesia patients received": 48202,
      "mean difference 95 confidence": 43759,
      "difference 95 confidence interval": 24590,
      "95 confidence interval 01": 6377,
      "materials methods prospective randomized": 43513,
      "using 10 cm visual": 85285,
      "endoscopic sinus surgery ess": 28865,
      "randomized clinical trial conducted": 67046,
      "2020 data analyzed november": 2898,
      "visual analog scale score": 86313,
      "pain brief pain inventory": 56502,
      "pain severity pain interference": 57826,
      "groups similar demographic characteristics": 34326,
      "visual analog scale scores": 86314,
      "randomized clinical trial patients": 67048,
      "purpose study compare postoperative": 66575,
      "study compare postoperative pain": 78004,
      "anterior cruciate ligament acl": 11105,
      "cruciate ligament acl reconstruction": 21325,
      "patients receiving adductor canal": 59836,
      "receiving adductor canal block": 68322,
      "adductor canal block acb": 7947,
      "prospective cohort study patients": 65822,
      "cohort study patients undergoing": 17399,
      "325 mg oxycodone acetaminophen": 3960,
      "using numeric rating scale": 85530,
      "total postoperative opioid consumption": 81891,
      "converted oral morphine equivalents": 20738,
      "oral morphine equivalents omes": 53583,
      "mean postoperative pain scores": 43843,
      "pain scores similar groups": 57785,
      "pain opioid consumption aclr": 57281,
      "subjective physiological effects oxycodone": 78663,
      "multiple linear regression models": 48284,
      "opioid analgesics fentanyl oxycodone": 51498,
      "opioid use odds ratio": 52548,
      "confidence interval ci 16": 19465,
      "persistent opioid use discharge": 60921,
      "articles met inclusion criteria": 11800,
      "morphine milligram equivalents mme": 47775,
      "milligram equivalents mme used": 46465,
      "95 ci 44 74": 6298,
      "10 tablets mg oxycodone": 938,
      "background purpose study determine": 13187,
      "surgery methods patients undergoing": 79465,
      "methods patients undergoing ambulatory": 45446,
      "pain visual analog scale": 57978,
      "visual analog scale pain": 86308,
      "opioid consumption adverse effects": 51607,
      "30 60 90 120": 3698,
      "patients experienced nausea vomiting": 59281,
      "levels nucleus accumbens nac": 41581,
      "abuse deterrent formulation extended": 6688,
      "deterrent formulation extended release": 24111,
      "formulation extended release oxycodone": 32343,
      "primary objective study assess": 65047,
      "adult volunteers aged 18": 8529,
      "parameters included maximum plasma": 58162,
      "included maximum plasma concentration": 37477,
      "maximum plasma concentration cmax": 43606,
      "oxycodone methods healthy subjects": 55402,
      "day ingested 10 mg": 22324,
      "time curve auc infinity": 81235,
      "curve auc infinity oxycodone": 21520,
      "auc infinity oxycodone increased": 12633,
      "infinity oxycodone increased fold": 38545,
      "oxycodone increased fold range": 55247,
      "increased fold range fold": 37918,
      "peak plasma concentration fold": 60318,
      "pharmacodynamic effects oxycodone modestly": 61065,
      "avoid opioid related adverse": 12961,
      "opioid related adverse effects": 52302,
      "patient reported pain outcomes": 58740,
      "july 2018 january 2019": 40525,
      "surgeons academic medical center": 79267,
      "surgery main outcomes measures": 79451,
      "prescription refills patient reported": 64399,
      "spearman rank order correlation": 76554,
      "rank order correlation used": 67364,
      "05 considered statistically significant": 508,
      "considered statistically significant results": 19657,
      "women mean sd age": 87224,
      "mean sd age 38": 43860,
      "men mean sd age": 44802,
      "narcotic use patients undergoing": 48620,
      "opioid use patient reported": 52561,
      "patient satisfaction level evidence": 58763,
      "institutional review board approval": 39100,
      "received single dose oxycodone": 68273,
      "admission intensive care unit": 8410,
      "effective treatment chronic pain": 27716,
      "national institute drug abuse": 48694,
      "substance abuse mental health": 78798,
      "abuse mental health services": 6775,
      "mental health services administration": 44824,
      "data centers disease control": 21900,
      "centers disease control prevention": 15568,
      "placebo controlled study investigated": 61705,
      "cardiac surgery patients methods": 14985,
      "patients received oxycodone 05": 59809,
      "received oxycodone 05 mg": 68230,
      "oxycodone 05 mg kg": 54486,
      "placebo group significant difference": 61752,
      "mini mental state examination": 46565,
      "significantly lower pregabalin group": 75805,
      "opioid consumption cardiac surgery": 51614,
      "objective purpose study examine": 50481,
      "methods cross sectional study": 45296,
      "codeine fentanyl hydrocodone hydromorphone": 17232,
      "treat chronic non cancer": 82289,
      "long term use opioids": 42362,
      "purpose study investigate effect": 66586,
      "study investigate effect oxycodone": 78271,
      "sprague dawley sd rats": 76776,
      "quantitative polymerase chain reaction": 66803,
      "polymerase chain reaction qpcr": 62203,
      "group statistically significant differences": 34034,
      "patients history substance abuse": 59367,
      "toll like receptor tlr4": 81649,
      "cross blood brain barrier": 21247,
      "brain derived neurotrophic factor": 14335,
      "derived neurotrophic factor bdnf": 23632,
      "long term opioid therapy": 42340,
      "patients chronic low pain": 59069,
      "endo pharmaceuticals chadds ford": 28839,
      "release cr oxycodone immediate": 69824,
      "cr oxycodone immediate release": 21090,
      "rating scale nrs pain": 67662,
      "scale nrs pain scores": 73517,
      "patients received cr oxycodone": 59774,
      "pain 12 months surgery": 56369,
      "pain ratings postoperative days": 57475,
      "conclusions present study demonstrated": 19177,
      "patient controlled analgesia iv": 58584,
      "controlled analgesia iv pca": 20452,
      "criteria randomized controlled trials": 21214,
      "studies meta analysis performed": 77775,
      "analog scale pain scores": 10528,
      "52 95 confidence interval": 4984,
      "relatively small sample size": 69791,
      "pharmaceutical benefits scheme dispensing": 61018,
      "opioid dispensing 90 days": 51719,
      "leading cause death americans": 41302,
      "catheter related bladder discomfort": 15318,
      "related bladder discomfort crbd": 69565,
      "compared control group incidence": 18119,
      "significantly lower oxycodone group": 75799,
      "compared group vas scores": 18171,
      "setting victoria australia cases": 74851,
      "mental health substance use": 44826,
      "06 95 ci 01": 582,
      "95 ci 01 11": 6225,
      "time series analysis showed": 81374,
      "22 95 ci 05": 3030,
      "serotonin norepinephrine reuptake inhibitor": 74680,
      "norepinephrine reuptake inhibitor aim": 49891,
      "aim study investigate effect": 9425,
      "rural appalachian drug users": 73046,
      "lifetime past 30 day": 41752,
      "negative binomial regression used": 49065,
      "diagnostic statistical manual mental": 24345,
      "statistical manual mental disorders": 77179,
      "manual mental disorders fourth": 43332,
      "mental disorders fourth edition": 44818,
      "drug liking moment drug": 26686,
      "liking moment drug liking": 41866,
      "national survey drug use": 48722,
      "survey drug use health": 79710,
      "drug use health nsduh": 26836,
      "abuse deterrent opioid formulations": 6699,
      "growing public health crisis": 34375,
      "used non steroidal anti": 85034,
      "low oral bioavailability naloxone": 42513,
      "acute opioid withdrawal symptoms": 7657,
      "following oral intravenous administration": 32171,
      "intravenous administration oxycodone naloxone": 39815,
      "objective aim study investigate": 50372,
      "data collected included patient": 21908,
      "50 ng ml high": 4873,
      "sensitive liquid chromatography tandem": 74545,
      "tandem mass spectrometry method": 80366,
      "inter intra day variability": 39358,
      "cross sectional study conducted": 21265,
      "daily dose ddd 1000": 21727,
      "day oral morphine equivalent": 22349,
      "increase strong opioid prescribing": 37806,
      "group continuous epidural infusion": 33711,
      "continuous epidural infusion bupivacaine": 20167,
      "epidural infusion bupivacaine fentanyl": 29183,
      "morphine oxycodone fentanyl respectively": 47825,
      "opioid misuse public health": 51947,
      "misuse public health crisis": 46745,
      "automated reports consolidated ordering": 12758,
      "use patients chronic pain": 84613,
      "pain severe require daily": 57823,
      "severe require daily clock": 75017,
      "require daily clock long": 70803,
      "daily clock long term": 21708,
      "clock long term opioid": 17051,
      "long term opioid treatment": 42341,
      "term opioid treatment alternative": 80648,
      "opioid treatment alternative treatment": 52441,
      "treatment alternative treatment options": 82443,
      "alternative treatment options inadequate": 9748,
      "linear mixed effects model": 42018,
      "pain trial registration clinicaltrials": 57943,
      "drug drug interactions cyp2d6": 26603,
      "morphine equivalent dose pain": 47661,
      "methods retrospective cohort design": 45539,
      "veterans health administration va": 86180,
      "additional research needed determine": 7892,
      "copyright 2016 john wiley": 20761,
      "2016 john wiley sons": 2750,
      "conclusions consumption opioid analgesics": 19063,
      "oral long acting opioids": 53562,
      "long acting opioids oxycodone": 42304,
      "opioids oxycodone controlled release": 53134,
      "oxymorphone extended release er": 56243,
      "oxycodone cr oxymorphone er": 54905,
      "characteristics including age sex": 15866,
      "using pearson chi square": 85555,
      "pearson chi square test": 60335,
      "using generalized linear models": 85410,
      "oxymorphone er 40 mg": 56237,
      "patients taking oxycodone cr": 60037,
      "patients chronic pain syndromes": 59085,
      "used management moderate severe": 84998,
      "moderate severe acute chronic": 47166,
      "effects complicate pain management": 27871,
      "poison center drug diversion": 62148,
      "treatment center programs combined": 82472,
      "opioid formulations extended release": 51816,
      "perspective article presents results": 60963,
      "abuse deterrent formulation adf": 6687,
      "pain therapeutics san mateo": 57911,
      "therapeutics san mateo ca": 80975,
      "king pharmaceuticals bristol tn": 40849,
      "oxycontin purdue pharma lp": 56176,
      "purdue pharma lp stamford": 66501,
      "pharma lp stamford ct": 61011,
      "percocet endo pharmaceuticals chadds": 60534,
      "pharmaceuticals chadds ford pa": 61051,
      "vicodin abbott laboratories abbott": 86198,
      "abbott laboratories abbott park": 6516,
      "laboratories abbott park il": 41021,
      "ibuprofen oxycodone pain management": 36367,
      "demographic clinical characteristics associated": 23278,
      "use oxycodone associated increased": 84583,
      "23 95 ci 07": 3087,
      "design prospective randomized double": 23767,
      "setting university teaching hospital": 74846,
      "hours study drug administration": 35860,
      "administration main outcome measures": 8292,
      "main outcome measures pain": 42842,
      "outcome measures pain intensity": 53944,
      "background acute postoperative pain": 13006,
      "methods medical records patients": 45380,
      "rating scale nrs score": 67665,
      "prospective randomised double blind": 65857,
      "cro group received 10": 21241,
      "group received 10 mg": 33945,
      "received 10 mg cro": 68091,
      "initial dose 10 mg": 38838,
      "group received placebo tablet": 33962,
      "group experienced significantly nausea": 33776,
      "opioid use morphine equivalents": 52541,
      "methods total 51 patients": 45615,
      "geometric means 95 confidence": 33125,
      "95 confidence interval 34": 6390,
      "naloxone opioid receptor antagonist": 48473,
      "opioid receptor antagonist used": 52247,
      "widely used opioid receptor": 87070,
      "used opioid receptor agonist": 85050,
      "oxycodone hydrocodone morphine fentanyl": 55210,
      "conditioned place preference test": 19301,
      "place preference test oxycodone": 61606,
      "oxycodone 01 mg kg": 54479,
      "mg kg produced dose": 46022,
      "kg produced dose dependent": 40794,
      "produced dose dependent increases": 65381,
      "increased place preference induced": 37986,
      "induced oxycodone mg kg": 38439,
      "oxycodone mg kg induced": 55424,
      "dopamine release nucleus accumbens": 25725,
      "dose 01 mg kg": 25776,
      "patients prescribed opioid acetaminophen": 59678,
      "retrospective cohort study using": 72134,
      "oxycodone acetaminophen hydrocodone acetaminophen": 54644,
      "12 95 confidence interval": 1270,
      "confidence interval ci 12": 19462,
      "morphine hydrocodone hydromorphone oxycodone": 47719,
      "hydrocodone hydromorphone oxycodone oxymorphone": 36094,
      "opioid use disorder oud": 52504,
      "produced dose dependent increase": 65380,
      "dose dependent increase tail": 25870,
      "dependent increase tail flick": 23512,
      "moderate severe pain patients": 47203,
      "cross sectional study using": 21268,
      "causes significant postoperative pain": 15403,
      "increase 95 ci 13": 37726,
      "performance liquid chromatography tandem": 60559,
      "ng ml vitreous humor": 49460,
      "orthopedic injury related pain": 53825,
      "injury related pain children": 38994,
      "methods prospective randomized double": 45494,
      "using generalized estimating equation": 85406,
      "treatment groups statistically significant": 82610,
      "groups statistically significant differences": 34330,
      "demographic characteristics drug use": 23270,
      "abuse deterrent formulations adfs": 6691,
      "significantly higher compared placebo": 75721,
      "compared crushed oxycodone ir": 18131,
      "pruritus somnolence dizziness conclusions": 66310,
      "fourier transform infrared spectroscopy": 32432,
      "profile oxycodone compared morphine": 65497,
      "baseline 30 60 90": 13411,
      "30 60 90 min": 3699,
      "min drug administration results": 46523,
      "background opioid analgesics commonly": 13106,
      "opioid analgesics commonly prescribed": 51489,
      "release oxycodone immediate release": 69949,
      "materials methods retrospective cohort": 43516,
      "cohort study using linked": 17407,
      "international classification diseases 9th": 39475,
      "proportions patients oxycodone group": 65794,
      "odds ratio 95 confidence": 50927,
      "ratio 95 confidence interval": 67756,
      "related surveillance radars poison": 69691,
      "surveillance radars poison center": 79686,
      "radars poison center program": 66950,
      "10 95 ci 14": 735,
      "drugs commonly used treatment": 26916,
      "natural opiates morphine codeine": 48745,
      "opiates morphine codeine synthetic": 51333,
      "oral oxycodone self administration": 53641,
      "used treat severe pain": 85173,
      "automation reports consolidated orders": 12766,
      "medical use opioid analgesics": 44416,
      "use opioid analgesics treat": 84544,
      "using interrupted time series": 85446,
      "general anesthesia oxycodone hydrochloride": 32964,
      "anesthesia oxycodone hydrochloride semisynthetic": 10928,
      "oxycodone hydrochloride semisynthetic opioid": 55196,
      "therapeutic effect visceral pain": 80937,
      "general anesthesia randomly divided": 32969,
      "anesthesia randomly divided groups": 10945,
      "group group oxycodone hydrochloride": 33801,
      "including mean arterial pressure": 37634,
      "mean arterial pressure heart": 43718,
      "arterial pressure heart rate": 11718,
      "blood pressure heart rate": 14146,
      "group ii group iii": 33821,
      "significantly lower group 05": 75787,
      "january 2013 december 31": 40444,
      "tapentadol group oxycodone group": 80415,
      "opioid related hospitalizations deaths": 52320,
      "opioid related morbidity mortality": 52322,
      "prescribed long acting opioids": 63882,
      "design setting participants retrospective": 23800,
      "setting participants retrospective cohort": 74806,
      "participants retrospective cohort study": 58364,
      "long acting opioid group": 42297,
      "95 ci 24 39": 6267,
      "long acting opioids chronic": 42302,
      "acting opioids chronic noncancer": 7411,
      "opioids chronic noncancer pain": 52779,
      "chronic noncancer pain compared": 16228,
      "opioid analgesics patients moderate": 51522,
      "analgesics patients moderate severe": 10480,
      "patients moderate severe chronic": 59522,
      "nonmedical use prescription pain": 49791,
      "release oxycodone designed resist": 69932,
      "united states past decades": 83818,
      "programs researched abuse diversion": 65564,
      "prescription opioid analgesics oxycodone": 64289,
      "opioid analgesics oxycodone hydrocodone": 51515,
      "poison centers substance abuse": 62152,
      "centers substance abuse treatment": 15575,
      "substance abuse treatment centers": 78801,
      "present study aimed investigate": 64645,
      "opioid related adverse event": 52303,
      "related adverse event reports": 69552,
      "radical retropubic prostatectomy rrp": 66961,
      "methods consecutive patients scheduled": 45291,
      "oxycodone hydrochloride 10 mg": 55177,
      "analogue scale vas time": 10563,
      "median duration hospital stay": 44220,
      "including morphine milligram equivalents": 37641,
      "12 95 ci 10": 1265,
      "95 ci 10 14": 6239,
      "combined vivo vitro data": 17677,
      "management moderate severe pain": 43211,
      "opioid analgesics abuse diversion": 51479,
      "data poison center drug": 22049,
      "survey key informants patients": 79717,
      "unique recipients dispensed drug": 83761,
      "using linear regression model": 85461,
      "oxycodone 120 mg day": 54515,
      "selective serotonin reuptake inhibitor": 74444,
      "serotonin reuptake inhibitor antidepressants": 74684,
      "significant public health problem": 75610,
      "double blind randomized placebo": 26376,
      "blind randomized placebo controlled": 13976,
      "anti inflammatory drugs acetaminophen": 11128,
      "opioids skeletal muscle relaxants": 53304,
      "mg oxycodone mg acetaminophen": 46126,
      "oxycodone mg acetaminophen 325": 55413,
      "main outcomes measures primary": 42851,
      "outcomes measures primary outcome": 54054,
      "cyclobenzaprine oxycodone acetaminophen naproxen": 21555,
      "long term management chronic": 42338,
      "oxycodone acetaminophen commonly prescribed": 54637,
      "use long acting opioids": 84460,
      "international classification diseases ninth": 39476,
      "classification diseases ninth revision": 16680,
      "diseases ninth revision clinical": 25358,
      "ninth revision clinical modification": 49494,
      "long acting opioids patients": 42306,
      "human immunodeficiency virus hiv": 35956,
      "conventional opioids morphine oxycodone": 20699,
      "opioids morphine oxycodone fentanyl": 53075,
      "methods randomized double blinded": 45512,
      "blinded placebo controlled trial": 14010,
      "allocated groups oxycodone group": 9614,
      "group group patients received": 33804,
      "used cancer pain relief": 84867,
      "randomised placebo controlled trial": 67032,
      "buprenorphine fentanyl hydromorphone morphine": 14544,
      "95 confidence intervals cis": 6399,
      "95 ci 04 22": 6230,
      "95 ci 04 21": 6229,
      "25 95 ci 03": 3344,
      "postoperative pain objective aim": 62898,
      "pain objective aim study": 57260,
      "objective aim study evaluate": 50371,
      "controlled double blind study": 20487,
      "blind study setting university": 13986,
      "setting university affiliated hospital": 74844,
      "asked rate pain 10": 11845,
      "rate pain 10 min": 67499,
      "pain 10 min using": 56351,
      "10 min using visual": 862,
      "min using visual analogue": 46558,
      "pain 10 severe pain": 56357,
      "postanaesthesia care unit pacu": 62632,
      "care unit pacu patients": 15091,
      "patients received intravenous oxycodone": 59788,
      "received intravenous oxycodone mg": 68180,
      "oxycodone mg 10 min": 55410,
      "oxycodone secondary endpoints included": 55868,
      "score significantly different groups": 73791,
      "randomized multicenter double blind": 67123,
      "opioid receptor binding affinity": 52252,
      "patients chemotherapy induced peripheral": 59063,
      "chemotherapy induced peripheral neuropathy": 15968,
      "pain following orthopedic surgery": 56793,
      "treatment postoperative pain following": 82773,
      "united states department health": 83789,
      "states department health human": 77092,
      "department health human services": 23435,
      "mice treated morphine oxycodone": 46325,
      "morphine oxycodone produced significant": 47854,
      "using australian bureau statistics": 85314,
      "national minimum data set": 48702,
      "patients chronic non malignant": 59074,
      "95 confidence interval 27": 6388,
      "prescription opioid dependent patients": 64293,
      "healthy male female volunteers": 34825,
      "electronic health record ehr": 28534,
      "interrupted time series analyses": 39539,
      "overdose death rates increased": 54276,
      "issue united states past": 40329,
      "use opioid analgesics treatment": 84545,
      "acute respiratory distress syndrome": 7701,
      "cox proportional hazards regression": 21032,
      "proportional hazards regression model": 65788,
      "hazards regression model used": 34623,
      "lower mortality risk compared": 42651,
      "retrospective cohort study conducted": 72127,
      "cohort study conducted using": 17388,
      "prescription drug monitoring program": 64214,
      "drug monitoring program pdmp": 26717,
      "oral oxycodone 10 20": 53615,
      "oxycodone 10 20 40": 54494,
      "chronic noncancer pain growing": 16230,
      "statistically significant differences primary": 77215,
      "objective purpose study determine": 50480,
      "patients discharged emergency department": 59207,
      "discharged emergency department ed": 25196,
      "emergency department ed acute": 28673,
      "opioids end study period": 52884,
      "use morphine fentanyl oxycodone": 84503,
      "long acting opioid analgesic": 42294,
      "treatment chronic severe nonmalignant": 82491,
      "chronic severe nonmalignant pain": 16342,
      "twice daily oxycodone 10": 83300,
      "daily oxycodone 10 mg": 21787,
      "pain baseline 14 days": 56491,
      "american society anaesthesiologists physical": 9801,
      "society anaesthesiologists physical status": 76370,
      "hours surgery significantly lower": 35871,
      "body movement respiratory depression": 14202,
      "experience lower postoperative pain": 30582,
      "current opioid epidemic united": 21451,
      "opioid epidemic united states": 51783,
      "high risk opioid use": 35175,
      "using world health organization": 85686,
      "opioids oxycodone fentanyl morphine": 53136,
      "opioid illicit drug use": 51840,
      "administration single oral dose": 8376,
      "single dose orally administered": 76084,
      "objective evaluate cost effectiveness": 50413,
      "study conducted using australian": 78035,
      "cost effectiveness analysis conducted": 20874,
      "commonly prescribed opioids hydrocodone": 17868,
      "prescribed opioids hydrocodone oxycodone": 63930,
      "number opioid prescriptions dispensed": 50196,
      "days supply opioids results": 22636,
      "primary outcome number oxycodone": 65074,
      "outcome number oxycodone tablets": 53961,
      "median number oxycodone tablets": 44255,
      "group interquartile range 10": 33834,
      "repeated cross sectional study": 70405,
      "cross sectional study setting": 21267,
      "expressed defined daily doses": 30816,
      "methods randomized single blinded": 45519,
      "randomly assigned control group": 67218,
      "provide better pain control": 66039,
      "selective serotonin norepinephrine reuptake": 74442,
      "oxycodone doses 10 mg": 55002,
      "randomized double blind fashion": 67103,
      "given current opioid crisis": 33163,
      "results thirty patients completed": 72014,
      "thirty patients completed study": 81109,
      "consumption similar groups patients": 20021,
      "11 10 ng ml": 1091,
      "aberrant drug related behaviors": 6546,
      "extended release oxycodone acetaminophen": 30892,
      "fixed dose combination analgesic": 31875,
      "pain research design methods": 57632,
      "methods open label extension": 45412,
      "open label extension ole": 51162,
      "tablets er oc apap": 80155,
      "12 hours 14 days": 1293,
      "adverse events physical examinations": 8792,
      "gastrointestinal events including nausea": 32881,
      "receiver operating characteristic curve": 68310,
      "pain numerical rating scale": 57256,
      "short term long term": 75193,
      "publicly available government data": 66417,
      "year old woman history": 87472,
      "design post hoc analysis": 23755,
      "post hoc analysis data": 62574,
      "enrolled randomized double blind": 29017,
      "parallel group placebo controlled": 58136,
      "oxycodone group compared placebo": 55127,
      "group compared placebo group": 33691,
      "group 30 placebo group": 33596,
      "regarding opioid use disposal": 69260,
      "term opioid treatment chronic": 80649,
      "aim study assess effect": 9405,
      "male sprague dawley rats": 43058,
      "sprague dawley rats treated": 76774,
      "postoperative pain control important": 62859,
      "methods institutional review board": 45365,
      "patients undergoing elective laparoscopic": 60099,
      "laparoscopic inguinal hernia repair": 41103,
      "group received normal saline": 33958,
      "pain assessed using visual": 56466,
      "assessed using visual analog": 12091,
      "using visual analog scale": 85665,
      "did significantly differ groups": 24507,
      "speaking women 18 years": 76550,
      "women 18 years older": 87194,
      "18 years older undergoing": 2114,
      "group consumed significantly oxycodone": 33708,
      "achieving adequate pain control": 7334,
      "aim study evaluate analgesic": 9417,
      "release ir oxycodone ir": 69880,
      "randomized controlled trial rct": 67077,
      "analysis groups compared using": 10694,
      "groups compared using analysis": 34154,
      "compared using analysis covariance": 18336,
      "received single oral dose": 68277,
      "pain intensity 12 hours": 56883,
      "active pharmaceutical ingredients apis": 7528,
      "compared strong opioids morphine": 18316,
      "risk factors associated opioid": 72565,
      "factors associated opioid induced": 31078,
      "korea veterans hospital performed": 40949,
      "veterans hospital performed data": 86183,
      "male patients aged 65": 43048,
      "patients aged 65 years": 58976,
      "aged 65 years older": 9192,
      "65 years older received": 5429,
      "binomial variables describing patient": 13833,
      "variables describing patient related": 85892,
      "constructed associations variables frequency": 19811,
      "determined odds ratio adjusted": 24077,
      "odds ratio adjusted odds": 50930,
      "ratio adjusted odds ratio": 67760,
      "adjusted odds ratio aor": 8045,
      "odds ratio aor calculated": 50932,
      "adverse events gastrointestinal problems": 8759,
      "10 95 ci 11": 733,
      "95 ci 11 31": 6243,
      "traumatic brain injury tbi": 82268,
      "morphine oxycodone fentanyl buprenorphine": 47823,
      "substance use disorders opioid": 78814,
      "associated higher risk opioid": 12285,
      "higher risk opioid related": 35319,
      "significantly reduces postoperative pain": 75854,
      "disease control prevention cdc": 25327,
      "opioids design setting participants": 52843,
      "design setting participants cross": 23799,
      "setting participants cross sectional": 74804,
      "participants cross sectional study": 58294,
      "eligible patients 18 years": 28592,
      "patients 18 years older": 58837,
      "patients included study mean": 59401,
      "95 95 ci 91": 6214,
      "relatively low affinity mu": 69782,
      "low affinity mu opioid": 42451,
      "study compare risk opioid": 78006,
      "using logistic regression model": 85471,
      "pooled using random effects": 62250,
      "using random effects model": 85588,
      "lower tapentadol oxycodone odds": 42713,
      "tapentadol oxycodone odds ratio": 80456,
      "odds ratio 35 95": 50914,
      "ratio 35 95 confidence": 67731,
      "35 95 confidence interval": 4076,
      "prescription opioid po dependence": 64310,
      "methods retrospective case series": 45534,
      "daily oral morphine equivalent": 21780,
      "oral morphine equivalent ome": 53578,
      "mean age 41 years": 43680,
      "age 41 years sd": 9005,
      "photorefractive keratectomy prk methods": 61377,
      "study 60 patients received": 77901,
      "difference pain scores groups": 24658,
      "prevent postoperative nausea vomiting": 64852,
      "patients methods prospective double": 59503,
      "methods prospective double blind": 45484,
      "standard general anesthetic technique": 76912,
      "drugs metabolized cytochrome p450": 26998,
      "using tail flick latency": 85635,
      "brain males females estrus": 14346,
      "large inter individual variation": 41134,
      "transversus abdominis plane tap": 82254,
      "double blind randomized clinical": 26372,
      "blind randomized clinical trial": 13970,
      "visual analogue score vas": 86331,
      "patient satisfaction results total": 58773,
      "patients admitted inpatient rehabilitation": 58953,
      "degrees 95 ci 13": 23182,
      "100 000 people year": 976,
      "prospective double blinded randomized": 65832,
      "double blinded randomized controlled": 26397,
      "blinded randomized controlled trial": 14015,
      "42 patients did receive": 4470,
      "careful selection effective analgesic": 15107,
      "selection effective analgesic regimen": 74420,
      "effective analgesic regimen based": 27596,
      "analgesic regimen based type": 10311,
      "regimen based type pain": 69301,
      "based type pain patient": 13399,
      "type pain patient expected": 83344,
      "pain patient expected prevent": 57334,
      "patient expected prevent stress": 58635,
      "expected prevent stress anxiety": 30561,
      "prevent stress anxiety associated": 64856,
      "stress anxiety associated breakthrough": 77487,
      "anxiety associated breakthrough pain": 11270,
      "clinician develop variety effective": 17024,
      "develop variety effective safe": 24162,
      "variety effective safe analgesic": 85952,
      "effective safe analgesic regimens": 27696,
      "safe analgesic regimens based": 73073,
      "analgesic regimens based estimates": 10321,
      "regimens based estimates anticipated": 69333,
      "based estimates anticipated pain": 13318,
      "estimates anticipated pain intensity": 29645,
      "rats data support feasibility": 67851,
      "design cross sectional survey": 23708,
      "oxycodone frequently prescribed opioid": 55109,
      "opioid overdose deaths increased": 52013,
      "blind placebo controlled randomized": 13959,
      "placebo controlled randomized trial": 61698,
      "surgery interventions patients randomized": 79430,
      "interventions patients randomized receive": 39675,
      "oxycodone mg administered intravenously": 55415,
      "rescue analgesia main outcome": 70929,
      "analgesia main outcome measures": 10013,
      "outcome measures oxycodone consumption": 53942,
      "mean difference 24 95": 43754,
      "conclusion etoricoxib 120 mg": 18902,
      "neonatal opioid withdrawal syndrome": 49100,
      "opioid withdrawal syndrome nows": 52649,
      "control moderate severe pain": 20368,
      "moderate severe pain advanced": 47191,
      "morphine hydromorphone oxymorphone tapentadol": 47725,
      "design systematic review methods": 23815,
      "adults chronic noncancer pain": 8559,
      "recommendations assessment development evaluations": 68595,
      "confidence interval ci 23": 19469,
      "95 ci 11 24": 6242,
      "moderate quality evidence common": 47160,
      "total knee replacement tkr": 81830,
      "postoperative pain opioid requirements": 62902,
      "nonselective nonsteroidal anti inflammatory": 49845,
      "oxycodone acetaminophen oxycodone acetaminophen": 54652,
      "18 95 confidence interval": 2079,
      "confidence interval ci 05": 19459,
      "19 95 ci 07": 2181,
      "studies long acting opioids": 77766,
      "long acting opioids associated": 42301,
      "non cancer pain methods": 49582,
      "95 ci 29 16": 6274,
      "major public health crisis": 42971,
      "current medications treat opioid": 21446,
      "treat opioid withdrawal symptoms": 82308,
      "positive allosteric modulators pams": 62452,
      "significance statement opioid use": 75415,
      "limited abuse liability effects": 41915,
      "receptor positive allosteric modulator": 68521,
      "mouse model oxycodone dependence": 48035,
      "viable strategy treat opioid": 86191,
      "design institutional review board": 23721,
      "institutional review board approved": 39101,
      "setting academic tertiary care": 74763,
      "measurements main results pain": 44022,
      "postoperative pain control reduce": 62861,
      "reduce postoperative pain opioid": 68885,
      "postoperative pain opioid usage": 62903,
      "liquid chromatography mass spectrometry": 42083,
      "short long term pain": 75183,
      "abuse deterrent extended release": 6685,
      "marketed morphine sulfate er": 43420,
      "drug liking visual analog": 26693,
      "liking visual analog scale": 41875,
      "results thirty participants completed": 72012,
      "significantly lower drug liking": 75784,
      "background purpose study evaluate": 13188,
      "double blind parallel group": 26362,
      "blind parallel group study": 13946,
      "10 20 30 mg": 684,
      "mg oxycodone ir 10": 46123,
      "ir 10 mg placebo": 40194,
      "20 30 mg doses": 2284,
      "patients requiring rescue medication": 59916,
      "adverse events similar groups": 8814,
      "pain relief compared placebo": 57530,
      "oxycodone opioid receptor antagonist": 55573,
      "year old female patient": 87458,
      "old female patient presented": 51007,
      "retrospective cross sectional study": 72140,
      "use opioids 90 days": 84555,
      "central nervous cns depression": 15596,
      "years interquartile range iqr": 87602,
      "primary outcome proportion subjects": 65090,
      "provides effective pain relief": 66213,
      "methods prospective observational study": 45488,
      "groups received oxycodone mg": 34288,
      "pain intensity evaluated using": 56906,
      "evaluated using visual analogue": 29934,
      "analogue scale vas 10": 10559,
      "using western ontario mcmaster": 85677,
      "western ontario mcmaster universities": 87005,
      "ontario mcmaster universities osteoarthritis": 51131,
      "mcmaster universities osteoarthritis index": 43632,
      "universities osteoarthritis index womac": 83851,
      "active placebo controlled crossover": 7531,
      "placebo controlled crossover design": 61681,
      "intravenous ketamine mg kg": 39850,
      "primary endpoint maximum effect": 65028,
      "endpoint maximum effect max": 28892,
      "liking vas max scores": 41872,
      "opioid use disorders oud": 52508,
      "fixed dose combination analgesics": 31876,
      "public health problem worldwide": 66396,
      "oral oxycodone 30 mg": 53622,
      "heart rate blood pressure": 34873,
      "mu opioid agonist effects": 48118,
      "opioid agonist effects miosis": 51425,
      "associated considerable postoperative pain": 12239,
      "prospective randomized placebo controlled": 65869,
      "randomized placebo controlled trial": 67154,
      "kappa delta opioid receptor": 40587,
      "design retrospective observational study": 23789,
      "calculated supply adjusted rates": 14707,
      "using poisson regression used": 85566,
      "poisson regression used multinomial": 62170,
      "regression used multinomial logistic": 69469,
      "used multinomial logistic regression": 85018,
      "multinomial logistic regression compare": 48256,
      "logistic regression compare demographic": 42266,
      "100 000 oral morphine": 974,
      "opioid use associated increased": 52472,
      "patients rheumatoid arthritis ra": 59929,
      "rheumatoid arthritis ra methods": 72458,
      "self controlled case series": 74484,
      "incidence rate ratio irr": 37310,
      "95 confidence interval 95": 6393,
      "confidence interval 95 ci": 19457,
      "long acting opioid use": 42299,
      "purpose compare efficacy oral": 66526,
      "using visual analog pain": 85664,
      "visual analog pain scale": 86304,
      "repeated measures analysis variance": 70413,
      "measures analysis variance anova": 44042,
      "significantly higher placebo group": 75737,
      "known risk factor opioid": 40931,
      "predictors long term use": 63590,
      "conducted retrospective cohort study": 19404,
      "used multivariable logistic regression": 85022,
      "multivariable logistic regression assess": 48327,
      "logistic regression assess association": 42264,
      "area receiver operating characteristic": 11639,
      "odds ratio 30 95": 50912,
      "ratio 30 95 confidence": 67728,
      "30 95 confidence interval": 3710,
      "dose 90 morphine milligram": 25816,
      "90 morphine milligram equivalents": 6110,
      "intensive care unit icu": 39335,
      "randomized controlled studies needed": 67067,
      "acute chronic pain clinical": 7621,
      "total number opioid prescriptions": 81851,
      "adverse events reported study": 8803,
      "prescription opioid analgesics heroin": 64288,
      "opioid therapy nonmalignant pain": 52418,
      "rate ratios rrs 95": 67511,
      "ratios rrs 95 confidence": 67834,
      "rrs 95 confidence intervals": 73025,
      "rr 21 95 ci": 72909,
      "rr 43 95 ci": 72929,
      "95 ci 47 00": 6302,
      "conducted interrupted time series": 19369,
      "52 year old man": 5002,
      "intravenous self administration oxycodone": 39885,
      "did alter oxycodone self": 24408,
      "alter oxycodone self administration": 9684,
      "non medical use prescription": 49636,
      "medical use prescription drugs": 44422,
      "codeine morphine oxycodone compared": 17260,
      "misuse abuse prescription opioids": 46711,
      "rectus sheath block rsb": 68813,
      "completed study statistically significant": 18499,
      "group mean 13 mg": 33853,
      "mg kg 95 confidence": 45953,
      "kg 95 confidence interval": 40690,
      "95 confidence interval 07": 6380,
      "95 confidence interval 05": 6378,
      "postoperative pain relief patients": 62913,
      "pain relief patients undergoing": 57567,
      "rsb aim present study": 73030,
      "aim present study evaluate": 9397,
      "post anaesthesia care unit": 62556,
      "cumulative oxycodone consumption 24": 21404,
      "oxycodone consumption 24 hours": 54854,
      "consumption 24 hours surgery": 19879,
      "24 48 hours postoperatively": 3169,
      "selective opioid receptor antagonist": 74439,
      "minimally invasive surgical techniques": 46588,
      "study included 60 patients": 78251,
      "assisted laparoscopic radical prostatectomy": 12198,
      "mg celecoxib 400 mg": 45820,
      "celecoxib 400 mg orally": 15453,
      "mg hours oxycodone mg": 45910,
      "acetaminophen 325 mg tablets": 7130,
      "mg tablets hours needed": 46231,
      "tablets hours needed pain": 80164,
      "opioid use significantly reduced": 52593,
      "postoperative opioid use patients": 62829,
      "opioid use patients undergoing": 52563,
      "associated non medical use": 12349,
      "non medical use pharmaceutical": 49635,
      "patterns opioid use cohort": 60218,
      "people regularly tamper pharmaceutical": 60425,
      "regularly tamper pharmaceutical opioids": 69489,
      "opioids australia design methods": 52739,
      "australia design methods data": 12688,
      "new south wales nsw": 49376,
      "people tamper pharmaceutical opioids": 60429,
      "background effective postoperative pain": 13045,
      "effective postoperative pain management": 27676,
      "extended release liposomal bupivacaine": 30881,
      "study design randomized double": 78087,
      "design randomized double blinded": 23775,
      "postoperative day pain scores": 62742,
      "group placebo group postoperative": 33916,
      "pain scores postoperative day": 57766,
      "statistically significant difference morphine": 77210,
      "generic extended release oxycodone": 33049,
      "patients sickle cell disease": 59978,
      "001 visual analog scale": 222,
      "pain patients sickle cell": 57359,
      "health care providers patients": 34684,
      "background nonmedical use prescription": 13092,
      "nonmedical use prescription opioid": 49789,
      "opioids people inject drugs": 53170,
      "people inject drugs pwid": 60415,
      "methods data derived prospective": 45301,
      "data derived prospective cohort": 21942,
      "derived prospective cohort studies": 23635,
      "13 95 confidence interval": 1479,
      "illicit prescription opioid use": 36650,
      "symptoms associated opioid withdrawal": 79875,
      "acetaminophen codeine 300 mg": 7164,
      "self reported pain scores": 74501,
      "new formulation extended release": 49331,
      "extended release oxycodone oxycontin": 30897,
      "legitimate need pain control": 41385,
      "growing problem united states": 34371,
      "abuse deterrent formulations opioids": 6692,
      "patients treated opioid analgesics": 60064,
      "methadone maintenance treatment mmt": 45097,
      "using time series analysis": 85642,
      "results statistically significant increase": 71967,
      "significant increase total number": 75562,
      "opioid pills prescribed patient": 52064,
      "current study aimed examine": 21476,
      "10 20 40 mg": 686,
      "40 mg oxycodone 10": 4353,
      "similar oxycodone data suggest": 75968,
      "study evaluated efficacy safety": 78182,
      "evaluated efficacy safety tapentadol": 29882,
      "efficacy safety tapentadol extended": 28391,
      "safety tapentadol extended release": 73230,
      "extended release er compared": 30863,
      "release er compared oxycodone": 69840,
      "er compared oxycodone controlled": 29410,
      "compared oxycodone controlled release": 18238,
      "controlled release cr management": 20538,
      "release cr management moderate": 69819,
      "cr management moderate severe": 21067,
      "cancer pain research design": 14855,
      "blind active controlled study": 13919,
      "weeks double blind treatment": 86908,
      "treatment clinicaltrials gov identifier": 82498,
      "main outcome measures study": 42845,
      "average pain intensity 11": 12923,
      "pain intensity 11 point": 56881,
      "intensity 11 point numerical": 39220,
      "emergent adverse events teaes": 28705,
      "difference change pain intensity": 24601,
      "change pain intensity baseline": 15740,
      "tapentadol er oxycodone cr": 80405,
      "06 95 confidence interval": 585,
      "upper limit 95 ci": 84009,
      "lower tapentadol er group": 42710,
      "better gastrointestinal tolerability profile": 13715,
      "gastrointestinal tolerability profile oxycodone": 32895,
      "tolerability profile oxycodone cr": 81550,
      "prevention treatment opioid abuse": 64888,
      "micro opioid receptor agonist": 46341,
      "kappa opioid receptor agonist": 40593,
      "non selective opioid receptor": 49682,
      "showed significant positive correlation": 75304,
      "management chronic moderate severe": 43163,
      "cost utility analysis performed": 20890,
      "utility analysis performed using": 85722,
      "adjusted life year qaly": 8032,
      "pharmaceutical opioid overdose rates": 61035,
      "sydney medically supervised injecting": 79848,
      "medically supervised injecting centre": 44430,
      "supervised injecting centre msic": 79158,
      "opioids nonsteroidal anti inflammatory": 53101,
      "analgesia reduce postoperative pain": 10083,
      "pain opioid consumption patients": 57283,
      "opioid consumption patients undergoing": 51645,
      "methods eighty patients undergoing": 45329,
      "scale nrs pain score": 73516,
      "nrs pain scores significantly": 50070,
      "pain scores significantly lower": 57783,
      "scores significantly lower group": 73992,
      "group median interquartile range": 33858,
      "median interquartile range iqr": 44232,
      "methods healthy participants 10": 45349,
      "completed subject double blind": 18502,
      "placebo controlled randomized outpatient": 61697,
      "controlled randomized outpatient study": 20533,
      "randomized outpatient study sessions": 67139,
      "outpatient study sessions completed": 54147,
      "subjective effects drug liking": 78650,
      "effects background opioid use": 27837,
      "background opioid use disorder": 13117,
      "commonly used pharmaceutical opioids": 17894,
      "supply adjusted rates presentations": 79179,
      "multinomial logistic regression used": 48257,
      "opioids patients chronic pain": 53160,
      "hydrocodone oxycodone hydromorphone oxymorphone": 36117,
      "milligram equivalents mme dispensed": 46462,
      "continuous positive airway pressure": 20184,
      "acute chronic moderate severe": 7619,
      "study selection data extraction": 78480,
      "treat acute chronic pain": 82273,
      "buprenorphine fentanyl hydrocodone hydromorphone": 14542,
      "fentanyl hydrocodone hydromorphone morphine": 31492,
      "hydrocodone hydromorphone morphine methadone": 36090,
      "using researched abuse diversion": 85597,
      "present study designed determine": 64651,
      "effects single oral dose": 28164,
      "oral dose morphine oxycodone": 53523,
      "materials methods double blind": 43507,
      "blind placebo controlled crossover": 13953,
      "opioid analgesics commonly used": 51490,
      "design setting retrospective analysis": 23802,
      "abuse warning network dawn": 6911,
      "addiction severity index multimedia": 7772,
      "severity index multimedia version": 75042,
      "index multimedia version asi": 38199,
      "multimedia version asi mv": 48196,
      "adults assessed substance abuse": 8548,
      "assessed substance abuse treatment": 12069,
      "results past 30 day": 71838,
      "prevalence past 30 day": 64801,
      "randomized controlled double blinded": 67061,
      "double dummy subject crossover": 26410,
      "results difference primary outcome": 71663,
      "primary outcome measures pain": 65072,
      "opana er endo pharmaceuticals": 51143,
      "pubmed embase cochrane databases": 66449,
      "studies healthy volunteers patients": 77739,
      "data national survey drug": 22017,
      "drug use health survey": 26837,
      "year old man dead": 87464,
      "anilino phenethyl piperidine anpp": 10989,
      "involving buprenorphine fentanyl hydrocodone": 40125,
      "fentanyl hydrocodone hydromorphone methadone": 31491,
      "hydrocodone hydromorphone methadone morphine": 36088,
      "hydromorphone methadone morphine oxycodone": 36189,
      "fentanyl hydrocodone methadone oxycodone": 31494,
      "major public health problem": 42973,
      "fentanyl hydromorphone morphine oxycodone": 31500,
      "annual defined daily doses": 11016,
      "defined daily doses 1000": 23131,
      "study design retrospective cohort": 78089,
      "retrospective cohort study objective": 72129,
      "cohort study objective aim": 17397,
      "study objective aim study": 78330,
      "objective aim study determine": 50370,
      "acute months subacute acute": 7644,
      "months subacute acute use": 47476,
      "subacute acute use use": 78586,
      "acute use use months": 7709,
      "use use months chronic": 84795,
      "use months chronic subacute": 84498,
      "months chronic subacute use": 47435,
      "chronic subacute use use": 16346,
      "subacute use use months": 78591,
      "multivariate logistic regression used": 48348,
      "opioid na\u00efve patients year": 51993,
      "na\u00efve patients year reoperation": 48850,
      "patients year reoperation rate": 60186,
      "year reoperation rate compared": 87496,
      "reoperation rate compared 25": 70374,
      "age sex charlson comorbidity": 9116,
      "sex charlson comorbidity index": 75065,
      "opioid medications associated increased": 51911,
      "medications associated increased reoperations": 44594,
      "objectives objective study evaluate": 50572,
      "methods cross sectional survey": 45297,
      "cancer experience moderate severe": 14781,
      "experience moderate severe pain": 30585,
      "tapentadol novel centrally acting": 80448,
      "novel centrally acting analgesic": 50006,
      "relief cancer pain adults": 70107,
      "reference lists retrieved papers": 69136,
      "additional trials identified electronic": 7903,
      "trials identified electronic searches": 83149,
      "controlled trials rcts tapentadol": 20645,
      "adults moderate severe cancer": 8570,
      "authors independently extracted data": 12738,
      "standard form assessed risk": 76909,
      "form assessed risk bias": 32275,
      "assessed risk bias extracted": 12057,
      "data study design participant": 22124,
      "study design participant details": 78073,
      "design participant details interventions": 23741,
      "participant details interventions outcomes": 58256,
      "adverse events main results": 8769,
      "events main results included": 30066,
      "scores patient global impression": 73944,
      "patient global impression change": 58651,
      "efficacy reported adverse events": 28351,
      "bias open label design": 13771,
      "pain relief adverse events": 57522,
      "prescription mg oxycodone tablets": 64256,
      "active comparator cohort study": 7487,
      "endpoint cumulative oxycodone consumed": 28885,
      "secondary endpoints pain scores": 74229,
      "endpoints pain scores numeric": 28917,
      "pain scores numeric rating": 57747,
      "scores numeric rating scale": 73922,
      "nonlinear mixed effect modeling": 49759,
      "risk pharmacokinetic drug interactions": 72636,
      "chromatography mass spectrometry gc": 16163,
      "mass spectrometry gc ms": 43461,
      "clinical trials evaluated efficacy": 16947,
      "comparing tapentadol extended release": 18362,
      "patients global impression change": 59330,
      "tapentadol er compared placebo": 80402,
      "23 95 confidence interval": 3090,
      "pharmacodynamics pharmacokinetics efficacy tolerability": 61090,
      "pharmacokinetics efficacy tolerability dosing": 61170,
      "efficacy tolerability dosing role": 28404,
      "immediate release ir extended": 36719,
      "release ir extended release": 69875,
      "ir extended release er": 40227,
      "data source medline pubmed": 22110,
      "source medline pubmed search": 76498,
      "additional references obtained bibliographies": 7889,
      "references obtained bibliographies study": 69149,
      "obtained bibliographies study selection": 50763,
      "opioid receptor agonist structurally": 52242,
      "receptor agonist structurally similar": 68467,
      "oxymorphone er superior placebo": 56239,
      "oxycodone cr morphine cr": 54901,
      "expected opioid effects comparable": 30558,
      "opioid effects comparable oxycodone": 51761,
      "indicated relief moderate severe": 38247,
      "hepatic impairment child pugh": 34955,
      "impairment child pugh class": 36887,
      "renal impairment creatinine clearance": 70363,
      "newest oral opioid enter": 49413,
      "oral opioid enter crowded": 53606,
      "opioid enter crowded marketplace": 51767,
      "enter crowded marketplace totaling": 29053,
      "does appear unique assets": 25676,
      "appear unique assets liabilities": 11389,
      "unique assets liabilities considered": 83754,
      "assets liabilities considered oral": 12162,
      "liabilities considered oral opioids": 41635,
      "persistent pain moderate severe": 60925,
      "pain moderate severe intensity": 57206,
      "anti inflammatory analgesic properties": 11121,
      "valdecoxib 10 mg day": 85763,
      "10 mg day effective": 811,
      "american college rheumatology 20": 9794,
      "provided effective pain relief": 66132,
      "naproxen sodium 550 mg": 48573,
      "oxycodone 10 mg plus": 54502,
      "10 mg plus paracetamol": 843,
      "mg plus paracetamol acetaminophen": 46167,
      "provided similar pain relief": 66161,
      "prescription opioids hydrocodone oxycodone": 64340,
      "opioids hydrocodone oxycodone hydromorphone": 52958,
      "using negative binomial regression": 85514,
      "analgesic regimen postoperative pain": 10317,
      "medication related adverse effects": 44557,
      "multimodal pain management protocol": 48229,
      "prescription drug monitoring programs": 64215,
      "drug monitoring programs pdmps": 26719,
      "human abuse potential studies": 35941,
      "pain fifth vital sign": 56782,
      "treated opioid use disorder": 82357,
      "opioid related hospital admissions": 52318,
      "prescription opioid use increased": 64318,
      "opioid analgesics treatment pain": 51532,
      "influx blood brain barrier": 38613,
      "self administration progressive ratio": 74475,
      "network meta analysis nma": 49162,
      "fentanyl hydromorphone methadone morphine": 31498,
      "methadone morphine oxycodone tapentadol": 45106,
      "analgesic treatment chronic pain": 10350,
      "retrospective observational cohort study": 72147,
      "cox proportional hazards models": 21031,
      "adjusted hazard ratio hr": 8025,
      "defined daily doses ddds": 23133,
      "statewide prescription drug monitoring": 77164,
      "methadone morphine oxycodone tramadol": 45107,
      "low dose opioid antagonists": 42476,
      "evidence animal human studies": 30145,
      "methods conducted retrospective cohort": 45285,
      "used multivariable poisson regression": 85024,
      "patients using long acting": 60170,
      "using long acting opioids": 85474,
      "individual long acting opioids": 38300,
      "reinforcing effects commonly abused": 69525,
      "mg 70 kg buprenorphine": 45766,
      "120 mg day oral": 1405,
      "mg day oral morphine": 45858,
      "dose related increases positive": 26049,
      "related increases positive subjective": 69624,
      "positive subjective ratings feel": 62497,
      "subjective ratings feel good": 78669,
      "ratings feel good drug": 67699,
      "feel good drug effect": 31333,
      "good drug effect like": 33305,
      "drug effect like drug": 26609,
      "data suggest abuse liability": 22129,
      "milk plasma concentration ratio": 46445,
      "opioids buprenorphine fentanyl hydrocodone": 52758,
      "using solid phase extraction": 85619,
      "gc ms electron impact": 32919,
      "using selected ion monitoring": 85606,
      "selected ion monitoring gc": 74390,
      "ion monitoring gc ms": 40144,
      "study design prospective observational": 78082,
      "design prospective observational study": 23763,
      "prospective observational study objective": 65849,
      "observational study objective aim": 50631,
      "record daily opioid use": 68655,
      "daily opioid use pain": 21777,
      "opioid use pain levels": 52555,
      "use pain levels level": 84596,
      "understanding postoperative opioid consumption": 83650,
      "opioid use converted oral": 52489,
      "use converted oral morphine": 84284,
      "pills oxycodone mg equivalents": 61527,
      "patients 27 did use": 58849,
      "27 did use opioids": 3492,
      "sickle cell disease scd": 75371,
      "evidence based guidelines exist": 30158,
      "analgesics nonsteroidal anti inflammatory": 10458,
      "opioid medications morphine oxycodone": 51917,
      "gold standard pain management": 33286,
      "opioids morphine fentanyl oxycodone": 53071,
      "mg oral morphine equivalent": 46085,
      "oral morphine equivalent dose": 53577,
      "case report 41 year": 15187,
      "report 41 year old": 70445,
      "sold oxycodone hydrocodone alprazolam": 76421,
      "prescription opioid pain relievers": 64308,
      "analgesic mechanisms action opioid": 10269,
      "mechanisms action opioid receptor": 44139,
      "action opioid receptor agonism": 7440,
      "opioid receptor agonism norepinephrine": 52237,
      "receptor agonism norepinephrine reuptake": 68460,
      "agonism norepinephrine reuptake inhibition": 9275,
      "individuals assessed substance abuse": 38338,
      "substance abuse treatment navippro": 78802,
      "2012 examined prevalence prescription": 2601,
      "examined prevalence prescription adjusted": 30409,
      "prevalence prescription adjusted prevalence": 64806,
      "past 30 day abuse": 58456,
      "extended release er formulations": 30866,
      "24 48 hours surgery": 3170,
      "treatment acute moderate severe": 82428,
      "surgery methods multicenter randomized": 79463,
      "methods multicenter randomized double": 45391,
      "multicenter randomized double blind": 48171,
      "active placebo controlled parallel": 7532,
      "placebo controlled parallel group": 61692,
      "controlled parallel group study": 20513,
      "aged 18 years undergoing": 9170,
      "mild moderate severe pain": 46432,
      "mm 100 mm visual": 46926,
      "pain 100 worst pain": 56363,
      "10 20 mg oxycodone": 688,
      "ir 15 mg placebo": 40201,
      "primary efficacy end point": 65005,
      "demographic characteristics similar groups": 23275,
      "active treatments compared placebo": 7542,
      "15 mg 24 hours": 1750,
      "pain intensity significantly lower": 56948,
      "ir 15 mg compared": 40200,
      "groups respectively proportions patients": 34303,
      "analgesia moderate severe pain": 10028,
      "hydrocodone codeine oxycodone tramadol": 36070,
      "defined emergency department visit": 23139,
      "short acting opioids incidence": 75160,
      "er morphine er oxycodone": 29443,
      "adults severe chronic pain": 8581,
      "severe chronic pain adequately": 74935,
      "chronic pain adequately managed": 16257,
      "pain adequately managed opioid": 56418,
      "adequately managed opioid analgesics": 7981,
      "objectives aim study compare": 50539,
      "severe chronic nonmalignant pain": 74933,
      "second line opioid data": 74189,
      "randomized clinical trials clinical": 67050,
      "treatment severe chronic pain": 82839,
      "treatment patients severe chronic": 82751,
      "treating opioid use disorder": 82402,
      "increased substantially study period": 38035,
      "prescribed opioid use disorder": 63917,
      "risk opioid use disorder": 72623,
      "opioid use disorder opioid": 52503,
      "use prescription drug monitoring": 84651,
      "american academy otolaryngology head": 9790,
      "academy otolaryngology head neck": 6967,
      "otolaryngology head neck surgery": 53887,
      "national health medical research": 48687,
      "health medical research council": 34734,
      "systematic reviews randomized controlled": 80003,
      "reviews randomized controlled trials": 72420,
      "effective postoperative pain control": 27675,
      "25 95 ci 25": 3345,
      "95 ci 25 26": 6269,
      "95 ci 39 39": 6289,
      "aim current study evaluate": 9383,
      "fellowship trained foot ankle": 31347,
      "narcotic use level evidence": 48618,
      "use level evidence level": 84452,
      "level evidence level iii": 41474,
      "background multimodal analgesia protocols": 13086,
      "patients admitted level trauma": 58955,
      "admitted level trauma center": 8430,
      "inhibitors selective serotonin reuptake": 38810,
      "selective serotonin reuptake inhibitors": 74445,
      "serotonin reuptake inhibitors serotonin": 74686,
      "reuptake inhibitors serotonin norepinephrine": 72207,
      "inhibitors serotonin norepinephrine reuptake": 38813,
      "serotonin norepinephrine reuptake inhibitors": 74681,
      "united states aimed identify": 83779,
      "surgery benign gynecologic indications": 79336,
      "pain control patient population": 56636,
      "injecting drug users idu": 38928,
      "multivariable logistic regression used": 48329,
      "past 30 day use": 58457,
      "30 day use oxycontin": 3723,
      "descriptive statistics chi square": 23683,
      "statistics chi square tests": 77245,
      "logistic regression used calculate": 42275,
      "regression used calculate adjusted": 69462,
      "adjusted odds ratios aor": 8047,
      "mean age 45 years": 43683,
      "copyright 2017 john wiley": 20764,
      "2017 john wiley sons": 2786,
      "total hip arthroplasty tha": 81812,
      "oxycodone mg equivalents oe": 55418,
      "patients undergoing primary tha": 60124,
      "90 day opioid filling": 6088,
      "evidence level iii retrospective": 30211,
      "level iii retrospective prognostic": 41494,
      "iii retrospective prognostic cohort": 36598,
      "retrospective prognostic cohort study": 72156,
      "prognostic cohort study background": 65530,
      "confidence interval ci 15": 19464,
      "used treatment moderate severe": 85181,
      "opioid induced neurotoxicity oin": 51866,
      "median time onset oin": 44290,
      "monoacetylmorphine buprenorphine codeine dihydrocodeine": 47358,
      "hydrocodone hydromorphone morphine oxycodone": 36091,
      "hydromorphone morphine oxycodone oxymorphone": 36196,
      "prospective double blinded placebo": 65831,
      "placebo controlled trial setting": 61709,
      "paracetamol non steroidal anti": 58105,
      "anti inflammatory drugs morphine": 11129,
      "secondary outcomes included pain": 74248,
      "outcomes included pain scores": 54037,
      "pain scores rest activity": 57775,
      "controlled release oxycodone cr": 20557,
      "extended release abuse deterrent": 30856,
      "extended release oxycodone extended": 30895,
      "release oxycodone extended release": 69938,
      "release abuse deterrent opioid": 69807,
      "annual medical cost savings": 11022,
      "non abuse deterrent opioids": 49563,
      "open inguinal hernia repair": 51154,
      "patients undergoing elective lower": 60100,
      "mg ketorolac 30 mg": 45946,
      "intravenous ketorolac 30 mg": 39853,
      "codeine tramadol hydrocodone oxycodone": 17292,
      "number prescribed schedule ii": 50237,
      "total morphine milligram equivalent": 81846,
      "morphine milligram equivalent mme": 47769,
      "evaluate evidence use opioids": 29799,
      "efficacy safety patient satisfaction": 28378,
      "study randomized controlled trial": 78449,
      "animal models acute chronic": 10998,
      "general anesthesia randomly assigned": 32968,
      "pain scores worst pain": 57799,
      "pain postanesthesia care unit": 57389,
      "pain scores opioid use": 57753,
      "iqvia compuscript converted defined": 40188,
      "design retrospective chart review": 23784,
      "retrospective chart review setting": 72120,
      "chart review setting tertiary": 15932,
      "50 patients received intravenous": 4884,
      "lc ms ms method": 41269,
      "computed tomography ct guided": 18657,
      "conducted liquid chromatography tandem": 19374,
      "methadone ethylidene dimethyl diphenylpyrrolidine": 45069,
      "ethylidene dimethyl diphenylpyrrolidine eddp": 29706,
      "strong opioid morphine oxycodone": 77534,
      "residents aged 65 years": 71073,
      "treatment opioid abuse dependence": 82699,
      "treatment prescription opioid abuse": 82782,
      "received institutional review board": 68170,
      "student test used compare": 77599,
      "collected pain management patients": 17469,
      "codeine morphine hydrocodone hydromorphone": 17256,
      "opioid epidemic continues impact": 51772,
      "united states new strategies": 83808,
      "study design population based": 78078,
      "population based descriptive study": 62311,
      "prescription drug abuse epidemic": 64205,
      "drug enforcement agency dea": 26620,
      "enforcement agency dea schedule": 28930,
      "opioids tramadol tilidine naloxone": 53348,
      "oxycodone hydromorphone fentanyl methadone": 55221,
      "hydromorphone fentanyl methadone buprenorphine": 36172,
      "prescription opioid users history": 64321,
      "aged 18 64 years": 9162,
      "opioid naive patients undergoing": 51973,
      "opioid prescriptions filled opioid": 52188,
      "total oral morphine equivalents": 81872,
      "prescription opioid abuse overdose": 64277,
      "using multiple cause death": 85506,
      "multiple cause death data": 48263,
      "national center health statistics": 48671,
      "prescription opioids increased dramatically": 64343,
      "formulations long acting opioids": 32386,
      "performed systematic review evaluate": 60639,
      "lack evidence based guidelines": 41055,
      "postoperative pain opioid use": 62904,
      "opioid use study design": 52598,
      "combination oxycodone mg acetaminophen": 17588,
      "significant difference postoperative pain": 75491,
      "postoperative pain control following": 62858,
      "patients immediate postoperative period": 59378,
      "using patient controlled analgesia": 85551,
      "patient controlled analgesia pain": 58588,
      "use patient controlled analgesia": 84608,
      "patient controlled analgesia results": 58592,
      "used patient controlled analgesia": 85070,
      "patient controlled analgesia postoperative": 58590,
      "controlled analgesia postoperative pain": 20463,
      "postoperative pain management patients": 62885,
      "lower mean pain scores": 42646,
      "98 95 confidence interval": 6462,
      "postoperative pain control patients": 62860,
      "pain control patients undergoing": 56640,
      "randomly divided groups group": 67234,
      "pro inflammatory cytokine levels": 65208,
      "postoperative pain intensity measured": 62878,
      "patients undergoing upper extremity": 60135,
      "patients received brachial plexus": 59769,
      "group received iv morphine": 33954,
      "received iv morphine mg": 68188,
      "patients instructed acetaminophen 325": 59418,
      "instructed acetaminophen 325 mg": 39106,
      "acetaminophen 325 mg oxycodone": 7128,
      "325 mg oxycodone mg": 3961,
      "24 acetaminophen oxycodone use": 3186,
      "short long term outcomes": 75182,
      "extended release oxycodone products": 30898,
      "extended release opioid analgesics": 30887,
      "women undergoing laparoscopic hysterectomy": 87254,
      "anxiety depression pain catastrophizing": 11273,
      "150 morphine milligram equivalents": 1817,
      "morphine milligram equivalents equivalent": 47773,
      "milligram equivalents equivalent 20": 46458,
      "equivalents equivalent 20 tablets": 29351,
      "37 morphine milligram equivalents": 4199,
      "patients undergoing laparoscopic hysterectomy": 60109,
      "acute postoperative pain control": 7687,
      "state level opioid prescription": 77051,
      "setting united states participants": 74841,
      "95 confidence interval 001": 6376,
      "randomised controlled trial setting": 67016,
      "001 non steroidal anti": 164,
      "use urine drug testing": 84792,
      "opioid analgesic prescribing practices": 51467,
      "plasma elimination half life": 61932,
      "provide effective pain relief": 66054,
      "opioid therapy chronic pain": 52409,
      "pain objective objective study": 57265,
      "setting retrospective cohort study": 74815,
      "kaiser permanente northern california": 40579,
      "permanente northern california kpnc": 60902,
      "january 2009 june 2010": 40432,
      "main outcome measures total": 42846,
      "receiving long acting opioids": 68349,
      "used treat moderate severe": 85169,
      "potential severe adverse effects": 63229,
      "case reports case series": 15197,
      "analgesics mainstay pain management": 10446,
      "partial mu opioid receptor": 58245,
      "combination opioid agonist antagonist": 17577,
      "aged 25 34 years": 9183,
      "guanosine 35 thio triphosphate": 34394,
      "patients randomized open label": 59737,
      "methods patients scheduled undergo": 45443,
      "surgery randomly assigned receive": 79551,
      "randomly assigned receive opioid": 67227,
      "end surgery patients received": 28825,
      "10 numeric rating scale": 878,
      "scale pain 10 worst": 73530,
      "pain 10 worst pain": 56359,
      "group experienced treatment emergent": 33778,
      "experienced treatment emergent adverse": 30634,
      "incidence treatment emergent adverse": 37326,
      "emergent adverse events comparable": 28703,
      "addiction related surveillance streetrx": 7763,
      "related surveillance streetrx program": 69694,
      "medications opioid use disorder": 44655,
      "morphine codeine semi synthetic": 47607,
      "codeine semi synthetic derivatives": 17287,
      "oxycodone opioid antagonist naloxone": 55569,
      "year old white man": 87469,
      "long term treatment patients": 42358,
      "abuse significant public health": 6876,
      "public health problem countries": 66395,
      "tricyclic antidepressants selective serotonin": 83220,
      "antidepressants selective serotonin norepinephrine": 11180,
      "morphine sulfate oxycodone hydrochloride": 47943,
      "commonly used pain management": 17891,
      "cleft lip repair decreased": 16730,
      "significantly lower patients receiving": 75803,
      "children undergoing cleft lip": 16076,
      "surgery design setting participants": 79375,
      "main outcomes measures addition": 42850,
      "postoperative nausea vomiting significantly": 62806,
      "nausea vomiting significantly reduced": 48817,
      "oxycodone er morphine er": 55041,
      "using grading recommendations assessment": 85421,
      "quality evidence strong opioids": 66697,
      "used treatment acute chronic": 85176,
      "treatment acute chronic pain": 82426,
      "opioid receptor antagonist naloxone": 52246,
      "fentanyl induced respiratory depression": 31507,
      "induced antinociception hot plate": 38384,
      "antinociception hot plate assay": 11225,
      "effective preventing oxycodone induced": 27684,
      "preventing oxycodone induced antinociception": 64868,
      "opioids codeine tramadol oxycodone": 52793,
      "proton pump inhibitors ppis": 66012,
      "acetaminophen nonsteroidal anti inflammatory": 7215,
      "opioids oxycodone hydrocodone tramadol": 53138,
      "evaluated information deemed relevant": 29895,
      "information deemed relevant included": 38641,
      "treat patients chronic pain": 82312,
      "chronic pain use drugs": 16323,
      "heroin oxycodone methadone fentanyl": 35025,
      "data drug abuse warning": 21954,
      "non medical use opioids": 49633,
      "respiratory depressant effects opioids": 71265,
      "receptor types mu delta": 68534,
      "types mu delta kappa": 83370,
      "metabolism commonly used opioids": 44927,
      "drugs acting different mechanisms": 26873,
      "overdose deaths united states": 54284,
      "ah 7921 mt 45": 9356,
      "half life parent opioid": 34519,
      "opioid treatment chronic pain": 52444,
      "adverse effect profile analgesic": 8633,
      "case 57 year old": 15161,
      "10 100 ng ml": 663,
      "ng ml oxycodone 100": 49451,
      "ml oxycodone 100 000": 46887,
      "oxycodone 100 000 ng": 54507,
      "100 000 ng ml": 971,
      "prescription opioid addiction treatment": 64283,
      "opioid addiction treatment study": 51403,
      "addiction treatment study poats": 7776,
      "clinical opiate withdrawal scale": 16846,
      "opiate withdrawal scale cows": 51317,
      "main outcomes measures proportion": 42852,
      "prescriptions long acting opioids": 64510,
      "maintenance treatment mmt methods": 42924,
      "cross sectional study included": 21266,
      "12 95 ci 32": 1268,
      "oral morphine milligram equivalents": 53586,
      "morphine milligram equivalents mmes": 47776,
      "day secondary outcomes included": 22413,
      "clinically significant difference pain": 17002,
      "significant difference pain scores": 75488,
      "systematic review meta analysis": 79993,
      "based systematic review meta": 13392,
      "extended release versus oxycodone": 30907,
      "negative impact quality life": 49079,
      "quality life patients cancer": 66738,
      "randomized clinical trials published": 67051,
      "post herpetic neuralgia phn": 62570,
      "morphine oxycodone widely used": 47864,
      "prescription monitoring programs pmps": 64261,
      "moderate severe pain different": 47197,
      "ir patients moderate severe": 40256,
      "efficacy safety oxymorphone er": 28375,
      "opioid experienced opioid na\u00efve": 51792,
      "experienced opioid na\u00efve patients": 30620,
      "56 year old man": 5111,
      "year old man presented": 87465,
      "using truven health analytics": 85650,
      "truven health analytics marketscan": 83259,
      "hydrocodone codeine oxycodone oxymorphone": 36069,
      "codeine oxycodone oxymorphone methadone": 17271,
      "oxycodone oxymorphone methadone fentanyl": 55619,
      "proportion patients receiving tramadol": 65772,
      "prevalence prescription opioid po": 64808,
      "patients impaired renal hepatic": 59383,
      "impaired renal hepatic function": 36879,
      "studies case reports included": 77660,
      "used caution close patient": 84871,
      "caution close patient monitoring": 15412,
      "mean age 26 years": 43677,
      "purpose study evaluate impact": 66582,
      "opioid prescription filling patients": 52148,
      "prescription filling patients undergoing": 64226,
      "patients undergoing total knee": 60132,
      "undergoing total knee arthroplasty": 83589,
      "commercially available insurance database": 17719,
      "insurance database 2010 2018": 39148,
      "states opioid limiting legislation": 77131,
      "multivariable linear logistic regression": 48322,
      "states opioid legislation legislation": 77129,
      "opioid legislation legislation targeting": 51885,
      "legislation legislation targeting duration": 41375,
      "prescribed treatment moderate severe": 63998,
      "opioid induced hyperalgesia oih": 51862,
      "chronic pain opioid therapy": 16291,
      "results survey response rate": 72004,
      "chronic pain conditions associated": 16269,
      "opioids morphine fentanyl hydromorphone": 53070,
      "morphine fentanyl hydromorphone oxycodone": 47691,
      "united states food drug": 83796,
      "states food drug administration": 77104,
      "crisis united states canada": 21184,
      "milligram morphine equivalents mmes": 46474,
      "followed tramadol acetaminophen oxycodone": 32086,
      "year old female presented": 87459,
      "population based administrative data": 62305,
      "acute postoperative pain remains": 7692,
      "manage acute postoperative pain": 43116,
      "extended release epidural morphine": 30859,
      "opioids growing public health": 52939,
      "opiates morphine codeine semi": 51332,
      "specimens liquid chromatography tandem": 76642,
      "impact patients quality life": 36838,
      "repetitive transcranial magnetic stimulation": 70425,
      "transcranial magnetic stimulation rtms": 82129,
      "oxycodone naloxone prolonged release": 55516,
      "naloxone prolonged release tablets": 48509,
      "prescription drug misuse abuse": 64212,
      "treatment somatic visceral pain": 82848,
      "causes chronic abdominal pain": 15394,
      "milligram morphine equivalents mme": 46473,
      "urban safety net hospital": 84035,
      "positive urine drug test": 62506,
      "sinus surgery ess study": 76151,
      "surgery ess study design": 79395,
      "study design case series": 78066,
      "design case series planned": 23702,
      "case series planned data": 15205,
      "series planned data collection": 74663,
      "planned data collection setting": 61883,
      "oxycodone acetaminophen 325 mg": 54631,
      "postoperative period pain management": 62940,
      "10 cm visual analogue": 747,
      "cm visual analogue scale": 17092,
      "postoperative pain remains common": 62916,
      "enhanced recovery surgery eras": 28975,
      "acetaminophen non steroidal anti": 7212,
      "transcutaneous electrical nerve stimulation": 82140,
      "case report patient developed": 15193,
      "57 year old woman": 5142,
      "year old woman presented": 87473,
      "drug interaction probability scale": 26662,
      "pain prescription opioid abuse": 57413,
      "kg diclofenac mg kg": 40718,
      "mg kg significantly reduced": 46030,
      "methods retrospective case control": 45533,
      "retrospective case control study": 72114,
      "31 95 ci 17": 3863,
      "95 ci 17 45": 6256,
      "common long acting opioids": 17766,
      "aor 51 95 ci": 11311,
      "51 95 ci 46": 4953,
      "aor 39 95 ci": 11302,
      "aor 33 95 ci": 11299,
      "aor 56 95 ci": 11317,
      "methods single center randomized": 45580,
      "single center randomized controlled": 76065,
      "center randomized controlled trial": 15547,
      "randomized controlled trial conducted": 67073,
      "opioid use postoperative pain": 52570,
      "delta opioid receptors dor": 23241,
      "opioid prescription use patients": 52168,
      "percent patients received opioid": 60478,
      "patients received opioid prescription": 59802,
      "state prescription drug monitoring": 77063,
      "drug monitoring program database": 26716,
      "using 11 point numerical": 85291,
      "numerical rating scales nrs": 50322,
      "patients completed study interventions": 59116,
      "adverse drug reactions adrs": 8627,
      "summary 48 year old": 79093,
      "methicillin resistant staphylococcus aureus": 45159,
      "oxycodone transdermal fentanyl oral": 56023,
      "transdermal fentanyl oral morphine": 82151,
      "chronic malignant nonmalignant pain": 16207,
      "chronic low pain chronic": 16201,
      "reduction pain intensity compared": 69087,
      "95 confidence interval 17": 6384,
      "pain control patients cancer": 56639,
      "multimodal procedure specific analgesia": 48244,
      "term opioid use compared": 80651,
      "milligram equivalent mme prescribed": 46453,
      "objective evaluate opioid prescribing": 50426,
      "20 ml liposomal bupivacaine": 2362,
      "patient reported pain scores": 58741,
      "patients met inclusion criteria": 59494,
      "average visual analog scale": 12945,
      "analog scale pain score": 10527,
      "scale pain score postoperative": 73536,
      "postoperative day postoperative day": 62751,
      "selection criteria randomised controlled": 74412,
      "criteria randomised controlled trials": 21211,
      "data collection analysis authors": 21915,
      "collection analysis authors independently": 17497,
      "analysis authors independently assessed": 10642,
      "authors independently assessed studies": 12736,
      "regard sex age bmi": 69236,
      "lower incidence nausea 18": 42632,
      "amitriptyline nortriptyline codeine oxycodone": 9826,
      "clinical decision support tools": 16785,
      "objective study evaluate effectiveness": 50510,
      "morphine equivalent daily doses": 47658,
      "equivalent daily doses medd": 29298,
      "pain databases data treatment": 56682,
      "studies met inclusion criteria": 77772,
      "health status quality life": 34780,
      "opioid antagonists naloxone naltrexone": 51542,
      "patients chronic pain opioids": 59084,
      "option management moderate severe": 53456,
      "morphine oxymorphone hydromorphone oxycodone": 47867,
      "short long acting opioids": 75180,
      "long acting short acting": 42310,
      "conditions patients chronic pain": 19326,
      "patients receiving long acting": 59842,
      "long acting opioid formulations": 42296,
      "related quality life hrqol": 69677,
      "surgery methods prospective cohort": 79467,
      "methods prospective cohort study": 45482,
      "hospital anxiety depression scale": 35566,
      "pain intensity similar groups": 56950,
      "analgesics codeine fentanyl oxycodone": 10393,
      "release formulations oxycodone morphine": 69866,
      "long acting opioids increased": 42303,
      "women opioid use disorder": 87232,
      "related overdose deaths united": 69650,
      "individuals entering substance abuse": 38344,
      "entering substance abuse treatment": 29066,
      "substance abuse treatment opioid": 78803,
      "abuse treatment opioid use": 6900,
      "treatment opioid use disorder": 82705,
      "methods retrospective chart review": 45536,
      "main outcome measures number": 42841,
      "use opioids treat pain": 84573,
      "prescribed opioids codeine oxycodone": 63923,
      "leading cause morbidity mortality": 41307,
      "cause morbidity mortality united": 15363,
      "morbidity mortality united states": 47515,
      "mortality united states opioid": 47999,
      "united states opioid use": 83812,
      "growing public health concern": 34374,
      "purpose quality improvement project": 66558,
      "mu opioid receptor agonists": 48126,
      "opioid na\u00efve opioid tolerant": 51983,
      "patients moderate severe cancer": 59521,
      "clinically relevant pain relief": 16996,
      "pain relief days median": 57534,
      "pain intensity significantly decreased": 56947,
      "moderate severe cancer related": 47173,
      "severe cancer related pain": 74924,
      "sample chronic pain patients": 73296,
      "chronic pain patients prescribed": 16303,
      "odds ratio 77 95": 50924,
      "cancer pain chronic cancer": 14821,
      "pain chronic cancer pain": 56538,
      "non cancer pain associated": 49579,
      "patients high risk nsaid": 59359,
      "high risk nsaid related": 35173,
      "strong opioids morphine hydromorphone": 77552,
      "opioids morphine hydromorphone oxycodone": 53073,
      "non cancer pain cancer": 49580,
      "cancer pain cancer pain": 14819,
      "providing adequate pain relief": 66250,
      "neuropathic pain rat model": 49257,
      "24 hours following surgery": 3219,
      "postoperative opioid use pain": 62828,
      "opioid use pain scores": 52557,
      "pain scores movement lower": 57739,
      "pain scores time intervals": 57788,
      "significant differences noted groups": 75509,
      "aim study evaluate impact": 9420,
      "study evaluate impact time": 78172,
      "evaluate impact time state": 29809,
      "90 day perioperative opioid": 6090,
      "day perioperative opioid prescribing": 22371,
      "opioid prescription filling oxycodone": 52147,
      "prescription filling oxycodone mg": 64224,
      "filling oxycodone mg equivalents": 31720,
      "abuse potential administered intravenously": 6812,
      "potential abuse prescription opioids": 63123,
      "effort combat opioid epidemic": 28432,
      "admitted intensive care unit": 8426,
      "patients chronic pain background": 59081,
      "pain opioid use following": 57292,
      "number opioid tablets consumed": 50199,
      "opioid tablets consumed results": 52395,
      "mean visual analog scale": 43903,
      "significantly lower dexamethasone group": 75781,
      "postoperative day compared control": 62738,
      "disease control prevention guidelines": 25328,
      "january 2017 december 31": 40455,
      "2017 december 31 2017": 2780,
      "received opioid prescription discharge": 68220,
      "median days interquartile range": 44212,
      "patient controlled analgesia oxycodone": 58587,
      "equally effective safe postoperative": 29243,
      "effective safe postoperative analgesia": 27700,
      "strong opioids opioid na\u00efve": 77554,
      "opioids opioid na\u00efve patients": 53121,
      "noradrenaline reuptake inhibition single": 49875,
      "reuptake inhibition single molecule": 72200,
      "inhibition single molecule mechanisms": 38788,
      "year safety study tapentadol": 87501,
      "mandated risk evaluation mitigation": 43303,
      "pain management patients undergoing": 57099,
      "prospective double blind placebo": 65828,
      "adverse events recorded results": 8798,
      "group significant difference groups": 34011,
      "groups incidence adverse events": 34219,
      "adverse events common adverse": 8737,
      "events common adverse events": 30023,
      "associated significant postoperative pain": 12429,
      "provides adequate pain relief": 66202,
      "prospective randomized single blinded": 65871,
      "buprenorphine codeine fentanyl hydrocodone": 14532,
      "hydrocodone hydromorphone meperidine methadone": 36086,
      "hydromorphone meperidine methadone morphine": 36185,
      "meperidine methadone morphine oxycodone": 44844,
      "methadone morphine oxycodone oxymorphone": 45105,
      "milligram equivalents mmes calculated": 46467,
      "codeine fentanyl hydromorphone methadone": 17234,
      "retrospective case series study": 72116,
      "results mean age patients": 71766,
      "adverse events occurred conclusions": 8779,
      "adverse events background emergency": 8733,
      "events background emergency department": 30018,
      "background emergency department ed": 13053,
      "emergency department ed patients": 28676,
      "use disorder oud methods": 84324,
      "chief complaint chronic pain": 16003,
      "department ed patients received": 23428,
      "ed patients aged 18": 27342,
      "intraoperative blood loss postoperative": 39769,
      "length hospital stay similar": 41403,
      "physical status ii patients": 61414,
      "morphine patient controlled analgesia": 47871,
      "patient controlled analgesia oral": 58586,
      "controlled analgesia oral analgesics": 20455,
      "wong baker faces pain": 87262,
      "baker faces pain rating": 13226,
      "faces pain rating scale": 31025,
      "patient controlled analgesia group": 58583,
      "controlled analgesia pca pump": 20461,
      "10 mg hours needed": 818,
      "results significant differences groups": 71955,
      "differences groups demographic clinical": 24747,
      "substance use mental health": 78820,
      "logistic regression analysis showed": 42261,
      "use mental health problems": 84479,
      "evaluate opioid prescribing patterns": 29819,
      "truven health marketscan commercial": 83261,
      "health marketscan commercial claims": 34730,
      "marketscan commercial claims encounters": 43435,
      "opioid use results study": 52588,
      "total morphine milligram equivalents": 81847,
      "milligram equivalents mme prescribed": 46463,
      "background peripheral nerve blocks": 13156,
      "12 24 hours postoperatively": 1238,
      "reported visual analog scale": 70679,
      "pain levels 24 hours": 57014,
      "retrospective comparative study objective": 72137,
      "patients undergoing open abdominal": 60116,
      "conclusion multimodal pain control": 18930,
      "disease presented emergency department": 25342,
      "fentanyl patient controlled analgesia": 31564,
      "methyl aspartate nmda receptor": 45643,
      "tolerance opioid induced hyperalgesia": 81594,
      "self reported pain intensity": 74499,
      "design single center retrospective": 23806,
      "setting academic urban safety": 74765,
      "academic urban safety net": 6962,
      "mg interquartile range iqr": 45929,
      "analgesia fewer undesirable effects": 9980,
      "patients undergoing cardiac surgery": 60092,
      "aged 18 years underwent": 9171,
      "24 hours postoperatively postoperative": 3227,
      "postoperative day secondary outcomes": 62755,
      "opioids statistically significant difference": 53311,
      "significant difference postoperative opioid": 75490,
      "total postoperative opioid requirements": 81892,
      "inguinal hernia repair ihr": 38755,
      "abdominis plane tap block": 6540,
      "abuse potential prescription opioids": 6829,
      "eds past decade methods": 27372,
      "past decade methods data": 58462,
      "national hospital ambulatory medical": 48691,
      "hospital ambulatory medical care": 35562,
      "ambulatory medical care survey": 9768,
      "pain related ed visits": 57512,
      "codeine hydrocodone hydromorphone morphine": 17243,
      "stratified drug enforcement agency": 77452,
      "adverse effects opioid analgesics": 8678,
      "abuse deterrent opioid formulation": 6698,
      "acting opioid receptor antagonist": 7405,
      "developed acute opioid withdrawal": 24168,
      "severe chronic low pain": 74931,
      "scale visual analog scale": 73584,
      "frequentist network meta analysis": 32540,
      "cochrane risk bias tool": 17186,
      "tail withdrawal latency water": 80254,
      "withdrawal latency water temperature": 87137,
      "risks associated opioid use": 72671,
      "rapid eye movement rem": 67384,
      "eye movement rem sleep": 31004,
      "methods patients undergoing elective": 45448,
      "measured morphine milligram equivalents": 43979,
      "prescription opioids particularly oxycodone": 64359,
      "cancer related neuropathic pain": 14907,
      "numerical rating scale primary": 50316,
      "common terminology criteria adverse": 17818,
      "terminology criteria adverse events": 80698,
      "united states limited data": 83802,
      "odds ratio 36 95": 50916,
      "ratio 36 95 confidence": 67734,
      "36 95 confidence interval": 4126,
      "49 95 confidence interval": 4773,
      "95 confidence interval 10": 6381,
      "82 95 ci 79": 5905,
      "public health concern risk": 66379,
      "pain vs moderate pain": 57983,
      "aor 57 95 ci": 11320,
      "aor 55 95 ci": 11314,
      "prescription opioid misuse index": 64302,
      "opioid misuse index pomi": 51942,
      "adults chronic non cancer": 8557,
      "median morphine milligram equivalent": 44248,
      "analogue scale vas score": 10561,
      "patients total hip replacement": 60055,
      "total hip replacement thr": 81815,
      "opioid prescriptions patients undergoing": 52205,
      "performed cross sectional analysis": 60582,
      "2015 truven health marketscan": 2725,
      "treatment chronic pain conditions": 82488,
      "aged 18 34 years": 9158,
      "population based cohort study": 62309,
      "patients filled opioid prescription": 59306,
      "32 mg morphine equivalent": 3931,
      "conclusions chronic opioid users": 19044,
      "epidemic prescription opioid use": 29148,
      "public health concern study": 66380,
      "study design cross sectional": 78069,
      "adjusted odds ratios ors": 8048,
      "odds ratios ors 95": 50938,
      "ratios ors 95 confidence": 67829,
      "ors 95 confidence intervals": 53814,
      "implant based breast reconstruction": 36918,
      "based breast reconstruction methods": 13290,
      "retrospective chart review performed": 72119,
      "clinical question level evidence": 16879,
      "question level evidence therapeutic": 66881,
      "level evidence therapeutic iii": 41480,
      "semisynthetic opioid receptor agonist": 74526,
      "extended release er formulation": 30865,
      "release er formulation oxymorphone": 69843,
      "using liquid chromatography mass": 85467,
      "chromatography mass spectrometry lc": 16164,
      "mass spectrometry lc ms": 43466,
      "spectrometry lc ms ms": 76667,
      "increased dramatically north america": 37908,
      "using generalized linear mixed": 85408,
      "intrathecal morphine postoperative pain": 39802,
      "morphine postoperative pain management": 47881,
      "intrathecal morphine postoperative analgesia": 39801,
      "interquartile range iqr 10": 39529,
      "incidence nausea vomiting pruritus": 37285,
      "opioid analgesics past decades": 51519,
      "anatomical therapeutic chemical classification": 10884,
      "present case series demonstrate": 64612,
      "measured 10 numeric rating": 43954,
      "numeric rating scale median": 50298,
      "avoided opioid use entirely": 12971,
      "mg oxycodone postoperative day": 46137,
      "patients aged 16 years": 58969,
      "drug related deaths west": 26771,
      "related deaths west virginia": 69587,
      "deaths west virginia wv": 22793,
      "west virginia wv united": 86997,
      "virginia wv united states": 86242,
      "wv united states methods": 87387,
      "wv drug related deaths": 87384,
      "drug related deaths 2005": 26770,
      "liquid chromatography coupled tandem": 42078,
      "chromatography coupled tandem mass": 16156,
      "coupled tandem mass spectrometry": 20980,
      "tandem mass spectrometry lc": 80365,
      "lc ms ms separation": 41270,
      "prescription monitoring program pmp": 64259,
      "study tapentadol immediate release": 78535,
      "internal consistency convergent validity": 39459,
      "confirmatory factor analysis conducted": 19501,
      "showed good psychometric properties": 75253,
      "displayed good convergent validity": 25473,
      "fit priori factor structure": 31861,
      "priori factor structure highly": 65183,
      "perspective considered results recent": 60966,
      "considered results recent studies": 19647,
      "results recent studies data": 71907,
      "recent studies data suggest": 68424,
      "provide valid responsive efficient": 66114,
      "valid responsive efficient assessment": 85779,
      "clinical trials clinical research": 16942,
      "trials clinical research examining": 83116,
      "anaesthesia randomly allocated receive": 9878,
      "postoperative days secondary outcomes": 62767,
      "discharge length hospital stay": 25134,
      "excessive sedation respiratory depression": 30465,
      "length hospital stay conclusions": 41400,
      "associated postoperative opioid consumption": 12383,
      "surgery methods eighty patients": 79461,
      "20 ml 375 ropivacaine": 2359,
      "secondary outcomes postoperative pain": 74255,
      "postoperative pain intensity opioid": 62879,
      "pain intensity opioid consumption": 56923,
      "16 95 ci 11": 1866,
      "oxycodone consumption significantly lower": 54870,
      "24 24 48 48": 3152,
      "rating scale scores significantly": 67678,
      "scale scores significantly lower": 73562,
      "postoperative period patients undergoing": 62942,
      "patients undergoing gastrointestinal surgery": 60104,
      "logistic regression used examine": 42276,
      "multivariable logistic regression models": 48328,
      "47 95 ci 40": 4657,
      "treatment substance use disorder": 82865,
      "opioids prescribed long term": 53208,
      "use substance use disorder": 84762,
      "multivariate regression analyses used": 48353,
      "odds ratios 95 confidence": 50935,
      "ratios 95 confidence intervals": 67816,
      "17 95 ci 00": 1955,
      "use aor 62 95": 84201,
      "aor 62 95 ci": 11325,
      "95 ci 47 80": 6303,
      "control group patients did": 20335,
      "odds ratio 41 95": 50920,
      "ratio 41 95 confidence": 67739,
      "41 95 confidence interval": 4420,
      "review english language articles": 72292,
      "january 2015 december 31": 40449,
      "2015 december 31 2015": 2702,
      "review board approved retrospective": 72270,
      "discharged home postoperative day": 25201,
      "home postoperative day pod": 35521,
      "severe pain mu opioid": 74988,
      "confidence interval ci 17": 19466,
      "95 ci 11 60": 6244,
      "03 95 ci 69": 413,
      "surgery study design retrospective": 79597,
      "study design retrospective review": 78090,
      "600 mg oral gabapentin": 5289,
      "postoperative pain medication log": 62889,
      "pain measured visual analog": 57141,
      "measured visual analog scale": 44010,
      "used data analysis results": 84902,
      "pain opioid use postoperative": 57293,
      "oxycodone fentanyl morphine methadone": 55084,
      "statistically significant reduction total": 77229,
      "significant reduction total opioid": 75618,
      "reduction total opioid prescriptions": 69106,
      "population based ecological study": 62313,
      "2017 logistic regression used": 2791,
      "logistic regression used identify": 42277,
      "past year prescription opioid": 58478,
      "heroin prescription opioids fentanyl": 35029,
      "tamper resistant abuse deterrent": 80335,
      "reported pain scores number": 70616,
      "outcomes regarding opioid use": 54084,
      "misuse opioid use disorder": 46732,
      "drug testing results 10": 26810,
      "severe pain opioid na\u00efve": 74993,
      "abuse potential respiratory depression": 6831,
      "study design randomized controlled": 78086,
      "trial level evidence methods": 83033,
      "methods patients undergoing arthroscopic": 45447,
      "self reported drug use": 74496,
      "increased risk opioid related": 38017,
      "hospital length stay results": 35600,
      "morphine milligram equivalents day": 47772,
      "chronic pain pain score": 16296,
      "patients undergoing open inguinal": 60117,
      "undergoing open inguinal hernia": 83559,
      "tertiary academic medical center": 80730,
      "opioid consumption 48 hours": 51604,
      "consumption 48 hours surgery": 19886,
      "48 hours surgery secondary": 4728,
      "scores opioid related adverse": 73932,
      "48 hour postoperative oxycodone": 4708,
      "significant reduction pain scores": 75616,
      "reduction pain scores 24": 69089,
      "pain scores 24 hours": 57699,
      "differences secondary outcomes conclusions": 24813,
      "misuse abuse addiction overdose": 46705,
      "risk opioid abuse misuse": 72613,
      "year old male history": 87461,
      "world health organization analgesic": 87309,
      "health organization analgesic ladder": 34742,
      "conversion table used standardize": 20717,
      "table used standardize opioid": 80080,
      "used standardize opioid analgesic": 85139,
      "standardize opioid analgesic doses": 76949,
      "oral morphine equivalent prescribed": 53579,
      "daily oral morphine equivalents": 21781,
      "study patients aged 18": 78366,
      "39 95 ci 32": 4268,
      "study design single center": 78093,
      "patients underwent single level": 60153,
      "october 2014 october 2019": 50882,
      "patient satisfaction pain control": 58767,
      "satisfaction pain control methods": 73412,
      "patients complete press ganey": 59108,
      "hospital consumer assessment healthcare": 35575,
      "consumer assessment healthcare providers": 19858,
      "assessment healthcare providers systems": 12122,
      "healthcare providers systems hcahps": 34803,
      "converted milligram morphine equivalents": 20729,
      "average opioids prescribed discharge": 12917,
      "satisfaction pain control opioid": 73413,
      "pain control opioid consumption": 56631,
      "cancer pain cncp remains": 14823,
      "post discharge opioid use": 62565,
      "opioids converted oral morphine": 52825,
      "patients 65 years age": 58888,
      "younger patients 65 years": 87741,
      "adverse events aes laboratory": 8727,
      "reduce post operative pain": 68879,
      "pain quality life qol": 57454,
      "oxycodone acetaminophen mg 325": 54647,
      "acetaminophen mg 325 mg": 7204,
      "multivariable regression used identify": 48337,
      "sustained release oral morphine": 79793,
      "release oral morphine oxycodone": 69914,
      "methods patients chronic pain": 45434,
      "brief pain inventory short": 14434,
      "pain inventory short form": 56980,
      "36 item short form": 4133,
      "mean standard deviation age": 43881,
      "commonly prescribed opioids oxycodone": 17869,
      "midst national opioid crisis": 46412,
      "current procedural terminology codes": 21463,
      "methods population based cohort": 45466,
      "cohort study used data": 17404,
      "erector spinae plane esp": 29500,
      "spinae plane esp block": 76697,
      "opioid consumption breast surgery": 51611,
      "consumption breast surgery patients": 19901,
      "24 hour opioid consumption": 3206,
      "consumption patient controlled analgesia": 19983,
      "blind placebo controlled trials": 13963,
      "mg oxycodone 10 mg": 46095,
      "morphine milligram equivalents using": 47777,
      "neurons ventral tegmental area": 49221,
      "ventral tegmental area vta": 86067,
      "included patients aged 18": 37508,
      "long term opioid users": 42343,
      "opioid na\u00efve patients received": 51990,
      "patients received opioid prescriptions": 59803,
      "associated long term opioid": 12322,
      "progression long term use": 65575,
      "long term use opioid": 42361,
      "place preference cpp assay": 61602,
      "confidence interval ci 42": 19472,
      "converted morphine milligram equivalents": 20735,
      "treat opioid use disorder": 82306,
      "opioid use disorder prescription": 52505,
      "use disorder prescription opioid": 84326,
      "analgesic anti inflammatory antipyretic": 10153,
      "significantly effective placebo treatment": 75695,
      "moderate severe pain primary": 47205,
      "bleeding time platelet aggregation": 13914,
      "treatment osteoarthritis rheumatoid arthritis": 82718,
      "moderate severe pain associated": 47192,
      "opioid prescribing consumption methods": 52092,
      "median number doses prescribed": 44253,
      "30 interquartile range iqr": 3744,
      "acute postoperative pain patients": 7691,
      "inguinal hernia repair patients": 38756,
      "received rofecoxib 50 mg": 68262,
      "undergoing inguinal hernia repair": 83543,
      "report moderate severe pain": 70464,
      "moderate severe pain surgery": 47206,
      "years scheduled undergo elective": 87662,
      "ibuprofen oxycodone primary outcome": 36369,
      "score 24 hours surgery": 73720,
      "data analyzed using independent": 21879,
      "15 95 ci 24": 1722,
      "median difference 95 ci": 44215,
      "study aimed evaluate impact": 77929,
      "rr 44 95 ci": 72932,
      "44 95 ci 39": 4538,
      "methods prospective quality improvement": 45490,
      "use injection drug use": 84436,
      "injection drug use increasing": 38945,
      "surgery methods randomized double": 79471,
      "randomly assigned following groups": 67220,
      "groups general anesthesia group": 34205,
      "academic tertiary care hospital": 6957,
      "contacted telephone asked participate": 20059,
      "opioid consumption significantly different": 51663,
      "increases non medical use": 38064,
      "prospective observational study performed": 65850,
      "used treatment acute pain": 85177,
      "methods search medline embase": 45559,
      "randomized controlled trials comparing": 67081,
      "controlled trials comparing opioids": 20631,
      "2005 june 30 2009": 2469,
      "methods using bc ministry": 45623,
      "using bc ministry health": 85324,
      "total knee arthroplasty tka": 81827,
      "using generalized linear modeling": 85409,
      "percentages patients dispensed opioids": 60522,
      "chronic neuropathic pain cnp": 16219,
      "opioid epidemic north america": 51775,
      "extended release opioid products": 30888,
      "aim study characterize use": 9409,
      "setting study took place": 74832,
      "daily morphine equivalent doses": 21765,
      "morphine oxycodone fentanyl tapentadol": 47826,
      "opioids management chronic non": 53038,
      "management chronic non cancer": 43165,
      "opioid related effects patient": 52310,
      "tapentadol centrally acting analgesic": 80388,
      "centrally acting analgesic mechanisms": 15623,
      "acting analgesic mechanisms action": 7375,
      "analgesic mechanisms action micro": 10268,
      "mechanisms action micro opioid": 44137,
      "opioid agonism norepinephrine reuptake": 51420,
      "effects analgesic tolerance dependence": 27822,
      "national ambulatory medical care": 48667,
      "rr 74 95 ci": 72972,
      "opioids hydrocodone oxycodone morphine": 52959,
      "patients opioid use disorder": 59594,
      "pain short acting opioids": 57831,
      "methods randomized controlled trial": 45509,
      "randomized controlled trial compared": 67072,
      "epidural analgesia postoperative pain": 29171,
      "adult patients aged 18": 8510,
      "ml ropivacaine 20 ml": 46901,
      "postoperative pain nausea vomiting": 62892,
      "95 confidence intervals 95": 6397,
      "confidence intervals 95 ci": 19481,
      "opioid related adverse drug": 52300,
      "mu opioid receptors mors": 48134,
      "present study tested hypothesis": 64665,
      "warm water tail withdrawal": 86717,
      "water tail withdrawal procedure": 86762,
      "naltrexone 032 mg kg": 48537,
      "fentanyl produced dose dependent": 31577,
      "produced dose dependent antinociception": 65378,
      "efficacy 17 cyclopropylmethyl 14\u03b2": 28211,
      "17 cyclopropylmethyl 14\u03b2 dihyroxy": 1963,
      "cyclopropylmethyl 14\u03b2 dihyroxy 5\u03b1": 21566,
      "14\u03b2 dihyroxy 5\u03b1 epoxy": 1665,
      "dihyroxy 5\u03b1 epoxy 6\u03b1": 25001,
      "5\u03b1 epoxy 6\u03b1 isoquinolyl": 5216,
      "epoxy 6\u03b1 isoquinolyl acetamindo": 29220,
      "patients received ultrasound guided": 59831,
      "primary outcome pain movement": 65082,
      "difference 95 ci 001": 24584,
      "study objective primary objective": 78340,
      "setting tertiary care academic": 74836,
      "measurements main results total": 44023,
      "results total 100 patients": 72020,
      "patients completed preoperative survey": 59114,
      "number pills prescribed 10": 50230,
      "provides effective analgesia reduces": 66211,
      "intravenous morphine patient controlled": 39860,
      "48 72 hours postoperatively": 4694,
      "european clinical trials database": 29739,
      "positron emission tomography pet": 62518,
      "blood oxygen level dependent": 14137,
      "oxygen level dependent bold": 56203,
      "endothelin et receptors involved": 28873,
      "assess analgesic efficacy safety": 11910,
      "efficacy safety single dose": 28386,
      "patients presenting emergency department": 59694,
      "australian new zealand clinical": 12705,
      "new zealand clinical trials": 49396,
      "zealand clinical trials registry": 87753,
      "emergency department ed methods": 28675,
      "aged 15 years older": 9148,
      "age sex race ethnicity": 9120,
      "surgery methods retrospective cohort": 79473,
      "item short form health": 40349,
      "short form health survey": 75172,
      "form health survey sf": 32281,
      "health survey sf 36": 34788,
      "numeric rating scale scores": 50301,
      "physicians treating patients chronic": 61451,
      "annual opioid prescriptions 10": 11028,
      "opioid prescriptions 10 000": 52173,
      "rr 88 95 ci": 73003,
      "95 ci 33 58": 6280,
      "rr 80 95 ci": 72985,
      "association initial opioid prescription": 12479,
      "patients older 18 years": 59577,
      "15 interquartile range 12": 1740,
      "interquartile range 12 20": 39517,
      "did opioid prescription conclusion": 24470,
      "opioid prescription conclusion opioid": 52139,
      "epidemic prescription opioid abuse": 29147,
      "patients receiving long term": 59843,
      "following robot assisted laparoscopic": 32196,
      "mg celecoxib 200 mg": 45818,
      "pain scores different time": 57721,
      "odds ratio 28 95": 50910,
      "ratio 28 95 confidence": 67725,
      "28 95 confidence interval": 3553,
      "26 95 ci 10": 3441,
      "2015 isi web science": 2709,
      "treatment data collection analysis": 82538,
      "trials met inclusion criteria": 83164,
      "37 95 confidence interval": 4187,
      "rr 81 95 ci": 72988,
      "low quality evidence studies": 42545,
      "rr 69 95 ci": 72966,
      "rr 63 95 ci": 72957,
      "rr 54 95 ci": 72947,
      "standardised mean difference smd": 76943,
      "rr 33 95 ci": 72921,
      "low moderate quality evidence": 42502,
      "aes adverse events saes": 8869,
      "assessment development evaluation grade": 12113,
      "rr 17 95 ci": 72906,
      "rr 73 95 ci": 72969,
      "rr 55 95 ci": 72950,
      "aim compare opioid prescribing": 9380,
      "opioid prescribing rates patients": 52125,
      "dosages morphine milligram equivalents": 25769,
      "according centers disease control": 7039,
      "opioid prescribing patterns patients": 52118,
      "term opioid use patients": 80653,
      "cohort study using data": 17406,
      "median interquartile range 64": 44231,
      "median interquartile range 10": 44230,
      "risk factors increased opioid": 72568,
      "inpatient opioid use patients": 39018,
      "md anderson symptom inventory": 43638,
      "linear mixed effects models": 42019,
      "post operative opioid prescribing": 62600,
      "tolerability tapentadol extended release": 81559,
      "opioid receptor agonist norepinephrine": 52240,
      "50 250 mg twice": 4811,
      "250 mg twice daily": 3397,
      "therapy patients moderate severe": 81048,
      "methods randomized open label": 45515,
      "randomized open label phase": 67132,
      "mean pain intensity score": 43828,
      "randomized receive twice daily": 67181,
      "treatment tapentadol er 100": 82871,
      "doses rescue medication day": 26265,
      "tapentadol er associated lower": 80400,
      "er associated lower incidence": 29402,
      "gastrointestinal treatment emergent adverse": 32900,
      "safe effective pain control": 73082,
      "confidence interval ci 43": 19473,
      "95 ci 12 10": 6246,
      "aor 63 95 ci": 11328,
      "year prescription opioid use": 87488,
      "95 ci conclusions relevance": 6359,
      "conclusions relevance findings suggest": 19194,
      "background pain common feature": 13143,
      "pain common feature childhood": 56568,
      "common feature childhood adolescence": 17756,
      "feature childhood adolescence world": 31294,
      "childhood adolescence world young": 16017,
      "adolescence world young people": 8438,
      "world young people pain": 87322,
      "young people pain chronic": 87722,
      "people pain chronic world": 60421,
      "pain chronic world health": 56544,
      "chronic world health organization": 16357,
      "health organization guidelines pharmacological": 34744,
      "organization guidelines pharmacological treatments": 53769,
      "guidelines pharmacological treatments children": 34460,
      "pharmacological treatments children persisting": 61238,
      "treatments children persisting pain": 82901,
      "children persisting pain acknowledge": 16068,
      "persisting pain acknowledge pain": 60937,
      "pain acknowledge pain children": 56408,
      "acknowledge pain children major": 7350,
      "pain children major public": 56534,
      "children major public health": 16057,
      "major public health concern": 42970,
      "public health concern high": 66378,
      "health concern high significance": 34694,
      "concern high significance parts": 18825,
      "high significance parts world": 35184,
      "past pain largely dismissed": 58473,
      "pain largely dismissed frequently": 56997,
      "largely dismissed frequently left": 41166,
      "dismissed frequently left untreated": 25364,
      "views children pain changed": 86229,
      "children pain changed time": 16065,
      "pain changed time relief": 56524,
      "changed time relief pain": 15768,
      "time relief pain seen": 81357,
      "designed suite seven reviews": 23850,
      "suite seven reviews chronic": 79058,
      "seven reviews chronic non": 74877,
      "reviews chronic non cancer": 72405,
      "pain cancer pain looking": 56508,
      "cancer pain looking antidepressants": 14831,
      "pain looking antidepressants antiepileptic": 57036,
      "looking antidepressants antiepileptic drugs": 42411,
      "antidepressants antiepileptic drugs non": 11174,
      "antiepileptic drugs non steroidal": 11197,
      "drugs non steroidal anti": 27007,
      "anti inflammatory drugs opioids": 11131,
      "inflammatory drugs opioids paracetamol": 38570,
      "review evidence children pain": 72299,
      "morbidity children adolescents world": 47510,
      "children adolescents world today": 16030,
      "associated pain major health": 12375,
      "pain major health concern": 57046,
      "opioids used worldwide treatment": 53378,
      "used worldwide treatment pain": 85193,
      "opioid receptors central nervous": 52271,
      "opioids generally available healthcare": 52931,
      "generally available healthcare settings": 33012,
      "include buprenorphine codeine fentanyl": 37353,
      "buprenorphine codeine fentanyl hydromorphone": 14533,
      "morphine oxycodone tramadol opioids": 47860,
      "adequate pain relief children": 7967,
      "pain relief children using": 57527,
      "relief children using opioids": 70110,
      "children using opioids acceptable": 16081,
      "using opioids acceptable grade": 85542,
      "opioids acceptable grade adverse": 52697,
      "acceptable grade adverse effects": 6982,
      "grade adverse effects recommended": 33367,
      "adverse effects recommended method": 8690,
      "dose gradually titrated effect": 25917,
      "effect child objectives assess": 27432,
      "child objectives assess analgesic": 16010,
      "efficacy adverse events opioids": 28221,
      "adverse events opioids used": 8783,
      "events opioids used treat": 30089,
      "opioids used treat chronic": 53374,
      "used treat chronic non": 85165,
      "pain children adolescents aged": 56530,
      "children adolescents aged birth": 16025,
      "adolescents aged birth 17": 8456,
      "aged birth 17 years": 9204,
      "birth 17 years setting": 13880,
      "17 years setting search": 1996,
      "years setting search methods": 87668,
      "setting search methods searched": 74818,
      "controlled trials central cochrane": 20625,
      "trials central cochrane library": 83109,
      "central cochrane library medline": 15584,
      "medline ovid embase ovid": 44744,
      "ovid embase ovid inception": 54374,
      "retrieved studies reviews searched": 72098,
      "studies reviews searched online": 77837,
      "reviews searched online clinical": 72423,
      "searched online clinical trial": 74160,
      "clinical trial registries selection": 16936,
      "trial registries selection criteria": 83081,
      "registries selection criteria randomised": 69402,
      "blinding dose route treating": 14029,
      "pain children adolescents comparing": 56532,
      "children adolescents comparing opioids": 16028,
      "adolescents comparing opioids placebo": 8460,
      "comparing opioids placebo active": 18354,
      "opioids placebo active comparator": 53176,
      "review authors independently assessed": 72261,
      "independently assessed studies eligibility": 38174,
      "assessed studies eligibility planned": 12065,
      "studies eligibility planned use": 77709,
      "eligibility planned use dichotomous": 28578,
      "planned use dichotomous data": 61887,
      "use dichotomous data calculate": 84307,
      "calculate risk ratio number": 14681,
      "risk ratio number needed": 72650,
      "ratio number needed treat": 67783,
      "standard methods assessed grade": 76918,
      "methods assessed grade grading": 45259,
      "assessed grade grading recommendations": 12008,
      "assessment development evaluation planned": 12114,
      "development evaluation planned create": 24228,
      "evaluation planned create summary": 29963,
      "planned create summary findings": 61880,
      "create summary findings table": 21145,
      "table main results studies": 80076,
      "rated quality evidence low": 67537,
      "quality evidence low downgraded": 66694,
      "support refute use opioids": 79212,
      "refute use opioids treat": 69231,
      "efficacy harm use opioids": 28276,
      "harm use opioids treat": 34585,
      "pain children adolescents background": 56531,
      "95 ci 42 79": 6295,
      "selection criteria included rcts": 74410,
      "participants low certainty evidence": 58322,
      "rr 13 95 ci": 72897,
      "rr 66 95 ci": 72963,
      "rr 02 95 ci": 72887,
      "rr 50 95 ci": 72941,
      "treatment arms authors conclusions": 82450,
      "retrospective cohort study used": 72133,
      "december 31 2016 data": 22837,
      "commercial medicare advantage insurance": 17713,
      "conclusions relevance cohort study": 19190,
      "drug use drug treatment": 26834,
      "risk factors long term": 72570,
      "term opioid users year": 80655,
      "aor 77 95 ci": 11334,
      "aor 72 95 ci": 11331,
      "minimal clinically important difference": 46572,
      "mean age 61 years": 43696,
      "ratio 55 95 ci": 67744,
      "pain management moderate severe": 57084,
      "evaluate analgesic efficacy safety": 29772,
      "intravenous acetaminophen compared placebo": 39812,
      "subjects moderate severe pain": 78716,
      "moderate severe pain abdominal": 47190,
      "blind placebo controlled parallel": 13957,
      "parallel group study conducted": 58140,
      "subjects aged 18 80": 78682,
      "aged 18 80 years": 9166,
      "visual analog scale point": 86309,
      "laboratory tests results total": 41037,
      "white mean sd age": 87022,
      "treatment emergent aes teaes": 82577,
      "attention deficit hyperactivity disorder": 12566,
      "double blind randomised controlled": 26370,
      "blind randomised controlled trial": 13967,
      "ethics dissemination study approved": 29696,
      "family members people use": 31185,
      "opioid substitution therapy ost": 52385,
      "cochrane database systematic reviews": 17173,
      "cohort studies cross sectional": 17381,
      "studies cross sectional surveys": 77685,
      "rr 79 95 ci": 72982,
      "chemoradiotherapy": 15959,
      "nasopharyngeal": 48661,
      "shandong": 75112,
      "sun": 79118,
      "yat": 87417,
      "sen": 74530,
      "radiotherapy": 66974,
      "8th": 6067,
      "cap": 14942,
      "controllable": 20441,
      "summarised": 79084,
      "1390": 1542,
      "1110": 1165,
      "attrition": 12619,
      "resuscitation": 72067,
      "microsomes": 46379,
      "hlms": 35493,
      "calculation": 14714,
      "macro": 42795,
      "sas": 73381,
      "1211": 1419,
      "604": 5295,
      "anorexia": 11043,
      "mc": 43622,
      "handled": 34560,
      "myristate": 48385,
      "maintains": 42903,
      "interdisciplinary": 39411,
      "diets": 24538,
      "forced": 32246,
      "switches": 79828,
      "professor": 65469,
      "336": 4010,
      "344": 4048,
      "needling": 49053,
      "egfr": 28446,
      "erk": 29503,
      "mda": 43640,
      "chemotherapeutic": 15960,
      "stimulatory": 77377,
      "activates": 7465,
      "mitochondria": 46771,
      "933": 6181,
      "assayed": 11889,
      "physicochemical": 61453,
      "dilution": 25013,
      "protected": 65917,
      "thanks": 80897,
      "acceptance": 6986,
      "486": 4760,
      "sleeping": 76239,
      "electrochemical": 28517,
      "detector": 23968,
      "wise": 87110,
      "formula": 32315,
      "clarifying": 16647,
      "cycles": 21547,
      "586": 5173,
      "948": 6204,
      "830": 5942,
      "vaginally": 85759,
      "celiac": 15467,
      "disappeared": 25084,
      "q12": 66615,
      "classed": 16665,
      "lessened": 41423,
      "intolerance": 39706,
      "rotated": 72819,
      "sc": 73477,
      "560": 5114,
      "helps": 34917,
      "24th": 3314,
      "carryover": 15148,
      "intergroup": 39436,
      "stabilize": 76831,
      "oxaliplatin": 54380,
      "holds": 35504,
      "countermeasures": 20948,
      "emphasizes": 28731,
      "sensitivities": 74552,
      "node": 49556,
      "anxious": 11289,
      "lightheadedness": 41768,
      "persist": 60911,
      "utmost": 85748,
      "microsphere": 46381,
      "dysphagia": 27229,
      "gastrostomy": 32901,
      "histologically": 35438,
      "documentation": 25662,
      "cognizant": 17331,
      "generalization": 32995,
      "antitussives": 11263,
      "collaborative": 17435,
      "graded": 33380,
      "nrss": 50086,
      "trajectories": 82016,
      "intercept": 39405,
      "path": 58498,
      "auc0": 12642,
      "jp": 40497,
      "965": 6431,
      "pts": 66372,
      "259": 3409,
      "618": 5326,
      "certification": 15668,
      "trail": 81996,
      "520": 5004,
      "mirogabalin": 46686,
      "t8": 80069,
      "667": 5468,
      "resembling": 71052,
      "269": 3470,
      "salivary": 73279,
      "contributions": 20251,
      "118aa": 1193,
      "ag": 8962,
      "gg": 33140,
      "a118g": 6505,
      "amed": 9777,
      "791": 5805,
      "332": 4006,
      "587": 5174,
      "passing": 58441,
      "duct": 27115,
      "fine": 31839,
      "429": 4492,
      "417": 4442,
      "nutritional": 50347,
      "vessel": 86171,
      "endothelium": 28874,
      "gradual": 33388,
      "acted": 7370,
      "mitogen": 46772,
      "preintervention": 63708,
      "corpus": 20795,
      "ovarian": 54172,
      "pharmacoeconomics": 61093,
      "1948": 2206,
      "mos": 48002,
      "thoracoscopic": 81126,
      "vats": 86041,
      "suffered": 78961,
      "attainment": 12545,
      "diarrhoea": 24359,
      "acetonitrile": 7268,
      "buffer": 14474,
      "mobile": 47000,
      "runs": 73041,
      "portable": 62413,
      "closed": 17070,
      "holistic": 35505,
      "tends": 80602,
      "504": 4936,
      "dropout": 26476,
      "pathologically": 58502,
      "065": 596,
      "itchy": 40344,
      "oinv": 50994,
      "prophylactically": 65730,
      "comfortable": 17692,
      "cease": 15441,
      "laxatives": 41257,
      "abilities": 6547,
      "signed": 75398,
      "basing": 13475,
      "abovementioned": 6580,
      "similarity": 76008,
      "ct2": 21363,
      "douleur": 26416,
      "neuropathique": 49271,
      "dn4": 25651,
      "depended": 23457,
      "seriously": 74667,
      "1330": 1528,
      "style": 78574,
      "beck": 13508,
      "trait": 82013,
      "catalyzed": 15282,
      "commissioned": 17725,
      "acknowledged": 7351,
      "dehydration": 23184,
      "725": 5639,
      "scant": 73597,
      "t60": 80067,
      "abated": 6512,
      "overtime": 54363,
      "lactulose": 41075,
      "walk": 86695,
      "m6g": 42786,
      "3600": 4154,
      "preferentially": 63635,
      "crm": 21234,
      "alive": 9576,
      "nas": 48649,
      "memorial": 44789,
      "alertness": 9555,
      "agitated": 9265,
      "173": 2006,
      "shizuoka": 75147,
      "genders": 32940,
      "elucidated": 28624,
      "bulk": 14480,
      "attained": 12543,
      "oxc": 54386,
      "fp": 32443,
      "658": 5442,
      "689": 5512,
      "dt": 27108,
      "562": 5116,
      "conversions": 20719,
      "1072": 1070,
      "408": 4406,
      "1414": 1641,
      "recommends": 68641,
      "myeloma": 48380,
      "manageable": 43128,
      "mcs": 43633,
      "screener": 74034,
      "rifampin": 72469,
      "deeply": 23095,
      "cirrhotic": 16584,
      "t28": 80061,
      "fragile": 32466,
      "c15": 14640,
      "pal": 58029,
      "wore": 87266,
      "accords": 7070,
      "319": 3898,
      "882": 6049,
      "extraordinary": 30973,
      "reminder": 70326,
      "advise": 8859,
      "round": 72832,
      "collegium": 17512,
      "canton": 14940,
      "microspheres": 46383,
      "tubes": 83274,
      "enzalutamide": 29095,
      "switchers": 79827,
      "cipn": 16564,
      "ntx": 50111,
      "numbness": 50288,
      "tingling": 81440,
      "totally": 81918,
      "react": 67941,
      "anticipation": 11161,
      "resort": 71124,
      "belgium": 13577,
      "cared": 15098,
      "lifestyle": 41746,
      "ib": 36333,
      "iib": 36577,
      "regimes": 69338,
      "individualize": 38316,
      "organs": 53778,
      "immunotherapy": 36792,
      "974": 6451,
      "702": 5578,
      "digestive": 24979,
      "412": 4438,
      "pes": 60981,
      "quadrant": 66654,
      "aforementioned": 8956,
      "worsen": 87331,
      "441": 4553,
      "433": 4515,
      "mtt": 48103,
      "cytotoxic": 21675,
      "pudendal": 66458,
      "tamsulosin": 80355,
      "urination": 84065,
      "smooth": 76341,
      "embolization": 28659,
      "gallbladder": 32822,
      "262": 3461,
      "parenchyma": 58189,
      "278": 3526,
      "bring": 14437,
      "complicates": 18545,
      "compensating": 18406,
      "handout": 34563,
      "asking": 11851,
      "obviates": 50791,
      "nonprofit": 49836,
      "sponsors": 76749,
      "dysfunctional": 27224,
      "empower": 28750,
      "nr": 50052,
      "sequences": 74630,
      "refilled": 69170,
      "vertebral": 86166,
      "medial": 44169,
      "biopsies": 13862,
      "elucidates": 28625,
      "coping": 20754,
      "articular": 11809,
      "2700": 3514,
      "predictability": 63557,
      "triggers": 83225,
      "postprandial": 63040,
      "042": 461,
      "pp": 63295,
      "579": 5149,
      "alkaline": 9577,
      "bisphosphonates": 13892,
      "caregiver": 15114,
      "sores": 76476,
      "confronted": 19527,
      "transdermally": 82173,
      "bundles": 14482,
      "esophageal": 29542,
      "angina": 10979,
      "pacemaker": 56319,
      "patent": 58497,
      "microorganisms": 46374,
      "invasively": 39974,
      "page": 56341,
      "writing": 87371,
      "compatibility": 18402,
      "acetylcholine": 7273,
      "green": 33516,
      "orange": 53699,
      "juice": 40506,
      "cure": 21421,
      "del": 23187,
      "territory": 80726,
      "concrete": 19262,
      "bringing": 14438,
      "directors": 25066,
      "sheets": 75134,
      "disciplinary": 25214,
      "ritodrine": 72687,
      "uterus": 85709,
      "mediastinal": 44302,
      "undifferentiated": 83714,
      "contractions": 20205,
      "contraction": 20203,
      "insufficiently": 39133,
      "undergraduate": 83596,
      "postgraduate": 62654,
      "beds": 13512,
      "districts": 25575,
      "employers": 28745,
      "debated": 22798,
      "stressed": 77493,
      "edr": 27367,
      "textbooks": 80891,
      "edrs": 27368,
      "teams": 80540,
      "advocated": 8862,
      "electronically": 28548,
      "appraisal": 11446,
      "predetermined": 63544,
      "outweighed": 54171,
      "confer": 19427,
      "abstraction": 6632,
      "poorer": 62277,
      "homogeneous": 35534,
      "scopolamine": 73695,
      "beerse": 13514,
      "colon": 17516,
      "olanzapine": 50996,
      "persistently": 60932,
      "os": 53845,
      "resumption": 72066,
      "flaws": 31906,
      "weakness": 86802,
      "855": 5998,
      "mirna": 46683,
      "signatures": 75397,
      "mirnas": 46685,
      "strengthening": 77477,
      "3p": 4300,
      "7a": 5815,
      "5p": 5210,
      "7f": 5817,
      "artificial": 11812,
      "listserv": 42110,
      "unsuitable": 83952,
      "overarching": 54265,
      "leverage": 41618,
      "dissatisfaction": 25509,
      "realistic": 68010,
      "scans": 73596,
      "lymph": 42774,
      "cyclophosphamide": 21562,
      "baclofen": 13217,
      "folic": 32006,
      "dysfunctions": 27225,
      "trouble": 83246,
      "tolerating": 81644,
      "emetics": 28717,
      "nightly": 49476,
      "workup": 87301,
      "antagonizes": 11099,
      "mindful": 46561,
      "hoped": 35538,
      "prognosis": 65526,
      "handbook": 34557,
      "2725": 3518,
      "precluded": 63539,
      "equi": 29252,
      "reviewer": 72394,
      "interfered": 39418,
      "capturing": 14963,
      "justifying": 40572,
      "millennium": 46447,
      "unavailable": 83458,
      "permission": 60906,
      "titles": 81460,
      "disagreements": 25083,
      "mandatory": 43304,
      "nefopam": 49057,
      "sap": 73378,
      "pgic": 60998,
      "transforaminal": 82183,
      "490": 4784,
      "479": 4679,
      "numerically": 50325,
      "closer": 17079,
      "1987": 2223,
      "assumption": 12509,
      "equivalency": 29277,
      "undetectable": 83710,
      "bit": 13893,
      "guiding": 34477,
      "genome": 33092,
      "815": 5896,
      "replication": 70440,
      "suggestive": 79034,
      "fits": 31862,
      "entitled": 29079,
      "amstar": 9858,
      "679": 5490,
      "endocrine": 28842,
      "epidemiologists": 29162,
      "conferences": 19432,
      "safety cost": 73137,
      "hydrochloride controlled": 36012,
      "sr morphine": 76813,
      "pain titration": 57921,
      "decision tree": 22851,
      "dose cr": 25853,
      "oxycodone sr": 55929,
      "respectively oral": 71225,
      "administered treat": 8191,
      "break pain": 14389,
      "2019 results": 2883,
      "study meta": 78308,
      "98 respectively": 6473,
      "probability cost": 65218,
      "option compared": 53450,
      "standardized nursing": 76974,
      "effect oxycontin": 27522,
      "evaluated patients": 29906,
      "oxycontin opioid": 56158,
      "abuse history": 6731,
      "groups receive": 34284,
      "receive standardized": 68080,
      "oral oxycontin": 53646,
      "oxycontin analgesic": 56117,
      "effect assessed": 27422,
      "assessed comparison": 11992,
      "scale treatment": 73568,
      "treatment safety": 82826,
      "cancer control": 14774,
      "evaluate quality": 29838,
      "life results": 41730,
      "taking oxycontin": 80320,
      "included text": 37565,
      "text article": 80882,
      "nursing care": 50339,
      "improve analgesic": 37055,
      "life quality": 41727,
      "sun yat": 79119,
      "yat sen": 87418,
      "sen university": 74531,
      "dose adjusted": 25820,
      "degree pain": 23173,
      "significantly relieved": 75857,
      "effect adverse": 27417,
      "effects quality": 28120,
      "groups analyzed": 34133,
      "oxycontin significantly": 56185,
      "effect significant": 27558,
      "significant patients": 75594,
      "need intervention": 48933,
      "care improve": 15032,
      "patient quality": 58723,
      "safety oxycontin": 73189,
      "oxycontin tablets": 56186,
      "tablets controlled": 80136,
      "mg relieving": 46201,
      "relieving moderate": 70232,
      "pain method": 57175,
      "method multicenter": 45189,
      "multicenter open": 48163,
      "label prospective": 40991,
      "prospective self": 65876,
      "pain relieved": 57601,
      "patients drug": 59227,
      "administration oxycontin": 8329,
      "tablets showed": 80214,
      "efficacy relieving": 28345,
      "baseline average": 13417,
      "subjects lower": 78708,
      "tablets week": 80232,
      "week weeks": 86880,
      "rate reached": 67512,
      "8th week": 6068,
      "descending order": 23646,
      "demonstrated fast": 23339,
      "control superior": 20427,
      "pain good": 56809,
      "good safety": 33329,
      "profile pain": 65501,
      "disease oxycodone": 25335,
      "oxycodone line": 55338,
      "line choice": 41986,
      "pain oxycontin": 57314,
      "analgesic oxycontin": 10286,
      "onset peak": 51123,
      "similar immediate": 75935,
      "dose limited": 25944,
      "various factors": 85967,
      "reduce patient": 68876,
      "members required": 44784,
      "state achieved": 77031,
      "pain improve": 56847,
      "survival article": 79755,
      "treatment procedure": 82787,
      "treated high": 82340,
      "reference clinical": 69128,
      "practitioners background": 63450,
      "treatment strong": 82856,
      "patients tolerated": 60049,
      "patients aim": 58983,
      "associated better": 12224,
      "relief tolerability": 70197,
      "conference proceedings": 19431,
      "march 2014": 43363,
      "studies contacted": 77680,
      "contacted authors": 20051,
      "restrictions applied": 71463,
      "comparing oxycodone": 18355,
      "studies according": 77640,
      "intensity data": 39240,
      "inverse variance": 39992,
      "method data": 45176,
      "patient preference": 58711,
      "outcome assessed": 53903,
      "grade approach": 33368,
      "17 studies": 1987,
      "enrolled randomised": 29014,
      "compared controlled": 18122,
      "oxycodone pooled": 55700,
      "studies similar": 77846,
      "treatment acceptability": 82420,
      "acceptability adverse": 6977,
      "cr groups": 21064,
      "events studies": 30125,
      "studies indicated": 77754,
      "indicated pain": 38242,
      "intensity did": 39243,
      "smd 14": 76318,
      "32 low": 3927,
      "marked differences": 43393,
      "differences adverse": 24710,
      "oxycodone various": 56073,
      "various formulations": 85969,
      "clear superiority": 16708,
      "studies small": 77850,
      "opioid conclusions": 51596,
      "consistent recent": 19714,
      "differences analysis": 24714,
      "head studies": 34652,
      "means clinical": 43924,
      "line oral": 41992,
      "woman known": 87187,
      "suspected suicide": 79766,
      "hospitalization emergency": 35655,
      "institutional policies": 39095,
      "needed provide": 49032,
      "anticancer drugs": 11153,
      "prescribed study": 63983,
      "determine interaction": 24019,
      "uplc ms": 83995,
      "method used": 45220,
      "used simultaneous": 85132,
      "simultaneous determination": 76034,
      "determination oxycodone": 23983,
      "rats given": 67861,
      "ms used": 48097,
      "study interaction": 78263,
      "rat human": 67418,
      "human liver": 35959,
      "liver microsomes": 42183,
      "microsomes hlms": 46380,
      "results long": 71752,
      "max oxycodone": 43556,
      "oxycodone indicating": 55257,
      "inhibited oxycodone": 38773,
      "oxycodone vitro": 56082,
      "vitro kinetic": 86361,
      "inhibited metabolism": 38771,
      "metabolism oxycodone": 44936,
      "power calculation": 63290,
      "calculation performed": 14715,
      "using macro": 85477,
      "trials involving": 83153,
      "involved control": 40096,
      "included aes": 37416,
      "aes dizziness": 8874,
      "dizziness rr": 25643,
      "94 95": 6189,
      "nausea rr": 48781,
      "26 21": 3426,
      "vomiting rr": 86476,
      "15 37": 1699,
      "rr 86": 72995,
      "constipation rr": 19782,
      "rr 98": 73017,
      "rr 97": 73014,
      "pruritus rr": 66303,
      "rr 76": 72976,
      "30 01": 3662,
      "62 36": 5331,
      "rr 47": 72936,
      "power analysis": 63289,
      "aes low": 8876,
      "statistical power": 77183,
      "efficacy fewer": 28269,
      "events compared": 30027,
      "analgesics cancer": 10385,
      "pain line": 57022,
      "associated superior": 12447,
      "relief fewer": 70127,
      "low background": 42452,
      "study intended": 78262,
      "assess quality": 11955,
      "methods oxycodone": 45418,
      "pubmed database": 66445,
      "past 20": 58451,
      "years 10": 87520,
      "reviews meta": 72415,
      "pain conclusions": 56584,
      "reduce misuse": 68854,
      "opioids new": 53089,
      "oxycodone myristate": 55484,
      "maintains extended": 42904,
      "physical manipulation": 61404,
      "blood levels": 14126,
      "woman metastatic": 87188,
      "metastatic breast": 45027,
      "er hydrocodone": 29422,
      "management decreased": 43175,
      "low fat": 42487,
      "education patient": 27388,
      "conclusion efficacy": 18895,
      "interdisciplinary team": 39412,
      "team approach": 80538,
      "evidence novel": 30228,
      "methods relevant": 45523,
      "relevant randomized": 70071,
      "rcts searched": 67920,
      "searched electronic": 74148,
      "including pubmed": 37667,
      "science embase": 73680,
      "scientific journal": 73687,
      "traditional chinese": 81983,
      "chinese medicine": 16094,
      "efficacy moderate": 28298,
      "group oral": 33882,
      "group rr": 33992,
      "rr 04": 72888,
      "13 05": 1449,
      "rr 30": 72916,
      "21 42": 2953,
      "groups rr": 34310,
      "26 15": 3423,
      "15 11": 1674,
      "11 05": 1088,
      "scores significant": 73985,
      "efficacy rectal": 28340,
      "administration considered": 8233,
      "patients difficulty": 59200,
      "opioid widely": 52640,
      "prescribed cancer": 63828,
      "work study": 87287,
      "serum oxycodone": 74703,
      "pharmacokinetics calculated": 61161,
      "using compartment": 85352,
      "clearance volume": 16719,
      "constant rate": 19742,
      "relative error": 69748,
      "model applied": 47026,
      "applied assess": 11433,
      "assess residual": 11962,
      "variability population": 85874,
      "variability cl": 85864,
      "total clearance": 81786,
      "class reduced": 16664,
      "serum concentration": 74693,
      "clear dose": 16702,
      "useful evaluating": 85205,
      "evaluating pharmacokinetics": 29949,
      "evaluate outcomes": 29822,
      "switching oxycodone": 79837,
      "admitted acute": 8420,
      "unit patients": 83769,
      "consecutive sample": 19568,
      "oxycodone switched": 55973,
      "switched different": 79824,
      "balance analgesia": 13229,
      "switching results": 79839,
      "reliable method": 70084,
      "doses studies": 26278,
      "performed confirm": 60578,
      "confirm results": 19495,
      "japan oxycodone": 40467,
      "hydrochloride injection": 36028,
      "pharmacokinetic analysis": 61106,
      "hydrochloride administered": 36009,
      "infusion dose": 38704,
      "according pain": 7053,
      "intensity patients": 39289,
      "pain pharmacokinetic": 57371,
      "patients estimated": 59260,
      "subcutaneous infusion": 78602,
      "infusion respectively": 38726,
      "infusion results": 38727,
      "total 66": 81764,
      "cancer randomly": 14899,
      "observation group": 50598,
      "group 34": 33602,
      "treated oral": 82359,
      "weeks moderate": 86925,
      "hydrochloride tablets": 36039,
      "day weeks": 22450,
      "weeks changes": 86897,
      "scores observed": 73927,
      "groups treatment": 34340,
      "reactions recorded": 67968,
      "groups evaluated": 34195,
      "rate 90": 67440,
      "27 30": 3479,
      "groups lower": 34227,
      "05 incidence": 519,
      "reactions 23": 67952,
      "reactions background": 67956,
      "patients little": 59451,
      "known direct": 40905,
      "effects mechanisms": 27986,
      "mechanisms oxycodone": 44149,
      "assays performed": 11895,
      "types cancer": 83364,
      "growth factor": 34378,
      "factor receptor": 31059,
      "oxidative stress": 54398,
      "chemotherapeutic drugs": 15963,
      "drug mechanism": 26701,
      "level oxycodone": 41509,
      "multiple biological": 48260,
      "death conclusions": 22703,
      "conclusions work": 19244,
      "signaling oxycodone": 75390,
      "dose failure": 25904,
      "non end": 49595,
      "factors affect": 31067,
      "2019 collected": 2859,
      "following criteria": 32116,
      "scale points": 73542,
      "titrated effective": 81470,
      "therapeutic dose": 80929,
      "suitable patients": 79054,
      "patients clinical": 59091,
      "clinical visits": 16971,
      "visits average": 86279,
      "scale visit": 73581,
      "group non": 33873,
      "group results": 33989,
      "009 pain": 283,
      "ratio 001": 67711,
      "investigate characteristics": 40000,
      "variability oxycodone": 85871,
      "dosing methods": 26317,
      "cancer receiving": 14902,
      "range 120": 67255,
      "days range": 22604,
      "dose plasma": 26013,
      "ml range": 46895,
      "spectrometry detection": 76659,
      "effects modeling": 28002,
      "population values": 62398,
      "coefficient variation": 17313,
      "absorption rate": 6614,
      "rate constant": 67453,
      "73 31": 5646,
      "weight sex": 86984,
      "serum albumin": 74692,
      "concentration did": 18693,
      "liver function": 42178,
      "function test": 32683,
      "values lowest": 85845,
      "despite reports": 23902,
      "reports patient": 70737,
      "characteristics significantly": 15881,
      "affect oxycodone": 8908,
      "current prescribing": 21457,
      "requires investigation": 70893,
      "cancer undergoing": 14917,
      "controlled prospective": 20526,
      "approval written": 11527,
      "consent obtained": 19579,
      "210 patients": 2991,
      "hours pain": 35808,
      "life adverse": 41684,
      "costs hospital": 20897,
      "evaluated compared": 29869,
      "results numeric": 71799,
      "001 12": 97,
      "001 24": 100,
      "48 001": 4681,
      "different 12": 24836,
      "lower treated": 42717,
      "treated groups": 82339,
      "groups placebo": 34267,
      "opioids authors": 52740,
      "pca devices": 60262,
      "ml diluted": 46856,
      "room temperature": 72779,
      "indicating high": 38261,
      "chromatography combined": 16153,
      "technique results": 80545,
      "oxycodone solutions": 55926,
      "order evaluate": 53713,
      "evaluate potential": 29834,
      "neuropathic cancer": 49223,
      "selected model": 74391,
      "difficult pain": 24966,
      "relevant evidence": 70056,
      "evidence discussion": 30184,
      "oxycodone neuropathic": 55533,
      "reviewed finally": 72380,
      "trials review": 83198,
      "changed dramatically": 15761,
      "new approaches": 49311,
      "specific guidelines": 76593,
      "complex cases": 18527,
      "oxycodone particularly": 55644,
      "compared 45": 18082,
      "started open": 77008,
      "achieve stable": 7306,
      "control 48": 20266,
      "48 followed": 4702,
      "followed double": 32056,
      "periods days": 60817,
      "daily telephone": 21809,
      "telephone contact": 80569,
      "patient investigator": 58667,
      "asked assess": 11835,
      "evaluations performed": 29973,
      "end double": 28790,
      "patients allowed": 58987,
      "allowed use": 9640,
      "use escape": 84355,
      "opioid oral": 52007,
      "patients evaluable": 59262,
      "opioids provided": 53232,
      "provided comparable": 66127,
      "combined patients": 17666,
      "patients consumed": 59140,
      "adverse experiences": 8827,
      "patients similar": 59982,
      "significantly vomiting": 75867,
      "vomiting occurred": 86463,
      "constipation common": 19754,
      "oxycodone purpose": 55788,
      "qol patients": 66634,
      "larger doses": 41174,
      "methods use": 45618,
      "oxycodone adjuvant": 54682,
      "observed weeks": 50731,
      "weeks data": 86902,
      "receiving high": 68339,
      "2009 march": 2529,
      "march 2010": 43359,
      "2010 results": 2569,
      "followed weeks": 32089,
      "weeks pain": 86931,
      "mean numeric": 43813,
      "increased mean": 37946,
      "mean 130": 43659,
      "activity walking": 7595,
      "improved weeks": 37139,
      "128 patients": 1440,
      "patients complained": 59105,
      "effects did": 27892,
      "determined pharmacokinetics": 24082,
      "determine oxycodone": 24033,
      "nonlinear squares": 49762,
      "calculation pharmacokinetic": 14716,
      "examined factors": 30381,
      "clearance oxycodone": 16717,
      "multiple regression": 48294,
      "step wise": 77328,
      "method pharmacokinetic": 45199,
      "follows oxycodone": 32230,
      "significantly correlated": 75670,
      "age presence": 9106,
      "concentration blood": 18679,
      "widespread prescription": 87085,
      "prescription study": 64411,
      "aimed provide": 9464,
      "injection study": 38972,
      "consisted trials": 19684,
      "endpoint pain": 28895,
      "effects moderate": 28004,
      "safety sustained": 73226,
      "pain material": 57132,
      "methods adult": 45239,
      "recruited randomly": 68796,
      "tablets 12": 80111,
      "12 hourly": 1290,
      "cycles required": 21548,
      "predictive factors": 63572,
      "performance effects": 60551,
      "effects ninety": 28023,
      "94 patients": 6196,
      "86 patients": 6008,
      "group achieved": 33661,
      "increased response": 38007,
      "rate patients": 67501,
      "morphine titration": 47954,
      "score oxycodone": 73767,
      "groups severe": 34314,
      "better tolerated": 13742,
      "morphine background": 47585,
      "background controlled": 13030,
      "constipation naloxone": 19764,
      "oxycodone ox": 55591,
      "open labeled": 51190,
      "phase iv": 61303,
      "iv study": 40404,
      "pain numeric": 57250,
      "treat itt": 82296,
      "randomized oxn": 67140,
      "groups oxn": 34253,
      "day titrated": 22428,
      "maximum 80": 43582,
      "endpoint change": 28880,
      "baseline week": 13468,
      "inferiority margin": 38531,
      "analgesic rescue": 10328,
      "medication intake": 44507,
      "bowel habits": 14284,
      "laxative intake": 41255,
      "qol safety": 66635,
      "efficacy data": 28244,
      "efficacy analysis": 28225,
      "analysis week": 10793,
      "week mean": 86848,
      "group 59": 33630,
      "lower limit": 42638,
      "sided 95": 75373,
      "001 oxn": 172,
      "groups did": 34180,
      "terms analgesic": 80702,
      "conclusions oxn": 19142,
      "cr non": 21072,
      "terms pain": 80712,
      "profile studies": 65510,
      "larger populations": 41179,
      "needed investigate": 49012,
      "effectiveness oxn": 27773,
      "effect vaginal": 27580,
      "administration controlled": 8235,
      "observe adverse": 50641,
      "new choice": 49313,
      "taken opioid": 80287,
      "continued patients": 20141,
      "patients switching": 60027,
      "complete relief": 18451,
      "20 significant": 2379,
      "moderate relief": 47161,
      "relief slight": 70190,
      "slight relief": 76248,
      "relief relief": 70178,
      "main adverse": 42822,
      "effective simple": 27703,
      "trials shown": 83199,
      "reports results": 70739,
      "results open": 71806,
      "open prospective": 51198,
      "trials trials": 83207,
      "pain inadequate": 56854,
      "physicians pain": 61443,
      "therapy monitored": 81030,
      "inadequate analgesia": 37227,
      "life parameters": 41716,
      "satisfaction high": 73400,
      "celiac plexus": 15468,
      "hospital severe": 35630,
      "pain administered": 56419,
      "insufficient pain": 39130,
      "complained severe": 18423,
      "loss appetite": 42432,
      "tapering oxycodone": 80483,
      "brain computed": 14325,
      "mg immediately": 45922,
      "immediately improved": 36745,
      "withdrawal present": 87145,
      "considered objective": 19640,
      "treatments acute": 82896,
      "release oxy": 69918,
      "oxy cr": 54444,
      "116 patients": 1184,
      "divided oxycodone": 25626,
      "cr 10": 21050,
      "mg q12": 46188,
      "analgesia score": 10103,
      "14 21": 1561,
      "groups frequency": 34202,
      "starting day": 77012,
      "cr 05": 21049,
      "improvements qol": 37177,
      "treatment oxy": 82724,
      "05 patients": 538,
      "treated oxy": 82362,
      "symptoms did": 79881,
      "study 05": 77878,
      "acute episodes": 7630,
      "episodes chronic": 29207,
      "failed respond": 31142,
      "conservative treatment": 19599,
      "chinese patients": 16095,
      "drug available": 26538,
      "trial carried": 83005,
      "china patients": 16088,
      "enrolled received": 29023,
      "evaluated adverse": 29859,
      "216 patients": 3001,
      "females aged": 31387,
      "22 84": 3027,
      "84 years": 5968,
      "enrolled total": 29027,
      "total mean": 81832,
      "daily dosages": 21721,
      "level days": 41457,
      "administration dose": 8250,
      "medication pain": 44533,
      "significantly 01": 75645,
      "events included": 30058,
      "vomiting drowsiness": 86457,
      "week 25": 86827,
      "patients purpose": 59720,
      "administered 12": 8096,
      "hours immediate": 35783,
      "methods cancer": 45264,
      "therapy moderate": 81028,
      "randomized cr": 67086,
      "assessed times": 12072,
      "slight moderate": 76246,
      "scale poor": 73543,
      "poor fair": 62257,
      "fair good": 31156,
      "intensity remained": 39303,
      "patients protocol": 59714,
      "acceptable pain": 6983,
      "events cr": 30036,
      "ir 186": 40202,
      "186 oxycodone": 2144,
      "conclusion cr": 18883,
      "daily managing": 21754,
      "associated fewer": 12261,
      "study safety": 78474,
      "safety controlled": 73133,
      "tablets oxycontin": 80192,
      "usual clinical": 85691,
      "study open": 78345,
      "month treatment": 47415,
      "included 87": 37407,
      "12 hr": 1307,
      "typical clinical": 83382,
      "use adverse": 84180,
      "weeks study": 86956,
      "patients 49": 58873,
      "baseline study": 13461,
      "score slight": 73795,
      "doses showed": 26270,
      "significant modest": 75578,
      "occurred 66": 50829,
      "rescue doses": 70945,
      "control increasing": 20355,
      "decreased course": 22989,
      "successfully used": 78928,
      "importantly effects": 37043,
      "time concomitant": 81227,
      "31 july": 3868,
      "prospectively patients": 65901,
      "injection site": 38970,
      "ml administered": 46848,
      "rotation oxycodone": 72822,
      "studied equivalent": 77613,
      "oxycodone ratio": 55799,
      "mean ratio": 43848,
      "ratio hydromorphone": 67772,
      "conclude oxycodone": 18852,
      "alternative opioid": 9729,
      "agonist opioids": 9300,
      "analgesic ceiling": 10161,
      "effect cancer": 27428,
      "doses fentanyl": 26187,
      "fentanyl authors": 31443,
      "patient cancer": 58547,
      "consisted 12": 19672,
      "day transdermal": 22432,
      "\u03bcg fentanyl": 87787,
      "fentanyl injection": 31508,
      "mg equivalent": 45882,
      "adjustment necessary": 8070,
      "dose equivalent": 25898,
      "equivalent 25": 29288,
      "injection total": 38973,
      "affects patients": 8936,
      "patients stages": 59991,
      "stages disease": 76873,
      "morphine considered": 47619,
      "pain numerous": 57257,
      "profile purpose": 65505,
      "line strong": 41998,
      "observational trial": 50636,
      "days dosage": 22516,
      "individualized patient": 38320,
      "achieved pain": 7322,
      "males mean": 43078,
      "66 11": 5446,
      "84 day": 5959,
      "assessed 10": 11974,
      "scale decreased": 73502,
      "significantly day": 75672,
      "22 baseline": 3031,
      "mean 11": 43655,
      "21 adverse": 2962,
      "discontinued study": 25249,
      "study adverse": 77915,
      "efficacious tolerated": 28206,
      "separate trials": 74590,
      "trials compared": 83120,
      "formulation study": 32367,
      "label titration": 41004,
      "oxycodone maximum": 55373,
      "dose 400": 25806,
      "period 21": 60698,
      "similar design": 75912,
      "dose 80": 25812,
      "converted oxycodone": 20740,
      "oxycodone respect": 55843,
      "achieving stable": 7338,
      "achieved stable": 7325,
      "constipation somnolence": 19788,
      "frequently cited": 32547,
      "reasons treatment": 68022,
      "oral cr": 53511,
      "used relieve": 85110,
      "life study": 41737,
      "day controlled": 22286,
      "oxycodone control": 54878,
      "retrospective clinical": 72121,
      "cancer treated": 14915,
      "included high": 37460,
      "cases results": 15261,
      "131 patients": 1521,
      "solid tumors": 76432,
      "pain achieved": 56405,
      "effective dose": 27613,
      "18 11": 2030,
      "71 mg": 5592,
      "day resulting": 22405,
      "relief mean": 70139,
      "days combination": 22494,
      "79 patients": 5801,
      "included gabapentin": 37459,
      "pregabalin 10": 63654,
      "patients main": 59465,
      "dizziness drowsiness": 25637,
      "treatment conclusions": 82518,
      "showed high": 75258,
      "effectively relieve": 27738,
      "relieve moderate": 70214,
      "opioid titration": 52425,
      "best way": 13696,
      "hour rapid": 35716,
      "pain randomly": 57460,
      "group morphine": 33865,
      "hours analgesic": 35750,
      "reactions treatment": 67975,
      "treatment observed": 82692,
      "analysis 51": 10631,
      "group 013": 33539,
      "hours 24": 35735,
      "experienced multiple": 30613,
      "respectively quality": 71240,
      "rapid titration": 67398,
      "btp episodes": 14464,
      "morphine days": 47635,
      "patients crossed": 59163,
      "vas 100": 86000,
      "questionnaire patients": 66895,
      "global ratings": 33233,
      "treatment preference": 82774,
      "preference results": 63629,
      "men 13": 44794,
      "24 20": 3148,
      "carryover effect": 15149,
      "pain prior": 57433,
      "approved japan": 11544,
      "sites japan": 76166,
      "day respectively": 22404,
      "efficacy evaluated": 28267,
      "intergroup difference": 39437,
      "using baseline": 85320,
      "baseline visual": 13465,
      "change vas": 15757,
      "results non": 71794,
      "mm mm": 46935,
      "mm non": 46936,
      "determined study": 24089,
      "patients hydromorphone": 59374,
      "hydromorphone group": 36174,
      "65 84": 5411,
      "84 oxycodone": 5962,
      "group frequently": 33785,
      "observed adverse": 50649,
      "events somnolence": 30124,
      "constipation vomiting": 19795,
      "adult outpatients": 8503,
      "age moderate": 9090,
      "days open": 22563,
      "dose provided": 26024,
      "provided efficacy": 66133,
      "parameters comparable": 58156,
      "treatment followed": 82589,
      "medication 10": 44446,
      "sulfate 15": 79063,
      "included brief": 37430,
      "complete blood": 18439,
      "efficacy variables": 28418,
      "using mixed": 85496,
      "model treatment": 47084,
      "sequence period": 74629,
      "patients entered": 59252,
      "titration stabilization": 81483,
      "stabilization phase": 76830,
      "drug 42": 26497,
      "completed double": 18467,
      "blind phase": 13947,
      "phase mean": 61306,
      "91 mg": 6139,
      "groups approximately": 34134,
      "opioid adverse": 51413,
      "required half": 70840,
      "half milligram": 34524,
      "pain 72": 56396,
      "provided adequate": 66118,
      "adequate relief": 7973,
      "relief similar": 70188,
      "chemotherapeutic agent": 15961,
      "treatment colorectal": 82501,
      "problematic patients": 65253,
      "patients seven": 59960,
      "oxaliplatin administration": 54381,
      "administration seven": 8369,
      "experienced intolerable": 30608,
      "continued days": 20132,
      "patients declined": 59171,
      "hydrochloride hydrate": 36026,
      "min prior": 46545,
      "successfully reduced": 78925,
      "fast acting": 31200,
      "pain commonly": 56571,
      "current treatments": 21483,
      "treatments include": 82909,
      "guidelines available": 34429,
      "ii study": 36573,
      "compared efficacy": 18145,
      "tolerability dose": 81530,
      "strategies oxycodone": 77418,
      "patients 75": 58898,
      "oxycodone fixed": 55094,
      "evaluated daily": 29871,
      "endpoint reduction": 28899,
      "time analgesia": 81207,
      "difference 15": 24572,
      "patients arm": 59000,
      "achieved overall": 7320,
      "controlling baseline": 20656,
      "gender baseline": 32930,
      "effects group": 27934,
      "vs 66": 86608,
      "vs 44": 86579,
      "effectively controlled": 27730,
      "pain according": 56403,
      "000 women": 49,
      "pain sensitivities": 57812,
      "rest motion": 71425,
      "measured intravenous": 43973,
      "patient requested": 58745,
      "individuals analgesic": 38335,
      "concentration increased": 18698,
      "increased 21": 37841,
      "node biopsy": 49557,
      "pain preoperative": 57405,
      "associated analgesic": 12220,
      "cyp2d6 cyp3a": 21593,
      "analgesic concentration": 10169,
      "background people": 13152,
      "pain people": 57363,
      "updated version": 83985,
      "version original": 86089,
      "original cochrane": 53785,
      "cochrane review": 17181,
      "oxycodone route": 55858,
      "november 2016": 50035,
      "applied language": 11434,
      "intensity relief": 39302,
      "assessed included": 12010,
      "grade main": 33378,
      "rr 78": 72979,
      "dizziness lightheadedness": 25638,
      "drowsiness somnolence": 26491,
      "somnolence rr": 76468,
      "rr 14": 72898,
      "rr 85": 72992,
      "56 28": 5097,
      "rr 46": 72933,
      "38 15": 4227,
      "discontinuation adverse": 25221,
      "analysis seven": 10765,
      "better treatment": 13745,
      "analysis did": 10674,
      "ci 78": 16494,
      "33 76": 3984,
      "29 vomiting": 3617,
      "rr 06": 72891,
      "rr 52": 72942,
      "remaining studies": 70284,
      "low low": 42494,
      "conclusions changed": 19040,
      "relief overall": 70158,
      "clinically insignificant": 16982,
      "benefit pain": 13621,
      "analgesics available": 10381,
      "malignant malignant": 43094,
      "bound oxycodone": 14262,
      "profile administered": 65472,
      "capsule hypothesized": 14956,
      "gastrostomy tube": 32902,
      "dependence methods": 23473,
      "performed prospective": 60615,
      "prospective trial": 65888,
      "trial enrolled": 83021,
      "analgesia prescribed": 10068,
      "pain ladder": 56991,
      "oxycodone initiated": 55280,
      "titrated weekly": 81473,
      "effect quality": 27541,
      "inventory primary": 39981,
      "oxycodone discontinuation": 54976,
      "pain resolution": 57633,
      "results eligible": 71679,
      "patient perceived": 58702,
      "feasibility safety": 31285,
      "status adverse": 77253,
      "effect associated": 27423,
      "describes elderly": 23665,
      "elderly male": 28473,
      "returned baseline": 72193,
      "rapid decline": 67377,
      "events occur": 30079,
      "methods patient": 45423,
      "biochemical parameters": 13845,
      "dose reasons": 26040,
      "122 patients": 1421,
      "14 opioids": 1617,
      "clinically available": 16975,
      "patch oxycodone": 58494,
      "oxycodone tamper": 55986,
      "resistant tablet": 71108,
      "use contribute": 84272,
      "drugs ex": 26954,
      "development novel": 24237,
      "novel analgesics": 50002,
      "analgesics adverse": 10372,
      "depression objectives": 23586,
      "relief treatment": 70202,
      "review randomized": 72348,
      "trials studies": 83201,
      "analysis standardized": 10771,
      "standardized mean": 76963,
      "scores differed": 73866,
      "differed oxycodone": 24561,
      "pooled standardized": 62246,
      "difference 04": 24565,
      "analyses pain": 10599,
      "compared hydromorphone": 18180,
      "review forms": 72306,
      "forms basis": 32307,
      "basis guidelines": 13478,
      "european palliative": 29745,
      "care research": 15071,
      "research collaborative": 70989,
      "collaborative opioid": 17436,
      "opioid guidelines": 51831,
      "guidelines project": 34465,
      "care objectives": 15046,
      "identify assess": 36488,
      "reviews cochrane": 72407,
      "trials medline": 83159,
      "cinahl systematically": 16558,
      "searched addition": 74134,
      "addition hand": 7804,
      "hand searching": 34550,
      "searching relevant": 74172,
      "included reported": 37541,
      "outcome relevant": 53986,
      "relevant use": 70076,
      "oxycodone adult": 54693,
      "route oxycodone": 72846,
      "direct comparator": 25040,
      "comparator required": 17997,
      "required inclusion": 70843,
      "inclusion studies": 37695,
      "excluded patients": 30477,
      "patients previously": 59697,
      "effects poor": 28090,
      "narrative systematic": 48643,
      "studies formulate": 77734,
      "formulate guidelines": 32322,
      "guidelines results": 34471,
      "results original": 71815,
      "original studies": 53789,
      "included trials": 37571,
      "randomized trials": 67203,
      "compared different": 18138,
      "oxycodone additional": 54680,
      "evidence included": 30196,
      "analysis limitations": 10704,
      "cancer palliative": 14862,
      "populations oxycodone": 62407,
      "oxycodone recommended": 55808,
      "recommended alternative": 68616,
      "pain compare": 56574,
      "111 patients": 1164,
      "fixed combination": 31871,
      "received 30": 68099,
      "supplemental analgesic": 79162,
      "05 day": 509,
      "ir groups": 40232,
      "discontinuation rates": 25230,
      "difference treatment": 24697,
      "given 12": 33150,
      "daily total": 21810,
      "offers benefits": 50960,
      "benefits twice": 13640,
      "assessment efficacy": 12117,
      "protocol continuous": 65966,
      "morphine rescue": 47917,
      "rescue dose": 70944,
      "treated days": 82336,
      "hours steady": 35857,
      "consumption mean": 19949,
      "mean rescue": 43853,
      "reached 24": 67934,
      "hours moderate": 35796,
      "84 percent": 5965,
      "percent pain": 60471,
      "treatment good": 82593,
      "protocol shown": 65997,
      "prospective comparative": 65823,
      "fentanyl commonly": 31454,
      "pain drugs": 56734,
      "depending patient": 23550,
      "determining impact": 24098,
      "fentanyl cancer": 31449,
      "classified groups": 16687,
      "groups according": 34124,
      "change percentage": 15741,
      "patients good": 59331,
      "patients numerical": 59561,
      "compared significant": 18308,
      "difference percentage": 24662,
      "rotation fentanyl": 72821,
      "clinical risk": 16896,
      "pain expectation": 56768,
      "pain tests": 57907,
      "surgery recorded": 79552,
      "recorded pain": 68686,
      "formed initial": 32301,
      "needed adequate": 48974,
      "pain higher": 56826,
      "pain initially": 56874,
      "psychological factors": 66341,
      "results confirm": 71641,
      "report preoperative": 70472,
      "pain completed": 56577,
      "oxycodone open": 55562,
      "oxycodone qid": 55789,
      "days followed": 22523,
      "dose mean": 25948,
      "scores correlated": 73856,
      "repeat dosing": 70394,
      "conditions oral": 19321,
      "provided analgesia": 66121,
      "pain predominant": 57403,
      "oxycodone cyp3a4": 54919,
      "cyp3a4 mediated": 21640,
      "demethylation noroxycodone": 23263,
      "undergoes demethylation": 83506,
      "oxymorphone cyp2d6": 56232,
      "cyp2d6 aim": 21589,
      "effects mild": 27992,
      "cyp3a4 inhibitor": 21638,
      "pharmacokinetics orally": 61176,
      "method study": 45217,
      "pain continued": 56596,
      "doses cr": 26166,
      "hours plasma": 35815,
      "measured hours": 43970,
      "day cr": 22289,
      "administered day": 8117,
      "oxycodone dosing": 55005,
      "measured day": 43963,
      "increased area": 37876,
      "curve auc0": 21523,
      "auc0 oxycodone": 12644,
      "25 001": 3317,
      "oxycodone 57": 54586,
      "36 001": 4112,
      "24 02": 3142,
      "receiving multiple": 68357,
      "significantly altered": 75653,
      "concentration levels": 18699,
      "levels appear": 41544,
      "response morphine": 71351,
      "good therapeutic": 33332,
      "oxycodone increasingly": 55253,
      "vs oral": 86666,
      "line second": 41996,
      "switching treatment": 79842,
      "phase patients": 61307,
      "reported adequate": 70495,
      "analgesia unacceptable": 10124,
      "unacceptable adverse": 83449,
      "effects switched": 28176,
      "numbers patients": 50285,
      "patients responding": 59921,
      "62 oxycodone": 5338,
      "12 67": 1259,
      "67 oxycodone": 5478,
      "95 response": 6409,
      "scores morphine": 73905,
      "conclusion population": 18964,
      "support opioid": 79205,
      "background patterns": 13151,
      "opioids documented": 52866,
      "using healthcare": 85423,
      "patient months": 58683,
      "groups estimated": 34194,
      "beginning therapy": 13523,
      "therapy cr": 81004,
      "respectively 16": 71153,
      "16 25": 1852,
      "months 10": 47426,
      "23 24": 3076,
      "24 29": 3156,
      "respectively multivariate": 71216,
      "50 16": 4807,
      "01 higher": 312,
      "pts cancer": 66373,
      "review post": 72336,
      "statistical tests": 77189,
      "findings important": 31789,
      "research quality": 71023,
      "quality criteria": 66687,
      "recommendations use": 68614,
      "impairment background": 36883,
      "aims efficacy": 9480,
      "cancer associated": 14762,
      "did pain": 24472,
      "10 weeks": 953,
      "results 48": 71570,
      "registered patients": 69380,
      "22 patients": 3038,
      "did induce": 24457,
      "decreased comparison": 22985,
      "baseline scores": 13459,
      "10 statistical": 930,
      "weeks 12": 86889,
      "average opioid": 12912,
      "consumption groups": 19929,
      "groups different": 34186,
      "pain did": 56713,
      "medicated oxycodone": 44444,
      "large impact": 41128,
      "routinely performed": 72870,
      "unclear performed": 83477,
      "oxycodone development": 54961,
      "white blood": 87015,
      "liver kidney": 42180,
      "total 60": 81759,
      "60 morphine": 5266,
      "significantly patients": 75830,
      "hospice palliative": 35551,
      "showed opioids": 75282,
      "explore clinical": 30719,
      "effect patients": 27527,
      "gabapentin treatment": 32806,
      "analog score": 10544,
      "trial group": 83026,
      "group administered": 33664,
      "administered oxycontin": 8161,
      "oxycontin placebo": 56171,
      "placebo trial": 61848,
      "post treatment": 62626,
      "oxycontin daily": 56133,
      "quality score": 66760,
      "observed week": 50730,
      "groups 05": 34089,
      "group 33": 33600,
      "33 11": 3977,
      "001 average": 110,
      "group post": 33921,
      "greater control": 33435,
      "46 vs": 4633,
      "vs 43": 86578,
      "001 post": 190,
      "drowsiness dizziness": 26489,
      "higher control": 35222,
      "used severe": 85124,
      "effectively decreased": 27731,
      "decreased dose": 22991,
      "relief reduced": 70177,
      "receiving oral": 68363,
      "study hospitalized": 78232,
      "oxycodone april": 54729,
      "2013 april": 2626,
      "30 2020": 3678,
      "oxycodone initiation": 55281,
      "initiation study": 38900,
      "study number": 78326,
      "use pregabalin": 84642,
      "independent risk": 38166,
      "especially early": 29553,
      "clinical models": 16838,
      "terms efficacy": 80706,
      "receive 30": 68044,
      "mg opioid": 46076,
      "according clinical": 7040,
      "clinical needs": 16841,
      "intensity recorded": 39301,
      "t3 t4": 80063,
      "groups ox": 34252,
      "period study": 60796,
      "literature limited": 42117,
      "opiates used": 51342,
      "management materials": 43196,
      "2013 october": 2635,
      "analyzed retrospectively": 10856,
      "opiates including": 51326,
      "used analyze": 84845,
      "analyze factors": 10816,
      "85 41": 5978,
      "23 10": 3070,
      "24 14": 3146,
      "opiate group": 51300,
      "01 risk": 325,
      "opiate type": 51312,
      "study use": 78555,
      "2007 reviewed": 2494,
      "received controlled": 68129,
      "oxycodone identified": 55228,
      "10 10": 659,
      "10 96": 738,
      "follow average": 32013,
      "improvement 10": 37141,
      "oxycodone tolerated": 56005,
      "dizziness nausea": 25639,
      "pain fully": 56799,
      "effective medication": 27643,
      "possibility using": 62526,
      "using saliva": 85602,
      "asked provide": 11842,
      "time blood": 81217,
      "samples samples": 73362,
      "taken dose": 80281,
      "plasma saliva": 61955,
      "oxycodone metabolite": 55385,
      "spectrometric detection": 76654,
      "ranging 10": 67355,
      "median 40": 44191,
      "noroxycodone ranged": 49943,
      "oxycodone range": 55793,
      "higher plasma": 35300,
      "poor correlation": 62255,
      "noroxycodone plasma": 49942,
      "noroxycodone concentrations": 49927,
      "patients questioned": 59725,
      "preferred method": 63640,
      "method conclusion": 45175,
      "conclusion high": 18907,
      "studies therapeutic": 77867,
      "therapeutic monitoring": 80949,
      "opioids essential": 52890,
      "died cancer": 24525,
      "prevalence prescribed": 64803,
      "prior death": 65140,
      "days death": 22509,
      "prevalence opioids": 64796,
      "decreased prevalence": 23032,
      "prevalence 10": 64768,
      "13 fentanyl": 1486,
      "prevalence decreased": 64780,
      "period conclusion": 60715,
      "clinical responses": 16893,
      "remain clarified": 70246,
      "evaluated clinical": 29866,
      "non genetic": 49602,
      "starting oral": 77020,
      "vomiting incidence": 86460,
      "higher females": 35241,
      "females males": 31393,
      "concentration significantly": 18721,
      "higher female": 35239,
      "patients male": 59471,
      "group ag": 33667,
      "ag gg": 8963,
      "gg group": 33141,
      "oprm1 a118g": 53413,
      "gender affected": 32928,
      "recommended moderate": 68628,
      "cancer impaired": 14786,
      "function affect": 32625,
      "opioid metabolism": 51926,
      "metabolism aim": 44921,
      "aim systematic": 9427,
      "impairment methods": 36900,
      "conducted following": 19360,
      "adolescents 18": 8452,
      "impairment defined": 36893,
      "study defined": 78054,
      "studies appraised": 77646,
      "appraised using": 11448,
      "evaluation results": 29966,
      "eligible heterogeneity": 28581,
      "heterogeneity meant": 35049,
      "meant meta": 43927,
      "formulated preferred": 32324,
      "review little": 72317,
      "little clinical": 42146,
      "evidence overall": 30238,
      "quality existing": 66700,
      "impairment low": 36896,
      "low remains": 42547,
      "remains need": 70301,
      "need high": 48923,
      "85 vs": 5991,
      "group score": 33999,
      "score eventually": 73746,
      "nrs significantly": 50082,
      "patients 45": 58869,
      "days vs": 22652,
      "introduction low": 39932,
      "pain stage": 57857,
      "sufficiently effective": 78978,
      "mg cancer": 45814,
      "geriatric patients": 33128,
      "necessary patients": 48890,
      "71 12": 5587,
      "study indicate": 78257,
      "constant level": 19741,
      "use transdermal": 84779,
      "established method": 29587,
      "choice opioids": 16115,
      "significant methodological": 75577,
      "aimed comparing": 9441,
      "testing heterogeneity": 80820,
      "eudract number": 29723,
      "carried patients": 15139,
      "10 rating": 912,
      "point percentage": 62104,
      "average follow": 12891,
      "follow pain": 32022,
      "enrolled 47": 28997,
      "94 oxycodone": 6195,
      "analgesia 10": 9891,
      "function patient": 32663,
      "patient subgroups": 58790,
      "results interpretation": 71736,
      "step iii": 77323,
      "opioids relevant": 53254,
      "randomized studies": 67189,
      "vomiting patients": 86466,
      "analgesics relief": 10493,
      "2008 december": 2505,
      "potentially affecting": 63250,
      "response used": 71380,
      "oxycodone presence": 55749,
      "ordered logistic": 53728,
      "vomiting cancer": 86449,
      "steroid use": 77340,
      "dopamine d2": 25719,
      "d2 blockers": 21680,
      "closely associated": 17073,
      "prophylaxis nausea": 65732,
      "prophylactic medication": 65727,
      "acute phase": 7681,
      "proteins response": 65947,
      "noroxycodone determined": 49930,
      "titration dose": 81476,
      "concentration lower": 18700,
      "lower concentration": 42587,
      "incidence central": 37263,
      "metabolism clinical": 44924,
      "oxycodone observed": 55550,
      "concentration associated": 18678,
      "oxycodone metabolic": 55382,
      "blood vessel": 14161,
      "plays important": 62004,
      "cancer opioids": 14809,
      "used clinic": 84877,
      "mechanisms opioids": 44148,
      "umbilical vein": 83443,
      "vitro model": 86364,
      "toxicity drugs": 81933,
      "fentanyl 100": 31411,
      "fentanyl reduced": 31582,
      "withdrawal oxycodone": 87140,
      "effect decreasing": 27442,
      "pathway observed": 58515,
      "observed increased": 50684,
      "increased phosphorylation": 37983,
      "mitogen activated": 46773,
      "activated protein": 7463,
      "exposed morphine": 30742,
      "mapk inhibitor": 43351,
      "nonopioid component": 49809,
      "component oxycodone": 18583,
      "following case": 32108,
      "report opioid": 70465,
      "cancer patient": 14864,
      "supports use": 79235,
      "indicates oral": 38254,
      "oxycodone parenteral": 55641,
      "care inpatient": 15036,
      "methods preintervention": 45473,
      "preintervention postintervention": 63710,
      "ancillary staff": 10887,
      "urban tertiary": 84037,
      "staff education": 76856,
      "care order": 15048,
      "care hours": 15029,
      "life data": 41693,
      "administered days": 8118,
      "specifically morphine": 76628,
      "morphine 47": 47561,
      "81 001": 5880,
      "increase significantly": 37803,
      "opioids 16": 52661,
      "16 73": 1863,
      "73 patients": 5657,
      "mg 72": 45767,
      "52 mg": 4989,
      "life increased": 41703,
      "care program": 15065,
      "investigated efficacy": 40040,
      "cervical cancer": 15672,
      "control using": 20439,
      "using nonsteroidal": 85521,
      "level mean": 41500,
      "18 92": 2073,
      "patients nausea": 59537,
      "patients incidence": 59389,
      "successfully treated": 78927,
      "oxycodone case": 54768,
      "intentional overdose": 39349,
      "overdose oxycodone": 54310,
      "treatment case": 82469,
      "ethical challenges": 29685,
      "challenges managing": 15704,
      "clinic methods": 16741,
      "treatment selected": 82830,
      "selected divided": 74386,
      "respectively appeared": 71170,
      "morphine injection": 47736,
      "symptomatic treatment": 79870,
      "rates morphine": 67596,
      "54 31": 5041,
      "groups 14": 34099,
      "15 44": 1701,
      "analgesics reduced": 10491,
      "differences compared": 24725,
      "designed demonstrate": 23830,
      "compared twice": 18331,
      "daily sustained": 21807,
      "oxycodone subjects": 55954,
      "continuous opioid": 20178,
      "titration maintenance": 81478,
      "maintenance periods": 42915,
      "followed optional": 32076,
      "extension phase": 30911,
      "phase 28": 61272,
      "28 weeks": 3579,
      "assess long": 11939,
      "term safety": 80666,
      "efficacy outcomes": 28311,
      "pain right": 57652,
      "treatment difference": 82550,
      "oxycodone median": 55380,
      "median values": 44298,
      "study mos": 78315,
      "mos sleep": 48003,
      "life measured": 41705,
      "measured short": 43997,
      "form 36": 32269,
      "groups showed": 34317,
      "shown treatment": 75354,
      "difference treatments": 24699,
      "hydromorphone study": 36224,
      "study medications": 78307,
      "medications equivalent": 44618,
      "tolerated treatment": 81642,
      "pain video": 57974,
      "video assisted": 86214,
      "assisted thoracoscopic": 12201,
      "thoracoscopic surgery": 81127,
      "surgery vats": 79618,
      "reviewed patients": 72388,
      "underwent vats": 83703,
      "vats lung": 86042,
      "divided subgroups": 25628,
      "analgesia sufentanil": 10116,
      "days rest": 22609,
      "rest cough": 71415,
      "cough groups": 20916,
      "nrs cough": 50060,
      "higher 50": 35200,
      "02 vs": 379,
      "26 09": 3417,
      "oxycodone nrs": 55545,
      "nrs higher": 50062,
      "surgery contrast": 79355,
      "patients positive": 59653,
      "surgery lung": 79446,
      "opioids beneficial": 52749,
      "analgesic protocols": 10307,
      "replacing morphine": 70437,
      "changed following": 15762,
      "multicentre study": 48176,
      "day orally": 22350,
      "deemed appropriate": 23082,
      "rescue medications": 70961,
      "global assessment": 33219,
      "scores primary": 73959,
      "fentanyl levels": 31514,
      "measured immediately": 43971,
      "patch days": 58489,
      "results percentage": 71863,
      "patients category": 59057,
      "assessment score": 12138,
      "previously used": 64964,
      "findings obtained": 31799,
      "scores total": 74002,
      "78 90": 5778,
      "included nausea": 37489,
      "nausea 31": 48764,
      "26 30": 3429,
      "22 25": 3017,
      "10 mean": 782,
      "fentanyl concentration": 31457,
      "concentration determined": 18692,
      "employed study": 28742,
      "switching morphine": 79834,
      "analgesics study": 10505,
      "explore effect": 30720,
      "rectal cancer": 68804,
      "cancer general": 14782,
      "enrolled randomly": 29020,
      "underwent general": 83681,
      "anesthesia end": 10909,
      "morphine hydrochloride": 47716,
      "differences statistically": 24820,
      "points oxycodone": 62137,
      "medication study": 44568,
      "relief primary": 70172,
      "significant analgesia": 75426,
      "analgesia evident": 9968,
      "evident secondary": 30299,
      "ii pain": 36568,
      "success rate": 78906,
      "63 24": 5355,
      "effects appeared": 27826,
      "respiratory suppression": 71296,
      "procedure using": 65291,
      "electrochemical detection": 28518,
      "detection quantitation": 23964,
      "quantitation oxycodone": 66793,
      "methanol acetonitrile": 45155,
      "phosphate buffer": 61365,
      "mobile phase": 47001,
      "calibration curve": 14725,
      "linear range": 42026,
      "ml 100": 46822,
      "ml recovery": 46896,
      "recovery oxycodone": 68750,
      "relative standard": 69768,
      "standard deviations": 76900,
      "assay oxycodone": 11882,
      "method developed": 45178,
      "effects based": 27838,
      "oxymorphone noroxycodone": 56264,
      "effects monitored": 28005,
      "weeks titration": 86963,
      "ratios noroxycodone": 67825,
      "incidence somnolence": 37323,
      "affect incidence": 8902,
      "conclusion cancer": 18865,
      "cyp3a cyp2d6": 21630,
      "alterations pharmacokinetics": 9692,
      "pharmacokinetics associated": 61159,
      "options include": 53472,
      "regularly scheduled": 69486,
      "bolus effect": 14215,
      "portable infusion": 62414,
      "trial compare": 83006,
      "pain requiring": 57624,
      "parenteral route": 58215,
      "portable pump": 62415,
      "hours followed": 35775,
      "study closed": 77994,
      "nausea drowsiness": 48772,
      "categorical rating": 15292,
      "number breakthrough": 50142,
      "global rating": 33232,
      "effectiveness adverse": 27745,
      "required confirm": 70828,
      "type diabetes": 83323,
      "highlights importance": 35381,
      "patients living": 59455,
      "group present": 33933,
      "distressing symptom": 25552,
      "increase frequency": 37748,
      "experiencing pain": 30649,
      "pain having": 56818,
      "15 people": 1784,
      "pain fail": 56776,
      "physical psychological": 61410,
      "determine analgesic": 23988,
      "pain incidence": 56857,
      "severity adverse": 75033,
      "trials registers": 83191,
      "active pain": 7524,
      "previously identified": 64945,
      "pain worse": 57991,
      "data binary": 21891,
      "treat basis": 82284,
      "continuous data": 20161,
      "estimated mean": 29630,
      "ci used": 16541,
      "used random": 85097,
      "completed primary": 18487,
      "grade created": 33369,
      "findings tables": 31833,
      "tables main": 80082,
      "adult participants": 8504,
      "participants compared": 58286,
      "low unclear": 42562,
      "blinding outcome": 14030,
      "potential conflict": 63151,
      "analysis collected": 10650,
      "deviation sd": 24264,
      "hydromorphone 28": 36154,
      "19 oxycodone": 2188,
      "30 25": 3682,
      "higher score": 35323,
      "worse pain": 87329,
      "pain subscale": 57881,
      "morphine 101": 47535,
      "10 higher": 770,
      "data demonstrated": 21939,
      "demonstrated similar": 23369,
      "similar effect": 75916,
      "comparisons pain": 18387,
      "data showed": 22107,
      "participants trials": 58378,
      "nausea constipation": 48768,
      "generally showed": 33025,
      "trial period": 83051,
      "disease progression": 25344,
      "groups overall": 34251,
      "effect estimates": 27453,
      "publication bias": 66410,
      "little difference": 42152,
      "hydromorphone opioids": 36200,
      "opioids terms": 53335,
      "intensity reported": 39304,
      "participants generally": 58310,
      "comparable drugs": 17953,
      "consistent analgesic": 19691,
      "considered use": 19661,
      "pain experiencing": 56773,
      "sleep disturbance": 76220,
      "studies limited": 77763,
      "range study": 67334,
      "outcomes impact": 54029,
      "demonstrate superiority": 23326,
      "research larger": 71011,
      "required objective": 70848,
      "divided control": 25618,
      "experimental groups": 30663,
      "life compared": 41690,
      "120 patients": 1412,
      "difference detected": 24607,
      "regarding age": 69242,
      "score patients": 73771,
      "respectively decreased": 71184,
      "treatment respectively": 82814,
      "reduced treatment": 68984,
      "daily consumption": 21710,
      "54 19": 5039,
      "treatment decreased": 82543,
      "terms quality": 80718,
      "better performance": 13729,
      "daily activity": 21696,
      "activity mood": 7573,
      "significant low": 75575,
      "constipation observed": 19770,
      "35 vs": 4096,
      "49 026": 4768,
      "tablets effective": 80150,
      "tablets associated": 80126,
      "vomiting oinv": 86464,
      "prophylactic antiemetics": 65726,
      "prophylactic treatment": 65728,
      "patients started": 59993,
      "assigned ratio": 12175,
      "ratio receive": 67794,
      "given times": 33200,
      "emetic episodes": 28716,
      "proportion treatment": 65782,
      "2013 february": 2630,
      "60 placebo": 5276,
      "placebo 60": 61638,
      "vs 63": 86603,
      "likely experience": 41807,
      "experience severe": 30592,
      "severe somnolence": 75023,
      "conclusion routine": 18984,
      "initiation treatment": 38901,
      "specific patient": 76610,
      "cause adverse": 15344,
      "concentrations pain": 18802,
      "difficult reach": 24969,
      "assess usefulness": 11972,
      "oral fluid": 53536,
      "fentanyl pain": 31558,
      "separate days": 74586,
      "patients detectable": 59182,
      "samples plasma": 73355,
      "plasma ratio": 61954,
      "active transporter": 7537,
      "fentanyl conclusion": 31459,
      "concentration relationship": 18718,
      "changed oxycodone": 15764,
      "reliable dosing": 70081,
      "dosing patients": 26322,
      "patients monitored": 59526,
      "reach level": 67929,
      "patients tested": 60043,
      "did achieve": 24400,
      "poor metabolizer": 62264,
      "provide extra": 66063,
      "constipation objective": 19769,
      "immediate short": 36741,
      "term benefits": 80620,
      "benefits harms": 13630,
      "medication change": 44466,
      "24 72": 3177,
      "range 210": 67271,
      "regardless medication": 69286,
      "medication changed": 44467,
      "pain constipation": 56593,
      "constipation scores": 19783,
      "laxatives conclusions": 41258,
      "work suggests": 87288,
      "regarding effect": 69249,
      "significant contributor": 75449,
      "important pain": 37021,
      "levels investigated": 41571,
      "patients lung": 59463,
      "282 patients": 3584,
      "level patients": 41514,
      "fixed low": 31883,
      "increased gradually": 37925,
      "required higher": 70841,
      "determined compared": 24062,
      "relative low": 69752,
      "female 31": 31350,
      "similar differences": 75913,
      "opioids equivalent": 52887,
      "chosen study": 16143,
      "relief numeric": 70148,
      "applied pcia": 11440,
      "30 sufentanil": 3797,
      "34 oxycodone": 4029,
      "constipation 11": 19744,
      "depression associated": 23572,
      "significant intergroup": 75571,
      "severe breakthrough": 74915,
      "effect effect": 27450,
      "oxycodone aims": 54703,
      "evaluates efficacy": 29940,
      "year pain": 87479,
      "nrs months": 50064,
      "oxycodone starting": 55931,
      "relief chronic": 70111,
      "existing pharmacological": 30529,
      "options treatment": 53475,
      "pain included": 56858,
      "index bmi": 38191,
      "status time": 77269,
      "dose use": 26105,
      "cyp3a4 inducer": 21637,
      "inhibitor use": 38797,
      "number medications": 50169,
      "taken 24": 80268,
      "analyses results": 10609,
      "results sex": 71944,
      "inducers inhibitors": 38468,
      "dose number": 25971,
      "ratio total": 67803,
      "blood sample": 14149,
      "conclusion women": 19019,
      "effects previously": 28109,
      "previously investigated": 64946,
      "patients oxymorphone": 59617,
      "european organisation": 29742,
      "organisation research": 53758,
      "research treatment": 71035,
      "life questionnaire": 41728,
      "success treatment": 78908,
      "intensity associated": 39232,
      "control effects": 20297,
      "noroxymorphone compared": 49945,
      "concentrations opioid": 18786,
      "enzyme cyp": 29099,
      "activity study": 7590,
      "evaluate oxycodone": 29823,
      "metabolic ratio": 44911,
      "oxycodone inversely": 55301,
      "concentration contrast": 18686,
      "somnolence conclusions": 76462,
      "based genetic": 13322,
      "cyp2d6 cyp3a5": 21595,
      "abcb1 oprm1": 6521,
      "oxymorphone determined": 56234,
      "titrated dose": 81467,
      "oxycodone escalation": 55044,
      "significantly alter": 75652,
      "12 significantly": 1362,
      "higher cyp2d6": 35226,
      "cyp2d6 extensive": 21601,
      "metabolizers intermediate": 45007,
      "consider morphine": 19605,
      "pain individual": 56869,
      "individual responses": 38309,
      "responses vary": 71396,
      "compared analgesic": 18096,
      "therapy safety": 81065,
      "requiring step": 70914,
      "patients worse": 60183,
      "trial recruited": 83062,
      "decreased weeks": 23054,
      "morphine 14": 47539,
      "changes treatment": 15826,
      "dose 32": 25802,
      "27 morphine": 3501,
      "reactions opioids": 67965,
      "https clinicaltrials": 35930,
      "gov ct2": 33342,
      "important problem": 37024,
      "pain improves": 56850,
      "2004 2008": 2451,
      "pain mild": 57195,
      "results visual": 72053,
      "group 25": 33588,
      "group regular": 33972,
      "background thirty": 13207,
      "patients suffer": 60015,
      "including neuropathic": 37647,
      "patients great": 59333,
      "aiming improve": 9470,
      "methods month": 45386,
      "follow prospective": 32031,
      "douleur neuropathique": 26417,
      "neuropathique questionnaire": 49272,
      "recruited results": 68797,
      "pain 33": 56381,
      "decrease month": 22901,
      "relief conclusions": 70120,
      "pharmaceutical treatment": 61045,
      "greater effect": 33441,
      "based oxycodone": 13348,
      "time 12": 81191,
      "day observation": 22342,
      "consumption rate": 20003,
      "recorded analgesic": 68668,
      "effect evaluated": 27454,
      "evaluated groups": 29887,
      "pain decreased": 56689,
      "increased treatment": 38039,
      "lower control": 42590,
      "reactions constipation": 67959,
      "constipation drowsiness": 19761,
      "effect rate": 27543,
      "group superior": 34042,
      "19 30": 2170,
      "conclusion basis": 18864,
      "improve health": 37063,
      "pain enhance": 56756,
      "medication reduce": 44551,
      "reduce adverse": 68833,
      "control reported": 20412,
      "reported inadequate": 70569,
      "induced oral": 38436,
      "shows good": 75360,
      "pharmacological efficacy": 61215,
      "patients unable": 60080,
      "adequately controlled": 7977,
      "pain doses": 56732,
      "produce intolerable": 65363,
      "aim opioid": 9393,
      "treatment strategy": 82855,
      "effects aes": 27815,
      "investigated patients": 40049,
      "group multicentre": 33868,
      "study 42": 77894,
      "methadone methadone": 45100,
      "recorded daily": 68676,
      "outcome average": 53906,
      "900 mg": 6122,
      "difference ci": 24602,
      "severe sedation": 75021,
      "trend pain": 82951,
      "tests postoperative": 80861,
      "analgesia study": 10114,
      "women methods": 87226,
      "consenting patients": 19586,
      "beck depression": 13509,
      "depression inventory": 23582,
      "trait anxiety": 82014,
      "exposed experimental": 30740,
      "propofol remifentanil": 65737,
      "number previous": 50244,
      "anxiety related": 11283,
      "20 significantly": 2380,
      "consumption weak": 20042,
      "cold pressure": 17428,
      "pressure tests": 64748,
      "variability pain": 85872,
      "modified factors": 47239,
      "oxymorphone active": 56219,
      "oxycodone formed": 55101,
      "reaction catalyzed": 67943,
      "cyp2d6 polymorphic": 21620,
      "polymorphic genetic": 62210,
      "role oxymorphone": 72756,
      "clear study": 16707,
      "study controlled": 78041,
      "morphine examined": 47685,
      "pain cr": 56671,
      "plasma morphine": 61941,
      "morphine concentrations": 47616,
      "concentrations higher": 18767,
      "oxycodone consistent": 54848,
      "concentrations presented": 18807,
      "presented significant": 64698,
      "irrespective disease": 40278,
      "years use": 87686,
      "including education": 37615,
      "patients july": 59429,
      "particular concern": 58399,
      "potential influence": 63174,
      "lead earlier": 41287,
      "institute health": 39070,
      "health research": 34767,
      "approximation possible": 11595,
      "pain search": 57802,
      "assessed adverse": 11983,
      "cochrane reviews": 17183,
      "pain taken": 57899,
      "journal publication": 40495,
      "articles data": 11796,
      "experiencing adverse": 30639,
      "calculated proportion": 14698,
      "individual treatment": 38313,
      "groups fewer": 34198,
      "fewer 50": 31627,
      "50 participants": 4881,
      "studies participants": 77803,
      "50 70": 4820,
      "medication adverse": 44455,
      "measures patient": 44080,
      "direct evidence": 25047,
      "events people": 30097,
      "concomitant medication": 19251,
      "medication data": 44482,
      "provide broad": 66042,
      "development appropriate": 24214,
      "aid clinical": 9367,
      "expert consensus": 30687,
      "protocol controlled": 65967,
      "work aimed": 87268,
      "used statistical": 85140,
      "differences variables": 24831,
      "used comparison": 84891,
      "groups value": 34346,
      "different level": 24879,
      "option patients": 53462,
      "analgesia intolerable": 10004,
      "recommendations methods": 68607,
      "pertinent publications": 60976,
      "results individual": 71734,
      "analysis previous": 10740,
      "analyzed morphine": 10844,
      "hydromorphone buprenorphine": 36160,
      "methadone used": 45135,
      "frequency effects": 32514,
      "effects rarely": 28124,
      "improve analgesia": 37054,
      "analgesia patient": 10047,
      "success opioid": 78904,
      "appears depend": 11400,
      "painkillers oxycodone": 58016,
      "tablet taken": 80105,
      "group days": 33726,
      "01 05": 289,
      "05 pain": 537,
      "higher 86": 35201,
      "05 reduction": 544,
      "reduce dose": 68838,
      "better safety": 13738,
      "pain debate": 56686,
      "designed randomized": 23841,
      "trials results": 83196,
      "morphine observed": 47791,
      "21 30": 2950,
      "11 87": 1118,
      "indicating comparable": 38259,
      "comparable safety": 17971,
      "groups meta": 34236,
      "ci 90": 16507,
      "75 38": 5697,
      "evidence superior": 30267,
      "morphine provided": 47898,
      "oral combination": 53501,
      "antagonist oxycodone": 11070,
      "pr chronic": 63315,
      "observation consecutive": 50597,
      "patients uncontrolled": 60082,
      "14 30": 1566,
      "baseline measured": 13441,
      "days oxn": 22572,
      "dosage escalation": 25746,
      "bowel dysfunction": 14265,
      "safety effects": 73144,
      "nineteen patients": 49481,
      "64 12": 5381,
      "91 101": 6131,
      "pr resulted": 63364,
      "93 34": 6170,
      "effects decreased": 27886,
      "impact life": 36820,
      "reducing number": 69017,
      "groups immediate": 34215,
      "used prophylaxis": 85090,
      "good analgesia": 33296,
      "analgesia obtained": 10035,
      "obtained opioids": 50771,
      "analgesics greater": 10426,
      "pain ability": 56400,
      "scores consumption": 73854,
      "consumption rescue": 20010,
      "morphine common": 47610,
      "effects included": 27948,
      "constipation bowel": 19751,
      "index scores": 38209,
      "normal range": 49905,
      "range treatment": 67336,
      "randomised trial": 67037,
      "concentrations methadone": 18777,
      "glucuronide m6g": 33251,
      "methadone 16": 45037,
      "range 90": 67299,
      "3600 mg": 4155,
      "group 43": 33613,
      "morphine m6g": 47749,
      "methadone showed": 45127,
      "showed low": 75269,
      "low correlation": 42463,
      "patients dropped": 59224,
      "group 38": 33606,
      "patient suffered": 58791,
      "dropout rate": 26477,
      "methadone followed": 45076,
      "kappa receptors": 40598,
      "control days": 20292,
      "point patients": 62103,
      "needed order": 49019,
      "effects number": 28026,
      "morphine tablets": 47948,
      "total 22": 81742,
      "38 higher": 4240,
      "suggest combination": 78987,
      "sites action": 76164,
      "useful alternative": 85199,
      "study documents": 78127,
      "strategy patients": 77441,
      "results male": 71759,
      "10 female": 761,
      "patients 47": 58871,
      "47 77": 4651,
      "weeks total": 86964,
      "patients alive": 58985,
      "methadone patients": 45119,
      "average mg": 12894,
      "morphine iv": 47739,
      "dose methadone": 25957,
      "control significant": 20421,
      "15 moderate": 1775,
      "unchanged patients": 83471,
      "analgesia good": 9985,
      "average numeric": 12909,
      "sedation decreased": 74311,
      "decreased 65": 22970,
      "scale 20": 73490,
      "patients improvement": 59387,
      "cognitive status": 17330,
      "assessment scale": 12137,
      "improvement average": 37144,
      "23 prior": 3110,
      "decreased alertness": 22978,
      "methadone effective": 45065,
      "treatment refractory": 82801,
      "working group": 87296,
      "morphine management": 47750,
      "pain revised": 57651,
      "guidance use": 34400,
      "analgesics introduced": 10439,
      "situations described": 76175,
      "supporting evidence": 79226,
      "strength evidence": 77474,
      "opioids increases": 52991,
      "opioids remains": 53262,
      "discuss possible": 25283,
      "possible differences": 62532,
      "performed search": 60630,
      "medicine used": 44714,
      "quality assessment": 66679,
      "surgical departments": 79628,
      "rated moderate": 67531,
      "quality information": 66716,
      "route timing": 72848,
      "timing administration": 81439,
      "missing pain": 46699,
      "important risk": 37027,
      "conclusion data": 18887,
      "perioperative risk": 60851,
      "studies compare": 77666,
      "compare different": 18015,
      "pain responsive": 57638,
      "studies single": 77847,
      "opioid studies": 52380,
      "days admission": 22484,
      "pain nociceptive": 57239,
      "age primary": 9107,
      "analgesics secondary": 10500,
      "fentanyl plasma": 31568,
      "plasma level": 61936,
      "3d significantly": 4296,
      "pain 67": 56395,
      "10 52": 717,
      "40 10": 4309,
      "67 40": 5471,
      "20 100": 2270,
      "38 54": 4231,
      "54 39": 5042,
      "ml significantly": 46911,
      "pain respectively": 57635,
      "associated type": 12458,
      "confounding factors": 19524,
      "opioids palliative": 53147,
      "time objectives": 81298,
      "compared 114": 18064,
      "114 patients": 1178,
      "shizuoka cancer": 75148,
      "center june": 15530,
      "28 morphine": 3561,
      "fentanyl groups": 31486,
      "groups 43": 34112,
      "groups 21": 34103,
      "conclusions incidence": 19097,
      "useful opioid": 85208,
      "gender primary": 32936,
      "patients setting": 59957,
      "primary diagnosis": 64997,
      "analysis final": 10686,
      "patients according": 58919,
      "performed chi": 60574,
      "compare mean": 18032,
      "group dose": 33756,
      "highly significant": 35404,
      "doses 120": 26124,
      "patients 40": 58864,
      "patients 90": 58908,
      "age older": 9094,
      "age associated": 9059,
      "investigation warranted": 40074,
      "adjuvant medication": 8082,
      "medication therapy": 44573,
      "neuropathic inflammatory": 49226,
      "clock administration": 17047,
      "release strong": 70007,
      "shown improve": 75340,
      "improve compliance": 37058,
      "treatment outcome": 82720,
      "revealed relevant": 72223,
      "relevant differences": 70053,
      "differences different": 24734,
      "opioids respect": 53271,
      "respect efficacy": 71132,
      "oxycodone appear": 54724,
      "morphine lack": 47741,
      "metabolites patients": 44983,
      "patients decreased": 59172,
      "result morphine": 71482,
      "pain hydromorphone": 56839,
      "safer alternatives": 73112,
      "certain patient": 15656,
      "common type": 17822,
      "previously demonstrated": 64939,
      "cancer effects": 14778,
      "work investigated": 87277,
      "investigated effects": 40039,
      "hematopoietic stem": 34931,
      "status oxycodone": 77262,
      "sensitive oxycodone": 74548,
      "chemotherapy drug": 15965,
      "using genetic": 85412,
      "oxycodone work": 56102,
      "ability oxycodone": 6554,
      "bone cancer": 14231,
      "control type": 20438,
      "pain analgesics": 56450,
      "placebo tablets": 61835,
      "patients kept": 59430,
      "difference pid": 24663,
      "consumption additional": 19890,
      "included short": 37553,
      "treatment end": 82578,
      "paracetamol placebo": 58113,
      "day 001": 22236,
      "decreased 21": 22950,
      "paracetamol group": 58100,
      "phase 001": 61269,
      "important additional": 36991,
      "conducted open": 19380,
      "titration study": 81485,
      "developed mg": 24183,
      "analgesics previous": 10484,
      "weeks enrolled": 86912,
      "assessment analgesic": 12106,
      "18 20": 2033,
      "attained stable": 12544,
      "thirds patients": 81096,
      "patients attained": 59018,
      "time days": 81243,
      "intake patients": 39184,
      "indicates lower": 38253,
      "formulation make": 32348,
      "titrate dose": 81465,
      "patients sensitive": 59955,
      "studies risk": 77838,
      "study surveyed": 78529,
      "patient background": 58544,
      "2010 april": 2549,
      "factors early": 31091,
      "respectively initial": 71202,
      "earlier patients": 27243,
      "log rank": 42247,
      "available regarding": 12834,
      "filling prescriptions": 31725,
      "27 823": 3485,
      "hospital mortality": 35603,
      "mortality results": 47993,
      "mortality rate": 47991,
      "patient years": 58816,
      "earlier data": 27241,
      "patients filling": 59307,
      "associated transdermal": 12455,
      "death oxycodone": 22713,
      "typical adverse": 83380,
      "event associated": 29980,
      "pain hospitalization": 56836,
      "april 2015": 11606,
      "2015 march": 2712,
      "univariate analyses": 83837,
      "univariate analysis": 83838,
      "observed 30": 50646,
      "extracted independent": 30958,
      "ratio 98": 67757,
      "young women": 87724,
      "women increased": 87217,
      "august 2014": 12664,
      "2018 incidence": 2821,
      "27 00": 3472,
      "suggesting similar": 79031,
      "study sites": 78505,
      "republic korea": 70780,
      "aged 19": 9172,
      "included worst": 37581,
      "worst current": 87338,
      "intensity patient": 39287,
      "dose adverse": 25827,
      "groups achieved": 34125,
      "achieved 50": 7310,
      "reduction average": 69044,
      "intensity moderate": 39269,
      "day versus": 22445,
      "groups versus": 34349,
      "faster pain": 31218,
      "events adverse": 30006,
      "reactions similar": 67973,
      "morphine trial": 47965,
      "registered clinicaltrials": 69376,
      "dose medd": 25953,
      "determine cr": 23998,
      "determined patients": 24081,
      "successfully discharged": 78921,
      "discharged oral": 25207,
      "dose used": 26106,
      "morphine 163": 47542,
      "0001 median": 68,
      "11 46": 1112,
      "84 13": 5952,
      "mg iv": 45936,
      "mg 0004": 45681,
      "study mg": 78311,
      "hydromorphone 11": 36148,
      "based regimen": 13373,
      "agents including": 9230,
      "oxaliplatin induced": 54382,
      "established investigated": 29586,
      "study 64": 77903,
      "oxycodone concomitantly": 54840,
      "concomitantly administered": 19258,
      "patients oxy": 59610,
      "group additional": 33662,
      "treatment course": 82529,
      "version results": 86092,
      "discontinued patients": 25245,
      "median numbers": 44259,
      "groups 13": 34098,
      "13 range": 1504,
      "05 median": 524,
      "483 mg": 4758,
      "patients underlying": 60138,
      "causing adverse": 15405,
      "voriconazole oxycodone": 86493,
      "drug effective": 26611,
      "multiple myeloma": 48287,
      "assessed effectiveness": 11998,
      "previous analgesic": 64898,
      "oxycodone intensity": 55288,
      "interference pain": 39426,
      "global patient": 33231,
      "evaluation efficacy": 29953,
      "performed results": 60621,
      "average dose": 12889,
      "mg pain": 46147,
      "trend decreasing": 82942,
      "values observed": 85847,
      "intensity effects": 39255,
      "observed 23": 50645,
      "effective conclusion": 27607,
      "rapidly increased": 67403,
      "onset opioids": 51119,
      "matter debate": 43542,
      "reported cases": 70514,
      "different causes": 24849,
      "sublingual fentanyl": 78756,
      "relief quality": 70175,
      "regimen methods": 69312,
      "methods subgroup": 45595,
      "recently completed": 68441,
      "performed according": 60568,
      "recording pain": 68713,
      "status assessed": 77254,
      "form 12": 32268,
      "questionnaire hospital": 66894,
      "54 67": 5043,
      "included 39": 37398,
      "29 35": 3600,
      "relief achieved": 70097,
      "vs 38": 86572,
      "mental component": 44813,
      "summary mcs": 79107,
      "mcs sf": 43634,
      "44 69": 4534,
      "95 76": 6210,
      "38 47": 4230,
      "aes reported": 8883,
      "treatment breakthrough": 82460,
      "medication objective": 44524,
      "survey describing": 79704,
      "patients community": 59098,
      "consistent cancer": 19692,
      "form bpi": 32277,
      "disability scale": 25074,
      "questionnaire results": 66898,
      "112 patients": 1172,
      "reported experiencing": 70544,
      "minutes median": 46656,
      "pain onset": 57275,
      "incidental pain": 37339,
      "using medication": 85485,
      "onset opioid": 51118,
      "24 reported": 3272,
      "preceding 24": 63500,
      "social relations": 76359,
      "sleep enjoyment": 76222,
      "enjoyment life": 28981,
      "life conclusion": 41692,
      "opportunities improve": 53403,
      "assess dose": 11926,
      "admitted severe": 8432,
      "prospectively assessed": 65891,
      "symptom assessment": 79857,
      "conclusion observation": 18935,
      "intravenous boluses": 39820,
      "patient considered": 58575,
      "clinical situation": 16904,
      "effective bolus": 27603,
      "mean initial": 43782,
      "51 mg": 4957,
      "69 mg": 5523,
      "occurred mean": 50839,
      "mean days": 43748,
      "days standard": 22626,
      "ratio 12": 67718,
      "resulted rapid": 71513,
      "necessary confirm": 48880,
      "noroxycodone cyp3a": 49929,
      "rifampin strong": 72471,
      "strong inducer": 77519,
      "inducer drug": 38464,
      "decrease effect": 22893,
      "multi drug": 48145,
      "metastatic lesion": 45029,
      "pain 1000": 56364,
      "oxycodone ineffective": 55272,
      "able control": 6566,
      "conclusions patient": 19153,
      "increasing risk": 38124,
      "interactions rifampin": 39403,
      "rifampin oxycodone": 72470,
      "notably patients": 49983,
      "using high": 85425,
      "lead oxycodone": 41296,
      "hydromorphone extended": 36167,
      "24 week": 3289,
      "flexible dose": 31909,
      "pain total": 57927,
      "extension study": 30914,
      "measure change": 43935,
      "baseline weeks": 13469,
      "similar changes": 75904,
      "similar improvements": 75937,
      "including pain": 37661,
      "rated good": 67530,
      "patients oros": 59599,
      "receiving oros": 68364,
      "52 patients": 4992,
      "maintained year": 42896,
      "noninferiority efficacy": 49747,
      "mg followed": 45893,
      "days dose": 22517,
      "dose maintenance": 25947,
      "weekly visits": 86886,
      "pain past": 57329,
      "past 24": 58453,
      "randomized patients": 67144,
      "70 oxycodone": 5567,
      "81 patients": 5888,
      "square mean": 76793,
      "score covariate": 73739,
      "noninferiority margin": 49748,
      "cr 12": 21052,
      "12 treatment": 1367,
      "noninferior oxycodone": 49743,
      "tolerated perspective": 81637,
      "demonstrates clinical": 23376,
      "oral prolonged": 53656,
      "tablets oxn": 80186,
      "oxn treatment": 54435,
      "associated codeine": 12233,
      "tramadol patients": 82099,
      "gradually increased": 33391,
      "visits evaluated": 86283,
      "nrs patients": 50071,
      "results clinically": 71625,
      "reported median": 70583,
      "bfi score": 13759,
      "cases detected": 15233,
      "remaining 30": 70281,
      "treatment led": 82638,
      "led significant": 41341,
      "37 16": 4172,
      "16 001": 1838,
      "scores showed": 73984,
      "88 13": 6037,
      "009 conclusions": 281,
      "oxn considered": 54413,
      "option fragile": 53452,
      "fragile population": 32467,
      "opioids randomized": 53238,
      "treatment 28": 82418,
      "normal work": 49913,
      "bpi sf": 14301,
      "lower consumption": 42589,
      "effects according": 27803,
      "treatment continued": 82521,
      "rarely observed": 67409,
      "observed opioids": 50696,
      "opioids improved": 52970,
      "improved overall": 37115,
      "improving physical": 37201,
      "qlq c15": 66630,
      "c15 pal": 14641,
      "improvement physical": 37158,
      "induced negative": 38429,
      "determine dosing": 24003,
      "performed methods": 60604,
      "june november": 40561,
      "november 2008": 50028,
      "cancer outpatients": 14810,
      "patients 88": 58907,
      "patch 72": 58482,
      "worsening pain": 87335,
      "took medication": 81670,
      "prescribed dosing": 63855,
      "patients felt": 59299,
      "survey demonstrated": 79703,
      "patients manner": 59476,
      "manner inconsistent": 43324,
      "inconsistent standard": 37708,
      "btp medication": 14466,
      "design multicenter": 23726,
      "using immediate": 85435,
      "ongoing drug": 51083,
      "baseline measurements": 13442,
      "dose equianalgesic": 25897,
      "equianalgesic oxycodone": 29264,
      "using controlled": 85359,
      "ratio patients": 67790,
      "parameters measured": 58165,
      "measured baseline": 43959,
      "98 completed": 6464,
      "frequency day": 32513,
      "93 00": 6169,
      "0001 daily": 61,
      "pain frequency": 56796,
      "decreased 44": 22963,
      "decreased 11": 22939,
      "61 percent": 5319,
      "patients constipation": 59137,
      "dizziness conclusion": 25633,
      "cancer 30": 14761,
      "major negative": 42961,
      "life opioid": 41711,
      "like drugs": 41775,
      "objectives provide": 50584,
      "identified systematic": 36476,
      "number unique": 50273,
      "associated range": 12398,
      "range different": 67309,
      "different formulation": 24869,
      "various routes": 85976,
      "larger study": 41186,
      "comparisons outcomes": 18386,
      "outcomes opioids": 54066,
      "absolute numbers": 6599,
      "oxycodone indicated": 55256,
      "indicated average": 38232,
      "scores range": 73961,
      "event reported": 29991,
      "small study": 76307,
      "conclusions quality": 19180,
      "20 people": 2372,
      "extent effectiveness": 30925,
      "people experience": 60409,
      "experience adverse": 30570,
      "nausea 10": 48757,
      "updated cochrane": 83982,
      "review previously": 72339,
      "method pain": 45194,
      "identified 19": 36417,
      "19 new": 2186,
      "taken 12": 80267,
      "versus immediate": 86123,
      "taken hours": 80284,
      "13 drowsiness": 1485,
      "15 low": 1743,
      "evidence data": 30179,
      "groups low": 34226,
      "morphine reported": 47914,
      "scale clinically": 73499,
      "participants achieving": 58275,
      "relief rr": 70181,
      "95 10": 6206,
      "rr 75": 72973,
      "showed adverse": 75227,
      "effect potential": 27531,
      "rr 93": 73007,
      "77 12": 5755,
      "evidence little": 30216,
      "significant did": 75466,
      "chronic medical": 16208,
      "prevention management": 64875,
      "related complications": 69574,
      "equal higher": 29231,
      "recent development": 68397,
      "new guidelines": 49333,
      "efficacy new": 28301,
      "ratio using": 67806,
      "release rescue": 70000,
      "based therapy": 13393,
      "medical oncology": 44373,
      "fentanyl administered": 31430,
      "stable analgesic": 76837,
      "patients obtained": 59571,
      "based opioid": 13343,
      "experiencing persistent": 30650,
      "treatment transdermal": 82875,
      "multicenter observational": 48160,
      "results days": 71652,
      "cr pain": 21105,
      "decreased 38": 22960,
      "71 001": 5586,
      "75 001": 5692,
      "maintained stable": 42894,
      "stable study": 76850,
      "patients suffered": 60016,
      "transdermal therapy": 82171,
      "19 44": 2174,
      "significantly 21": 75648,
      "oral treatment": 53681,
      "treatment 001": 82413,
      "improved satisfaction": 37131,
      "satisfaction quality": 73422,
      "morphine recently": 47905,
      "round clock": 72833,
      "deterrent microsphere": 24118,
      "microsphere capsule": 46382,
      "er collegium": 29404,
      "collegium pharmaceutical": 17513,
      "pharmaceutical canton": 61019,
      "canton massachusetts": 14941,
      "approved fda": 11536,
      "microspheres administered": 46384,
      "enteral tubes": 29056,
      "acting formulation": 7383,
      "formulation case": 32335,
      "initiated oxycodone": 38882,
      "enteral tube": 29055,
      "tube administration": 83273,
      "administration control": 8234,
      "outcome patient": 53975,
      "new findings": 49327,
      "administration medications": 8298,
      "common occurring": 17776,
      "required effective": 70832,
      "conversion opioid": 20709,
      "opioid problematic": 52221,
      "study explores": 78208,
      "unit secondary": 83771,
      "drug substantial": 26796,
      "large variability": 41160,
      "implications study": 36969,
      "demonstrates need": 23378,
      "trials background": 83106,
      "requiring pain": 70909,
      "medication opioids": 44527,
      "opioids mainstay": 53032,
      "antagonist treatment": 11073,
      "inducer cytochrome": 38463,
      "cyp 3a4": 21572,
      "cyp2d6 objective": 21615,
      "label arm": 40970,
      "dose 15": 25791,
      "arm received": 11674,
      "metabolites quantified": 44986,
      "validated liquid": 85788,
      "method results": 45210,
      "respectively 44": 71158,
      "44 001": 4522,
      "004 compared": 258,
      "74 001": 5668,
      "contrast auc": 20213,
      "conclusion administration": 18859,
      "setting palliative": 74798,
      "service patients": 74722,
      "inpatients patients": 39039,
      "february 1996": 31304,
      "produced partial": 65400,
      "partial complete": 58239,
      "25 cases": 3348,
      "vomiting 13": 86443,
      "13 19": 1457,
      "associated renal": 12409,
      "effects differed": 27893,
      "differed opioids": 24560,
      "trial opioid": 83042,
      "morphine non": 47789,
      "switching alternative": 79830,
      "prospectively recruited": 65904,
      "responders patients": 71325,
      "analgesia minimal": 10020,
      "unacceptable effects": 83450,
      "results prospective": 71896,
      "good response": 33327,
      "responders patient": 71324,
      "186 patients": 2145,
      "achieved successful": 7327,
      "additional controlled": 7850,
      "controlled switched": 20603,
      "opioid overall": 52008,
      "effects achieved": 27804,
      "achieved 96": 7313,
      "different clinical": 24852,
      "significantly improves": 75752,
      "develop test": 24157,
      "neuropathy cipn": 49277,
      "week multicenter": 86852,
      "single arm": 76052,
      "80 40": 5829,
      "day needed": 22341,
      "needed primary": 49028,
      "score weeks": 73813,
      "weeks secondary": 86953,
      "functional assessment": 32690,
      "sd dose": 74079,
      "0001 patients": 76,
      "significantly smaller": 75862,
      "score week": 73812,
      "30 vs": 3805,
      "total scores": 81903,
      "improvements observed": 37175,
      "sd change": 74076,
      "tests vital": 80868,
      "naloxone added": 48427,
      "provided additional": 66117,
      "management breakthrough": 43156,
      "pain units": 57954,
      "levels care": 41548,
      "patient needs": 58686,
      "fentanyl dosing": 31469,
      "recommendations help": 68605,
      "evidence patients": 30244,
      "methods qualitative": 45499,
      "patients females": 59301,
      "88 years": 6046,
      "years results": 87658,
      "morphine medical": 47751,
      "analgesics represent": 10494,
      "include limited": 37357,
      "limited overall": 41949,
      "practical issues": 63388,
      "time order": 81307,
      "factors relating": 31130,
      "particularly high": 58410,
      "countries including": 20955,
      "addressing pain": 7941,
      "organization step": 53773,
      "studies opioids": 77797,
      "pain partially": 57326,
      "tolerability profiles": 81552,
      "noncancer related": 49716,
      "individual dose": 38291,
      "opioids shown": 53295,
      "shown efficacy": 75338,
      "pain diseases": 56727,
      "maintaining analgesic": 42899,
      "appropriate drug": 11501,
      "drug chosen": 26547,
      "chosen based": 16142,
      "guidelines serve": 34472,
      "serve foundation": 74710,
      "recommendations expert": 68599,
      "practice use": 63419,
      "pain role": 57654,
      "hepatic renal": 34959,
      "function opioids": 32660,
      "drug metabolites": 26707,
      "metabolites increased": 44970,
      "renal dysfunction": 70353,
      "opioids respiratory": 53272,
      "depression significant": 23599,
      "cns drugs": 17116,
      "depression used": 23606,
      "considered treating": 19658,
      "decreased efficacy": 22995,
      "characteristics used": 15885,
      "taking consideration": 80302,
      "profile opioids": 65492,
      "event profile": 29986,
      "varies greatly": 85946,
      "especially regarding": 29564,
      "effects safe": 28149,
      "helps reduce": 34918,
      "preparations including": 63780,
      "increase patient": 37780,
      "compliance objectives": 18535,
      "factors requiring": 31131,
      "requiring high": 70901,
      "25 \u03bcg": 3392,
      "impacting pain": 36861,
      "analysis carried": 10646,
      "total protein": 81898,
      "advanced age": 8592,
      "male sex": 43055,
      "discussion study": 25312,
      "need higher": 48926,
      "relief palliative": 70164,
      "care context": 15015,
      "intensity interference": 39260,
      "modified brief": 47236,
      "observational nonrandomized": 50613,
      "pain registry": 57508,
      "registry data": 69404,
      "outpatient settings": 54143,
      "episodes noncancer": 29209,
      "requiring treatment": 70919,
      "medication containing": 44479,
      "containing oxycodone": 20080,
      "release needed": 69895,
      "basis days": 13477,
      "modified bpi": 47235,
      "interference general": 39424,
      "overall sample": 54255,
      "patients 133": 58828,
      "patients arthritis": 59003,
      "148 patients": 1658,
      "patients injury": 59414,
      "injury trauma": 38999,
      "performing better": 60652,
      "cohort group": 17359,
      "conclusion consistent": 18878,
      "patients seen": 59951,
      "ambulatory setting": 9771,
      "properties bpi": 65705,
      "vomiting frequent": 86458,
      "reported incidence": 70570,
      "varies widely": 85947,
      "incidence risk": 37315,
      "inpatients cancer": 39038,
      "agent oxycodone": 9218,
      "00 21": 6,
      "suitable analysis": 79053,
      "07 furthermore": 605,
      "patients addition": 58940,
      "18 opioid": 2098,
      "group decrease": 33727,
      "decrease new": 22903,
      "treatment alpha": 82440,
      "step opioids": 77326,
      "analgesia tolerability": 10123,
      "patients 14": 58829,
      "opioids baseline": 52748,
      "occurred oral": 50840,
      "49 cases": 4774,
      "opioids recorded": 53245,
      "occur frequently": 50821,
      "used baseline": 84857,
      "availability opioid": 12784,
      "established treatment": 29595,
      "associated sepsis": 12416,
      "upper quadrant": 84010,
      "aims identify": 9486,
      "methods searches": 45565,
      "identified inclusion": 36440,
      "according individual": 7046,
      "offer potential": 50950,
      "interventions shown": 39681,
      "approach using": 11486,
      "effectively manage": 27733,
      "primary goal": 65038,
      "prescribed sustained": 63985,
      "constipation severity": 19785,
      "caregivers patients": 15117,
      "settings study": 74863,
      "included 12": 37377,
      "12 000": 1199,
      "july december": 40532,
      "design retrospectively": 23792,
      "examined prescribing": 30405,
      "ratings pain": 67703,
      "shorter length": 75211,
      "observed pain": 50698,
      "receiving fentanyl": 68336,
      "advanced illness": 8599,
      "diminished ability": 25023,
      "published issue": 66431,
      "10 2016": 690,
      "disease progresses": 25343,
      "outcomes specific": 54097,
      "study early": 78141,
      "data calculated": 21896,
      "results new": 71789,
      "studies review": 77833,
      "included adults": 37412,
      "59 years": 5194,
      "proportion men": 65749,
      "bias overall": 13772,
      "studies including": 77752,
      "including children": 37598,
      "placebo comparison": 61668,
      "clear evidence": 16703,
      "evidence difference": 30182,
      "rr 91": 73004,
      "defined 50": 23122,
      "rate hydromorphone": 67474,
      "uncertain rr": 83465,
      "233 participants": 3128,
      "evidence specific": 30259,
      "24 days": 3195,
      "treatment morphine": 82671,
      "constipation compared": 19756,
      "evidence clear": 30173,
      "rr 87": 72998,
      "rr 15": 72901,
      "71 88": 5588,
      "compared fentanyl": 18160,
      "82 participants": 5909,
      "evidence benefits": 30167,
      "dizziness constipation": 25636,
      "fentanyl outcome": 31544,
      "opiate addiction": 51285,
      "therapy notably": 81035,
      "comparison opioids": 18372,
      "cell lines": 15482,
      "values calculated": 85834,
      "rates determined": 67567,
      "50 60": 4818,
      "mtt assay": 48104,
      "able block": 6564,
      "cells vitro": 15505,
      "concentrations effective": 18759,
      "enrolled 25": 28994,
      "evaluated rate": 29916,
      "control provided": 20406,
      "intense pain": 39209,
      "oxycodone allowed": 54707,
      "approximately fold": 11580,
      "metabolites observed": 44977,
      "parameters oxycodone": 58168,
      "major adverse": 42928,
      "drug celecoxib": 26545,
      "neuralgia methods": 49173,
      "random number": 66999,
      "number table": 50263,
      "table method": 80077,
      "treatment clinical": 82494,
      "groups participants": 34261,
      "group decreased": 33728,
      "significantly time": 75866,
      "treatment 10": 82415,
      "tamsulosin hydrochloride": 80356,
      "release capsules": 69809,
      "retention occurred": 72078,
      "improved compared": 37103,
      "improvement significant": 37164,
      "certain extent": 15653,
      "reduce consumption": 68837,
      "registration chinese": 69384,
      "compare time": 18060,
      "pain 35": 56382,
      "35 minutes": 4086,
      "used morphine": 85013,
      "relief following": 70131,
      "faster oxycodone": 31217,
      "goal study": 33277,
      "213 patients": 2995,
      "receive celecoxib": 68048,
      "hours days": 35764,
      "score 12": 73709,
      "suffering severe": 78968,
      "25 36": 3334,
      "prophylactic analgesia": 65725,
      "278 95": 3527,
      "independent factors": 38158,
      "factors severe": 31133,
      "superior oxycodone": 79133,
      "oxycodone celecoxib": 54774,
      "celecoxib pain": 15462,
      "methodology used": 45232,
      "trials oral": 83174,
      "controlled superiority": 20602,
      "randomized non": 67127,
      "hydromorphone identified": 36178,
      "comparison effects": 18367,
      "effects showed": 28155,
      "showed minor": 75273,
      "conclusion evidence": 18903,
      "comparison morphine": 18370,
      "events frequently": 30047,
      "result need": 71483,
      "oral extended": 53531,
      "provides clinicians": 66205,
      "new oral": 49348,
      "oral er": 53530,
      "oxymorphone following": 56246,
      "cr treated": 21112,
      "stabilized dose": 76833,
      "preference patients": 63628,
      "scale adverse": 73495,
      "total 86": 81772,
      "entered open": 29060,
      "assigned oxycodone": 12171,
      "80 completed": 5839,
      "respectively 59": 71161,
      "59 63": 5184,
      "differences daily": 24728,
      "scheduled opioid": 73650,
      "dose oxymorphone": 26001,
      "relief comparable": 70114,
      "tolerability results": 81553,
      "likely need": 41819,
      "complications understanding": 18572,
      "meperidine propoxyphene": 44850,
      "good alternatives": 33295,
      "acute confusion": 7627,
      "certain drugs": 15652,
      "common negatively": 17772,
      "analgesics patient": 10477,
      "data incidence": 21986,
      "satisfaction care": 73390,
      "lacking methods": 41066,
      "analyzed 18": 10820,
      "outpatient oncology": 54124,
      "pain intervention": 56968,
      "management information": 43191,
      "handout patients": 34564,
      "effectiveness implementing": 27763,
      "nursing protocol": 50344,
      "personalized pain": 60954,
      "increase percentage": 37781,
      "achieved 84": 7312,
      "oncology clinics": 51071,
      "protocols opioid": 66004,
      "findings literature": 31795,
      "potentially safer": 63267,
      "obviates need": 50792,
      "patient undergoing": 58804,
      "providing sufficient": 66272,
      "treat breakthrough": 82285,
      "reducing adverse": 69012,
      "pain satisfactory": 57658,
      "achieved 70": 7311,
      "pain receive": 57477,
      "combination nonsteroidal": 17571,
      "therapeutic guidelines": 80942,
      "opioids mean": 53039,
      "achieve analgesic": 7294,
      "55 mg": 5077,
      "doses 80": 26142,
      "80 patients": 5857,
      "patients resulting": 59923,
      "opioids reduced": 53247,
      "therapy early": 81010,
      "alleviation pain": 9608,
      "guidelines educational": 34437,
      "educational programs": 27405,
      "concern patients": 18831,
      "patients solid": 59986,
      "mainstay analgesic": 42874,
      "therapy associated": 80989,
      "essential drug": 29575,
      "evidence superiority": 30268,
      "methadone useful": 45136,
      "difficult manage": 24964,
      "transdermal opioids": 82161,
      "opioid improve": 51841,
      "patient support": 58793,
      "gain insight": 32814,
      "staff members": 76857,
      "addiction cancer": 7740,
      "acetaminophen having": 7189,
      "fentanyl major": 31518,
      "major opioids": 42964,
      "group percent": 33910,
      "groups combined": 34144,
      "mg incidence": 45923,
      "31 percent": 3877,
      "001 incidence": 146,
      "group combined": 33682,
      "pain centers": 56518,
      "efficacy assessed": 28227,
      "frequent buprenorphine": 32533,
      "groups morphine": 34239,
      "times frequent": 81424,
      "increase dose": 37745,
      "observed 33": 50647,
      "patients vs": 60177,
      "conclusions observed": 19131,
      "results small": 71962,
      "nature study": 48752,
      "study allow": 77946,
      "variability opioids": 85870,
      "opioids address": 52706,
      "indicated patients": 38243,
      "efficacy risk": 28353,
      "dependency limit": 23494,
      "practice aim": 63390,
      "extracted national": 30961,
      "time analyzed": 81211,
      "initiated treatment": 38884,
      "prescription months": 64263,
      "years 51": 87542,
      "contact health": 20047,
      "trials oxycodone": 83175,
      "psychiatric comorbidity": 66323,
      "need better": 48911,
      "effort needed": 28433,
      "needed improve": 49010,
      "27 year": 3510,
      "history type": 35488,
      "year history": 87443,
      "presented hospital": 64693,
      "tomography scan": 81655,
      "leg pain": 41361,
      "managed acetaminophen": 43130,
      "lidocaine patch": 41673,
      "pain young": 57997,
      "young man": 87719,
      "cause effects": 15354,
      "effects common": 27855,
      "common nausea": 17771,
      "impair quality": 36868,
      "review undertaken": 72367,
      "guidelines design": 34434,
      "embase 1980": 28636,
      "recommendations results": 68613,
      "follows opioid": 32229,
      "use antiemetics": 84198,
      "opioid recommendations": 52286,
      "method patients": 45198,
      "patients increasing": 59405,
      "increasing pain": 38116,
      "newer opioids": 49407,
      "different adverse": 24837,
      "profiles compared": 65516,
      "therapeutic options": 80953,
      "conventional analgesic": 20691,
      "important evaluate": 37007,
      "evaluate risk": 29842,
      "11 year": 1157,
      "transplantation complained": 82237,
      "articular pain": 11811,
      "initiated dose": 38878,
      "resulting high": 71528,
      "dose switching": 26091,
      "switching fentanyl": 79832,
      "pain change": 56521,
      "frequency oxycodone": 32523,
      "coping efforts": 20755,
      "anxiety opioid": 11280,
      "opioid education": 51755,
      "providers opioid": 66187,
      "prescription appropriate": 64167,
      "use provide": 84673,
      "education taking": 27397,
      "assess characteristics": 11915,
      "abdominal visceral": 6534,
      "analysis pain": 10724,
      "minutes 10": 46641,
      "medications doses": 44616,
      "pain sd": 57801,
      "patients 97": 58913,
      "day sd": 22410,
      "sd 51": 74069,
      "patients 82": 58903,
      "ingestion food": 38743,
      "042 associated": 462,
      "use nonsteroidal": 84524,
      "drugs findings": 26961,
      "longitudinal studies": 42402,
      "opioids 2005": 52668,
      "cancer year": 14919,
      "based national": 13338,
      "data cancer": 21897,
      "males opioid": 43080,
      "82 percent": 5911,
      "increased 39": 37853,
      "percent period": 60482,
      "previous month": 64906,
      "cancer increased": 14787,
      "001 odds": 167,
      "opioids potential": 53197,
      "purpose article": 66520,
      "respectively 14": 71152,
      "respectively 29": 71157,
      "deceased patients": 22813,
      "disease patient": 25337,
      "opioids 179": 52663,
      "oxycodone introduction": 55300,
      "analgesics reduce": 10490,
      "mg intravenously": 45932,
      "intravenously administered": 39892,
      "administered consecutive": 8114,
      "analyzed patients": 10851,
      "reduced dose": 68919,
      "liver renal": 42185,
      "toxicity observed": 81934,
      "decreased varying": 23052,
      "using bone": 85325,
      "paper explores": 58079,
      "questionnaire distributed": 66893,
      "nurses reported": 50337,
      "97 codeine": 6441,
      "problems opioid": 65259,
      "administration reported": 8359,
      "treatment modalities": 82661,
      "treatment follow": 82588,
      "dipyrone non": 25035,
      "naloxone moderate": 48463,
      "pain transdermal": 57930,
      "application fentanyl": 11424,
      "oncology department": 51072,
      "disease stage": 25351,
      "social workers": 76361,
      "pharmacological nonpharmacological": 61224,
      "old chronic": 51002,
      "pain increasingly": 56866,
      "importance recognizing": 36987,
      "difficult present": 24968,
      "control oral": 20380,
      "oxycodone preparation": 55738,
      "flexion hip": 31913,
      "neurological symptoms": 49202,
      "pain indicates": 56868,
      "gastric cancer": 32852,
      "patient underwent": 58805,
      "conventional analgesics": 20692,
      "subcutaneous oxycodone": 78606,
      "reported common": 70522,
      "common practice": 17795,
      "leading significant": 41315,
      "identify common": 36498,
      "palliative medicine": 58052,
      "medicine practitioners": 44712,
      "parenteral opioid": 58209,
      "majority respondents": 42998,
      "using conversion": 85360,
      "recommendations conclusion": 68598,
      "safety prescribing": 73202,
      "woman diagnosed": 87185,
      "bypass surgery": 14636,
      "chemotherapy radiotherapy": 15969,
      "10 months": 871,
      "administered pain": 8162,
      "discontinued nausea": 25241,
      "did worsen": 24521,
      "september 11": 74606,
      "11 2016": 1102,
      "using strong": 85630,
      "non invasively": 49620,
      "hand foot": 34549,
      "took average": 81669,
      "average 10": 12855,
      "patient analysis": 58539,
      "optimal doses": 53422,
      "cancer multiple": 14797,
      "metastasis confirmed": 45025,
      "confirmed significant": 19509,
      "effects optimal": 28048,
      "dose vitamin": 26108,
      "marked decrease": 43392,
      "toxic substances": 81928,
      "marked increase": 43394,
      "containing high": 20075,
      "medicine oxycodone": 44709,
      "chronic diseases": 16191,
      "achieve pain": 7301,
      "pain pharmacological": 57372,
      "medication physical": 44537,
      "monitoring pain": 47332,
      "appropriate therapy": 11517,
      "therapy provides": 81055,
      "best patient": 13691,
      "opiate drugs": 51298,
      "staff use": 76859,
      "july 2010": 40514,
      "regional health": 69355,
      "opioids traditionally": 53342,
      "administered low": 8148,
      "impact aim": 36797,
      "according data": 7043,
      "data flow": 21972,
      "diagnosis treatment": 24340,
      "management essential": 43181,
      "approximately 75": 11576,
      "doses nonsteroidal": 26222,
      "pain uterine": 57967,
      "40 year": 4384,
      "pain intermittent": 56966,
      "imaging positron": 36685,
      "uterine contractions": 85706,
      "caused uterine": 15390,
      "uterine contraction": 85705,
      "major cause": 42930,
      "affects millions": 8935,
      "insufficiently controlled": 39134,
      "update new": 83979,
      "new data": 49318,
      "treatment recommendations": 82799,
      "care included": 15033,
      "health law": 34727,
      "control program": 20403,
      "education included": 27383,
      "2014 pediatric": 2673,
      "codeine pethidine": 17276,
      "involved opioid": 40103,
      "pharmacotherapy cancer": 61249,
      "dose avoid": 25833,
      "overdosing associated": 54338,
      "negative outcomes": 49080,
      "generally used": 33035,
      "ratios indicated": 67824,
      "dose administration": 25826,
      "setting chronic": 74772,
      "emerging evidence": 28712,
      "studies heterogeneous": 77741,
      "correlated dose": 20811,
      "opioid switch": 52389,
      "warrant consideration": 86724,
      "represents challenge": 70766,
      "challenge patients": 15692,
      "medications treatment": 44692,
      "growing clinical": 34361,
      "optimal patient": 53429,
      "stressed patients": 77494,
      "patients current": 59164,
      "history addiction": 35449,
      "behavioral problems": 13550,
      "deemed necessary": 23084,
      "necessary treatment": 48892,
      "ratio edr": 67768,
      "series case": 74653,
      "accurately reflect": 7106,
      "based best": 13287,
      "best available": 13684,
      "management potential": 43243,
      "account patient": 7075,
      "institution specific": 39083,
      "specific factors": 76591,
      "dosages titrated": 25771,
      "large variations": 41161,
      "prescribing clinical": 64040,
      "review carried": 72271,
      "used analyse": 84843,
      "overall 95": 54181,
      "17 fentanyl": 1969,
      "mean 47": 43667,
      "47 mg": 4659,
      "mg significant": 46216,
      "different patterns": 24908,
      "trial examined": 83025,
      "assessed numerical": 12021,
      "analyzed descriptive": 10827,
      "22 tramadol": 3043,
      "gastrointestinal symptoms": 32891,
      "symptoms especially": 79884,
      "underlying mechanisms": 83608,
      "adjustment using": 8074,
      "evidence oral": 30234,
      "conducted medline": 19376,
      "trials databases": 83133,
      "limited time": 41965,
      "october 2009": 50874,
      "using text": 85639,
      "databases cochrane": 22195,
      "studies total": 77868,
      "tolerability data": 81529,
      "na\u00efve non": 48833,
      "populations cancer": 62405,
      "suggesting oral": 79029,
      "ladder opioid": 41077,
      "therapy used": 81076,
      "used increasingly": 84973,
      "medline 1950": 44727,
      "opioids defined": 52838,
      "defined ladder": 23141,
      "agonists examined": 9327,
      "pain eligible": 56751,
      "studies contained": 77681,
      "contained data": 20064,
      "effects key": 27962,
      "examined morphine": 30393,
      "morphine combination": 47609,
      "methadone conclusion": 45060,
      "effects combination": 27851,
      "needed clarify": 48990,
      "therapy background": 80990,
      "pain mitigate": 57199,
      "mitigate opioid": 46763,
      "care clinic": 15010,
      "center identified": 15525,
      "25 pre": 3381,
      "29 90": 3604,
      "successful reducing": 78915,
      "scores overall": 73934,
      "did correlate": 24427,
      "appropriate treatment": 11518,
      "according published": 7062,
      "understanding efficacy": 83634,
      "trials comparative": 83119,
      "studies adverse": 77644,
      "data abstraction": 21858,
      "quality trials": 66765,
      "different long": 24881,
      "different efficacy": 24868,
      "opioids class": 52784,
      "effective safer": 27701,
      "opioids subgroup": 53319,
      "tolerability buprenorphine": 81521,
      "international association": 39469,
      "association study": 12491,
      "comparing buprenorphine": 18346,
      "trials included": 83150,
      "different intervention": 24876,
      "11 studies": 1152,
      "respectively buprenorphine": 71174,
      "profile patient": 65503,
      "ratings did": 67692,
      "analgesia duration": 9956,
      "duration adverse": 27151,
      "placebo different": 61722,
      "doses transdermal": 26293,
      "line option": 41991,
      "documentation pain": 25663,
      "pain characteristics": 56526,
      "patients days": 59170,
      "life methods": 41708,
      "collected retrospectively": 17482,
      "sample included": 73303,
      "included 220": 37388,
      "extracted patients": 30962,
      "care results": 15076,
      "consistently documented": 19720,
      "odds having": 50898,
      "having severe": 34612,
      "pain times": 57920,
      "higher cancer": 35214,
      "receiving analgesics": 68324,
      "analgesics classified": 10388,
      "higher noncancer": 35271,
      "assessed intensity": 12011,
      "pain poorly": 57383,
      "poorly documented": 62282,
      "management long": 43195,
      "formulation hydromorphone": 32344,
      "hydromorphone use": 36231,
      "sr formulations": 76812,
      "beerse belgium": 13515,
      "provided evidence": 66136,
      "presence alcohol": 64583,
      "strategies randomized": 77422,
      "patients home": 59368,
      "database performed": 22179,
      "data compared": 21919,
      "opioid cohort": 51586,
      "identify difference": 36500,
      "pain groups": 56814,
      "analyzed study": 10859,
      "daily methadone": 21757,
      "methadone doses": 45063,
      "despite potential": 23894,
      "methadone commonly": 45057,
      "significant challenge": 75435,
      "59 year": 5192,
      "patient control": 58577,
      "complained pain": 18422,
      "buprenorphine patch": 14580,
      "opioid craving": 51680,
      "study institution": 78261,
      "treatment complicated": 82513,
      "search literature": 74114,
      "studies methodological": 77776,
      "dose data": 25857,
      "data allow": 21869,
      "experimental data": 30660,
      "100 oral": 1008,
      "ratio 75": 67749,
      "evidence robust": 30256,
      "data relatively": 22090,
      "limitations evidence": 41901,
      "influenced factors": 38603,
      "recommended patients": 68634,
      "opioids cornerstone": 52826,
      "pain regardless": 57503,
      "develop opioid": 24152,
      "increasing doses": 38103,
      "possibility opioid": 62525,
      "discussion opioid": 25305,
      "clinically reasonable": 16987,
      "addition low": 7809,
      "benefit opioid": 13618,
      "adjunctive pain": 8010,
      "research network": 71020,
      "addressed pain": 7937,
      "ladder step": 41078,
      "step ii": 77322,
      "pain general": 56804,
      "cancer primary": 14898,
      "carbamazepine phenytoin": 14967,
      "tramadol dextropropoxyphene": 82054,
      "dextropropoxyphene dihydrocodeine": 24300,
      "dihydrocodeine morphine": 24993,
      "morphine 19": 47545,
      "10 opioids": 883,
      "fentanyl 14": 31414,
      "observed large": 50686,
      "opioids countries": 52827,
      "countries finally": 20954,
      "minority patients": 46630,
      "currently exist": 21495,
      "mirna signatures": 46684,
      "differentially regulated": 24946,
      "potential pharmacodynamic": 63204,
      "mor stimulation": 47504,
      "mir 423": 46681,
      "423 3p": 4487,
      "let 7a": 41431,
      "7a 5p": 5816,
      "let 7f": 41433,
      "7f 5p": 5818,
      "mir 144": 46676,
      "144 3p": 1646,
      "mir 215": 46678,
      "mir 363": 46679,
      "363 3p": 4159,
      "plasma mirna": 61940,
      "correlation observed": 20831,
      "observed analgesic": 50651,
      "efficacy putative": 28338,
      "hydromorphone results": 36223,
      "settings needed": 74856,
      "needed assess": 48978,
      "medical treatments": 44411,
      "medical charts": 44345,
      "effect model": 27488,
      "acetaminophen administration": 7149,
      "administration decreased": 8242,
      "59 45": 5182,
      "increased 41": 37855,
      "morphine use": 47966,
      "increased 45": 37858,
      "47 40": 4648,
      "ml day": 46854,
      "life medical": 41707,
      "treatments increased": 82912,
      "assist pain": 12189,
      "physicians use": 61452,
      "results response": 71920,
      "certified pediatric": 15670,
      "84 94": 5956,
      "51 compared": 4955,
      "comfortable using": 17693,
      "level comfort": 41450,
      "opioids information": 52999,
      "targeted education": 80496,
      "efficacy relief": 28344,
      "administration guidelines": 8271,
      "greater understanding": 33498,
      "using databases": 85372,
      "databases identified": 22199,
      "observational cross": 50610,
      "reviews included": 72413,
      "thirteen studies": 81100,
      "oxycodone general": 55112,
      "administration parenteral": 8333,
      "using self": 85607,
      "discussion challenges": 25301,
      "standardization opioid": 76945,
      "using specific": 85620,
      "methods hospital": 45353,
      "sleep disorders": 76219,
      "enrolled mean": 29004,
      "release commonly": 69811,
      "used short": 85125,
      "analgesic followed": 10254,
      "followed intravenous": 32063,
      "showed association": 75230,
      "lower quality": 42693,
      "published prospective": 66435,
      "patients naive": 59533,
      "naive opioids": 48400,
      "studies describing": 77697,
      "31 treatment": 3880,
      "characteristics reported": 15878,
      "reported rates": 70637,
      "reported aes": 70504,
      "85 vomiting": 5990,
      "studies especially": 77713,
      "important issue": 37015,
      "daily clinical": 21704,
      "events type": 30131,
      "systematic assessment": 79973,
      "need studies": 48957,
      "receiving transdermal": 68384,
      "influence changes": 38587,
      "skin pain": 76208,
      "patients normal": 59557,
      "using nrs": 85525,
      "significantly related": 75856,
      "lead poor": 41297,
      "2010 conducted": 2552,
      "hydrocodone oxymorphone": 36124,
      "dosing clinical": 26308,
      "opioid hydromorphone": 51836,
      "does produce": 25688,
      "degree dose": 23172,
      "hydromorphone twice": 36229,
      "requiring continuous": 70899,
      "continuous clock": 20157,
      "clock opioid": 17052,
      "analgesia extended": 9970,
      "extended period": 30852,
      "moderate hepatic": 47147,
      "clearance 30": 16710,
      "60 ml": 5264,
      "min conclusion": 46515,
      "available management": 12820,
      "context purpose": 20111,
      "test evidence": 80770,
      "primary study": 65111,
      "assess patient": 11946,
      "based efficacy": 13315,
      "published time": 66440,
      "study implementation": 78244,
      "following drugs": 32128,
      "patch gabapentin": 58492,
      "escalation drug": 29529,
      "combinations treatment": 17632,
      "drugs patient": 27033,
      "satisfaction assessed": 73388,
      "weeks results": 86952,
      "severity 001": 75031,
      "activity 001": 7555,
      "walking ability": 86699,
      "ability perform": 6556,
      "001 patient": 181,
      "treatment result": 82818,
      "result improved": 71479,
      "improved symptoms": 37134,
      "paclitaxel induced": 56327,
      "induced painful": 38441,
      "55 year": 5081,
      "stage iib": 76864,
      "taking medications": 80308,
      "did reveal": 24500,
      "underwent routine": 83692,
      "lymph node": 42775,
      "disease treatment": 25353,
      "left sided": 41348,
      "folic acid": 32007,
      "conclusion patient": 18953,
      "overdoses opioids": 54332,
      "causative factors": 15341,
      "changed dose": 15760,
      "opioids safe": 53282,
      "administration reduced": 8358,
      "experience symptoms": 30596,
      "anxiety insomnia": 11277,
      "life randomized": 41729,
      "prophylactic use": 65729,
      "tolerating treatment": 81645,
      "refractory multiple": 69223,
      "anti emetics": 11118,
      "muscle weakness": 48363,
      "symptoms depression": 79880,
      "improve symptoms": 37090,
      "workup revealed": 87302,
      "symptoms cancer": 79876,
      "iv ketamine": 40380,
      "transitioned oral": 82207,
      "10 started": 929,
      "dose addition": 25819,
      "despite escalating": 23877,
      "doses ketamine": 26208,
      "days mg": 22556,
      "patient discharged": 58622,
      "hours patient": 35811,
      "patient dose": 58625,
      "requirements decreased": 70878,
      "decreased 61": 22969,
      "total ome": 81857,
      "transition oral": 82204,
      "ketamine effective": 40609,
      "effective tolerable": 27708,
      "pain aim": 56436,
      "evaluate frequency": 29803,
      "using protocol": 85579,
      "opioids routes": 53280,
      "morphine 100": 47534,
      "fentanyl intravenous": 31509,
      "methadone 20": 45038,
      "changed initial": 15763,
      "response acute": 71332,
      "overall 103": 54178,
      "days presence": 22596,
      "relationship identified": 69717,
      "adjuvant medications": 8083,
      "effects negative": 28022,
      "patients achieve": 58921,
      "related toxicity": 69702,
      "hydromorphone recommended": 36221,
      "extraction form": 30965,
      "inclusion assessed": 37685,
      "described cochrane": 23649,
      "cochrane handbook": 17175,
      "half studies": 34532,
      "results meta": 71777,
      "involved chronic": 40094,
      "conditions cancer": 19313,
      "analgesic limited": 10264,
      "drugs context": 26923,
      "equi analgesic": 29253,
      "reviewer conclusions": 72395,
      "hydromorphone potent": 36217,
      "analgesic clinical": 10163,
      "similar mu": 75952,
      "pain affect": 56433,
      "psychological state": 66345,
      "care medicine": 15042,
      "hospital june": 35597,
      "retrospectively results": 72182,
      "analysis factors": 10685,
      "affecting use": 8929,
      "proportion male": 65748,
      "60 69": 5228,
      "69 years": 5528,
      "requirements oxycodone": 70886,
      "highest frequency": 35348,
      "low overall": 42516,
      "elderly men": 28474,
      "control needs": 20371,
      "countries patients": 20959,
      "administration median": 8296,
      "17 combination": 1959,
      "min median": 46535,
      "reported mild": 70586,
      "pain 37": 56383,
      "patients stated": 59996,
      "pain interfered": 56960,
      "interfered daily": 39419,
      "opioids rescue": 53269,
      "oxycodone whilst": 56092,
      "using non": 85516,
      "took rescue": 81676,
      "medication time": 44574,
      "pain percent": 57364,
      "consider using": 19607,
      "positive response": 62486,
      "seventy percent": 74891,
      "associated male": 12329,
      "medication diary": 44486,
      "setting community": 74775,
      "settings australia": 74853,
      "doses medication": 26213,
      "calculated opioid": 14694,
      "used sample": 85121,
      "hydromorphone median": 36182,
      "interpretation opioid": 39503,
      "utilisation oral": 85711,
      "doses recommended": 26261,
      "management symptoms": 43273,
      "account significant": 7077,
      "oral injectable": 53552,
      "prescribing objective": 64089,
      "identified pharmacy": 36456,
      "criteria drug": 21194,
      "study prescribed": 78422,
      "13 nausea": 1493,
      "death considered": 22704,
      "prescribing fentanyl": 64057,
      "type analysis": 83320,
      "analysis useful": 10788,
      "patients requires": 59909,
      "simple effective": 76018,
      "continue experience": 20121,
      "drugs new": 27004,
      "strategies field": 77415,
      "minimise adverse": 46590,
      "analgesics addition": 10368,
      "promising results": 65657,
      "component neuropathic": 18580,
      "number clinical": 50146,
      "treating neuropathic": 82397,
      "patients anorexia": 58995,
      "offer improved": 50948,
      "effects providing": 28117,
      "opioids act": 52700,
      "appears kappa": 11402,
      "combined morphine": 17656,
      "current situation": 21466,
      "methods questionnaires": 45503,
      "care service": 15077,
      "service provision": 74723,
      "association hospice": 12473,
      "regulation opioid": 69497,
      "different stages": 24922,
      "data monitoring": 22012,
      "monitoring development": 47320,
      "variability response": 85877,
      "project aimed": 65587,
      "clinical investigation": 16830,
      "search embase": 74111,
      "embase pubmed": 28653,
      "independent reviewers": 38165,
      "provide details": 66049,
      "assessment using": 12146,
      "cohort cross": 17354,
      "young age": 87716,
      "gastrointestinal cancer": 32872,
      "anxiety sleep": 11284,
      "associated worse": 12465,
      "identified literature": 36443,
      "gender ethnicity": 32935,
      "2014 italian": 2663,
      "tramadol conclusions": 82050,
      "studies cancer": 77656,
      "factors enhance": 31092,
      "assess performance": 11949,
      "eighty consecutive": 28453,
      "57 men": 5130,
      "age 69": 9046,
      "10 standard": 927,
      "92 years": 6159,
      "protocol 50": 65954,
      "mg ondansetron": 46075,
      "standard 40": 76887,
      "mg infusion": 45925,
      "group standard": 34028,
      "score 30": 73723,
      "benefit risk": 13625,
      "sap compared": 73379,
      "compared 15": 18067,
      "15 35": 1696,
      "analysis procedures": 10744,
      "procedures showed": 65325,
      "32 14": 3905,
      "events particularly": 30092,
      "reinforcing analgesic": 69522,
      "protocol combining": 65961,
      "suggests different": 79037,
      "identified randomized": 36460,
      "2011 issue": 2583,
      "1980 november": 2219,
      "control trials": 20437,
      "considered inclusion": 19634,
      "beneficial harmful": 13598,
      "effects methadone": 27990,
      "181 participants": 2133,
      "76 participants": 5743,
      "study phases": 78408,
      "approximately weeks": 11593,
      "weeks respectively": 86951,
      "average months": 12897,
      "reported average": 70508,
      "improvements versus": 37178,
      "placebo outcomes": 61790,
      "methadone second": 45126,
      "statistically superior": 77238,
      "versus 42": 86108,
      "33 50": 3982,
      "50 morphine": 4868,
      "efficacy methadone": 28297,
      "data pooled": 22050,
      "studies conclusions": 77672,
      "conclusions regarding": 19187,
      "trial included": 83029,
      "chronic refractory": 16336,
      "standard group": 76913,
      "baseline values": 13464,
      "values 001": 85830,
      "higher standard": 35327,
      "showed near": 75277,
      "027 conclusions": 396,
      "initial treatment": 38873,
      "records consecutive": 68718,
      "regarding demographics": 69245,
      "patients returned": 59925,
      "defined point": 23145,
      "point 30": 62076,
      "170 patients": 2000,
      "opioid median": 51899,
      "age 59": 9030,
      "symptom distress": 79862,
      "dose 52": 25811,
      "24 conclusion": 3192,
      "conclusion median": 18925,
      "dose background": 25834,
      "remain scarce": 70252,
      "codes results": 17307,
      "age mean": 9089,
      "time mean": 81285,
      "oxycodone 39": 54569,
      "fentanyl 32": 31426,
      "32 52": 3916,
      "patients respectively": 59917,
      "respectively prescription": 71236,
      "patterns varied": 60232,
      "numerically lower": 50326,
      "month death": 47385,
      "used use": 85186,
      "data primary": 22066,
      "analgesic procedures": 10302,
      "unit significant": 83772,
      "differences regarding": 24802,
      "therapy 001": 80984,
      "procedures 001": 65293,
      "001 pain": 178,
      "pain uncontrolled": 57949,
      "surgery 50": 79308,
      "drugs significant": 27072,
      "regular administration": 69474,
      "administration 24": 8208,
      "methadone increased": 45085,
      "reduction use": 69107,
      "years significant": 87670,
      "dose ranging": 26031,
      "opioids neurosurgical": 53088,
      "invasive procedures": 39970,
      "levels associated": 41547,
      "associated toxicity": 12454,
      "pain bowel": 56497,
      "function cancer": 32636,
      "symptoms methods": 79895,
      "range 150": 67260,
      "mean serum": 43877,
      "morphine concentration": 47615,
      "concentration 53": 18674,
      "17 mean": 1973,
      "mixed model": 46800,
      "decreases mean": 23058,
      "mean worst": 43908,
      "scores weeks": 74016,
      "weeks change": 86896,
      "levels compared": 41550,
      "quite bit": 66925,
      "37 weeks": 4206,
      "low complication": 42459,
      "complication rate": 18553,
      "rate observed": 67488,
      "levels reducing": 41602,
      "patients implications": 59384,
      "function warrants": 32686,
      "warrants study": 86738,
      "treatment established": 82582,
      "poorly known": 62283,
      "clinical genetic": 16818,
      "factors impacting": 31097,
      "genome wide": 33093,
      "august 2006": 12660,
      "december 2010": 22820,
      "included 187": 37385,
      "explored associations": 30731,
      "16 genes": 1873,
      "surgery age": 79317,
      "age american": 9055,
      "used post": 85078,
      "logistic model": 42253,
      "028 conclusions": 398,
      "approach did": 11456,
      "support role": 79213,
      "dopamine receptors": 25722,
      "paracetamol review": 58114,
      "using pharmacological": 85560,
      "pain negative": 57231,
      "focused pain": 31975,
      "nerve compression": 49123,
      "pain currently": 56674,
      "2017 searched": 2805,
      "tested opioids": 80810,
      "opioids adults": 52710,
      "participants aged": 58279,
      "lack available": 41046,
      "analyses undertaken": 10616,
      "analgesics buprenorphine": 10384,
      "library issue": 41663,
      "issue 12": 40319,
      "gov http": 33343,
      "february 2015": 31307,
      "studies systematic": 77859,
      "reviews additional": 72402,
      "studies selection": 77839,
      "design comparing": 23703,
      "data pertaining": 22044,
      "details including": 23920,
      "characteristics previous": 15875,
      "summarised results": 79085,
      "studies buprenorphine": 77655,
      "studies differences": 77701,
      "terms effects": 80705,
      "vomiting adverse": 86446,
      "intramuscular group": 39741,
      "associated faster": 12259,
      "reporting bias": 70685,
      "evidence outcomes": 30235,
      "pain strong": 57866,
      "increases patient": 38070,
      "patient prescriber": 58716,
      "transdermal route": 82169,
      "challenging manage": 15709,
      "efficacy long": 28287,
      "use weeks": 84809,
      "data 14": 21845,
      "investigated 14": 40033,
      "administered time": 8188,
      "months duration": 47439,
      "high using": 35189,
      "event outcomes": 29985,
      "ranged low": 67351,
      "assessment quality": 12133,
      "events led": 30062,
      "evidence risk": 30255,
      "calculated equivalent": 14690,
      "levorphanol methadone": 41628,
      "tilidine tramadol": 81185,
      "total 18": 81734,
      "participants 12": 58265,
      "placebo risk": 61821,
      "constipation dizziness": 19760,
      "pruritus vomiting": 66313,
      "data adverse": 21867,
      "number adverse": 50136,
      "opioids cncp": 52787,
      "based adverse": 13273,
      "demonstrated long": 23351,
      "occur opioid": 50822,
      "reported included": 70571,
      "concerns adverse": 18841,
      "including dependence": 37607,
      "prescribed potent": 63957,
      "potent pain": 63116,
      "active passive": 7525,
      "making treatment": 43015,
      "treatment preferences": 82775,
      "protocol study": 66000,
      "patient preferences": 58712,
      "generated using": 33038,
      "iterative process": 40356,
      "review study": 72361,
      "survey administered": 79694,
      "administered groups": 8130,
      "differ substantially": 24553,
      "terms age": 80701,
      "treatment modality": 82662,
      "latent class": 41231,
      "class analysis": 16652,
      "used explore": 84935,
      "summary available": 79095,
      "available national": 12824,
      "national drug": 48682,
      "used improve": 84968,
      "treatment goals": 82592,
      "efficacy safety cost": 28357,
      "safety cost effectiveness": 73138,
      "oxycodone hydrochloride controlled": 55180,
      "hydrochloride controlled release": 36013,
      "cr oxycodone morphine": 21093,
      "initial dose cr": 38839,
      "dose cr oxycodone": 25854,
      "meta analysis showed": 44901,
      "cost effective option": 20867,
      "effective option compared": 27655,
      "oxycontin opioid abuse": 56159,
      "patients study groups": 60009,
      "analgesic effect assessed": 10196,
      "quality life results": 66745,
      "included text article": 37566,
      "standardized nursing care": 76975,
      "improve analgesic efficacy": 37056,
      "aim study aims": 9403,
      "sun yat sen": 79120,
      "yat sen university": 87419,
      "control group respectively": 20341,
      "degree pain relief": 23176,
      "combination analgesic drugs": 17546,
      "effects quality life": 28121,
      "significant difference total": 75493,
      "significantly improve quality": 75747,
      "patients moderate pain": 59519,
      "analgesic efficacy reduce": 10246,
      "improve patient quality": 37075,
      "patient quality life": 58724,
      "efficacy safety oxycontin": 28372,
      "safety oxycontin tablets": 73190,
      "oxycontin tablets controlled": 56187,
      "tablets controlled release": 80137,
      "hydrochloride 10 20": 36006,
      "40 mg relieving": 4356,
      "mg relieving moderate": 46202,
      "relieving moderate severe": 70233,
      "pain method multicenter": 57176,
      "method multicenter open": 45190,
      "multicenter open label": 48164,
      "open label prospective": 51176,
      "label prospective self": 40992,
      "prospective self controlled": 65877,
      "self controlled clinical": 74485,
      "results pain relieved": 71832,
      "patients drug administration": 59228,
      "drug administration oxycontin": 26525,
      "administration oxycontin tablets": 8330,
      "oxycontin tablets showed": 56191,
      "tablets showed good": 80215,
      "showed good clinical": 75250,
      "good clinical efficacy": 33298,
      "clinical efficacy relieving": 16805,
      "efficacy relieving moderate": 28346,
      "cancer pain compared": 14824,
      "baseline average pain": 13418,
      "average pain scores": 12929,
      "lower average pain": 42580,
      "response rate reached": 71365,
      "oxycontin tablets demonstrated": 56189,
      "tablets demonstrated fast": 80143,
      "demonstrated fast onset": 23340,
      "pain control superior": 56661,
      "control superior efficacy": 20428,
      "superior efficacy relieving": 79127,
      "pain good safety": 56810,
      "good safety profile": 33330,
      "opioid analgesic oxycontin": 51464,
      "similar immediate release": 75936,
      "different types pain": 24934,
      "cancer pain long": 14828,
      "treated high dose": 82341,
      "treatment strong opioids": 82858,
      "pain relief tolerability": 57589,
      "pain adults data": 56423,
      "adults data collection": 8561,
      "pain intensity data": 56893,
      "overall quality evidence": 54238,
      "compared controlled release": 18123,
      "pooled analysis studies": 62240,
      "oxycodone pain intensity": 55630,
      "interval ci 06": 39576,
      "treatment acceptability adverse": 82421,
      "acceptability adverse events": 6978,
      "oxycodone cr oxycodone": 54903,
      "adverse events studies": 8816,
      "pain intensity did": 56896,
      "smd 14 95": 76319,
      "oxycodone various formulations": 56074,
      "similar levels pain": 75943,
      "levels pain relief": 41590,
      "conclusions consistent recent": 19060,
      "head head studies": 34647,
      "opioids relief cancer": 53256,
      "cancer pain background": 14817,
      "cancer patients experience": 14873,
      "patients experience pain": 59275,
      "experience pain medical": 30588,
      "uplc ms ms": 83996,
      "used simultaneous determination": 85133,
      "dawley rats given": 22225,
      "rats given oxycodone": 67862,
      "ms ms used": 48092,
      "ms used determine": 48098,
      "human liver microsomes": 35961,
      "liver microsomes hlms": 42184,
      "inhibited metabolism oxycodone": 38772,
      "oxycodone vitro vivo": 56083,
      "meta analysis determine": 44892,
      "risk rr 95": 72658,
      "rr 95 confidence": 73011,
      "opioids cancer related": 52765,
      "94 95 ci": 6190,
      "rr 86 95": 72996,
      "rr 98 95": 73018,
      "98 95 ci": 6460,
      "rr 97 95": 73015,
      "rr 76 95": 72977,
      "rr 47 95": 72937,
      "significant difference oxycodone": 75485,
      "adverse events compared": 8741,
      "analgesics cancer pain": 10386,
      "relief fewer adverse": 70128,
      "effects compared strong": 27867,
      "background oxycodone widely": 13139,
      "pain non cancer": 57241,
      "cancer pain study": 14858,
      "past 20 years": 58452,
      "reviews meta analysis": 72416,
      "blind randomized controlled": 13971,
      "adverse effects oxycodone": 8681,
      "effects oxycodone high": 28064,
      "maintains extended release": 42905,
      "extended release properties": 30901,
      "blood levels oxycodone": 14127,
      "total daily opioid": 81796,
      "improve pain control": 37071,
      "objective study aims": 50494,
      "study aims evaluate": 77942,
      "aims evaluate efficacy": 9482,
      "efficacy safety oxycodone": 28371,
      "relevant randomized controlled": 70072,
      "searched electronic databases": 74149,
      "databases including pubmed": 22202,
      "web science embase": 86814,
      "meta analysis results": 44899,
      "results showed statistically": 71949,
      "severe pain control": 74975,
      "rr 04 95": 72889,
      "rr 30 95": 72917,
      "scores significant difference": 73986,
      "significant differences efficacy": 75502,
      "pain patients difficulty": 57345,
      "prescribed cancer patients": 63829,
      "cancer patients pain": 14884,
      "aim work study": 9432,
      "population pharmacokinetics oxycodone": 62376,
      "pharmacokinetics oxycodone patients": 61180,
      "pharmacokinetics calculated using": 61162,
      "using compartment model": 85353,
      "clearance volume distribution": 16720,
      "variability population pharmacokinetics": 85875,
      "concentration oxycodone increased": 18710,
      "cancer pain purpose": 14848,
      "purpose aim study": 66516,
      "methods prospective study": 45496,
      "balance analgesia adverse": 13230,
      "associated opioid therapy": 12361,
      "high doses oxycodone": 35093,
      "oxycodone hydrochloride injection": 55189,
      "administration oxycodone hydrochloride": 8327,
      "oxycodone hydrochloride administered": 55178,
      "according pain intensity": 7054,
      "pain intensity patients": 56928,
      "pharmacokinetic parameters plasma": 61127,
      "total 66 patients": 81765,
      "cancer randomly divided": 14900,
      "control group 32": 20314,
      "patients given oxycodone": 59327,
      "day weeks changes": 22451,
      "adverse reactions recorded": 8847,
      "observation group higher": 50601,
      "control group 05": 20307,
      "nrs scores groups": 50080,
      "observation group control": 50599,
      "group 05 incidence": 33554,
      "observation group lower": 50603,
      "group 05 conclusion": 33552,
      "adverse reactions background": 8840,
      "treatment pain cancer": 82734,
      "cancer patients little": 14876,
      "patients little known": 59452,
      "oxycodone treatment results": 56032,
      "end dose failure": 28786,
      "pain patients methods": 57349,
      "met following criteria": 44874,
      "following criteria patients": 32117,
      "rating scale visit": 67681,
      "009 pain site": 284,
      "odds ratio 001": 50905,
      "advanced cancer receiving": 8596,
      "39 ng ml": 4273,
      "ng ml range": 49453,
      "mass spectrometry detection": 43459,
      "performed using nonlinear": 60649,
      "mixed effects modeling": 46793,
      "model order absorption": 47066,
      "best described data": 13689,
      "absorption rate constant": 6615,
      "liver function test": 42179,
      "requires investigation purpose": 70894,
      "purpose evaluate analgesic": 66532,
      "evaluate analgesic effect": 29769,
      "materials methods randomized": 43514,
      "controlled prospective clinical": 20527,
      "board approval written": 14180,
      "approval written informed": 11528,
      "informed consent obtained": 38679,
      "group received 20": 33946,
      "received 20 mg": 68097,
      "12 12 24": 1212,
      "hours pain intensity": 35809,
      "quality life adverse": 66718,
      "results numeric rating": 71800,
      "scale scores pain": 73559,
      "scores pain intensity": 73939,
      "001 24 48": 101,
      "significantly different 12": 75688,
      "significantly lower treated": 75811,
      "groups placebo group": 34268,
      "life adverse events": 41686,
      "patients objectives aim": 59566,
      "concentrations determined using": 18756,
      "liquid chromatography combined": 42076,
      "results significant change": 71952,
      "conclusion study indicates": 19002,
      "cancer pain management": 14833,
      "neuropathic cancer pain": 49224,
      "oxycodone neuropathic pain": 55534,
      "neuropathic pain syndromes": 49265,
      "started open label": 77009,
      "pain control 48": 56600,
      "followed double blind": 32057,
      "blind study using": 13987,
      "dose ratio oxycodone": 26038,
      "end double blind": 28791,
      "patients consumed significantly": 59146,
      "oxycodone total opioid": 56007,
      "incidence adverse experiences": 37261,
      "constipation common oxycodone": 19755,
      "life qol patients": 41724,
      "life adverse effects": 41685,
      "cancer patients receiving": 14889,
      "patients receiving high": 59838,
      "receiving high dose": 68340,
      "2009 march 2010": 2530,
      "weeks pain intensity": 86932,
      "mean numeric rating": 43814,
      "adverse effects constipation": 8651,
      "adverse effects did": 8652,
      "conclusion study suggests": 19006,
      "used treatment options": 85182,
      "determined pharmacokinetics oxycodone": 24083,
      "patients pain control": 59619,
      "calculation pharmacokinetic parameters": 14717,
      "multiple regression analysis": 48295,
      "method pharmacokinetic parameters": 45200,
      "adverse effects moderate": 8667,
      "cancer pain treatment": 14860,
      "aims investigate effect": 9489,
      "safety sustained release": 73227,
      "sustained release oxycodone": 79794,
      "pain material methods": 57133,
      "methods adult patients": 45242,
      "results primary end": 71892,
      "included proportion patients": 37523,
      "achieved adequate pain": 7315,
      "mild moderate adverse": 46427,
      "effects similar groups": 28159,
      "001 conclusion use": 120,
      "background controlled release": 13031,
      "effect opioid induced": 27508,
      "randomized open labeled": 67135,
      "phase iv study": 61304,
      "study enrolled patients": 78155,
      "pain numeric rating": 57252,
      "treat itt population": 82297,
      "20 mg 10": 2329,
      "mg 10 mg": 45701,
      "day titrated maximum": 22429,
      "80 mg 40": 5847,
      "mg day weeks": 45868,
      "endpoint change nrs": 28882,
      "pain score baseline": 57670,
      "non inferiority margin": 49614,
      "analgesic rescue medication": 10329,
      "life qol safety": 41725,
      "qol safety assessments": 66636,
      "week mean change": 86849,
      "scores significantly different": 73988,
      "sided 95 confidence": 75374,
      "groups did differ": 34181,
      "terms pain reduction": 80713,
      "oxycodone orally administered": 55585,
      "administration controlled release": 8236,
      "observe adverse events": 50642,
      "adverse events provide": 8793,
      "provide new choice": 66078,
      "oral administration methods": 53487,
      "relief moderate relief": 70144,
      "relief slight relief": 70191,
      "onset analgesic effect": 51111,
      "controlled trials shown": 20647,
      "clinical efficacy tolerability": 16808,
      "patient satisfaction high": 58761,
      "240 mg day": 3296,
      "insufficient pain relief": 39131,
      "pain relief pain": 57561,
      "160 mg day": 1905,
      "brain computed tomography": 14326,
      "opioid withdrawal present": 52644,
      "withdrawal present case": 87146,
      "study evaluate efficacy": 78168,
      "acute pain episodes": 7669,
      "divided oxycodone group": 25627,
      "oxycodone group oxy": 55136,
      "cr 10 mg": 21051,
      "adverse effects treatment": 8705,
      "days 14 21": 22463,
      "14 21 28": 1562,
      "cr placebo groups": 21108,
      "placebo group 05": 61734,
      "withdrawal symptoms did": 87161,
      "acute episodes chronic": 7631,
      "objective oxycodone semisynthetic": 50460,
      "opioid analgesic drug": 51456,
      "oxycodone tablet formulation": 55976,
      "evaluated adverse effects": 29860,
      "adverse events included": 8764,
      "nausea vomiting drowsiness": 48799,
      "patients purpose study": 59721,
      "clinical efficacy oxycodone": 16804,
      "release cr tablets": 69828,
      "administered 12 hours": 8097,
      "12 hours immediate": 1299,
      "hours immediate release": 35784,
      "ir oxycodone tablets": 40252,
      "times daily patients": 81419,
      "methods cancer patients": 45265,
      "therapy moderate severe": 81029,
      "randomized cr oxycodone": 67087,
      "cr oxycodone 12": 21075,
      "oxycodone 12 hours": 54512,
      "oxycodone times daily": 55997,
      "pain intensity assessed": 56887,
      "assessed times daily": 12073,
      "slight moderate severe": 76247,
      "poor fair good": 62258,
      "pain intensity remained": 56937,
      "mg range 20": 46196,
      "mg range 40": 46197,
      "adverse events cr": 8749,
      "ir 186 oxycodone": 40203,
      "conclusion cr oxycodone": 18884,
      "related pain associated": 69655,
      "pain associated fewer": 56473,
      "safety controlled release": 73134,
      "cr oxycodone tablets": 21100,
      "patients patients received": 59638,
      "completed 12 weeks": 18460,
      "12 weeks study": 1386,
      "doses showed significant": 26271,
      "increase total daily": 37814,
      "cr oxycodone dose": 21084,
      "occurred 66 patients": 50830,
      "12 week study": 1376,
      "half patients used": 34527,
      "rescue doses day": 70946,
      "pain control increasing": 56622,
      "12 week period": 1373,
      "cancer patients received": 14888,
      "mean ratio hydromorphone": 43849,
      "ratio hydromorphone oxycodone": 67773,
      "hydromorphone oxycodone hydromorphone": 36206,
      "converted morphine equivalent": 20731,
      "oxycodone effective safe": 55016,
      "analgesic ceiling effect": 10162,
      "effect cancer pain": 27429,
      "tolerance analgesic effect": 81570,
      "analgesic effect opioid": 10204,
      "mg day transdermal": 45866,
      "day transdermal fentanyl": 22433,
      "transdermal fentanyl patches": 82156,
      "moderate dose fentanyl": 47141,
      "total dose oxycodone": 81801,
      "strong opioid treatment": 77540,
      "similar efficacy safety": 75919,
      "safety profile purpose": 73209,
      "efficacy tolerability oxycodone": 28407,
      "tolerability oxycodone cr": 81545,
      "line strong opioid": 41999,
      "10 point numerical": 903,
      "patients treated oral": 60066,
      "treated oral oxycodone": 82360,
      "pain adverse events": 56431,
      "males mean age": 43079,
      "intensity assessed 10": 39230,
      "rating scale decreased": 67654,
      "opioid related events": 52311,
      "patients discontinued study": 59212,
      "study adverse events": 77916,
      "oral oxycodone administered": 53624,
      "oxycodone administered 12": 54684,
      "oxycodone times day": 55998,
      "cancer pain randomized": 14849,
      "open label titration": 51186,
      "dose 400 mg": 25807,
      "study similar design": 78501,
      "dose 80 mg": 25813,
      "opioid analgesics results": 51525,
      "results studies showed": 71975,
      "degree pain control": 23174,
      "adverse effects studies": 8703,
      "oral cr oxycodone": 53512,
      "cr oxycodone ir": 21091,
      "patients chronic moderate": 59070,
      "severe pain background": 74971,
      "pain background opioid": 56481,
      "used relieve pain": 85111,
      "pain patients cancer": 57340,
      "quality life study": 66748,
      "life study aimed": 41738,
      "aimed investigate efficacy": 9459,
      "investigate efficacy tolerability": 40011,
      "150 mg day": 1809,
      "day controlled release": 22287,
      "pain patients advanced": 57337,
      "methods retrospective clinical": 45537,
      "included high dose": 37461,
      "patients achieved pain": 58925,
      "achieved pain relief": 7323,
      "pain relief mean": 57546,
      "mean treatment duration": 43897,
      "effects high dose": 27939,
      "patients discontinued treatment": 59213,
      "relieve moderate severe": 70215,
      "treatment background opioid": 82457,
      "methods opioid na\u00efve": 45415,
      "na\u00efve patients moderate": 48843,
      "randomly divided oxycodone": 67236,
      "oxycodone group morphine": 55133,
      "group morphine group": 33866,
      "tablets 12 hours": 80112,
      "12 hours dose": 1298,
      "dose oxycodone sustained": 25998,
      "adverse reactions treatment": 8852,
      "analysis 51 patients": 10632,
      "12 hours 24": 1294,
      "hours 24 hours": 35736,
      "24 hours significantly": 3232,
      "hours significantly lower": 35850,
      "oxycodone group experienced": 55128,
      "oxycodone group significantly": 55140,
      "significantly higher morphine": 75731,
      "study period significant": 78396,
      "release oxycodone reduce": 69974,
      "half life study": 34520,
      "efficacy safety controlled": 28355,
      "patients methods thirty": 59510,
      "randomized controlled release": 67064,
      "intensity assessed using": 39231,
      "scale vas 100": 73572,
      "vas 100 mm": 86001,
      "effects assessed using": 27830,
      "results patients completed": 71844,
      "significant differences adverse": 75499,
      "pain methods multicenter": 57182,
      "controlled randomized double": 20530,
      "patients 20 years": 58840,
      "20 years age": 2391,
      "mg day 10": 45850,
      "mg day respectively": 45863,
      "baseline visual analog": 13466,
      "change vas score": 15758,
      "observed adverse events": 50650,
      "adverse events somnolence": 8815,
      "safety oxymorphone extended": 73194,
      "er oxycodone controlled": 29454,
      "methods randomized multicenter": 45513,
      "years age moderate": 87563,
      "age moderate severe": 9091,
      "days open label": 22564,
      "achieve stable dose": 7307,
      "blind treatment phase": 13991,
      "morphine sulfate 15": 47937,
      "sulfate 15 mg": 79064,
      "15 mg tablets": 1766,
      "included brief pain": 37431,
      "analyzed using mixed": 10870,
      "using mixed effects": 85497,
      "titration stabilization phase": 81484,
      "received dose study": 68141,
      "completed double blind": 18468,
      "double blind phase": 26363,
      "scores groups mean": 73884,
      "rescue medication use": 70959,
      "medication use low": 44579,
      "opioid adverse events": 51415,
      "patients achieved stable": 58927,
      "achieved stable dose": 7326,
      "patients seven patients": 59961,
      "oxycodone hydrochloride hydrate": 55188,
      "neuropathic pain commonly": 49237,
      "phase ii study": 61290,
      "study compared efficacy": 78010,
      "compared efficacy tolerability": 18147,
      "combination therapy methods": 17614,
      "neuropathic pain previously": 49255,
      "oxycodone doses patients": 55004,
      "patients evaluated daily": 59266,
      "primary endpoint reduction": 65034,
      "adverse effects study": 8704,
      "intravenous oxycodone administered": 39868,
      "mean oxycodone concentration": 43822,
      "chronic pain preoperative": 16304,
      "pain preoperative pain": 57406,
      "updated version original": 83986,
      "version original cochrane": 86090,
      "cochrane review published": 17182,
      "pain intensity relief": 56936,
      "using grade main": 85417,
      "grade main results": 33379,
      "pain relief similar": 57583,
      "showed significant differences": 75299,
      "rr 58 95": 72952,
      "rr 14 95": 72899,
      "rr 85 95": 72993,
      "pruritus rr 46": 66304,
      "rr 46 95": 72934,
      "relief significantly better": 70187,
      "95 ci 78": 6334,
      "ci 33 76": 16435,
      "rr 06 95": 72892,
      "cr oxycodone compared": 21080,
      "rr 52 95": 72943,
      "pain relief overall": 57559,
      "cr oxycodone did": 21083,
      "morphine oxycodone potent": 47850,
      "oxycodone potent analgesics": 55714,
      "extended release immediate": 30877,
      "non malignant malignant": 49625,
      "analgesia patients undergoing": 10053,
      "mg morphine sulfate": 46063,
      "effect quality life": 27542,
      "pain inventory primary": 56977,
      "commonly prescribed pain": 17870,
      "report describes elderly": 70455,
      "oxycodone acetaminophen hours": 54642,
      "health care team": 34686,
      "dose patients cancer": 26005,
      "cancer pain opioid": 14840,
      "daily oxycodone dose": 21789,
      "poor pain control": 62269,
      "transdermal patch oxycodone": 82167,
      "oxycodone tamper resistant": 55987,
      "treatment non cancer": 82683,
      "non cancer chronic": 49574,
      "contribute opioid crisis": 20228,
      "development novel analgesics": 24238,
      "respiratory depression objectives": 71280,
      "objectives assess efficacy": 50547,
      "assess efficacy tolerability": 11934,
      "methods searched central": 45561,
      "meta analyses showed": 44888,
      "pain intensity adverse": 56886,
      "adverse events did": 8751,
      "events did significantly": 30041,
      "significantly better pain": 75663,
      "pain relief treatment": 57594,
      "systematic review randomized": 79995,
      "review randomized controlled": 72349,
      "analysis standardized mean": 10772,
      "standardized mean differences": 76966,
      "differences pain scores": 24779,
      "pain scores differed": 57717,
      "pooled standardized mean": 62247,
      "standardized mean difference": 76964,
      "04 95 confidence": 449,
      "interval ci 29": 39589,
      "scores higher oxycodone": 73888,
      "supporting use opioid": 79229,
      "related pain background": 69656,
      "pain background oxycodone": 56483,
      "oxycodone used opioid": 56060,
      "literature review forms": 42129,
      "review forms basis": 72307,
      "forms basis guidelines": 32308,
      "european palliative care": 29746,
      "palliative care research": 58043,
      "care research collaborative": 15072,
      "research collaborative opioid": 70990,
      "collaborative opioid guidelines": 17437,
      "opioid guidelines project": 51832,
      "palliative care objectives": 58038,
      "study identify assess": 78239,
      "identify assess quality": 36489,
      "assess quality evidence": 11956,
      "systematic reviews cochrane": 79998,
      "reviews cochrane central": 72408,
      "controlled trials medline": 20638,
      "trials medline embase": 83160,
      "embase cinahl systematically": 28639,
      "cinahl systematically searched": 16559,
      "systematically searched addition": 80014,
      "searched addition hand": 74135,
      "addition hand searching": 7805,
      "hand searching relevant": 34551,
      "searching relevant journals": 74173,
      "studies included reported": 77749,
      "included reported clinical": 37542,
      "reported clinical outcome": 70519,
      "clinical outcome relevant": 16849,
      "outcome relevant use": 53987,
      "adult patients moderate": 8515,
      "direct comparator required": 25041,
      "comparator required inclusion": 17998,
      "required inclusion studies": 70844,
      "narrative systematic review": 48644,
      "assess quality studies": 11957,
      "quality studies formulate": 66763,
      "studies formulate guidelines": 77735,
      "controlled trials compared": 20629,
      "trials compared different": 83121,
      "evidence included trials": 30197,
      "cancer palliative care": 14863,
      "hydromorphone cancer related": 36162,
      "compare effectiveness safety": 18019,
      "received 30 mg": 68101,
      "mg cr oxycodone": 45840,
      "mg ir oxycodone": 45935,
      "baseline pain intensity": 13448,
      "day mean pain": 22333,
      "ir groups respectively": 40233,
      "groups respectively 05": 34299,
      "significant difference treatment": 75494,
      "difference treatment groups": 24698,
      "adverse events study": 8817,
      "assessment efficacy tolerability": 12118,
      "patients self reported": 59954,
      "opioid adverse effects": 51414,
      "50 percent patients": 4889,
      "morphine consumption mean": 47623,
      "adverse effects patients": 8686,
      "treatment good excellent": 82594,
      "oxycodone fentanyl commonly": 55074,
      "fentanyl commonly used": 31455,
      "commonly used control": 17878,
      "cancer pain drugs": 14825,
      "fentanyl cancer patients": 31450,
      "cancer patients patients": 14885,
      "patients classified groups": 59090,
      "good pain control": 33319,
      "noted groups groups": 49989,
      "clinical risk factors": 16897,
      "prospective study included": 65886,
      "satisfactory pain relief": 73452,
      "recorded pain intensity": 68687,
      "recorded using numerical": 68709,
      "factors associated higher": 31073,
      "postoperative pain higher": 62872,
      "pain higher pain": 56827,
      "postoperative pain associated": 62849,
      "pain associated higher": 56474,
      "psychological factors results": 66342,
      "sd pain intensity": 74088,
      "pain intensity 10": 56879,
      "ir cr oxycodone": 40218,
      "cyp3a4 mediated demethylation": 21641,
      "cyp2d6 aim study": 21590,
      "pharmacokinetics orally administered": 61177,
      "study design open": 78070,
      "design open label": 23733,
      "doses cr oxycodone": 26167,
      "12 hours plasma": 1304,
      "concentration oxycodone metabolites": 18711,
      "oxycodone administered day": 54685,
      "day day results": 22294,
      "increased area plasma": 37877,
      "time curve auc0": 81237,
      "curve auc0 oxycodone": 21524,
      "36 001 decreased": 4113,
      "day compared day": 22279,
      "patients receiving multiple": 59847,
      "receiving multiple doses": 68358,
      "interindividual variation response": 39444,
      "pain 30 patients": 56380,
      "oxycodone increasingly used": 55254,
      "increasingly used opioid": 38138,
      "oral oxycodone used": 53644,
      "line second line": 41997,
      "pain methods prospective": 57187,
      "reported adequate pain": 70496,
      "analgesia unacceptable adverse": 10125,
      "results patients recruited": 71856,
      "95 response rate": 6410,
      "data provide evidence": 22071,
      "cr oxycodone transdermal": 21101,
      "therapy cr oxycodone": 81005,
      "synthetic opioid agonist": 79953,
      "release cr formulation": 69817,
      "release ir formulation": 69876,
      "opioid consumption compared": 51615,
      "consumption compared standard": 19906,
      "pain evaluated using": 56762,
      "group average pain": 33673,
      "vas scores groups": 86024,
      "significantly decreased comparison": 75676,
      "scores statistically different": 73996,
      "different groups week": 24874,
      "group vs control": 34075,
      "vs control group": 86641,
      "average opioid consumption": 12913,
      "opioid consumption groups": 51623,
      "pain clinical trial": 56551,
      "administration morphine oxycodone": 8306,
      "significantly patients treated": 75831,
      "patients treated morphine": 60062,
      "odds ratio 60": 50921,
      "60 95 confidence": 5246,
      "previous studies showed": 64920,
      "opioids objective study": 53108,
      "objective study explore": 50516,
      "clinical effect patients": 16796,
      "visual analog score": 86320,
      "control group 30": 20313,
      "control group administered": 20317,
      "treatment daily dose": 82535,
      "comparable groups 05": 17956,
      "group 33 11": 33601,
      "001 average daily": 111,
      "greater control group": 33436,
      "higher control group": 35223,
      "pain relief reduced": 57574,
      "frequency opioid induced": 32520,
      "patients receiving oral": 59853,
      "center retrospective study": 15551,
      "days oxycodone initiation": 22576,
      "regression analysis performed": 69423,
      "oxycodone results total": 55854,
      "regression analysis revealed": 69426,
      "independent risk factors": 38167,
      "opioids included study": 52975,
      "study patients randomized": 78372,
      "randomized receive 30": 67168,
      "management materials methods": 43197,
      "materials methods january": 43510,
      "patients received single": 59821,
      "including morphine oxycodone": 37642,
      "regression analysis used": 69428,
      "patients included final": 59394,
      "68 patients received": 5502,
      "pain management objective": 57086,
      "assess efficacy safety": 11932,
      "release oxycodone patients": 69964,
      "oxycodone patients moderate": 55659,
      "records patients treated": 68722,
      "received controlled release": 68130,
      "pain score 10": 57663,
      "score 10 96": 73707,
      "daily dose oxycodone": 21731,
      "oxycodone 25 mg": 54543,
      "mg day patients": 45860,
      "daily dose 40": 21724,
      "conclusion use opioids": 19017,
      "neuropathic pain fully": 49245,
      "present study shows": 64663,
      "release sr oxycodone": 70006,
      "release oxycodone plasma": 69966,
      "concentrations measured using": 18776,
      "mass spectrometric detection": 43454,
      "saliva samples collected": 73278,
      "600 mg day": 5287,
      "oxycodone noroxycodone ranged": 55543,
      "higher plasma concentrations": 35302,
      "oxycodone noroxycodone plasma": 55542,
      "oxycodone noroxycodone concentrations": 55539,
      "levels oxycodone major": 41588,
      "oxycodone major metabolite": 55357,
      "patients methods patients": 59500,
      "patients died cancer": 59197,
      "2019 included study": 2868,
      "opioids cancer pain": 52763,
      "average opioid dose": 12914,
      "opioid dose 30": 51731,
      "30 days death": 3726,
      "results total number": 72035,
      "total number patients": 81855,
      "study period conclusion": 78385,
      "genetic factors oxycodone": 33075,
      "induced nausea vomiting": 38427,
      "higher females males": 35242,
      "significantly higher female": 75726,
      "patients male patients": 59472,
      "purpose opioids recommended": 66539,
      "opioids recommended moderate": 53243,
      "recommended moderate severe": 68629,
      "patients cancer impaired": 59041,
      "impaired hepatic function": 36874,
      "function affect opioid": 32626,
      "affect opioid metabolism": 8906,
      "opioid metabolism aim": 51927,
      "metabolism aim systematic": 44922,
      "aim systematic review": 9428,
      "review evaluate evidence": 72294,
      "impairment methods systematic": 36901,
      "systematic review conducted": 79984,
      "review conducted following": 72279,
      "conducted following databases": 19361,
      "following databases searched": 32120,
      "eligible studies met": 28597,
      "studies met following": 77769,
      "criteria patients cancer": 21208,
      "pain taking opioid": 57901,
      "taking opioid defined": 80315,
      "eligible studies appraised": 28595,
      "studies appraised using": 77647,
      "appraised using grading": 11449,
      "eligible heterogeneity meant": 28582,
      "heterogeneity meant meta": 35050,
      "meant meta analysis": 43928,
      "meta analysis possible": 44896,
      "recommendations formulated preferred": 68601,
      "formulated preferred opioid": 32325,
      "preferred opioid patients": 63642,
      "review little clinical": 72318,
      "little clinical evidence": 42147,
      "evidence overall quality": 30239,
      "overall quality existing": 54239,
      "quality existing evidence": 66701,
      "existing evidence opioid": 30526,
      "impairment low remains": 36897,
      "low remains need": 42548,
      "remains need high": 70302,
      "need high quality": 48924,
      "quality clinical studies": 66682,
      "clinical studies examining": 16911,
      "moderate pain group": 47156,
      "nrs score 10": 50077,
      "results total dose": 72034,
      "pain nrs significantly": 57248,
      "events comparable groups": 30026,
      "comparable groups conclusions": 17957,
      "groups conclusions study": 34162,
      "dose adjustment necessary": 25822,
      "use transdermal fentanyl": 84780,
      "14 days patients": 1588,
      "common opioid effects": 17780,
      "end point percentage": 28803,
      "regression models results": 69450,
      "risk difference 95": 72545,
      "scale pain intensity": 73531,
      "renal function patient": 70357,
      "tolerability analgesic efficacy": 81517,
      "analgesic efficacy morphine": 10238,
      "line treatment moderate": 42004,
      "step iii opioids": 77325,
      "nausea vomiting patients": 48805,
      "opioid analgesics time": 51528,
      "analgesics time methods": 10508,
      "opioid analgesics relief": 51524,
      "january 2008 december": 40426,
      "nausea vomiting cancer": 48793,
      "vomiting cancer patients": 86450,
      "cancer patients results": 14890,
      "dopamine d2 blockers": 25720,
      "clinical responses oxycodone": 16894,
      "patients methods seven": 59506,
      "cancer pain enrolled": 14826,
      "oxycodone metabolism clinical": 55384,
      "plays important role": 62005,
      "chronic pain cancer": 16262,
      "mitogen activated protein": 46774,
      "activated protein kinase": 7464,
      "pain united states": 57953,
      "dose combination acetaminophen": 25840,
      "following case report": 32109,
      "doses oral oxycodone": 26232,
      "indicates oral oxycodone": 38255,
      "effect high dose": 27464,
      "study evaluate effects": 78167,
      "methods preintervention postintervention": 45474,
      "urban tertiary care": 84038,
      "opioid administered oral": 51406,
      "opioid medication days": 51903,
      "treatment opioid analgesics": 82701,
      "investigated efficacy safety": 40041,
      "pain patients included": 57348,
      "pain control using": 56666,
      "using nonsteroidal anti": 85522,
      "day patients experienced": 22364,
      "patients experienced adverse": 59277,
      "adverse events including": 8765,
      "study patients moderate": 78369,
      "treated controlled release": 82329,
      "palliative care setting": 58047,
      "rate adverse reactions": 67444,
      "rates adverse reactions": 67556,
      "group study designed": 34037,
      "study designed demonstrate": 78098,
      "compared twice daily": 18332,
      "twice daily sustained": 83304,
      "daily sustained release": 21808,
      "continuous opioid therapy": 20179,
      "assess long term": 11940,
      "long term safety": 42350,
      "term safety efficacy": 80667,
      "randomized treatment groups": 67197,
      "efficacy analysis showed": 28226,
      "outcomes study mos": 54100,
      "study mos sleep": 78316,
      "quality life measured": 66730,
      "measured short form": 43998,
      "short form 36": 75167,
      "results open label": 71807,
      "postoperative pain video": 62930,
      "pain video assisted": 57975,
      "video assisted thoracoscopic": 86215,
      "assisted thoracoscopic surgery": 12202,
      "thoracoscopic surgery vats": 81130,
      "lung cancer patients": 42764,
      "patients underwent vats": 60156,
      "underwent vats lung": 83704,
      "postoperative analgesia sufentanil": 62709,
      "groups conclusions patients": 34161,
      "pain early postoperative": 56739,
      "thoracoscopic surgery lung": 81128,
      "surgery lung cancer": 79447,
      "management background objectives": 43153,
      "higher dose fentanyl": 35231,
      "pain methods open": 57183,
      "injection oral oxycodone": 38961,
      "fentanyl levels measured": 31515,
      "patient global assessment": 58648,
      "global assessment score": 33221,
      "high patient satisfaction": 35135,
      "10 mean sd": 783,
      "increased incidence adverse": 37932,
      "incidence adverse drug": 37255,
      "opioid analgesics study": 51527,
      "explore effect oxycodone": 30721,
      "effect oxycodone hydrochloride": 27519,
      "cancer general anesthesia": 14783,
      "enrolled randomly divided": 29022,
      "group 40 patients": 33609,
      "40 patients underwent": 4373,
      "patients underwent general": 60142,
      "anesthesia end surgery": 10910,
      "ml oxycodone hydrochloride": 46888,
      "groups different time": 34187,
      "differences statistically significant": 24821,
      "time points oxycodone": 81339,
      "surgery oxycodone hydrochloride": 79493,
      "medication study aimed": 44569,
      "aimed evaluate effectiveness": 9448,
      "experienced severe pain": 30625,
      "pain relief primary": 57569,
      "oxycodone oxycodone group": 55606,
      "morphine morphine group": 47783,
      "oxycodone group 19": 55124,
      "adverse effects appeared": 8640,
      "linear range 10": 42027,
      "ng ml 100": 49431,
      "ml 100 ng": 46823,
      "ng ml recovery": 49454,
      "relative standard deviations": 69769,
      "induced adverse effects": 38373,
      "adverse effects based": 8645,
      "concentrations oxycodone oxymorphone": 18798,
      "oxycodone oxymorphone noroxycodone": 55620,
      "oxymorphone noroxycodone determined": 56265,
      "adverse effects monitored": 8668,
      "associated higher incidence": 12280,
      "adverse effects conclusion": 8649,
      "opioid treatment cancer": 52442,
      "pain patients recruited": 57357,
      "pain requiring opioid": 57625,
      "requiring opioid therapy": 70906,
      "mean visual analogue": 43904,
      "score vas pain": 73807,
      "rating score pain": 67685,
      "incidence severity adverse": 37319,
      "severity adverse events": 75035,
      "95 ci used": 6371,
      "used random effects": 85098,
      "bias included studies": 13768,
      "using grade created": 85415,
      "grade created summary": 33370,
      "summary findings tables": 79103,
      "findings tables main": 31834,
      "tables main results": 80083,
      "intensity measured visual": 39266,
      "measured visual analogue": 44012,
      "standard deviation sd": 76899,
      "adverse effects nausea": 8669,
      "effects nausea constipation": 28015,
      "nausea constipation vomiting": 48769,
      "showed difference groups": 75241,
      "terms analgesic efficacy": 80703,
      "pain intensity reported": 56938,
      "quality life compared": 66722,
      "results total 120": 72025,
      "total 120 patients": 81721,
      "pain score patients": 57678,
      "significantly reduced treatment": 75850,
      "mg respectively lower": 46205,
      "control group difference": 20322,
      "treatment control groups": 82523,
      "group statistical significance": 34030,
      "terms quality life": 80719,
      "patients treatment group": 60074,
      "group 05 patients": 33555,
      "05 patients groups": 540,
      "effects constipation nausea": 27878,
      "vs 49 026": 86586,
      "background opioid induced": 13111,
      "nausea vomiting oinv": 48803,
      "controlled trials evaluated": 20634,
      "receive oral oxycodone": 68064,
      "randomly assigned ratio": 67223,
      "assigned ratio receive": 12176,
      "given times daily": 33201,
      "primary endpoint proportion": 65032,
      "patients assigned receive": 59016,
      "groups patients received": 34264,
      "conclusion routine use": 18985,
      "preventing opioid induced": 64864,
      "samples plasma concentrations": 73356,
      "compared morphine fentanyl": 18208,
      "changed oxycodone fentanyl": 15765,
      "statistically significant improvements": 77223,
      "nausea vomiting occurred": 48802,
      "hospice palliative care": 35552,
      "risk opioid induced": 72614,
      "induced constipation objective": 38400,
      "immediate short term": 36742,
      "24 72 hours": 3178,
      "lower opioid doses": 42660,
      "pain constipation scores": 56594,
      "patients lung cancer": 59464,
      "lung cancer methods": 42763,
      "opioid administration opioid": 51411,
      "fixed low dose": 31884,
      "doses opioids required": 26229,
      "required higher doses": 70842,
      "equivalent doses oxycodone": 29308,
      "patients pain methods": 59622,
      "methods patients allocated": 45431,
      "pain relief numeric": 57551,
      "relief numeric rating": 70149,
      "observed results total": 50716,
      "improved pain control": 37117,
      "respiratory depression associated": 71270,
      "severe breakthrough pain": 74916,
      "study evaluates efficacy": 78188,
      "patients non cancer": 59551,
      "decreased significantly baseline": 23042,
      "oxycodone starting dose": 55932,
      "dose 12 mg": 25788,
      "relief chronic pain": 70112,
      "patients aim study": 58984,
      "sex age body": 75060,
      "mass index bmi": 43451,
      "time oxycodone dose": 81309,
      "regression analyses results": 69419,
      "oxymorphone oxycodone ratio": 56274,
      "effects oxycodone assessed": 28057,
      "pain included pain": 56859,
      "european organisation research": 29743,
      "organisation research treatment": 53759,
      "research treatment cancer": 71036,
      "quality life questionnaire": 66743,
      "function assessed using": 32631,
      "whitney tests results": 87036,
      "results serum concentrations": 71938,
      "associated pain intensity": 12373,
      "pain control effects": 56614,
      "conclusion study patients": 19003,
      "cytochrome p450 enzyme": 21661,
      "p450 enzyme cyp": 56312,
      "cancer patients associated": 14870,
      "cyp2d6 cyp3a5 abcb1": 21596,
      "cyp3a5 abcb1 oprm1": 21645,
      "noroxycodone oxymorphone determined": 49936,
      "did significantly alter": 24504,
      "cyp2d6 extensive metabolizers": 21602,
      "metabolizers intermediate metabolizers": 45008,
      "treatment chronic cancer": 82480,
      "compared analgesic efficacy": 18097,
      "severe pain requiring": 75001,
      "requiring step iii": 70915,
      "transdermal fentanyl buprenorphine": 82146,
      "measured 10 numerical": 43955,
      "worst pain intensity": 87345,
      "adverse reactions opioids": 8845,
      "https clinicaltrials gov": 35931,
      "clinicaltrials gov ct2": 17017,
      "pain mild moderate": 57196,
      "results visual analog": 72054,
      "pain significantly lower": 57843,
      "oxycodone used pain": 56062,
      "loss significantly lower": 42439,
      "pain including neuropathic": 56861,
      "including neuropathic pain": 37648,
      "pain relief conclusions": 57532,
      "extended release tablet": 30902,
      "total 60 patients": 81760,
      "orally 10 mg": 53687,
      "equivalent oxycodone consumption": 29327,
      "analgesic effect evaluated": 10199,
      "group lower control": 33842,
      "lower control group": 42591,
      "group higher control": 33813,
      "adverse reactions constipation": 8841,
      "effectively relieve pain": 27739,
      "pain control reported": 56651,
      "previous studies shown": 64921,
      "shows good efficacy": 75361,
      "severe pain particularly": 74995,
      "adverse effects aes": 8639,
      "lower pain intensity": 42669,
      "parallel group multicentre": 58133,
      "group multicentre study": 33869,
      "days primary outcome": 22598,
      "primary outcome average": 65057,
      "postoperative analgesia study": 62708,
      "genetic factors related": 33076,
      "pain persistent pain": 57369,
      "beck depression inventory": 13510,
      "cold pain intensity": 17423,
      "cold pain sensitivity": 17424,
      "postoperative pain oxycodone": 62905,
      "pain oxycodone opioid": 57313,
      "oxycodone opioid analgesic": 55565,
      "oxymorphone active metabolite": 56220,
      "oxymorphone analgesic effect": 56223,
      "study controlled release": 78042,
      "oxycodone morphine examined": 55470,
      "pain cr oxycodone": 56672,
      "plasma morphine concentrations": 61942,
      "patients end life": 59245,
      "national institute health": 48695,
      "pain search methods": 57803,
      "participants experiencing adverse": 58305,
      "experiencing adverse events": 30641,
      "fewer 50 participants": 31628,
      "medication adverse events": 44457,
      "pain adverse event": 56430,
      "adverse events people": 8790,
      "cancer pain treated": 14859,
      "pain treated morphine": 57934,
      "protocol controlled release": 65968,
      "cr oxycodone background": 21079,
      "oxycodone given 12": 55115,
      "given 12 hours": 33151,
      "used statistical analysis": 85141,
      "patients opioid tolerant": 59590,
      "square test used": 76798,
      "chronic cancer related": 16187,
      "inadequate analgesia intolerable": 37228,
      "systematic review literature": 79991,
      "adult patients chronic": 8512,
      "oxycodone fentanyl hydromorphone": 55078,
      "analgesia patient satisfaction": 10048,
      "success opioid rotation": 78905,
      "prolonged release tablet": 65637,
      "control group days": 20320,
      "treatment groups conclusion": 82602,
      "relieve pain reduce": 70218,
      "pain reduce dose": 57489,
      "methods systematic search": 45603,
      "including pubmed embase": 37668,
      "controlled trials results": 20646,
      "trials results total": 83197,
      "effect oxycodone morphine": 27520,
      "comparable safety profiles": 17972,
      "95 ci 90": 6347,
      "95 ci 60": 6316,
      "severe chronic cancer": 74928,
      "oral combination opioid": 53502,
      "oxn pr treatment": 54432,
      "80 mg daily": 5849,
      "severe pain nrs": 74989,
      "resulted significant reduction": 71520,
      "bowel function improved": 14275,
      "conclusions oxn pr": 19143,
      "highly effective tolerated": 35395,
      "effects aim study": 27817,
      "adverse effects oral": 8680,
      "effects oral morphine": 28050,
      "rating scale score": 67676,
      "opioids patients randomized": 53161,
      "randomized morphine oxycodone": 67120,
      "patients assessed baseline": 59009,
      "groups immediate release": 34216,
      "nociceptive neuropathic pain": 49551,
      "associated negative impact": 12344,
      "negative impact pain": 49076,
      "common adverse effects": 17730,
      "constipation bowel function": 19752,
      "impact pain patients": 36832,
      "pain opioid effects": 57284,
      "opioid effects assessed": 51759,
      "methadone morphine morphine": 45102,
      "morphine morphine glucuronide": 47780,
      "morphine glucuronide m6g": 47701,
      "outcome number patients": 53962,
      "methadone showed low": 45128,
      "antinociceptive effect morphine": 11240,
      "pain control days": 56610,
      "analogue scale pain": 10553,
      "scale pain satisfaction": 73534,
      "adverse effects number": 8674,
      "higher patients receiving": 35292,
      "compared patients receiving": 18254,
      "morphine oxycodone results": 47856,
      "useful alternative morphine": 85200,
      "pain control significant": 56657,
      "opioid analgesics introduced": 51506,
      "increases risk adverse": 38082,
      "results studies included": 71973,
      "route timing administration": 72849,
      "important risk factors": 37029,
      "conclusion data suggest": 18888,
      "pain background pain": 56484,
      "studies single dose": 77848,
      "clinical practice methods": 16866,
      "linear regression used": 42034,
      "pain assessed results": 56463,
      "20 80 mg": 2306,
      "opioids palliative care": 53148,
      "shizuoka cancer center": 75149,
      "center june 2012": 15531,
      "oxycodone fentanyl groups": 55076,
      "patients setting study": 59958,
      "setting study included": 74829,
      "design retrospective analysis": 23781,
      "performed chi square": 60575,
      "used compare mean": 84887,
      "used compare opioid": 84888,
      "doses 120 mg": 26125,
      "90 years age": 6120,
      "years age older": 87566,
      "opioid dose conclusions": 51732,
      "patient age associated": 58537,
      "investigation warranted determine": 40075,
      "high opioid doses": 35127,
      "sustained release strong": 79798,
      "revealed relevant differences": 72224,
      "severe pain hydromorphone": 74981,
      "opioid used treatment": 52613,
      "oxycodone dose dependently": 54992,
      "oxycodone did affect": 54966,
      "bone cancer pain": 14232,
      "phase patients received": 61309,
      "patients received placebo": 59816,
      "oxycodone paracetamol 325": 55636,
      "primary endpoint pain": 65030,
      "endpoint pain intensity": 28896,
      "intensity difference pid": 39247,
      "breakthrough pain rescue": 14404,
      "included short form": 37554,
      "breakthrough pain day": 14399,
      "oxycodone paracetamol group": 55638,
      "good good excellent": 33316,
      "additional pain control": 7879,
      "conducted open label": 19381,
      "mg tablet 12": 46227,
      "taking opioid analgesics": 80314,
      "efficacy safety study": 28387,
      "safety study period": 73224,
      "study period results": 78395,
      "results eighteen patients": 71673,
      "patients taking opioid": 60033,
      "divided groups based": 25622,
      "interval ci 09": 39577,
      "log rank test": 42248,
      "transdermal fentanyl oxycodone": 82152,
      "patients filling prescriptions": 59309,
      "associated transdermal fentanyl": 12456,
      "opioids study performed": 53318,
      "release oxycodone er": 69935,
      "associated oxycodone induced": 12370,
      "odds ratio 98": 50928,
      "background opioids known": 13122,
      "opioids objectives determine": 53110,
      "previously opioid naive": 64950,
      "naive patients methods": 48406,
      "september 30 2018": 74623,
      "ci 15 32": 16402,
      "study group received": 78218,
      "received intravenous iv": 68177,
      "average nrs score": 12903,
      "pain intensity patient": 56926,
      "dose adverse events": 25828,
      "reduction average pain": 69045,
      "pain intensity moderate": 56914,
      "faster pain relief": 31219,
      "compared morphine patient": 18210,
      "adverse events adverse": 8723,
      "drug reactions similar": 26759,
      "reactions similar groups": 67974,
      "similar groups conclusions": 75928,
      "similar analgesic efficacy": 75898,
      "trial registered clinicaltrials": 83065,
      "registered clinicaltrials gov": 69377,
      "iv hydromorphone oral": 40378,
      "equivalent daily dose": 29295,
      "daily dose medd": 21730,
      "morphine oxycodone methods": 47840,
      "linear regression analysis": 42029,
      "mg dose used": 45878,
      "patients receiving 30": 59833,
      "receiving 30 mg": 68316,
      "30 mg iv": 3759,
      "equivalent mg oral": 29313,
      "11 46 mg": 1113,
      "used treat patients": 85171,
      "patients methods single": 59508,
      "patients oxy group": 59611,
      "observed patients non": 50701,
      "oxy group patients": 54452,
      "oxy group 05": 54450,
      "causing adverse effects": 15406,
      "study assessed effectiveness": 77971,
      "mg pain intensity": 46148,
      "related pain effective": 69659,
      "use opioids cancer": 84558,
      "rapid onset opioids": 67393,
      "objective assess effect": 50378,
      "pain relief quality": 57572,
      "relief quality life": 70176,
      "cancer pain according": 14813,
      "vs oxycodone naloxone": 86669,
      "short form 12": 75166,
      "pain relief achieved": 57520,
      "mental component summary": 44814,
      "component summary mcs": 18590,
      "scores significantly improved": 73990,
      "treatment breakthrough pain": 82461,
      "opioid medication objective": 51905,
      "patients cancer methods": 59043,
      "methods data national": 45303,
      "structured telephone interview": 77593,
      "short form bpi": 75169,
      "total 112 patients": 81711,
      "patients reported mean": 59890,
      "preceding 24 hours": 63501,
      "sleep enjoyment life": 76223,
      "pain relief cancer": 57525,
      "symptom assessment scale": 79858,
      "oral oxycodone using": 53645,
      "respectively significant change": 71245,
      "background oxycodone semisynthetic": 13134,
      "rifampin strong inducer": 72472,
      "strong inducer drug": 77520,
      "inducer drug metabolizing": 38465,
      "mg day oxycodone": 45859,
      "able control pain": 6567,
      "using high doses": 85426,
      "hydromorphone extended release": 36168,
      "er opioid analgesics": 29450,
      "flexible dose study": 31910,
      "daily oxycodone cr": 21788,
      "label extension study": 40977,
      "received oxycodone cr": 68234,
      "efficacy measure change": 28292,
      "change baseline weeks": 15727,
      "mean change pain": 43733,
      "global assessment efficacy": 33220,
      "patients oros hydromorphone": 59600,
      "receiving oros hydromorphone": 68365,
      "discontinued treatment adverse": 25251,
      "chinese patients moderate": 16096,
      "32 mg oxycodone": 3932,
      "oxycodone cr 10": 54890,
      "10 40 mg": 708,
      "endpoint change baseline": 28881,
      "change baseline end": 15724,
      "worst pain past": 87346,
      "mean age 53": 43690,
      "square mean difference": 76794,
      "oxycodone cr 12": 54892,
      "noninferior oxycodone cr": 49744,
      "tolerated perspective article": 81638,
      "treatment groups treatment": 82612,
      "aimed assess efficacy": 9436,
      "oral prolonged release": 53657,
      "codeine tramadol patients": 17296,
      "scale nrs patients": 73518,
      "significant adverse effects": 75424,
      "adverse effects reported": 8694,
      "remaining 30 patients": 70282,
      "patients assessed efficacy": 59010,
      "led significant reduction": 41342,
      "reduction mean pain": 69066,
      "option fragile population": 53453,
      "treatment 28 days": 82419,
      "improving physical functioning": 37202,
      "qlq c15 pal": 66631,
      "results study enrolled": 71980,
      "release oral opioids": 69915,
      "used patients manner": 85072,
      "patients manner inconsistent": 59477,
      "manner inconsistent standard": 43325,
      "objective evaluate effectiveness": 50415,
      "korean patients chronic": 40952,
      "label phase iv": 40989,
      "using immediate release": 85436,
      "day day 14": 22293,
      "assessed using numerical": 12088,
      "percent patients constipation": 60474,
      "severe pain major": 74985,
      "major negative impact": 42962,
      "quality life opioid": 66734,
      "used opioid drugs": 85045,
      "oxycodone tramadol tapentadol": 56018,
      "analgesic efficacy opioids": 10240,
      "methods identified systematic": 45355,
      "identified systematic reviews": 36477,
      "reviews cochrane library": 72410,
      "14 days starting": 1594,
      "events adverse events": 30007,
      "various routes administration": 85977,
      "opioids codeine morphine": 52790,
      "codeine morphine methadone": 17258,
      "codeine hydromorphone methadone": 17246,
      "placebo active control": 61651,
      "14 days oxycodone": 1587,
      "pain scores range": 57769,
      "adverse event reported": 8715,
      "severe pain given": 74980,
      "experience adverse events": 30571,
      "review previously published": 72340,
      "method pain relief": 45196,
      "certainty evidence using": 15663,
      "12 hours oxycodone": 1301,
      "versus immediate release": 86124,
      "effect adverse events": 27418,
      "15 low certainty": 1744,
      "certainty evidence data": 15659,
      "scale clinically significant": 73500,
      "proportion participants achieving": 65756,
      "pain relief rr": 57576,
      "rr 75 95": 72974,
      "rr 93 95": 73008,
      "low low certainty": 42495,
      "certainty evidence little": 15660,
      "evidence little difference": 30217,
      "little difference pain": 42153,
      "difference pain intensity": 24654,
      "intensity pain relief": 39285,
      "oxycodone clinically significant": 54788,
      "clinically significant did": 17000,
      "certainty evidence low": 15662,
      "prevention management opioid": 64876,
      "management opioid related": 43221,
      "opioid related complications": 52306,
      "significant national attention": 75584,
      "data suggest patients": 22132,
      "known risk factors": 40932,
      "opioid based therapy": 51560,
      "fentanyl administered patients": 31431,
      "cr oxycodone patients": 21094,
      "patients experiencing persistent": 59290,
      "multicenter observational study": 48162,
      "oral opioid therapy": 53608,
      "10 pain 10": 889,
      "oxycodone cr pain": 54906,
      "improved significantly 21": 37133,
      "opioid oxycodone cr": 52027,
      "short acting oral": 75161,
      "acting oral morphine": 7420,
      "abuse deterrent microsphere": 6695,
      "deterrent microsphere capsule": 24119,
      "release formulation oxycodone": 69863,
      "formulation oxycodone myristate": 32353,
      "xtampza er collegium": 87411,
      "er collegium pharmaceutical": 29405,
      "collegium pharmaceutical canton": 17514,
      "pharmaceutical canton massachusetts": 61020,
      "long acting formulation": 42287,
      "primary outcome patient": 65085,
      "median time pain": 44291,
      "safety profile oxycodone": 73208,
      "related pain control": 69658,
      "study demonstrates need": 78060,
      "clinical trials background": 16940,
      "p450 cyp 3a4": 56309,
      "potential drug drug": 63159,
      "open label arm": 51158,
      "performed patients received": 60610,
      "metabolites quantified using": 44987,
      "using validated liquid": 85656,
      "validated liquid chromatography": 85789,
      "active metabolite oxymorphone": 7519,
      "oxycodone active metabolite": 54671,
      "severity adverse effects": 75034,
      "setting palliative care": 74799,
      "effects pain control": 28078,
      "partial complete relief": 58240,
      "adverse effects opioids": 8679,
      "switching alternative opioid": 79831,
      "analgesia minimal effects": 10021,
      "successful pain control": 78914,
      "improves pain control": 37185,
      "pain control studies": 56659,
      "peripheral neuropathy cipn": 60878,
      "doses patients received": 26248,
      "patients received 20": 59764,
      "20 10 mg": 2269,
      "80 40 mg": 5830,
      "needed primary endpoint": 49029,
      "results mean standard": 71769,
      "mean sd change": 43861,
      "clinically significant changes": 16999,
      "laboratory tests vital": 41038,
      "tests vital signs": 80869,
      "additional pain relief": 7881,
      "patients cancer patients": 59046,
      "conclusion cancer patients": 18866,
      "analgesics pain treatment": 10471,
      "pain osteoarthritis rheumatoid": 57302,
      "health organization step": 34747,
      "organization step iii": 53774,
      "opioids mainstay pain": 53033,
      "treatment cancer patients": 82467,
      "based published data": 13370,
      "noncancer related pain": 49717,
      "maintaining analgesic efficacy": 42901,
      "guidelines serve foundation": 34473,
      "patients renal dysfunction": 59881,
      "longer time interval": 42391,
      "line choice opioid": 41987,
      "opioids respiratory depression": 53273,
      "nervous cns drugs": 49138,
      "providing adequate analgesia": 66248,
      "adverse event profile": 8710,
      "requiring high dose": 70902,
      "fentanyl patients cancer": 31566,
      "pain methods participants": 57185,
      "mg oxycodone 40": 46103,
      "opioid switching results": 52391,
      "pain relief palliative": 57563,
      "relief palliative care": 70165,
      "pain intensity interference": 56909,
      "modified brief pain": 47237,
      "patients noncancer pain": 59554,
      "prospective multicenter observational": 65837,
      "multicenter observational nonrandomized": 48161,
      "patient pain registry": 58701,
      "patients acute episodes": 58935,
      "acute episodes noncancer": 7632,
      "episodes noncancer pain": 29210,
      "noncancer pain requiring": 49713,
      "pain requiring treatment": 57627,
      "requiring treatment prescription": 70920,
      "treatment prescription medication": 82779,
      "prescription medication containing": 64249,
      "medication containing oxycodone": 44480,
      "containing oxycodone immediate": 20081,
      "immediate release needed": 36726,
      "release needed basis": 69896,
      "needed basis days": 48983,
      "patients injury trauma": 59415,
      "psychometric properties bpi": 66349,
      "nausea vomiting frequent": 48800,
      "pain management oxycodone": 57094,
      "incidence risk factors": 37316,
      "risk factor oxycodone": 72562,
      "pain treatment opioid": 57938,
      "acting opioids recorded": 7417,
      "effects occur frequently": 28032,
      "common adverse event": 17731,
      "electronic databases medline": 28531,
      "approach using combination": 11487,
      "prescribed sustained release": 63986,
      "results patients prescribed": 71852,
      "pain constipation severity": 56595,
      "patients prescribed morphine": 59676,
      "prescribed morphine oxycodone": 63896,
      "morphine oxycodone average": 47807,
      "shorter length stay": 75212,
      "morphine oxycodone conclusion": 47814,
      "difference observed pain": 24641,
      "specific adverse events": 76580,
      "analysis primary outcome": 10742,
      "outcome pain intensity": 53970,
      "intensity measured using": 39264,
      "rr 91 95": 73005,
      "greater pain relief": 33474,
      "rr 87 95": 72999,
      "rr 15 95": 72902,
      "evidence benefits harms": 30168,
      "evidence support refute": 30272,
      "used pain treatment": 85065,
      "patients enrolled 25": 59248,
      "patients achieved adequate": 58923,
      "pain control provided": 56647,
      "daily dose increased": 21729,
      "fold increase morphine": 31995,
      "significant negative correlation": 75586,
      "oral oxycodone effective": 53628,
      "inflammatory drug celecoxib": 38558,
      "random number table": 67000,
      "number table method": 50264,
      "control group 24": 20312,
      "scale nrs scores": 73521,
      "group decreased significantly": 33729,
      "group 05 compared": 33551,
      "urinary retention occurred": 84061,
      "trial registration chinese": 83068,
      "registration chinese clinical": 69385,
      "time onset pain": 81301,
      "oxycodone hydromorphone methadone": 55222,
      "time meaningful pain": 81287,
      "pain relief following": 57540,
      "goal study compare": 33278,
      "compare analgesic effect": 18006,
      "oxycodone patients undergoing": 55663,
      "213 patients enrolled": 2996,
      "patients enrolled patients": 59250,
      "12 hours days": 1297,
      "pain scores pain": 57756,
      "groups results mean": 34307,
      "results mean pain": 71768,
      "pain score 12": 57665,
      "patients suffering severe": 60020,
      "factors severe pain": 31134,
      "control fewer adverse": 20300,
      "oral opioids morphine": 53611,
      "studies conducted patients": 77674,
      "morphine oxycodone showed": 47857,
      "adverse events frequently": 8757,
      "oral extended release": 53532,
      "release cr morphine": 69820,
      "oxycodone patients methods": 55658,
      "oxycodone cr treated": 54910,
      "scale adverse events": 73496,
      "patients entered open": 59253,
      "entered open label": 29061,
      "significant differences daily": 75500,
      "daily pain intensity": 21793,
      "greater morphine cr": 33459,
      "provided adequate pain": 66119,
      "pain relief comparable": 57528,
      "65 years likely": 5426,
      "opioid analgesics patient": 51520,
      "patient reported data": 58734,
      "pain levels opioid": 57018,
      "acting opioid prescriptions": 7403,
      "treat breakthrough pain": 82286,
      "analgesic effects achieved": 10216,
      "combination nonsteroidal anti": 17572,
      "commonly administered opioids": 17837,
      "doses 80 mg": 26143,
      "therapy early stage": 81011,
      "neuropathic pain symptom": 49263,
      "strong opioids hydromorphone": 77548,
      "opioids hydromorphone oxycodone": 52961,
      "oxycodone fentanyl major": 55079,
      "authors conducted retrospective": 12726,
      "conducted retrospective chart": 19401,
      "prevent opioid induced": 64847,
      "001 significant difference": 208,
      "difference incidence nausea": 24624,
      "001 incidence somnolence": 147,
      "effective preventing opioid": 27681,
      "analgesic efficacy assessed": 10229,
      "endpoints pain intensity": 28915,
      "buprenorphine fentanyl oxycodone": 14547,
      "fentanyl oxycodone groups": 31550,
      "limit use clinical": 41894,
      "use clinical practice": 84241,
      "clinical practice aim": 16860,
      "practice aim study": 63391,
      "related chronic pain": 69571,
      "contact health care": 20048,
      "clinical trials oxycodone": 16954,
      "27 year old": 3511,
      "computed tomography scan": 18658,
      "resonance imaging revealed": 71122,
      "impair quality life": 36869,
      "management opioid induced": 43220,
      "controlled trials conducted": 20632,
      "treat opioid induced": 82304,
      "route administration opioid": 72840,
      "analysis pain intensity": 10725,
      "respectively mean duration": 71209,
      "associated use oxycodone": 12461,
      "use nonsteroidal anti": 84525,
      "patients study used": 60010,
      "norwegian prescription database": 49976,
      "results study population": 71985,
      "study period oxycodone": 78391,
      "life compared previous": 41691,
      "likely receive opioids": 41833,
      "increased odds opioid": 37959,
      "odds opioid prescriptions": 50901,
      "days prior death": 22602,
      "80 patients enrolled": 5858,
      "final analysis compared": 31741,
      "analgesic medication oxycodone": 10271,
      "decreased varying degrees": 23053,
      "management breakthrough pain": 43157,
      "online questionnaire distributed": 51102,
      "urgent need develop": 84044,
      "year old chronic": 87456,
      "pain neuropathic component": 57234,
      "present case report": 64610,
      "pain control oral": 56633,
      "online survey completed": 51104,
      "results majority respondents": 71758,
      "equianalgesic doses morphine": 29260,
      "old woman diagnosed": 51023,
      "artery bypass surgery": 11729,
      "september 11 2016": 74607,
      "achieve pain control": 7302,
      "medical staff use": 44406,
      "care pain management": 15050,
      "methadone buprenorphine fentanyl": 45051,
      "administered low doses": 8149,
      "background effective pain": 13042,
      "pain management essential": 57069,
      "doses nonsteroidal anti": 26223,
      "40 year old": 4385,
      "imaging positron emission": 36686,
      "quality life conclusion": 66723,
      "related pain major": 69662,
      "pain major public": 57048,
      "palliative care inpatient": 58036,
      "care inpatient unit": 15037,
      "morphine codeine pethidine": 47605,
      "pharmacotherapy cancer related": 61250,
      "associated negative outcomes": 12345,
      "single dose administration": 76077,
      "search published literature": 74125,
      "represents challenge patients": 70767,
      "opioid medications chronic": 51912,
      "pain patients undergoing": 57361,
      "misuse opioid medications": 46730,
      "series case reports": 74654,
      "level evidence available": 41467,
      "pain management potential": 57102,
      "aims study document": 9501,
      "opioid use conclusion": 52484,
      "purpose prospective clinical": 66551,
      "prospective clinical trial": 65816,
      "using different opioid": 85380,
      "literature review performed": 42131,
      "search conducted medline": 74110,
      "controlled trials databases": 20633,
      "efficacy tolerability data": 28402,
      "opioid na\u00efve non": 51980,
      "analgesic ladder opioid": 10263,
      "opioid agonists examined": 51431,
      "studies contained data": 77682,
      "oxycodone fentanyl methadone": 55080,
      "prospective randomized trials": 65874,
      "opioid therapy background": 52406,
      "cancer methods retrospective": 14796,
      "pain scores total": 57789,
      "specific opioid analgesics": 76605,
      "pain scores overall": 57754,
      "understanding efficacy safety": 83635,
      "pain randomized trials": 57459,
      "using electronic databases": 85390,
      "assessed using data": 12087,
      "different long acting": 24882,
      "trials comparing buprenorphine": 83123,
      "ratings did differ": 67693,
      "doses transdermal buprenorphine": 26294,
      "patients background pain": 59028,
      "data collected retrospectively": 21912,
      "data extracted patients": 21967,
      "odds having severe": 50899,
      "higher cancer patients": 35215,
      "cancer patient receiving": 14865,
      "oxycodone times higher": 55999,
      "cancer patients 10": 14867,
      "assessed intensity pain": 12012,
      "effective option pain": 27656,
      "option pain management": 53461,
      "pain management long": 57078,
      "release formulation hydromorphone": 69862,
      "morphine oxycodone comparable": 47812,
      "month period time": 47402,
      "release oxycodone transdermal": 69982,
      "similar groups group": 75930,
      "30 patients compared": 3786,
      "pain opioid addiction": 57279,
      "59 year old": 5193,
      "oxycodone fentanyl patient": 55085,
      "scores opioid consumption": 73930,
      "18 month period": 2094,
      "mean daily pain": 43746,
      "daily pain scores": 21797,
      "larger sample size": 41182,
      "systematic search literature": 80005,
      "100 oral morphine": 1009,
      "tolerance chronic pain": 81574,
      "experience severe pain": 30593,
      "addition low dose": 7810,
      "aspartate receptor antagonist": 11857,
      "frequently used non": 32584,
      "used non opioid": 85031,
      "opioid moderate severe": 51951,
      "fentanyl 14 oxycodone": 31415,
      "receptor mor agonists": 68511,
      "mir 423 3p": 46682,
      "let 7a 5p": 41432,
      "let 7f 5p": 41434,
      "mir 144 3p": 46677,
      "mir 363 3p": 46680,
      "hydromorphone oxycodone patients": 36209,
      "correlation observed analgesic": 20832,
      "palliative care settings": 58048,
      "administration increased 41": 8276,
      "oxycodone use decreased": 56050,
      "use conclusions findings": 84262,
      "assist pain management": 12190,
      "pain patients objective": 57350,
      "members american academy": 44776,
      "results response rate": 71921,
      "evidence opioid use": 30232,
      "commonly used management": 17884,
      "included randomized controlled": 37536,
      "observational cross sectional": 50611,
      "general opioid use": 32979,
      "opioid use hydromorphone": 52521,
      "reported opioid related": 70596,
      "related adverse effect": 69548,
      "evaluated results total": 29918,
      "did receive treatment": 24487,
      "immediate release commonly": 36710,
      "short acting analgesic": 75155,
      "lower quality life": 42694,
      "published prospective studies": 66436,
      "reporting adverse events": 70684,
      "fentanyl methadone hydromorphone": 31524,
      "patients naive opioids": 59534,
      "daily clinical practice": 21705,
      "adverse events type": 8822,
      "patients receiving transdermal": 59862,
      "receiving transdermal fentanyl": 68385,
      "transdermal fentanyl patch": 82155,
      "evaluate influence changes": 29812,
      "hydromorphone twice daily": 36230,
      "indicated management moderate": 38237,
      "continuous clock opioid": 20158,
      "clock opioid analgesia": 17053,
      "opioid analgesia extended": 51442,
      "analgesia extended period": 9971,
      "creatinine clearance 30": 21156,
      "60 ml min": 5265,
      "schedule opioids including": 73630,
      "objective assess patient": 50381,
      "assess patient reported": 11947,
      "lidocaine patch gabapentin": 41675,
      "oxycodone tramadol morphine": 56016,
      "dose dose escalation": 25886,
      "12 weeks results": 1385,
      "function patient satisfaction": 32664,
      "55 year old": 5082,
      "patients receiving opioids": 59852,
      "opioids patients received": 53162,
      "daily dose patients": 21732,
      "background cancer patients": 13021,
      "quality life randomized": 66744,
      "potential benefits risks": 63142,
      "symptoms cancer patients": 79877,
      "metastatic breast cancer": 45028,
      "intravenous iv ketamine": 39844,
      "initial pain score": 38864,
      "despite escalating doses": 23878,
      "increased mg kg": 37948,
      "average pain score": 12928,
      "pain scores patient": 57757,
      "cancer pain aim": 14815,
      "pain aim study": 56437,
      "intravenous fentanyl oral": 39828,
      "according clinical response": 7041,
      "control adverse effects": 20273,
      "adverse effects related": 8693,
      "effective method improve": 27646,
      "poor pain relief": 62271,
      "adverse effects negative": 8672,
      "pain search strategy": 57804,
      "data extraction form": 21969,
      "described cochrane handbook": 23650,
      "subjects included review": 78705,
      "results meta analysis": 71778,
      "involved chronic pain": 40095,
      "pain conditions cancer": 56588,
      "effect profile patient": 27539,
      "small numbers patients": 76292,
      "dose related adverse": 26046,
      "similar mu opioid": 75953,
      "2018 june 2019": 2828,
      "factors affecting use": 31069,
      "cancer patients age": 14869,
      "higher female male": 35240,
      "60 69 years": 5229,
      "conclusions majority patients": 19119,
      "european countries patients": 29741,
      "pain interfered daily": 56961,
      "opioids rescue medication": 53270,
      "non pharmacological interventions": 49669,
      "rescue medication time": 70958,
      "seventy percent patients": 74892,
      "prescribed opioids chronic": 63921,
      "opioid doses used": 51741,
      "fentanyl oral hydromorphone": 31541,
      "opioid utilisation oral": 52627,
      "utilisation oral morphine": 85712,
      "account significant proportion": 7078,
      "continue experience pain": 20122,
      "minimise adverse effects": 46591,
      "component neuropathic pain": 18581,
      "neuropathic pain drugs": 49242,
      "number clinical studies": 50147,
      "clinical studies demonstrated": 16909,
      "treating neuropathic pain": 82398,
      "analgesia fewer adverse": 9975,
      "oxycodone appears kappa": 54726,
      "appears kappa opioid": 11403,
      "palliative care service": 58045,
      "international association hospice": 39470,
      "association hospice palliative": 12474,
      "regulation opioid prescribing": 69498,
      "opioid prescribing practice": 52120,
      "patient variability response": 58812,
      "variability response opioids": 85878,
      "systematic literature search": 79980,
      "cohort cross sectional": 17355,
      "pain anxiety sleep": 56455,
      "codeine oxycodone fentanyl": 17266,
      "fentanyl tramadol conclusions": 31603,
      "materials methods eighty": 43508,
      "methods eighty consecutive": 45327,
      "10 standard deviation": 928,
      "years age range": 87567,
      "protocol 50 mg": 65955,
      "50 mg tramadol": 4863,
      "score 30 100": 73724,
      "ci 32 14": 16432,
      "differences adverse events": 24711,
      "adverse events particularly": 8786,
      "use chronic non": 84236,
      "identified randomized controlled": 36461,
      "reported average pain": 70509,
      "significant improvements versus": 75556,
      "improvements versus placebo": 37179,
      "20 mg daily": 2338,
      "differences pain reduction": 24778,
      "methods randomized clinical": 45506,
      "clinical trial included": 16929,
      "outcome measures patient": 53946,
      "groups compared baseline": 34147,
      "group 027 conclusions": 33544,
      "improve efficacy safety": 37060,
      "opioids cancer patients": 52764,
      "point 30 reduction": 62077,
      "opioid median age": 51900,
      "age 59 years": 9031,
      "40 mg hydrocodone": 4349,
      "strong opioids commonly": 77544,
      "codeine tramadol methadone": 17293,
      "methadone increased 001": 45086,
      "use oral morphine": 84576,
      "opioid administration route": 51412,
      "oral opioid dose": 53604,
      "background opioids remain": 13125,
      "pain bowel function": 56498,
      "bowel function cancer": 14269,
      "cancer related symptoms": 14910,
      "weeks postoperatively results": 86941,
      "ng ml 20": 49435,
      "linear mixed model": 42020,
      "mean worst pain": 43909,
      "symptom severity interference": 79867,
      "low complication rate": 42460,
      "clinical genetic factors": 16819,
      "undergoing breast cancer": 83515,
      "age american society": 9056,
      "results provide support": 71899,
      "pain using pharmacological": 57962,
      "cochrane library issue": 17178,
      "library issue 12": 41664,
      "clinicaltrials gov http": 17018,
      "studies systematic reviews": 77860,
      "studies selection criteria": 77840,
      "compared different doses": 18139,
      "dizziness nausea vomiting": 25640,
      "nausea vomiting adverse": 48791,
      "vomiting adverse events": 86447,
      "pain strong opioids": 57867,
      "opioid use weeks": 52608,
      "evidence outcomes using": 30236,
      "outcomes using grade": 54107,
      "adverse events led": 8766,
      "codeine dextropropoxyphene dihydrocodeine": 17223,
      "oxycodone oxymorphone tapentadol": 55626,
      "increased risk experiencing": 38014,
      "experiencing adverse event": 30640,
      "42 95 confidence": 4457,
      "data adverse events": 21868,
      "number adverse events": 50138,
      "based adverse events": 13274,
      "demonstrated long term": 23352,
      "effects including dependence": 27950,
      "convenience sample patients": 20687,
      "latent class analysis": 41232,
      "analysis used explore": 10787,
      "efficacy safety cost effectiveness": 28358,
      "oxycodone hydrochloride controlled release": 55181,
      "hydrochloride controlled release tablets": 36015,
      "initial dose cr oxycodone": 38840,
      "oral immediate release morphine": 53549,
      "cost effective option compared": 20868,
      "sun yat sen university": 79121,
      "significantly improve quality life": 75748,
      "improve quality life patients": 37087,
      "efficacy safety oxycontin tablets": 28373,
      "safety oxycontin tablets controlled": 73191,
      "oxycontin tablets controlled release": 56188,
      "tablets controlled release oxycodone": 80138,
      "release oxycodone hydrochloride 10": 69945,
      "oxycodone hydrochloride 10 20": 55176,
      "hydrochloride 10 20 40": 36007,
      "20 40 mg relieving": 2296,
      "40 mg relieving moderate": 4357,
      "mg relieving moderate severe": 46203,
      "pain method multicenter open": 57177,
      "method multicenter open label": 45191,
      "multicenter open label prospective": 48165,
      "open label prospective self": 51177,
      "label prospective self controlled": 40993,
      "prospective self controlled clinical": 65878,
      "patients drug administration oxycontin": 59229,
      "drug administration oxycontin tablets": 26526,
      "administration oxycontin tablets showed": 8331,
      "oxycontin tablets showed good": 56192,
      "tablets showed good clinical": 80216,
      "showed good clinical efficacy": 75251,
      "good clinical efficacy relieving": 33299,
      "clinical efficacy relieving moderate": 16806,
      "efficacy relieving moderate severe": 28347,
      "lower average pain scores": 42581,
      "oxycontin tablets demonstrated fast": 56190,
      "tablets demonstrated fast onset": 80144,
      "pain control superior efficacy": 56662,
      "control superior efficacy relieving": 20429,
      "superior efficacy relieving moderate": 79128,
      "pain good safety profile": 56811,
      "strong opioids oxycodone morphine": 77556,
      "pain adults data collection": 56424,
      "adults data collection analysis": 8562,
      "confidence interval ci 06": 19460,
      "treatment acceptability adverse events": 82422,
      "smd 14 95 ci": 76320,
      "similar levels pain relief": 75944,
      "opioids relief cancer pain": 53257,
      "cancer patients experience pain": 14874,
      "sprague dawley rats given": 76771,
      "human liver microsomes hlms": 35962,
      "relative risk rr 95": 69765,
      "risk rr 95 confidence": 72659,
      "rr 95 confidence intervals": 73013,
      "opioids cancer related pain": 52766,
      "rr 86 95 ci": 72997,
      "rr 98 95 ci": 73019,
      "rr 97 95 ci": 73016,
      "rr 76 95 ci": 72978,
      "rr 47 95 ci": 72938,
      "relief fewer adverse effects": 70129,
      "adverse effects compared strong": 8648,
      "effects compared strong opioids": 27868,
      "non cancer pain study": 49584,
      "double blind randomized controlled": 26373,
      "blind randomized controlled trial": 13972,
      "total daily opioid dose": 81797,
      "aims evaluate efficacy safety": 9483,
      "evaluate efficacy safety oxycodone": 29795,
      "results showed statistically significant": 71950,
      "showed statistically significant difference": 75315,
      "moderate severe pain control": 47196,
      "rr 04 95 ci": 72890,
      "group statistically significant difference": 34033,
      "balance analgesia adverse effects": 13231,
      "observation group control group": 50600,
      "group control group 05": 33715,
      "control group 05 incidence": 20309,
      "control group 05 conclusion": 20308,
      "cancer patients little known": 14877,
      "met following criteria patients": 44875,
      "numerical rating scale visit": 50320,
      "purpose study aimed investigate": 66570,
      "mg twice daily mean": 46252,
      "tandem mass spectrometry detection": 80363,
      "performed using nonlinear mixed": 60650,
      "nonlinear mixed effects modeling": 49761,
      "compartment model order absorption": 18396,
      "review board approval written": 72268,
      "board approval written informed": 14181,
      "approval written informed consent": 11529,
      "written informed consent obtained": 87377,
      "patients group received 20": 59340,
      "results numeric rating scale": 71801,
      "significantly lower group group": 75788,
      "group significant difference observed": 34012,
      "quality life adverse events": 66720,
      "patients objectives aim study": 59567,
      "performance liquid chromatography combined": 60555,
      "patients chronic cancer pain": 59067,
      "quality life qol patients": 66741,
      "quality life adverse effects": 66719,
      "patients receiving high dose": 59839,
      "mean numeric rating scale": 43815,
      "study aims investigate effect": 77945,
      "results primary end point": 71893,
      "secondary end points included": 74221,
      "achieved adequate pain control": 7316,
      "adverse effects similar groups": 8702,
      "controlled release oxycodone naloxone": 20563,
      "present study designed assess": 64650,
      "pain numeric rating scale": 57253,
      "20 mg 10 mg": 2330,
      "80 mg 40 mg": 5848,
      "40 mg day weeks": 4348,
      "nrs pain score baseline": 50068,
      "quality life qol safety": 66742,
      "life qol safety assessments": 41726,
      "pain scores significantly different": 57782,
      "sided 95 confidence interval": 75375,
      "groups did differ significantly": 34182,
      "administration controlled release oxycodone": 8237,
      "controlled release oxycodone tablets": 20568,
      "pain non cancer related": 57242,
      "brain computed tomography ct": 14327,
      "opioid withdrawal present case": 52645,
      "aim study evaluate efficacy": 9419,
      "design randomised double blind": 23770,
      "days 14 21 28": 22464,
      "background objective oxycodone semisynthetic": 13095,
      "release oxycodone tablet formulation": 69978,
      "management moderate severe cancer": 43209,
      "purpose study evaluate efficacy": 66581,
      "hydrochloride controlled release cr": 36014,
      "controlled release cr tablets": 20541,
      "12 hours immediate release": 1300,
      "cr oxycodone 12 hours": 21076,
      "safety controlled release cr": 73135,
      "release cr oxycodone tablets": 69827,
      "mean ratio hydromorphone oxycodone": 43850,
      "converted morphine equivalent dose": 20732,
      "tolerance analgesic effect opioid": 81571,
      "mg day transdermal fentanyl": 45867,
      "day transdermal fentanyl patches": 22434,
      "similar efficacy safety profile": 75920,
      "cancer patients methods prospective": 14880,
      "10 point numerical rating": 904,
      "patients treated oral oxycodone": 60067,
      "pain intensity assessed 10": 56888,
      "numerical rating scale decreased": 50313,
      "randomized open label titration": 67134,
      "cr oxycodone ir oxycodone": 21092,
      "oxycodone patients chronic moderate": 55656,
      "patients chronic moderate severe": 59071,
      "moderate severe pain background": 47193,
      "pain background opioid analgesics": 56482,
      "quality life study aimed": 66749,
      "controlled release oxycodone 10": 20553,
      "patients achieved pain relief": 58926,
      "relieve moderate severe cancer": 70216,
      "methods opioid na\u00efve patients": 45416,
      "opioid na\u00efve patients moderate": 51989,
      "na\u00efve patients moderate severe": 48844,
      "oxycodone group morphine group": 55134,
      "dose oxycodone sustained release": 25999,
      "12 hours 24 hours": 1295,
      "oxycodone group significantly higher": 55141,
      "elimination half life study": 28615,
      "compare efficacy safety controlled": 18025,
      "efficacy safety controlled release": 28356,
      "randomized controlled release oxycodone": 67065,
      "pain intensity assessed using": 56889,
      "scale vas 100 mm": 73573,
      "results patients completed study": 71845,
      "aimed investigate efficacy safety": 9460,
      "na\u00efve cancer patients moderate": 48829,
      "severe cancer pain methods": 74920,
      "controlled randomized double blind": 20531,
      "baseline visual analog scale": 13467,
      "compare analgesic efficacy safety": 18009,
      "analgesic efficacy safety oxymorphone": 10248,
      "efficacy safety oxymorphone extended": 28376,
      "safety oxymorphone extended release": 73195,
      "release er oxycodone controlled": 69848,
      "er oxycodone controlled release": 29455,
      "years age moderate severe": 87564,
      "double blind treatment phase": 26388,
      "morphine sulfate 15 mg": 47938,
      "included brief pain inventory": 37432,
      "received dose study drug": 68142,
      "completed double blind phase": 18469,
      "mean pain intensity scores": 43829,
      "rescue medication use low": 70960,
      "patients achieved stable dose": 58928,
      "study compared efficacy tolerability": 78012,
      "chronic pain preoperative pain": 16305,
      "updated version original cochrane": 83987,
      "using grade main results": 85418,
      "rr 58 95 ci": 72953,
      "rr 14 95 ci": 72900,
      "rr 85 95 ci": 72994,
      "pruritus rr 46 95": 66305,
      "rr 46 95 ci": 72935,
      "pain relief significantly better": 57582,
      "14 95 ci 01": 1577,
      "95 ci 33 76": 6281,
      "rr 06 95 ci": 72893,
      "rr 52 95 ci": 72944,
      "levels pain relief overall": 41591,
      "extended release immediate release": 30878,
      "brief pain inventory primary": 14432,
      "dose patients cancer pain": 26006,
      "non cancer chronic pain": 49575,
      "methods searched central medline": 45562,
      "adverse events did significantly": 8752,
      "significantly better pain relief": 75665,
      "systematic review randomized controlled": 79996,
      "review randomized controlled trials": 72350,
      "04 95 confidence interval": 450,
      "confidence interval ci 29": 19471,
      "pain scores higher oxycodone": 57728,
      "cancer related pain background": 14909,
      "oxycodone used opioid analgesic": 56061,
      "systematic literature review forms": 79978,
      "literature review forms basis": 42130,
      "review forms basis guidelines": 72308,
      "european palliative care research": 29747,
      "palliative care research collaborative": 58044,
      "care research collaborative opioid": 15073,
      "research collaborative opioid guidelines": 70991,
      "collaborative opioid guidelines project": 17438,
      "objective study identify assess": 50518,
      "study identify assess quality": 78240,
      "identify assess quality evidence": 36490,
      "database systematic reviews cochrane": 22191,
      "systematic reviews cochrane central": 79999,
      "reviews cochrane central register": 72409,
      "register controlled trials medline": 69374,
      "controlled trials medline embase": 20639,
      "trials medline embase cinahl": 83161,
      "medline embase cinahl systematically": 44736,
      "embase cinahl systematically searched": 28640,
      "cinahl systematically searched addition": 16560,
      "systematically searched addition hand": 80015,
      "searched addition hand searching": 74136,
      "addition hand searching relevant": 7806,
      "hand searching relevant journals": 34552,
      "studies included reported clinical": 77750,
      "included reported clinical outcome": 37543,
      "reported clinical outcome relevant": 70520,
      "clinical outcome relevant use": 16850,
      "adult patients moderate severe": 8516,
      "direct comparator required inclusion": 25042,
      "comparator required inclusion studies": 17999,
      "assess quality studies formulate": 11958,
      "quality studies formulate guidelines": 66764,
      "randomized controlled trials compared": 67080,
      "hydromorphone cancer related pain": 36163,
      "mg cr oxycodone tablets": 45841,
      "significant difference treatment groups": 75495,
      "oxycodone fentanyl commonly used": 55075,
      "recorded using numerical rating": 68710,
      "randomized double blind treatment": 67109,
      "mean sd pain intensity": 43868,
      "oxycodone opioid receptor agonist": 55572,
      "cyp2d6 aim study investigate": 21591,
      "study design open label": 78071,
      "design open label single": 23734,
      "plasma concentration oxycodone metabolites": 61904,
      "increased area plasma concentration": 37878,
      "concentration time curve auc0": 18725,
      "time curve auc0 oxycodone": 81238,
      "patients receiving multiple doses": 59848,
      "oxycodone increasingly used opioid": 55255,
      "adequate pain control patients": 7963,
      "treatment controlled release cr": 82526,
      "cr oxycodone transdermal fentanyl": 21102,
      "semi synthetic opioid agonist": 74514,
      "controlled release cr formulation": 20537,
      "immediate release ir formulation": 36720,
      "pain evaluated using visual": 56763,
      "pain vas scores groups": 57972,
      "group vs control group": 34076,
      "pain clinical trial registration": 56552,
      "odds ratio 60 95": 50922,
      "ratio 60 95 confidence": 67747,
      "60 95 confidence interval": 5247,
      "aim study determine frequency": 9414,
      "methods single center retrospective": 45581,
      "single center retrospective study": 76068,
      "logistic regression analysis performed": 42259,
      "logistic regression analysis revealed": 42260,
      "85 95 ci 13": 5981,
      "patients randomized receive 30": 59740,
      "logistic regression analysis used": 42262,
      "patients included final analysis": 59395,
      "objective assess efficacy safety": 50380,
      "safety controlled release oxycodone": 73136,
      "controlled release oxycodone patients": 20565,
      "oxycodone patients moderate severe": 55660,
      "methods retrospective observational study": 45545,
      "use controlled release oxycodone": 84277,
      "received controlled release oxycodone": 68131,
      "pain score 10 96": 57664,
      "sustained release sr oxycodone": 79797,
      "immediate release oxycodone plasma": 36734,
      "concentrations oxycodone noroxycodone plasma": 18795,
      "cancer patients methods patients": 14879,
      "results total number patients": 72036,
      "purpose opioids recommended moderate": 66540,
      "opioids recommended moderate severe": 53244,
      "recommended moderate severe cancer": 68630,
      "severe cancer pain patients": 74921,
      "cancer pain patients cancer": 14844,
      "pain patients cancer impaired": 57341,
      "function affect opioid metabolism": 32627,
      "affect opioid metabolism aim": 8907,
      "opioid metabolism aim systematic": 51928,
      "metabolism aim systematic review": 44923,
      "aim systematic review evaluate": 9429,
      "systematic review evaluate evidence": 79989,
      "impairment methods systematic review": 36902,
      "methods systematic review conducted": 45602,
      "systematic review conducted following": 79985,
      "review conducted following databases": 72280,
      "conducted following databases searched": 19362,
      "eligible studies met following": 28598,
      "studies met following criteria": 77770,
      "following criteria patients cancer": 32118,
      "pain taking opioid defined": 57902,
      "eligible studies appraised using": 28596,
      "studies appraised using grading": 77648,
      "eligible heterogeneity meant meta": 28583,
      "heterogeneity meant meta analysis": 35051,
      "meant meta analysis possible": 43929,
      "recommendations formulated preferred opioid": 68602,
      "formulated preferred opioid patients": 32326,
      "review little clinical evidence": 72319,
      "evidence overall quality existing": 30240,
      "overall quality existing evidence": 54240,
      "quality existing evidence opioid": 66702,
      "impairment low remains need": 36898,
      "low remains need high": 42549,
      "remains need high quality": 70303,
      "need high quality clinical": 48925,
      "high quality clinical studies": 35155,
      "quality clinical studies examining": 66683,
      "incidence adverse events comparable": 37260,
      "adverse events comparable groups": 8740,
      "primary end point percentage": 65016,
      "risk difference 95 ci": 72546,
      "difference 95 ci 11": 24587,
      "numerical rating scale pain": 50315,
      "line treatment moderate severe": 42005,
      "oral opioid analgesics time": 53602,
      "opioid analgesics time methods": 51529,
      "nausea vomiting cancer patients": 48794,
      "opioid induced nausea vomiting": 51864,
      "chronic pain cancer patients": 16263,
      "mitogen activated protein kinase": 46775,
      "fixed dose combination acetaminophen": 31874,
      "purpose study evaluate effects": 66580,
      "number patients received opioid": 50220,
      "cancer pain patients included": 14845,
      "treatment controlled release oxycodone": 82527,
      "using nonsteroidal anti inflammatory": 85523,
      "mg day patients experienced": 45861,
      "patients experienced adverse events": 59278,
      "study patients moderate severe": 78370,
      "treated controlled release oxycodone": 82330,
      "parallel group study designed": 58141,
      "group study designed demonstrate": 34038,
      "twice daily sustained release": 83305,
      "long term safety efficacy": 42351,
      "medical outcomes study mos": 44377,
      "outcomes study mos sleep": 54101,
      "postoperative pain video assisted": 62931,
      "video assisted thoracoscopic surgery": 86216,
      "assisted thoracoscopic surgery vats": 12203,
      "acute postoperative pain methods": 7688,
      "patients underwent vats lung": 60157,
      "pain early postoperative period": 56740,
      "thoracoscopic surgery lung cancer": 81129,
      "cancer pain methods open": 14835,
      "pain methods open label": 57184,
      "incidence adverse drug reactions": 37256,
      "group 40 patients underwent": 33610,
      "ml oxycodone hydrochloride mg": 46889,
      "groups different time points": 34188,
      "ng ml 100 ng": 49432,
      "ml 100 ng ml": 46824,
      "opioid induced adverse effects": 51849,
      "plasma concentrations oxycodone oxymorphone": 61920,
      "concentrations oxycodone oxymorphone noroxycodone": 18799,
      "oxycodone oxymorphone noroxycodone determined": 55621,
      "pain requiring opioid therapy": 57626,
      "analogue score vas pain": 10567,
      "incidence severity adverse events": 37321,
      "rr 95 confidence interval": 73012,
      "assessed risk bias included": 12058,
      "risk bias included studies": 72533,
      "evidence using grade created": 30293,
      "using grade created summary": 85416,
      "grade created summary findings": 33371,
      "created summary findings tables": 21149,
      "summary findings tables main": 79104,
      "findings tables main results": 31835,
      "tables main results included": 80084,
      "pain intensity measured visual": 56912,
      "measured visual analogue scale": 44013,
      "mean standard deviation sd": 43882,
      "adverse effects nausea constipation": 8670,
      "oxycodone prolonged release tablets": 55777,
      "results total 120 patients": 72026,
      "control group difference statistically": 20323,
      "group control group difference": 33717,
      "effects constipation nausea vomiting": 27879,
      "lower incidence nausea vomiting": 42633,
      "background opioid induced nausea": 13112,
      "induced nausea vomiting oinv": 38428,
      "controlled trials evaluated efficacy": 20635,
      "randomly assigned ratio receive": 67224,
      "primary endpoint proportion patients": 65033,
      "preventing opioid induced nausea": 64865,
      "patients chronic opioid therapy": 59078,
      "samples plasma concentrations oxycodone": 73357,
      "achieve adequate pain control": 7292,
      "risk opioid induced constipation": 72615,
      "opioid induced constipation objective": 51858,
      "pain relief numeric rating": 57552,
      "relief numeric rating scale": 70150,
      "patients non cancer pain": 59552,
      "oxycodone widely used treatment": 56099,
      "sex age body mass": 75061,
      "body mass index bmi": 14199,
      "european organisation research treatment": 29744,
      "organisation research treatment cancer": 53760,
      "mann whitney tests results": 43320,
      "cytochrome p450 enzyme cyp": 21662,
      "plasma concentrations oxycodone metabolites": 61917,
      "cyp2d6 cyp3a5 abcb1 oprm1": 21597,
      "treatment chronic cancer pain": 82481,
      "requiring step iii opioids": 70916,
      "measured 10 numerical rating": 43956,
      "https clinicaltrials gov ct2": 35932,
      "results visual analog scale": 72055,
      "analog scale scores pain": 10535,
      "pain including neuropathic pain": 56862,
      "patients mean age 62": 59482,
      "hydrochloride extended release tablet": 36018,
      "observation group lower control": 50604,
      "group lower control group": 33843,
      "observation group higher control": 50602,
      "group higher control group": 33814,
      "lower control group 05": 42592,
      "parallel group multicentre study": 58134,
      "days primary outcome average": 22599,
      "acute postoperative pain oxycodone": 7690,
      "oxymorphone active metabolite oxycodone": 56221,
      "oxymorphone analgesic effect oxycodone": 56224,
      "release cr oxycodone morphine": 69825,
      "chronic cancer pain background": 16186,
      "participants experiencing adverse events": 58307,
      "proportion participants experiencing adverse": 65758,
      "oxycodone given 12 hours": 55116,
      "dose immediate release ir": 25928,
      "patients opioid tolerant patients": 59591,
      "chi square test used": 15988,
      "morphine oxycodone fentanyl hydromorphone": 47824,
      "group control group 30": 33716,
      "relieve pain reduce dose": 70219,
      "databases including pubmed embase": 22203,
      "randomized controlled trials results": 67085,
      "analgesic effect oxycodone morphine": 10206,
      "moderate severe chronic cancer": 47175,
      "severe chronic cancer pain": 74929,
      "constipation bowel function index": 19753,
      "methadone morphine morphine glucuronide": 45103,
      "morphine morphine glucuronide m6g": 47781,
      "primary outcome number patients": 65075,
      "visual analogue scale pain": 86325,
      "analogue scale pain satisfaction": 10554,
      "cancer pain patients using": 14846,
      "patients setting study included": 59959,
      "treatment chronic severe pain": 82492,
      "opioid used treatment moderate": 52614,
      "oxycodone paracetamol 325 mg": 55637,
      "primary endpoint pain intensity": 65031,
      "pain intensity difference pid": 56899,
      "study assess efficacy tolerability": 77965,
      "analgesic efficacy safety study": 10249,
      "patients taking opioid analgesics": 60034,
      "transdermal fentanyl oxycodone cr": 82153,
      "fentanyl oxycodone cr morphine": 31549,
      "extended release oxycodone er": 30893,
      "opioid naive patients methods": 51972,
      "95 ci 15 32": 6252,
      "adverse drug reactions similar": 8628,
      "trial registered clinicaltrials gov": 83066,
      "oral morphine equivalent daily": 53576,
      "morphine equivalent daily dose": 47657,
      "equivalent daily dose medd": 29296,
      "patients receiving 30 mg": 59834,
      "patients methods single center": 59509,
      "use opioids cancer pain": 84559,
      "pain relief quality life": 57573,
      "mental component summary mcs": 44815,
      "inventory short form bpi": 39985,
      "background oxycodone semisynthetic opioid": 13135,
      "oxycodone semisynthetic opioid receptor": 55888,
      "used pain control patients": 85062,
      "rifampin strong inducer drug": 72473,
      "strong inducer drug metabolizing": 77521,
      "inducer drug metabolizing enzymes": 38466,
      "twice daily oxycodone cr": 83301,
      "week open label extension": 86856,
      "open label extension study": 51165,
      "primary efficacy measure change": 65010,
      "patients discontinued treatment adverse": 59214,
      "chinese patients moderate severe": 16097,
      "aimed assess efficacy safety": 9437,
      "rating scale nrs patients": 67663,
      "patients severe pain nrs": 59969,
      "used patients manner inconsistent": 85073,
      "patients manner inconsistent standard": 59478,
      "reported adequate pain relief": 70497,
      "open label phase iv": 51175,
      "label phase iv study": 40990,
      "assessed using numerical rating": 12089,
      "impact quality life opioid": 36849,
      "commonly used treat moderate": 17902,
      "morphine oxycodone tramadol tapentadol": 47861,
      "methods identified systematic reviews": 45356,
      "systematic reviews cochrane library": 80000,
      "adverse events adverse events": 8724,
      "moderate severe pain given": 47199,
      "certainty evidence using grade": 15664,
      "15 low certainty evidence": 1745,
      "low certainty evidence data": 42457,
      "rr 75 95 ci": 72975,
      "low low certainty evidence": 42496,
      "low certainty evidence little": 42458,
      "certainty evidence little difference": 15661,
      "little difference pain intensity": 42154,
      "pain intensity pain relief": 56925,
      "prevention management opioid related": 64877,
      "risk opioid related complications": 72620,
      "aim study assess efficacy": 9406,
      "release cr oxycodone patients": 69826,
      "cancer non cancer related": 14803,
      "abuse deterrent microsphere capsule": 6696,
      "extended release formulation oxycodone": 30875,
      "xtampza er collegium pharmaceutical": 87412,
      "er collegium pharmaceutical canton": 29406,
      "collegium pharmaceutical canton massachusetts": 17515,
      "cytochrome p450 cyp 3a4": 21659,
      "patients received single dose": 59822,
      "using validated liquid chromatography": 85657,
      "validated liquid chromatography tandem": 85790,
      "oxycodone active metabolite oxymorphone": 54672,
      "incidence severity adverse effects": 37320,
      "adverse effects pain control": 8683,
      "80 40 mg day": 5831,
      "results mean standard deviation": 71770,
      "laboratory tests vital signs": 41039,
      "pain osteoarthritis rheumatoid arthritis": 57303,
      "world health organization step": 87312,
      "health organization step iii": 34748,
      "organization step iii opioids": 53775,
      "central nervous cns drugs": 15597,
      "mg oxycodone 40 mg": 46104,
      "pain relief palliative care": 57564,
      "modified brief pain inventory": 47238,
      "prospective multicenter observational nonrandomized": 65838,
      "patients acute episodes noncancer": 58936,
      "acute episodes noncancer pain": 7633,
      "episodes noncancer pain requiring": 29211,
      "noncancer pain requiring treatment": 49714,
      "pain requiring treatment prescription": 57628,
      "requiring treatment prescription medication": 70921,
      "treatment prescription medication containing": 82780,
      "prescription medication containing oxycodone": 64250,
      "medication containing oxycodone immediate": 44481,
      "containing oxycodone immediate release": 20082,
      "oxycodone immediate release needed": 55233,
      "immediate release needed basis": 36727,
      "release needed basis days": 69897,
      "length stay results patients": 41415,
      "search methods searched central": 74119,
      "reported pain intensity pain": 70610,
      "analysis primary outcome pain": 10743,
      "primary outcome pain intensity": 65080,
      "pain intensity measured using": 56911,
      "rr 91 95 ci": 73006,
      "99 95 ci 84": 6486,
      "rr 87 95 ci": 73000,
      "rr 15 95 ci": 72903,
      "reported adverse events nausea": 70503,
      "insufficient evidence support refute": 39127,
      "activation opioid receptor mor": 7475,
      "patients achieved adequate pain": 58924,
      "effects nausea vomiting constipation": 28019,
      "anti inflammatory drug celecoxib": 11124,
      "random number table method": 67001,
      "rating scale nrs scores": 67666,
      "trial registration chinese clinical": 83069,
      "registration chinese clinical trial": 69386,
      "time onset pain relief": 81302,
      "time meaningful pain relief": 81288,
      "compared groups results mean": 18174,
      "pain control fewer adverse": 56616,
      "severe cancer pain randomized": 74922,
      "controlled release cr morphine": 20539,
      "patients entered open label": 59254,
      "long acting opioid prescriptions": 42298,
      "combination nonsteroidal anti inflammatory": 17573,
      "conducted retrospective chart review": 19402,
      "significant difference incidence nausea": 75475,
      "effective preventing opioid induced": 27682,
      "patients severe chronic pain": 59964,
      "clinical practice aim study": 16861,
      "magnetic resonance imaging revealed": 42804,
      "randomized controlled trials conducted": 67082,
      "objective objective study assess": 50449,
      "use nonsteroidal anti inflammatory": 84526,
      "results study population consisted": 71986,
      "increased odds opioid prescriptions": 37960,
      "80 patients enrolled study": 5859,
      "included final analysis compared": 37455,
      "year old woman diagnosed": 87471,
      "coronary artery bypass surgery": 20785,
      "methadone buprenorphine fentanyl oxycodone": 45052,
      "background effective pain management": 13043,
      "doses nonsteroidal anti inflammatory": 26224,
      "imaging positron emission tomography": 36687,
      "pain major public health": 57049,
      "palliative care inpatient unit": 58037,
      "systematic literature review performed": 79979,
      "literature search conducted medline": 42134,
      "register controlled trials databases": 69373,
      "oral morphine oxycodone hydromorphone": 53591,
      "associated decreased pain scores": 12248,
      "compared short acting opioids": 18307,
      "different long acting opioids": 24883,
      "patients background pain common": 59029,
      "effective option pain management": 27657,
      "prescribed long acting opioid": 63881,
      "release oxycodone transdermal fentanyl": 69983,
      "oxycodone fentanyl patient controlled": 55086,
      "pain scores opioid consumption": 57752,
      "mean daily pain scores": 43747,
      "methyl aspartate receptor antagonist": 45645,
      "use non opioid analgesics": 84516,
      "used non opioid analgesics": 85032,
      "opioid moderate severe pain": 51952,
      "oral sustained release morphine": 53672,
      "opioid receptor mor agonists": 52263,
      "objective study aimed investigate": 50493,
      "chronic pain patients objective": 16301,
      "opioids commonly used management": 52804,
      "included randomized controlled trials": 37537,
      "reported opioid related adverse": 70597,
      "opioid related adverse effect": 52301,
      "oxycodone immediate release commonly": 55231,
      "oxycodone fentanyl methadone hydromorphone": 55081,
      "patients receiving transdermal fentanyl": 59863,
      "indicated management moderate severe": 38238,
      "continuous clock opioid analgesia": 20159,
      "clock opioid analgesia extended": 17054,
      "opioid analgesia extended period": 51443,
      "objective assess patient reported": 50382,
      "opioids patients received opioid": 53163,
      "background cancer patients experience": 13022,
      "randomized placebo controlled trials": 67155,
      "poor pain control adverse": 62270,
      "pain control adverse effects": 56603,
      "acute chronic pain conditions": 7622,
      "similar mu opioid receptor": 75954,
      "lung cancer patients methods": 42765,
      "non cancer pain patients": 49583,
      "transdermal fentanyl oral hydromorphone": 82150,
      "used strong opioids chronic": 85147,
      "opioid utilisation oral morphine": 52628,
      "utilisation oral morphine equivalent": 85713,
      "analgesia fewer adverse effects": 9976,
      "oxycodone appears kappa opioid": 54727,
      "international association hospice palliative": 39471,
      "association hospice palliative care": 12475,
      "inter patient variability response": 39361,
      "patient variability response opioids": 58813,
      "opioids morphine codeine oxycodone": 53068,
      "morphine codeine oxycodone fentanyl": 47604,
      "oxycodone fentanyl tramadol conclusions": 55091,
      "materials methods eighty consecutive": 43509,
      "27 95 ci 32": 3488,
      "95 ci 32 14": 6278,
      "use chronic non cancer": 84237,
      "identified randomized controlled trials": 36462,
      "average pain intensity pain": 12924,
      "significant improvements versus placebo": 75557,
      "methods randomized clinical trial": 45507,
      "randomized clinical trial included": 67047,
      "intensity measured visual analog": 39267,
      "secondary outcome measures patient": 74240,
      "strong opioids commonly used": 77545,
      "undergoing breast cancer surgery": 83516,
      "central cochrane library issue": 15583,
      "cochrane library issue 12": 17179,
      "evidence outcomes using grade": 30237,
      "morphine oxycodone oxymorphone tapentadol": 47847,
      "42 95 confidence interval": 4458,
      "808": 5876,
      "bonferroni": 14241,
      "normalizes": 49918,
      "gravity": 33408,
      "lean": 41319,
      "sensing": 74540,
      "naphthalene": 48560,
      "hydrophobic": 36234,
      "fluorescence": 31950,
      "reading": 67988,
      "mainstream": 42880,
      "reactivity": 67981,
      "shipped": 75144,
      "projecting": 65594,
      "projection": 65595,
      "hair": 34507,
      "060": 591,
      "formaldehyde": 32291,
      "scanning": 73595,
      "energy": 28923,
      "voltammetry": 86389,
      "impedance": 36910,
      "eis": 28463,
      "\u03bcmol": 87801,
      "nmol": 49521,
      "graphical": 33407,
      "diagnostics": 24347,
      "electrode": 28519,
      "coated": 17129,
      "feb": 31300,
      "approximated": 11554,
      "1067": 1067,
      "ascribed": 11826,
      "manufacturing": 43340,
      "deuterated": 24139,
      "derivatized": 23627,
      "ve": 86043,
      "spectrometer": 76652,
      "column": 17530,
      "ammonium": 9829,
      "hydroxycodeinone": 36246,
      "ketone": 40624,
      "comet": 17689,
      "links": 42060,
      "duodenal": 27138,
      "duodenum": 27139,
      "surprise": 79667,
      "examiners": 30420,
      "unidentified": 83729,
      "oxidized": 54401,
      "electrospray": 28552,
      "oxidation": 54393,
      "fragmentation": 32469,
      "hydrogen": 36140,
      "c8": 14657,
      "285": 3587,
      "complying": 18575,
      "tailoring": 80263,
      "069": 599,
      "lcms": 41273,
      "quantitate": 66790,
      "860": 6013,
      "770": 5769,
      "residue": 71085,
      "analyte": 10795,
      "labelled": 41013,
      "d5": 21683,
      "contaminant": 20089,
      "bypassed": 14637,
      "isotopic": 40312,
      "capillary": 14949,
      "ce": 15439,
      "fused": 32755,
      "stemming": 77316,
      "incubations": 38154,
      "cytosol": 21674,
      "s9": 73057,
      "hydrolyzed": 36143,
      "asymmetry": 12520,
      "diol": 25026,
      "aqueous": 11616,
      "unresolved": 83934,
      "roc": 72715,
      "exclude": 30473,
      "samhsa": 73284,
      "workplace": 87299,
      "719": 5608,
      "butyl": 14628,
      "dryness": 27103,
      "microl": 46369,
      "1789": 2020,
      "acetylated": 7271,
      "990": 6494,
      "surfaces": 79259,
      "immunosorbent": 36784,
      "covalent": 21005,
      "benzoylecgonine": 13671,
      "ldd": 41275,
      "swabs": 79803,
      "wetted": 87010,
      "validating": 85796,
      "\u03bcl": 87799,
      "flight": 31921,
      "fillers": 31714,
      "atenolol": 12524,
      "deposited": 23556,
      "steel": 77308,
      "metal": 45020,
      "991": 6495,
      "998": 6501,
      "solvent": 76451,
      "norhydrocodone": 49894,
      "sevenfold": 74881,
      "sixfold": 76176,
      "metabolically": 44913,
      "packed": 56323,
      "sorbent": 76473,
      "incorporates": 37712,
      "valve": 85855,
      "enabling": 28761,
      "eliminates": 28607,
      "optimum": 53447,
      "workflows": 87293,
      "h2o": 34494,
      "acyl": 7714,
      "glucuronides": 33255,
      "pmol": 62042,
      "aliquots": 9575,
      "simpler": 76021,
      "biologically": 13856,
      "filtrate": 31734,
      "interpretive": 39511,
      "substantiate": 78867,
      "resolve": 71115,
      "6\u03b2": 5545,
      "054": 568,
      "comprehend": 18619,
      "075": 614,
      "percentiles": 60524,
      "reagents": 67997,
      "reagent": 67996,
      "turning": 83287,
      "lysergic": 42779,
      "diethylamide": 24537,
      "athletes": 12525,
      "merits": 44856,
      "dried": 26456,
      "probes": 65230,
      "compensated": 18405,
      "rp": 72880,
      "2mm": 3653,
      "acetylmorphine": 7279,
      "stainless": 76876,
      "buffered": 14475,
      "barbiturate": 13246,
      "neutralization": 49301,
      "polymeric": 62204,
      "resin": 71087,
      "confined": 19489,
      "derivation": 23617,
      "acetylation": 7272,
      "workload": 87298,
      "derivatization": 23626,
      "mother": 48005,
      "methylenedioxy": 45651,
      "freeze": 32503,
      "genetics": 33091,
      "motivate": 48015,
      "2746": 3521,
      "hlm": 35492,
      "accuracies": 7097,
      "incubated": 38150,
      "p450s": 56314,
      "cyps": 21648,
      "isobaric": 40294,
      "interferences": 39431,
      "lactose": 41074,
      "1700": 2001,
      "monitors": 47349,
      "cutoffs": 21539,
      "unintentionally": 83746,
      "923": 6163,
      "852": 5996,
      "fractions": 32453,
      "arithmetic": 11660,
      "environments": 29094,
      "red": 68820,
      "phenanthrene": 61333,
      "lloq": 42192,
      "bench": 13588,
      "overdosed": 54322,
      "wastewaters": 86753,
      "intakes": 39189,
      "optical": 53417,
      "nanoparticles": 48559,
      "nps": 50051,
      "silver": 75891,
      "chip": 16098,
      "platforms": 61986,
      "frozen": 32605,
      "suboptimal": 78766,
      "acetylcodeine": 7275,
      "sciences": 73683,
      "solve": 76450,
      "chlorprothixene": 16106,
      "polar": 62171,
      "modifiers": 47249,
      "norcodeine": 49882,
      "instrumentation": 39116,
      "adulterate": 8533,
      "federally": 31323,
      "monoclonal": 47365,
      "mabs": 42789,
      "fl": 31891,
      "mab": 42788,
      "displaced": 25467,
      "ic50": 36383,
      "fatty": 31253,
      "ethyl": 29701,
      "sequentially": 74634,
      "propionic": 65733,
      "hydroxyl": 36247,
      "mam": 43106,
      "layer": 41260,
      "calibrator": 14726,
      "spike": 76691,
      "pools": 62252,
      "concordant": 19261,
      "pharmacologically": 61239,
      "meprobamate": 44854,
      "521": 5005,
      "1895": 2153,
      "officer": 50972,
      "duid": 27116,
      "methylenedioxyamphetamine": 45654,
      "1400": 1638,
      "identities": 36545,
      "spans": 76524,
      "recovering": 68732,
      "purified": 66510,
      "hrms": 35898,
      "tof": 81510,
      "employs": 28749,
      "fragment": 32468,
      "253": 3403,
      "993": 6496,
      "velocity": 86051,
      "programming": 65552,
      "handheld": 34558,
      "785": 5791,
      "remote": 70328,
      "imfs": 36691,
      "washed": 86740,
      "wash": 86739,
      "render": 70368,
      "525": 5010,
      "chloroform": 16104,
      "catalyst": 15279,
      "c2": 14643,
      "isocratic": 40298,
      "xenobiotics": 87402,
      "newborn": 49398,
      "adsorption": 8482,
      "ps": 66314,
      "norbuprenorphine": 49881,
      "pediatrician": 60365,
      "intrapartum": 39785,
      "differentiated": 24949,
      "ephedrine": 29120,
      "extreme": 30979,
      "telehealth": 80564,
      "keeping": 40601,
      "masses": 43476,
      "synovial": 79938,
      "diclazepam": 24378,
      "conjugation": 19539,
      "nucleophilic": 50119,
      "moiety": 47271,
      "situ": 76170,
      "adduction": 7943,
      "297": 3629,
      "hydroxybutyric": 36244,
      "cloned": 17059,
      "microfluidic": 46354,
      "microscope": 46375,
      "cobalt": 17130,
      "kadian": 40575,
      "avinza": 12956,
      "ames": 9812,
      "chromosomal": 16177,
      "chromosome": 16178,
      "straightforward": 77402,
      "norpropoxyphene": 49953,
      "unhydrolyzed": 83728,
      "threefold": 81146,
      "ab": 6510,
      "coc": 17131,
      "wastewater": 86751,
      "removals": 70333,
      "otps": 53889,
      "otp": 53888,
      "removing": 70337,
      "extents": 30932,
      "rsd": 73031,
      "buspirone": 14623,
      "genesis": 33069,
      "isotope": 40311,
      "decedent": 22814,
      "anhydroecgonine": 10983,
      "ecgonine": 27300,
      "chlorpheniramine": 16105,
      "trimethyl": 83229,
      "molding": 47277,
      "phenobarbital": 61343,
      "promethazine": 65648,
      "mitoxantrone": 46776,
      "methylamphetamine": 45649,
      "performances": 60563,
      "cathinone": 15325,
      "oxidant": 54389,
      "fluoroquinolones": 31955,
      "mp": 48063,
      "versatility": 86082,
      "impart": 36909,
      "accelerating": 6972,
      "pen": 60383,
      "atrazine": 12537,
      "friendly": 32597,
      "929": 6167,
      "feces": 31315,
      "bases": 13470,
      "deposition": 23557,
      "incubation": 38153,
      "diluting": 25012,
      "factorial": 31065,
      "pulverized": 66476,
      "cords": 20771,
      "857": 6000,
      "normorphine": 49923,
      "residues": 71086,
      "bearing": 13504,
      "reportable": 70482,
      "height": 34890,
      "sides": 75376,
      "unobserved": 83912,
      "shipping": 75145,
      "mephedrone": 44852,
      "methylenedioxyethylamphetamine": 45655,
      "pseudoephedrine": 66317,
      "qualifying": 66661,
      "hydroxybutyrate": 36243,
      "hydroxide": 36235,
      "chiral": 16099,
      "dehydrogenase": 23185,
      "leakage": 41318,
      "depletion": 23554,
      "synthesised": 79942,
      "miniature": 46566,
      "permissible": 60905,
      "repeatability": 70396,
      "zinc": 87762,
      "1098": 1078,
      "ia": 36331,
      "prevalences": 64823,
      "cme": 17099,
      "capillaries": 14948,
      "leveraging": 41620,
      "phe": 61332,
      "stands": 76996,
      "definitively": 23164,
      "itchiness": 40341,
      "von": 86490,
      "regensburg": 69294,
      "9mg": 6503,
      "fatally": 31248,
      "bloodstream": 14162,
      "analyzes": 10876,
      "officers": 50973,
      "excludes": 30482,
      "workflow": 87292,
      "prick": 64972,
      "mutual": 48376,
      "stabilities": 76825,
      "hydroxybenzoylecgonine": 36242,
      "chlordiazepoxide": 16100,
      "hydroxyalprazolam": 36241,
      "unstable": 83945,
      "births": 13884,
      "triplets": 83238,
      "multiples": 48304,
      "r\u00b2": 73054,
      "transitioning": 82209,
      "100mm": 1047,
      "616": 5325,
      "737": 5664,
      "twin": 83311,
      "preferably": 63619,
      "tt": 83269,
      "ultimate": 83414,
      "ethylidine": 29707,
      "schemes": 73664,
      "cation": 15327,
      "extracting": 30963,
      "modules": 47269,
      "transfers": 82182,
      "configuration": 19488,
      "999": 6502,
      "valerylfentanyl": 85771,
      "sec": 74177,
      "triage": 82991,
      "statuses": 77270,
      "commonest": 17825,
      "fibers": 31677,
      "ethylamphetamine": 29702,
      "repeatable": 70397,
      "equilibration": 29267,
      "tenfold": 80603,
      "deciding": 22842,
      "perfect": 60545,
      "amines": 9819,
      "interpatient": 39492,
      "ppi": 63297,
      "pipette": 61562,
      "tip": 81441,
      "preconcentration": 63540,
      "atlantic": 12526,
      "degraded": 23169,
      "utilizes": 85743,
      "diamhap": 24352,
      "tetanus": 80870,
      "toxoid": 81960,
      "crotonylfentanyl": 21312,
      "fluoro": 31952,
      "alfentanyl": 9563,
      "differentiate low": 24948,
      "low medium": 42498,
      "medium high": 44723,
      "thirty healthy": 81102,
      "daily oxycontin": 21791,
      "state naltrexone": 77054,
      "levels detected": 41553,
      "urine oxycodone": 84080,
      "fourth day": 32436,
      "values results": 85852,
      "conclusions contrast": 19065,
      "lean body": 41320,
      "cross reactive": 21252,
      "experiments performed": 30683,
      "metabolites using": 44988,
      "using direct": 85381,
      "described time": 23661,
      "oxycontin widely": 56197,
      "reported having": 70552,
      "degree abuse": 23171,
      "potential complications": 63150,
      "maternal drug": 43521,
      "use using": 84797,
      "cross reactivity": 21253,
      "high concentration": 35075,
      "concentration drug": 18695,
      "drug present": 26747,
      "detection oxycodone": 23962,
      "routinely used": 72873,
      "purpose retrospective": 66562,
      "therapeutic concentrations": 80928,
      "including ease": 37614,
      "free drug": 32488,
      "circulating blood": 16573,
      "closely related": 17076,
      "urine concentrations": 84069,
      "significantly years": 75870,
      "pain killing": 56987,
      "drugs specifically": 27079,
      "retrospectively studied": 72184,
      "attempt establish": 12547,
      "studied oral": 77621,
      "prior testing": 65174,
      "median concentration": 44204,
      "blood plasma": 14141,
      "median plasma": 44274,
      "provide foundation": 66064,
      "poorly characterized": 62279,
      "concentration 100": 18668,
      "100 pg": 1016,
      "april june": 11614,
      "require validation": 70814,
      "concentrations methods": 18778,
      "oxycodone oxc": 55592,
      "range 01": 67243,
      "human urine": 35977,
      "used analgesic": 84841,
      "care addition": 15001,
      "present blood": 64606,
      "behavior oxycodone": 13536,
      "oxycodone main": 55350,
      "main metabolites": 42834,
      "concentration measurements": 18703,
      "modeled using": 47093,
      "oxycodone excretion": 55050,
      "samples containing": 73340,
      "allowed estimation": 9637,
      "analysis samples": 10761,
      "rapid metabolizers": 67388,
      "monitoring used": 47347,
      "drugs finding": 26960,
      "hydrocodone patient": 36125,
      "hydrocodone patients": 36126,
      "function oxycodone": 32661,
      "oxycodone 72": 54596,
      "specimens oxycodone": 76643,
      "concentrations 50": 18741,
      "ml 16": 46829,
      "hydrocodone conclusions": 36075,
      "high frequency": 35104,
      "process oxycodone": 65339,
      "medications significant": 44674,
      "ml hydrocodone": 46863,
      "ml values": 46916,
      "aware possibility": 12983,
      "low concentrations": 42462,
      "analgesic used": 10357,
      "presence concentration": 64587,
      "drug blood": 26540,
      "mixed mode": 46799,
      "extracts analyzed": 30970,
      "paper authors": 58075,
      "developed method": 24181,
      "mass spectrometer": 43452,
      "performed 96": 60567,
      "phase composed": 61279,
      "mm ammonium": 46931,
      "validation method": 85799,
      "successfully applied": 78919,
      "rats 14": 67839,
      "14 hydroxycodeinone": 1601,
      "comet assay": 17690,
      "slight decrease": 76245,
      "previously conducted": 64937,
      "320 mg": 3943,
      "day similar": 22419,
      "disease cancer": 25321,
      "prescriptions oxycontin": 64532,
      "medical examiners": 44362,
      "admissions deaths": 8414,
      "deaths resulting": 22781,
      "testing procedures": 80835,
      "region oxycodone": 69345,
      "evidence known": 30202,
      "pathways oxycodone": 58528,
      "electrospray ionization": 28553,
      "ionization tandem": 40147,
      "corresponding oxycodone": 20847,
      "method quantification": 45207,
      "phase consisted": 61280,
      "useful management": 85207,
      "develop validate": 24159,
      "predict oxycodone": 63552,
      "used help": 84952,
      "patients complying": 59124,
      "studied 20": 77606,
      "black women": 13903,
      "weight 97": 86973,
      "32 kg": 3926,
      "regimen using": 69329,
      "pharmacokinetics measured": 61174,
      "measured oxycodone": 43985,
      "regimen patient": 69318,
      "10 90": 730,
      "normal patient": 49904,
      "testing routinely": 80841,
      "decreased sensitivity": 23039,
      "sensitivity oxycodone": 74561,
      "assay use": 11886,
      "use qualitative": 84676,
      "sensitivity specificity": 74563,
      "used new": 85029,
      "subsequently used": 78788,
      "absence oxycodone": 6589,
      "metabolite noroxycodone": 44954,
      "study establish": 78157,
      "value oxycodone": 85823,
      "population used": 62396,
      "oxycodone taking": 55985,
      "prescription month": 64262,
      "period sensitivity": 60789,
      "100 respectively": 1021,
      "compounds evaluated": 18609,
      "result using": 71497,
      "41 prescribed": 4430,
      "sensitive specific": 74549,
      "screening results": 74047,
      "analysis evaluate": 10680,
      "analysis examined": 10683,
      "lcms ms": 41274,
      "ml 95": 46845,
      "noroxycodone concentration": 49926,
      "98 ng": 6468,
      "relationship exists": 69716,
      "concentrations lower": 18771,
      "possible explanations": 62537,
      "used qualitative": 85093,
      "rates similar": 67636,
      "physicochemical properties": 61454,
      "lead important": 41291,
      "evaluated oxycodone": 29903,
      "quantification method": 66773,
      "oxymorphone low": 56256,
      "10 pg": 898,
      "reference standard": 69143,
      "non negligible": 49644,
      "applied analysis": 11432,
      "human plasma": 35968,
      "min respectively": 46547,
      "ml noroxycodone": 46884,
      "assess pharmacokinetics": 11951,
      "employed assess": 28740,
      "liver cytosol": 42174,
      "liver s9": 42186,
      "differences data": 24729,
      "data document": 21949,
      "aqueous solution": 11617,
      "oxycodone peak": 55666,
      "decreased rates": 23033,
      "free oxycodone": 32490,
      "oxycodone 50": 54578,
      "metabolites oxymorphone": 44980,
      "oxycodone glucuronide": 55118,
      "ml identified": 46864,
      "ms analysis": 48078,
      "results codeine": 71627,
      "subsequently tested": 78787,
      "rate hospital": 67472,
      "offers good": 50961,
      "better choice": 13707,
      "screened positive": 74033,
      "drug screening": 26784,
      "regimen opioid": 69316,
      "subjects groups": 78701,
      "day performed": 22366,
      "performed receiver": 60618,
      "characteristic roc": 15844,
      "distribution data": 25558,
      "methods groups": 45343,
      "members groups": 44780,
      "groups calculated": 34140,
      "roc curves": 72716,
      "rates different": 67572,
      "controlled conditions": 20472,
      "drug measurements": 26700,
      "range 80": 67298,
      "greater negative": 33461,
      "guidelines federal": 34441,
      "subjects followed": 78699,
      "min 30": 46508,
      "time 34": 81199,
      "facilitate interpretation": 31033,
      "concentrations plasma": 18804,
      "chromatography hplc": 16160,
      "range 100": 67249,
      "ranging 15": 67356,
      "poor quality": 62273,
      "quantity purpose": 66843,
      "25 ng": 3371,
      "ml 30": 46835,
      "blood ratio": 14148,
      "12 26": 1243,
      "26 disparities": 3443,
      "blood oxycodone": 14133,
      "management patient": 43232,
      "monitored using": 47314,
      "methods 48": 45236,
      "using lc": 85455,
      "assay showed": 11885,
      "values obtained": 85848,
      "direct injection": 25048,
      "10 microl": 857,
      "equal volume": 29235,
      "oxymorphone rat": 56283,
      "content oxycodone": 20100,
      "methods utilized": 45626,
      "ammonium acetate": 9830,
      "assayed using": 11890,
      "using fast": 85395,
      "present urine": 64675,
      "positive pressure": 62480,
      "identified quantified": 36459,
      "correlation coefficients": 20827,
      "oxymorphone respectively": 56284,
      "narcotic drug": 48595,
      "evaluate patient": 29826,
      "compliance set": 18538,
      "developed validated": 24199,
      "oxymorphone methods": 56261,
      "methods extraction": 45338,
      "obtained simple": 50783,
      "chromatographic separation": 16148,
      "separation achieved": 74597,
      "mean absolute": 43672,
      "06 15": 577,
      "15 ng": 1776,
      "feasibility clinical": 31283,
      "provided excellent": 66137,
      "effective drug": 27618,
      "treatment range": 82795,
      "screening drug": 74044,
      "enzyme linked": 29101,
      "linked immunosorbent": 42052,
      "immunosorbent assay": 36785,
      "assay elisa": 11878,
      "drug time": 26815,
      "drugs simultaneously": 27076,
      "different drugs": 24865,
      "benzoylecgonine metabolite": 13675,
      "metabolite cocaine": 44943,
      "marijuana oxycodone": 43384,
      "50 studied": 4899,
      "limited effects": 41929,
      "validated using": 85794,
      "ms following": 48084,
      "initial screening": 38870,
      "collected using": 17489,
      "drugs present": 27043,
      "respectively percentage": 71232,
      "usa oxycodone": 84110,
      "causes severe": 15400,
      "reactions respiratory": 67970,
      "adjust dosage": 8013,
      "oxy using": 54467,
      "using 100": 85286,
      "method using": 45221,
      "useful adjust": 85197,
      "avoid adverse": 12958,
      "time flight": 81264,
      "flight mass": 31922,
      "active ingredients": 7514,
      "intact formulations": 39170,
      "25 18": 3325,
      "morphine opiates": 47792,
      "oxycodone negative": 55531,
      "75 000": 5690,
      "hydromorphone 12": 36150,
      "study sensitivity": 78482,
      "oxidative metabolites": 54397,
      "13 20": 1458,
      "ml 200": 46831,
      "performance determined": 60550,
      "control samples": 20415,
      "provide good": 66065,
      "administration male": 8293,
      "female sprague": 31376,
      "oxycodone oxidative": 55593,
      "single bolus": 76057,
      "mean sem": 43876,
      "clearance intravenous": 16715,
      "concentration versus": 18730,
      "fold 01": 31983,
      "low respectively": 42550,
      "finding consistent": 31760,
      "metabolism noroxycodone": 44933,
      "auc ratios": 12638,
      "approximately 12": 11559,
      "ratios greater": 67823,
      "greater male": 33456,
      "female compared": 31357,
      "compared male": 18198,
      "exposure metabolically": 30777,
      "metabolically derived": 44914,
      "noroxycodone higher": 49931,
      "sd rat": 74092,
      "opiates codeine": 51322,
      "delivered directly": 23207,
      "small volumes": 76309,
      "sample matrix": 73307,
      "metabolites including": 44969,
      "opioids carry": 52768,
      "related compounds": 69575,
      "extraction oxycodone": 30966,
      "consistently high": 19722,
      "methods assess": 45256,
      "patient basis": 58545,
      "procedures drug": 65301,
      "levels oral": 41585,
      "established pharmacokinetic": 29592,
      "state concentration": 77036,
      "state plasma": 77060,
      "quantitatively analyzed": 66815,
      "analyzed liquid": 10837,
      "converted equivalent": 20726,
      "range oral": 67328,
      "concentrations compared": 18753,
      "results high": 71711,
      "paired samples": 58023,
      "knowledge pain": 40889,
      "risk assessment": 72521,
      "oxycodone steady": 55936,
      "state background": 77035,
      "patient treatment": 58802,
      "drug excretion": 26625,
      "identifying patients": 36544,
      "metabolism drugs": 44930,
      "analytical method": 10801,
      "used human": 84957,
      "05 10": 475,
      "highest concentrations": 35342,
      "concentration tmax": 18729,
      "15 56": 1705,
      "56 \u03bcg": 5113,
      "12 \u03bcg": 1394,
      "ml 14": 46827,
      "14 67": 1572,
      "better comprehend": 13709,
      "hair specimens": 34508,
      "fentanyl opiates": 31537,
      "tramadol propoxyphene": 82106,
      "200 pg": 2409,
      "mg fentanyl": 45891,
      "strong analgesic": 77509,
      "effects widely": 28195,
      "pain interpretation": 56967,
      "concentrations postmortem": 18805,
      "postmortem cases": 62674,
      "concentrations fatal": 18762,
      "levels study": 41612,
      "define reference": 23116,
      "intoxications non": 39711,
      "non intoxications": 49618,
      "displayed high": 25474,
      "analyzed concentrations": 10824,
      "13 \u03bcg": 1514,
      "concentration cases": 18682,
      "use specific": 84742,
      "effects addition": 27807,
      "opioids federal": 52907,
      "study characterized": 77987,
      "oral 20": 53480,
      "spectrometry limit": 76668,
      "19 mean": 2184,
      "concentration 50": 18673,
      "provide information": 66074,
      "selection appropriate": 74404,
      "appropriate test": 11516,
      "samples gas": 73344,
      "samples included": 73348,
      "samples needed": 73349,
      "sample addition": 73290,
      "ml 12": 46826,
      "oxycodone determination": 54952,
      "frequently seen": 32580,
      "oxycodone weekly": 56090,
      "buprenorphine patient": 14581,
      "oxycodone period": 55670,
      "taking morphine": 80309,
      "morphine taking": 47950,
      "aware high": 12982,
      "objective use": 50533,
      "reviewed results": 72391,
      "lysergic acid": 42780,
      "acid diethylamide": 7342,
      "prescribed abused": 63812,
      "oxycodone warranted": 56087,
      "concentrations drugs": 18758,
      "evaluate relative": 29841,
      "implement new": 36924,
      "dried urine": 26457,
      "according international": 7049,
      "international guidelines": 39481,
      "significant advantages": 75422,
      "low volumes": 42565,
      "including neonates": 37646,
      "negatively impacted": 49088,
      "rapid drug": 67379,
      "difficulty obtaining": 24974,
      "coupled high": 20974,
      "represents potential": 70771,
      "potential solution": 63231,
      "high sensitivity": 35181,
      "sample volumes": 73320,
      "respectively using": 71258,
      "potential pharmacokinetic": 63205,
      "chromatography electrospray": 16157,
      "opioid analogues": 51535,
      "mm column": 46933,
      "necessary develop": 48881,
      "spectrometry hplc": 76662,
      "range 300": 67282,
      "day relative": 22403,
      "method capable": 45173,
      "parent compound": 58191,
      "morphine acetylmorphine": 47571,
      "stainless steel": 76877,
      "able produce": 6573,
      "opiates routine": 51339,
      "analysis opiates": 10717,
      "testing udt": 80845,
      "limitations including": 41903,
      "using automated": 85315,
      "plasma using": 61963,
      "removal plasma": 70332,
      "analyzed single": 10858,
      "management introduction": 43193,
      "negative urine": 49083,
      "method simultaneous": 45213,
      "compared house": 18178,
      "compared 13": 18066,
      "compared serum": 18304,
      "commonly performed": 17858,
      "percent samples": 60491,
      "amphetamine methamphetamine": 9847,
      "methamphetamine methylenedioxy": 45146,
      "methylenedioxy methamphetamine": 45653,
      "methamphetamine 14": 45138,
      "results retrospective": 71925,
      "use adults": 84179,
      "use young": 84816,
      "higher national": 35269,
      "specific liquid": 76596,
      "stable plasma": 76849,
      "hours lower": 35792,
      "routinely seen": 72872,
      "patients united": 60158,
      "defined presence": 23152,
      "visits visits": 86297,
      "higher percent": 35295,
      "buprenorphine 89": 14516,
      "89 percent": 6062,
      "69 percent": 5525,
      "fentanyl 95": 31428,
      "90 percent": 6115,
      "96 percent": 6425,
      "93 percent": 6177,
      "morphine 92": 47569,
      "87 percent": 6026,
      "medications higher": 44624,
      "improve patients": 37077,
      "develop model": 24149,
      "medication prescription": 44542,
      "setting pain": 74797,
      "participants seven": 58369,
      "levels reported": 41603,
      "abstracted electronic": 6629,
      "measures adherence": 44038,
      "using objective": 85534,
      "addictive disorders": 7782,
      "considerable variability": 19615,
      "prescribed dose": 63853,
      "contributed significantly": 20234,
      "predictive models": 63575,
      "suggest model": 78999,
      "model provide": 47076,
      "levels clinical": 41549,
      "useful assessing": 85202,
      "blind clinical": 13922,
      "underwent standard": 83697,
      "abused opiate": 6918,
      "opiate oxycodone": 51305,
      "technology reduce": 80556,
      "setting background": 74771,
      "characterized study": 15914,
      "evaluation treatment": 29969,
      "reported prescriptions": 70631,
      "comparable higher": 17958,
      "cocaine 15": 17134,
      "specific drugs": 76587,
      "drugs medications": 26994,
      "certain clinical": 15651,
      "relative differences": 69744,
      "testing opioid": 80827,
      "increasingly associated": 38132,
      "associated overdose": 12367,
      "developed oxycodone": 24190,
      "12 matrices": 1317,
      "oxycodone 75": 54599,
      "18 analytes": 2080,
      "kg mean": 40758,
      "mean concentrations": 43735,
      "17 oxycodone": 1979,
      "incubated hlm": 38151,
      "panel recombinant": 58066,
      "recombinant human": 68578,
      "human cytochrome": 35948,
      "cytochrome p450s": 21664,
      "noroxycodone cyp2d6": 49928,
      "oxymorphone results": 56285,
      "vitro metabolism": 86363,
      "drug identification": 26648,
      "positive opiates": 62472,
      "ph respectively": 61001,
      "using ph": 85556,
      "respectively samples": 71243,
      "metabolites potential": 44985,
      "investigating drug": 40064,
      "detection limits": 23958,
      "pharmaceutical formulation": 61025,
      "49 times": 4780,
      "ppm results": 63300,
      "conditions average": 19311,
      "size 23": 76180,
      "value times": 85826,
      "data acquisition": 21864,
      "presence drug": 64588,
      "sensitive methods": 74547,
      "evaluated frequency": 29886,
      "additional opiates": 7871,
      "results medication": 71776,
      "05 35": 484,
      "calculated ratio": 14700,
      "opioids determine": 52846,
      "reported patient": 70619,
      "medications listed": 44639,
      "test findings": 80771,
      "results examined": 71689,
      "presence drugs": 64589,
      "prevalent patient": 64834,
      "assay using": 11888,
      "deuterated analogues": 24140,
      "glucuronide oxycodone": 33253,
      "novel synthetic": 50023,
      "years drugs": 87587,
      "abuse increasing": 6738,
      "new compounds": 49316,
      "compounds include": 18613,
      "ready availability": 67994,
      "drugs like": 26989,
      "using synthetic": 85632,
      "synthetic fentanyl": 79950,
      "method able": 45164,
      "able detect": 6569,
      "method includes": 45183,
      "metabolite fentanyl": 44947,
      "common method": 17769,
      "analgesic metabolized": 10273,
      "use majority": 84465,
      "detectable oxycodone": 23933,
      "women compared": 87209,
      "compared men": 18203,
      "age 49": 9014,
      "cyp2d6 inhibitor": 21609,
      "inhibition cyp2d6": 38779,
      "patient factors": 58638,
      "suggest increased": 78996,
      "eastern central": 27284,
      "using red": 85594,
      "phenanthrene type": 61334,
      "conventional opioid": 20696,
      "described report": 23658,
      "using commercially": 85348,
      "available enzyme": 12800,
      "produced greater": 65386,
      "directed oxycodone": 25054,
      "patient responses": 58748,
      "source variability": 76502,
      "differences absorption": 24707,
      "absorption metabolism": 6611,
      "unmet need": 83906,
      "quantify opioids": 66786,
      "results method": 71780,
      "15 lower": 1746,
      "samples prepared": 73359,
      "prepared using": 63789,
      "blood ranged": 14147,
      "able accurately": 6562,
      "number commonly": 50148,
      "opioids major": 53034,
      "metabolites plasma": 44984,
      "blood collected": 14113,
      "misuse major": 46725,
      "major concern": 42936,
      "procedures detecting": 65300,
      "monitoring drugs": 47322,
      "low sample": 42554,
      "reaction times": 67950,
      "despite progress": 23897,
      "clinical diagnostic": 16790,
      "opioids recent": 53240,
      "discussed background": 25289,
      "reduce associated": 68834,
      "vs 100": 86524,
      "vs 84": 86625,
      "vs 73": 86615,
      "83 vs": 5939,
      "100 vs": 1023,
      "opiates cocaine": 51321,
      "negative drug": 49070,
      "caution especially": 15413,
      "acetylmorphine acetylcodeine": 7280,
      "acetylcodeine oxycodone": 7276,
      "used codeine": 84884,
      "methodology applied": 45230,
      "forensic sciences": 32264,
      "different strategies": 24923,
      "mixture compounds": 46810,
      "high resolution": 35164,
      "resolution mass": 71111,
      "technique used": 80546,
      "used low": 84990,
      "chemical properties": 15951,
      "analyzed real": 10853,
      "ms addition": 48077,
      "opportunity evaluate": 53406,
      "evaluate prevalence": 29836,
      "codeine norcodeine": 17262,
      "approximately thirds": 11588,
      "varied 34": 85932,
      "substantial number": 78853,
      "identified contained": 36433,
      "screening assays": 74041,
      "specific oxycodone": 76609,
      "frequently encountered": 32550,
      "office chief": 50968,
      "chief medical": 16005,
      "development validation": 24256,
      "case samples": 15200,
      "target compounds": 80485,
      "use united": 84788,
      "ml 11": 46825,
      "ml 50": 46840,
      "opioids blood": 52752,
      "blood using": 14160,
      "concerns observed": 18844,
      "work presented": 87282,
      "controlled using": 20650,
      "monoclonal antibodies": 47366,
      "antibodies mabs": 11148,
      "urinary metabolite": 84056,
      "metabolite heroin": 44948,
      "effective concentrations": 27606,
      "opiates heroin": 51325,
      "heroin metabolites": 35012,
      "comparison using": 18383,
      "good agreement": 33292,
      "agreement single": 9351,
      "abuse pregnancy": 6834,
      "risk neonatal": 72601,
      "population opioid": 62364,
      "2007 january": 2492,
      "17 respectively": 1985,
      "61 95": 5309,
      "result oxycodone": 71485,
      "cocaine oxycodone": 17160,
      "fatty acid": 31254,
      "correlation maternal": 20829,
      "ranged 10": 67340,
      "monoacetylmorphine mam": 47359,
      "blood serum": 14158,
      "emerging drug": 28711,
      "chromatography time": 16175,
      "33 drugs": 3993,
      "technique called": 80544,
      "additional analysis": 7843,
      "300 100": 3809,
      "determined lc": 24068,
      "determine sensitivity": 24051,
      "opioids concentration": 52810,
      "showed poor": 75289,
      "values determined": 85840,
      "ml 90": 46844,
      "showing minimal": 75325,
      "clinical environment": 16809,
      "non targeted": 49692,
      "screening method": 74045,
      "multiple classes": 48265,
      "order investigate": 53715,
      "investigate issue": 40017,
      "glucuronide codeine": 33249,
      "codeine glucuronide": 17237,
      "hydromorphone glucuronide": 36173,
      "previously analyzed": 64933,
      "relevant concentration": 70049,
      "provides cost": 66208,
      "labeled drug": 41010,
      "competitive binding": 18413,
      "cocaine metabolite": 17151,
      "maintained study": 42895,
      "rapid reliable": 67396,
      "developed implemented": 24178,
      "cases presented": 15257,
      "presence high": 64593,
      "trial results": 83084,
      "cases 95": 15221,
      "needed additional": 48972,
      "demonstrated high": 23342,
      "drugs blood": 26896,
      "lc separation": 41272,
      "metabolites morphine": 44973,
      "methadone cocaine": 45055,
      "methamphetamine methylenedioxymethamphetamine": 45149,
      "min day": 46516,
      "glucuronide metabolites": 33252,
      "metabolite noroxymorphone": 44955,
      "using 50": 85297,
      "patients provides": 59718,
      "regarding patient": 69268,
      "synthetic opiates": 79951,
      "drug provides": 26752,
      "26 36": 3431,
      "22 31": 3019,
      "31 respectively": 3879,
      "opiate drug": 51297,
      "22 21": 3015,
      "rates 20": 67546,
      "17 26": 1942,
      "respectively drug": 71190,
      "rates years": 67648,
      "78 oxycodone": 5782,
      "04 respectively": 455,
      "2012 increased": 2602,
      "increased 44": 37857,
      "previous year": 64931,
      "2012 rates": 2611,
      "significant abuse": 75419,
      "drugs oral": 27021,
      "toxicological investigation": 81943,
      "influence drug": 38590,
      "duid cases": 27117,
      "programs method": 65556,
      "included 30": 37392,
      "30 drugs": 3735,
      "tetrahydrocannabinol amphetamine": 80876,
      "cocaine benzoylecgonine": 17141,
      "oxazepam temazepam": 54385,
      "ii drug": 36558,
      "followed lc": 32064,
      "2019 standard": 2884,
      "drug method": 26711,
      "minor metabolic": 46626,
      "conversion codeine": 20707,
      "setting 13": 74760,
      "13 pain": 1500,
      "chronically treated": 16360,
      "hydromorphone reporting": 36222,
      "morphine treated": 47960,
      "amounts ranging": 9839,
      "high 10": 35064,
      "tended lower": 80598,
      "patients comparison": 59104,
      "metabolite morphine": 44953,
      "restricted settings": 71459,
      "medical reasons": 44391,
      "confirmation procedures": 19497,
      "used medical": 85004,
      "oxymorphone codeine": 56229,
      "clinical circumstances": 16770,
      "knowledge previous": 40892,
      "report examines": 70458,
      "glucuronide conjugates": 33250,
      "methods effective": 45323,
      "including significant": 37673,
      "hydromorphone codeine": 36164,
      "catalyzed reaction": 15283,
      "enzyme cyp2d6": 29100,
      "process using": 65342,
      "spectrometry hrms": 76664,
      "postmortem drug": 62677,
      "quantification performed": 66776,
      "evaluated additional": 29858,
      "analytical range": 10804,
      "showed comparable": 75234,
      "noroxymorphone oxymorphone": 49951,
      "did exceed": 24449,
      "analyte concentrations": 10796,
      "dosing study": 26334,
      "study male": 78297,
      "ingestion oxycodone": 38745,
      "max values": 43563,
      "12 ng": 1343,
      "metabolites minor": 44972,
      "attributed oxycodone": 12612,
      "depending individual": 23549,
      "naltrexone administration": 48538,
      "seven opioid": 74867,
      "oxymorphone detected": 56233,
      "detected postmortem": 23947,
      "25 mm": 3369,
      "time 14": 81192,
      "000 overdose": 33,
      "abuse synthetic": 6891,
      "measured directly": 43964,
      "respectively analysis": 71169,
      "\u00b5g ml": 87775,
      "tablets analyzed": 80125,
      "sampling analysis": 73370,
      "view use": 86223,
      "testing performed": 80831,
      "using fda": 85396,
      "opioid 10": 51349,
      "method measured": 45188,
      "range 50": 67291,
      "50 100": 4800,
      "morphine metabolite": 47753,
      "88 20": 6038,
      "metabolite hydrocodone": 44950,
      "10 hydromorphone": 773,
      "95 oxycodone": 6404,
      "provide guidelines": 66068,
      "levels typically": 41615,
      "drug specific": 26793,
      "rate 06": 67423,
      "oxycodone 74": 54598,
      "cocaine morphine": 17155,
      "rate heroin": 67470,
      "low number": 42506,
      "civilian population": 16605,
      "analysis compounds": 10658,
      "significant intensity": 75569,
      "study concluded": 78020,
      "groups order": 34250,
      "achieving satisfactory": 7337,
      "approach resulted": 11477,
      "program screened": 65545,
      "concentration 10": 18667,
      "concentrations ranging": 18809,
      "ranging 16": 67357,
      "61 000": 5304,
      "000 codeine": 19,
      "codeine 60": 17207,
      "hydromorphone 10": 36147,
      "produced high": 65387,
      "useful tool": 85214,
      "potential users": 63245,
      "drugs extracted": 26957,
      "75 ng": 5713,
      "opiates synthetic": 51340,
      "40 \u03bcg": 4388,
      "procedure overall": 65277,
      "using 20": 85294,
      "10 16": 675,
      "demethylated metabolites": 23258,
      "morphine respectively": 47918,
      "fragmentation patterns": 32470,
      "compounds oral": 18616,
      "specific mass": 76600,
      "introduction analysis": 39924,
      "analysis pediatric": 10729,
      "various xenobiotics": 85985,
      "cocaine opiates": 17158,
      "using single": 85615,
      "methamphetamine mda": 45142,
      "mda mdma": 43641,
      "mdma cocaine": 43645,
      "methadone codeine": 45056,
      "mdma morphine": 43648,
      "especially useful": 29565,
      "impaired driving": 36872,
      "analytical results": 10805,
      "decreases plasma": 23065,
      "day approximately": 22270,
      "27 lower": 3494,
      "lower fentanyl": 42619,
      "antidepressants drugs": 11177,
      "analysis sample": 10760,
      "sample collected": 73297,
      "used survey": 85152,
      "survey research": 79730,
      "use nonmedical": 84519,
      "nonmedical prescription": 49776,
      "drugs participants": 27030,
      "able confirm": 6565,
      "reported cocaine": 70521,
      "use marijuana": 84467,
      "use cocaine": 84242,
      "testing increased": 80823,
      "non reported": 49676,
      "oxycodone ranging": 55795,
      "14 22": 1564,
      "22 conclusions": 3032,
      "select drugs": 74383,
      "fetal exposure": 31620,
      "infants mothers": 38507,
      "drugs amphetamine": 26882,
      "methamphetamine methylenedioxyamphetamine": 45148,
      "different compounds": 24854,
      "opioids 48": 52679,
      "drug withdrawal": 26863,
      "47 600": 4650,
      "deaths reported": 22779,
      "reported associated": 70507,
      "prescription painkillers": 64380,
      "heroin synthetic": 35035,
      "accidental overdoses": 7018,
      "calls involving": 14736,
      "study addressed": 77909,
      "following vivo": 32221,
      "vivo exposure": 86379,
      "background increased": 13065,
      "led greater": 41338,
      "oral fluids": 53537,
      "established methods": 29588,
      "cocaine amphetamine": 17138,
      "testing potential": 80833,
      "potential limitations": 63182,
      "oxycodone methylenedioxymethamphetamine": 55405,
      "methylenedioxymethamphetamine ecstasy": 45657,
      "performed drug": 60587,
      "challenges conclusions": 15703,
      "conclusions survey": 19230,
      "survey results": 79734,
      "patterns drug": 60203,
      "opioids lower": 53029,
      "fentanyl furanyl": 31481,
      "opioids serum": 53291,
      "tof ms": 81511,
      "pharmaceutical preparations": 61042,
      "laboratory setting": 41031,
      "mixtures oxycodone": 46817,
      "available cases": 12793,
      "cocaine opiate": 17157,
      "negative controls": 49068,
      "positive cocaine": 62456,
      "benzoylecgonine morphine": 13677,
      "vitreous urine": 86352,
      "authors recommend": 12745,
      "concentrations individual": 18769,
      "compounds exhibited": 18610,
      "phencyclidine pcp": 61337,
      "common mechanism": 17767,
      "endogenous exogenous": 28846,
      "abuse tested": 6892,
      "including diazepam": 37609,
      "overall present": 54234,
      "specific assay": 76582,
      "tested morphine": 80809,
      "assess possibility": 11952,
      "metabolism morphine": 44932,
      "ml 36": 46836,
      "ml results": 46898,
      "earlier work": 27246,
      "oxycodone free": 55106,
      "free morphine": 32489,
      "effects concentrations": 27873,
      "concentrations analytes": 18744,
      "concentration differences": 18694,
      "differences blood": 24721,
      "evaluated selected": 29922,
      "study sum": 78522,
      "biological samples": 13853,
      "qualitative quantitative": 66666,
      "including alprazolam": 37592,
      "hydroxybutyric acid": 36245,
      "screening study": 74048,
      "study illustrates": 78241,
      "similar purpose": 75985,
      "cases submitted": 15267,
      "75 85": 5700,
      "method employed": 45179,
      "75 opioid": 5717,
      "confirmed cases": 19503,
      "acetylmorphine detected": 7282,
      "primarily gas": 64975,
      "assay improved": 11880,
      "period studied": 60794,
      "methods performing": 45460,
      "validation study": 85801,
      "used device": 84914,
      "codeine patient": 17275,
      "contained codeine": 20063,
      "ml 24": 46832,
      "20 50": 2299,
      "prescription codeine": 64179,
      "use control": 84273,
      "evaluated data": 29872,
      "naloxone hydromorphone": 48454,
      "levorphanol oxycodone": 41629,
      "oxycodone state": 55933,
      "demonstrated lack": 23350,
      "analysis drugs": 10676,
      "used variety": 85187,
      "influence drugs": 38591,
      "drugs duid": 26947,
      "blood ph": 14140,
      "examples include": 30431,
      "benzodiazepines barbiturates": 13656,
      "low volume": 42564,
      "methods sensitive": 45570,
      "compare efficiency": 18027,
      "opioids tested": 53336,
      "enzyme source": 29109,
      "method choice": 45174,
      "guidelines physicians": 34461,
      "synthetic semisynthetic": 79964,
      "required specifically": 70865,
      "meperidine normeperidine": 44845,
      "normeperidine methadone": 49922,
      "propoxyphene norpropoxyphene": 65805,
      "tramadol desmethyltramadol": 82053,
      "naloxone naloxone": 48465,
      "naloxone glucuronide": 48452,
      "exposure demonstrated": 30758,
      "2005 2007": 2459,
      "cocaine cannabinoids": 17144,
      "benzodiazepines methadone": 13665,
      "abuse significantly": 6877,
      "ratio 26": 67722,
      "demonstrated effective": 23336,
      "identify phase": 36520,
      "developed analysis": 24169,
      "48 mg": 4735,
      "led identification": 41339,
      "previously unknown": 64962,
      "clinical testing": 16920,
      "quantitative method": 66800,
      "norhydrocodone oxycodone": 49895,
      "cocaine coc": 17145,
      "wastewater concentrations": 86752,
      "transformation products": 82188,
      "abuse wastewater": 6912,
      "analysis low": 10705,
      "using manual": 85479,
      "sufentanil opioid": 78947,
      "oxycodone pentazocine": 55667,
      "ms samples": 48094,
      "performed based": 60572,
      "included assessment": 37428,
      "quantification opioid": 66774,
      "low therapeutic": 42560,
      "drugs prior": 27046,
      "anhydroecgonine methyl": 10984,
      "smoking ingestion": 76339,
      "cocaine drugs": 17147,
      "abuse identified": 6732,
      "ecgonine methyl": 27301,
      "drugs single": 27077,
      "biological specimens": 13854,
      "hydromorphone monoacetylmorphine": 36192,
      "use indicated": 84430,
      "method incorporates": 45184,
      "ranged 78": 67349,
      "investigate potential": 40023,
      "time monitoring": 81295,
      "dosages mg": 25766,
      "ml detected": 46855,
      "approach capable": 11455,
      "monitoring drug": 47321,
      "delivery pain": 23226,
      "therapy mainstay": 81024,
      "use blood": 84224,
      "spectrometry assay": 76657,
      "10 major": 779,
      "method single": 45216,
      "metabolites opiates": 44978,
      "hydrocodone oral": 36110,
      "road safety": 72699,
      "safety victoria": 73240,
      "acetylmorphine methadone": 7283,
      "ketamine detected": 40608,
      "detected cases": 23938,
      "analysis patient": 10726,
      "traditional approach": 81982,
      "various modes": 85971,
      "techniques including": 80548,
      "techniques using": 80551,
      "cases seventy": 15262,
      "opiates benzodiazepines": 51320,
      "acetylmorphine morphine": 7284,
      "difference response": 24679,
      "screening approach": 74039,
      "umbilical cord": 83440,
      "cord tissue": 20770,
      "report incidence": 70461,
      "2015 october": 2714,
      "october 2016": 50884,
      "2016 september": 2761,
      "numbers drugs": 50280,
      "25 20": 3327,
      "exposure infants": 30769,
      "interventions curb": 39658,
      "single exposure": 76102,
      "drug ingestion": 26655,
      "drug facilitated": 26631,
      "oxycodone promethazine": 55778,
      "reported time": 70667,
      "results background": 71610,
      "cutoffs established": 21540,
      "data determined": 21944,
      "determined liquid": 24071,
      "analysis calculate": 10645,
      "methods methods": 45382,
      "highest lowest": 35353,
      "lowest value": 42738,
      "established using": 29596,
      "97 percent": 6446,
      "codeine lower": 17250,
      "representative population": 70758,
      "medication compliance": 44472,
      "intravenous delivery": 39821,
      "varying concentrations": 85993,
      "therapeutic drugs": 80934,
      "results commonly": 71634,
      "including illicit": 37624,
      "potential applications": 63134,
      "treatment setting": 82834,
      "support clinical": 79188,
      "observations shown": 50638,
      "determine specific": 24052,
      "morphine present": 47887,
      "prescribed illicit": 63871,
      "discuss principles": 25285,
      "toxicology results": 81954,
      "common benzodiazepines": 17735,
      "toxicology cases": 81948,
      "adequate information": 7960,
      "medical providers": 44389,
      "overdoses drug": 54327,
      "phase liquid": 61305,
      "hydromorphone 02": 36145,
      "extent drug": 30924,
      "analytical methods": 10802,
      "methods allow": 45246,
      "screening confirmation": 74042,
      "drugs cocaine": 26910,
      "using chemical": 85335,
      "misuse drugs": 46719,
      "analysis observed": 10716,
      "management clinics": 43168,
      "used groups": 84948,
      "groups prescribed": 34276,
      "higher subjects": 35329,
      "prescription versus": 64419,
      "versus prescribed": 86156,
      "marijuana cocaine": 43383,
      "excess sedation": 30456,
      "leading respiratory": 41313,
      "volume number": 86399,
      "number drugs": 50159,
      "evaluated oral": 29902,
      "groups follows": 34201,
      "11 study": 1153,
      "used illicit": 84966,
      "drugs cannabis": 26900,
      "option use": 53466,
      "achieve sufficient": 7308,
      "ranged 25": 67345,
      "drug exposed": 26626,
      "coupled electrospray": 20971,
      "morphine glucuronides": 47703,
      "data required": 22093,
      "patients compliance": 59121,
      "simple powerful": 76020,
      "methadone heroin": 45079,
      "assay fentanyl": 11879,
      "slightly better": 76250,
      "findings blood": 31772,
      "number compounds": 50149,
      "respectively similar": 71249,
      "06 vs": 590,
      "01 respectively": 324,
      "suggesting higher": 79027,
      "blood observed": 14131,
      "observed significant": 50717,
      "unused opioid": 83960,
      "drug potency": 26743,
      "cell membrane": 15483,
      "tramadol drugs": 82058,
      "categories based": 15296,
      "100 nm": 1007,
      "alfentanil methadone": 9561,
      "drugs support": 27087,
      "paucity literature": 60237,
      "disposition drugs": 25499,
      "cases identified": 15240,
      "majority decedents": 42984,
      "individuals ages": 38334,
      "death drug": 22707,
      "prevalent drugs": 64828,
      "detected blood": 23936,
      "included antidepressants": 37424,
      "higher blood": 35209,
      "methods forensic": 45342,
      "parameters include": 58159,
      "reference material": 69138,
      "alprazolam cocaine": 9676,
      "based recovery": 13372,
      "factors evaluated": 31093,
      "parameters maximum": 58164,
      "risk based": 72523,
      "pregnancy methods": 63691,
      "analyzed national": 10845,
      "clinical care": 16762,
      "based institutional": 13329,
      "performed study": 60634,
      "previous institutional": 64903,
      "institutional data": 39092,
      "factors clinical": 31083,
      "institution state": 39086,
      "population identified": 62339,
      "patients dependent": 59177,
      "day buprenorphine": 22274,
      "analyzed total": 10860,
      "drug ratios": 26754,
      "33 15": 3978,
      "drug ratio": 26753,
      "07 23": 601,
      "methadone piritramide": 45120,
      "developed fully": 24176,
      "samples patients": 73354,
      "analyses gave": 10593,
      "attending physicians": 12558,
      "drug residues": 26775,
      "samples acetaminophen": 73327,
      "oxycodone ketamine": 55323,
      "synthetic cannabinoids": 79947,
      "using dna": 85382,
      "ct number": 21362,
      "profile examined": 65486,
      "interpretation blood": 39498,
      "left right": 41347,
      "decedents using": 22817,
      "vascular access": 86032,
      "collected time": 17488,
      "phencyclidine tricyclic": 61338,
      "central blood": 15580,
      "elisa results": 28620,
      "results 100": 71538,
      "drug targets": 26803,
      "novel study": 50022,
      "preliminary data": 63712,
      "concentrations drug": 18757,
      "assessing effectiveness": 12101,
      "use simple": 84735,
      "required validate": 70867,
      "ability achieve": 6549,
      "practices purpose": 63438,
      "application oral": 11427,
      "detect illicit": 23928,
      "population studied": 62389,
      "blood cell": 14111,
      "using corresponding": 85361,
      "standards method": 76992,
      "term stability": 80668,
      "compounds included": 18614,
      "included amphetamine": 37419,
      "various combinations": 85963,
      "gamma hydroxybutyrate": 32825,
      "peak area": 60302,
      "use automated": 84215,
      "differences control": 24726,
      "viability decrease": 86186,
      "synthesised characterised": 79943,
      "solutions using": 76449,
      "methods major": 45373,
      "target drugs": 80489,
      "optimized conditions": 53444,
      "86 respectively": 6010,
      "therapy methadone": 81025,
      "able rapidly": 6574,
      "propoxyphene blood": 65802,
      "39 100": 4260,
      "100 \u00b5g": 1027,
      "hrms analysis": 35899,
      "ms electrospray": 48082,
      "included morphine": 37487,
      "large particles": 41142,
      "ranged 13": 67342,
      "overall direct": 54194,
      "special concern": 76559,
      "sensitivity drug": 74559,
      "significant problem": 75605,
      "providing rapid": 66268,
      "including cocaine": 37599,
      "heroin amphetamine": 34986,
      "effect low": 27477,
      "attractive alternative": 12605,
      "solution problem": 76446,
      "increase concentrations": 37737,
      "parent compounds": 58192,
      "increase present": 37793,
      "method quantify": 45208,
      "known drug": 40906,
      "opioids independent": 52994,
      "mg samples": 46212,
      "mg relative": 46200,
      "average concentrations": 12879,
      "alcohol withdrawal": 9547,
      "metabolites analyzed": 44964,
      "methadone metabolite": 45099,
      "speciosa alkaloids": 76648,
      "tramadol abuse": 82031,
      "conclusion analysis": 18861,
      "spectrometry based": 76658,
      "safety association": 73125,
      "detected frequently": 23943,
      "fatally injured": 31249,
      "injured drivers": 38982,
      "effects body": 27839,
      "chewing smoking": 15983,
      "study analyzes": 77953,
      "samples 20": 73326,
      "23 54": 3082,
      "old 11": 50998,
      "45 female": 4585,
      "nervous depressants": 49139,
      "current methodology": 21447,
      "methodology analysis": 45229,
      "sub therapeutic": 78582,
      "samples data": 73341,
      "management regimens": 43256,
      "gained popularity": 32816,
      "popularity recent": 62293,
      "reliable results": 70087,
      "15 20": 1679,
      "benzoylecgonine hydrocodone": 13673,
      "10 different": 759,
      "approximately 60": 11574,
      "good correlation": 33302,
      "tests study": 80865,
      "cocaine opioid": 17159,
      "included hydrocodone": 37465,
      "alprazolam alpha": 9671,
      "alpha hydroxyalprazolam": 9666,
      "using mass": 85481,
      "20 37": 2286,
      "weeks observed": 86927,
      "increase 23": 37720,
      "changes 20": 15770,
      "stability study": 76828,
      "little published": 42166,
      "study review": 78471,
      "metabolite detected": 44946,
      "data identified": 21982,
      "identified reference": 36464,
      "metabolites identified": 44968,
      "present low": 64622,
      "low concentration": 42461,
      "differences prescribed": 24792,
      "fentanyl 12": 31413,
      "ranged 82": 67350,
      "quantification detection": 66771,
      "did interfere": 24459,
      "reduced approximately": 68911,
      "50 compared": 4830,
      "performed institutional": 60599,
      "testing ordered": 80828,
      "2012 august": 2595,
      "cases 21": 15217,
      "use identified": 84412,
      "10 cases": 744,
      "common compounds": 17745,
      "compounds detected": 18607,
      "tramadol tested": 82114,
      "identified cases": 36426,
      "cases significant": 15264,
      "rate detection": 67459,
      "medications specifically": 44679,
      "yielded similar": 87700,
      "type drugs": 83325,
      "assay allows": 11876,
      "using uplc": 85653,
      "ranged 02": 67339,
      "german society": 33131,
      "body fluids": 14193,
      "cord drug": 20766,
      "detected drug": 23942,
      "investigated retrospective": 40054,
      "data academic": 21860,
      "24 morphine": 3249,
      "21 57": 2956,
      "diagnosis acute": 24330,
      "compounds quantified": 18618,
      "assess severity": 11965,
      "drugs active": 26874,
      "electronically stored": 28549,
      "used months": 85012,
      "tested compounds": 80798,
      "range conclusion": 67306,
      "procedure allowed": 65268,
      "ethylidine dimethyl": 29708,
      "cation exchange": 15328,
      "minutes using": 46664,
      "internal external": 39460,
      "cocaine tramadol": 17162,
      "benzoylecgonine cocaine": 13672,
      "performed different": 60586,
      "resulted improved": 71507,
      "naloxone metabolites": 48458,
      "cause type": 15375,
      "analytical toxicology": 10806,
      "challenged 10": 15696,
      "use adult": 84178,
      "injury mechanism": 38989,
      "alcohol concentration": 9527,
      "concentration mg": 18704,
      "reviewed retrospectively": 72392,
      "oxycodone tested": 55991,
      "positive alcohol": 62448,
      "upper limb": 84006,
      "common injuries": 17762,
      "adults presenting": 8574,
      "criteria identify": 21198,
      "range drugs": 67312,
      "compound high": 18602,
      "cocaine mdma": 17150,
      "mdma methadone": 43647,
      "range established": 67315,
      "low level": 42492,
      "10 29": 701,
      "positive findings": 62465,
      "use samples": 84714,
      "validated analytical": 85783,
      "procedures including": 65308,
      "present 14": 64603,
      "methylenedioxy ethylamphetamine": 45652,
      "total concentration": 81787,
      "overall ranged": 54242,
      "11 compared": 1127,
      "median 41": 44192,
      "samples high": 73347,
      "ml 01": 46821,
      "methods objective": 45402,
      "mother newborn": 48007,
      "evidence drugs": 30186,
      "administered directly": 8121,
      "patterns observed": 60213,
      "patterns commonly": 60199,
      "conclusions interpretation": 19104,
      "patterns drugs": 60205,
      "use extent": 84368,
      "use frequency": 84375,
      "study considered": 78038,
      "terms selectivity": 80722,
      "determine optimal": 24031,
      "60 80": 5236,
      "priori defined": 65180,
      "defined 15": 23120,
      "provided valuable": 66167,
      "valuable information": 85815,
      "compared ability": 18091,
      "assigned random": 12172,
      "random numbers": 67002,
      "83 94": 5928,
      "45 drug": 4584,
      "group samples": 33994,
      "100 100": 981,
      "used quantitate": 85095,
      "population contained": 62322,
      "normal concentration": 49900,
      "desipramine imipramine": 23859,
      "urine concentration": 84068,
      "67 mg": 5477,
      "pump inhibitor": 66478,
      "18 36": 2047,
      "36 years": 4152,
      "54 004": 5037,
      "opioid lower": 51892,
      "age prescribed": 9105,
      "abuse non": 6784,
      "tramadol pethidine": 82100,
      "target opioids": 80491,
      "characterized using": 15915,
      "analysis addition": 10633,
      "15 50": 1703,
      "determination oas": 23981,
      "use occurring": 84534,
      "substances cocaine": 78825,
      "negatively affect": 49085,
      "substances patients": 78835,
      "provided urine": 66165,
      "centers 2013": 15565,
      "exposures buprenorphine": 30803,
      "nonprescribed substance": 49834,
      "did did": 24432,
      "150 000": 1806,
      "47 58": 4649,
      "years 46": 87540,
      "oxycodone positivity": 55705,
      "patients private": 59703,
      "relevance cross": 70031,
      "study patterns": 78377,
      "related patients": 69664,
      "heroin acetylmorphine": 34982,
      "challenging task": 15710,
      "task simple": 80519,
      "combined ultra": 17672,
      "apparent dissociation": 11379,
      "dissociation constant": 25524,
      "greatly reducing": 33515,
      "reducing heroin": 69015,
      "bound heroin": 14261,
      "tetanus toxoid": 80871,
      "toxoid tt": 81961,
      "50 inhibition": 4844,
      "inhibition concentration": 38777,
      "ic50 values": 36384,
      "similar trends": 76005,
      "induced antibodies": 38379,
      "antibodies bound": 11146,
      "oxycodone cocaine": 54793,
      "cocaine nicotine": 17156,
      "hapten design": 34572,
      "increased 2012": 37838,
      "deaths 2016": 22737,
      "substances illicit": 78831,
      "ranged 15": 67343,
      "17 meperidine": 1974,
      "11 tramadol": 1154,
      "drugs fentanyl": 26959,
      "methods including": 45359,
      "low medium high": 42499,
      "lean body mass": 41321,
      "present study highlights": 64660,
      "objective purpose retrospective": 50477,
      "purpose retrospective study": 66563,
      "prescription pain medications": 64378,
      "range oxycodone concentrations": 67331,
      "drug concentrations pain": 26562,
      "addiction overdose death": 7752,
      "oxycodone main metabolites": 55351,
      "relevant concentrations oxycodone": 70051,
      "increasing concentrations oxycodone": 38097,
      "ultra rapid metabolizers": 83424,
      "risk adverse events": 72516,
      "drug monitoring used": 26720,
      "pain patients opioid": 57351,
      "oxycodone concentrations 50": 54830,
      "ng ml 16": 49434,
      "ng ml hydrocodone": 49443,
      "ng ml values": 49458,
      "doses oxycodone oxycodone": 26242,
      "opioid analgesic used": 51473,
      "mobile phase composed": 47002,
      "10 mm ammonium": 869,
      "320 mg kg": 3944,
      "160 mg kg": 1906,
      "oxycodone use patients": 56054,
      "use patients moderate": 84614,
      "metabolic pathways oxycodone": 44910,
      "electrospray ionization tandem": 28554,
      "ionization tandem mass": 40148,
      "used study oxycodone": 85150,
      "oxycodone dosing regimens": 55007,
      "oxycodone dosing regimen": 55006,
      "purpose analysis evaluate": 66519,
      "ng ml 95": 49438,
      "ml 95 ci": 46846,
      "98 ng ml": 6469,
      "ng ml noroxycodone": 49449,
      "20 mg oral": 2344,
      "mg oral dose": 46081,
      "oral dose oxycodone": 53524,
      "dose oxycodone hydrochloride": 25991,
      "human liver cytosol": 35960,
      "oxycodone metabolites oxymorphone": 55391,
      "ng ml identified": 49444,
      "urine drug screening": 84073,
      "performed receiver operating": 60619,
      "operating characteristic roc": 51211,
      "dosage forms oxycodone": 25749,
      "study demonstrates time": 78061,
      "12 healthy subjects": 1285,
      "min 30 min": 46509,
      "oxycodone concentrations plasma": 54834,
      "liquid chromatography hplc": 42081,
      "following intravenous infusion": 32148,
      "25 ng ml": 3372,
      "ng ml 30": 49436,
      "blood oxycodone concentrations": 14134,
      "pain management patient": 57097,
      "oxycodone concentrations determined": 54831,
      "using lc ms": 85456,
      "concentrations 100 ng": 18738,
      "oxycodone metabolite oxymorphone": 55387,
      "oxycodone oxymorphone rat": 55624,
      "brain oxymorphone noroxycodone": 14356,
      "mm ammonium acetate": 46932,
      "oxycodone oxymorphone respectively": 55625,
      "therapeutic drug monitoring": 80933,
      "plasma urine samples": 61962,
      "chromatographic separation achieved": 16149,
      "15 ng ml": 1777,
      "enzyme linked immunosorbent": 29102,
      "linked immunosorbent assay": 42053,
      "immunosorbent assay elisa": 36786,
      "benzoylecgonine metabolite cocaine": 13676,
      "adverse reactions respiratory": 8849,
      "reactions respiratory depression": 67971,
      "useful adjust dosage": 85198,
      "time flight mass": 81265,
      "including codeine hydrocodone": 37601,
      "quality control samples": 66685,
      "oxidative metabolism oxycodone": 54396,
      "male female sprague": 43033,
      "female sprague dawley": 31377,
      "concentrations oxycodone oxidative": 18796,
      "oxycodone oxidative metabolites": 55594,
      "noroxycodone oxymorphone following": 49937,
      "plasma concentration versus": 61908,
      "concentration versus time": 18731,
      "versus time curves": 86161,
      "oral bioavailability oxycodone": 53499,
      "greater male female": 33457,
      "female compared male": 31358,
      "systemic exposure metabolically": 80025,
      "exposure metabolically derived": 30778,
      "oral administration oxycodone": 53489,
      "study pharmacodynamic effects": 78404,
      "structurally related compounds": 77583,
      "steady state concentration": 77304,
      "steady state plasma": 77307,
      "plasma oxycodone levels": 61949,
      "analyzed liquid chromatography": 10838,
      "knowledge pain management": 40890,
      "oxycodone steady state": 55937,
      "purpose study provide": 66588,
      "10 mg oc": 829,
      "analyzed using validated": 10873,
      "using validated method": 85658,
      "maximum concentration tmax": 43586,
      "including oxycodone tramadol": 37660,
      "strong analgesic effects": 77510,
      "concentrations postmortem cases": 18806,
      "intoxications non intoxications": 39712,
      "different causes death": 24850,
      "lower limit quantitation": 42639,
      "opioid abuse united": 51385,
      "adults administered single": 8539,
      "administered single oral": 8183,
      "20 mg dose": 2340,
      "mass spectrometry limit": 43467,
      "samples gas chromatography": 73345,
      "high dose morphine": 35086,
      "taking morphine taking": 80310,
      "morphine taking oxycodone": 47951,
      "lysergic acid diethylamide": 42781,
      "patients pain management": 59621,
      "oxycodone hydrocodone fentanyl": 55206,
      "small sample volumes": 76299,
      "liquid chromatography electrospray": 42079,
      "chromatography electrospray ionization": 16158,
      "oxycodone opioid agonist": 55564,
      "mass spectrometry hplc": 43462,
      "separation achieved using": 74598,
      "drug testing udt": 26811,
      "urine drug screen": 84072,
      "main metabolites oxymorphone": 42835,
      "metabolites oxymorphone noroxycodone": 44981,
      "oxymorphone noroxycodone noroxymorphone": 56266,
      "prescribed post operative": 63953,
      "pain management introduction": 57077,
      "oxycodone oxymorphone following": 55616,
      "retrospective study evaluate": 72170,
      "amphetamine methamphetamine methylenedioxy": 9850,
      "methamphetamine methylenedioxy methamphetamine": 45147,
      "drug use young": 26851,
      "use young adults": 84817,
      "sensitive specific liquid": 74550,
      "specific liquid chromatography": 76597,
      "48 hours lower": 4713,
      "pharmacokinetic studies patients": 61152,
      "oxycodone objective determine": 55548,
      "retrospective analysis conducted": 72108,
      "patients united states": 60159,
      "analyses used determine": 10619,
      "patients opioid prescription": 59587,
      "abstracted electronic medical": 6630,
      "oxycodone vs hydrocodone": 56085,
      "associated overdose deaths": 12368,
      "30 mg 70": 3753,
      "panel recombinant human": 58067,
      "human cytochrome p450s": 35949,
      "high drug concentrations": 35096,
      "treating pain patients": 82405,
      "using high performance": 85427,
      "morphine glucuronide oxycodone": 47702,
      "novel synthetic opioids": 50024,
      "recent years drugs": 68436,
      "synthetic opioids including": 79961,
      "opioids including fentanyl": 52977,
      "non medical opioid": 49629,
      "opioid analgesic metabolized": 51461,
      "oxycodone use majority": 56052,
      "older age group": 51035,
      "inhibition cyp2d6 cyp3a4": 38780,
      "using commercially available": 85349,
      "commercially available enzyme": 17716,
      "available enzyme linked": 12801,
      "opioids major metabolites": 53035,
      "major metabolites plasma": 42957,
      "opioids generally used": 52932,
      "fentanyl methadone morphine": 31525,
      "morphine acetylmorphine acetylcodeine": 47572,
      "acetylmorphine acetylcodeine oxycodone": 7281,
      "high resolution mass": 35165,
      "resolution mass spectrometry": 71112,
      "analyzed real time": 10854,
      "hydromorphone oxycodone noroxycodone": 36207,
      "assays revealed oxycodone": 11897,
      "office chief medical": 50969,
      "chief medical examiner": 16006,
      "use united states": 84789,
      "ng ml 11": 49433,
      "monoclonal antibodies mabs": 47367,
      "morphine opiates morphine": 47793,
      "urinary metabolite heroin": 84057,
      "metabolite heroin morphine": 44949,
      "concentration dependent manner": 18691,
      "showed good agreement": 75249,
      "good agreement single": 33293,
      "opioid abuse pregnancy": 51376,
      "61 95 confidence": 5311,
      "significant correlation maternal": 75453,
      "ms ms analysis": 48087,
      "determined lc ms": 24069,
      "flight mass spectrometry": 31923,
      "glucuronide oxycodone oxymorphone": 33254,
      "effective alternative conventional": 27587,
      "competitive binding assay": 18414,
      "relatively high concentrations": 69777,
      "analysis results significant": 10755,
      "included following drugs": 37458,
      "morphine oxycodone buprenorphine": 47809,
      "methamphetamine methylenedioxymethamphetamine mdma": 45150,
      "opioid metabolite oxycodone": 51930,
      "healthy subjects administered": 34845,
      "10 mg controlled": 804,
      "drug use interpretation": 26841,
      "goal study evaluate": 33280,
      "study approved institutional": 77956,
      "driving influence drug": 26470,
      "delta tetrahydrocannabinol amphetamine": 23245,
      "followed lc ms": 32065,
      "morphine treated patients": 47961,
      "hydromorphone oxymorphone codeine": 36212,
      "codeine dihydrocodeine hydrocodone": 17226,
      "liquid chromatography time": 42088,
      "chromatography time flight": 16176,
      "oxycodone hydrocodone oxymorphone": 55212,
      "mass spectrometry hrms": 43464,
      "oxycodone blood samples": 54752,
      "blood samples collected": 14152,
      "12 ng ml": 1344,
      "including fentanyl hydrocodone": 37620,
      "50 100 ng": 4803,
      "75 ng ml": 5714,
      "retrospective analysis data": 72109,
      "opiates synthetic opiates": 51341,
      "prescription pain relievers": 64379,
      "long term exposure": 42335,
      "amphetamine methamphetamine mda": 9848,
      "methamphetamine mda mdma": 45143,
      "mda mdma morphine": 43642,
      "use nonmedical prescription": 84520,
      "nonmedical prescription opioid": 49779,
      "self reported use": 74502,
      "drugs amphetamine methamphetamine": 26883,
      "oxycodone methadone tramadol": 55398,
      "opioids including prescription": 52982,
      "heroin synthetic opioids": 35036,
      "synthetic opioids fentanyl": 79960,
      "widely used drug": 87064,
      "oxycodone methylenedioxymethamphetamine ecstasy": 55406,
      "commonly abused drugs": 17828,
      "drugs oxycodone fentanyl": 27025,
      "fentanyl related compounds": 31584,
      "fentanyl furanyl fentanyl": 31482,
      "illicit drug market": 36633,
      "cocaine benzoylecgonine morphine": 17142,
      "drugs abuse tested": 26868,
      "morphine codeine hydromorphone": 47602,
      "hydromorphone hydrocodone oxymorphone": 36177,
      "ng ml 36": 49437,
      "purpose review study": 66567,
      "including alprazolam clonazepam": 37593,
      "primarily gas chromatography": 64976,
      "driving influence drugs": 26471,
      "influence drugs duid": 38592,
      "buprenorphine methadone fentanyl": 14560,
      "opioids pain management": 53146,
      "meperidine normeperidine methadone": 44846,
      "odds ratio 26": 50908,
      "phase phase ii": 61311,
      "drugs abuse wastewater": 26869,
      "heroin methadone morphine": 35014,
      "drugs low therapeutic": 26992,
      "anhydroecgonine methyl ester": 10985,
      "ecgonine methyl ester": 27302,
      "method simultaneous determination": 45214,
      "codeine oxycodone hydromorphone": 17268,
      "potential clinical applications": 63147,
      "real time monitoring": 68002,
      "management opioid therapy": 43222,
      "opioid therapy mainstay": 52415,
      "mass spectrometry assay": 43457,
      "road safety victoria": 72700,
      "drugs abuse including": 26867,
      "drugs prescribed patient": 27041,
      "october 2013 september": 50879,
      "october 2016 september": 50885,
      "single multiple doses": 76124,
      "purpose study use": 66591,
      "opioids buprenorphine morphine": 52760,
      "results commonly used": 71635,
      "including illicit drugs": 37625,
      "illicit drugs using": 36639,
      "clinical observations shown": 16843,
      "patients treated buprenorphine": 60060,
      "history opioid dependence": 35470,
      "illicit drugs commonly": 36638,
      "pain management clinics": 57062,
      "drug use significantly": 26849,
      "use concurrent use": 84266,
      "use marijuana cocaine": 84468,
      "leading respiratory depression": 41314,
      "study evaluated oral": 78185,
      "pain patients compared": 57343,
      "opiates oxycodone benzodiazepines": 51336,
      "study population pain": 78414,
      "used illicit drugs": 84967,
      "coupled electrospray ionization": 20972,
      "opioids buprenorphine codeine": 52754,
      "postmortem toxicology testing": 62685,
      "similar results obtained": 75993,
      "disposal unused opioid": 25491,
      "tramadol codeine meperidine": 82042,
      "cause death drug": 15350,
      "higher blood levels": 35210,
      "use pregnancy methods": 84644,
      "metabolite parent drug": 44959,
      "parent drug ratios": 58196,
      "buprenorphine codeine oxycodone": 14534,
      "useful tool monitoring": 85215,
      "tool monitoring drug": 81687,
      "morphine oxycodone ketamine": 47838,
      "interpretation blood drug": 39499,
      "study supports use": 78527,
      "practices purpose study": 63439,
      "detect illicit drug": 23929,
      "cell viability decrease": 15491,
      "ms electrospray ionization": 48083,
      "drugs including cocaine": 26978,
      "heroin amphetamine methamphetamine": 34987,
      "known drug users": 40907,
      "mass spectrometry based": 43458,
      "fatally injured drivers": 31250,
      "central nervous depressants": 15598,
      "pain management regimens": 57113,
      "popularity recent years": 62294,
      "benzoylecgonine hydrocodone hydromorphone": 13674,
      "alprazolam alpha hydroxyalprazolam": 9672,
      "using mass spectrometry": 85482,
      "conducted using data": 19422,
      "using data national": 85371,
      "medical center data": 44339,
      "performed institutional review": 60600,
      "approved retrospective chart": 11546,
      "august 2015 august": 12667,
      "use did differ": 84310,
      "oxycodone commonly detected": 54809,
      "naloxone naltrexone oxycodone": 48467,
      "university medical center": 83870,
      "body fluids tissues": 14194,
      "data academic medical": 21861,
      "use heroin cocaine": 84395,
      "heroin buprenorphine methadone": 34990,
      "oxycodone buprenorphine naloxone": 54762,
      "heroin morphine codeine": 35017,
      "patients presenting ed": 59692,
      "blood alcohol concentration": 14105,
      "use abuse drugs": 84164,
      "methods objective study": 45403,
      "single academic medical": 76046,
      "positive drug screens": 62461,
      "provided valuable information": 66168,
      "study compared ability": 78008,
      "proton pump inhibitor": 66010,
      "significantly lower mean": 75793,
      "significantly higher mean": 75730,
      "years age groups": 87561,
      "age groups approximately": 9079,
      "vs 54 004": 86593,
      "prescribed opioids patients": 63934,
      "seven opioid analgesics": 74868,
      "included patients prescribed": 37509,
      "provided urine specimens": 66166,
      "prescription main outcomes": 64244,
      "aged 18 24": 9154,
      "18 24 years": 2038,
      "patients private insurance": 59704,
      "conclusions relevance cross": 19191,
      "relevance cross sectional": 70032,
      "heroin acetylmorphine morphine": 34983,
      "apparent dissociation constant": 11380,
      "tetanus toxoid tt": 80872,
      "50 inhibition concentration": 4845,
      "induced antibodies bound": 38380,
      "antibodies bound heroin": 11147,
      "synthetic opioid related": 79957,
      "poly drug use": 62190,
      "objective purpose retrospective study": 50478,
      "treating chronic pain patients": 82392,
      "semisynthetic opioid analgesic used": 74524,
      "use patients moderate severe": 84615,
      "electrospray ionization tandem mass": 28555,
      "ionization tandem mass spectrometry": 40149,
      "ng ml 95 ci": 49439,
      "98 ng ml range": 6470,
      "mg oral dose oxycodone": 46082,
      "oral dose oxycodone hydrochloride": 53525,
      "controlled release formulation oxycodone": 20543,
      "performed receiver operating characteristic": 60620,
      "receiver operating characteristic roc": 68311,
      "performance liquid chromatography hplc": 60557,
      "using lc ms ms": 85457,
      "enzyme linked immunosorbent assay": 29103,
      "linked immunosorbent assay elisa": 42054,
      "adverse reactions respiratory depression": 8850,
      "including codeine hydrocodone hydromorphone": 37602,
      "male female sprague dawley": 43034,
      "plasma concentrations oxycodone oxidative": 61919,
      "concentrations oxycodone oxidative metabolites": 18797,
      "plasma concentration versus time": 61909,
      "concentration versus time curves": 18732,
      "systemic exposure metabolically derived": 80026,
      "study pharmacodynamic effects oxycodone": 78405,
      "analyzed liquid chromatography tandem": 10839,
      "tandem mass spectrometry used": 80368,
      "analyzed using validated method": 10874,
      "used treat acute chronic": 85162,
      "prescription opioid abuse united": 64280,
      "opioid abuse united states": 51386,
      "samples gas chromatography mass": 73346,
      "taking morphine taking oxycodone": 80311,
      "performance liquid chromatography electrospray": 60556,
      "liquid chromatography electrospray ionization": 42080,
      "chromatography electrospray ionization tandem": 16159,
      "chromatographic separation achieved using": 16150,
      "studies single dose administration": 77849,
      "urine drug testing udt": 84077,
      "patients prescribed opioid analgesics": 59679,
      "positive urine drug screen": 62504,
      "metabolites oxymorphone noroxycodone noroxymorphone": 44982,
      "purpose retrospective study evaluate": 66564,
      "amphetamine methamphetamine methylenedioxy methamphetamine": 9851,
      "sensitive specific liquid chromatography": 74551,
      "abstracted electronic medical record": 6631,
      "30 mg 70 kg": 3754,
      "using high performance liquid": 85428,
      "morphine morphine glucuronide oxycodone": 47782,
      "oxycodone opioid analgesic metabolized": 55566,
      "p450 cyp 2d6 3a4": 56307,
      "commercially available enzyme linked": 17717,
      "available enzyme linked immunosorbent": 12802,
      "oxycodone fentanyl methadone morphine": 55082,
      "morphine acetylmorphine acetylcodeine oxycodone": 47573,
      "high resolution mass spectrometry": 35166,
      "office chief medical examiner": 50970,
      "urinary metabolite heroin morphine": 84058,
      "61 95 confidence interval": 5312,
      "determined lc ms ms": 24070,
      "time flight mass spectrometry": 81266,
      "flight mass spectrometry lc": 31924,
      "10 mg controlled release": 805,
      "codeine dihydrocodeine hydrocodone oxycodone": 17227,
      "liquid chromatography time flight": 42089,
      "resolution mass spectrometry hrms": 71113,
      "oxycodone blood samples collected": 54753,
      "hydrocodone hydromorphone oxycodone noroxycodone": 36093,
      "use prescription pain relievers": 84659,
      "amphetamine methamphetamine mda mdma": 9849,
      "methamphetamine mda mdma morphine": 45144,
      "use nonmedical prescription opioid": 84521,
      "nonmedical prescription opioid use": 49780,
      "heroin synthetic opioids fentanyl": 35037,
      "primarily gas chromatography mass": 64977,
      "driving influence drugs duid": 26472,
      "pain management opioid therapy": 57090,
      "relieving moderate severe chronic": 70234,
      "tandem mass spectrometry assay": 80362,
      "coupled electrospray ionization tandem": 20973,
      "opioids buprenorphine codeine fentanyl": 52756,
      "objectives objective study determine": 50571,
      "metabolite parent drug ratios": 44960,
      "lc ms ms analysis": 41268,
      "academic medical center data": 6953,
      "performed institutional review board": 60601,
      "board approved retrospective chart": 14184,
      "approved retrospective chart review": 11547,
      "use did differ significantly": 84311,
      "data academic medical center": 21862,
      "using liquid chromatography electrospray": 85466,
      "single academic medical center": 76047,
      "years age groups approximately": 87562,
      "prescription main outcomes measures": 64245,
      "aged 18 24 years": 9155,
      "conclusions relevance cross sectional": 19192,
      "relevance cross sectional study": 70033,
      "induced antibodies bound heroin": 38381,
      "machine": 42791,
      "architectures": 11619,
      "forecasting": 32257,
      "neurosurgery": 49287,
      "930": 6179,
      "nondrug": 49735,
      "pointing": 62116,
      "educate": 27373,
      "refine": 69182,
      "970": 6448,
      "sphincter": 76684,
      "upwards": 84024,
      "817": 5898,
      "758": 5730,
      "511": 4967,
      "nonstudy": 49860,
      "367": 4164,
      "severities": 75029,
      "thyroidectomy": 81168,
      "standardizing": 76989,
      "835": 5945,
      "652": 5437,
      "376": 4217,
      "unplanned": 83913,
      "convalescence": 20682,
      "abdominopelvic": 6541,
      "fulfill": 32610,
      "diversity": 25608,
      "lww": 42771,
      "dcr": 22665,
      "pancreaticoduodenectomy": 58060,
      "75th": 5731,
      "molars": 47276,
      "sagittal": 73241,
      "craniofacial": 21128,
      "palate": 58031,
      "050": 564,
      "truncated": 83255,
      "opt": 53416,
      "combatting": 17538,
      "ibu": 36337,
      "alignment": 9570,
      "ibd": 36334,
      "unmasked": 83901,
      "438": 4519,
      "fight": 31692,
      "incisions": 37348,
      "allergies": 9589,
      "connecticut": 19544,
      "495": 4789,
      "maximizing": 43578,
      "distal": 25530,
      "expulsion": 30842,
      "439": 4520,
      "instillation": 39066,
      "asymmetrical": 12519,
      "methocarbamol": 45162,
      "outer": 54109,
      "infraclavicular": 38683,
      "fig": 31691,
      "needing": 49049,
      "senior": 74532,
      "jaw": 40472,
      "mandibular": 43306,
      "xl": 87406,
      "prednisone": 63599,
      "trimethoprim": 83227,
      "plain": 61865,
      "ser": 74640,
      "dr": 26426,
      "dermatologic": 23639,
      "556": 5089,
      "397": 4288,
      "tunnel": 83284,
      "disabilities": 25067,
      "quickdash": 66917,
      "639": 5376,
      "sdd": 74098,
      "referenced": 69145,
      "cs": 21357,
      "321": 3945,
      "laminectomy": 41081,
      "logbooks": 42250,
      "discharging": 25213,
      "actionable": 7454,
      "benchmarks": 13591,
      "hispanic": 35432,
      "663": 5465,
      "modifiable": 47229,
      "qualified": 66660,
      "unanticipated": 83456,
      "211": 2992,
      "meds": 44754,
      "roux": 72874,
      "931": 6180,
      "manifesting": 43311,
      "amelioration": 9781,
      "095": 647,
      "nonopiate": 49800,
      "mandate": 43299,
      "582": 5170,
      "30th": 3837,
      "otc": 53881,
      "081": 629,
      "251": 3401,
      "ooxy": 51137,
      "gastro": 32857,
      "centred": 15636,
      "curative": 21414,
      "carpal": 15128,
      "rotator": 72824,
      "cuff": 21375,
      "leveraged": 41619,
      "iterations": 40354,
      "hd": 34642,
      "incisional": 37346,
      "chiari": 15994,
      "fossa": 32424,
      "alternated": 9711,
      "laryngoscopy": 41203,
      "ostomy": 53876,
      "reversals": 72234,
      "ses": 74728,
      "792": 5806,
      "exit": 30534,
      "israeli": 40316,
      "width": 87088,
      "accredited": 7085,
      "sports": 76765,
      "aligned": 9569,
      "personalizing": 60955,
      "1375": 1537,
      "clinicopathologic": 17040,
      "594": 5197,
      "forefoot": 32258,
      "hindfoot": 35412,
      "blocker": 14085,
      "1473": 1656,
      "advocates": 8863,
      "amputations": 9857,
      "301": 3824,
      "reconstructions": 68649,
      "unnecessarily": 83910,
      "632": 5374,
      "postimplementation": 62662,
      "1185": 1192,
      "researcher": 71043,
      "beneficiary": 13612,
      "372": 4212,
      "osteopathic": 53874,
      "0007": 90,
      "cartilage": 15150,
      "741": 5681,
      "interpretability": 39496,
      "903": 6123,
      "nonphysician": 49831,
      "494": 4788,
      "attendings": 12561,
      "assign": 12163,
      "normative": 49920,
      "libitum": 41660,
      "glycopyrrolate": 33267,
      "resiniferatoxin": 71088,
      "educated": 27375,
      "charcoal": 15918,
      "dispose": 25493,
      "tens": 80607,
      "thousands": 81140,
      "johns": 40481,
      "hopkins": 35540,
      "q6": 66620,
      "secondarily": 74200,
      "multisystem": 48312,
      "289": 3591,
      "ckd": 16606,
      "univariable": 83835,
      "combating": 17537,
      "equals": 29246,
      "awp": 12986,
      "subtracting": 78893,
      "294": 3626,
      "governing": 33347,
      "780": 5788,
      "judiciously": 40505,
      "overlapped": 54343,
      "appointments": 11445,
      "computing": 18663,
      "austria": 12710,
      "25th": 3410,
      "translates": 82214,
      "ssris": 76819,
      "unstructured": 83947,
      "f1": 31008,
      "imply": 36974,
      "575": 5147,
      "399": 4290,
      "refinement": 69184,
      "514": 4970,
      "response prescribed": 71359,
      "drug dose": 26596,
      "trial error": 83022,
      "error furthermore": 29510,
      "portion patients": 62420,
      "machine learning": 42792,
      "crisis little": 21171,
      "use trends": 84784,
      "postoperative hospital": 62776,
      "large academic": 41118,
      "2018 methods": 2830,
      "consumed opioids": 19838,
      "weak tramadol": 86796,
      "performed estimate": 60589,
      "estimate annual": 29604,
      "13 17": 1455,
      "year 2007": 87426,
      "current approaches": 21426,
      "data driven": 21951,
      "opiate prescribing": 51308,
      "personal practice": 60948,
      "reduction program": 69095,
      "medications decrease": 44612,
      "prescribing using": 64145,
      "individual provider": 38307,
      "routine postoperative": 72864,
      "postoperative follow": 62773,
      "performed total": 60642,
      "data led": 22001,
      "additional 150": 7836,
      "months conclusion": 47436,
      "improves patient": 37187,
      "objectives little": 50567,
      "little data": 42149,
      "available opioid": 12825,
      "adult population": 8522,
      "tonsillectomy adenoidectomy": 81662,
      "old received": 51018,
      "november 2019": 50037,
      "2019 august": 2857,
      "2020 included": 2901,
      "survey included": 79712,
      "included visual": 37574,
      "pain postoperatively": 57397,
      "dosage patients": 25759,
      "consumed 12": 19823,
      "cohort pain": 17365,
      "reported highest": 70564,
      "day prescription": 22389,
      "larger initial": 41175,
      "prescriptions did": 64472,
      "conclusion significant": 18993,
      "consumption reduce": 20006,
      "refills study": 69181,
      "study needed": 78322,
      "use objective": 84529,
      "investigate association": 39998,
      "initial opioids": 38858,
      "developing new": 24203,
      "new persistent": 49358,
      "2016 included": 2746,
      "included 35": 37394,
      "heart valve": 34876,
      "index procedure": 38206,
      "exposures opioid": 30806,
      "developed new": 24184,
      "90 180": 6076,
      "discharge multivariable": 25142,
      "81 vs": 5889,
      "valve surgery": 85857,
      "surgery mean": 79455,
      "61 12": 5305,
      "use substantial": 84764,
      "decreased heart": 23001,
      "001 increased": 149,
      "failure chronic": 31147,
      "disease diabetes": 25329,
      "kidney failure": 40823,
      "01 02": 288,
      "06 30": 578,
      "30 chronic": 3713,
      "10 56": 718,
      "02 001": 349,
      "001 furthermore": 139,
      "discharge significantly": 25175,
      "used extensively": 84936,
      "nearly 10": 48863,
      "limit opioid": 41888,
      "discharge objective": 25145,
      "designed test": 23851,
      "oxycodone surgery": 55968,
      "surgery summary": 79600,
      "2017 michigan": 2795,
      "guidelines recommended": 34469,
      "50 tablets": 4901,
      "potency differences": 63072,
      "recommend number": 68582,
      "number mg": 50170,
      "adults underwent": 8585,
      "hospitals michigan": 35670,
      "oxycodone january": 55321,
      "2018 31": 2812,
      "2019 primary": 2880,
      "meaningful difference": 43914,
      "consumption pills": 19988,
      "included self": 37548,
      "opioid refills": 52290,
      "included adjusting": 37410,
      "covariates patients": 21011,
      "consumed tablets": 19853,
      "overdose leading": 54298,
      "cause injury": 15357,
      "death united": 22726,
      "states studies": 77151,
      "reported satisfaction": 70643,
      "period period": 60772,
      "prescribing analysis": 64030,
      "general surgical": 32990,
      "surgical operations": 79637,
      "march august": 43374,
      "survey approximately": 79695,
      "outpatient encounters": 54119,
      "encounters results": 28776,
      "58 years": 5167,
      "decreased 90": 22973,
      "decreased 28": 22954,
      "responded survey": 71300,
      "satisfaction ratings": 73426,
      "vs 70": 86612,
      "65 69": 5406,
      "study periods": 78400,
      "vs 59": 86598,
      "lack consensus": 41047,
      "role multimodal": 72750,
      "multimodal postoperative": 48238,
      "information recorded": 38667,
      "oxycodone scheduled": 55864,
      "scheduled acetaminophen": 73634,
      "race opioid": 66941,
      "predominantly male": 63604,
      "sd range": 74091,
      "use dose": 84342,
      "doses compared": 26158,
      "factor significantly": 31060,
      "cohorts patients": 17413,
      "significantly doses": 75691,
      "refills methods": 69175,
      "57 experienced": 5128,
      "med prescribed": 44161,
      "results mild": 71783,
      "range equivalent": 67314,
      "33 80": 3985,
      "80 oxycodone": 5854,
      "interval 25": 39563,
      "interval 14": 39557,
      "asa score": 11821,
      "interval 92": 39571,
      "01 preoperative": 321,
      "02 conclusion": 365,
      "adoption opioid": 8470,
      "determine postoperative": 24038,
      "women randomized": 87238,
      "standardized preoperative": 76985,
      "controlling variables": 20662,
      "significant univariate": 75640,
      "analysis surgery": 10777,
      "84 participants": 5963,
      "participants postoperative": 58342,
      "ratio 23": 67721,
      "23 012": 3069,
      "012 95": 334,
      "nonopioid medication": 49810,
      "acetaminophen similar": 7251,
      "women received": 87239,
      "received preoperative": 68252,
      "understand opioid": 83625,
      "surgery using": 79616,
      "included women": 37580,
      "2018 october": 2832,
      "prescription tablets": 64413,
      "tablets oral": 80184,
      "oral narcotic": 53593,
      "collected preoperatively": 17477,
      "questions regarding": 66911,
      "mme secondary": 46978,
      "refill rate": 69164,
      "standard statistical": 76933,
      "analysis total": 10780,
      "37 mme": 4195,
      "inventory scores": 39982,
      "extremely satisfied": 30983,
      "satisfied pain": 73458,
      "refill conclusions": 69160,
      "surgery used": 79615,
      "scores high": 73886,
      "satisfaction rates": 73425,
      "period limited": 60741,
      "adequacy pain": 7955,
      "period nonopioid": 60756,
      "based postoperative": 13358,
      "analgesia methods": 10018,
      "approval patients": 11525,
      "based visual": 13401,
      "groups 49": 34117,
      "score study": 73798,
      "groups hour": 34213,
      "day vs": 22446,
      "conclusion randomized": 18976,
      "treated nonopioid": 82353,
      "implemented reduce": 36952,
      "objectives purpose": 50585,
      "taken methods": 80285,
      "underwent elective": 83678,
      "surgery different": 79381,
      "control received": 20409,
      "pain separate": 57814,
      "group took": 34049,
      "compromising pain": 18642,
      "period 2010": 60693,
      "2010 17": 2538,
      "equivalents year": 29382,
      "2014 17": 2646,
      "morphine reduced": 47908,
      "surgery consumption": 79354,
      "increased 28": 37846,
      "largest increase": 41193,
      "studied oxycodone": 77623,
      "unplanned emergency": 83914,
      "visits readmissions": 86290,
      "conducted double": 19354,
      "randomized blinded": 67043,
      "ketorolac 10": 40634,
      "taken needed": 80286,
      "study outcome": 78350,
      "questionnaire scores": 66899,
      "ketorolac groups": 40649,
      "groups comparable": 34145,
      "differences postoperative": 24788,
      "medication rescue": 44562,
      "05 higher": 518,
      "score 28": 73722,
      "receiving ketorolac": 68345,
      "sd vs": 74095,
      "02 difference": 368,
      "postoperative physician": 62952,
      "control similar": 20423,
      "use post": 84630,
      "continued investigation": 20136,
      "reducing postoperative": 69029,
      "states prescribing": 77142,
      "design designed": 23711,
      "postoperative survey": 62971,
      "given consecutive": 33160,
      "pills needed": 61521,
      "postoperative factors": 62772,
      "tablets needed": 80180,
      "median pills": 44273,
      "pill prescription": 61494,
      "increased consumption": 37896,
      "factor associated": 31052,
      "consumption race": 20002,
      "operative factors": 51252,
      "retrospective nature": 72144,
      "cohort conclusions": 17352,
      "guidelines standardized": 34474,
      "consumption work": 20044,
      "offer similar": 50951,
      "video abstract": 86211,
      "abstract http": 6623,
      "http links": 35923,
      "links lww": 42061,
      "lww com": 42772,
      "surgery remains": 79560,
      "ibuprofen ketorolac": 36359,
      "ketorolac results": 40657,
      "patient hospitalization": 58659,
      "hospitalization following": 35656,
      "range total": 67335,
      "total omes": 81858,
      "administered following": 8129,
      "surgery high": 79415,
      "69 oxycodone": 5524,
      "despite relatively": 23901,
      "individuals high": 38347,
      "pills day": 61508,
      "used text": 85155,
      "demographic perioperative": 23288,
      "75th percentile": 5732,
      "included academic": 37409,
      "academic centers": 6944,
      "mme consumed": 46956,
      "median ibuprofen": 44225,
      "19 10": 2158,
      "median pain": 44267,
      "mme use": 46979,
      "index greater": 38194,
      "greater 30": 33423,
      "01 chronic": 303,
      "elevated blood": 28559,
      "03 significant": 421,
      "significant multivariate": 75581,
      "patients consume": 59139,
      "28 mme": 3560,
      "mme 10": 46948,
      "tablets addition": 80121,
      "chronic postoperative": 16330,
      "taken weeks": 80295,
      "weeks following": 86914,
      "median 10": 44171,
      "postoperatively multivariate": 63009,
      "included excluded": 37452,
      "15 27": 1684,
      "acetaminophen celecoxib": 7158,
      "78 28": 5775,
      "21 36": 2951,
      "36 received": 4145,
      "medications hospital": 44625,
      "equivalents interquartile": 29355,
      "iqr oxycodone": 40182,
      "mg 29": 45736,
      "mg 23": 45729,
      "used 10": 84819,
      "10 iqr": 776,
      "05 001": 471,
      "increased understanding": 38040,
      "improve prescribing": 37083,
      "patterns discharge": 60202,
      "study quantified": 78440,
      "days limited": 22548,
      "limited single": 41960,
      "consumption postoperatively": 19996,
      "unused patients": 83966,
      "prescribed management": 63886,
      "pain removal": 57613,
      "removal impacted": 70330,
      "impacted molars": 36859,
      "determine oral": 24032,
      "larger amounts": 41172,
      "pretreated patients": 64761,
      "drug prescribed": 26744,
      "prescribed narcotic": 63897,
      "results 384": 71566,
      "did prescribe": 24477,
      "prescribed 40": 63810,
      "drugs appropriate": 26888,
      "control measures": 20361,
      "avoided background": 12968,
      "naloxone reduce": 48513,
      "examined feasibility": 30382,
      "feasibility study": 31286,
      "received analgesia": 68117,
      "protocol compliance": 65963,
      "solid food": 76429,
      "received allocated": 68114,
      "allocated intervention": 9616,
      "treat cohort": 82294,
      "23 control": 3094,
      "difference 10": 24567,
      "group shorter": 34003,
      "mean 78": 43668,
      "www clinicaltrials": 87392,
      "boston children": 14254,
      "subjects excluded": 78696,
      "study postoperative": 78416,
      "prescriptions instructions": 64503,
      "variable total": 85883,
      "electronic questionnaire": 28542,
      "questionnaire day": 66890,
      "54 male": 5046,
      "male age": 43021,
      "use 18": 84144,
      "mean oral": 43818,
      "higher 003": 35197,
      "requirements mean": 70883,
      "caution necessary": 15414,
      "necessary avoid": 48878,
      "analysis based": 10643,
      "intensity 51": 39224,
      "consumption time": 20030,
      "opioid allowed": 51437,
      "correlated number": 20814,
      "dose 26": 25799,
      "intensity time": 39319,
      "opioid request": 52335,
      "affect pain": 8909,
      "pain period": 57366,
      "aims review": 9497,
      "manage post": 43122,
      "clinical scenarios": 16898,
      "achieve post": 7305,
      "operative analgesia": 51243,
      "received 22": 68098,
      "percent aged": 60454,
      "aged greater": 9206,
      "years 32": 87539,
      "cases compared": 15228,
      "results preliminary": 71884,
      "19 84": 2178,
      "reasons discrepancies": 68019,
      "expectations pain": 30549,
      "use important": 84420,
      "crisis purpose": 21175,
      "patients single": 59984,
      "center undergoing": 15559,
      "15 tablets": 1794,
      "ibuprofen ibu": 36357,
      "ibu 600": 36338,
      "tablets oxy": 80187,
      "oxy 15": 54438,
      "pill count": 61490,
      "endpoint results": 28900,
      "analysis significant": 10769,
      "noted patient": 49991,
      "pills compared": 61502,
      "compared nsaid": 18219,
      "008 differences": 278,
      "differences median": 24758,
      "total pill": 81886,
      "equivalent postoperative": 29331,
      "compared opiates": 18225,
      "number postoperative": 50233,
      "suggest surgeons": 79016,
      "patient need": 58685,
      "reduce excessive": 68842,
      "guideline based": 34418,
      "consumption patterns": 19986,
      "conducted single": 19408,
      "included main": 37473,
      "mg pills": 46160,
      "categorized groups": 15307,
      "based consumption": 13300,
      "prescription quantity": 64390,
      "17 10": 1929,
      "consumed mean": 19832,
      "pills discharge": 61510,
      "mg pill": 46158,
      "consumed pills": 19845,
      "001 prescribing": 193,
      "12 pills": 1355,
      "excess pills": 30454,
      "opioids excess": 52900,
      "states evidence": 77100,
      "decrease prescribed": 22922,
      "unknown objective": 83882,
      "satisfaction postoperative": 73420,
      "used number": 85036,
      "excess tablets": 30457,
      "controlled noninferiority": 20507,
      "noninferiority trial": 49749,
      "trial women": 83097,
      "overnight hospitalization": 54349,
      "assigned randomly": 12173,
      "28 tablets": 3575,
      "age undergoing": 9130,
      "catastrophizing scale": 15285,
      "scale addition": 73494,
      "addition opioid": 7819,
      "patients white": 60180,
      "common surgery": 17812,
      "surgery hysterectomy": 79419,
      "groups 15": 34100,
      "93 vs": 6178,
      "requiring additional": 70898,
      "prescription frequently": 64229,
      "range overall": 67329,
      "surgeons consider": 79270,
      "consider prescribing": 19606,
      "prescribing 10": 64026,
      "repair surgery": 70386,
      "using administrative": 85301,
      "health claims": 34689,
      "australian government": 12698,
      "government department": 33351,
      "18 100": 2028,
      "measures outcome": 44073,
      "cessation opioids": 15677,
      "users defined": 85235,
      "opioids post": 53187,
      "discharged oxycodone": 25208,
      "given frequency": 33169,
      "patients important": 59385,
      "postoperative outpatient": 62835,
      "outpatient narcotic": 54123,
      "significant role": 75632,
      "ome 10": 51053,
      "oxycodone lowest": 55347,
      "need narcotics": 48936,
      "narcotics methods": 48633,
      "observational pilot": 50614,
      "37 ome": 4200,
      "study 52": 77897,
      "52 male": 4988,
      "home significantly": 35524,
      "visited emergency": 86271,
      "control day": 20291,
      "prescribed level": 63877,
      "therapeutic study": 80962,
      "level purpose": 41520,
      "prescription narcotic": 64265,
      "narcotic abuse": 48581,
      "surplus medication": 79665,
      "source prescription": 76501,
      "assessed prescribing": 12043,
      "underwent surgery": 83698,
      "university utah": 83874,
      "surveys performed": 79752,
      "type quantity": 83350,
      "prescribed quantity": 63967,
      "quantity leftover": 66827,
      "study hydrocodone": 78233,
      "hydrocodone prescribed": 36127,
      "patients requested": 59900,
      "total 67": 81766,
      "educate patients": 27374,
      "decreasing quantity": 23074,
      "complete survey": 18456,
      "following pre": 32185,
      "significantly mg": 75815,
      "20 001": 2265,
      "used fewer": 84940,
      "vs 003": 86504,
      "average score": 12935,
      "score standard": 73796,
      "33 10": 3976,
      "55 89": 5068,
      "vs 94": 86632,
      "use compromising": 84256,
      "fight opioid": 31693,
      "analgesics common": 10396,
      "component pain": 18584,
      "following low": 32159,
      "prescribing time": 64141,
      "assessed trends": 12075,
      "consumed weeks": 19854,
      "taking narcotics": 80312,
      "weeks mean": 86924,
      "reduction narcotic": 69069,
      "increasing rate": 38122,
      "satisfaction following": 73396,
      "consecutive series": 19569,
      "undergoing secondary": 83575,
      "pain questionnaire": 57455,
      "times postoperative": 81432,
      "patients queried": 59724,
      "stopped taking": 77391,
      "tablets following": 80160,
      "following secondary": 32197,
      "experienced mild": 30609,
      "reduction 18": 69035,
      "difference average": 24596,
      "conclusions commonly": 19051,
      "regimen provides": 69325,
      "relief satisfaction": 70182,
      "number leftover": 50168,
      "leftover tablets": 41358,
      "elective ambulatory": 28485,
      "year increased": 87445,
      "need postoperative": 48948,
      "data relating": 22089,
      "dosage frequency": 25751,
      "patients narcotic": 59536,
      "hydromorphone tramadol": 36227,
      "ranging 20": 67358,
      "somewhat satisfied": 76460,
      "day half": 22317,
      "acetaminophen widely": 7262,
      "data recommend": 22084,
      "reduction patient": 69090,
      "pain best": 56494,
      "management model": 43205,
      "model patients": 47073,
      "reconstructive surgery": 68651,
      "undergoing inpatient": 83544,
      "stay surgery": 77296,
      "protocol included": 65975,
      "preoperatively postoperative": 63775,
      "postoperative weeks": 62987,
      "prescription controlled": 64187,
      "patients called": 59039,
      "monitoring reporting": 47344,
      "received narcotic": 68210,
      "equivalents secondary": 29378,
      "spearman rho": 76555,
      "05 results": 546,
      "total 113": 81712,
      "weeks time": 86962,
      "weeks 19": 86892,
      "overall refill": 54246,
      "495 patients": 4790,
      "did clinically": 24420,
      "prescribing allows": 64028,
      "protocol pain": 65983,
      "satisfaction study": 73441,
      "adult ed": 8490,
      "patients distal": 59220,
      "receive 10": 68037,
      "return ed": 72187,
      "care visits": 15097,
      "missed work": 46696,
      "function analgesic": 32628,
      "subjects enrolled": 78693,
      "27 77": 3484,
      "77 subjects": 5766,
      "24 64": 3174,
      "therapy group": 81018,
      "groups secondary": 34311,
      "measures compared": 44051,
      "treatment ibuprofen": 82618,
      "dental procedures": 23410,
      "age 19": 8980,
      "treated surgical": 82379,
      "procedures included": 65307,
      "study reviewed": 78472,
      "models patients": 47121,
      "preexisting pain": 63615,
      "prescribing analgesics": 64029,
      "scores postdischarge": 73955,
      "analysis randomized": 10751,
      "analysis evaluated": 10681,
      "use mg": 84486,
      "mme calculated": 46954,
      "assessed postoperative": 12038,
      "randomized multimodal": 67125,
      "22 37": 3021,
      "hospital needed": 35604,
      "conclusions postoperative": 19164,
      "performed large": 60602,
      "large urban": 41157,
      "academic health": 6947,
      "data postoperative": 22054,
      "months analyzed": 47430,
      "equivalent pills": 29330,
      "pills iqr": 61513,
      "taking median": 80306,
      "tablet equivalents": 80092,
      "17 40": 1944,
      "responders opioid": 71323,
      "naive vs": 48409,
      "vs opioid": 86665,
      "similar median": 75948,
      "pills postoperatively": 61532,
      "respectively statistically": 71251,
      "patient centered": 58551,
      "allow development": 9632,
      "spinal nerve": 76724,
      "cause significant": 15374,
      "patients shown": 59975,
      "shown use": 75355,
      "large population": 41145,
      "variety factors": 85953,
      "reduction following": 69059,
      "including number": 37654,
      "duration surgery": 27185,
      "results self": 71934,
      "anesthesia comparable": 10906,
      "comparable rates": 17969,
      "given ibuprofen": 33174,
      "sites postoperative": 76168,
      "longer period": 42384,
      "time duration": 81256,
      "size did": 76183,
      "pain statistically": 57861,
      "significant larger": 75572,
      "pain involve": 56982,
      "vicodin percocet": 86202,
      "control purpose": 20407,
      "patients evaluate": 59264,
      "20 lower": 2326,
      "lower score": 42700,
      "10 lower": 778,
      "results baseline": 71612,
      "na\u00efve group": 48832,
      "increased groups": 37927,
      "005 patients": 266,
      "001 weeks": 226,
      "mean bpi": 43730,
      "group 045": 33548,
      "assess safety": 11964,
      "consisted patients": 19683,
      "discharge implementation": 25127,
      "protocol resulted": 65994,
      "dramatic reduction": 26436,
      "evaluates opioid": 29942,
      "common procedure": 17801,
      "open minimally": 51192,
      "surgery open": 79484,
      "71 vs": 5602,
      "female vs": 31381,
      "patients open": 59578,
      "open patients": 51196,
      "vs 52": 86590,
      "scores using": 74007,
      "scale similar": 73564,
      "86 vs": 6012,
      "98 vs": 6474,
      "amounts opioids": 9837,
      "opioids open": 53117,
      "113 225": 1174,
      "equivalents vs": 29381,
      "iqr 60": 40178,
      "44 42": 4530,
      "normal body": 49899,
      "75 prescribed": 5720,
      "time survey": 81389,
      "survey 12": 79692,
      "clinically similar": 17007,
      "oxycodone sufficient": 55959,
      "senior authors": 74533,
      "based oral": 13347,
      "groups comprised": 34155,
      "data statistical": 22118,
      "acetaminophen groups": 7188,
      "difference oral": 24646,
      "administration acetaminophen": 8210,
      "acetaminophen associated": 7157,
      "effect postoperative": 27530,
      "postoperative acetaminophen": 62694,
      "period purpose": 60781,
      "effect individual": 27466,
      "characteristics age": 15846,
      "125 patients": 1430,
      "18 65": 2061,
      "variable opioid": 85880,
      "consumption measured": 19951,
      "mme patients": 46971,
      "outcome variables": 54003,
      "period hospitalization": 60731,
      "consisted oxycodone": 19682,
      "test statistical": 80784,
      "16 women": 1899,
      "years 18": 87526,
      "hospital average": 35568,
      "patients 77": 58900,
      "women reported": 87240,
      "reported postoperative": 70628,
      "vs consumed": 86639,
      "vs 78": 86620,
      "25 years": 3391,
      "years required": 87656,
      "112 mme": 1171,
      "mme opioid": 46969,
      "pain required": 57621,
      "required opioid": 70849,
      "surgery conclusion": 79350,
      "surgery objectives": 79480,
      "role current": 72737,
      "undergoing endoscopic": 83533,
      "collected baseline": 17450,
      "anxiety pain": 11281,
      "telephone follow": 80571,
      "refills postoperative": 69178,
      "001 preoperative": 192,
      "days 33": 22472,
      "33 001": 3975,
      "mme conclusions": 46955,
      "minimal opioid": 46578,
      "influence opioid": 38593,
      "consumption level": 19945,
      "evidence laryngoscope": 30203,
      "2022 objective": 2919,
      "utilization pain": 85732,
      "study utilizing": 78566,
      "acetaminophen 15": 7116,
      "nonopioid multimodal": 49812,
      "regimen results": 69327,
      "patient significant": 58783,
      "phone calls": 61361,
      "clinic visits": 16747,
      "17 cohort": 1958,
      "nonopioid treatment": 49816,
      "treatment regimen": 82802,
      "drugs second": 27069,
      "received ketorolac": 68189,
      "ketorolac oxycodone": 40653,
      "drugs recorded": 27056,
      "visits versus": 86296,
      "versus 15": 86100,
      "conclusions addition": 19027,
      "blocking agent": 14088,
      "interventions background": 39656,
      "overprescribing opioids": 54356,
      "opioids diverted": 52865,
      "characterize opioid": 15896,
      "prospective cross": 65825,
      "survey settings": 79736,
      "2018 september": 2844,
      "anesthesia received": 10946,
      "pills median": 61516,
      "10 range": 911,
      "50 followed": 4838,
      "median 15": 44176,
      "15 range": 1788,
      "28 range": 3567,
      "unused pills": 83967,
      "median 14": 44174,
      "30 17": 3668,
      "levels following": 41565,
      "reported minimal": 70587,
      "procedure performed": 65280,
      "management outpatient": 43226,
      "71 96": 5591,
      "82 233": 5900,
      "opioids 10": 52657,
      "western united": 87006,
      "prescribed conclusion": 63840,
      "conclusion retrospective": 18982,
      "location significant": 42226,
      "important patients": 37022,
      "aimed analyze": 9434,
      "guide postoperative": 34407,
      "prescribing methods": 64079,
      "collected opioid": 17466,
      "insurance type": 39156,
      "disabilities arm": 25068,
      "arm shoulder": 11678,
      "shoulder hand": 75222,
      "equivalent units": 29335,
      "tunnel release": 83285,
      "115 vs": 1182,
      "vs 40": 86574,
      "workers compensation": 87291,
      "03 postoperative": 420,
      "functional scores": 32711,
      "opioids purpose": 53236,
      "outpatient upper": 54152,
      "extremity surgery": 30989,
      "medication methods": 44516,
      "phone interview": 61362,
      "gender procedure": 32937,
      "medication regimen": 44553,
      "control number": 20372,
      "eligible subjects": 28600,
      "contact patient": 20049,
      "250 patients": 3400,
      "undergoing bone": 83513,
      "14 pills": 1624,
      "half subjects": 34534,
      "subject reported": 78641,
      "hand wrist": 34556,
      "type study": 83355,
      "evidence prognostic": 30248,
      "complications length": 18562,
      "perioperative anesthesia": 60829,
      "anesthesia multimodal": 10923,
      "demonstrated safety": 23363,
      "methods quality": 45500,
      "healthy patients": 34838,
      "elective colorectal": 28487,
      "feed score": 31327,
      "management bowel": 43154,
      "total narcotic": 81848,
      "efficacy pre": 28330,
      "pain adult": 56420,
      "surgery obstructive": 79481,
      "preoperative oral": 63752,
      "dose pregabalin": 26019,
      "consisted intravenous": 19677,
      "pregabalin plus": 63677,
      "celecoxib placebo": 15463,
      "consumption hour": 19934,
      "05 mean": 523,
      "daily narcotic": 21768,
      "narcotic pill": 48603,
      "daily visual": 21815,
      "scores vs": 74014,
      "mean intravenous": 43783,
      "judicious use": 40504,
      "associated preoperative": 12386,
      "outcomes increased": 54045,
      "development chronic": 24218,
      "persistent postsurgical": 60930,
      "induced ventilatory": 38459,
      "ventilatory impairment": 86063,
      "associated withdrawal": 12464,
      "use certain": 84230,
      "guidelines published": 34466,
      "opioids routinely": 53281,
      "marketing long": 43424,
      "1994 2014": 2232,
      "year calculated": 87434,
      "filled index": 31704,
      "prescription assessed": 64168,
      "dose prescription": 26021,
      "dose postoperative": 26015,
      "80 filled": 5842,
      "prescription surgery": 64412,
      "filled increased": 31703,
      "84 85": 5955,
      "lumbar laminectomy": 42755,
      "arthroplasty total": 11746,
      "odds filling": 50897,
      "prescription exceeded": 64220,
      "32 01": 3902,
      "30 23": 3680,
      "insured patients": 39161,
      "broader opioid": 14450,
      "late 1990s": 41221,
      "reconstruction patients": 68646,
      "quantity duration": 66826,
      "characteristics examined": 15862,
      "associations postoperative": 12499,
      "total 45": 81752,
      "used 15": 84822,
      "18 71": 2065,
      "71 oxycodone": 5595,
      "equivalents consumed": 29343,
      "discharge associated": 25107,
      "additional oxycodone": 7877,
      "equivalent consumed": 29291,
      "increase days": 37740,
      "provide benchmark": 66034,
      "surgeons use": 79281,
      "high inpatient": 35112,
      "patients counseled": 59159,
      "duration outpatient": 27173,
      "nonnarcotic pain": 49798,
      "30 2014": 3673,
      "pills decreased": 61509,
      "fewer pills": 31662,
      "prescribed time": 63989,
      "variation number": 85915,
      "room improvement": 72775,
      "hours longer": 35791,
      "operation discharge": 51217,
      "pill equivalents": 61492,
      "equivalents prescribed": 29374,
      "thirty mg": 81103,
      "leftover pills": 41357,
      "groups 001": 34085,
      "99 99": 6487,
      "100 mme": 1002,
      "group 82": 33647,
      "group overall": 33883,
      "trial prospectively": 83053,
      "disposal excess": 25482,
      "underwent major": 83687,
      "operation january": 51220,
      "total 155": 81724,
      "155 patients": 1830,
      "use 77": 84160,
      "60 pills": 5275,
      "major open": 42963,
      "overall 60": 54180,
      "counseling regarding": 20925,
      "procedures methods": 65315,
      "undergoing common": 83523,
      "procedures single": 65326,
      "2018 patients": 2836,
      "surgery asked": 79324,
      "asked report": 11847,
      "consumption discharge": 19919,
      "discharge instructions": 25129,
      "handling practices": 34562,
      "median quantity": 44277,
      "vs tablets": 86679,
      "proper disposal": 65698,
      "82 prescriptions": 5912,
      "following common": 32113,
      "indicating potential": 38266,
      "home opioid": 35514,
      "week following": 86842,
      "age interquartile": 9084,
      "iqr 69": 40179,
      "majority white": 42999,
      "white 85": 87014,
      "equivalents percent": 29373,
      "35 65": 4069,
      "opioids median": 53041,
      "age lower": 9086,
      "region majority": 69343,
      "equivalents background": 29341,
      "contributor opioid": 20253,
      "underwent laparoscopic": 83685,
      "mme results": 46977,
      "results seventy": 71941,
      "pain concerns": 56582,
      "discharge following": 25123,
      "analgesia opioids": 10040,
      "25 mme": 3370,
      "patients 361": 58860,
      "mean milligram": 43795,
      "increased conclusion": 37895,
      "management critical": 43173,
      "study measure": 78302,
      "stronger codeine": 77567,
      "codeine 30": 17199,
      "standardized protocol": 76986,
      "opioid free": 51818,
      "free postoperative": 32491,
      "primary predictor": 65103,
      "predictor variable": 63582,
      "control assessed": 20276,
      "compare number": 18034,
      "results march": 71760,
      "15 85": 1717,
      "85 yr": 5993,
      "years postoperative": 87637,
      "recorded total": 68707,
      "fold decrease": 31986,
      "surgery setting": 79583,
      "participants recruited": 58358,
      "54 women": 5055,
      "pills participants": 61528,
      "used mean": 85001,
      "equivalent 18": 29283,
      "increase preoperative": 37786,
      "prescription associated": 64170,
      "19 35": 2172,
      "preoperative history": 63743,
      "prescription high": 64233,
      "postoperatively additionally": 62993,
      "prescribing include": 64066,
      "monitoring objective": 47328,
      "prescriptions specific": 64560,
      "roux en": 72875,
      "en gastric": 28756,
      "2018 retrospectively": 2843,
      "opioid protocol": 52224,
      "november 2017": 50036,
      "surgery residents": 79563,
      "post protocol": 62615,
      "300 ml": 3818,
      "reduction background": 69046,
      "analysis prospective": 10745,
      "controlled data": 20482,
      "demographics surgical": 23307,
      "recovery unit": 68771,
      "stay discharge": 77276,
      "discharge postoperative": 25162,
      "postoperative morning": 62792,
      "morning surgery": 47520,
      "surgery weeks": 79620,
      "pain recovery": 57487,
      "surgery associated": 79326,
      "underwent spinal": 83696,
      "surgery conclusions": 79352,
      "intense postoperative": 39210,
      "common short": 17808,
      "greater likelihood": 33454,
      "likelihood pain": 41791,
      "pain weeks": 57987,
      "weeks background": 86895,
      "guideline design": 34419,
      "varied range": 85939,
      "required refills": 70859,
      "total pills": 81887,
      "001 home": 145,
      "limited retrospective": 41956,
      "center design": 15518,
      "design opioid": 23736,
      "widely variable": 87077,
      "highly dependent": 35392,
      "usage patterns": 84129,
      "background controversy": 13032,
      "associated relief": 12408,
      "patient presentation": 58718,
      "sessions required": 74748,
      "subsequent surgery": 78781,
      "results single": 71959,
      "occurred 20": 50827,
      "follow years": 32042,
      "vs 81": 86623,
      "80 03": 5822,
      "improvement clinical": 37148,
      "institution patients": 39080,
      "2012 2018": 2594,
      "2018 objective": 2831,
      "prescriptions immediate": 64498,
      "significant mortality": 75580,
      "following spinal": 32199,
      "methods inclusion": 45360,
      "underwent 10": 83673,
      "pod pod": 62066,
      "course opioids": 20996,
      "day mme": 22338,
      "standard reference": 76931,
      "opioids 80": 52686,
      "equivalent 10": 29279,
      "dosage prescription": 25760,
      "significant predictor": 75602,
      "analgesics did": 10414,
      "30 compared": 3715,
      "prescriptions light": 64506,
      "dosing recommendations": 26327,
      "recommendations american": 68591,
      "examine effectiveness": 30339,
      "prescribed control": 63844,
      "concern regarding": 18832,
      "curb opioid": 21416,
      "renal surgery": 70366,
      "2017 single": 2806,
      "naive opioid": 48399,
      "pdmp query": 60297,
      "pdmp queries": 60296,
      "harm associated": 34576,
      "receive ketorolac": 68054,
      "acetaminophen opioid": 7217,
      "week postoperatively": 86867,
      "pills used": 61548,
      "constipation adverse": 19747,
      "events assessed": 30012,
      "analgesia non": 10031,
      "score groups": 73751,
      "results analyses": 71599,
      "analyses based": 10584,
      "ketorolac group": 40645,
      "group 46": 33616,
      "46 oxycodone": 4628,
      "demographics type": 23308,
      "94 sd": 6197,
      "17 84": 1951,
      "rates constipation": 67566,
      "32 conclusions": 3922,
      "analgesics considered": 10403,
      "background overprescribing": 13129,
      "versus high": 86122,
      "reported utilization": 70675,
      "month discharge": 47386,
      "regression procedures": 69454,
      "high post": 35142,
      "rate 86": 67439,
      "pills week": 61549,
      "combinations acetaminophen": 17620,
      "24 hospital": 3202,
      "quantity opiates": 66832,
      "july 2020": 40530,
      "conducted patient": 19384,
      "results pod": 71872,
      "sd 36": 74068,
      "patients grade": 59332,
      "13 oxycodone": 1499,
      "surgery overall": 79491,
      "evaluate prescribing": 29835,
      "practices opioid": 63431,
      "outpatient open": 54125,
      "laparoscopic surgeries": 41109,
      "week discharge": 86836,
      "quantified number": 66780,
      "variety procedures": 85955,
      "prescribing compared": 64042,
      "equally represented": 29245,
      "years prescribed": 87640,
      "percent tramadol": 60496,
      "tramadol 22": 82026,
      "mean consumption": 43736,
      "despite low": 23891,
      "high satisfaction": 35178,
      "control 10": 20261,
      "percent reported": 60488,
      "counter otc": 20935,
      "conclusions week": 19243,
      "week outpatient": 86857,
      "development patient": 24245,
      "unintentional deaths": 83743,
      "discharge days": 25115,
      "taken clinical": 80273,
      "extracted medical": 30959,
      "60 14": 5224,
      "years sex": 87669,
      "acetaminophen 26": 7121,
      "mme interquartile": 46965,
      "medications postoperative": 44661,
      "prescriptions postoperative": 64543,
      "programs shown": 65565,
      "known regarding": 40928,
      "implementation enhanced": 36927,
      "guide opioid": 34405,
      "improvements group": 37174,
      "reductions opioid": 69115,
      "2016 april": 2735,
      "gabapentin tramadol": 32805,
      "acetaminophen ketorolac": 7200,
      "used account": 84829,
      "downward trend": 26423,
      "assisted thoracic": 12199,
      "18 morphine": 2096,
      "sustained reduction": 79782,
      "did impact": 24452,
      "impact hospital": 36815,
      "readmission rates": 67991,
      "days odds": 22561,
      "administration background": 8221,
      "unique analgesic": 83751,
      "oxycodone ooxy": 55561,
      "reduce hospital": 68844,
      "undergone elective": 83595,
      "gastro intestinal": 32858,
      "complete postoperative": 18448,
      "buprenorphine oral": 14572,
      "2017 primary": 2802,
      "nrs 11": 50055,
      "associated outcome": 12366,
      "reduced 24": 68900,
      "requirements postoperative": 70889,
      "mg 04": 45694,
      "04 nrs": 453,
      "associated similar": 12440,
      "change practice": 15743,
      "analgesia delivered": 9947,
      "surgery prospective": 79539,
      "confirm observed": 19494,
      "patient centred": 58552,
      "centred outcomes": 15637,
      "72 prescribed": 5631,
      "institution study": 39087,
      "implemented intervention": 36947,
      "intervention targeting": 39651,
      "targeting key": 80503,
      "37 intervention": 4191,
      "prescribed decreased": 63848,
      "42 12": 4447,
      "refills did": 69173,
      "significantly change": 75667,
      "vs conclusion": 86637,
      "procedures increasing": 65309,
      "provides rationale": 66236,
      "similar interventions": 75938,
      "prescribed united": 64000,
      "identify ways": 36540,
      "patients determine": 59183,
      "procedures institution": 65310,
      "carpal tunnel": 15129,
      "arthroscopic rotator": 11752,
      "rotator cuff": 72825,
      "cuff repair": 21377,
      "lumbar decompression": 42754,
      "opioid equivalents": 51788,
      "performed analyses": 60569,
      "results prescribing": 71886,
      "wide variation": 87048,
      "80 pills": 5860,
      "requested received": 70792,
      "prescribed standard": 63981,
      "cases study": 15266,
      "study year": 78569,
      "prescribed percent": 63948,
      "appropriate disposal": 11499,
      "effective prescribing": 27678,
      "diversion community": 25591,
      "community background": 17914,
      "prescribed excess": 63859,
      "postoperative prescription": 62953,
      "2019 70": 2855,
      "identify trends": 36539,
      "outcomes time": 54103,
      "underwent procedures": 83691,
      "intervention prescription": 39646,
      "oxycodone month": 55464,
      "tablets month": 80179,
      "relative increase": 69749,
      "sd prescription": 74090,
      "001 satisfaction": 203,
      "specific prescribing": 76612,
      "consensus guidelines": 19576,
      "used step": 85143,
      "conduct systematic": 19333,
      "ibuprofen group": 36356,
      "comorbidities conclusions": 17934,
      "associations patient": 12498,
      "information important": 38652,
      "history narcotic": 35465,
      "usage postoperative": 84130,
      "surgical data": 79627,
      "overall benefit": 54188,
      "benefit analgesia": 13615,
      "44 57": 4532,
      "age 54": 9023,
      "multivariate linear": 48345,
      "narcotic requirement": 48610,
      "higher postoperative": 35304,
      "sparing analgesia": 76528,
      "objectives previous": 50578,
      "conducted results": 19398,
      "demographics preoperative": 23302,
      "values comparable": 85835,
      "associated shorter": 12422,
      "use cost": 84285,
      "postoperative complication": 62725,
      "group single": 34023,
      "operative times": 51270,
      "use surgery": 84768,
      "chiari malformation": 15995,
      "protocol implemented": 65973,
      "scheduled nonsteroidal": 73649,
      "46 78": 4623,
      "used protocol": 85091,
      "usage lower": 84123,
      "predicted mean": 63563,
      "mean decrease": 43749,
      "antiemetic requirements": 11189,
      "protocol scheduled": 65996,
      "acetaminophen diazepam": 7178,
      "survey determine": 79706,
      "distributed members": 25555,
      "prescribed adults": 63816,
      "postoperatively children": 62994,
      "60 doses": 5251,
      "direct laryngoscopy": 25049,
      "study identifies": 78237,
      "help combat": 34898,
      "education opioid": 27385,
      "open procedure": 51197,
      "based survey": 13389,
      "survey distributed": 79707,
      "milligram oxycodone": 46475,
      "assessed compared": 11991,
      "using wilcoxon": 85678,
      "wilcoxon signed": 87093,
      "signed rank": 75399,
      "university based": 83855,
      "center participants": 15536,
      "medical school": 44401,
      "effects fewer": 27926,
      "multidisciplinary approach": 48180,
      "process starting": 65341,
      "ketorolac lidocaine": 40650,
      "nefopam oxycodone": 49059,
      "oxycodone parecoxib": 55640,
      "included 18": 37384,
      "incidence moderate": 37279,
      "conclusion nefopam": 18931,
      "limited small": 41961,
      "states associated": 77082,
      "respiratory dysfunction": 71291,
      "thoracic pain": 81120,
      "role reducing": 72766,
      "studied case": 77607,
      "blocks oxycodone": 14093,
      "catheter placement": 15315,
      "catheter place": 15314,
      "catheter removed": 15320,
      "removed patient": 70336,
      "mean cost": 43737,
      "years despite": 87583,
      "previously defined": 64938,
      "methods cohort": 45272,
      "guideline recommended": 34423,
      "included 100": 37374,
      "mean prescription": 43846,
      "prescription change": 64174,
      "200 000": 2394,
      "mg prescribed": 46178,
      "25 low": 3360,
      "pills significant": 61542,
      "groups discussion": 34189,
      "discussion patients": 25307,
      "sparing multimodal": 76531,
      "hydromorphone breakthrough": 36158,
      "pain standard": 57858,
      "needed acetaminophen": 48969,
      "scale secondary": 73563,
      "scores inpatient": 73896,
      "consumption outpatient": 19969,
      "consumption visual": 20038,
      "arm required": 11676,
      "required detect": 70829,
      "difference 25": 24576,
      "therapy patient": 81044,
      "demographics similar": 23306,
      "mm vs": 46942,
      "40 mm": 4364,
      "mm 03": 46923,
      "vs 04": 86515,
      "91 001": 6130,
      "hour follow": 35699,
      "ibuprofen patients": 36372,
      "surgery 96": 79310,
      "offers improved": 50962,
      "significantly limit": 75767,
      "background post": 13163,
      "design adult": 23695,
      "free discharge": 32487,
      "patient called": 58546,
      "prescription older": 64269,
      "ci 002": 16365,
      "independent predictors": 38163,
      "opportunities opioid": 53404,
      "undergo surgery": 83504,
      "programs united": 65566,
      "prescribed higher": 63868,
      "largest difference": 41189,
      "seen high": 74358,
      "high prescribers": 35148,
      "prescribers defined": 64016,
      "procedures evaluated": 65303,
      "prescribing need": 64083,
      "16 30": 1855,
      "methods postoperative": 45471,
      "reconstruction single": 68648,
      "equivalent number": 29320,
      "days hospital": 22532,
      "reconstruction results": 68647,
      "12 19": 1222,
      "19 42": 2173,
      "taking 15": 80298,
      "70 reported": 5571,
      "studies exist": 77725,
      "comparisons groups": 18385,
      "58 male": 5159,
      "residents reported": 71081,
      "guidelines acute": 34427,
      "attending surgeons": 12560,
      "opioids laparoscopic": 53012,
      "vs 74": 86616,
      "residents prescribe": 71078,
      "prescriptions operation": 64525,
      "effect single": 27560,
      "orthopedic patients": 53827,
      "undergoing knee": 83545,
      "set prescribing": 74757,
      "decrease opioids": 22911,
      "period interventions": 60737,
      "practices reviewed": 63441,
      "prescriptions pediatric": 64537,
      "001 decrease": 127,
      "decrease approximately": 22885,
      "reduced number": 68948,
      "currently consensus": 21492,
      "day 72": 22261,
      "66 49": 5447,
      "39 41": 4262,
      "surgeons reported": 79280,
      "prescribing nonopioid": 64086,
      "discharge changes": 25109,
      "background united": 13209,
      "conducted methods": 19377,
      "appropriate results": 11515,
      "38 average": 4238,
      "mmes number": 46986,
      "tablets 60": 80119,
      "60 prescribers": 5277,
      "respondents indicated": 71311,
      "conclusions considerable": 19056,
      "using lowest": 85476,
      "lowest dose": 42729,
      "address gap": 7924,
      "prescribing recommendations": 64131,
      "expert panel": 30690,
      "methods 15": 45234,
      "panel included": 58065,
      "specific recommendations": 76618,
      "opioid quantities": 52227,
      "nonopioid therapies": 49815,
      "2020 march": 2904,
      "participating hospitals": 58391,
      "hospitals used": 35675,
      "determine changes": 23993,
      "total 33": 81748,
      "second year": 74199,
      "surgery decreased": 79367,
      "38 mg": 4241,
      "001 25": 102,
      "prescribed number": 63901,
      "based strategies": 13382,
      "data multiple": 22013,
      "2018 data": 2817,
      "surveys chart": 79747,
      "systems states": 80044,
      "recent consensus": 68393,
      "reports compared": 70715,
      "compared prospectively": 18285,
      "aggregated data": 9255,
      "percent did": 60460,
      "median consumption": 44206,
      "consumption mg": 19954,
      "greater 75th": 33425,
      "consumption conclusions": 19908,
      "provider prescription": 66178,
      "drugs received": 27052,
      "postoperative phone": 62950,
      "seeking additional": 74347,
      "patients immediately": 59379,
      "immediately surgery": 36753,
      "addiction united": 7777,
      "effective practice": 27677,
      "dramatic decrease": 26432,
      "characterize prescribing": 15904,
      "clinicopathologic data": 17041,
      "collected including": 17463,
      "score 74": 73725,
      "patients length": 59444,
      "vs 58": 86597,
      "equivalents hospital": 29353,
      "significantly influenced": 75759,
      "regimen associated": 69297,
      "conducted subjects": 19414,
      "explored results": 30733,
      "criteria inclusion": 21203,
      "inclusion study": 37696,
      "13 percent": 1502,
      "refill patients": 69161,
      "hours 60": 35740,
      "factors age": 31070,
      "exposure range": 30789,
      "equivalents mg": 29357,
      "period reduce": 60784,
      "findings clinical": 31773,
      "background 2016": 13002,
      "provider group": 66175,
      "opioid maximum": 51897,
      "outpatient foot": 54120,
      "regression coefficients": 69433,
      "model opioid": 47062,
      "hindfoot ankle": 35413,
      "prescribed 18": 63805,
      "used 47": 84828,
      "bony procedures": 14243,
      "001 ankle": 109,
      "present modified": 64623,
      "ii prospective": 36571,
      "outpatient procedures": 54140,
      "protocol compared": 65962,
      "compared month": 18206,
      "pre implementation": 63468,
      "post implementation": 62575,
      "28 16": 3536,
      "number additional": 50135,
      "month postoperative": 47406,
      "significantly post": 75832,
      "group pre": 33930,
      "prescribed reduced": 63970,
      "patients month": 59527,
      "demonstrated success": 23372,
      "leading increase": 41311,
      "number secondary": 50254,
      "suggest fewer": 78992,
      "patients leaving": 59442,
      "crisis study": 21179,
      "intervention given": 39632,
      "given prescription": 33190,
      "recorded analysed": 68669,
      "according patient": 7055,
      "significantly predicted": 75836,
      "opioid 001": 51348,
      "years training": 87680,
      "analyses supported": 10614,
      "patient discharge": 58621,
      "interventions aimed": 39655,
      "compare prospectively": 18049,
      "standardized clinical": 76952,
      "patients converted": 59158,
      "age preoperative": 9104,
      "score hospital": 73753,
      "room time": 72780,
      "time significantly": 81378,
      "versus 55": 86111,
      "55 hours": 5075,
      "estimated blood": 29621,
      "ml 0001": 46819,
      "17 15": 1934,
      "04 time": 457,
      "002 conclusions": 236,
      "twice long": 83310,
      "medication discharge": 44487,
      "outcomes determine": 54021,
      "misuse response": 46748,
      "prospectively maintained": 65899,
      "maintained database": 42886,
      "use reoperations": 84692,
      "years 29": 87538,
      "risk misuse": 72598,
      "risk prolonged": 72644,
      "surgery increases": 79426,
      "elective surgeries": 28500,
      "institution january": 39076,
      "relationship perioperative": 69724,
      "consisted 14": 19673,
      "44 54": 4531,
      "oxycodone 0001": 54473,
      "known complication": 40904,
      "surgery higher": 79416,
      "messaging platform": 44865,
      "platform used": 61985,
      "patients responded": 59920,
      "median tablets": 44287,
      "left unused": 41350,
      "opioids relative": 53253,
      "clinicians policy": 17036,
      "commonly oxycodone": 17857,
      "use include": 84423,
      "provider education": 66174,
      "education use": 27399,
      "use multimodal": 84504,
      "regimens including": 69334,
      "medication needed": 44521,
      "scheduled dosing": 73642,
      "use local": 84457,
      "blocks patient": 14094,
      "opioid safety": 52354,
      "medication background": 44464,
      "background current": 13033,
      "societal levels": 76364,
      "study survey": 78528,
      "85 percent": 5989,
      "average 36": 12867,
      "reported consuming": 70527,
      "57 percent": 5136,
      "control 05": 20260,
      "prescribed nearly": 63899,
      "study prescribing": 78423,
      "prescribing based": 64034,
      "database used": 22192,
      "72 vs": 5633,
      "acetaminophen 60": 7137,
      "protocol improve": 65974,
      "prescribing culture": 64046,
      "department objectives": 23438,
      "impact preoperative": 36841,
      "risk stratification": 72661,
      "reporting study": 70705,
      "satisfaction surveys": 73443,
      "evaluated cohorts": 29867,
      "postimplementation group": 62663,
      "302 patients": 3826,
      "decreased incidence": 23002,
      "tramadol common": 82047,
      "discharge medication": 25138,
      "protocol significantly": 65998,
      "maintaining high": 42902,
      "2020 background": 2892,
      "methods retrospectively": 45549,
      "bypass graft": 14630,
      "graft cabg": 33396,
      "cabg procedures": 14663,
      "exposed patients": 30747,
      "use 30": 84152,
      "patterns similar": 60228,
      "10 relative": 913,
      "incidence chronic": 37264,
      "patients 21": 58842,
      "22 001": 3007,
      "develop alternative": 24143,
      "high compared": 35074,
      "regarding optimal": 69262,
      "limited purpose": 41954,
      "cardiac operations": 14982,
      "enrollment patients": 29035,
      "patient diary": 58619,
      "34 used": 4038,
      "younger 60": 87731,
      "use smoking": 84738,
      "support need": 79203,
      "development prescription": 24248,
      "surgery introduction": 79433,
      "patterns important": 60208,
      "dispensing drugs": 25448,
      "medicare beneficiary": 44436,
      "prescription 2013": 64152,
      "written orthopaedic": 87378,
      "prescriptions received": 64553,
      "geographic regions": 33112,
      "results 2013": 71551,
      "acetaminophen 47": 7132,
      "guidelines orthopaedic": 34453,
      "patterns objectives": 60212,
      "eras pathway": 29491,
      "improvement program": 37159,
      "2017 april": 2771,
      "eras cohort": 29488,
      "gastric bypass": 32851,
      "51 109": 4948,
      "45 71": 4576,
      "low median": 42497,
      "inpatient morphine": 39013,
      "stay 05": 77272,
      "recommend prescribing": 68583,
      "preoperative acetaminophen": 63733,
      "pre incisional": 63469,
      "intraoperative ketorolac": 39772,
      "50 112": 4804,
      "home prescription": 35522,
      "represents significant": 70772,
      "use breast": 84225,
      "pain pathway": 57330,
      "pathway implemented": 58512,
      "surgery addition": 79312,
      "special care": 76558,
      "different amounts": 24842,
      "institution enrolled": 39074,
      "phone survey": 61363,
      "consumed discharge": 19828,
      "patient information": 58664,
      "total 170": 81733,
      "discharge asked": 25106,
      "total 99": 81776,
      "consumed median": 19834,
      "overprescribed opioids": 54352,
      "opioids overprescribing": 53130,
      "surgeons increasingly": 79274,
      "formation study": 32298,
      "perioperative ketorolac": 60835,
      "adult women": 8530,
      "undergoing reduction": 83572,
      "ketorolac administration": 40641,
      "500 consecutive": 4916,
      "ketorolac perioperative": 40655,
      "total intraoperative": 81819,
      "opioids adolescents": 52709,
      "iii importance": 36586,
      "epidemic physicians": 29144,
      "11 2020": 1103,
      "2021 exposures": 2913,
      "obtained opioid": 50770,
      "opioid quantity": 52228,
      "declined year": 22872,
      "absolute decrease": 6594,
      "obtained 2009": 50757,
      "absolute increase": 6597,
      "increase 2009": 37719,
      "obtained fewer": 50768,
      "period suggesting": 60799,
      "increased objective": 37957,
      "frequency postoperative": 32527,
      "versus vs": 86164,
      "revision surgery": 72430,
      "rate results": 67515,
      "analgesia adult": 9905,
      "condition pain": 19281,
      "cases opioids": 15249,
      "adult tonsillectomy": 8524,
      "rehabilitation programs": 69509,
      "underwent tonsillectomy": 83700,
      "percent women": 60505,
      "acetaminophen initial": 7198,
      "received 60": 68107,
      "days tonsillectomy": 22645,
      "38 year": 4248,
      "treatment year": 82892,
      "alcohol marijuana": 9535,
      "conclusion short": 18991,
      "post tonsillectomy": 62623,
      "tonsillectomy pain": 81665,
      "does result": 25692,
      "term narcotic": 80641,
      "medication treatment": 44575,
      "tonsillectomy patients": 81666,
      "evidence patient": 30243,
      "use standardized": 84745,
      "performed independent": 60598,
      "sufficient information": 78972,
      "knee hip": 40863,
      "tablets studies": 80218,
      "inclusion exclusion": 37691,
      "criteria conclusion": 21193,
      "provide recommendations": 66092,
      "making background": 43008,
      "following various": 32220,
      "2015 september": 2721,
      "pre vs": 63496,
      "44 01": 4523,
      "surgery vs": 79619,
      "aor 89": 11335,
      "10 01": 656,
      "01 oxycodone": 319,
      "aor 10": 11294,
      "associated provider": 12397,
      "modal pain": 47010,
      "randomized group": 67115,
      "trend lower": 82947,
      "median 32": 44190,
      "21 05": 2936,
      "brief educational": 14427,
      "intervention decrease": 39628,
      "contributing opioid": 20244,
      "evaluate perioperative": 29829,
      "44 22": 4525,
      "22 50": 3025,
      "rho 65": 72463,
      "14 48": 1571,
      "86 pills": 6009,
      "laparoscopic bariatric": 41093,
      "background rates": 13190,
      "using cumulative": 85367,
      "senior residents": 74534,
      "junior residents": 40565,
      "management education": 43179,
      "instructions authors": 39110,
      "method systematic": 45218,
      "published 2009": 66423,
      "2009 2019": 2520,
      "postoperative discharge": 62769,
      "patients demographic": 59175,
      "collected electronic": 17457,
      "26 17": 3425,
      "age surgery": 9127,
      "surgery female": 79400,
      "described literature": 23656,
      "medical professionals": 44388,
      "use result": 84702,
      "centre retrospective": 15634,
      "group 54": 33625,
      "99 0001": 6481,
      "catheters used": 15324,
      "confirm clinical": 19491,
      "magnitude postoperative": 42816,
      "procedures summary": 65328,
      "database stratified": 22185,
      "stratified preoperative": 77453,
      "naive sporadic": 48408,
      "defined prescriptions": 23149,
      "filled months": 31705,
      "preceding surgery": 63504,
      "filled 30": 31700,
      "interpretation results": 39505,
      "likely chronic": 41800,
      "pills naive": 61519,
      "pills chronic": 61501,
      "surgery 15": 79297,
      "prescriptions conclusion": 64461,
      "time chronic": 81220,
      "importantly work": 37044,
      "surgery level": 79439,
      "introduction managing": 39933,
      "individualized approach": 38318,
      "surgical team": 79654,
      "narcotic pills": 48604,
      "decreased 12": 22940,
      "surgery institution": 79427,
      "intervention 48": 39623,
      "patients excess": 59269,
      "excess medication": 30451,
      "surgeries 001": 79283,
      "patient provider": 58722,
      "allowing patients": 9643,
      "increased patient": 37978,
      "epidemic authors": 29127,
      "receiving multimodal": 68356,
      "fewer morphine": 31645,
      "maintaining adequate": 42898,
      "study evaluating": 78191,
      "protocol beginning": 65960,
      "cohort 10": 17336,
      "protocol implementation": 65972,
      "iv ketorolac": 40381,
      "protocol opioids": 65982,
      "ad libitum": 7716,
      "compared retrospective": 18299,
      "21 versus": 2985,
      "63 002": 5350,
      "20 02": 2266,
      "02 16": 353,
      "versus 13": 86098,
      "hour time": 35720,
      "multimodal opioid": 48220,
      "common complication": 17744,
      "various studies": 85979,
      "interventions postoperative": 39678,
      "rcts investigating": 67916,
      "investigating efficacy": 40066,
      "review evaluated": 72295,
      "drugs analyzed": 26886,
      "higher efficacy": 35236,
      "significant efficacy": 75538,
      "control intravenous": 20358,
      "diphenhydramine glycopyrrolate": 25029,
      "paracetamol parecoxib": 58112,
      "showed efficacy": 75245,
      "points compared": 62127,
      "educational materials": 27404,
      "design performed": 23746,
      "activated charcoal": 7461,
      "operative visit": 51272,
      "enrolled 31": 28996,
      "32 percent": 3936,
      "10 laparoscopic": 777,
      "19 percent": 2191,
      "39 percent": 4276,
      "percent 22": 60448,
      "option medication": 53457,
      "surgery demonstrating": 79368,
      "001 increase": 148,
      "study clearly": 77991,
      "patients safety": 59935,
      "tens thousands": 80608,
      "year objective": 87453,
      "knowledge gaps": 40885,
      "orthopedic providers": 53831,
      "common orthopedic": 17788,
      "prescription writing": 64421,
      "writing process": 87372,
      "academic hospitals": 6949,
      "johns hopkins": 40482,
      "55 oxycodone": 5078,
      "inverse correlation": 39987,
      "relevant changes": 70047,
      "79 percent": 5802,
      "orthopedic postoperative": 53829,
      "undergoing operative": 83560,
      "pills counted": 61505,
      "counted standardized": 20930,
      "standardized equivalent": 76955,
      "online prescription": 51100,
      "consumption total": 20033,
      "iii comparative": 36584,
      "disproportionate risk": 25504,
      "novel multimodal": 50016,
      "consisted 100": 19671,
      "q6 hours": 66621,
      "analogue pain": 10549,
      "scale postoperative": 73544,
      "patients 33": 58857,
      "pathway significant": 58520,
      "observed preoperative": 50707,
      "intraoperative variables": 39783,
      "treatments statistically": 82929,
      "differences average": 24716,
      "free treatment": 32494,
      "study june": 78283,
      "inpatients prescribed": 39040,
      "opioid general": 51824,
      "patients prophylactic": 59711,
      "regression analyze": 69429,
      "met study": 44882,
      "increasing age": 38092,
      "oxycodone 59": 54587,
      "compared medical": 18202,
      "regimen future": 69307,
      "rates background": 67558,
      "background assess": 13016,
      "prevalence incidence": 64787,
      "analgesics methods": 10448,
      "points pain": 62138,
      "assessment evaluated": 12119,
      "day home": 22319,
      "time time": 81391,
      "nrs used": 50083,
      "subgroups defined": 78621,
      "pain longer": 57033,
      "intensity location": 39261,
      "group chronic": 33680,
      "present patients": 64625,
      "pain located": 57029,
      "compared surgery": 18321,
      "paracetamol used": 58120,
      "pain developed": 56706,
      "background variability": 13216,
      "exists opioid": 30532,
      "resulting prescription": 71533,
      "na\u00efve adult": 48826,
      "376 patients": 4218,
      "patients preintervention": 59666,
      "ome prescribed": 51062,
      "225 mg": 3058,
      "containing opioid": 20079,
      "requiring refills": 70910,
      "multimodal therapy": 48249,
      "consumption women": 20043,
      "study assessing": 77976,
      "home week": 35526,
      "collected daily": 17453,
      "consumption calculated": 19902,
      "administration postoperative": 8338,
      "postoperative anesthesia": 62718,
      "anesthesia recovery": 10947,
      "consumption quartile": 20001,
      "80 women": 5862,
      "analyzed mean": 10840,
      "60 88": 5238,
      "years women": 87690,
      "underwent vaginal": 83702,
      "older women": 51045,
      "eras protocols": 29494,
      "protocols use": 66006,
      "surgery improves": 79423,
      "control decreases": 20293,
      "2020 june": 2903,
      "pre eras": 63466,
      "eras group": 29489,
      "eras patients": 29492,
      "given celecoxib": 33156,
      "celecoxib gabapentin": 15459,
      "gabapentin acetaminophen": 32789,
      "day complications": 22280,
      "results 50": 71571,
      "patients eras": 59258,
      "chronic kidney": 16195,
      "kidney disease": 40822,
      "analgesia compared": 9931,
      "001 cumulative": 125,
      "control 12": 20262,
      "control discharge": 20295,
      "discharge similar": 25176,
      "score vs": 73811,
      "use eras": 84354,
      "noninferior pain": 49745,
      "stay patients": 77285,
      "surgery investigated": 79434,
      "perioperative details": 60832,
      "usage opioid": 84125,
      "prescribed 12": 63804,
      "12 interquartile": 1308,
      "requested refill": 70793,
      "37 61": 4183,
      "iqr 36": 40174,
      "examined postoperative": 30403,
      "age 56": 9025,
      "38 75": 4234,
      "consumed 15": 19824,
      "50 used": 4904,
      "opioids differences": 52852,
      "compared 75": 18089,
      "75 56": 5698,
      "07 conclusion": 604,
      "benefit additional": 13614,
      "outpatient orthopedic": 54133,
      "details morphine": 23923,
      "regression performed": 69453,
      "utilization rate": 85735,
      "rate 50": 67436,
      "identified independent": 36441,
      "consumption large": 19944,
      "observed patient": 50699,
      "face challenging": 31014,
      "practices hypothesized": 63426,
      "consensus ideal": 19577,
      "ideal opioid": 36405,
      "prescribing select": 64137,
      "outpatient surgical": 54150,
      "discharge 20": 25096,
      "panel recommendations": 58068,
      "tablets 20": 80115,
      "16 20": 1849,
      "opioid amounts": 51439,
      "currently overprescribing": 21502,
      "trends postoperative": 82980,
      "seven days": 74866,
      "postoperatively total": 63031,
      "baseline 65": 13415,
      "175 mmes": 2014,
      "2013 67": 2624,
      "remained study": 70277,
      "need identify": 48928,
      "requires opioid": 70895,
      "adolescent young": 8448,
      "analysis case": 10647,
      "prescribed prescriptions": 63961,
      "prescriptions converted": 64465,
      "oxycodone equals": 55028,
      "performed controlling": 60579,
      "weight gender": 86979,
      "race insurance": 66940,
      "advanced practice": 8600,
      "25 opioid": 3374,
      "ome 95": 51054,
      "interval 38": 39567,
      "high prescribing": 35149,
      "prescription amounts": 64164,
      "interval 32": 39565,
      "variability prescribing": 85876,
      "clear need": 16706,
      "background prior": 13178,
      "prior literature": 65157,
      "emergence opioid": 28667,
      "practices united": 63444,
      "methods separate": 45571,
      "data phase": 22045,
      "surgery centers": 79343,
      "measure consumption": 43937,
      "average wholesale": 12946,
      "wholesale price": 87038,
      "price awp": 64967,
      "awp minus": 12987,
      "differences cost": 24727,
      "results phase": 71869,
      "187 001": 2147,
      "96 001": 6417,
      "individual medications": 38301,
      "significant cost": 75455,
      "elective orthopedic": 28498,
      "study funded": 78213,
      "study administrative": 77911,
      "states commercial": 77085,
      "2018 participants": 2835,
      "participants opioid": 58332,
      "use starting": 84746,
      "lasting 90": 41209,
      "opioid fills": 51809,
      "associated 20": 12209,
      "increase adjusted": 37728,
      "41 increase": 4424,
      "surgery similar": 79587,
      "providers use": 66197,
      "caution prescribing": 15417,
      "medication regimens": 44554,
      "efficacy multimodal": 28300,
      "design primary": 23756,
      "use secondary": 84719,
      "constipation patients": 19776,
      "postoperative treatment": 62976,
      "included specific": 37555,
      "intraoperative medications": 39775,
      "narcotics ibuprofen": 48632,
      "ibuprofen narcotics": 36363,
      "oral hydrocodone": 53544,
      "postoperatively week": 63036,
      "care arm": 15003,
      "arm patients": 11672,
      "fewer intravenous": 31641,
      "vs 104": 86525,
      "31 29": 3856,
      "29 mg": 3608,
      "significantly multimodal": 75818,
      "147 mg": 1654,
      "162 mg": 1912,
      "use hospital": 84404,
      "postoperatively conclusion": 62996,
      "providing equivalent": 66260,
      "equivalent pain": 29328,
      "surgery unclear": 79613,
      "related risks": 69682,
      "used individually": 84974,
      "individually linked": 38323,
      "64 65": 5383,
      "69 70": 5516,
      "70 74": 5553,
      "74 75": 5671,
      "subsequent opioid": 78778,
      "procedure results": 65284,
      "results surgical": 72001,
      "age 001": 8965,
      "001 trend": 217,
      "dose initial": 25937,
      "trends conclusions": 82962,
      "age postoperative": 9102,
      "risk long": 72590,
      "term analgesic": 80617,
      "previously prescribed": 64953,
      "canada april": 14748,
      "1997 december": 2240,
      "opioid days": 51694,
      "defined prescription": 23148,
      "nsaids used": 50106,
      "regression examine": 69441,
      "surgery opioids": 79489,
      "days 15": 22467,
      "15 year": 1802,
      "year compared": 87436,
      "discharge 30": 25098,
      "nsaid users": 50097,
      "conclusion prescription": 18971,
      "analgesics immediately": 10430,
      "frequently older": 32561,
      "risk medications": 72596,
      "underwent isolated": 83684,
      "offered enrollment": 50956,
      "standard prescription": 76929,
      "provided patient": 66147,
      "preoperatively participants": 63772,
      "completed baseline": 18463,
      "baseline demographic": 13427,
      "index pain": 38203,
      "likert pain": 41851,
      "period primary": 60778,
      "82 patients": 5910,
      "criteria 40": 21188,
      "40 randomized": 4376,
      "prescription 001": 64147,
      "001 18": 99,
      "25 standard": 3385,
      "participants using": 58382,
      "opioids average": 52743,
      "arm 001": 11663,
      "prescriptions groups": 64493,
      "calendar days": 14721,
      "prior year": 65178,
      "discontinuation results": 25231,
      "characteristics comorbidities": 15851,
      "27 42": 3481,
      "reduced odds": 68949,
      "32 49": 3915,
      "oxycodone aor": 54722,
      "04 79": 446,
      "discontinuation conclusions": 25222,
      "users surgery": 85274,
      "recognized important": 68573,
      "important contributor": 37002,
      "access procedures": 7001,
      "use information": 84433,
      "follow appointments": 32011,
      "25th 75th": 3411,
      "pills pills": 61531,
      "suggests patients": 79041,
      "medication 50": 44450,
      "using lower": 85475,
      "analgesia recommended": 10080,
      "upper arm": 84000,
      "surgery large": 79438,
      "patient telephone": 58799,
      "use calculated": 84227,
      "use group": 84384,
      "reviewed opioids": 72386,
      "005 resulting": 267,
      "surgery prescribed": 79531,
      "exert analgesic": 30500,
      "inhibitors ssris": 38814,
      "reduce effectiveness": 68840,
      "learning approach": 41326,
      "prescribed combination": 63836,
      "combination postoperative": 17599,
      "natural language": 48741,
      "language processing": 41085,
      "unstructured data": 83948,
      "data medications": 22008,
      "surgery evaluate": 79397,
      "model using": 47091,
      "repeated 10": 70399,
      "patients symptoms": 60029,
      "opioid 18": 51351,
      "f1 score": 31009,
      "ssri group": 76818,
      "significantly worse": 75868,
      "accurately predicted": 7105,
      "score using": 73805,
      "87 81": 6019,
      "provide direct": 66050,
      "direct clinical": 25038,
      "ssris inhibit": 76820,
      "opioid effectiveness": 51757,
      "opioid study": 52381,
      "direct acting": 25037,
      "guidelines patients": 34457,
      "common orthopaedic": 17787,
      "tka tha": 81490,
      "effort reduce": 28434,
      "questions purposes": 66910,
      "day refill": 22400,
      "primary tka": 65116,
      "quantity refill": 66844,
      "rate methods": 67483,
      "new institutional": 49335,
      "maximum postoperative": 43610,
      "prescription 400": 64155,
      "care institution": 15038,
      "psychiatric illness": 66327,
      "neuropathy cancer": 49276,
      "ordered 30": 53726,
      "difference medians": 24630,
      "difference patients": 24661,
      "versus 35": 86106,
      "undergoing tha": 83583,
      "implementation institutional": 36935,
      "number patient": 50216,
      "provides proof": 66234,
      "current report": 21464,
      "term data": 80625,
      "determine longitudinal": 24022,
      "procedures level": 65311,
      "ii therapeutic": 36574,
      "patterns based": 60197,
      "usage 24": 84112,
      "included number": 37490,
      "results 77": 71583,
      "77 eligible": 5759,
      "took 10": 81668,
      "32 prescribed": 3937,
      "15 0001": 1668,
      "10 21": 692,
      "rate remained": 67513,
      "protocol adherence": 65956,
      "size cohort": 76182,
      "took significantly": 81677,
      "used guide": 84949,
      "pain orthopedic": 57299,
      "procedures use": 65331,
      "improvement study": 37165,
      "taken oxycodone": 80289,
      "outcomes self": 54094,
      "10 representing": 915,
      "procedures results": 65324,
      "51 women": 4964,
      "iqr 32": 40173,
      "56 years": 5112,
      "32 59": 3918,
      "80 72": 5833,
      "80 75": 5834,
      "reported consumption": 70529,
      "patients 64": 58885,
      "relevance quality": 70038,
      "differed patient": 24562,
      "opioids importance": 52966,
      "use characterized": 84233,
      "studies patient": 77804,
      "large prospective": 41148,
      "30 2016": 3674,
      "preoperative patient": 63756,
      "age 31": 8991,
      "years adjusted": 87557,
      "22 42": 3022,
      "current use": 21486,
      "60 higher": 5255,
      "medical comorbidities": 44347,
      "society anesthesiology": 76382,
      "aor 47": 11306,
      "undergoing lower": 83549,
      "aor 61": 11321,
      "12 45": 1253,
      "group undergoing": 34058,
      "study preoperative": 78421,
      "measures patients": 44081,
      "guide future": 34404,
      "significant portion patients": 75596,
      "operative pain management": 51265,
      "crisis little known": 21172,
      "hospital opioid use": 35608,
      "hospital opioid consumption": 35606,
      "oral oxycodone increased": 53630,
      "despite increased use": 23885,
      "increased use strong": 38044,
      "overall opioid use": 54220,
      "opioid use decreased": 52491,
      "opioid use patterns": 52564,
      "opioid diversion misuse": 51727,
      "opiate pain medications": 51307,
      "800 mg tablets": 5868,
      "little data available": 42150,
      "november 2019 august": 50038,
      "2019 august 2020": 2858,
      "included visual analog": 37575,
      "50 morphine milligram": 4869,
      "associated decreased opioid": 12245,
      "decreased opioid use": 23017,
      "result increased opioid": 71481,
      "increased opioid consumption": 37963,
      "opioid consumption reduce": 51656,
      "study needed confirm": 78323,
      "opioid use objective": 52544,
      "initial opioids prescribed": 38859,
      "developing new persistent": 24204,
      "new persistent opioid": 49359,
      "use design setting": 84302,
      "administrative claims database": 8397,
      "claims database january": 16628,
      "days index procedure": 22538,
      "developed new persistent": 24185,
      "90 180 days": 6077,
      "180 days surgery": 2123,
      "discharge multivariable logistic": 25143,
      "heart valve surgery": 34877,
      "surgery mean sd": 79456,
      "61 12 years": 5306,
      "valve surgery patients": 85858,
      "kidney failure chronic": 40824,
      "failure chronic pain": 31148,
      "risk new persistent": 72603,
      "objective study designed": 50504,
      "study designed test": 78103,
      "designed test hypothesis": 23852,
      "surgery summary background": 79601,
      "2018 31 2019": 2813,
      "2019 primary outcome": 2881,
      "included self reported": 37549,
      "opioid refills results": 52291,
      "refills results total": 69180,
      "conclusions patients prescribed": 19155,
      "guidelines recommend number": 34468,
      "number mg oxycodone": 50171,
      "opioid overdose leading": 52016,
      "overdose leading cause": 54299,
      "leading cause injury": 41304,
      "cause injury related": 15358,
      "death united states": 22727,
      "united states studies": 83826,
      "decreased opioid prescribing": 23016,
      "opioid prescribing analysis": 52084,
      "general surgical operations": 32991,
      "patients data analyzed": 59168,
      "age 58 years": 9029,
      "number opioid pills": 50191,
      "pills prescription decreased": 61539,
      "difference overall satisfaction": 24648,
      "multimodal postoperative analgesia": 48239,
      "methods data opioid": 45305,
      "scheduled acetaminophen ibuprofen": 73635,
      "number opioid doses": 50189,
      "median age years": 44203,
      "years mean number": 87612,
      "patients used opioids": 60166,
      "factor significantly associated": 31061,
      "significantly associated opioid": 75657,
      "excessive opioid prescriptions": 30462,
      "seventy patients undergoing": 74890,
      "dose med prescribed": 25951,
      "med prescribed results": 44162,
      "80 oxycodone mg": 5855,
      "na\u00efve opioid experienced": 48835,
      "confidence interval 25": 19449,
      "confidence interval 14": 19444,
      "11 95 confidence": 1121,
      "confidence interval 92": 19455,
      "day postoperative pain": 22386,
      "analysis surgery type": 10778,
      "highest opioid use": 35358,
      "similar groups 05": 75925,
      "05 conclusions despite": 504,
      "pain scores women": 57797,
      "needed determine optimal": 48996,
      "october 2019 patients": 50889,
      "scores patient satisfaction": 73945,
      "pain inventory scores": 56978,
      "worst pain highest": 87343,
      "postoperative day median": 62740,
      "satisfied pain control": 73459,
      "conclusions patients undergoing": 19157,
      "low pain scores": 42530,
      "opioid based analgesia": 51556,
      "method pain control": 45195,
      "adequacy pain control": 7956,
      "aimed evaluate efficacy": 9449,
      "based postoperative analgesia": 13359,
      "board approval patients": 14179,
      "based visual analog": 13402,
      "control group received": 20338,
      "opioid based postoperative": 51558,
      "scores measured visual": 73902,
      "use converted morphine": 84281,
      "postoperative day vs": 62757,
      "objectives purpose study": 50586,
      "randomized prospective study": 67159,
      "patients randomly divided": 59752,
      "group control received": 33719,
      "average daily pain": 12885,
      "patients group took": 59342,
      "group took average": 34050,
      "oxycodone patients group": 55657,
      "pain scores conclusions": 57711,
      "compromising pain control": 18643,
      "consumption oxycodone increased": 19972,
      "largest increase oxycodone": 41194,
      "unplanned emergency department": 83915,
      "methods patients randomized": 45436,
      "oxycodone mg ketorolac": 55420,
      "mg ketorolac 10": 45943,
      "ketorolac 10 mg": 40635,
      "breakthrough pain primary": 14402,
      "primary study outcome": 65112,
      "differences postoperative pain": 24790,
      "higher maximum pain": 35260,
      "pain scores days": 57713,
      "patients receiving ketorolac": 59840,
      "mean sd vs": 43873,
      "opioid use post": 52567,
      "background opioids prescribed": 13124,
      "related deaths united": 69584,
      "united states prescribing": 83819,
      "analyzed data opioid": 10826,
      "data opioid prescription": 22030,
      "consecutive patients undergoing": 19565,
      "associated increased consumption": 12298,
      "patient operative factors": 58691,
      "video abstract http": 86212,
      "abstract http links": 6624,
      "http links lww": 35924,
      "links lww com": 42062,
      "inpatient opioid consumption": 39015,
      "opioid consumption following": 51621,
      "adult patients underwent": 8521,
      "design prospective multicenter": 23761,
      "used text messaging": 85156,
      "daily opioid consumption": 21773,
      "associated high opioid": 12275,
      "significant multivariate analysis": 75582,
      "75 mme 10": 5712,
      "10 oxycodone tablets": 886,
      "oxycodone tablets addition": 55979,
      "chronic postoperative opioid": 16331,
      "use opioid abuse": 84542,
      "medication taken weeks": 44572,
      "opioids weeks postoperatively": 53390,
      "multivariate analyses performed": 48340,
      "acetaminophen celecoxib pregabalin": 7160,
      "equivalents interquartile range": 29356,
      "range iqr oxycodone": 67321,
      "oxycodone prescribed discharge": 55741,
      "mg 100 mg": 45706,
      "prescribing patterns discharge": 64105,
      "high opioid consumption": 35126,
      "prescribed management pain": 63887,
      "removal impacted molars": 70331,
      "present study determine": 64655,
      "study determine oral": 78113,
      "needed adequate postoperative": 48975,
      "use postoperatively conclusions": 84636,
      "naloxone reduce opioid": 48514,
      "reduce opioid induced": 68861,
      "study examined feasibility": 78200,
      "methods single centre": 45582,
      "oxycodone primary endpoints": 55758,
      "results eighty patients": 71675,
      "received allocated intervention": 68115,
      "day similar groups": 22420,
      "23 control group": 3095,
      "patients oxycodone naloxone": 59616,
      "group shorter time": 34004,
      "opioid consumption mean": 51629,
      "www clinicaltrials gov": 87393,
      "prescribing practices purpose": 64120,
      "purpose study quantify": 66589,
      "study quantify opioid": 78442,
      "boston children hospital": 14255,
      "complete study postoperative": 18454,
      "study postoperative prescriptions": 78417,
      "postoperative prescriptions instructions": 62955,
      "opioid use inpatient": 52526,
      "electronic questionnaire day": 28543,
      "questionnaire day postoperative": 66891,
      "day postoperative days": 22385,
      "statistics calculated results": 77242,
      "postoperative opioid analgesia": 62812,
      "opioid requirements mean": 52342,
      "pain level postoperative": 57009,
      "conclusion opioid use": 18939,
      "caution necessary avoid": 15415,
      "non linear mixed": 49622,
      "opioid consumption postoperative": 51649,
      "nrs scores pain": 50081,
      "pain intensity 51": 56885,
      "opioid consumption time": 51669,
      "related pain intensity": 69660,
      "pain intensity time": 56953,
      "time opioid request": 81304,
      "study highlights importance": 78229,
      "manage post operative": 43123,
      "pain following oral": 56790,
      "following oral surgery": 32173,
      "post operative analgesia": 62589,
      "patient expectations pain": 58632,
      "crisis purpose evaluate": 21176,
      "purpose evaluate efficacy": 66533,
      "pain narcotic use": 57223,
      "subjects randomized groups": 78727,
      "tablets oxycodone acetaminophen": 80189,
      "ibu 600 mg": 36339,
      "met primary endpoint": 44880,
      "analysis significant differences": 10770,
      "differences noted patient": 24762,
      "group used significantly": 34061,
      "used significantly lower": 85129,
      "compared nsaid group": 18220,
      "vs 008 differences": 86509,
      "opioid consumption patterns": 51646,
      "study conducted single": 78031,
      "conducted single tertiary": 19409,
      "patients underwent elective": 60141,
      "oxycodone mg pills": 55438,
      "consumption 24 hour": 19877,
      "consumed mean 10": 19833,
      "oxycodone mg pill": 55436,
      "patients consumed pills": 59145,
      "independently associated increased": 38178,
      "limitations study limited": 41911,
      "study limited single": 78291,
      "outpatient opioid consumption": 54127,
      "patients consumed opioid": 59142,
      "consumed opioid pills": 19837,
      "prescribed opioids excess": 63927,
      "opioid use 24": 52464,
      "use 24 hours": 84151,
      "opioid crisis united": 51688,
      "united states evidence": 83794,
      "patient satisfaction postoperative": 58769,
      "quantity opioid prescription": 66835,
      "randomized controlled noninferiority": 67062,
      "controlled noninferiority trial": 20508,
      "patients assigned randomly": 59015,
      "years age undergoing": 87568,
      "pain catastrophizing scale": 56515,
      "opioid prescription patients": 52157,
      "patients received multimodal": 59798,
      "received multimodal pain": 68206,
      "patients asked complete": 59006,
      "use primary outcome": 84667,
      "outcome patient satisfaction": 53976,
      "majority patients white": 42995,
      "range 14 vs": 67258,
      "unused opioid tablets": 83962,
      "quantity opioid tablets": 66837,
      "australian government department": 12699,
      "government department veterans": 33352,
      "days post discharge": 22584,
      "75 ome 10": 5716,
      "prospective observational pilot": 65844,
      "observational pilot study": 50615,
      "breakthrough pain postoperative": 14401,
      "pain control results": 56653,
      "number oxycodone pills": 50212,
      "additional opioid prescriptions": 7873,
      "visited emergency department": 86272,
      "pain control day": 56609,
      "prescribed level evidence": 63878,
      "evidence therapeutic study": 30284,
      "therapeutic study level": 80964,
      "type quantity medication": 83351,
      "quantity medication prescribed": 66830,
      "medication prescribed quantity": 44539,
      "prescribed quantity leftover": 63968,
      "quantity leftover medication": 66828,
      "patients participated study": 59633,
      "patients satisfied pain": 59940,
      "total 67 patients": 81767,
      "evidence based prescribing": 30163,
      "calculated results total": 14703,
      "significantly mg oxycodone": 75816,
      "score standard deviation": 73797,
      "reduce opioid prescriptions": 68864,
      "use compromising pain": 84257,
      "opioid analgesics common": 51487,
      "opioid prescribing time": 52127,
      "trends hydrocodone acetaminophen": 82968,
      "oxycodone acetaminophen prescribed": 54659,
      "prescribed opioids commonly": 63924,
      "patients underwent outpatient": 60149,
      "surgery data collected": 79363,
      "significant reduction narcotic": 75612,
      "use opioids pain": 84564,
      "opioids pain control": 53145,
      "control patient satisfaction": 20387,
      "patient satisfaction following": 58759,
      "use pain level": 84594,
      "stopped taking opioids": 77392,
      "satisfied pain management": 73460,
      "significant difference average": 75470,
      "difference average pain": 24597,
      "pain relief satisfaction": 57577,
      "30 opioid tablets": 3779,
      "postoperative narcotic pain": 62799,
      "eighty percent patients": 28459,
      "analgesia postoperative day": 10063,
      "postoperative day patient": 62743,
      "day patient reported": 22362,
      "reported satisfaction pain": 70644,
      "postoperative day half": 62739,
      "acetaminophen widely used": 7263,
      "opioid prescription patterns": 52158,
      "pain management model": 57082,
      "protocol included preoperative": 65976,
      "multimodal pain regimen": 48235,
      "questions regarding pain": 66912,
      "equivalents secondary outcomes": 29379,
      "05 results total": 548,
      "results total 113": 72021,
      "total 113 patients": 81713,
      "fewer oxycodone mg": 31658,
      "postdischarge pain control": 62643,
      "protocol pain management": 65984,
      "patient satisfaction study": 58777,
      "conducted randomized controlled": 19393,
      "adult ed patients": 8491,
      "randomized receive 10": 67162,
      "14 days secondary": 1592,
      "subjects enrolled study": 78694,
      "groups secondary outcome": 34312,
      "outcome measures compared": 53935,
      "age 19 years": 8981,
      "narcotics pain scores": 48636,
      "pain scores postdischarge": 57764,
      "scores results patients": 73978,
      "randomized multimodal pain": 67126,
      "day average pain": 22272,
      "week average pain": 86831,
      "consumption pain intensity": 19976,
      "using automated text": 85316,
      "large urban academic": 41158,
      "urban academic health": 84027,
      "adult patients 18": 8506,
      "intensity patient reported": 39288,
      "quantity opioids prescribed": 66839,
      "opioids prescribed consumed": 53205,
      "median pain intensity": 44268,
      "patients prescribed median": 59674,
      "mg oxycodone equivalent": 46112,
      "oxycodone equivalent pills": 55035,
      "reported taking median": 70664,
      "respectively statistically significant": 71252,
      "using real time": 85593,
      "evidence based opioid": 30160,
      "based opioid prescribing": 13344,
      "pain reduction following": 57498,
      "postoperative pain results": 62917,
      "longer period time": 42385,
      "pain statistically significant": 57862,
      "pain control purpose": 56648,
      "pain negative impact": 57232,
      "spine surgery patients": 76730,
      "weeks surgery methods": 86959,
      "21 days surgery": 2968,
      "surgery results baseline": 79568,
      "opioid na\u00efve group": 51979,
      "group opioid na\u00efve": 33881,
      "prospective study aimed": 65885,
      "associated lower odds": 12328,
      "study evaluates opioid": 78190,
      "open minimally invasive": 51193,
      "consumption data converted": 19911,
      "data converted morphine": 21928,
      "vs 65 years": 86607,
      "patients open patients": 59579,
      "pain scores using": 57790,
      "associated increased opioid": 12304,
      "decrease opioid consumption": 22908,
      "received long acting": 68193,
      "oxycodone iv morphine": 55319,
      "patients received iv": 59789,
      "postoperative period purpose": 62944,
      "surgery postoperative pain": 79529,
      "observational study conducted": 50625,
      "18 65 years": 2062,
      "main outcome variable": 42847,
      "equivalents mme patients": 29360,
      "opioid nonopioid analgesic": 52002,
      "analgesic consumption 24": 10171,
      "test statistical analysis": 80785,
      "value 05 considered": 85821,
      "reported postoperative pain": 70629,
      "consumed opioid analgesic": 19836,
      "groups reported similar": 34295,
      "pain required opioid": 57622,
      "conclusion based study": 18863,
      "increased opioid analgesic": 37962,
      "role current opioid": 72738,
      "prospective observational cohort": 65842,
      "cohort study included": 17394,
      "mme patients received": 46972,
      "patients received 10": 59762,
      "mg oxycodone 75": 46105,
      "48 hours primary": 4719,
      "hours primary outcome": 35834,
      "increased postoperative pain": 37990,
      "10 95 confidence": 736,
      "influence opioid use": 38594,
      "opioid consumption level": 51626,
      "consumption level evidence": 19946,
      "level evidence laryngoscope": 41471,
      "patients randomized control": 59731,
      "oxycodone acetaminophen combination": 54635,
      "patients randomized treatment": 59744,
      "drugs recorded results": 27057,
      "abuse objective study": 6790,
      "characterize opioid prescribing": 15897,
      "settings patients treated": 74860,
      "2018 september 2019": 2845,
      "discharge opioid prescription": 25147,
      "opioid prescription refills": 52163,
      "28 patients received": 3565,
      "median 10 range": 44172,
      "fewer opioid pills": 31650,
      "reported higher pain": 70562,
      "limitations study included": 41910,
      "pain management outpatient": 57093,
      "55 years old": 5084,
      "western united states": 87007,
      "postoperative pain important": 62873,
      "study aimed analyze": 77919,
      "opioid prescribing methods": 52108,
      "2016 june 2017": 2752,
      "disabilities arm shoulder": 25069,
      "arm shoulder hand": 11679,
      "visits results patients": 86292,
      "morphine equivalent units": 47667,
      "patients consumed oxycodone": 59144,
      "outpatient upper extremity": 54153,
      "upper extremity surgery": 84004,
      "extremity surgery patients": 30990,
      "age gender procedure": 9074,
      "pain control number": 56627,
      "study oxycodone hydrocodone": 78354,
      "patients undergoing bone": 60089,
      "overall patients consumed": 54228,
      "type study level": 83356,
      "study level evidence": 78286,
      "level evidence prognostic": 41478,
      "anesthesia multimodal analgesia": 10924,
      "methods quality improvement": 45501,
      "healthy patients undergoing": 34839,
      "elective colorectal surgery": 28488,
      "score pain score": 73769,
      "pain management bowel": 57056,
      "management bowel function": 43155,
      "study determine efficacy": 78109,
      "efficacy pre emptive": 28331,
      "pain adult patients": 56421,
      "surgery obstructive sleep": 79482,
      "group postoperative period": 33927,
      "analgesia oral oxycodone": 10043,
      "vs mg 05": 86657,
      "development chronic pain": 24219,
      "gastrointestinal adverse effects": 32865,
      "opioid induced ventilatory": 51869,
      "induced ventilatory impairment": 38460,
      "cost effectiveness analyses": 20872,
      "marketing long acting": 43425,
      "commercial claims data": 17702,
      "claims data set": 16624,
      "postoperative morphine milligram": 62795,
      "opioid prescription surgery": 52165,
      "knee arthroplasty total": 40860,
      "arthroplasty total hip": 11747,
      "patients postoperative opioid": 59658,
      "introduction long acting": 39931,
      "postoperative outpatient opioid": 62836,
      "use methods patients": 84484,
      "use results total": 84707,
      "mg tablet equivalents": 46228,
      "number oxycodone mg": 50210,
      "data provide benchmark": 22070,
      "duration outpatient opioid": 27174,
      "median number pills": 44256,
      "multivariate analysis demonstrated": 48343,
      "significantly fewer pills": 75704,
      "fewer pills prescribed": 31663,
      "responsible opioid prescribing": 71403,
      "operation discharge patients": 51218,
      "opioids based opioid": 52747,
      "patients undergoing major": 60113,
      "patients underwent major": 60147,
      "use disposal results": 84337,
      "disposal results total": 25489,
      "total 155 patients": 81725,
      "included analysis patients": 37422,
      "patient counseling regarding": 58600,
      "perioperative opioid use": 60843,
      "opioid use aim": 52469,
      "patients undergoing common": 60093,
      "asked report opioid": 11848,
      "opioid consumption discharge": 51620,
      "median quantity opioid": 44278,
      "quantity opioid prescribed": 66834,
      "prescribing introduction opioid": 64072,
      "opioid prescribing objective": 52113,
      "demographic characteristics results": 23273,
      "patients included median": 59397,
      "median age interquartile": 44201,
      "age interquartile range": 9085,
      "range iqr 69": 67320,
      "years majority white": 87610,
      "reported higher levels": 70561,
      "younger age lower": 87734,
      "contributor opioid epidemic": 20254,
      "equivalents mme results": 29363,
      "results seventy patients": 71942,
      "average mme consumed": 12896,
      "hospital discharge following": 35581,
      "evidence level ii": 30205,
      "exact tests results": 30321,
      "mean milligram morphine": 43796,
      "pain management critical": 57065,
      "study measure change": 78303,
      "codeine 30 mg": 17200,
      "opioid free postoperative": 51819,
      "free postoperative pain": 32492,
      "surgical procedures performed": 79648,
      "primary predictor variable": 65104,
      "pain control assessed": 56604,
      "days 14 days": 22465,
      "mean age 49": 43686,
      "equivalent 18 oxycodone": 29284,
      "18 oxycodone mg": 2101,
      "pain opioid prescribing": 57286,
      "improve postoperative opioid": 37080,
      "opioid prescribing include": 52103,
      "significantly reduces opioid": 75852,
      "roux en gastric": 72876,
      "30 2018 retrospectively": 3676,
      "hospital stay days": 35633,
      "setting study set": 74830,
      "study population included": 78413,
      "use weeks surgery": 84810,
      "methods subgroup analysis": 45596,
      "patient demographics surgical": 58615,
      "weeks surgery results": 86961,
      "pain score surgery": 57684,
      "intense postoperative pain": 39211,
      "consumption patterns following": 19987,
      "study setting study": 78492,
      "single center design": 76059,
      "conclusions opioid prescribing": 19134,
      "statistically significant decrease": 77205,
      "significant decrease pain": 75462,
      "decrease pain scores": 22916,
      "pain scores vs": 57795,
      "001 oxycodone equivalent": 175,
      "associated significant improvement": 12425,
      "study single institution": 78504,
      "institution patients undergoing": 39081,
      "included patients underwent": 37511,
      "day pod pod": 22377,
      "30 pain scores": 3783,
      "prescribed opioids 40": 63919,
      "equivalent 10 tablets": 29280,
      "opioid prescriptions light": 52195,
      "curb opioid prescribing": 21417,
      "opioid prescriptions emergency": 52186,
      "reducing postoperative opioid": 69030,
      "large academic hospital": 41119,
      "opioid naive opioid": 51969,
      "introduction opioids used": 39945,
      "opioids used manage": 53369,
      "used reduce opioid": 85103,
      "reduce opioid usage": 68867,
      "clinical trial compare": 16924,
      "opioid therapy pain": 52420,
      "therapy pain management": 81043,
      "opioid oxycodone acetaminophen": 52025,
      "constipation adverse events": 19748,
      "adverse events assessed": 8729,
      "non opioid analgesia": 49647,
      "results analyses based": 71600,
      "postoperative pain data": 62862,
      "opioid group difference": 51827,
      "50 mg oxycodone": 4860,
      "response rate 86": 71364,
      "pain pills week": 57379,
      "discharge methods retrospective": 25140,
      "surgery conclusion patients": 79351,
      "use immediate postoperative": 84417,
      "pain medication requested": 57158,
      "opioid prescribing compared": 52090,
      "mean age 59": 43692,
      "percent tramadol 22": 60497,
      "tramadol 22 percent": 82027,
      "reported high satisfaction": 70559,
      "outpatient surgery patients": 54149,
      "patients study design": 60006,
      "na\u00efve patients undergoing": 48847,
      "patients recorded pain": 59866,
      "recorded pain scores": 68689,
      "scores number opioid": 73919,
      "extracted medical record": 30960,
      "surveys mean age": 79751,
      "mean age 60": 43693,
      "prescribed postoperative pain": 63955,
      "followed oxycodone acetaminophen": 32079,
      "oxycodone acetaminophen 26": 54629,
      "mme interquartile range": 46966,
      "oxycodone pills iqr": 55686,
      "opioid prescriptions postoperative": 52208,
      "little known regarding": 42164,
      "implementation enhanced recovery": 36928,
      "standardized multimodal analgesic": 76971,
      "rate opioid prescriptions": 67490,
      "assisted thoracic surgery": 12200,
      "intraoperative opioid administration": 39778,
      "sustained reduction opioid": 79783,
      "reduction opioid prescriptions": 69077,
      "days odds ratio": 22562,
      "17 95 confidence": 1956,
      "subgroup analysis showed": 78618,
      "analysis showed significant": 10767,
      "oral oxycodone ooxy": 53636,
      "reduce hospital length": 68845,
      "acute pain total": 7677,
      "buprenorphine oral oxycodone": 14573,
      "hospital stay los": 35635,
      "factors associated outcome": 31079,
      "outcome measures results": 53953,
      "requirements postoperative day": 70890,
      "controlled analgesia delivered": 20447,
      "surgery prospective randomized": 79540,
      "patient centred outcomes": 58553,
      "based prescribing guidelines": 13363,
      "analysis used compare": 10786,
      "frequency opioid prescription": 32521,
      "refills did significantly": 69174,
      "did significantly change": 24505,
      "13 vs 14": 1512,
      "prescribed united states": 64001,
      "prescribing practices methods": 64118,
      "practices methods performed": 63429,
      "number unused pills": 50275,
      "carpal tunnel release": 15130,
      "arthroscopic rotator cuff": 11753,
      "rotator cuff repair": 72826,
      "equivalents oxycodone mg": 29372,
      "disposal unused opioids": 25492,
      "pills prescribed discharge": 61535,
      "unused opioid pills": 83961,
      "methods collected data": 45274,
      "mean sd prescription": 43870,
      "mg oxycodone 12": 46096,
      "opioid consumption decreased": 51618,
      "pain care results": 56512,
      "opioid prescribing using": 52129,
      "using evidence based": 85393,
      "oxycodone mg oral": 55433,
      "postoperative pain group": 62871,
      "procedure specific opioid": 65287,
      "specific opioid prescribing": 76606,
      "little data exist": 42151,
      "concerns regarding opioid": 18846,
      "age 54 years": 9024,
      "24 hour postoperative": 3207,
      "associated higher postoperative": 12282,
      "patient demographics preoperative": 58611,
      "postoperative oxycodone use": 62841,
      "opioid use surgery": 52599,
      "oxycodone intravenous morphine": 55294,
      "outcome total opioid": 54000,
      "opioid requirement patients": 52338,
      "length stay conclusions": 41406,
      "pain following common": 56789,
      "pain medication prescribed": 57157,
      "conclusion study identifies": 19001,
      "using wilcoxon signed": 85679,
      "wilcoxon signed rank": 87094,
      "medical center participants": 44340,
      "incidence moderate severe": 37280,
      "united states associated": 83781,
      "celiac plexus blocks": 15469,
      "thoracic paravertebral nerve": 81123,
      "population objective study": 62363,
      "study included 100": 78247,
      "included 100 patients": 37375,
      "significantly reduced opioid": 75846,
      "prescription opioid overdose": 64304,
      "important risk factor": 37028,
      "oxycodone mg prescribed": 55440,
      "pain following ambulatory": 56787,
      "opioid sparing multimodal": 52368,
      "multimodal postoperative pain": 48240,
      "standard postoperative pain": 76927,
      "regimen patients undergoing": 69320,
      "design multicenter randomized": 23727,
      "multicenter randomized controlled": 48168,
      "controlled trial women": 20620,
      "women undergoing vaginal": 87255,
      "surgery patients randomized": 79512,
      "hydromorphone breakthrough pain": 36159,
      "oxycodone intravenous hydromorphone": 55293,
      "analog scale secondary": 10536,
      "outpatient pain medication": 54135,
      "pain medication consumption": 57151,
      "consumption visual analog": 20039,
      "patients arm required": 59001,
      "arm required detect": 11677,
      "mean difference 25": 43755,
      "pain score lower": 57675,
      "median pain scores": 44270,
      "compared oxycodone acetaminophen": 18235,
      "acetaminophen ibuprofen patients": 7197,
      "96 hours postoperatively": 6423,
      "differences patient satisfaction": 24781,
      "satisfaction quality recovery": 73423,
      "95 ci 002": 6222,
      "patients undergo surgery": 60084,
      "programs united states": 65567,
      "associated significantly decreased": 12434,
      "significantly decreased opioid": 75678,
      "opioid prescribing need": 52110,
      "postoperative patient reported": 62933,
      "majority patients undergoing": 42994,
      "equivalent number mg": 29321,
      "range 12 19": 67253,
      "day follow visit": 22314,
      "patients reported taking": 59893,
      "orthopedic patients undergoing": 53828,
      "patients undergoing knee": 60107,
      "retrospective observational setting": 72148,
      "prescribing practices reviewed": 64122,
      "opioid prescriptions pediatric": 52206,
      "prescriptions pediatric patients": 64538,
      "study evaluated opioid": 78184,
      "10 12 months": 669,
      "prescribing nonopioid analgesics": 64087,
      "changes opioid prescribing": 15803,
      "background united states": 13210,
      "conclusions considerable variability": 19057,
      "2020 march 2021": 2905,
      "used determine changes": 84911,
      "prescriptions decreased significantly": 64469,
      "001 median number": 155,
      "approach resulted significant": 11478,
      "address opioid epidemic": 7929,
      "greater 75th percentile": 33426,
      "methods performed retrospective": 45454,
      "performed retrospective chart": 60625,
      "inflammatory drugs received": 38572,
      "postoperative phone calls": 62951,
      "addiction united states": 7778,
      "safe effective practice": 73085,
      "characterize prescribing patterns": 15905,
      "opioids opioid consumption": 53119,
      "opioid consumption study": 51666,
      "consumption study design": 20027,
      "university hospital subjects": 83865,
      "data collected including": 21909,
      "mean maximum pain": 43791,
      "pain score 74": 57668,
      "conclusion population patients": 18965,
      "higher postoperative pain": 35305,
      "population methods retrospective": 62356,
      "year surgery patients": 87507,
      "surgery patients followed": 79506,
      "period months surgery": 60752,
      "factors associated prescription": 31081,
      "daily morphine milligram": 21766,
      "equivalents 10 mg": 29339,
      "mg oxycodone hours": 46119,
      "opioid exposure range": 51798,
      "opioids purpose study": 53237,
      "purpose study prospectively": 66587,
      "undergoing outpatient foot": 83564,
      "outpatient foot ankle": 54121,
      "patients opioid consumption": 59582,
      "model opioid consumption": 47063,
      "opioids patients used": 53166,
      "level ii prospective": 41487,
      "ii prospective observational": 36572,
      "study background opioid": 77979,
      "background opioid prescribing": 13114,
      "prescriptions month period": 64516,
      "showed significant decrease": 75297,
      "group 001 total": 33531,
      "pills prescribed reduced": 61537,
      "opioid crisis study": 51685,
      "crisis study aimed": 21180,
      "study aimed characterise": 77921,
      "cohort study consecutive": 17389,
      "consecutive patients presenting": 19563,
      "median age 50": 44198,
      "frequently prescribed analgesic": 32569,
      "aimed reducing opioid": 9466,
      "methods study included": 45591,
      "estimated blood loss": 29622,
      "pain medication discharge": 57152,
      "based postoperative opioid": 13360,
      "prospectively maintained database": 65900,
      "receiving opioid prescription": 68361,
      "opioid use reoperations": 52583,
      "primary outcome difference": 65061,
      "consumed results patients": 19849,
      "results patients met": 71850,
      "evaluate opioid use": 29820,
      "risk prolonged use": 72647,
      "patients methods using": 59512,
      "institution january 2014": 39077,
      "perioperative opioid prescription": 60841,
      "opioid prescription 90": 52133,
      "days surgery patients": 22639,
      "risk persistent opioid": 72631,
      "analysis opioid non": 10719,
      "surgery opioid na\u00efve": 79487,
      "evaluate opioid consumption": 29817,
      "text messaging platform": 80886,
      "opioid use measured": 52534,
      "day median tablets": 22335,
      "overall study period": 54261,
      "request opioid refill": 70786,
      "use multimodal pain": 84505,
      "predictors opioid consumption": 63592,
      "chronic pain syndrome": 16316,
      "opioid use total": 52601,
      "average 36 mg": 12868,
      "36 mg oxycodone": 4136,
      "reported consuming average": 70528,
      "opioid consumption conclusions": 51616,
      "study prescribing patterns": 78424,
      "database used identify": 22193,
      "age 48 years": 9013,
      "proportion patients filling": 65765,
      "refill rates increased": 69168,
      "evaluated cohorts patients": 29868,
      "group results total": 33990,
      "148 patients underwent": 1659,
      "management protocol significantly": 43250,
      "methods retrospectively reviewed": 45550,
      "artery bypass graft": 11724,
      "bypass graft cabg": 14631,
      "compared opioid na\u00efve": 18229,
      "patients prescribed total": 59683,
      "ongoing opioid use": 51088,
      "prescribing limited purpose": 64077,
      "used opioids discharge": 85053,
      "opioids discharge median": 52859,
      "milligram equivalents interquartile": 46459,
      "history substance use": 35485,
      "pain score day": 57672,
      "drugs purpose study": 27050,
      "purpose study characterize": 66572,
      "recent trends opioid": 68433,
      "methods study used": 45594,
      "number prescriptions written": 50243,
      "prescriptions written orthopaedic": 64574,
      "opioids hydrocodone acetaminophen": 52956,
      "nonopioid pain medications": 49814,
      "pain medications increased": 57165,
      "opioid prescriptions increase": 52192,
      "opioid prescription volume": 52169,
      "quality improvement program": 66709,
      "cohort compared patients": 17350,
      "en gastric bypass": 28757,
      "median inpatient morphine": 44227,
      "higher morphine equivalent": 35264,
      "discharged home prescription": 25202,
      "conclusions multimodal nonopioid": 19123,
      "multimodal nonopioid pain": 48219,
      "pills opioid prescription": 61524,
      "total 99 patients": 81777,
      "opioids prescribed patients": 53211,
      "patients overprescribed opioids": 59607,
      "risk factors opioid": 72571,
      "adult women undergoing": 8531,
      "received intravenous ketorolac": 68178,
      "ketorolac perioperative period": 40656,
      "use associated lower": 84212,
      "lower total intraoperative": 42716,
      "opioid epidemic physicians": 51777,
      "opioid prescription days": 52141,
      "type opioid quantity": 83338,
      "public health concerns": 66382,
      "june 30 2020": 40559,
      "postoperative pain commonly": 62855,
      "patients underwent tonsillectomy": 60154,
      "year surgery results": 87508,
      "patients received 60": 59765,
      "refill rate 30": 69165,
      "25 patients received": 3378,
      "patients received additional": 59767,
      "conclusion short term": 18992,
      "post tonsillectomy pain": 62624,
      "abuse treatment program": 6901,
      "mitigate risk opioid": 46765,
      "adult tonsillectomy patients": 8525,
      "knee hip arthroplasty": 40864,
      "use higher postoperative": 84398,
      "inclusion exclusion criteria": 37692,
      "use varies widely": 84800,
      "decision making background": 22845,
      "2015 september 2017": 2722,
      "aor 89 95": 11336,
      "aor 10 95": 11295,
      "factors associated provider": 31082,
      "reducing opioid consumption": 69021,
      "randomized single center": 67185,
      "multi modal pain": 48150,
      "opioids control group": 52822,
      "brief educational intervention": 14428,
      "surgery patients background": 79503,
      "background overprescribing opioids": 13130,
      "patients underwent laparoscopic": 60145,
      "multimodal analgesia used": 48208,
      "week follow visit": 86841,
      "001 patients required": 184,
      "laparoscopic bariatric surgery": 41094,
      "opioid use background": 52473,
      "pain management education": 57067,
      "method systematic review": 45219,
      "collected electronic medical": 17458,
      "percentage patients receiving": 60514,
      "35 mg kg": 4084,
      "17 patients received": 1981,
      "received opioids commonly": 68223,
      "40 mg kg": 4350,
      "significantly associated higher": 75655,
      "variability opioid prescribing": 85868,
      "patients described literature": 59179,
      "postoperative period background": 62937,
      "opioid use result": 52586,
      "single centre retrospective": 76075,
      "2017 april 2018": 2772,
      "cohort study performed": 17400,
      "duration magnitude postoperative": 27164,
      "magnitude postoperative opioid": 42817,
      "procedures summary background": 65329,
      "opioid prescription methods": 52155,
      "database stratified preoperative": 22186,
      "stratified preoperative opioid": 77454,
      "defined prescriptions filled": 23150,
      "prescriptions filled months": 64488,
      "use defined time": 84296,
      "magnitude opioid use": 42814,
      "filled 30 days": 31701,
      "30 days post": 3730,
      "days post op": 22585,
      "naive patients likely": 48404,
      "patients likely chronic": 59449,
      "users opioid prescription": 85258,
      "pills naive vs": 61520,
      "prescriptions conclusion opioid": 64462,
      "use postoperative opioids": 84633,
      "naive patients continued": 48403,
      "prescriptions year surgery": 64576,
      "surgery level evidence": 79440,
      "pharmacy records patients": 61264,
      "number narcotic pills": 50176,
      "pre intervention post": 63473,
      "disposal excess medication": 25483,
      "increased patient satisfaction": 37979,
      "opioid epidemic authors": 51770,
      "postoperatively patients received": 63016,
      "intravenous iv ketorolac": 39845,
      "verbal numeric rating": 86072,
      "multimodal opioid sparing": 48221,
      "opioid sparing analgesia": 52365,
      "reduces opioid use": 68998,
      "systematically searched identify": 80016,
      "efficacy different drugs": 28250,
      "various time points": 85983,
      "time points compared": 81336,
      "efficacy adverse effects": 28217,
      "study design performed": 78075,
      "opioids post operative": 53188,
      "post operative visit": 62608,
      "patients average age": 59020,
      "patients successfully completed": 60012,
      "orthopedic surgeons highest": 53834,
      "prescription writing process": 64422,
      "mg pill equivalents": 46159,
      "clinically relevant changes": 16989,
      "immediate postoperative opioid": 36703,
      "patients undergoing operative": 60118,
      "postoperative visit opioid": 62979,
      "visit opioid pills": 86266,
      "opioid pills counted": 52060,
      "pills counted standardized": 61506,
      "counted standardized equivalent": 20931,
      "standardized equivalent number": 76956,
      "patients consumed median": 59141,
      "use conclusion study": 84259,
      "level iii comparative": 41491,
      "hours pain scores": 35810,
      "pain scores collected": 57707,
      "scores collected using": 73847,
      "visual analogue pain": 86322,
      "days results data": 22611,
      "differences observed preoperative": 24766,
      "treatments statistically different": 82930,
      "differences average pain": 24717,
      "met study criteria": 44883,
      "morphine 84 95": 47567,
      "opioid prescriptions did": 52183,
      "patients time points": 60046,
      "pain assessment evaluated": 56470,
      "scale nrs used": 73523,
      "nrs used assess": 50084,
      "pain pain intensity": 57318,
      "group chronic pain": 33681,
      "chronic pain present": 16307,
      "pain present patients": 57416,
      "followed tramadol oxycodone": 32087,
      "chronic pain developed": 16272,
      "cohort study evaluated": 17392,
      "opioid na\u00efve adult": 51976,
      "mg 75 mg": 45769,
      "001 fewer patients": 138,
      "001 patients received": 183,
      "patients requiring refills": 59914,
      "opioid consumption women": 51672,
      "analysis prospective cohort": 10746,
      "opioid consumption calculated": 51612,
      "opioid consumption quartile": 51653,
      "analyzed mean sd": 10841,
      "14 years range": 1634,
      "surgery eras protocols": 79391,
      "pain control decreases": 56611,
      "patients eras group": 59259,
      "eras group compared": 29490,
      "chronic kidney disease": 16196,
      "days vs days": 22653,
      "group 001 cumulative": 33528,
      "pain control discharge": 56613,
      "discharge similar groups": 25177,
      "similar groups pain": 75932,
      "pain score vs": 57690,
      "05 conclusion study": 502,
      "length stay patients": 41412,
      "stay patients undergoing": 77286,
      "reported opioid usage": 70598,
      "univariate multivariable regression": 83841,
      "used identify factors": 84960,
      "12 interquartile range": 1309,
      "requests opioid refills": 70798,
      "prescriptions associated increased": 64451,
      "69 years patients": 5529,
      "differences postoperative opioid": 24789,
      "recent opioid exposure": 68412,
      "following outpatient orthopedic": 32180,
      "collected patient demographics": 17471,
      "type opioid prescription": 83337,
      "identify independent predictors": 36509,
      "pills left unused": 61515,
      "higher opioid consumption": 35278,
      "14 001 conclusion": 1546,
      "associated opioid consumption": 12355,
      "variation opioid prescribing": 85918,
      "prescribing practices hypothesized": 64117,
      "outpatient opioid prescribing": 54129,
      "currently overprescribing opioids": 21503,
      "opioid crisis purpose": 51684,
      "na\u00efve patients 18": 48839,
      "sd age 50": 74075,
      "percentage patients filling": 60513,
      "prescribed opioid dose": 63910,
      "opioids increased risk": 52989,
      "adolescent young adult": 8449,
      "prescribed opioid general": 63911,
      "regression analysis demonstrated": 69422,
      "ome 95 confidence": 51055,
      "confidence interval 38": 19453,
      "confidence interval 32": 19451,
      "practices united states": 63445,
      "states opioid prescribing": 77132,
      "ambulatory surgery centers": 9775,
      "average wholesale price": 12947,
      "wholesale price awp": 87039,
      "price awp minus": 64968,
      "consumed patient decreased": 19842,
      "001 oxycodone cr": 174,
      "10 mg 001": 787,
      "mg 001 morphine": 45683,
      "elective orthopedic surgery": 28499,
      "risk prolonged opioid": 72645,
      "design observational study": 23731,
      "united states commercial": 83784,
      "2009 june 30": 2528,
      "june 30 2018": 40558,
      "opioid use starting": 52594,
      "lasting 90 days": 41210,
      "opioid use relative": 52582,
      "use secondary outcomes": 84721,
      "included preoperative postoperative": 37516,
      "intraoperative postoperative intravenous": 39780,
      "postoperative day week": 62758,
      "usual care arm": 85689,
      "used significantly fewer": 85128,
      "15 mg vs": 1768,
      "mg 001 significant": 45684,
      "postoperative time point": 62974,
      "weeks postoperatively conclusion": 86940,
      "opioid related risks": 52328,
      "surgical procedures methods": 79647,
      "64 65 69": 5384,
      "65 69 70": 5407,
      "69 70 74": 5517,
      "70 74 75": 5554,
      "opioid prescription decreased": 52142,
      "proportion opioid na\u00efve": 65753,
      "risk long term": 72591,
      "long term analgesic": 42324,
      "prescribed analgesics methods": 63820,
      "ontario canada april": 51128,
      "december 31 2008": 22833,
      "use defined prescription": 84295,
      "secondary analysis examined": 74209,
      "drugs nsaids used": 27013,
      "logistic regression examine": 42268,
      "high risk medications": 35171,
      "control satisfaction pain": 20417,
      "control opioid use": 20378,
      "design patients underwent": 23745,
      "prospective randomized open": 65866,
      "participants randomized receive": 58347,
      "daily pain score": 21796,
      "number opioids used": 50206,
      "forms pain management": 32313,
      "inclusion criteria 40": 37687,
      "opioid prescription 001": 52131,
      "fewer opioid prescriptions": 31651,
      "unused opioids community": 83964,
      "similar pain control": 75971,
      "matched cohort study": 43486,
      "defined opioid prescription": 23143,
      "primary outcome time": 65095,
      "interval ci 27": 39588,
      "mean preoperative opioid": 43845,
      "ci 04 79": 16375,
      "opioid prescriptions methods": 52197,
      "performed retrospective review": 60629,
      "review patients underwent": 72333,
      "patient factors including": 58639,
      "factors including age": 31100,
      "opioid benzodiazepine use": 51562,
      "eighty patients underwent": 28457,
      "25th 75th percentile": 3412,
      "opioid use conclusions": 52485,
      "2017 december 2017": 2778,
      "exert analgesic effects": 30501,
      "reuptake inhibitors ssris": 72208,
      "machine learning approach": 42793,
      "combination postoperative pain": 17600,
      "natural language processing": 48742,
      "significantly worse pain": 75869,
      "difference pain control": 24653,
      "week week follow": 86878,
      "pre operative pain": 63479,
      "pain score using": 57687,
      "direct clinical evidence": 25039,
      "current prescribing patterns": 21458,
      "undergoing common orthopaedic": 83524,
      "discharge 30 day": 25099,
      "30 day refill": 3719,
      "day refill rates": 22402,
      "factors influence opioid": 31108,
      "50 tablets mg": 4902,
      "tertiary care institution": 80738,
      "sex race body": 75083,
      "day refill rate": 22401,
      "associated prescription quantity": 12391,
      "conclusions study provides": 19222,
      "provides proof concept": 66235,
      "procedures level evidence": 65312,
      "level ii therapeutic": 41489,
      "therapeutic study background": 80963,
      "patients design single": 59181,
      "opioid usage 24": 52458,
      "usage 24 hours": 84113,
      "hours discharge patients": 35766,
      "number prescribed opioids": 50235,
      "results 77 eligible": 71584,
      "77 eligible patients": 5760,
      "prescribed fewer tablets": 63861,
      "patients took significantly": 60052,
      "took significantly fewer": 81678,
      "opioid consumption used": 51671,
      "quality improvement study": 66712,
      "improvement study conducted": 37166,
      "tablets prescribed patient": 80206,
      "outcomes self reported": 54095,
      "pain scale 10": 57660,
      "age 56 years": 9026,
      "sd pain score": 74089,
      "12 mean sd": 1319,
      "self reported consumption": 74493,
      "use opioids common": 84560,
      "opioid use characterized": 52477,
      "care academic medical": 14998,
      "common opioids used": 17785,
      "american society anesthesiology": 9807,
      "aor 47 95": 11307,
      "ci 37 58": 16441,
      "patients undergoing lower": 60111,
      "undergoing lower extremity": 83550,
      "aor 61 95": 11322,
      "61 95 ci": 5310,
      "group conclusions relevance": 33701,
      "patient reported outcome": 58735,
      "reported outcome measures": 70603,
      "outcome measures patients": 53947,
      "post operative pain management": 62604,
      "increased use strong opioids": 38045,
      "november 2019 august 2020": 50039,
      "included visual analog scale": 37576,
      "50 morphine milligram equivalents": 4870,
      "associated decreased opioid use": 12246,
      "new persistent opioid use": 49360,
      "discharge multivariable logistic regression": 25144,
      "kidney failure chronic pain": 40825,
      "risk new persistent opioid": 72604,
      "study designed test hypothesis": 78104,
      "surgery summary background data": 79602,
      "included self reported pain": 37550,
      "opioid refills results total": 52292,
      "opioid overdose leading cause": 52017,
      "overdose leading cause injury": 54300,
      "leading cause injury related": 41305,
      "mean number opioid doses": 43808,
      "number opioid doses prescribed": 50190,
      "methods seventy patients undergoing": 45577,
      "equivalent dose med prescribed": 29303,
      "dose med prescribed results": 25952,
      "opioid na\u00efve opioid experienced": 51982,
      "na\u00efve opioid experienced patients": 48836,
      "95 confidence interval 25": 6387,
      "95 confidence interval 14": 6383,
      "11 95 confidence interval": 1122,
      "95 confidence interval 92": 6392,
      "number mg oxycodone tablets": 50173,
      "research needed determine optimal": 71018,
      "objective study aimed evaluate": 50492,
      "brief pain inventory scores": 14433,
      "review board approval patients": 72267,
      "based visual analog scale": 13403,
      "opioid based postoperative analgesia": 51559,
      "pain scores measured visual": 57736,
      "use converted morphine equivalent": 84282,
      "objectives purpose study determine": 50587,
      "unplanned emergency department visits": 83916,
      "mg ketorolac 10 mg": 45944,
      "analogue scale pain score": 10555,
      "days secondary outcomes included": 22620,
      "differences postoperative pain scores": 24791,
      "related deaths united states": 69585,
      "video abstract http links": 86213,
      "abstract http links lww": 6625,
      "http links lww com": 35925,
      "multimodal pain management strategies": 48231,
      "surgery study design prospective": 79596,
      "daily opioid consumption pain": 21774,
      "associated high opioid use": 12277,
      "chronic postoperative opioid use": 16332,
      "interquartile range iqr oxycodone": 39531,
      "associated high opioid consumption": 12276,
      "adequate postoperative pain control": 7971,
      "prescribing practices purpose study": 64121,
      "purpose study quantify opioid": 66590,
      "did complete study postoperative": 24423,
      "complete study postoperative prescriptions": 18455,
      "study postoperative prescriptions instructions": 78418,
      "total postoperative opioid use": 81893,
      "postoperative opioid use inpatient": 62827,
      "electronic questionnaire day postoperative": 28544,
      "questionnaire day postoperative days": 66892,
      "pain level postoperative day": 57010,
      "scale nrs scores pain": 73522,
      "pain following oral surgery": 56791,
      "crisis purpose evaluate efficacy": 21177,
      "tablets oxycodone acetaminophen 325": 80190,
      "significant differences noted patient": 75510,
      "study conducted single tertiary": 78032,
      "conducted single tertiary care": 19410,
      "single tertiary care center": 76145,
      "patients consumed opioid pills": 59143,
      "opioid crisis united states": 51689,
      "objective primary objective study": 50474,
      "primary objective study compare": 65048,
      "randomized controlled noninferiority trial": 67063,
      "18 years age undergoing": 2111,
      "interquartile range 14 vs": 39519,
      "australian government department veterans": 12700,
      "government department veterans affairs": 33353,
      "90 days post discharge": 6098,
      "prospective observational pilot study": 65845,
      "results patients included study": 71849,
      "level evidence therapeutic study": 41482,
      "evidence therapeutic study level": 30285,
      "type quantity medication prescribed": 83352,
      "quantity medication prescribed quantity": 66831,
      "medication prescribed quantity leftover": 44540,
      "prescribed quantity leftover medication": 63969,
      "hydrocodone acetaminophen oxycodone acetaminophen": 36058,
      "opioids commonly used postoperative": 52805,
      "pain control patient satisfaction": 56637,
      "surgery methods prospective study": 79469,
      "significant difference average pain": 75471,
      "difference average pain scores": 24598,
      "study aimed evaluate efficacy": 77928,
      "results total 113 patients": 72022,
      "fewer oxycodone mg tablets": 31659,
      "methods conducted randomized controlled": 45282,
      "conducted randomized controlled trial": 19394,
      "statistically significant differences groups": 77214,
      "opioid consumption pain intensity": 51640,
      "using automated text messaging": 85317,
      "large urban academic health": 41159,
      "adult patients 18 years": 8507,
      "pain intensity patient reported": 56927,
      "tablets mg oxycodone equivalent": 80178,
      "mg oxycodone equivalent pills": 46113,
      "evidence based opioid prescribing": 30161,
      "21 days surgery results": 2969,
      "days surgery results baseline": 22642,
      "consumption data converted morphine": 19912,
      "data converted morphine milligram": 21929,
      "objective study aimed determine": 50491,
      "included pain scores opioid": 37503,
      "prospective observational study conducted": 65848,
      "intensity measured using numeric": 39265,
      "value 05 considered statistically": 85822,
      "role current opioid epidemic": 72739,
      "methods prospective observational cohort": 45487,
      "prospective observational cohort study": 65843,
      "cohort study included patients": 17395,
      "equivalents mme patients received": 29361,
      "48 hours primary outcome": 4720,
      "postoperative opioid use associated": 62826,
      "opioid use postoperative days": 52569,
      "10 95 confidence interval": 737,
      "opioid consumption level evidence": 51627,
      "disabilities arm shoulder hand": 25070,
      "outpatient upper extremity surgery": 54154,
      "type study level evidence": 83357,
      "pain management bowel function": 57057,
      "surgery obstructive sleep apnea": 79483,
      "patients methods prospective randomized": 59504,
      "blinded placebo controlled study": 14009,
      "adult patients undergoing elective": 8520,
      "placebo group postoperative period": 61749,
      "results statistically significant differences": 71966,
      "gastrointestinal adverse effects nausea": 32866,
      "adverse effects nausea vomiting": 8671,
      "opioid induced ventilatory impairment": 51870,
      "commercial claims data set": 17703,
      "postoperative morphine milligram equivalents": 62796,
      "total knee arthroplasty total": 81828,
      "knee arthroplasty total hip": 40861,
      "arthroplasty total hip arthroplasty": 11748,
      "opioid use methods patients": 52537,
      "opioid use results total": 52589,
      "oxycodone mg tablet equivalents": 55442,
      "opioid use disposal results": 52510,
      "use disposal results total": 84338,
      "efforts reduce opioid prescribing": 28444,
      "median age interquartile range": 44202,
      "interquartile range iqr 69": 39530,
      "factors associated increased risk": 31076,
      "associated increased risk opioid": 12308,
      "milligram equivalents mme results": 46464,
      "level evidence level ii": 41473,
      "fisher exact tests results": 31855,
      "opioid free postoperative pain": 51820,
      "retrospective cohort study patients": 72130,
      "equivalent 18 oxycodone mg": 29285,
      "opioid use weeks surgery": 52609,
      "opioid consumption patterns following": 51647,
      "statistically significant decrease pain": 77206,
      "significant decrease pain scores": 75463,
      "postoperative day pod pod": 62747,
      "used reduce opioid usage": 85104,
      "opioid therapy pain management": 52421,
      "constipation adverse events assessed": 19749,
      "independent risk factors associated": 38168,
      "use immediate postoperative period": 84418,
      "percent tramadol 22 percent": 60498,
      "number opioid pills prescribed": 50193,
      "percent patients prescribed opioids": 60476,
      "patients reported high satisfaction": 59887,
      "patients study design prospective": 60007,
      "patients recorded pain scores": 59868,
      "pain scores number opioid": 57745,
      "mme interquartile range iqr": 46967,
      "implementation enhanced recovery surgery": 36929,
      "standardized multimodal analgesic regimen": 76972,
      "sustained reduction opioid prescriptions": 79784,
      "reduce hospital length stay": 68846,
      "length hospital stay los": 41401,
      "patient controlled analgesia delivered": 58581,
      "evidence based prescribing guidelines": 30164,
      "postoperative opioid prescribing practices": 62820,
      "prescribing practices methods performed": 64119,
      "arthroscopic rotator cuff repair": 11754,
      "opioid pills prescribed discharge": 52063,
      "specific opioid prescribing guidelines": 76607,
      "primary outcome total opioid": 65097,
      "trends opioid prescribing patterns": 82975,
      "determine opioid prescribing patterns": 24029,
      "postoperative pain following common": 62870,
      "using wilcoxon signed rank": 85680,
      "resulted significant reduction narcotic": 71521,
      "opioid consumption 24 hours": 51601,
      "study included 100 patients": 78248,
      "postoperative pain following ambulatory": 62868,
      "objective objective study determine": 50450,
      "multimodal postoperative pain regimen": 48241,
      "multicenter randomized controlled trial": 48169,
      "randomized controlled trial women": 67078,
      "breakthrough pain primary outcome": 14403,
      "visual analog scale secondary": 86315,
      "consumption visual analog scale": 20040,
      "patients arm required detect": 59002,
      "equivalent number mg oxycodone": 29322,
      "design retrospective observational setting": 23788,
      "urban tertiary care academic": 84039,
      "opioid prescriptions pediatric patients": 52207,
      "number opioids prescribed discharge": 50204,
      "opioid prescriptions decreased significantly": 52182,
      "methods performed retrospective chart": 45455,
      "performed retrospective chart review": 60626,
      "anti inflammatory drugs received": 11133,
      "characterize prescribing patterns opioids": 15906,
      "opioid consumption study design": 51667,
      "mean maximum pain score": 43792,
      "population methods retrospective cohort": 62357,
      "daily morphine milligram equivalents": 21767,
      "10 mg oxycodone hours": 834,
      "patients undergoing outpatient foot": 60120,
      "undergoing outpatient foot ankle": 83565,
      "outpatient foot ankle surgery": 54122,
      "evidence level ii prospective": 30206,
      "level ii prospective observational": 41488,
      "opioid crisis study aimed": 51686,
      "cohort study consecutive patients": 17390,
      "presenting emergency department ed": 64705,
      "median age 50 years": 44199,
      "methods conducted retrospective review": 45287,
      "patients receiving opioid prescription": 59851,
      "results patients met inclusion": 71851,
      "chronic opioid use results": 16244,
      "risk persistent opioid use": 72632,
      "objective evaluate opioid consumption": 50425,
      "average 36 mg oxycodone": 12869,
      "postoperative pain management protocol": 62886,
      "pain management protocol significantly": 57108,
      "chronic opioid use methods": 16243,
      "coronary artery bypass graft": 20783,
      "artery bypass graft cabg": 11725,
      "methods consecutive patients undergoing": 45292,
      "patients opioid use months": 59595,
      "used opioids discharge median": 85054,
      "morphine milligram equivalents interquartile": 47774,
      "milligram equivalents interquartile range": 46460,
      "recent trends opioid prescribing": 68434,
      "prescribed opioids hydrocodone acetaminophen": 63929,
      "methods patients undergoing primary": 45451,
      "roux en gastric bypass": 72877,
      "conclusions multimodal nonopioid pain": 19124,
      "main outcome measures patient": 42843,
      "mg 325 mg oxycodone": 45743,
      "refill rate 30 days": 69166,
      "substance abuse treatment program": 78804,
      "aor 89 95 ci": 11337,
      "aor 10 95 ci": 11296,
      "patients received opioids commonly": 59805,
      "retrospective cohort study performed": 72131,
      "duration magnitude postoperative opioid": 27165,
      "procedures summary background data": 65330,
      "database stratified preoperative opioid": 22187,
      "stratified preoperative opioid use": 77455,
      "defined prescriptions filled months": 23151,
      "duration opioid use defined": 27170,
      "opioid use defined time": 52495,
      "magnitude opioid use defined": 42815,
      "naive patients likely chronic": 48405,
      "users opioid prescription surgery": 85259,
      "opioid prescriptions year surgery": 52215,
      "pre intervention post intervention": 63474,
      "verbal numeric rating scale": 86073,
      "multimodal opioid sparing analgesia": 48222,
      "systematically searched identify randomized": 80017,
      "oxycodone mg pill equivalents": 55437,
      "postoperative visit opioid pills": 62980,
      "visit opioid pills counted": 86267,
      "opioid pills counted standardized": 52061,
      "pills counted standardized equivalent": 61507,
      "counted standardized equivalent number": 20932,
      "standardized equivalent number mg": 76957,
      "number mg oxycodone pills": 50172,
      "regression analysis performed determine": 69424,
      "use conclusion study demonstrated": 84260,
      "patients level evidence level": 59447,
      "evidence level iii comparative": 30209,
      "pain scores collected using": 57708,
      "morphine 84 95 ci": 47568,
      "12 95 ci 13": 1266,
      "rating scale nrs used": 67667,
      "scale nrs used assess": 73524,
      "cohort study evaluated opioid": 17393,
      "analyzed mean sd age": 10842,
      "recovery surgery eras protocols": 68766,
      "improves pain control decreases": 37186,
      "length stay patients undergoing": 41413,
      "regression used identify factors": 69466,
      "used identify factors associated": 84961,
      "12 interquartile range iqr": 1310,
      "opioid prescriptions associated increased": 52177,
      "methods retrospective analysis conducted": 45531,
      "adult patients chronic pain": 8513,
      "opioid na\u00efve patients 18": 51985,
      "use prescription opioids increased": 84657,
      "adolescent young adult patients": 8450,
      "ome 95 confidence interval": 51056,
      "95 confidence interval 38": 6391,
      "95 confidence interval 32": 6389,
      "following orthopedic surgery patients": 32177,
      "average wholesale price awp": 12948,
      "wholesale price awp minus": 87040,
      "oxycodone cr 10 mg": 54891,
      "risk prolonged opioid use": 72646,
      "january 2009 june 30": 40433,
      "patients undergoing elective surgery": 60101,
      "objective study evaluate efficacy": 50511,
      "regimen included preoperative postoperative": 69310,
      "mg 001 significant differences": 45685,
      "significant differences pain scores": 75514,
      "64 65 69 70": 5385,
      "65 69 70 74": 5408,
      "69 70 74 75": 5518,
      "postoperative opioid prescriptions identified": 62822,
      "risk long term opioid": 72592,
      "term opioid use defined": 80652,
      "opioid use defined prescription": 52494,
      "inflammatory drugs nsaids used": 38568,
      "associated long term use": 12323,
      "pain control satisfaction pain": 56655,
      "pain control opioid use": 56632,
      "prospective randomized open label": 65867,
      "average daily pain score": 12887,
      "met inclusion criteria 40": 44878,
      "patients chronic opioid users": 59079,
      "confidence interval ci 27": 19470,
      "95 ci 04 79": 6231,
      "postoperative opioid prescriptions methods": 62823,
      "methods performed retrospective review": 45457,
      "patient factors including age": 58640,
      "factors including age sex": 31101,
      "serotonin reuptake inhibitors ssris": 74687,
      "patients undergoing common orthopaedic": 60094,
      "opioid na\u00efve patients undergoing": 51992,
      "na\u00efve patients undergoing primary": 48848,
      "50 tablets mg oxycodone": 4903,
      "age sex race body": 9119,
      "sex race body mass": 75084,
      "30 day refill rate": 3720,
      "procedures level evidence level": 65313,
      "evidence level ii therapeutic": 30207,
      "opioid usage 24 hours": 52459,
      "results 77 eligible patients": 71585,
      "acute postoperative pain opioid": 7689,
      "quality improvement study conducted": 66713,
      "mean sd pain score": 43869,
      "quantity opioids prescribed patients": 66840,
      "tertiary care academic medical": 80734,
      "care academic medical center": 14999,
      "06 95 ci 05": 583,
      "aor 47 95 ci": 11308,
      "47 95 ci 37": 4656,
      "95 ci 37 58": 6286,
      "patients undergoing lower extremity": 60112,
      "patient reported outcome measures": 58736,
      "5r": 5211,
      "epoxymorphinan": 29221,
      "482": 4756,
      "bonding": 14229,
      "der": 23616,
      "cascade": 15151,
      "stoichiometric": 77384,
      "dye": 27209,
      "implicating": 36958,
      "signalling": 75394,
      "desensitization": 23690,
      "3h": 4297,
      "azide": 12993,
      "aldehyde": 9553,
      "henry": 34946,
      "accomplish": 7029,
      "amine": 9818,
      "ganglion": 32830,
      "littermates": 42143,
      "pave": 60238,
      "ca3": 14661,
      "presynaptic": 64755,
      "inward": 40137,
      "firing": 31846,
      "nociceptin": 49531,
      "orphanin": 53805,
      "nop": 49867,
      "lever": 41617,
      "ro64": 72696,
      "6198": 5328,
      "113397": 1176,
      "mop": 47485,
      "nonhuman": 49738,
      "primates": 65122,
      "pruritis": 66294,
      "nalfurafine": 48413,
      "00032": 85,
      "0032": 252,
      "retesting": 72086,
      "organism": 53762,
      "hydroxylation": 36249,
      "hotplate": 35690,
      "penetrate": 60385,
      "naloxonazine": 48419,
      "naltrindole": 48552,
      "norbinaltorphimine": 49880,
      "intraperitoneal": 39786,
      "binaltorphimine": 13804,
      "streptozotocin": 77482,
      "leu": 41439,
      "displacement": 25468,
      "distinctly": 25541,
      "dm": 25650,
      "neuroprotective": 49283,
      "paradigms": 58122,
      "cpm": 21040,
      "bridged": 14425,
      "exacerbates": 30313,
      "icr": 36394,
      "rearing": 68012,
      "coeruleus": 17316,
      "gpcrs": 33362,
      "conductance": 19335,
      "internalization": 39465,
      "downstream": 26421,
      "frey": 32595,
      "neurotransmission": 49293,
      "damaged": 21820,
      "chloro": 16103,
      "monoxide": 47377,
      "affords": 8955,
      "prevents": 64891,
      "ovx": 54376,
      "monofilament": 47369,
      "prodynorphin": 65462,
      "proopiomelanocortin": 65686,
      "hybridization": 35996,
      "dynorphin": 27220,
      "retested": 72085,
      "primate": 65121,
      "formalin": 32292,
      "osteoarthritic": 53855,
      "methiodide": 45161,
      "norketamine": 49896,
      "circuitry": 16569,
      "pinch": 61556,
      "sixth": 76178,
      "paradoxical": 58123,
      "anesthetized": 10976,
      "dysphoric": 27231,
      "periaqueductal": 60660,
      "trv130": 83263,
      "pag": 56340,
      "abnormality": 6578,
      "neurobiological": 49181,
      "terminals": 80691,
      "disinhibition": 25359,
      "ipscs": 40155,
      "gated": 32903,
      "inwardly": 40138,
      "rectifying": 68807,
      "kir": 40851,
      "ipsc": 40154,
      "mntx": 46998,
      "inferences": 38522,
      "knock": 40873,
      "ko": 40938,
      "mimics": 46502,
      "character": 15838,
      "phosphorylated": 61372,
      "dysphoria": 27230,
      "nhps": 49465,
      "impairing": 36880,
      "hydroxytryptamine": 36251,
      "lend": 41395,
      "nonresponder": 49840,
      "postbaseline": 62637,
      "nonsignificantly": 49849,
      "neurochemical": 49187,
      "adenylyl": 7952,
      "cyclase": 21543,
      "adaptations": 7719,
      "cfa": 15679,
      "downregulation": 26420,
      "pica": 61484,
      "fos": 32422,
      "duke": 27118,
      "salvinorin": 73283,
      "tibia": 81169,
      "girk": 33146,
      "oil": 50992,
      "themed": 80905,
      "dx": 27203,
      "doi": 25695,
      "1111": 1166,
      "bph": 14293,
      "occupancy": 50819,
      "gly": 33261,
      "ol": 50995,
      "fluorophenyl": 31953,
      "quinolin": 66922,
      "menthol": 44833,
      "distension": 25537,
      "esophagus": 29543,
      "proestrus": 65463,
      "returning": 72195,
      "endorphin": 28855,
      "jnk": 40474,
      "roots": 72785,
      "spastic": 76539,
      "oxytocin": 56292,
      "bioactive": 13834,
      "morphological": 47974,
      "arranged": 11694,
      "orderly": 53730,
      "stream": 77460,
      "icss": 36395,
      "originating": 53798,
      "chemokine": 15957,
      "cultured": 21381,
      "indirectly": 38285,
      "interplay": 39493,
      "heterodimerization": 35047,
      "kd": 40600,
      "p38": 56300,
      "erk1": 29504,
      "ca2": 14660,
      "counteract": 20936,
      "\u03b12\u03b4": 87780,
      "subunit": 78897,
      "slice": 76242,
      "tyrosine": 83397,
      "hydroxylase": 36248,
      "enrichment": 28992,
      "pertussis": 60978,
      "unstressed": 83946,
      "creb": 21158,
      "noting": 49995,
      "glycerol": 33263,
      "parallels": 58150,
      "neurobiology": 49184,
      "bedside": 13513,
      "activator": 7482,
      "chemokines": 15958,
      "kop": 40940,
      "subarachnoid": 78595,
      "muscarinic": 48358,
      "cannula": 14938,
      "eta": 29673,
      "etb": 29676,
      "ngf": 49461,
      "squirrel": 76808,
      "obstacle": 50739,
      "insensitive": 39046,
      "dihydromorphinone": 24997,
      "lorcaserin": 42420,
      "tfr": 80892,
      "sb242084": 73476,
      "boundaries": 14263,
      "gonadally": 33287,
      "avenue": 12852,
      "translationally": 82220,
      "293": 3625,
      "recruit": 68788,
      "recruiting": 68800,
      "restless": 71446,
      "rls": 72690,
      "ampa": 9841,
      "dendritic": 23387,
      "amygdala": 9859,
      "insular": 39137,
      "orbitofrontal": 53700,
      "irls": 40271,
      "timeout": 81410,
      "pomc": 62231,
      "penk": 60391,
      "pdyn": 60299,
      "remedies": 70320,
      "cooling": 20747,
      "kp": 40954,
      "rob": 72703,
      "determines": 24096,
      "glucuronidation": 33247,
      "methylamine": 45648,
      "fails": 31144,
      "nadph": 48395,
      "etonitazene": 29713,
      "embryonic": 28660,
      "minireview": 46618,
      "chlornaltrexamine": 16102,
      "cna": 17104,
      "asic": 11832,
      "endomorphin": 28854,
      "isoforms": 40302,
      "arteries": 11721,
      "environmentally": 29093,
      "inert": 38495,
      "rich": 72468,
      "calmodulin": 14738,
      "stably": 76854,
      "arising": 11659,
      "neuro": 49179,
      "hyperpolarisation": 36271,
      "nucleotide": 50120,
      "sympathetic": 79852,
      "blunts": 14170,
      "inactivity": 37225,
      "cue": 21369,
      "implying": 36975,
      "endocytic": 28843,
      "pinpoint": 61557,
      "burgeoning": 14610,
      "synergizes": 79936,
      "6beta": 5535,
      "dat": 21840,
      "ovary": 54176,
      "bridge": 14424,
      "cornerstones": 20778,
      "exaggerated": 30322,
      "dogs": 25694,
      "homogenates": 35532,
      "dog": 25693,
      "cea": 15440,
      "zebrafish": 87754,
      "danio": 21829,
      "rerio": 70922,
      "reproduction": 70776,
      "mammals": 43107,
      "larval": 41200,
      "ro": 72695,
      "pretreatments": 64766,
      "segregated": 74375,
      "basolateral": 13482,
      "nonanalgesic": 49699,
      "exogenously": 30537,
      "upstream": 84016,
      "promoter": 65668,
      "upregulating": 84013,
      "antiopioid": 11255,
      "synthetase": 79945,
      "transmembrane": 82223,
      "endogenously": 28852,
      "reaction oxycodone": 67945,
      "hydrogen bonding": 36141,
      "continuous flow": 20168,
      "studies highlighting": 77743,
      "findings recent": 31813,
      "opioid tolerability": 52426,
      "different ways": 24936,
      "novel mu": 50014,
      "oxycodone unlike": 56042,
      "does cause": 25677,
      "improved effect": 37106,
      "overall yield": 54264,
      "16 11": 1843,
      "steps respectively": 77332,
      "provided new": 66142,
      "concerns safety": 18848,
      "medical community": 44346,
      "therapies include": 80977,
      "include drugs": 37354,
      "enhance analgesia": 28949,
      "requirement effects": 70872,
      "effects sex": 28154,
      "responses opioids": 71391,
      "attention recent": 12573,
      "molecular mechanisms": 47287,
      "using warm": 85672,
      "serotonin ht": 74671,
      "2a receptor": 3635,
      "receptor ht": 68496,
      "dependently enhanced": 23544,
      "pharmacological inhibition": 61216,
      "induced conditioned": 38396,
      "cpp reduced": 21045,
      "locomotor sensitization": 42242,
      "pave way": 60239,
      "clinical evaluation": 16811,
      "potential sex": 63230,
      "adjuvant oxycodone": 8085,
      "role mediating": 72746,
      "hippocampal ca3": 35428,
      "clamp recordings": 16639,
      "glutamate release": 33257,
      "blocked nonselective": 14083,
      "nociceptin orphanin": 49532,
      "orphanin fq": 53806,
      "fq nop": 32446,
      "nop receptor": 49868,
      "activation nop": 7471,
      "nop receptors": 49871,
      "effects abused": 27802,
      "oxycodone discrimination": 54977,
      "mice trained": 46318,
      "discriminate mg": 25271,
      "generalization tests": 32996,
      "ro64 6198": 72697,
      "occurred dose": 50833,
      "reversed naloxone": 72239,
      "naloxone pretreatment": 48505,
      "training dose": 82009,
      "reversed effects": 72238,
      "doses resulted": 26266,
      "modulate subjective": 47256,
      "characterization oxycodone": 15887,
      "oxycodone discriminative": 54978,
      "effective medications": 27644,
      "opioid peptide": 52049,
      "mop receptor": 47489,
      "fq peptide": 32448,
      "mop agonists": 47488,
      "agonist activity": 9277,
      "nonhuman primates": 49739,
      "induce effects": 38368,
      "mop agonist": 47486,
      "therapeutic action": 80916,
      "abuse rationale": 6855,
      "effects combined": 27853,
      "enhance antinociceptive": 28953,
      "kor agonists": 40944,
      "nalfurafine oxycodone": 48415,
      "methods self": 45568,
      "rats self": 67890,
      "oxycodone 056": 54487,
      "032 32": 426,
      "0032 mg": 253,
      "ratio schedule": 67797,
      "schedule reinforcement": 73631,
      "assay male": 11881,
      "rats received": 67882,
      "kg nalfurafine": 40765,
      "single drugs": 76099,
      "kor antagonist": 40945,
      "blocked effect": 14082,
      "behavioral measures": 13548,
      "reduces oxycodone": 68999,
      "typical kor": 83383,
      "agonists given": 9329,
      "pregabalin pregabalin": 63680,
      "use prevalent": 84663,
      "opioids occur": 53112,
      "effects pregabalin": 28101,
      "sedation studied": 74333,
      "studied using": 77632,
      "metabolites brain": 44965,
      "spectrometry results": 76671,
      "plate test": 61974,
      "test morphine": 80775,
      "pregabalin 50": 63659,
      "kg daily": 40709,
      "daily did": 21718,
      "did prevent": 24478,
      "conclusions pregabalin": 19167,
      "morphine acute": 47574,
      "results intrathecal": 71744,
      "longer lasting": 42378,
      "oxycodone 200": 54535,
      "kg 15": 40685,
      "morphine indicating": 47727,
      "motor function": 48027,
      "function observed": 32658,
      "test doses": 80766,
      "doses studied": 26277,
      "potent mu": 63105,
      "negligible role": 49092,
      "analgesia systemic": 10118,
      "systemic administration": 80020,
      "duration effect": 27159,
      "min compared": 46514,
      "phase compared": 61277,
      "180 min": 2125,
      "administration range": 8354,
      "antagonist norbinaltorphimine": 11069,
      "did attenuate": 24412,
      "attenuate antinociceptive": 12578,
      "pain humans": 56838,
      "case oxycodone": 15181,
      "oxycodone instead": 55285,
      "rats administered": 67841,
      "control rats": 20408,
      "excellent pain": 30441,
      "effects controlled": 27881,
      "required evaluate": 70835,
      "treatment rats": 82796,
      "antagonist binaltorphimine": 11058,
      "binaltorphimine bni": 13805,
      "selective antagonist": 74425,
      "nerve injury": 49128,
      "constriction injury": 19806,
      "diabetic rats": 24320,
      "oxycodone maintained": 55353,
      "leu enkephalin": 41440,
      "support notion": 79204,
      "distinctly different": 25542,
      "background neuropathic": 13088,
      "troublesome difficult": 83248,
      "better efficacy": 13710,
      "dextromethorphan dm": 24296,
      "enhanced acute": 28965,
      "effects examined": 27918,
      "enhanced oxycodone": 28971,
      "effect mg": 27486,
      "kg furthermore": 40729,
      "furthermore oxycodone": 32751,
      "conclusion combined": 18874,
      "combined use": 17673,
      "mechanisms effects": 44141,
      "oxycodone magnitude": 55349,
      "minutes administration": 46643,
      "001 pairwise": 179,
      "pairwise comparisons": 58028,
      "revealed relative": 72222,
      "reduced 60": 68902,
      "current experimental": 21436,
      "effects furthermore": 27930,
      "mechanisms opioid": 44147,
      "known subject": 40934,
      "differences pronounced": 24796,
      "pronounced patients": 65683,
      "study adds": 77910,
      "pain greater": 56812,
      "pain stimulation": 57863,
      "findings studies": 31821,
      "orally oxycodone": 53697,
      "placebo double": 61724,
      "13 conclusion": 1481,
      "behavioral studies": 13553,
      "current studies": 21472,
      "regimen morphine": 69314,
      "extend previous": 30847,
      "behaviors preclinical": 13566,
      "behaviors male": 13563,
      "behaviors used": 13567,
      "analgesics produce": 10486,
      "general motor": 32977,
      "expected analgesic": 30552,
      "oxycodone 32": 54557,
      "doses lower": 26210,
      "induced depression": 38405,
      "amphetamine 32": 9843,
      "stimulated locomotion": 77363,
      "support utility": 79219,
      "framework evaluate": 32481,
      "diazepam amphetamine": 24370,
      "mice chronic": 46275,
      "morphine results": 47919,
      "locus coeruleus": 42245,
      "receptors gpcrs": 68542,
      "activity chronic": 7559,
      "receptor kinase": 68501,
      "met enkephalin": 44872,
      "sustained opioid": 79778,
      "process results": 65340,
      "dependent mechanism": 23520,
      "tolerance induced": 81588,
      "recently showed": 68450,
      "drug rats": 26755,
      "use receptor": 84680,
      "pain examined": 56767,
      "von frey": 86491,
      "treated rats": 82374,
      "relationship plasma": 69725,
      "controlled experimental": 20497,
      "effective plasma": 27669,
      "intrinsic pharmacological": 39908,
      "naltrexone ntx": 48546,
      "pain behavior": 56493,
      "oxycodone exacerbated": 55048,
      "dose ntx": 25970,
      "plus ultra": 62035,
      "markedly enhanced": 43400,
      "oxytrex oxycodone": 56294,
      "days given": 22527,
      "reduced efficacy": 68925,
      "inverse relationship": 39991,
      "role determining": 72740,
      "hydrocodone determined": 36080,
      "operational model": 51234,
      "continuously infused": 20198,
      "higher analgesic": 35204,
      "efficacy drug": 28251,
      "lower analgesic": 42576,
      "efficacy drugs": 28252,
      "effective doses": 27617,
      "compared continuous": 18115,
      "formulations continuous": 32374,
      "carbon monoxide": 14970,
      "allowed preparation": 9638,
      "antinociception using": 11234,
      "oxycodone female": 55070,
      "mice ovariectomized": 46300,
      "ovariectomized ovx": 54174,
      "opioids assessed": 52732,
      "using von": 85670,
      "monofilament test": 47370,
      "limited oxycodone": 41950,
      "exhibited significant": 30515,
      "genes opioid": 33065,
      "situ hybridization": 76171,
      "group spinal": 34027,
      "expression dynorphin": 30833,
      "treatment lack": 82635,
      "rodent studies": 72720,
      "methods mice": 45383,
      "mice examined": 46282,
      "daily study": 21806,
      "time opioids": 81306,
      "opioids produced": 53228,
      "produced comparable": 65375,
      "effective suppressing": 27706,
      "differences various": 24832,
      "oxycodone 300": 54555,
      "orally po": 53698,
      "tests conducted": 80856,
      "min administration": 46511,
      "rodents humans": 72722,
      "investigated sex": 40058,
      "analgesia nociception": 10030,
      "observed differences": 50672,
      "activity oxycodone": 7578,
      "analgesia using": 10129,
      "compared males": 18200,
      "consistent analgesia": 19690,
      "using microdialysis": 85495,
      "noroxycodone levels": 49932,
      "levels likely": 41573,
      "humans oxycodone": 35987,
      "different pain": 24901,
      "rats used": 67902,
      "osteoarthritic pain": 53856,
      "morphine terms": 47953,
      "model drugs": 47044,
      "drugs reduced": 27058,
      "pain knee": 56988,
      "naloxone methiodide": 48459,
      "reduced morphine": 68943,
      "effects peripheral": 28085,
      "peripheral mu": 60865,
      "main finding": 42830,
      "better antinociceptive": 13705,
      "morphine effect": 47653,
      "induced pain": 38440,
      "hyperalgesia oxycodone": 36262,
      "option treat": 53464,
      "pharmacokinetic interaction": 61116,
      "morphine ketamine": 47740,
      "unclear studied": 83479,
      "effects ketamine": 27961,
      "ketamine norketamine": 40615,
      "attenuation morphine": 12599,
      "interactions methods": 39397,
      "methods morphine": 45387,
      "received subcutaneous": 68287,
      "day acute": 22266,
      "attenuated morphine": 12586,
      "conclusions ketamine": 19107,
      "effectively oxycodone": 27734,
      "partly explain": 58429,
      "minor effects": 46625,
      "visceral analgesia": 86252,
      "pain measurements": 57142,
      "measurements taken": 44033,
      "taken baseline": 80272,
      "approach effect": 11457,
      "effect compartment": 27437,
      "related plasma": 69666,
      "administered 30": 8102,
      "behavioural tests": 13573,
      "30 90": 3705,
      "plasma brain": 61896,
      "enhanced antinociceptive": 28969,
      "83 respectively": 5937,
      "chronic morphine": 16212,
      "opioid known": 51882,
      "attenuates opioid": 12596,
      "chronic effects": 16192,
      "withdrawal response": 87151,
      "oxycodone equianalgesic": 55029,
      "activity response": 7586,
      "role behavioral": 72734,
      "novel treatments": 50026,
      "knee joint": 40865,
      "novel compounds": 50007,
      "given recent": 33192,
      "tested separately": 80815,
      "reductions occurred": 69114,
      "consistent clinically": 19694,
      "doses standard": 26276,
      "treatments osteoarthritis": 82919,
      "diminish abuse": 25021,
      "effects mu": 28009,
      "dysphoric effects": 27232,
      "effects objectives": 28029,
      "thermal antinociceptive": 81079,
      "oxycodone nalfurafine": 55485,
      "nalfurafine decreased": 48414,
      "function reinforcer": 32676,
      "effects reducing": 28132,
      "oxycodone poorly": 55701,
      "administration led": 8284,
      "brain spinal": 14366,
      "spontaneous locomotor": 76757,
      "motor dysfunction": 48026,
      "lower efficacy": 42609,
      "periaqueductal gray": 60661,
      "intrathecal administration": 39791,
      "doses subcutaneous": 26281,
      "pain produce": 57437,
      "increase likelihood": 37754,
      "likelihood abuse": 41788,
      "mu agonist": 48106,
      "comparable mu": 17963,
      "preclinical data": 63528,
      "data investigating": 21996,
      "investigating effects": 40065,
      "assessed relative": 12048,
      "self administering": 74458,
      "administering drugs": 8194,
      "pr schedule": 63365,
      "trv130 mg": 83264,
      "effective self": 27702,
      "threshold scores": 81153,
      "scores treatment": 74004,
      "antinociceptive effectiveness": 11244,
      "ability opioids": 6553,
      "opioids distinct": 52864,
      "15 45": 1702,
      "attenuation oxycodone": 12601,
      "02 \u03bcg": 380,
      "morphine 05": 47530,
      "05 \u03bcg": 563,
      "modification opioid": 47231,
      "pain investigated": 56981,
      "like behavior": 41772,
      "animals oxycodone": 11003,
      "multiple pain": 48291,
      "anticonvulsants gabapentin": 11165,
      "thermal stimulus": 81087,
      "oxycodone gabapentin": 55110,
      "mice using": 46329,
      "using hot": 85430,
      "50 52": 4815,
      "52 morphine": 4990,
      "dependent results": 23534,
      "anti nociception": 11136,
      "nociceptive effects": 49542,
      "kg tapentadol": 40810,
      "kg showed": 40804,
      "pathways involved": 58527,
      "treatment large": 82636,
      "neurobiological mechanisms": 49182,
      "study define": 78053,
      "molecular changes": 47280,
      "lasting analgesic": 41212,
      "approach oxycodone": 11468,
      "oxycodone maintains": 55354,
      "optimal analgesic": 53419,
      "addition using": 7834,
      "receptor expression": 68491,
      "condition providing": 19285,
      "demonstrated previously": 23360,
      "opioid action": 51393,
      "inwardly rectifying": 40139,
      "model important": 47052,
      "important site": 37033,
      "streptozotocin induced": 77483,
      "diabetic mice": 24313,
      "mice significantly": 46313,
      "mice oral": 46299,
      "pretreatment selective": 64765,
      "effect peak": 27528,
      "mice naltrindole": 46297,
      "methylnaltrexone mntx": 45663,
      "proposed potential": 65799,
      "elicited opioid": 28571,
      "mice methods": 46295,
      "tested acute": 80796,
      "assessed oxycodone": 12029,
      "dependently attenuated": 23542,
      "ntx dose": 50112,
      "peripherally restricted": 60893,
      "using male": 85478,
      "ko mice": 40939,
      "receptor involved": 68500,
      "effect mor": 27491,
      "10mg kg": 1080,
      "kg block": 40695,
      "mice brain": 46274,
      "developed basis": 24172,
      "inhibition opioid": 38784,
      "regular dose": 69476,
      "respectively significantly": 71248,
      "studied potential": 77628,
      "potential treatments": 63242,
      "produce effects": 65362,
      "atypical kor": 12621,
      "protein biased": 65924,
      "male rhesus": 43051,
      "0001 001": 53,
      "combined mor": 17654,
      "tested mg": 80807,
      "lesser degree": 41426,
      "effects relatively": 28137,
      "addiction associated": 7738,
      "induced behavioral": 38387,
      "opioids function": 52924,
      "literature pertaining": 42120,
      "experimentally induced": 30677,
      "effects male": 27982,
      "female c57bl": 31356,
      "morphine saline": 47920,
      "understood purpose": 83657,
      "define role": 23117,
      "awake rats": 12979,
      "measured oral": 43982,
      "baseline value": 13463,
      "effect spinal": 27566,
      "acting receptor": 7423,
      "different tissues": 24930,
      "mor signaling": 47503,
      "chronic opiate": 16236,
      "treatment distinct": 82554,
      "dependence mice": 23474,
      "intracellular regulatory": 39729,
      "mice following": 46288,
      "signs precipitated": 75881,
      "naloxone following": 48451,
      "opiate agonist": 51286,
      "severe withdrawal": 75025,
      "tested results": 80814,
      "results lend": 71748,
      "lend evidence": 41396,
      "rats present": 67875,
      "investigate possibility": 40022,
      "enriched enrollment": 28986,
      "receive mg": 68056,
      "period subsequent": 60798,
      "administration medication": 8297,
      "combination produced": 17602,
      "01 effect": 309,
      "smaller oxycodone": 76314,
      "007 oxycodone": 275,
      "treatment comparisons": 82511,
      "differences treatments": 24828,
      "effects healthy": 27936,
      "antinociception respiratory": 11231,
      "does lead": 25682,
      "adenylyl cyclase": 7953,
      "seen morphine": 74360,
      "efficacy onset": 28305,
      "useful treatment": 85217,
      "pain recently": 57483,
      "recently demonstrated": 68442,
      "superior opioids": 79130,
      "optimize care": 53441,
      "acute severe": 7703,
      "untoward effects": 83956,
      "nausea decreased": 48770,
      "need effective": 48920,
      "effective long": 27632,
      "term analgesia": 80616,
      "analgesia remains": 10092,
      "novel strategies": 50020,
      "review highlights": 72310,
      "pharmacokinetic changes": 61108,
      "metabolizing enzyme": 45014,
      "signaling pathways": 75392,
      "aspects opioid": 11862,
      "complete freund": 18445,
      "freund adjuvant": 32590,
      "adjuvant cfa": 8079,
      "cfa induced": 15680,
      "effect fentanyl": 27456,
      "effect methadone": 27484,
      "gray pag": 33411,
      "\u03bcg \u03bcl": 87798,
      "minutes nearly": 46657,
      "following subsequent": 32200,
      "sites following": 76165,
      "following systemic": 32209,
      "buprenorphine occurred": 14570,
      "rats previous": 67877,
      "demonstrate mu": 23318,
      "antinociception following": 11222,
      "varies depending": 85945,
      "functional selectivity": 32714,
      "address issue": 7926,
      "studies estimated": 77715,
      "kg 24": 40686,
      "affect patient": 8910,
      "response mg": 71349,
      "intake model": 39182,
      "control oxycodone": 20382,
      "fos positive": 32423,
      "positive neurons": 62470,
      "compared water": 18339,
      "water controls": 86756,
      "controls expected": 20670,
      "effect greater": 27462,
      "response effect": 71343,
      "induced significant": 38457,
      "effect non": 27500,
      "time dependently": 81248,
      "fentanyl 05": 31408,
      "did oxycodone": 24471,
      "075 mg": 615,
      "suggested oxycodone": 79024,
      "pain ambulatory": 56442,
      "ligands effective": 41763,
      "analysis combined": 10652,
      "schedule controlled": 73612,
      "controlled responding": 20577,
      "studied dose": 77609,
      "addition analysis": 7796,
      "bfi 17": 13756,
      "supra additive": 79249,
      "operant responding": 51205,
      "pain addition": 56414,
      "addition data": 7799,
      "nalfurafine reduced": 48417,
      "produce effect": 65361,
      "agonists treatment": 9341,
      "challenging clinical": 15708,
      "understanding mechanisms": 83636,
      "study rats": 78452,
      "groups sham": 34315,
      "antinociception fentanyl": 11221,
      "fentanyl partial": 31559,
      "based background": 13286,
      "channel blocker": 15834,
      "intrathecally administered": 39806,
      "administered rats": 8177,
      "neuropathy background": 49275,
      "assessed mice": 12016,
      "relief acceptable": 70095,
      "acceptable tolerability": 6985,
      "observations suggest": 50639,
      "suggest subtle": 79015,
      "vivo profiles": 86381,
      "approach male": 11462,
      "shaped dose": 75116,
      "prolonged respiratory": 65640,
      "linked articles": 42048,
      "articles article": 11793,
      "article themed": 11789,
      "themed section": 80906,
      "section opioids": 74269,
      "new pathways": 49355,
      "pathways functional": 58524,
      "selectivity view": 74448,
      "view articles": 86220,
      "articles section": 11806,
      "section visit": 74274,
      "visit http": 86261,
      "http dx": 35920,
      "dx doi": 27204,
      "doi org": 25696,
      "org 10": 53744,
      "10 1111": 665,
      "1111 bph": 1167,
      "bph 2015": 14294,
      "2015 172": 2686,
      "172 issue": 2005,
      "doses 25": 26134,
      "administered produced": 8174,
      "kg selective": 40803,
      "methadone enantiomers": 45066,
      "similar dose": 75914,
      "tests mechanical": 80858,
      "cold allodynia": 17421,
      "drugs methadone": 26999,
      "administration conclusion": 8231,
      "injury pain": 38990,
      "pain methadone": 57174,
      "opioids opioids": 53124,
      "morphine greater": 47704,
      "rats compared": 67845,
      "agonist low": 9288,
      "sensitivity pain": 74562,
      "rats contrast": 67847,
      "receptor occupancy": 68514,
      "administration mor": 8304,
      "pain various": 57968,
      "lower body": 42584,
      "unbound plasma": 83462,
      "concentrations greater": 18766,
      "displayed significant": 25475,
      "pain cold": 56560,
      "efficacy equivalent": 28265,
      "suggests potential": 79043,
      "therapy remains": 81058,
      "unclear objective": 83475,
      "continued development": 20134,
      "oxycodone long": 55340,
      "19 days": 2182,
      "results rats": 71903,
      "treatment ed": 82562,
      "treatment combined": 82504,
      "genes associated": 33056,
      "post injury": 62576,
      "useful clinically": 85203,
      "requirements improve": 70882,
      "oxycodone centrally": 54775,
      "intravenously orally": 39898,
      "tolerance threshold": 81604,
      "detection tolerance": 23966,
      "cuff pressure": 21376,
      "min dosing": 46520,
      "dosing results": 26330,
      "002 compared": 235,
      "designed examine": 23836,
      "hyperalgesia sex": 36263,
      "vehicle treated": 86046,
      "effective male": 27635,
      "rats greater": 67864,
      "greater magnitude": 33455,
      "rats did": 67853,
      "result greater": 71476,
      "oxycodone butorphanol": 54763,
      "rats producing": 67878,
      "demonstrate sex": 23324,
      "responsiveness opioid": 71409,
      "pain like": 57019,
      "like state": 41784,
      "inhibition acute": 38776,
      "morphine pretreated": 47888,
      "pretreated mice": 64759,
      "following fentanyl": 32134,
      "binding opioid": 13819,
      "50 33": 4813,
      "indicated high": 38235,
      "furthermore results": 32752,
      "support prediction": 79209,
      "suggested use": 79025,
      "study randomised": 78446,
      "study experimental": 78206,
      "drugs model": 27002,
      "showed effect": 75244,
      "oxycodone useful": 56064,
      "acute repeated": 7698,
      "neuropathy pain": 49279,
      "potent efficacious": 63101,
      "oxycodone efficacy": 55021,
      "findings demonstrate": 31779,
      "efficacy chronic": 28234,
      "oxycodone sham": 55897,
      "gray matter": 33410,
      "addition morphine": 7812,
      "induced rewarding": 38456,
      "state increased": 77047,
      "increased 35": 37851,
      "lower lower": 42640,
      "mice findings": 46287,
      "oxycodone shows": 55907,
      "effect neuropathic": 27497,
      "significant concern": 75446,
      "pain alters": 56441,
      "liability commonly": 41639,
      "rats implanted": 67866,
      "stimulation vta": 77375,
      "second group": 74184,
      "intrathecal clonidine": 39793,
      "assessed effects": 11999,
      "icss similar": 36396,
      "present data": 64613,
      "positive reinforcing": 62483,
      "injury addition": 38987,
      "micro receptor": 46342,
      "agonist buprenorphine": 9280,
      "opioid subtype": 52387,
      "alternative means": 9723,
      "painful peripheral": 58008,
      "pain hypersensitivity": 56841,
      "administration spinal": 8377,
      "injection induced": 38951,
      "cultured astrocytes": 21382,
      "dependently decreased": 23543,
      "primary neurons": 65041,
      "reduced increase": 68935,
      "reports literature": 70731,
      "literature shown": 42136,
      "dependent suppression": 23537,
      "suggest morphine": 79000,
      "interplay opioid": 39494,
      "level direct": 41460,
      "opioid mop": 51956,
      "interactions effects": 39394,
      "effects prolonged": 28113,
      "plasma membrane": 61939,
      "80 70": 5832,
      "new strategy": 49378,
      "strategy counteract": 77432,
      "counteract opioid": 20937,
      "useful adjunct": 85195,
      "antagonists enhance": 11078,
      "agonists decrease": 9322,
      "ketamine oxycodone": 40619,
      "oxycodone interactions": 55289,
      "\u03b12\u03b4 subunit": 87781,
      "subunit ca": 78898,
      "increased therapeutic": 38037,
      "316 10mg": 3890,
      "morphine 64": 47564,
      "64 mg": 5389,
      "316 16": 3892,
      "maximal efficacy": 43574,
      "efficacy 21": 28212,
      "96 63": 6419,
      "63 mg": 5361,
      "dose combinations": 25846,
      "tapentadol dose": 80394,
      "open field": 51149,
      "tapentadol significant": 80469,
      "events include": 30057,
      "using brain": 85329,
      "brain slice": 14364,
      "preparations previous": 63784,
      "transgenic mice": 82192,
      "tyrosine hydroxylase": 83398,
      "monoclonal antibody": 47368,
      "processes results": 65347,
      "specific regulation": 76619,
      "identified key": 36442,
      "differentially expressed": 24944,
      "expressed genes": 30818,
      "methods based": 45263,
      "rats control": 67848,
      "performed gene": 60594,
      "network used": 49164,
      "reaction pcr": 67947,
      "38 genes": 4239,
      "refractory neuropathy": 69225,
      "opioids effectively": 52877,
      "rats rats": 67881,
      "rats exhibited": 67857,
      "antinociceptive potency": 11248,
      "previously normal": 64947,
      "consideration given": 19621,
      "using immunofluorescence": 85437,
      "inflammation including": 38547,
      "reduced mechanical": 68941,
      "exhibited higher": 30512,
      "activity enzymes": 7566,
      "represent major": 70746,
      "response analgesics": 71335,
      "periarticular injections": 60665,
      "alterations did": 9691,
      "acetaminophen 40": 7131,
      "ibuprofen 10": 36342,
      "40 160": 4313,
      "kg results": 40797,
      "indicator drug": 38277,
      "showed little": 75267,
      "pain reflects": 57501,
      "important aspect": 36994,
      "human pain": 35967,
      "studies improve": 77746,
      "new analgesics": 49309,
      "mice peripheral": 46304,
      "effect analgesia": 27420,
      "induced opioids": 38435,
      "exposed chronic": 30739,
      "showed analgesic": 75229,
      "appears particularly": 11404,
      "development effective": 24223,
      "withdrawal acute": 87116,
      "reduced naloxone": 68944,
      "withdrawal revealed": 87153,
      "activation markers": 7469,
      "cytokines chemokines": 21671,
      "spontaneous withdrawal": 76761,
      "induced hyperactivity": 38415,
      "recorded 12": 68662,
      "withdrawal study": 87159,
      "delayed relative": 23192,
      "attenuate opioid": 12581,
      "levels altered": 41542,
      "potentiated analgesia": 63277,
      "morphine exposure": 47687,
      "contribute analgesic": 20223,
      "study uses": 78560,
      "mouse brain": 48032,
      "performed quantitative": 60617,
      "guide cannula": 34402,
      "behavioral checklist": 13544,
      "microg administered": 46356,
      "unlikely affect": 83897,
      "partly mediated": 58430,
      "eta receptor": 29675,
      "designed investigate": 23838,
      "withdrawal effect": 87128,
      "mice opioid": 46298,
      "withdrawal precipitated": 87142,
      "eta etb": 29674,
      "nerve growth": 49125,
      "factor ngf": 31055,
      "changes expression": 15785,
      "expression oxycodone": 30838,
      "modified warm": 47246,
      "maintained operant": 42888,
      "squirrel monkeys": 76809,
      "median effective": 44221,
      "dose ed": 25891,
      "used quantitative": 85096,
      "therapeutic index": 80944,
      "analyses suggest": 10613,
      "receptor mechanisms": 68506,
      "values 13": 85832,
      "13 57": 1470,
      "mechanisms underlie": 44153,
      "mice showed": 46312,
      "signs withdrawal": 75884,
      "weight accompanied": 86974,
      "naloxonazine insensitive": 48420,
      "treatment naloxone": 82675,
      "mice withdrawal": 46330,
      "symptoms observed": 79896,
      "insensitive sites": 39047,
      "effects caused": 27843,
      "caused opioid": 15386,
      "male wistar": 43066,
      "rats dose": 67854,
      "doses drugs": 26183,
      "caused dose": 15382,
      "acting mor": 7389,
      "opiate abuse": 51284,
      "dependence morphine": 23476,
      "mediating opioid": 44321,
      "withdrawal recently": 87149,
      "shown block": 75330,
      "implications findings": 36962,
      "presented opioid": 64695,
      "aim reduce": 9398,
      "needed achieve": 48970,
      "effects alternative": 27818,
      "2c receptor": 3642,
      "2c agonist": 3639,
      "recently reported": 68449,
      "reported reduce": 70639,
      "administration lorcaserin": 8288,
      "2c antagonist": 3640,
      "antagonist sb242084": 11072,
      "administration intrathecal": 8280,
      "augmentation oxycodone": 12656,
      "lorcaserin did": 42421,
      "brain blood": 14321,
      "represent new": 70747,
      "new pharmacological": 49361,
      "article special": 11786,
      "special issue": 76560,
      "issue entitled": 40322,
      "effective drugs": 27619,
      "produce adverse": 65355,
      "receptor protein": 68522,
      "oxycodone resulting": 55850,
      "nociception mice": 49538,
      "lead molecule": 41295,
      "valuable insights": 85816,
      "biased mu": 13777,
      "unknown aim": 83877,
      "primates methods": 65123,
      "compared clinically": 18105,
      "gonadally intact": 33288,
      "intact adult": 39166,
      "10 males": 780,
      "effects 05": 27790,
      "oxycodone like": 55336,
      "schedules reinforcement": 73660,
      "intravenous drug": 39825,
      "similar clinically": 75907,
      "identified novel": 36450,
      "alter reinforcing": 9688,
      "translationally relevant": 82221,
      "painful symptoms": 58013,
      "neuropathy diabetic": 49278,
      "states increased": 77110,
      "changes neuropathic": 15798,
      "treatments neuropathic": 82914,
      "states oxycodone": 77135,
      "oxycodone mu": 55481,
      "pain provides": 57444,
      "potent agonist": 63089,
      "oxycodone moderate": 55458,
      "efficacy low": 28288,
      "fentanyl efficacy": 31470,
      "oxycodone weak": 56089,
      "insignificant efficacy": 39055,
      "depression constipation": 23577,
      "rats findings": 67859,
      "restless legs": 71447,
      "legs syndrome": 41393,
      "syndrome rls": 79922,
      "rls symptoms": 72691,
      "sensory motor": 74574,
      "improving sleep": 37207,
      "amino hydroxy": 9821,
      "hydroxy methyl": 36240,
      "dendritic spine": 23388,
      "opioids line": 53021,
      "used acute": 84832,
      "genetic molecular": 33077,
      "treatment rls": 82824,
      "complication long": 18549,
      "received attention": 68118,
      "patients rls": 59933,
      "known involved": 40915,
      "insular cortex": 39138,
      "orbitofrontal cortex": 53701,
      "severe rls": 75020,
      "considered efficacious": 19631,
      "efficacy combination": 28235,
      "group rating": 33939,
      "scale irls": 73503,
      "weeks 15": 86890,
      "term trials": 80676,
      "investigated present": 40051,
      "present experiments": 64619,
      "differing efficacy": 24955,
      "ratio 10": 67716,
      "acetylcholine receptor": 7274,
      "limited adverse": 41917,
      "adjuvant pain": 8086,
      "decreased clinically": 22984,
      "results evidence": 71687,
      "repeated twice": 70419,
      "does alter": 25673,
      "affect levels": 8903,
      "proopiomelanocortin pomc": 65687,
      "neuropathy associated": 49274,
      "therapy present": 81053,
      "using chronic": 85339,
      "treatment protocols": 82791,
      "triphosphate binding": 83232,
      "efficacy determined": 28247,
      "studies mice": 77779,
      "mice continuously": 46277,
      "conducted spinal": 19411,
      "mice tested": 46316,
      "enkephalin morphine": 28983,
      "binding receptor": 13821,
      "determine type": 24054,
      "used rodent": 85118,
      "compare temporal": 18058,
      "characteristics different": 15858,
      "types evoked": 83367,
      "pain responses": 57637,
      "gabapentin amitriptyline": 32790,
      "highly responsive": 35401,
      "induced pruritus": 38447,
      "administration symptoms": 8384,
      "directly indirectly": 25063,
      "neurotransmitter systems": 49295,
      "mrna levels": 48071,
      "opioids mice": 53054,
      "effect intravenous": 27467,
      "intravenous injections": 39838,
      "chemotherapeutic agents": 15962,
      "effects analgesics": 27823,
      "scientific basis": 73685,
      "human clinical": 35946,
      "search identified": 74112,
      "threshold mechanical": 81151,
      "pain subgroup": 57879,
      "using approach": 85308,
      "rats sensitive": 67894,
      "rat strains": 67421,
      "literature regard": 42124,
      "consistent present": 19710,
      "structure morphine": 77589,
      "males compared": 43071,
      "fentanyl potency": 31570,
      "rats establish": 67856,
      "mice compared": 46276,
      "results nktr": 71792,
      "maximal effects": 43573,
      "hot water": 35687,
      "species differences": 76576,
      "antinociception rats": 11230,
      "increased water": 38047,
      "morphine relative": 47911,
      "doses nktr": 26220,
      "conclusions nktr": 19128,
      "potential maintaining": 63184,
      "does induce": 25680,
      "induce opioid": 38369,
      "pre treated": 63491,
      "agonists like": 9333,
      "dependent signaling": 23535,
      "agonists induce": 9332,
      "buprenorphine hydromorphone": 14552,
      "plays key": 62006,
      "multi dimensional": 48144,
      "pd models": 60292,
      "pd relationship": 60294,
      "effects major": 27981,
      "pd oxycodone": 60293,
      "short onset": 75184,
      "pd data": 60290,
      "better predict": 13733,
      "specific clinical": 76585,
      "actions opioids": 7456,
      "using cell": 85334,
      "time treatment": 81392,
      "extracellular ph": 30941,
      "opioid involvement": 51881,
      "oxycodone potentiate": 55721,
      "knockout rats": 40876,
      "chemicals rapidly": 15955,
      "access novel": 6994,
      "beneficial properties": 13605,
      "reaction parameters": 67946,
      "order achieve": 53705,
      "recent results": 68420,
      "target development": 80487,
      "analgesics despite": 10413,
      "bfi results": 13758,
      "rats learned": 67867,
      "recent molecular": 68410,
      "molecular analyses": 47279,
      "cells stably": 15503,
      "pain arising": 56459,
      "relatively common": 69774,
      "provides insights": 66225,
      "brain mechanisms": 14347,
      "processes including": 65345,
      "neural plasticity": 49169,
      "calcium channels": 14674,
      "sympathetic nervous": 79853,
      "imaging techniques": 36690,
      "affecting pain": 8927,
      "evidence different": 30183,
      "strategies available": 77409,
      "antidepressants topical": 11181,
      "patch capsaicin": 58483,
      "experience clinically": 30573,
      "frequently experience": 32552,
      "unable tolerate": 83447,
      "remaining patients": 70283,
      "relief combination": 70113,
      "relief trials": 70204,
      "combinations analgesics": 17621,
      "combination use": 17618,
      "additive supra": 7918,
      "event profiles": 29988,
      "treatments failed": 82907,
      "cord stimulation": 20769,
      "motor cortex": 48025,
      "considered introduction": 19636,
      "basic science": 13474,
      "science research": 73681,
      "potential improve": 63173,
      "improve therapeutic": 37091,
      "opioid pharmacodynamics": 52051,
      "trials opioid": 83172,
      "dose levels": 25943,
      "factor predicting": 31058,
      "effects need": 28021,
      "known influence": 40914,
      "used conjunction": 84895,
      "values fold": 85842,
      "fold fold": 31990,
      "opioids enhance": 52885,
      "inhibition gastrointestinal": 38783,
      "arterial pco": 11715,
      "properties linked": 65711,
      "discrimination learning": 25277,
      "analgesic ed": 10194,
      "treatments opioid": 82916,
      "oxycontin vicodin": 56196,
      "serve novel": 74712,
      "active compounds": 7492,
      "mice indicated": 46291,
      "indicated previously": 38244,
      "effects dependent": 27887,
      "therapeutic targets": 80965,
      "relies heavily": 70210,
      "associated undesirable": 12459,
      "54 mg": 5047,
      "mechanistic studies": 44158,
      "dynamics md": 27218,
      "md simulation": 43639,
      "interactions opioid": 39399,
      "agonist mu": 9290,
      "endogenous pain": 28851,
      "available clinical": 12794,
      "issues related": 40334,
      "addiction essential": 7743,
      "analgesic synergy": 10341,
      "codeine active": 17209,
      "analgesia given": 9984,
      "opioids thought": 53337,
      "observed efficacy": 50678,
      "inducing analgesia": 38472,
      "vivo addition": 86377,
      "buprenorphine hydrocodone": 14550,
      "activity assays": 7557,
      "mice demonstrated": 46278,
      "inhibitor duloxetine": 38794,
      "future investigation": 32764,
      "agonist receptor": 9305,
      "functional characteristics": 32692,
      "human mu": 35963,
      "versus 14": 86099,
      "manner using": 43328,
      "intrinsic efficacy": 39907,
      "greater relative": 33488,
      "regardless route": 69290,
      "model provides": 47077,
      "human data": 35950,
      "data suggested": 22133,
      "relief single": 70189,
      "mg study": 46223,
      "ascending doses": 11823,
      "subjects evaluated": 78695,
      "following high": 32138,
      "concentration area": 18677,
      "split doses": 76740,
      "decrease pupil": 22924,
      "following multiple": 32163,
      "proportional increase": 65789,
      "increase maximum": 37755,
      "life hours": 41698,
      "generally dose": 33014,
      "continued study": 20143,
      "dependence liability": 23472,
      "observed chronic": 50661,
      "induced physical": 38444,
      "drugs limited": 26990,
      "administration prescription": 8342,
      "mainstay treatment": 42879,
      "peptide receptor": 60440,
      "mice response": 46309,
      "suggest use": 79019,
      "combined action": 17639,
      "action mu": 7435,
      "cortex thalamus": 20852,
      "delta mu": 23237,
      "hydrocodone considered": 36076,
      "despite analgesic": 23871,
      "cardiovascular gastrointestinal": 14995,
      "compared classical": 18103,
      "using range": 85589,
      "neuropathic mixed": 49228,
      "levels mice": 41577,
      "selective antagonists": 74426,
      "fentanyl levorphanol": 31516,
      "levels similar": 41610,
      "receptor gene": 68493,
      "gene oprm1": 32947,
      "emphasizes need": 28732,
      "levels using": 41616,
      "trials pain": 83176,
      "local systemic": 42215,
      "analysis gene": 10689,
      "transcription factor": 82131,
      "poorly managed": 62284,
      "effects combinations": 27852,
      "produces analgesia": 65419,
      "various pain": 85974,
      "central nucleus": 15602,
      "nucleus amygdala": 50128,
      "amygdala cea": 9860,
      "neuronal responses": 49214,
      "dose tapentadol": 26093,
      "tapentadol naloxone": 80444,
      "resulted dose": 71503,
      "decrease right": 22927,
      "neuronal activity": 49209,
      "small molecules": 76288,
      "subtype selectivity": 78895,
      "mouse models": 48036,
      "somatic withdrawal": 76457,
      "antagonists combination": 11077,
      "fentanyl analgesic": 31438,
      "synergistic effects": 79934,
      "effect according": 27412,
      "dose ranges": 26030,
      "naltrexone mg": 48543,
      "treatment conditions": 82519,
      "conditions results": 19329,
      "experience analgesic": 30572,
      "improved increasing": 37111,
      "35 11": 4056,
      "higher median": 35262,
      "findings opioid": 31801,
      "safe pain": 73096,
      "therapy analgesic": 80988,
      "limited lack": 41937,
      "zebrafish danio": 87755,
      "danio rerio": 21830,
      "rate respiratory": 67514,
      "induces analgesia": 38470,
      "effects reversed": 28147,
      "agonist nalfurafine": 9293,
      "examined following": 30383,
      "antinociception doses": 11219,
      "antagonist sb": 11071,
      "range dose": 67310,
      "conditions opioid": 19320,
      "rate decreasing": 67457,
      "decreasing effects": 23069,
      "mediated antinociception": 44305,
      "mechanical nociception": 44113,
      "populations small": 62408,
      "nociceptive neurons": 49547,
      "receptor inhibition": 68498,
      "mice exhibited": 46283,
      "subcutaneous doses": 78601,
      "results peripheral": 71864,
      "areas involved": 11648,
      "basolateral amygdala": 13483,
      "peripherally mediated": 60892,
      "plant derived": 61891,
      "peripheral neuropathic": 60875,
      "reveal novel": 72211,
      "novel mechanism": 50013,
      "opioids greatly": 52934,
      "produced long": 65392,
      "did compromise": 24424,
      "30 fold": 3737,
      "responses unlike": 71395,
      "translational potential": 82219,
      "effective treatments": 27721,
      "lead drug": 41286,
      "receptor kop": 68502,
      "mixed opioid": 46804,
      "negative effects": 49072,
      "aversive effects": 12955,
      "mice rats": 46307,
      "addictive pain": 7785,
      "effect generally": 27461,
      "analgesia does": 9954,
      "limiting factor": 41973,
      "therapy considered": 81000,
      "commonly identified": 17851,
      "opioid given": 51825,
      "cellular molecular": 15507,
      "administration individuals": 8277,
      "analgesia sedation": 10106,
      "pupillary constriction": 66491,
      "develop different": 24144,
      "sedation euphoria": 74312,
      "intrinsic activity": 39906,
      "likely clinically": 41801,
      "internalization desensitization": 39466,
      "altered metabolism": 9702,
      "increased ratio": 38003,
      "doses analgesic": 26148,
      "short lived": 75177,
      "tolerance clinical": 81575,
      "clinical consequences": 16774,
      "wide margin": 87043,
      "genetic polymorphism": 33078,
      "avoid unnecessary": 12963,
      "simultaneous administration": 76033,
      "alpha agonist": 9664,
      "dose rapidly": 26033,
      "clonidine dexmedetomidine": 17062,
      "continuous dosing": 20162,
      "dosing opioid": 26318,
      "icu setting": 36400,
      "seen clinically": 74356,
      "consisting simultaneous": 19727,
      "undergoes extensive": 83507,
      "mouse mu": 48037,
      "useful tools": 85216,
      "site specific": 76160,
      "recent findings recent": 68403,
      "novel mu opioid": 50015,
      "improved effect profiles": 37107,
      "19 23 24": 2167,
      "opioids effective analgesics": 52873,
      "attention recent years": 12574,
      "molecular mechanisms underlying": 47288,
      "serotonin ht 2a": 74672,
      "ht 2a receptor": 35908,
      "dose dependently enhanced": 25877,
      "oxycodone male female": 55364,
      "did affect oxycodone": 24403,
      "oxycodone induced conditioned": 55264,
      "induced conditioned place": 38397,
      "reduced oxycodone induced": 68960,
      "induced locomotor sensitization": 38422,
      "abuse related behavior": 6861,
      "patch clamp recordings": 58485,
      "inhibitory effect oxycodone": 38820,
      "nociceptin orphanin fq": 49533,
      "orphanin fq nop": 53807,
      "fq nop receptor": 32447,
      "activation nop receptors": 7472,
      "methods adult male": 45240,
      "adult male c57bl": 8493,
      "male c57bl mice": 43024,
      "c57bl mice trained": 14654,
      "mice trained discriminate": 46319,
      "trained discriminate mg": 81999,
      "discriminate mg kg": 25272,
      "kg oxycodone vehicle": 40783,
      "reversed naloxone pretreatment": 72240,
      "administration mg kg": 8301,
      "response rates compared": 71367,
      "compared oxycodone conclusions": 18236,
      "conclusions results provide": 19203,
      "provide additional evidence": 66029,
      "nop receptor activation": 49869,
      "oxycodone discriminative stimulus": 54979,
      "orphanin fq peptide": 53809,
      "mop receptor agonist": 47490,
      "partial agonist activity": 58237,
      "depression abuse potential": 23568,
      "opioid abuse rationale": 51380,
      "typical adverse effects": 83381,
      "reduce abuse related": 68831,
      "enhance antinociceptive effects": 28954,
      "methods self administration": 45569,
      "self administration study": 74480,
      "administration study male": 8381,
      "study male sprague": 78298,
      "rats self administered": 67891,
      "self administered intravenous": 74455,
      "administered intravenous oxycodone": 8145,
      "oxycodone 056 mg": 54488,
      "032 32 mg": 427,
      "0032 mg kg": 254,
      "progressive ratio schedule": 65580,
      "ratio schedule reinforcement": 67798,
      "18 mg kg": 2091,
      "mg kg nalfurafine": 46001,
      "reduced oxycodone self": 68963,
      "self administration dose": 74463,
      "administration dose dependent": 8251,
      "drugs drug combinations": 26945,
      "conclusion study demonstrates": 19000,
      "background oxycodone increasingly": 13132,
      "morphine induced antinociception": 47731,
      "mass spectrometry results": 43470,
      "hot plate test": 35686,
      "morphine mg kg": 47762,
      "pregabalin 10 mg": 63655,
      "mg kg administered": 45954,
      "mg kg daily": 45964,
      "oxycodone morphine acute": 55468,
      "significantly longer lasting": 75771,
      "morphine indicating opioid": 47728,
      "indicating opioid receptor": 38264,
      "10 25 mg": 697,
      "25 mg kg": 3364,
      "results study indicate": 71982,
      "potent mu opioid": 63106,
      "oxycodone antinociceptive effects": 54721,
      "approximately 90 min": 11578,
      "receptor antagonists shown": 68482,
      "opioid agonists morphine": 51433,
      "attenuate antinociceptive effects": 12579,
      "analgesic doses oxycodone": 10185,
      "reduction opioid related": 69078,
      "controlled clinical trials": 20471,
      "antagonist binaltorphimine bni": 11059,
      "12 24 weeks": 1240,
      "background neuropathic pain": 13089,
      "neuropathic pain treatment": 49267,
      "oxycodone produced dose": 55763,
      "mg kg furthermore": 45975,
      "effective dose oxycodone": 27616,
      "tested effects oxycodone": 80803,
      "oxycodone active placebo": 54673,
      "significant effects oxycodone": 75537,
      "001 pairwise comparisons": 180,
      "current experimental conditions": 21437,
      "greater analgesic effect": 33431,
      "oxycodone response skin": 55847,
      "volunteers methods healthy": 86424,
      "15 mg orally": 1762,
      "placebo double blind": 61725,
      "peripheral nerve injury": 60873,
      "opioids fentanyl oxycodone": 52913,
      "pain study evaluated": 57876,
      "doses did alter": 26178,
      "oxycodone 32 mg": 54558,
      "amphetamine 32 mg": 9844,
      "coupled receptors gpcrs": 20977,
      "agonists morphine oxycodone": 9336,
      "use receptor agonists": 84681,
      "rewarding effects morphine": 72439,
      "rats results suggest": 67888,
      "neuropathic pain patients": 49251,
      "neuropathic pain clinical": 49235,
      "adverse effect profiles": 8634,
      "animal models oxycodone": 10999,
      "higher plasma concentration": 35301,
      "antinociceptive effect oxycodone": 11243,
      "dose opioid antagonist": 25974,
      "spinal cord tissue": 76712,
      "dose naltrexone ntx": 25967,
      "low dose ntx": 42474,
      "plus ultra low": 62036,
      "promising new treatment": 65656,
      "results suggest opioid": 71994,
      "mice ovariectomized ovx": 46301,
      "effects opioids assessed": 28042,
      "opioids assessed using": 52733,
      "using von frey": 85671,
      "genes opioid receptors": 33066,
      "objective study compared": 50502,
      "morphine produced significant": 47893,
      "conclusions study demonstrated": 19218,
      "dawley rats administered": 22224,
      "30 min prior": 3768,
      "30 mg kg": 3762,
      "sex differences opioid": 75072,
      "oxycodone metabolite levels": 55386,
      "analgesia using tail": 10130,
      "oxycodone morphine opioid": 55478,
      "evidence effectiveness safety": 30188,
      "different pain models": 24902,
      "test morphine oxycodone": 80776,
      "peripheral mu opioid": 60866,
      "14 days post": 1589,
      "attenuation morphine oxycodone": 12600,
      "day oxycodone mg": 22354,
      "rats received subcutaneous": 67883,
      "received subcutaneous injections": 68288,
      "morphine oxycodone brain": 47808,
      "analgesia study investigated": 10115,
      "oral morphine 30": 53573,
      "mg oxycodone 15": 46097,
      "pain tests performed": 57908,
      "100 mg kg": 994,
      "oxycodone 75 mg": 54600,
      "induced antinociception using": 38385,
      "administered 30 min": 8103,
      "oxycodone clinically used": 54789,
      "used strong opioid": 85145,
      "morphine oxycodone discharge": 47818,
      "male rats following": 43050,
      "oxycodone equianalgesic doses": 55030,
      "chronic treatment oxycodone": 16351,
      "pain given recent": 56807,
      "objectives current study": 50552,
      "progressive ratio pr": 65578,
      "reinforcing effects oxycodone": 69526,
      "oxycodone nalfurafine oxycodone": 55486,
      "nalfurafine oxycodone nalfurafine": 48416,
      "thermal antinociceptive effects": 81080,
      "effects oxycodone background": 28058,
      "induced morphine oxycodone": 38424,
      "brain spinal cord": 14367,
      "spontaneous locomotor activity": 76758,
      "oxycodone highly effective": 55162,
      "study assessed relative": 77974,
      "rats self administering": 67893,
      "ratio pr schedule": 67792,
      "pr schedule reinforcement": 63366,
      "self administration male": 74467,
      "administration male sprague": 8294,
      "dawley rats self": 22227,
      "trv130 mg kg": 83265,
      "reduce abuse potential": 68830,
      "pain background purpose": 56485,
      "opioids recent studies": 53241,
      "studies shown opioids": 77844,
      "severe pain investigated": 74984,
      "neuropathic pain oxycodone": 49250,
      "multiple pain models": 48292,
      "using hot plate": 85431,
      "effect opioid receptor": 27509,
      "inflammatory neuropathic pain": 38577,
      "opioids tramadol tapentadol": 53346,
      "anti nociceptive effects": 11138,
      "kg dose dependently": 40721,
      "56 mg kg": 5103,
      "dose 30 mg": 25801,
      "mg kg showed": 46028,
      "receptor agonist used": 68468,
      "agonist used treatment": 9313,
      "neurobiological mechanisms underlying": 49183,
      "optimal analgesic effect": 53420,
      "diabetic mice oral": 24314,
      "significantly reduced oxycodone": 75847,
      "goal study determine": 33279,
      "opioid analgesics morphine": 51508,
      "analgesics morphine oxycodone": 10451,
      "dose dependently attenuated": 25875,
      "oxycodone used clinically": 56059,
      "receptor kor agonists": 68504,
      "adult male rhesus": 8496,
      "male rhesus monkeys": 43052,
      "0001 001 mg": 54,
      "combined mor agonist": 17655,
      "dose tested mg": 26095,
      "tested mg kg": 80808,
      "effects combined oxycodone": 27854,
      "opioid induced behavioral": 51853,
      "induced behavioral effects": 38388,
      "morphine oxycodone produce": 47852,
      "male female c57bl": 43028,
      "oxycodone male mice": 55365,
      "mice antinociceptive effects": 46272,
      "morphine oxycodone equipotent": 47820,
      "understood purpose study": 83658,
      "measured oral morphine": 43983,
      "physical dependence mice": 61391,
      "methadone fentanyl oxycodone": 45074,
      "24 mg kg": 3243,
      "results lend evidence": 71749,
      "rats present study": 67876,
      "receive mg kg": 68057,
      "blind crossover design": 13930,
      "produced significantly higher": 65410,
      "interval ci 48": 39593,
      "ci 48 01": 16461,
      "significant differences treatments": 75522,
      "effects associated opioid": 27832,
      "useful treatment opioid": 85218,
      "currently available opioid": 21490,
      "effective long term": 27633,
      "long term analgesia": 42323,
      "narcotic analgesics fentanyl": 48590,
      "fentanyl oxycodone methadone": 31553,
      "complete freund adjuvant": 18446,
      "freund adjuvant cfa": 32591,
      "adjuvant cfa induced": 8080,
      "periaqueductal gray pag": 60662,
      "effects commonly used": 27861,
      "opioids oxycodone methadone": 53139,
      "demonstrate mu opioid": 23319,
      "perspective study demonstrates": 60971,
      "efficacy opioid agonists": 28307,
      "mg kg 24": 45950,
      "dose response curves": 26065,
      "effects nausea emesis": 28016,
      "response mg kg": 71350,
      "10 50 mg": 715,
      "075 mg kg": 616,
      "mg kg reversed": 46025,
      "neuropathic pain analgesic": 49232,
      "profile oxycodone different": 65499,
      "study systematically examined": 78532,
      "schedule controlled responding": 73613,
      "groups sham group": 34316,
      "previous studies suggested": 64922,
      "pain relief acceptable": 57518,
      "relief acceptable tolerability": 70096,
      "experimental approach male": 30657,
      "rats given single": 67863,
      "water tail flick": 86760,
      "dose response curve": 26064,
      "prolonged respiratory depression": 65641,
      "linked articles article": 42049,
      "articles article themed": 11794,
      "article themed section": 11790,
      "themed section opioids": 80907,
      "section opioids new": 74270,
      "opioids new pathways": 53090,
      "new pathways functional": 49356,
      "pathways functional selectivity": 58525,
      "functional selectivity view": 32715,
      "selectivity view articles": 74449,
      "view articles section": 86221,
      "articles section visit": 11807,
      "section visit http": 74275,
      "visit http dx": 86262,
      "http dx doi": 35921,
      "dx doi org": 27205,
      "doi org 10": 25697,
      "org 10 1111": 53745,
      "10 1111 bph": 666,
      "1111 bph 2015": 1168,
      "bph 2015 172": 14295,
      "2015 172 issue": 2687,
      "treated oxycodone mg": 82366,
      "doses 25 mg": 26135,
      "mg kg selective": 46027,
      "oxycodone similar dose": 55919,
      "compared male rats": 18199,
      "female male rats": 31363,
      "aims present study": 9494,
      "unbound plasma concentrations": 83463,
      "pain cold pressor": 56561,
      "efficacy equivalent oxycodone": 28266,
      "conclusion study supports": 19007,
      "therapy remains unclear": 81059,
      "remains unclear objective": 70313,
      "treatment combined oxycodone": 82505,
      "conclusions combination therapy": 19049,
      "combination therapy oxycodone": 17615,
      "pain remains difficult": 57612,
      "kg oxycodone 10": 40776,
      "opioid requirements improve": 52341,
      "oxycodone centrally acting": 54776,
      "active controlled double": 7497,
      "controlled double dummy": 20490,
      "administered intravenously orally": 8147,
      "pain tolerance threshold": 57923,
      "pressure pain detection": 64746,
      "pain detection tolerance": 56703,
      "detection tolerance thresholds": 23967,
      "visceral pain oxycodone": 86254,
      "study designed examine": 78101,
      "hyperalgesia sex differences": 36264,
      "peripherally acting opioid": 60891,
      "responsiveness opioid analgesics": 71410,
      "receptors present study": 68556,
      "neuropathic pain like": 49246,
      "morphine pretreated mice": 47889,
      "concentration mg ml": 18705,
      "effects compared morphine": 27865,
      "24 healthy subjects": 3201,
      "oxycodone useful alternative": 56065,
      "effects acute repeated": 27806,
      "oxycodone induced rewarding": 55271,
      "oxycodone significantly lower": 55914,
      "findings provide evidence": 31811,
      "effect neuropathic pain": 27498,
      "abuse liability commonly": 6749,
      "liability commonly abused": 41640,
      "commonly abused prescription": 17831,
      "prescription opioids methods": 64350,
      "conclusions present data": 19175,
      "positive reinforcing effects": 62484,
      "micro opioid agonist": 46339,
      "preclinical studies investigating": 63536,
      "micro receptor agonist": 46343,
      "buprenorphine partial agonist": 14577,
      "painful peripheral neuropathy": 58009,
      "dose dependently decreased": 25876,
      "results suggest morphine": 71993,
      "counteract opioid induced": 20938,
      "nmda receptor antagonists": 49520,
      "present study determined": 64656,
      "316 10mg kg": 3891,
      "64 mg kg": 5390,
      "316 16 mg": 3893,
      "16 mg kg": 1880,
      "ed 50 values": 27324,
      "use drug drug": 84345,
      "preparations previous studies": 63785,
      "oxymorphone caused significant": 56228,
      "differentially expressed genes": 24945,
      "neuropathic pain using": 49268,
      "chain reaction pcr": 15688,
      "results total 38": 72030,
      "mrna protein levels": 48074,
      "oxycodone 56 mg": 54584,
      "treatment combination oxycodone": 82503,
      "40 160 mg": 4314,
      "mg kg results": 46024,
      "neuropathic pain remains": 49260,
      "pain remains challenge": 57610,
      "study performed using": 78379,
      "mice exposed chronic": 46285,
      "reduced naloxone precipitated": 68945,
      "attenuated morphine induced": 12587,
      "opioid oxycodone studied": 52033,
      "dawley rats implanted": 22226,
      "dose time dependent": 26098,
      "severe withdrawal symptoms": 75026,
      "study designed investigate": 78102,
      "withdrawal precipitated opioid": 87143,
      "precipitated opioid antagonist": 63513,
      "nerve growth factor": 49126,
      "growth factor ngf": 34379,
      "significantly decreased oxycodone": 75680,
      "attenuate opioid induced": 12582,
      "modified warm water": 47247,
      "median effective dose": 44222,
      "effective dose ed": 27614,
      "dose ed 50": 25892,
      "opioid receptor subtypes": 52268,
      "antagonist naloxone methiodide": 11067,
      "body weight accompanied": 14208,
      "physical dependence induced": 61390,
      "induced opioid receptor": 38433,
      "naloxonazine insensitive sites": 48421,
      "male wistar rats": 43067,
      "caused dose dependent": 15383,
      "oxycodone potent opioid": 55718,
      "serotonin ht 2c": 74674,
      "ht 2c receptor": 35913,
      "2c receptor ht": 3643,
      "receptor ht 2c": 68497,
      "ht 2c agonist": 35910,
      "ht 2c antagonist": 35911,
      "2c antagonist sb242084": 3641,
      "lorcaserin did alter": 42422,
      "brain blood concentrations": 14322,
      "blood concentrations oxycodone": 14117,
      "represent new pharmacological": 70748,
      "article special issue": 11787,
      "special issue entitled": 76561,
      "effective drugs treatment": 27620,
      "produce adverse effects": 65356,
      "opioid mop receptor": 51957,
      "clinically used opioid": 17012,
      "binding opioid receptors": 13820,
      "biased mu opioid": 13778,
      "compared clinically used": 18106,
      "receptor agonists oxycodone": 68471,
      "drug self administration": 26791,
      "gonadally intact adult": 33289,
      "changes neuropathic pain": 15799,
      "treatments neuropathic pain": 82915,
      "oxycodone mu opioid": 55482,
      "used management neuropathic": 84999,
      "respiratory depression constipation": 71275,
      "restless legs syndrome": 71448,
      "legs syndrome rls": 41394,
      "amino hydroxy methyl": 9822,
      "opioids line treatment": 53022,
      "used acute chronic": 84833,
      "complication long term": 18550,
      "controlled study performed": 20593,
      "patients severe rls": 59971,
      "naloxone patients severe": 48484,
      "10 mg twice": 854,
      "study group rating": 78216,
      "group rating scale": 33940,
      "groups 12 weeks": 34096,
      "12 weeks 15": 1378,
      "experiments conducted determine": 30682,
      "prescription opioids remain": 64367,
      "limited adverse effects": 41918,
      "present results indicate": 64634,
      "performance results suggest": 60561,
      "doses prescription opioids": 26253,
      "administration did affect": 8249,
      "study examined efficacy": 78199,
      "present results suggest": 64635,
      "mechanism based treatment": 44129,
      "commonly used rodent": 17897,
      "opioid induced pruritus": 51868,
      "morphine administration symptoms": 47579,
      "analgesic effect intravenous": 10201,
      "human clinical trials": 35947,
      "oxycodone tramadol increased": 56015,
      "consistent present study": 19711,
      "hydrocodone hydromorphone oxymorphone": 36095,
      "males compared females": 43072,
      "relative morphine fentanyl": 69754,
      "results nktr 181": 71793,
      "hot water tail": 35688,
      "90 confidence interval": 6083,
      "doses nktr 181": 26221,
      "conclusions nktr 181": 19129,
      "maintaining analgesic effect": 42900,
      "plays key role": 62007,
      "pk pd relationship": 61584,
      "pk pd data": 61583,
      "oxycodone results demonstrate": 55852,
      "treatment options available": 82712,
      "managing neuropathic pain": 43290,
      "lidocaine patch capsaicin": 41674,
      "favourable safety profile": 31269,
      "patients experience clinically": 59273,
      "experience clinically meaningful": 30574,
      "patients frequently experience": 59317,
      "treatment clinical practice": 82495,
      "pain relief trials": 57596,
      "additive supra additive": 7919,
      "adverse event profiles": 8712,
      "spinal cord stimulation": 76711,
      "narrow therapeutic index": 48648,
      "used improve opioid": 84969,
      "clinical trials opioid": 16953,
      "little known influence": 42161,
      "using tail withdrawal": 85636,
      "54 mg kg": 5048,
      "molecular dynamics md": 47283,
      "dynamics md simulation": 27219,
      "agonist mu opioid": 9291,
      "issues related opioid": 40335,
      "clinically used opioids": 17013,
      "buprenorphine hydrocodone hydromorphone": 14551,
      "oxymorphone tapentadol tramadol": 56287,
      "human mu opioid": 35964,
      "pain relief single": 57584,
      "following high fat": 32139,
      "maximum concentration area": 43584,
      "decrease pupil diameter": 22925,
      "multiple dose administration": 48271,
      "half life hours": 34516,
      "induced physical dependence": 38445,
      "acute chronic effects": 7617,
      "acute chronic administration": 7616,
      "administration prescription opioids": 8343,
      "development opioid induced": 24241,
      "related opioid agonists": 69643,
      "delta kappa opioid": 23234,
      "buprenorphine partial mu": 14578,
      "pain despite analgesic": 56701,
      "relatively little known": 69779,
      "nociceptive neuropathic mixed": 49549,
      "neuropathic mixed pain": 49229,
      "including morphine fentanyl": 37638,
      "opioid receptor gene": 52255,
      "receptor gene oprm1": 68494,
      "adverse effects addition": 8638,
      "analysis gene expression": 10690,
      "endogenous opioids opioid": 28850,
      "central nucleus amygdala": 15603,
      "nucleus amygdala cea": 50129,
      "pain studies investigated": 57871,
      "overdose opioid use": 54306,
      "receptor antagonists combination": 68478,
      "naltrexone mg kg": 48544,
      "zebrafish danio rerio": 87756,
      "effects mu opioid": 28010,
      "dose dependent decreases": 25867,
      "rate decreasing effects": 67458,
      "response opioid analgesics": 71354,
      "morphine buprenorphine tramadol": 47593,
      "effects peripheral opioid": 28086,
      "peripherally restricted opioid": 60894,
      "peripheral neuropathic pain": 60876,
      "action mu opioid": 7436,
      "produced long lasting": 65393,
      "mop agonist oxycodone": 47487,
      "nop receptor agonists": 49870,
      "pain abuse liability": 56402,
      "opioid receptor kop": 52257,
      "mixed opioid receptor": 46805,
      "non addictive pain": 49567,
      "addictive pain medications": 7786,
      "analgesic effect generally": 10200,
      "chronic pain therapy": 16319,
      "opioids commonly identified": 52801,
      "studies clinical experience": 77664,
      "mouse mu opioid": 48038,
      "serotonin ht 2a receptor": 74673,
      "oxycodone induced conditioned place": 55265,
      "induced conditioned place preference": 38398,
      "reduced oxycodone induced locomotor": 68962,
      "oxycodone induced locomotor sensitization": 55268,
      "cell patch clamp recordings": 15486,
      "nociceptin orphanin fq nop": 49534,
      "orphanin fq nop receptor": 53808,
      "methods adult male c57bl": 45241,
      "adult male c57bl mice": 8494,
      "male c57bl mice trained": 43025,
      "c57bl mice trained discriminate": 14655,
      "mice trained discriminate mg": 46320,
      "trained discriminate mg kg": 82000,
      "discriminate mg kg oxycodone": 25273,
      "mg kg oxycodone vehicle": 46014,
      "nociceptin orphanin fq peptide": 49535,
      "respiratory depression abuse potential": 71268,
      "safe effective pain relief": 73083,
      "prescription opioid abuse rationale": 64278,
      "kappa opioid receptor kor": 40595,
      "receptor mor agonist oxycodone": 68510,
      "enhance antinociceptive effects oxycodone": 28955,
      "oxycodone self administration oxycodone": 55878,
      "self administration study male": 74481,
      "administration study male sprague": 8382,
      "study male sprague dawley": 78299,
      "rats self administered intravenous": 67892,
      "oxycodone 056 mg kg": 54489,
      "032 32 mg kg": 428,
      "progressive ratio schedule reinforcement": 65581,
      "reduced oxycodone self administration": 68964,
      "oxycodone self administration dose": 55876,
      "self administration dose dependent": 74464,
      "morphine indicating opioid receptor": 47729,
      "potent mu opioid receptor": 63107,
      "analgesics commonly used treat": 10400,
      "analgesic doses oxycodone morphine": 10186,
      "oxycodone produced dose dependent": 55764,
      "dose 10 mg kg": 25782,
      "single oral dose oxycodone": 76132,
      "greater analgesic effect oxycodone": 33432,
      "healthy volunteers methods healthy": 34855,
      "volunteers methods healthy volunteers": 86425,
      "morphine 30 mg orally": 47557,
      "oxycodone 15 mg orally": 54522,
      "oxycodone 32 mg kg": 54559,
      "amphetamine 32 mg kg": 9845,
      "protein coupled receptors gpcrs": 65929,
      "opioid agonists morphine oxycodone": 51434,
      "ultra low dose opioid": 83421,
      "low dose naltrexone ntx": 42473,
      "ultra low dose ntx": 83420,
      "plus ultra low dose": 62037,
      "sprague dawley rats administered": 76770,
      "10 mg kg morphine": 824,
      "morphine mg kg oxycodone": 47763,
      "analgesia using tail flick": 10131,
      "rats received subcutaneous injections": 67884,
      "tandem mass spectrometry results": 80367,
      "oral morphine 30 mg": 53574,
      "oxycodone nalfurafine oxycodone nalfurafine": 55487,
      "oxycodone metabolites oxymorphone noroxycodone": 55392,
      "mu opioid receptor activation": 48123,
      "mu opioid agonists oxycodone": 48121,
      "progressive ratio pr schedule": 65579,
      "ratio pr schedule reinforcement": 67793,
      "self administration male sprague": 74468,
      "administration male sprague dawley": 8295,
      "sprague dawley rats self": 76773,
      "dawley rats self administered": 22228,
      "oxycodone produced significant dose": 55768,
      "mg kg dose dependently": 45971,
      "opioid receptor agonist used": 52243,
      "receptor agonist used treatment": 68469,
      "mu opioid receptor antagonist": 48127,
      "reduced oxycodone induced antinociception": 68961,
      "opioid analgesics morphine oxycodone": 51509,
      "chromatography mass spectrometry results": 16165,
      "morphine 30 mg kg": 47556,
      "opioid receptor kor agonists": 52259,
      "adult male rhesus monkeys": 8497,
      "dose tested mg kg": 26096,
      "opioid induced behavioral effects": 51854,
      "effects present study evaluated": 28108,
      "24 mg kg day": 3244,
      "25 mg kg oxycodone": 3365,
      "double blind crossover design": 26349,
      "confidence interval ci 48": 19475,
      "difference 95 ci 14": 24588,
      "adverse effects associated opioid": 8643,
      "commonly used treat acute": 17901,
      "effective long term analgesia": 27634,
      "complete freund adjuvant cfa": 18447,
      "freund adjuvant cfa induced": 32592,
      "pain relief acceptable tolerability": 57519,
      "warm water tail flick": 86716,
      "linked articles article themed": 42050,
      "articles article themed section": 11795,
      "article themed section opioids": 11791,
      "themed section opioids new": 80908,
      "section opioids new pathways": 74271,
      "opioids new pathways functional": 53091,
      "new pathways functional selectivity": 49357,
      "pathways functional selectivity view": 58526,
      "functional selectivity view articles": 32716,
      "selectivity view articles section": 74450,
      "view articles section visit": 86222,
      "articles section visit http": 11808,
      "section visit http dx": 74276,
      "visit http dx doi": 86263,
      "http dx doi org": 35922,
      "dx doi org 10": 27206,
      "doi org 10 1111": 25698,
      "org 10 1111 bph": 53746,
      "10 1111 bph 2015": 667,
      "1111 bph 2015 172": 1169,
      "bph 2015 172 issue": 14296,
      "doses 25 mg kg": 26136,
      "pain cold pressor test": 56562,
      "conclusions combination therapy oxycodone": 19050,
      "mg kg oxycodone 10": 46009,
      "dose oxycodone mg kg": 25994,
      "oxycodone centrally acting opioid": 54777,
      "active controlled double dummy": 7498,
      "mg kg administered intravenously": 45955,
      "pain detection tolerance thresholds": 56704,
      "present study designed examine": 64653,
      "peripheral opioid receptors present": 60882,
      "opioid receptors present study": 52283,
      "receptors present study investigated": 68558,
      "pain aim study investigate": 56438,
      "background prescription opioid abuse": 13170,
      "prescription opioid abuse significant": 64279,
      "abuse liability commonly abused": 6750,
      "commonly abused prescription opioids": 17833,
      "effects commonly abused prescription": 27859,
      "opioids chronic pain opioid": 52783,
      "316 16 mg kg": 3894,
      "polymerase chain reaction pcr": 62202,
      "oxycodone 56 mg kg": 54585,
      "provide pain relief improve": 66090,
      "sprague dawley rats implanted": 76772,
      "use opioids pain management": 84565,
      "withdrawal precipitated opioid antagonist": 87144,
      "precipitated opioid antagonist naloxone": 63514,
      "nerve growth factor ngf": 49127,
      "modified warm water tail": 47248,
      "median effective dose ed": 44223,
      "effective dose ed 50": 27615,
      "receptors present study designed": 68557,
      "receptor antagonist naloxone methiodide": 68475,
      "induced opioid receptor agonists": 38434,
      "ht 2c receptor ht": 35914,
      "2c receptor ht 2c": 3644,
      "ht 2c antagonist sb242084": 35912,
      "article special issue entitled": 11788,
      "oxycodone mu opioid receptor": 55483,
      "used management neuropathic pain": 85000,
      "restless legs syndrome rls": 71449,
      "used acute chronic pain": 84834,
      "complication long term opioid": 18551,
      "release oxycodone naloxone patients": 69956,
      "oxycodone naloxone patients severe": 55511,
      "10 mg twice daily": 855,
      "study group rating scale": 78217,
      "groups 12 weeks 15": 34097,
      "female sprague dawley rats": 31378,
      "hot water tail flick": 35689,
      "opioids oxycodone methadone tramadol": 53140,
      "patients experience clinically meaningful": 59274,
      "experience clinically meaningful pain": 30575,
      "molecular dynamics md simulation": 47284,
      "agonist mu opioid receptor": 9292,
      "mu opioid receptor binding": 48129,
      "oxycodone 10 mg immediate": 54499,
      "mu delta kappa opioid": 48109,
      "delta kappa opioid receptors": 23235,
      "buprenorphine partial mu opioid": 14579,
      "nociceptive neuropathic mixed pain": 49550,
      "mu opioid receptor gene": 48130,
      "opioid receptor gene oprm1": 52256,
      "central nucleus amygdala cea": 15604,
      "overdose opioid use disorders": 54307,
      "mu opioid receptor antagonists": 48128,
      "opioid receptor antagonists combination": 52249,
      "effects mu opioid agonists": 28011,
      "produced dose dependent decreases": 65379,
      "01 mg kg dose": 318,
      "kappa opioid receptor kop": 40594,
      "mixed opioid receptor agonist": 46806,
      "non addictive pain medications": 49568,
      "preservation": 64714,
      "epigenetics": 29199,
      "suds": 78936,
      "hurdle": 35993,
      "sud": 78934,
      "brains": 14372,
      "intersection": 39544,
      "integrate": 39191,
      "chronicity": 16361,
      "reinstatement": 69530,
      "chambers": 15711,
      "fetus": 31621,
      "canonical": 14939,
      "endocannabinoid": 28840,
      "inactivate": 37218,
      "fr3": 32451,
      "incidentally": 37340,
      "suppressive": 79247,
      "339": 4013,
      "23a": 3137,
      "sacrificed": 73062,
      "scm": 73692,
      "fa": 31011,
      "homogeneity": 35533,
      "mri": 48066,
      "psychostimulant": 66364,
      "dysregulation": 27235,
      "corticosterone": 20856,
      "abundant": 6635,
      "elaborated": 28467,
      "surprising": 79668,
      "sections": 74296,
      "dark": 21835,
      "counterbalanced": 20942,
      "happy": 34569,
      "sucrose": 78931,
      "persists": 60938,
      "wane": 86702,
      "virulent": 86246,
      "psychopharmacological": 66359,
      "audio": 12648,
      "environmental": 29092,
      "habit": 34496,
      "dissected": 25511,
      "htr2a": 35918,
      "compute": 18651,
      "maladaptive": 43016,
      "cages": 14671,
      "gavage": 32913,
      "drink": 26458,
      "retraction": 72090,
      "corroborated": 20850,
      "spared": 76526,
      "vesicles": 86169,
      "pulled": 66462,
      "parietal": 58224,
      "synuclein": 79965,
      "subpopulation": 78769,
      "snp": 76350,
      "phenoxy": 61351,
      "immobility": 36761,
      "balb": 13240,
      "f2": 31010,
      "viral": 86237,
      "pharmacogenetics": 61101,
      "rebound": 68027,
      "vulnerabilities": 86685,
      "methylenedioxypyrovalerone": 45659,
      "mdpv": 43649,
      "cathinones": 15326,
      "electric": 28503,
      "stabilizer": 76834,
      "consequent": 19596,
      "normalize": 49916,
      "impulsive": 37209,
      "nonhumans": 49740,
      "segments": 74374,
      "veins": 86050,
      "hydrolase": 36142,
      "flavin": 31903,
      "monooxygenase": 47371,
      "microsomal": 46378,
      "evans": 29974,
      "dissolved": 25528,
      "underpinnings": 83612,
      "reproductive": 70777,
      "architecture": 11618,
      "circuit": 16568,
      "pleasure": 62013,
      "music": 48372,
      "chills": 16085,
      "neuroendocrine": 49192,
      "morbid": 47505,
      "conditionally": 19293,
      "glucocorticoid": 33243,
      "experimentation": 30678,
      "neurokinin": 49197,
      "postpartum": 63037,
      "dyad": 27208,
      "responds": 71328,
      "shield": 75136,
      "parental": 58202,
      "surgically": 79661,
      "strata": 77406,
      "breakpoint": 14393,
      "motivates": 48017,
      "antiretroviral": 11261,
      "precipitant": 63505,
      "unfolding": 83726,
      "discounted": 25256,
      "innate": 39001,
      "discounting": 25257,
      "wt": 87380,
      "pellet": 60375,
      "tending": 80600,
      "mimicking": 46501,
      "propyl": 65810,
      "1r": 2254,
      "underlies": 83598,
      "vistas": 86298,
      "abcg2": 6522,
      "atpase": 12534,
      "culminated": 21378,
      "playing": 62000,
      "ha": 34495,
      "tone": 81656,
      "ahead": 9357,
      "s1": 73055,
      "p3": 56299,
      "threonine": 81148,
      "glp": 33242,
      "ai": 9365,
      "deactivation": 22681,
      "fiber": 31676,
      "basket": 13481,
      "simulates": 76028,
      "impairs": 36908,
      "spatially": 76543,
      "situational": 76173,
      "incentives": 37248,
      "samidorphan": 73285,
      "agouti": 9343,
      "f0": 31007,
      "igg": 36549,
      "precipitous": 63519,
      "boost": 14246,
      "mdd": 43643,
      "prt": 66290,
      "verifying": 86079,
      "constrain": 19803,
      "job": 40475,
      "threaten": 81143,
      "prompting": 65675,
      "returns": 72196,
      "1mg": 2252,
      "manifest": 43307,
      "oprd1": 53410,
      "oprk1": 53411,
      "sensorimotor": 74569,
      "contrasting": 20220,
      "trying": 83267,
      "bbb": 13491,
      "pivotal": 61570,
      "outs": 54167,
      "elevations": 28567,
      "unidirectional": 83730,
      "biophysical": 13861,
      "significant potential": 75601,
      "overdoses reached": 54334,
      "oxycodone responses": 55848,
      "remain unknown": 70257,
      "effect opiate": 27502,
      "finally effect": 31753,
      "rats samples": 67889,
      "disorders suds": 25407,
      "pervasive society": 60980,
      "medication development": 44485,
      "nearly impossible": 48870,
      "population includes": 62341,
      "preservation methods": 64715,
      "available free": 12807,
      "free charge": 32486,
      "non profit": 49673,
      "aspect pain": 11859,
      "oxycodone pharmacological": 55681,
      "administration taken": 8386,
      "addictive like": 7784,
      "painkillers united": 58017,
      "resulted lower": 71510,
      "non severe": 49683,
      "time injury": 81277,
      "days chronic": 22493,
      "administration associated": 8220,
      "weeks months": 86926,
      "associated elevated": 12257,
      "analgesics exhibit": 10421,
      "studied rats": 77629,
      "rates behavioral": 67559,
      "pain rate": 57465,
      "suggest high": 78993,
      "use highly": 84399,
      "assess oral": 11942,
      "associated specific": 12443,
      "sessions oxycodone": 74746,
      "oxycodone removed": 55832,
      "line prior": 41995,
      "conclusions taken": 19231,
      "oxycodone alcohol": 54704,
      "widespread abuse": 87080,
      "shown cross": 75332,
      "cross placenta": 21251,
      "integrated approach": 39193,
      "determine role": 24050,
      "attenuated oxycodone": 12591,
      "administration required": 8360,
      "orally intravenously": 53695,
      "cause drug": 15352,
      "cue induced": 21370,
      "induced reinstatement": 38450,
      "administration addition": 8212,
      "oral drug": 53528,
      "disorder oxycodone": 25384,
      "anxiolytic properties": 11287,
      "32 56": 3917,
      "males treated": 43085,
      "collected clinical": 17451,
      "collected specified": 17484,
      "specified time": 76633,
      "time drug": 81255,
      "treatment total": 82874,
      "opioid reinforcement": 52296,
      "influences drug": 38606,
      "examine opioid": 30349,
      "day following": 22315,
      "dopamine uptake": 25726,
      "15 compared": 1726,
      "na\u00efve rats": 48851,
      "rats reduced": 67885,
      "sustained oxycodone": 79779,
      "drug acute": 26517,
      "acute drug": 7629,
      "reducing drug": 69013,
      "infusion 12": 38695,
      "day 13": 22244,
      "increases time": 38087,
      "drug craving": 26571,
      "opioid focused": 51810,
      "heroin craving": 34995,
      "determined effect": 24064,
      "incubated oxycodone": 38152,
      "heroin study": 35034,
      "common comorbidities": 17743,
      "received repeated": 68259,
      "measured drug": 43965,
      "correlated drug": 20812,
      "imaging mri": 36684,
      "interaction drugs": 39370,
      "suffering addiction": 78964,
      "using vitro": 85668,
      "methamphetamine meth": 45145,
      "drug conditions": 26565,
      "oxycodone pre": 55730,
      "extended periods": 30853,
      "preference drugs": 63623,
      "increased nonmedical": 37953,
      "oxycodone females": 55071,
      "levels higher": 41567,
      "baseline following": 13435,
      "course oxycodone": 20997,
      "females highest": 31392,
      "suggest male": 78998,
      "emerged significant": 28664,
      "fatalities recent": 31245,
      "oxycodone selected": 55870,
      "choice procedure": 16119,
      "effects tested": 28181,
      "oxycodone markedly": 55369,
      "recent decades": 68396,
      "effects particularly": 28080,
      "ml post": 46893,
      "conditions daily": 19315,
      "test sessions": 80783,
      "increased numbers": 37956,
      "deliveries increased": 23211,
      "increased decreased": 37900,
      "highest concentration": 35341,
      "using novel": 85524,
      "kg days": 40713,
      "provides useful": 66243,
      "effects highly": 27941,
      "highly abused": 35387,
      "withdrawal associated": 87118,
      "sleep disturbances": 76221,
      "prevents oxycodone": 64892,
      "water intake": 86757,
      "kg undergoing": 40818,
      "associated increases": 12310,
      "intake observed": 39183,
      "know little": 40878,
      "objective examined": 50431,
      "presentation positive": 64682,
      "basis methods": 13479,
      "oxy produced": 54465,
      "produced subjective": 65415,
      "alter behavioral": 9680,
      "activity primary": 7582,
      "oxy did": 54445,
      "abuse led": 6745,
      "crisis development": 21170,
      "oral sucrose": 53667,
      "oxycodone persistent": 55672,
      "decreases oxycodone": 23062,
      "kg administrated": 40693,
      "stress induced": 77490,
      "cpp results": 21046,
      "adolescents adults": 8453,
      "models investigate": 47116,
      "old adult": 50999,
      "mice mice": 46296,
      "dependent oxycodone": 23524,
      "lower initial": 42634,
      "abuse deaths": 6674,
      "prescription oral": 64373,
      "designed oral": 23839,
      "model drug": 47043,
      "followed increasing": 32061,
      "genetic predisposition": 33080,
      "025 mg": 390,
      "ml 001": 46820,
      "72 17": 5610,
      "21 41": 2952,
      "incidence prescription": 37302,
      "administration frequency": 8269,
      "kg twice": 40816,
      "dependence effects": 23469,
      "differed groups": 24559,
      "reinforcing properties": 69529,
      "efficacious treatment": 28207,
      "pain significant": 57836,
      "reduced reinforcing": 68978,
      "including combination": 37603,
      "effects explain": 27923,
      "administration present": 8344,
      "kg injection": 40744,
      "combination ratio": 17609,
      "effects rats": 28125,
      "oxycodone reached": 55803,
      "issue study": 40326,
      "study focuses": 78212,
      "following genes": 32135,
      "effects long": 27973,
      "sessions effect": 74744,
      "extended oxycodone": 30851,
      "administered 14": 8098,
      "daily extended": 21747,
      "sessions sessions": 74749,
      "escalation oxycodone": 29531,
      "analgesia alleviate": 9911,
      "alleviate opioid": 9598,
      "infusion slightly": 38731,
      "infusion intravenous": 38709,
      "suggesting reduced": 79030,
      "ntx doses": 50113,
      "kg drug": 40722,
      "addition ultra": 7831,
      "addiction study": 7773,
      "intraperitoneally injected": 39788,
      "withdrawal expression": 87130,
      "hypothesis tested": 36300,
      "oxycodone impaired": 55237,
      "tested drug": 80800,
      "discontinuation study": 25232,
      "oral gavage": 53541,
      "ketamine morphine": 40614,
      "abrupt discontinuation": 6582,
      "showed evidence": 75246,
      "infants neonatal": 38508,
      "pregnancy delivery": 63689,
      "controls differences": 20669,
      "relative control": 69742,
      "finally oxycodone": 31754,
      "model oral": 47064,
      "states currently": 77088,
      "cns disorders": 17115,
      "volumes oxycodone": 86405,
      "respectively findings": 71194,
      "frontal parietal": 32603,
      "years oxycodone": 87630,
      "identified strong": 36472,
      "administration studied": 8378,
      "novel measures": 50012,
      "rats using": 67903,
      "hplc ms": 35885,
      "measures changes": 44049,
      "single nucleotide": 76125,
      "nucleotide polymorphism": 50121,
      "polymorphism snp": 62213,
      "detected differences": 23941,
      "sa history": 73059,
      "small molecule": 76287,
      "sucrose solution": 78932,
      "methyl phenoxy": 45647,
      "studied effectiveness": 77611,
      "abuse single": 6878,
      "use examined": 84361,
      "reinstatement drug": 69531,
      "fr schedule": 32450,
      "understanding pharmacogenomics": 83645,
      "brain concentration": 14328,
      "showed robust": 75294,
      "inactive metabolite": 37222,
      "fewer 10": 31625,
      "gene variant": 32948,
      "p450 enzymes": 56313,
      "findings genetic": 31782,
      "genetic variation": 33087,
      "increased oxymorphone": 37973,
      "drug cue": 26572,
      "prenatal oxycodone": 63729,
      "expression determined": 30830,
      "determined western": 24093,
      "blot analysis": 14164,
      "congenital malformations": 19532,
      "time birth": 81216,
      "birth weight": 13883,
      "use humans": 84406,
      "current animal": 21424,
      "model extended": 47048,
      "differences plasma": 24787,
      "rebound increase": 68028,
      "analysis predicted": 10738,
      "opioids mu": 53077,
      "impact diverse": 36804,
      "expression numerous": 30837,
      "genes related": 33067,
      "undergo major": 83503,
      "development dependence": 24222,
      "dependence recent": 23485,
      "preventing drug": 64862,
      "oxy mg": 54459,
      "rats oxy": 67872,
      "analgesics little": 10443,
      "methylenedioxypyrovalerone mdpv": 45660,
      "objectives present": 50577,
      "greater overall": 33467,
      "consequences drug": 19589,
      "new form": 49328,
      "treatment prevent": 82783,
      "escalating prescription": 29526,
      "sessions week": 74752,
      "drug access": 26514,
      "state associated": 77033,
      "longer periods": 42386,
      "baseline procedure": 13455,
      "rats showed": 67895,
      "minimal impact": 46574,
      "behavior introduction": 13531,
      "medicines agency": 44716,
      "products methods": 65452,
      "opiate like": 51301,
      "discontinuation syndrome": 25233,
      "syndrome following": 79917,
      "treatment cessation": 82475,
      "controlled controlled": 20473,
      "constipation reduced": 19779,
      "did block": 24413,
      "major effects": 42945,
      "oxycodone potential": 55719,
      "constipation current": 19759,
      "rising public": 72500,
      "concern importantly": 18826,
      "impact overall": 36827,
      "goal current": 33271,
      "compared adult": 18095,
      "adult c57bl": 8487,
      "11 underwent": 1155,
      "levels lower": 41574,
      "controls age": 20667,
      "correlation oxycodone": 20834,
      "significant drug": 75531,
      "mice overall": 46302,
      "pharmacotherapies opioid": 61246,
      "limiting use": 41977,
      "transporter expression": 82244,
      "illicit abuse": 36629,
      "examine potential": 30353,
      "microarray analysis": 46345,
      "flavin containing": 31904,
      "containing monooxygenase": 20078,
      "poses major": 62436,
      "develop interventions": 24148,
      "leading higher": 41310,
      "oxycodone experimental": 55055,
      "did pre": 24475,
      "05 25": 483,
      "heroin induced": 35009,
      "test retest": 80782,
      "additional time": 7899,
      "time effort": 81258,
      "effects prescription": 28103,
      "injection non": 38958,
      "discontinuation oxycodone": 25225,
      "withdrawal conclusions": 87121,
      "taken present": 80291,
      "developed oral": 24188,
      "consumption model": 19955,
      "consumption using": 20037,
      "women reproductive": 87241,
      "reproductive age": 70778,
      "corresponding increase": 20846,
      "indicated number": 38240,
      "number non": 50186,
      "vitro findings": 86360,
      "administering opioid": 8196,
      "participants performed": 58341,
      "pharmacological intervention": 61217,
      "did modulate": 24464,
      "subjective reports": 78670,
      "skin conductance": 76199,
      "known hiv": 40913,
      "behavior mice": 13533,
      "approximately 130": 11560,
      "day united": 22438,
      "states prescription": 77143,
      "40 deaths": 4335,
      "routes recreational": 72858,
      "recreational users": 68785,
      "administration model": 8303,
      "consistent prior": 19713,
      "alcohol cocaine": 9526,
      "studied methods": 77617,
      "administered doses": 8123,
      "kg administration": 40694,
      "prior oxycodone": 65163,
      "stimulating effects": 77365,
      "following withdrawal": 32224,
      "mice lower": 46294,
      "female counterparts": 31359,
      "treatment specific": 82849,
      "findings open": 31800,
      "abuse reached": 6856,
      "reached epidemic": 67935,
      "epidemic levels": 29133,
      "states drugs": 77096,
      "age significant": 9122,
      "oxycodone pregnancy": 55735,
      "postpartum oxycodone": 63038,
      "effects oprm1": 28047,
      "showed increased": 75265,
      "potential avenues": 63138,
      "prescribed abusing": 63813,
      "patterns methods": 60210,
      "age 12": 8970,
      "results maternal": 71761,
      "maternal blood": 43519,
      "genes including": 33063,
      "network analysis": 49157,
      "oxy vs": 54468,
      "poor treatment": 62276,
      "oxycodone described": 54944,
      "cue reactivity": 21372,
      "hypothesis selective": 36298,
      "approved united": 11550,
      "delivery oxycodone": 23225,
      "infusion pump": 38723,
      "range lorcaserin": 67322,
      "ability lorcaserin": 6552,
      "abuse specific": 6880,
      "adolescent opioid": 8443,
      "adolescent oxycodone": 8444,
      "oxycodone saline": 55862,
      "saline injections": 73264,
      "showed strong": 75316,
      "history results": 35481,
      "did suggest": 24513,
      "adults study": 8582,
      "infusion days": 38701,
      "administered 25": 8101,
      "administered significantly": 8180,
      "groups lowest": 34228,
      "lower number": 42653,
      "number infusions": 50165,
      "states lead": 77114,
      "underwent week": 83705,
      "treatment assessed": 82451,
      "sa oxycodone": 73060,
      "subsequent oxycodone": 78779,
      "methods adolescent": 45238,
      "administration 14": 8205,
      "followed 14": 32047,
      "procedure 10": 65267,
      "results mice": 71782,
      "reduced antinociceptive": 68909,
      "na\u00efve female": 48831,
      "differentially affect": 24942,
      "males results": 43082,
      "opioid following": 51812,
      "newly identified": 49418,
      "viable treatment": 86192,
      "opioids occurs": 53113,
      "effect naltrexone": 27495,
      "administration pr": 8339,
      "antagonist currently": 11062,
      "abuse treated": 6895,
      "oxycodone enhanced": 55025,
      "training treatment": 82012,
      "using rat": 85590,
      "areas results": 11650,
      "modelling oxycodone": 47103,
      "pharmacokinetics dynamics": 61167,
      "use transition": 84781,
      "growing drug": 34364,
      "abuse previous": 6845,
      "exposure relative": 30791,
      "precipitant drug": 63506,
      "follow study": 32036,
      "study 30": 77890,
      "administration long": 8286,
      "administration commonly": 8228,
      "prevent acquisition": 64841,
      "did impair": 24453,
      "opioid remifentanil": 52331,
      "treatment high": 82615,
      "dose remifentanil": 26054,
      "comparisons showed": 18390,
      "suggests people": 79042,
      "significant impairment": 75548,
      "oxycodone conditions": 54845,
      "evidence increase": 30198,
      "oxycodone separate": 55891,
      "oxycodone distribution": 54987,
      "delivery results": 23227,
      "observed plasma": 50704,
      "influence abuse": 38584,
      "treatment recently": 82798,
      "earlier studies": 27244,
      "rt pcr": 73033,
      "investigation potential": 40071,
      "cocaine abuse": 17135,
      "disorder limited": 25375,
      "currently approved": 21488,
      "promise attenuating": 65653,
      "potential treatment": 63239,
      "1h indole": 2251,
      "increased blood": 37885,
      "support continued": 79190,
      "disorders significance": 25402,
      "new treatments": 49384,
      "adversely impact": 8855,
      "changes blood": 15775,
      "development treatment": 24254,
      "analgesics clinic": 10389,
      "increased following": 37919,
      "prevent prescription": 64853,
      "possible targets": 62551,
      "using procedure": 85577,
      "effects exposure": 27924,
      "crisis new": 21173,
      "entitled new": 29080,
      "new vistas": 49387,
      "vistas opioid": 86299,
      "remains understudied": 70314,
      "changes gene": 15787,
      "identified organic": 36451,
      "affinity status": 8948,
      "atpase assay": 12536,
      "brain uptake": 14371,
      "uptake studies": 84022,
      "response drug": 71342,
      "epidemic significantly": 29153,
      "economic stability": 27314,
      "biological underpinnings": 13855,
      "susceptibility opioid": 79759,
      "characterize oxycodone": 15898,
      "consumption tolerance": 20032,
      "cue stimuli": 21373,
      "findings revealed": 31817,
      "measures including": 44062,
      "rationale prescription": 67810,
      "adolescent prescription": 8446,
      "adolescent male": 8442,
      "increased 300": 37848,
      "based treatments": 13396,
      "therapeutic approach": 80919,
      "cocaine alcohol": 17137,
      "schedule opioid": 73628,
      "treatment admissions": 82431,
      "past 10": 58446,
      "development severity": 24250,
      "severity treatment": 75052,
      "preclinical study": 63538,
      "administration procedures": 8347,
      "vs low": 86654,
      "low oxycodone": 42517,
      "behaviors individuals": 13561,
      "better models": 13718,
      "humans characterized": 35982,
      "using addiction": 85298,
      "high addiction": 35069,
      "observed individuals": 50685,
      "disorder background": 25369,
      "administration leading": 8283,
      "rats 30": 67840,
      "effects medications": 27988,
      "factors increase": 31102,
      "small non": 76289,
      "non coding": 49589,
      "behavior methods": 13532,
      "rest increased": 71423,
      "abuse prior": 6846,
      "failed acquire": 31138,
      "using intravenous": 85447,
      "12 measured": 1320,
      "intake using": 39188,
      "reinforcement compared": 69517,
      "50 26": 4812,
      "days home": 22531,
      "kg oxy": 40774,
      "effect oxy": 27514,
      "individual response": 38308,
      "collected assessment": 17449,
      "salivary cortisol": 73280,
      "nucleotide polymorphisms": 50123,
      "dependent populations": 23530,
      "significantly 05": 75646,
      "cortisol levels": 20858,
      "compared individuals": 18188,
      "medication widely": 44587,
      "drug limited": 26694,
      "effect utero": 27579,
      "function prescription": 32670,
      "abuse public": 6850,
      "especially females": 29556,
      "newly generated": 49417,
      "stimulation physical": 77372,
      "data combined": 21918,
      "support potential": 79207,
      "effectiveness current": 27756,
      "aimed identifying": 9456,
      "disorder growing": 25374,
      "thoroughly investigated": 81135,
      "oxycodone experienced": 55054,
      "receptors dopamine": 68539,
      "attenuated opioid": 12588,
      "molecular targets": 47290,
      "use recently": 84679,
      "recently opioid": 68445,
      "withdrawal using": 87168,
      "oxycodone intoxication": 55290,
      "associated altered": 12219,
      "allele carriers": 9584,
      "hours day": 35763,
      "pumps containing": 66482,
      "levels results": 41605,
      "moderate doses": 47142,
      "change activity": 15720,
      "signal intensity": 75385,
      "anesthesia t1": 10948,
      "results brain": 71616,
      "elevated levels": 28560,
      "increased oxy": 37970,
      "likelihood estimation": 41789,
      "analgesics particularly": 10474,
      "expanding treatment": 30542,
      "abuse critical": 6672,
      "novel high": 50011,
      "administration rapidly": 8355,
      "decreased oral": 23018,
      "showed time": 75320,
      "decreased levels": 23006,
      "affective cognitive": 8931,
      "demonstrated greater": 23341,
      "concern united": 18835,
      "investigate mechanisms": 40018,
      "opioid physical": 52055,
      "morphine fewer": 47695,
      "challenged mg": 15697,
      "48 post": 4743,
      "post withdrawal": 62627,
      "effects positive": 28091,
      "use resulted": 84703,
      "resulted increased": 71508,
      "increased non": 37952,
      "users younger": 85278,
      "model simulates": 47080,
      "increase non": 37759,
      "strategies especially": 77414,
      "reported single": 70654,
      "cocaine 10": 17133,
      "results enhanced": 71681,
      "cpp conclusions": 21043,
      "decades opioid": 22810,
      "abuse risen": 6869,
      "critically important": 21233,
      "enhance sensitivity": 28961,
      "effectiveness attenuating": 27749,
      "drugs occur": 27016,
      "opioids differing": 52856,
      "day subjects": 22422,
      "suggest utility": 79020,
      "information help": 38651,
      "help inform": 34907,
      "inform physicians": 38620,
      "methoxy methyl": 45639,
      "regions opioid": 69364,
      "reduced degree": 68917,
      "abuse assessed": 6652,
      "rats microdialysis": 67870,
      "given large": 33178,
      "differing mechanisms": 24956,
      "action adult": 7428,
      "oxycodone cis": 54780,
      "dark agouti": 21836,
      "received intravenously": 68182,
      "levels determined": 41554,
      "min injection": 46526,
      "effect baseline": 27425,
      "higher males": 35258,
      "oxycodone increases": 55251,
      "response high": 71347,
      "management commonly": 43169,
      "opioids differentially": 52855,
      "indicating need": 38262,
      "need improve": 48929,
      "oxycodone finding": 55093,
      "injection combined": 38940,
      "studies oxy": 77801,
      "behavioral tests": 13554,
      "females higher": 31391,
      "receptor genes": 68495,
      "saline control": 73257,
      "ng kg": 49429,
      "effects used": 28190,
      "females sensitive": 31400,
      "states midst": 77120,
      "midst opioid": 46413,
      "cocaine addition": 17136,
      "increased pr": 37991,
      "oxycodone surprisingly": 55969,
      "data identify": 21983,
      "associated impaired": 12292,
      "received intra": 68172,
      "pain resulted": 57647,
      "need understand": 48963,
      "released opioids": 70023,
      "unknown opioid": 83885,
      "analgesic exposure": 10253,
      "likely important": 41813,
      "stimulating hormone": 77367,
      "patients controls": 59157,
      "levels total": 41614,
      "score subscale": 73799,
      "abuse report": 6864,
      "series novel": 74659,
      "mice reduced": 46308,
      "target opioid": 80490,
      "dependence treatment": 23491,
      "development human": 24231,
      "related dysfunction": 69593,
      "known neurotoxic": 40918,
      "related psychomotor": 69674,
      "response decreased": 71341,
      "related substance": 69687,
      "observed months": 50693,
      "model chronic": 47035,
      "exposure level": 30773,
      "seen humans": 74359,
      "reduce inflammation": 68849,
      "liability using": 41654,
      "absence drug": 6588,
      "binding receptors": 13822,
      "stimulants opioids": 77358,
      "use liquid": 84456,
      "mechanisms play": 44151,
      "important roles": 37032,
      "similar previous": 75982,
      "conditions including": 19318,
      "including major": 37631,
      "depressive disorder": 23608,
      "disorder mdd": 25378,
      "means identify": 43925,
      "function respectively": 32677,
      "drugs enhance": 26951,
      "scopolamine oxycodone": 73696,
      "drugs analgesics": 26885,
      "defects infants": 23103,
      "susceptible opioid": 79761,
      "hormones associated": 35546,
      "associated maternal": 12331,
      "use remains": 84691,
      "greater levels": 33453,
      "available conclusions": 12795,
      "kg hydromorphone": 40735,
      "1mg kg": 2253,
      "state euphoria": 77041,
      "particularly young": 58425,
      "outcomes resulting": 54090,
      "history opiate": 35466,
      "challenges associated": 15702,
      "chronic exposure": 16193,
      "authors present": 12743,
      "management including": 43188,
      "model evaluate": 47047,
      "switch methadone": 79821,
      "maintained methadone": 42887,
      "methadone investigated": 45087,
      "birth associated": 13881,
      "associated symptoms": 12449,
      "development clinical": 24220,
      "different molecular": 24889,
      "seconds minutes": 74264,
      "necessary identify": 48885,
      "predict clinical": 63549,
      "agents recent": 9241,
      "recent preclinical": 68415,
      "oxycodone extensively": 55062,
      "following repeated": 32193,
      "antagonists supporting": 11089,
      "modulation opioid": 47263,
      "nicotine alcohol": 49469,
      "trials finally": 83146,
      "represents novel": 70770,
      "target treatment": 80492,
      "disorders including": 25395,
      "properties systemic": 65720,
      "parameters opioid": 58167,
      "barrier bbb": 13255,
      "bbb permeability": 13492,
      "males conclusions": 43073,
      "disorders sud": 25406,
      "treatment sud": 82866,
      "following key": 32155,
      "based extensive": 13320,
      "extensive preclinical": 30919,
      "agonists definition": 9323,
      "clinical proof": 16876,
      "thought exert": 81137,
      "administration nonopioid": 8312,
      "used behavioral": 84858,
      "supporting role": 79227,
      "effects including opioid": 27952,
      "including opioid use": 37656,
      "effects oxycodone suggesting": 28074,
      "self administered oxycodone": 74456,
      "pain management treatment": 57127,
      "use disorders suds": 84335,
      "opioids oxycodone pain": 53142,
      "painkillers united states": 58018,
      "effects opioids important": 28043,
      "results suggest high": 71992,
      "abuse major public": 6768,
      "shown cross placenta": 75333,
      "time points results": 81341,
      "cue induced reinstatement": 21371,
      "samples collected specified": 73335,
      "collected specified time": 17485,
      "self administration rats": 74476,
      "oxycodone abused prescription": 54622,
      "treatments opioid use": 82917,
      "resonance imaging mri": 71121,
      "opioid oxycodone oxy": 52030,
      "nonmedical use oxycodone": 49786,
      "opioid overdose fatalities": 52015,
      "fatalities recent years": 31246,
      "increasing doses oxycodone": 38104,
      "oxycodone dose dependent": 54991,
      "highly abused prescription": 35388,
      "day 14 mg": 22247,
      "study healthy adults": 78223,
      "received placebo 10": 68245,
      "20 mg oxy": 2346,
      "produced subjective effects": 65416,
      "oxy did decrease": 54446,
      "drugs recent studies": 27054,
      "recent studies suggest": 68427,
      "mg kg administrated": 45956,
      "oxycodone major public": 55360,
      "multiple doses oxycodone": 48275,
      "mg kg mean": 45997,
      "incidence prescription opioid": 37303,
      "30 60 minutes": 3702,
      "mg kg twice": 46036,
      "administration present study": 8345,
      "mg kg injection": 45987,
      "study mg kg": 78312,
      "addiction prescription opioid": 7756,
      "medical use oxycodone": 44418,
      "effects long term": 27974,
      "results oxycodone groups": 71825,
      "oxycodone self administered": 55873,
      "analgesia alleviate opioid": 9912,
      "alleviate opioid tolerance": 9599,
      "addition ultra low": 7832,
      "oxycodone treated rats": 56026,
      "physical dependence withdrawal": 61393,
      "prescription opioids pregnancy": 64362,
      "united states currently": 83787,
      "recent studies suggested": 68428,
      "spectrometry hplc ms": 76663,
      "single nucleotide polymorphism": 76126,
      "nucleotide polymorphism snp": 50122,
      "severe opioid use": 74965,
      "reinstatement drug seeking": 69532,
      "total oxycodone intake": 81876,
      "cytochrome p450 enzymes": 21663,
      "development central nervous": 24217,
      "opioid tolerance withdrawal": 52430,
      "possible adverse effect": 62530,
      "prenatal oxycodone exposure": 63730,
      "expression determined western": 30831,
      "determined western blot": 24094,
      "western blot analysis": 87000,
      "widely abused drugs": 87053,
      "current animal models": 21425,
      "significantly higher level": 75729,
      "opioids mu opioid": 53078,
      "escalating prescription opioid": 29527,
      "oxycodone intravenous self": 55295,
      "sessions sessions week": 74750,
      "acting opioid antagonist": 7400,
      "efficacy oxycodone mice": 28318,
      "rising public health": 72501,
      "goal current study": 33272,
      "current study shows": 21479,
      "illicit use prescription": 36657,
      "self administration increased": 74466,
      "pharmacotherapies opioid use": 61247,
      "previous opioid exposure": 64909,
      "oxycodone self administering": 55874,
      "use illicit abuse": 84414,
      "increased past decade": 37977,
      "aim study examine": 9421,
      "twice day days": 83308,
      "flavin containing monooxygenase": 31905,
      "mg kg heroin": 45979,
      "findings suggest use": 31827,
      "additional time effort": 7900,
      "effects prescription opioid": 28104,
      "discontinuation oxycodone treatment": 25226,
      "opioid withdrawal conclusions": 52642,
      "developed oral oxycodone": 24189,
      "oral oxycodone consumption": 53626,
      "oral opioid consumption": 53603,
      "women reproductive age": 87242,
      "effects oxycodone development": 28060,
      "day united states": 22439,
      "united states prescription": 83820,
      "states prescription opioids": 77145,
      "approximately 40 deaths": 11571,
      "route administration common": 72839,
      "self administration model": 74469,
      "mg kg administration": 45957,
      "stimulating effects oxycodone": 77366,
      "abuse reached epidemic": 6857,
      "united states drugs": 83791,
      "drugs frequently used": 26963,
      "discussion results suggest": 25311,
      "approved united states": 11551,
      "dose range lorcaserin": 26029,
      "25 75 mg": 3341,
      "significantly oxycodone doses": 75827,
      "women likely men": 87219,
      "reinforcing efficacy oxycodone": 69528,
      "nociceptive effects oxycodone": 49543,
      "oxycodone dose mg": 54994,
      "reduced antinociceptive effect": 68910,
      "self administration significantly": 74479,
      "prescription opioids occurs": 64353,
      "treatment oxycodone abuse": 82726,
      "effects oxycodone used": 28075,
      "opioid misuse major": 51943,
      "misuse major public": 46726,
      "opioids commonly abused": 52800,
      "fastest growing drug": 31222,
      "following oxycodone exposure": 32182,
      "objective explore effect": 50433,
      "administration long acting": 8287,
      "administration commonly used": 8229,
      "overall results suggest": 54251,
      "high dose remifentanil": 35090,
      "intravenous oxycodone self": 39875,
      "influence abuse liability": 38585,
      "use disorder limited": 84321,
      "shown promise attenuating": 75348,
      "potential treatment opioid": 63240,
      "increased blood pressure": 37886,
      "support continued development": 79191,
      "use disorders significance": 84332,
      "disorders significance statement": 25403,
      "changes blood pressure": 15776,
      "development treatment opioid": 24255,
      "potent analgesics used": 63095,
      "abused prescription drugs": 6923,
      "prescription opioids pain": 64357,
      "issue entitled new": 40323,
      "entitled new vistas": 29081,
      "new vistas opioid": 49388,
      "vistas opioid pharmacology": 86300,
      "used opioid agonist": 85042,
      "affinity status oxycodone": 8949,
      "studies demonstrated oxycodone": 77695,
      "opioid medications pain": 51920,
      "medications pain management": 44659,
      "opioid epidemic significantly": 51781,
      "characterize oxycodone related": 15899,
      "rationale prescription opioid": 67811,
      "adolescent prescription opioid": 8447,
      "high risk developing": 35170,
      "reached epidemic proportions": 67936,
      "past 10 years": 58447,
      "self administration procedures": 74473,
      "use disorder background": 84318,
      "background opioids effective": 13121,
      "oxycodone administration results": 54691,
      "urgent need identify": 84045,
      "used treatment chronic": 85178,
      "administration oxycodone fentanyl": 8326,
      "schedule reinforcement compared": 73632,
      "mg kg oxy": 46007,
      "alcohol drugs abuse": 9533,
      "samples collected assessment": 73334,
      "single nucleotide polymorphisms": 76128,
      "function prescription opioid": 32671,
      "opioid abuse public": 51378,
      "abuse public health": 6851,
      "oxycodone mice rats": 55446,
      "support potential use": 79208,
      "drug use recently": 26847,
      "using rat model": 85591,
      "studies needed better": 77783,
      "needed better understand": 48986,
      "significantly oxycodone compared": 75826,
      "moderate doses oxycodone": 47143,
      "treatment opioid addiction": 82700,
      "kg twice daily": 40817,
      "maximum likelihood estimation": 43593,
      "abuse addiction prescription": 6645,
      "14 days following": 1586,
      "20 30 40": 2282,
      "10 min oxycodone": 860,
      "opioid analgesics particularly": 51517,
      "significant abuse potential": 75420,
      "induced reinstatement drug": 38451,
      "protein levels increased": 65941,
      "concern united states": 18836,
      "opioid physical dependence": 52056,
      "challenged mg kg": 15698,
      "24 48 post": 3171,
      "patterns drug use": 60204,
      "users younger likely": 85279,
      "younger likely female": 87738,
      "past decades opioid": 58464,
      "opioid abuse risen": 51382,
      "drug use abuse": 26830,
      "agonist opioid receptor": 9299,
      "morphine decreased oxycodone": 47638,
      "role development opioid": 72742,
      "differing mechanisms action": 24957,
      "widely used pain": 87072,
      "pain management commonly": 57063,
      "opioid analgesics associated": 51483,
      "need improve understanding": 48930,
      "doses oxycodone hydrocodone": 26236,
      "oxycodone showed significantly": 55902,
      "showed significantly greater": 75306,
      "provides evidence supporting": 66216,
      "oxycodone reduced mean": 55813,
      "reduced mean number": 68940,
      "conclusions results demonstrate": 19201,
      "liability oxycodone oxy": 41645,
      "opioid antagonists enhance": 51540,
      "mg kg days": 45967,
      "united states midst": 83805,
      "states midst opioid": 77121,
      "midst opioid epidemic": 46414,
      "mg kg 10": 45949,
      "exposure opioid analgesic": 30781,
      "opioid analgesic exposure": 51458,
      "opioid dependence treatment": 51702,
      "play important roles": 61992,
      "major depressive disorder": 42940,
      "depressive disorder mdd": 23609,
      "control pain associated": 20384,
      "history opiate use": 35467,
      "pregnant women opioid": 63700,
      "pattern opioid use": 60193,
      "recent preclinical studies": 68416,
      "brain barrier bbb": 14318,
      "barrier bbb permeability": 13256,
      "decreases opioid use": 23061,
      "use disorders sud": 84334,
      "evidence supporting role": 30276,
      "substance use disorders suds": 78816,
      "abuse major public health": 6769,
      "blood samples collected specified": 14154,
      "samples collected specified time": 73336,
      "treatments opioid use disorder": 82918,
      "treating opioid use disorders": 82403,
      "commonly abused prescription opioid": 17832,
      "magnetic resonance imaging mri": 42803,
      "highly abused prescription opioid": 35389,
      "intravenously self administer oxycodone": 39902,
      "prescription opioid use disorders": 64317,
      "oxycodone major public health": 55361,
      "doses oxycodone mg kg": 26239,
      "incidence prescription opioid abuse": 37304,
      "addiction prescription opioid abuse": 7757,
      "non medical use oxycodone": 49634,
      "analgesia alleviate opioid tolerance": 9913,
      "addition ultra low dose": 7833,
      "10 mg kg day": 823,
      "tandem mass spectrometry hplc": 80364,
      "mass spectrometry hplc ms": 43463,
      "abused prescription opioid oxycodone": 6925,
      "single nucleotide polymorphism snp": 76127,
      "expression determined western blot": 30832,
      "determined western blot analysis": 24095,
      "opioids mu opioid receptor": 53079,
      "oxycodone intravenous self administration": 55296,
      "use prescription opioid analgesics": 84655,
      "oxycodone self administration increased": 55877,
      "treatment pain opioid use": 82739,
      "pain opioid use disorder": 57291,
      "effects prescription opioid oxycodone": 28105,
      "day united states prescription": 22440,
      "united states prescription opioids": 83822,
      "oxycodone mg kg administration": 55422,
      "oxycodone dose dependently increased": 54993,
      "anti nociceptive effects oxycodone": 11139,
      "oxycodone dose mg kg": 54995,
      "oxycodone self administration significantly": 55880,
      "prescription opioid misuse major": 64303,
      "opioid misuse major public": 51944,
      "misuse major public health": 46727,
      "intravenous oxycodone self administration": 39876,
      "opioid use disorder limited": 52502,
      "potential treatment opioid use": 63241,
      "increased blood pressure heart": 37887,
      "use disorders significance statement": 84333,
      "disorders significance statement opioid": 25404,
      "changes blood pressure heart": 15777,
      "potent analgesics used treat": 63096,
      "treatment opioid use disorders": 82706,
      "special issue entitled new": 76562,
      "issue entitled new vistas": 40324,
      "entitled new vistas opioid": 29082,
      "new vistas opioid pharmacology": 49389,
      "15 mg kg injection": 1759,
      "rationale prescription opioid abuse": 67812,
      "opioid use disorder background": 52500,
      "present study designed test": 64654,
      "used treatment chronic pain": 85179,
      "opioid abuse public health": 51379,
      "present study designed evaluate": 64652,
      "medications treat opioid use": 44690,
      "mg kg twice daily": 46037,
      "abuse addiction prescription opioid": 6646,
      "10 20 30 40": 683,
      "induced reinstatement drug seeking": 38452,
      "reinstatement drug seeking behavior": 69533,
      "users younger likely female": 85280,
      "mu kappa delta opioid": 48113,
      "opioids widely used pain": 53395,
      "widely used pain management": 87073,
      "doses oxycodone hydrocodone morphine": 26237,
      "oxycodone showed significantly greater": 55903,
      "abuse liability oxycodone oxy": 6755,
      "dose opioid antagonists enhance": 25976,
      "united states midst opioid": 83806,
      "states midst opioid epidemic": 77122,
      "major depressive disorder mdd": 42941,
      "16 mg kg oxycodone": 1881,
      "pregnant women opioid use": 63701,
      "blood brain barrier bbb": 14109,
      "brain barrier bbb permeability": 14319,
      "substance use disorders sud": 78815,
      "opioid use disorders opioid": 52507,
      "provides evidence supporting role": 66217,
      "tibial": 81170,
      "haemoglobin": 34505,
      "asleep": 11852,
      "knees": 40872,
      "096": 648,
      "454": 4609,
      "mobilized": 47006,
      "ka": 40574,
      "arthroplasties": 11735,
      "arthroscopically": 11756,
      "pma": 62041,
      "holding": 35503,
      "walked": 86697,
      "locked": 42235,
      "rom": 72771,
      "brace": 14305,
      "evacuation": 29758,
      "243": 3302,
      "arthroscopy": 11757,
      "impingement": 36914,
      "1089": 1075,
      "consumptions": 20045,
      "730": 5662,
      "tooth": 81693,
      "ultrasonography": 83430,
      "popliteal": 62288,
      "staged": 76871,
      "hematomas": 34929,
      "intraarticular": 39725,
      "logistical": 42280,
      "interferes": 39432,
      "fibre": 31678,
      "sponsor": 76747,
      "0014": 230,
      "ameliorating": 9780,
      "0019": 233,
      "3250": 3967,
      "neuromodulation": 49204,
      "nprs": 50050,
      "2097": 2930,
      "580": 5168,
      "893": 6065,
      "pounds": 63283,
      "cocktail": 17190,
      "sedating": 74304,
      "desaturations": 23644,
      "671": 5484,
      "adrenaline": 8474,
      "peroral": 60910,
      "methylprednisolone": 45665,
      "postop": 62689,
      "iliaca": 36615,
      "metamizole": 45022,
      "robustly": 72713,
      "hinder": 35410,
      "nonoperative": 49799,
      "standardisation": 76939,
      "cite": 16592,
      "464": 4640,
      "timepoint": 81411,
      "889": 6053,
      "postoperation": 62690,
      "harris": 34599,
      "hhs": 35058,
      "pod3": 62073,
      "supplementary": 79167,
      "heel": 34889,
      "disturbing": 25579,
      "stump": 78573,
      "849": 5972,
      "postamputation": 62628,
      "coagulation": 17124,
      "lock": 42233,
      "obturator": 50790,
      "416": 4441,
      "335": 4009,
      "midnight": 46408,
      "313": 3887,
      "cryotherapy": 21355,
      "circumference": 16577,
      "pod2": 62071,
      "orthostatic": 53843,
      "mac": 42790,
      "declaration": 22858,
      "freestanding": 32502,
      "adhering": 7999,
      "pleased": 62012,
      "provoking": 66283,
      "haemodynamics": 34504,
      "mobilisation": 47003,
      "16th": 1923,
      "hamstring": 34545,
      "ischaemia": 40285,
      "noncardiac": 49718,
      "antihypertensive": 11208,
      "hypertensive": 36276,
      "o2": 50349,
      "wk": 87181,
      "oxford": 54388,
      "ta": 80071,
      "suction": 78933,
      "wasted": 86750,
      "mmol": 46990,
      "denervation": 23389,
      "abbreviated": 6519,
      "chi2": 15992,
      "sufentanil group": 78938,
      "status examination": 77256,
      "scores secondary": 73981,
      "3rd postoperative": 4303,
      "vs 51": 86589,
      "consumption analgesic": 19893,
      "pruritus significantly": 66307,
      "decrease adverse": 22884,
      "delayed recovery": 23191,
      "recovery function": 68745,
      "rehabilitative services": 69511,
      "functional recovery": 32710,
      "recovery rehabilitation": 68756,
      "arthroplasty randomized": 11740,
      "hours groups": 35778,
      "measure scores": 43949,
      "received oxycontin": 68237,
      "passive motion": 58444,
      "conclusions preemptive": 19166,
      "analgesia relative": 10089,
      "relative opioid": 69755,
      "studies objective": 77792,
      "objective goal": 50434,
      "dose regimen": 26044,
      "acetaminophen fixed": 7183,
      "mg fixed": 45892,
      "regimen mg": 69313,
      "time weighted": 81399,
      "approximately twice": 11591,
      "respectively moderate": 71212,
      "severe gastrointestinal": 74944,
      "dose produced": 26022,
      "greater benefit": 33433,
      "acetaminophen conclusions": 7176,
      "rate moderate": 67487,
      "acetaminophen management": 7201,
      "opioids usually": 53381,
      "therapeutic opioid": 80950,
      "prolonged period": 65618,
      "providing sustained": 66273,
      "needed 24": 48967,
      "24 36": 3158,
      "60 72": 5233,
      "0001 pain": 75,
      "group times": 34048,
      "needed group": 49005,
      "group sedation": 34001,
      "experienced vomiting": 30635,
      "surgery provides": 79542,
      "ligament repair": 41759,
      "ambulatory basis": 9763,
      "analgesic benefit": 10157,
      "presented chronic": 64687,
      "chronic debilitating": 16190,
      "knee pain": 40868,
      "similar clinical": 75906,
      "alternative fentanyl": 9720,
      "fentanyl management": 31519,
      "management early": 43178,
      "replacement methods": 70430,
      "intubation minutes": 39961,
      "patients intravenous": 59421,
      "administered breakthrough": 8109,
      "pacu significantly": 56332,
      "05 fewer": 515,
      "conclusions single": 19214,
      "effective fentanyl": 27624,
      "alternative drug": 9719,
      "recovery total": 68768,
      "spinal anaesthesia": 76700,
      "groups 40": 34111,
      "higher spinal": 35326,
      "200 vs": 2410,
      "hospital complications": 35572,
      "anaesthesia group": 9868,
      "haemoglobin levels": 34506,
      "falling asleep": 31163,
      "findings discussed": 31780,
      "arthroplasty methods": 11737,
      "174 patients": 2010,
      "matched age": 43483,
      "oxycontin results": 56183,
      "compared nonusers": 18218,
      "consumption 46": 19882,
      "equivalents 001": 29337,
      "46 25": 4620,
      "home ambulatory": 35507,
      "matched patient": 43490,
      "gender body": 32932,
      "index health": 38195,
      "inherent limitations": 38766,
      "care provider": 15067,
      "recorded physical": 68691,
      "regimens methods": 69336,
      "number steps": 50261,
      "opioid placebo": 52067,
      "groups number": 34245,
      "groups increased": 34221,
      "surgery tapentadol": 79604,
      "prescriptions time": 64567,
      "currently lacking": 21499,
      "determined annual": 24060,
      "prescribing rate": 64127,
      "medication prescriptions": 44543,
      "expressed number": 30820,
      "number defined": 50153,
      "primary osteoarthritis": 65054,
      "increased 38": 37852,
      "preoperative prescriptions": 63758,
      "acetaminophen study": 7252,
      "assisted anterior": 12195,
      "ketorolac 60": 40639,
      "site surgery": 76162,
      "scheduled doses": 73641,
      "2nd postoperative": 3655,
      "patients 95": 58912,
      "elevated pain": 28562,
      "preemptive multimodal": 63610,
      "multiple analgesics": 48259,
      "primary total": 65117,
      "arthroplasty single": 11741,
      "course hospital": 20989,
      "differences remained": 24805,
      "consumed postoperative": 19847,
      "opioids exhibited": 52902,
      "function methods": 32657,
      "present randomized": 64631,
      "assessed preoperatively": 12042,
      "day year": 22454,
      "year post": 87484,
      "95 vs": 6411,
      "higher case": 35216,
      "group controls": 33723,
      "37 vs": 4205,
      "brace group": 14306,
      "groups surgery": 34333,
      "term functional": 80633,
      "blocks reduce": 14099,
      "50 did": 4834,
      "did group": 24451,
      "group multimodal": 33870,
      "vas postoperative": 86014,
      "postoperative vas": 62977,
      "18 postoperative": 2104,
      "group 002": 33532,
      "days significantly": 22624,
      "conclusions pre": 19165,
      "group early": 33760,
      "postoperative rehabilitation": 62963,
      "oxn group": 54415,
      "postoperative outcome": 62833,
      "using bowel": 85326,
      "recorded safety": 68699,
      "levels oxn": 41586,
      "values oxn": 85849,
      "group 018": 33540,
      "patients oxn": 59608,
      "respectively adverse": 71165,
      "conclusion conclusion": 18877,
      "conclusion oxn": 18946,
      "better functional": 13712,
      "reduced using": 68986,
      "prolonged released": 65639,
      "oxn compared": 54412,
      "study post": 78415,
      "treatment intravenous": 82633,
      "received similar": 68269,
      "238 patients": 3135,
      "similar characteristics": 75905,
      "40 19": 4315,
      "morphine requirements": 47916,
      "15 26": 1683,
      "19 11": 2159,
      "28 mg": 3559,
      "vomiting vs": 86489,
      "scores conclusion": 73852,
      "hours compared": 35758,
      "prevalent condition": 64826,
      "analgesic regime": 10308,
      "arthroplasty study": 11742,
      "patients follow": 59310,
      "02 significant": 377,
      "lowest tapentadol": 42737,
      "undergoing hip": 83538,
      "received institution": 68165,
      "institution standard": 39084,
      "prescribed breakthrough": 63825,
      "taking acetaminophen": 80299,
      "acetaminophen 24": 7120,
      "reached oxycodone": 67937,
      "contacted daily": 20052,
      "daily asked": 21697,
      "treatment statistically": 82852,
      "differences respect": 24808,
      "factors groups": 31094,
      "groups preoperatively": 34275,
      "use statistically": 84748,
      "different number": 24891,
      "treatment vs": 82887,
      "pills control": 61504,
      "acetaminophen effect": 7181,
      "effect reducing": 27545,
      "reducing patient": 69028,
      "evidence ii": 30194,
      "trial background": 83004,
      "patient completed": 58567,
      "30 group": 3738,
      "73 90": 5648,
      "001 90": 104,
      "discharge 26": 25097,
      "group requested": 33981,
      "scores 30": 73835,
      "outcome scores": 53991,
      "prescribing fewer": 64058,
      "difference patient": 24659,
      "level randomized": 41521,
      "trial objectives": 83039,
      "nurse administered": 50333,
      "use anti": 84194,
      "drugs similar": 27074,
      "stay objective": 77281,
      "evaluated feasibility": 29885,
      "pr management": 63332,
      "methods studies": 45586,
      "pr compared": 63317,
      "compared prolonged": 18282,
      "oxy pr": 54461,
      "patients knee": 59437,
      "pr oxy": 63347,
      "pr groups": 63329,
      "tolerability oxn": 81543,
      "improvements bowel": 37171,
      "pr similar": 63372,
      "pr reduced": 63363,
      "patients carrying": 59053,
      "improved bowel": 37099,
      "function background": 32633,
      "standard patient": 76925,
      "replacement surgery": 70431,
      "126 patients": 1434,
      "intensity 24": 39223,
      "vs 023": 86512,
      "intensity vs": 39330,
      "medication mean": 44514,
      "mg 126": 45711,
      "43 mg": 4503,
      "mg 006": 45687,
      "general satisfaction": 32987,
      "provided better": 66123,
      "consumption differences": 19918,
      "present substantial": 64668,
      "related overdoses": 69651,
      "overdoses united": 54335,
      "urban hospital": 84031,
      "bupivacaine control": 14493,
      "26 37": 3432,
      "likely require": 41843,
      "reduction 50": 69037,
      "group 09": 33556,
      "management significantly": 43264,
      "orthopedics 2021": 53841,
      "2021 44": 2912,
      "institutional protocol": 39097,
      "blocks patients": 14095,
      "block wore": 14075,
      "guided continuous": 34411,
      "attending surgeon": 12559,
      "series included": 74657,
      "included 24": 37389,
      "24 total": 3283,
      "outcomes collected": 54016,
      "pod 14": 62064,
      "sensory deficits": 74573,
      "median 25": 44182,
      "25 oxycodone": 3375,
      "iqr 43": 40176,
      "series purpose": 74664,
      "mg diclofenac": 45871,
      "intra articular": 39716,
      "ropivacaine injected": 72799,
      "anesthesia methods": 10922,
      "blind investigation": 13940,
      "received 50": 68104,
      "ml saline": 46904,
      "prn needed": 65200,
      "tablets given": 80161,
      "taken patients": 80290,
      "diclofenac groups": 24388,
      "pain hours": 56837,
      "reduced vas": 68987,
      "ropivacaine did": 72793,
      "patients demonstrate": 59176,
      "doses intravenous": 26205,
      "versus combination": 86115,
      "ratio methods": 67776,
      "trial 40": 82996,
      "levels reached": 41600,
      "doses study": 26279,
      "minutes patients": 46659,
      "baseline treatment": 13462,
      "10 patient": 894,
      "group discontinued": 33755,
      "group pca": 33909,
      "group 37": 33605,
      "experiencing moderate": 30642,
      "trials data": 83131,
      "states use": 77157,
      "opioids combat": 52795,
      "approximately patients": 11585,
      "address pain": 7930,
      "therapy shown": 81068,
      "shown decrease": 75334,
      "decrease use": 22934,
      "medication compared": 44471,
      "following arthroscopic": 32102,
      "center prospective": 15542,
      "enrollment opioid": 29031,
      "analysis 28": 10629,
      "satisfaction groups": 73399,
      "02 compared": 364,
      "patients trend": 60076,
      "block procedure": 14057,
      "anesthesiology asa": 10963,
      "asa ii": 11815,
      "propofol infusion": 65736,
      "ketoprofen end": 40629,
      "used rescue": 85113,
      "recorded surgery": 68701,
      "patient excluded": 58629,
      "excluded analysis": 30475,
      "analysis group": 10691,
      "block prolongs": 14058,
      "recommended postoperative": 68635,
      "relief total": 70200,
      "trial performed": 83050,
      "primary unilateral": 65120,
      "patients comparing": 59103,
      "session postoperative": 74735,
      "provided significantly": 66155,
      "25 64": 3339,
      "consumption equivalent": 19922,
      "equivalent groups": 29310,
      "38 55": 4232,
      "regimen primary": 69324,
      "tka study": 81489,
      "received 400": 68102,
      "pregabalin placebo": 63676,
      "postoperative consumption": 62727,
      "analgesia secondary": 10104,
      "similar mean": 75947,
      "versus 19": 86104,
      "using pre": 85570,
      "anaesthesia methods": 9870,
      "aged 60": 9189,
      "analgesia ivpca": 10008,
      "regular analgesia": 69475,
      "antiemetic doses": 11185,
      "number antiemetic": 50139,
      "required 24": 70817,
      "24 significantly": 3274,
      "vs 56": 86595,
      "background duloxetine": 13040,
      "effective chronic": 27604,
      "hypothesized administration": 36308,
      "triple blinded": 83235,
      "regimen including": 69311,
      "ambulation postoperative": 9761,
      "placebo versus": 61853,
      "placebo statistically": 61830,
      "consumption difference": 19917,
      "14 002": 1547,
      "period nausea": 60755,
      "difference effects": 24612,
      "effects anxiety": 27825,
      "important goal": 37010,
      "efficacy postoperative": 28328,
      "intramuscular ketorolac": 39742,
      "device postoperative": 24270,
      "monitored hours": 47311,
      "vomiting urinary": 86486,
      "retention pruritus": 72079,
      "pruritus dizziness": 66297,
      "morning postoperative": 47518,
      "surgery 20": 79298,
      "provide comparable": 66043,
      "femoral tibial": 31404,
      "various postoperative": 85975,
      "weeks 24": 86893,
      "results lower": 71753,
      "years postoperatively": 87638,
      "postoperatively purpose": 63020,
      "arthroscopy methods": 11758,
      "randomized postoperative": 67156,
      "received preemptive": 68249,
      "consumption documented": 19920,
      "recorded 30": 68665,
      "minutes postoperatively": 46661,
      "postoperatively 18": 62991,
      "18 hours": 2086,
      "injection bupivacaine": 38939,
      "cause relatively": 15370,
      "lasting analgesia": 41211,
      "improve physical": 37078,
      "requirements methods": 70885,
      "multicentre phase": 48175,
      "ii trial": 36575,
      "years body": 87573,
      "kg m2": 40753,
      "anesthesiologists asa": 10954,
      "scheduled primary": 73652,
      "surgery conducted": 79353,
      "hours oral": 35803,
      "hours auc": 35753,
      "scores obtained": 73928,
      "hours daily": 35762,
      "28 42": 3543,
      "available preliminary": 12829,
      "placebo 70": 61640,
      "received significantly": 68268,
      "significantly rescue": 75858,
      "19 32": 2171,
      "total intravenous": 81820,
      "motion rom": 48014,
      "group 03": 33545,
      "having higher": 34605,
      "reported 14": 70485,
      "combined spinal": 17669,
      "spinal epidural": 76716,
      "group dexmedetomidine": 33737,
      "dex group": 24276,
      "hemodynamic parameters": 34938,
      "changes groups": 15789,
      "diastolic arterial": 24363,
      "product compared": 65428,
      "groups measured": 34233,
      "inflammatory reaction": 38579,
      "background single": 13196,
      "block analgesia": 14038,
      "analgesia spinal": 10111,
      "successful day": 78910,
      "prospectively determined": 65894,
      "anesthesia intravenous": 10921,
      "intravenous sedation": 39882,
      "perioperative multimodal": 60837,
      "30 ml": 3773,
      "bolus saline": 14224,
      "infusion group": 38706,
      "days 50": 22474,
      "patients nrs": 59560,
      "scores 001": 73818,
      "days group": 22528,
      "higher nrs": 35272,
      "cold therapy": 17429,
      "therapy postoperative": 81049,
      "pain outpatient": 57307,
      "outpatient arthroscopic": 54115,
      "needed days": 48994,
      "continuous passive": 20181,
      "hours cold": 35756,
      "41 hours": 4422,
      "group 79": 33645,
      "vicodin use": 86203,
      "group use": 34059,
      "use 001": 84134,
      "knee flexion": 40862,
      "combination oxn": 17581,
      "block ropivacaine": 14066,
      "postoperative continuous": 62728,
      "ropivacaine ml": 72802,
      "release oxn": 69917,
      "administration 12": 8204,
      "mg bolus": 45808,
      "rest dynamic": 71421,
      "postoperatively secondary": 63025,
      "results oxn": 71820,
      "consumption 12": 19869,
      "40 conclusions": 4334,
      "study immediate": 78242,
      "oxn experienced": 54414,
      "points 90": 62121,
      "repair included": 70382,
      "preoperatively 90": 63767,
      "postoperatively multiple": 63008,
      "multiple logistic": 48285,
      "regressions used": 69472,
      "mmes prescribed": 46987,
      "prescribed initial": 63874,
      "94 mmes": 6193,
      "10 85": 729,
      "impact legislation": 36819,
      "satisfaction functional": 73397,
      "nsaid studies": 50095,
      "ketoprofen days": 40628,
      "anesthesia randomized": 10939,
      "diclofenac 75": 24385,
      "ketoprofen 100": 40626,
      "room followed": 72774,
      "diclofenac 150": 24380,
      "second study": 74197,
      "22 15": 3011,
      "37 21": 4174,
      "mg ketoprofen": 45940,
      "ketoprofen group": 40630,
      "respectively placebo": 71233,
      "placebo postoperative": 61803,
      "scores vas": 74008,
      "better placebo": 13730,
      "placebo ketoprofen": 61768,
      "opioids tka": 53339,
      "likely request": 41842,
      "months data": 47437,
      "score total": 73802,
      "commonly discharged": 17845,
      "90 hydromorphone": 6102,
      "total prescribed": 81894,
      "155 mg": 1829,
      "mg preoperative": 46176,
      "63 16": 5353,
      "60 13": 5223,
      "rate did": 67460,
      "number refills": 50248,
      "methods pain": 45419,
      "patients femoral": 59302,
      "treat symptoms": 82318,
      "following knee": 32156,
      "applied patients": 11439,
      "create evidence": 21138,
      "scale nprs": 73509,
      "scale satisfaction": 73555,
      "scores week": 74015,
      "74 patients": 5677,
      "did consume": 24426,
      "score conclusion": 73737,
      "conclusion current": 18885,
      "spite low": 76736,
      "rates low": 67592,
      "shot spinal": 75220,
      "immediate perioperative": 36700,
      "sustained analgesia": 79776,
      "articular injections": 11810,
      "injection 60": 38935,
      "ropivacaine mg": 72800,
      "normal renal": 49907,
      "antiemetics administered": 11193,
      "given 10": 33149,
      "stay decreased": 77275,
      "associated moderate": 12336,
      "block compared": 14042,
      "bupivacaine 20": 14490,
      "performed post": 60611,
      "did need": 24465,
      "itching seen": 40343,
      "patients effects": 59239,
      "dramatically past": 26442,
      "management primary": 43247,
      "oral group": 53542,
      "satisfaction rate": 73424,
      "control total": 20434,
      "western countries": 87002,
      "intervention strategies": 39649,
      "prescription year": 64423,
      "months year": 47480,
      "preoperative opioids": 63751,
      "years 56": 87545,
      "population women": 62402,
      "2018 opioid": 2834,
      "rates given": 67580,
      "outcome opioids": 53966,
      "rates year": 67647,
      "comparing time": 18363,
      "analyses stratified": 10612,
      "results proportion": 71895,
      "increased 25": 37844,
      "mme 001": 46946,
      "prescriptions mme": 64514,
      "61 mme": 5314,
      "43 55": 4496,
      "prescriptions orthopaedic": 64529,
      "surgeons address": 79268,
      "effects preoperative": 28102,
      "prescribing preoperative": 64123,
      "background optimal": 13127,
      "analgesia primary": 10071,
      "controlled epidural": 20495,
      "readiness discharge": 67987,
      "discharge decreased": 25116,
      "group bupivacaine": 33674,
      "minimal nausea": 46575,
      "time readiness": 81348,
      "18 31": 2043,
      "31 80": 3860,
      "consumption oral": 19965,
      "compared 90": 18090,
      "related symptom": 69695,
      "distress scale": 25549,
      "40 scores": 4378,
      "satisfaction similar": 73440,
      "similar conclusions": 75909,
      "decrease time": 22930,
      "choice analgesic": 16109,
      "infiltration analgesia": 38537,
      "equal analgesic": 29228,
      "1st post": 2257,
      "spinal anaesthetic": 76703,
      "scores vital": 74013,
      "vital parameters": 86340,
      "effects post": 28092,
      "median 25th": 44183,
      "75th percentiles": 5733,
      "oxycodone demand": 54936,
      "demand differed": 23248,
      "ponv incidence": 62235,
      "certain advantages": 15650,
      "regarding early": 69248,
      "early post": 27264,
      "level conclusions": 41452,
      "associated nausea": 12341,
      "common group": 17758,
      "using preoperative": 85571,
      "postoperative intraarticular": 62781,
      "underwent arthroscopic": 83675,
      "results preoperative": 71885,
      "intraarticular analgesia": 39726,
      "dose long": 25946,
      "postoperative year": 62988,
      "opioid 30": 51354,
      "days operation": 22565,
      "days used": 22649,
      "analyses adjusted": 10582,
      "increased prescribed": 37992,
      "opioids preferred": 53200,
      "37 increase": 4190,
      "respectively 100": 71151,
      "mme increase": 46964,
      "small effect": 76277,
      "effect long": 27475,
      "use prevalence": 84662,
      "prevalence 25": 64769,
      "prescribed prescription": 63960,
      "practitioners prescribed": 63451,
      "consecutive prescriptions": 19567,
      "hospital prescription": 35620,
      "dose small": 26079,
      "small increased": 76282,
      "protocol exists": 65971,
      "opioid need": 51995,
      "interference score": 39429,
      "state controlled": 77037,
      "91 72": 6133,
      "score 14": 73712,
      "significance conclusion": 75404,
      "demonstrated statistically": 23370,
      "celecoxib postoperative": 15464,
      "group celecoxib": 33678,
      "celecoxib group": 15460,
      "analgesia consumption": 9937,
      "consumption satisfaction": 20014,
      "rest decreased": 71418,
      "similarly pain": 76014,
      "group furthermore": 33786,
      "pethidine consumption": 60985,
      "mg lower": 46042,
      "increased analgesic": 37872,
      "higher patient": 35288,
      "satisfaction comparable": 73391,
      "compared celecoxib": 18101,
      "hypothesized patients": 36313,
      "component multimodal": 18578,
      "consumption assessed": 19896,
      "32 22": 3906,
      "22 47": 3024,
      "providing analgesia": 66251,
      "intake background": 39178,
      "used multimodal": 85015,
      "24 hrs": 3238,
      "received neuraxial": 68211,
      "receive pregabalin": 68073,
      "regimen following": 69306,
      "opioid mixture": 51949,
      "fentanyl microg": 31530,
      "rescue pain": 70972,
      "medication consisted": 44476,
      "administered drugs": 8125,
      "questionnaires including": 66904,
      "5d sf": 5205,
      "improves early": 37182,
      "sparing protocols": 76535,
      "medication purpose": 44547,
      "medications total": 44686,
      "101 patients": 1049,
      "distance ambulated": 25536,
      "mean 20": 43660,
      "23 18": 3073,
      "small clinically": 76274,
      "stimulation tens": 77374,
      "participants receiving": 58355,
      "receiving placebo": 68372,
      "placebo tens": 61837,
      "care hypothesized": 15030,
      "blinded treatment": 14023,
      "sensory tests": 74578,
      "greater reduction": 33485,
      "postoperative mechanical": 62788,
      "movement pain": 48049,
      "placebo influence": 61766,
      "analgesia reported": 10094,
      "scores nrs": 73917,
      "rebound pain": 68029,
      "perineural catheter": 60672,
      "50 hours": 4840,
      "hours saline": 35845,
      "days indicating": 22539,
      "computed results": 18654,
      "receiving saline": 68377,
      "scores hour": 73889,
      "conclusions anesthesia": 19032,
      "care protocol": 15066,
      "approximately 33": 11568,
      "anesthetic analgesic": 10967,
      "protocols associated": 66002,
      "associated respiratory": 12411,
      "protocol associated": 65958,
      "2008 2012": 2500,
      "oxyhemoglobin desaturations": 56214,
      "sedation results": 74328,
      "depression observed": 23587,
      "anesthetic techniques": 10974,
      "01 general": 311,
      "anesthesia neuraxial": 10925,
      "background continuous": 13029,
      "control protocol": 20404,
      "protocol involving": 65979,
      "continuous ropivacaine": 20187,
      "ninety subjects": 49490,
      "assigned groups": 12169,
      "injection group": 38949,
      "received bolus": 68121,
      "differ treatment": 24557,
      "groups largest": 34224,
      "morphine methods": 47759,
      "background randomized": 13189,
      "56 patients": 5105,
      "different patient": 24904,
      "examines effect": 30424,
      "2007 2011": 2487,
      "method patient": 45197,
      "immediately postoperatively": 36750,
      "choice pain": 16117,
      "220 patients": 3052,
      "patients 175": 58833,
      "groups respect": 34297,
      "joint surgeries": 40492,
      "lengths stay": 41417,
      "fusion surgery": 32757,
      "surgery regardless": 79557,
      "regardless surgical": 69291,
      "despite extensive": 23880,
      "dose glucocorticoid": 25914,
      "saline surgery": 73275,
      "anaesthesia patients": 9872,
      "pain hip": 56831,
      "operation overall": 51221,
      "assessments 04": 12148,
      "effects complications": 27872,
      "complications observed": 18564,
      "analgesia immediate": 9992,
      "safety aspects": 73121,
      "hip fracture": 35418,
      "surgery multimodal": 79477,
      "clinical value": 16969,
      "fracture randomly": 32459,
      "receive preemptive": 68072,
      "injections group": 38976,
      "compared regard": 18291,
      "amounts fentanyl": 9835,
      "frequency use": 32531,
      "level observed": 41504,
      "total fentanyl": 81806,
      "fourth postoperative": 32439,
      "reduces total": 69009,
      "hip fractures": 35420,
      "fractures background": 32463,
      "prescribing orthopedic": 64095,
      "prescription record": 64396,
      "73 pills": 5659,
      "year postop": 87485,
      "investigated safety": 40056,
      "incidence drug": 37268,
      "wound complications": 87356,
      "night operation": 49474,
      "operation postoperative": 51225,
      "day background": 22273,
      "limited literature": 41938,
      "opioids pre": 53199,
      "surgery identify": 79420,
      "assessed change": 11989,
      "change total": 15755,
      "regression estimated": 69440,
      "estimated risk": 29638,
      "reduction incidence": 69060,
      "compared nonopioid": 18217,
      "users chronic": 85229,
      "conclusion reduction": 18977,
      "demographics pain": 23300,
      "additional data": 7853,
      "statistically lower": 77196,
      "hours prior": 35835,
      "reported statistically": 70657,
      "device pain": 24269,
      "decrease risk": 22928,
      "questions included": 66907,
      "night hospital": 49473,
      "average length": 12893,
      "prescription 38": 64154,
      "average 15": 12859,
      "unused oxycodone": 83965,
      "results help": 71710,
      "patients generally": 59323,
      "fascia iliaca": 31194,
      "combined nonopioid": 17659,
      "oxycodone perioperative": 55671,
      "2019 participants": 2877,
      "total 109": 81707,
      "109 patients": 1077,
      "measurements pain": 44027,
      "nrs rest": 50072,
      "period 48": 60705,
      "48 main": 4732,
      "subsequently excluded": 78784,
      "level measured": 41501,
      "lower rest": 42697,
      "001 additionally": 108,
      "time 001": 81187,
      "similarly higher": 76012,
      "effective form": 27625,
      "form analgesia": 32272,
      "level patient": 41512,
      "satisfaction analgesic": 73387,
      "patients induced": 59408,
      "gauge spinal": 32912,
      "better postoperative": 13731,
      "doses group": 26193,
      "group saline": 33993,
      "patients bupivacaine": 59037,
      "experienced increase": 30606,
      "ward incidence": 86709,
      "vomiting similar": 86484,
      "technical problems": 80542,
      "efficacy continuous": 28240,
      "surgery experience": 79399,
      "management objectives": 43216,
      "effectiveness adding": 27744,
      "postoperative regimen": 62962,
      "study double": 78130,
      "scores points": 73951,
      "point pain": 62101,
      "sleep improved": 76224,
      "additional adverse": 7837,
      "reported somnolence": 70656,
      "showed higher": 75259,
      "increased satisfaction": 38023,
      "thirty milligrams": 81104,
      "surgery provided": 79541,
      "scores adverse": 73838,
      "addition multimodal": 7813,
      "multimodal oral": 48223,
      "reduce acute": 68832,
      "anesthesia included": 10914,
      "wound infiltration": 87361,
      "infiltration ropivacaine": 38538,
      "hrs surgery": 35904,
      "45 degrees": 4582,
      "38 93": 4235,
      "22 10": 3008,
      "mg did": 45872,
      "ml median": 46874,
      "oral rofecoxib": 53661,
      "block range": 14061,
      "intervention using": 39652,
      "address high": 7925,
      "readmission rate": 67990,
      "rate 42": 67433,
      "rate 20": 67429,
      "received sustained": 68292,
      "conclusion observed": 18936,
      "collected weeks": 17492,
      "platform results": 61984,
      "daily short": 21804,
      "cite article": 16593,
      "article bone": 11762,
      "bone joint": 14235,
      "background bilateral": 13018,
      "patients anticipated": 58997,
      "prolonged recovery": 65620,
      "impact perioperative": 36839,
      "operative analgesic": 51244,
      "lower non": 42652,
      "vs 111": 86527,
      "005 significant": 268,
      "groups timepoint": 34338,
      "conclusions recommend": 19184,
      "potentially problematic": 63264,
      "multimodal management": 48216,
      "receive acetaminophen": 68046,
      "mg available": 45801,
      "patients celecoxib": 59058,
      "vomiting 05": 86440,
      "administration celecoxib": 8225,
      "background present": 13172,
      "years surgery": 87677,
      "discharge primary": 25167,
      "adjusting multiple": 8066,
      "sex comorbidities": 75066,
      "results 30": 71562,
      "cohort adjusted": 17347,
      "associated small": 12442,
      "study 22": 77886,
      "exposure defined": 30757,
      "prescription morphine": 64264,
      "total patient": 81881,
      "77 increased": 5761,
      "iii purpose": 36591,
      "assess administration": 11904,
      "study controls": 78043,
      "groups pre": 34273,
      "operatively study": 51280,
      "complications results": 18571,
      "operative days": 51249,
      "complications noted": 18563,
      "rest day": 71417,
      "significantly decreases": 75681,
      "level inflammatory": 41495,
      "determine preoperative": 24041,
      "weeks postoperation": 86937,
      "rescue drugs": 70947,
      "postoperative length": 62784,
      "recorded measured": 68683,
      "28 54": 3544,
      "addition significant": 7826,
      "correlation active": 20825,
      "clinicians assess": 17026,
      "analgesia preoperative": 10067,
      "fractures methods": 32465,
      "fracture randomized": 32458,
      "blind controlled": 13925,
      "admission emergency": 8404,
      "additional analgesic": 7840,
      "comparable baseline": 17951,
      "14 09": 1549,
      "11 57": 1116,
      "57 mg": 5131,
      "better pre": 13732,
      "fractures compared": 32464,
      "therapeutic level": 80948,
      "opioids local": 53024,
      "intrathecal analgesia": 39792,
      "combined low": 17651,
      "morphine infusion": 47733,
      "vas scale": 86019,
      "good postoperative": 33321,
      "infusion did": 38703,
      "medication required": 44560,
      "management recognized": 43254,
      "adjunct general": 8002,
      "improved postoperative": 37123,
      "pacu total": 56335,
      "consumption surgical": 20029,
      "results cases": 71618,
      "cases excluded": 15237,
      "total 96": 81775,
      "weight height": 86980,
      "rates nausea": 67597,
      "inadequate postoperative": 37232,
      "safe procedure": 73102,
      "ropivacaine infiltration": 72797,
      "analgesia randomized": 10079,
      "rest mobilization": 71424,
      "similar low": 75945,
      "knee amputation": 40856,
      "phantom limb": 61005,
      "pain extremity": 56775,
      "bupivacaine 10": 14487,
      "infused 10": 38692,
      "oxycodone postoperatively": 55712,
      "surgery wound": 79621,
      "ropivacaine 10": 72787,
      "reduced groups": 68932,
      "relationship total": 69728,
      "oxycodone 82": 54605,
      "82 common": 5906,
      "observed decrease": 50671,
      "decreasing number": 23070,
      "29 year": 3619,
      "pregnant woman": 63698,
      "weeks gestation": 86915,
      "reported severe": 70645,
      "severity scale": 75049,
      "pain persisted": 57367,
      "30 minute": 3769,
      "status days": 77255,
      "reported reductions": 70640,
      "trend improved": 82944,
      "exists management": 30531,
      "understanding pain": 83642,
      "associated patient": 12376,
      "strategies study": 77425,
      "scale lower": 73504,
      "evaluated patient": 29905,
      "2008 november": 2507,
      "30 2010": 3671,
      "63 female": 5359,
      "mean body": 43727,
      "bmi 31": 14175,
      "given day": 33164,
      "levels reduced": 41601,
      "reduced half": 68933,
      "course intravenous": 20992,
      "regimes control": 69339,
      "compared primary": 18280,
      "opioids secondary": 53288,
      "total 162": 81729,
      "lower groups": 42627,
      "function better": 32634,
      "outcomes prolonged": 54078,
      "effectively inhibit": 27732,
      "outcomes new": 54058,
      "formulation designed": 32339,
      "2013 august": 2627,
      "outcome measurement": 53929,
      "included length": 37470,
      "stay overall": 77283,
      "satisfaction using": 73445,
      "pod compared": 62065,
      "compared 72": 18088,
      "group pod": 33918,
      "group 94": 33653,
      "group similar": 34022,
      "bupivacaine did": 14494,
      "benefit compared": 13616,
      "36 surgery": 4147,
      "ml bolus": 46849,
      "bolus ml": 14221,
      "mg os": 46089,
      "effect models": 27490,
      "models random": 47129,
      "random intercept": 66998,
      "results local": 71751,
      "consumption nrs": 19959,
      "scores muscle": 73908,
      "consumption background": 19897,
      "prescribed associated": 63821,
      "increase pill": 37782,
      "associated approximately": 12222,
      "morphine provides": 47899,
      "analgesia arthroscopic": 9916,
      "sedation using": 74334,
      "provides longer": 66226,
      "duration postoperative": 27178,
      "analgesia 24": 9894,
      "administered surgery": 8187,
      "use expected": 84364,
      "resident physicians": 71066,
      "registered nurses": 69379,
      "individual inpatient": 38296,
      "calculated total": 14708,
      "total usage": 81913,
      "discharge persistent": 25161,
      "associated persistent": 12378,
      "28 55": 3545,
      "55 002": 5065,
      "hours associated": 35752,
      "prescribing regulations": 64134,
      "refill patterns": 69162,
      "weeks postsurgery": 86942,
      "64 group": 5388,
      "04 conclusion": 451,
      "consume opioids": 19820,
      "methods randomly": 45520,
      "continuous cryotherapy": 20160,
      "analgesics postoperative": 10482,
      "severe complications": 74939,
      "postoperative drainage": 62770,
      "total blood": 81781,
      "scale rest": 73550,
      "pod1 pod2": 62070,
      "pod2 pod3": 62072,
      "postoperative month": 62791,
      "05 groups": 517,
      "site infection": 76158,
      "complications background": 18557,
      "study primary": 78429,
      "completed using": 18512,
      "test categorical": 80755,
      "categorical data": 15289,
      "total 500": 81753,
      "included overall": 37498,
      "25 total": 3389,
      "lower preoperative": 42687,
      "diastolic blood": 24364,
      "posterior approach": 62653,
      "intravenous fluid": 39829,
      "fluid volume": 31944,
      "perioperative variables": 60855,
      "analysis study": 10774,
      "outcome cumulative": 53911,
      "outcomes include": 54030,
      "stay duration": 77277,
      "complications readmissions": 18567,
      "life prolonged": 41722,
      "prolonged pain": 65617,
      "declaration helsinki": 22859,
      "international peer": 39482,
      "containing bupivacaine": 20071,
      "dose meloxicam": 25956,
      "bupivacaine 12": 14488,
      "pregabalin postoperative": 63679,
      "request additional": 70783,
      "discharge readiness": 25169,
      "consumption low": 19947,
      "use peripheral": 84621,
      "blocks total": 14102,
      "saline respectively": 73271,
      "unit results": 83770,
      "scores placebo": 73949,
      "walk 24": 86696,
      "hours comparable": 35757,
      "180 90": 2119,
      "block did": 14043,
      "performed general": 60595,
      "favorable outcomes": 31259,
      "patient comorbidities": 58566,
      "injection liposomal": 38953,
      "satisfaction measured": 73406,
      "386 patients": 4255,
      "inclusion patients": 37693,
      "patients american": 58988,
      "anesthesiologists physical": 10960,
      "received epidural": 68146,
      "rate infusion": 67479,
      "slightly lower": 76257,
      "respectively groups": 71197,
      "respect nausea": 71134,
      "conclusions small": 19215,
      "dose ropivacaine": 26072,
      "slightly decreased": 76251,
      "dose rofecoxib": 26071,
      "lateral femoral": 41241,
      "femoral cutaneous": 31403,
      "placebo given": 61731,
      "anaesthesia primary": 9874,
      "24 time": 3282,
      "involved patient": 40108,
      "intervention results": 39648,
      "outcome group": 53918,
      "27 mm": 3498,
      "31 mm": 3873,
      "outcomes observed": 54061,
      "block combined": 14041,
      "paracetamol ibuprofen": 58101,
      "anaesthetic injection": 9885,
      "served control": 74716,
      "movement assessed": 48045,
      "difference nrs": 24638,
      "48 operation": 4736,
      "pain joint": 56985,
      "satisfaction outcomes": 73407,
      "outcomes purpose": 54080,
      "celecoxib oxycodone": 15461,
      "block 30": 14034,
      "group 60": 33631,
      "usage time": 84132,
      "325 patients": 3966,
      "earlier time": 27245,
      "able ambulate": 6563,
      "conclusions liposomal": 19111,
      "bupivacaine resulted": 14509,
      "scores 12": 73829,
      "background perioperative": 13153,
      "noncardiac surgery": 49719,
      "surgery impact": 79421,
      "impact analgesic": 36798,
      "lasting min": 41214,
      "assessed morning": 12017,
      "30 epi": 3736,
      "evaluable efficacy": 29760,
      "patients 41": 58865,
      "vs time": 86680,
      "002 significant": 240,
      "groups differences": 34185,
      "differences number": 24764,
      "pain 40": 56385,
      "40 lower": 4341,
      "agents preferred": 9237,
      "preferred analgesic": 63637,
      "analgesic postoperatively": 10290,
      "associated potential": 12385,
      "efficacy ketorolac": 28286,
      "drug analgesic": 26533,
      "agent postoperative": 9219,
      "discharge ketorolac": 25130,
      "oral ketorolac": 53557,
      "ketorolac discharge": 40643,
      "utilization recorded": 85736,
      "outcomes obtained": 54062,
      "age cohort": 9068,
      "patients female": 59300,
      "preoperative demographics": 63739,
      "demographics comorbidities": 23298,
      "groups days": 34170,
      "patients ketorolac": 59433,
      "fewer narcotic": 31646,
      "22 36": 3020,
      "difference functional": 24615,
      "events groups": 30050,
      "use adjunctive": 84174,
      "ketorolac substantially": 40658,
      "substantially reduces": 78862,
      "reduces narcotic": 68990,
      "analyze effect": 10814,
      "routine discharge": 72862,
      "rates refill": 67630,
      "mmes discharge": 46985,
      "type significant": 83354,
      "29 001": 3593,
      "highest risk": 35369,
      "rates hip": 67586,
      "appropriate opioids": 11506,
      "opioid alcohol": 51436,
      "disorder chronic": 25370,
      "management case": 43159,
      "47 year": 4667,
      "severe headache": 74947,
      "vomiting hours": 86459,
      "organ specific": 53754,
      "result severe": 71490,
      "prolong analgesic": 65604,
      "vs 002": 86503,
      "therapy significantly": 81069,
      "total 160": 81727,
      "160 patients": 1908,
      "placebo daily": 61714,
      "consumption surgery": 20028,
      "placebo opioid": 61787,
      "sleep conclusion": 76215,
      "mg achieved": 45793,
      "choice treatment": 16124,
      "39 10": 4259,
      "years difference": 87584,
      "difference 11": 24568,
      "12 ci": 1273,
      "performed months": 60605,
      "determine effectiveness": 24007,
      "age 17": 8974,
      "17 54": 1947,
      "years standard": 87672,
      "underwent open": 83688,
      "injection local": 38955,
      "period common": 60714,
      "average 50": 12872,
      "average 16": 12860,
      "21 day": 2966,
      "local injection": 42210,
      "volume blood": 86391,
      "function using": 32685,
      "patients years": 60187,
      "significantly mean": 75814,
      "total volume": 81915,
      "postoperative haemoglobin": 62775,
      "block safe": 14069,
      "pca study": 60272,
      "surgery followed": 79401,
      "ropivacaine infusion": 72798,
      "outcome rate": 53984,
      "pca groups": 60265,
      "consumption iv": 19942,
      "reduced administration": 68907,
      "mg 13": 45712,
      "day mg": 22336,
      "respectively 0005": 71145,
      "day 11": 22241,
      "computer assisted": 18660,
      "consumption improving": 19937,
      "blinded randomised": 14012,
      "additive effect": 7915,
      "scheduled tka": 73654,
      "escape medication": 29533,
      "measurements patient": 44028,
      "results 102": 71539,
      "102 patients": 1054,
      "groups contained": 34165,
      "week patients": 86860,
      "sub analysis": 78576,
      "week significant": 86871,
      "groups active": 34127,
      "groups weeks": 34354,
      "background pregabalin": 13167,
      "cause sedation": 15371,
      "sedation confusion": 74310,
      "reduces pain": 69000,
      "received capsules": 68124,
      "capsules containing": 14958,
      "mg capsules": 45815,
      "rest ambulation": 71414,
      "satisfaction 10": 73383,
      "pregabalin pain": 63674,
      "decreased patient": 23023,
      "perioperative pregabalin": 60850,
      "stay following": 77278,
      "mg tabs": 46235,
      "mg postoperatively": 46170,
      "pre op": 63475,
      "daily week": 21816,
      "taken average": 80271,
      "consumed similarly": 19852,
      "medications recommended": 44668,
      "provide estimates": 66060,
      "use hip": 84400,
      "size calculation": 76181,
      "additional oral": 7874,
      "41 52": 4414,
      "used 30": 84826,
      "weeks preceding": 86943,
      "prescribing level": 64073,
      "pain arthroscopic": 56460,
      "subjects subjects": 78744,
      "20 minutes": 2356,
      "satisfaction survey": 73442,
      "chi2 tests": 15993,
      "intraoperative medication": 39774,
      "rofecoxib group": 72727,
      "group 63": 33634,
      "63 02": 5351,
      "rofecoxib effective": 72726,
      "longer analgesic": 42367,
      "effect rofecoxib": 27554,
      "compare gastrointestinal": 18030,
      "assess treatment": 11970,
      "efficacy functional": 28272,
      "consumption hospitalization": 19933,
      "hospitalization significantly": 35660,
      "greater satisfaction": 33493,
      "method analgesia": 45168,
      "outcomes knee": 54046,
      "womac pain": 87183,
      "day continuous": 22285,
      "showed superior": 75317,
      "analgesia higher": 9989,
      "result prolonged": 71488,
      "study perioperative": 78401,
      "underwent similar": 83693,
      "placebo celecoxib": 61667,
      "surgery 200": 79299,
      "10 postoperative": 907,
      "outcomes reduction": 54081,
      "results celecoxib": 71619,
      "required patient": 70854,
      "10 surgery": 934,
      "oxycodone home": 55163,
      "001 active": 107,
      "having greater": 34603,
      "celecoxib compared": 15455,
      "better overall": 13721,
      "group sufentanil group": 34041,
      "postoperative analgesic consumption": 62711,
      "methods patients admitted": 45428,
      "release oxycodone mg": 69951,
      "oxycodone mg hours": 55419,
      "results baseline demographic": 71613,
      "patients received oxycontin": 59814,
      "reported significantly pain": 70652,
      "objective goal study": 50435,
      "versus oxycodone acetaminophen": 86140,
      "oxycodone acetaminophen fixed": 54640,
      "pain total knee": 57928,
      "mg 16 mg": 45720,
      "325 mg treatment": 3965,
      "weighted sum pain": 86988,
      "dose oxycodone acetaminophen": 25988,
      "oxycodone acetaminophen similar": 54663,
      "respectively moderate severe": 71213,
      "moderate severe gastrointestinal": 47180,
      "severe gastrointestinal adverse": 74945,
      "general activity walking": 32951,
      "activity walking ability": 7596,
      "oxycodone acetaminophen conclusions": 54638,
      "treated patients lower": 82372,
      "alternative oxycodone acetaminophen": 9732,
      "designed study determine": 23847,
      "cr oxycodone effective": 21085,
      "analgesic regimen oxycodone": 10315,
      "mg needed oxycodone": 46070,
      "needed oxycodone 10": 49021,
      "cr oxycodone 20": 21077,
      "24 36 48": 3159,
      "cr oxycodone group": 21087,
      "group lower pain": 33847,
      "sedation scores significantly": 74332,
      "group compared groups": 33687,
      "surgery provides effective": 79543,
      "formulation oxycodone patients": 32355,
      "cruciate ligament repair": 21327,
      "provides significant analgesic": 66238,
      "oxycodone mg oxycodone": 55435,
      "mg oxycodone group": 46115,
      "patients intravenous patient": 59422,
      "administered breakthrough pain": 8110,
      "24 48 surgery": 3172,
      "pacu significantly lower": 56333,
      "oxycodone effective fentanyl": 55015,
      "recovery total knee": 68769,
      "patient controlled oxycodone": 58598,
      "median oxycodone consumption": 44266,
      "pain pain management": 57319,
      "consumption pain management": 19977,
      "general anaesthesia group": 32955,
      "background opioid therapy": 13115,
      "undergoing total joint": 83586,
      "matched age gender": 43484,
      "10 patients received": 896,
      "patients discharged home": 59208,
      "gender body mass": 32933,
      "001 conclusions study": 123,
      "selected patients undergoing": 74398,
      "prospective randomized controlled": 65861,
      "health care provider": 34682,
      "analgesic regimens methods": 10322,
      "randomized controlled study": 67068,
      "oxycodone cr groups": 54898,
      "opioid placebo group": 52068,
      "annual opioid prescribing": 11026,
      "opioid prescribing rate": 52123,
      "2013 2018 patients": 2622,
      "number defined daily": 50154,
      "defined daily dosages": 23127,
      "preoperative opioid prescriptions": 63749,
      "dispensed opioid year": 25430,
      "release oxycodone compared": 69926,
      "group controlled release": 33721,
      "study group compared": 78215,
      "following total joint": 32215,
      "cruciate ligament reconstruction": 21326,
      "ketorolac 60 mg": 40640,
      "patients received scheduled": 59820,
      "received scheduled doses": 68267,
      "2nd postoperative day": 3656,
      "elevated pain scores": 28563,
      "preemptive multimodal analgesia": 63611,
      "pain following total": 56794,
      "seventy patients received": 74888,
      "therapy results patients": 81063,
      "course hospital stay": 20990,
      "vs 37 mg": 86571,
      "differences remained significant": 24806,
      "purpose investigate effect": 66535,
      "vas pain score": 86010,
      "significantly higher case": 75719,
      "nerve blocks reduce": 49120,
      "blocks reduce postoperative": 14100,
      "100 patients underwent": 1013,
      "2017 patients received": 2801,
      "days significantly lower": 22625,
      "lower group 001": 42623,
      "days postoperatively significantly": 22591,
      "postoperatively significantly lower": 63029,
      "ultrasound guided single": 83435,
      "study examine effect": 78196,
      "examine effect postoperative": 30338,
      "control group early": 20324,
      "group early postoperative": 33761,
      "early postoperative rehabilitation": 27270,
      "evaluated using bowel": 29928,
      "using bowel function": 85327,
      "differences groups regarding": 24750,
      "oxn group patients": 54416,
      "effect treatment group": 27577,
      "compare opioid related": 18037,
      "operative pain treatment": 51266,
      "patients similar characteristics": 59983,
      "intravenous morphine requirements": 39861,
      "vs 12 mg": 86529,
      "vs 16 mg": 86541,
      "37 mg vs": 4193,
      "mg vs 19": 46261,
      "multimodal analgesic regime": 48212,
      "included pain intensity": 37501,
      "pain previous 24": 57424,
      "previous 24 hours": 64895,
      "adverse effects measured": 8663,
      "02 significant differences": 378,
      "did significantly improve": 24508,
      "improve pain relief": 37073,
      "patients undergoing hip": 60106,
      "randomized groups control": 67117,
      "group received institution": 33950,
      "received institution standard": 68166,
      "institution standard care": 39085,
      "acetaminophen prescribed tablets": 7242,
      "prescribed tablets hours": 63988,
      "650 mg acetaminophen": 5432,
      "prescribed breakthrough pain": 63826,
      "contacted daily asked": 20053,
      "daily asked report": 21698,
      "report opioid use": 70466,
      "completed study 40": 18496,
      "significant differences respect": 75517,
      "patient specific factors": 58785,
      "group did use": 33744,
      "did use statistically": 24517,
      "use statistically significant": 84749,
      "statistically significant different": 77217,
      "significant different number": 75525,
      "different number narcotics": 24892,
      "number narcotics control": 50179,
      "narcotics control group": 48629,
      "group postoperative week": 33929,
      "effect reducing number": 27546,
      "reducing number narcotic": 69018,
      "narcotic pills consumed": 48605,
      "na\u00efve patients following": 48840,
      "level evidence ii": 41469,
      "group vs 73": 34074,
      "pain scores 30": 57700,
      "reported outcome scores": 70604,
      "outcome scores weeks": 53994,
      "scores weeks postoperatively": 74017,
      "increase pain scores": 37779,
      "difference patient reported": 24660,
      "evidence level randomized": 30213,
      "level randomized controlled": 41522,
      "controlled trial objectives": 20613,
      "severe post operative": 75008,
      "compared patients treated": 18255,
      "opioids methods retrospective": 53053,
      "received oxycodone intravenous": 68235,
      "use anti emetic": 84195,
      "similar groups median": 75931,
      "dose intravenous morphine": 25939,
      "oxn pr management": 54426,
      "oxn pr compared": 54422,
      "compared prolonged release": 18283,
      "oxycodone oxy pr": 55601,
      "pr treatment compared": 63379,
      "oxn pr oxy": 54427,
      "pr oxy pr": 63348,
      "efficacy tolerability oxn": 28406,
      "pr compared opioids": 63318,
      "significant improvements bowel": 75553,
      "improvements bowel function": 37172,
      "oxn pr reduced": 54431,
      "pain management including": 57074,
      "management including oral": 43189,
      "analysis compare effectiveness": 10654,
      "hip replacement surgery": 35424,
      "received oral opioid": 68226,
      "pain intensity 24": 56884,
      "pain intensity vs": 56959,
      "frequency nausea vomiting": 32518,
      "opioid consumption differences": 51619,
      "present substantial risk": 64669,
      "opioid related overdoses": 52327,
      "overdoses united states": 54336,
      "modal pain regimen": 47011,
      "control group did": 20321,
      "patients included mean": 59396,
      "mean number mg": 43805,
      "pain management significantly": 57119,
      "significantly fewer opioid": 75702,
      "orthopedics 2021 44": 53842,
      "investigate safety efficacy": 40028,
      "evidence level iv": 30212,
      "case series purpose": 15206,
      "postoperative analgesic effects": 62713,
      "double blind investigation": 26357,
      "received 50 mg": 68105,
      "20 ml ropivacaine": 2363,
      "scores hours postoperatively": 73891,
      "tolerability profile comparable": 81548,
      "objective study evaluated": 50513,
      "center randomized double": 15548,
      "doses study drug": 26280,
      "dose titration phase": 26100,
      "iv morphine oxycodone": 40385,
      "group experienced nausea": 33772,
      "patients experiencing moderate": 59288,
      "experiencing moderate severe": 30643,
      "clinical trials data": 16944,
      "united states use": 83828,
      "single center prospective": 76062,
      "325 mg needed": 3958,
      "325 mg hours": 3956,
      "24 hours 48": 3211,
      "events patient satisfaction": 30094,
      "satisfaction results patients": 73429,
      "analysis 28 patients": 10630,
      "group significant differences": 34013,
      "patient satisfaction groups": 58760,
      "patients opioid group": 59584,
      "consumption postoperative day": 19992,
      "nsaid group patients": 50090,
      "opioid group patients": 51828,
      "prospective comparative study": 65824,
      "aim aim study": 9372,
      "society anesthesiology asa": 76383,
      "morphine mg used": 47764,
      "used rescue analgesic": 85115,
      "assessed using 11": 12081,
      "analgesia group group": 9987,
      "group did differ": 33742,
      "underwent general anesthesia": 83682,
      "cause adverse effects": 15345,
      "pain relief total": 57592,
      "trial compared efficacy": 83010,
      "april 2014 august": 11603,
      "consumption 24 48": 19875,
      "48 hours total": 4729,
      "morphine equivalents 24": 47670,
      "provided significantly better": 66156,
      "control postoperative day": 20395,
      "pain regimen primary": 57506,
      "arthroplasty tka study": 11745,
      "oxycodone control group": 54879,
      "hours surgery patients": 35867,
      "oxycodone group received": 55138,
      "group received 400": 33947,
      "received 400 mg": 68103,
      "mg pregabalin 10": 46174,
      "placebo primary outcome": 61806,
      "analgesia secondary outcomes": 10105,
      "secondary outcomes time": 74258,
      "pain assessed visual": 56467,
      "time hospital discharge": 81272,
      "total morphine consumption": 81841,
      "controlled analgesia ivpca": 20453,
      "pain rest movement": 57645,
      "differences primary outcome": 24795,
      "score secondary outcome": 73785,
      "number antiemetic doses": 50140,
      "conclusions oral analgesia": 19138,
      "blinded randomized placebo": 14016,
      "days starting day": 22629,
      "starting day surgery": 77013,
      "day surgery patients": 22425,
      "analgesic regimen including": 10314,
      "needed primary outcome": 49030,
      "outcome pain score": 53974,
      "placebo statistically significant": 61831,
      "difference mean milligram": 24627,
      "difference effects anxiety": 24613,
      "90 patients undergoing": 6113,
      "device postoperative analgesia": 24271,
      "postoperative analgesia patients": 62705,
      "nausea vomiting urinary": 48820,
      "vomiting urinary retention": 86487,
      "urinary retention pruritus": 84062,
      "morning postoperative day": 47519,
      "patients discharged 24": 59203,
      "morphine group 05": 47706,
      "narcotic consumption visual": 48593,
      "pain score compared": 57671,
      "postoperative time points": 62975,
      "results lower vas": 71754,
      "lower vas pain": 42722,
      "randomized controlled clinical": 67059,
      "follow years postoperatively": 32043,
      "randomized postoperative pain": 67157,
      "20 ml bupivacaine": 2360,
      "surgery results patients": 79569,
      "scores recorded 30": 73964,
      "recorded 30 minutes": 68666,
      "30 minutes postoperatively": 3772,
      "controlled trial background": 20608,
      "long lasting analgesia": 42316,
      "reduce opioid requirements": 68866,
      "phase ii trial": 61291,
      "years body mass": 87574,
      "society anesthesiologists asa": 76375,
      "anesthesiologists asa physical": 10955,
      "scheduled primary unilateral": 73653,
      "nerve block postoperative": 49114,
      "analgesia consisted intravenous": 9935,
      "consisted intravenous patient": 19678,
      "pain scores obtained": 57750,
      "24 hours daily": 3214,
      "patient satisfaction assessed": 58755,
      "group single centre": 34024,
      "group received significantly": 33964,
      "rescue opioid medication": 70966,
      "10 21 mg": 693,
      "21 mg vs": 2976,
      "placebo group mean": 61743,
      "15 36 mg": 1698,
      "opioid morphine equivalents": 51961,
      "range motion rom": 67325,
      "better pain scores": 13726,
      "study compared effects": 78009,
      "vs oxycodone patients": 86670,
      "combined spinal epidural": 17670,
      "spinal epidural anesthesia": 76717,
      "dex group oxycodone": 24277,
      "values comparable groups": 85836,
      "background single injection": 13197,
      "successful day discharge": 78911,
      "days methods patients": 22555,
      "preoperatively postoperative days": 63776,
      "prospective randomized study": 65872,
      "therapy postoperative pain": 81050,
      "surgery daily pain": 79361,
      "pain medication requirements": 57160,
      "postoperative period total": 62947,
      "methods patients received": 45441,
      "nerve block ropivacaine": 49116,
      "infusion ropivacaine ml": 38729,
      "10 10 mg": 660,
      "rest dynamic pain": 71422,
      "postoperatively secondary outcomes": 63026,
      "results oxn group": 71821,
      "difference pain score": 24655,
      "significant differences total": 75519,
      "prolonged release oxn": 65626,
      "purpose determine effect": 66530,
      "time points 90": 81335,
      "90 days postoperatively": 6099,
      "postoperatively methods patients": 63007,
      "preoperatively 90 days": 63768,
      "equivalents mmes prescribed": 29367,
      "diclofenac 75 mg": 24386,
      "ketoprofen 100 mg": 40627,
      "recovery room followed": 68758,
      "diclofenac 150 mg": 24381,
      "300 mg day": 3814,
      "mg day placebo": 45862,
      "37 21 mg": 4175,
      "mg ketoprofen group": 45941,
      "mg respectively placebo": 46206,
      "ketoprofen group placebo": 40631,
      "pain scores vas": 57791,
      "rate did differ": 67461,
      "methods pain control": 45420,
      "create evidence based": 21139,
      "prescription methods prospective": 64253,
      "methods prospective multicenter": 45485,
      "rating scale nprs": 67656,
      "study patients prescribed": 78371,
      "single shot spinal": 76139,
      "intra articular injections": 39717,
      "ml ropivacaine mg": 46902,
      "normal renal function": 49908,
      "30 mg ketorolac": 3761,
      "length stay decreased": 41408,
      "associated moderate severe": 12337,
      "20 patients received": 2370,
      "preservative free morphine": 64718,
      "bupivacaine mg kg": 14505,
      "oxycodone given rescue": 55117,
      "rescue analgesic patients": 70938,
      "group did need": 33743,
      "additional doses oxycodone": 7856,
      "period mean pain": 60747,
      "groups patients satisfied": 34265,
      "satisfied pain therapy": 73461,
      "pain management primary": 57106,
      "medication adverse effects": 44456,
      "group showed lower": 34006,
      "pain control total": 56665,
      "opioid prescription year": 52170,
      "changes opioid prescription": 15804,
      "period 10 12": 60678,
      "opioid prescriptions increased": 52193,
      "surgeons address opioid": 79269,
      "associated negative effects": 12343,
      "optimal postoperative analgesia": 53431,
      "postoperative analgesia primary": 62706,
      "controlled study compared": 20586,
      "patient controlled epidural": 58594,
      "controlled epidural analgesia": 20496,
      "pain scores methods": 57737,
      "time readiness discharge": 81349,
      "opioid consumption oral": 51635,
      "consumption oral morphine": 19966,
      "opioid related symptom": 52329,
      "related symptom distress": 69696,
      "symptom distress scale": 79863,
      "patient satisfaction similar": 58776,
      "pain potential effects": 57399,
      "local infiltration analgesia": 42209,
      "equal analgesic efficacy": 29229,
      "1st post operative": 2258,
      "group mg morphine": 33862,
      "pain scores vital": 57794,
      "plasma concentrations determined": 61911,
      "median 25th 75th": 44184,
      "25th 75th percentiles": 3413,
      "demand differed significantly": 23249,
      "15 10 25": 1672,
      "25 mg vs": 3366,
      "did vary significantly": 24520,
      "early post operative": 27265,
      "pain management using": 57131,
      "patients underwent arthroscopic": 60140,
      "opioid 30 days": 51355,
      "term use defined": 80678,
      "regression analyses adjusted": 69416,
      "opioid oxycodone increased": 52029,
      "increased prescribed opioid": 37993,
      "effect long term": 27476,
      "small increased risk": 76283,
      "increased risk prolonged": 38020,
      "subjective pain threshold": 78659,
      "state controlled substance": 77038,
      "demonstrated statistically significant": 23371,
      "compared efficacy safety": 18146,
      "enrolled randomly assigned": 29021,
      "randomly assigned oxycodone": 67222,
      "group celecoxib group": 33679,
      "pain rest motion": 57644,
      "score 24 48": 73718,
      "different groups conclusion": 24873,
      "higher patient satisfaction": 35289,
      "patient satisfaction comparable": 58756,
      "controlled trial compare": 20609,
      "30 ml ropivacaine": 3774,
      "hours secondary outcomes": 35847,
      "morphine consumption 48": 47621,
      "48 hours opioid": 4714,
      "related effects post": 69601,
      "hypothesized patients receiving": 36314,
      "morphine consumption pain": 47624,
      "results pain scores": 71834,
      "opioid use groups": 52516,
      "adverse effects methods": 8664,
      "patients received neuraxial": 59799,
      "oral analgesics oxycodone": 53495,
      "oxycodone acetaminophen patients": 54654,
      "randomized receive pregabalin": 67177,
      "50 mg 12": 4850,
      "use adverse effects": 84181,
      "perioperative administration pregabalin": 60825,
      "analgesic regimen following": 10313,
      "ropivacaine mg ml": 72801,
      "mg ml fentanyl": 46056,
      "rescue pain medication": 70973,
      "pain medication consisted": 57150,
      "regarding pain relief": 69267,
      "multimodal pain treatment": 48237,
      "microg ml 12": 46362,
      "eq 5d sf": 29226,
      "opioid sparing protocols": 52372,
      "18 mg group": 2090,
      "mean hospital stay": 43779,
      "50 patients required": 4885,
      "nerve stimulation tens": 49131,
      "quantitative sensory tests": 66812,
      "nrs scale 10": 50075,
      "analyzed patients receiving": 10852,
      "patients receiving saline": 59857,
      "nerve block duration": 49112,
      "increased 95 confidence": 37868,
      "pain scores hour": 57729,
      "associated respiratory depression": 12412,
      "peripheral nerve blockade": 60869,
      "severe pain despite": 74976,
      "respiratory depression observed": 71281,
      "depression observed patients": 23588,
      "pain control protocol": 56645,
      "hours surgery compared": 35863,
      "randomly assigned groups": 67221,
      "patients groups receive": 59345,
      "did differ treatment": 24445,
      "controlled study 12": 20585,
      "hours postoperatively patients": 35826,
      "study examines effect": 78204,
      "differences groups respect": 24751,
      "days 95 confidence": 22480,
      "associated severe pain": 12418,
      "spinal anaesthesia patients": 76701,
      "anaesthesia patients received": 9873,
      "patients received standardized": 59826,
      "surgery secondary endpoints": 79579,
      "pain scores 48": 57701,
      "hip fracture surgery": 35419,
      "undergoing hip fracture": 83539,
      "level postoperative days": 41517,
      "group patient satisfaction": 33899,
      "consumption postoperative pain": 19994,
      "opioid prescribing orthopedic": 52115,
      "investigated safety efficacy": 40057,
      "incidence drug related": 37269,
      "oxycodone codeine acetaminophen": 54795,
      "users chronic users": 85230,
      "reduction opioid use": 69079,
      "control group receiving": 20340,
      "statistically lower pain": 77197,
      "group reported lower": 33977,
      "reported lower pain": 70578,
      "24 hours prior": 3229,
      "statistically different control": 77194,
      "reported statistically lower": 70658,
      "data patients opioid": 22041,
      "opioid use baseline": 52474,
      "combined nonopioid analgesics": 17660,
      "center open label": 15534,
      "label study setting": 41002,
      "hospital study conducted": 35644,
      "2018 2019 participants": 2809,
      "total 109 patients": 81708,
      "scale nrs rest": 73519,
      "total dose postoperative": 81802,
      "dose postoperative oxycodone": 26016,
      "postoperative oxycodone required": 62839,
      "follow period 48": 32027,
      "period 48 main": 60706,
      "48 main results": 4733,
      "subsequently excluded analysis": 78785,
      "group received standard": 33966,
      "pain level measured": 57007,
      "significantly higher control": 75722,
      "rescue analgesia significantly": 70933,
      "group higher rate": 33816,
      "reduces need opioids": 68994,
      "level patient satisfaction": 41513,
      "mg provided significantly": 46185,
      "nausea vomiting similar": 48818,
      "background patients undergoing": 13150,
      "pain management objectives": 57087,
      "study double blind": 78131,
      "treatment group received": 82598,
      "pain scores points": 57763,
      "adverse effects acute": 8637,
      "improved pain scores": 37119,
      "additional adverse effects": 7838,
      "somnolence dizziness confusion": 76465,
      "patients present study": 59688,
      "pain scores adverse": 57702,
      "scores adverse effects": 73839,
      "addition multimodal oral": 7814,
      "multimodal oral analgesic": 48224,
      "oral analgesic regimen": 53492,
      "wound infiltration ropivacaine": 87362,
      "analgesic regimen consisting": 10312,
      "using 100 mm": 85287,
      "surgery secondary end": 79577,
      "end points pain": 28810,
      "cumulative consumption oxycodone": 21392,
      "group 20 14": 33582,
      "10 mg 24": 794,
      "24 mg vs": 3246,
      "mg vs 10": 46260,
      "10 mg 15": 790,
      "mg 15 mg": 45716,
      "acetaminophen celecoxib gabapentin": 7159,
      "analgesic efficacy continuous": 10234,
      "prospective randomized trial": 65873,
      "randomized trial patients": 67201,
      "anesthesia randomized receive": 10940,
      "equivalent pain scores": 29329,
      "significantly nausea vomiting": 75820,
      "introduction pain management": 39948,
      "discharge secondary outcomes": 25174,
      "strong opioid medications": 77532,
      "patients received sustained": 59827,
      "received sustained release": 68293,
      "daily pain levels": 21794,
      "mean oral morphine": 43819,
      "mg oxycodone patient": 46130,
      "cite article bone": 16594,
      "article bone joint": 11763,
      "opioid consumption methods": 51632,
      "mg iv dexamethasone": 45938,
      "post operative analgesic": 62590,
      "days results mean": 22612,
      "group 47 mg": 33618,
      "47 mg vs": 4660,
      "potentially problematic opioid": 63265,
      "pain orthopedic surgery": 57300,
      "analgesic efficacy administering": 10225,
      "discharge patients instructed": 25158,
      "200 mg 12": 2398,
      "10 mg available": 802,
      "rescue analgesia results": 70931,
      "analgesia results patients": 10098,
      "likely experience pain": 41808,
      "nausea vomiting 05": 48789,
      "used oxycodone postoperative": 85059,
      "results support use": 71999,
      "surgery background present": 79332,
      "background present study": 13173,
      "naive patients aged": 48402,
      "aged 18 75": 9163,
      "18 75 years": 2067,
      "age sex comorbidities": 9117,
      "opioid exposure defined": 51796,
      "postoperatively multivariate regression": 63010,
      "results total patient": 72038,
      "level iii purpose": 41492,
      "65 years old": 5427,
      "pre operatively study": 63481,
      "nonopioid analgesic agents": 49805,
      "post operative days": 62593,
      "hours post operatively": 35818,
      "pain rest day": 57642,
      "study determine preoperative": 78114,
      "score 12 weeks": 73710,
      "postoperative length stay": 62785,
      "trauma center patients": 82261,
      "admission emergency department": 8405,
      "rating scale used": 67680,
      "comparable baseline characteristics": 17952,
      "group consisted 50": 33703,
      "evidence therapeutic level": 30283,
      "adverse effects evaluated": 8656,
      "combined low dose": 17652,
      "good postoperative analgesia": 33322,
      "pain management recognized": 57111,
      "improved postoperative pain": 37125,
      "block postoperative pain": 14055,
      "45 60 minutes": 4574,
      "oxycodone consumption surgical": 54872,
      "reported pain score": 70614,
      "group 56 patients": 33628,
      "age weight height": 9134,
      "nerve block group": 49113,
      "rates nausea vomiting": 67598,
      "results pain rest": 71833,
      "phantom limb pain": 61006,
      "hours patient required": 35812,
      "ropivacaine 10 ml": 72788,
      "day surgery total": 22426,
      "postoperative day results": 62753,
      "analgesic regimen used": 10318,
      "scores 10 10": 73823,
      "stable pain scores": 76847,
      "term adverse effects": 80615,
      "understanding pain management": 83643,
      "pain management methods": 57080,
      "pain numeric pain": 57251,
      "mean body mass": 43728,
      "physical function quality": 61398,
      "regimes control group": 69340,
      "total 162 patients": 81730,
      "group group postoperative": 33805,
      "reduce pain improve": 68873,
      "hours post surgery": 35819,
      "outcomes included length": 54033,
      "included length stay": 37471,
      "surgery pain control": 79496,
      "results average pain": 71609,
      "similar oxycodone ir": 75969,
      "background study aimed": 13202,
      "ml bolus ml": 46850,
      "mg iv acetaminophen": 45937,
      "analgesia primary outcome": 10072,
      "mixed effect models": 46790,
      "statistically significant 05": 77199,
      "rescue opioid analgesia": 70964,
      "opioid analgesia compared": 51441,
      "opioid consumption background": 51609,
      "days post operatively": 22587,
      "evaluated analgesic effect": 29862,
      "anesthesia patients undergoing": 10933,
      "group received mg": 33956,
      "time opioid use": 81305,
      "surgery opioid use": 79488,
      "provides longer duration": 66227,
      "duration postoperative analgesia": 27179,
      "longer duration analgesia": 42370,
      "included prospective observational": 37525,
      "observational study single": 50635,
      "hospital discharge persistent": 35583,
      "model used identify": 47088,
      "history alcohol abuse": 35451,
      "risk persistent use": 72633,
      "number pills dispensed": 50227,
      "following surgery results": 32205,
      "mg range 10": 46195,
      "weeks surgery compared": 86958,
      "methods randomly divided": 45521,
      "saline 10 ml": 73255,
      "group primary outcomes": 33937,
      "significant differences postoperative": 75515,
      "total blood loss": 81782,
      "day pod1 pod2": 22379,
      "total consumption oxycodone": 81790,
      "surgical site infection": 79652,
      "square test categorical": 76796,
      "test categorical data": 80756,
      "logistic regression performed": 42271,
      "performed results total": 60622,
      "results total 500": 72032,
      "patients included overall": 59398,
      "18 25 total": 2040,
      "diastolic blood pressure": 24365,
      "oxycodone tramadol use": 56019,
      "primary outcome cumulative": 65060,
      "intravenous oxycodone consumption": 39870,
      "controlled analgesia 24": 20446,
      "analgesia 24 postoperative": 9895,
      "secondary outcomes include": 74244,
      "hospital stay duration": 35634,
      "international peer reviewed": 39483,
      "low dose meloxicam": 42471,
      "anesthesia patients received": 10932,
      "bupivacaine 12 mg": 14489,
      "preoperative acetaminophen celecoxib": 63734,
      "pain control pain": 56634,
      "pain scores remained": 57773,
      "hours surgery mean": 35866,
      "mean total opioid": 43894,
      "nerve blocks total": 49122,
      "placebo group using": 61754,
      "using 20 ml": 85295,
      "care unit results": 15092,
      "results median iqr": 71775,
      "pain scores placebo": 57761,
      "injection liposomal bupivacaine": 38954,
      "acetaminophen oxycodone needed": 7224,
      "oxycodone needed basis": 55529,
      "patient satisfaction measured": 58764,
      "follow visit results": 32040,
      "patients american society": 58989,
      "society anesthesiologists physical": 76380,
      "anesthesiologists physical status": 10961,
      "blinded study patients": 14022,
      "patients received epidural": 59778,
      "required significantly rescue": 70864,
      "pain medication oxycodone": 57156,
      "mean difference groups": 43760,
      "low dose ropivacaine": 42482,
      "antiinflammatory drugs nsaids": 11212,
      "provide effective postoperative": 66055,
      "placebo group received": 61750,
      "group postoperative time": 33928,
      "lateral femoral cutaneous": 41242,
      "parallel group trial": 58142,
      "ml saline group": 46907,
      "anaesthesia primary outcome": 9875,
      "outcome pain measured": 53971,
      "primary outcome group": 65063,
      "ropivacaine group placebo": 72795,
      "opioid use time": 52600,
      "donor site pain": 25713,
      "local anaesthetic injection": 42201,
      "assessed numerical rating": 12022,
      "difference oxycodone consumption": 24650,
      "patient satisfaction outcomes": 58765,
      "narcotic usage patients": 48613,
      "block 30 ml": 14035,
      "10 ml saline": 866,
      "group postoperative pain": 33925,
      "scores narcotic usage": 73910,
      "treatment groups results": 82607,
      "age gender race": 9075,
      "12 hours postoperatively": 1305,
      "conclusions liposomal bupivacaine": 19112,
      "pain scores 12": 57697,
      "surgery impact analgesic": 79422,
      "elderly patients undergoing": 28482,
      "patients evaluable efficacy": 59263,
      "oral narcotic agents": 53594,
      "narcotic agents preferred": 48585,
      "agents preferred analgesic": 9238,
      "preferred analgesic postoperatively": 63638,
      "potential abuse study": 63124,
      "abuse study evaluates": 6883,
      "evaluates efficacy ketorolac": 29941,
      "agent postoperative pain": 9220,
      "standard care pain": 76892,
      "care pain protocol": 15052,
      "discharge ketorolac group": 25131,
      "oral ketorolac discharge": 53558,
      "ketorolac discharge pain": 40644,
      "narcotic utilization recorded": 48623,
      "utilization recorded times": 85737,
      "recorded times day": 68705,
      "day days surgery": 22296,
      "results final analysis": 71695,
      "final analysis included": 31742,
      "mean age cohort": 43706,
      "observed preoperative demographics": 50708,
      "preoperative demographics comorbidities": 63740,
      "functional scores groups": 32712,
      "scores groups days": 73882,
      "groups days surgery": 34171,
      "surgery patients ketorolac": 79508,
      "patients ketorolac group": 59434,
      "ketorolac group consumed": 40646,
      "group consumed mean": 33706,
      "fewer narcotic pills": 31647,
      "functional outcome scores": 32705,
      "adverse events groups": 8760,
      "events groups reported": 30051,
      "groups reported cases": 34294,
      "ketorolac substantially reduces": 40659,
      "substantially reduces narcotic": 78863,
      "reduces narcotic utilization": 68991,
      "tablets prescribed discharge": 80205,
      "mmes prescribed significantly": 46988,
      "mg tablets prescribed": 46233,
      "47 year old": 4668,
      "nausea vomiting hours": 48801,
      "prolong analgesic duration": 65605,
      "long term functional": 42336,
      "mean oxycodone consumption": 43823,
      "20 mg versus": 2353,
      "second day surgery": 74182,
      "methods total 160": 45612,
      "total 160 patients": 81728,
      "received 60 mg": 68108,
      "cumulative opioid consumption": 21398,
      "opioid consumption surgery": 51668,
      "surgery postoperative day": 79528,
      "opioid consumption opioid": 51634,
      "consumption mean sd": 19950,
      "difference 11 ci": 24569,
      "ci 10 year": 16387,
      "pain medication required": 57159,
      "daily pain medication": 21795,
      "years standard deviation": 87673,
      "51 years patients": 4966,
      "patients underwent open": 60148,
      "prescribed average 50": 63823,
      "patients increased risk": 59404,
      "groups compared results": 34152,
      "compared results study": 18297,
      "greater proportion patients": 33483,
      "proportion patients received": 65769,
      "group exhibited significantly": 33770,
      "significantly higher pain": 75734,
      "nerve block safe": 49117,
      "pain related outcomes": 57514,
      "primary outcome rate": 65091,
      "iv morphine consumption": 40383,
      "scores rest movement": 73973,
      "postoperative day 11": 62734,
      "compared iv pca": 18195,
      "reducing postoperative pain": 69031,
      "rating scale satisfaction": 67675,
      "pain protocol patients": 57440,
      "higher doses effective": 35233,
      "controlled study tested": 20594,
      "patients 30 group": 58853,
      "30 group received": 3739,
      "received capsules containing": 68125,
      "day pod 14": 22376,
      "opioid consumption analgesic": 51608,
      "effect pregabalin pain": 27533,
      "decreased patient satisfaction": 23024,
      "length stay following": 41409,
      "prospective single center": 65881,
      "treatment groups group": 82604,
      "groups group control": 34208,
      "medication oxycodone acetaminophen": 44532,
      "600 mg orally": 5290,
      "dose group control": 25919,
      "weeks secondary outcomes": 86954,
      "preoperative pain scores": 63755,
      "milligram equivalents consumed": 46455,
      "groups compared control": 34148,
      "opioid use hip": 52519,
      "eligible inclusion study": 28586,
      "sample size calculation": 73316,
      "additional oral morphine": 7875,
      "opioid prescribing level": 52105,
      "prescribing level evidence": 64074,
      "postoperative pain arthroscopic": 62845,
      "50 mg oral": 4859,
      "mg iv ketorolac": 45939,
      "proportion patients reporting": 65773,
      "patients reporting pain": 59897,
      "05 considered significant": 506,
      "24 hours vs": 3236,
      "analgesic effect rofecoxib": 10209,
      "trial compared analgesic": 83008,
      "analgesic efficacy functional": 10236,
      "oxycodone consumption hospitalization": 54862,
      "group showed significantly": 34007,
      "component multimodal analgesia": 18579,
      "patients underwent similar": 60151,
      "infusion patient controlled": 38720,
      "numerical rating score": 50323,
      "surgery 200 mg": 79300,
      "associated improved clinical": 12294,
      "improved clinical outcomes": 37101,
      "results celecoxib group": 71620,
      "postoperative period placebo": 62943,
      "celecoxib compared placebo": 15456,
      "long term benefits": 42327,
      "immediate release oxycodone mg": 36733,
      "moderate severe pain conditions": 47195,
      "randomized open label study": 67133,
      "mg 325 mg treatment": 45744,
      "respectively moderate severe gastrointestinal": 71214,
      "severe gastrointestinal adverse events": 74946,
      "general activity walking ability": 32952,
      "relieving moderate severe pain": 70235,
      "mg needed oxycodone 10": 46071,
      "needed oxycodone 10 mg": 49022,
      "10 mg cr oxycodone": 807,
      "cr oxycodone 20 mg": 21078,
      "group lower pain scores": 33848,
      "surgery provides effective analgesia": 79544,
      "anterior cruciate ligament repair": 11107,
      "23 year old woman": 3121,
      "patients intravenous patient controlled": 59423,
      "12 24 48 surgery": 1236,
      "12 24 48 hours": 1235,
      "recovery total knee arthroplasty": 68770,
      "postoperative opioid consumption pain": 62816,
      "opioid consumption pain management": 51641,
      "undergoing total joint arthroplasty": 83587,
      "gender body mass index": 32934,
      "conclusions study provides evidence": 19223,
      "prospective randomized controlled trial": 65862,
      "background aim study investigate": 13010,
      "er oxycodone cr groups": 29457,
      "controlled release oxycodone compared": 20555,
      "group controlled release oxycodone": 33722,
      "anterior cruciate ligament reconstruction": 11106,
      "oral oxycodone 10 mg": 53616,
      "mg hours needed pain": 45908,
      "scale pain scores postoperative": 73538,
      "day compared control group": 22278,
      "peripheral nerve blocks reduce": 60871,
      "nerve blocks reduce postoperative": 49121,
      "blocks reduce postoperative pain": 14101,
      "aim study evaluate effects": 9418,
      "significantly lower group 001": 75786,
      "days postoperatively significantly lower": 22592,
      "oxycodone consumption postoperative days": 54867,
      "control group early postoperative": 20325,
      "evaluated using bowel function": 29929,
      "using bowel function index": 85328,
      "significant differences groups regarding": 75505,
      "post operative pain treatment": 62605,
      "37 mg vs 19": 4194,
      "pain previous 24 hours": 57425,
      "compared oxycodone cr placebo": 18240,
      "randomized groups control group": 67118,
      "control group received institution": 20339,
      "group received institution standard": 33951,
      "received institution standard care": 68167,
      "mg oxycodone acetaminophen prescribed": 46107,
      "oxycodone acetaminophen prescribed tablets": 54660,
      "acetaminophen prescribed tablets hours": 7243,
      "contacted daily asked report": 20054,
      "daily asked report opioid": 21699,
      "asked report opioid use": 11849,
      "pain using visual analog": 57964,
      "statistically significant differences respect": 77216,
      "group did use statistically": 33745,
      "did use statistically significant": 24518,
      "use statistically significant different": 84750,
      "statistically significant different number": 77218,
      "significant different number narcotics": 75526,
      "different number narcotics control": 24893,
      "number narcotics control group": 50180,
      "narcotics control group postoperative": 48630,
      "control group postoperative week": 20337,
      "effect reducing number narcotic": 27547,
      "reducing number narcotic pills": 69019,
      "number narcotic pills consumed": 50177,
      "opioid na\u00efve patients following": 51986,
      "number opioid pills consumed": 50192,
      "difference pain scores 30": 24657,
      "patient reported outcome scores": 58737,
      "outcome scores weeks postoperatively": 53995,
      "level evidence level randomized": 41476,
      "evidence level randomized controlled": 30214,
      "level randomized controlled trial": 41523,
      "randomized controlled trial objectives": 67075,
      "severe post operative pain": 75009,
      "patients received oxycodone intravenous": 59812,
      "oral prolonged release oxycodone": 53658,
      "compared prolonged release oxycodone": 18284,
      "prolonged release oxycodone oxy": 65629,
      "release oxycodone oxy pr": 69960,
      "oxn pr oxy pr": 54428,
      "oxn pr compared opioids": 54423,
      "significant improvements bowel function": 75554,
      "total hip replacement surgery": 81814,
      "multi modal pain regimen": 48151,
      "pain rating scale scores": 57471,
      "mean number mg oxycodone": 43806,
      "mg oxycodone tablets prescribed": 46143,
      "reduction opioids prescribed patients": 69082,
      "level evidence level iv": 41475,
      "randomized double blind investigation": 67104,
      "results statistically significant difference": 71965,
      "study evaluated efficacy tolerability": 78183,
      "center randomized double blind": 15549,
      "patients received iv morphine": 59790,
      "patients experiencing moderate severe": 59289,
      "experiencing moderate severe postoperative": 30644,
      "acetaminophen 325 mg needed": 7127,
      "325 mg hours needed": 3957,
      "hours 24 hours 48": 35737,
      "24 hours 48 hours": 3212,
      "adverse events patient satisfaction": 8788,
      "events patient satisfaction results": 30095,
      "patient satisfaction results patients": 58772,
      "opioid consumption postoperative day": 51650,
      "american society anesthesiology asa": 9808,
      "assessed using 11 point": 12082,
      "mean nrs pain score": 43802,
      "consumption 24 48 hours": 19876,
      "significantly better pain control": 75664,
      "pain control postoperative day": 56642,
      "knee arthroplasty tka study": 40859,
      "group received 400 mg": 33948,
      "150 mg pregabalin 10": 1813,
      "mg pregabalin 10 mg": 46175,
      "postoperative pain assessed visual": 62848,
      "patients randomly allocated receive": 59748,
      "patient controlled analgesia ivpca": 58585,
      "score secondary outcome measures": 73786,
      "blinded randomized placebo controlled": 14017,
      "placebo controlled trial patients": 61708,
      "primary outcome pain score": 65084,
      "oral oxycodone intravenous morphine": 53632,
      "nausea vomiting urinary retention": 48821,
      "patients discharged 24 hours": 59204,
      "discharged 24 hours surgery": 25189,
      "postoperative pain assessed using": 62847,
      "narcotic consumption visual analog": 48594,
      "scale vas pain score": 73576,
      "results lower vas pain": 71755,
      "randomized controlled trial background": 67070,
      "years body mass index": 87575,
      "american society anesthesiologists asa": 9803,
      "society anesthesiologists asa physical": 76376,
      "anesthesiologists asa physical status": 10956,
      "analgesia consisted intravenous patient": 9936,
      "consisted intravenous patient controlled": 19679,
      "reduce postoperative pain scores": 68886,
      "combined spinal epidural anesthesia": 17671,
      "anesthesia randomly assigned control": 10943,
      "purpose study determine oral": 66577,
      "release oxycodone naloxone combination": 69954,
      "significant difference pain score": 75487,
      "showed significant differences total": 75300,
      "preoperatively 90 days postoperatively": 63769,
      "milligram equivalents mmes prescribed": 46468,
      "diclofenac 150 mg day": 24382,
      "ketoprofen group placebo group": 40632,
      "placebo group 05 patients": 61735,
      "compared control group patients": 18120,
      "create evidence based guideline": 21140,
      "opioid prescription methods prospective": 52156,
      "pain rating scale nprs": 57469,
      "period mean pain scores": 60748,
      "effects similar groups patients": 28161,
      "similar groups patients satisfied": 75934,
      "groups patients satisfied pain": 34266,
      "patients satisfied pain therapy": 59941,
      "provided adequate pain control": 66120,
      "adequate pain control total": 7964,
      "significantly decreased opioid consumption": 75679,
      "changes opioid prescription rates": 15805,
      "difference 95 ci 10": 24586,
      "placebo controlled study compared": 61704,
      "use patient controlled epidural": 84609,
      "patient controlled epidural analgesia": 58595,
      "03 95 ci 09": 412,
      "opioid consumption oral morphine": 51636,
      "consumption oral morphine equivalents": 19967,
      "opioid related symptom distress": 52330,
      "related symptom distress scale": 69697,
      "analgesic efficacy adverse effects": 10227,
      "effects nausea vomiting compared": 28018,
      "1st post operative day": 2259,
      "median 25th 75th percentiles": 44185,
      "15 10 25 mg": 1673,
      "10 25 mg vs": 698,
      "pain scores patient satisfaction": 57758,
      "methods prospective randomized study": 45495,
      "long term use defined": 42360,
      "logistic regression analyses adjusted": 42256,
      "controlled study compared efficacy": 20587,
      "study compared efficacy safety": 78011,
      "randomized controlled trial compare": 67071,
      "hours secondary outcomes included": 35848,
      "morphine consumption 48 hours": 47622,
      "morphine consumption pain scores": 47625,
      "rating scale pain scores": 67672,
      "effects similar groups conclusions": 28160,
      "electrical nerve stimulation tens": 28507,
      "increased 95 confidence interval": 37869,
      "respiratory depression observed patients": 71282,
      "patients underwent general anesthesia": 60143,
      "24 hours surgery compared": 3234,
      "converted morphine equivalent doses": 20733,
      "placebo controlled study 12": 61703,
      "48 hours postoperatively patients": 4718,
      "days 95 confidence interval": 22481,
      "spinal anaesthesia patients received": 76702,
      "surgery secondary endpoints pain": 79580,
      "undergoing hip fracture surgery": 83540,
      "consumption postoperative pain management": 19995,
      "incidence drug related adverse": 37270,
      "drug related adverse effects": 26763,
      "postoperative pain patients undergoing": 62907,
      "group reported lower pain": 33978,
      "reported lower pain scores": 70579,
      "statistically different control group": 77195,
      "reported statistically lower pain": 70659,
      "mean number oxycodone mg": 43810,
      "single center open label": 76061,
      "open label study setting": 51185,
      "label study setting single": 41003,
      "pain rating scale nrs": 57470,
      "rating scale nrs rest": 67664,
      "total dose postoperative oxycodone": 81803,
      "dose postoperative oxycodone required": 26017,
      "related adverse events patient": 69555,
      "follow period 48 main": 32028,
      "significantly higher control group": 75723,
      "mg provided significantly better": 46186,
      "incidence nausea vomiting similar": 37286,
      "controlled trial patients undergoing": 20616,
      "satisfaction results patients enrolled": 73430,
      "pain scores adverse effects": 57703,
      "multimodal oral analgesic regimen": 48225,
      "using 100 mm visual": 85288,
      "surgery secondary end points": 79578,
      "secondary end points pain": 74222,
      "oxycodone mg 10 mg": 55409,
      "vs 10 mg 15": 86523,
      "10 mg 15 mg": 791,
      "randomized trial patients undergoing": 67202,
      "patients received sustained release": 59828,
      "cite article bone joint": 16595,
      "group 47 mg vs": 33619,
      "oxycodone 10 mg available": 54498,
      "rescue analgesia results patients": 70932,
      "incidence postoperative nausea vomiting": 37301,
      "postoperative nausea vomiting 05": 62804,
      "surgery background present study": 79333,
      "opioid naive patients aged": 51971,
      "aged 18 75 years": 9164,
      "evidence level iii purpose": 30210,
      "purpose aim study assess": 66517,
      "patients 65 years old": 58889,
      "opioid nonopioid analgesic agents": 52003,
      "postoperative length stay los": 62786,
      "level trauma center patients": 41533,
      "numeric rating scale used": 50302,
      "level evidence therapeutic level": 41481,
      "related adverse effects evaluated": 69550,
      "improved postoperative pain control": 37126,
      "nerve block postoperative pain": 49115,
      "30 45 60 minutes": 3693,
      "higher morphine equivalent doses": 35265,
      "patients received oral opioid": 59807,
      "ml ropivacaine mg ml": 46903,
      "mean body mass index": 43729,
      "physical function quality life": 61399,
      "study assess efficacy safety": 77964,
      "assess efficacy safety prolonged": 11933,
      "secondary outcomes included length": 74247,
      "outcomes included length stay": 54034,
      "background study aimed investigate": 13203,
      "provides longer duration analgesia": 66228,
      "persistent opioid use defined": 60920,
      "regression model used identify": 69446,
      "associated increased risk persistent": 12309,
      "postoperative day pod1 pod2": 62749,
      "chi square test categorical": 15987,
      "square test categorical data": 76797,
      "patient controlled analgesia 24": 58580,
      "mean total opioid consumption": 43895,
      "peripheral nerve blocks total": 60872,
      "patients american society anesthesiologists": 58990,
      "american society anesthesiologists physical": 9806,
      "society anesthesiologists physical status": 76381,
      "double blinded study patients": 26400,
      "nonsteroidal antiinflammatory drugs nsaids": 49859,
      "provide effective postoperative analgesia": 66056,
      "primary outcome pain measured": 65081,
      "assessed numerical rating scale": 12023,
      "10 ml saline group": 867,
      "group postoperative pain scores": 33926,
      "pain scores narcotic usage": 57741,
      "oral narcotic agents preferred": 53595,
      "narcotic agents preferred analgesic": 48586,
      "agents preferred analgesic postoperatively": 9239,
      "potential abuse study evaluates": 63125,
      "abuse study evaluates efficacy": 6884,
      "study evaluates efficacy ketorolac": 78189,
      "agent postoperative pain control": 9221,
      "methods adult patients undergoing": 45243,
      "group received standard care": 33967,
      "standard care pain protocol": 76893,
      "oral ketorolac discharge pain": 53559,
      "narcotic utilization recorded times": 48624,
      "utilization recorded times day": 85738,
      "recorded times day days": 68706,
      "times day days surgery": 81422,
      "results final analysis included": 71696,
      "differences observed preoperative demographics": 24767,
      "observed preoperative demographics comorbidities": 50709,
      "functional scores groups days": 32713,
      "scores groups days surgery": 73883,
      "groups days surgery patients": 34172,
      "days surgery patients ketorolac": 22640,
      "surgery patients ketorolac group": 79509,
      "patients ketorolac group consumed": 59435,
      "ketorolac group consumed mean": 40647,
      "functional outcome scores weeks": 32706,
      "adverse events groups reported": 8761,
      "events groups reported cases": 30052,
      "ketorolac substantially reduces narcotic": 40660,
      "substantially reduces narcotic utilization": 78864,
      "opioid tablets prescribed discharge": 52400,
      "oxycodone mg tablets prescribed": 55444,
      "methods total 160 patients": 45613,
      "patients received 60 mg": 59766,
      "opioid consumption mean sd": 51630,
      "purpose purpose study compare": 66555,
      "factors associated increased opioid": 31075,
      "years standard deviation sd": 87674,
      "pain scores rest movement": 57777,
      "numerical rating scale satisfaction": 50318,
      "placebo controlled study tested": 61706,
      "controlled study tested hypothesis": 20595,
      "patients 30 group received": 58854,
      "postoperative day pod 14": 62746,
      "acute chronic pain opioid": 7623,
      "pain opioid consumption analgesic": 57282,
      "clinical trial registration clinicaltrials": 16933,
      "postoperative pain scores opioid": 62920,
      "prospective single center randomized": 65882,
      "randomized treatment groups group": 67198,
      "treatment groups group control": 82605,
      "morphine milligram equivalents consumed": 47771,
      "groups compared control group": 34149,
      "improve postoperative pain control": 37082,
      "additional oral morphine equivalents": 7876,
      "opioid prescribing level evidence": 52106,
      "prescribing level evidence level": 64075,
      "aim study compare analgesic": 9411,
      "study design prospective randomized": 78084,
      "30 mg iv ketorolac": 3760,
      "primary outcome measure proportion": 65070,
      "proportion patients reporting pain": 65774,
      "difference statistically significant conclusion": 24691,
      "surgery methods prospective randomized": 79468,
      "trial compared analgesic efficacy": 83009,
      "group showed significantly greater": 34008,
      "patients randomly assigned groups": 59750,
      "surgery 200 mg 12": 79301,
      "associated improved clinical outcomes": 12295,
      "reduces postoperative pain opioid": 69005,
      "targiniq": 80512,
      "targinact": 80509,
      "harder": 34574,
      "lumen": 42759,
      "radiolabelled": 66968,
      "2454": 3307,
      "satisfying": 73465,
      "streamlined": 77461,
      "475": 4675,
      "implies": 36973,
      "emollients": 28724,
      "elasticity": 28468,
      "microcirculation": 46349,
      "lsm": 42747,
      "napp": 48561,
      "3b": 4293,
      "fdc": 31279,
      "502": 4931,
      "prematurely": 63720,
      "euroqol": 29754,
      "3l": 4298,
      "springerlink": 76784,
      "474": 4674,
      "emptying": 28752,
      "gastroesophageal": 32861,
      "reflux": 69196,
      "cramping": 21125,
      "satisfactorily": 73446,
      "1322": 1524,
      "sds": 74099,
      "weakened": 86797,
      "dixon": 25630,
      "semiautomatic": 74517,
      "733": 5663,
      "i\u00b2": 40408,
      "counteracting": 20939,
      "hyperhidrosis": 36267,
      "intestine": 39700,
      "antegrade": 11100,
      "balloon": 13241,
      "pac": 56316,
      "sym": 79849,
      "algometry": 9565,
      "transverse": 82250,
      "lying": 42773,
      "crt": 21319,
      "preserving": 64721,
      "rectosigmoid": 68808,
      "secretory": 74267,
      "1343": 1531,
      "nntb": 49527,
      "721": 5637,
      "880": 6047,
      "707": 5580,
      "clarification": 16641,
      "familiarity": 31176,
      "alvimopan": 9756,
      "pamoras": 58055,
      "preventative": 64858,
      "adl": 8089,
      "396": 4287,
      "pcs": 60284,
      "281": 3582,
      "684": 5508,
      "crohn": 21242,
      "1378": 1538,
      "ebm": 27296,
      "undefined": 83497,
      "consortium": 19736,
      "review update": 72368,
      "available treating": 12846,
      "include opioid": 37360,
      "induced bowel": 38392,
      "possess limited": 62520,
      "targeted approach": 80494,
      "oxn tablet": 54433,
      "administration demonstrated": 8243,
      "important drug": 37005,
      "led discontinuation": 41335,
      "pr naloxone": 63337,
      "oxy analgesia": 54442,
      "reported phase": 70623,
      "iii studies": 36599,
      "constipation consistent": 19758,
      "doses important": 26201,
      "efficacy use": 28416,
      "associated frequently": 12266,
      "impacts patients": 36864,
      "address underlying": 7935,
      "therapy prolonged": 81054,
      "pr oxycodone": 63349,
      "patients benefit": 59034,
      "oxycodone pr": 55723,
      "targin targiniq": 80507,
      "targiniq targinact": 80513,
      "analgesics aim": 10374,
      "week randomized": 86868,
      "iii trials": 36603,
      "pain plus": 57381,
      "pr improved": 63330,
      "index compared": 38192,
      "additionally oxycodone": 7906,
      "pr generally": 63325,
      "pain comparative": 56573,
      "pr effective": 63323,
      "objectives opioids": 50575,
      "colonic motility": 17518,
      "bid oxycodone": 13786,
      "days segmental": 22621,
      "treatment higher": 82616,
      "ml compared": 46852,
      "treatment resulted": 82819,
      "bowel movements": 14286,
      "pr oral": 63344,
      "administered pr": 8170,
      "pain mainly": 57043,
      "week maintenance": 86846,
      "comparable placebo": 17968,
      "placebo 05": 61612,
      "doses naloxone": 26219,
      "naloxone ratio": 48512,
      "improvement bowel": 37146,
      "oxycodone gastrointestinal": 55111,
      "gastrointestinal gi": 32883,
      "transit time": 82197,
      "effect methods": 27485,
      "showed 20": 75226,
      "arrival time": 11704,
      "naloxone 20": 48425,
      "placebo difference": 61720,
      "geometric centre": 33120,
      "colonic transit": 17519,
      "time effect": 81257,
      "estimated incremental": 29627,
      "oxn treated": 54434,
      "oxy patients": 54460,
      "prospective non": 65839,
      "efficacy bowel": 28232,
      "observed cases": 50658,
      "registration trial": 69397,
      "final visit": 31751,
      "30 15": 3666,
      "opioid pretreated": 52218,
      "respectively efficacy": 71192,
      "reported good": 70547,
      "51 cases": 4954,
      "achieved good": 7318,
      "years methods": 87617,
      "cognitive functions": 17327,
      "screener opioid": 74035,
      "opioid assessment": 51548,
      "assessment patients": 12129,
      "revised score": 72425,
      "study long": 78292,
      "stable low": 76842,
      "profile particular": 65502,
      "pr oxn": 63346,
      "52 female": 4986,
      "use pr": 84640,
      "na\u00efve experienced": 48830,
      "week double": 86837,
      "group multicenter": 33867,
      "pooled primary": 62242,
      "pooled data": 62241,
      "efficacy observed": 28304,
      "subsequent time": 78782,
      "ae incidence": 8865,
      "groups 61": 34119,
      "pr provides": 63361,
      "pr improves": 63331,
      "efficacy trial": 28415,
      "needed postoperative": 49026,
      "product oxycodone": 65434,
      "undergoing spine": 83578,
      "89 oxycodone": 6060,
      "constipation 21": 19746,
      "days constipation": 22500,
      "baseline groups": 13436,
      "compared 44": 18081,
      "constipation significantly": 19786,
      "na\u00efve subjects": 48853,
      "naloxone beneficial": 48434,
      "use analgesic": 84192,
      "dummy parallel": 27130,
      "day oxn": 22351,
      "weeks efficacy": 86911,
      "assessments conducted": 12150,
      "sf scores": 75101,
      "rate analgesic": 67445,
      "pr overall": 63345,
      "evaluate tolerability": 29849,
      "mg pr": 46171,
      "measured opioid": 43981,
      "10 daily": 753,
      "spontaneous bowel": 76753,
      "conducted cancer": 19346,
      "results greater": 71705,
      "greater reductions": 33486,
      "week onwards": 86853,
      "approximately doubled": 11579,
      "25 decrease": 3354,
      "population reported": 62382,
      "naloxone represents": 48515,
      "reliable pain": 70085,
      "trial compares": 83011,
      "traditional opioid": 81986,
      "morphine mor": 47778,
      "healthcare research": 34804,
      "german pain": 33130,
      "centers germany": 15569,
      "patients adverse": 58960,
      "event related": 29990,
      "related study": 69683,
      "50 improvement": 4841,
      "function study": 32682,
      "oxn patients": 54419,
      "80 001": 5821,
      "23 001": 3067,
      "differences oxy": 24773,
      "intensity functional": 39258,
      "49 48": 4769,
      "tolerability lower": 81535,
      "efficacy oxy": 28314,
      "used relieving": 85112,
      "reporting efficacy": 70687,
      "safety outcome": 73182,
      "therapeutic area": 80921,
      "area great": 11630,
      "great unmet": 33416,
      "need combination": 48913,
      "combination tablet": 17610,
      "patients effective": 59235,
      "analgesia improving": 9999,
      "comorbidities requiring": 17937,
      "market tapentadol": 43416,
      "patients discontinuing": 59215,
      "discontinuing treatment": 25254,
      "rr 61": 72954,
      "pr vs": 63384,
      "reported effective": 70540,
      "intensity neuropathic": 39273,
      "efficacy quality": 28339,
      "clinical advantages": 16754,
      "transition time": 82205,
      "states treatment": 77154,
      "presence adverse": 64582,
      "effectiveness profile": 27776,
      "cost qaly": 20883,
      "case tap": 15213,
      "reduction drug": 69056,
      "visits pain": 86287,
      "relief assessed": 70102,
      "59 13": 5181,
      "significant clinically": 75445,
      "units 001": 83831,
      "significantly adverse": 75649,
      "mainstay management": 42875,
      "documented recent": 25666,
      "strategies treatment": 77427,
      "promising strategy": 65658,
      "alleviate chronic": 9593,
      "change pgic": 15742,
      "doses daily": 26168,
      "rescue paracetamol": 70974,
      "years 54": 87544,
      "97 completed": 6442,
      "completed weeks": 18514,
      "study limitations": 78288,
      "generalizability findings": 32993,
      "function reduced": 32675,
      "receiving increasing": 68343,
      "used present": 85086,
      "options combination": 53470,
      "efficacy objective": 28303,
      "review safety": 72355,
      "january 2002": 40418,
      "naloxone different": 48445,
      "demonstrates efficacy": 23377,
      "typically occur": 83393,
      "therapy introduction": 81022,
      "conducted western": 19423,
      "therapy randomized": 81056,
      "pr primary": 63356,
      "included safety": 37547,
      "scores comparable": 73848,
      "greater oxn": 33468,
      "mean lsm": 43785,
      "lsm difference": 42748,
      "similar non": 75955,
      "aes nausea": 8878,
      "dizziness vs": 25645,
      "pr provided": 63359,
      "severe musculoskeletal": 74954,
      "pain pre": 57402,
      "existing opioid": 30528,
      "pr formulation": 63324,
      "term post": 80661,
      "pr 10": 63303,
      "operatively oxycodone": 51275,
      "72 period": 5626,
      "constipation effects": 19762,
      "variables use": 85902,
      "72 post": 5627,
      "addition naloxone": 7815,
      "pr tablets": 63377,
      "targinact napp": 80510,
      "napp pharmaceuticals": 48562,
      "release combination": 69810,
      "receptors locally": 68545,
      "locally gut": 42219,
      "previous treatment": 64928,
      "design week": 23820,
      "phase 3b": 61273,
      "3b study": 4294,
      "belgium netherlands": 13578,
      "protocol population": 65988,
      "24 points": 3261,
      "pr significantly": 63370,
      "evaluated 24": 29855,
      "constipation results": 19781,
      "sd daily": 74077,
      "maximum 120": 43580,
      "180 mg": 2124,
      "mg bowel": 45809,
      "decrease seen": 22929,
      "new safety": 49370,
      "equivalent efficacy": 29309,
      "observed cancer": 50656,
      "mg provides": 46187,
      "effects dose": 27904,
      "cancer significance": 14912,
      "case 52": 15156,
      "randomised clinical": 67009,
      "pr methods": 63335,
      "intervention groups": 39634,
      "placebo following": 61729,
      "investigator global": 40081,
      "ranked good": 67371,
      "83 79": 5926,
      "compared 71": 18087,
      "71 patients": 5596,
      "groups dose": 34190,
      "patients preferred": 59664,
      "therapy severe": 81066,
      "tolerability background": 81519,
      "continue opioid": 20124,
      "pharmacokinetic results": 61148,
      "study multiple": 78318,
      "dose bioequivalence": 25835,
      "studies open": 77793,
      "crossover studies": 21297,
      "subjects randomly": 78730,
      "110 mg": 1162,
      "dose strength": 26081,
      "combined dose": 17644,
      "220 mg": 3049,
      "pr 40": 63306,
      "pr 20": 63305,
      "34 subjects": 4035,
      "treatments considered": 82905,
      "study visit": 78568,
      "44 years": 4550,
      "years weight": 87689,
      "75 kg": 5703,
      "kg body": 40697,
      "24 kg": 3239,
      "auc values": 12641,
      "mean max": 43788,
      "40 45": 4320,
      "45 128": 4564,
      "01 15": 292,
      "78 11": 5774,
      "kg significant": 40805,
      "24 ng": 3250,
      "pr tablet": 63376,
      "tablet respectively": 80100,
      "16 13": 1845,
      "option chronic": 53449,
      "presenting moderate": 64706,
      "nrs day": 50061,
      "results 53": 71573,
      "patients 71": 58895,
      "score 26": 73721,
      "001 reduced": 196,
      "activities brief": 7546,
      "pr considered": 63319,
      "population warrants": 62399,
      "investigation randomized": 40073,
      "aging population": 9264,
      "elderly opioid": 28475,
      "treatment defined": 82544,
      "women severe": 87246,
      "0001 use": 82,
      "decreased 15": 22942,
      "condition significantly": 19286,
      "population increases": 62343,
      "drugs despite": 26931,
      "low systemic": 42559,
      "opioids prolonged": 53229,
      "consisting oxycodone": 19726,
      "use sole": 84740,
      "evidence related": 30252,
      "pr showed": 63369,
      "equivalent analgesic": 29290,
      "bfi pain": 13757,
      "5d 3l": 5204,
      "28 reduction": 3568,
      "reduction control": 69052,
      "range groups": 67317,
      "favor oxn": 31256,
      "pr superior": 63373,
      "superior effectiveness": 79125,
      "reactions compared": 67958,
      "groups used": 34343,
      "used controlled": 84898,
      "experimental study": 30675,
      "transit times": 82198,
      "times colonic": 81416,
      "correlated self": 20817,
      "study treatments": 78548,
      "treatments oxycodone": 82920,
      "placebo objective": 61783,
      "05 discussion": 514,
      "symptoms controlled": 79879,
      "groups subjective": 34332,
      "symptoms experienced": 79886,
      "assessed introduction": 12013,
      "efficacy demonstrated": 28246,
      "month retrospective": 47410,
      "scale rescue": 73549,
      "completed months": 18474,
      "intensity 001": 39216,
      "pgic score": 60999,
      "clinical differences": 16791,
      "naloxone effective": 48447,
      "relief bowel": 70104,
      "daily management": 21752,
      "options limited": 53473,
      "previous medication": 64905,
      "supplementary material": 79168,
      "available springerlink": 12839,
      "label oxn": 40980,
      "pr 52": 63309,
      "extension phases": 30912,
      "phases studies": 61329,
      "using average": 85319,
      "results improvement": 71722,
      "meaningful reduction": 43918,
      "29 26": 3598,
      "26 24": 3427,
      "conclusions inferences": 19101,
      "gastroesophageal reflux": 32862,
      "patients management": 59475,
      "intensity quality": 39295,
      "euroqol dimensions": 29756,
      "209 patients": 2929,
      "efficacy mean": 28290,
      "characteristics data": 15854,
      "12 81": 1262,
      "individual patients": 38306,
      "admitted patients": 8431,
      "administered patient": 8163,
      "naloxone versus": 48530,
      "groups validity": 34345,
      "validity responsiveness": 85804,
      "23 29": 3078,
      "range 26": 67277,
      "score change": 73734,
      "change 12": 15714,
      "analyses clinical": 10585,
      "control bowel": 20278,
      "known cause": 40903,
      "randomised open": 67026,
      "patients titrated": 60047,
      "13 0001": 1445,
      "discharge discussion": 25118,
      "study phase": 78407,
      "phase showed": 61319,
      "ratio combination": 67765,
      "used relief": 85107,
      "embase web": 28654,
      "patients prolonged": 59708,
      "severity duration": 75038,
      "decreases incidence": 23057,
      "intermediate term": 39451,
      "severity patient": 75047,
      "16 19": 1848,
      "pain pr": 57400,
      "added benefit": 7729,
      "trials patient": 83178,
      "constipation reported": 19780,
      "15 weeks": 1800,
      "using work": 85681,
      "work productivity": 87283,
      "productivity activity": 65439,
      "activity impairment": 7568,
      "impairment questionnaire": 36905,
      "using bayesian": 85321,
      "ratio 40": 67735,
      "tapentadol associated": 80385,
      "time missed": 81293,
      "lower overall": 42663,
      "informed medical": 38681,
      "efficacy fixed": 28270,
      "extension studies": 30913,
      "previously completed": 64936,
      "59 12": 5180,
      "sleep interference": 76225,
      "interference bpi": 39421,
      "score sd": 73783,
      "27 74": 3483,
      "20 24": 2279,
      "24 01": 3141,
      "relevant improvements": 70059,
      "trial assessed": 83002,
      "assessed safety": 12059,
      "constipation study": 19789,
      "multicenter trial": 48173,
      "secondary exploratory": 74230,
      "groups consistent": 34164,
      "consistent expected": 19696,
      "limited dose": 41925,
      "recommended management": 68625,
      "potentially cause": 63251,
      "bioavailability patients": 13841,
      "hospital inpatients": 35595,
      "dose milligrams": 25960,
      "received average": 68119,
      "receiving doses": 68332,
      "trials phase": 83183,
      "assessed impact": 12009,
      "combination patients": 17597,
      "265 patients": 3465,
      "11 0001": 1085,
      "furthermore improvements": 32748,
      "consistent reported": 19715,
      "new unexpected": 49385,
      "reactions attributable": 67955,
      "targeted treatment": 80500,
      "using search": 85603,
      "mg 80": 45772,
      "measures subjective": 44100,
      "subjective experience": 78654,
      "factors methods": 31117,
      "days assessed": 22488,
      "strong association": 77512,
      "received active": 68112,
      "reached significance": 67938,
      "evaluate long": 29813,
      "blind db": 13933,
      "form low": 32283,
      "period improvement": 60734,
      "week db": 86835,
      "db phase": 22661,
      "intravenous midazolam": 39856,
      "midazolam intravenous": 46394,
      "extreme caution": 30980,
      "blinded crossover": 13998,
      "23 kg": 3098,
      "kg range": 40795,
      "25 known": 3359,
      "subjects treated": 78747,
      "measures mixed": 44066,
      "mixed models": 46801,
      "13 ml": 1491,
      "increase 24": 37721,
      "2019 50": 2854,
      "setting thirty": 74838,
      "requirement discharge": 70871,
      "month results": 47409,
      "opioids month": 53063,
      "surgery related": 79559,
      "acting non": 7395,
      "secondary effects": 74213,
      "rescue antiemetics": 70942,
      "used did": 84915,
      "grade intensity": 33376,
      "future study": 32777,
      "events treatment": 30129,
      "update cochrane": 83976,
      "receiving palliative": 68370,
      "rcts assessed": 67911,
      "authors assessed": 12718,
      "data trials": 22147,
      "trials primary": 83184,
      "oxycodone subcutaneous": 55949,
      "74 moderate": 5675,
      "mg rr": 46209,
      "events moderate": 30071,
      "analysis trials": 10782,
      "hours rr": 35844,
      "19 placebo": 2192,
      "events trials": 30130,
      "rr 82": 72989,
      "evidence suggest": 30264,
      "did assess": 24411,
      "hours weeks": 35877,
      "does increase": 25679,
      "current trials": 21485,
      "effects children": 27846,
      "multiple studies": 48300,
      "pivotal studies": 61571,
      "trials demonstrated": 83134,
      "80 120": 5824,
      "trials described": 83135,
      "approved countries": 11532,
      "analgesics adults": 10371,
      "counteracting opioid": 20940,
      "week clinical": 86832,
      "noninferior analgesia": 49742,
      "analgesia improvements": 9998,
      "world studies": 87316,
      "reported commonly": 70523,
      "commonly occurring": 17856,
      "option consider": 53451,
      "naloxone available": 48433,
      "oxycodone oxn": 55595,
      "review available": 72263,
      "literature conducted": 42114,
      "gi events": 33143,
      "practice observations": 63406,
      "pr combination": 63316,
      "allow patients": 9634,
      "crossover trials": 21311,
      "long fast": 42313,
      "fast antegrade": 31201,
      "shorter oxycodone": 75213,
      "time faster": 81261,
      "placebo 40": 61633,
      "mainly caused": 42871,
      "include physical": 37366,
      "fluid intake": 31942,
      "form opioid": 32287,
      "daily placebo": 21799,
      "placebo baseline": 61664,
      "furthermore functional": 32747,
      "probe used": 65229,
      "pac sym": 56317,
      "regulate opioid": 69491,
      "efficacy regarding": 28342,
      "function efficacy": 32643,
      "safety analgesic": 73119,
      "conclusion treatment": 19015,
      "multifaceted approach": 48185,
      "designed address": 23825,
      "trials observational": 83170,
      "evidence clinical": 30174,
      "tailored individual": 80261,
      "dose absence": 25817,
      "relevant dose": 70054,
      "related non": 69640,
      "laxative therapy": 41256,
      "therapy research": 81061,
      "modes action": 47221,
      "completed randomized": 18490,
      "20 120": 2273,
      "respectively use": 71257,
      "sd reduction": 74094,
      "pain 23": 56376,
      "treatment aims": 82437,
      "function gastrointestinal": 32648,
      "evaluated treatment": 29925,
      "001 14": 98,
      "002 number": 239,
      "intestinal effects": 39698,
      "demonstrated association": 23331,
      "type iii": 83329,
      "influence different": 38589,
      "prevalent oxycodone": 64833,
      "prevalent patients": 64835,
      "using propensity": 85578,
      "decreased points": 23028,
      "responder rates": 71319,
      "improved baseline": 37098,
      "days 60": 22475,
      "events 28": 30005,
      "component score": 18587,
      "score points": 73772,
      "respectively 001": 71146,
      "similar oxy": 75965,
      "investigated background": 40034,
      "present significant": 64640,
      "population remains": 62381,
      "58 female": 5158,
      "non responsive": 49678,
      "conclusion pilot": 18962,
      "current knowledge": 21442,
      "knowledge pathophysiology": 40891,
      "volunteers controlled": 86417,
      "setting highly": 74778,
      "pressure algometry": 64738,
      "using questionnaires": 85585,
      "scale patient": 73539,
      "middle low": 46406,
      "surgery median": 79458,
      "14 12": 1551,
      "independent predictor": 38162,
      "tolerated oxycodone": 81635,
      "low osteoarthritis": 42514,
      "analyses using": 10620,
      "10 trial": 947,
      "day trial": 22437,
      "statistics results": 77248,
      "showed tapentadol": 75318,
      "placebo better": 61665,
      "ir including": 40234,
      "05 lower": 522,
      "discussion patient": 25306,
      "function associated": 32632,
      "allows easy": 9648,
      "relative contribution": 69741,
      "randomised cross": 67019,
      "transport parameters": 82240,
      "change occurred": 15735,
      "occurred placebo": 50843,
      "treatments 05": 82895,
      "poor adherence": 62254,
      "patients performed": 59644,
      "years 66": 87555,
      "66 percent": 5458,
      "tapentadol 37": 80378,
      "37 percent": 4203,
      "29 21": 3596,
      "severe constipation": 74940,
      "dose treatment": 26103,
      "dose hydromorphone": 25924,
      "hydromorphone associated": 36157,
      "profile favorable": 65488,
      "doses average": 26151,
      "consecutive visits": 19570,
      "11 50": 1114,
      "42 percent": 4472,
      "function severe": 32680,
      "naloxone fentanyl": 48449,
      "included 10": 37373,
      "reported oral": 70601,
      "medium term": 44725,
      "threefold greater": 81147,
      "rr 00": 72882,
      "outcome nntb": 53958,
      "nntb 95": 49528,
      "reported low": 70576,
      "rr 34": 72922,
      "13 15": 1453,
      "dose risk": 26070,
      "85 25": 5977,
      "rr 25": 72913,
      "intensity low": 39262,
      "13 trials": 1509,
      "76 13": 5735,
      "mg greater": 45898,
      "10 39": 706,
      "26 participants": 3450,
      "84 34": 5953,
      "evidence authors": 30146,
      "low trials": 42561,
      "children opioid": 16061,
      "60 treated": 5280,
      "demonstrates significant": 23381,
      "comparison patients": 18374,
      "carefully considered": 15109,
      "endpoint incidence": 28889,
      "prevention opioid": 64879,
      "vomiting background": 86448,
      "nonmalignant chronic": 49764,
      "2001 20": 2428,
      "usage long": 84120,
      "use adjusted": 84175,
      "review recommended": 72352,
      "common oral": 17786,
      "perspective methods": 60968,
      "antiemetic laxative": 11187,
      "opioid index": 51846,
      "gamma regression": 32826,
      "97 vs": 6447,
      "05 vs": 562,
      "00 days": 13,
      "months index": 47447,
      "total health": 81807,
      "morbidity patients": 47516,
      "received immediate": 68160,
      "outcome follow": 53917,
      "postoperative orders": 62832,
      "obstruction patients": 50745,
      "conclusion immediate": 18911,
      "large extent": 41127,
      "significantly impair": 75743,
      "traditional oral": 81988,
      "45 50": 4571,
      "symptoms frequently": 79889,
      "management issues": 43194,
      "psychological social": 66344,
      "analgesic adjuvant": 10144,
      "step analgesic": 77320,
      "equianalgesic dosing": 29262,
      "constipation opioid": 19774,
      "likely suffer": 41845,
      "secondary aim": 74203,
      "agouti da": 9344,
      "assigned treatments": 12184,
      "severity recorded": 75048,
      "controls 03": 20664,
      "03 addition": 414,
      "review chronic": 72272,
      "pathophysiology diagnosis": 58509,
      "use appears": 84202,
      "tramadol based": 82036,
      "study showing": 78496,
      "lacking background": 41065,
      "possible mechanism": 62539,
      "according presumed": 7057,
      "provide satisfactory": 66098,
      "satisfactory relief": 73455,
      "relief review": 70180,
      "treatment noncancer": 82684,
      "shown attenuate": 75329,
      "induced motor": 38425,
      "summary availability": 79094,
      "review opioid": 72327,
      "difficult diagnose": 24963,
      "antagonists pamoras": 11082,
      "novel therapies": 50025,
      "results 130": 71544,
      "life higher": 41697,
      "effects gastrointestinal": 27931,
      "english text": 28945,
      "text version": 80888,
      "version article": 86084,
      "ii clinical": 36555,
      "developed treatment": 24196,
      "affecting central": 8925,
      "patient using": 58810,
      "mental behavioral": 44812,
      "examine efficacy": 30341,
      "iii randomized": 36592,
      "studies subjects": 77853,
      "days diagnosed": 22512,
      "overall treatment": 54262,
      "improvement baseline": 37145,
      "symptoms examined": 79885,
      "oxycodone 159": 54524,
      "mean changes": 43734,
      "0001 increased": 64,
      "analyses patients": 10600,
      "dose 200": 25796,
      "interference opioid": 39425,
      "baseline maintenance": 13439,
      "controlled phase": 20517,
      "studies setting": 77841,
      "centers united": 15576,
      "response criteria": 71338,
      "weeks weeks": 86968,
      "increases proportion": 38079,
      "response 12": 71331,
      "efficacy results": 28352,
      "event incidences": 29984,
      "generally comparable": 33013,
      "groups regardless": 34292,
      "conclusion post": 18966,
      "mg showed": 46215,
      "efficacy treating": 28413,
      "impact health": 36812,
      "hrqol design": 35901,
      "day prospective": 22395,
      "registry setting": 69408,
      "pain months": 57212,
      "measurements modified": 44024,
      "scale 12": 73487,
      "12 item": 1311,
      "physical pcs": 61408,
      "pcs mental": 60285,
      "28 repeated": 3569,
      "models provided": 47126,
      "provided estimates": 66134,
      "estimates impact": 29648,
      "hrqol results": 35902,
      "points opioid": 62136,
      "analyzed including": 10834,
      "achievement adequate": 7330,
      "control long": 20359,
      "day duration": 22307,
      "duration adequate": 27149,
      "sum test": 79080,
      "models statistical": 47131,
      "30 24": 3681,
      "22 17": 3012,
      "76 patients": 5744,
      "median nrs": 44249,
      "18 52": 2053,
      "vs 71": 86613,
      "002 non": 238,
      "21 11": 2937,
      "complex medical": 18529,
      "pain extremely": 56774,
      "crohn disease": 21243,
      "pain clear": 56548,
      "challenge clinical": 15691,
      "medications provide": 44664,
      "provide relief": 66095,
      "various adverse": 85959,
      "interventions potential": 39679,
      "abuse constipation": 6667,
      "64 50": 5382,
      "50 51": 4814,
      "medications necessary": 44648,
      "guide treatment": 34409,
      "set analyze": 74754,
      "used included": 84971,
      "studies considered": 77679,
      "according criteria": 7042,
      "evaluation psychological": 29965,
      "minimize adverse": 46595,
      "medications clinical": 44601,
      "analysis published": 10749,
      "doses highest": 26198,
      "efficacy based": 28230,
      "endpoints including": 28912,
      "number spontaneous": 50258,
      "analysis combination": 10651,
      "trials low": 83155,
      "diverse patient": 25584,
      "efficacy lower": 28289,
      "therapeutic response": 80960,
      "analgesics increasing": 10438,
      "number types": 50272,
      "analgesic products": 10303,
      "available increasing": 12815,
      "affect quality": 8911,
      "additional factors": 7862,
      "comorbidities concomitant": 17935,
      "limited utility": 41967,
      "pain dose": 56731,
      "appropriate line": 11502,
      "associations use": 12503,
      "gastric emptying": 32854,
      "life health": 41696,
      "relative oral": 69756,
      "upper gastrointestinal": 84005,
      "gastrointestinal disorders": 32876,
      "effects diabetic": 27891,
      "05 opioid": 531,
      "use antiemetic": 84197,
      "upper abdominal": 83998,
      "patients diabetic": 59187,
      "basis studies": 13480,
      "opioid induced bowel": 51855,
      "induced bowel dysfunction": 38393,
      "naloxone oxn tablet": 48479,
      "bowel function oxycodone": 14279,
      "function compared oxycodone": 32638,
      "minimizing opioid related": 46606,
      "release pr naloxone": 69989,
      "reported phase ii": 70624,
      "phase iii studies": 61298,
      "release oxycodone plus": 69967,
      "oxycodone plus naloxone": 55697,
      "impacts patients quality": 36865,
      "effective treatment options": 27720,
      "release pr oxycodone": 69991,
      "pr oxycodone pr": 63352,
      "oxycodone pr naloxone": 55727,
      "pr naloxone targin": 63342,
      "naloxone targin targiniq": 48523,
      "targin targiniq targinact": 80508,
      "opioid analgesics aim": 51482,
      "12 week randomized": 1374,
      "week randomized double": 86869,
      "blind phase iii": 13948,
      "phase iii trials": 61301,
      "iii trials patients": 36604,
      "trials patients moderate": 83180,
      "naloxone pr generally": 48490,
      "pr generally tolerated": 63326,
      "frequently reported adverse": 32576,
      "naloxone pr group": 48492,
      "pr group compared": 63328,
      "group compared oxycodone": 33689,
      "chronic pain particularly": 16297,
      "50 mg bid": 4851,
      "mg bid oxycodone": 45805,
      "10 mg bid": 803,
      "14 days segmental": 1593,
      "gastrointestinal effects assessed": 32878,
      "tapentadol oxycodone treatment": 80457,
      "pain treatment background": 57936,
      "blinded study evaluated": 14021,
      "study evaluated analgesic": 78177,
      "evaluated analgesic efficacy": 29863,
      "release pr oral": 69990,
      "bowel function assessed": 14267,
      "40 mg naloxone": 4351,
      "phase compared placebo": 61278,
      "oxycodone naloxone ratio": 55517,
      "improvement bowel function": 37147,
      "study healthy volunteers": 78226,
      "effect single doses": 27561,
      "single doses oxycodone": 76097,
      "received oxycodone 10": 68231,
      "oxycodone naloxone 20": 55491,
      "mg versus oxycodone": 46257,
      "mg compared placebo": 45829,
      "10 mg significantly": 847,
      "significantly reduced mean": 75845,
      "data phase iii": 22046,
      "cost pain therapy": 20882,
      "probabilistic sensitivity analyses": 65213,
      "analyses performed results": 10602,
      "estimated incremental cost": 29628,
      "pr oxycodone naloxone": 63350,
      "study analgesic efficacy": 77949,
      "analgesic efficacy bowel": 10230,
      "efficacy bowel function": 28233,
      "function assessed patients": 32630,
      "evaluated using brief": 29930,
      "inventory bpi sf": 39977,
      "pain 24 hours": 56378,
      "opioid pretreated patients": 52219,
      "0001 mean daily": 67,
      "dose oxycodone increased": 25992,
      "screener opioid assessment": 74036,
      "opioid assessment patients": 51549,
      "assessment patients pain": 12130,
      "patients pain revised": 59623,
      "low risk aberrant": 42552,
      "bowel function patients": 14280,
      "naloxone pr oxn": 48495,
      "12 week double": 1371,
      "week double blind": 86838,
      "parallel group multicenter": 58132,
      "pr naloxone pr": 63338,
      "naloxone pr oxycodone": 48496,
      "naloxone pr versus": 48501,
      "pr versus oxycodone": 63382,
      "versus oxycodone pr": 86146,
      "mg day results": 45864,
      "day results statistically": 22407,
      "patients main outcome": 59466,
      "patients undergoing spine": 60127,
      "opioid na\u00efve subjects": 51994,
      "analgesia compared oxycodone": 9932,
      "pain methods randomized": 57188,
      "double dummy parallel": 26406,
      "dummy parallel group": 27131,
      "form bpi sf": 32278,
      "score significantly lower": 73793,
      "bpi sf scores": 14302,
      "containing oxycodone naloxone": 20083,
      "evaluate tolerability efficacy": 29850,
      "methods patients randomised": 45435,
      "spontaneous bowel movements": 76755,
      "conducted cancer patients": 19347,
      "results greater reductions": 71706,
      "mean change baseline": 43732,
      "compared equivalent doses": 18153,
      "providing comparable analgesic": 66256,
      "comparable analgesic efficacy": 17950,
      "using oxycodone naloxone": 85545,
      "acting formulation oxycodone": 7384,
      "combination opioid analgesic": 17578,
      "reliable pain control": 70086,
      "safety tolerability oxycodone": 73233,
      "low pain randomized": 42529,
      "adverse event related": 8714,
      "50 improvement pain": 4842,
      "bowel function study": 14283,
      "pain intensity functional": 56907,
      "associated significantly better": 12433,
      "better tolerability lower": 13741,
      "adverse effects particularly": 8684,
      "therapeutic area great": 80922,
      "area great unmet": 11631,
      "great unmet need": 33417,
      "unmet need combination": 83907,
      "need combination tablet": 48914,
      "patients effective analgesia": 59236,
      "effective analgesia improving": 27590,
      "analgesia improving opioid": 10000,
      "improving opioid induced": 37196,
      "percentage patients discontinuing": 60511,
      "patients discontinuing treatment": 59216,
      "low pain neuropathic": 42525,
      "reducing pain intensity": 69026,
      "pain intensity neuropathic": 56917,
      "analgesic efficacy quality": 10245,
      "patient data results": 58603,
      "pain relief assessed": 57523,
      "daily dose 20": 21723,
      "mainstay management patients": 42876,
      "pain analgesic efficacy": 56446,
      "analgesic efficacy opioid": 10239,
      "effective management opioid": 27638,
      "provided effective analgesia": 66130,
      "analgesic effectiveness tolerability": 10213,
      "adult patients treated": 8518,
      "pain intensity numerical": 56919,
      "impression change pgic": 37051,
      "need rescue analgesics": 48954,
      "study limitations study": 78289,
      "bowel function reduced": 14281,
      "relatively low doses": 69783,
      "release oxycodone effective": 69933,
      "objective review safety": 50488,
      "treatment patients experiencing": 82748,
      "different patient groups": 24905,
      "chronic pain using": 16325,
      "function patients moderate": 32666,
      "clock opioid therapy": 17055,
      "opioid therapy randomized": 52423,
      "greater oxn pr": 33469,
      "squares mean lsm": 76805,
      "mean lsm difference": 43786,
      "lsm difference 95": 42749,
      "pain scores week": 57796,
      "related aes nausea": 69558,
      "moderate severe musculoskeletal": 47184,
      "severe musculoskeletal pain": 74955,
      "release pr formulation": 69988,
      "clinical effects oxycodone": 16800,
      "short term post": 75198,
      "term post operative": 80662,
      "oxycodone pr 10": 55724,
      "pr 10 mg": 63304,
      "10 mg naloxone": 828,
      "24 post operatively": 3265,
      "post operatively oxycodone": 62611,
      "oxycodone tablets 24": 55978,
      "operative days results": 51251,
      "addition naloxone oxycodone": 7816,
      "naloxone oxycodone pr": 48482,
      "targinact napp pharmaceuticals": 80511,
      "action oxycodone opioid": 7443,
      "oxycodone opioid receptors": 55574,
      "opioid receptors locally": 52274,
      "receptors locally gut": 68546,
      "design week open": 23821,
      "label phase 3b": 40987,
      "phase 3b study": 61274,
      "24 points 95": 3262,
      "known opioid related": 40921,
      "events conclusion study": 30029,
      "patients previously treated": 59698,
      "naloxone pr significantly": 48498,
      "80 mg methods": 5851,
      "label extension phase": 40975,
      "randomized comparative study": 67054,
      "mean sd daily": 43862,
      "mg bowel function": 45810,
      "average pain 24": 12921,
      "new safety concerns": 49371,
      "observed cancer patients": 50657,
      "80 mg oxycodone": 5852,
      "peripherally acting mu": 60889,
      "case 52 year": 15157,
      "randomised clinical trial": 67010,
      "oxycodone administered oral": 54687,
      "naloxone pr methods": 48494,
      "patients followed weeks": 59313,
      "phase patients investigators": 61308,
      "patient investigator global": 58668,
      "patients receiving placebo": 59855,
      "oxycodone pr improves": 55726,
      "management adverse events": 43149,
      "results single dose": 71960,
      "single dose study": 76094,
      "study multiple dose": 78319,
      "studies open label": 77794,
      "male female subjects": 43035,
      "study subjects randomly": 78518,
      "subjects randomly assigned": 78732,
      "pr 40 mg": 63307,
      "multiple dose study": 48273,
      "kg body mass": 40698,
      "oxycodone concentration time": 54827,
      "mean max values": 43789,
      "sd age 36": 74072,
      "24 ng ml": 3251,
      "findings consistent results": 31777,
      "presenting moderate severe": 64707,
      "scale nrs day": 73514,
      "events assessed results": 30013,
      "assessed results 53": 12052,
      "patients enrolled mean": 59249,
      "daily activities brief": 21693,
      "activities brief pain": 7547,
      "oxn pr considered": 54424,
      "severe pain pain": 74994,
      "patients patients methods": 59637,
      "response treatment defined": 71379,
      "mean average pain": 43722,
      "dose 11 mg": 25786,
      "paracetamol nonsteroidal anti": 58107,
      "opioids prolonged release": 53230,
      "formulation consisting oxycodone": 32337,
      "analgesic effect compared": 10198,
      "efficacy compared oxycodone": 28238,
      "study total 162": 78545,
      "index bfi pain": 38189,
      "eq 5d 3l": 29225,
      "group patients experienced": 33903,
      "favor oxn pr": 31257,
      "pr superior effectiveness": 63374,
      "transit times colonic": 82199,
      "correlated self reported": 20818,
      "subgroup analyses performed": 78616,
      "completed months treatment": 18475,
      "pain intensity 001": 56878,
      "001 vs baseline": 225,
      "daily management chronic": 21753,
      "open label oxn": 51168,
      "label oxn pr": 40981,
      "analgesic effect background": 10197,
      "starting dose 10": 77015,
      "pain intensity quality": 56931,
      "intensity quality life": 39296,
      "using data clinical": 85370,
      "oxycodone naloxone versus": 55524,
      "placebo group included": 61742,
      "known groups validity": 40912,
      "data clinical trials": 21905,
      "analyses clinical trials": 10586,
      "treatment oxycodone naloxone": 82728,
      "randomised open label": 67027,
      "05 results patients": 547,
      "included mean age": 37479,
      "period 14 days": 60683,
      "recent studies indicated": 68425,
      "prolonged release extended": 65622,
      "pubmed embase web": 66450,
      "embase web science": 28655,
      "patients oxn pr": 59609,
      "patients prolonged release": 59709,
      "clinically meaningful difference": 16984,
      "addition pain relief": 7823,
      "dose combination prolonged": 25844,
      "double blind controlled": 26344,
      "patients exposed opioids": 59292,
      "weeks double blinded": 86909,
      "using work productivity": 85682,
      "work productivity activity": 87284,
      "productivity activity impairment": 65440,
      "activity impairment questionnaire": 7569,
      "odds ratio 40": 50917,
      "ratio 40 95": 67736,
      "pain study design": 57875,
      "label extension studies": 40976,
      "studies patients previously": 77807,
      "blind study received": 13984,
      "assessed pain using": 12031,
      "sleep interference bpi": 76226,
      "observed conclusion results": 50666,
      "term efficacy tolerability": 80631,
      "combination oxycodone pr": 17593,
      "clinically relevant improvements": 16993,
      "iii clinical trial": 36582,
      "clinical trial assessed": 16922,
      "trial assessed safety": 83003,
      "assessed safety efficacy": 12060,
      "ratio combination oxycodone": 67766,
      "range 20 mg": 67268,
      "12 weeks primary": 1384,
      "consistent expected opioid": 19697,
      "expected opioid analgesics": 30556,
      "naloxone pr superior": 48500,
      "pr superior oxycodone": 63375,
      "randomised clinical trials": 67011,
      "analgesic efficacy oral": 10241,
      "design retrospective case": 23782,
      "participants eighty patients": 58299,
      "patients receiving doses": 59837,
      "received similar number": 68270,
      "study assessed impact": 77973,
      "scores comparable groups": 73849,
      "adverse reactions attributable": 8839,
      "common opioid adverse": 17778,
      "oxycodone provides analgesia": 55784,
      "search performed using": 74123,
      "oxycodone naloxone opioid": 55507,
      "mg 80 mg": 45773,
      "received placebo tapentadol": 68247,
      "objective subjective measures": 50524,
      "evaluate long term": 29814,
      "double blind db": 26352,
      "double blinded crossover": 26392,
      "23 kg range": 3099,
      "release oxycodone placebo": 69965,
      "intraclass correlation coefficients": 39733,
      "repeated measures mixed": 70415,
      "measures mixed models": 44067,
      "compared placebo mean": 18268,
      "oxycodone treatment compared": 56028,
      "treatment compared placebo": 82509,
      "center prospective observational": 15543,
      "measures pain scores": 44079,
      "measures primary end": 44087,
      "study participants 12": 78360,
      "major adverse events": 42929,
      "adverse events treatment": 8820,
      "receiving palliative care": 68371,
      "trials rcts assessed": 83187,
      "bias extracted data": 13766,
      "impact pain relief": 36834,
      "relief primary outcome": 70173,
      "naloxone did increase": 48444,
      "adverse events moderate": 8773,
      "events moderate quality": 30072,
      "quality evidence difference": 66692,
      "adverse events trials": 8821,
      "rr 82 95": 72990,
      "120 mg oxycodone": 1407,
      "80 120 mg": 5825,
      "gastrointestinal gi tract": 32884,
      "counteracting opioid induced": 20941,
      "12 week clinical": 1370,
      "pr significantly improved": 63371,
      "real world studies": 68009,
      "useful treatment option": 85219,
      "effects prolonged release": 28114,
      "oxycodone oxn pr": 55596,
      "pr management chronic": 63333,
      "clinical practice observations": 16867,
      "long fast antegrade": 42314,
      "time faster oxycodone": 81262,
      "blind randomized crossover": 13973,
      "randomized crossover trial": 67093,
      "improvement quality life": 37163,
      "approach pain management": 11470,
      "euphoric effects oxycodone": 29728,
      "effects oxycodone methods": 28069,
      "trials observational studies": 83171,
      "pain musculoskeletal pain": 57221,
      "evidence clinical trials": 30175,
      "lowest effective dose": 42732,
      "clinically relevant dose": 16991,
      "completed randomized double": 18491,
      "oxn pr 20": 54421,
      "20 120 mg": 2274,
      "day 12 weeks": 22243,
      "mean sd reduction": 43872,
      "pr provided effective": 63360,
      "analgesia patients moderate": 10050,
      "effects opioids objective": 28044,
      "compared different opioids": 18140,
      "median 24 hour": 44180,
      "reducing opioid dose": 69022,
      "reducing opioid related": 69023,
      "opioid related gastrointestinal": 52313,
      "groups pain intensity": 34259,
      "rates similar groups": 67637,
      "overall incidence drug": 54207,
      "significantly greater extent": 75708,
      "form 36 physical": 32270,
      "physical component score": 61385,
      "001 conclusion patients": 119,
      "chronic pain received": 16309,
      "conclusion pilot study": 18963,
      "healthy volunteers controlled": 34852,
      "results compared baseline": 71637,
      "functional outcomes patients": 32709,
      "year surgery median": 87506,
      "better tolerated oxycodone": 13743,
      "90 day trial": 6092,
      "showed tapentadol ir": 75319,
      "lower tapentadol ir": 42711,
      "tapentadol ir treatment": 80434,
      "associated tapentadol ir": 12452,
      "placebo controlled randomised": 61695,
      "adverse effects assessed": 8641,
      "common adverse effect": 17729,
      "adverse effect opioid": 8630,
      "effect opioid analgesic": 27505,
      "morphine oxycodone controlled": 47817,
      "oxycodone controlled clinical": 54881,
      "oxycodone naloxone hydromorphone": 55503,
      "equivalent dose treatment": 29306,
      "conclusions patients receiving": 19156,
      "term treatment opioids": 80674,
      "non opioid users": 49657,
      "bowel function severe": 14282,
      "oxycodone naloxone fentanyl": 55501,
      "rr 00 95": 72883,
      "00 95 confidence": 11,
      "interval ci 59": 39594,
      "beneficial outcome nntb": 13601,
      "nntb 95 ci": 49529,
      "rr 34 95": 72923,
      "evidence low dose": 30221,
      "mg rr 25": 46210,
      "rr 25 95": 72914,
      "naloxone versus placebo": 48531,
      "ci 84 34": 16501,
      "evidence authors conclusions": 30147,
      "spontaneous bowel movement": 76754,
      "primary endpoint incidence": 65026,
      "incidence opioid induced": 37291,
      "constipation significantly lower": 19787,
      "nausea vomiting background": 48792,
      "design study conducted": 23808,
      "pain patients received": 57356,
      "opioids transdermal fentanyl": 53350,
      "fentanyl oxycodone hcl": 31551,
      "malignant nonmalignant chronic": 43098,
      "nonmalignant chronic pain": 49765,
      "usage long acting": 84121,
      "patients followed months": 59312,
      "compared results total": 18298,
      "opioid use adjusted": 52468,
      "compared receiving oxycodone": 18290,
      "adverse effects common": 8646,
      "oxycodone hydrocodone containing": 55205,
      "patients analyzed patients": 58994,
      "mean total health": 43890,
      "total health care": 81808,
      "opioid treatment significant": 52453,
      "patients received immediate": 59783,
      "morphine oxycodone naloxone": 47841,
      "hydrocodone oxycodone codeine": 36112,
      "action opioid analgesics": 7438,
      "secondary aim determine": 74204,
      "dark agouti da": 21837,
      "kg oral gavage": 40771,
      "175 mg kg": 2013,
      "patients receiving naloxone": 59849,
      "opioid use common": 52481,
      "cancer receiving opioids": 14903,
      "provide satisfactory relief": 66099,
      "pain control bowel": 56606,
      "receptor antagonists pamoras": 68479,
      "english text version": 28946,
      "text version article": 80889,
      "efficacy pain control": 28321,
      "phase ii clinical": 61285,
      "ii clinical trial": 36556,
      "adverse effects main": 8661,
      "examine efficacy safety": 30342,
      "design data pooled": 23710,
      "phase iii randomized": 61296,
      "iii randomized double": 36593,
      "12 weeks treatment": 1388,
      "vs placebo patients": 86673,
      "event profile similar": 29987,
      "generally tolerated treatment": 33033,
      "defined post hoc": 23147,
      "pooled analysis data": 62239,
      "data 12 week": 21843,
      "placebo controlled phase": 61693,
      "controlled phase studies": 20520,
      "centers united states": 15577,
      "mg versus placebo": 46258,
      "adverse event incidences": 8709,
      "impact health related": 36813,
      "registry setting outpatient": 69409,
      "setting outpatient settings": 74795,
      "outpatient settings participants": 54144,
      "12 item short": 1312,
      "survey sf 12": 79738,
      "physical pcs mental": 61409,
      "pcs mental component": 60286,
      "21 28 repeated": 2948,
      "28 repeated measures": 3570,
      "mixed models provided": 46802,
      "models provided estimates": 47127,
      "provided estimates impact": 66135,
      "nausea 31 percent": 48765,
      "31 percent vs": 3878,
      "percent vs 19": 60501,
      "vs 19 percent": 86545,
      "pain control long": 56623,
      "duration adequate pain": 27150,
      "signed rank sum": 75400,
      "rank sum test": 67368,
      "multiple regression models": 48296,
      "regression models statistical": 69451,
      "remains challenge clinical": 70287,
      "medications provide relief": 44665,
      "various adverse effects": 85960,
      "medications commonly used": 44606,
      "constipation nausea pruritus": 19766,
      "morphine fentanyl oxymorphone": 47693,
      "meta analysis published": 44897,
      "studies methods search": 77778,
      "dose evaluated efficacy": 25901,
      "number spontaneous bowel": 50259,
      "trials low risk": 83156,
      "opioid analgesics increasing": 51505,
      "opioid analgesic products": 51470,
      "affect quality life": 8912,
      "fixed dose combinations": 31879,
      "oxycodone naloxone available": 55493,
      "quality life health": 66726,
      "oxycodone methadone hydromorphone": 55397,
      "methadone hydromorphone buprenorphine": 45084,
      "upper abdominal pain": 83999,
      "opioid use prevalent": 52575,
      "use prevalent patients": 84664,
      "adverse outcomes opioid": 8835,
      "outcomes opioid use": 54065,
      "opioid induced bowel dysfunction": 51856,
      "prolonged release pr naloxone": 65634,
      "release oxycodone plus naloxone": 69968,
      "impacts patients quality life": 36866,
      "prolonged release pr oxycodone": 65636,
      "combination prolonged release pr": 17608,
      "release pr oxycodone pr": 69992,
      "pr oxycodone pr naloxone": 63353,
      "oxycodone pr naloxone targin": 55729,
      "pr naloxone targin targiniq": 63343,
      "naloxone targin targiniq targinact": 48524,
      "12 week randomized double": 1375,
      "week randomized double blind": 86870,
      "randomized double blind phase": 67106,
      "double blind phase iii": 26364,
      "phase iii trials patients": 61302,
      "trials patients moderate severe": 83181,
      "oxycodone naloxone pr generally": 55513,
      "naloxone pr generally tolerated": 48491,
      "frequently reported adverse events": 32577,
      "naloxone pr group compared": 48493,
      "severe chronic pain particularly": 74938,
      "double blinded study evaluated": 26399,
      "study evaluated analgesic efficacy": 78178,
      "prolonged release pr oral": 65635,
      "20 40 mg day": 2295,
      "probabilistic sensitivity analyses performed": 65214,
      "sensitivity analyses performed results": 74557,
      "estimated incremental cost effectiveness": 29629,
      "study evaluate efficacy safety": 78169,
      "analgesic efficacy bowel function": 10231,
      "bowel function assessed patients": 14268,
      "evaluated using brief pain": 29931,
      "pain inventory bpi sf": 56976,
      "screener opioid assessment patients": 74037,
      "opioid assessment patients pain": 51550,
      "assessment patients pain revised": 12131,
      "12 week double blind": 1372,
      "oxycodone pr naloxone pr": 55728,
      "pr naloxone pr oxycodone": 63340,
      "naloxone pr oxycodone pr": 48497,
      "pr naloxone pr versus": 63341,
      "naloxone pr versus oxycodone": 48502,
      "pr versus oxycodone pr": 63383,
      "day results statistically significant": 22408,
      "oxycodone controlled release tablets": 54886,
      "patients main outcome measure": 59467,
      "cancer pain methods randomized": 14837,
      "pain methods randomized double": 57189,
      "double dummy parallel group": 26407,
      "short form bpi sf": 75170,
      "providing comparable analgesic efficacy": 66257,
      "long acting formulation oxycodone": 42288,
      "50 improvement pain intensity": 4843,
      "therapeutic area great unmet": 80923,
      "area great unmet need": 11632,
      "great unmet need combination": 33418,
      "unmet need combination tablet": 83908,
      "patients effective analgesia improving": 59237,
      "effective analgesia improving opioid": 27591,
      "analgesia improving opioid induced": 10001,
      "improving opioid induced bowel": 37197,
      "chronic low pain neuropathic": 16203,
      "low pain neuropathic component": 42526,
      "pain intensity numerical rating": 56920,
      "global impression change pgic": 33228,
      "controlled release oxycodone effective": 20559,
      "patients requiring opioid therapy": 59912,
      "function patients moderate severe": 32667,
      "moderate severe pain opioid": 47201,
      "patients 18 years age": 58836,
      "squares mean lsm difference": 76806,
      "mean lsm difference 95": 43787,
      "lsm difference 95 ci": 42750,
      "moderate severe musculoskeletal pain": 47185,
      "oxycodone prolonged release pr": 55776,
      "prolonged release pr formulation": 65633,
      "short term post operative": 75199,
      "term post operative pain": 80663,
      "oxycodone pr 10 mg": 55725,
      "post operative days results": 62595,
      "pr naloxone pr group": 63339,
      "addition naloxone oxycodone pr": 7817,
      "action oxycodone opioid receptors": 7444,
      "oxycodone opioid receptors locally": 55575,
      "opioid receptors locally gut": 52275,
      "design week open label": 23822,
      "open label phase 3b": 51174,
      "label phase 3b study": 40988,
      "24 points 95 ci": 3263,
      "known opioid related adverse": 40922,
      "adverse events conclusion study": 8743,
      "open label extension phase": 51163,
      "mg bowel function index": 45811,
      "peripherally acting mu opioid": 60890,
      "case 52 year old": 15158,
      "kg body mass index": 40699,
      "plasma oxycodone concentration time": 61947,
      "mean sd age 36": 43859,
      "rating scale nrs day": 67661,
      "daily activities brief pain": 21694,
      "activities brief pain inventory": 7548,
      "moderate severe pain pain": 47202,
      "discontinued treatment adverse events": 25252,
      "paracetamol nonsteroidal anti inflammatory": 58108,
      "function index bfi pain": 32653,
      "severe chronic pain methods": 74936,
      "open label oxn pr": 51169,
      "objective study assess efficacy": 50497,
      "moderate severe pain methods": 47200,
      "starting dose 10 mg": 77016,
      "pain intensity quality life": 56932,
      "12 95 ci 15": 1267,
      "prolonged release extended release": 65623,
      "pubmed embase web science": 66451,
      "patients prolonged release oxycodone": 59710,
      "fixed dose combination prolonged": 31878,
      "dose combination prolonged release": 25845,
      "mean pain intensity decreased": 43827,
      "randomized double blind controlled": 67099,
      "trials evaluated efficacy safety": 83142,
      "using work productivity activity": 85683,
      "work productivity activity impairment": 87285,
      "productivity activity impairment questionnaire": 65441,
      "odds ratio 40 95": 50918,
      "open label extension studies": 51164,
      "double blind study received": 26383,
      "long term efficacy tolerability": 42334,
      "combination oxycodone pr naloxone": 17594,
      "phase iii clinical trial": 61294,
      "clinical trial assessed safety": 16923,
      "patients randomized receive oxycodone": 59741,
      "consistent expected opioid analgesics": 19698,
      "blind double dummy parallel": 13938,
      "common opioid adverse effects": 17779,
      "placebo controlled crossover trial": 61683,
      "evaluate long term safety": 29815,
      "cancer pain long term": 14829,
      "randomized double blinded crossover": 67112,
      "prolonged release oxycodone placebo": 65630,
      "repeated measures mixed models": 70416,
      "oxycodone treatment compared placebo": 56029,
      "design single center prospective": 23805,
      "single center prospective observational": 76063,
      "controlled trials rcts assessed": 20643,
      "risk bias extracted data": 72531,
      "pain relief primary outcome": 57570,
      "oxycodone naloxone did increase": 55500,
      "adverse events moderate quality": 8774,
      "events moderate quality evidence": 30073,
      "participants experiencing adverse event": 58306,
      "rr 82 95 ci": 72991,
      "increases risk adverse events": 38083,
      "naloxone prolonged release pr": 48508,
      "oxycodone naloxone pr significantly": 55514,
      "naloxone pr significantly improved": 48499,
      "pr management chronic pain": 63334,
      "methods double blind randomized": 45319,
      "double blind randomized crossover": 26374,
      "release oxycodone naloxone pr": 69957,
      "low pain neuropathic pain": 42527,
      "completed randomized double blind": 18492,
      "mg day 12 weeks": 45852,
      "analgesia patients moderate severe": 10051,
      "pr oxycodone naloxone pr": 63351,
      "median 24 hour opioid": 44181,
      "objective study compare efficacy": 50501,
      "short form 36 physical": 75168,
      "form 36 physical component": 32271,
      "36 physical component score": 4144,
      "adverse effect opioid analgesic": 8631,
      "effect opioid analgesic therapy": 27506,
      "morphine equivalent dose treatment": 47662,
      "long term treatment opioids": 42357,
      "central medline embase cinahl": 15591,
      "00 95 confidence interval": 12,
      "confidence interval ci 59": 19476,
      "additional beneficial outcome nntb": 7847,
      "rr 34 95 ci": 72924,
      "mg rr 25 95": 46211,
      "rr 25 95 ci": 72915,
      "95 ci 84 34": 6341,
      "objectives aim study evaluate": 50540,
      "incidence opioid induced effects": 37292,
      "transdermal fentanyl oxycodone hcl": 82154,
      "fentanyl oxycodone hcl controlled": 31552,
      "hcl controlled release cr": 34632,
      "release cr morphine cr": 69821,
      "malignant nonmalignant chronic pain": 43099,
      "usage long acting opioids": 84122,
      "prescription oxycodone hydrocodone containing": 64376,
      "mean total health care": 43891,
      "total health care costs": 81809,
      "hydrocodone oxycodone codeine tramadol": 36113,
      "mg kg oral gavage": 46005,
      "patients advanced cancer receiving": 58959,
      "advanced cancer receiving opioids": 8597,
      "english text version article": 28947,
      "phase ii clinical trial": 61286,
      "phase iii randomized double": 61297,
      "iii randomized double blind": 36594,
      "blind placebo controlled studies": 13960,
      "adverse event profile similar": 8711,
      "common treatment emergent adverse": 17821,
      "emergent adverse events nausea": 28704,
      "effective generally tolerated treatment": 27628,
      "data 12 week randomized": 21844,
      "blind placebo controlled phase": 13958,
      "impact health related quality": 36814,
      "registry setting outpatient settings": 69410,
      "setting outpatient settings participants": 74796,
      "12 item short form": 1313,
      "health survey sf 12": 34787,
      "14 21 28 repeated": 1563,
      "21 28 repeated measures": 2949,
      "28 repeated measures mixed": 3571,
      "measures mixed models provided": 44068,
      "mixed models provided estimates": 46803,
      "models provided estimates impact": 47128,
      "percent vs 19 percent": 60502,
      "wilcoxon signed rank sum": 87095,
      "signed rank sum test": 75401,
      "opioid receptor antagonists pamoras": 52250,
      "review meta analysis published": 72324,
      "number spontaneous bowel movements": 50260,
      "trials low risk bias": 83157,
      "opioid use prevalent patients": 52576,
      "adverse outcomes opioid use": 8836,
      "labour": 41041,
      "circulatory": 16576,
      "flows": 31936,
      "nct": 48855,
      "ug": 83405,
      "spo2": 76743,
      "secondly": 74262,
      "sheep": 75132,
      "vena": 86052,
      "cava": 15425,
      "carotid": 15127,
      "oslo": 53846,
      "cerebellum": 15640,
      "12h": 1442,
      "expertise": 30691,
      "neurology": 49203,
      "looked": 42407,
      "correctional": 20802,
      "551": 5087,
      "rrr": 73021,
      "obviously": 50794,
      "herpes": 35041,
      "simplex": 76022,
      "numbered": 50276,
      "opaque": 51144,
      "sealed": 74102,
      "polysomnographic": 62223,
      "publicized": 66412,
      "mcgill": 43625,
      "sept": 74603,
      "preimplementation": 63704,
      "883": 6050,
      "0018": 232,
      "gmr": 33269,
      "1057": 1063,
      "acuity": 7604,
      "spina": 76693,
      "694": 5532,
      "advisable": 8858,
      "economically": 27316,
      "ethnically": 29698,
      "decongestants": 22880,
      "contraceptives": 20199,
      "acetylsalicylic": 7285,
      "temperament": 80580,
      "wearing": 86808,
      "442": 4554,
      "079": 620,
      "921": 6161,
      "ending": 28835,
      "curricula": 21514,
      "professions": 65468,
      "partner": 58432,
      "infective": 38520,
      "antidiabetic": 11182,
      "lispro": 42098,
      "tubal": 83270,
      "hyperbaric": 36265,
      "unexposed": 83724,
      "unmeasured": 83902,
      "trapezius": 82256,
      "syncopal": 79913,
      "cpd": 21039,
      "cotinine": 20912,
      "emr": 28753,
      "subfascial": 78613,
      "incarcerated": 37246,
      "erem": 29501,
      "autocorrelation": 12751,
      "expedited": 30563,
      "pillars": 61496,
      "701": 5577,
      "plausibility": 61987,
      "oxycodone derivative": 54942,
      "dependence overdose": 23482,
      "opioids public": 53234,
      "63 632": 5356,
      "drugs sold": 27078,
      "delivery common": 23218,
      "post cesarean": 62560,
      "community design": 17916,
      "survey design": 79705,
      "conduct study": 19332,
      "labor delivery": 41016,
      "pain safe": 57655,
      "follow phone": 32030,
      "women participated": 87233,
      "operative patients": 51267,
      "decisions regarding": 22857,
      "placebo onset": 61786,
      "scores numerical": 73923,
      "dosing primary": 26325,
      "outcome maximum": 53923,
      "outcomes maximum": 54048,
      "pain stratified": 57865,
      "duration maximum": 27166,
      "group 86": 33650,
      "placebo 75": 61641,
      "range 02": 67244,
      "02 10": 351,
      "medication experiencing": 44498,
      "experiencing nausea": 30645,
      "43 reported": 4508,
      "opioids difficult": 52857,
      "new regimen": 49368,
      "recorded following": 68682,
      "protocol introduced": 65978,
      "paracetamol diclofenac": 58098,
      "178 patients": 2019,
      "movement vs": 48056,
      "recovery scores": 68762,
      "exposure safety": 30795,
      "collected plasma": 17474,
      "14 ng": 1612,
      "26 respectively": 3454,
      "median scores": 44281,
      "infusion device": 38702,
      "recovery groups": 68746,
      "receive postoperative": 68071,
      "relief iv": 70136,
      "assessed numeric": 12018,
      "differences nrs": 24763,
      "scores satisfaction": 73980,
      "uterine artery": 85704,
      "flow velocity": 31935,
      "kg placebo": 40786,
      "contraction pain": 20204,
      "measured parameters": 43988,
      "min study": 46552,
      "149 american": 1661,
      "outpatients scheduled": 54162,
      "surgeries general": 79285,
      "08 mg": 625,
      "ug kg": 83406,
      "surgery second": 79575,
      "120 participants": 1411,
      "40 group": 4337,
      "rate mean": 67482,
      "spo2 90": 76744,
      "higher groups": 35250,
      "05 group": 516,
      "followed group": 32059,
      "conclusion analgesic": 18860,
      "compounds oxycodone": 18617,
      "exposure intravenous": 30771,
      "open labelled": 51191,
      "oxycodone boluses": 54756,
      "cumulative dose": 21393,
      "life hr": 41699,
      "\u03bcg 14": 87786,
      "plasma 14": 61895,
      "14 \u03bcg": 1635,
      "oxycodone pregnant": 55736,
      "vena cava": 86053,
      "minutes 60": 46642,
      "60 ng": 5267,
      "kg intravenously": 40749,
      "accumulation oxymorphone": 7096,
      "international concern": 39480,
      "oslo university": 53847,
      "survey pain": 79725,
      "numerical scale": 50324,
      "reported 34": 70487,
      "requirement 24": 70869,
      "device 24": 24267,
      "nausea 24": 48763,
      "women treatment": 87250,
      "women dispensed": 87211,
      "group women": 34080,
      "women prescribed": 87236,
      "83 95": 5929,
      "299 76": 3633,
      "laparotomy randomized": 41116,
      "followed mg": 32067,
      "tissue samples": 81453,
      "tissue concentrations": 81448,
      "plasma oxymorphone": 61951,
      "accumulation oxycodone": 7095,
      "background primary": 13177,
      "group intrathecal": 33836,
      "diclofenac paracetamol": 24394,
      "low similar": 42556,
      "request similar": 70788,
      "group 87": 33651,
      "pruritus associated": 66296,
      "maternal use": 43531,
      "breast milk": 14408,
      "oxycodone cs": 54916,
      "analysed oxycodone": 10575,
      "subsequent 48": 78776,
      "risk breast": 72537,
      "uncertainty regarding": 83467,
      "approach implemented": 11460,
      "scheduled nonopioid": 73648,
      "comparison pre": 18378,
      "preintervention group": 63709,
      "group intervention": 33835,
      "morphine intraoperatively": 47737,
      "new practice": 49362,
      "using chi": 85336,
      "47 participants": 4662,
      "decreased 49": 22965,
      "approach managing": 11464,
      "pain overall": 57308,
      "maternal cyp2d6": 43520,
      "mother infant": 48006,
      "polymorphisms genes": 62219,
      "genes cyp2d6": 33057,
      "oprm1 abcb1": 53414,
      "metabolism response": 44939,
      "response results": 71370,
      "variants genes": 85912,
      "interval 06": 39553,
      "breastfeeding mothers": 14414,
      "performed procedures": 60614,
      "medical encounters": 44358,
      "study looked": 78293,
      "consumed post": 19846,
      "154 women": 1827,
      "results providers": 71900,
      "prescriptions percent": 64539,
      "identify association": 36491,
      "institution july": 39078,
      "2018 identified": 2820,
      "discharge stratified": 25178,
      "black white": 13902,
      "using multivariable": 85507,
      "multiple sensitivity": 48297,
      "vaginal delivery": 85758,
      "delivery did": 23220,
      "number inpatient": 50166,
      "prevalence substance": 64817,
      "use general": 84381,
      "types prescription": 83377,
      "oxymorphone morphine": 56262,
      "exposure year": 30801,
      "odds prescription": 50903,
      "marker substance": 43405,
      "risk behaviors": 72525,
      "oxycodone suitable": 55963,
      "009 respectively": 285,
      "shorter group": 75210,
      "groups terms": 34334,
      "68 10": 5493,
      "cause higher": 15356,
      "program using": 65547,
      "40 40": 4319,
      "postoperative multimodal": 62797,
      "24 followed": 3197,
      "treatment lasted": 82637,
      "days outcome": 22570,
      "rest vs": 71435,
      "38 001": 4224,
      "vs 138": 86532,
      "002 duration": 237,
      "vs 007": 86507,
      "control lower": 20360,
      "oral oxy": 53612,
      "intrathecal opioids": 39803,
      "approach needed": 11466,
      "phase aimed": 61275,
      "months design": 47438,
      "herpes simplex": 35042,
      "abuse total": 6894,
      "nurse practitioner": 50334,
      "strategies control": 77411,
      "intensity secondary": 39311,
      "61 participants": 5317,
      "control intervention": 20356,
      "014 95": 341,
      "experiencing severe": 30651,
      "section results": 74273,
      "acetaminophen following": 7184,
      "routine scheduled": 72865,
      "medications control": 44610,
      "gov number": 33345,
      "order sets": 53724,
      "standardized manner": 76962,
      "total doses": 81804,
      "labeled study": 41011,
      "drug given": 26639,
      "given 60": 33153,
      "consented study": 19584,
      "medications consumed": 44609,
      "receiving intravenous": 68344,
      "ibuprofen used": 36378,
      "study dose": 78129,
      "administration significant": 8371,
      "control objective": 20373,
      "days gestation": 22526,
      "given demand": 33165,
      "vs 72": 86614,
      "highest pain": 35361,
      "interval 22": 39561,
      "administer analgesics": 8091,
      "pain raising": 57456,
      "relief methods": 70142,
      "recruited randomized": 68795,
      "group receive": 33942,
      "registration clinical": 69387,
      "ratios rr": 67831,
      "2018 results": 2842,
      "65 30": 5405,
      "associated younger": 12466,
      "ratio standard": 67800,
      "substance monitoring": 78806,
      "groups women": 34355,
      "12 16": 1216,
      "30 001": 3661,
      "001 50": 103,
      "29 89": 3603,
      "outcomes did": 54022,
      "individualized opioid": 38319,
      "trials registration": 83192,
      "management oral": 43224,
      "recordings conducted": 68715,
      "administered intervals": 8142,
      "results post": 71875,
      "001 placebo": 186,
      "markedly altered": 43397,
      "analgesia reducing": 10086,
      "reducing oxycodone": 69024,
      "metropolitan area": 45672,
      "education primary": 27392,
      "prescription number": 64267,
      "proportion non": 65751,
      "decreased 30": 22956,
      "conducted cross": 19349,
      "sectional time": 74294,
      "funded prescriptions": 32733,
      "opioids postpartum": 53194,
      "2000 march": 2425,
      "march 31": 43373,
      "2017 intervention": 2783,
      "2010 12": 2535,
      "period observed": 60758,
      "relative increases": 69750,
      "safety maternal": 73166,
      "received intrathecal": 68174,
      "postoperatively received": 63021,
      "received mean": 68196,
      "received parecoxib": 68240,
      "001 reported": 199,
      "sectional single": 74285,
      "mcgill pain": 43626,
      "models assessed": 47110,
      "04 mg": 452,
      "resulted pain": 71511,
      "point higher": 62085,
      "use research": 84700,
      "required address": 70823,
      "address multiple": 7927,
      "owing concerns": 54378,
      "conducted population": 19386,
      "2012 june": 2604,
      "people initiated": 60411,
      "identified 70": 36419,
      "codeine 49": 17204,
      "compared people": 18257,
      "association prescription": 12488,
      "ropivacaine placebo": 72805,
      "ml end": 46857,
      "needed 48": 48968,
      "operatively secondary": 51278,
      "according intention": 7047,
      "mg ropivacaine": 46208,
      "combinations tramadol": 17631,
      "predetermined intervals": 63545,
      "requested additional": 70790,
      "need supplemental": 48959,
      "84 versus": 5967,
      "versus 48": 86109,
      "48 respectively": 4747,
      "use supplemental": 84767,
      "0001 number": 71,
      "design conducted": 23705,
      "asked pain": 11839,
      "implementation post": 36941,
      "significantly pre": 75835,
      "conclusion implementing": 18913,
      "decrease inpatient": 22897,
      "control data": 20290,
      "key points": 40673,
      "consumption purpose": 20000,
      "purpose primary": 66548,
      "32 40": 3911,
      "40 48": 4321,
      "differences vas": 24833,
      "increased demand": 37901,
      "increased vas": 38046,
      "oxycodone expensive": 55053,
      "analgesic pca": 10289,
      "patients completing": 59119,
      "dispensed ibuprofen": 25425,
      "acetaminophen analgesia": 7150,
      "usage data": 84116,
      "acetaminophen usage": 7258,
      "12 participants": 1350,
      "lower previously": 42690,
      "allow better": 9631,
      "tailoring opioid": 80264,
      "improvement patient": 37157,
      "acetaminophen oral": 7218,
      "reported total": 70668,
      "non hispanic": 49604,
      "scores pod1": 73950,
      "vas rest": 86017,
      "hispanic white": 35434,
      "racial disparities": 66946,
      "control protocols": 20405,
      "effects provider": 28116,
      "received pain": 68238,
      "nsaid opioid": 50092,
      "evaluated percentage": 29907,
      "results hospital": 71715,
      "implementation new": 36936,
      "analgesia associated": 9919,
      "report presents": 70475,
      "assess benefits": 11913,
      "fashion groups": 31197,
      "received ml": 68202,
      "retention respiratory": 72080,
      "opioid containing": 51673,
      "007 conclusions": 274,
      "need oral": 48942,
      "educational video": 27407,
      "center eligible": 15521,
      "randomized ratio": 67160,
      "medication acetaminophen": 44452,
      "ibuprofen use": 36377,
      "23 group": 3097,
      "groups 20": 34101,
      "2019 december": 2863,
      "control did": 20294,
      "august 2019": 12671,
      "received 1000": 68094,
      "acetaminophen 30": 7123,
      "time recovery": 81351,
      "oral ibuprofen": 53546,
      "45 18": 4566,
      "reduced inpatient": 68936,
      "postpartum period": 63039,
      "group 184": 33578,
      "symptoms oxycodone": 79900,
      "03 06": 402,
      "31 21": 3855,
      "participants cohort": 58284,
      "46 states": 4631,
      "january 2000": 40416,
      "2000 december": 2424,
      "exposure different": 30760,
      "relative risks": 69766,
      "risks rrs": 72683,
      "adjusted exposure": 8021,
      "cohort comprised": 17351,
      "commonly dispensed": 17846,
      "years compared": 87580,
      "73 56": 5647,
      "oxycodone 87": 54607,
      "hydromorphone 03": 36146,
      "life opioids": 41712,
      "relevance results": 70039,
      "ropivacaine \u03bcg": 72809,
      "ml sufentanil": 46912,
      "sufentanil postoperative": 78952,
      "satisfaction analgesia": 73386,
      "receiving continuous": 68327,
      "incisional pain": 37347,
      "management group": 43183,
      "scores determined": 73862,
      "ibuprofen total": 36375,
      "test continuous": 80759,
      "88 51": 6039,
      "32 79": 3919,
      "22 13": 3010,
      "25 19": 3326,
      "adjusted differences": 8020,
      "type conclusion": 83321,
      "reduction postoperative": 69092,
      "skin contact": 76200,
      "trial study": 83091,
      "73 001": 5643,
      "20 70": 2304,
      "40 06": 4308,
      "methods efficacy": 45324,
      "impact change": 36801,
      "july 2014": 40517,
      "hours acetaminophen": 35746,
      "end case": 28784,
      "iv 15": 40361,
      "hours doses": 35770,
      "maximum reported": 43614,
      "scores need": 73914,
      "48 36": 4685,
      "73 0001": 5642,
      "0001 time": 80,
      "medication significantly": 44566,
      "need dose": 48919,
      "regimen objective": 69315,
      "acetaminophen resulted": 7249,
      "cohort including": 17363,
      "delivery unit": 23230,
      "23 weeks": 3118,
      "greater prolonged": 33481,
      "icu stay": 36401,
      "combined medication": 17653,
      "medication group": 44501,
      "respect opioid": 71135,
      "1997 2005": 2238,
      "women physicians": 87235,
      "management remains": 43257,
      "analgesics early": 10417,
      "80 adult": 5838,
      "women age": 87199,
      "800 \u03bcg": 5869,
      "doses taken": 26284,
      "91 women": 6144,
      "opiates compared": 51324,
      "anaesthetic used": 9887,
      "ropivacaine wound": 72808,
      "infusion saline": 38730,
      "oxycodone visual": 56081,
      "recovery parameters": 68751,
      "recorded 48": 68667,
      "compared ropivacaine": 18301,
      "24 mean": 3241,
      "infusion groups": 38707,
      "control continuous": 20286,
      "46 24": 4619,
      "abuse lead": 6744,
      "examined demographics": 30373,
      "demographics patterns": 23301,
      "admitted january": 8427,
      "2001 2004": 2431,
      "included demographics": 37443,
      "including specific": 37675,
      "information included": 38653,
      "need research": 48956,
      "03 13": 403,
      "economically disadvantaged": 27317,
      "acetylsalicylic acid": 7286,
      "sampling time": 73372,
      "recommendations provided": 68609,
      "potential sources": 63232,
      "morphine high": 47713,
      "oxycodone requirements": 55839,
      "choice results": 16120,
      "satisfaction did": 73394,
      "choice mean": 16113,
      "group high": 33811,
      "versus low": 86129,
      "vomiting 01": 86439,
      "01 requiring": 323,
      "treatment 04": 82414,
      "analgesic needs": 10278,
      "oxycodone women": 56101,
      "intervention decreases": 39629,
      "compared institutional": 18189,
      "groups intervention": 34222,
      "qualitative data": 66664,
      "variable oxycodone": 85881,
      "oxycodone milligrams": 55452,
      "participants groups": 58312,
      "lower day": 42596,
      "majority individuals": 42985,
      "management postoperatively": 43242,
      "insurance program": 39154,
      "analyzed according": 10821,
      "strength opioid": 77475,
      "opioid weak": 52636,
      "opioids prevalence": 53221,
      "2005 2015": 2465,
      "morphine 029": 47528,
      "08 oxycodone": 627,
      "duration duration": 27158,
      "conclusions given": 19091,
      "longer treatment": 42392,
      "need assess": 48909,
      "focus groups": 31970,
      "based assumption": 13283,
      "set change": 74755,
      "hour later": 35703,
      "treatment nausea": 82676,
      "change median": 15732,
      "increase average": 37734,
      "vomiting 30": 86444,
      "ci conclusion": 16522,
      "experienced increased": 30607,
      "control 001": 20259,
      "increase opiate": 37764,
      "10 following": 767,
      "control 60": 20267,
      "using cross": 85364,
      "reduction services": 69100,
      "examined lifetime": 30388,
      "outcomes used": 54105,
      "regression estimate": 69439,
      "prevalence ratios": 64812,
      "ratios pr": 67830,
      "pr 95": 63312,
      "results approximately": 71605,
      "included prescription": 37518,
      "69 40": 5514,
      "increase survival": 37809,
      "increase associated": 37732,
      "support services": 79215,
      "unknown investigated": 83879,
      "2015 analyzed": 2694,
      "increased annually": 37873,
      "drug categories": 26543,
      "antihypertensive drugs": 11209,
      "magnesium sulfate": 42799,
      "insulin lispro": 39140,
      "frequently occurred": 32560,
      "20 commonly": 2312,
      "medications significantly": 44675,
      "tubal ligation": 83271,
      "causes postoperative": 15398,
      "received spinal": 68279,
      "mg hyperbaric": 45914,
      "hyperbaric bupivacaine": 36266,
      "pain intense": 56875,
      "0001 morphine": 69,
      "provides improved": 66221,
      "management post": 43239,
      "enrolled july": 29002,
      "48 measured": 4734,
      "score results": 73781,
      "versus oral": 86138,
      "23 conclusions": 3093,
      "treating post": 82411,
      "syndrome secondary": 79923,
      "maximum 30": 43581,
      "sd number": 74085,
      "discharge rates": 25168,
      "using results": 85598,
      "test analyses": 80753,
      "26 01": 3416,
      "implementation phase": 36940,
      "having effect": 34601,
      "decreased 24": 22951,
      "higher study": 35328,
      "data resulted": 22094,
      "marketscan database": 43436,
      "2003 2015": 2448,
      "2015 opioid": 2715,
      "results 345": 71563,
      "codeine 13": 17195,
      "13 odds": 1496,
      "higher using": 35336,
      "73 02": 5644,
      "research determine": 71002,
      "january 1999": 40414,
      "1999 september": 2246,
      "prescribed included": 63873,
      "13 38": 1467,
      "study 96": 77907,
      "gabapentin placebo": 32801,
      "patients 73": 58897,
      "hours postprocedure": 35829,
      "09 75": 640,
      "addition gabapentin": 7802,
      "immediately procedure": 36752,
      "administration based": 8222,
      "demand methods": 23250,
      "dosing group": 26312,
      "reduced 64": 68903,
      "conclusion scheduled": 18989,
      "delivery improve": 23221,
      "sought establish": 76486,
      "anesthesia enrolled": 10911,
      "morphine addition": 47575,
      "addition subjects": 7830,
      "prespecified noninferiority": 64723,
      "analgesics overall": 10467,
      "recovery adverse": 68735,
      "difference median": 24629,
      "ci mg": 16533,
      "satisfaction 24": 73384,
      "hours relative": 35839,
      "syndrome presented": 79921,
      "elective cesarean": 28486,
      "sustained years": 79800,
      "upper extremities": 84001,
      "trapezius muscle": 82257,
      "syncopal episodes": 79914,
      "rectal suppositories": 68805,
      "300 opioid": 3821,
      "quarter 2018": 66851,
      "discharge increased": 25128,
      "decrease exposure": 22895,
      "oral sedation": 53665,
      "sedation pain": 74323,
      "sedation 10": 74306,
      "mg lorazepam": 46040,
      "sedation groups": 74314,
      "depression stress": 23601,
      "sedation conclusion": 74308,
      "equivalent intravenous": 29311,
      "background treatment": 13208,
      "healthy women": 34863,
      "anaesthesia paracetamol": 9871,
      "correlated significantly": 20819,
      "52 23": 4974,
      "tool identify": 81684,
      "reaction causing": 67944,
      "time perceived": 81319,
      "25 days": 3352,
      "days conclusion": 22498,
      "greater reported": 33489,
      "background combination": 13027,
      "delivery clinical": 23217,
      "scheduled non": 73647,
      "group 120": 33567,
      "analgesics needed": 10454,
      "daily compared": 21709,
      "similar study": 75994,
      "acetaminophen administered": 7148,
      "analgesics compromising": 10402,
      "analgesia fentanyl": 9972,
      "intravenous transdermal": 39889,
      "plasma total": 61960,
      "10 animals": 741,
      "animals received": 11004,
      "received \u03bcg": 68305,
      "bolus operation": 14222,
      "received fentanyl": 68148,
      "pharmacokinetic modelling": 61120,
      "rate showed": 67517,
      "high interindividual": 35113,
      "period particularly": 60766,
      "follow regarding": 32032,
      "2016 march": 2753,
      "analyzed individually": 10835,
      "prescription hospital": 64235,
      "opioids varied": 53383,
      "ranged 20": 67344,
      "45 respectively": 4600,
      "follow similar": 32034,
      "clear consensus": 16699,
      "cigarettes day": 16555,
      "opioids nicotine": 53092,
      "trial smoking": 83089,
      "metabolite ratio": 44961,
      "involving methadone": 40129,
      "42 ng": 4465,
      "order oxycodone": 53717,
      "investigated materials": 40044,
      "determined total": 24090,
      "difference discharge": 24610,
      "significant influence": 75568,
      "period remain": 60786,
      "prospective longitudinal": 65835,
      "review determine": 72284,
      "effectiveness intervention": 27764,
      "intervention pre": 39644,
      "prescriptions reduce": 64555,
      "reduce risks": 68893,
      "data women": 22158,
      "activity hospital": 7567,
      "findings showed": 31818,
      "analysis women": 10794,
      "collected information": 17464,
      "severity opioid": 75044,
      "53 compared": 5021,
      "ci 61": 16477,
      "00 mg": 14,
      "00 27": 7,
      "doses higher": 26197,
      "associated variation": 12463,
      "92 75": 6151,
      "33 compared": 3991,
      "compared epidural": 18148,
      "physiologic saline": 61456,
      "10 dose": 760,
      "evaluated numerical": 29900,
      "concentrations levobupivacaine": 18770,
      "results epidural": 71682,
      "vs 006": 86506,
      "able walk": 6575,
      "period low": 60742,
      "relief patient": 70166,
      "good alternative": 33294,
      "quantify extent": 66784,
      "identify associations": 36492,
      "intervention clinical": 39625,
      "oxycodone 47": 54576,
      "medications received": 44666,
      "respectively 65": 71162,
      "defined cohort": 23124,
      "insurance plan": 39153,
      "prevalence exposure": 64783,
      "2005 12": 2458,
      "12 2011": 1225,
      "given conjunction": 33159,
      "effects resulting": 28144,
      "fentanyl 200": 31419,
      "200 \u00b5g": 2411,
      "postoperatively visual": 63033,
      "recorded time": 68703,
      "01 fewer": 310,
      "acetaminophen 500": 7135,
      "cohorts identified": 17412,
      "prescriptions different": 64474,
      "pregnancy patient": 63692,
      "prescriptions 180": 64432,
      "prevalence approximately": 64772,
      "abdominal pelvic": 6530,
      "pain migraine": 57193,
      "substantial regional": 78857,
      "variation observed": 85916,
      "growing awareness": 34358,
      "compared commercially": 18112,
      "guidelines chronic": 34431,
      "use excluded": 84362,
      "range daily": 67307,
      "equivalents respectively": 29376,
      "78 72": 5776,
      "consumption high": 19930,
      "pain decreasing": 56690,
      "risks long": 72676,
      "outcomes prescription": 54075,
      "tennessee tn": 80606,
      "determine patterns": 24037,
      "prescription history": 64234,
      "16 2013": 1850,
      "2013 11": 2617,
      "support implementation": 79198,
      "implementation evidence": 36931,
      "based care": 13291,
      "provides good": 66218,
      "recent phase": 68414,
      "study extended": 78209,
      "morphine erem": 47682,
      "prolonged analgesia": 65611,
      "conventional morphine": 20695,
      "intrathecal injection": 39794,
      "10 mcg": 781,
      "received ibuprofen": 68159,
      "erem provides": 29502,
      "events purpose": 30101,
      "database linked": 22174,
      "medications dispensed": 44615,
      "dispensed year": 25436,
      "modeling results": 47097,
      "rate dropped": 67462,
      "30 33": 3686,
      "rates did": 67571,
      "implementation eras": 36930,
      "protocol single": 65999,
      "catheter removal": 15319,
      "early ambulation": 27252,
      "total 250": 81745,
      "baseline demographics": 13430,
      "entire protocol": 29074,
      "day 05": 22237,
      "effectively applied": 27726,
      "substantial impact": 78848,
      "include education": 37355,
      "education pain": 27386,
      "management included": 43186,
      "immediately postoperation": 36748,
      "women body": 87206,
      "kg scheduled": 40802,
      "compared 66": 18085,
      "21 26": 2946,
      "28 standard": 3573,
      "compared 67": 18086,
      "treatment differed": 82549,
      "criteria 30": 21187,
      "22 women": 3046,
      "15 24": 1682,
      "25 28": 3329,
      "opioids pregnant": 53202,
      "controversial objective": 20679,
      "medicaid claims": 44328,
      "vital statistics": 86348,
      "disorder followed": 25373,
      "obtained pharmacy": 50775,
      "outcome overall": 53967,
      "defined 10": 23119,
      "mothers received": 48009,
      "adjusted relative": 8054,
      "needed establish": 48998,
      "pharmacy prescription": 61261,
      "followed day": 32054,
      "death non": 22712,
      "dosage morphine": 25753,
      "events higher": 30053,
      "total dosage": 81799,
      "women low": 87220,
      "tablets 10": 80109,
      "tablets increased": 80166,
      "analgesia post": 10061,
      "group trials": 34057,
      "trials eligible": 83139,
      "quasi randomised": 66866,
      "assessed trial": 12076,
      "trial quality": 83056,
      "outcome risk": 53989,
      "analgesia versus": 10133,
      "01 studies": 329,
      "difference need": 24636,
      "rr 11": 72894,
      "22 trials": 3044,
      "63 women": 5370,
      "39 79": 4265,
      "study 72": 77904,
      "relief 50": 70094,
      "differ terms": 24554,
      "07 study": 609,
      "analgesics need": 10452,
      "rr 65": 72958,
      "interval effect": 39598,
      "15 69": 1712,
      "opioid versus": 52631,
      "received non": 68213,
      "cost treatment": 20887,
      "drugs group": 26968,
      "high versus": 35192,
      "doses drug": 26182,
      "relatively studies": 69793,
      "prescription opioids public": 64365,
      "opioids public health": 53235,
      "post cesarean section": 62561,
      "results women participated": 72060,
      "post operative patients": 62606,
      "conducted randomized double": 19395,
      "10 mg oral": 830,
      "oxycodone placebo onset": 55689,
      "800 mg ibuprofen": 5867,
      "report pain scores": 70469,
      "pain scores numerical": 57748,
      "scores numerical rating": 73924,
      "worst pain 24": 87340,
      "primary outcome maximum": 65067,
      "clinically important pain": 16980,
      "oxycodone consumption pain": 54864,
      "postoperative analgesic protocol": 62714,
      "30 mg 20": 3751,
      "mg 20 40": 45725,
      "conclusion results study": 18980,
      "initial dose mg": 38841,
      "dose 05 mg": 25778,
      "administered hours later": 8136,
      "relief assessed using": 70103,
      "14 ng ml": 1613,
      "median pain score": 44269,
      "score 10 oxycodone": 73708,
      "30 minutes administration": 3771,
      "score range 10": 73777,
      "adverse effects mild": 8665,
      "pain relief iv": 57544,
      "satisfaction pain treatment": 73417,
      "assessed numeric rating": 12019,
      "pain scores satisfaction": 57779,
      "iv pca group": 40400,
      "experienced nausea 001": 30615,
      "nausea 001 vomiting": 48756,
      "mg kg placebo": 46016,
      "surgeries general anesthesia": 79286,
      "06 mg kg": 589,
      "08 mg kg": 626,
      "group group control": 33794,
      "included visual analogue": 37577,
      "study 40 group": 77893,
      "exposure intravenous oxycodone": 30772,
      "intravenous oxycodone pain": 39874,
      "mg cumulative dose": 45845,
      "kg oxycodone intravenously": 40780,
      "samples collected 24": 73333,
      "randomized receive mg": 67171,
      "60 ng ml": 5268,
      "mg kg intravenously": 45991,
      "oxycodone concentrations similar": 54836,
      "oslo university hospital": 53848,
      "24 hours post": 3223,
      "surgery aim study": 79320,
      "point numerical scale": 62098,
      "opioid requirement 24": 52337,
      "assigned randomly receive": 12174,
      "oxycodone acetaminophen morphine": 54648,
      "analgesia device 24": 9950,
      "assessed visual analog": 12093,
      "assessed results patients": 12054,
      "fewer effects compared": 31637,
      "83 95 ci": 5930,
      "oxycodone treatment pain": 56030,
      "followed mg kg": 32068,
      "good effect profile": 33309,
      "double dummy placebo": 26408,
      "group intrathecal morphine": 33837,
      "analgesic request similar": 10325,
      "worst pain scores": 87347,
      "conclusion oral oxycodone": 18944,
      "intrathecal morphine intraoperatively": 39799,
      "analyzed using chi": 10864,
      "using chi square": 85337,
      "milligram morphine equivalent": 46471,
      "confidence interval 06": 19440,
      "commonly performed procedures": 17859,
      "prescribed consumed post": 63843,
      "opioids post operatively": 53189,
      "july 2018 october": 40526,
      "2018 october 2018": 2833,
      "prescribed discharge stratified": 63851,
      "multiple sensitivity analyses": 48298,
      "high prevalence substance": 35152,
      "prevalence substance use": 64818,
      "opioid use general": 52515,
      "use methods data": 84482,
      "regression used assess": 69460,
      "types prescription opioids": 83378,
      "prescription opioids assessed": 64325,
      "opioid use findings": 52513,
      "oxycodone superior opioids": 55965,
      "superior opioids treatment": 79131,
      "opioids treatment visceral": 53357,
      "study investigated effects": 78277,
      "vs 14 min": 86535,
      "duration analgesia significantly": 27153,
      "significantly longer group": 75769,
      "longer group group": 42375,
      "group 10 vs": 33559,
      "prolong duration analgesia": 65607,
      "current standard care": 21469,
      "days outcome measures": 22571,
      "pain control lower": 56624,
      "observed patients receiving": 50702,
      "pain intensity secondary": 56945,
      "included patient global": 37505,
      "group pain intensity": 33895,
      "014 95 ci": 342,
      "group reported pain": 33979,
      "experiencing severe pain": 30652,
      "concern opioid abuse": 18828,
      "clinicaltrials gov number": 17020,
      "100 ml saline": 998,
      "ml saline placebo": 46908,
      "patients consented study": 59135,
      "baseline demographic characteristics": 13428,
      "demographic characteristics including": 23272,
      "significantly reduced compared": 75843,
      "conclusion intravenous acetaminophen": 18918,
      "pain control objective": 56628,
      "controlled study enrolled": 20588,
      "median pain vas": 44271,
      "confidence interval 22": 19448,
      "controlled trial evaluate": 20612,
      "blocks patients received": 14096,
      "pain relief methods": 57549,
      "oxycodone used rescue": 56063,
      "group required oxycodone": 33984,
      "oxycodone breakthrough pain": 54759,
      "trial registration clinical": 83070,
      "socioeconomic status greater": 76400,
      "30 tablets mg": 3799,
      "controlled substance monitoring": 20598,
      "substance monitoring database": 78807,
      "16 vs 30": 1896,
      "pain outcomes did": 57306,
      "clinical trials registration": 16959,
      "pain management oral": 57092,
      "placebo methods prospective": 61779,
      "trial design used": 83019,
      "increases risk new": 38084,
      "health records consecutive": 34763,
      "conducted cross sectional": 19350,
      "cross sectional time": 21271,
      "sectional time series": 74295,
      "publicly funded prescriptions": 66419,
      "women prescribed opioids": 87237,
      "significant changes opioid": 75443,
      "overall opioid prescribing": 54218,
      "cross sectional single": 21262,
      "sectional single centre": 74286,
      "mcgill pain questionnaire": 43627,
      "opioid use research": 52585,
      "methods conducted population": 45277,
      "conducted population based": 19387,
      "people initiated oxycodone": 60412,
      "results year study": 72062,
      "oxycodone compared people": 54822,
      "post operatively secondary": 62612,
      "operatively secondary outcomes": 51279,
      "according intention treat": 7048,
      "29 mg placebo": 3609,
      "groups pain scores": 34260,
      "objectives compare efficacy": 50550,
      "methods patients randomly": 45439,
      "effects evaluated results": 27916,
      "group lower mean": 33845,
      "respectively 0001 use": 71144,
      "drug administration following": 26524,
      "study design conducted": 78067,
      "opioid discharge prescriptions": 51713,
      "complete survey data": 18457,
      "10 point scale": 905,
      "number pills consumed": 50226,
      "opioid consumption purpose": 51652,
      "purpose primary objective": 66549,
      "superior pain relief": 79136,
      "assigned receive intravenous": 12178,
      "pain experience patients": 56771,
      "ibuprofen oxycodone acetaminophen": 36365,
      "oxycodone acetaminophen analgesia": 54632,
      "50 reported opioid": 4895,
      "study period conclusions": 78386,
      "pain previously reported": 57428,
      "better pain related": 13724,
      "surgery eras protocol": 79390,
      "management study design": 43270,
      "acetaminophen oral oxycodone": 7219,
      "scores lower postoperative": 73899,
      "pain scores pod1": 57762,
      "non hispanic white": 49605,
      "pain control protocols": 56646,
      "objective aim determine": 50366,
      "history drug abuse": 35458,
      "positive urine toxicology": 62508,
      "oxycodone consumption day": 54858,
      "multimodal analgesia associated": 48199,
      "clinical decision making": 16783,
      "enrolled patients randomized": 29009,
      "patients randomized double": 59732,
      "scores pain rest": 73941,
      "effects including nausea": 27951,
      "urinary retention respiratory": 84063,
      "retention respiratory depression": 72081,
      "significant difference oral": 75483,
      "pain control primary": 56644,
      "groups 20 15": 34102,
      "july 2019 december": 40529,
      "pain control did": 56612,
      "august 2019 patients": 12672,
      "received 1000 mg": 68095,
      "acetaminophen 30 mg": 7124,
      "time recovery room": 81352,
      "inpatient outpatient opioid": 39021,
      "patients satisfaction pain": 59937,
      "study design retrospectively": 78091,
      "day range 10": 22398,
      "range 10 mg": 67248,
      "significantly likely experience": 75764,
      "types opioids prescribed": 83373,
      "setting participants cohort": 74801,
      "participants cohort study": 58285,
      "prescriptions 90 days": 64442,
      "relative risks rrs": 69767,
      "use opioid treatment": 84552,
      "results cohort comprised": 71629,
      "tramadol oxycodone methadone": 82095,
      "analyses conclusions relevance": 10589,
      "conclusions relevance results": 19196,
      "analgesia ropivacaine \u03bcg": 10100,
      "ropivacaine \u03bcg ml": 72810,
      "\u03bcg ml sufentanil": 87796,
      "pain 12 24": 56366,
      "12 24 36": 1232,
      "groups postoperative pain": 34271,
      "pain management group": 57071,
      "pain control study": 56660,
      "received iv ketorolac": 68186,
      "group received oral": 33959,
      "groups results remained": 34308,
      "study compare effectiveness": 78000,
      "drugs nsaids acetaminophen": 27010,
      "performed retrospective analysis": 60624,
      "protocol patients received": 65986,
      "iv 15 mg": 40362,
      "need rescue opioid": 48955,
      "patient demographics intraoperative": 58610,
      "medication significantly longer": 44567,
      "oxycodone acetaminophen resulted": 54662,
      "labor delivery unit": 41017,
      "collected retrospective chart": 17480,
      "chart review total": 15933,
      "group took significantly": 34051,
      "associated reduced inpatient": 12401,
      "reduced inpatient opioid": 68937,
      "population based case": 62306,
      "based case control": 13293,
      "statistically significantly associated": 77233,
      "pain management remains": 57114,
      "mg paracetamol 1000": 46150,
      "interval ci 21": 39586,
      "reduce oxycodone consumption": 68871,
      "oxycodone consumption compared": 54856,
      "vs 45 mg": 86581,
      "intrathecal morphine group": 39798,
      "primary outcome oxycodone": 65078,
      "mg 24 48": 45731,
      "48 hours 05": 4710,
      "low dose group": 42469,
      "guide opioid prescribing": 34406,
      "promising strategy reduce": 65659,
      "lower day compared": 42597,
      "pain management postoperatively": 57101,
      "treatment strong opioid": 82857,
      "filled prescription opioid": 31711,
      "codeine commonly dispensed": 17214,
      "commonly dispensed opioid": 17847,
      "hydromorphone 11 morphine": 36149,
      "longer treatment duration": 42393,
      "order set change": 53723,
      "initial dose oxycodone": 38843,
      "10 mg 10": 788,
      "48 hours secondary": 4723,
      "nausea vomiting 30": 48790,
      "ratio 95 ci": 67754,
      "95 ci conclusion": 6357,
      "methods patients treated": 45444,
      "using cross sectional": 85365,
      "harm reduction services": 34581,
      "prevalence ratios pr": 64813,
      "largely unknown investigated": 41170,
      "causes postoperative pain": 15399,
      "postoperative pain designed": 62863,
      "intrathecal morphine analgesia": 39797,
      "received spinal anesthesia": 68280,
      "mg hyperbaric bupivacaine": 45915,
      "ml saline control": 46905,
      "saline control group": 73258,
      "postoperative analgesia provided": 62707,
      "500 mg oxycodone": 4920,
      "0001 morphine group": 70,
      "group oxycodone mg": 33891,
      "improved postoperative analgesia": 37124,
      "enrolled july 2015": 29003,
      "95 ci opioid": 6367,
      "decreases opioid prescribing": 23060,
      "primary outcome mean": 65068,
      "mean sd number": 43865,
      "secondary outcomes including": 74251,
      "outcomes including opioid": 54044,
      "tablets prescribed decreased": 80204,
      "significant decrease number": 75461,
      "decrease number opioid": 22905,
      "95 ci 59": 6315,
      "mg oxycodone weeks": 46144,
      "january 1999 september": 40415,
      "objective evaluate effect": 50414,
      "hour postoperative period": 35714,
      "postoperative period results": 62945,
      "ci 09 75": 16383,
      "conclusion addition gabapentin": 18858,
      "did reduce postoperative": 24489,
      "primary objective evaluate": 65044,
      "demand methods retrospective": 23251,
      "oxycodone use 24": 56049,
      "72 postoperatively results": 5630,
      "opioid consumption measured": 51631,
      "recovery adverse effects": 68736,
      "48 hour opioid": 4705,
      "48 hours pain": 4715,
      "hours relative risk": 35840,
      "rr 22 95": 72911,
      "effects satisfaction pain": 28152,
      "treatment post operative": 82769,
      "pain significant problem": 57838,
      "pain score vas": 57688,
      "screening tool identify": 74052,
      "online survey survey": 51105,
      "including tramadol oxycodone": 37681,
      "opioid administration methods": 51410,
      "patients received spinal": 59823,
      "similar study groups": 75995,
      "study groups conclusions": 78221,
      "opioid use consistent": 52486,
      "analgesia fentanyl used": 9973,
      "received \u03bcg kg": 68306,
      "high interindividual variability": 35114,
      "opioid medications currently": 51915,
      "united states january": 83799,
      "opioid prescription time": 52166,
      "regression examine associations": 69442,
      "42 ng ml": 4466,
      "patient opioid exposure": 58694,
      "investigated materials methods": 40045,
      "mme consumed patients": 46957,
      "group 32 patients": 33599,
      "design prospective longitudinal": 23760,
      "clinical care settings": 16763,
      "95 ci 61": 6317,
      "groups median iqr": 34235,
      "opioid pills used": 52065,
      "plasma concentrations levobupivacaine": 61912,
      "results epidural group": 71683,
      "pain relief patient": 57565,
      "opioid medications received": 51923,
      "opioid use large": 52530,
      "methods data study": 45307,
      "women dispensed opioid": 87212,
      "women dispensed opioids": 87213,
      "design randomized prospective": 23778,
      "fentanyl 200 \u00b5g": 31421,
      "postoperatively visual analog": 63034,
      "recorded 24 hours": 68664,
      "acetaminophen 500 mg": 7136,
      "oxycodone mg 24": 55411,
      "opioid utilization patterns": 52630,
      "prevalence chronic opioid": 64776,
      "prescriptions 180 days": 64433,
      "followed oxycodone tramadol": 32080,
      "pain migraine headache": 57194,
      "compared commercially insured": 18113,
      "guidelines chronic pain": 34432,
      "risks long term": 72677,
      "patterns prescription opioid": 60227,
      "analgesic use decreased": 10354,
      "implementation evidence based": 36932,
      "epidural morphine erem": 29188,
      "analgesic consumption pain": 10174,
      "patients received intrathecal": 59786,
      "fentanyl 10 mcg": 31410,
      "10 mg administered": 801,
      "significantly improved pain": 75751,
      "difference adverse event": 24592,
      "adverse events purpose": 8794,
      "hydromorphone tramadol codeine": 36228,
      "results total 250": 72028,
      "scores postoperative days": 73958,
      "use objective study": 84530,
      "education pain management": 27387,
      "pain management included": 57073,
      "pain score results": 57681,
      "decreased postoperative pain": 23030,
      "single institution july": 76110,
      "2014 june 30": 2666,
      "june 30 2016": 40557,
      "compared non hispanic": 18215,
      "objective evaluate association": 50409,
      "2008 december 31": 2506,
      "use disorder followed": 84320,
      "prescription opioid exposure": 64298,
      "dispensing prescription opioid": 25455,
      "primary outcome overall": 65077,
      "adjusted relative risk": 8055,
      "pharmacy prescription data": 61262,
      "related death non": 69579,
      "use secondary analyses": 84720,
      "incidence rate opioid": 37308,
      "prescription rate opioid": 64392,
      "10 tablets increased": 936,
      "opioid prescription commonly": 52135,
      "increase risk opioid": 37800,
      "independently assessed trial": 38175,
      "assessed trial quality": 12077,
      "trial quality extracted": 83057,
      "quality extracted data": 66704,
      "need additional pain": 48906,
      "primary outcome risk": 65092,
      "33 95 confidence": 3988,
      "ci 39 79": 16445,
      "pain relief 50": 57517,
      "did differ terms": 24443,
      "analgesics need additional": 10453,
      "rr 65 95": 72959,
      "relief opioid analgesics": 70156,
      "non opioid versus": 49658,
      "high quality trials": 35157,
      "high versus low": 35193,
      "misuse prescription opioids public": 46740,
      "prescription opioids public health": 64366,
      "10 mg oral oxycodone": 831,
      "pain scores numerical rating": 57749,
      "scores numerical rating scale": 73925,
      "numerical rating scale 10": 50312,
      "worst pain 24 hours": 87341,
      "numerical rating scale results": 50317,
      "oxycodone consumption pain scores": 54865,
      "30 mg 20 40": 3752,
      "initial dose mg kg": 38842,
      "dose 05 mg kg": 25779,
      "05 mg kg administered": 527,
      "intensity pain relief assessed": 39286,
      "pain relief assessed using": 57524,
      "adverse effects recorded results": 8692,
      "assessed numeric rating scale": 12020,
      "surgeries general anesthesia randomly": 79287,
      "group group control group": 33795,
      "included visual analogue scale": 37578,
      "difference statistically significant 05": 24690,
      "mg kg oxycodone intravenously": 46012,
      "blood samples collected 24": 14153,
      "randomized receive mg kg": 67172,
      "60 ng ml range": 5269,
      "24 hours post surgery": 3224,
      "11 point numerical scale": 1149,
      "controlled analgesia device 24": 20449,
      "pain assessed visual analog": 56468,
      "analyzed using chi square": 10865,
      "using chi square test": 85338,
      "95 confidence interval 06": 6379,
      "july 2018 october 2018": 40527,
      "number oxycodone mg tablets": 50211,
      "logistic regression used assess": 42274,
      "oxycodone superior opioids treatment": 55966,
      "superior opioids treatment visceral": 79132,
      "opioids treatment visceral pain": 53358,
      "significantly longer group group": 75770,
      "registered clinicaltrials gov number": 69378,
      "baseline demographic characteristics including": 13429,
      "95 confidence interval 22": 6386,
      "randomized controlled trial evaluate": 67074,
      "lower socioeconomic status greater": 42704,
      "30 tablets mg oxycodone": 3800,
      "controlled substance monitoring database": 20599,
      "randomized placebo controlled cross": 67150,
      "increases risk new persistent": 38085,
      "electronic health records consecutive": 28536,
      "cross sectional time series": 21272,
      "cross sectional single centre": 21263,
      "methods conducted population based": 45278,
      "results year study period": 72063,
      "methods double blind trial": 45320,
      "post operatively secondary outcomes": 62613,
      "differences groups pain scores": 24749,
      "scores patient satisfaction scores": 73946,
      "methods patients randomly assigned": 45440,
      "treatment main outcome measures": 82649,
      "adverse effects evaluated results": 8657,
      "group lower mean pain": 33846,
      "lower mean pain score": 42645,
      "25 tablets oxycodone mg": 3388,
      "randomly assigned receive intravenous": 67226,
      "recovery surgery eras protocol": 68765,
      "pain scores lower postoperative": 57734,
      "patients randomized double blind": 59733,
      "scale scores pain rest": 73560,
      "urinary retention respiratory depression": 84064,
      "statistically significant difference oral": 77211,
      "medication use pain scores": 44581,
      "satisfaction pain control did": 73411,
      "scale pain 10 severe": 73529,
      "inpatient outpatient opioid consumption": 39022,
      "design setting participants cohort": 23798,
      "setting participants cohort study": 74802,
      "epidural analgesia ropivacaine \u03bcg": 29173,
      "analgesia ropivacaine \u03bcg ml": 10101,
      "ropivacaine \u03bcg ml sufentanil": 72811,
      "mg immediate release tablets": 45921,
      "pain scores compared groups": 57710,
      "purpose study compare effectiveness": 66574,
      "randomized placebo controlled crossover": 67151,
      "inflammatory drugs nsaids acetaminophen": 38565,
      "data collected retrospective chart": 21911,
      "collected retrospective chart review": 17481,
      "patients received oxycodone acetaminophen": 59810,
      "group took significantly fewer": 34052,
      "difference 95 ci 04": 24585,
      "associated reduced inpatient opioid": 12402,
      "population based case control": 62307,
      "based case control study": 13294,
      "mg paracetamol 1000 mg": 46151,
      "confidence interval ci 21": 19468,
      "codeine commonly dispensed opioid": 17215,
      "odds ratio 95 ci": 50926,
      "using cross sectional data": 85366,
      "ml saline control group": 46906,
      "500 mg oxycodone mg": 4921,
      "control group oxycodone mg": 20333,
      "group oxycodone mg acetaminophen": 33892,
      "number opioids prescribed patients": 50205,
      "secondary outcomes including opioid": 74252,
      "opioid tablets prescribed decreased": 52399,
      "52 95 ci 49": 4982,
      "15 95 ci 11": 1721,
      "secondary outcome measures included": 74239,
      "24 hour postoperative period": 3208,
      "26 95 ci 09": 3440,
      "95 ci 09 75": 6237,
      "did reduce postoperative pain": 24490,
      "acetaminophen oxycodone use 24": 7227,
      "total opioid consumption measured": 81863,
      "48 hour opioid consumption": 4706,
      "rr 22 95 ci": 72912,
      "treatment post operative pain": 82770,
      "opioids including tramadol oxycodone": 52984,
      "patients received spinal anesthesia": 59824,
      "study design prospective longitudinal": 78081,
      "number opioid pills used": 50194,
      "methods conducted retrospective chart": 45284,
      "postoperatively visual analog scale": 63035,
      "vas pain scores seen": 86013,
      "mg oxycodone mg 24": 46125,
      "associated increased odds opioid": 12303,
      "release epidural morphine erem": 69833,
      "postoperative analgesic consumption pain": 62712,
      "16 95 ci 15": 1867,
      "retrospective cohort study included": 72128,
      "visual analog pain scores": 86305,
      "pain scores postoperative days": 57767,
      "methods performed retrospective cohort": 45456,
      "2014 june 30 2016": 2667,
      "january 2008 december 31": 40427,
      "opioid use disorder followed": 52501,
      "01 95 ci 80": 299,
      "opioid prescription rate opioid": 52161,
      "opioid prescription commonly prescribed": 52136,
      "independently assessed trial quality": 38176,
      "assessed trial quality extracted": 12078,
      "trial quality extracted data": 83058,
      "33 95 confidence interval": 3989,
      "95 ci 39 79": 6290,
      "rr 65 95 ci": 72960,
      "pain relief opioid analgesics": 57557,
      "mec": 44108,
      "t9": 80070,
      "suturing": 79802,
      "llc": 42191,
      "wedge": 86822,
      "dizzy": 25646,
      "unified": 83731,
      "328": 3972,
      "vertigo": 86168,
      "multiplying": 48309,
      "deserve": 23691,
      "enflurane": 28924,
      "waves": 86771,
      "053": 567,
      "073": 612,
      "ao": 11291,
      "1160": 1185,
      "sigmoidectomy": 75381,
      "diverticular": 25614,
      "succinylcholine": 78930,
      "spirometry": 76734,
      "spi": 76685,
      "blindly": 14031,
      "capital": 14951,
      "881": 6048,
      "entropy": 29085,
      "showproj": 75356,
      "proj": 65585,
      "solids": 76433,
      "healed": 34663,
      "habitually": 34499,
      "aortic": 11342,
      "esketamine": 29537,
      "homeostasis": 35528,
      "oximeter": 54406,
      "oxycodone determine": 54953,
      "blood sampled": 14150,
      "sample obtained": 73308,
      "54 oxycodone": 5050,
      "model lean": 47054,
      "mass age": 43447,
      "significant covariates": 75456,
      "showed median": 75272,
      "ml second": 46909,
      "open surgery": 51201,
      "63 17": 5354,
      "16 63": 1862,
      "28 19": 3537,
      "early termination": 27274,
      "postoperative pcia": 62935,
      "pain superior": 57888,
      "effect preoperative": 27534,
      "intravenous sufentanil": 39887,
      "postoperative sufentanil": 62970,
      "group various": 34064,
      "group 70": 33639,
      "100 oxycodone": 1010,
      "200 \u03bcg": 2412,
      "peripheral oxygen": 60883,
      "incidence complications": 37265,
      "rate complications": 67452,
      "monitoring adverse": 47316,
      "hours hours": 35780,
      "systolic blood": 80046,
      "affect sleep": 8913,
      "percocet group": 60535,
      "daily controlled": 21711,
      "release group": 69867,
      "somnolence nausea": 76466,
      "nausea conclusion": 48767,
      "established evaluated": 29585,
      "relief obtained": 70152,
      "time second": 81369,
      "ml conclusion": 46853,
      "35 ng": 4087,
      "operative period": 51268,
      "receive saline": 68075,
      "kg mg": 40759,
      "group 53": 33624,
      "allocated oxycodone": 9617,
      "sufentanil groups": 78942,
      "background infusion": 13070,
      "total 200": 81738,
      "surgery major": 79452,
      "group nausea": 33871,
      "patients sufentanil": 60013,
      "showed better": 75231,
      "blinded observer": 14002,
      "resting coughing": 71440,
      "groups 48": 34114,
      "hour cumulative": 35694,
      "influence age": 38586,
      "years gender": 87594,
      "surgery standard": 79591,
      "hydrochloride 05": 36002,
      "001 plasma": 187,
      "conclusions elderly": 19079,
      "patients plasma": 59652,
      "level compared": 41451,
      "aged patients": 9207,
      "mg addition": 45794,
      "orally day": 53693,
      "combination fentanyl": 17557,
      "original study": 53792,
      "alternative analgesic": 9714,
      "opioids trauma": 53352,
      "extremity trauma": 30991,
      "injection patients": 38965,
      "seen objective": 74361,
      "recorded compared": 68672,
      "group case": 33675,
      "risk groups": 72578,
      "analgesia superior": 10117,
      "group general": 33787,
      "results general": 71702,
      "05 statistically": 553,
      "according age": 7034,
      "66 80": 5450,
      "dose decreased": 25862,
      "placebo 25": 61627,
      "25 hour": 3358,
      "hour surgery": 35719,
      "awake alert": 12978,
      "tolerated oral": 81633,
      "preoperative administration": 63735,
      "intravenously mg": 39896,
      "administered tramadol": 8190,
      "dose dexamethasone": 25881,
      "doses dexamethasone": 26174,
      "amounts analgesics": 9834,
      "differ study": 24551,
      "conclusions iv": 19106,
      "dexamethasone 10": 24281,
      "used induction": 84975,
      "ed 95": 27325,
      "iv bolus": 40368,
      "determine ed": 24005,
      "observed min": 50692,
      "injection results": 38969,
      "including 29": 37585,
      "01 common": 304,
      "events dizziness": 30043,
      "affected ed": 8916,
      "method reducing": 45209,
      "40 placebo": 4375,
      "forced vital": 32249,
      "vital capacity": 86339,
      "forced expiratory": 32247,
      "expiratory volume": 30695,
      "72 postoperative": 5628,
      "mg 51": 45756,
      "15 pain": 1782,
      "pulmonary function": 66467,
      "incidences adverse": 37330,
      "interval 20": 39559,
      "mg conclusion": 45831,
      "surgery post": 79525,
      "complementary analgesic": 18435,
      "dose given": 25913,
      "undergoing closed": 83521,
      "closed reduction": 17071,
      "bone fracture": 14233,
      "group drug": 33759,
      "measured groups": 43966,
      "rate pre": 67502,
      "applied oxycodone": 11435,
      "injection anesthesia": 38937,
      "patients observation": 59568,
      "significantly significant": 75861,
      "30 05": 3663,
      "05 scores": 549,
      "17 02": 1927,
      "04 05": 441,
      "total 119": 81717,
      "119 patients": 1196,
      "patients highest": 59361,
      "placebo orally": 61789,
      "programmed deliver": 65550,
      "63 total": 5367,
      "10 grade": 768,
      "study 62": 77902,
      "maintenance general": 42910,
      "kg used": 40819,
      "time 16": 81194,
      "16 minutes": 1882,
      "care taken": 15084,
      "\u00b5g kg": 87774,
      "lowest group": 42733,
      "injection mg": 38956,
      "oxycodone minutes": 55455,
      "study observe": 78343,
      "combinations postoperative": 17629,
      "surgery group": 79409,
      "oxycodone diluted": 54972,
      "diluted 100": 25010,
      "12 minute": 1328,
      "stage n2": 76866,
      "n2 sleep": 48389,
      "001 comparisons": 117,
      "times respectively": 81435,
      "anaesthesia induction": 9869,
      "fentanyl administration": 31432,
      "years randomly": 87649,
      "minutes fentanyl": 46650,
      "analysed results": 10577,
      "end 12": 28782,
      "hours controlled": 35761,
      "calculated multiplying": 14692,
      "despite clinical": 23872,
      "investigated drug": 40037,
      "evaluation objective": 29959,
      "small moderate": 76286,
      "evaluated pharmacokinetics": 29909,
      "studied interventions": 77616,
      "patients mg": 59513,
      "stable patients": 76848,
      "oxycodone varied": 56072,
      "varied hours": 85938,
      "elimination oxycodone": 28617,
      "pressure bp": 64739,
      "percentage increase": 60508,
      "15 increase": 1737,
      "15 significantly": 1792,
      "practice using": 63420,
      "kg induction": 40741,
      "safety evaluated": 73150,
      "methods dose": 45315,
      "type groups": 83326,
      "trials performed": 83182,
      "group estimated": 33767,
      "estimated oxycodone": 29635,
      "060 mg": 592,
      "administered management": 8150,
      "advantages opioids": 8616,
      "conducted according": 19342,
      "preferred reporting": 63644,
      "reporting items": 70693,
      "items systematic": 40351,
      "participants results": 58361,
      "analgesics 24": 10363,
      "levels satisfaction": 41606,
      "24 operation": 3253,
      "operation 001": 51215,
      "difference satisfaction": 24681,
      "aimed evaluating": 9452,
      "sufentanil induced": 78943,
      "02 mg": 371,
      "sufentanil injection": 78944,
      "oxycodone 02": 54480,
      "volunteers study": 86436,
      "acetaminophen placebo": 7238,
      "placebo placebo": 61802,
      "administered induction": 8139,
      "administered end": 8127,
      "function following": 32647,
      "100 \u03bcg": 1029,
      "41 included": 4423,
      "preemptive analgesia": 63609,
      "stress hormone": 77489,
      "groups visual": 34350,
      "surgery completed": 79349,
      "kg continuous": 40707,
      "infusion mg": 38712,
      "vomiting day": 86453,
      "surgery resulted": 79566,
      "resulted clinically": 71501,
      "semisynthetic thebaine": 74527,
      "thebaine derivative": 80901,
      "derivative opioid": 23619,
      "pain intravenous": 56972,
      "pca patients": 60268,
      "satisfaction sedation": 73437,
      "level effects": 41464,
      "consumption group": 19928,
      "placebo standardised": 61829,
      "45 44": 4570,
      "important adverse": 36992,
      "dosage mg": 25752,
      "efficacy paracetamol": 28322,
      "70 ng": 5566,
      "48 conclusion": 4700,
      "provide efficient": 66059,
      "surgery subjects": 79598,
      "second plasma": 74192,
      "73 10": 5645,
      "median 52": 44193,
      "24 79": 3179,
      "range 33": 67283,
      "decreased respiratory": 23035,
      "conclusion present": 18972,
      "decreased fentanyl": 22997,
      "group point": 33919,
      "postoperatively significant": 63027,
      "responses did": 71386,
      "treatments used": 82935,
      "investigate factors": 40013,
      "used sufentanil": 85151,
      "maintenance postoperative": 42917,
      "total 193": 81736,
      "events recovery": 30106,
      "op patients": 51139,
      "satisfaction group": 73398,
      "ml postoperative": 46894,
      "level sedation": 41524,
      "provides similar": 66239,
      "nrs 12": 50056,
      "scale nausea": 73507,
      "postoperative hour": 62777,
      "hours postoperative": 35822,
      "according principles": 7060,
      "patients complicated": 59123,
      "diverticular disease": 25615,
      "coughing motion": 20919,
      "pregabalin anticonvulsant": 63661,
      "pregabalin 300": 63658,
      "dose repeated": 26056,
      "24h surgery": 3313,
      "conclusion perioperative": 18961,
      "setting iv": 74782,
      "iv department": 40369,
      "minor surgery": 46628,
      "anesthesia interventions": 10920,
      "oxide oxygen": 54400,
      "drugs placebo": 27036,
      "included double": 37444,
      "remifentanil used": 70325,
      "min used": 46555,
      "consumption 90": 19887,
      "groups conducted": 34163,
      "total 57": 81757,
      "12 active": 1271,
      "analgesia pump": 10078,
      "scale 48": 73493,
      "stay recorded": 77288,
      "rest postoperative": 71430,
      "vs single": 86678,
      "group 025": 33542,
      "rarely studied": 67413,
      "test control": 80760,
      "opioid consuming": 51598,
      "preoperatively patient": 63773,
      "pharmacokinetic simulations": 61150,
      "concentration 30": 18670,
      "used pharmacokinetic": 85077,
      "tool identifying": 81685,
      "drugs general": 26966,
      "analgesia conventional": 9943,
      "50 control": 4832,
      "tachycardia hypertension": 80237,
      "scales pain": 73591,
      "scores postanesthesia": 73952,
      "clinical parameters": 16854,
      "randomly double": 67237,
      "double blindly": 26402,
      "25 placebo": 3380,
      "oxycodone inhibiting": 55278,
      "june october": 40562,
      "males aged": 43070,
      "medical university": 44412,
      "group elderly": 33763,
      "intravenously patient": 39899,
      "min later": 46532,
      "maximum mean": 43594,
      "half maximal": 34522,
      "groups adverse": 34130,
      "results 26": 71558,
      "13 cases": 1480,
      "conclusion ed": 18894,
      "standard anaesthetic": 76888,
      "cro age": 21237,
      "compare methods": 18033,
      "period 24": 60699,
      "seen pain": 74363,
      "patients cro": 59161,
      "analgesia reduction": 10087,
      "requirement analgesia": 70870,
      "risk pain": 72628,
      "pain complications": 56579,
      "evaluation time": 29968,
      "peri postoperative": 60659,
      "differences use": 24829,
      "abdominal mass": 6526,
      "scores objective": 73926,
      "evaluate adverse": 29767,
      "17 higher": 1970,
      "46 49": 4622,
      "comparing effect": 18348,
      "events satisfaction": 30118,
      "movement group": 48047,
      "oxycodone good": 55119,
      "randomised prospective": 67033,
      "patients unknown": 60160,
      "correlation plasma": 20836,
      "patients statistically": 59997,
      "correlation individual": 20828,
      "nefopam group": 49058,
      "ketorolac mg": 40651,
      "surgery evaluation": 79398,
      "dosage titrated": 25763,
      "protocol based": 65959,
      "34 microg": 4026,
      "methods time": 45610,
      "group terms": 34045,
      "analgesia potency": 10065,
      "severity effects": 75039,
      "respiration rate": 71261,
      "surgery 04": 79293,
      "result adverse": 71470,
      "demonstrated designed": 23334,
      "20 increase": 2322,
      "increase heart": 37749,
      "oxycodone introduced": 55299,
      "95 male": 6403,
      "patient determined": 58616,
      "response previous": 71360,
      "group recorded": 33969,
      "vomiting significant": 86480,
      "article outlines": 11773,
      "anesthesiology patient": 10964,
      "patient classification": 58560,
      "midazolam oxycodone": 46397,
      "limb movement": 41877,
      "limb movements": 41878,
      "higher degrees": 35228,
      "preemptive oxycodone": 63612,
      "preemptive sufentanil": 63613,
      "measured serum": 43996,
      "38 68": 4233,
      "10 49": 713,
      "cn showproj": 17101,
      "showproj aspx": 75357,
      "aspx proj": 11872,
      "oxycodone immediately": 55234,
      "20 compared": 2313,
      "valve replacement": 85856,
      "response effects": 71345,
      "administrated oxycodone": 8200,
      "effective post": 27670,
      "surgery valdecoxib": 79617,
      "groups dexamethasone": 34179,
      "potential alternative": 63132,
      "agent provide": 9222,
      "undergoing oral": 83561,
      "agents combination": 9227,
      "ketamine midazolam": 40613,
      "combination agents": 17542,
      "hysterectomy trial": 36328,
      "patients appropriate": 58999,
      "anesthetic management": 10969,
      "included induction": 37467,
      "parenteral ketorolac": 58205,
      "ketorolac oral": 40652,
      "patients day": 59169,
      "nausea patient": 48777,
      "outcomes related": 54085,
      "discharge follow": 25122,
      "procedure analgesic": 65269,
      "small doses": 76276,
      "combined drugs": 17646,
      "effects use": 28189,
      "duration procedure": 27180,
      "trial published": 83055,
      "trial status": 83090,
      "time manuscript": 81280,
      "manuscript submission": 43342,
      "study recruitment": 78456,
      "outcome surgical": 53997,
      "open group": 51150,
      "patients closed": 59094,
      "group healed": 33810,
      "weight 59": 86971,
      "results bioavailability": 71614,
      "bioavailability intranasal": 13836,
      "half time": 34535,
      "min analgesic": 46512,
      "fentanyl analgesia": 31437,
      "administration intranasal": 8279,
      "analgesia prolonged": 10073,
      "used cardiac": 84868,
      "grafting heart": 33399,
      "64 \u03bcg": 5396,
      "deep breathing": 23091,
      "chest tubes": 15974,
      "significant factor": 75539,
      "consumption daily": 19909,
      "consumption multivariable": 19958,
      "chest tube": 15973,
      "15 microg": 1769,
      "intervals significantly": 39616,
      "pharmacological agents": 61207,
      "included published": 37526,
      "shown significant": 75352,
      "agents patient": 9235,
      "associated sedation": 12415,
      "changes patient": 15810,
      "doses sedative": 26268,
      "effect time": 27570,
      "sweden patients": 79810,
      "collected end": 17459,
      "according protocol": 7061,
      "anesthesia elective": 10908,
      "non cardiac": 49588,
      "case 66": 15162,
      "analgesia accomplished": 9898,
      "etoricoxib oxycodone": 29717,
      "oximetry spo2": 54408,
      "pulse oximeter": 66469,
      "15 female": 1733,
      "pain followed": 56785,
      "standard practice": 76928,
      "94 vs": 6198,
      "2019 june": 2870,
      "group according": 33660,
      "05 study": 555,
      "surgery differences": 79380,
      "day operation": 22343,
      "analgesia unknown": 10126,
      "patients 39": 58863,
      "12 single": 1363,
      "scale 24": 73491,
      "postoperatively nrs": 63011,
      "undergoing coronary": 83525,
      "institution tertiary": 39088,
      "tertiary level": 80742,
      "level university": 41534,
      "placebo 45": 61634,
      "range 29": 67280,
      "group 99": 33659,
      "efficacy intrathecal": 28284,
      "methods primary": 45479,
      "pacu pain": 56330,
      "cumulative total": 21412,
      "total iv": 81821,
      "scores pacu": 73937,
      "conclusion intrathecal": 18916,
      "background compare": 13028,
      "kg dexmedetomidine": 40714,
      "included hospital": 37464,
      "concomitant analgesic": 19247,
      "vs 004": 86505,
      "result higher": 71477,
      "hypotension longer": 36288,
      "requiring evaluation": 70900,
      "study parallel": 78357,
      "patients ninety": 59547,
      "using 12": 85292,
      "confer benefit": 19428,
      "low frequency": 42488,
      "death associated": 22693,
      "outcome methods": 53956,
      "42 mean": 4462,
      "173 patients": 2007,
      "patient awake": 58543,
      "history hypertension": 35460,
      "day 94": 22264,
      "important factors": 37009,
      "stay shorter": 77292,
      "shorter eras": 75209,
      "lower eras": 42613,
      "patients 17": 58832,
      "paravertebral space": 58185,
      "pain shoulder": 57833,
      "fentanyl requirements": 31586,
      "model lean body": 47055,
      "body mass age": 14196,
      "mass age significant": 43448,
      "age significant covariates": 9123,
      "36 hours surgery": 4130,
      "groups conclusions oxycodone": 34160,
      "effects assessed results": 27829,
      "oxycodone reduce postoperative": 55811,
      "group 70 oxycodone": 33640,
      "group 100 oxycodone": 33561,
      "peripheral oxygen saturation": 60884,
      "administration study drug": 8380,
      "assessed results oxycodone": 12053,
      "following time points": 32212,
      "monitoring adverse events": 47317,
      "hours hours 12": 35781,
      "hours 12 hours": 35731,
      "systolic blood pressure": 80047,
      "qor 40 scores": 66642,
      "oxycodone analgesic regimens": 54713,
      "daily controlled release": 21712,
      "scale postoperative day": 73545,
      "rescue medication adverse": 70949,
      "pain postoperative days": 57395,
      "early pain control": 27262,
      "provide better analgesia": 66036,
      "better analgesia fewer": 13701,
      "analgesia fewer effects": 9977,
      "release oxycodone analgesic": 69925,
      "oxycodone 10 15": 54492,
      "pain relief obtained": 57554,
      "35 ng ml": 4088,
      "oxycodone acute pain": 54675,
      "kg mg kg": 40760,
      "groups demonstrated significant": 34177,
      "compare analgesic effects": 18007,
      "randomly allocated oxycodone": 67214,
      "oxycodone sufentanil groups": 55957,
      "background infusion oxycodone": 13071,
      "sufentanil group primary": 78939,
      "results total 200": 72027,
      "total 200 patients": 81739,
      "enrolled patients randomly": 29010,
      "oxycodone group nausea": 55135,
      "including nausea vomiting": 37645,
      "vomiting pruritus respiratory": 86469,
      "patients sufentanil group": 60014,
      "cancer methods ninety": 14794,
      "significant differences vas": 75523,
      "groups 48 hours": 34115,
      "significant analgesic effect": 75428,
      "oxycodone hydrochloride 05": 55173,
      "hydrochloride 05 mg": 36003,
      "001 plasma concentrations": 188,
      "scores significantly higher": 73989,
      "significantly higher dose": 75725,
      "cr oxycodone placebo": 21095,
      "plasma concentration max": 61902,
      "oxycodone did improve": 54967,
      "cr oxycodone hydrochloride": 21088,
      "relief pain patients": 70162,
      "vas score pain": 86021,
      "mg 10 30": 45698,
      "use opioids trauma": 84570,
      "opioids trauma patients": 53353,
      "controlled study evaluated": 20589,
      "recorded compared groups": 68673,
      "oxycodone postoperative analgesia": 55708,
      "doses oxycodone combination": 26234,
      "patients divided groups": 59222,
      "groups group oxycodone": 34209,
      "05 statistically significant": 554,
      "scores 001 lower": 73819,
      "10 mg effective": 813,
      "intravenously mg kg": 39897,
      "received intravenous sufentanil": 68181,
      "number patients administered": 50218,
      "induction anesthesia patients": 38477,
      "26 mg kg": 3446,
      "versus placebo 001": 86148,
      "22 mg kg": 3035,
      "did differ study": 24441,
      "differ study groups": 24552,
      "placebo group 001": 61733,
      "dexamethasone 10 mg": 24282,
      "patients adverse events": 58961,
      "kg 95 ci": 40688,
      "adverse events dizziness": 8754,
      "seventy patients scheduled": 74889,
      "forced vital capacity": 32250,
      "forced expiratory volume": 32248,
      "incidences adverse effects": 37331,
      "hoc analysis performed": 35498,
      "confidence interval 20": 19446,
      "undergoing closed reduction": 83522,
      "significant difference change": 75472,
      "05 postoperative pain": 543,
      "related effects background": 69598,
      "effects different doses": 27895,
      "total 119 patients": 81718,
      "midazolam mg kg": 46396,
      "125 mg kg": 1428,
      "oxycodone group patients": 55137,
      "group patients undergoing": 33908,
      "age 42 years": 9007,
      "oxycodone placebo orally": 55690,
      "provided patient controlled": 66148,
      "placebo groups mean": 61757,
      "oxycodone group median": 55132,
      "mg kg used": 46038,
      "postoperative analgesia oxycodone": 62704,
      "reactions recorded results": 67969,
      "injection mg kg": 38957,
      "prospective randomized clinical": 65859,
      "general anesthesia enrolled": 32959,
      "divided groups according": 25621,
      "group mg kg": 33861,
      "oxycodone diluted 100": 54973,
      "diluted 100 ml": 25011,
      "kg oxycodone combined": 40777,
      "stage n2 sleep": 76867,
      "general anaesthesia induction": 32956,
      "evaluate efficacy different": 29793,
      "years randomly assigned": 87650,
      "equal volume normal": 29236,
      "significantly lower groups": 75790,
      "iv pca morphine": 40401,
      "significant reductions pain": 75622,
      "events constipation nausea": 30034,
      "iv oxycodone morphine": 40394,
      "10 mg vs": 856,
      "study evaluated pharmacokinetics": 78186,
      "groups 10 patients": 34093,
      "rate mg kg": 67485,
      "blind study conducted": 13980,
      "blood pressure bp": 14144,
      "postoperative analgesia opioid": 62703,
      "mg kg induction": 45985,
      "change significantly time": 15751,
      "oxycodone shown effective": 55906,
      "early postoperative analgesia": 27267,
      "administration results total": 8363,
      "opioids administered management": 52708,
      "review conducted according": 72278,
      "preferred reporting items": 63645,
      "reporting items systematic": 70694,
      "items systematic reviews": 40352,
      "systematic reviews meta": 80001,
      "patient satisfaction did": 58758,
      "group mg oxycodone": 33863,
      "02 mg kg": 372,
      "sufentanil group received": 78941,
      "sufentanil injection anesthesia": 78945,
      "injection anesthesia induction": 38938,
      "patients group group": 59336,
      "compared group 05": 18168,
      "healthy volunteers study": 34862,
      "end surgery pain": 28823,
      "postoperative analgesia control": 62701,
      "group received oxycodone": 33960,
      "rescue medication effects": 70952,
      "compared morphine patients": 18211,
      "intravenous injection 10": 39836,
      "groups visual analogue": 34351,
      "mg kg continuous": 45962,
      "kg continuous infusion": 40708,
      "infusion mg kg": 38713,
      "postoperative pain incidence": 62874,
      "95 ci mg": 6366,
      "recovery bowel function": 68741,
      "oxycodone semisynthetic thebaine": 55889,
      "semisynthetic thebaine derivative": 74528,
      "thebaine derivative opioid": 80902,
      "used relief moderate": 85108,
      "postoperative pain intravenous": 62880,
      "received mg oxycodone": 68201,
      "important adverse events": 36993,
      "effect intravenous oxycodone": 27468,
      "fentanyl 200 microg": 31420,
      "oxycodone conclusions oxycodone": 54839,
      "provided better analgesia": 66124,
      "used present study": 85087,
      "surgery patients provided": 79511,
      "oxycodone dose needed": 54996,
      "needed pain relief": 49024,
      "group pain relief": 33896,
      "50 mg group": 4855,
      "needed achieve pain": 48971,
      "achieve pain relief": 7304,
      "decreased respiratory rate": 23036,
      "rescue opioid analgesic": 70965,
      "observed treatment groups": 50725,
      "responses did differ": 71387,
      "underwent laparoscopic surgery": 83686,
      "maintenance postoperative analgesia": 42918,
      "objectives study aimed": 50590,
      "enrolled randomized groups": 29019,
      "adverse events recovery": 8799,
      "efficacy patient controlled": 28324,
      "data primary outcome": 22067,
      "scale nrs 12": 73512,
      "scale nausea vomiting": 73508,
      "14 days results": 1591,
      "experienced significant pain": 30627,
      "overall complication rate": 54191,
      "300 600 mg": 3811,
      "analogue scale scores": 10557,
      "hours 12 24": 35730,
      "45 mg kg": 4590,
      "setting iv department": 74783,
      "iv department surgery": 40370,
      "general anesthesia interventions": 32962,
      "nitrous oxide oxygen": 49505,
      "study drug conclusion": 78134,
      "operative pain control": 51264,
      "pain analgesic consumption": 56445,
      "analgesic consumption methods": 10172,
      "consumption methods patients": 19953,
      "included double blind": 37445,
      "oxycodone mg orally": 55434,
      "rescue analgesic medication": 70937,
      "05 oxycodone consumption": 534,
      "oxycodone consumption similar": 54871,
      "similar groups conclusion": 75927,
      "total 57 patients": 81758,
      "randomized control group": 67056,
      "controlled analgesia pump": 20464,
      "stay recorded results": 77289,
      "oxycodone consumption 12": 54852,
      "group compared control": 33685,
      "groups significantly different": 34323,
      "treatment pain patients": 82740,
      "recorded postoperative pain": 68693,
      "scores postanesthesia care": 73953,
      "randomly double blindly": 67238,
      "assigned treatment group": 12183,
      "patients received ketorolac": 59791,
      "administered patient controlled": 8164,
      "scale pain rest": 73533,
      "effects postoperative nausea": 28094,
      "rescue analgesic consumption": 70936,
      "oxycodone increased patient": 55249,
      "january 2009 march": 40434,
      "difference seen pain": 24683,
      "patients cro group": 59162,
      "intravenous bolus oxycodone": 39819,
      "standardized postoperative opioid": 76983,
      "months postoperatively results": 47466,
      "fair good good": 31157,
      "comparing effect different": 18349,
      "given intravenous injection": 33176,
      "adverse events satisfaction": 8811,
      "pain rest decreased": 57643,
      "assigned receive oxycodone": 12180,
      "nrs rest coughing": 50073,
      "cancer patients unknown": 14896,
      "rest movement significantly": 71427,
      "primary endpoint number": 65029,
      "increase heart rate": 37750,
      "20 69 years": 2303,
      "society anesthesiology patient": 76384,
      "anesthesiology patient classification": 10965,
      "vomiting dizziness drowsiness": 86455,
      "satisfaction postoperative analgesia": 73421,
      "interval ci 45": 39592,
      "incidence rates adverse": 37312,
      "patients reported higher": 59888,
      "oxycodone effective treatment": 55017,
      "analgesia evaluated pain": 9967,
      "24 surgery results": 3279,
      "group conclusions preemptive": 33700,
      "registration clinical trials": 69388,
      "org cn showproj": 53748,
      "cn showproj aspx": 17102,
      "showproj aspx proj": 75358,
      "effective post operative": 27671,
      "patients groups received": 59346,
      "operative days groups": 51250,
      "needed rescue medication": 49034,
      "single agent provide": 76050,
      "aimed investigate effect": 9458,
      "severe somnolence dizziness": 75024,
      "pain nausea patient": 57225,
      "provide adequate pain": 66031,
      "blind controlled trial": 13926,
      "secondary endpoints include": 74226,
      "time manuscript submission": 81281,
      "open group 001": 51151,
      "times day oxycodone": 81423,
      "assayed using liquid": 11891,
      "bypass grafting heart": 14634,
      "grafting heart valve": 33400,
      "oxycodone postoperative pain": 55710,
      "analogue scale 48": 10552,
      "rest deep breathing": 71420,
      "results mean daily": 71767,
      "opioid consumption similar": 51664,
      "lower opioid use": 42661,
      "pain need opioids": 57229,
      "agents patient population": 9236,
      "present case 66": 64608,
      "case 66 year": 15163,
      "pulse oximetry spo2": 66471,
      "2019 june 2020": 2871,
      "decreased 24 hours": 22952,
      "differ significantly patients": 24549,
      "patients undergoing coronary": 60095,
      "undergoing coronary artery": 83526,
      "setting single institution": 74822,
      "single institution tertiary": 76111,
      "institution tertiary level": 39089,
      "tertiary level university": 80743,
      "level university hospital": 41535,
      "university hospital participants": 83862,
      "scores adverse events": 73840,
      "satisfaction pain therapy": 73416,
      "efficacy intrathecal morphine": 28285,
      "prospectively enrolled randomized": 65897,
      "unit pacu pain": 83767,
      "decrease total opioid": 22933,
      "\u03bcg kg dexmedetomidine": 87791,
      "significant changes blood": 75441,
      "outcomes included hospital": 54032,
      "study parallel groups": 78358,
      "time discharge readiness": 81253,
      "analgesia immediate postoperative": 9993,
      "mean age 48": 43684,
      "intravenous morphine sulfate": 39862,
      "protocol patients undergoing": 65987,
      "hospital stay shorter": 35639,
      "postoperative opioid demand": 62817,
      "scores different groups": 73869,
      "similar groups difference": 75929,
      "model lean body mass": 47056,
      "lean body mass age": 41322,
      "body mass age significant": 14197,
      "mass age significant covariates": 43449,
      "received normal saline placebo": 68216,
      "hours hours 12 hours": 35782,
      "hours 12 hours 24": 35732,
      "daily controlled release oxycodone": 21713,
      "medication adverse events recorded": 44458,
      "immediate release oxycodone acetaminophen": 36732,
      "provide better analgesia fewer": 66037,
      "better analgesia fewer effects": 13702,
      "analgesia fewer effects compared": 9978,
      "compared controlled release oxycodone": 18124,
      "oxycodone acute pain management": 54676,
      "postanesthesia care unit pacu": 62636,
      "enrolled patients randomly assigned": 29011,
      "nausea vomiting pruritus respiratory": 48808,
      "vomiting pruritus respiratory depression": 86470,
      "cancer methods ninety patients": 14795,
      "results significant differences vas": 71956,
      "groups 48 hours postoperatively": 34116,
      "oxycodone hydrochloride 05 mg": 55174,
      "hydrochloride 05 mg kg": 36004,
      "001 plasma concentrations oxycodone": 189,
      "peak plasma concentration max": 60319,
      "oral controlled release cr": 53506,
      "oxycodone 20 mg day": 54533,
      "use opioids trauma patients": 84571,
      "recorded compared groups results": 68674,
      "patients divided groups group": 59223,
      "divided groups group oxycodone": 25624,
      "double blind study patients": 26382,
      "did differ study groups": 24442,
      "mg kg 95 ci": 45952,
      "95 confidence interval 20": 6385,
      "patients randomly divided groups": 59753,
      "125 mg kg oxycodone": 1429,
      "mg oxycodone placebo orally": 46134,
      "provided patient controlled analgesia": 66149,
      "oxycodone group experienced significantly": 55129,
      "measured oral morphine equivalent": 43984,
      "adverse reactions recorded results": 8848,
      "methods prospective randomized clinical": 45492,
      "oxycodone diluted 100 ml": 54974,
      "equal volume normal saline": 29237,
      "significant reductions pain intensity": 75623,
      "common adverse events constipation": 17733,
      "adverse events constipation nausea": 8748,
      "events constipation nausea pruritus": 30035,
      "double blind study conducted": 26380,
      "did change significantly time": 24418,
      "preferred reporting items systematic": 63646,
      "reporting items systematic reviews": 70695,
      "items systematic reviews meta": 40353,
      "results studies included review": 71974,
      "sufentanil injection anesthesia induction": 78946,
      "received oxycodone 10 mg": 68232,
      "randomised double blind placebo": 67023,
      "mg kg continuous infusion": 45963,
      "oxycodone semisynthetic thebaine derivative": 55890,
      "semisynthetic thebaine derivative opioid": 74529,
      "used relief moderate severe": 85109,
      "patients received 10 mg": 59763,
      "analgesia opioid sparing effect": 10039,
      "groups postoperative pain scores": 34272,
      "sufentanil group primary outcome": 78940,
      "patients underwent laparoscopic surgery": 60146,
      "rating scale nrs 12": 67659,
      "visual analogue scale scores": 86327,
      "incidence adverse effects study": 37258,
      "setting iv department surgery": 74784,
      "iv department surgery helsinki": 40371,
      "surgery general anesthesia interventions": 79407,
      "post operative pain control": 62603,
      "analgesic consumption methods patients": 10173,
      "study evaluate analgesic efficacy": 78163,
      "methods prospective randomized controlled": 45493,
      "patient controlled analgesia pump": 58591,
      "scores postanesthesia care unit": 73954,
      "administered patient controlled analgesia": 8165,
      "rating scale pain rest": 67670,
      "effects postoperative nausea vomiting": 28095,
      "poor fair good good": 62259,
      "randomly assigned receive oxycodone": 67228,
      "scores rest movement significantly": 73974,
      "rest movement significantly lower": 71428,
      "dose 10 mg oxycodone": 25783,
      "american society anesthesiology patient": 9809,
      "society anesthesiology patient classification": 76385,
      "nausea vomiting dizziness drowsiness": 48798,
      "confidence interval ci 45": 19474,
      "trial registration clinical trials": 83071,
      "chictr org cn showproj": 15999,
      "org cn showproj aspx": 53749,
      "cn showproj aspx proj": 17103,
      "methods patients randomized groups": 45437,
      "post operative days groups": 62594,
      "study aimed investigate effect": 77934,
      "double blind controlled trial": 26345,
      "prospective randomized clinical trial": 65860,
      "assayed using liquid chromatography": 11892,
      "artery bypass grafting heart": 11728,
      "bypass grafting heart valve": 14635,
      "grafting heart valve surgery": 33401,
      "visual analogue scale 48": 86324,
      "present case 66 year": 64609,
      "case 66 year old": 15164,
      "did differ significantly patients": 24439,
      "90 patients undergoing coronary": 6114,
      "patients undergoing coronary artery": 60096,
      "undergoing coronary artery bypass": 83527,
      "setting single institution tertiary": 74823,
      "single institution tertiary level": 76112,
      "institution tertiary level university": 39090,
      "tertiary level university hospital": 80744,
      "level university hospital participants": 41536,
      "postoperative opioid consumption groups": 62815,
      "care unit pacu pain": 15090,
      "significant changes blood pressure": 75442,
      "secondary outcomes included hospital": 74246,
      "wilcoxon rank sum test": 87092,
      "analgesia immediate postoperative period": 9994,
      "mean age 48 years": 43685,
      "prerandomization": 63793,
      "678": 5489,
      "nonelderly": 49736,
      "1023": 1056,
      "603": 5294,
      "sprid": 76782,
      "810": 5891,
      "qd": 66627,
      "multidose": 48182,
      "hap": 34568,
      "sae": 73063,
      "820": 5914,
      "mbma": 43621,
      "spare": 76525,
      "armamentarium": 11681,
      "summaries": 79082,
      "nnth": 49530,
      "humanized": 35980,
      "610": 5322,
      "clbp": 16694,
      "excellence": 30438,
      "cumbersome": 21385,
      "2974": 3630,
      "920": 6160,
      "826": 5920,
      "vertical": 86167,
      "extrinsic": 30992,
      "2135": 2997,
      "fulranumab": 32620,
      "0021": 242,
      "replacements": 70435,
      "progressing": 65571,
      "osteonecrosis": 53873,
      "noncompliant": 49725,
      "lansoprazole": 41087,
      "subdomain": 78610,
      "calf": 14723,
      "forest": 32266,
      "exploiting": 30709,
      "denoted": 23396,
      "polyneuropathic": 62220,
      "statin": 77166,
      "suggestion": 79032,
      "80mg": 5878,
      "erosions": 29508,
      "posttreatment": 63059,
      "emotionally": 28727,
      "gmbh": 33268,
      "americas": 9811,
      "piroxicam": 61565,
      "oa patients": 50352,
      "sparing os": 76532,
      "obtained estimates": 50767,
      "using pharmacokinetic": 85559,
      "population pk": 62377,
      "pk modeling": 61577,
      "using cox": 85362,
      "increased exposure": 37912,
      "reported vitro": 70680,
      "vitro receptor": 86368,
      "analysis supports": 10776,
      "remoxy king": 70341,
      "acquired pfizer": 7358,
      "pfizer march": 60992,
      "enrollment randomized": 29036,
      "randomized withdrawal": 67206,
      "years experienced": 87590,
      "experienced moderate": 30610,
      "weeks open": 86928,
      "remoxy mg": 70344,
      "bid patients": 13787,
      "weeks range": 86950,
      "assessment study": 12142,
      "life safety": 41731,
      "consistent opioids": 19707,
      "efficacy remoxy": 28348,
      "setting sites": 74824,
      "sites patients": 76167,
      "severe low": 74951,
      "dose remoxy": 26055,
      "001 month": 158,
      "month 12": 47382,
      "12 quality": 1357,
      "efficacious patients": 28203,
      "58 12": 5152,
      "component scores": 18588,
      "defined efficacy": 23136,
      "month extension": 47389,
      "treatment additional": 82430,
      "pain mood": 57213,
      "life long": 41704,
      "efforts patients": 28441,
      "indicate controlled": 38219,
      "randomized phase": 67147,
      "ratio treatment": 67804,
      "30 versus": 3804,
      "versus 51": 86110,
      "constipation occurred": 19771,
      "significantly earlier": 75692,
      "ir 0001": 40191,
      "period followed": 60726,
      "followed 12": 32045,
      "cr 20": 21053,
      "entire 12": 29071,
      "values early": 85841,
      "342 patients": 4046,
      "gastrointestinal related": 32887,
      "related teaes": 69700,
      "26 88": 3437,
      "ir pain": 40253,
      "relief sum": 70193,
      "sum total": 79081,
      "groups clinical": 34143,
      "mean spid": 43878,
      "placebo data": 61715,
      "trial data": 83016,
      "000 annual": 17,
      "51 001": 4945,
      "cr mean": 21068,
      "quantitative systematic": 66813,
      "based analgesic": 13277,
      "ci calculated": 16519,
      "810 patients": 5892,
      "agent indicated": 9217,
      "associated fatalities": 12260,
      "tap oxycodone": 80375,
      "identified case": 36425,
      "provide valuable": 66115,
      "reference future": 69130,
      "cases tap": 15268,
      "814 patients": 5895,
      "mg associated": 45799,
      "ir similar": 40259,
      "oxycodone intended": 55287,
      "discusses potential": 25298,
      "available europe": 12803,
      "day dose": 22301,
      "day maintenance": 22331,
      "mg qd": 46192,
      "relief complete": 70118,
      "days included": 22536,
      "index medical": 38196,
      "signs monitored": 75877,
      "efficacy measures": 28295,
      "relief score": 70184,
      "point time": 62111,
      "variables results": 85899,
      "age 63": 9038,
      "63 years": 5371,
      "years commonly": 87579,
      "score median": 73761,
      "global evaluation": 33223,
      "35 29": 4062,
      "35 25": 4061,
      "day 90": 22262,
      "day evaluated": 22310,
      "mg formulation": 45894,
      "trial randomized": 83059,
      "provide superior": 66104,
      "tapentadol provided": 80466,
      "small bowel": 76273,
      "group double": 33757,
      "opiate effects": 51299,
      "suggest acute": 78983,
      "trials active": 83100,
      "tolerability assessed": 81518,
      "reporting results": 70702,
      "respectively assessed": 71171,
      "change overall": 15737,
      "12 dose": 1279,
      "drug primary": 26749,
      "higher incidences": 35253,
      "incidences teaes": 37334,
      "pre specified": 63490,
      "assessed phase": 12037,
      "including single": 37674,
      "active comparators": 7491,
      "potential hap": 63170,
      "apap ir": 11352,
      "apap placebo": 11358,
      "occurred similar": 50845,
      "doses ir": 26206,
      "hcl apap": 34629,
      "apap tablets": 11359,
      "aes constipation": 8873,
      "trials reported": 83195,
      "conclusions safety": 19209,
      "pr 50": 63308,
      "final evaluation": 31745,
      "minus oxycodone": 46633,
      "demonstrated primary": 23361,
      "managing severe": 43298,
      "despite recent": 23899,
      "need study": 48958,
      "based meta": 13334,
      "analysis mbma": 10708,
      "level efficacy": 41465,
      "dropout rates": 26478,
      "modeling approach": 47095,
      "50 maximum": 4847,
      "47 84": 4653,
      "revealed opioids": 72219,
      "opioids tolerated": 53340,
      "05 01": 472,
      "ratings randomized": 67708,
      "euroqol dimension": 29755,
      "placebo results": 61820,
      "lower 14": 42569,
      "studies established": 77714,
      "mg q4": 46189,
      "q4 6h": 66619,
      "ir evaluated": 40224,
      "intensity study": 39318,
      "ir group": 40231,
      "reported 44": 70490,
      "headache 11": 34655,
      "intensity measurements": 39268,
      "providing similar": 66269,
      "drug approved": 26535,
      "orthopedic trauma": 53839,
      "sufficient analgesia": 78970,
      "perioperative oral": 60844,
      "trial primary": 83052,
      "safety effect": 73141,
      "sum score": 79079,
      "patients 16": 58831,
      "49 oxycodone": 4778,
      "14 non": 1614,
      "pre defined": 63463,
      "came cost": 14742,
      "participated randomized": 58388,
      "hours 005": 35727,
      "001 comparison": 116,
      "participants subjects": 58373,
      "receive active": 68047,
      "defined composite": 23125,
      "evaluate 30": 29763,
      "appeared related": 11395,
      "represent useful": 70751,
      "blind week": 13994,
      "respectively maintenance": 71205,
      "18 44": 2049,
      "efficacious safe": 28205,
      "methods dataset": 45308,
      "10 month": 870,
      "60 83": 5237,
      "ci relative": 16537,
      "conclusion hypothesis": 18908,
      "hypothesis generating": 36295,
      "identified combinations": 36430,
      "pain prevalent": 57421,
      "worldwide opioids": 87324,
      "uptake inhibitor": 84019,
      "information selection": 38671,
      "trials inclusion": 83151,
      "data performed": 22043,
      "fixed effect": 31881,
      "analyses primary": 10606,
      "responder rate": 71318,
      "studies 12": 77635,
      "trial open": 83040,
      "treatment number": 82686,
      "showed non": 75278,
      "associated 50": 12210,
      "42 60": 4451,
      "15 overall": 1779,
      "improvement tapentadol": 37168,
      "pooled results": 62244,
      "higher quality": 35313,
      "joint replacement": 40491,
      "spid days": 76688,
      "51 male": 4956,
      "26 oxycodone": 3449,
      "18 28": 2041,
      "score versus": 73808,
      "analyses oxycodone": 10598,
      "stratified age": 77449,
      "showed numerically": 75280,
      "dizziness somnolence": 25644,
      "comparable active": 17944,
      "lowest oxycodone": 42735,
      "elderly oxycodone": 28477,
      "pain sub": 57877,
      "sub optimally": 78580,
      "responsive prior": 71407,
      "treatments performed": 82924,
      "evaluated baseline": 29865,
      "period week": 60812,
      "release study": 70008,
      "preoperatively 12": 63765,
      "ci group": 16529,
      "studies 15": 77638,
      "label active": 40968,
      "er management": 29437,
      "16 respectively": 1891,
      "er demonstrated": 29413,
      "osteoarthritis low": 53861,
      "154 patients": 1826,
      "female 50": 31351,
      "indicating pain": 38265,
      "measures quality": 44092,
      "years treatment": 87681,
      "study lasting": 78284,
      "hours double": 35772,
      "study stable": 78510,
      "improved controlled": 37104,
      "events safety": 30117,
      "discussion treatment": 25313,
      "pain clbp": 56547,
      "clbp compared": 16695,
      "clbp methods": 16696,
      "model estimated": 47046,
      "naproxen celecoxib": 48566,
      "treatment clbp": 82493,
      "years greater": 87595,
      "events level": 30063,
      "administration new": 8308,
      "needed oral": 49018,
      "rate 60": 67437,
      "considering overall": 19666,
      "tolerability outcomes": 81542,
      "period using": 60807,
      "001 results": 202,
      "36 domains": 4128,
      "general health": 32973,
      "june 2009": 40541,
      "analysis indicates": 10702,
      "oxycodone analyzed": 54716,
      "study ra": 78443,
      "treatment started": 82851,
      "started oxycodone": 77010,
      "mg adverse": 45798,
      "alternative non": 9728,
      "steroidal antiinflammatory": 77346,
      "different treatments": 24932,
      "appears sensitive": 11411,
      "hormone concentrations": 35544,
      "mechanistic hypothesis": 44157,
      "dose comparison": 25848,
      "morphine healthy": 47710,
      "centers medical": 15570,
      "points postdose": 62139,
      "postdose study": 62647,
      "volunteers similar": 86435,
      "similar baseline": 75902,
      "dosing mean": 26316,
      "86 mg": 6007,
      "baseline endpoint": 13432,
      "smaller compared": 76311,
      "translate reduced": 82212,
      "times week": 81437,
      "varying pain": 85996,
      "pain suggests": 57886,
      "weighted mean": 86986,
      "05 total": 558,
      "tolerability evaluated": 81534,
      "related higher": 69615,
      "higher treatment": 35334,
      "orthopedic pain": 53826,
      "tolerability measures": 81536,
      "33 19": 3979,
      "29 15": 3594,
      "constipation vs": 19796,
      "aes monitored": 8877,
      "placebo 95": 61643,
      "46 001": 4615,
      "mg background": 45802,
      "assessments study": 12156,
      "05 11": 476,
      "endpoint overall": 28894,
      "90 oxycodone": 6111,
      "celecoxib diclofenac": 15457,
      "diclofenac naproxen": 24393,
      "cohort 55": 17341,
      "discontinuation oral": 25224,
      "463 patients": 4639,
      "patients greater": 59334,
      "activity results": 7587,
      "safety health": 73156,
      "criteria used": 21223,
      "pivotal study": 61572,
      "treat population": 82314,
      "period 15": 60684,
      "pr demonstrated": 63320,
      "outcomes 30": 54008,
      "summary index": 79105,
      "comparator controlled": 17991,
      "methods phase": 45462,
      "scores baseline": 73844,
      "fda clinical": 31277,
      "weeks 16": 86891,
      "placebo 77": 61642,
      "placebo generally": 61730,
      "tolerated trial": 81643,
      "pain reduces": 57492,
      "reduces quality": 69006,
      "analgesic prescribed": 10296,
      "discontinue treatment": 25239,
      "search randomized": 74126,
      "searched included": 74153,
      "included pubmed": 37527,
      "diabetic peripheral": 24317,
      "neuropathy treatment": 49281,
      "profile superior": 65511,
      "providing greater": 66262,
      "profile relative": 65506,
      "november 2010": 50029,
      "considered trials": 19660,
      "trials different": 83137,
      "withdrawal design": 87124,
      "evaluated including": 29891,
      "oxymorphone performed": 56278,
      "life furthermore": 41695,
      "events significantly": 30121,
      "treatments significantly": 82927,
      "supporting efficacy": 79225,
      "decade treatment": 22808,
      "naproxen plus": 48570,
      "agents oxycodone": 9234,
      "similar traditional": 76000,
      "nsaid therapy": 50096,
      "comparators conclusions": 18002,
      "ability clinicians": 6550,
      "sustained 12": 79775,
      "provides consistent": 66207,
      "demonstrated analgesic": 23330,
      "producing analgesia": 65422,
      "approximately times": 11589,
      "profile effects": 65485,
      "discuss role": 25287,
      "treatment years": 82893,
      "oral treatments": 53682,
      "articles performed": 11801,
      "performed pubmed": 60616,
      "march 2013": 43362,
      "baseline change": 13419,
      "comparison performed": 18375,
      "oxycodone worse": 56103,
      "trends overall": 82978,
      "pooled randomized": 62243,
      "australia new": 12690,
      "shown tolerated": 75353,
      "point treatment": 62112,
      "treatment responders": 82815,
      "pr 65": 63310,
      "tapentadol assess": 80384,
      "assess adverse": 11905,
      "reporting guidelines": 70690,
      "individuals abusing": 38331,
      "unlikely cause": 83898,
      "cancer population": 14897,
      "does require": 25691,
      "metabolic activation": 44904,
      "trials controlled": 83129,
      "oxycodone osteoarthritis": 55586,
      "functional interference": 32699,
      "reliability validity": 70078,
      "effectively relieves": 27740,
      "increasing patient": 38117,
      "reported possible": 70627,
      "58 year": 5165,
      "activity conclusions": 7560,
      "professionals aware": 65466,
      "thorough history": 81133,
      "factors obtained": 31118,
      "furthermore low": 32749,
      "level abuse": 41447,
      "sufficient produce": 78976,
      "therapy showed": 81067,
      "63 received": 5366,
      "60 mean": 5257,
      "66 baseline": 5454,
      "main analysis": 42824,
      "population change": 62316,
      "12 0001": 1200,
      "tapentadol transdermal": 80475,
      "prior opioids": 65161,
      "treatment week": 82888,
      "time common": 81222,
      "major symptoms": 42979,
      "methods quantify": 45502,
      "47 30": 4647,
      "behavioural effects": 13572,
      "large controlled": 41124,
      "analgesia placebo": 10060,
      "morphine taken": 47949,
      "provided greater": 66138,
      "understand factors": 83623,
      "controlled active": 20443,
      "ranging study": 67360,
      "er 20": 29386,
      "121 oxycodone": 1418,
      "pretreatment posttreatment": 64764,
      "variables discussion": 85893,
      "suggest patient": 79007,
      "patient doing": 58624,
      "patient likely": 58673,
      "feeling better": 31335,
      "contribution opioid": 20248,
      "contribution analgesia": 20246,
      "percent contribution": 60458,
      "vivo data": 86378,
      "data estimate": 21959,
      "estimate contribution": 29606,
      "consistent various": 19718,
      "tablets objective": 80181,
      "lists articles": 42104,
      "dental extraction": 23401,
      "extraction pain": 30967,
      "conclusions short": 19212,
      "common form": 17757,
      "28 july": 3558,
      "criteria studies": 21218,
      "calculated pain": 14695,
      "function smd": 32681,
      "events frequent": 30046,
      "events non": 30077,
      "duration conducted": 27156,
      "effectiveness evaluated": 27762,
      "rates accounting": 67551,
      "efficacy related": 28343,
      "opioids 18": 52664,
      "opioids 19": 52665,
      "mean baseline": 43723,
      "patients discuss": 59217,
      "debate updated": 22797,
      "cochrane systematic": 17187,
      "methods screened": 45554,
      "screened medline": 74030,
      "medline scopus": 44749,
      "scopus cochrane": 73698,
      "central october": 15605,
      "2013 reference": 2638,
      "reference sections": 69140,
      "sections original": 74297,
      "rcts opioids": 67917,
      "weeks using": 86966,
      "model absolute": 47019,
      "differences rd": 24798,
      "rd calculated": 67925,
      "calculated categorical": 14684,
      "differences smd": 24816,
      "smd continuous": 76331,
      "median study": 44282,
      "opioids superior": 53323,
      "intensity smd": 39317,
      "smd 22": 76322,
      "participants opioids": 58333,
      "placebo 50": 61635,
      "reduction rd": 69098,
      "00 07": 3,
      "placebo terms": 61838,
      "placebo improving": 61763,
      "functioning smd": 32725,
      "dropped frequently": 26483,
      "frequently opioids": 32562,
      "placebo rd": 61810,
      "rd 17": 67924,
      "participants number": 58329,
      "needed harm": 49007,
      "frequency adverse": 32509,
      "events sae": 30114,
      "sae deaths": 73064,
      "efficacy inferior": 28281,
      "inferior terms": 38527,
      "terms tolerability": 80723,
      "intensity physical": 39290,
      "placebo did": 61717,
      "terms safety": 80720,
      "safety conclusion": 73132,
      "conclusion safety": 18986,
      "placebo limited": 61769,
      "limited low": 41941,
      "number sae": 50249,
      "deaths short": 22783,
      "considered selected": 19651,
      "nonpharmacological therapies": 49830,
      "article freely": 11769,
      "freely available": 32497,
      "springerlink supplemental": 76785,
      "supplemental background": 79163,
      "period data": 60720,
      "baseline patients": 13454,
      "medication baseline": 44465,
      "beats minute": 13507,
      "approved usa": 11552,
      "including nonsteroidal": 37651,
      "long time": 42364,
      "treatment persistent": 82758,
      "naproxen tramadol": 48574,
      "population high": 62338,
      "aes conclusion": 8872,
      "opioids nearly": 53084,
      "vs nonopioid": 86664,
      "effects design": 27888,
      "range 19": 67266,
      "58 mean": 5160,
      "group nonopioid": 33874,
      "performed 15": 60566,
      "2012 checked": 2596,
      "treatment people": 82752,
      "excluded studies": 30481,
      "identified 12": 36415,
      "beneficial pain": 13602,
      "smd 28": 76326,
      "difference improvement": 24622,
      "15 opioids": 1778,
      "smd 26": 76323,
      "function scores": 32679,
      "units opioids": 83834,
      "administration daily": 8239,
      "001 evidence": 136,
      "drop outs": 26475,
      "trials participants": 83177,
      "dropped adverse": 26481,
      "experienced withdrawal": 30636,
      "pain outcome": 57304,
      "did include": 24455,
      "persistent pain despite": 60923,
      "opioid sparing os": 52369,
      "population pk parameters": 62378,
      "vitro receptor binding": 86369,
      "pk pd analysis": 61582,
      "remoxy king pharmaceuticals": 70342,
      "acquired pfizer march": 7359,
      "pfizer march 2011": 60993,
      "enriched enrollment randomized": 28989,
      "enrollment randomized withdrawal": 29037,
      "label titration phase": 41005,
      "experienced moderate severe": 30611,
      "weeks open label": 86929,
      "remoxy mg twice": 70345,
      "period primary endpoint": 60779,
      "quality life safety": 66746,
      "reported significantly better": 70648,
      "profile consistent opioids": 65482,
      "profile similar opioids": 65508,
      "similar opioids objective": 75960,
      "opioids objective evaluate": 53107,
      "objective evaluate long": 50422,
      "setting sites patients": 74825,
      "moderate severe low": 47182,
      "severe low pain": 74952,
      "assessments included adverse": 12152,
      "ratings pain intensity": 67704,
      "time points 001": 81332,
      "efficacy end points": 28260,
      "higher proportion oxycodone": 35311,
      "efficacy safety treatment": 28393,
      "oxycodone oxycontin tablets": 55612,
      "term use patients": 80681,
      "pain methods thirty": 57191,
      "placebo reducing pain": 61812,
      "effective safe patients": 27698,
      "pain methods double": 57180,
      "placebo control groups": 61672,
      "received tapentadol ir": 68297,
      "100 mg oxycodone": 995,
      "ir 50 100": 40209,
      "50 100 mg": 4801,
      "results post hoc": 71876,
      "followed 12 week": 32046,
      "week maintenance period": 86847,
      "twice daily placebo": 83303,
      "reported treatment emergent": 70670,
      "active controlled phase": 7501,
      "controlled phase iii": 20519,
      "primary endpoint sum": 65035,
      "pain relief sum": 57586,
      "relief sum pain": 70194,
      "rescue medication patient": 70954,
      "medication patient global": 44535,
      "overall incidence adverse": 54206,
      "placebo oxycodone controlled": 61794,
      "clinical trial data": 16927,
      "oxycodone cr mean": 54899,
      "oxycodone pain treatment": 55634,
      "intervals ci calculated": 39608,
      "ci calculated results": 16520,
      "opioid acute pain": 51398,
      "double blind clinical": 26341,
      "daily extended release": 21748,
      "14 day dose": 1583,
      "day dose titration": 22302,
      "relief complete relief": 70119,
      "mos sleep scale": 48004,
      "vital signs monitored": 86346,
      "mean pain relief": 43830,
      "pain relief score": 57579,
      "end point time": 28805,
      "mean age 63": 43699,
      "age 63 years": 9039,
      "intensity decreased baseline": 39242,
      "patient global evaluation": 58649,
      "low pain methods": 42523,
      "day 90 day": 22263,
      "50 pain intensity": 4877,
      "10 mg respectively": 844,
      "relief pain intensity": 70161,
      "statistical analysis results": 77174,
      "provide superior pain": 66105,
      "acute pain background": 7663,
      "parallel group double": 58130,
      "group double blind": 33758,
      "doses tested oxycodone": 26288,
      "data suggest acute": 22130,
      "severe pain objective": 74990,
      "objective evaluate relative": 50427,
      "50 75 mg": 4822,
      "study drug primary": 78136,
      "treatment groups conclusions": 82603,
      "significant improvements observed": 75555,
      "recreational users prescription": 68786,
      "ir er oc": 40221,
      "abuse potential hap": 6819,
      "oc apap ir": 50800,
      "apap ir oc": 11353,
      "study patients chronic": 78367,
      "tramadol hcl apap": 82066,
      "oc apap tablets": 50802,
      "conclusions safety tolerability": 19210,
      "neuropathic pain component": 49238,
      "patients average pain": 59021,
      "10 mg mg": 825,
      "40 mg 20": 4343,
      "mg plus oxycodone": 46165,
      "background despite recent": 13037,
      "aspects opioids used": 11864,
      "model based meta": 47030,
      "based meta analysis": 13335,
      "meta analysis mbma": 44893,
      "001 mean sd": 153,
      "10 mg results": 845,
      "mg q4 6h": 46190,
      "pain intensity study": 56952,
      "intent treat patients": 39338,
      "treat patients received": 82313,
      "nausea 18 vs": 48762,
      "18 vs 29": 2108,
      "pain intensity measurements": 56913,
      "providing similar pain": 66270,
      "acute pain patients": 7672,
      "pain patients aged": 57338,
      "associated significant reductions": 12431,
      "administration extended release": 8262,
      "sd daily pain": 74078,
      "effects equianalgesic doses": 27913,
      "equianalgesic doses compared": 29259,
      "meta analysis randomized": 44898,
      "pain low pain": 57038,
      "percent pain relief": 60472,
      "50 percent pain": 4887,
      "respectively maintenance period": 71206,
      "23 vs 46": 3116,
      "average 10 month": 12856,
      "ci 60 83": 16476,
      "exploratory study identified": 30716,
      "pain prevalent condition": 57422,
      "objectives determine efficacy": 50556,
      "extracted data performed": 30953,
      "active control oxycodone": 7494,
      "effects main results": 27979,
      "studies 12 weeks": 77636,
      "trial open label": 83041,
      "treatment number needed": 82687,
      "discontinuing treatment adverse": 25255,
      "ci 12 12": 16397,
      "ci 42 60": 16449,
      "pooled results studies": 62245,
      "aes nausea vomiting": 8879,
      "white mean age": 87020,
      "mg associated significantly": 45800,
      "study investigated efficacy": 78278,
      "pain score versus": 57689,
      "placebo 001 oxycodone": 61610,
      "comparable active treatments": 17945,
      "acetaminophen codeine acetaminophen": 7165,
      "pain sub optimally": 57878,
      "randomized single blind": 67183,
      "intervention patients received": 39640,
      "used rescue analgesia": 85114,
      "95 ci group": 6364,
      "open label active": 51156,
      "label active controlled": 40969,
      "er management moderate": 29438,
      "hydrochloride hcl controlled": 36022,
      "25 patients respectively": 3379,
      "chronic osteoarthritis low": 16249,
      "osteoarthritis low pain": 53862,
      "dose patients received": 26007,
      "measures quality life": 44093,
      "patients received controlled": 59771,
      "hours double blind": 35773,
      "primary efficacy variables": 65013,
      "release oxycodone significantly": 69976,
      "oxycodone significantly superior": 55916,
      "significantly superior placebo": 75864,
      "adverse events safety": 8810,
      "resulted significant pain": 71519,
      "low pain clbp": 42520,
      "intravenous iv administration": 39842,
      "low pain patients": 42528,
      "day primary endpoint": 22392,
      "patients pain intensity": 59620,
      "intensity neuropathic pain": 39274,
      "tapentadol oxycodone buprenorphine": 80452,
      "decreased time conclusions": 23049,
      "study randomized receive": 78450,
      "greater reductions pain": 33487,
      "treatment oxycodone cr": 82727,
      "2009 december 2015": 2525,
      "oxycodone acetaminophen pain": 54653,
      "oxycodone acetaminophen treatment": 54665,
      "effective oxycodone acetaminophen": 27659,
      "non steroidal antiinflammatory": 49689,
      "steroidal antiinflammatory drugs": 77347,
      "studies conducted study": 77675,
      "study single dose": 78503,
      "single dose comparison": 76078,
      "evaluated 24 hours": 29856,
      "time points postdose": 81340,
      "therapeutic dose range": 80930,
      "oxycodone cr 20": 54893,
      "patients mild moderate": 59515,
      "period 12 weeks": 60681,
      "12 weeks patients": 1382,
      "cross study design": 21275,
      "pain objective assess": 57261,
      "severe pain compared": 74973,
      "maintenance period patients": 42914,
      "period patients received": 60769,
      "opioid agonist activity": 51422,
      "outcome measures efficacy": 53937,
      "events aes monitored": 30011,
      "placebo 95 confidence": 61645,
      "patients received dose": 59777,
      "month period treatment": 47403,
      "pharmacokinetic drug drug": 61113,
      "acute pain adults": 7660,
      "efficacy safety health": 28362,
      "safety health related": 73157,
      "intent treat population": 39340,
      "mg bid placebo": 45806,
      "pr demonstrated significant": 63321,
      "active comparator controlled": 7488,
      "controlled study patients": 20592,
      "administration fda clinical": 8264,
      "12 weeks 16": 1379,
      "resulted significantly better": 71523,
      "generally tolerated trial": 33034,
      "pain reduces quality": 57493,
      "reduces quality life": 69007,
      "databases searched included": 22208,
      "searched included pubmed": 74154,
      "diabetic peripheral neuropathy": 24318,
      "profile superior oxycodone": 65512,
      "pain management chronic": 57060,
      "transdermal buprenorphine transdermal": 82143,
      "buprenorphine transdermal fentanyl": 14595,
      "quality life furthermore": 66725,
      "conduct systematic review": 19334,
      "controlled trials active": 20622,
      "trials active comparators": 83101,
      "adverse events level": 8767,
      "support efficacy safety": 79194,
      "short term trials": 75200,
      "treatment patients methods": 82749,
      "given oxycodone acetaminophen": 33184,
      "phase ii iii": 61288,
      "clinical studies patients": 16916,
      "severe acute postoperative": 74905,
      "approximately times potent": 11590,
      "pain conditions including": 56589,
      "baseline change baseline": 13420,
      "data pooled randomized": 22051,
      "australia new zealand": 12691,
      "assess adverse events": 11906,
      "used measure pain": 85003,
      "reliability validity responsiveness": 70079,
      "58 year old": 5166,
      "pain 10 scale": 56355,
      "treated oxycodone acetaminophen": 82364,
      "treatment objective objective": 82690,
      "treatment week 12": 82889,
      "yielded similar results": 87701,
      "rheumatoid arthritis pain": 72456,
      "mg day significantly": 45865,
      "24 36 hours": 3160,
      "significantly better analgesia": 75661,
      "oral surgery valdecoxib": 53669,
      "did cause significant": 24415,
      "performed using data": 60648,
      "placebo controlled active": 61674,
      "controlled active controlled": 20444,
      "active controlled parallel": 7499,
      "dose ranging study": 26032,
      "er 20 mg": 29387,
      "adverse effects different": 8653,
      "reference lists articles": 69133,
      "dental extraction pain": 23402,
      "release er placebo": 69850,
      "12 hours primary": 1306,
      "analog scale 100": 10525,
      "placebo 95 ci": 61644,
      "relieving pain improving": 70239,
      "treatment option patients": 82710,
      "objectives determine effects": 50555,
      "oral transdermal opioids": 53677,
      "selection criteria studies": 74413,
      "criteria studies included": 21219,
      "adverse events frequent": 8756,
      "drugs nsaids opioids": 27012,
      "mean baseline pain": 43724,
      "greater pain reduction": 33473,
      "efficacy tolerability safety": 28409,
      "cochrane systematic review": 17188,
      "systematic review efficacy": 79986,
      "methods screened medline": 45555,
      "screened medline scopus": 74031,
      "medline scopus cochrane": 44750,
      "scopus cochrane central": 73699,
      "trials central october": 83112,
      "central october 2013": 15606,
      "october 2013 reference": 50877,
      "2013 reference sections": 2639,
      "reference sections original": 69141,
      "sections original studies": 74298,
      "original studies systematic": 53790,
      "trials rcts opioids": 83188,
      "effects model absolute": 27999,
      "model absolute risk": 47020,
      "absolute risk differences": 6602,
      "risk differences rd": 72549,
      "differences rd calculated": 24799,
      "rd calculated categorical": 67926,
      "calculated categorical data": 14685,
      "categorical data standardized": 15290,
      "data standardized mean": 22115,
      "mean differences smd": 43765,
      "differences smd continuous": 24817,
      "smd continuous variables": 76332,
      "continuous variables results": 20194,
      "variables results included": 85900,
      "participants median study": 58324,
      "median study duration": 44283,
      "study duration 12": 78140,
      "buprenorphine hydromorphone morphine": 14553,
      "opioids superior placebo": 53324,
      "superior placebo reducing": 79142,
      "pain intensity smd": 56951,
      "participants opioids superior": 58334,
      "superior placebo 50": 79138,
      "placebo 50 pain": 61636,
      "pain reduction rd": 57499,
      "superior placebo terms": 79145,
      "superior placebo improving": 79140,
      "placebo improving physical": 61764,
      "physical functioning smd": 61401,
      "functioning smd 22": 32726,
      "participants patients dropped": 58339,
      "patients dropped frequently": 59225,
      "dropped frequently opioids": 26484,
      "frequently opioids placebo": 32563,
      "opioids placebo rd": 53180,
      "participants number needed": 58330,
      "number needed harm": 50183,
      "difference opioids placebo": 24645,
      "frequency adverse events": 32510,
      "adverse events sae": 8807,
      "events sae deaths": 30115,
      "conclusion opioids superior": 18941,
      "placebo terms efficacy": 61839,
      "terms efficacy inferior": 80707,
      "efficacy inferior terms": 28282,
      "inferior terms tolerability": 38528,
      "opioids placebo did": 53178,
      "placebo did differ": 61718,
      "differ terms safety": 24555,
      "terms safety conclusion": 80721,
      "conclusion safety opioids": 18987,
      "safety opioids compared": 73179,
      "compared placebo limited": 18266,
      "placebo limited low": 61770,
      "limited low number": 41942,
      "low number sae": 42507,
      "number sae deaths": 50250,
      "sae deaths short": 73065,
      "deaths short term": 22784,
      "opioid therapy considered": 52410,
      "therapy considered selected": 81001,
      "version article freely": 86085,
      "article freely available": 11770,
      "freely available springerlink": 32498,
      "available springerlink supplemental": 12840,
      "springerlink supplemental background": 76786,
      "blind treatment period": 13990,
      "er oxycodone hcl": 29459,
      "acetaminophen treatment moderate": 7256,
      "including nonsteroidal anti": 37652,
      "strong weak opioids": 77565,
      "opioid vs nonopioid": 52635,
      "acetaminophen paracetamol nonsteroidal": 7232,
      "update cochrane review": 83977,
      "smd 28 95": 76327,
      "smd 26 95": 76324,
      "administration daily dose": 8240,
      "function adverse events": 32624,
      "dropped adverse events": 26482,
      "mean age 60 years": 43694,
      "negative impact pain relief": 49077,
      "remoxy king pharmaceuticals bristol": 70343,
      "acquired pfizer march 2011": 7360,
      "enriched enrollment randomized withdrawal": 28990,
      "open label titration phase": 51187,
      "remoxy mg twice daily": 70346,
      "mg twice daily bid": 46251,
      "profile similar opioids objective": 65509,
      "similar opioids objective evaluate": 75961,
      "objective evaluate long term": 50423,
      "moderate severe low pain": 47183,
      "assessments included adverse events": 12153,
      "primary efficacy end points": 65006,
      "long term use patients": 42363,
      "pain methods thirty patients": 57192,
      "placebo reducing pain intensity": 61813,
      "pain methods double blind": 57181,
      "experienced moderate severe pain": 30612,
      "received tapentadol ir 50": 68298,
      "65 years age older": 5425,
      "tapentadol ir 50 100": 80429,
      "ir 50 100 mg": 40210,
      "50 100 mg oxycodone": 4802,
      "nausea vomiting significantly lower": 48816,
      "mg twice daily oxycodone": 46253,
      "average daily pain intensity": 12886,
      "reported treatment emergent adverse": 70671,
      "placebo active controlled phase": 61654,
      "active controlled phase iii": 7502,
      "total pain relief sum": 81879,
      "pain relief sum pain": 57587,
      "relief sum pain intensity": 70195,
      "use rescue medication patient": 84698,
      "rescue medication patient global": 70955,
      "15 mg compared placebo": 1752,
      "significantly lower incidence nausea": 75792,
      "placebo oxycodone controlled release": 61795,
      "confidence intervals ci calculated": 19484,
      "intervals ci calculated results": 39609,
      "systematic literature search conducted": 79981,
      "randomized double blind clinical": 67098,
      "objective study compared efficacy": 50503,
      "14 day dose titration": 1584,
      "study mos sleep scale": 78317,
      "mean age 63 years": 43700,
      "pain intensity decreased baseline": 56895,
      "methods post hoc analysis": 45470,
      "oxycodone 10 mg significantly": 54503,
      "greater pain relief reduced": 33475,
      "pain relief pain intensity": 57562,
      "used statistical analysis results": 85142,
      "parallel group double blind": 58131,
      "recreational users prescription opioids": 68787,
      "ir er oc apap": 40222,
      "human abuse potential hap": 35939,
      "er oc apap ir": 29447,
      "oc apap ir oc": 50801,
      "apap ir oc apap": 11354,
      "ir oc apap tablets": 40240,
      "pain neuropathic pain component": 57236,
      "patients average pain intensity": 59022,
      "40 mg 20 mg": 4344,
      "model based meta analysis": 47031,
      "based meta analysis mbma": 13336,
      "intent treat patients received": 39339,
      "providing similar pain relief": 66271,
      "mean sd daily pain": 43863,
      "oxycodone 10 mg twice": 54504,
      "50 percent pain relief": 4888,
      "adverse effects main results": 8662,
      "treatment number needed treat": 82688,
      "10 95 ci 12": 734,
      "95 ci 12 12": 6247,
      "95 ci 42 60": 6294,
      "reported adverse events aes": 70502,
      "associated significantly lower incidence": 12439,
      "oxycodone acetaminophen codeine acetaminophen": 54634,
      "outcome measures pain scores": 53945,
      "similar analgesic efficacy oxycodone": 75899,
      "open label active controlled": 51157,
      "er management moderate severe": 29439,
      "oxycodone hydrochloride hcl controlled": 55186,
      "hydrochloride hcl controlled release": 36023,
      "patients received oxycodone cr": 59811,
      "chronic osteoarthritis low pain": 16250,
      "low pain methods patients": 42524,
      "patients received controlled release": 59772,
      "controlled release oxycodone placebo": 20566,
      "average pain intensity scores": 12925,
      "controlled release oxycodone significantly": 20567,
      "oxycodone significantly superior placebo": 55917,
      "chronic low pain clbp": 16202,
      "chronic low pain patients": 16204,
      "pain intensity neuropathic pain": 56918,
      "non steroidal antiinflammatory drugs": 49690,
      "pain objective assess efficacy": 57262,
      "moderate severe pain compared": 47194,
      "group significant differences observed": 34014,
      "significant pain relief compared": 75593,
      "moderate severe chronic low": 47176,
      "mg oxycodone hcl controlled": 46117,
      "pain scores adverse events": 57704,
      "adverse events aes monitored": 8728,
      "placebo 95 confidence interval": 61646,
      "methods patients randomized receive": 45438,
      "pharmacokinetic drug drug interactions": 61114,
      "efficacy safety health related": 28363,
      "safety health related quality": 73158,
      "placebo active comparator controlled": 61649,
      "drug administration fda clinical": 26523,
      "pain reduces quality life": 57494,
      "databases searched included pubmed": 22209,
      "associated adverse effects including": 12217,
      "transdermal buprenorphine transdermal fentanyl": 82144,
      "controlled trials active comparators": 20623,
      "moderate severe acute postoperative": 47168,
      "severe acute postoperative pain": 74906,
      "related adverse events compared": 69554,
      "naranjo probability scale revealed": 48578,
      "treatment objective objective study": 82691,
      "osteoarthritis rheumatoid arthritis pain": 53871,
      "provided significantly better analgesia": 66157,
      "analysis performed using data": 10733,
      "multicenter double blind placebo": 48159,
      "placebo controlled active controlled": 61675,
      "active controlled parallel group": 7500,
      "extended release er placebo": 30870,
      "placebo active controlled parallel": 61653,
      "visual analog scale 100": 86307,
      "selection criteria studies included": 74414,
      "inflammatory drugs nsaids opioids": 38567,
      "safety opioid therapy chronic": 73177,
      "cochrane systematic review efficacy": 17189,
      "systematic review efficacy safety": 79987,
      "review efficacy safety opioids": 72289,
      "methods screened medline scopus": 45556,
      "screened medline scopus cochrane": 74032,
      "medline scopus cochrane central": 44751,
      "scopus cochrane central register": 73700,
      "controlled trials central october": 20627,
      "trials central october 2013": 83113,
      "central october 2013 reference": 15607,
      "october 2013 reference sections": 50878,
      "2013 reference sections original": 2640,
      "reference sections original studies": 69142,
      "sections original studies systematic": 74299,
      "original studies systematic reviews": 53791,
      "studies systematic reviews randomized": 77861,
      "controlled trials rcts opioids": 20644,
      "included double blind randomized": 37446,
      "randomized placebo controlled studies": 67153,
      "random effects model absolute": 66997,
      "effects model absolute risk": 28000,
      "model absolute risk differences": 47021,
      "absolute risk differences rd": 6603,
      "risk differences rd calculated": 72550,
      "differences rd calculated categorical": 24800,
      "rd calculated categorical data": 67927,
      "calculated categorical data standardized": 14686,
      "categorical data standardized mean": 15291,
      "data standardized mean differences": 22116,
      "standardized mean differences smd": 76967,
      "mean differences smd continuous": 43766,
      "differences smd continuous variables": 24818,
      "smd continuous variables results": 76333,
      "continuous variables results included": 20195,
      "participants median study duration": 58325,
      "median study duration 12": 44284,
      "opioids superior placebo reducing": 53327,
      "superior placebo reducing pain": 79143,
      "reducing pain intensity smd": 69027,
      "participants opioids superior placebo": 58335,
      "opioids superior placebo 50": 53325,
      "superior placebo 50 pain": 79139,
      "placebo 50 pain reduction": 61637,
      "50 pain reduction rd": 4879,
      "opioids superior placebo terms": 53328,
      "opioids superior placebo improving": 53326,
      "superior placebo improving physical": 79141,
      "placebo improving physical functioning": 61765,
      "improving physical functioning smd": 37203,
      "physical functioning smd 22": 61402,
      "participants patients dropped frequently": 58340,
      "patients dropped frequently opioids": 59226,
      "dropped frequently opioids placebo": 26485,
      "frequently opioids placebo rd": 32564,
      "participants number needed harm": 58331,
      "significant difference opioids placebo": 75482,
      "frequency adverse events sae": 32511,
      "adverse events sae deaths": 8808,
      "conclusion opioids superior placebo": 18942,
      "superior placebo terms efficacy": 79146,
      "placebo terms efficacy inferior": 61840,
      "terms efficacy inferior terms": 80708,
      "efficacy inferior terms tolerability": 28283,
      "opioids placebo did differ": 53179,
      "placebo did differ terms": 61719,
      "did differ terms safety": 24444,
      "differ terms safety conclusion": 24556,
      "conclusion safety opioids compared": 18988,
      "safety opioids compared placebo": 73180,
      "opioids compared placebo limited": 52809,
      "compared placebo limited low": 18267,
      "placebo limited low number": 61771,
      "limited low number sae": 41943,
      "low number sae deaths": 42508,
      "number sae deaths short": 50251,
      "sae deaths short term": 73066,
      "deaths short term opioid": 22785,
      "short term opioid therapy": 75196,
      "term opioid therapy considered": 80646,
      "opioid therapy considered selected": 52411,
      "text version article freely": 80890,
      "version article freely available": 86086,
      "article freely available springerlink": 11771,
      "freely available springerlink supplemental": 32499,
      "available springerlink supplemental background": 12841,
      "double blind treatment period": 26387,
      "acetaminophen treatment moderate severe": 7257,
      "severe pain objective objective": 74991,
      "including nonsteroidal anti inflammatory": 37653,
      "acetaminophen paracetamol nonsteroidal anti": 7233,
      "update cochrane review published": 83978,
      "smd 28 95 ci": 76328,
      "smd 26 95 ci": 76325,
      "sort": 76477,
      "798": 5813,
      "iowa": 40152,
      "precipitously": 63520,
      "suicides": 79050,
      "regionally": 69362,
      "prototype": 66014,
      "exclusive": 30489,
      "blacks": 13904,
      "amidst": 9816,
      "equating": 29249,
      "toxicologists": 81946,
      "31st": 3899,
      "492": 4786,
      "acetylcysteine": 7277,
      "fragments": 32471,
      "envenomation": 29090,
      "k2": 40573,
      "grow": 34356,
      "affluent": 8950,
      "spaces": 76519,
      "chlorzoxazone": 16107,
      "orphenadrine": 53810,
      "metaxalone": 45031,
      "nonmedically": 49794,
      "mississippi": 46700,
      "contaminants": 20090,
      "ref": 69122,
      "outbreaks": 53900,
      "769": 5753,
      "404": 4401,
      "intervene": 39621,
      "insurer": 39162,
      "dictated": 24397,
      "amoxicillin": 9840,
      "suggestions": 79033,
      "quadruple": 66657,
      "building": 14476,
      "stores": 77400,
      "figure": 31695,
      "alimentary": 9572,
      "levomepromazine": 41626,
      "linkages": 42046,
      "nonwhite": 49866,
      "river": 72689,
      "midwestern": 46416,
      "witnessed": 87179,
      "638": 5375,
      "1149": 1179,
      "uncover": 83495,
      "analgetic": 10519,
      "increment": 38141,
      "subcommittee": 78596,
      "ingestions": 38748,
      "postinjury": 62664,
      "health issues": 34726,
      "individuals experiencing": 38346,
      "overdoses poisonings": 54333,
      "identified participants": 36453,
      "opioids active": 52701,
      "medications drugs": 44617,
      "family social": 31187,
      "consecutive negative": 19560,
      "impaired cognition": 36871,
      "patterns oxycodone": 60221,
      "outcome objective": 53963,
      "drug poisoning": 26740,
      "states united": 77155,
      "rates state": 67638,
      "state using": 77070,
      "results fold": 71698,
      "12 100": 1208,
      "sales drug": 73249,
      "distribution drug": 25559,
      "level dispensing": 41461,
      "period 2005": 60690,
      "2005 2016": 2466,
      "stratified sample": 77456,
      "rates assessed": 67557,
      "increased dispensing": 37903,
      "formulations significant": 32407,
      "levels dispensing": 41556,
      "deaths likely": 22766,
      "need addressed": 48907,
      "consistent pattern": 19708,
      "data useful": 22153,
      "studies consider": 77678,
      "study emergency": 78145,
      "related pharmaceutical": 69665,
      "populous state": 62410,
      "prescribed pharmaceutical": 63949,
      "true extent": 83252,
      "analysis determined": 10673,
      "opioid month": 51954,
      "associated addition": 12214,
      "prevention background": 64870,
      "alcohol tobacco": 9542,
      "abuse increases": 6737,
      "generic products": 33052,
      "abuse extended": 6723,
      "questionnaires completed": 66902,
      "network results": 49163,
      "results introduction": 71745,
      "patch did": 58490,
      "increase sales": 37801,
      "abuse er": 6720,
      "likelihood prescription": 41792,
      "case subjects": 15210,
      "deaths involved": 22761,
      "trend similar": 82953,
      "similar magnitude": 75946,
      "support possibility": 79206,
      "influence risk": 38600,
      "characterize abuse": 15889,
      "oxycontin number": 56154,
      "aim using": 9430,
      "information guide": 38649,
      "reduction interventions": 69062,
      "surveys drug": 79749,
      "opioids collectively": 52794,
      "opioid fentanyl": 51805,
      "market associated": 43409,
      "associated large": 12316,
      "compared rates": 18287,
      "regression identified": 69443,
      "death involving": 22710,
      "age 15": 8972,
      "resistant reformulation": 71105,
      "use practices": 84641,
      "practices prior": 63437,
      "1990 2013": 2226,
      "face significant": 31019,
      "background international": 13072,
      "driven increased": 26462,
      "type heroin": 83328,
      "opioids age": 52715,
      "2001 2012": 2434,
      "2012 results": 2612,
      "deaths occurred": 22769,
      "15 74": 1714,
      "68 male": 5498,
      "heroin overdose": 35021,
      "incident rate": 37336,
      "largely driven": 41167,
      "45 54": 4572,
      "increase study": 37807,
      "period 2012": 60694,
      "deaths higher": 22754,
      "including restrictive": 37671,
      "rates methamphetamine": 67593,
      "overall increase": 54208,
      "2005 2010": 2461,
      "2010 compared": 2550,
      "obtained prescribing": 50776,
      "care information": 15035,
      "increases prescribing": 38076,
      "paracetamol codeine": 58096,
      "500 fewer": 4917,
      "assessed conclusions": 11993,
      "involving drug": 40127,
      "drug poisonings": 26741,
      "2014 opioid": 2670,
      "rates identified": 67589,
      "using age": 85302,
      "population estimates": 62330,
      "intentional opioid": 39348,
      "poisonings 60": 62161,
      "tramadol heroin": 82067,
      "state average": 77034,
      "2002 2015": 2440,
      "2015 identified": 2706,
      "identified children": 36427,
      "aged 10": 9139,
      "old compared": 51003,
      "45 prescribed": 4598,
      "overdose opioids": 54308,
      "53 oxycodone": 5022,
      "15 conclusions": 1728,
      "associations type": 12501,
      "dispensed daily": 25421,
      "inpatient hospitalization": 39012,
      "care visit": 15096,
      "overall rate": 54243,
      "overdose events": 54291,
      "000 observed": 30,
      "fold increased": 31997,
      "adolescents received": 8461,
      "years later": 87607,
      "canada role": 14750,
      "trends deaths": 82964,
      "hydrocodone 32": 36047,
      "highest exposure": 35347,
      "dispensed prescriptions": 25435,
      "11 39": 1110,
      "rates ed": 67575,
      "opioids highest": 52951,
      "ci codeine": 16521,
      "females codeine": 31388,
      "41 49": 4413,
      "intentional self": 39350,
      "prospective registry": 65875,
      "multicenter database": 48156,
      "entered database": 29058,
      "antidepressants 16": 11169,
      "sole agent": 76424,
      "designer drugs": 23855,
      "related intoxications": 69628,
      "related post": 69667,
      "dextropropoxyphene fentanyl": 24301,
      "urban opioid": 84032,
      "2010 2012": 2540,
      "commonly cocaine": 17841,
      "american individuals": 9795,
      "areas significantly": 11651,
      "children younger": 16084,
      "described results": 23659,
      "effect treated": 27575,
      "household number": 35880,
      "analysis adult": 10635,
      "multivariable model": 48330,
      "determine characteristics": 23994,
      "academic emergency": 6945,
      "age 44": 9008,
      "42 female": 4460,
      "therapeutic error": 80941,
      "51 versus": 4962,
      "conclusion emergency": 18896,
      "overdose patients": 54311,
      "insurance databases": 39150,
      "analysis quantified": 10750,
      "control outcome": 20381,
      "potential confounding": 63153,
      "group comparisons": 33692,
      "45 20": 4567,
      "treated analysis": 82323,
      "antagonists treatment": 11090,
      "deaths methods": 22767,
      "program results": 65544,
      "oxycodone involved": 55303,
      "greatest number": 33503,
      "oxycodone deaths": 54930,
      "release 72": 69804,
      "72 prescriptions": 5632,
      "linear trends": 42038,
      "associations pain": 12497,
      "results estimated": 71685,
      "23 34": 3079,
      "34 pain": 4030,
      "systems opioid": 80040,
      "data abuse": 21859,
      "rates er": 67576,
      "different populations": 24913,
      "differences level": 24754,
      "accidents suicides": 7021,
      "men aged": 44797,
      "20 49": 2298,
      "effects adolescent": 27811,
      "68 opioids": 5499,
      "sd years": 74097,
      "slightly half": 76253,
      "30 treated": 3803,
      "results alcohol": 71597,
      "lower predicted": 42684,
      "associated multiple": 12339,
      "health implications": 34717,
      "potency methods": 63077,
      "units dispensed": 83833,
      "dispensed number": 25427,
      "considered individual": 19635,
      "assess concurrent": 11919,
      "cause premature": 15368,
      "premature mortality": 63719,
      "states internationally": 77111,
      "explore extent": 30723,
      "access heroin": 6991,
      "surge use": 79262,
      "delivery opioids": 23222,
      "rates fatal": 67577,
      "deaths use": 22789,
      "methods individuals": 45361,
      "used code": 84883,
      "drug likely": 26677,
      "70 11": 5549,
      "deaths compared": 22747,
      "inform prevention": 38622,
      "recent rise": 68421,
      "developed methodology": 24182,
      "methods number": 45401,
      "quarter 2004": 66848,
      "combination drug": 17555,
      "total 15": 81723,
      "combinations identified": 17623,
      "analgesics additional": 10369,
      "effectiveness various": 27788,
      "interventions designed": 39660,
      "use finally": 84372,
      "based approaches": 13282,
      "ensuring adequate": 29048,
      "linked heroin": 42051,
      "evidence limited": 30215,
      "reports methods": 70733,
      "29 years": 3620,
      "cases associated": 15223,
      "21 19": 2940,
      "occurs wide": 50869,
      "outcomes needed": 54057,
      "medication overdose": 44529,
      "changes year": 15830,
      "identified deaths": 36435,
      "opioid sales": 52355,
      "sales increased": 73251,
      "deaths increasing": 22759,
      "substances substances": 78838,
      "contributing deaths": 20240,
      "usa methods": 84109,
      "opioids aggregate": 52717,
      "days prescription": 22595,
      "analyses restricted": 10608,
      "false discovery": 31166,
      "discovery rate": 25265,
      "account multiple": 7074,
      "multiple testing": 48302,
      "data 1999": 21847,
      "racial differences": 66945,
      "age standardized": 9125,
      "increasing 31": 38090,
      "population increasing": 62344,
      "mortality major": 47987,
      "examine characteristics": 30336,
      "characteristics self": 15880,
      "toxicology data": 81949,
      "hydrocodone benzodiazepines": 36065,
      "death significantly": 22723,
      "death compared": 22700,
      "harm background": 34577,
      "identifying drug": 36542,
      "health insurer": 34721,
      "2015 patients": 2716,
      "persons aged": 60958,
      "years dispensed": 87586,
      "person days": 60941,
      "53 pairs": 5023,
      "34 unique": 4037,
      "21 88": 2959,
      "37 53": 4181,
      "interactions associated": 39386,
      "elucidate potential": 28623,
      "including alcohol": 37591,
      "drugs fatal": 26958,
      "countries recent": 20960,
      "trends demonstrated": 82965,
      "95 incidence": 6402,
      "positive effect": 62463,
      "trend analysis": 82940,
      "examines changes": 30423,
      "general drug": 32972,
      "prescription illegal": 64236,
      "including methadone": 37635,
      "hydrocodone barbiturates": 36062,
      "usage increased": 84119,
      "largest increases": 41195,
      "increases broad": 38054,
      "80 25": 5828,
      "02 hydrocodone": 369,
      "methadone 27": 45040,
      "toronto ontario": 81701,
      "31 2013": 3846,
      "prevention program": 64882,
      "exclusively prescription": 30491,
      "washington state": 86743,
      "2003 2010": 2447,
      "computed age": 18653,
      "oxycodone methamphetamine": 55399,
      "25 drugs": 3355,
      "21 identified": 2972,
      "data background": 21885,
      "australia 2000": 12680,
      "2015 extracted": 2705,
      "online database": 51098,
      "findings autopsy": 31770,
      "autopsy toxicology": 12772,
      "period relative": 60785,
      "major cities": 42934,
      "death attributed": 22694,
      "attributed pos": 12613,
      "use problems": 84669,
      "prescribing increase": 64067,
      "treatment particularly": 82744,
      "42 249": 4448,
      "prevention programs": 64883,
      "describes opioid": 23666,
      "circumstances surrounding": 16580,
      "deaths approximately": 22740,
      "surrounding opioid": 79675,
      "high dosage": 35083,
      "members friends": 44779,
      "ddd population": 22674,
      "chemical atc": 15947,
      "atc code": 12523,
      "alimentary tract": 9573,
      "tract metabolism": 81977,
      "pregabalin possibly": 63678,
      "drug epidemic": 26622,
      "drug problems": 26750,
      "introduction 2013": 39916,
      "law intended": 41251,
      "abuse years": 6914,
      "benzodiazepines frequently": 13662,
      "urgent public": 84046,
      "measures used": 44104,
      "matching approach": 43494,
      "findings include": 31790,
      "people dying": 60407,
      "data state": 22117,
      "time death": 81244,
      "monitor use": 47309,
      "estimated number": 29632,
      "increased sharply": 38025,
      "snorting smoking": 76349,
      "background impact": 13064,
      "identify patterns": 36517,
      "years 2006": 87529,
      "2006 2008": 2472,
      "switched opioid": 79825,
      "personal history": 60947,
      "2017 october": 2798,
      "showed overall": 75283,
      "changes statistically": 15822,
      "use amphetamine": 84190,
      "relatively new": 69785,
      "rates region": 67631,
      "increased sweden": 38036,
      "illicit substance": 36652,
      "death prescription": 22715,
      "register based": 69368,
      "based observational": 13340,
      "temporal associations": 80585,
      "alprazolam diazepam": 9677,
      "methadone alprazolam": 45045,
      "caution patients": 15416,
      "identified series": 36469,
      "information source": 38673,
      "deaths objective": 22768,
      "abuse suicide": 6887,
      "calls intentional": 14735,
      "lower 0001": 42567,
      "overdose significant": 54319,
      "characteristics decedents": 15855,
      "service national": 74721,
      "overdose using": 54321,
      "drugs examined": 26955,
      "examined recent": 30410,
      "cases 1149": 15216,
      "revealed increasing": 72214,
      "drug involved": 26672,
      "period methods": 60750,
      "opioid methadone": 51932,
      "opioids trends": 53359,
      "trends time": 82988,
      "cited prescription": 16597,
      "medications benzodiazepines": 44598,
      "compared heroin": 18176,
      "non whites": 49697,
      "implications public": 36967,
      "linking data": 42059,
      "death 38": 22691,
      "dispensed codeine": 25420,
      "2013 2015": 2618,
      "diverted prescription": 25611,
      "drugs increased": 26981,
      "multiple providers": 48293,
      "age aor": 9057,
      "prescription prescription": 64388,
      "buprenorphine aor": 14519,
      "ci hydromorphone": 16531,
      "ci patients": 16536,
      "way prescribers": 86778,
      "trends specific": 82987,
      "2019 methods": 2875,
      "2015 predominantly": 2717,
      "polydrug combinations": 62193,
      "heroin 10": 34979,
      "ongoing overdose": 51089,
      "medications increasing": 44634,
      "2011 results": 2587,
      "years 2007": 87531,
      "10 commonly": 748,
      "half 45": 34510,
      "health impact": 34716,
      "data compiled": 21921,
      "2012 declined": 2598,
      "2012 opioid": 2609,
      "significant relationship": 75626,
      "opioids delivered": 52839,
      "using social": 85616,
      "focusing specific": 31979,
      "18 hydrocodone": 2087,
      "hydrocodone 10": 36043,
      "patterns controlled": 60200,
      "substances cs": 78828,
      "ed drug": 27331,
      "opioid benzodiazepines": 51563,
      "aims aims": 9474,
      "toxicology database": 81950,
      "cases postmortem": 15253,
      "tramadol clonazepam": 82039,
      "residence time": 71061,
      "death blood": 22695,
      "year findings": 87439,
      "tramadol prevalent": 82105,
      "prevalent non": 64830,
      "prescribed psychoactive": 63964,
      "months injury": 47448,
      "toxicology screen": 81955,
      "tricyclic antidepressant": 83215,
      "independent association": 38157,
      "34 included": 4024,
      "vs 036": 86514,
      "health disorders": 34708,
      "presents opportunity": 64712,
      "related fatal": 69605,
      "dependent measures": 23519,
      "highest individuals": 35350,
      "36 compared": 4127,
      "10 51": 716,
      "eligible medicaid": 28587,
      "03 55": 409,
      "filled oxycodone": 31709,
      "codeine used": 17299,
      "findings guide": 31783,
      "greatest risk": 33506,
      "opioid central": 51572,
      "post study": 62618,
      "million commercially": 46486,
      "30 2013": 3672,
      "claims opioid": 16634,
      "members aged": 44773,
      "medicine 13": 44703,
      "release 27": 69802,
      "sulfate extended": 79066,
      "public health issues": 66393,
      "inadequately treated chronic": 37238,
      "outcome objective determine": 53964,
      "states united states": 77156,
      "12 100 000": 1209,
      "population level dispensing": 62346,
      "results consistent pattern": 71646,
      "observational study emergency": 50626,
      "study emergency department": 78146,
      "naloxone tapentadol tramadol": 48521,
      "fold increase oxycodone": 31996,
      "overall opioid related": 54219,
      "abuse extended release": 6724,
      "patch did significantly": 58491,
      "conclusions data suggest": 19071,
      "likelihood prescription opioid": 41793,
      "conducted retrospective population": 19405,
      "deaths involved oxycodone": 22762,
      "synthetic opioid fentanyl": 79956,
      "tamper resistant reformulation": 80343,
      "reformulation oxycodone 80": 69214,
      "drug use practices": 26846,
      "examine trends opioid": 30365,
      "opioids age gender": 52716,
      "increase study period": 37808,
      "including restrictive prescribing": 37672,
      "opioids prescription opioids": 53217,
      "children aged 10": 16033,
      "opioid prescription assessed": 52134,
      "prescription assessed associations": 64169,
      "associations type opioid": 12502,
      "health care visit": 34688,
      "100 000 observed": 972,
      "opioid analgesics methods": 51507,
      "100 000 children": 969,
      "intentional self harm": 39351,
      "codeine dextropropoxyphene fentanyl": 17224,
      "prescription opioid overdoses": 64305,
      "african american individuals": 8959,
      "background aims prescription": 13013,
      "determine characteristics associated": 23995,
      "mean age 44": 43681,
      "conclusion emergency department": 18897,
      "states prescription opioid": 77144,
      "associated opioid overdose": 12357,
      "group comparisons patients": 33693,
      "ci 45 20": 16455,
      "methods study population": 45593,
      "opioid treatment programs": 52452,
      "use abuse prescription": 84165,
      "concomitant opioid use": 19254,
      "related drug abuse": 69591,
      "secondary analysis data": 74208,
      "oxycodone fentanyl hydrocodone": 55077,
      "public health implications": 66389,
      "dispensing rates prescription": 25458,
      "rates prescription opioids": 67625,
      "cause premature mortality": 15369,
      "heroin overdose rates": 35022,
      "united states internationally": 83798,
      "opioid analgesics additional": 51480,
      "cases identified mean": 15241,
      "related deaths increased": 69582,
      "prescription opioid sales": 64314,
      "opioid sales increased": 52356,
      "prescription opioids long": 64345,
      "false discovery rate": 31167,
      "drug overdose mortality": 26734,
      "health concern united": 34697,
      "overdose deaths compared": 54278,
      "study examine characteristics": 78195,
      "prescription controlled substance": 64188,
      "oxycodone hydrocodone benzodiazepines": 55204,
      "death significantly higher": 22724,
      "adjusted rate ratios": 8051,
      "potential drug interaction": 63161,
      "prescription illegal drugs": 64237,
      "oxycodone hydrocodone barbiturates": 55202,
      "hydrocodone barbiturates benzodiazepines": 36063,
      "frequently reported opioids": 32579,
      "findings autopsy toxicology": 31771,
      "increased risk death": 38010,
      "substance use problems": 78821,
      "july 2016 june": 40520,
      "family members friends": 31183,
      "therapeutic chemical atc": 80925,
      "alimentary tract metabolism": 9574,
      "associated prescription opioids": 12390,
      "urgent public health": 84047,
      "data drug overdose": 21955,
      "filling oxycodone prescription": 31721,
      "significantly likely prescribed": 75765,
      "synthetic opioids methadone": 79962,
      "years 2006 2008": 87530,
      "used opioids prescribed": 85055,
      "used obtain data": 85040,
      "changes statistically significant": 15823,
      "patients statistically significant": 59998,
      "statistically significant effect": 77219,
      "deaths increased sweden": 22758,
      "countries recent decades": 20961,
      "previous research suggests": 64915,
      "opioids prescription drugs": 53216,
      "illicit substance use": 36653,
      "time death prescription": 81245,
      "based observational study": 13341,
      "data suggested use": 22134,
      "study identified series": 78236,
      "overdose deaths objective": 54282,
      "study using national": 78564,
      "significantly lower 0001": 75773,
      "examined recent trends": 30411,
      "associated abuse misuse": 12212,
      "11 year period": 1158,
      "year period methods": 87483,
      "regression analyses conducted": 69417,
      "heroin prescription opioid": 35027,
      "significant increases opioid": 75567,
      "implications public health": 36968,
      "diverted prescription opioids": 25612,
      "associated male sex": 12330,
      "2015 2019 methods": 2691,
      "data ims health": 21985,
      "nearly half 45": 48869,
      "public health impact": 66388,
      "states opioid epidemic": 77127,
      "prescription opioid consumption": 64290,
      "opioid consumption oxycodone": 51638,
      "statistically significant relationship": 77230,
      "prescribing patterns controlled": 64103,
      "patterns controlled substances": 60201,
      "controlled substances cs": 20601,
      "patients filling prescription": 59308,
      "cases postmortem cases": 15254,
      "interval ci 10": 39578,
      "prescribed psychoactive drugs": 63965,
      "patients 12 months": 58826,
      "mental health disorders": 44820,
      "identify patients risk": 36516,
      "related factors associated": 69604,
      "associated opioid related": 12360,
      "opioid related fatal": 52312,
      "used assess patient": 84852,
      "aged 35 44": 9185,
      "35 44 years": 4065,
      "unknown objective determine": 83883,
      "million commercially insured": 46487,
      "used compare pre": 84889,
      "compare pre post": 18046,
      "members aged 18": 44774,
      "morphine sulfate extended": 47940,
      "sulfate extended release": 79067,
      "observational study emergency department": 50627,
      "oxycodone oxycodone naloxone tapentadol": 55608,
      "oxycodone naloxone tapentadol tramadol": 55520,
      "abuse extended release oxycodone": 6725,
      "methods conducted retrospective population": 45286,
      "conducted retrospective population based": 19406,
      "68 95 confidence interval": 5497,
      "reformulation oxycodone 80 mg": 69215,
      "opioid related overdose deaths": 52326,
      "increased risk opioid overdose": 38016,
      "risk opioid related harm": 72621,
      "study emergency department ed": 78147,
      "prescription opioids buprenorphine codeine": 64330,
      "opioids buprenorphine codeine dextropropoxyphene": 52755,
      "buprenorphine codeine dextropropoxyphene fentanyl": 14529,
      "weak opioids codeine tramadol": 86793,
      "patients mean age 44": 59481,
      "united states prescription opioid": 83821,
      "patients long term opioid": 59458,
      "14 95 ci 53": 1578,
      "use abuse prescription opioids": 84166,
      "cases identified mean age": 15242,
      "near real time data": 48861,
      "abuse misuse prescription opioids": 6782,
      "prescription opioids long term": 64346,
      "public health concern united": 66381,
      "health concern united states": 34698,
      "drug overdose deaths compared": 26733,
      "prescribed opioids oxycodone hydrocodone": 63932,
      "oxycodone hydrocodone barbiturates benzodiazepines": 55203,
      "hydrocodone barbiturates benzodiazepines cocaine": 36064,
      "july 2016 june 2017": 40521,
      "anatomical therapeutic chemical atc": 10883,
      "methods population based study": 45467,
      "cohort study using national": 17408,
      "using linear regression models": 85462,
      "oral morphine equivalents day": 53581,
      "prescription opioid use past": 64319,
      "state prescription monitoring program": 77065,
      "united states opioid epidemic": 83811,
      "prescribing patterns controlled substances": 64104,
      "confidence interval ci 10": 19461,
      "aged 35 44 years": 9186,
      "million commercially insured members": 46488,
      "used compare pre post": 84890,
      "morphine sulfate extended release": 47941,
      "1800": 2128,
      "kaplan": 40581,
      "meier": 44762,
      "knowing": 40879,
      "vigorously": 86233,
      "reassurance": 68025,
      "staying": 77298,
      "hyd": 35997,
      "sociodemographics": 76396,
      "friedman": 32596,
      "polyneuropathy": 62221,
      "finished": 31842,
      "neuropathies": 49270,
      "descriptors": 23689,
      "jadad": 40409,
      "pectin": 60339,
      "decrements": 23078,
      "675": 5487,
      "oxycontin er": 56137,
      "er subjects": 29471,
      "bodily pain": 14188,
      "005 mental": 265,
      "groups end": 34191,
      "ability work": 6559,
      "randomized parallel": 67142,
      "day oxycontin": 22356,
      "subjects ages": 78683,
      "30 70": 3703,
      "weeks 002": 86888,
      "mg 91": 45778,
      "trial demonstrated": 83017,
      "continued report": 20142,
      "ibuprofen compared": 36353,
      "performed significantly": 60631,
      "2008 performed": 2510,
      "respectively differences": 71186,
      "discharge adverse": 25104,
      "10 325": 704,
      "patient exhibited": 58630,
      "start patient": 77003,
      "patients partial": 59628,
      "design oxycodone": 23738,
      "development data": 24221,
      "pain neck": 57227,
      "monotherapy combination": 47374,
      "symptoms sleep": 79907,
      "results report": 71914,
      "conclusions understanding": 19239,
      "withdrawal double": 87125,
      "controlled enriched": 20492,
      "enrollment parallel": 29032,
      "required average": 70826,
      "blind maintenance": 13941,
      "evaluated based": 29864,
      "kaplan meier": 40582,
      "placebo using": 61852,
      "placebo observed": 61785,
      "observed 18": 50644,
      "pain 62": 56391,
      "profiles similar": 65520,
      "phases conclusions": 61325,
      "pain community": 56572,
      "outpatient population": 54137,
      "iv prospective": 40403,
      "dosing allowed": 26306,
      "allowed weeks": 9641,
      "scores sf": 73983,
      "patient clinician": 58562,
      "current therapy": 21481,
      "groups experienced": 34197,
      "24 groups": 3199,
      "therapy 24": 80986,
      "patients persistent": 59646,
      "controlled period": 20515,
      "release 10": 69801,
      "severe baseline": 74914,
      "conclusions controlled": 19066,
      "consequences oxycodone": 19593,
      "adults united": 8586,
      "survey consisted": 79700,
      "costs calculated": 20895,
      "half respondents": 34530,
      "female 63": 31352,
      "years 14": 87524,
      "respondents frequently": 71309,
      "increased 19": 37830,
      "increased 61": 37862,
      "chemical manipulation": 15949,
      "required dose": 70831,
      "daily 10": 21686,
      "dose defined": 25863,
      "defined dose": 23134,
      "long short": 42318,
      "dosage short": 25761,
      "twice likely": 83309,
      "patterns fentanyl": 60206,
      "prescribing information": 64070,
      "information pi": 38661,
      "observational multicenter": 50612,
      "speaking patients": 76547,
      "tablets administration": 80123,
      "median tablet": 44286,
      "administration tablets": 8385,
      "reported duration": 70538,
      "41 reported": 4431,
      "14 reported": 1626,
      "mechanisms pain": 44150,
      "mg 50": 45755,
      "compared active": 18093,
      "predict pain": 63553,
      "variants drug": 85910,
      "enzymes genes": 29112,
      "pharmacogenetic variants": 61100,
      "candidate genes": 14923,
      "effects predicted": 28100,
      "personalized medicine": 60953,
      "day prior": 22394,
      "ratings 24": 67689,
      "predict individual": 63551,
      "included 51": 37401,
      "treatment furthermore": 82591,
      "results combined": 71632,
      "health patient": 34750,
      "medicine department": 44706,
      "uninsured patients": 83738,
      "prescriptions dropped": 64478,
      "percent drop": 60463,
      "lead increases": 41294,
      "appropriate analgesic": 11497,
      "ceiling dose": 15446,
      "effects minimal": 27993,
      "efficacy active": 28213,
      "medication multiple": 44520,
      "placebo 0001": 61608,
      "treatment does": 82555,
      "improves opioid": 37183,
      "diversion guidelines": 25595,
      "shown reduce": 75351,
      "trial non": 83038,
      "combines oxycodone": 17679,
      "received lower": 68195,
      "002 vs": 241,
      "score 03": 73704,
      "recommended clinical": 68618,
      "analgesics widely": 10517,
      "misuse overdose": 46734,
      "controlled triple": 20649,
      "analgesic controlled": 10175,
      "reassurance advice": 68026,
      "effectiveness outcomes": 27772,
      "analgesics 12": 10361,
      "dissemination ethical": 25515,
      "ethical approval": 29684,
      "results disseminated": 71666,
      "conference presentations": 19430,
      "problematic drug": 65251,
      "behavior results": 13539,
      "investigators reported": 40084,
      "release objective": 69900,
      "effects analgesia": 27819,
      "seven day": 74865,
      "additional weeks": 7904,
      "weeks acetaminophen": 86894,
      "results 83": 71587,
      "patients 54": 58876,
      "23 mm": 3103,
      "continue receiving": 20126,
      "treatments provide": 82926,
      "tolerable level": 81566,
      "dose fixed": 25907,
      "use 03": 84136,
      "used randomized": 85099,
      "oxycodone xtampza": 56104,
      "randomized active": 67042,
      "results supported": 72000,
      "tolerated new": 81632,
      "conclusion xtampza": 19021,
      "clinically statistically": 17008,
      "400 600": 4390,
      "\u03bcg followed": 87788,
      "scale 15": 73488,
      "differences spid": 24819,
      "showed differences": 75242,
      "larger proportion": 41180,
      "45 minutes": 4592,
      "require careful": 70800,
      "potential lower": 63183,
      "currently taking": 21508,
      "detailed data": 23913,
      "effects collected": 27850,
      "average 45": 12871,
      "years 85": 87556,
      "days 84": 22476,
      "42 001": 4446,
      "survey respondents": 79731,
      "oxycodone majority": 55362,
      "stable opioid": 76844,
      "day double": 22304,
      "79 mg": 5800,
      "10 58": 719,
      "day adverse": 22268,
      "analgesic acute": 10141,
      "years presenting": 87642,
      "nsw australia": 50110,
      "identical placebo": 36408,
      "participants female": 58308,
      "male 33": 43018,
      "151 participants": 1822,
      "analysis mean": 10709,
      "event versus": 29998,
      "given significant": 33197,
      "pain anti": 56453,
      "83 single": 5938,
      "48 79": 4696,
      "sulfate patients": 79070,
      "month posttreatment": 47407,
      "pain activity": 56410,
      "medication hours": 44502,
      "naproxen group": 48568,
      "abuse behavior": 6654,
      "sleep opioid": 76229,
      "used significant": 85126,
      "release hydrocodone": 69868,
      "period additionally": 60710,
      "analgesics decreased": 10411,
      "considered convenient": 19628,
      "controlled treatment": 20604,
      "121 15": 1417,
      "15 83": 1716,
      "differences age": 24712,
      "extremity pain": 30988,
      "trial subjects": 83092,
      "minutes hour": 46651,
      "relief ed": 70124,
      "02 reported": 375,
      "pain safety": 57656,
      "naive experienced": 48397,
      "men 63": 44796,
      "practice objective": 63405,
      "costs pain": 20902,
      "range 44": 67288,
      "postoperative cohort": 62724,
      "pcs pain": 60287,
      "10 44": 709,
      "question does": 66878,
      "ed presentation": 27348,
      "portion study": 62421,
      "continue treatment": 20127,
      "group scores": 34000,
      "score 18": 73715,
      "18 fentanyl": 2085,
      "process drug": 65336,
      "efficacy given": 28273,
      "hours drug": 35774,
      "knowledge drug": 40883,
      "trial 12": 82995,
      "periods fentanyl": 60818,
      "phase 112": 61270,
      "minutes mean": 46655,
      "clinicians reported": 17038,
      "efficacy harms": 28277,
      "included open": 37493,
      "26 weeks": 3457,
      "39 finished": 4269,
      "label period": 40985,
      "period end": 60725,
      "19 03": 2156,
      "cncp patients": 17108,
      "treatment randomized": 82794,
      "control immediate": 20351,
      "period 59": 60708,
      "respectively double": 71188,
      "treatment demonstrated": 82546,
      "based low": 13331,
      "diabetic polyneuropathy": 24319,
      "placebo conclusions": 61669,
      "22 year": 3047,
      "unique considerations": 83755,
      "form mcgill": 32284,
      "trial immediate": 83028,
      "pain predominantly": 57404,
      "previous evidence": 64901,
      "pain qualities": 57451,
      "frequently recommended": 32574,
      "daily number": 21769,
      "use average": 84216,
      "required mean": 70847,
      "additional daily": 7851,
      "pain newer": 57238,
      "12 neuropathic": 1341,
      "strong morphine": 77522,
      "groups opioids": 34249,
      "using higher": 85429,
      "70 microg": 5565,
      "administered higher": 8133,
      "study completed": 78018,
      "effective patients": 27665,
      "doses chosen": 26154,
      "drugs adverse": 26876,
      "range 105": 67250,
      "suggested opioid": 79023,
      "used effectively": 84926,
      "benefits parenteral": 13634,
      "available united": 12850,
      "opportunity improve": 53407,
      "events essential": 30044,
      "essential effective": 29576,
      "focus pain": 31971,
      "pain occurs": 57271,
      "transmucosal administration": 82230,
      "fentanyl spray": 31593,
      "properties make": 65713,
      "precipitating opioid": 63517,
      "primary time": 65115,
      "trial provide": 83054,
      "analysis plan": 10734,
      "driving performance": 26473,
      "performance cognition": 60549,
      "prospective group": 65834,
      "effects end": 27910,
      "model analysis": 47025,
      "regarding rate": 69278,
      "events different": 30042,
      "duration symptoms": 27186,
      "95 16": 6207,
      "29 months": 3610,
      "showed highest": 75260,
      "reduction conclusion": 69049,
      "pharmacokinetic characteristics": 61109,
      "background updated": 13212,
      "head comparisons": 34644,
      "included 13": 37379,
      "evidence significant": 30258,
      "morphine reference": 47909,
      "effectiveness clear": 27752,
      "reference treatment": 69144,
      "fentanyl 29": 31425,
      "present systematic": 64671,
      "responded positively": 71299,
      "patients peripheral": 59645,
      "reduce intensity": 68850,
      "prevalent types": 64838,
      "improvement following": 37150,
      "placebo response": 61819,
      "early clinical": 27253,
      "intensity cold": 39235,
      "amylase activity": 9862,
      "22 2017": 3014,
      "label long": 40978,
      "33 days": 3992,
      "neuropathy studies": 49280,
      "17 treatment": 1988,
      "hydromorphone tapentadol": 36226,
      "29 37": 3601,
      "21 0001": 2934,
      "ci significant": 16539,
      "review group": 72309,
      "opioids monotherapy": 53062,
      "tramadol examined": 82060,
      "smd 47": 76329,
      "37 15": 4171,
      "evidence trial": 30287,
      "95 63": 6208,
      "comprehensive assessment": 18622,
      "scores improved significantly": 73894,
      "randomized parallel group": 67143,
      "extended release capsules": 30857,
      "oxycontin er oxycodone": 56138,
      "dose study design": 26086,
      "efficacy safety sustained": 28388,
      "performed significantly better": 60632,
      "discharge adverse effects": 25105,
      "achieve analgesic effect": 7295,
      "level pain relief": 41511,
      "differences incidence adverse": 24753,
      "release er opioid": 69845,
      "12 oxycodone acetaminophen": 1348,
      "10 325 mg": 705,
      "10 mg daily": 809,
      "mg daily days": 45847,
      "opioid withdrawal scale": 52646,
      "design study used": 23810,
      "randomized withdrawal double": 67207,
      "withdrawal double blind": 87126,
      "placebo controlled enriched": 61688,
      "controlled enriched enrollment": 20493,
      "enriched enrollment parallel": 28987,
      "enrollment parallel group": 29033,
      "efficacy oxycodone deterx": 28316,
      "xtampza er compared": 87413,
      "double blind maintenance": 26358,
      "blind maintenance phase": 13942,
      "tolerability oxycodone deterx": 81546,
      "conclusions oxycodone deterx": 19146,
      "study registered clinicaltrials": 78458,
      "patients treatment groups": 60075,
      "patients persistent pain": 59647,
      "controlled period crossover": 20516,
      "immediate release 10": 36708,
      "patients pain scores": 59624,
      "moderate severe baseline": 47170,
      "conclusions controlled release": 19067,
      "adults united states": 8587,
      "use oxycodone cr": 84584,
      "approximately half respondents": 11582,
      "respondents frequently reported": 71310,
      "variability opioid response": 85869,
      "physical chemical manipulation": 61382,
      "twice daily 10": 83292,
      "typically reported opioids": 83396,
      "median total oxycodone": 44297,
      "release oxycodone prescribed": 69970,
      "doses transdermal fentanyl": 26295,
      "hours oxycodone hcl": 35806,
      "multivariate regression model": 48354,
      "tablets administration tablets": 80124,
      "duration pain relief": 27177,
      "relief 12 hours": 70093,
      "days 14 reported": 22466,
      "linear mixed models": 42021,
      "genetic variants drug": 33085,
      "variants drug metabolizing": 85911,
      "genetic factors drug": 33074,
      "pain ratings 24": 57473,
      "eighty patients included": 28455,
      "pain treatment objective": 57937,
      "patients participants patients": 59630,
      "appropriate analgesic drug": 11498,
      "analgesics controlled release": 10407,
      "abuse misuse addiction": 6778,
      "reduce pain opioid": 68875,
      "opioid abuse risk": 51383,
      "clinical abuse potential": 16750,
      "group received lower": 33955,
      "05 patients global": 539,
      "placebo controlled triple": 61711,
      "analgesic controlled release": 10176,
      "naloxone 20 mg": 48426,
      "opioid analgesics 12": 51476,
      "analgesics 12 months": 10362,
      "ethics dissemination ethical": 29691,
      "dissemination ethical approval": 25516,
      "trial results disseminated": 83085,
      "treatment noncancer pain": 82685,
      "mean sd range": 43871,
      "investigators reported cases": 40085,
      "release objective evaluate": 69901,
      "receive 10 mg": 68038,
      "lower drug use": 42608,
      "study used randomized": 78558,
      "used randomized double": 85100,
      "oxycodone xtampza er": 56105,
      "xtampza er treatment": 87416,
      "conclusion xtampza er": 19022,
      "xtampza er resulted": 87415,
      "clinically statistically significant": 17009,
      "oxycodone 15 30": 54519,
      "scale 15 minutes": 73489,
      "efficacy measures included": 28296,
      "intensity differences spid": 39253,
      "versus oxycodone mean": 86145,
      "secondary efficacy measures": 74216,
      "abuse potential lower": 6821,
      "vs 42 001": 86577,
      "years randomized receive": 87648,
      "day double blind": 22305,
      "day adverse events": 22269,
      "safe effective controlling": 73077,
      "opioid analgesic acute": 51448,
      "placebo weeks primary": 61856,
      "included primary analysis": 37521,
      "adverse event versus": 8719,
      "given significant difference": 33198,
      "30 pain reduction": 3782,
      "ci 48 79": 16462,
      "inflammatory drug opioid": 38560,
      "participants underwent week": 58380,
      "morphine sulfate patients": 47944,
      "ir oxycodone methods": 40249,
      "opioid analgesics decreased": 51494,
      "frequently reported opioid": 32578,
      "controlled treatment period": 20605,
      "years 65 years": 87554,
      "use concomitant medications": 84264,
      "14 patients respectively": 1622,
      "potentially clinically significant": 63253,
      "clinically important differences": 16979,
      "time required achieve": 81361,
      "10 pain scale": 892,
      "day follow conclusions": 22313,
      "pain relief ed": 57536,
      "relief ed patients": 70125,
      "placebo treatment moderate": 61846,
      "period significantly different": 60792,
      "average nrs pain": 12901,
      "placebo group experienced": 61741,
      "placebo 12 weeks": 61619,
      "plasma concentrations results": 61921,
      "received 30 days": 68100,
      "mental health related": 44822,
      "oxycodone acetaminophen placebo": 54656,
      "treating acute low": 82385,
      "department ed presentation": 23429,
      "placebo objective evaluate": 61784,
      "pain randomly assigned": 57461,
      "active controlled crossover": 7496,
      "measure pain intensity": 43941,
      "open label period": 51172,
      "endpoint average pain": 28879,
      "results primary analysis": 71891,
      "respectively double blind": 71189,
      "compared placebo conclusions": 18263,
      "short form mcgill": 75173,
      "form mcgill pain": 32285,
      "previous research demonstrated": 64914,
      "patient reported adverse": 58732,
      "mean daily number": 43742,
      "daily number doses": 21770,
      "additional daily doses": 7852,
      "risk misuse addiction": 72599,
      "medline embase central": 44734,
      "12 neuropathic pain": 1342,
      "drugs adverse effects": 26877,
      "treatment persistent pain": 82759,
      "morphine oxycodone available": 47805,
      "oxycodone available united": 54740,
      "available united states": 12851,
      "adverse events essential": 8755,
      "15 minutes drug": 1772,
      "intranasal fentanyl spray": 39750,
      "chronic pain reduce": 16310,
      "outcomes collected weeks": 54017,
      "used assess effect": 84850,
      "opioids effective treatment": 52876,
      "statistical analysis plan": 77173,
      "treatment transdermal fentanyl": 82876,
      "clinical trials rcts": 16957,
      "adverse events different": 8753,
      "head head comparisons": 34646,
      "evaluation grade approach": 29955,
      "methods performed systematic": 45458,
      "present systematic review": 64672,
      "superior placebo results": 79144,
      "data open label": 22026,
      "open label long": 51166,
      "label long term": 40979,
      "20 mg twice": 2352,
      "opioid dose patients": 51734,
      "diabetic neuropathy studies": 24316,
      "95 ci significant": 6369,
      "ci significant difference": 16540,
      "background use opioids": 13214,
      "smd 47 95": 76330,
      "difference compared placebo": 24604,
      "quality evidence trial": 66699,
      "efficacy safety sustained release": 28389,
      "extended release er opioid": 30867,
      "randomized withdrawal double blind": 67208,
      "withdrawal double blind placebo": 87127,
      "blind placebo controlled enriched": 13955,
      "placebo controlled enriched enrollment": 61689,
      "controlled enriched enrollment parallel": 20494,
      "enriched enrollment parallel group": 28988,
      "enrollment parallel group multicenter": 29034,
      "double blind maintenance phase": 26359,
      "registration study registered clinicaltrials": 69396,
      "study registered clinicaltrials gov": 78459,
      "immediate release oxycodone tablets": 36735,
      "conclusions controlled release oxycodone": 19068,
      "chronic pain patients pain": 16302,
      "average age 41 years": 12875,
      "12 hours oxycodone hcl": 1302,
      "genetic variants drug metabolizing": 33086,
      "results eighty patients included": 71676,
      "opioid analgesics controlled release": 51492,
      "analgesics controlled release oxycodone": 10408,
      "clinical abuse potential studies": 16751,
      "analgesic controlled release oxycodone": 10177,
      "medication related adverse events": 44558,
      "ethics dissemination ethical approval": 29692,
      "study used randomized double": 78559,
      "used randomized double blind": 85101,
      "patients chronic pain methods": 59082,
      "pain intensity differences spid": 56904,
      "anti inflammatory drug opioid": 11126,
      "pain relief ed patients": 57537,
      "placebo treatment moderate severe": 61847,
      "average nrs pain scores": 12902,
      "study main outcome measures": 78296,
      "treating acute low pain": 82386,
      "emergency department ed presentation": 28677,
      "primary endpoint average pain": 65020,
      "hydromorphone morphine oxycodone tramadol": 36197,
      "short form mcgill pain": 75174,
      "form mcgill pain questionnaire": 32286,
      "patient reported adverse events": 58733,
      "mean daily number doses": 43743,
      "searched medline embase central": 74157,
      "morphine oxycodone available united": 47806,
      "oxycodone available united states": 54741,
      "15 minutes drug administration": 1773,
      "treatment chronic pain reduce": 82489,
      "randomized clinical trials rcts": 67052,
      "standardized mean difference smd": 76965,
      "development evaluation grade approach": 24226,
      "methods performed systematic review": 45459,
      "open label long term": 51167,
      "painful diabetic neuropathy studies": 58005,
      "95 ci significant difference": 6370,
      "sociocultural": 76389,
      "diverting": 25616,
      "talking": 80326,
      "associates": 12467,
      "gateway": 32904,
      "liable": 41655,
      "endorsing": 28858,
      "1014": 1050,
      "everyday": 30139,
      "acquiring": 7361,
      "administrators": 8402,
      "popularly": 62295,
      "campus": 14745,
      "module": 47268,
      "intoxicated": 39708,
      "dissimilar": 25522,
      "brings": 14439,
      "hazardous": 34618,
      "commonplace": 17905,
      "531": 5028,
      "constituent": 19797,
      "forecasted": 32256,
      "inquiring": 39044,
      "sellers": 74506,
      "spring": 76783,
      "northeastern": 49962,
      "risk behavior": 72524,
      "oxycontin august": 56120,
      "state year": 77071,
      "oxycontin associated": 56119,
      "pre reformulation": 63488,
      "deterrent oxycontin": 24125,
      "misuse pharmaceutical": 46736,
      "reduce likelihood": 68851,
      "oxycontin reformulated": 56178,
      "difficult abuse": 24960,
      "2006 2013": 2475,
      "sociodemographic geographic": 76395,
      "2013 prevalence": 2637,
      "aor 45": 11303,
      "years reformulation": 87654,
      "reformulation prevalence": 69218,
      "profile oxycontin": 65500,
      "oxycontin using": 56195,
      "understanding needed": 83637,
      "oxycontin use": 56193,
      "use population": 84628,
      "focus areas": 31969,
      "percent sample": 60490,
      "directly physicians": 25064,
      "group 73": 33642,
      "history recreational": 35480,
      "oxycontin prescription": 56172,
      "oxycontin opioids": 56160,
      "21 year": 2987,
      "results interrupted": 71739,
      "use 2010": 84149,
      "2010 reformulation": 2568,
      "reformulation compared": 69211,
      "incidence observed": 37289,
      "compared 2010": 18073,
      "cases oxycontin": 15251,
      "compare individuals": 18031,
      "individuals rural": 38356,
      "rural appalachia": 73043,
      "oxycontin related": 56180,
      "subjects significantly": 78743,
      "identify pain": 36513,
      "use american": 84189,
      "market entry": 43410,
      "navippro surveillance": 48824,
      "percent change": 60455,
      "decline abuse": 22862,
      "oxycontin observed": 56155,
      "observed years": 50732,
      "sample individuals": 73304,
      "formulation product": 32362,
      "related oxycontin": 69653,
      "addition half": 7803,
      "oxycontin formulation": 56144,
      "persons year": 60959,
      "year data": 87438,
      "analysis serves": 10763,
      "patient just": 58669,
      "unintended consequences": 83740,
      "deaths used": 22790,
      "used 2005": 84824,
      "2005 2014": 2464,
      "sectional national": 74282,
      "exposed group": 30741,
      "net reduction": 49153,
      "effects reformulation": 28133,
      "qualitative study": 66668,
      "oxycontin released": 56181,
      "investigate oxycodone": 40020,
      "desirable drug": 23861,
      "gateway drug": 32905,
      "liable abuse": 41656,
      "monitoring future": 47323,
      "moderate effect": 47144,
      "differences frequency": 24743,
      "prevention objective": 64878,
      "vicodin oxycontin": 86201,
      "use reporting": 84694,
      "assessed used": 12079,
      "likely provide": 41831,
      "respectively females": 71193,
      "use consistently": 84269,
      "response conclusion": 71337,
      "population specific": 62387,
      "specific interventions": 76595,
      "socio demographic": 76387,
      "versus drug": 86121,
      "drug dealers": 26573,
      "point differences": 62084,
      "individuals addicted": 38332,
      "oxycontin drugs": 56136,
      "treatment history": 82617,
      "individuals use": 38360,
      "associated life": 12319,
      "life time": 41741,
      "injection oxycontin": 38963,
      "oxycontin years": 56198,
      "use 01": 84135,
      "abuse tobacco": 6893,
      "population 2009": 62299,
      "oxycontin 18": 56108,
      "year 13": 87421,
      "likely used": 41848,
      "given use": 33204,
      "march 2012": 43361,
      "changes use": 15827,
      "opioids substances": 53321,
      "2006 2018": 2479,
      "opioids cannabis": 52767,
      "experimental interrupted": 30664,
      "visits study": 86293,
      "oxycontin heroin": 56145,
      "16 12": 1844,
      "time 11": 81190,
      "02 19": 354,
      "time 10": 81188,
      "2014 tamper": 2677,
      "resistant controlled": 71095,
      "released australia": 70022,
      "australia aimed": 12681,
      "cohort 606": 17343,
      "606 people": 5297,
      "2014 wave": 2682,
      "wave august": 86768,
      "25 compared": 3351,
      "groups odds": 34247,
      "decreased conclusions": 22986,
      "reductions oxycodone": 69116,
      "oxycodone tampering": 55988,
      "tampering high": 80351,
      "used following": 84941,
      "used compute": 84892,
      "data recent": 22083,
      "multi level": 48148,
      "including development": 37608,
      "intravenous heroin": 39831,
      "range analgesics": 67302,
      "drug injected": 26656,
      "use australia": 84213,
      "examination pharmaceutical": 30327,
      "volunteers participated": 86427,
      "impact abuse": 36794,
      "examines associations": 30422,
      "areas high": 11646,
      "including ethanol": 37618,
      "toxicological results": 81944,
      "discussed study": 25296,
      "behavior assessment": 13527,
      "practices treatment": 63443,
      "authors examined": 12729,
      "period 2002": 60688,
      "prevalent persons": 64836,
      "behaviors heroin": 13560,
      "use histories": 84401,
      "users used": 85276,
      "risk occurred": 72610,
      "24 similar": 3275,
      "use age": 84182,
      "understand trends": 83630,
      "trends prevalence": 82985,
      "estimates average": 29646,
      "average 18": 12861,
      "specific products": 76617,
      "medical nonmedical": 44372,
      "included medical": 37482,
      "legal family": 41365,
      "conclusions large": 19108,
      "drugs similarly": 27075,
      "opioids formed": 52918,
      "month injecting": 47393,
      "injecting snorting": 38930,
      "participants prescribed": 58343,
      "examined gender": 30384,
      "public use": 66407,
      "examined logistic": 30389,
      "procedures conducted": 65297,
      "10 females": 762,
      "products oxycontin": 65457,
      "early use": 27276,
      "trajectories opioid": 82017,
      "nasal inhalation": 48653,
      "switching heroin": 79833,
      "decreased cost": 22988,
      "internet based": 39488,
      "students completed": 77602,
      "acetaminophen oxycontin": 7228,
      "xanax alprazolam": 87398,
      "widespread non": 87081,
      "reported increased": 70573,
      "similarities differences": 76007,
      "rates large": 67591,
      "related problems": 69673,
      "comprehensive understanding": 18630,
      "use 2005": 84148,
      "male 85": 43020,
      "pr 79": 63311,
      "diverted use": 25613,
      "warrants research": 86737,
      "57 years": 5143,
      "white male": 87016,
      "commonly seen": 17874,
      "reports illicit": 70726,
      "users including": 85246,
      "absolute differences": 6596,
      "day prevalence": 22390,
      "term recall": 80665,
      "42 opioid": 4467,
      "factor contributing": 31054,
      "interviews assessing": 39694,
      "use taking": 84773,
      "2017 national": 2796,
      "work demonstrated": 87271,
      "examined differences": 30374,
      "database inception": 22170,
      "literature results": 42126,
      "final review": 31747,
      "type substance": 83358,
      "benzodiazepines present": 13670,
      "trend time": 82954,
      "time number": 81296,
      "prescription abuse": 64158,
      "history prescription": 35474,
      "did abuse": 24399,
      "likely history": 41812,
      "abuse likely": 6763,
      "showed characteristic": 75232,
      "early course": 27254,
      "city population": 16602,
      "community setting": 17928,
      "setting setting": 74820,
      "participants 43": 58272,
      "use 20": 84147,
      "project describes": 65590,
      "easily accessible": 27281,
      "adult non": 8498,
      "differently depending": 24953,
      "completed interviews": 18471,
      "28 41": 3542,
      "001 half": 142,
      "participants 45": 58273,
      "participants emphasized": 58300,
      "role active": 72731,
      "key demographic": 40665,
      "use measures": 84471,
      "participants studied": 58370,
      "extent non": 30926,
      "background availability": 13017,
      "opioids decreases": 52837,
      "increases prescription": 38077,
      "substances common": 78826,
      "collected drug": 17456,
      "methadone july": 45088,
      "positive opioid": 62473,
      "estimated prevalence": 29636,
      "located northeastern": 42221,
      "northeastern united": 49963,
      "34 standard": 4033,
      "respectively 90": 71163,
      "association abuse deterrent": 12470,
      "oxycontin august 2010": 56121,
      "abuse deterrent oxycontin": 6702,
      "deterrent oxycontin associated": 24126,
      "12 years older": 1392,
      "significantly higher prevalence": 75738,
      "aor 45 95": 11304,
      "diversion abuse major": 25587,
      "opioid pain reliever": 52039,
      "oxycontin abuse deterrent": 56113,
      "deterrent properties methods": 24130,
      "use oxycontin prescription": 84591,
      "oxycontin prescription opioids": 56173,
      "results interrupted time": 71740,
      "individuals rural appalachia": 38357,
      "using addiction severity": 85299,
      "reformulated oxycontin observed": 69203,
      "sample individuals assessed": 73305,
      "assessed substance use": 12070,
      "prescription opioids reported": 64368,
      "oxycodone oxycontin purdue": 55610,
      "age 12 years": 8971,
      "cross sectional national": 21259,
      "statistically significant effects": 77220,
      "diagnosed opioid dependence": 24325,
      "abuse dependence liability": 6677,
      "significant differences frequency": 75503,
      "results highlight need": 71713,
      "opioid use prevalence": 52574,
      "study sought characterize": 78508,
      "drug use history": 26839,
      "oxycodone use opioid": 56053,
      "seventy percent subjects": 74893,
      "oxycontin use injection": 56194,
      "drug use study": 26850,
      "quasi experimental interrupted": 66864,
      "experimental interrupted time": 30665,
      "april 2014 tamper": 11604,
      "2014 tamper resistant": 2678,
      "tamper resistant controlled": 80336,
      "resistant controlled release": 71096,
      "prospective cohort 606": 65818,
      "cohort 606 people": 17344,
      "606 people regularly": 5298,
      "january march 2014": 40464,
      "march 2014 wave": 43364,
      "2014 wave august": 2683,
      "wave august 2014": 86769,
      "august 2014 wave": 12665,
      "oxycodone group 05": 55123,
      "opioids illicit drugs": 52964,
      "injecting drug use": 38926,
      "impact abuse deterrent": 36795,
      "study examines associations": 78203,
      "drugs including ethanol": 26979,
      "prescription drug abusers": 64207,
      "drug use histories": 26838,
      "use oxycodone hydrocodone": 84586,
      "significantly higher odds": 75732,
      "nonmedical use specific": 49793,
      "outcome measures data": 53936,
      "nonmedical prescription drug": 49777,
      "prescription drug use": 64216,
      "nonmedical opioid users": 49775,
      "cohort people tamper": 17370,
      "pharmaceutical opioids formed": 61039,
      "introduction reformulated oxycontin": 39953,
      "reformulated oxycontin methods": 69202,
      "prior introduction reformulated": 65154,
      "moderate severe anxiety": 47169,
      "conclusions findings highlight": 19085,
      "use pain relievers": 84599,
      "examined logistic regression": 30390,
      "prescribed illicit drugs": 63872,
      "prescribed pain relievers": 63945,
      "internet based survey": 39489,
      "widespread non medical": 87082,
      "use prescription medications": 84653,
      "inform prevention treatment": 38623,
      "substance use related": 78822,
      "present data opioid": 64614,
      "demonstrated significantly greater": 23367,
      "30 day prevalence": 3718,
      "long term recall": 42349,
      "use commonly prescribed": 84251,
      "drug users methods": 26856,
      "previously reported literature": 64957,
      "2016 2017 national": 2729,
      "codeine oxycodone opioids": 17269,
      "introduction opioid use": 39942,
      "clinicians policy makers": 17037,
      "methadone buprenorphine naltrexone": 45053,
      "conclusions study highlights": 19220,
      "release oxycodone use": 69985,
      "drug use measures": 26843,
      "extent opioids prescribed": 30929,
      "increases prescription opioid": 38078,
      "prescription opioids drugs": 64333,
      "located northeastern united": 42222,
      "northeastern united states": 49964,
      "34 standard deviation": 4034,
      "results self reported": 71935,
      "treatment outcome methods": 82721,
      "baseline patient characteristics": 13452,
      "opioid use history": 52520,
      "specific prescription opioid": 76614,
      "abuse deterrent oxycontin associated": 6703,
      "aor 45 95 ci": 11305,
      "oxycontin abuse deterrent properties": 56114,
      "abuse deterrent properties methods": 6706,
      "use oxycontin prescription opioids": 84592,
      "results interrupted time series": 71741,
      "using addiction severity index": 85300,
      "sample individuals assessed substance": 73306,
      "individuals assessed substance use": 38339,
      "oxycodone oxycontin purdue pharma": 55611,
      "introduction abuse deterrent oxycontin": 39920,
      "statistically significant differences frequency": 77213,
      "injection drug use study": 38946,
      "quasi experimental interrupted time": 66865,
      "experimental interrupted time series": 30666,
      "april 2014 tamper resistant": 11605,
      "2014 tamper resistant controlled": 2679,
      "tamper resistant controlled release": 80337,
      "resistant controlled release oxycodone": 71097,
      "prospective cohort 606 people": 65819,
      "cohort 606 people regularly": 17345,
      "january march 2014 wave": 40465,
      "march 2014 wave august": 43365,
      "2014 wave august 2014": 2684,
      "wave august 2014 wave": 86770,
      "medical use pharmaceutical opioids": 44420,
      "nonmedical prescription drug use": 49778,
      "cohort people tamper pharmaceutical": 17371,
      "tamper pharmaceutical opioids formed": 80332,
      "following introduction reformulated oxycontin": 32154,
      "prior introduction reformulated oxycontin": 65155,
      "widespread non medical use": 87083,
      "use commonly prescribed opioids": 84252,
      "introduction opioid use disorder": 39943,
      "located northeastern united states": 42223,
      "opioid extended release oxycodone": 51803,
      "dentistry": 23416,
      "totpar6": 81920,
      "xartemis": 87399,
      "xr": 87407,
      "717": 5607,
      "sit": 76154,
      "498": 4792,
      "radiography": 66967,
      "expense": 30566,
      "bromfenac": 14454,
      "muscular": 48366,
      "disk": 25360,
      "anxiolysis": 11285,
      "lactating": 41071,
      "nauseated": 48822,
      "redeemed": 68824,
      "ea": 27238,
      "sore": 76474,
      "uncomfortable": 83481,
      "developmentally": 24258,
      "graduate": 33394,
      "dealt": 22689,
      "460": 4636,
      "attendees": 12556,
      "sulfamethoxazole": 79061,
      "fluoxetine": 31957,
      "pain likely": 57020,
      "countries use": 20964,
      "surpassed morphine": 79663,
      "favorable pharmacokinetics": 31260,
      "administration enteral": 8258,
      "tolerated single": 81639,
      "indicate acute": 38217,
      "analgesic delivery": 10179,
      "strategies postoperative": 77420,
      "effectiveness iv": 27765,
      "control higher": 20350,
      "efficacy single": 28395,
      "10 650": 722,
      "effect duration": 27449,
      "patients active": 58932,
      "difference hours": 24621,
      "agonist useful": 9314,
      "postoperative administration": 62695,
      "arms included": 11687,
      "mg combination": 45823,
      "food study": 32240,
      "period way": 60809,
      "ibuprofen 400": 36344,
      "overnight fast": 54348,
      "dose single": 26078,
      "standardized high": 76960,
      "treatments studies": 82931,
      "170 cm": 1998,
      "subjects 11": 78673,
      "height 181": 34891,
      "181 cm": 2130,
      "administered combined": 8112,
      "fasted state": 31211,
      "state 103": 77030,
      "88 102": 6036,
      "absorption extent": 6610,
      "dose pharmacokinetic": 26009,
      "relief occurred": 70153,
      "minutes oxycodone": 46658,
      "objectives dental": 50553,
      "molar extractions": 47274,
      "drugs superior": 27086,
      "experience similar": 30595,
      "effect new": 27499,
      "xartemis xr": 87400,
      "lasts 12": 41219,
      "formulation allows": 32332,
      "discourage abuse": 25259,
      "abuse clinicians": 6661,
      "based prespecified": 13365,
      "primarily white": 64982,
      "ratings analgesic": 67690,
      "events highest": 30054,
      "surgery combination": 79346,
      "retrospective pre": 72152,
      "pain nonpharmacological": 57245,
      "107 patients": 1069,
      "administered ed": 8126,
      "following emergency": 32130,
      "ingestion study": 38746,
      "detect clinically": 23926,
      "pain situations": 57847,
      "12 2013": 1226,
      "relief versus": 70207,
      "results searches": 71932,
      "examined dose": 30375,
      "participants needed": 58328,
      "combination placebo": 17598,
      "balanced treatment": 13235,
      "outcome reduction": 53985,
      "min 03": 46505,
      "nrs mean": 50063,
      "baseline 60": 13413,
      "molar extraction": 47273,
      "187 oxycodone": 2148,
      "12 52": 1255,
      "placebo 002": 61611,
      "tolerated subjects": 81641,
      "combining paracetamol": 17686,
      "triage nurse": 82992,
      "32 23": 3907,
      "patients caregivers": 59052,
      "rapidly produced": 67405,
      "administration hour": 8272,
      "hours area": 35751,
      "drowsiness vomiting": 26492,
      "previous review": 64916,
      "strategy cochrane": 77431,
      "calculated numbers": 14693,
      "outcome combination": 53909,
      "therapy duration": 81009,
      "relief non": 70147,
      "vas rating": 86015,
      "min patients": 46544,
      "versus codeine": 86114,
      "13 16": 1454,
      "89 73": 6057,
      "doses bromfenac": 26153,
      "doses analgesics": 26149,
      "ed subjects": 27352,
      "scores drugs": 73872,
      "points safety": 62142,
      "favorable safety": 31261,
      "profile background": 65478,
      "mg 61": 45760,
      "68 05": 5492,
      "compared treatments": 18329,
      "including acetaminophen": 37588,
      "06 31": 579,
      "relief scale": 70183,
      "result better": 71472,
      "hydrocodone ibuprofen": 36096,
      "hour intervals": 35702,
      "estimated time": 29639,
      "mg 600": 45758,
      "16 times": 1894,
      "endpoints patient": 28918,
      "63 white": 5369,
      "acetaminophen 20": 7119,
      "administration objective": 8313,
      "lasting days": 41213,
      "assigned study": 12181,
      "efficacy included": 28278,
      "relief scores": 70185,
      "nervous gastrointestinal": 49142,
      "prescribed removal": 63973,
      "unknown purpose": 83889,
      "dispensed 20": 25418,
      "included average": 37429,
      "highest daily": 35343,
      "significant burden": 75434,
      "iii trial": 36602,
      "following interventions": 32146,
      "ibuprofen reported": 36373,
      "medication associated": 44462,
      "inadequate relief": 37233,
      "versus acetaminophen": 86113,
      "37 conclusion": 4188,
      "associated medication": 12332,
      "morphine gabapentin": 47698,
      "patients 182": 58838,
      "outcomes showed": 54096,
      "net change": 49150,
      "ed objectives": 27334,
      "treating physician": 82410,
      "recorded 10": 68661,
      "therapy 22": 80985,
      "drug oral": 26727,
      "score primary": 73774,
      "placement randomized": 61860,
      "receiving prescription": 68373,
      "ed associated": 27328,
      "annual census": 11011,
      "relief given": 70132,
      "high end": 35098,
      "tests appropriate": 80855,
      "36 14": 4116,
      "subjects receiving": 78737,
      "analgesic treat": 10347,
      "nonopioid alternative": 49802,
      "oxycodone 325": 54560,
      "worst possible": 87348,
      "possible pain": 62543,
      "score adverse": 73728,
      "research assess": 70980,
      "literature provides": 42122,
      "scarce data": 73600,
      "combination analgesia": 17544,
      "analgesia anxiolysis": 9915,
      "administration analgesia": 8215,
      "frequently 50": 32542,
      "05 length": 520,
      "pain discharged": 56724,
      "telephone day": 80570,
      "discharge group": 25124,
      "baseline nrs": 13444,
      "similar conclusion": 75908,
      "assess dental": 11924,
      "provided modest": 66141,
      "study conduct": 78023,
      "neuropathic origin": 49230,
      "tramadol combination": 82046,
      "pregnant lactating": 63695,
      "lactating women": 41072,
      "musculoskeletal injuries": 48369,
      "detrimental effects": 24138,
      "ed setting": 27350,
      "gaining popularity": 32818,
      "ibuprofen effective": 36355,
      "profile oral": 65493,
      "active analgesic": 7484,
      "music therapy": 48373,
      "analgesics emergency": 10419,
      "outcome treatment": 54001,
      "ci findings": 16528,
      "safe acute": 73069,
      "molar surgery": 47275,
      "scores totpar6": 74003,
      "reported analgesic": 70506,
      "effect fewer": 27457,
      "rapid absorption": 67376,
      "participants evaluated": 58302,
      "prespecified time": 64724,
      "purpose assess": 66521,
      "potentially eligible": 63254,
      "analgesia ea": 9957,
      "rarely used": 67414,
      "therapy conclusions": 80999,
      "consistent documentation": 19695,
      "society anesthesia": 76371,
      "anesthesia intensive": 10918,
      "dental practice": 23407,
      "practice government": 63398,
      "provide optimal": 66084,
      "tool results": 81689,
      "patients medication": 59488,
      "adult aged": 8486,
      "experience intense": 30578,
      "determine availability": 23991,
      "departments methods": 23454,
      "results responses": 71922,
      "responses collected": 71384,
      "ed triage": 27353,
      "improves time": 37190,
      "medications 10": 44589,
      "medication included": 44504,
      "included sex": 37552,
      "residents participated": 71077,
      "001 oral": 169,
      "children post": 16069,
      "post graduate": 62567,
      "allows administration": 9645,
      "28 21": 3538,
      "effect making": 27479,
      "reporting statistical": 70703,
      "varied 30": 85931,
      "mg comparison": 45830,
      "data potentially": 22055,
      "level training": 41530,
      "standardized pain": 76977,
      "drugs nsaid": 27008,
      "respondents preferred": 71313,
      "children emergency": 16044,
      "methods paper": 45421,
      "trimethoprim sulfamethoxazole": 83228,
      "scores immediately": 73892,
      "volume use": 86402,
      "conducted english": 19355,
      "terms drug": 80704,
      "paroxetine fluoxetine": 58232,
      "recent alcohol": 68389,
      "research use": 71037,
      "chronic prescription": 16335,
      "inhibitors including": 38804,
      "conclusions considering": 19058,
      "interacting drugs": 39367,
      "interacting drug": 39366,
      "management method": 43201,
      "relief vs": 70208,
      "dose analgesics": 25830,
      "60 600": 5227,
      "10 1000": 664,
      "inhibitor used": 38798,
      "treat nnt": 82301,
      "design outcome": 23737,
      "participants reporting": 58360,
      "clinical data oxycodone": 16780,
      "short term management": 75194,
      "strategies postoperative pain": 77421,
      "evaluate effectiveness iv": 29790,
      "included review studies": 37546,
      "10 650 mg": 723,
      "groups achieved similar": 34126,
      "patients treated single": 60072,
      "placebo group 96": 61738,
      "vs 23 001": 86550,
      "23 001 compared": 3068,
      "active drug placebo": 7509,
      "patients reporting adverse": 59896,
      "mg 1000 mg": 45708,
      "label randomized single": 40996,
      "randomized single dose": 67186,
      "period way crossover": 60810,
      "ibuprofen 400 mg": 36345,
      "single dose single": 76093,
      "standardized high fat": 76961,
      "auc auc infinity": 12629,
      "male subjects included": 43060,
      "height 181 cm": 34892,
      "rate oxycodone absorption": 67495,
      "single dose pharmacokinetic": 76088,
      "ir oxycodone 15": 40244,
      "pain relief occurred": 57555,
      "cr oxycodone safe": 21099,
      "databases searched medline": 22210,
      "authors independently screened": 12740,
      "conclusions oxycodone produced": 19147,
      "inflammatory drugs superior": 38573,
      "single agent oxycodone": 76049,
      "receive single dose": 68077,
      "groups 05 patients": 34090,
      "adverse events highest": 8762,
      "retrospective pre post": 72153,
      "post intervention patients": 62578,
      "oxycodone acetaminophen provides": 54661,
      "following emergency department": 32131,
      "department ed discharge": 23424,
      "blind clinical trial": 13923,
      "ed patients acute": 27340,
      "hydrocodone acetaminophen mg": 36056,
      "ingestion study drug": 38747,
      "significantly oxycodone acetaminophen": 75825,
      "pain relief versus": 57599,
      "oxycodone significantly different": 55912,
      "acute pain emergency": 7668,
      "mg acetaminophen 10": 45785,
      "acetaminophen 10 mg": 7112,
      "similar groups 30": 75926,
      "short term pain": 75197,
      "term pain relief": 80660,
      "187 oxycodone mg": 2149,
      "mg oxycodone produced": 46138,
      "adverse effects significantly": 8700,
      "dose conclusions results": 25851,
      "ibuprofen 10 mg": 36343,
      "postoperative pain increased": 62876,
      "search strategy cochrane": 74129,
      "11 oxycodone 10": 1139,
      "oxycodone effective analgesic": 55014,
      "analgesic acute postoperative": 10142,
      "commonly used non": 17886,
      "longer duration action": 42369,
      "pain relief non": 57550,
      "outcomes included mean": 54035,
      "acetaminophen oxycodone combination": 7222,
      "mg acetaminophen 650": 45789,
      "significantly better overall": 75662,
      "acetaminophen oxycodone group": 7223,
      "subjects randomly allocated": 78731,
      "pain scores drugs": 57722,
      "scores drugs adverse": 73873,
      "common oxycodone group": 17791,
      "favorable safety profile": 31262,
      "safety profile background": 73204,
      "500 mg placebo": 4922,
      "parallel group single": 58138,
      "ci 06 31": 16378,
      "plus oxycodone 10": 62029,
      "pain relief scale": 57578,
      "patients experiencing adverse": 59287,
      "placebo conclusions study": 61670,
      "10 mg 650": 796,
      "mg 600 mg": 45759,
      "oxycodone acetaminophen 20": 54628,
      "patients experienced fewer": 59279,
      "percentage patients experiencing": 60512,
      "administration objective study": 8314,
      "measures efficacy included": 44056,
      "included mean daily": 37480,
      "pain relief scores": 57580,
      "addition significant differences": 7827,
      "central nervous gastrointestinal": 15600,
      "unknown purpose study": 83890,
      "june october 2018": 40563,
      "mg tablets tablets": 46234,
      "oral opioid use": 53609,
      "pain significant burden": 57837,
      "need pain medication": 48946,
      "provides improved analgesia": 66222,
      "phase iii trial": 61300,
      "majority participants female": 42992,
      "rescue oxycodone consumption": 70970,
      "line treatment acute": 42003,
      "overall benefit risk": 54189,
      "high abuse liability": 35066,
      "objective determine oral": 50400,
      "325 mg 10": 3951,
      "mg 10 650": 45699,
      "effects overall satisfaction": 28054,
      "reported patients received": 70621,
      "oxycodone acetaminophen 15": 54627,
      "secondary outcomes showed": 74257,
      "conclusions oral morphine": 19139,
      "ed objectives objective": 27335,
      "prior drug administration": 65144,
      "evaluate pain management": 29825,
      "pain relief given": 57541,
      "age 36 14": 8997,
      "36 14 years": 4117,
      "analgesic effect patients": 10208,
      "trial conducted urban": 83015,
      "1000 mg acetaminophen": 1036,
      "mg acetaminophen mg": 45791,
      "acetaminophen mg oxycodone": 7205,
      "mg oxycodone 325": 46100,
      "oxycodone 325 mg": 54561,
      "worst possible pain": 87349,
      "pain score sd": 57682,
      "score adverse events": 73729,
      "statistically significant clinically": 77202,
      "degree pain experienced": 23175,
      "analyzed using multivariate": 10871,
      "using multivariate regression": 85509,
      "clinically significant reduction": 17006,
      "blind trial setting": 13993,
      "325 mg codeine": 3955,
      "proportion patients 50": 65761,
      "300 mg oxycodone": 3816,
      "650 mg placebo": 5435,
      "statistically significantly greater": 77234,
      "significantly greater pain": 75712,
      "versus placebo significantly": 86153,
      "significantly greater effect": 75707,
      "weak opioid strong": 86789,
      "opioid strong opioid": 52376,
      "pregnant lactating women": 63696,
      "profile oral opioids": 65494,
      "baseline 60 minutes": 13414,
      "patients receiving mg": 59846,
      "95 ci findings": 6363,
      "effect fewer effects": 27458,
      "prespecified time points": 64725,
      "dose related effects": 26047,
      "epidural analgesia ea": 29168,
      "drugs gabapentin pregabalin": 26965,
      "pain therapy conclusions": 57913,
      "society anesthesia intensive": 76372,
      "anesthesia intensive care": 10919,
      "department ed setting": 23430,
      "emergency medicine physicians": 28692,
      "methods retrospective data": 45543,
      "pain medications did": 57164,
      "opioid analgesic administration": 51450,
      "decreased 28 21": 22955,
      "100 mg diclofenac": 993,
      "children emergency department": 16045,
      "pain management modalities": 57081,
      "objectives objective determine": 50569,
      "scores groups significant": 73885,
      "pubmed search conducted": 66456,
      "search conducted english": 74108,
      "conducted english language": 19356,
      "clinically significant drug": 17003,
      "significant drug drug": 75532,
      "drug interactions including": 26668,
      "pain management method": 57079,
      "pain relief vs": 57600,
      "short term effects": 75189,
      "needed treat nnt": 49044,
      "oxycodone postoperative pain management": 55711,
      "vs 23 001 compared": 86551,
      "center open label randomized": 15535,
      "open label randomized single": 51180,
      "label randomized single dose": 40997,
      "randomized single dose period": 67188,
      "period way crossover study": 60811,
      "compared immediate release ir": 18184,
      "anti inflammatory drugs superior": 11134,
      "following emergency department ed": 32132,
      "emergency department ed discharge": 28674,
      "double blind clinical trial": 26342,
      "randomised double blind clinical": 67022,
      "pain emergency department ed": 56754,
      "mg acetaminophen 10 mg": 45786,
      "acetaminophen 10 mg oxycodone": 7113,
      "single dose oxycodone mg": 76086,
      "10 mg oxycodone produced": 838,
      "analgesic acute postoperative pain": 10143,
      "mean visual analogue scale": 43905,
      "mg acetaminophen 650 mg": 45790,
      "pain scores drugs adverse": 57723,
      "scores drugs adverse effects": 73874,
      "drugs adverse effects assessed": 26878,
      "secondary efficacy measures included": 74217,
      "plus oxycodone 10 mg": 62030,
      "oxycodone 10 mg placebo": 54501,
      "10 mg 650 mg": 797,
      "325 mg tablets tablets": 3964,
      "10 mg acetaminophen 650": 800,
      "acetaminophen 650 mg acetaminophen": 7140,
      "650 mg acetaminophen 650": 5433,
      "325 mg 10 650": 3952,
      "mg 10 650 mg": 45700,
      "department ed patients methods": 23427,
      "ed patients methods prospective": 27344,
      "additional pain relief given": 7882,
      "sd age 36 14": 74073,
      "age 36 14 years": 8998,
      "mg acetaminophen mg oxycodone": 45792,
      "acetaminophen mg oxycodone 325": 7206,
      "mg oxycodone 325 mg": 46101,
      "oxycodone 325 mg acetaminophen": 54562,
      "consecutive adult patients underwent": 19557,
      "analyzed using multivariate regression": 10872,
      "double blind trial setting": 26390,
      "10 650 mg placebo": 724,
      "significantly greater pain relief": 75713,
      "weak opioid strong opioid": 86790,
      "society anesthesia intensive care": 76373,
      "emergency department ed setting": 28678,
      "pain scores groups significant": 57726,
      "pubmed search conducted english": 66457,
      "search conducted english language": 74109,
      "conducted english language articles": 19357,
      "significant drug drug interactions": 75533,
      "pharmacodynamically": 61081,
      "066": 597,
      "livers": 42188,
      "associate": 12206,
      "accentuated": 6973,
      "personalize": 60951,
      "latest": 41243,
      "miconazole": 46335,
      "clarithromycin": 16648,
      "pharmacokinetically": 61155,
      "nhp": 49464,
      "cyp1a2": 21575,
      "mirroring": 46689,
      "pyrosequencing": 66613,
      "overrepresented": 54359,
      "ems": 28754,
      "saturable": 73466,
      "ugt": 83407,
      "michaelis": 46331,
      "menten": 44831,
      "ugt2b7": 83408,
      "cyp2b6": 21576,
      "caco": 14668,
      "bcrp": 13497,
      "hepatocytes": 34967,
      "preincubation": 63707,
      "1240": 1424,
      "famotidine": 31188,
      "pantoprazole": 58069,
      "anticipate": 11155,
      "turnover": 83288,
      "accorded": 7032,
      "recollection": 68576,
      "cations": 15329,
      "brands": 14385,
      "triazolam": 83211,
      "cyp2c8": 21581,
      "statins": 77167,
      "necessitate": 48893,
      "2260": 3062,
      "antiviral": 11264,
      "antivirals": 11265,
      "pioglitazone": 61558,
      "forms controlled": 32309,
      "pharmacokinetics oral": 61175,
      "morphine higher": 47714,
      "slightly longer": 76256,
      "understanding oxycodone": 83641,
      "organ function": 53753,
      "literature published": 42123,
      "absorption profile": 6613,
      "distribution metabolism": 25560,
      "necessary especially": 48882,
      "needed fully": 49003,
      "understood oxycodone": 83656,
      "hour administration": 35692,
      "plasma protein": 61952,
      "weak analgesic": 86783,
      "used simultaneously": 85134,
      "oxycodone primarily": 55756,
      "cyp2d6 substrates": 21626,
      "non functional": 49600,
      "functional alleles": 32689,
      "oxycodone dosage": 54989,
      "higher variability": 35337,
      "pharmacologically active": 61240,
      "result substantial": 71494,
      "literature clinical": 42112,
      "interactions ddi": 39391,
      "auc ratio": 12637,
      "oxycodone fold": 55095,
      "compared mean": 18201,
      "affect expression": 8900,
      "kinetic parameters": 40840,
      "enzyme activity": 29098,
      "genotype phenotype": 33098,
      "serve reference": 74713,
      "precision medicine": 63524,
      "analgesic commonly": 10166,
      "substrate specificity": 78886,
      "cl predicted": 16610,
      "total systemic": 81908,
      "genetic variability": 33083,
      "methods 30": 45235,
      "metabolism phenotype": 44938,
      "based cyp2d6": 13303,
      "oxycodone children": 54778,
      "assess pharmacokinetic": 11950,
      "dependent cyp2d6": 23503,
      "genotyping performed": 33105,
      "affects pharmacokinetics": 8937,
      "elimination phase": 28618,
      "nonoral routes": 49821,
      "intranasal abuse": 39746,
      "methods vitro": 45628,
      "reduced max": 68938,
      "intended oral": 39206,
      "potential iv": 63181,
      "nasal abuse": 48651,
      "active substances": 7535,
      "oral drugs": 53529,
      "constant drug": 19740,
      "im pm": 36673,
      "15 respectively": 1789,
      "potential provide": 63214,
      "pharmacokinetics background": 61160,
      "2d6 cyp2d6": 3649,
      "subjective pharmacodynamic": 78660,
      "psychomotor function": 66354,
      "10 subjects": 933,
      "alter pharmacodynamic": 9685,
      "subject oxycodone": 78631,
      "oxycodone cyp2d6": 54917,
      "altered pharmacokinetics": 9703,
      "design phases": 23748,
      "day pre": 22388,
      "reduced area": 68912,
      "cyp2d6 dependent": 21598,
      "crossover placebo": 21291,
      "subjects given": 78700,
      "mean elimination": 43774,
      "pharmacogenetic analyses": 61097,
      "pk data": 61575,
      "pharmacodynamics oral": 61084,
      "volunteers ingested": 86422,
      "48 hr": 4730,
      "area oxycodone": 11633,
      "products increase": 65449,
      "polymorphisms drug": 62218,
      "performed 10": 60565,
      "genotyped cyp2d6": 33100,
      "im ultrarapid": 36677,
      "occasions oxycodone": 50816,
      "kg given": 40730,
      "psychomotor effects": 66353,
      "toxicity assessed": 81931,
      "cyp2d6 poor": 21622,
      "85 mg": 5987,
      "parameters compared": 58157,
      "17 90": 1952,
      "washout periods": 86748,
      "patients incident": 59390,
      "difference proportions": 24674,
      "approved study": 11548,
      "authors studied": 12750,
      "noroxymorphone determined": 49946,
      "determined 48": 24059,
      "oxycodone necessary": 55527,
      "objective increased": 50438,
      "enzymes important": 29113,
      "focused use": 31976,
      "using patients": 85552,
      "oxycodone analysed": 54714,
      "combinations oxycodone": 17627,
      "young elderly": 87718,
      "oxycodone clarithromycin": 54781,
      "magnitude effect": 42811,
      "auc0 infinity": 12643,
      "oxycodone seen": 55869,
      "cm weight": 17093,
      "time profiles": 81346,
      "primary pharmacokinetic": 65102,
      "concentration vs": 18733,
      "activity associated": 7558,
      "cases categorized": 15227,
      "compared extensive": 18158,
      "groups showing": 34318,
      "known alter": 40902,
      "ratios fold": 67822,
      "metabolizers pms": 45010,
      "cyp2d6 variation": 21627,
      "world impact": 87313,
      "impact genetic": 36811,
      "evaluating drug": 29945,
      "reported pharmacokinetic": 70622,
      "identified adverse": 36421,
      "oxycodone quetiapine": 55791,
      "considered selecting": 19652,
      "pk pharmacodynamic": 61585,
      "normal doses": 49901,
      "17 42": 1945,
      "responsible metabolism": 71401,
      "cyp2d6 metabolism": 21612,
      "cyp2d6 oxycodone": 21617,
      "determine cyp2d6": 23999,
      "oxycodone ondansetron": 55560,
      "interaction cyp2d6": 39369,
      "drug effectiveness": 26612,
      "cyp2d6 substrate": 21625,
      "enzymes responsible": 29115,
      "potent inhibitors": 63103,
      "oxycodone receiving": 55805,
      "2000 2020": 2423,
      "fluoxetine paroxetine": 31958,
      "50 15": 4806,
      "indicating greater": 38260,
      "oxycodone demethylated": 54937,
      "activity poor": 7579,
      "evaluated randomized": 29915,
      "including 33": 37587,
      "volunteers pain": 86426,
      "thresholds single": 81156,
      "single electrical": 76100,
      "stimulation cold": 77369,
      "time area": 81212,
      "metabolic enzymes": 44906,
      "followed michaelis": 32069,
      "michaelis menten": 46332,
      "menten kinetics": 44832,
      "min mg": 46536,
      "inhibitors oxycodone": 38806,
      "determine inhibitory": 24018,
      "represents comprehensive": 70768,
      "opioids frequent": 52919,
      "reduction methods": 69067,
      "introduces new": 39913,
      "gp bcrp": 33357,
      "acute doses": 7628,
      "presence benzodiazepines": 64584,
      "present fatal": 64620,
      "fatal drug": 31230,
      "exceptionally low": 30448,
      "reasons explain": 68020,
      "potentially toxic": 63269,
      "considered useful": 19662,
      "unknown mechanism": 83880,
      "atpase activity": 12535,
      "mg min": 46054,
      "microl min": 46370,
      "human intestinal": 35957,
      "cyp2d6 methadone": 21614,
      "1000 \u00b5m": 1044,
      "maximal inhibitory": 43575,
      "studies explore": 77726,
      "hormones testosterone": 35547,
      "conjugation ugt": 19540,
      "cyp450 2d6": 21647,
      "relevance data": 70034,
      "treatment ultimately": 82880,
      "oxycodone specific": 55927,
      "isotopic dilution": 40313,
      "study rate": 78451,
      "gp substrates": 33360,
      "substrates digoxin": 78889,
      "ondansetron oxycodone": 51079,
      "values contribution": 85838,
      "various brands": 85962,
      "effect activated": 27413,
      "pharmacokinetics drugs": 61166,
      "reviewed publications": 72389,
      "reporting drug": 70686,
      "dosing adjustments": 26305,
      "intravenous route": 39881,
      "therapeutic outcomes": 80954,
      "need careful": 48912,
      "examine literature": 30348,
      "decreased effect": 22993,
      "agent selection": 9223,
      "treatment initiation": 82629,
      "amitriptyline oxycodone": 9827,
      "evaluation clinical": 29952,
      "presence comorbidities": 64586,
      "interaction occurs": 39374,
      "models constructed": 47112,
      "various dosages": 85964,
      "digoxin verapamil": 24986,
      "clinicians vigilant": 17039,
      "oral morphine higher": 53584,
      "events purpose review": 30102,
      "necessary especially elderly": 48883,
      "studies needed fully": 77787,
      "needed fully understand": 49004,
      "plasma protein binding": 61953,
      "oxycodone half life": 55145,
      "40 80 mg": 4330,
      "effects common opioids": 27856,
      "use opioid oxycodone": 84550,
      "p450 cyp enzymes": 56310,
      "non functional alleles": 49601,
      "result substantial changes": 71495,
      "pharmacokinetic pbpk model": 61129,
      "drug interactions ddi": 26666,
      "approximately 40 60": 11570,
      "opioid analgesic commonly": 51452,
      "analgesic commonly prescribed": 10167,
      "dependent cyp2d6 activity": 23504,
      "30 90 180": 3706,
      "study healthy subjects": 78225,
      "doses oxycodone pain": 26243,
      "intranasal abuse potential": 39747,
      "extended release profile": 30900,
      "p450 2d6 cyp2d6": 56303,
      "24 hours drug": 3217,
      "number adverse effects": 50137,
      "alter pharmacodynamic effects": 9686,
      "oxycodone methods randomized": 55403,
      "study design phases": 78076,
      "effects compared placebo": 27866,
      "crossover placebo controlled": 21292,
      "pharmacokinetic pharmacodynamic parameters": 61134,
      "mean elimination half": 43775,
      "pharmacokinetic pk data": 61141,
      "pharmacokinetics pharmacodynamics oral": 61182,
      "pharmacodynamics oral oxycodone": 61085,
      "mg kg given": 45976,
      "cyp2d6 poor metabolizers": 21623,
      "12 healthy volunteers": 1286,
      "pharmacological effects oxycodone": 61214,
      "pharmacokinetic parameters compared": 61124,
      "objective assess relative": 50383,
      "opioid analgesic prescribed": 51465,
      "oxymorphone noroxymorphone determined": 56268,
      "noroxymorphone determined 48": 49947,
      "86 respectively 001": 6011,
      "effects oxycodone enhanced": 28062,
      "concentration time profiles": 18728,
      "patients requiring oxycodone": 59913,
      "concentration vs time": 18734,
      "concentrations compared extensive": 18754,
      "poor metabolizers pms": 62267,
      "real world impact": 68008,
      "non genetic factors": 49603,
      "identified adverse events": 36422,
      "pharmacokinetic pk pharmacodynamic": 61142,
      "pk pharmacodynamic pd": 61586,
      "academic emergency department": 6946,
      "enzymes responsible metabolism": 29116,
      "activity poor metabolizers": 7580,
      "healthy volunteers pain": 34856,
      "tolerance thresholds single": 81606,
      "thresholds single electrical": 81157,
      "stimulation cold pressor": 77370,
      "pain time area": 57919,
      "followed michaelis menten": 32070,
      "michaelis menten kinetics": 46333,
      "phase ii drug": 61287,
      "half maximal inhibitory": 34523,
      "future studies explore": 32775,
      "methadone fentanyl buprenorphine": 45072,
      "fentanyl buprenorphine tramadol": 31448,
      "hplc ms ms": 35886,
      "gp substrates digoxin": 33361,
      "effect activated charcoal": 27414,
      "implications clinical practice": 36961,
      "play role drug": 61998,
      "adverse events purpose review": 8795,
      "release controlled release oxycodone": 69815,
      "clinical studies needed fully": 16914,
      "studies needed fully understand": 77788,
      "20 40 80 mg": 2292,
      "cytochrome p450 cyp enzymes": 21660,
      "based pharmacokinetic pbpk model": 13355,
      "drug drug interactions ddi": 26604,
      "opioid analgesic commonly prescribed": 51453,
      "cytochrome p450 2d6 cyp2d6": 21654,
      "crossover placebo controlled study": 21293,
      "mean elimination half life": 43776,
      "pharmacokinetics pharmacodynamics oral oxycodone": 61183,
      "oxycodone concentration time curve": 54828,
      "metabolites noroxycodone oxymorphone noroxymorphone": 44976,
      "noroxycodone oxymorphone noroxymorphone determined": 49940,
      "oxymorphone noroxymorphone determined 48": 56269,
      "pharmacokinetic pk pharmacodynamic pd": 61143,
      "cyp2d6 poor metabolizers pms": 21624,
      "analgesic effect intravenous oxycodone": 10202,
      "tolerance thresholds single electrical": 81607,
      "stimulation cold pressor test": 77371,
      "followed michaelis menten kinetics": 32071,
      "potential drug drug interactions": 63160,
      "hplc ms ms method": 35887,
      "discern": 25088,
      "pectus": 60341,
      "excavatum": 30432,
      "pkpd": 61592,
      "hybrid": 35995,
      "bisphosphonate": 13890,
      "expect": 30546,
      "annotated": 11008,
      "embedding": 28657,
      "corrections": 20803,
      "affordability": 8951,
      "353": 4103,
      "amide": 9814,
      "expands": 30543,
      "oxcarbazepine": 54387,
      "doors": 25715,
      "defective": 23101,
      "adhered": 7991,
      "normally": 49919,
      "b1": 12994,
      "prolonged duration": 65612,
      "enrolled divided": 28999,
      "pectus excavatum": 60342,
      "undergoing spinal": 83576,
      "users increased": 85247,
      "contribute abuse": 20222,
      "subjective analgesic": 78645,
      "produced typical": 65417,
      "miosis decreased": 46669,
      "subjective responses": 78671,
      "populations opioid": 62406,
      "better opioid": 13719,
      "method population": 45201,
      "pkpd model": 61593,
      "large differences": 41125,
      "oxycodone thirty": 55994,
      "effect measured": 27483,
      "25 reduction": 3383,
      "time auc": 81213,
      "auc adverse": 12626,
      "times 24": 81414,
      "pain rated": 57466,
      "according numeric": 7051,
      "ratings conclusion": 67691,
      "selection cancer": 74405,
      "treated regular": 82375,
      "33 baseline": 3990,
      "results 140": 71545,
      "378 subjects": 4221,
      "20 group": 2317,
      "received alternative": 68116,
      "participants 001": 58262,
      "280 vs": 3581,
      "relationship pain": 69723,
      "respectively dosage": 71187,
      "prescribed medicines": 63892,
      "showed group": 75256,
      "particularly useful": 58423,
      "bisphosphonate administration": 13891,
      "unmet medical": 83904,
      "medical need": 44369,
      "white participants": 87027,
      "association studies": 12490,
      "experimental cold": 30658,
      "european pharmacogenetic": 29748,
      "pharmacogenetic opioid": 61098,
      "meperidine buprenorphine": 44840,
      "xenobiotics blood": 87403,
      "interference effects": 39423,
      "additionally participants": 7907,
      "risk dependence": 72542,
      "healthcare systems": 34809,
      "medical settings": 44403,
      "evaluated perioperative": 29908,
      "perioperative care": 60830,
      "methods implementation": 45357,
      "prescribing records": 64132,
      "results 78": 71586,
      "total medications": 81835,
      "results generally": 71704,
      "pilot data": 61551,
      "decisions clinical": 22854,
      "studies exploring": 77727,
      "requirements recorded": 70891,
      "strongest association": 77571,
      "strongest effects": 77572,
      "pain described": 56695,
      "genetic data": 33071,
      "therapeutic interventions": 80947,
      "practice narrative": 63403,
      "moderate evidence": 47146,
      "necessary clarify": 48879,
      "effects human": 27944,
      "volunteers experimental": 86419,
      "data previously": 22065,
      "volunteers used": 86437,
      "nineteen opioid": 49480,
      "children prescribed": 16070,
      "decreased prescribing": 23031,
      "education electronic": 27380,
      "increased provider": 37997,
      "oxycodone perceived": 55668,
      "changes reporting": 15820,
      "results recommendations": 71908,
      "analysis cohort": 10649,
      "management currently": 43174,
      "adjustment based": 8069,
      "concentrations therapeutic": 18816,
      "different general": 24871,
      "total 80": 81769,
      "include increased": 37356,
      "selection dose": 74417,
      "patient outcome": 58697,
      "fundamental role": 32731,
      "impacts opioid": 36863,
      "effects average": 27833,
      "considerable variation": 19616,
      "potentially lead": 63262,
      "associated intense": 12312,
      "pain response": 57636,
      "respectively studies": 71253,
      "effects discussion": 27900,
      "drug accumulation": 26515,
      "small pk": 76294,
      "pk differences": 61576,
      "close monitoring": 17067,
      "carbamazepine oxcarbazepine": 14966,
      "tissue damage": 81449,
      "evidence demonstrating": 30181,
      "criteria oral": 21206,
      "estimated odds": 29633,
      "adherence rate": 7997,
      "current practices": 21456,
      "data 30": 21853,
      "altered function": 9697,
      "decisions patients": 22856,
      "children 17": 16021,
      "adults age": 8541,
      "data prescriber": 22058,
      "ongoing research": 51093,
      "designed studies": 23845,
      "population frequency": 62331,
      "drug metabolized": 26708,
      "hydrocodone 40": 36049,
      "coronavirus disease": 20787,
      "disease 2019": 25316,
      "2019 covid": 2861,
      "using simulation": 85614,
      "protocol occurred": 65981,
      "postoperative medication": 62789,
      "demonstrated higher": 23343,
      "deemed feasible": 23083,
      "data indicated": 21992,
      "inform treatment": 38627,
      "methods descriptive": 45310,
      "272 patients": 3517,
      "available medical": 12821,
      "solution evaluated": 76442,
      "evidence inform": 30201,
      "prescribing identify": 64064,
      "maximum score": 43615,
      "score maximum": 73759,
      "examination clinical": 30326,
      "analyses assessed": 10583,
      "center hospital": 15524,
      "ci analysis": 16518,
      "estimating prevalence": 29658,
      "serial cross": 74645,
      "children hospitals": 16053,
      "approximately million": 11583,
      "years observed": 87622,
      "analyzed june": 10836,
      "status adequately": 77252,
      "initial analgesia": 38828,
      "aimed investigate impact": 9461,
      "undergoing spinal fusion": 83577,
      "opioid users increased": 52622,
      "effects miosis decreased": 27996,
      "miosis decreased pain": 46670,
      "decreased pain perception": 23021,
      "dependent increases positive": 23514,
      "positive subjective responses": 62498,
      "opioids abuse liability": 52694,
      "method population pharmacokinetic": 45202,
      "hours postoperatively pain": 35825,
      "10 worst possible": 956,
      "opioid selection cancer": 52359,
      "selection cancer pain": 74406,
      "achieve pain reduction": 7303,
      "30 day treatment": 3721,
      "initiating opioid therapy": 38889,
      "showed group patients": 75257,
      "unmet medical need": 83905,
      "30 june 2017": 3746,
      "general anesthesia included": 32961,
      "12 mg kg": 1325,
      "european pharmacogenetic opioid": 29749,
      "pharmacogenetic opioid study": 61099,
      "pain pain relief": 57320,
      "use general population": 84382,
      "ongoing opioid crisis": 51086,
      "opioid crisis current": 51683,
      "opioid treatment acute": 52439,
      "study aimed identify": 77932,
      "44 years age": 4551,
      "day post operative": 22381,
      "post operative period": 62607,
      "treatment significant implications": 82842,
      "anesthesiologists asa score": 10957,
      "data clinical practice": 21903,
      "evidence supports use": 30278,
      "healthy volunteers experimental": 34853,
      "oxycodone response pain": 55846,
      "education electronic health": 27381,
      "pain management currently": 57066,
      "oxycodone consumption conclusion": 54857,
      "conducted retrospective analysis": 19400,
      "conventional pain management": 20701,
      "children 17 years": 16022,
      "prescribing methods retrospective": 64081,
      "pain sleep conclusion": 57850,
      "coronavirus disease 2019": 20788,
      "disease 2019 covid": 25317,
      "2019 covid 19": 2862,
      "recorded pain level": 68688,
      "daily 10 days": 21687,
      "average pain level": 12926,
      "preclinical clinical studies": 63527,
      "clinical studies suggest": 16917,
      "step iii opioid": 77324,
      "opioid therapy cancer": 52407,
      "serial cross sectional": 74646,
      "data analyzed june": 21875,
      "frequently prescribed medications": 32570,
      "hydrocodone commonly prescribed": 36073,
      "resulting increased risk": 71530,
      "study aimed investigate impact": 77935,
      "effects oral oxycodone 10": 28052,
      "agonist effects miosis decreased": 9287,
      "effects miosis decreased pain": 27997,
      "miosis decreased pain perception": 46671,
      "dose dependent increases positive": 25872,
      "dependent increases positive subjective": 23515,
      "increases positive subjective responses": 38075,
      "pain 10 worst possible": 56360,
      "10 worst possible pain": 957,
      "opioid selection cancer pain": 52360,
      "european pharmacogenetic opioid study": 29750,
      "society anesthesiologists asa score": 76377,
      "education electronic health record": 27382,
      "fentanyl morphine oxycodone hydromorphone": 31535,
      "opioid use pain management": 52556,
      "self reported pain score": 74500,
      "coronavirus disease 2019 covid": 20789,
      "disease 2019 covid 19": 25318,
      "patients recorded pain level": 59867,
      "serial cross sectional study": 74647,
      "paroxysmal": 58234,
      "fish": 31850,
      "metformin": 45032,
      "sufferers": 78962,
      "ami": 9813,
      "symmetric": 79851,
      "sequela": 74626,
      "scientifically": 73689,
      "carnitine": 15125,
      "dermatomal": 23640,
      "seventh": 74884,
      "infected": 38511,
      "gastritis": 32856,
      "valproic": 85808,
      "vasoconstriction": 86037,
      "ace": 7107,
      "hopefully": 35539,
      "scores visual": 74010,
      "assessed potential": 12040,
      "severe painful": 75006,
      "gabapentin significantly": 32804,
      "lack therapeutic": 41061,
      "cohort days": 17356,
      "term complications": 80622,
      "months evaluated": 47440,
      "alternate treatment": 9710,
      "safe management": 73090,
      "pain 22": 56375,
      "delivered oxycodone": 23209,
      "month history": 47392,
      "history left": 35462,
      "diagnosis idiopathic": 24334,
      "pregabalin 75": 63660,
      "titration dosing": 81477,
      "vas following": 86005,
      "dosage analgesic": 25744,
      "nearly 95": 48866,
      "tablets 16": 80114,
      "treatments different": 82906,
      "edition diagnosis": 27366,
      "sham controlled": 75107,
      "department pain": 23440,
      "intractable pain": 39737,
      "dose average": 25832,
      "compare therapeutic": 18059,
      "epidural block": 29175,
      "points 05": 62119,
      "reactions group": 67962,
      "combined drug": 17645,
      "frequently occur": 32559,
      "efficacy following": 28271,
      "analgesics administered": 10370,
      "16 healthy": 1874,
      "combined 10": 17635,
      "subjective psychomotor": 78664,
      "psychomotor physiological": 66356,
      "assessed sessions": 12062,
      "increases subjective": 38086,
      "psychomotor performance": 66355,
      "liability related": 41649,
      "pregabalin dose": 63665,
      "produced increases": 65391,
      "drug abused": 26511,
      "studies pregabalin": 77815,
      "subjects 50": 78677,
      "frequently subjects": 32581,
      "days 01": 22458,
      "difference regard": 24677,
      "clinical aspects": 16757,
      "delta ligands": 23236,
      "ligands gabapentin": 41764,
      "2011 march": 2584,
      "27 individuals": 3493,
      "small fiber": 76279,
      "antidepressants amitriptyline": 11170,
      "research setting": 71027,
      "identify potentially": 36522,
      "accurate diagnosis": 7101,
      "score nrs": 73762,
      "gabapentin dosage": 32794,
      "recurrence rate": 68815,
      "practice introduction": 63401,
      "reduce severity": 68894,
      "agents considered": 9229,
      "42 year": 4478,
      "academy neurology": 6964,
      "great variability": 33419,
      "comparison different": 18366,
      "treatments needed": 82913,
      "head trials": 34653,
      "objectives acute": 50536,
      "alleviation acute": 9607,
      "dermatomal distribution": 23641,
      "definition clinical": 23161,
      "months healing": 47444,
      "acting agents": 7372,
      "helpful patients": 34916,
      "difference vas": 24701,
      "doses treatment": 26296,
      "benefit opioids": 13619,
      "effective relatively": 27688,
      "line therapies": 42000,
      "line approaches": 41985,
      "order compare": 53707,
      "conditions single": 19330,
      "conditions concluded": 19314,
      "information effects": 38646,
      "total 40": 81750,
      "medications vs": 44697,
      "substrates conclusions": 78888,
      "need medical": 48934,
      "symptomatic relief": 79869,
      "shown promising": 75349,
      "promising treatment": 65660,
      "valproic acid": 85809,
      "studies support": 77858,
      "discuss potential": 25284,
      "patient concerns": 58571,
      "treatment commenced": 82506,
      "treatment considered": 82520,
      "role play": 72763,
      "medications widely": 44698,
      "sodium valproate": 76408,
      "selected evaluating": 74387,
      "cox inhibition": 21026,
      "trials available": 83105,
      "51 00": 4944,
      "effectively assess": 27727,
      "pain scores visual": 57792,
      "scores visual analogue": 74011,
      "medications significantly decreased": 44676,
      "associated significant morbidity": 12427,
      "moderate severe painful": 47208,
      "21 mg day": 2975,
      "resulted pain relief": 71512,
      "oxycodone relative placebo": 55825,
      "measured using 10": 44003,
      "scale vas following": 73574,
      "dosage analgesic efficacy": 25745,
      "treated oxycodone group": 82365,
      "mean daily oxycodone": 43745,
      "time points 05": 81333,
      "combined 10 mg": 17636,
      "mg oxycodone subjective": 46139,
      "oxycodone subjective psychomotor": 55952,
      "subjective psychomotor physiological": 78665,
      "psychomotor physiological measures": 66357,
      "physiological measures assessed": 61465,
      "measures assessed sessions": 44048,
      "abuse liability related": 6759,
      "liability related subjective": 41650,
      "oxycodone produced increases": 55765,
      "subjective effects including": 78651,
      "occurred frequently subjects": 50835,
      "patients completed trial": 59118,
      "january 2011 march": 40439,
      "average numeric rating": 12910,
      "90 mg day": 6104,
      "oxycodone consumption decreased": 54859,
      "randomised controlled clinical": 67013,
      "25 mg 50": 3363,
      "type diabetes mellitus": 83324,
      "clinical research setting": 16889,
      "clinical practice introduction": 16865,
      "42 year old": 4479,
      "relevant evidence based": 70057,
      "american academy neurology": 9788,
      "head head trials": 34648,
      "results total 40": 72031,
      "medications widely used": 44699,
      "effects studies necessary": 28169,
      "clinical trials evaluating": 16948,
      "tramadol oxycodone hydromorphone": 82094,
      "pain scores visual analogue": 57793,
      "scores visual analogue scale": 74012,
      "200 mg 12 hours": 2399,
      "combined 10 mg oxycodone": 17637,
      "10 mg oxycodone subjective": 839,
      "mg oxycodone subjective psychomotor": 46140,
      "oxycodone subjective psychomotor physiological": 55953,
      "subjective psychomotor physiological measures": 78666,
      "psychomotor physiological measures assessed": 66358,
      "physiological measures assessed sessions": 61466,
      "produced dose related increases": 65383,
      "abuse liability related subjective": 6760,
      "liability related subjective effects": 41651,
      "related subjective effects drug": 69686,
      "average numeric rating scale": 12911,
      "randomised controlled clinical trials": 67014,
      "42 year old female": 4480,
      "30 mg kg administered": 3763,
      "rests": 71468,
      "speculate": 76678,
      "pleasant": 62011,
      "estimations": 29661,
      "711": 5605,
      "hill": 35409,
      "coherence": 17333,
      "substantive": 78869,
      "oxycodone middle": 55449,
      "middle age": 46401,
      "underwent baseline": 83676,
      "35 85": 4072,
      "effects pupil": 28118,
      "analgesics affected": 10373,
      "affected patients": 8920,
      "highest patients": 35362,
      "study intranasal": 78266,
      "sessions day": 74741,
      "conducted days": 19352,
      "days subjects": 22632,
      "intervals drug": 39612,
      "misuse higher": 46721,
      "day groups": 22316,
      "20 male": 2327,
      "suggest possible": 79009,
      "combination methods": 17567,
      "conditions absorption": 19306,
      "min approximately": 46513,
      "reaction time": 67949,
      "related manner": 69630,
      "19 received": 2194,
      "intact oxycontin": 39175,
      "crushed oxycontin": 21345,
      "setting proposed": 74811,
      "males 14": 43069,
      "reported alcohol": 70505,
      "scale ratings": 73548,
      "differences pharmacodynamic": 24783,
      "report abuse": 70446,
      "seventy subjects": 74897,
      "lower end": 42610,
      "respectively higher": 71199,
      "higher end": 35238,
      "suggestive evidence": 79035,
      "demonstrated impact": 23344,
      "total 11": 81709,
      "assessment necessary": 12126,
      "evaluate human": 29804,
      "research site": 71029,
      "site subjects": 76161,
      "age 25": 8988,
      "inventory morphine": 39978,
      "design results": 23779,
      "increased rapidly": 37998,
      "liking secondary": 41868,
      "capable producing": 14946,
      "drugs did": 26934,
      "carisoprodol oxycodone": 15122,
      "studied population": 77626,
      "population non": 62361,
      "people objectives": 60416,
      "abusers use": 6936,
      "usa management": 84108,
      "following tampering": 32210,
      "states little": 77118,
      "dose oxy": 25985,
      "block standard": 14071,
      "attempt reduce": 12548,
      "30 300": 3684,
      "acetaminophen pharmacokinetics": 7237,
      "followed similar": 32082,
      "longer max": 42380,
      "sustained treatment": 79799,
      "increasing public": 38120,
      "methods inpatient": 45362,
      "disorder non": 25379,
      "lower active": 42575,
      "studies current": 77686,
      "current investigation": 21441,
      "fashion participants": 31198,
      "weeks identical": 86917,
      "second week": 74198,
      "meaningful differences": 43915,
      "procedure reduce": 65283,
      "assessed differences": 11997,
      "dose crossover": 25855,
      "181 vs": 2134,
      "peak drug": 60304,
      "decreased risk": 23038,
      "ntx results": 50114,
      "drug visual": 26861,
      "matched placebo": 43491,
      "degrees pain": 23183,
      "effects pre": 28099,
      "currently marketed": 21501,
      "design subjects": 23811,
      "abuse physical": 6807,
      "introduction nonmedical": 39936,
      "effects significant": 28156,
      "conclusions gabapentin": 19090,
      "majority oxycodone": 42989,
      "million persons": 46494,
      "did diminish": 24446,
      "oxycodone rapidly": 55796,
      "oxymorphone fold": 56245,
      "relative prescription": 69760,
      "drugs chosen": 26906,
      "placebo high": 61759,
      "potent hydrocodone": 63102,
      "max visual": 43564,
      "drug scores": 26781,
      "variables influence": 85897,
      "history presence": 35475,
      "overall abuse": 54182,
      "deterrent labeling": 24117,
      "data currently": 21934,
      "outcomes 12": 54006,
      "decreased 31": 22957,
      "previous 30": 64896,
      "subjects taking": 78746,
      "dependence objective": 23477,
      "pain medications study": 57168,
      "oxycodone middle age": 55450,
      "middle age older": 46402,
      "age older adults": 9095,
      "administration 10 mg": 8203,
      "prescribing opioid medications": 64093,
      "opioid analgesics affected": 51481,
      "crossover study intranasal": 21307,
      "objectives primary aim": 50580,
      "dose related manner": 26050,
      "analog scale ratings": 10531,
      "objective evaluate human": 50419,
      "evaluate human abuse": 29805,
      "clinical research site": 16890,
      "research site subjects": 71030,
      "included drug effects": 37448,
      "center inventory morphine": 15527,
      "inventory morphine benzedrine": 39979,
      "drug liking secondary": 26688,
      "safety tolerability assessed": 73232,
      "united states little": 83803,
      "nondependent recreational users": 49732,
      "30 300 mg": 3685,
      "max significantly longer": 43560,
      "frequently used treatment": 32588,
      "nonmedical use abuse": 49783,
      "increasing public health": 38121,
      "healthy adult participants": 34813,
      "iv opioid use": 40389,
      "mg 10 ml": 45703,
      "differences oxycodone hydrocodone": 24775,
      "significantly lower active": 75777,
      "single dose crossover": 76079,
      "seventy subjects randomized": 74898,
      "increased opioid prescribing": 37964,
      "experienced opioid abusers": 30618,
      "drug visual analog": 26862,
      "analgesics did significantly": 10415,
      "opioid abuse physical": 51375,
      "introduction nonmedical use": 39937,
      "design randomized placebo": 23776,
      "approximately million persons": 11584,
      "iv abuse potential": 40364,
      "dose oxycodone self": 25997,
      "mg mg respectively": 46052,
      "max visual analog": 43565,
      "1000 mg oxycodone": 1037,
      "respectively adverse events": 71166,
      "analgesics abuse deterrent": 10365,
      "abuse deterrent labeling": 6694,
      "outcomes 12 months": 54007,
      "previous 30 days": 64897,
      "current study addressed": 21474,
      "dependence objective objective": 23478,
      "oxycodone middle age older": 55451,
      "middle age older adults": 46403,
      "objectives primary aim study": 50581,
      "visual analog scale ratings": 86311,
      "objective evaluate human abuse": 50420,
      "evaluate human abuse potential": 29806,
      "period crossover study enrolled": 60719,
      "clinical research site subjects": 16891,
      "included drug effects questionnaire": 37449,
      "research center inventory morphine": 70985,
      "center inventory morphine benzedrine": 15528,
      "inventory morphine benzedrine group": 39980,
      "nondependent recreational users prescription": 49733,
      "opioids frequently used treatment": 52923,
      "20 mg 10 ml": 2331,
      "mg 10 ml saline": 45704,
      "randomized single dose crossover": 67187,
      "introduction nonmedical use prescription": 39938,
      "design randomized placebo controlled": 23777,
      "max visual analog scale": 43566,
      "opioid analgesics abuse deterrent": 51478,
      "dependence objective objective study": 23479,
      "supraclavicular": 79250,
      "correlating": 20823,
      "casting": 15277,
      "plateau": 61975,
      "fellows": 31343,
      "nonunion": 49864,
      "493": 4787,
      "clavicle": 16693,
      "elbow": 28469,
      "multinational": 48252,
      "913": 6145,
      "12 yr": 1393,
      "atorvastatin 10": 12529,
      "associated intravenous": 12315,
      "change 95": 15717,
      "analysis 27": 10628,
      "15 median": 1747,
      "rated satisfaction": 67538,
      "inferior combination": 38525,
      "management regimen": 43255,
      "regimen compared": 69303,
      "fixation distal": 31866,
      "distal radius": 25531,
      "radius fractures": 66976,
      "bone healing": 14234,
      "lead decreased": 41283,
      "tended greater": 80597,
      "age 11": 8968,
      "safe option": 73095,
      "supraclavicular nerve": 79251,
      "provide greater": 66066,
      "august 22": 12674,
      "collected week": 17491,
      "lieu opioids": 41680,
      "10 fewer": 764,
      "background regional": 13193,
      "40 24": 4317,
      "26 16": 3424,
      "ropivacaine patients": 72803,
      "inpatient surgery": 39033,
      "cases acute": 15222,
      "kg max": 40756,
      "max mg": 43553,
      "reduction doses": 69055,
      "fewer complications": 31634,
      "changes rates": 15817,
      "distal upper": 25533,
      "administration ed": 8254,
      "attendings fellows": 12562,
      "discharge children": 25110,
      "receiving outpatient": 68366,
      "20 received": 2376,
      "medicine resident": 44713,
      "national insurance": 48696,
      "collected telephone": 17487,
      "conclusions pediatric": 19158,
      "authors complete": 12719,
      "complete description": 18441,
      "description levels": 23672,
      "evidence objectives": 30230,
      "pills time": 61546,
      "main risk": 42865,
      "days ibuprofen": 22533,
      "breakthrough oxycodone": 14396,
      "effects linear": 27971,
      "study hypothesis": 78234,
      "states august": 77083,
      "respondents asked": 71306,
      "residents prescribed": 71079,
      "mme 16": 46949,
      "demonstrated influence": 23348,
      "non analgesic": 49570,
      "tramadol 0001": 82020,
      "particular risk": 58405,
      "population united": 62394,
      "despite prevalence": 23896,
      "measures overall": 44074,
      "overall quantities": 54241,
      "thousand seventy": 81139,
      "abuse small": 6879,
      "small effects": 76278,
      "milliequivalents mmes": 46449,
      "median 140": 44175,
      "hours postoperation": 35821,
      "prescriber level": 64010,
      "risk accidental": 72507,
      "100 27": 988,
      "demographics significant": 23304,
      "undergoing distal": 83528,
      "commonly prescribe": 17860,
      "repair opioid": 70384,
      "background population": 13162,
      "primary exposure": 65037,
      "subjects 12": 78674,
      "weak analgesics": 86784,
      "88 01": 6035,
      "setting pediatric": 74810,
      "discharged ed": 25193,
      "15 children": 1725,
      "hispanic patients": 35433,
      "controls data": 20668,
      "studied including": 77614,
      "ketorolac patients": 40654,
      "ketorolac associated": 40642,
      "12 codeine": 1274,
      "tramadol 13": 82022,
      "35 80": 4071,
      "period 933": 60709,
      "patient day": 58604,
      "91 mme": 6140,
      "equivalent 11": 29281,
      "receiving general": 68338,
      "difference recovery": 24676,
      "time did": 81250,
      "declined participate": 22869,
      "analgesics consumed": 10404,
      "\u03bcg 001": 87785,
      "\u03bcg \u03bcg": 87797,
      "atorvastatin 10 mg": 12530,
      "intervals 95 cis": 39606,
      "results seventy subjects": 71943,
      "change 95 ci": 15718,
      "following surgical treatment": 32208,
      "rated satisfaction analgesia": 67539,
      "non inferior combination": 49610,
      "pain management regimen": 57112,
      "fixation distal radius": 31867,
      "distal radius fractures": 25532,
      "increase oxycodone use": 37776,
      "children aged 17": 16036,
      "pain score significantly": 57683,
      "children aged 16": 16034,
      "age 11 years": 8969,
      "standardized pain management": 76978,
      "supraclavicular nerve blocks": 79252,
      "safe effective treatment": 73086,
      "scores 10 postoperative": 73824,
      "10 mg tablets": 849,
      "block ropivacaine patients": 14067,
      "ropivacaine patients received": 72804,
      "received epidural analgesia": 68147,
      "statistical models including": 77182,
      "mg kg max": 45995,
      "kg max mg": 40757,
      "overall pain scores": 54224,
      "distal upper extremity": 25534,
      "opioid administration ed": 51409,
      "emergency medicine resident": 28693,
      "70 oxycodone mg": 5568,
      "instructions authors complete": 39111,
      "authors complete description": 12720,
      "complete description levels": 18442,
      "description levels evidence": 23673,
      "levels evidence objectives": 41562,
      "abuse risk factors": 6871,
      "use design retrospective": 84301,
      "abuse drug abuse": 6715,
      "levels evidence level": 41561,
      "single blinded study": 76055,
      "days ibuprofen group": 22534,
      "76 mean number": 5742,
      "evaluated using national": 29932,
      "significantly associated increased": 75656,
      "disorders opioid related": 25397,
      "united states august": 83782,
      "prescription opioids state": 64370,
      "non analgesic medications": 49571,
      "acetaminophen hydrocodone bitartrate": 7193,
      "population united states": 62395,
      "months post op": 47463,
      "morphine milliequivalents mmes": 47766,
      "postoperatively results postoperative": 63024,
      "patient demographics significant": 58613,
      "demographics significant predictors": 23305,
      "patients undergoing distal": 60097,
      "prescribing oxycodone mg": 64097,
      "10 vs 24": 951,
      "adjusted multiple comparisons": 8040,
      "vs 10 95": 86520,
      "72 hour postoperative": 5617,
      "children aged 18": 16038,
      "ci 21 26": 16413,
      "white non hispanic": 87026,
      "likely prescribed opioids": 41828,
      "ketorolac group received": 40648,
      "use 12 months": 84140,
      "met study inclusion": 44884,
      "11 mg oxycodone": 1134,
      "outcome scores did": 53992,
      "12 weeks postoperatively": 1383,
      "confidence intervals 95 cis": 19482,
      "pain score 24 hours": 57667,
      "multimodal pain management regimen": 48230,
      "fixation distal radius fractures": 31868,
      "children aged 17 years": 16037,
      "children aged 16 years": 16035,
      "pain scores 10 postoperative": 57694,
      "mean oral morphine equivalent": 43820,
      "patients received epidural analgesia": 59779,
      "consumption 48 hours postoperatively": 19885,
      "mg kg max mg": 45996,
      "oxycodone mg kg max": 55426,
      "methods retrospective study conducted": 45548,
      "center prospective observational study": 15544,
      "instructions authors complete description": 39112,
      "authors complete description levels": 12721,
      "complete description levels evidence": 18443,
      "description levels evidence objectives": 23674,
      "pain purpose study evaluate": 57449,
      "use disorders opioid related": 84330,
      "patient demographics significant predictors": 58614,
      "vs 10 95 ci": 86521,
      "surgery level evidence level": 79441,
      "children aged 18 years": 16039,
      "23 95 ci 21": 3088,
      "95 ci 21 26": 6261,
      "based cohort study conducted": 13298,
      "met study inclusion criteria": 44885,
      "outcome scores did differ": 53993,
      "envelope": 29089,
      "infusing": 38693,
      "infuse": 38690,
      "685": 5509,
      "aggressively": 9261,
      "impose": 37045,
      "rigorously": 72485,
      "accrued": 7086,
      "territories": 80725,
      "intramuscular administration": 39740,
      "offer effective": 50947,
      "home oral": 35515,
      "tablet consumption": 80090,
      "data comparing": 21920,
      "available present": 12831,
      "followed postoperative": 32081,
      "versus single": 86158,
      "sealed envelope": 74103,
      "received discharge": 68139,
      "outcomes vas": 54108,
      "day addition": 22267,
      "intercostal nerves": 39410,
      "background posterior": 13164,
      "history recent": 35479,
      "included 37": 37395,
      "consensus exists": 19575,
      "group discharged": 33754,
      "tablets rescue": 80211,
      "0001 significantly": 79,
      "prescription contrast": 64186,
      "document daily": 25661,
      "surgery twice": 79610,
      "subjects recorded": 78738,
      "32 41": 3912,
      "pain lowest": 57041,
      "enrolled 30": 28995,
      "hr ml": 35895,
      "protocol consisted": 65964,
      "difference use": 24700,
      "adding preoperative": 7792,
      "40 52": 4323,
      "increase 25": 37722,
      "patient surgery": 58795,
      "entire sample": 29075,
      "sample stratified": 73318,
      "using sequential": 85608,
      "acetaminophen ketoprofen": 7199,
      "sequential order": 74633,
      "24 hr": 3237,
      "hr different": 35892,
      "59 mg": 5189,
      "study 28": 77889,
      "groups day": 34169,
      "blocks methods": 14092,
      "age 57": 9027,
      "history trauma": 35486,
      "pregabalin multimodal": 63670,
      "controlled anesthesia": 20466,
      "evaluating pain": 29948,
      "group visual": 34069,
      "single prophylactic": 76136,
      "intravenous dose": 39823,
      "surgery control": 79356,
      "26 hours": 3444,
      "group year": 34081,
      "dexamethasone improves": 24285,
      "months background": 47431,
      "04 significant": 456,
      "currently developed": 21493,
      "included interventions": 37468,
      "conclusions ultrasound": 19237,
      "hydromorphone postoperative": 36216,
      "reported helpful": 70554,
      "acid oxycodone": 7343,
      "noted pain": 49990,
      "sleep satisfaction": 76236,
      "triple blind": 83234,
      "trials level": 83154,
      "scale measurements": 73505,
      "oral pregabalin": 53654,
      "disability surgical": 25075,
      "ml ketamine": 46866,
      "ml 15": 46828,
      "narcotics consumption": 48627,
      "use visual": 84803,
      "week 14": 86825,
      "exist suggest": 30521,
      "duration quantity": 27181,
      "postoperatively corresponding": 62998,
      "guidelines 21": 34426,
      "surgeries associated": 79284,
      "31 17": 3842,
      "drug hypothesis": 26647,
      "measurements postoperative": 44030,
      "establish quantify": 29580,
      "total 55": 81756,
      "2014 cohort": 2658,
      "states territories": 77152,
      "76 fewer": 5740,
      "medical visits": 44425,
      "23 visits": 3114,
      "radiological examination": 66973,
      "surgery design prospective": 79370,
      "discharged home oral": 25198,
      "10 postoperative day": 908,
      "study compared single": 78014,
      "compared single dose": 18311,
      "mg vs 44": 46263,
      "safe effective method": 73078,
      "analysis included 37": 10699,
      "included 37 patients": 37396,
      "group conclusion results": 33697,
      "surgery associated severe": 79327,
      "associated severe postoperative": 12419,
      "surgery enrolled randomised": 79387,
      "opioids background opioid": 52745,
      "group vs 17": 34073,
      "group satisfied pain": 33996,
      "surgery result substantial": 79565,
      "control group group": 20327,
      "average pain postoperative": 12927,
      "presentation case report": 64678,
      "week following surgery": 86843,
      "pain recorded results": 57486,
      "used significantly oxycodone": 85130,
      "oxycodone compared patients": 54821,
      "significant difference use": 75496,
      "chart review patients": 15929,
      "results total 119": 72023,
      "analgesic drugs methods": 10192,
      "information regarding postoperative": 38669,
      "control group tramadol": 20344,
      "ir er oxycodone": 40223,
      "discharged day surgery": 25192,
      "analogue pain scores": 10550,
      "data included demographics": 21988,
      "14 patients required": 1621,
      "10 mg patients": 840,
      "overall pain control": 54223,
      "different opioid medications": 24896,
      "patient controlled anesthesia": 58593,
      "group visual analog": 34070,
      "reduced opioid consumption": 68952,
      "blind study evaluate": 13981,
      "surgery control group": 79357,
      "10 placebo group": 901,
      "oxycodone consumption 10": 54851,
      "dexamethasone improves early": 24286,
      "12 months background": 1334,
      "included interventions patients": 37469,
      "conclusions ultrasound guided": 19238,
      "pain 10 10": 56349,
      "frequently experience pain": 32553,
      "acetylsalicylic acid oxycodone": 7287,
      "opioid use visual": 52605,
      "use visual analog": 84804,
      "misuse abuse opioid": 46708,
      "based opioid prescription": 13345,
      "hours postoperatively results": 35828,
      "comparable analgesic effect": 17949,
      "satisfaction scores significantly": 73436,
      "visits study period": 86294,
      "surgery design prospective randomized": 79371,
      "patients discharged home oral": 59209,
      "study compared single dose": 78015,
      "final analysis included 37": 31743,
      "analysis included 37 patients": 10700,
      "surgery associated severe postoperative": 79328,
      "associated severe postoperative pain": 12420,
      "group satisfied pain management": 33997,
      "subjects randomly assigned receive": 78733,
      "satisfaction pain management patients": 73415,
      "group control group group": 33718,
      "results total 119 patients": 72024,
      "group visual analog scale": 34071,
      "double blind study evaluate": 26381,
      "blind study evaluate effect": 13982,
      "patients frequently experience pain": 59318,
      "regarding postoperative pain management": 69274,
      "opioid use visual analog": 52606,
      "evidence based opioid prescription": 30162,
      "based opioid prescription guidelines": 13346,
      "24 hours postoperatively results": 3228,
      "pain scores different groups": 57720,
      "eros": 29507,
      "extrapolate": 30974,
      "devise": 24273,
      "partitioning": 58427,
      "promotion": 65672,
      "recipient": 68564,
      "disagreement": 25082,
      "heaviest": 34886,
      "autoregressive": 12773,
      "2010 oxycodone": 2566,
      "insured medicaid": 39159,
      "annual patient": 11029,
      "websites used": 86819,
      "new source": 49373,
      "prescription numbers": 64268,
      "prescriptions used": 64570,
      "die day": 24523,
      "level methods": 41503,
      "needed using": 49048,
      "2019 prescriptions": 2879,
      "aggressive pain": 9258,
      "use opiate": 84539,
      "geographic variation": 33113,
      "18 million": 2092,
      "184 patients": 2140,
      "potency high": 63075,
      "choice appropriate": 16110,
      "opioids years": 53398,
      "oxycodone dispensed": 54981,
      "hydromorphone prescriptions": 36218,
      "23 2015": 3074,
      "14 year": 1632,
      "prescribers received": 64023,
      "results 2009": 71550,
      "national efforts": 48683,
      "stratified sociodemographic": 77458,
      "need tailored": 48960,
      "codeine prescription": 17280,
      "twofold higher": 83313,
      "17 conclusion": 1960,
      "systems objective": 80039,
      "iqvia national": 40189,
      "national sales": 48717,
      "highest use": 35370,
      "brand oxycontin": 14382,
      "oxycontin conclusions": 56127,
      "prescribing public": 64125,
      "prescriptions 1997": 64434,
      "conclusions dramatic": 19075,
      "declined 2012": 22865,
      "available article": 12791,
      "insured individuals": 39158,
      "prescribing needed": 64084,
      "residents initiated": 71074,
      "commonly initiated": 17852,
      "interval 57": 39569,
      "57 47": 5125,
      "analysis national": 10713,
      "greatest increase": 33501,
      "increased 18": 37829,
      "states data": 77089,
      "drug claims": 26548,
      "proportions population": 65795,
      "population aged": 62301,
      "reporting illicit": 70691,
      "reliever prescription": 70224,
      "identify frequently": 36505,
      "therapy greatly": 81017,
      "analyzed oxycodone": 10848,
      "prescriber type": 64013,
      "results annual": 71604,
      "stable years": 76853,
      "increased focus": 37915,
      "men highest": 44799,
      "highest women": 35371,
      "aged 85": 9199,
      "89 years": 6063,
      "prescriptions calculated": 64456,
      "remained fairly": 70262,
      "fairly stable": 31159,
      "prescribed caution": 63830,
      "2013 increase": 2632,
      "utilization measures": 85730,
      "based utilization": 13400,
      "claims large": 16632,
      "year index": 87446,
      "compounds compared": 18606,
      "trends prescriptions": 82984,
      "using primary": 85576,
      "care database": 15018,
      "using common": 85350,
      "patient identifiers": 58660,
      "85 0001": 5975,
      "users use": 85275,
      "provider characteristics": 66173,
      "different controlled": 24857,
      "medications objectives": 44652,
      "largest relative": 41198,
      "dispensing 2015": 25438,
      "eligible study": 28599,
      "dispensings 1000": 25464,
      "population increase": 62342,
      "rates codeine": 67562,
      "sample drawn": 73300,
      "parent reported": 58200,
      "31 million": 3872,
      "clinical demographic": 16787,
      "chronic obstructive": 16233,
      "obstructive pulmonary": 50747,
      "pulmonary disease": 66464,
      "research methods": 71012,
      "introduction new formulation": 39935,
      "reformulated er oxycodone": 69199,
      "commercially insured medicaid": 17722,
      "opioid prescription data": 52140,
      "better understand opioid": 13749,
      "oxycodone hydromorphone buprenorphine": 55217,
      "prevalence opioid prescription": 64792,
      "opioids increased age": 52987,
      "methods descriptive study": 45311,
      "analgesics widely used": 10518,
      "increase prescription oxycodone": 37790,
      "aggressive pain treatment": 9259,
      "release oxycodone methadone": 69950,
      "prescription claims data": 64177,
      "dose 12 \u03bcg": 25789,
      "routes administration oral": 72854,
      "trends prescription opioid": 82983,
      "prescription opioid utilisation": 64322,
      "trends opioid use": 82977,
      "22 percent oxycodone": 3040,
      "percent opioid prescriptions": 60468,
      "data opioid consumption": 22028,
      "opioid analgesic prescriptions": 51469,
      "conclusions dramatic increase": 19076,
      "increase prescriptions dispensed": 37792,
      "commercially insured individuals": 17721,
      "opioid prescribing needed": 52111,
      "confidence interval 57": 19454,
      "geographic variation opioid": 33114,
      "ddd 1000 population": 22671,
      "prescription drug claims": 64208,
      "drug claims database": 26549,
      "rates opioid analgesics": 67607,
      "pain reliever prescription": 57604,
      "identify frequently prescribed": 36506,
      "use remained stable": 84690,
      "increase use non": 37818,
      "oxycodone increased significantly": 55250,
      "prevalence opioid use": 64795,
      "times higher morphine": 81428,
      "impact prescribing practices": 36843,
      "appropriate use opioids": 11520,
      "older people objectives": 51039,
      "opioid prescriptions calculated": 52179,
      "remained fairly stable": 70263,
      "prescribed caution background": 63831,
      "non opioid weak": 49659,
      "opioid weak opioid": 52637,
      "primary care database": 64992,
      "oxycodone hydromorphone codeine": 55219,
      "2016 december 2018": 2742,
      "receiving prescriptions multiple": 68375,
      "prescriptions multiple providers": 64520,
      "largest relative increase": 41199,
      "dispensings 1000 population": 25465,
      "aged 85 years": 9200,
      "morphine oral controlled": 47797,
      "chronic obstructive pulmonary": 16234,
      "obstructive pulmonary disease": 50748,
      "morphine commonly used opioid": 47613,
      "repeated cross sectional analysis": 70404,
      "ddd 1000 population day": 22672,
      "prescription drug claims database": 64209,
      "prevalence opioid prescriptions calculated": 64794,
      "non opioid weak opioid": 49660,
      "opioid weak opioid strong": 52638,
      "24 95 ci 15": 3183,
      "receiving prescriptions multiple providers": 68376,
      "morphine oral controlled release": 47798,
      "chronic obstructive pulmonary disease": 16235,
      "finely": 31840,
      "coarsely": 17127,
      "mpa": 48064,
      "impulse": 37208,
      "1444": 1648,
      "8000": 5870,
      "authors developed": 12727,
      "source oxycodone": 76499,
      "tablets oc": 80182,
      "resistance crushing": 71091,
      "tablets finely": 80159,
      "profile expected": 65487,
      "subjects conclusions": 78690,
      "oxycodone release": 55828,
      "serial blood": 74643,
      "drug content": 26567,
      "tablets bioequivalent": 80127,
      "determined pre": 24084,
      "14 minutes": 1609,
      "function introduction": 32654,
      "arir novel": 11655,
      "appropriate dosage": 11500,
      "identified significant": 36470,
      "new extended": 49325,
      "oxycodone quantified": 55790,
      "formulations treatment": 32412,
      "tablets ir": 80172,
      "derived using": 23636,
      "allow effective": 9633,
      "significantly consistent": 75669,
      "nasal route": 48656,
      "observed subjects": 50720,
      "rate extent": 67466,
      "formulation showed": 32366,
      "generally healthy": 33015,
      "healthy children": 34816,
      "induction anaesthesia": 38475,
      "concentration observed": 18708,
      "84 68": 5954,
      "visits 15": 86275,
      "state half": 77045,
      "55 controlled": 5072,
      "vitro dissolution": 86355,
      "dissolution data": 25526,
      "gastric fluid": 32855,
      "99 conclusions": 6489,
      "release rates": 69999,
      "groups children": 34142,
      "conducted 24": 19339,
      "formulation type": 32368,
      "hydrochloride results": 36035,
      "showed mean": 75271,
      "008 respectively": 279,
      "excreted urine": 30493,
      "dose suggesting": 26090,
      "showed pk": 75288,
      "model allowed": 47024,
      "using effect": 85387,
      "oxycodone materials": 55370,
      "needed avoid": 48980,
      "failure drug": 31149,
      "dose population": 26014,
      "biphasic immediate": 13871,
      "apap 325": 11346,
      "opioids trial": 53360,
      "race age": 66934,
      "estimation methods": 29660,
      "17 lower": 1972,
      "necessary large": 48887,
      "significant source": 75636,
      "men 21": 44795,
      "quantified impact": 66779,
      "test data": 80762,
      "distribution volume": 25570,
      "subjects normal": 78717,
      "tablets designed": 80145,
      "meal fasted": 43651,
      "71 microg": 5593,
      "administered acetaminophen": 8107,
      "department days": 23421,
      "oral ingestion": 53551,
      "apap oxycodone": 11357,
      "ml intravenous": 46865,
      "max time maximum": 43562,
      "safety profile expected": 73207,
      "release er tablet": 69851,
      "serial blood samples": 74644,
      "er tablets bioequivalent": 29476,
      "physical chemical properties": 61383,
      "linear mixed effect": 42016,
      "new extended release": 49326,
      "40 mg tablets": 4359,
      "background patients chronic": 13148,
      "oxycodone plasma clearance": 55692,
      "strong opioid drug": 77530,
      "opioid drug products": 51745,
      "generally healthy children": 33016,
      "healthy children aged": 34817,
      "oxycodone concentration significantly": 54826,
      "steady state half": 77305,
      "state half life": 77046,
      "55 controlled release": 5073,
      "methods vitro dissolution": 45629,
      "vitro dissolution data": 86356,
      "pharmacokinetic pharmacodynamic model": 61132,
      "oxycodone hydrochloride results": 55194,
      "mg oral controlled": 46079,
      "effect oxycodone pharmacokinetics": 27521,
      "oxycodone pharmacokinetics pk": 55679,
      "oxycodone materials methods": 55371,
      "anova repeated measures": 11046,
      "biphasic immediate release": 13872,
      "apap 325 mg": 11347,
      "administered hours oxycodone": 8137,
      "hours oxycodone dosing": 35805,
      "studies needed investigate": 77789,
      "renal hepatic impairment": 70360,
      "impaired renal function": 36877,
      "drug concentration time": 26558,
      "71 microg ml": 5594,
      "prescription opioid products": 64312,
      "emergency department days": 28671,
      "cross study healthy": 21276,
      "maximum plasma concentration max": 43607,
      "extended release er tablet": 30871,
      "methods open label randomized": 45413,
      "background patients chronic pain": 13149,
      "generally healthy children aged": 33017,
      "clearance volume distribution steady": 16721,
      "distribution steady state half": 25568,
      "steady state half life": 77306,
      "20 mg oral controlled": 2345,
      "mg oral controlled release": 46080,
      "biphasic immediate release ir": 13873,
      "administered hours oxycodone dosing": 8138,
      "er oc apap tablets": 29448,
      "presented emergency department days": 64692,
      "od": 50893,
      "minimised": 46592,
      "print": 65132,
      "northwest": 49968,
      "defeat": 23097,
      "3q2009": 4301,
      "arima": 11652,
      "template": 80583,
      "invaluable": 39963,
      "undue": 83715,
      "reformulating": 69209,
      "favorite": 31265,
      "roas": 72702,
      "polyethylene oxide": 62197,
      "90 05": 6071,
      "term trajectories": 80671,
      "viral infections": 86238,
      "infective endocarditis": 38521,
      "marketing sale": 43426,
      "health national": 34735,
      "prescription audit": 64171,
      "following august": 32103,
      "use accounting": 84167,
      "role precipitating": 72765,
      "reformulated version": 69207,
      "drugs controlled": 26925,
      "positive impact": 62468,
      "impact public": 36845,
      "year years": 87515,
      "databases doctor": 22198,
      "referred oxycodone": 69156,
      "chart audits": 15925,
      "formulations qualitative": 32404,
      "behaviors lead": 13562,
      "surveillance collects": 79680,
      "introduction adf": 39922,
      "inhaled injected": 38764,
      "adf technology": 7987,
      "making opioid": 43012,
      "ratio ero": 67769,
      "oxycodone fatalities": 55069,
      "characteristics reformulated": 15877,
      "2014 developed": 2661,
      "oxycontin following": 56143,
      "methods tampering": 45607,
      "sources pharmaceutical": 76506,
      "oxycontin 45": 56111,
      "confirmed reduction": 19508,
      "term introduction": 80636,
      "switch drugs": 79818,
      "drugs reformulated": 27059,
      "market study": 43415,
      "oxycodone demographic": 54938,
      "compared original": 18232,
      "autoregressive integrated": 12774,
      "integrated moving": 39195,
      "moving average": 48060,
      "average arima": 12877,
      "abuse changes": 6659,
      "conclusions methodology": 19120,
      "years january": 87605,
      "2003 december": 2449,
      "resistant crushing": 71098,
      "19 2010": 2163,
      "major changes": 42933,
      "relative effectiveness": 69746,
      "ended questions": 28834,
      "er adf": 29399,
      "difficult manipulate": 24965,
      "2010 september": 2570,
      "abuse reformulated": 6859,
      "particularly injecting": 58411,
      "snorting routes": 76348,
      "annual surveys": 11032,
      "sales oxycodone": 73252,
      "observed population": 50705,
      "2010 vs": 2571,
      "involving abuse": 40121,
      "development implementation": 24232,
      "changes individual": 15793,
      "reformulation post": 69217,
      "2010 march": 2563,
      "declined 53": 22866,
      "drugs introduction": 26983,
      "introduction results": 39954,
      "little impact": 42158,
      "specific long": 76598,
      "market purpose": 43412,
      "approved extended": 11534,
      "oxycodone percocet": 55669,
      "18 overall": 2099,
      "data 2012": 21849,
      "dispensing oxycodone": 25452,
      "level shift": 41525,
      "use warrants": 84806,
      "available products": 12832,
      "overdose overdose": 54309,
      "calculated rates": 14699,
      "100 population": 1020,
      "2012 july": 2603,
      "moderate uptake": 47213,
      "influence rate": 38599,
      "rate use": 67522,
      "oxycodone reformulated": 55816,
      "abuse nonoral": 6785,
      "administration roas": 8364,
      "2010 reformulated": 2567,
      "abuse pharmaceutical": 6806,
      "categories drug": 15297,
      "tampering compared": 80348,
      "conclusions drugs": 19077,
      "background infective": 13068,
      "determine removal": 24047,
      "fold study": 32002,
      "results ir": 71746,
      "web monitoring": 86811,
      "monitoring data": 47318,
      "reported health": 70553,
      "design used compare": 23817,
      "long term trajectories": 42354,
      "ims health national": 37215,
      "national prescription audit": 48711,
      "following august 2010": 32104,
      "reformulated version oxycontin": 69208,
      "drugs potential abuse": 27039,
      "impact public health": 36846,
      "deterrent properties deter": 24129,
      "abuse overdose risks": 6798,
      "designed reduce abuse": 23843,
      "ci 23 29": 16416,
      "nonoral routes administration": 49822,
      "administration oral use": 8322,
      "deterrent characteristics reformulated": 24105,
      "data sources pharmaceutical": 22112,
      "oxycontin conclusions data": 56128,
      "short term introduction": 75191,
      "switch drugs reformulated": 79819,
      "drugs reformulated oxycontin": 27060,
      "autoregressive integrated moving": 12775,
      "integrated moving average": 39196,
      "moving average arima": 48061,
      "release tablets oxycontin": 70014,
      "january 2003 december": 40420,
      "study assessed effects": 77972,
      "particularly injecting snorting": 58412,
      "injecting snorting routes": 38931,
      "observed population level": 50706,
      "misuse addiction overdose": 46713,
      "fda approved extended": 31275,
      "approved extended release": 11535,
      "studies opioid analgesics": 77796,
      "opioid use warrants": 52607,
      "available opioid formulations": 12826,
      "oxycodone er oxycodone": 55042,
      "abuse nonoral routes": 6786,
      "routes administration roas": 72856,
      "non prescription opioids": 49672,
      "tampering compared ir": 80349,
      "background infective endocarditis": 13069,
      "release er abuse": 69837,
      "er abuse deterrent": 29397,
      "fold study period": 32003,
      "web monitoring data": 86812,
      "xtampza er abuse": 87410,
      "objective study evaluate impact": 50512,
      "abuse addiction overdose death": 6644,
      "abuse deterrent properties deter": 6705,
      "26 95 ci 23": 3442,
      "95 ci 23 29": 6264,
      "routes administration oral use": 72855,
      "abuse deterrent characteristics reformulated": 6683,
      "introduction abuse deterrent formulation": 39919,
      "switch drugs reformulated oxycontin": 79820,
      "autoregressive integrated moving average": 12776,
      "integrated moving average arima": 39197,
      "oxycontin extended release oxycodone": 56141,
      "particularly injecting snorting routes": 58413,
      "abuse misuse addiction overdose": 6779,
      "misuse addiction overdose death": 46714,
      "fda approved extended release": 31276,
      "abuse nonoral routes administration": 6787,
      "nonoral routes administration roas": 49823,
      "extended release er abuse": 30862,
      "release er abuse deterrent": 69838,
      "er abuse deterrent formulation": 29398,
      "prescription opioid analgesics abuse": 64287,
      "dopa": 25716,
      "amantadine": 9757,
      "sorely": 76475,
      "innovation": 39004,
      "hemodialysis": 34933,
      "potential new": 63193,
      "197 patients": 2215,
      "control symptoms": 20431,
      "37 42": 4178,
      "absorption distribution": 6609,
      "inhibitors good": 38803,
      "presented week": 64700,
      "medications tramadol": 44687,
      "future clinical": 32760,
      "movement disorder": 48046,
      "acid clonidine": 7341,
      "stage renal": 76868,
      "considered including": 19633,
      "genetic susceptibility": 33081,
      "disease common": 25324,
      "time taken": 81390,
      "online surveys": 51106,
      "formulations median": 32387,
      "patient oriented": 58696,
      "available case": 12792,
      "ranging 400": 67359,
      "period day": 60721,
      "adjunct therapy": 8004,
      "46 year": 4634,
      "days blood": 22492,
      "randomly assigned study": 67229,
      "ci 37 42": 16440,
      "different drugs studies": 24866,
      "valproic acid clonidine": 85810,
      "end stage renal": 28816,
      "stage renal disease": 76869,
      "oxycodone formulations median": 55105,
      "46 year old": 4635,
      "patient acute renal": 58533,
      "47 year old woman": 4669,
      "end stage renal disease": 28817,
      "patients impaired renal function": 59382,
      "patient acute renal failure": 58534,
      "instrumented": 39117,
      "folds": 32004,
      "luminal": 42760,
      "censored": 15509,
      "neurovascular": 49299,
      "brain compared": 14324,
      "concentration brain": 18680,
      "potential strategy": 63233,
      "deficient mice": 23109,
      "15 13": 1676,
      "oxycodone amitriptyline": 54710,
      "kinetics oxycodone": 40845,
      "developed prediction": 24191,
      "distribution brain": 25557,
      "methodology accurately": 45228,
      "identification characterization": 36411,
      "results vitro": 72056,
      "used blood": 84861,
      "parameters relative": 58174,
      "opioids pharmacokinetic": 53173,
      "tissue blood": 81447,
      "2011 oxycodone": 2586,
      "obtained results": 50782,
      "ms total": 48096,
      "despite presence": 23895,
      "effects local": 27972,
      "130 people": 1518,
      "varying sizes": 85997,
      "tertiary amine": 80731,
      "toxic drugs": 81925,
      "clonidine oxycodone": 17064,
      "oxycodone nicotine": 55536,
      "nicotine cocaine": 49470,
      "pharmacological target": 61231,
      "determined specific": 24088,
      "develop drug": 24145,
      "mean 95 confidence": 43671,
      "concentrations brain blood": 18749,
      "concentration brain blood": 18681,
      "centrally acting drugs": 15624,
      "acting drugs opioids": 7380,
      "higher brain blood": 35212,
      "brain blood ratio": 14323,
      "ms ms total": 48091,
      "better understanding needed": 13752,
      "selected model drugs": 74392,
      "centrally acting drugs opioids": 15625,
      "higher brain blood ratio": 35213,
      "lc ms ms total": 41271,
      "centralized": 15619,
      "listing": 42102,
      "scotland": 74023,
      "pack": 56320,
      "481": 4755,
      "influencing prescribing": 38608,
      "patches opioid": 58496,
      "sample 15": 73288,
      "younger children": 87735,
      "reduce practice": 68888,
      "benefits opioid": 13632,
      "cohort consisted": 17353,
      "estimates number": 29650,
      "12 2010": 1224,
      "compared general": 18163,
      "showed decreasing": 75238,
      "decreasing trends": 23075,
      "year trends": 87512,
      "community use": 17931,
      "15 fold": 1735,
      "30 months": 3775,
      "pharmacies open": 61055,
      "2014 compared": 2659,
      "oa prescribing": 50353,
      "2014 2014": 2648,
      "prescribing non": 64085,
      "prescription benzodiazepines": 64172,
      "dental conditions": 23400,
      "1000 people": 1038,
      "opioids 2018": 52669,
      "2017 31": 2770,
      "prescriptions 000": 64425,
      "estimate total": 29616,
      "rates use": 67646,
      "conclusions substantial": 19229,
      "effective way": 27723,
      "receipt prescription": 68035,
      "relative decrease": 69743,
      "2014 2020": 2654,
      "year conclusion": 87437,
      "pain increasing": 56865,
      "prescriptions dose": 64477,
      "data findings": 21971,
      "doses dispensed": 26180,
      "use associated adverse": 84208,
      "product information pi": 65432,
      "series analysis conducted": 74651,
      "risks benefits opioid": 72673,
      "compared general population": 18164,
      "seven percent opioid": 74873,
      "prescribing methods data": 64080,
      "showed decreasing trends": 75239,
      "respectively conclusion study": 71179,
      "use increased significantly": 84428,
      "used estimate total": 84930,
      "increase prescribing opioid": 37788,
      "cost effective way": 20870,
      "time series analysis conducted": 81373,
      "opioid prescribing methods data": 52109,
      "objective objective study identify": 50453,
      "nontoxic": 49862,
      "intervertebral": 39687,
      "espb": 29548,
      "mmed": 46982,
      "24 26": 3154,
      "period discharged": 60724,
      "surgery children": 79344,
      "regimen reducing": 69326,
      "receive multimodal": 68059,
      "appear safe": 11385,
      "causing pain": 15407,
      "period higher": 60730,
      "dexmedetomidine group": 24294,
      "showed stable": 75312,
      "improve surgical": 37089,
      "undergoing posterior": 83567,
      "initial implementation": 38851,
      "factors development": 31088,
      "pain goal": 56808,
      "hydrocodone 13": 36044,
      "analgesic related": 10323,
      "consumption 001": 19864,
      "compared pca": 18256,
      "aged 11": 9140,
      "sex patients": 75081,
      "celecoxib vs": 15466,
      "celecoxib effective": 15458,
      "available diversion": 12797,
      "declined steadily": 22871,
      "half study": 34533,
      "used formulate": 84942,
      "data information": 21994,
      "17 30": 1943,
      "home pain": 35516,
      "19 prescribed": 2193,
      "evaluate short": 29846,
      "supplemented acetaminophen": 79171,
      "control thirty": 20432,
      "group induction": 33828,
      "parent satisfaction": 58201,
      "practices patients": 63433,
      "001 proportion": 194,
      "prescriptions adult": 64446,
      "months preoperatively": 47467,
      "demand pain": 23253,
      "population shown": 62386,
      "spinal fusion surgery": 76719,
      "oral opioid formulations": 53607,
      "surgery postoperative analgesia": 79527,
      "placebo group pain": 61746,
      "guidelines opioid use": 34452,
      "study period discharged": 78387,
      "excellent pain control": 30442,
      "used postoperative analgesics": 85080,
      "postoperative pain children": 62853,
      "patients undergoing posterior": 60122,
      "predictive factors development": 63573,
      "chronic pain goal": 16276,
      "randomized receive celecoxib": 67169,
      "consumption 001 lower": 19865,
      "release oxycodone postoperative": 69969,
      "tramadol hydromorphone oxycodone": 82072,
      "appropriate post discharge": 11512,
      "design prospective quality": 23764,
      "opioid abuse increasing": 51371,
      "evaluate short term": 29847,
      "kg placebo group": 40787,
      "06 mg 05": 588,
      "oxycodone consumption group": 54861,
      "challenge patients undergoing": 15693,
      "patients receiving prescriptions": 59856,
      "30 min patients": 3767,
      "patient population shown": 58707,
      "length hospital stay shorter": 41402,
      "commonly used postoperative analgesics": 17896,
      "related effects patient satisfaction": 69600,
      "group experienced nausea vomiting": 33773,
      "study design prospective quality": 78083,
      "design prospective quality improvement": 23765,
      "prescription opioid abuse increasing": 64276,
      "mg kg placebo group": 46017,
      "single center randomized double": 76066,
      "05 oxycodone consumption group": 535,
      "vanderbilt": 85861,
      "bar": 13245,
      "graphic": 33406,
      "butalbital": 14624,
      "interrater": 39533,
      "minnesota": 46621,
      "43 66": 4497,
      "white race": 87029,
      "statistics logistic": 77246,
      "coded prescription": 17193,
      "did methods": 24462,
      "illegal opioid": 36625,
      "period august": 60711,
      "measure rates": 43947,
      "account clustering": 7073,
      "caring patients": 15120,
      "2010 declined": 2556,
      "patients processed": 59705,
      "interrater reliability": 39534,
      "federal law": 31322,
      "abuse finally": 6727,
      "patient opioids": 58695,
      "accurately identifying": 7104,
      "specific medications": 76602,
      "analgesics line": 10442,
      "regimen children": 69302,
      "ed pain": 27337,
      "increase oxycodone prescriptions": 37775,
      "white race age": 87030,
      "abuse addiction study": 6647,
      "descriptive statistics logistic": 23684,
      "statistics logistic regression": 77247,
      "likely prescribed oxycodone": 41829,
      "interval ci 13": 39580,
      "compared did methods": 18136,
      "proportion patients given": 65766,
      "based postoperative pain": 13361,
      "pain regimen children": 57505,
      "descriptive statistics logistic regression": 23685,
      "confidence interval ci 13": 19463,
      "polymers": 62205,
      "blockage": 14080,
      "preparing": 63791,
      "oxycodone 06": 54490,
      "increase difficulty": 37743,
      "release kinetics": 69882,
      "toxicological findings": 81941,
      "pharmaceutical manufacturing": 61030,
      "plasma distribution": 61926,
      "promoting early": 65671,
      "subjects achieving": 78678,
      "optimal drug": 53424,
      "human use": 35978,
      "reduced fentanyl": 68928,
      "initiation retention": 38899,
      "complement existing": 18433,
      "behavioral changes": 13543,
      "public health threat": 66402,
      "prescription opioids provide": 64364,
      "study describes development": 78063,
      "submandibular": 78760,
      "season": 74174,
      "tonsillar": 81660,
      "radiologic": 66971,
      "reduced consumption": 68916,
      "quantitative evaluation": 66799,
      "narcotics significantly": 48639,
      "small statistically": 76303,
      "25 gauge": 3356,
      "confirm initial": 19493,
      "children given": 16048,
      "initial diagnosis": 38833,
      "standardized method": 76969,
      "type analgesic": 83319,
      "related total": 69701,
      "time 10 min": 81189,
      "controlled phase clinical": 20518,
      "scores decreased 24": 73860,
      "objective study use": 50522,
      "associated intense postoperative": 12313,
      "24 hours oxycodone": 3221,
      "small statistically significant": 76304,
      "children given ibuprofen": 16049,
      "placebo controlled phase clinical": 61694,
      "associated intense postoperative pain": 12314,
      "small statistically significant differences": 76305,
      "destruction": 23911,
      "esrd": 29569,
      "haemodialysis": 34501,
      "mitral": 46782,
      "agonist tramadol": 9309,
      "dialysis patients": 24349,
      "hemodialysis hd": 34934,
      "techniques used": 80550,
      "hemodialysis patients": 34935,
      "disease esrd": 25330,
      "abuse presented": 6841,
      "performed days": 60584,
      "presence renal dysfunction": 64601,
      "oxycodone used caution": 56058,
      "renal disease esrd": 70352,
      "stage renal disease esrd": 76870,
      "miss": 46694,
      "trafficked": 81994,
      "products investigated": 65451,
      "discussed drug": 25291,
      "importance including": 36981,
      "future monitoring": 32765,
      "sales drugs": 73250,
      "valid estimate": 85774,
      "compounds metabolites": 18615,
      "hydrocodone oxycodone oxymorphone": 36121,
      "highlights importance including": 35382,
      "opioid drugs metabolites": 51751,
      "suggest abuse drugs": 78981,
      "methadone fentanyl sufentanil": 45075,
      "pilot study evaluated": 61553,
      "inform public health interventions": 38626,
      "silk": 75890,
      "filtering": 31732,
      "nonpharmacological nonopioid": 49829,
      "help fight": 34902,
      "compared oxycontin": 18245,
      "product methods": 65433,
      "increasing amounts": 38093,
      "need considered": 48916,
      "work potential": 87281,
      "referring": 69157,
      "address current": 7923,
      "period june": 60739,
      "majority 85": 42982,
      "pain renal": 57614,
      "month period june": 47400,
      "posted": 62651,
      "categorization": 15302,
      "indexed": 38214,
      "15 34": 1695,
      "consequences drug abuse": 19590
    }
  }
}